Browse by Poster Presenter

Schedule at a Glance

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Browse by Poster Presenter

Type here to filter the list

A
Abbate, Cynthia

Moleculin Biotech, Inc
(P 183) A PHASE 1B/2 STUDY OF LIPOSOMAL ANNAMYCIN (ANN) IN SUBJECTS WITH PREVIOUSLY TREATED SOFT-TISSUE SARCOMAS (STS) WITH PULMONARY METASTASES
Cynthia Abbate
Favorite
Abbate, Franco

Intensity Therapeutics
(P 164) INTRATUMORAL INT230-6 (CISPLATIN, VINBLASTINE, SHAO) ALONE OR WITH IPILIMUMAB PROLONGED SURVIVAL WITH FAVORABLE SAFETY AND IMMUNE ACTIVATION IN ADULTS WITH REFRACTORY SARCOMAS (NCT 03058289)
Franco Abbate
Favorite
Abbinanti, Susan

Northwestern Memorial Hospital
(P 219) ELECTIVE DISCONTINUATION OF SORAFENIB TREATMENT IN DESMOID TUMORS: A RETROSPECTIVE ANALYSIS WITH IMPLICATIONS FOR CLINICAL PRACTICE
Susan Abbinanti
Favorite
Abbou, Samuel

Gustave Roussy Cancer Campus
(P 75) REAL-WORLD DATA ON REGORAFENIB AND CABOZANTINIB IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH RELAPSED OSTEOSARCOMA AND EWING SARCOMA INCLUDED IN THE SACHA-FRANCE STUDY
Samuel Abbou
Favorite
Abdelhafez, Yasser

University of California Davis Health
(P 233) MULTI-CENTER EXTERNAL VALIDATION OF AN AUTOMATED MODEL DIFFERENTIATING ALT FROM LIPOMA USING RADIOMICS AND DEEP-LEARNING BASED SEGMENTATION
Yasser Abdelhafez
Favorite
Abdeltawab, Asmaa.A.

Faculty of medicines Asyut University
(P 370) SYNOVIAL SARCOMA; ROLE OF ADJUVANT CHEMOTHERAPY IN SURGICALLY TREATED PATIETNS WITH NO METASTASIS; A SEER STAT ANALYSIS.
Asmaa.A. Abdeltawab
Favorite
(P 419) AGE ADJUSTED TRENDS IN PATIENTS WITH SYNOVIAL SARCOMA
Asmaa.A. Abdeltawab
Favorite
Abdul Razak, Albiruni Ryan

Princess Margaret Cancer Center
(P 164) INTRATUMORAL INT230-6 (CISPLATIN, VINBLASTINE, SHAO) ALONE OR WITH IPILIMUMAB PROLONGED SURVIVAL WITH FAVORABLE SAFETY AND IMMUNE ACTIVATION IN ADULTS WITH REFRACTORY SARCOMAS (NCT 03058289)
Albiruni Ryan Abdul Razak
Favorite
(P 215) IMPACT OF FRONTLINE SYSTEMIC TREATMENT CHOICE ON CLINICAL OUTCOME IN ADVANCED LEIOMYOSARCOMA: A MULTI-CENTRE RETROSPECTIVE CANSARCC STUDY
Albiruni Ryan Abdul Razak
Favorite
(P 260) TARGETING HOMOLOGOUS RECOMBINATION DEFICIENCY (HRD) IN LEIOMYOSARCOMA WITH COMBINATION OF PARP INHIBITORS (PARPI) AND CHEMOTHERAPY (CTX).
Albiruni Ryan Abdul Razak
Favorite
(P 543) MANEUVER STUDY: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF PIMICOTINIB (ABSK021) TO ASSESS THE EFFICACY AND SAFETY IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR
Albiruni Ryan Abdul Razak
Favorite
Abdulla, Suha

University College London Hospital
(P 422) CLINICAL UTILITY OF WHOLE GENOME SEQUENCING IN SARCOMA FOR THE IDENTIFICATION OF ACTIONABLE MUTATIONS: A RETROSPECTIVE COHORT ANALYSIS
Suha Abdulla
Favorite
Abegglen, Lisa

Huntsman Cancer Institute/University of Utah
(P 412) LEIOMYOSARCOMA POLYANEUPLOID CANCER CELLS DEVELOP IN RESPONSE TO CHEMOTHERAPY AND CONTRIBUTE TO CHEMORESISTANCE
Lisa Abegglen
Favorite
Abraham, Christopher

Washington University in St Louis
(P 187) PALLIATIVE LATTICE STEREOTACTIC BODY RADIOTHERAPY FOR PATIENTS WITH SARCOMA
Christopher Abraham
Favorite
Abusabha, Yasser

University of Michigan Medical School
(P 403) THE IMPACT OF PATIENT, TUMOR, AND TREATMENT FACTORS ON SURVIVAL AND METASTASIS OUTCOMES IN PATIENTS WITH MYXOID LIPOSARCOMA
Yasser Abusabha
Favorite
Acem, Ibtissam

Erasmus Medical Center
(P 505) LOCAL RECURRENCE IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS: A MULTICENTER COHORT STUDY
Ibtissam Acem
Favorite
Achacoso, Ninah

Kaiser Permanente
(P 224) CO-MUTATION-DEPENDENT PROGNOSIS IN PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA
Ninah Achacoso
Favorite
Acharya, Sunil

University of Texas MD Anderson
(P 122) TARGETING CD70 USING CAR NK CELLS TO ENHANCE NK CELLS CYTOLYTIC EFFECT AGAINST OSTEOSARCOMA
Sunil Acharya
Favorite
Achiwa, Issei

Daiichi Sankyo, Co., Ltd
(P 168) A PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF PEXIDARTINIB IN ASIAN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR
Issei Achiwa
Favorite
Ackerman, Alexander

Ghent University
(P 291) DEVELOPMENT OF A LIVE TISSUE SARCOMA BIOBANK TO SUPPORT THE CREATION OF PATIENT-DERIVED TRANSLATIONAL MODELS
Alexander Ackerman
Favorite
(P 295) ORTHOTOPIC XENOGRAFTS OF PAIRED SARCOMA PRIMARY TUMOUR, LOCAL RELAPSE AND METASTATIC SITES REVEALS PHENOTYPIC HETEROGENEITY IN A MINIMAL RESIDUAL DISEASE MODEL
Alexander Ackerman
Favorite
Acuña, Alexander

Rush University Medical Center - - Chicago, IL
(P 307) IS RADIOTHERAPY NECESSARY FOR MANAGEMENT OF LOW GRADE MYXOID LIPOSARCOMA? A SYSTEMATIC REVIEW
Alexander Acuña
Favorite
(P 506) THE EFFECT OF TIMING BETWEEN PRE-OPERATIVE EMBOLIZATION AND SURGERY: A RETROSPECTIVE ANALYSIS OF HYPERVASCULAR BONE METASTASES
Alexander Acuña
Favorite
Adalbert, Jenna

University of Miami
(P 154) BARRIERS TO CARE FOR MUSCULOSKELETAL TUMORS
Jenna Adalbert
Favorite
Adam, Diane

Oncological department of Institut Bergonié
(P 521) HOW TO MANAGE ABDOMINAL PARIETECTOMY, REVIEW OF EXPERIENCE IN INSTITUT BERGONIE
Diane Adam
Favorite
(P 523) IN-BETWEEN SARCOMA: A CATEGORY OF HIGH RISK OF RECURRENCE AND POOR OUTCOME
Diane Adam
Favorite
Adámková Krákorová, Dagmar

Masaryk Memorial Cancer Institute Brno, Czech Republic
(P 152) EVALUATING DIAGNOSTIC APPROACHES TO DERMATOFIBROSARCOMA PROTUBERANS: AN OPPORTUNITY TO REDUCE THE NUMBER OF INTERVENTIONS
Dagmar Adámková Krákorová
Favorite
(P 342) THE EVALUATION AND OUTCOMES OF MESENTERIC AND INTRA-ABDOMINAL DESMOIDS: A TARPSWG STUDY
Dagmar Adámková Krákorová
Favorite
Adams, Bonne

TRACON Pharmaceuticals Inc
(P 112) PHASE 1/2 STUDY OF YH001, A CTLA-4 ANTIBODY WITH THE SUBCUTANEOUSLY ADMINISTERED PD-L1 ANTIBODY ENVAFOLIMAB, WITH OR WITHOUT DOXORUBICIN IN PATIENTS WITH ADVANCED OR METASTATIC SOFT TISSUE SARCOMA
Bonne Adams
Favorite
(P 531) ENVASARC: A PIVOTAL TRIAL OF ENVAFOLIMAB AND ENVAFOLIMAB IN COMBINATION WITH IPILIMUMAB IN PATIENTS WITH ADVANCED OR METASTATIC UPS OR MFS WHO HAVE PROGRESSED ON PRIOR CHEMOTHERAPY
Bonne Adams
Favorite
Adams, Diana

Macarthur Cancer Therapy Centre
(P 386) GENOMIC PROFILING OF GYNAECOLOGICAL SARCOMAS: REPORT FROM THE AUSTRALIA-WIDE PRECISION ONCOLOGY PROGRAM
Diana Adams
Favorite
Addington, Mark

The Ohio State University Wexner Medical Center
(P 311) ROBUST VMAT TREATMENT PLANNING FOR EXTREMITY SOFT TISSUE SARCOMAS
Mark Addington
Favorite
Adnani, Lata

McGill University
(P 65) PROFILING EXTRACELLULAR VESICLES AND NANOPARTICLES IN OSTEOSARCOMA
Lata Adnani
Favorite
Adriazola Vicente, Paul

Hospital Nacional Edgardo Rebagliati Martins - Universidad Ricardo Palma
(P 330) TREATMENT VARIATIONS, OUTCOMES AND PATTERNS OF RECURRENCE AFTER CURATIVE INTENT TREATMENT FOR PRIMARY RETROPERITONEAL SARCOMAS IN LATIN AMERICA. FIRST COLLABORATIVE LATAMSARC STUDY
Paul Adriazola Vicente
Favorite
Aerts, Isabelle

Institut Curie
(P 75) REAL-WORLD DATA ON REGORAFENIB AND CABOZANTINIB IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH RELAPSED OSTEOSARCOMA AND EWING SARCOMA INCLUDED IN THE SACHA-FRANCE STUDY
Isabelle Aerts
Favorite
Agaram, Narasimhan

Memorial Sloan Kettering Cancer Center
(P 555) A PILOT PHASE II STUDY TO EVALUATE THE SMALL MOLECULE TIGILANOL TIGLATE IN PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA: CLINICAL TRIAL IN PROGRESS
Narasimhan Agaram
Favorite
Aggerholm-Pedersen, Ninna

Department of Oncology, Aarhus University Hospital
(P 157) QUALITY OF LIFE DURING TREATMENT FOR METASTATIC SARCOMA - FEASIBILITY OF ELECTRONIC PATIENT REPORTED OUTCOMES
Ninna Aggerholm-Pedersen
Favorite
Aghababazadeh, Masoumeh

McGill University
(P 434) MECHANISMS OF CHEMORESISTANCE IN CIC-DUX4 SARCOMA AS DETERMINED BY IN VIVO FUNCTIONAL GENOMICS
Masoumeh Aghababazadeh
Favorite
Agresta, Samuel

Foghorn Therapeutics
(P 271) PHARMACODYNAMICS AND MECHANISTIC IMPACTS OF FHD-609, A BROMODOMAIN-CONTAINING PROTEIN 9 DEGRADER, IN A PHASE 1 STUDY IN PATIENTS WITH ADVANCED SYNOVIAL SARCOMA OR SMARCB1-LOSS TUMORS
Samuel Agresta
Favorite
Aguiar Jr., Samuel

AC Camargo Cancer Center
(P 192) ROLE OF MAGNETIC RESONANCE IMAGING IN THE PREDICTION OF HISTOLOGICAL GRADE IN SOFT TISSUE SARCOMAS.
Samuel Aguiar Jr.
Favorite
Aguiar, Samuel

A.C. Camargo
(P 342) THE EVALUATION AND OUTCOMES OF MESENTERIC AND INTRA-ABDOMINAL DESMOIDS: A TARPSWG STUDY
Samuel Aguiar
Favorite
Aguil, Gema

Fundación Centro Oncológico de Integración Regional
(P 142) THE SARCOMA EUROPEAN AND LATIN AMERICAN NETWORK (SELNET) PROJECT: OVERVIEW OF THE MAIN RESULTS OF THE SELNET REGISTRY
Gema Aguil
Favorite
Aguirre, Marta

Department of Oncological Mathematics, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
(P 222) EXPLORING THE IMPACT OF NGS ON DIAGNOSTICS AND TREATMENT OF SARCOMA: INSIGHTS FROM REAL-WORLD DATA ACROSS MULTIPLE INSTITUTIONS IN EUROPE
Marta Aguirre
Favorite
Agulnik, Mark

City of Hope, Department of Medical Oncology & Therapeutics Research
(P 135) UNMET NEEDS IN LOCALLY ADVANCED (UNRESECTABLE) OR METASTATIC DEDIFFERENTIATED LIPOSARCOMA AND EXPECTATIONS FOR CLINICAL TRIALS: AN INTERNATIONAL DELPHI CONSENSUS STUDY
Mark Agulnik
Favorite
(P 172) PHASE 2 RESULTS FROM THE RINGSIDE PHASE 2/3 TRIAL OF AL102 FOR TREATMENT OF DESMOID TUMORS
Mark Agulnik
Favorite
(P 178) INITIAL RESULTS FROM A PHASE 1 STUDY OF CFT8634, A NOVEL BIFUCTIONAL DEGRADATION ACTIVATING COMPOUND (BIDAC) DEGRADER OF BRD9, IN SYNOVIAL SARCOMA AND SMARCB1-NULL TUMORS
Mark Agulnik
Favorite
(P 180) HEALTH RELATED QUALITY OF LIFE OF PATIENTS WITH ADVANCED LEIOMYOSARCOMA AND OTHER SOFT TISSUE SARCOMAS TREATED WITH CABOZANTINIB AND TEMOZOLOMIDE
Mark Agulnik
Favorite
(P 334) CHARACTERISTICS AND OUTCOMES FOR PATIENTS IN THE UNITED STATES WITH DEDIFFERENTIATED LIPOSARCOMA FROM A REAL-WORLD DATA SET
Mark Agulnik
Favorite
(P 526) EVALUATION OF THE SURGICAL MANAGEMENT OF THE SKELETON IN PATIENTS WITH OLLIER'S DISEASE AND MAFUCCI SYNDROME
Mark Agulnik
Favorite
Agyemang, Clement

The University of Texas MD Anderson Cancer Center
(P 426) MULTI-OMIC ANALYSIS OF DESMOPLASTIC SMALL ROUND CELL TUMORS REVEAL DISTINCT LINEAGES
Clement Agyemang
Favorite
(P 427) UNDERSTANDING THE MOLECULAR DRIVERS THAT REGULATE EWING SARCOMA CELL FATE
Clement Agyemang
Favorite
Ahari, Amir

Sarcoma Oncology Center
(P 117) INTERIM ANALYSIS OF PHASE 2 STUDY: A METRONOMIC REGIMEN USING GEMCITABINE, DOXORUBICIN, DOCETAXEL AND NIVOLUMAB FOR ADVANCED LEIOMYOSARCOMA (NCT04535713)
Amir Ahari
Favorite
(P 383) AI ANALYSIS SHOWS ENHANCED CCNG1 ONCOGENE EXPRESSION IN SARCOMA TUMORS AND SUPPORTS THE USE OF DELTAREX-G, A CCNG1 INHIBITOR, AS PLATFORM THERAPY FOR ADVANCED SARCOMA
Amir Ahari
Favorite
Ahcene Djaballah, Selma

Oncology 3 Unit, Department of Oncology, Veneto Institute of Oncology IOV - IRCCS
(P 171) SEX DIFFERENCES IN OUTCOMES AND TOXICITY IN PATIENTS TREATED FOR SARCOMA IN A REFERENCE CENTER
Selma Ahcene Djaballah
Favorite
Ahlstrom, Marie

Dpt of Oncology, Skane University Hospital, Lund, Sweden
(P 195) MULTIPLE MYXOMA EFFECTIVELY TREATED WITH PAZOPANIB - A CASE REPORT
Marie Ahlstrom
Favorite
Ahmed, Leliftu

Washington University in St. Louis
(P 274) TYK2 AND MEK COMBINATION THERAPY IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS AND OTHER SOFT TISSUE SARCOMAS
Leliftu Ahmed
Favorite
Ahmed, Mahbubl

University College London Hospital
(P 92) DOSIMETRIC CHARACTERISTICS, OUTCOMES AND PROGNOSTIC FACTORS OF PATIENTS WITH EXTRACRANIAL CHORDOMAS AND CHONDROSARCOMAS TREATED WITH HIGH DOSE RADIOTHERAPY: A LARGE SINGLE INSTITUTION COHORT
Mahbubl Ahmed
Favorite
(P 145) OUTCOMES OF BREAST ANGIOSARCOMA UNDERGOING TREATMENT IN A SPECIALIST CENTRE
Mahbubl Ahmed
Favorite
(P 325) OUTCOMES AFTER MODERN THREE-DIMENSIONAL CONFORMAL RADIOTHERAPY AND INTENSITY MODULATED RADIOTHERAPY TO TREAT SARCOMAS ARISING IN THE HAND: A RETROSPECTIVE SERIES
Mahbubl Ahmed
Favorite
Ahmed, Midhat

University College London Hospital
(P 422) CLINICAL UTILITY OF WHOLE GENOME SEQUENCING IN SARCOMA FOR THE IDENTIFICATION OF ACTIONABLE MUTATIONS: A RETROSPECTIVE COHORT ANALYSIS
Midhat Ahmed
Favorite
Ahmed, Safia

Mayo Clinic Arizona
(P 02) PEDIATRIC SYNOVIAL SARCOMA: A REVIEW OF 21 CASES FROM A SINGLE INSTITUTION
Safia Ahmed
Favorite
(P 68) METASTASIS-DIRECTED RADIOTHERAPY FOR EWING SARCOMA PATIENTS ENROLLED ON AEWS1221: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP (COG)
Safia Ahmed
Favorite
(P 81) OPTIMIZING EWING SARCOMA AND OSTEOSARCOMA BIOPSY ACQUISITION: CONSENSUS RECOMMENDATIONS FROM THE CHILDREN'S ONCOLOGY GROUP BONE TUMOR COMMITTEE
Safia Ahmed
Favorite
(P 306) USE OF PENCIL BEAM SCANNING PROTON RADIOTHERAPY IN MOBILE SPINE CHORDOMAS
Safia Ahmed
Favorite
(P 312) MANAGEMENT OF ADULT HEAD AND NECK SOFT TISSUE SARCOMA: THE MAYO CLINIC EXPERIENCE
Safia Ahmed
Favorite
(P 465) UNPLANNED EXCISION OF SYNOVIAL SARCOMA: FACTORS ASSOCIATED WITH RECURRENCE AND SURVIVAL
Safia Ahmed
Favorite
Ahrens, William

Atrium Health
(P 258) THE CRITICALITY OF OXIDATIVE PHOSPHORYLATION IN SYNOVIAL SARCOMA METASTASIS
William Ahrens
Favorite
Aiba, Hisaki

Nagoya City University
(P 396) COMPREHENSIVE WHOLE-GENOME MOLECULAR PROFILING IN BONE AND SOFT TISSUE SARCOMA: MULTI-OMICS ANALYSIS OF 627 CASES ACROSS HISTOLOGIC SUBTYPES
Hisaki Aiba
Favorite
Aibara, Yuki

Tokyo Dental College Ichikawa General Hospital
(P 87) ANGIOSARCOMA OF THE ILIUM TREATED WITH HEMIPELVECTOMY AND HIP TRANSPOSITION FOLLOWED BY POSTOPERATIVE CHEMOTHERAPY WITH PAZOPANIB: A CASE REPORT
Yuki Aibara
Favorite
Aisner, Dara

University of Colorado - Anschutz Medical Campus
(P 237) SECONDARY REARRANGEMENT CREATING A PLEC-EML4-ALK DOUBLE FUSION AS A MECHANISM OF RESISTANCE TO CRIZOTINIB IN AN EML4-ALK-POSITIVE INFLAMMATORY MYOFIBROBLASTIC TUMOR
Dara Aisner
Favorite
Aitchison, Alexandra Hunter

Duke University School of Medicine
(P 299) EXPLORING THE IMMUNOLIGHT MECHANISM OF ACTION IN A GENETICALLY ENGINEERED MOUSE MODEL OF SOFT TISSUE SARCOMA
Alexandra Hunter Aitchison
Favorite
Aiyegbusi, Olalekan

University of Birmingham
(P 345) CLINICIAN SURVEY - CURRENT GLOBAL PRACTICE FOR SARCOMA SURVEILLANCE FOLLOWING RESECTION OF PRIMARY RETROPERITONEAL, ABDOMINAL, AND PELVIC SARCOMA
Olalekan Aiyegbusi
Favorite
Akbulut, Merve

Department of Medical Oncology, West German Cancer Center, University Hospital Essen
(P 248) FIBROBLAST ACTIVATION PROTEIN ALPHA -DIRECTED IMAGING AND THERAPY OF SOLITARY FIBROUS TUMOR
Merve Akbulut
Favorite
Akdemir, Kadir

MD Anderson Cancer Center
(P 83) CLINICO-GENOMIC PROFILING OF CONVENTIONAL AND DEDIFFERENTIATED CHONDROSARCOMAS REVEALS TP53 MUTATION TO BE ASSOCIATED WITH WORSE OUTCOMES
Kadir Akdemir
Favorite
(P 360) TP53 ALTERATIONS IN SARCOMAS: AN ANALYSIS FROM THE AACR-GENIE DATABASE
Kadir Akdemir
Favorite
Akiyama, Toru

Saitama Medical Centre, Jichimedical University
(P 74) SACRAL CHORDOMA: A RANDOMIZED & OBSERVATIONAL STUDY ON SURGERY VS DEFINITIVE RADIOTHERAPY IN PRIMARY LOCALIZED DISEASE (SACRO). INTERIM ANALYSIS
Toru Akiyama
Favorite
Akumuo, Rita

Department of General Surgery, Temple University Hospital,
(P 152) EVALUATING DIAGNOSTIC APPROACHES TO DERMATOFIBROSARCOMA PROTUBERANS: AN OPPORTUNITY TO REDUCE THE NUMBER OF INTERVENTIONS
Rita Akumuo
Favorite
Alaggio, Rita

Bambino Gesu Children's Hospital, IRCCS
(P 202) INFLAMMATORY MYOFIBROBLASTIC TUMOUR WITH ROS1 GENE FUSIONS IN CHILDREN AND YOUNG ADOLESCENTS
Rita Alaggio
Favorite
Al-Awar, Rima

OICR
(P 260) TARGETING HOMOLOGOUS RECOMBINATION DEFICIENCY (HRD) IN LEIOMYOSARCOMA WITH COMBINATION OF PARP INHIBITORS (PARPI) AND CHEMOTHERAPY (CTX).
Rima Al-Awar
Favorite
Albarrán, Verónica

Hospital Clínico San Carlos
(P 515) ENDOBRONCHIAL NAVIGATION AS AN INTRAOPERATORY TOOL FOR RESECTION OF SMALL PULMONARY METASTASES IN SARCOMA PATIENTS
Verónica Albarrán
Favorite
Albert, Catherine

Seattle Children's Hospital, University of Washington, Fred Hutchinson Cancer Center,
(P 81) OPTIMIZING EWING SARCOMA AND OSTEOSARCOMA BIOPSY ACQUISITION: CONSENSUS RECOMMENDATIONS FROM THE CHILDREN'S ONCOLOGY GROUP BONE TUMOR COMMITTEE
Catherine Albert
Favorite
(P 161) EFFICACY, SAFETY, AND TREATMENT HOLD WAIT-AND-SEE OUTCOMES OF LAROTRECTINIB IN PEDIATRIC PATIENTS WITH TRK FUSION SARCOMAS
Catherine Albert
Favorite
Albertsmeier, Markus

Department of General, Visceral and Transplantation Surgery, University Hospital, Ludwig-Maximilians-University (LMU) Munich, Germany
(P 118) TIM-3 QUALIFIES AS A POTENTIAL IMMUNOTHERAPEUTIC TARGET IN SPECIFIC SUBSETS OF PATIENTS WITH HIGH-RISK SOFT TISSUE SARCOMAS (HR-STS)
Markus Albertsmeier
Favorite
Albertsmeier, Markus

LMU University Hospital
(P 153) PRIORITY SETTING PARNTERSHIP RETROPERITONEAL SOFT TISSUE SARCOMAS
Markus Albertsmeier
Favorite
(P 348) RESECTION OF RECURRENT RETROPERITONEAL SOFT TISSUE SARCOMAS: ARE INTENSIVE MULTIMODAL TREATMENTS ASSOCIATED WITH INCREASED PERIOPERATIVE MORBIDITY?
Markus Albertsmeier
Favorite
Albertsmeier, Markus

Department of General, Visceral and Transplantation Surgery, University Hospital, Ludwig-Maximilians-University (LMU) Munich, Germany
(P 557) UNRAVELING THE ROLE OF LOCAL THERAPY FOR PATIENTS WITH OLIGOMETASTATIC SOFT TISSUE SARCOMA - A RETROSPECTIVE MULTICENTER TRIAL OF BAVARIAN UNIVERSITY HOSPITALS
Markus Albertsmeier
Favorite
Alcindor, Thierry

McGill University
(P 188) IMPACT OF NIROGACESTAT ON FUNCTIONAL STATUS IN PATIENTS WITH DESMOID TUMORS: RESULTS FROM THE PHASE 3 DEFI STUDY
Thierry Alcindor
Favorite
Alektiar, Kaled

Memorial Sloan Kettering
(P 343) STEREOTACTIC BODY RADIATION THERAPY (SBRT) IN ADVANCED/RECURRENT RETROPERITONEAL SARCOMA: PRELIMINARY RESULTS
Kaled Alektiar
Favorite
Alen, Verónica

Hospital Clínico San Carlos
(P 515) ENDOBRONCHIAL NAVIGATION AS AN INTRAOPERATORY TOOL FOR RESECTION OF SMALL PULMONARY METASTASES IN SARCOMA PATIENTS
Verónica Alen
Favorite
Alessandrino, Francesco

Sylvester Comprehensive Cancer Center
(P 226) SIGNATERA TESTING TO IDENTIFY MINIMAL RESIDUAL DISEASE IN HIGH GRADE SARCOMA
Francesco Alessandrino
Favorite
Alexiev, Borislav

Northwestern Memorial Hospital
(P 219) ELECTIVE DISCONTINUATION OF SORAFENIB TREATMENT IN DESMOID TUMORS: A RETROSPECTIVE ANALYSIS WITH IMPLICATIONS FOR CLINICAL PRACTICE
Borislav Alexiev
Favorite
Alex, Jonathan

Univeristy of Calgary
(P 110) GCAR1: GPNMB CAR T THERAPY FOR MIT FAMILY TRANSLOCATION POSITIVE CANCERS
Jonathan Alex
Favorite
Alfaraidy, Meshal

University of Toronto
(P 443) SURGICAL RESECTION OF EXTREMITY EWING'S SARCOMA BASED ON POST-CHEMOTHERAPY TUMOUR VOLUME RESULTS IN SAFE MARGINS
Meshal Alfaraidy
Favorite
(P 484) OBESITY INCREASES THE RISK OF MAJOR WOUND COMPLICATIONS FOLLOWING PELVIC RESECTION FOR BONE SARCOMA
Meshal Alfaraidy
Favorite
Alferiev, Ivan

University of Pennsylvania Perelman School of Medicine; Children's Hospital of Philadelphia
(P 565) AN EARLY PHASE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF PEEL-224 IN PATIENTS WITH ADVANCED SOLID TUMORS
Ivan Alferiev
Favorite
Al-Hardan, Waleed

University of Miami Miller School of Medicine
(P 485) SUBTROCHANTERIC NON-UNION AFTER INTRAMEDULLARY NAILING DUE TO PATHOLOGICAL FRACTURE:PROXIMAL FEMORAL REPLACEMENT AS A SALVAGE APPROACH
Waleed Al-Hardan
Favorite
Ali, Amro

C4 Therapeutics
(P 178) INITIAL RESULTS FROM A PHASE 1 STUDY OF CFT8634, A NOVEL BIFUCTIONAL DEGRADATION ACTIVATING COMPOUND (BIDAC) DEGRADER OF BRD9, IN SYNOVIAL SARCOMA AND SMARCB1-NULL TUMORS
Amro Ali
Favorite
Ali, Areeba

Houston Methodist Research Institute
(P 405) PRIMARY CARDIAC ANGIOSARCOMA- GENOMIC AND MOLECULAR LANDSCAPE
Areeba Ali
Favorite
Aliberti, Sandra

Candiolo Cancer Institute IRCCS FPO
(P 262) ESTABLISHMENT AND CHARACTERIZATION OF THE FIRST RADIATION-INDUCED, PATIENT-DERIVED ANGIOSARCOMA CELL LINE
Sandra Aliberti
Favorite
Al-Ibraheemi, Alyaa

Boston Children's Hospital
(P 81) OPTIMIZING EWING SARCOMA AND OSTEOSARCOMA BIOPSY ACQUISITION: CONSENSUS RECOMMENDATIONS FROM THE CHILDREN'S ONCOLOGY GROUP BONE TUMOR COMMITTEE
Alyaa Al-Ibraheemi
Favorite
Alicja Juszczak-Kosela, Katarzyna

Pfizer Inc
(P 556) EVALUATION OF PALBOCICLIB (IBRANCE®) IN COMBINATION WITH CHEMOTHERAPY IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY EWING SARCOMA OR NEUROBLASTOMA
Katarzyna Alicja Juszczak-Kosela
Favorite
Allajbej, Albina

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 431) TREATMENT STRATEGY AND PROGNOSTIC FACTORS IN EXTRASKELETAL EWING SARCOMA: AN INSTITUTIONAL RETROSPECTIVE ANALYSIS
Albina Allajbej
Favorite
Allaway, Robert

Sage Bionetworks
(P 250) SHARING HIGH-QUALITY SAMPLES AND DATA TO THE NF1 RESEARCH COMMUNITY: THE ROLE OF THE JOHNS HOPKINS NF1 BIOSPECIMEN REPOSITORY
Robert Allaway
Favorite
Allen, Bryan

University of Iowa
(P 115) EFFICACY AND CORREALTIVE ANALYSIS OF USING NEOADJUVANT INTRATUMORAL HIGH DOSE TALIMOGENE LAHERPAREPVEC (TVEC) WITH CONCURRENT RADIATION IN HIGH-RISK EXTREMITY AND TRUNK SOFT-TISSUE SARCOMAS
Bryan Allen
Favorite
Allen, Mitchell
(P 146) CHARACTERIZING THE PATIENT JOURNEY TO A DIAGNOSIS OF DESMOID TUMOR: DESMOID TUMOR RESEARCH FOUNDATION NATURAL HISTORY STUDY
Mitchell Allen
Favorite
Allen-Rhoades, Wendy

Mayo Clinic
(P 02) PEDIATRIC SYNOVIAL SARCOMA: A REVIEW OF 21 CASES FROM A SINGLE INSTITUTION
Wendy Allen-Rhoades
Favorite
(P 440) LONG TERM OUTCOMES OF EWING SARCOMA OF THE FOOT AND ANKLE
Wendy Allen-Rhoades
Favorite
Allred, Jacob

Mayo Clinic
(P 207) A MULTICENTER PHASE II STUDY OF CABOZANTINIB PLUS NIVOLUMAB FOR PATIENTS WITH ADVANCED ANGIOSARCOMA PREVIOUSLY TREATED WITH A TAXANE: ALLIANCE A091902
Jacob Allred
Favorite
Alman, Benjamin

Duke University
(P 72) CO-EXPRESSION OF LEUKOCYTE CYTOSOLIC PROTEIN 1 AND MATRIX METALLOPROTEINASES ARE INTEGRAL FOR METASTATIC PROGRESSION OF CHONDROSARCOMA
Benjamin Alman
Favorite
(P 375) IDENTIFICATION OF METASTATIC CELLS IN UNDIFFERENTIATED PLEOMORPHIC SARCOMA: SINGLE CELL RNA SEQUENCING AND CIBERSORT ANALYSIS
Benjamin Alman
Favorite
(P 393) INVESTIGATING THE ROLE OF HDACS IN THE PROGRESSION OF METASTATIC UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Benjamin Alman
Favorite
Almassalha, Luay

Northwestern University Feinberg School of Medicine
(P 365) MULTIMODAL ANALYSIS OF NUCLEAR AND GENOMIC ORGANIZATION IN RHABDOMYOSARCOMA AND NORMAL MYOGENIC CELLS
Luay Almassalha
Favorite
Almerey, Tariq

The Mayo Clinic
(P 99) M2 MACROPHAGE INFILTRATION IS ASSOCIATED WITH EARLY DISEASE RECURRENCE FOLLOWING CURATIVE INTENT SURGICAL RESECTION IN SOFT-TISSUE SARCOMAS
Tariq Almerey
Favorite
Aloysius, Tony

University of Cambridge
(P 204) RADIATION-INDUCED ANGIOSARCOMA OF THE BREAST: RETROSPECTIVE ANALYSIS AT A REGIONAL TREATMENT CENTRE
Tony Aloysius
Favorite
Al-Rohil, Rami

Duke University Hospital
(P 509) GIANT CELL TUMOR OF BONE IN THE PEDIATRIC POPULATION: A RETROSPECTIVE STUDY HIGHLIGHTING CASES OF METAPHYSEAL ONLY LOCATION AND INCREASED LOCAL RECURRENCE RATES IN SKELETALLY IMMATURE PATIENTS
Rami Al-Rohil
Favorite
Altendorf-Hofmann, Annelore

Department of General, Visceral and Vascular Surgery, Friedrich-Schiller University Jena, Germany
(P 118) TIM-3 QUALIFIES AS A POTENTIAL IMMUNOTHERAPEUTIC TARGET IN SPECIFIC SUBSETS OF PATIENTS WITH HIGH-RISK SOFT TISSUE SARCOMAS (HR-STS)
Annelore Altendorf-Hofmann
Favorite
Álvarez Álvarez, Rosa

Medical Oncology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
(P 175) TRABECTEDIN PLUS RADIOTHERAPY ON SYMPHTOMATIC ADVANCED SARCOMA PATIENTS, RESULTS FROM THE SYNERGIAS STUDY: A SPANISH GROUP FOR RESEARCH IN SARCOMA (GEIS) PHASE II STUDY
Rosa Álvarez Álvarez
Favorite
(P 222) EXPLORING THE IMPACT OF NGS ON DIAGNOSTICS AND TREATMENT OF SARCOMA: INSIGHTS FROM REAL-WORLD DATA ACROSS MULTIPLE INSTITUTIONS IN EUROPE
Rosa Álvarez Álvarez
Favorite
(P 385) FIRST IN HUMAN PHASE I TRIAL OF A NOVEL DRUG DELIVERY IMPLANT MATRIX WITH SN-38 (CEB-01) FOR RETROPERITONEAL SOFT TISSUE SARCOMA
Rosa Álvarez Álvarez
Favorite
(P 517) PULMONARY METASTASECTOMY FOR SARCOMA: A SINGLE-INSTITUTION EXPERIENCE
Rosa Álvarez Álvarez
Favorite
A
Alvarez, Ana

HU Gregorio Marañon
(P 175) TRABECTEDIN PLUS RADIOTHERAPY ON SYMPHTOMATIC ADVANCED SARCOMA PATIENTS, RESULTS FROM THE SYNERGIAS STUDY: A SPANISH GROUP FOR RESEARCH IN SARCOMA (GEIS) PHASE II STUDY
Ana Alvarez
Favorite
Aly, Amr

Faculty of medicines Suez Canal University
(P 370) SYNOVIAL SARCOMA; ROLE OF ADJUVANT CHEMOTHERAPY IN SURGICALLY TREATED PATIETNS WITH NO METASTASIS; A SEER STAT ANALYSIS.
Amr Aly
Favorite
(P 419) AGE ADJUSTED TRENDS IN PATIENTS WITH SYNOVIAL SARCOMA
Amr Aly
Favorite
(P 423) PRIMARY GLIOSARCOMA; IMPACT OF ADJUVANT CHEMO(RADIO)THERAPY ON SURVIVAL OUTCOME
Amr Aly
Favorite
Amary, Fernanda

Department of Histopathology, Royal National Orthopaedic Hospital, Stanmore, UK
(P 04) THE CELL ATLAS OF CLEAR CELL SARCOMA
Fernanda Amary
Favorite
(P 381) THE GENOMIC LANDSCAPE OF CLEAR CELL SARCOMA
Fernanda Amary
Favorite
Amatruda, James

Children's Hospital Los Angeles
(P 430) UNIQUE HISTOLOGIC MORPHOLOGY OF EWING SARCOMA CELLS THAT HARBOR TP53 MUTATIONS
James Amatruda
Favorite
Amend, Sarah

Johns Hopkins School of Medicine
(P 412) LEIOMYOSARCOMA POLYANEUPLOID CANCER CELLS DEVELOP IN RESPONSE TO CHEMOTHERAPY AND CONTRIBUTE TO CHEMORESISTANCE
Sarah Amend
Favorite
Ameur, Adam

Uppsala University
(P 372) COPY NUMBER GAIN OF MDM2 IN ROD-SHAPED CHROMOSOMES PROVIDES CLUES TO EARLY STAGES IN CIRCULARIZED GENE AMPLIFICATION IN LIPOSARCOMA
Adam Ameur
Favorite
Amini, Behrang

MD Anderson cancer Center
(P 71) CHEMOTHERAPY AND PROGNOSTIC SIGNIFICANCE OF EXTENT OF DEDIFFERENTIATION IN DEDIFFERENTIATED PAROSTEAL OSTEOSARCOMA
Behrang Amini
Favorite
(P 221) EARLY RESULTS IN NOVEL USE OF CONTRAST-ENHANCED SUSCEPTIBILITY-WEIGHTED IMAGING IN THE ASSESSMENT OF RESPONSE AND PROGRESSION IN DESMOID FIBROMATOSIS: PILOT STUDY IN A SPECIALIZED CANCER INSTITUTION
Behrang Amini
Favorite
(P 239) CANCER RADIOMIC AND PERFUSION IMAGING (CARPI) AUTOMATED FRAMEWORK: VALIDATION ON MUSCULOSKELETAL TUMORS IN A SPECIALIZED CANCER CENTER
Behrang Amini
Favorite
(P 354) ROLE OF APPARENT DIFFUSION COEFFICIENT (ADC) MAP-BASED FIRST AND HIGH-ORDER RADIOMIC FEATURES IN DISCRIMINATING SACRAL CHORDOMAS AND CHONDROSARCOMAS WITH OVERLAPPING CONVENTIONAL IMAGING FEATURES
Behrang Amini
Favorite
(P 356) BASELINE AND POST-TREATMENT ADVANCED MRI OF EXTREMITIES SOFT-TISSUE NON-MYXOID UNDIFFERENTIATED PLEOMORPHIC SARCOMA.
Behrang Amini
Favorite
(P 357) APPARENT DIFFUSION COEFFICIENT (ADC) HIGH-ORDER RADIOMICS OF BASELINE AND POST-TREATMENT ADVANCED MRI OF EXTREMITY SOFT-TISSUE NON-MYXOID UNDIFFERENTIATED PLEOMORPHIC SARCOMA.
Behrang Amini
Favorite
(P 358) CONTRAST-ENHANCED SUSCEPTIBILITY IMAGING (CE-SWI) MORPHOLOGIC, FIRST & HIGH-ORDER RADIOMIC FEATURES VALUE IN ASSESSING TREATMENT RESPONSE IN EXTREMITY SOFT-TISSUE UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Behrang Amini
Favorite
(P 359) ROLE OF PERFUSION WEIGHTED IMAGING WITH DYNAMIC CONTRAST ENHANCED (PWI/DCE) FOR THE TREATMENT ASSESSMENT OF EXTREMITY SOFT-TISSUE NON-MYXOID UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Behrang Amini
Favorite
Amin, Neha

Washington University in St. Louis
(P 274) TYK2 AND MEK COMBINATION THERAPY IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS AND OTHER SOFT TISSUE SARCOMAS
Neha Amin
Favorite
Amirian, Soheyla

University of Georgia
(P 244) A DEEP FEW-SHOT META-LEARNING STRATEGY FOR AUTONOMOUS CLASSIFICATION OF BONE METASTASIS IN RADIONUCLIDE BONE SCANS
Soheyla Amirian
Favorite
Anastas, Jamie

Baylor College of Medicine
(P 121) IMPROVING THE EFFICACY OF GD2 CHIMERIC ANTIGEN RECEPTOR T-CELLS USING HISTONE DEACETYLASE INHIBITORS
Jamie Anastas
Favorite
Anazawa, Ukei

Tokyo Dental College Ichikawa General Hospital
(P 87) ANGIOSARCOMA OF THE ILIUM TREATED WITH HEMIPELVECTOMY AND HIP TRANSPOSITION FOLLOWED BY POSTOPERATIVE CHEMOTHERAPY WITH PAZOPANIB: A CASE REPORT
Ukei Anazawa
Favorite
Andelkovic, Vladimir

Princess Alexandra Hospital and Icon Cancer Centre
(P 172) PHASE 2 RESULTS FROM THE RINGSIDE PHASE 2/3 TRIAL OF AL102 FOR TREATMENT OF DESMOID TUMORS
Vladimir Andelkovic
Favorite
Önder, Hatice

Pediatrics III, University Hospital Essen, West German Cancer Center
(P 17) METASTASIS-SPECIFIC GENE EXPRESSION PATTERNS IN EWING SARCOMA
Hatice Önder
Favorite
A
Andersen, Clark

M.D. Anderson Cancer Center
(P 532) MISTOSUS: A PHASE 2 STUDY OF ISCADOR® P IMMUNOTHERAPY FOR PATIENTS WITH RELAPSED OSTEOSARCOMA AND RESECTED PULMONARY METASTASES
Clark Andersen
Favorite
Anderson, Carryn

University of Iowa
(P 115) EFFICACY AND CORREALTIVE ANALYSIS OF USING NEOADJUVANT INTRATUMORAL HIGH DOSE TALIMOGENE LAHERPAREPVEC (TVEC) WITH CONCURRENT RADIATION IN HIGH-RISK EXTREMITY AND TRUNK SOFT-TISSUE SARCOMAS
Carryn Anderson
Favorite
Anderson, Colin

Atrium Health
(P 258) THE CRITICALITY OF OXIDATIVE PHOSPHORYLATION IN SYNOVIAL SARCOMA METASTASIS
Colin Anderson
Favorite
Anderson, Emily

Massachusetts General Hospital
(P 384) SYSTEMATIC LITERATURE AND CLINICAL TRIAL REVIEW SHOWS TARGETABLE KINASE FUSIONS ARE COMMON IN PEDIATRIC, ADOLESCENT, AND YOUNG ADULT SOFT TISSUE SARCOMAS BUT CLINICAL TRIAL OPPORTUNITIES REMAIN RARE
Emily Anderson
Favorite
Anderson, Megan

Boston Childrens' Hospital and BIDMC
(P 529) THE MUSCULOSKELETAL TUMOR REGISTRY -- 2023 UPDATE AND OUTLOOK
Megan Anderson
Favorite
Anderson, Peter

Cleveland Clinic
(P 308) OPTIMAL BIOLOGIC EFFECTIVE DOSE OF STEREOTACTIC BODY RADIOTHERAPY FOR METASTATIC AND RECURRENT SARCOMA
Peter Anderson
Favorite
(P 429) SARCOMA FUSION GENE ANALYSIS YIELDS PROMISING HLA ANTIGEN FIT IN EWING SARCOMA AND DESMOPLASTIC SMALL ROUND CELL TUMOR
Peter Anderson
Favorite
(P 539) SARCOMA STEREOTACTIC BODY RADIOTHERAPY AND IMMUNE SYSTEM TRIAL
Peter Anderson
Favorite
Ando, Masashi

Aichi Cancer Center
(P 547) A PHASE II TRIAL OF TAZEMETOSTAT FOR PATIENTS WITH UNRESECTABLE OR METASTATIC EPITHELIOID SARCOMA (TAZETTA TRIAL)
Masashi Ando
Favorite
André, Nicolas

La Timone Hospital
(P 75) REAL-WORLD DATA ON REGORAFENIB AND CABOZANTINIB IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH RELAPSED OSTEOSARCOMA AND EWING SARCOMA INCLUDED IN THE SACHA-FRANCE STUDY
Nicolas André
Favorite
(P 212) REPORT ON THE EWING SARCOMA PATIENTS ENROLLED IN ARM D OF THE ACSE-ESMART TRIAL: PHASE I/II STUDY OF THE PARP INHIBITOR OLAPARIB IN COMBINATION WITH IRINOTECAN IN CHILDREN WITH ADVANCED MALIGNANCIES
Nicolas André
Favorite
Andreani, Lorenzo

Università di Pisa - Azienda Ospedaliera Universitaria Pisana, Pisa, Italy
(P 74) SACRAL CHORDOMA: A RANDOMIZED & OBSERVATIONAL STUDY ON SURGERY VS DEFINITIVE RADIOTHERAPY IN PRIMARY LOCALIZED DISEASE (SACRO). INTERIM ANALYSIS
Lorenzo Andreani
Favorite
Andreou, Dimosthenis

Medical University of Graz
(P 133) TEN RECOMMENDATIONTS FOR SARCOMA SURGERY: CONSENSUS OF THE SURGICAL SOCIETIES BASED ON THE GERMAN S3 GUIDELINE "ADULT SOFT TISSUE SARCOMA"
Dimosthenis Andreou
Favorite
(P 138) CONTROVERSIES IN THE MANAGEMENT OF PATIENTS WITH SOFT TISSUE SARCOMA: RESULTS AND RECOMMENDATIONS FROM THE FIRST CONFERENCE ON STATE OF SCIENCE IN SARCOMA (CSSS)
Dimosthenis Andreou
Favorite
(P 458) FREQUENCY IN CHANGE OF GRADING UPON LOCAL RECURRENCE OR DISTANT METASTASIS OF SOFT TISSUE SARCOMAS.
Dimosthenis Andreou
Favorite
(P 538) IEUROEWING TRIAL FOR LOCALIZED AND METASTATIC EWING SARCOMA
Dimosthenis Andreou
Favorite
Andrianov, Vasily

Inhibrx, Inc
(P 29) COMBINATION TREATMENT WITH TEMOZOLOMIDE AND THE DEATH RECEPTOR-5 AGONIST INBRX-109 EFFECTIVELY TARGETS SUCCINATE DEHYDROGENASE -DEFICIENT GASTROINTESTINAL STROMAL TUMOR
Vasily Andrianov
Favorite
(P 439) THE TETRAVALENT DEATH RECEPTOR 5 AGONIST INBRX-109 COMBINED WITH CHEMOTHERAPY IN EWING SARCOMA: PRELIMINARY DATA FROM A PHASE 1 STUDY
Vasily Andrianov
Favorite
Andrulis, Irene

The Lunenfeld-Tanenbaum Research Institute, Sinai Health System University of Toronto
(P 249) INVESTIGATING CLINICAL FACTORS ASSOCIATED WITH THE ESTABLISHMENT OF SUCCESSFUL PRIMARY HUMAN SOFT TISSUE SARCOMA CELL LINES
Irene Andrulis
Favorite
(P 352) DETERMINING THE CONTRIBUTIONS OF STAT1 TO THE UPS ANTI-TUMOR MICROENVIRONMENT
Irene Andrulis
Favorite
Angele, Martin

LMU University Hospital
(P 153) PRIORITY SETTING PARNTERSHIP RETROPERITONEAL SOFT TISSUE SARCOMAS
Martin Angele
Favorite
(P 348) RESECTION OF RECURRENT RETROPERITONEAL SOFT TISSUE SARCOMAS: ARE INTENSIVE MULTIMODAL TREATMENTS ASSOCIATED WITH INCREASED PERIOPERATIVE MORBIDITY?
Martin Angele
Favorite
Angeles, Christina

Department of Surgery, Rogel Cancer Center, University of Michigan
(P 293) GENERATION OF A SPONTANEOUS IMMUNOCOMPETENT MOUSE MODEL OF LIPOSARCOMA
Christina Angeles
Favorite
(P 342) THE EVALUATION AND OUTCOMES OF MESENTERIC AND INTRA-ABDOMINAL DESMOIDS: A TARPSWG STUDY
Christina Angeles
Favorite
(P 449) CIC-DUX4 sarcomas: A single-center review of clinical features and molecular aberrations identified through DNA sequencing
Christina Angeles
Favorite
Angelov, Lilyana

Cleveland Clinic
(P 308) OPTIMAL BIOLOGIC EFFECTIVE DOSE OF STEREOTACTIC BODY RADIOTHERAPY FOR METASTATIC AND RECURRENT SARCOMA
Lilyana Angelov
Favorite
Anjier, Ariana

University of Texas MD Anderson
(P 101) EPIGENETIC MODULATION OF NK CELLS IMPROVES TUMOR TRAFFICKING AND ENHANCES THERAPEUTIC EFFICACY AGAINST OSTEOSARCOMA
Ariana Anjier
Favorite
(P 122) TARGETING CD70 USING CAR NK CELLS TO ENHANCE NK CELLS CYTOLYTIC EFFECT AGAINST OSTEOSARCOMA
Ariana Anjier
Favorite
Anjo, Kenta

National Cancer Center Hospital
(P 10) ATEZOLIZUMAB IN JAPANESE PATIENTS WITH ADVANCED ALVEOLAR SOFT PART SARCOMA: A MULTI-CENTER, SINGLE-ARM, INVESTIGATOR-INITIATED PHASE 2 TRIAL (NCCH1907)
Kenta Anjo
Favorite
Annett, Alva

Research Institute of the McGill University Health Center
(P 64) OSTEOSARCOMA. PATIENT-DERIVED XENOGRAFTS MODELS TO RECAPITULATE PATIENTS' CHEMORESISTANCE AND METASTATIC DISEASE
Alva Annett
Favorite
(P 379) THE ROLE OF EZHIP IN DRIVING AGGRESSIVE OSTEOSARCOMA
Alva Annett
Favorite
Antkowiak, Mark

Department of Surgery, Division of Surgical Oncology, University of California San Diego
(P 28) RETROSPECTIVE ANALYSIS OF SUCCINATE DEHYDROGENASE (SDH)-DEFICIENT GASTROINTESTINAL STROMAL TUMOR (GIST) OUTCOMES: AN INTERNATIONAL STUDY OF 256 PATIENTS
Mark Antkowiak
Favorite
Antonescu, Cristina

Memorial Sloan Kettering Cancer Center
(P 24) COMPREHENSIVE ANALYSIS OF THE GENOMIC LANDSCAPE AND CLINICAL BEHAVIOR IN GIST USING NEXT GENERATION SEQUENCING (NGS, MSK-IMPACT)
Cristina Antonescu
Favorite
(P 257) CHARACTERIZING THE EVOLUTION AND THERAPEUTIC RESPONSE OF UNDIFFERENTIATED PLEOMORPHIC SARCOMAS USING MOUSE MODELS
Cristina Antonescu
Favorite
Antony, Mathew

MD Anderson cancer center
(P 221) EARLY RESULTS IN NOVEL USE OF CONTRAST-ENHANCED SUSCEPTIBILITY-WEIGHTED IMAGING IN THE ASSESSMENT OF RESPONSE AND PROGRESSION IN DESMOID FIBROMATOSIS: PILOT STUDY IN A SPECIALIZED CANCER INSTITUTION
Mathew Antony
Favorite
(P 239) CANCER RADIOMIC AND PERFUSION IMAGING (CARPI) AUTOMATED FRAMEWORK: VALIDATION ON MUSCULOSKELETAL TUMORS IN A SPECIALIZED CANCER CENTER
Mathew Antony
Favorite
(P 354) ROLE OF APPARENT DIFFUSION COEFFICIENT (ADC) MAP-BASED FIRST AND HIGH-ORDER RADIOMIC FEATURES IN DISCRIMINATING SACRAL CHORDOMAS AND CHONDROSARCOMAS WITH OVERLAPPING CONVENTIONAL IMAGING FEATURES
Mathew Antony
Favorite
(P 356) BASELINE AND POST-TREATMENT ADVANCED MRI OF EXTREMITIES SOFT-TISSUE NON-MYXOID UNDIFFERENTIATED PLEOMORPHIC SARCOMA.
Mathew Antony
Favorite
(P 357) APPARENT DIFFUSION COEFFICIENT (ADC) HIGH-ORDER RADIOMICS OF BASELINE AND POST-TREATMENT ADVANCED MRI OF EXTREMITY SOFT-TISSUE NON-MYXOID UNDIFFERENTIATED PLEOMORPHIC SARCOMA.
Mathew Antony
Favorite
(P 358) CONTRAST-ENHANCED SUSCEPTIBILITY IMAGING (CE-SWI) MORPHOLOGIC, FIRST & HIGH-ORDER RADIOMIC FEATURES VALUE IN ASSESSING TREATMENT RESPONSE IN EXTREMITY SOFT-TISSUE UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Mathew Antony
Favorite
(P 359) ROLE OF PERFUSION WEIGHTED IMAGING WITH DYNAMIC CONTRAST ENHANCED (PWI/DCE) FOR THE TREATMENT ASSESSMENT OF EXTREMITY SOFT-TISSUE NON-MYXOID UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Mathew Antony
Favorite
Anwar, Hanny

Royal National Orthopaedic Hospital
(P 561) EXPERIENCE OF PHYSICAL DISABILITIES AND CANCER-RELATED QUALITY OF LIFE AFTER SPINAL TUMORS- STUDY OF A NATIONAL SURVEY IN ENGLAND.
Hanny Anwar
Favorite
Aoyama, Ryoma

Tokyo Dental College Ichikawa General Hospital
(P 87) ANGIOSARCOMA OF THE ILIUM TREATED WITH HEMIPELVECTOMY AND HIP TRANSPOSITION FOLLOWED BY POSTOPERATIVE CHEMOTHERAPY WITH PAZOPANIB: A CASE REPORT
Ryoma Aoyama
Favorite
Apfelbaum, April

Dana Farber Cancer Institute
(P 448) CAF-LIKE EWING SARCOMA CELLS DEPOSIT PRO-TUMORIGENIC EXTRACELLULAR MATRIX IN RESPONSE TO TGF-BETA SIGNALING
April Apfelbaum
Favorite
Apicelli, Anthony

Washington University in St Louis
(P 187) PALLIATIVE LATTICE STEREOTACTIC BODY RADIOTHERAPY FOR PATIENTS WITH SARCOMA
Anthony Apicelli
Favorite
Apollonio, Giulia

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 431) TREATMENT STRATEGY AND PROGNOSTIC FACTORS IN EXTRASKELETAL EWING SARCOMA: AN INSTITUTIONAL RETROSPECTIVE ANALYSIS
Giulia Apollonio
Favorite
(P 432) LONG-LASTING DISEASE CONTROL WITH TRABECTEDIN IN A CASE OF METASTATIC EWSR1::PATZ1 SARCOMA
Giulia Apollonio
Favorite
Apostolidis, Leonidas

National Center for Tumor Diseases (NCT) Heidelberg
(P 27) A MULTICENTER RETROSPECTIVE STUDY ON THE CLINICAL BEHAVIOR OF SDH-DEFICIENT GIST
Leonidas Apostolidis
Favorite
Applebaum, Mark

Comer Children's Hospital/University of Chicago
(P 03) EVOLUTION OF CLINICALLY ACTIONABLE VARIANTS IN ADVANCED PEDIATRIC AND AYA BONE SARCOMAS
Mark Applebaum
Favorite
Appolloni, Viviana

Italian Sarcom Group
(P 74) SACRAL CHORDOMA: A RANDOMIZED & OBSERVATIONAL STUDY ON SURGERY VS DEFINITIVE RADIOTHERAPY IN PRIMARY LOCALIZED DISEASE (SACRO). INTERIM ANALYSIS
Viviana Appolloni
Favorite
(P 144) IMPLEMENTATION OF THE EUROPEAN CLINICAL TRIAL REGULATION: SURVEY OF THE ITALIAN SARCOMA GROUP CENTERS
Viviana Appolloni
Favorite
(P 378) MULTIOMICS PROFILING OF EPITHELIOID SARCOMA UNVEILS EPIGENETIC CIRCUITRIES THAT UNDERLIE THE PATHOBIOLOGY OF PROXIMAL AND CLASSIC SUBTYPES: RESULTS FROM THE ISG EPISOBS OBSERVATIONAL STUDY
Viviana Appolloni
Favorite
Arakaki, Motoko

National Cancer Center Hospital
(P 10) ATEZOLIZUMAB IN JAPANESE PATIENTS WITH ADVANCED ALVEOLAR SOFT PART SARCOMA: A MULTI-CENTER, SINGLE-ARM, INVESTIGATOR-INITIATED PHASE 2 TRIAL (NCCH1907)
Motoko Arakaki
Favorite
Arakawa, Ayumu

Department of Pediatric Oncology, National Cancer Center Hospital, Tokyo, Japan
(P 80) OPTIMIZING DOSE OF MAP THERAPY FOR CHILDREN, YOUNG ADULTS AND ADULTS WITH OSTEOSARCOMA; A SINGLE-CENTRE RETROSPECTIVE ANALYSIS
Ayumu Arakawa
Favorite
Araujo, Dejka

The University of Texas MD Anderson Cancer Center
(P 36) CLINICO-GENOMIC ANALYSIS OF KIT/PDGFRA/SDH WILD-TYPE GASTROINTESTINAL STROMAL TUMORS IDENTIFIES POTENTIAL DRIVER MUTATIONS
Dejka Araujo
Favorite
(P 71) CHEMOTHERAPY AND PROGNOSTIC SIGNIFICANCE OF EXTENT OF DEDIFFERENTIATION IN DEDIFFERENTIATED PAROSTEAL OSTEOSARCOMA
Dejka Araujo
Favorite
(P 100) HISTOLOGY SPECIFIC INTRATUMORAL B-CELL BIOLOGY IN ALVEOLAR SOFT-PART SARCOMAS (ASPS) IN RESPONSE TO DURVALUMAB-TREMELIMUMAB (D-T)
Dejka Araujo
Favorite
(P 123) DEDIFFERENTIATED LIPOSARCOMAS TREATED WITH IMMUNE CHECKPOINT BLOCKADE: THE MD ANDERSON EXPERIENCE
Dejka Araujo
Favorite
(P 256) EFFICACY AND TOXICITY OF VERTEPORFIN IN COMBINATION WITH PAZOPANIB TESTED IN A PATIENT-DERIVED SYNOVIAL SARCOMA XENOGRAFT
Dejka Araujo
Favorite
(P 394) LEIOMYOSARCOMA INTRATUMORAL MACROPHAGE INFILTRATES ARE ASSOCIATED WITH DISTINCT CLINICAL AND GENOMIC PRESENTATIONS
Dejka Araujo
Favorite
Archambaud, Baptiste

Gustave Roussy
(P 212) REPORT ON THE EWING SARCOMA PATIENTS ENROLLED IN ARM D OF THE ACSE-ESMART TRIAL: PHASE I/II STUDY OF THE PARP INHIBITOR OLAPARIB IN COMBINATION WITH IRINOTECAN IN CHILDREN WITH ADVANCED MALIGNANCIES
Baptiste Archambaud
Favorite
Argraves, Kelley

Clear Cell Sarcoma Foundation
(P 20) CLEAR CELL SARCOMA: PATIENT REPORTED REAL WORLD EVIDENCE
Kelley Argraves
Favorite
Arguello, Alexandra

Mayo Clinic
(P 02) PEDIATRIC SYNOVIAL SARCOMA: A REVIEW OF 21 CASES FROM A SINGLE INSTITUTION
Alexandra Arguello
Favorite
(P 59) CHONDROSARCOMA OF THE FLAT BONES: DIFFERENTIAL SURVIVAL BETWEEN HIGH GRADE LESIONS OF THE PELVIS AND SCAPULA
Alexandra Arguello
Favorite
(P 60) SKIP LESIONS IN CHONDROSARCOMA: IS WHOLE BONE IMAGING NECESSARY?
Alexandra Arguello
Favorite
(P 61) ADJACENT VENOUS TUMOR THROMBUS IN PRIMARY OSTEOSARCOMA OF THE PELVIS AND EXTREMITIES
Alexandra Arguello
Favorite
(P 62) PROSTHESIS-ASSOCIATED SARCOMA: A REVIEW OF 8 HIGH-GRADE LESIONS ARISING AROUND A TOTAL JOINT ARTHROPLASTY IMPLANT
Alexandra Arguello
Favorite
(P 440) LONG TERM OUTCOMES OF EWING SARCOMA OF THE FOOT AND ANKLE
Alexandra Arguello
Favorite
(P 465) UNPLANNED EXCISION OF SYNOVIAL SARCOMA: FACTORS ASSOCIATED WITH RECURRENCE AND SURVIVAL
Alexandra Arguello
Favorite
(P 482) COMPARISON OF RECONSTRUCTIVE TECHNIQUES FOR METASTATIC DISEASE IN THE PROXIMAL HUMERUS
Alexandra Arguello
Favorite
(P 491) COMPARISON OF FIXATION TECHNIQUES FOR METASTATIC DISEASE OF THE HUMERUS
Alexandra Arguello
Favorite
Ariel, Gal

Tel Aviv Medical Center
(P 240) IDENTIFYING PATIENTS AT HIGH RISK OF HIP FRACTURE DUE TO BONE TUMORS BY COMPUTATIONAL BIOMECHANICS: A RANDOMIZED PROSPECTIVE CLINICAL STUDY
Gal Ariel
Favorite
Armiraglio, Elisabetta

ASST Gaetano Pini - CTO
(P 431) TREATMENT STRATEGY AND PROGNOSTIC FACTORS IN EXTRASKELETAL EWING SARCOMA: AN INSTITUTIONAL RETROSPECTIVE ANALYSIS
Elisabetta Armiraglio
Favorite
Armstrong, Amy

Washington University, St. Louis Children’s Hospital
(P 542) ENROLLMENT OF PEDIATRIC PARTICIPANTS WITH MAGE-A4-POSITIVE SOLID TUMORS IN A PHASE 1/2, OPEN-LABEL, BASKET TRIAL OF AFAMITRESGENE AUTOLEUCEL ("AFAMI-CEL")
Amy Armstrong
Favorite
Armstrong, Valerie

Mayo Clinic, Arizona
(P 141) TREATMENT VARIABILITY IN SURGICAL MANAGEMENT OF PULMONARY OLIGOMETASTATIC SOFT TISSUE SARCOMA
Valerie Armstrong
Favorite
Arndt, Carola

Mayo Clinic
(P 165) MIDDLE EAR RHABDOMYOSARCOMA: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP
Carola Arndt
Favorite
Arnold, Michael

Children's Hospital of Colorado/University of Colorado
(P 409) IMMUNOHISTOCHEMICAL STAINING FOR MYOGENIN, AP2 BETA AND HMGA2 PREDICT FOXO1 FUSION STATUS IN RHABDOMYOSARCOMA: A REPORT FROM THE SOFT TISSUE COMMITTEE OF THE CHILDREN'S ONCOLOGY GROUP
Michael Arnold
Favorite
(P 425) CHARACTERIZATION OF RHABDOMYOSARCOMA WITH PAX7::FOXO1 FUSIONS: A REPORT FROM THE SOFT TISSUE COMMITTEE OF THE CHILDREN'S ONCOLOGY GROUP
Michael Arnold
Favorite
(P 438) ALVEOLAR RHABDOMYOSARCOMA WITH "BURKITT-LIKE" MORPHOLOGY IS ASSOCIATED WITH HIGH AMPLIFICATION OF MYCL
Michael Arnold
Favorite
Arora, Arshia

University of Miami
(P 158) SORAFENIB OR ANTHRACYCLINE-BASED CHEMOTHERAPY IN ADULT PATIENTS WITH PROGRESSIVE DESMOID TUMORS
Arshia Arora
Favorite
Arora, Puneet R

Director, Center for Infertility and Assisted Reproduction (CIFAR), Gurugram, India
(P 06) ONCOFERTILITY AND PREGNANCY IN ADOLESCENT AND YOUNG ADULT CANCERS: PHYSICIANS' KNOWLEDGE AND PREFERENCES IN A LARGE LOW-MIDDLE- INCOME COUNTRY
Puneet R Arora
Favorite
Arostegui, Martin

Biomedical Research Centre, University of British Columbia
(P 267) NEW MOUSE MODEL OF SYNOVIAL SARCOMA BASED ON CONDITIONAL EXPRESSION IN MESENCHYMAL PROGENITORS
Martin Arostegui
Favorite
Arpey, Nicholas

University of Florida
(P 474) PREDICTORS OF EARLY INTROWTH AND FAILURE FOLLOWING SHORT COMPRESS SPINDLE OSSEOINTEGRATION FIXATION AT THE LOWER EXTREMITIES
Nicholas Arpey
Favorite
Arpey, Nicholas

Northwestern Medicine
(P 481) CUSTOM ADAPTERS FOR COMPRESS SPINDLE OSSEOINTEGRATION FIXATION IN REVISION LIMB SALVAGE SURGERY OF THE DISTAL FEMUR: A CASE SERIES
Nicholas Arpey
Favorite
Arregui Valles, Marta

Medical Oncology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain
(P 517) PULMONARY METASTASECTOMY FOR SARCOMA: A SINGLE-INSTITUTION EXPERIENCE
Marta Arregui Valles
Favorite
Arrighetti, Noemi

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 109) INTENSE PRECLINICAL ACTIVITY BY B7H3-SPECIFIC CAR.CIK LYMPHOCYTES AGAINST EPITHELIOID SARCOMA
Noemi Arrighetti
Favorite
(P 272) A COMPARATIVE ASSESSMENT OF SELINEXOR WITH TRABECTEDIN OR LURBINECTEDIN IN PATIENT-DERIVED XENOGRAFTS (PDX) OF DEDIFFERENTIATED LIPOSARCOMA (DDLPS)
Noemi Arrighetti
Favorite
Arslan, Emre

The University of Texas MD Anderson Cancer Center
(P 426) MULTI-OMIC ANALYSIS OF DESMOPLASTIC SMALL ROUND CELL TUMORS REVEAL DISTINCT LINEAGES
Emre Arslan
Favorite
Arthur, Amani

The Institute of Cancer Research
(P 410) PROTEOMICS ANALYSIS IDENTIFIES A SIGNATURE THAT IMPROVES PROGNOSTIC RISK STRATIFICATION OF THE SARCULATOR NOMOGRAM IN PATIENTS WITH SOFT TISSUE SARCOMAS OF THE EXTREMITIES AND TRUNK WALL
Amani Arthur
Favorite
(P 417) MULTI-OMIC CHARACTERISATION OF MOLECULAR HETEROGENEITY AND NEOADJUVANT THERAPY RESPONSE IN SYNOVIAL SARCOMAS
Amani Arthur
Favorite
Artigas Raventós, Vicenç

Universitat Autònoma de Barcelona
(P 508) DREAM, UTOPIA OR REALISM? PROGNOSTIC FACTORS IN LUNG METASTASECTOMY OF DISSEMINATED SARCOMA DISEASE
Vicenç Artigas Raventós
Favorite
Asencio, Josè

Hospital UniversitarioGregorio Maranon, Madrid, Spain
(P 74) SACRAL CHORDOMA: A RANDOMIZED & OBSERVATIONAL STUDY ON SURGERY VS DEFINITIVE RADIOTHERAPY IN PRIMARY LOCALIZED DISEASE (SACRO). INTERIM ANALYSIS
Josè Asencio
Favorite
Asencio, José Manuel

Department of Surgery, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
(P 385) FIRST IN HUMAN PHASE I TRIAL OF A NOVEL DRUG DELIVERY IMPLANT MATRIX WITH SN-38 (CEB-01) FOR RETROPERITONEAL SOFT TISSUE SARCOMA
José Manuel Asencio
Favorite
Asgharzadeh, Shahab

Children's Hospital Los Angeles
(P 166) SARC038: A PHASE 2 STUDY OF REGORAFENIB IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH REFRACTORY OR RECURRENT OSTEOSARCOMA
Shahab Asgharzadeh
Favorite
Assmann, Yan

Mayo Clinic
(P 99) M2 MACROPHAGE INFILTRATION IS ASSOCIATED WITH EARLY DISEASE RECURRENCE FOLLOWING CURATIVE INTENT SURGICAL RESECTION IN SOFT-TISSUE SARCOMAS
Yan Assmann
Favorite
Atchison, TJ

The Ohio State University College of Medicine
(P 314) PRE-OPERATIVE RADIATION THERAPY INCREASES ADHERENCE IN PATIENTS WITH HIGH-RISK EXTREMITY SOFT TISSUE SARCOMA
TJ Atchison
Favorite
Atkins, Marvin

Houston Methodist Research Institute
(P 405) PRIMARY CARDIAC ANGIOSARCOMA- GENOMIC AND MOLECULAR LANDSCAPE
Marvin Atkins
Favorite
Attar, Samer

Northwestern Memorial Hospital
(P 219) ELECTIVE DISCONTINUATION OF SORAFENIB TREATMENT IN DESMOID TUMORS: A RETROSPECTIVE ANALYSIS WITH IMPLICATIONS FOR CLINICAL PRACTICE
Samer Attar
Favorite
(P 474) PREDICTORS OF EARLY INTROWTH AND FAILURE FOLLOWING SHORT COMPRESS SPINDLE OSSEOINTEGRATION FIXATION AT THE LOWER EXTREMITIES
Samer Attar
Favorite
(P 475) PRE-PLATING PRIOR TO INTERCALARY TUMOR RESECTION AND ALLOGRAFT RECONSTRUCTION: LESSONS LEARNED
Samer Attar
Favorite
(P 476) FAVORABLE RESULTS FOLLOWING TREATMENT OF UNICAMERAL BONE CYSTS WITH DOXYCYCLINE SCLEROGRAFT TECHNIQUE
Samer Attar
Favorite
(P 477) TREATMENT OF PROXIMAL FEMUR UNICAMERAL BONE CYSTS WITH DOXYCYCLINE SCLEROTHERAPY
Samer Attar
Favorite
(P 478) TREATMENT OF CHONDROBLASTOMA WITH PERCUTANEOUS CRYOABLATION
Samer Attar
Favorite
(P 480) TARGETED MUSCLE REINNERVATION FOR HIP DISARTICULATION - EVALUATION OF EARLY FUNCTIONAL OUTCOMES
Samer Attar
Favorite
(P 481) CUSTOM ADAPTERS FOR COMPRESS SPINDLE OSSEOINTEGRATION FIXATION IN REVISION LIMB SALVAGE SURGERY OF THE DISTAL FEMUR: A CASE SERIES
Samer Attar
Favorite
Attia, Steven

Mayo Clinic
(P 99) M2 MACROPHAGE INFILTRATION IS ASSOCIATED WITH EARLY DISEASE RECURRENCE FOLLOWING CURATIVE INTENT SURGICAL RESECTION IN SOFT-TISSUE SARCOMAS
Steven Attia
Favorite
(P 178) INITIAL RESULTS FROM A PHASE 1 STUDY OF CFT8634, A NOVEL BIFUCTIONAL DEGRADATION ACTIVATING COMPOUND (BIDAC) DEGRADER OF BRD9, IN SYNOVIAL SARCOMA AND SMARCB1-NULL TUMORS
Steven Attia
Favorite
(P 180) HEALTH RELATED QUALITY OF LIFE OF PATIENTS WITH ADVANCED LEIOMYOSARCOMA AND OTHER SOFT TISSUE SARCOMAS TREATED WITH CABOZANTINIB AND TEMOZOLOMIDE
Steven Attia
Favorite
(P 182) UPDATED RESULTS FROM AN ONGOING PHASE 1B STUDY OF UNESBULIN (PTC596) PLUS DACARBAZINE FOR THE TREATMENT OF PATIENTS WITH ADVANCED LEIOMYOSARCOMA
Steven Attia
Favorite
(P 191) SARC024 COHORT D: PHASE 2 TRIAL OF REGORAFENIB IN CHILDREN, ADOLESCENTS, AND ADULTS WITH RHABDOMYOSARCOMA
Steven Attia
Favorite
Attwood, Kristopher

Roswell Park Comprehensive Cancer Center
(P 247) HARNESSING EWING SARCOMA'S REPLICATION STRESS BY TARGETING DDK AND WEE1 IN COMBINATION
Kristopher Attwood
Favorite
Auger, Alexandra

CIUSSS Est-de-l'Île-de-Montréal
(P 134) IMPACT OF THE PARTNERSHIP BETWEEN TERTIARY CENTERS AND NON-SARCOMA RADIOLOGY CENTERS.
Alexandra Auger
Favorite
Ługowska, Iwona

Early Phase Clinical Trials Unit, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.
(P 09) A NOMOGRAM MODEL TO PREDICT THE OVERALL SURVIVAL OF ADOLESCENT AND YOUNG ADULT PATIENTS WITH LOCALLY ADVANCED EWING SARCOMA.
Iwona Ługowska
Favorite
(P 222) EXPLORING THE IMPACT OF NGS ON DIAGNOSTICS AND TREATMENT OF SARCOMA: INSIGHTS FROM REAL-WORLD DATA ACROSS MULTIPLE INSTITUTIONS IN EUROPE
Iwona Ługowska
Favorite
A
Augustin, Yolanda

The Royal Marsden Hospital
(P 318) DEVELOPMENT OF NOVEL OUTLINING GUIDELINES FOR NORMAL TISSUE STRUCTURES FOR LIMB SOFT TISSUE SARCOMA.
Yolanda Augustin
Favorite
Aukhadieva, Aida

BostonGene, Corp.
(P 420) COMPREHENSIVE MOLECULAR PROFILING AND TUMOR MICROENVIRONMENT CHARACTERISTICS OF RADIATION-INDUCED SARCOMA.
Aida Aukhadieva
Favorite
Austin, Emma

University College Hospital London
(P 321) IDENTIFYING RISK FACTORS FOR REDUCTION OF PROTON THERAPY RE-PLANS FOR PAEDIATRIC PATIENTS WITH PELVIC SARCOMAS
Emma Austin
Favorite
Austin, Shannon

Oregon State University
(P 179) PILOT STUDY OF A REMOTELY DELIVERED RESISTANCE EXERCISE TRAINING PROGRAM IN SARCOMA SURVIVORS
Shannon Austin
Favorite
Avutu, Viswatej

Memorial Sloan Kettering Cancer Center and the Weill Cornell College of Medicine
(P 24) COMPREHENSIVE ANALYSIS OF THE GENOMIC LANDSCAPE AND CLINICAL BEHAVIOR IN GIST USING NEXT GENERATION SEQUENCING (NGS, MSK-IMPACT)
Viswatej Avutu
Favorite
Azad, Nilofer

Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital
(P 164) INTRATUMORAL INT230-6 (CISPLATIN, VINBLASTINE, SHAO) ALONE OR WITH IPILIMUMAB PROLONGED SURVIVAL WITH FAVORABLE SAFETY AND IMMUNE ACTIVATION IN ADULTS WITH REFRACTORY SARCOMAS (NCT 03058289)
Nilofer Azad
Favorite
Azinovic, Ignacio

HU Fundación Jimenez Díaz
(P 175) TRABECTEDIN PLUS RADIOTHERAPY ON SYMPHTOMATIC ADVANCED SARCOMA PATIENTS, RESULTS FROM THE SYNERGIAS STUDY: A SPANISH GROUP FOR RESEARCH IN SARCOMA (GEIS) PHASE II STUDY
Ignacio Azinovic
Favorite
Azuma, Satoshi

National Cancer Center Hospital
(P 547) A PHASE II TRIAL OF TAZEMETOSTAT FOR PATIENTS WITH UNRESECTABLE OR METASTATIC EPITHELIOID SARCOMA (TAZETTA TRIAL)
Satoshi Azuma
Favorite
B
Babichev, Yael

Sinai Healthcare System
(P 108) EFFECT OF TUMOUR-TARGETED HYPERTHERMIA AND CHEMOTHERAPY ON THE IMMUNE PROFILE OF A MURINE MODEL OF EMBRYONAL RHABDOMYOSARCOMA
Yael Babichev
Favorite
(P 249) INVESTIGATING CLINICAL FACTORS ASSOCIATED WITH THE ESTABLISHMENT OF SUCCESSFUL PRIMARY HUMAN SOFT TISSUE SARCOMA CELL LINES
Yael Babichev
Favorite
(P 260) TARGETING HOMOLOGOUS RECOMBINATION DEFICIENCY (HRD) IN LEIOMYOSARCOMA WITH COMBINATION OF PARP INHIBITORS (PARPI) AND CHEMOTHERAPY (CTX).
Yael Babichev
Favorite
(P 265) SELECTIVE TARGETING OF BET FAMILY EPIGENETIC REGULATORS IN ADVANCED AND METASTATIC ALVEOLAR RHABDOMYOSARCOMA
Yael Babichev
Favorite
(P 421) USING TRANSCRIPTOMICS TO IDENTIFY LEIOMYOSARCOMA PATIENTS AT RISK OF METASTASIS
Yael Babichev
Favorite
BABIN, Guillaume

Oncological department of Institut Bergonié
(P 521) HOW TO MANAGE ABDOMINAL PARIETECTOMY, REVIEW OF EXPERIENCE IN INSTITUT BERGONIE
Guillaume BABIN
Favorite
Badalamenti, Giuseppe

Policlinico P. Giaccone
(P 49) EFFICACY OF RIPRETINIB IN A MULTICENTER EXPANDED ACCESS PROGRAM IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS HARBOURING NON-KIT EXON 11 MUTATIONS.
Giuseppe Badalamenti
Favorite
(P 159) IN BETWEEN OF LYMPHOMAS AND SARCOMAS: WHERE DO HISTIOCYTIC AND DENDRITIC CELL NEOPLASMS (HDCN) STAND? A RETROSPECTIVE, MULTI-INSTITUTIONAL STUDY FROM THE ITALIAN SARCOMA GROUP (ISG)
Giuseppe Badalamenti
Favorite
Badgett, Thomas

University of Kentucky College of Medicine
(P 551) PHASE II TRIAL OF GEMCITABINE AND NAB-PACLITAXEL IN PATIENTS WITH RECURRENT RHABDOMYOSARCOMA: A CLINICAL TRIAL IN PROGRESS FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION
Thomas Badgett
Favorite
Badiyan, Shahed

Washington University in St Louis
(P 187) PALLIATIVE LATTICE STEREOTACTIC BODY RADIOTHERAPY FOR PATIENTS WITH SARCOMA
Shahed Badiyan
Favorite
Baecklund, Fredrik

Stockholm, Karolinska University Hospital
(P 73) FOSTER CONSORTIUM, FIGHT OSTEOSARCOMA THROUGH EUROPEAN RESEARCH
Fredrik Baecklund
Favorite
Baelde, Hans

LUMC
(P 368) DECODING THE IMMUNOGENOMIC DETERMINANTS OF RADIOTHERAPY RESPONSE IN SOFT TISSUE SARCOMAS
Hans Baelde
Favorite
Bae, Susie

Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
(P 189) INTERNATIONAL RETROSPECTIVE STUDY FROM THE ULTRA-RARE SARCOMA WORKING GROUP ON LOW-GRADE FIBROMYXOID SARCOMA AND SCLEROSING EPITHELIOD FIBROSARCOMA: OUTCOME OF ADVANCED DISEASE AND SYSTEMIC THERAPIES
Susie Bae
Favorite
Bagaev, Alexander

BostonGene, Corp.
(P 420) COMPREHENSIVE MOLECULAR PROFILING AND TUMOR MICROENVIRONMENT CHARACTERISTICS OF RADIATION-INDUCED SARCOMA.
Alexander Bagaev
Favorite
Bagaria, Sanjay

Mayo Clinic
(P 99) M2 MACROPHAGE INFILTRATION IS ASSOCIATED WITH EARLY DISEASE RECURRENCE FOLLOWING CURATIVE INTENT SURGICAL RESECTION IN SOFT-TISSUE SARCOMAS
Sanjay Bagaria
Favorite
Bagué, Silvia

Hospital de la Santa Creu i Sant Pau
(P 507) PRIMARY CHEST WALL TUMORS OF MESENCHYMAL ORIGIN. EXPERIENCE OF A REFERENCE UNIT
Silvia Bagué
Favorite
(P 508) DREAM, UTOPIA OR REALISM? PROGNOSTIC FACTORS IN LUNG METASTASECTOMY OF DISSEMINATED SARCOMA DISEASE
Silvia Bagué
Favorite
Bague, Silvia

Hospital de la Santa Creu i Sant Pau
(P 313) SPACIALLY-FRACTIONATED RADIOTHERAPY (LATTICE) TREATMENT IN INOPERABLE NON-EXTREMITY BULKY SOFT-TISSUE SARCOMAS
Silvia Bague
Favorite
(P 503) SCAPULAR PROSTHESIS RECONSTRUCTION, EXPERIENCE IN OUR INSTITUTION
Silvia Bague
Favorite
(P 504) WHY DO SOME PATIENTS WITH SYNOVIAL SARCOMA HAVE BETTER FUNCTIONAL OUTCOMES AFTER RESECTION SURGERY? ANALYSIS OF 102 CASES
Silvia Bague
Favorite
Baia, Marco

Sarcoma Service, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
(P 126) CURRENT PRACTICE IN SPERMATIC CORD SARCOMA: ONCOLOGICAL TIMELINES AND OUTCOMES ACCORDING TO INITIAL RESECTIONS PERFORMED AT A LOCAL HOSPITAL VERSUS EARLY PATIENT REFERRAL TO A TERTIARY CENTRE.
Marco Baia
Favorite
(P 329) DISTANT METASTASIS IN RETROPERITONEAL LEIOMYOSARCOMA: TUMOR SIZE, GRADE AND MORE?
Marco Baia
Favorite
Bailey, Kelly

University of Pittsburgh School of Medicine
(P 81) OPTIMIZING EWING SARCOMA AND OSTEOSARCOMA BIOPSY ACQUISITION: CONSENSUS RECOMMENDATIONS FROM THE CHILDREN'S ONCOLOGY GROUP BONE TUMOR COMMITTEE
Kelly Bailey
Favorite
Baird, John

PTC Therapeutics, Inc.
(P 182) UPDATED RESULTS FROM AN ONGOING PHASE 1B STUDY OF UNESBULIN (PTC596) PLUS DACARBAZINE FOR THE TREATMENT OF PATIENTS WITH ADVANCED LEIOMYOSARCOMA
John Baird
Favorite
(P 548) A PHASE 2/3 STUDY EVALUATING THE EFFICACY AND SAFETY OF UNESBULIN IN ADVANCED LEIOMYOSARCOMA (SUNRISELMS)
John Baird
Favorite
Bajpai, Jyoti

Tata Memorial Centre,Homibhabha National University,Mumbai,India
(P 06) ONCOFERTILITY AND PREGNANCY IN ADOLESCENT AND YOUNG ADULT CANCERS: PHYSICIANS' KNOWLEDGE AND PREFERENCES IN A LARGE LOW-MIDDLE- INCOME COUNTRY
Jyoti Bajpai
Favorite
(P 189) INTERNATIONAL RETROSPECTIVE STUDY FROM THE ULTRA-RARE SARCOMA WORKING GROUP ON LOW-GRADE FIBROMYXOID SARCOMA AND SCLEROSING EPITHELIOD FIBROSARCOMA: OUTCOME OF ADVANCED DISEASE AND SYSTEMIC THERAPIES
Jyoti Bajpai
Favorite
(P 436) OUTCOME PROGNOSTICATORS IN ADOLESCENTS AND ADULTS WITH BONE SARCOMAS IN LOW-MIDDLE-INCOME COUNTRIES
Jyoti Bajpai
Favorite
Baker, Benjamin

Peter MacCallum Cancer Centre
(P 516) OUCOMES OF AGGRESSIVE RESECTION OF RADIATION INDUCED ANGIOSARCOMA OF THE BREAST
Benjamin Baker
Favorite
Bakker, Gertruud

Princess Máxima Center for Pediatric Oncology
(P 558) TRIAL IN PROGRESS: A PHASE 1/2 STUDY OF BRIGATINIB IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH ALK POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA OR INFLAMMATORY MYOFIBROBLASTIC TUMORS (ITCC-098)
Gertruud Bakker
Favorite
Bakkila, Baylee

Yale University
(P 158) SORAFENIB OR ANTHRACYCLINE-BASED CHEMOTHERAPY IN ADULT PATIENTS WITH PROGRESSIVE DESMOID TUMORS
Baylee Bakkila
Favorite
Baldaccini, Davide

IRCCS Humanitas Research Hospital
(P 327) LEARNING CURVE ANALYSIS IN RETROPERITONEAL SARCOMA SURGERY
Davide Baldaccini
Favorite
(P 457) LONG-TERM FOLLOW-UP OF PATIENTS WITH ATYPICAL LIPOMATOUS TUMOR (ALT) TREATED WITH MARGINAL RESECTION IN A REFERRAL CENTER
Davide Baldaccini
Favorite
Baldazzi, Davide

Unit of Oncogenetics and Functional Oncogenomics, Centro di Riferimento Oncologico di Aviano IRCCS, Aviano, Italy
(P 355) FUSION TRANSCRIPTOME PROFILING DEFINES THE MONOCLONAL NATURE OF MULTIFOCAL EPITHELIOID HEMANGIOMA OF BONE
Davide Baldazzi
Favorite
(P 378) MULTIOMICS PROFILING OF EPITHELIOID SARCOMA UNVEILS EPIGENETIC CIRCUITRIES THAT UNDERLIE THE PATHOBIOLOGY OF PROXIMAL AND CLASSIC SUBTYPES: RESULTS FROM THE ISG EPISOBS OBSERVATIONAL STUDY
Davide Baldazzi
Favorite
Baldi, Giacomo Giulio

Medical Oncology Department, "Santo Stefano" Hospital, Prato, Italy
(P 144) IMPLEMENTATION OF THE EUROPEAN CLINICAL TRIAL REGULATION: SURVEY OF THE ITALIAN SARCOMA GROUP CENTERS
Giacomo Giulio Baldi
Favorite
(P 159) IN BETWEEN OF LYMPHOMAS AND SARCOMAS: WHERE DO HISTIOCYTIC AND DENDRITIC CELL NEOPLASMS (HDCN) STAND? A RETROSPECTIVE, MULTI-INSTITUTIONAL STUDY FROM THE ITALIAN SARCOMA GROUP (ISG)
Giacomo Giulio Baldi
Favorite
(P 189) INTERNATIONAL RETROSPECTIVE STUDY FROM THE ULTRA-RARE SARCOMA WORKING GROUP ON LOW-GRADE FIBROMYXOID SARCOMA AND SCLEROSING EPITHELIOD FIBROSARCOMA: OUTCOME OF ADVANCED DISEASE AND SYSTEMIC THERAPIES
Giacomo Giulio Baldi
Favorite
(P 378) MULTIOMICS PROFILING OF EPITHELIOID SARCOMA UNVEILS EPIGENETIC CIRCUITRIES THAT UNDERLIE THE PATHOBIOLOGY OF PROXIMAL AND CLASSIC SUBTYPES: RESULTS FROM THE ISG EPISOBS OBSERVATIONAL STUDY
Giacomo Giulio Baldi
Favorite
(P 455) EXTRASKELETAL EWING SARCOMA: A MULTICENTRIC RETROSPECTIVE STUDY FROM THE ITALIAN SARCOMA GROUP
Giacomo Giulio Baldi
Favorite
Baldwin, Rebecca

Royal National Orthopaedic Hospital
(P 70) ICONIC (IMPROVING OUTCOMES THROUGH COLLABORATION IN OSTEOSARCOMA): A PROSPECTIVE OBSERVATIONAL COHORT STUDY FOR NEWLY DIAGNOSED OSTEOSARCOMA PATIENTS IN THE UNITED KINGDOM (UK)
Rebecca Baldwin
Favorite
Baliga, Sujith

The Ohio State University Wexner Medical Center
(P 315) SCALP VOLUMETRIC MODULATED ARC THERAPY USING 3D MILLED BOLUS: DOSIMITRY, TOXICITY AND OUTCOMES
Sujith Baliga
Favorite
Ballesteros-Perez, Alexandra

Certara
(P 271) PHARMACODYNAMICS AND MECHANISTIC IMPACTS OF FHD-609, A BROMODOMAIN-CONTAINING PROTEIN 9 DEGRADER, IN A PHASE 1 STUDY IN PATIENTS WITH ADVANCED SYNOVIAL SARCOMA OR SMARCB1-LOSS TUMORS
Alexandra Ballesteros-Perez
Favorite
Ball, Howard

Ball Pharma Consulting Group
(P 172) PHASE 2 RESULTS FROM THE RINGSIDE PHASE 2/3 TRIAL OF AL102 FOR TREATMENT OF DESMOID TUMORS
Howard Ball
Favorite
Ballinger, Mandy

Garvan Institute of Medical Research
(P 386) GENOMIC PROFILING OF GYNAECOLOGICAL SARCOMAS: REPORT FROM THE AUSTRALIA-WIDE PRECISION ONCOLOGY PROGRAM
Mandy Ballinger
Favorite
Ballman, Karla

Weil Cornell Graduate School of Medical Sciences
(P 166) SARC038: A PHASE 2 STUDY OF REGORAFENIB IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH REFRACTORY OR RECURRENT OSTEOSARCOMA
Karla Ballman
Favorite
(P 191) SARC024 COHORT D: PHASE 2 TRIAL OF REGORAFENIB IN CHILDREN, ADOLESCENTS, AND ADULTS WITH RHABDOMYOSARCOMA
Karla Ballman
Favorite
(P 541) ETCTN 10563: PHASE 1 STUDY OF PEPOSERTIB AND LIPOSOMAL DOXORUBICIN FOR ADVANCED OR METASTATIC LEIOMYOSARCOMA AND OTHER SARCOMAS
Karla Ballman
Favorite
Bambury, Richard

CUH
(P 213) EXPERIENCE WITH THE USE OF TRABECTEDIN IN ADVANCED SOFT TISSUE SARCOMA IN IRELAND
Richard Bambury
Favorite
Banavali, Shripad D

Tata memorial Centre, Mumbai
(P 06) ONCOFERTILITY AND PREGNANCY IN ADOLESCENT AND YOUNG ADULT CANCERS: PHYSICIANS' KNOWLEDGE AND PREFERENCES IN A LARGE LOW-MIDDLE- INCOME COUNTRY
Shripad D Banavali
Favorite
(P 436) OUTCOME PROGNOSTICATORS IN ADOLESCENTS AND ADULTS WITH BONE SARCOMAS IN LOW-MIDDLE-INCOME COUNTRIES
Shripad D Banavali
Favorite
Bandhlish, Anshu

University of Washington
(P 206) A SINGLE-ARM, PHASE II STUDY OF NEOADJUVANT PEMBROLIZUMAB COMBINED WITH RADIOTHERAPY IN THE PRIMARY TREATMENT OF SOFT TISSUE SARCOMAS.
Anshu Bandhlish
Favorite
Banerjee, Jineta

Sage Bionetworks
(P 250) SHARING HIGH-QUALITY SAMPLES AND DATA TO THE NF1 RESEARCH COMMUNITY: THE ROLE OF THE JOHNS HOPKINS NF1 BIOSPECIMEN REPOSITORY
Jineta Banerjee
Favorite
Banerjee, Tamalina

University of Saskatchewan
(P 148) MOVING TOWARDS THE OPTIMIZATION OF DIAGNOSIS FOR PATIENTS WITH SARCOMA: A 10-YEAR REVIEW OF EXTERNALLY CONSULTED SARCOMA CASES IN A GENERAL ANATOMICAL PATHOLOGY SERVICE
Tamalina Banerjee
Favorite
Banini, Marco

Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, Florence, Italy
(P 317) PROGNOSTIC FACTORS, CLINICAL AND TOXICITY OUTCOMES FROM A LARGE COHORT OF PATIENTS WITH SOFT TISSUE SARCOMA TREATED WITH PREOPERATIVE RADIATION THERAPY
Marco Banini
Favorite
(P 546) PRELIMINARY CLINICAL RESULTS OF AN ONGOING PHASE II TRIAL: SPRINT (SARCOMA PREOPERATIVE RADIATION WITH SIMULTANEOUS INTEGRATED BOOST)
Marco Banini
Favorite
Ban, Joy

Duke Univeristy
(P 375) IDENTIFICATION OF METASTATIC CELLS IN UNDIFFERENTIATED PLEOMORPHIC SARCOMA: SINGLE CELL RNA SEQUENCING AND CIBERSORT ANALYSIS
Joy Ban
Favorite
(P 393) INVESTIGATING THE ROLE OF HDACS IN THE PROGRESSION OF METASTATIC UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Joy Ban
Favorite
Banuet Gonzalez, Diego

David Geffen School of Medicine, University of California, Los Angeles
(P 19) EXTRACELLULAR VESICLE CLICK MAGBEADS: A MULTIFACETED LIQUID BIOPSY PLATFORM FOR PEDIATRIC SARCOMAS
Diego Banuet Gonzalez
Favorite
Banzato, Alberto

Cardiology Unit, Veneto Institute of Oncology IOV - IRCCS
(P 171) SEX DIFFERENCES IN OUTCOMES AND TOXICITY IN PATIENTS TREATED FOR SARCOMA IN A REFERENCE CENTER
Alberto Banzato
Favorite
Bari, Elia

University of Eastern Piedmont - Department of Pharmaceutical Sciences
(P 283) A TRIDIMENSIONAL PRECLINICAL MODEL TO STUDY HUMAN AND CANINE OSTEOSARCOMA DEVELOPMENT AND INTERACTION WITH TUMOR MICROENVIRONMENT
Elia Bari
Favorite
Barisella, Marta

Department of Pathology,Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
(P 272) A COMPARATIVE ASSESSMENT OF SELINEXOR WITH TRABECTEDIN OR LURBINECTEDIN IN PATIENT-DERIVED XENOGRAFTS (PDX) OF DEDIFFERENTIATED LIPOSARCOMA (DDLPS)
Marta Barisella
Favorite
(P 273) COMPARISON OF A PATIENT-DERIVED XENOGRAFTS (PDX) OF MYXOID PLEOMORPHIC LIPOSARCOMA (MPL) AND PLEOMORPHIC LIPOSARCOMA (PL) HIGHLIGHTS THE EFFECTIVENESS OF ERIBULIN IN A PDX OF MPL
Marta Barisella
Favorite
(P 378) MULTIOMICS PROFILING OF EPITHELIOID SARCOMA UNVEILS EPIGENETIC CIRCUITRIES THAT UNDERLIE THE PATHOBIOLOGY OF PROXIMAL AND CLASSIC SUBTYPES: RESULTS FROM THE ISG EPISOBS OBSERVATIONAL STUDY
Marta Barisella
Favorite
Barkholt, Pernille

Adcendo ApS
(P 349) THE UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR-ASSOCIATED PROTEIN (UPARAP) IS AN ATTRACTIVE TARGET FOR THE DEVELOPMENT OF ANTIBODY DRUG CONJUGATES FOR TREATMENT OF MESENCHYMAL MALIGNANCIES
Pernille Barkholt
Favorite
Baron, Leigh-Ann

BC Cancer
(P 22) RECALL EXPERIENCE FOR SURVIVORS OF PEDIATRIC RHABDOMYOSARCOMA TREATED AT A SINGLE INSTITUTION BETWEEN 1970 AND 2010
Leigh-Ann Baron
Favorite
Baron, Max

University of Miami
(P 154) BARRIERS TO CARE FOR MUSCULOSKELETAL TUMORS
Max Baron
Favorite
Barreto coelho, Priscila

University of Miami
(P 128) THE IMPACT OF HISPANIC ETHNICITY IN PRESENTATION AND OUTCOMES OF PATIENTS WITH SYNOVIAL SARCOMA
Priscila Barreto coelho
Favorite
(P 158) SORAFENIB OR ANTHRACYCLINE-BASED CHEMOTHERAPY IN ADULT PATIENTS WITH PROGRESSIVE DESMOID TUMORS
Priscila Barreto coelho
Favorite
(P 225) PAN-SARCOMA DATABASE (PSDB): A MODEL-VIEW-CONTROLLER FRAMEWORK UTILIZING REDCAP, SHINY, AND R TO CREATE A CONTINUOUS PIPELINE OF SARCOMA DATA
Priscila Barreto coelho
Favorite
(P 226) SIGNATERA TESTING TO IDENTIFY MINIMAL RESIDUAL DISEASE IN HIGH GRADE SARCOMA
Priscila Barreto coelho
Favorite
(P 361) MOLECULAR CHARACTERIZATION OF SOLITARY FIBROUS TUMORS BY ANATOMIC SITE AND NAB2::STAT6 FUSION VARIANT TYPE
Priscila Barreto coelho
Favorite
(P 366) SURVIVAL DISPARITIES IN HISPANIC PATIENTS WITH SARCOMA TESTED WITH NEXT-GENERATION SEQUENCING (NGS)
Priscila Barreto coelho
Favorite
(P 461) OUTCOMES FOR OLIGOMETASTATIC PULMONARY DISEASE RECURRENCE TREATED WITH SURGERY ALONE FOR PATIENTS WITH SOFT TISSUE SARCOMAS A CASE SERIES
Priscila Barreto coelho
Favorite
Barretta, Francesco

Fondazione IRCCS IStituto Nazionale dei Tumori, Milan, Italy
(P 329) DISTANT METASTASIS IN RETROPERITONEAL LEIOMYOSARCOMA: TUMOR SIZE, GRADE AND MORE?
Francesco Barretta
Favorite
(P 342) THE EVALUATION AND OUTCOMES OF MESENTERIC AND INTRA-ABDOMINAL DESMOIDS: A TARPSWG STUDY
Francesco Barretta
Favorite
Barrientos De Renshaw, Tomasa

Duke University
(P 393) INVESTIGATING THE ROLE OF HDACS IN THE PROGRESSION OF METASTATIC UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Tomasa Barrientos De Renshaw
Favorite
Barrus, Joshua

The Ohio State University Wexner Medical Center
(P 311) ROBUST VMAT TREATMENT PLANNING FOR EXTREMITY SOFT TISSUE SARCOMAS
Joshua Barrus
Favorite
Barry, Janie

CIUSSS Est-de-l'Île-de-Montréal
(P 134) IMPACT OF THE PARTNERSHIP BETWEEN TERTIARY CENTERS AND NON-SARCOMA RADIOLOGY CENTERS.
Janie Barry
Favorite
Bartelstein, Meredith

Memorial Sloan-Kettering Cancer Center
(P 529) THE MUSCULOSKELETAL TUMOR REGISTRY -- 2023 UPDATE AND OUTLOOK
Meredith Bartelstein
Favorite
Bartholomew, Alex

Duke University
(P 152) EVALUATING DIAGNOSTIC APPROACHES TO DERMATOFIBROSARCOMA PROTUBERANS: AN OPPORTUNITY TO REDUCE THE NUMBER OF INTERVENTIONS
Alex Bartholomew
Favorite
Bartlett, Edmund

Memorial Sloan Kettering Cancer Center
(P 24) COMPREHENSIVE ANALYSIS OF THE GENOMIC LANDSCAPE AND CLINICAL BEHAVIOR IN GIST USING NEXT GENERATION SEQUENCING (NGS, MSK-IMPACT)
Edmund Bartlett
Favorite
(P 343) STEREOTACTIC BODY RADIATION THERAPY (SBRT) IN ADVANCED/RECURRENT RETROPERITONEAL SARCOMA: PRELIMINARY RESULTS
Edmund Bartlett
Favorite
(P 555) A PILOT PHASE II STUDY TO EVALUATE THE SMALL MOLECULE TIGILANOL TIGLATE IN PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA: CLINICAL TRIAL IN PROGRESS
Edmund Bartlett
Favorite
Barve, Rahul

Memorial Sloan Kettering Cancer
(P 323) PERIPHERAL NEUROPATHY FOLLOWING INTRA-OPERATIVE RADIOTHERAPY FOR EXTREMITY SOFT TISSUE SARCOMA: A SINGLE INSTITUTION EXPERIENCE
Rahul Barve
Favorite
Barwad, Adarsh

Department of Pathology, All India Institute of Medical Sciences
(P 562) A PHASE 2, SINGLE ARM STUDY OF REGORAFENIB IN METASTATIC/UNRESECTABLE REFRACTORY SYNOVIAL SARCOMAS
Adarsh Barwad
Favorite
Basar, Rafet

University of Texas MD Anderson
(P 122) TARGETING CD70 USING CAR NK CELLS TO ENHANCE NK CELLS CYTOLYTIC EFFECT AGAINST OSTEOSARCOMA
Rafet Basar
Favorite
Basi, Akshay

The University of Texas MD Anderson Cancer Center
(P 426) MULTI-OMIC ANALYSIS OF DESMOPLASTIC SMALL ROUND CELL TUMORS REVEAL DISTINCT LINEAGES
Akshay Basi
Favorite
Basile, Georges

University of Montreal
(P 134) IMPACT OF THE PARTNERSHIP BETWEEN TERTIARY CENTERS AND NON-SARCOMA RADIOLOGY CENTERS.
Georges Basile
Favorite
Basile, Georges

Hôpital Maisonneuve-Rosemont
(P 245) IN VIVO USE OF RAMAN SPECTROSCOPY IN SOFT TISSUE SARCOMA RESECTION
Georges Basile
Favorite
Basso, Umberto

Oncology 1 Unit, Department of Oncology, Veneto Institute of Oncology IOV - IRCCS
(P 171) SEX DIFFERENCES IN OUTCOMES AND TOXICITY IN PATIENTS TREATED FOR SARCOMA IN A REFERENCE CENTER
Umberto Basso
Favorite
Bastucci, Silvia

IRCCS Istituto Nazionale Tumori Regina Elena
(P 144) IMPLEMENTATION OF THE EUROPEAN CLINICAL TRIAL REGULATION: SURVEY OF THE ITALIAN SARCOMA GROUP CENTERS
Silvia Bastucci
Favorite
Basu Mallick, Atrayee

Thomas Jefferson University Hospital
(P 361) MOLECULAR CHARACTERIZATION OF SOLITARY FIBROUS TUMORS BY ANATOMIC SITE AND NAB2::STAT6 FUSION VARIANT TYPE
Atrayee Basu Mallick
Favorite
(P 401) OVEREXPRESSION OF CYCLIN DEPENDENT KINASES AND CYCLINS ACROSS SARCOMAS BEYOND CDK4
Atrayee Basu Mallick
Favorite
Bauer, Sebastian

Department of Medical Oncology, West German Cancer Center, University Hospital Essen
(P 25) PREDICTING IMATINIB RESPONSES USING IN VITRO MODELS OF PDGFRA-MUTANT GASTROINTESTINAL STROMAL TUMOR
Sebastian Bauer
Favorite
(P 26) PHASE 1 STUDY OF IDRX-42 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS RESISTANT TO PRIOR SYSTEMIC THERAPY: EARLY RESULTS
Sebastian Bauer
Favorite
(P 47) PATIENT SURVIVAL IN METASTATIC GIST WITH IMATINIB-SENSITIVE MUTATIONS: REAL WORLD DATA FROM GERMAN REFERRAL CENTER (2008-2021)
Sebastian Bauer
Favorite
(P 49) EFFICACY OF RIPRETINIB IN A MULTICENTER EXPANDED ACCESS PROGRAM IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS HARBOURING NON-KIT EXON 11 MUTATIONS.
Sebastian Bauer
Favorite
(P 220) [68GA]GA-FAPI PET/CT AS NOVEL DIAGNOSTIC TOOL IN SARCOMA
Sebastian Bauer
Favorite
(P 234) GENOMIC LANDSCAPE OF CLEAR CELL SARCOMA
Sebastian Bauer
Favorite
(P 248) FIBROBLAST ACTIVATION PROTEIN ALPHA -DIRECTED IMAGING AND THERAPY OF SOLITARY FIBROUS TUMOR
Sebastian Bauer
Favorite
(P 275) GIST-BSF1: A NOVEL SCF-DEPENDENT, WILD-TYPE KIT CELL LINE PLATFORM THAT ALLOWS RAPID GENERATION OF ISOGENIC SUBLINES WITH BOTH IMATINIB-SENSITIVE AND IMATINIB-RESISTANT GENOTYPES
Sebastian Bauer
Favorite
(P 276) REVISITING IN- AND OFF LABEL DRUGS FREQUENTLY USED IN METASTATIC GIST USING A BROAD IN VITRO PROFILING PANEL OF PRIMARY AND SECONDARY KIT AND PDGFRA-MUTANT GIST CELLS – CLINICAL IMPLICATIONS
Sebastian Bauer
Favorite
(P 294) DNA-DAMAGE REPAIR DYSREGULATION AND CHEMOTHERAPY RESPONSE IN SARCOMA MODELS
Sebastian Bauer
Favorite
Baumhoer, Daniel

University Hospital Basel
(P 69) DEVELOPMENT AND MISSION OF THE HARMONIZATION INTERNATIONAL BONE SARCOMA CONSORTIUM (HIBISCUS)
Daniel Baumhoer
Favorite
(P 230) SARCDBASE: A TOOL FOR DETECTION OF GENETIC ALTERATIONS IN SARCOMA
Daniel Baumhoer
Favorite
(P 371) DISRUPTION OF THE TP53 LOCUS IN OSTEOSARCOMA LEADS TO TP53 PROMOTER GENE FUSIONS AND RESTORATION OF PARTS OF THE TP53 SIGNALLING PATHWAY
Daniel Baumhoer
Favorite
Beale, Philip

Concord Repatriation General Hospital
(P 386) GENOMIC PROFILING OF GYNAECOLOGICAL SARCOMAS: REPORT FROM THE AUSTRALIA-WIDE PRECISION ONCOLOGY PROGRAM
Philip Beale
Favorite
Beamer, Staci

Mayo Clinic Arizona
(P 141) TREATMENT VARIABILITY IN SURGICAL MANAGEMENT OF PULMONARY OLIGOMETASTATIC SOFT TISSUE SARCOMA
Staci Beamer
Favorite
Beane, Joal

The James Cancer Hospital / The Ohio State University
(P 301) REDUCING THE INVASIVE POTENTIAL OF DEDIFFERENTIATED LIPOSARCOMA BY TARGETING ALTERNATIVE RNA SPLICING MACHINERY
Joal Beane
Favorite
(P 314) PRE-OPERATIVE RADIATION THERAPY INCREASES ADHERENCE IN PATIENTS WITH HIGH-RISK EXTREMITY SOFT TISSUE SARCOMA
Joal Beane
Favorite
(P 347) INCIDENCE AND TIMING OF RECURRENCE AFTER ADJUVANT PALBOCICLIB IN COMPLETELY RESECTED RETROPERITONEAL LIPOSARCOMA
Joal Beane
Favorite
Beaupin, Lynda

Johns Hopkins All Children's Hospital
(P 193) Recent Trends in Sarcoma Trials for Children in the United States
Lynda Beaupin
Favorite
Beckingsale, Thomas

The Newcastle upon Tyne Hospitals NHS Foundation Trust
(P 228) WHAT IS THE SIGNIFICANCE OF INDETERMINATE PULMONARY NODULES IN HIGH GRADE SOFT TISSUE SARCOMA? A RETROSPECTIVE COHORT STUDY
Thomas Beckingsale
Favorite
Bedi, Meena

Medical College of Wisconsin
(P 181) REAL-WORLD EXPERIENCE WITH LIPOSOMAL DOXORUBICIN IN METASTATIC AND LOCALLY ADVANCED SARCOMA
Meena Bedi
Favorite
(P 473) GROIN PAINS: APPROACHES AND OUTCOMES FOR INGUINOFEMORAL SOFT TISSUE SARCOMAS
Meena Bedi
Favorite
Bedke, Jens

Klinikum Stuttgart
(P 133) TEN RECOMMENDATIONTS FOR SARCOMA SURGERY: CONSENSUS OF THE SURGICAL SOCIETIES BASED ON THE GERMAN S3 GUIDELINE "ADULT SOFT TISSUE SARCOMA"
Jens Bedke
Favorite
Bedniagin, Lev

BostonGene, Corp.
(P 420) COMPREHENSIVE MOLECULAR PROFILING AND TUMOR MICROENVIRONMENT CHARACTERISTICS OF RADIATION-INDUCED SARCOMA.
Lev Bedniagin
Favorite
Beeram, Murali

START Center for Cancer Care
(P 66) PHASE I STUDY OF THE MUTANT IDH1 INHIBITOR IVOSIDENIB: LONG-TERM SAFETY AND CLINICAL ACTIVITY IN PATIENTS WITH CONVENTIONAL CHONDROSARCOMA
Murali Beeram
Favorite
Beggs, Andrew

University of Birmingham
(P 282) AN EMBRYONIC ZEBRAFISH XENOGRAFT MODEL OF RHABDOMYOSARCOMA REVEALS GENOTYPE DEPENDENT TUMOUR VASCULARISATION DYNAMICS AND RESPONSE TO ANTI-ANGIOGENIC RECEPTOR TYROSINE KINASE INHIBITORS
Andrew Beggs
Favorite
Beird, Hannah

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
(P 89) GENERATION OF CHONDROCYTE-DERIVED MOUSE OSTEOSARCOMA MODELS - TRACKABLE SYSTEMS TO DELINEATE ONCOGENIC AND METASTATIC ENVENTS PRIOR TO TUMOROGENESIS
Hannah Beird
Favorite
(P 100) HISTOLOGY SPECIFIC INTRATUMORAL B-CELL BIOLOGY IN ALVEOLAR SOFT-PART SARCOMAS (ASPS) IN RESPONSE TO DURVALUMAB-TREMELIMUMAB (D-T)
Hannah Beird
Favorite
(P 256) EFFICACY AND TOXICITY OF VERTEPORFIN IN COMBINATION WITH PAZOPANIB TESTED IN A PATIENT-DERIVED SYNOVIAL SARCOMA XENOGRAFT
Hannah Beird
Favorite
(P 394) LEIOMYOSARCOMA INTRATUMORAL MACROPHAGE INFILTRATES ARE ASSOCIATED WITH DISTINCT CLINICAL AND GENOMIC PRESENTATIONS
Hannah Beird
Favorite
(P 405) PRIMARY CARDIAC ANGIOSARCOMA- GENOMIC AND MOLECULAR LANDSCAPE
Hannah Beird
Favorite
(P 426) MULTI-OMIC ANALYSIS OF DESMOPLASTIC SMALL ROUND CELL TUMORS REVEAL DISTINCT LINEAGES
Hannah Beird
Favorite
Beishuizen, Auke

Princess Máxima Center for Pediatric Oncology
(P 558) TRIAL IN PROGRESS: A PHASE 1/2 STUDY OF BRIGATINIB IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH ALK POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA OR INFLAMMATORY MYOFIBROBLASTIC TUMORS (ITCC-098)
Auke Beishuizen
Favorite
Belayneh, Rebekah

University of Pittsburgh Medical Center
(P 373) DEDIFFERENTIATED AND HIGH GRADE CHONDROSARCOMAS: HOW DOES ISOCITRATE DEHYDROGENASE STATUS APPRISE PROGNOSIS AND THERAPY?
Rebekah Belayneh
Favorite
Belda Sanchis, Josep

Hospital de la Santa Creu i Sant Pau
(P 507) PRIMARY CHEST WALL TUMORS OF MESENCHYMAL ORIGIN. EXPERIENCE OF A REFERENCE UNIT
Josep Belda Sanchis
Favorite
(P 508) DREAM, UTOPIA OR REALISM? PROGNOSTIC FACTORS IN LUNG METASTASECTOMY OF DISSEMINATED SARCOMA DISEASE
Josep Belda Sanchis
Favorite
Belinchon, Belén

HU La Paz
(P 175) TRABECTEDIN PLUS RADIOTHERAPY ON SYMPHTOMATIC ADVANCED SARCOMA PATIENTS, RESULTS FROM THE SYNERGIAS STUDY: A SPANISH GROUP FOR RESEARCH IN SARCOMA (GEIS) PHASE II STUDY
Belén Belinchon
Favorite
Belinsky, Martin

Fox Chase Cancer Center
(P 287) ESTABLISHMENT AND GENOMIC VALIDATION OF NOVEL PATIENT-DERIVED XENOGRAFT MODELS FOR DRUG DISCOVERY IN GASTROINTESTINAL STROMAL TUMOR
Martin Belinsky
Favorite
Bell, John

University of Ottawa
(P 110) GCAR1: GPNMB CAR T THERAPY FOR MIT FAMILY TRANSLOCATION POSITIVE CANCERS
John Bell
Favorite
Bello, Alexa

The University of Texas MD Anderson Cancer Center
(P 405) PRIMARY CARDIAC ANGIOSARCOMA- GENOMIC AND MOLECULAR LANDSCAPE
Alexa Bello
Favorite
Bellotti, Chiara

Istituto Ortopedico Rizzoli IRCCS, Osteoncology- Bone and Soft Tissue Sarcomas and Innovative Therapies Unit, Bologna, Italy
(P 253) THE EFFICACY OF MEDICATED PATCHES IN SOFT TISSUE SARCOMAS: IN-VITRO AND EX-VIVO VALIDATION.
Chiara Bellotti
Favorite
(P 283) A TRIDIMENSIONAL PRECLINICAL MODEL TO STUDY HUMAN AND CANINE OSTEOSARCOMA DEVELOPMENT AND INTERACTION WITH TUMOR MICROENVIRONMENT
Chiara Bellotti
Favorite
Bell, Timothy

SpringWorks Therapeutics, Inc.
(P 146) CHARACTERIZING THE PATIENT JOURNEY TO A DIAGNOSIS OF DESMOID TUMOR: DESMOID TUMOR RESEARCH FOUNDATION NATURAL HISTORY STUDY
Timothy Bell
Favorite
(P 188) IMPACT OF NIROGACESTAT ON FUNCTIONAL STATUS IN PATIENTS WITH DESMOID TUMORS: RESULTS FROM THE PHASE 3 DEFI STUDY
Timothy Bell
Favorite
Bell, Zoe

Newcastle University
(P 298) EVALUATING THE PHOTOTHERMAL AND CYTOTOXIC PROPERTIES OF INDOCYANINE GREEN IN VITRO FOR INTRAOPERATIVE PHOTOTHERMAL THERAPY IN SARCOMA
Zoe Bell
Favorite
Beltran, Joan

Cebiotex S.L., Barcelona, Spain
(P 385) FIRST IN HUMAN PHASE I TRIAL OF A NOVEL DRUG DELIVERY IMPLANT MATRIX WITH SN-38 (CEB-01) FOR RETROPERITONEAL SOFT TISSUE SARCOMA
Joan Beltran
Favorite
Belzberg, Allan

Johns Hopkins University
(P 250) SHARING HIGH-QUALITY SAMPLES AND DATA TO THE NF1 RESEARCH COMMUNITY: THE ROLE OF THE JOHNS HOPKINS NF1 BIOSPECIMEN REPOSITORY
Allan Belzberg
Favorite
Benaoudia, Sacha

University of Calgary
(P 110) GCAR1: GPNMB CAR T THERAPY FOR MIT FAMILY TRANSLOCATION POSITIVE CANCERS
Sacha Benaoudia
Favorite
Ben-Arush, Myriam

Rambam Medical Center, Joan and Sanford Weill Pediatric Hematology Oncology and Bone Marrow Transplantation Division, Ruth Rappaport Children's Hospital, Haifa
(P 209) PROGNOSTIC VALUE OF EARLY RADIOLOGIC TUMOUR VOLUME RESPONSE IN RHABDOMYOSARCOMA; RESULTS OF THE EUROPEAN PAEDIATRIC SOFT TISSUE SARCOMA STUDY GROUP RMS 2005 STUDY
Myriam Ben-Arush
Favorite
Bender, Lewis

Intensity Therapeutics Inc.
(P 164) INTRATUMORAL INT230-6 (CISPLATIN, VINBLASTINE, SHAO) ALONE OR WITH IPILIMUMAB PROLONGED SURVIVAL WITH FAVORABLE SAFETY AND IMMUNE ACTIVATION IN ADULTS WITH REFRACTORY SARCOMAS (NCT 03058289)
Lewis Bender
Favorite
Benini, Stefania

Department of Pathology, IRCCS Istituto Ortopedico Rizzoli
(P 283) A TRIDIMENSIONAL PRECLINICAL MODEL TO STUDY HUMAN AND CANINE OSTEOSARCOMA DEVELOPMENT AND INTERACTION WITH TUMOR MICROENVIRONMENT
Stefania Benini
Favorite
(P 355) FUSION TRANSCRIPTOME PROFILING DEFINES THE MONOCLONAL NATURE OF MULTIFOCAL EPITHELIOID HEMANGIOMA OF BONE
Stefania Benini
Favorite
Benjamin, Robert

The University of Texas MD Anderson Cancer Center
(P 71) CHEMOTHERAPY AND PROGNOSTIC SIGNIFICANCE OF EXTENT OF DEDIFFERENTIATION IN DEDIFFERENTIATED PAROSTEAL OSTEOSARCOMA
Robert Benjamin
Favorite
(P 100) HISTOLOGY SPECIFIC INTRATUMORAL B-CELL BIOLOGY IN ALVEOLAR SOFT-PART SARCOMAS (ASPS) IN RESPONSE TO DURVALUMAB-TREMELIMUMAB (D-T)
Robert Benjamin
Favorite
(P 405) PRIMARY CARDIAC ANGIOSARCOMA- GENOMIC AND MOLECULAR LANDSCAPE
Robert Benjamin
Favorite
Benson, charlotte

The Royal Marsden Hospital
(P 40) LONG TERM OUTCOMES OF NEOADJUVANT IMATINIB AND SURGICAL RESECTION OF RECTAL GASTROINTESTINAL STROMAL TUMOURS
charlotte Benson
Favorite
(P 188) IMPACT OF NIROGACESTAT ON FUNCTIONAL STATUS IN PATIENTS WITH DESMOID TUMORS: RESULTS FROM THE PHASE 3 DEFI STUDY
charlotte Benson
Favorite
Benzonelli, Irene

San Luigi Hospital
(P 144) IMPLEMENTATION OF THE EUROPEAN CLINICAL TRIAL REGULATION: SURVEY OF THE ITALIAN SARCOMA GROUP CENTERS
Irene Benzonelli
Favorite
Berclaz, Luc

Department of Internal Medicine III, University Hospital, Ludwig-Maximilians-University (LMU) Munich, Germany
(P 118) TIM-3 QUALIFIES AS A POTENTIAL IMMUNOTHERAPEUTIC TARGET IN SPECIFIC SUBSETS OF PATIENTS WITH HIGH-RISK SOFT TISSUE SARCOMAS (HR-STS)
Luc Berclaz
Favorite
(P 338) PREOPERATIVE RADIATION THERAPY IS NOT ASSOCIATED WITH ADVERSE POSTOPERATIVE OUTCOMES IN PATIENTS WITH RETROPERITONEAL SARCOMA
Luc Berclaz
Favorite
(P 557) UNRAVELING THE ROLE OF LOCAL THERAPY FOR PATIENTS WITH OLIGOMETASTATIC SOFT TISSUE SARCOMA - A RETROSPECTIVE MULTICENTER TRIAL OF BAVARIAN UNIVERSITY HOSPITALS
Luc Berclaz
Favorite
Bergamaschi, Laura

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
(P 363) Β-CATENIN MUTATIONS AND TRANSCRIPTOMIC REPROGRAMMING IN DESMOID FIBROMATOSIS (DF)
Laura Bergamaschi
Favorite
Berg, Rachel

Tempus Labs, Inc
(P 67) GENOMIC CHARACTERIZATION OF CHONDROSARCOMA: A RARE SARCOMA WITH CLINICAL RESPONSES TO IMMUNE CHECKPOINT INHIBITION
Rachel Berg
Favorite
Berg, Stephanie

Dana Farber Cancer Institute
(P 207) A MULTICENTER PHASE II STUDY OF CABOZANTINIB PLUS NIVOLUMAB FOR PATIENTS WITH ADVANCED ANGIOSARCOMA PREVIOUSLY TREATED WITH A TAXANE: ALLIANCE A091902
Stephanie Berg
Favorite
Berlanga, Pablo

Gustave Roussy Cancer Centre
(P 75) REAL-WORLD DATA ON REGORAFENIB AND CABOZANTINIB IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH RELAPSED OSTEOSARCOMA AND EWING SARCOMA INCLUDED IN THE SACHA-FRANCE STUDY
Pablo Berlanga
Favorite
(P 212) REPORT ON THE EWING SARCOMA PATIENTS ENROLLED IN ARM D OF THE ACSE-ESMART TRIAL: PHASE I/II STUDY OF THE PARP INHIBITOR OLAPARIB IN COMBINATION WITH IRINOTECAN IN CHILDREN WITH ADVANCED MALIGNANCIES
Pablo Berlanga
Favorite
Bernabé, María José

Hospital Clínico San Carlos
(P 515) ENDOBRONCHIAL NAVIGATION AS AN INTRAOPERATORY TOOL FOR RESECTION OF SMALL PULMONARY METASTASES IN SARCOMA PATIENTS
María José Bernabé
Favorite
Bernabeu, Daniel

HU La Paz
(P 174) SELISARC: A SPANISH GROUP FOR RESEARCH IN SARCOMA (GEIS) PHASE I/II TRIAL OF SELINEXOR PLUS GEMCITABINE IN SELECTED SARCOMA SUBTYPES: RESULTS OF THE PHASE I PART
Daniel Bernabeu
Favorite
Bernard-Bedard, Ericka

Department of Surgery, University of Ottawa
(P 152) EVALUATING DIAGNOSTIC APPROACHES TO DERMATOFIBROSARCOMA PROTUBERANS: AN OPPORTUNITY TO REDUCE THE NUMBER OF INTERVENTIONS
Ericka Bernard-Bedard
Favorite
Bernard-Gauthier, Vadim

Bayer Pharmaceuticals, Inc.
(P 161) EFFICACY, SAFETY, AND TREATMENT HOLD WAIT-AND-SEE OUTCOMES OF LAROTRECTINIB IN PEDIATRIC PATIENTS WITH TRK FUSION SARCOMAS
Vadim Bernard-Gauthier
Favorite
Berner, Jeanne-Marie

Oslo University Hospital
(P 23) GENOMIC COMPLEXITY AS A BIOMARKER FOR ADJUVANT IMATINIB TREATMENT IN HIGH-RISK GASTROINTESTINAL STROMAL TUMOR
Jeanne-Marie Berner
Favorite
Bernthal, Nicholas

University of California Los Angeles
(P 173) SAFETY, EFFICACY, AND PATIENT-REPORTED OUTCOMES WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED PRIOR ANTI–COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 UPDATE
Nicholas Bernthal
Favorite
(P 176) SAFETY, EFFICACY, AND PATIENT-REPORTED OUTCOMES WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED NO PRIOR ANTI–COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 UPDATE
Nicholas Bernthal
Favorite
Berruti, Alfredo

University of Brescia, ASST Spedali Civili
(P 159) IN BETWEEN OF LYMPHOMAS AND SARCOMAS: WHERE DO HISTIOCYTIC AND DENDRITIC CELL NEOPLASMS (HDCN) STAND? A RETROSPECTIVE, MULTI-INSTITUTIONAL STUDY FROM THE ITALIAN SARCOMA GROUP (ISG)
Alfredo Berruti
Favorite
Berthiaume, Marie-Josée

CIUSSS Est-de-l'Île-de-Montréal
(P 134) IMPACT OF THE PARTNERSHIP BETWEEN TERTIARY CENTERS AND NON-SARCOMA RADIOLOGY CENTERS.
Marie-Josée Berthiaume
Favorite
Bertulli, Rossella

Mesenchymal and rare cancer Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
(P 431) TREATMENT STRATEGY AND PROGNOSTIC FACTORS IN EXTRASKELETAL EWING SARCOMA: AN INSTITUTIONAL RETROSPECTIVE ANALYSIS
Rossella Bertulli
Favorite
(P 432) LONG-LASTING DISEASE CONTROL WITH TRABECTEDIN IN A CASE OF METASTATIC EWSR1::PATZ1 SARCOMA
Rossella Bertulli
Favorite
(P 455) EXTRASKELETAL EWING SARCOMA: A MULTICENTRIC RETROSPECTIVE STUDY FROM THE ITALIAN SARCOMA GROUP
Rossella Bertulli
Favorite
Bertuzzi, Alexia

Humanitas Research Hospital
(P 297) UNVEILING THE IMPACT OF INTRATUMORAL MICROBIOTA IN THE TREATMENT EFFICACY OF SOFT TISSUE SARCOMA
Alexia Bertuzzi
Favorite
(P 327) LEARNING CURVE ANALYSIS IN RETROPERITONEAL SARCOMA SURGERY
Alexia Bertuzzi
Favorite
(P 433) A 20-YEAR MONOCENTER EXPERIENCE ON CLINICAL CHARACTERISTICS AND OUTCOME OF EXTRASKELETAL EWING SARCOMA.
Alexia Bertuzzi
Favorite
(P 457) LONG-TERM FOLLOW-UP OF PATIENTS WITH ATYPICAL LIPOMATOUS TUMOR (ALT) TREATED WITH MARGINAL RESECTION IN A REFERRAL CENTER
Alexia Bertuzzi
Favorite
BESSEDE, Alban

Explicyte
(P 418) GENOMIC AND IMMUNOLOGICAL PROFILING OF PRIMARY AND DISTANT METASTASES OF SOFT TISSUE SARCOMAS
Alban BESSEDE
Favorite
Betel, Doron

Weill Cornell Medicine Graduate School of Medical Sciences
(P 257) CHARACTERIZING THE EVOLUTION AND THERAPEUTIC RESPONSE OF UNDIFFERENTIATED PLEOMORPHIC SARCOMAS USING MOUSE MODELS
Doron Betel
Favorite
Bethell, Mikhail

Duke University School of Medicine
(P 137) IMPACT OF SOCIAL DETERMINANTS OF HEALTH ON SARCOMA CARE: A SINGLE INSTITUTION EXPERIENCE
Mikhail Bethell
Favorite
Beumer, Jan

University of Pittsburgh Medical Center
(P 541) ETCTN 10563: PHASE 1 STUDY OF PEPOSERTIB AND LIPOSOMAL DOXORUBICIN FOR ADVANCED OR METASTATIC LEIOMYOSARCOMA AND OTHER SARCOMAS
Jan Beumer
Favorite
Bezerra, Tiago

AC Camargo Cancer Center
(P 192) ROLE OF MAGNETIC RESONANCE IMAGING IN THE PREDICTION OF HISTOLOGICAL GRADE IN SOFT TISSUE SARCOMAS.
Tiago Bezerra
Favorite
Bhachech, Niraja

Huntsman Cancer Institute/University of Utah
(P 412) LEIOMYOSARCOMA POLYANEUPLOID CANCER CELLS DEVELOP IN RESPONSE TO CHEMOTHERAPY AND CONTRIBUTE TO CHEMORESISTANCE
Niraja Bhachech
Favorite
Bhadri, Vivek

Chris O'Brien Lifehouse
(P 194) REAL WORLD OUTCOMES OF PATIENTS TREATED WITH GEMCITABINE AND DOCETAXEL FOR ADVANCED SOFT TISSUE SARCOMA IN AN AUSTRALIAN SARCOMA CENTRE
Vivek Bhadri
Favorite
(P 437) ULTRA-RARE UNDIFFERENTIATED SMALL ROUND CELL SARCOMA: HOW SHOULD WE TREAT THEM? AN ANALYSIS FORM THE GRACEFUL PROJECT
Vivek Bhadri
Favorite
(P 451) IMPACT OF TIME TO DIAGNOSIS - A PROSPECTIVE ANALYSIS OF THE EWING 2008 TRIAL
Vivek Bhadri
Favorite
Bhalla, Angela

The University of Texas MD Anderson Cancer Center
(P 269) PLASMA DNA METHYLATION-BASED BIOMARKERS FOR MPNST DETECTION IN PATIENTS WITH NEUROFIBROMATOSIS TYPE 1 (NF1)
Angela Bhalla
Favorite
Bhatia, Himanshi

Washington University in St. Louis
(P 274) TYK2 AND MEK COMBINATION THERAPY IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS AND OTHER SOFT TISSUE SARCOMAS
Himanshi Bhatia
Favorite
Bhise, Shruti

Fred Hutchinson Cancer Center
(P 448) CAF-LIKE EWING SARCOMA CELLS DEPOSIT PRO-TUMORIGENIC EXTRACELLULAR MATRIX IN RESPONSE TO TGF-BETA SIGNALING
Shruti Bhise
Favorite
Bhogal, Sumail

University of Pittsburgh Medical Center
(P 373) DEDIFFERENTIATED AND HIGH GRADE CHONDROSARCOMAS: HOW DOES ISOCITRATE DEHYDROGENASE STATUS APPRISE PROGNOSIS AND THERAPY?
Sumail Bhogal
Favorite
(P 466) INTRAOPERATIVE EVALUATION OF BONE AND SOFT TISSUE SARCOMA SURGICAL MARGINS WITH INDOCYANINE GREEN FLUORESCENCE IMAGING
Sumail Bhogal
Favorite
(P 544) INTRAOPERATIVE EVALUATION OF BONE AND SOFT TISSUE SARCOMA SURGICAL MARGINS WITH INDOCYANINE GREEN FLUORESCENCE IMAGING
Sumail Bhogal
Favorite
Bialick, Steven

Sylvester Comprehensive Cancer Center, University of Miami
(P 128) THE IMPACT OF HISPANIC ETHNICITY IN PRESENTATION AND OUTCOMES OF PATIENTS WITH SYNOVIAL SARCOMA
Steven Bialick
Favorite
(P 225) PAN-SARCOMA DATABASE (PSDB): A MODEL-VIEW-CONTROLLER FRAMEWORK UTILIZING REDCAP, SHINY, AND R TO CREATE A CONTINUOUS PIPELINE OF SARCOMA DATA
Steven Bialick
Favorite
(P 226) SIGNATERA TESTING TO IDENTIFY MINIMAL RESIDUAL DISEASE IN HIGH GRADE SARCOMA
Steven Bialick
Favorite
(P 361) MOLECULAR CHARACTERIZATION OF SOLITARY FIBROUS TUMORS BY ANATOMIC SITE AND NAB2::STAT6 FUSION VARIANT TYPE
Steven Bialick
Favorite
(P 366) SURVIVAL DISPARITIES IN HISPANIC PATIENTS WITH SARCOMA TESTED WITH NEXT-GENERATION SEQUENCING (NGS)
Steven Bialick
Favorite
(P 461) OUTCOMES FOR OLIGOMETASTATIC PULMONARY DISEASE RECURRENCE TREATED WITH SURGERY ALONE FOR PATIENTS WITH SOFT TISSUE SARCOMAS A CASE SERIES
Steven Bialick
Favorite
Bianchi, Giuseppe

Istituto Ortopedico Rizzoli IOR IRCCS, SC Third Orthopaedic Clinic and Traumatology, Bologna Italy
(P 01) EXTRASKELETAL EWING SARCOMA OF THE EXTREMITIES AND TRUNK IN < 25 YEARS OLD PATIENTS: A RETROSPECTIVE ANALYSIS OF A MONO-INSTITUTIONAL SERIES.
Giuseppe Bianchi
Favorite
(P 455) EXTRASKELETAL EWING SARCOMA: A MULTICENTRIC RETROSPECTIVE STUDY FROM THE ITALIAN SARCOMA GROUP
Giuseppe Bianchi
Favorite
Bickley, Sorrel

Sarcoma UK
(P 136) SETTING THE INTERNATIONAL RESEARCH AGENDA FOR SARCOMA WITH PATIENTS AND CARERS: PRELIMINARY RESULTS OF PHASE II OF THE SARCOMA PATIENT ADVOCACY GLOBAL NETWORK (SPAGN) PRIORITY SETTING PARTNERSHIP
Sorrel Bickley
Favorite
(P 150) VISUALISING SOFT TISSUE SARCOMA INCIDENCE DATA FOR PATIENT EMPOWERMENT
Sorrel Bickley
Favorite
(P 151) DEVELOPMENT AND IMPACT OF A PRIMARY CARE SARCOMA EDUCATION MODULE FOR ENGLAND AND WALES
Sorrel Bickley
Favorite
Bidgoli, Mahtab

Skåne University Hospital
(P 371) DISRUPTION OF THE TP53 LOCUS IN OSTEOSARCOMA LEADS TO TP53 PROMOTER GENE FUSIONS AND RESTORATION OF PARTS OF THE TP53 SIGNALLING PATHWAY
Mahtab Bidgoli
Favorite
Bielack, Stefan

Olgahospital Stuttgart
(P 69) DEVELOPMENT AND MISSION OF THE HARMONIZATION INTERNATIONAL BONE SARCOMA CONSORTIUM (HIBISCUS)
Stefan Bielack
Favorite
(P 73) FOSTER CONSORTIUM, FIGHT OSTEOSARCOMA THROUGH EUROPEAN RESEARCH
Stefan Bielack
Favorite
Bien, Jeffrey

Stanford University School of Medicine
(P 224) CO-MUTATION-DEPENDENT PROGNOSIS IN PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA
Jeffrey Bien
Favorite
Bie, Yuan

University of Guelph
(P 304) A COMPARATIVE ANALYSIS OF METABOLIC FLEXIBILITY IN OSTEOSARCOMA CELLS
Yuan Bie
Favorite
Biffart, Brookelyn

University of British Columbia
(P 215) IMPACT OF FRONTLINE SYSTEMIC TREATMENT CHOICE ON CLINICAL OUTCOME IN ADVANCED LEIOMYOSARCOMA: A MULTI-CENTRE RETROSPECTIVE CANSARCC STUDY
Brookelyn Biffart
Favorite
Bilska, Katarzyna

Department of Oncology and Surgical Oncology for Children and Youth, Mother and Child Institute, 01-211 Warsaw, Poland.
(P 09) A NOMOGRAM MODEL TO PREDICT THE OVERALL SURVIVAL OF ADOLESCENT AND YOUNG ADULT PATIENTS WITH LOCALLY ADVANCED EWING SARCOMA.
Katarzyna Bilska
Favorite
Bingham, Justus

Momentum Metrix
(P 111) INTERIM ANALYSIS OF A PHASE 1 STUDY USING IL12-FHAB WITH OPTIMIZED PHARMACOKINETICS
Justus Bingham
Favorite
Bini, Marta

INT Milan
(P 328) REAL-LIFE EXPERIENCE OF PAZOPANIB IN PATIENTS WITH ADVANCED UTERINE LEIOMYOSARCOMA (U-LMS) FROM TWO REFERRAL ITALIAN CENTERS
Marta Bini
Favorite
Binitie, Odion

H. Lee Moffitt Cancer Center
(P 81) OPTIMIZING EWING SARCOMA AND OSTEOSARCOMA BIOPSY ACQUISITION: CONSENSUS RECOMMENDATIONS FROM THE CHILDREN'S ONCOLOGY GROUP BONE TUMOR COMMITTEE
Odion Binitie
Favorite
(P 511) SIGNIFICANCE OF TIP TO APEX DISTANCE IN PATHOLOGICAL AND IMPENDING PATHOLOGICAL FRACTURES OF THE PROXIMAL FEMUR
Odion Binitie
Favorite
Biondi, Nicola

Precision Sarcoma Research Group, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg
(P 124) UNLOCKING THE POTENTIAL OF MEASLES VIRUS ONCOLYTIC IMMUNOTHERAPY FOR SARCOMA: BIOMARKER DISCOVERY AND THERAPEUTIC VACCINE DEVELOPMENT
Nicola Biondi
Favorite
Bird, Justin

The University of Texas MD Anderson Cancer Center
(P 83) CLINICO-GENOMIC PROFILING OF CONVENTIONAL AND DEDIFFERENTIATED CHONDROSARCOMAS REVEALS TP53 MUTATION TO BE ASSOCIATED WITH WORSE OUTCOMES
Justin Bird
Favorite
Birz, Suzi

University of Chicago
(P 69) DEVELOPMENT AND MISSION OF THE HARMONIZATION INTERNATIONAL BONE SARCOMA CONSORTIUM (HIBISCUS)
Suzi Birz
Favorite
Bishop, Andrew

MD Anderson Cancer Center
(P 123) DEDIFFERENTIATED LIPOSARCOMAS TREATED WITH IMMUNE CHECKPOINT BLOCKADE: THE MD ANDERSON EXPERIENCE
Andrew Bishop
Favorite
(P 394) LEIOMYOSARCOMA INTRATUMORAL MACROPHAGE INFILTRATES ARE ASSOCIATED WITH DISTINCT CLINICAL AND GENOMIC PRESENTATIONS
Andrew Bishop
Favorite
(P 510) PRIMARY BREAST ANGIOSARCOMA: CLINICAL AND PATHOLOGICAL FEATURES AND IMPACT ON OUTCOMES
Andrew Bishop
Favorite
Bisig, Bettina

CHUV
(P 103) LASTING COMPLETE RESPONSE TO PEMBROLIZUMAB IN MISMATCH REPAIR DEFICIENT CARDIAC SARCOMA: A GENOMIC CHARACTERIZATION
Bettina Bisig
Favorite
Bisogno, Gianni

Department of Pediatric Haematology and Oncology, University Hospital of Padua
(P 209) PROGNOSTIC VALUE OF EARLY RADIOLOGIC TUMOUR VOLUME RESPONSE IN RHABDOMYOSARCOMA; RESULTS OF THE EUROPEAN PAEDIATRIC SOFT TISSUE SARCOMA STUDY GROUP RMS 2005 STUDY
Gianni Bisogno
Favorite
Bjerkehagen, Bodil

Oslo University Hospital
(P 23) GENOMIC COMPLEXITY AS A BIOMARKER FOR ADJUVANT IMATINIB TREATMENT IN HIGH-RISK GASTROINTESTINAL STROMAL TUMOR
Bodil Bjerkehagen
Favorite
Bjornard, Kari

Division of Pediatric Hematology/Oncology, Riley Hospital for Children
(P 15) INTRAOSSEOUS RHABDOMYOSARCOMA OF THE CHEST WITH FUS:TFCP2 FUSION AND GERMLINE VARIANTS IN NF1 AND SBDS: NOVEL LOCATION AND MOLECULAR CHARACTERISTICS OF A RARE TUMOR
Kari Bjornard
Favorite
Black, Ralph

Fred Hutchinson Research Center
(P 206) A SINGLE-ARM, PHASE II STUDY OF NEOADJUVANT PEMBROLIZUMAB COMBINED WITH RADIOTHERAPY IN THE PRIMARY TREATMENT OF SOFT TISSUE SARCOMAS.
Ralph Black
Favorite
Blakaj, Dukagjin

The Ohio State University Wexner Medical Center
(P 315) SCALP VOLUMETRIC MODULATED ARC THERAPY USING 3D MILLED BOLUS: DOSIMITRY, TOXICITY AND OUTCOMES
Dukagjin Blakaj
Favorite
Blakeley, Jaishri

Johns Hopkins University
(P 250) SHARING HIGH-QUALITY SAMPLES AND DATA TO THE NF1 RESEARCH COMMUNITY: THE ROLE OF THE JOHNS HOPKINS NF1 BIOSPECIMEN REPOSITORY
Jaishri Blakeley
Favorite
Blakely, Andrew

Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
(P 28) RETROSPECTIVE ANALYSIS OF SUCCINATE DEHYDROGENASE (SDH)-DEFICIENT GASTROINTESTINAL STROMAL TUMOR (GIST) OUTCOMES: AN INTERNATIONAL STUDY OF 256 PATIENTS
Andrew Blakely
Favorite
Blanco Alcaina, Elena

Institute of Biomedicine of Sevilla, IBIS, Hospital Universitario Virgen del Rocío-HUVR, Consejo Superior de Investigaciones Científicas-CSIC
(P 279) PROTEIN PHOSPHATASE 2 A INHIBITION AS A MECHANISM TO ENHANCE DOXORUBICIN ACTIVITY
Elena Blanco Alcaina
Favorite
Blank, Alan

Rush University Medical Center
(P 63) EVALUATION OF LOCAL RECURRENCE AND DIAGNOSTIC DISCORDANCE IN CHONDROSARCOMA PATIENTS UNDERGOING PREOPERATIVE BIOPSY
Alan Blank
Favorite
(P 232) NOVEL MRI SCORING SYSTEM TO ASSESS OSSEOUS MALIGNANCY IN SOFT TISSUE SARCOMA PATIENTS FOLLOWING RADIOTHERAPY
Alan Blank
Favorite
(P 307) IS RADIOTHERAPY NECESSARY FOR MANAGEMENT OF LOW GRADE MYXOID LIPOSARCOMA? A SYSTEMATIC REVIEW
Alan Blank
Favorite
(P 377) EFFECTIVENESS OF INTERVENTIONAL RADIOLOGY GUIDED PROCEDURES FOR LOCALLY RECURRENT AND METASTATIC SARCOMA: SINGLE INSTITUTIONAL RESULTS
Alan Blank
Favorite
(P 467) DOES PERIOPERATIVE RADIATION AFFECT IMPLANT SURVIVORSHIP OF PRIMARY TOTAL HIP ARTHROPLASTY IN THE SETTING OF METASTATIC BONE DISEASE: A MULTICENTER STUDY
Alan Blank
Favorite
(P 468) OPIATE USE AFTER TOTAL HIP ARTHROPLASTY FOR METASTATIC BONE DISEASE
Alan Blank
Favorite
(P 506) THE EFFECT OF TIMING BETWEEN PRE-OPERATIVE EMBOLIZATION AND SURGERY: A RETROSPECTIVE ANALYSIS OF HYPERVASCULAR BONE METASTASES
Alan Blank
Favorite
Blankenship, Kaley

St. Jude Children's Research Hospital
(P 288) EVALUATION OF ATR AND WEE1 INHIBITORS COMBINED WITH NANO-LIPOSOMAL IRINOTECAN IN A LARGE COHORT OF RHABDOMYOSARCOMA XENOGRAFTS USING A TWIN MOUSE PRECLINICAL TRIAL DESIGN
Kaley Blankenship
Favorite
(P 303) PRECLINICAL EVALUATION OF PARP1 SELECTIVE INHIBITOR AZD5305 IN COMBINATION WITH DNA DAMAGING AGENTS IN EWING SARCOMA ORTHOTOPIC XENOGRAFT MODELS
Kaley Blankenship
Favorite
Blattmann, Claudia

Olgahospital
(P 161) EFFICACY, SAFETY, AND TREATMENT HOLD WAIT-AND-SEE OUTCOMES OF LAROTRECTINIB IN PEDIATRIC PATIENTS WITH TRK FUSION SARCOMAS
Claudia Blattmann
Favorite
Blay, Jean-Yves

Centre Léon-Bérard
(P 27) A MULTICENTER RETROSPECTIVE STUDY ON THE CLINICAL BEHAVIOR OF SDH-DEFICIENT GIST
Jean-Yves Blay
Favorite
(P 104) COMPREHENSIVE IMMUNE PROFILING UNVEILS A SUBSET OF LEIOMYOSARCOMA WITH HOT TUMOR IMMUNE MICROENVIRONMENT
Jean-Yves Blay
Favorite
(P 135) UNMET NEEDS IN LOCALLY ADVANCED (UNRESECTABLE) OR METASTATIC DEDIFFERENTIATED LIPOSARCOMA AND EXPECTATIONS FOR CLINICAL TRIALS: AN INTERNATIONAL DELPHI CONSENSUS STUDY
Jean-Yves Blay
Favorite
(P 138) CONTROVERSIES IN THE MANAGEMENT OF PATIENTS WITH SOFT TISSUE SARCOMA: RESULTS AND RECOMMENDATIONS FROM THE FIRST CONFERENCE ON STATE OF SCIENCE IN SARCOMA (CSSS)
Jean-Yves Blay
Favorite
(P 142) THE SARCOMA EUROPEAN AND LATIN AMERICAN NETWORK (SELNET) PROJECT: OVERVIEW OF THE MAIN RESULTS OF THE SELNET REGISTRY
Jean-Yves Blay
Favorite
(P 176) SAFETY, EFFICACY, AND PATIENT-REPORTED OUTCOMES WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED NO PRIOR ANTI–COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 UPDATE
Jean-Yves Blay
Favorite
(P 201) PLEOMORPHIC RHABDOMYOSARCOMAS: A NEW ENTITY ASSOCIATED WITH LYNCH SYNDROME? FIRST RESULTS OF SARCLYNCH NATIONAL STUDY
Jean-Yves Blay
Favorite
(P 382) NTRK1/2/3 FUSIONS DETECTION USING RNA-SEQ IN MESENCHYMAL TUMORS REVEALS ULTRA-RARE AND HISTO-SPECIFIC TARGETABLE ALTERATIONS: EXPERIENCE OF AN EXTENSIVE ROUTINE RESEARCH PROGRAM.
Jean-Yves Blay
Favorite
(P 435) ONCOGENIC FUSION YWHAE::NUTM2 DISRUPT EP300/BCOR INTERACTION
Jean-Yves Blay
Favorite
(P 548) A PHASE 2/3 STUDY EVALUATING THE EFFICACY AND SAFETY OF UNESBULIN IN ADVANCED LEIOMYOSARCOMA (SUNRISELMS)
Jean-Yves Blay
Favorite
Blazer, Dan

Duke University
(P 152) EVALUATING DIAGNOSTIC APPROACHES TO DERMATOFIBROSARCOMA PROTUBERANS: AN OPPORTUNITY TO REDUCE THE NUMBER OF INTERVENTIONS
Dan Blazer
Favorite
(P 340) CENTRAL BOOST RADIATION THERAPY CAN ACHIEVE DURABLE LOCAL RESPONSE IN UNRESECTABLE RETROPERITONEAL SARCOMA
Dan Blazer
Favorite
(P 342) THE EVALUATION AND OUTCOMES OF MESENTERIC AND INTRA-ABDOMINAL DESMOIDS: A TARPSWG STUDY
Dan Blazer
Favorite
Bleckman, Roos

University medical center Groningen
(P 32) IMPROVEMENT OF QUALITY AND TEXTBOOK OUTCOMES OF GASTRIC GASTROINTESTINAL STROMAL TUMOR (GIST) RESECTIONS IN THE PAST 13 YEARS; THE INFLUENCE OF MINIMAL INVASIVE SURGERY (MIS)
Roos Bleckman
Favorite
Bleris, Leonidas

Department of Bioengineering, University of Texas at Dallas
(P 261) EFFICACY OF BET INHIBITORS IN SOLITARY FIBROUS TUMOR: AN IN VITRO EVALUATION
Leonidas Bleris
Favorite
Bloem, Johan

Leiden University Medical Center
(P 55) RELATIVE WASH-IN RATE ON DYNAMIC CONTRAST-ENHANCED MRI AS A NEW PROGNOSTIC FACTOR IN PATIENTS WITH OSTEOSARCOMA; A POSSIBLE TOOL FOR PERSONALIZED SARCOMA-CARE?
Johan Bloem
Favorite
Blonski, Piotr

Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology
(P 162) LONG TERM SAFETY AND EFFICACY OF COMBINED DOXORUBICIN-IFOSFAMIDE CHEMOTHERAPY WITH PREOPERATIVE HYPOFRACTIONATED RADIOTHERAPY IN MARGINALLY RESECTABLE SOFT TISSUE SARCOMAS
Piotr Blonski
Favorite
(P 222) EXPLORING THE IMPACT OF NGS ON DIAGNOSTICS AND TREATMENT OF SARCOMA: INSIGHTS FROM REAL-WORLD DATA ACROSS MULTIPLE INSTITUTIONS IN EUROPE
Piotr Blonski
Favorite
Blum, Kelly

UCSF
(P 413) LINKING REAL-WORLD CLINICAL AND GENOMIC DATA IN RHABDOMYOSARCOMA: LEVERAGING AACR PROJECT GENIE AS A PATH TOWARD PRECISION ONCOLOGY IN RARE CANCERS
Kelly Blum
Favorite
Bobak, Klaudia

Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology
(P 162) LONG TERM SAFETY AND EFFICACY OF COMBINED DOXORUBICIN-IFOSFAMIDE CHEMOTHERAPY WITH PREOPERATIVE HYPOFRACTIONATED RADIOTHERAPY IN MARGINALLY RESECTABLE SOFT TISSUE SARCOMAS
Klaudia Bobak
Favorite
Boikos, Sosipatros

Georgetown Lombardi Comprehensive Cancer Center
(P 189) INTERNATIONAL RETROSPECTIVE STUDY FROM THE ULTRA-RARE SARCOMA WORKING GROUP ON LOW-GRADE FIBROMYXOID SARCOMA AND SCLEROSING EPITHELIOD FIBROSARCOMA: OUTCOME OF ADVANCED DISEASE AND SYSTEMIC THERAPIES
Sosipatros Boikos
Favorite
(P 361) MOLECULAR CHARACTERIZATION OF SOLITARY FIBROUS TUMORS BY ANATOMIC SITE AND NAB2::STAT6 FUSION VARIANT TYPE
Sosipatros Boikos
Favorite
(P 401) OVEREXPRESSION OF CYCLIN DEPENDENT KINASES AND CYCLINS ACROSS SARCOMAS BEYOND CDK4
Sosipatros Boikos
Favorite
Boi, Laurens

Ghent University
(P 296) EX VIVO SARCOMA CELL CULTURES FROM PAIRED PRIMARY, LOCAL RELAPSE AND METASTATIC SITES REVEALS PHENOTYPIC HETEROGENEITY
Laurens Boi
Favorite
BOLLARD, julien

Centre Léon Bérard
(P 104) COMPREHENSIVE IMMUNE PROFILING UNVEILS A SUBSET OF LEIOMYOSARCOMA WITH HOT TUMOR IMMUNE MICROENVIRONMENT
julien BOLLARD
Favorite
Bolshinsky, Maital

Oncology 1 Unit, Department of Oncology, Veneto Institute of Oncology IOV - IRCCS
(P 171) SEX DIFFERENCES IN OUTCOMES AND TOXICITY IN PATIENTS TREATED FOR SARCOMA IN A REFERENCE CENTER
Maital Bolshinsky
Favorite
Bonaparte, Ilaria

Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, Florence, Italy
(P 309) CLINICAL PATHOLOGICAL CHARACTERISTICS, PATTERN OF CARE AND SURVIVAL OF NON-METASTATIC BREAST ANGIOSARCOMA
Ilaria Bonaparte
Favorite
(P 317) PROGNOSTIC FACTORS, CLINICAL AND TOXICITY OUTCOMES FROM A LARGE COHORT OF PATIENTS WITH SOFT TISSUE SARCOMA TREATED WITH PREOPERATIVE RADIATION THERAPY
Ilaria Bonaparte
Favorite
Bone, Jeffrey

British Columbia Children's Hospital Research Institute
(P 512) PERIOPERATIVE BLOOD MANAGEMENT IN PEDIATRIC PATIENTS UNDERGOING PRIMARY OSTEOSARCOMA AND EWING SARCOMA RESECTION: A RETROSPECTIVE CASE NOTE REVIEW
Jeffrey Bone
Favorite
Bonel, Martina

Azienda Ospedale - Università Padova
(P 144) IMPLEMENTATION OF THE EUROPEAN CLINICAL TRIAL REGULATION: SURVEY OF THE ITALIAN SARCOMA GROUP CENTERS
Martina Bonel
Favorite
Bonenkamp, Han

Radboud university medical center
(P 32) IMPROVEMENT OF QUALITY AND TEXTBOOK OUTCOMES OF GASTRIC GASTROINTESTINAL STROMAL TUMOR (GIST) RESECTIONS IN THE PAST 13 YEARS; THE INFLUENCE OF MINIMAL INVASIVE SURGERY (MIS)
Han Bonenkamp
Favorite
(P 554) FIVE-YEAR OUTCOMES OF A NATIONWIDE PROSPECTIVE CLINICAL TRIAL ON ACTIVE SURVEILLENCE IN PATIENTS WITH NON-INTRAABDOMINAL DESMOID-TYPE FIBROMATOSIS
Han Bonenkamp
Favorite
Bonvalot, Sylvie

Institut Curie
(P 201) PLEOMORPHIC RHABDOMYOSARCOMAS: A NEW ENTITY ASSOCIATED WITH LYNCH SYNDROME? FIRST RESULTS OF SARCLYNCH NATIONAL STUDY
Sylvie Bonvalot
Favorite
(P 395) TARGETING CD44-MEDIATED IRON ENDOCYTOSIS IN DESMOID FIBROMATOSIS
Sylvie Bonvalot
Favorite
Boonstra-Schelfhorst, Maaike

Princess Máxima Center for Pediatric Oncology
(P 558) TRIAL IN PROGRESS: A PHASE 1/2 STUDY OF BRIGATINIB IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH ALK POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA OR INFLAMMATORY MYOFIBROBLASTIC TUMORS (ITCC-098)
Maaike Boonstra-Schelfhorst
Favorite
Borcherding, Dana

Washington University in St. Louis
(P 274) TYK2 AND MEK COMBINATION THERAPY IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS AND OTHER SOFT TISSUE SARCOMAS
Dana Borcherding
Favorite
Borchert, Sabrina

Institute of Pathology, West German Cancer Center, University Hospital Essen
(P 248) FIBROBLAST ACTIVATION PROTEIN ALPHA -DIRECTED IMAGING AND THERAPY OF SOLITARY FIBROUS TUMOR
Sabrina Borchert
Favorite
(P 294) DNA-DAMAGE REPAIR DYSREGULATION AND CHEMOTHERAPY RESPONSE IN SARCOMA MODELS
Sabrina Borchert
Favorite
Borghi, Alessandra

Sarcoma Service, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
(P 455) EXTRASKELETAL EWING SARCOMA: A MULTICENTRIC RETROSPECTIVE STUDY FROM THE ITALIAN SARCOMA GROUP
Alessandra Borghi
Favorite
Borinstein, Scott

Vanderbilt University Medical Center
(P 160) A PROSPECTIVE STUDY EVALUATING THE ASSOCIATION OF PATIENT-REPORTED OUTCOMES WITH ACTIVITY LEVEL AND SLEEP PATTERNS IN SARCOMA SURVIVORS
Scott Borinstein
Favorite
(P 210) FINANCIAL TOXICITY ASSOCIATED WITH THE TREATMENT OF SARCOMAS: A SINGLE INSTITUTION RETROSPECTIVE-PROSPECTIVE STUDY
Scott Borinstein
Favorite
(P 211) AN ANALYSIS OF SELF-REPORTED DEPRESSION IN SARCOMA PATIENTS
Scott Borinstein
Favorite
(P 380) NEXT GENERATION SEQUEINCING REVEALS TARGETABLE MUTATIONS IN MULTIPLE SARCOMA HISTOLOGIES
Scott Borinstein
Favorite
Borkowska, Aneta

Maria Sklodowska-Curie National Research Institute of Oncology
(P 21) YOUNG ADULTS WITH NONMETASTATIC OPERABLE OSTEOSARCOMA TREATED PERIOPERATIVELY WITH METHOTREXATE, DOXORUBICIN AND CISPLATIN SCHEDULE, SINGLE INSTITUTION REPORT
Aneta Borkowska
Favorite
Borkowska, Aneta

Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology
(P 95) LONG-TERM OUTCOMES OF PATIENTS DIAGNOSED WITH CHORDOMA OF THE SACRUM
Aneta Borkowska
Favorite
(P 162) LONG TERM SAFETY AND EFFICACY OF COMBINED DOXORUBICIN-IFOSFAMIDE CHEMOTHERAPY WITH PREOPERATIVE HYPOFRACTIONATED RADIOTHERAPY IN MARGINALLY RESECTABLE SOFT TISSUE SARCOMAS
Aneta Borkowska
Favorite
Borkowska, Aneta

Maria Sklodowska-Curie National Research Institute of Oncology, Department of Soft Tissue/Bone Sarcoma and Melanoma, Warsaw Poland
(P 310) PREOPERATIVE RADIOTHERAPY WITH HYPERTHERMIA IN RECURRENT AND RADIATION-INDUCED SARCOMAS: RESULTS OF A PHASE 2 CLINICAL TRIAL
Aneta Borkowska
Favorite
(P 545) NEOADJUVANT PEMBROLIZUMAB AND EFTILAGIMOD ALPHA WITH CONCURRENT RADIOTHERAPY IN PATIENTS WITH SELECTED SOFT TISSUE SARCOMA SUBTYPES (EFTISARC-NEO)
Aneta Borkowska
Favorite
Bossard, Carine

BioSplice
(P 270) ALTERNATIVE SPLICING (AS) REGULATION AS A NOVEL THERAPEUTIC TARGET IN SOFT-TISSUE SARCOMA (STS)
Carine Bossard
Favorite
Bouchoucha, Yassine

Institute Curie
(P 212) REPORT ON THE EWING SARCOMA PATIENTS ENROLLED IN ARM D OF THE ACSE-ESMART TRIAL: PHASE I/II STUDY OF THE PARP INHIBITOR OLAPARIB IN COMBINATION WITH IRINOTECAN IN CHILDREN WITH ADVANCED MALIGNANCIES
Yassine Bouchoucha
Favorite
Boudadi, Karim

Johns Hopkins University School of Medicine
(P 559) PROSPECTIVE PHASE II TRIAL OF PREOPERATIVE HYPOFRACTIONATED PROTON THERAPY FOR EXTREMITY AND TRUNCAL AND TRUNCAL SOFT TISSUE SARCOMA: THE PRONTO STUDY RATIONALE AND DESIGN
Karim Boudadi
Favorite
Boughdad, sarah

CHUV
(P 535) THERAGNOSTICS IN SOFT TISSUE SARCOMA USING A VASCULAR DISCRUPTION APPROACH
sarah Boughdad
Favorite
Boukovinas, Ioannis

Department of Medical Oncology, Bioclinic Hospital, 54622 Thessaloniki, Greece
(P 222) EXPLORING THE IMPACT OF NGS ON DIAGNOSTICS AND TREATMENT OF SARCOMA: INSIGHTS FROM REAL-WORLD DATA ACROSS MULTIPLE INSTITUTIONS IN EUROPE
Ioannis Boukovinas
Favorite
Boulva, Kerianne

The Centre hospitalier de l'Université de Montréal (CHUM)
(P 342) THE EVALUATION AND OUTCOMES OF MESENTERIC AND INTRA-ABDOMINAL DESMOIDS: A TARPSWG STUDY
Kerianne Boulva
Favorite
BOURDON, Aurélien

Institut Bergonié
(P 300) ANTI-TUMOR ACTIVITY OF PARP7 INHIBITOR RBN-2397 IN SOFT-TISSUE SARCOMAS
Aurélien BOURDON
Favorite
(P 418) GENOMIC AND IMMUNOLOGICAL PROFILING OF PRIMARY AND DISTANT METASTASES OF SOFT TISSUE SARCOMAS
Aurélien BOURDON
Favorite
Bournat, Juan

MD Anderson Cancer Center
(P 101) EPIGENETIC MODULATION OF NK CELLS IMPROVES TUMOR TRAFFICKING AND ENHANCES THERAPEUTIC EFFICACY AGAINST OSTEOSARCOMA
Juan Bournat
Favorite
Bouzein, Kathryn

University of Chicago
(P 69) DEVELOPMENT AND MISSION OF THE HARMONIZATION INTERNATIONAL BONE SARCOMA CONSORTIUM (HIBISCUS)
Kathryn Bouzein
Favorite
Bovee, Judith

LUMC
(P 55) RELATIVE WASH-IN RATE ON DYNAMIC CONTRAST-ENHANCED MRI AS A NEW PROGNOSTIC FACTOR IN PATIENTS WITH OSTEOSARCOMA; A POSSIBLE TOOL FOR PERSONALIZED SARCOMA-CARE?
Judith Bovee
Favorite
(P 368) DECODING THE IMMUNOGENOMIC DETERMINANTS OF RADIOTHERAPY RESPONSE IN SOFT TISSUE SARCOMAS
Judith Bovee
Favorite
(P 369) MAGEA ANTIGENS AS IMMUNOTHERAPEUTIC TARGETS FOR ADVANCED OSTEOSARCOMA
Judith Bovee
Favorite
Boye, Kjetil

Oslo University Hospital
(P 23) GENOMIC COMPLEXITY AS A BIOMARKER FOR ADJUVANT IMATINIB TREATMENT IN HIGH-RISK GASTROINTESTINAL STROMAL TUMOR
Kjetil Boye
Favorite
(P 73) FOSTER CONSORTIUM, FIGHT OSTEOSARCOMA THROUGH EUROPEAN RESEARCH
Kjetil Boye
Favorite
Bränström, Robert

Karolinska institutet
(P 243) EVALUATION OF THE USE OF WGS IN ROUTINE DIAGNOSTICS FOR BONE AND SOFT TISSUE TUMORS
Robert Bränström
Favorite
Braga, Daniele

humanitas research hospital
(P 297) UNVEILING THE IMPACT OF INTRATUMORAL MICROBIOTA IN THE TREATMENT EFFICACY OF SOFT TISSUE SARCOMA
Daniele Braga
Favorite
Brahmi, Mehdi

CENTRE LEON BERARD AND CANCER RESEARCH CENTER OF LYON (INSERM U1052-CNRS5286)
(P 104) COMPREHENSIVE IMMUNE PROFILING UNVEILS A SUBSET OF LEIOMYOSARCOMA WITH HOT TUMOR IMMUNE MICROENVIRONMENT
Mehdi Brahmi
Favorite
(P 382) NTRK1/2/3 FUSIONS DETECTION USING RNA-SEQ IN MESENCHYMAL TUMORS REVEALS ULTRA-RARE AND HISTO-SPECIFIC TARGETABLE ALTERATIONS: EXPERIENCE OF AN EXTENSIVE ROUTINE RESEARCH PROGRAM.
Mehdi Brahmi
Favorite
(P 435) ONCOGENIC FUSION YWHAE::NUTM2 DISRUPT EP300/BCOR INTERACTION
Mehdi Brahmi
Favorite
Bramanti, Stefania

Humanitas Research Hospital
(P 433) A 20-YEAR MONOCENTER EXPERIENCE ON CLINICAL CHARACTERISTICS AND OUTCOME OF EXTRASKELETAL EWING SARCOMA.
Stefania Bramanti
Favorite
Brar, Savtaj

Mount Sinai Hospital
(P 249) INVESTIGATING CLINICAL FACTORS ASSOCIATED WITH THE ESTABLISHMENT OF SUCCESSFUL PRIMARY HUMAN SOFT TISSUE SARCOMA CELL LINES
Savtaj Brar
Favorite
Braun, Katherine

Seattle Children's Research Institute
(P 448) CAF-LIKE EWING SARCOMA CELLS DEPOSIT PRO-TUMORIGENIC EXTRACELLULAR MATRIX IN RESPONSE TO TGF-BETA SIGNALING
Katherine Braun
Favorite
Breckenridge, Zackariah

University of Calgary
(P 110) GCAR1: GPNMB CAR T THERAPY FOR MIT FAMILY TRANSLOCATION POSITIVE CANCERS
Zackariah Breckenridge
Favorite
Brennan, Bernadette

Royal Manchester Children's Hospital
(P 69) DEVELOPMENT AND MISSION OF THE HARMONIZATION INTERNATIONAL BONE SARCOMA CONSORTIUM (HIBISCUS)
Bernadette Brennan
Favorite
(P 70) ICONIC (IMPROVING OUTCOMES THROUGH COLLABORATION IN OSTEOSARCOMA): A PROSPECTIVE OBSERVATIONAL COHORT STUDY FOR NEWLY DIAGNOSED OSTEOSARCOMA PATIENTS IN THE UNITED KINGDOM (UK)
Bernadette Brennan
Favorite
Bresler, Scott

Department of Pathology, University of Michigan
(P 293) GENERATION OF A SPONTANEOUS IMMUNOCOMPETENT MOUSE MODEL OF LIPOSARCOMA
Scott Bresler
Favorite
Bretcha, Pedro

Hospital Quironsalud Torrevieja
(P 407) PRECISION AND PERSONALIZED TREATMENT FOR SOFT TISSUE SARCOMAS. RESULTS OF A 10 PATIENTS SERIES WITH MOLECULAR PROFILING USING NEXT-GENERATION MASSIVE SEQUENCING
Pedro Bretcha
Favorite
Briaire-de Bruijn, Inge

LUMC
(P 368) DECODING THE IMMUNOGENOMIC DETERMINANTS OF RADIOTHERAPY RESPONSE IN SOFT TISSUE SARCOMAS
Inge Briaire-de Bruijn
Favorite
(P 369) MAGEA ANTIGENS AS IMMUNOTHERAPEUTIC TARGETS FOR ADVANCED OSTEOSARCOMA
Inge Briaire-de Bruijn
Favorite
Brichard, Bénédicte

Cliniques Universitaires Saint Luc
(P 451) IMPACT OF TIME TO DIAGNOSIS - A PROSPECTIVE ANALYSIS OF THE EWING 2008 TRIAL
Bénédicte Brichard
Favorite
Brich, Silvia

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 272) A COMPARATIVE ASSESSMENT OF SELINEXOR WITH TRABECTEDIN OR LURBINECTEDIN IN PATIENT-DERIVED XENOGRAFTS (PDX) OF DEDIFFERENTIATED LIPOSARCOMA (DDLPS)
Silvia Brich
Favorite
(P 273) COMPARISON OF A PATIENT-DERIVED XENOGRAFTS (PDX) OF MYXOID PLEOMORPHIC LIPOSARCOMA (MPL) AND PLEOMORPHIC LIPOSARCOMA (PL) HIGHLIGHTS THE EFFECTIVENESS OF ERIBULIN IN A PDX OF MPL
Silvia Brich
Favorite
Brigham, Don

Sarcoma Oncology Center
(P 116) UPDATE ON SAINT: RESULTS OF 100 PATIENTS TREATED WITH IPILIMUMAB (I), NIVOLUMAB (N) AND TRABECTEDIN (T) AS FIRST LINE THERAPY FOR ADVANCED SOFT TISSUE SARCOMA [NCT03138161]
Don Brigham
Favorite
(P 117) INTERIM ANALYSIS OF PHASE 2 STUDY: A METRONOMIC REGIMEN USING GEMCITABINE, DOXORUBICIN, DOCETAXEL AND NIVOLUMAB FOR ADVANCED LEIOMYOSARCOMA (NCT04535713)
Don Brigham
Favorite
(P 383) AI ANALYSIS SHOWS ENHANCED CCNG1 ONCOGENE EXPRESSION IN SARCOMA TUMORS AND SUPPORTS THE USE OF DELTAREX-G, A CCNG1 INHIBITOR, AS PLATFORM THERAPY FOR ADVANCED SARCOMA
Don Brigham
Favorite
Brigman, Brian

Duke University
(P 137) IMPACT OF SOCIAL DETERMINANTS OF HEALTH ON SARCOMA CARE: A SINGLE INSTITUTION EXPERIENCE
Brian Brigman
Favorite
(P 299) EXPLORING THE IMMUNOLIGHT MECHANISM OF ACTION IN A GENETICALLY ENGINEERED MOUSE MODEL OF SOFT TISSUE SARCOMA
Brian Brigman
Favorite
(P 509) GIANT CELL TUMOR OF BONE IN THE PEDIATRIC POPULATION: A RETROSPECTIVE STUDY HIGHLIGHTING CASES OF METAPHYSEAL ONLY LOCATION AND INCREASED LOCAL RECURRENCE RATES IN SKELETALLY IMMATURE PATIENTS
Brian Brigman
Favorite
Brinkmann, Elyse

University of Washington
(P 67) GENOMIC CHARACTERIZATION OF CHONDROSARCOMA: A RARE SARCOMA WITH CLINICAL RESPONSES TO IMMUNE CHECKPOINT INHIBITION
Elyse Brinkmann
Favorite
Brito, Ariadna

Cancer Research Center of Toulouse
(P 268) IMPACT OF CELLULAR FUSION IN THE ONCOGENESIS OF LEIOMYOSARCOMAS
Ariadna Brito
Favorite
Britschgi, Christian

University Hospital Zurich
(P 234) GENOMIC LANDSCAPE OF CLEAR CELL SARCOMA
Christian Britschgi
Favorite
Brockman, Qierra

University of Iowa
(P 286) EPIGENETIC MECHANISMS AND SIGNATURES OF SARCOMA PROGRESSION AND METASTASIS
Qierra Brockman
Favorite
Brodeur, Garrett

University of Pennsylvania Perelman School of Medicine; Children's Hospital of Philadelphia
(P 565) AN EARLY PHASE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF PEEL-224 IN PATIENTS WITH ADVANCED SOLID TUMORS
Garrett Brodeur
Favorite
Brodowicz, Thomas

Medical University of Vienna
(P 138) CONTROVERSIES IN THE MANAGEMENT OF PATIENTS WITH SOFT TISSUE SARCOMA: RESULTS AND RECOMMENDATIONS FROM THE FIRST CONFERENCE ON STATE OF SCIENCE IN SARCOMA (CSSS)
Thomas Brodowicz
Favorite
Broida, Samuel

Mayo Clinic (Rochester)
(P 02) PEDIATRIC SYNOVIAL SARCOMA: A REVIEW OF 21 CASES FROM A SINGLE INSTITUTION
Samuel Broida
Favorite
(P 59) CHONDROSARCOMA OF THE FLAT BONES: DIFFERENTIAL SURVIVAL BETWEEN HIGH GRADE LESIONS OF THE PELVIS AND SCAPULA
Samuel Broida
Favorite
(P 60) SKIP LESIONS IN CHONDROSARCOMA: IS WHOLE BONE IMAGING NECESSARY?
Samuel Broida
Favorite
(P 61) ADJACENT VENOUS TUMOR THROMBUS IN PRIMARY OSTEOSARCOMA OF THE PELVIS AND EXTREMITIES
Samuel Broida
Favorite
(P 62) PROSTHESIS-ASSOCIATED SARCOMA: A REVIEW OF 8 HIGH-GRADE LESIONS ARISING AROUND A TOTAL JOINT ARTHROPLASTY IMPLANT
Samuel Broida
Favorite
(P 465) UNPLANNED EXCISION OF SYNOVIAL SARCOMA: FACTORS ASSOCIATED WITH RECURRENCE AND SURVIVAL
Samuel Broida
Favorite
Broida, Samuel

Mayo Clinic
(P 518) OUTCOMES OF NON-ANGIOSARCOMA RADIATION-ASSOCIATED SOFT TISSUE SARCOMAS OF THE CHEST
Samuel Broida
Favorite
Brookes, Marcus

The Newcastle upon Tyne Hospitals NHS Foundation Trust
(P 228) WHAT IS THE SIGNIFICANCE OF INDETERMINATE PULMONARY NODULES IN HIGH GRADE SOFT TISSUE SARCOMA? A RETROSPECTIVE COHORT STUDY
Marcus Brookes
Favorite
Brookes, Marcus

Northern Bone and Soft Tissue Tumour Service
(P 298) EVALUATING THE PHOTOTHERMAL AND CYTOTOXIC PROPERTIES OF INDOCYANINE GREEN IN VITRO FOR INTRAOPERATIVE PHOTOTHERMAL THERAPY IN SARCOMA
Marcus Brookes
Favorite
(P 522) FLUORESCENCE GUIDED SURGERY WITH INDOCYANINE GREEN FOR SURGICAL RESECTION OF METASTATIC BONE AND SOFT TISSUE TUMOURS: A CASE SERIES
Marcus Brookes
Favorite
Broomfield, Jaye

The Royal Marsden Hospital
(P 40) LONG TERM OUTCOMES OF NEOADJUVANT IMATINIB AND SURGICAL RESECTION OF RECTAL GASTROINTESTINAL STROMAL TUMOURS
Jaye Broomfield
Favorite
Brosjö, Otte

Karolinska University Hospital
(P 371) DISRUPTION OF THE TP53 LOCUS IN OSTEOSARCOMA LEADS TO TP53 PROMOTER GENE FUSIONS AND RESTORATION OF PARTS OF THE TP53 SIGNALLING PATHWAY
Otte Brosjö
Favorite
Brotea-Mosoiu, Silvia

Oncology Institute of Bucharest
(P 432) LONG-LASTING DISEASE CONTROL WITH TRABECTEDIN IN A CASE OF METASTATIC EWSR1::PATZ1 SARCOMA
Silvia Brotea-Mosoiu
Favorite
Brouste, Véronique

Institut Bergonié
(P 523) IN-BETWEEN SARCOMA: A CATEGORY OF HIGH RISK OF RECURRENCE AND POOR OUTCOME
Véronique Brouste
Favorite
Brown, Amber

Division of Pediatric Hematology/Oncology, Riley Hospital for Children
(P 15) INTRAOSSEOUS RHABDOMYOSARCOMA OF THE CHEST WITH FUS:TFCP2 FUSION AND GERMLINE VARIANTS IN NF1 AND SBDS: NOVEL LOCATION AND MOLECULAR CHARACTERISTICS OF A RARE TUMOR
Amber Brown
Favorite
Browne, MaKenna

Duke University
(P 428) COMPREHENSIVE GENOMIC PROFILING OF CIC-DUX4 SARCOMA (CDS) CELL LINES AND MODELS
MaKenna Browne
Favorite
(P 450) INVESTIGATING THE THERAPEUTIC POTENTIAL OF SMALL MOLECULE INHIBITOR INOBRODIB AS A TREATMENT ALTERNATIVE FOR CIC-DUX4 SARCOMA
MaKenna Browne
Favorite
Brown, Jeffrey

Huntsman Cancer Institute
(P 93) INDETERMINATE CHEST LESIONS IN PATIENTS WITH BONE SARCOMA INCIDENTAL FINDING VERSUS METASTATIC DISEASE
Jeffrey Brown
Favorite
Brown, Jeffrey

Huntsman Cancer Institute, University of Utah
(P 246) IMMUNOCOMPETENT MODELING OF PLEOMORPHIC LIPOSARCOMA
Jeffrey Brown
Favorite
Brown, Samuel

University of Calgary
(P 415) NEOADJUVANT RADIOTHERAPY MODULATES THE TUMOUR MICROENVIRONMENT OF UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Samuel Brown
Favorite
Brugarolas, Antonio

Hospital Quironsalud Torrevieja
(P 407) PRECISION AND PERSONALIZED TREATMENT FOR SOFT TISSUE SARCOMAS. RESULTS OF A 10 PATIENTS SERIES WITH MOLECULAR PROFILING USING NEXT-GENERATION MASSIVE SEQUENCING
Antonio Brugarolas
Favorite
Brugières, Laurence

Gustave Roussy Cancer Campus
(P 558) TRIAL IN PROGRESS: A PHASE 1/2 STUDY OF BRIGATINIB IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH ALK POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA OR INFLAMMATORY MYOFIBROBLASTIC TUMORS (ITCC-098)
Laurence Brugières
Favorite
Brunello, Antonella

Oncology 1 Unit, Department of Oncology, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy
(P 159) IN BETWEEN OF LYMPHOMAS AND SARCOMAS: WHERE DO HISTIOCYTIC AND DENDRITIC CELL NEOPLASMS (HDCN) STAND? A RETROSPECTIVE, MULTI-INSTITUTIONAL STUDY FROM THE ITALIAN SARCOMA GROUP (ISG)
Antonella Brunello
Favorite
(P 171) SEX DIFFERENCES IN OUTCOMES AND TOXICITY IN PATIENTS TREATED FOR SARCOMA IN A REFERENCE CENTER
Antonella Brunello
Favorite
(P 189) INTERNATIONAL RETROSPECTIVE STUDY FROM THE ULTRA-RARE SARCOMA WORKING GROUP ON LOW-GRADE FIBROMYXOID SARCOMA AND SCLEROSING EPITHELIOD FIBROSARCOMA: OUTCOME OF ADVANCED DISEASE AND SYSTEMIC THERAPIES
Antonella Brunello
Favorite
(P 216) BRAIN METASTASES IN SARCOMA: A (NOT SO) RARE EVENT. THE EXPERIENCE OF A HIGH VOLUME CENTER
Antonella Brunello
Favorite
(P 378) MULTIOMICS PROFILING OF EPITHELIOID SARCOMA UNVEILS EPIGENETIC CIRCUITRIES THAT UNDERLIE THE PATHOBIOLOGY OF PROXIMAL AND CLASSIC SUBTYPES: RESULTS FROM THE ISG EPISOBS OBSERVATIONAL STUDY
Antonella Brunello
Favorite
(P 437) ULTRA-RARE UNDIFFERENTIATED SMALL ROUND CELL SARCOMA: HOW SHOULD WE TREAT THEM? AN ANALYSIS FORM THE GRACEFUL PROJECT
Antonella Brunello
Favorite
(P 455) EXTRASKELETAL EWING SARCOMA: A MULTICENTRIC RETROSPECTIVE STUDY FROM THE ITALIAN SARCOMA GROUP
Antonella Brunello
Favorite
Brusco, Silvia

Department of Oncology, University of Turin
(P 109) INTENSE PRECLINICAL ACTIVITY BY B7H3-SPECIFIC CAR.CIK LYMPHOCYTES AGAINST EPITHELIOID SARCOMA
Silvia Brusco
Favorite
(P 262) ESTABLISHMENT AND CHARACTERIZATION OF THE FIRST RADIATION-INDUCED, PATIENT-DERIVED ANGIOSARCOMA CELL LINE
Silvia Brusco
Favorite
Buac, Neil

Rush University Medical Center
(P 506) THE EFFECT OF TIMING BETWEEN PRE-OPERATIVE EMBOLIZATION AND SURGERY: A RETROSPECTIVE ANALYSIS OF HYPERVASCULAR BONE METASTASES
Neil Buac
Favorite
Buchan, Ann

The Christie NHS Foundation Trust
(P 190) DOES RESPONSE TO PRIOR CHEMOTHERAPY PREDICT OUTCOME FROM FURTHER SYSTEMIC TREATMENT IN ADVANCED LEIOMYOSARCOMA? A SINGLE UK CENTRE EXPERIENCE
Ann Buchan
Favorite
(P 337) CLINICAL OUTCOME OF THE PATIENTS WITH HIGH GRADE UTERINE SARCOMA: A SINGLE CENTRE REAL WORLD EXPERIENCE
Ann Buchan
Favorite
Budd, George

Cleveland Clinic
(P 112) PHASE 1/2 STUDY OF YH001, A CTLA-4 ANTIBODY WITH THE SUBCUTANEOUSLY ADMINISTERED PD-L1 ANTIBODY ENVAFOLIMAB, WITH OR WITHOUT DOXORUBICIN IN PATIENTS WITH ADVANCED OR METASTATIC SOFT TISSUE SARCOMA
George Budd
Favorite
(P 539) SARCOMA STEREOTACTIC BODY RADIOTHERAPY AND IMMUNE SYSTEM TRIAL
George Budd
Favorite
Buendia, Javier

Hospital Clinico san Carlos
(P 149) PSYCOLOGICAL SNAPSHOT OF SARCOMA PATIENTS FROM AN ACADEMIC, UNIVERSITY CENTER, HOSPITAL CLÍNICO SAN CARLOS (HCSC), MADRID, A SARCOMA NATIONAL REFERRAL CENTRE IN SPAIN
Javier Buendia
Favorite
Bui, Nam

Stanford University
(P 188) IMPACT OF NIROGACESTAT ON FUNCTIONAL STATUS IN PATIENTS WITH DESMOID TUMORS: RESULTS FROM THE PHASE 3 DEFI STUDY
Nam Bui
Favorite
(P 224) CO-MUTATION-DEPENDENT PROGNOSIS IN PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA
Nam Bui
Favorite
(P 552) RANDOMIZED PHASE II TRIAL OF CABOZANTINIB COMBINED WITH PD-1 AND CTLA-4 INHIBITION VERSUS CABOZANTINIB IN METASTATIC SOFT TISSUE SARCOMA.
Nam Bui
Favorite
Bulgarelli, jenny

IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) "Dino Amadori" S.r.l.
(P 533) SAFETY AND PRELIMINARY BIOLOGICAL ACTIVITY OF A PHASE II TRIAL OF AUTOLOGOUS DENDRITIC CELLS VACCINATION IN SARCOMAS.
jenny Bulgarelli
Favorite
Bult, Carol J

The Jackson Laboratory
(P 203) PRECLINICAL EVALUATION AMG 650, A SMALL MOLECULE INHIBITOR OF KIF18A, IN PEDIATRIC SOLID TUMORS BY THE PEDIATRIC PRECLINICAL IN VIVO TESTING (PIVOT) PROGRAM
Carol J Bult
Favorite
Bulusu, Ramesh

Department of Medical Oncology, Cambridge University Hospitals NHS Foundation Trust
(P 27) A MULTICENTER RETROSPECTIVE STUDY ON THE CLINICAL BEHAVIOR OF SDH-DEFICIENT GIST
Ramesh Bulusu
Favorite
Buonomenna, Ciriaco

Department of Radiology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
(P 333) SYSTEMIC TREATMENT IN INTRA-ABDOMINAL DESMOID-TYPE FIBROMATOSIS: A SINGLE INSTITUTION RETROSPECTIVE CASE SERIES ANALYSIS
Ciriaco Buonomenna
Favorite
Burcoveanu, Domnita-Ileana

Bayer HealthCare Pharmaceuticals, Inc.
(P 353) UPDATED EFFICACY AND SAFETY OF LAROTRECTINIB IN ADULT PATIENTS WITH TRK FUSION SARCOMAS
Domnita-Ileana Burcoveanu
Favorite
(P 550) ON-TRK: A NON-INTERVENTIONAL STUDY OF LAROTRECTINIB IN PATIENTS WITH TRK FUSION SOLID TUMORS
Domnita-Ileana Burcoveanu
Favorite
Burgess, Melissa

University of Pittsburgh Medical Center Hillman Cancer Center
(P 112) PHASE 1/2 STUDY OF YH001, A CTLA-4 ANTIBODY WITH THE SUBCUTANEOUSLY ADMINISTERED PD-L1 ANTIBODY ENVAFOLIMAB, WITH OR WITHOUT DOXORUBICIN IN PATIENTS WITH ADVANCED OR METASTATIC SOFT TISSUE SARCOMA
Melissa Burgess
Favorite
(P 114) PRIMARY ANALYSIS OF EFFICACY AND SAFETY OF LETETRESGENE AUTOLEUCEL (LETE-CEL) AS FIRST-LINE TREATMENT FOR UNRESECTABLE OR METASTATIC SYNOVIAL SARCOMA (SS); SUBSTUDY 1 OF IGNYTE-ESO
Melissa Burgess
Favorite
Burgoyne, Adam

Department of Medicine, Division of Hematology-Oncology, UC San Diego Health
(P 28) RETROSPECTIVE ANALYSIS OF SUCCINATE DEHYDROGENASE (SDH)-DEFICIENT GASTROINTESTINAL STROMAL TUMOR (GIST) OUTCOMES: AN INTERNATIONAL STUDY OF 256 PATIENTS
Adam Burgoyne
Favorite
(P 29) COMBINATION TREATMENT WITH TEMOZOLOMIDE AND THE DEATH RECEPTOR-5 AGONIST INBRX-109 EFFECTIVELY TARGETS SUCCINATE DEHYDROGENASE -DEFICIENT GASTROINTESTINAL STROMAL TUMOR
Adam Burgoyne
Favorite
Burke, Chelsey

Memorial Sloan Kettering Cancer Center
(P 289) IDENTIFICATION OF EFFECTIVE THERAPEUTIC COMBINATIONS WITH THE NUCLEAR EXPORT PROTEIN INHIBITOR, SELINEXOR, IN PEDIATRIC SOLID TUMORS
Chelsey Burke
Favorite
Burke, Zachary

Celveland Clinic Sarcoma Program
(P 77) PATIENT OUTCOMES AFTER OPEN VERSUS CORE NEEDLE BIOPSY IN LOWER EXTREMITY SARCOMA
Zachary Burke
Favorite
(P 242) WHOLE BODY PET/MRI FOR STAGING OF MYXOID LIPOSARCOMA
Zachary Burke
Favorite
(P 402) TISSUE PERFUSION AND WOUND HEALING AFTER SOFT TISSUE SARCOMA RESECTION
Zachary Burke
Favorite
(P 513) THE IMPACT OF MARGIN STATUS ON THE ONCOLOGIC OUTCOMES OF SURGICALLY TREATED DEDIFFERENTIATED LIPOSARCOMA OF THE EXTREMITIES
Zachary Burke
Favorite
(P 514) INTERSTITIAL BRACHYTHERAPY IN THE TREATMENT OF SOFT TISSUE SARCOMA: LOCAL RECURRENCE AND WOUND OUTCOMES
Zachary Burke
Favorite
Burkhard-Meier, Anton

Department of Internal Medicine III, University Hospital, Ludwig-Maximilians-University (LMU) Munich, Germany
(P 118) TIM-3 QUALIFIES AS A POTENTIAL IMMUNOTHERAPEUTIC TARGET IN SPECIFIC SUBSETS OF PATIENTS WITH HIGH-RISK SOFT TISSUE SARCOMAS (HR-STS)
Anton Burkhard-Meier
Favorite
(P 557) UNRAVELING THE ROLE OF LOCAL THERAPY FOR PATIENTS WITH OLIGOMETASTATIC SOFT TISSUE SARCOMA - A RETROSPECTIVE MULTICENTER TRIAL OF BAVARIAN UNIVERSITY HOSPITALS
Anton Burkhard-Meier
Favorite
Burks, Jared

The University of Texas MD Anderson Cancer Center
(P 426) MULTI-OMIC ANALYSIS OF DESMOPLASTIC SMALL ROUND CELL TUMORS REVEAL DISTINCT LINEAGES
Jared Burks
Favorite
Burlile, Jessica

Mayo Clinic Minnesota
(P 312) MANAGEMENT OF ADULT HEAD AND NECK SOFT TISSUE SARCOMA: THE MAYO CLINIC EXPERIENCE
Jessica Burlile
Favorite
Burner, Danielle

Duke University
(P 340) CENTRAL BOOST RADIATION THERAPY CAN ACHIEVE DURABLE LOCAL RESPONSE IN UNRESECTABLE RETROPERITONEAL SARCOMA
Danielle Burner
Favorite
Burns, Jessica

The Institute of Cancer Research
(P 404) PROTEOMIC PROFILING OF THE SOFT TISSUE SARCOMA MICROENVIRONMENT IDENTIFIES A PROGNOSTIC SIGNATURE BASED ON PROTEOGLYCAN EXPRESSION AND CD8+ TUMOUR INFILTRATING LYMPHOCYTES
Jessica Burns
Favorite
(P 410) PROTEOMICS ANALYSIS IDENTIFIES A SIGNATURE THAT IMPROVES PROGNOSTIC RISK STRATIFICATION OF THE SARCULATOR NOMOGRAM IN PATIENTS WITH SOFT TISSUE SARCOMAS OF THE EXTREMITIES AND TRUNK WALL
Jessica Burns
Favorite
Burris, Howard

Sarah Cannon Research Institute
(P 66) PHASE I STUDY OF THE MUTANT IDH1 INHIBITOR IVOSIDENIB: LONG-TERM SAFETY AND CLINICAL ACTIVITY IN PATIENTS WITH CONVENTIONAL CHONDROSARCOMA
Howard Burris
Favorite
Bustos, Ana

Hospital Clínico San Carlos
(P 515) ENDOBRONCHIAL NAVIGATION AS AN INTRAOPERATORY TOOL FOR RESECTION OF SMALL PULMONARY METASTASES IN SARCOMA PATIENTS
Ana Bustos
Favorite
Buxton, Allen

Public Health Institute, Children's Oncology Group
(P 68) METASTASIS-DIRECTED RADIOTHERAPY FOR EWING SARCOMA PATIENTS ENROLLED ON AEWS1221: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP (COG)
Allen Buxton
Favorite
Buzzaccarini, Maria Samaritana

Radiation Therapy Unit, Department of Oncology, Veneto Institute of Oncology IOV - IRCCS
(P 216) BRAIN METASTASES IN SARCOMA: A (NOT SO) RARE EVENT. THE EXPERIENCE OF A HIGH VOLUME CENTER
Maria Samaritana Buzzaccarini
Favorite
Byrd, Precious

MD Anderson Cancer Center
(P 36) CLINICO-GENOMIC ANALYSIS OF KIT/PDGFRA/SDH WILD-TYPE GASTROINTESTINAL STROMAL TUMORS IDENTIFIES POTENTIAL DRIVER MUTATIONS
Precious Byrd
Favorite
C
Cabeza, Beatriz

Hospital Clínico San Carlos
(P 515) ENDOBRONCHIAL NAVIGATION AS AN INTRAOPERATORY TOOL FOR RESECTION OF SMALL PULMONARY METASTASES IN SARCOMA PATIENTS
Beatriz Cabeza
Favorite
Cabrera, Maria

Hospital Clinico san Carlos
(P 149) PSYCOLOGICAL SNAPSHOT OF SARCOMA PATIENTS FROM AN ACADEMIC, UNIVERSITY CENTER, HOSPITAL CLÍNICO SAN CARLOS (HCSC), MADRID, A SARCOMA NATIONAL REFERRAL CENTRE IN SPAIN
Maria Cabrera
Favorite
Cacciamali, Andrea

Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia-Romagna, Laboratorio di Controllo di Prodotti Biologici, Centro di Referenza Nazionale per i Metodi Alternativi, Benessere e Cura degli Animali da Laboratorio
(P 283) A TRIDIMENSIONAL PRECLINICAL MODEL TO STUDY HUMAN AND CANINE OSTEOSARCOMA DEVELOPMENT AND INTERACTION WITH TUMOR MICROENVIRONMENT
Andrea Cacciamali
Favorite
Caccin, Elisabetta

Centro di Riferimento Oncologico (CRO), IRCCS
(P 144) IMPLEMENTATION OF THE EUROPEAN CLINICAL TRIAL REGULATION: SURVEY OF THE ITALIAN SARCOMA GROUP CENTERS
Elisabetta Caccin
Favorite
Cagnazzo, Celeste

AOU Città della Salute e della Scienza Presidio Ospedaliero Infantile Regina Margherita
(P 144) IMPLEMENTATION OF THE EUROPEAN CLINICAL TRIAL REGULATION: SURVEY OF THE ITALIAN SARCOMA GROUP CENTERS
Celeste Cagnazzo
Favorite
Cagney, Gerard

University College Dublin
(P 424) INTERNAL TANDEM DUPLICATION OF BCOR (BCOR-ITD) ALTERS THE TUMOR EPIGENOME
Gerard Cagney
Favorite
Cai, Kathy

Fox Chase Cancer Center
(P 287) ESTABLISHMENT AND GENOMIC VALIDATION OF NOVEL PATIENT-DERIVED XENOGRAFT MODELS FOR DRUG DISCOVERY IN GASTROINTESTINAL STROMAL TUMOR
Kathy Cai
Favorite
Calabrese, Chiara

Istituto Romagnolo per lo studio dei Tumori "Dino Amadori" IRST IRCCS, Preclinic and Osteoncology Unit, Meldola, Italy
(P 37) DISSECTING THE ROLE OF EXTRACELLULAR VESICLES IN THE MANAGEMENT OF GIST
Chiara Calabrese
Favorite
(P 253) THE EFFICACY OF MEDICATED PATCHES IN SOFT TISSUE SARCOMAS: IN-VITRO AND EX-VIVO VALIDATION.
Chiara Calabrese
Favorite
Calaminus, Gabriele

University Hospital Bonn
(P 538) IEUROEWING TRIAL FOR LOCALIZED AND METASTATIC EWING SARCOMA
Gabriele Calaminus
Favorite
Caldari, Emilia

Ospedale Morgagni Pierantoni
(P 533) SAFETY AND PRELIMINARY BIOLOGICAL ACTIVITY OF A PHASE II TRIAL OF AUTOLOGOUS DENDRITIC CELLS VACCINATION IN SARCOMAS.
Emilia Caldari
Favorite
Calder, Paul

Memorial Sloan Kettering Cancer Center
(P 289) IDENTIFICATION OF EFFECTIVE THERAPEUTIC COMBINATIONS WITH THE NUCLEAR EXPORT PROTEIN INHIBITOR, SELINEXOR, IN PEDIATRIC SOLID TUMORS
Paul Calder
Favorite
Califano, Andrea

Department of Systems Biology, Biomedical Informatics, Biochemistry and Molecular Biophysics, and Medicine, Herbert Irving Comprehensive Cancer Center, Columbia University
(P 289) IDENTIFICATION OF EFFECTIVE THERAPEUTIC COMBINATIONS WITH THE NUCLEAR EXPORT PROTEIN INHIBITOR, SELINEXOR, IN PEDIATRIC SOLID TUMORS
Andrea Califano
Favorite
Calizo, Ana

Johns Hopkins University
(P 250) SHARING HIGH-QUALITY SAMPLES AND DATA TO THE NF1 RESEARCH COMMUNITY: THE ROLE OF THE JOHNS HOPKINS NF1 BIOSPECIMEN REPOSITORY
Ana Calizo
Favorite
Callahan, Carson

The University of Texas MD Anderson Cancer Center
(P 269) PLASMA DNA METHYLATION-BASED BIOMARKERS FOR MPNST DETECTION IN PATIENTS WITH NEUROFIBROMATOSIS TYPE 1 (NF1)
Carson Callahan
Favorite
Callegaro, Dario

Sarcoma Service, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
(P 126) CURRENT PRACTICE IN SPERMATIC CORD SARCOMA: ONCOLOGICAL TIMELINES AND OUTCOMES ACCORDING TO INITIAL RESECTIONS PERFORMED AT A LOCAL HOSPITAL VERSUS EARLY PATIENT REFERRAL TO A TERTIARY CENTRE.
Dario Callegaro
Favorite
(P 329) DISTANT METASTASIS IN RETROPERITONEAL LEIOMYOSARCOMA: TUMOR SIZE, GRADE AND MORE?
Dario Callegaro
Favorite
(P 410) PROTEOMICS ANALYSIS IDENTIFIES A SIGNATURE THAT IMPROVES PROGNOSTIC RISK STRATIFICATION OF THE SARCULATOR NOMOGRAM IN PATIENTS WITH SOFT TISSUE SARCOMAS OF THE EXTREMITIES AND TRUNK WALL
Dario Callegaro
Favorite
(P 431) TREATMENT STRATEGY AND PROGNOSTIC FACTORS IN EXTRASKELETAL EWING SARCOMA: AN INSTITUTIONAL RETROSPECTIVE ANALYSIS
Dario Callegaro
Favorite
(P 455) EXTRASKELETAL EWING SARCOMA: A MULTICENTRIC RETROSPECTIVE STUDY FROM THE ITALIAN SARCOMA GROUP
Dario Callegaro
Favorite
Calles Blanco, Antonio

Medical Oncology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain
(P 517) PULMONARY METASTASECTOMY FOR SARCOMA: A SINGLE-INSTITUTION EXPERIENCE
Antonio Calles Blanco
Favorite
Call, Jerry

The Life Raft Group
(P 33) LONGITUDINAL FOLLOW UP OF GASTROINTESTINAL STROMAL TUMORS:DATA FROM THE LIFE RAFT GROUP INTERANTIONAL PATIENT REGISTRY
Jerry Call
Favorite
Calore, Federica

The Ohio State University Comprehensive Cancer Center
(P 335) EXTRACELLULAR VESICLE MDM2 DNA AS A BIOMARKER OF TUMOR PRESENCE AND RECURRENCE IN RETROPERITONEAL LIPOSARCOMA
Federica Calore
Favorite
Calpona, sebastiano

Irst
(P 364) EVALUATION OF THE PREDICTIVE ROLE OF SYSTEMIC AND INTRATUMORAL IMMUNITY IN PATIENTS WITH LOCALIZED LIPOSARCOMAS, MYXOFIBROSARCOMAS AND UNDIFFERENTIATED PLEOMORPHIS SARCOMAS
sebastiano Calpona
Favorite
(P 533) SAFETY AND PRELIMINARY BIOLOGICAL ACTIVITY OF A PHASE II TRIAL OF AUTOLOGOUS DENDRITIC CELLS VACCINATION IN SARCOMAS.
sebastiano Calpona
Favorite
Calvert, George

Norton Healthcare
(P 529) THE MUSCULOSKELETAL TUMOR REGISTRY -- 2023 UPDATE AND OUTLOOK
George Calvert
Favorite
Calvert, Paula

UHW
(P 213) EXPERIENCE WITH THE USE OF TRABECTEDIN IN ADVANCED SOFT TISSUE SARCOMA IN IRELAND
Paula Calvert
Favorite
Camacho, Luis

Center for Onc and Blood Disorders
(P 164) INTRATUMORAL INT230-6 (CISPLATIN, VINBLASTINE, SHAO) ALONE OR WITH IPILIMUMAB PROLONGED SURVIVAL WITH FAVORABLE SAFETY AND IMMUNE ACTIVATION IN ADULTS WITH REFRACTORY SARCOMAS (NCT 03058289)
Luis Camacho
Favorite
Cambier, Linda

Children's Hospital Los Angeles
(P 166) SARC038: A PHASE 2 STUDY OF REGORAFENIB IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH REFRACTORY OR RECURRENT OSTEOSARCOMA
Linda Cambier
Favorite
Cam, Maren

Nationwide Children's Hospital
(P 107) TRABECTEDIN AUGMENTS ONCOLYTIC HERPES SIMPLEX VIROIMMUNOTHERAPY EFFICACY IN PRECLINCAL BONE SARCOMA MODELS THROUGH ENHANCED IMMUNE-MEDIATED MECHANISMS
Maren Cam
Favorite
Campanacci, Domenico Andrea

Department of Orthopaedic Oncology and Reconstructive Surgery, Azienda Ospedaliero Universitaria Careggi, Firenze, Italy
(P 309) CLINICAL PATHOLOGICAL CHARACTERISTICS, PATTERN OF CARE AND SURVIVAL OF NON-METASTATIC BREAST ANGIOSARCOMA
Domenico Andrea Campanacci
Favorite
(P 317) PROGNOSTIC FACTORS, CLINICAL AND TOXICITY OUTCOMES FROM A LARGE COHORT OF PATIENTS WITH SOFT TISSUE SARCOMA TREATED WITH PREOPERATIVE RADIATION THERAPY
Domenico Andrea Campanacci
Favorite
(P 455) EXTRASKELETAL EWING SARCOMA: A MULTICENTRIC RETROSPECTIVE STUDY FROM THE ITALIAN SARCOMA GROUP
Domenico Andrea Campanacci
Favorite
(P 546) PRELIMINARY CLINICAL RESULTS OF AN ONGOING PHASE II TRIAL: SPRINT (SARCOMA PREOPERATIVE RADIATION WITH SIMULTANEOUS INTEGRATED BOOST)
Domenico Andrea Campanacci
Favorite
Campbell, Matthew

UT Southwestern Medical Center
(P 542) ENROLLMENT OF PEDIATRIC PARTICIPANTS WITH MAGE-A4-POSITIVE SOLID TUMORS IN A PHASE 1/2, OPEN-LABEL, BASKET TRIAL OF AFAMITRESGENE AUTOLEUCEL ("AFAMI-CEL")
Matthew Campbell
Favorite
Campbell, Shauna

Cleveland Clinic Foundation
(P 308) OPTIMAL BIOLOGIC EFFECTIVE DOSE OF STEREOTACTIC BODY RADIOTHERAPY FOR METASTATIC AND RECURRENT SARCOMA
Shauna Campbell
Favorite
(P 514) INTERSTITIAL BRACHYTHERAPY IN THE TREATMENT OF SOFT TISSUE SARCOMA: LOCAL RECURRENCE AND WOUND OUTCOMES
Shauna Campbell
Favorite
(P 539) SARCOMA STEREOTACTIC BODY RADIOTHERAPY AND IMMUNE SYSTEM TRIAL
Shauna Campbell
Favorite
Campos, Fernando

Medical Oncology Department, A.C.Camargo Cancer Center, São Paulo, SP, Brazil
(P 189) INTERNATIONAL RETROSPECTIVE STUDY FROM THE ULTRA-RARE SARCOMA WORKING GROUP ON LOW-GRADE FIBROMYXOID SARCOMA AND SCLEROSING EPITHELIOD FIBROSARCOMA: OUTCOME OF ADVANCED DISEASE AND SYSTEMIC THERAPIES
Fernando Campos
Favorite
(P 192) ROLE OF MAGNETIC RESONANCE IMAGING IN THE PREDICTION OF HISTOLOGICAL GRADE IN SOFT TISSUE SARCOMAS.
Fernando Campos
Favorite
(P 387) CLINICAL CHARACTERIZATION OF PATIENTS WITH LEIOMYOSARCOMA HARBORING THE R337H TP53 GERMINATIVE ALTERATION (LI-FRAUMENI SYNDROME) AND THE PROGNOSTIC IMPLICATION USING A PROPENSITY-SCORE MATCHED COHORT
Fernando Campos
Favorite
Campoverde, Leticia

University of Miami
(P 158) SORAFENIB OR ANTHRACYCLINE-BASED CHEMOTHERAPY IN ADULT PATIENTS WITH PROGRESSIVE DESMOID TUMORS
Leticia Campoverde
Favorite
Cananzi, Ferdinando Carlo Maria

IRCCS Humanitas Research Hospital
(P 297) UNVEILING THE IMPACT OF INTRATUMORAL MICROBIOTA IN THE TREATMENT EFFICACY OF SOFT TISSUE SARCOMA
Ferdinando Carlo Maria Cananzi
Favorite
(P 327) LEARNING CURVE ANALYSIS IN RETROPERITONEAL SARCOMA SURGERY
Ferdinando Carlo Maria Cananzi
Favorite
(P 457) LONG-TERM FOLLOW-UP OF PATIENTS WITH ATYPICAL LIPOMATOUS TUMOR (ALT) TREATED WITH MARGINAL RESECTION IN A REFERRAL CENTER
Ferdinando Carlo Maria Cananzi
Favorite
Cannon, Matthew

Nationwide Children's Hospital
(P 107) TRABECTEDIN AUGMENTS ONCOLYTIC HERPES SIMPLEX VIROIMMUNOTHERAPY EFFICACY IN PRECLINCAL BONE SARCOMA MODELS THROUGH ENHANCED IMMUNE-MEDIATED MECHANISMS
Matthew Cannon
Favorite
(P 456) SECLIDEMSTAT TREATMENT BLOCKS THE TRANSCRIPTIONAL FUNCTION OF MULTIPLE FET-FUSION PROTEINS
Matthew Cannon
Favorite
Cano Casas, Francesc

Universitat Politècnica de Catalunya (UPC), Barcelona, Spain
(P 385) FIRST IN HUMAN PHASE I TRIAL OF A NOVEL DRUG DELIVERY IMPLANT MATRIX WITH SN-38 (CEB-01) FOR RETROPERITONEAL SOFT TISSUE SARCOMA
Francesc Cano Casas
Favorite
Cantero-Duerksen, Laura

Instituto de Previsión Social. Asunción, Paraguay
(P 142) THE SARCOMA EUROPEAN AND LATIN AMERICAN NETWORK (SELNET) PROJECT: OVERVIEW OF THE MAIN RESULTS OF THE SELNET REGISTRY
Laura Cantero-Duerksen
Favorite
Cantor, Nicole

Campbell University
(P 299) EXPLORING THE IMMUNOLIGHT MECHANISM OF ACTION IN A GENETICALLY ENGINEERED MOUSE MODEL OF SOFT TISSUE SARCOMA
Nicole Cantor
Favorite
Canyete, Adela

Pediatric Hospital La Fe
(P 212) REPORT ON THE EWING SARCOMA PATIENTS ENROLLED IN ARM D OF THE ACSE-ESMART TRIAL: PHASE I/II STUDY OF THE PARP INHIBITOR OLAPARIB IN COMBINATION WITH IRINOTECAN IN CHILDREN WITH ADVANCED MALIGNANCIES
Adela Canyete
Favorite
cao, hui

Department of Gastrointestinal Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University
(P 39) MANAGEMENT PRACTICES OF GASTROINTESTINAL STROMAL TUMORS: A QUESTIONNAIRE SURVEY OF GENERAL SURGEONS IN CHINA
hui cao
Favorite
Cao, Rui

University of Minnesota
(P 414) GENOMIC ANALYSIS OF EWING SARCOMA AND HERNIA IDENTIFIES A POSITIVE GENETIC CORRELATION AND SUGGESTS BOTH ARE LINKED TO AN HMGA2 VARIANT
Rui Cao
Favorite
Capitini, Christian

Department of Pediatrics and Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health
(P 542) ENROLLMENT OF PEDIATRIC PARTICIPANTS WITH MAGE-A4-POSITIVE SOLID TUMORS IN A PHASE 1/2, OPEN-LABEL, BASKET TRIAL OF AFAMITRESGENE AUTOLEUCEL ("AFAMI-CEL")
Christian Capitini
Favorite
Capra, Michael

Children's Health Ireland (CHI)
(P 73) FOSTER CONSORTIUM, FIGHT OSTEOSARCOMA THROUGH EUROPEAN RESEARCH
Michael Capra
Favorite
Cardona, Diana

Duke University
(P 340) CENTRAL BOOST RADIATION THERAPY CAN ACHIEVE DURABLE LOCAL RESPONSE IN UNRESECTABLE RETROPERITONEAL SARCOMA
Diana Cardona
Favorite
(P 428) COMPREHENSIVE GENOMIC PROFILING OF CIC-DUX4 SARCOMA (CDS) CELL LINES AND MODELS
Diana Cardona
Favorite
Cardona, Kenneth

Department of Surgery, Winship Cancer Institute, Emory University
(P 152) EVALUATING DIAGNOSTIC APPROACHES TO DERMATOFIBROSARCOMA PROTUBERANS: AN OPPORTUNITY TO REDUCE THE NUMBER OF INTERVENTIONS
Kenneth Cardona
Favorite
(P 342) THE EVALUATION AND OUTCOMES OF MESENTERIC AND INTRA-ABDOMINAL DESMOIDS: A TARPSWG STUDY
Kenneth Cardona
Favorite
Cardwell, Maxwell

MCW
(P 473) GROIN PAINS: APPROACHES AND OUTCOMES FOR INGUINOFEMORAL SOFT TISSUE SARCOMAS
Maxwell Cardwell
Favorite
Cariboni, Umberto

Humanitas Research Hospital
(P 433) A 20-YEAR MONOCENTER EXPERIENCE ON CLINICAL CHARACTERISTICS AND OUTCOME OF EXTRASKELETAL EWING SARCOMA.
Umberto Cariboni
Favorite
Carloni, Sara

Humanitas University
(P 297) UNVEILING THE IMPACT OF INTRATUMORAL MICROBIOTA IN THE TREATMENT EFFICACY OF SOFT TISSUE SARCOMA
Sara Carloni
Favorite
Carlson, Holli

Monopar Therapeutics, Inc.
(P 184) PHASE 1B TRIAL OF CAMSIRUBICIN, A NOVEL DOXORUBICIN ANALOG, WITH CONCOMITANT PEGFILGRASTIM IN SUBJECTS WITH ADVANCED SOFT TISSUE SARCOMA TO IDENTIFY A NEW MTD/RP2D
Holli Carlson
Favorite
Carlson, Luke

University of Pittsburgh
(P 244) A DEEP FEW-SHOT META-LEARNING STRATEGY FOR AUTONOMOUS CLASSIFICATION OF BONE METASTASIS IN RADIONUCLIDE BONE SCANS
Luke Carlson
Favorite
Carney, John

Northwestern Medicine
(P 479) EXPANDABLE ENDOPROSTHESES: SHOULD WE CONSIDER NARROWING OUR INDICATIONS? A SYSTEMATIC REVIEW OF THE LITERATURE AND COMPARISON OF OUTCOMES BY AGE GROUPS
John Carney
Favorite
Caro, Claudia Haydee

The National Cancer Institute
(P 142) THE SARCOMA EUROPEAN AND LATIN AMERICAN NETWORK (SELNET) PROJECT: OVERVIEW OF THE MAIN RESULTS OF THE SELNET REGISTRY
Claudia Haydee Caro
Favorite
(P 331) MUSCULAR DEDIFFERENTIATION IN DEDIFFERENTIATED LIPOSARCOMA: INSIGHTS INTO INFLAMMATORY PROFILES USING THE NEUTROPHIL/LYMPHOCYTE RATIO AND PROGNOSTIC IMPLICATIONS
Claudia Haydee Caro
Favorite
Carpenter, Kendall

Boston Children's Hospital
(P 384) SYSTEMATIC LITERATURE AND CLINICAL TRIAL REVIEW SHOWS TARGETABLE KINASE FUSIONS ARE COMMON IN PEDIATRIC, ADOLESCENT, AND YOUNG ADULT SOFT TISSUE SARCOMAS BUT CLINICAL TRIAL OPPORTUNITIES REMAIN RARE
Kendall Carpenter
Favorite
Carrasco Garcia, Irene

Virgen del Rocio University Hospital
(P 113) IMMUNOSARC II: A SPANISH SARCOMA GROUP (GEIS) PHASE IB TRIAL OF DOXORUBICIN AND DACARBAZINE PLUS NIVOLUMAB IN FIRST LINE OF ADVANCED LEIOMYOSARCOMA
Irene Carrasco Garcia
Favorite
(P 142) THE SARCOMA EUROPEAN AND LATIN AMERICAN NETWORK (SELNET) PROJECT: OVERVIEW OF THE MAIN RESULTS OF THE SELNET REGISTRY
Irene Carrasco Garcia
Favorite
(P 453) ROLE OF SECOND-LINE TREATMENT IN EWING SARCOMAS WITH POOR PROGNOSIS AT DIAGNOSIS: EXPERIENCE OF A SPANISH REFERENCE CENTER.
Irene Carrasco Garcia
Favorite
Carrillo-Garcia, Jaime

Research Health Institute of Fundación Jiménez Díaz
(P 270) ALTERNATIVE SPLICING (AS) REGULATION AS A NOVEL THERAPEUTIC TARGET IN SOFT-TISSUE SARCOMA (STS)
Jaime Carrillo-Garcia
Favorite
Carrillo, Jaime

Health Research Institute-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM),
(P 279) PROTEIN PHOSPHATASE 2 A INHIBITION AS A MECHANISM TO ENHANCE DOXORUBICIN ACTIVITY
Jaime Carrillo
Favorite
Caruthers, Douglas

Washington University in St Louis
(P 187) PALLIATIVE LATTICE STEREOTACTIC BODY RADIOTHERAPY FOR PATIENTS WITH SARCOMA
Douglas Caruthers
Favorite
Carvalho, Nathália

A.C.Camargo Cancer Center
(P 387) CLINICAL CHARACTERIZATION OF PATIENTS WITH LEIOMYOSARCOMA HARBORING THE R337H TP53 GERMINATIVE ALTERATION (LI-FRAUMENI SYNDROME) AND THE PROGNOSTIC IMPLICATION USING A PROPENSITY-SCORE MATCHED COHORT
Nathália Carvalho
Favorite
Casadei, Lucia

The Ohio State University Comprehensive Cancer Center
(P 335) EXTRACELLULAR VESICLE MDM2 DNA AS A BIOMARKER OF TUMOR PRESENCE AND RECURRENCE IN RETROPERITONEAL LIPOSARCOMA
Lucia Casadei
Favorite
Casadei, roberto

Orthopedic Unit, Morgagni-Pierantoni Hospital, 47121 Forli, Italy
(P 253) THE EFFICACY OF MEDICATED PATCHES IN SOFT TISSUE SARCOMAS: IN-VITRO AND EX-VIVO VALIDATION.
roberto Casadei
Favorite
(P 364) EVALUATION OF THE PREDICTIVE ROLE OF SYSTEMIC AND INTRATUMORAL IMMUNITY IN PATIENTS WITH LOCALIZED LIPOSARCOMAS, MYXOFIBROSARCOMAS AND UNDIFFERENTIATED PLEOMORPHIS SARCOMAS
roberto Casadei
Favorite
(P 533) SAFETY AND PRELIMINARY BIOLOGICAL ACTIVITY OF A PHASE II TRIAL OF AUTOLOGOUS DENDRITIC CELLS VACCINATION IN SARCOMAS.
roberto Casadei
Favorite
Casado, Antonio

Hospital Universitario Clínico San Carlos
(P 149) PSYCOLOGICAL SNAPSHOT OF SARCOMA PATIENTS FROM AN ACADEMIC, UNIVERSITY CENTER, HOSPITAL CLÍNICO SAN CARLOS (HCSC), MADRID, A SARCOMA NATIONAL REFERRAL CENTRE IN SPAIN
Antonio Casado
Favorite
(P 174) SELISARC: A SPANISH GROUP FOR RESEARCH IN SARCOMA (GEIS) PHASE I/II TRIAL OF SELINEXOR PLUS GEMCITABINE IN SELECTED SARCOMA SUBTYPES: RESULTS OF THE PHASE I PART
Antonio Casado
Favorite
(P 175) TRABECTEDIN PLUS RADIOTHERAPY ON SYMPHTOMATIC ADVANCED SARCOMA PATIENTS, RESULTS FROM THE SYNERGIAS STUDY: A SPANISH GROUP FOR RESEARCH IN SARCOMA (GEIS) PHASE II STUDY
Antonio Casado
Favorite
(P 515) ENDOBRONCHIAL NAVIGATION AS AN INTRAOPERATORY TOOL FOR RESECTION OF SMALL PULMONARY METASTASES IN SARCOMA PATIENTS
Antonio Casado
Favorite
Casali, Paolo Giovanni

Department of Medical Oncology 2, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
(P 159) IN BETWEEN OF LYMPHOMAS AND SARCOMAS: WHERE DO HISTIOCYTIC AND DENDRITIC CELL NEOPLASMS (HDCN) STAND? A RETROSPECTIVE, MULTI-INSTITUTIONAL STUDY FROM THE ITALIAN SARCOMA GROUP (ISG)
Paolo Giovanni Casali
Favorite
(P 328) REAL-LIFE EXPERIENCE OF PAZOPANIB IN PATIENTS WITH ADVANCED UTERINE LEIOMYOSARCOMA (U-LMS) FROM TWO REFERRAL ITALIAN CENTERS
Paolo Giovanni Casali
Favorite
(P 333) SYSTEMIC TREATMENT IN INTRA-ABDOMINAL DESMOID-TYPE FIBROMATOSIS: A SINGLE INSTITUTION RETROSPECTIVE CASE SERIES ANALYSIS
Paolo Giovanni Casali
Favorite
(P 378) MULTIOMICS PROFILING OF EPITHELIOID SARCOMA UNVEILS EPIGENETIC CIRCUITRIES THAT UNDERLIE THE PATHOBIOLOGY OF PROXIMAL AND CLASSIC SUBTYPES: RESULTS FROM THE ISG EPISOBS OBSERVATIONAL STUDY
Paolo Giovanni Casali
Favorite
(P 431) TREATMENT STRATEGY AND PROGNOSTIC FACTORS IN EXTRASKELETAL EWING SARCOMA: AN INSTITUTIONAL RETROSPECTIVE ANALYSIS
Paolo Giovanni Casali
Favorite
(P 455) EXTRASKELETAL EWING SARCOMA: A MULTICENTRIC RETROSPECTIVE STUDY FROM THE ITALIAN SARCOMA GROUP
Paolo Giovanni Casali
Favorite
Casanova Zaragoza, Sonia

Hospital de la Santa Creu i Sant Pau
(P 503) SCAPULAR PROSTHESIS RECONSTRUCTION, EXPERIENCE IN OUR INSTITUTION
Sonia Casanova Zaragoza
Favorite
(P 504) WHY DO SOME PATIENTS WITH SYNOVIAL SARCOMA HAVE BETTER FUNCTIONAL OUTCOMES AFTER RESECTION SURGERY? ANALYSIS OF 102 CASES
Sonia Casanova Zaragoza
Favorite
(P 508) DREAM, UTOPIA OR REALISM? PROGNOSTIC FACTORS IN LUNG METASTASECTOMY OF DISSEMINATED SARCOMA DISEASE
Sonia Casanova Zaragoza
Favorite
Casanova, Michela

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 202) INFLAMMATORY MYOFIBROBLASTIC TUMOUR WITH ROS1 GENE FUSIONS IN CHILDREN AND YOUNG ADOLESCENTS
Michela Casanova
Favorite
(P 212) REPORT ON THE EWING SARCOMA PATIENTS ENROLLED IN ARM D OF THE ACSE-ESMART TRIAL: PHASE I/II STUDY OF THE PARP INHIBITOR OLAPARIB IN COMBINATION WITH IRINOTECAN IN CHILDREN WITH ADVANCED MALIGNANCIES
Michela Casanova
Favorite
(P 273) COMPARISON OF A PATIENT-DERIVED XENOGRAFTS (PDX) OF MYXOID PLEOMORPHIC LIPOSARCOMA (MPL) AND PLEOMORPHIC LIPOSARCOMA (PL) HIGHLIGHTS THE EFFECTIVENESS OF ERIBULIN IN A PDX OF MPL
Michela Casanova
Favorite
(P 558) TRIAL IN PROGRESS: A PHASE 1/2 STUDY OF BRIGATINIB IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH ALK POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA OR INFLAMMATORY MYOFIBROBLASTIC TUMORS (ITCC-098)
Michela Casanova
Favorite
Cascella, Tommaso

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 14) PERCUTANEOUS CRYOABLATION OF PROGRESSING EXTRA-ABDOMINAL DESMOID TUMOURS
Tommaso Cascella
Favorite
Castaneda-Wysocka, Patricia

Maria Sklodowska-Curie National Research Institute of Oncology, Department of Radiology, Warsaw Poland
(P 310) PREOPERATIVE RADIOTHERAPY WITH HYPERTHERMIA IN RECURRENT AND RADIATION-INDUCED SARCOMAS: RESULTS OF A PHASE 2 CLINICAL TRIAL
Patricia Castaneda-Wysocka
Favorite
Castillo Orozco, Ana

Research Institute of the McGill University Health Center
(P 64) OSTEOSARCOMA. PATIENT-DERIVED XENOGRAFTS MODELS TO RECAPITULATE PATIENTS' CHEMORESISTANCE AND METASTATIC DISEASE
Ana Castillo Orozco
Favorite
(P 434) MECHANISMS OF CHEMORESISTANCE IN CIC-DUX4 SARCOMA AS DETERMINED BY IN VIVO FUNCTIONAL GENOMICS
Ana Castillo Orozco
Favorite
Castro Boix, Sandra

Servicio de Cirugía General y Digestiva, Hospitals Universitario Vall d'Hebron, Barcelona, Spain.
(P 385) FIRST IN HUMAN PHASE I TRIAL OF A NOVEL DRUG DELIVERY IMPLANT MATRIX WITH SN-38 (CEB-01) FOR RETROPERITONEAL SOFT TISSUE SARCOMA
Sandra Castro Boix
Favorite
Castro Oliden, Victor

Instituto Nacional de Enfermedades Neoplasicas
(P 142) THE SARCOMA EUROPEAN AND LATIN AMERICAN NETWORK (SELNET) PROJECT: OVERVIEW OF THE MAIN RESULTS OF THE SELNET REGISTRY
Victor Castro Oliden
Favorite
Catin, Bruna

AC Camargo Cancer Center
(P 192) ROLE OF MAGNETIC RESONANCE IMAGING IN THE PREDICTION OF HISTOLOGICAL GRADE IN SOFT TISSUE SARCOMAS.
Bruna Catin
Favorite
Catton, Charles

Princess Margaret Cancer Centre
(P 483) DID THE COVID-19 PANDEMIC NEGATIVELY AFFECT OUTCOMES FOR PATIENTS WITH EXTREMITY SOFT TISSUE SARCOMAS?
Charles Catton
Favorite
Cauchin, Estelle

ICO
(P 201) PLEOMORPHIC RHABDOMYOSARCOMAS: A NEW ENTITY ASSOCIATED WITH LYNCH SYNDROME? FIRST RESULTS OF SARCLYNCH NATIONAL STUDY
Estelle Cauchin
Favorite
Caulin, Aleah

Peel Therapeutics
(P 565) AN EARLY PHASE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF PEEL-224 IN PATIENTS WITH ADVANCED SOLID TUMORS
Aleah Caulin
Favorite
Cavaliere, Davide

General and Oncologic Surgery, "Morgagni-Pierantoni" Hospital
(P 37) DISSECTING THE ROLE OF EXTRACELLULAR VESICLES IN THE MANAGEMENT OF GIST
Davide Cavaliere
Favorite
(P 364) EVALUATION OF THE PREDICTIVE ROLE OF SYSTEMIC AND INTRATUMORAL IMMUNITY IN PATIENTS WITH LOCALIZED LIPOSARCOMAS, MYXOFIBROSARCOMAS AND UNDIFFERENTIATED PLEOMORPHIS SARCOMAS
Davide Cavaliere
Favorite
(P 533) SAFETY AND PRELIMINARY BIOLOGICAL ACTIVITY OF A PHASE II TRIAL OF AUTOLOGOUS DENDRITIC CELLS VACCINATION IN SARCOMAS.
Davide Cavaliere
Favorite
Cavaliere, Silvia

Università Campus Bio-Medico di Roma
(P 263) HER2 AS A POTENTIAL NOVEL THERAPEUTIC TARGET IN SOFT TISSUE SARCOMAS
Silvia Cavaliere
Favorite
(P 264) CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS AND TRABECTEDIN IN SOFT TISSUE SARCOMA: A NOVEL POTENTIAL SYNERGY?
Silvia Cavaliere
Favorite
Cebrian, Juan Luis

Hospital Clinico San Carlos
(P 149) PSYCOLOGICAL SNAPSHOT OF SARCOMA PATIENTS FROM AN ACADEMIC, UNIVERSITY CENTER, HOSPITAL CLÍNICO SAN CARLOS (HCSC), MADRID, A SARCOMA NATIONAL REFERRAL CENTRE IN SPAIN
Juan Luis Cebrian
Favorite
Cencelj-Arnez, Romi

Institute of Oncology Ljubljana
(P 152) EVALUATING DIAGNOSTIC APPROACHES TO DERMATOFIBROSARCOMA PROTUBERANS: AN OPPORTUNITY TO REDUCE THE NUMBER OF INTERVENTIONS
Romi Cencelj-Arnez
Favorite
Cerqueira, Wagner

AC Camargo Cancer Center
(P 192) ROLE OF MAGNETIC RESONANCE IMAGING IN THE PREDICTION OF HISTOLOGICAL GRADE IN SOFT TISSUE SARCOMAS.
Wagner Cerqueira
Favorite
chacón, Matías

Instituto Alexander Fleming
(P 142) THE SARCOMA EUROPEAN AND LATIN AMERICAN NETWORK (SELNET) PROJECT: OVERVIEW OF THE MAIN RESULTS OF THE SELNET REGISTRY
Matías chacón
Favorite
Chadha, Madhumeeta

The Institute of Cancer Research
(P 410) PROTEOMICS ANALYSIS IDENTIFIES A SIGNATURE THAT IMPROVES PROGNOSTIC RISK STRATIFICATION OF THE SARCULATOR NOMOGRAM IN PATIENTS WITH SOFT TISSUE SARCOMAS OF THE EXTREMITIES AND TRUNK WALL
Madhumeeta Chadha
Favorite
(P 417) MULTI-OMIC CHARACTERISATION OF MOLECULAR HETEROGENEITY AND NEOADJUVANT THERAPY RESPONSE IN SYNOVIAL SARCOMAS
Madhumeeta Chadha
Favorite
CHAIRE, Vanessa

Institut Bergonié
(P 300) ANTI-TUMOR ACTIVITY OF PARP7 INHIBITOR RBN-2397 IN SOFT-TISSUE SARCOMAS
Vanessa CHAIRE
Favorite
(P 418) GENOMIC AND IMMUNOLOGICAL PROFILING OF PRIMARY AND DISTANT METASTASES OF SOFT TISSUE SARCOMAS
Vanessa CHAIRE
Favorite
Chalmers, Anna

Huntsman Cancer Institute, University of Utah
(P 135) UNMET NEEDS IN LOCALLY ADVANCED (UNRESECTABLE) OR METASTATIC DEDIFFERENTIATED LIPOSARCOMA AND EXPECTATIONS FOR CLINICAL TRIALS: AN INTERNATIONAL DELPHI CONSENSUS STUDY
Anna Chalmers
Favorite
Chan, Corey

Newcastle University
(P 228) WHAT IS THE SIGNIFICANCE OF INDETERMINATE PULMONARY NODULES IN HIGH GRADE SOFT TISSUE SARCOMA? A RETROSPECTIVE COHORT STUDY
Corey Chan
Favorite
(P 298) EVALUATING THE PHOTOTHERMAL AND CYTOTOXIC PROPERTIES OF INDOCYANINE GREEN IN VITRO FOR INTRAOPERATIVE PHOTOTHERMAL THERAPY IN SARCOMA
Corey Chan
Favorite
Chan, Corey

Northern Bone and Soft Tissue Tumour Service
(P 522) FLUORESCENCE GUIDED SURGERY WITH INDOCYANINE GREEN FOR SURGICAL RESECTION OF METASTATIC BONE AND SOFT TISSUE TUMOURS: A CASE SERIES
Corey Chan
Favorite
Chandler, Dawn

Nationwide Children's Hospital
(P 94) DEVELOPING NOVEL OLIGONUCLEOTIDE THERAPIES TO MODULATE INSULIN RECEPTOR ALTERNATIVE SPLICING IN PEDIATRIC BONE SARCOMAS
Dawn Chandler
Favorite
(P 305) A NEW MOUSE MODEL FOR TESTING SPLICE-SWITCHING THERAPIES IN RHABDOMYOSARCOMA
Dawn Chandler
Favorite
Chandran, Uma

University of Pittsburgh
(P 373) DEDIFFERENTIATED AND HIGH GRADE CHONDROSARCOMAS: HOW DOES ISOCITRATE DEHYDROGENASE STATUS APPRISE PROGNOSIS AND THERAPY?
Uma Chandran
Favorite
Chang, Alexander

University of Pittsburgh
(P 373) DEDIFFERENTIATED AND HIGH GRADE CHONDROSARCOMAS: HOW DOES ISOCITRATE DEHYDROGENASE STATUS APPRISE PROGNOSIS AND THERAPY?
Alexander Chang
Favorite
Chang, John

ProCure
(P 320) A PROSPECTIVE MULTICENTER EXPERIENCE OF PROTON THERAPY FOR RHABDOMYOSARCOMA AND EWING SARCOMA: OUTCOMES FROM THE PROTON COLLABORATIVE GROUP REGISTRY
John Chang
Favorite
Chang, Yu-Hui

Mayo Clinic Arizona
(P 141) TREATMENT VARIABILITY IN SURGICAL MANAGEMENT OF PULMONARY OLIGOMETASTATIC SOFT TISSUE SARCOMA
Yu-Hui Chang
Favorite
Chan, Jason

Memorial Sloan Kettering Cancer Center
(P 24) COMPREHENSIVE ANALYSIS OF THE GENOMIC LANDSCAPE AND CLINICAL BEHAVIOR IN GIST USING NEXT GENERATION SEQUENCING (NGS, MSK-IMPACT)
Jason Chan
Favorite
(P 257) CHARACTERIZING THE EVOLUTION AND THERAPEUTIC RESPONSE OF UNDIFFERENTIATED PLEOMORPHIC SARCOMAS USING MOUSE MODELS
Jason Chan
Favorite
Chan, Jason Yongsheng

National Cancer Centre Singapore
(P 285) TUMOUR-INFILTRATING MAST CELLS IN ANGIOSARCOMAS CORRELATE WITH CLINCIAL PHENOTYPES AND IMMUNO-ONCOLOGY PATHWAYS
Jason Yongsheng Chan
Favorite
Chan, Jennifer

University of Calgary
(P 110) GCAR1: GPNMB CAR T THERAPY FOR MIT FAMILY TRANSLOCATION POSITIVE CANCERS
Jennifer Chan
Favorite
Chan, Marina

Fred Hutchinson Cancer Center
(P 447) TARGETING FOCAL ADHESION KINASE AUGMENTS THE THERAPEUTIC POTENTIAL OF BROMODOMAIN INHIBITORS IN EWING SARCOMA
Marina Chan
Favorite
Chan, Timothy

Cleveland Clinic
(P 429) SARCOMA FUSION GENE ANALYSIS YIELDS PROMISING HLA ANTIGEN FIT IN EWING SARCOMA AND DESMOPLASTIC SMALL ROUND CELL TUMOR
Timothy Chan
Favorite
(P 539) SARCOMA STEREOTACTIC BODY RADIOTHERAPY AND IMMUNE SYSTEM TRIAL
Timothy Chan
Favorite
Chapela, Jorge

University of Buenos Aires, Angel H Roffo Institute of Oncology
(P 460) IMPACT OF RESIDUAL TUMOR AFTER RE-EXCISION IN PATIENTS WITH PRIOR UNPLANNED RESECTION OF EXTREMITY AND TRUNK SOFT TISSUE SARCOMAS
Jorge Chapela
Favorite
Charlson, John

Medical College of Wisconsin
(P 114) PRIMARY ANALYSIS OF EFFICACY AND SAFETY OF LETETRESGENE AUTOLEUCEL (LETE-CEL) AS FIRST-LINE TREATMENT FOR UNRESECTABLE OR METASTATIC SYNOVIAL SARCOMA (SS); SUBSTUDY 1 OF IGNYTE-ESO
John Charlson
Favorite
(P 180) HEALTH RELATED QUALITY OF LIFE OF PATIENTS WITH ADVANCED LEIOMYOSARCOMA AND OTHER SOFT TISSUE SARCOMAS TREATED WITH CABOZANTINIB AND TEMOZOLOMIDE
John Charlson
Favorite
(P 181) REAL-WORLD EXPERIENCE WITH LIPOSOMAL DOXORUBICIN IN METASTATIC AND LOCALLY ADVANCED SARCOMA
John Charlson
Favorite
(P 346) DETECTION OF GERMLINE VARIANTS IN PATIENTS DIAGNOSED WITH SOFT TISSUE SARCOMA USING EXPANDED
John Charlson
Favorite
(P 473) GROIN PAINS: APPROACHES AND OUTCOMES FOR INGUINOFEMORAL SOFT TISSUE SARCOMAS
John Charlson
Favorite
Chatziantoniou, Cyrano

Image Sciences Institute, UMC utrecht
(P 229) ON THE VARIABILITY IN THE ANALYSIS OF APPARENT DIFFUSION COEFFICIENT ESTIMATES FOR MULTICENTER DIFFUSION MRI DATA OF RHABDOMYOSARCOMA PATIENTS
Cyrano Chatziantoniou
Favorite
Chau, Bonny

University of Washington
(P 177) ANGIOSARCOMA: AN INCREASING PROBLEM IN THE UNITED STATES
Bonny Chau
Favorite
Chaudhuri, Aadel

Washington University in St Louis
(P 187) PALLIATIVE LATTICE STEREOTACTIC BODY RADIOTHERAPY FOR PATIENTS WITH SARCOMA
Aadel Chaudhuri
Favorite
Chavarria Murillo, Sonia Stephania

Hospital de la Santa Creu i Sant Pau
(P 507) PRIMARY CHEST WALL TUMORS OF MESENCHYMAL ORIGIN. EXPERIENCE OF A REFERENCE UNIT
Sonia Stephania Chavarria Murillo
Favorite
(P 508) DREAM, UTOPIA OR REALISM? PROGNOSTIC FACTORS IN LUNG METASTASECTOMY OF DISSEMINATED SARCOMA DISEASE
Sonia Stephania Chavarria Murillo
Favorite
Chawla, Akhil

Northwestern Memorial Hospital
(P 219) ELECTIVE DISCONTINUATION OF SORAFENIB TREATMENT IN DESMOID TUMORS: A RETROSPECTIVE ANALYSIS WITH IMPLICATIONS FOR CLINICAL PRACTICE
Akhil Chawla
Favorite
Chawla, Neal

Sarcoma Oncology Center
(P 116) UPDATE ON SAINT: RESULTS OF 100 PATIENTS TREATED WITH IPILIMUMAB (I), NIVOLUMAB (N) AND TRABECTEDIN (T) AS FIRST LINE THERAPY FOR ADVANCED SOFT TISSUE SARCOMA [NCT03138161]
Neal Chawla
Favorite
(P 117) INTERIM ANALYSIS OF PHASE 2 STUDY: A METRONOMIC REGIMEN USING GEMCITABINE, DOXORUBICIN, DOCETAXEL AND NIVOLUMAB FOR ADVANCED LEIOMYOSARCOMA (NCT04535713)
Neal Chawla
Favorite
(P 553) A PHASE 1/2A OPEN-LABEL, DOSE-ESCALATION/DOSE EXPANSION SAFETY, TOLERABILITY AND PHARMACOKINETIC STUDY OF IMX-110 IN PATIENTS WITH ADVANCED SOLID TUMORS
Neal Chawla
Favorite
Chawla, Sant

Sarcoma Oncology Center
(P 111) INTERIM ANALYSIS OF A PHASE 1 STUDY USING IL12-FHAB WITH OPTIMIZED PHARMACOKINETICS
Sant Chawla
Favorite
(P 112) PHASE 1/2 STUDY OF YH001, A CTLA-4 ANTIBODY WITH THE SUBCUTANEOUSLY ADMINISTERED PD-L1 ANTIBODY ENVAFOLIMAB, WITH OR WITHOUT DOXORUBICIN IN PATIENTS WITH ADVANCED OR METASTATIC SOFT TISSUE SARCOMA
Sant Chawla
Favorite
(P 116) UPDATE ON SAINT: RESULTS OF 100 PATIENTS TREATED WITH IPILIMUMAB (I), NIVOLUMAB (N) AND TRABECTEDIN (T) AS FIRST LINE THERAPY FOR ADVANCED SOFT TISSUE SARCOMA [NCT03138161]
Sant Chawla
Favorite
(P 117) INTERIM ANALYSIS OF PHASE 2 STUDY: A METRONOMIC REGIMEN USING GEMCITABINE, DOXORUBICIN, DOCETAXEL AND NIVOLUMAB FOR ADVANCED LEIOMYOSARCOMA (NCT04535713)
Sant Chawla
Favorite
(P 178) INITIAL RESULTS FROM A PHASE 1 STUDY OF CFT8634, A NOVEL BIFUCTIONAL DEGRADATION ACTIVATING COMPOUND (BIDAC) DEGRADER OF BRD9, IN SYNOVIAL SARCOMA AND SMARCB1-NULL TUMORS
Sant Chawla
Favorite
(P 183) A PHASE 1B/2 STUDY OF LIPOSOMAL ANNAMYCIN (ANN) IN SUBJECTS WITH PREVIOUSLY TREATED SOFT-TISSUE SARCOMAS (STS) WITH PULMONARY METASTASES
Sant Chawla
Favorite
(P 184) PHASE 1B TRIAL OF CAMSIRUBICIN, A NOVEL DOXORUBICIN ANALOG, WITH CONCOMITANT PEGFILGRASTIM IN SUBJECTS WITH ADVANCED SOFT TISSUE SARCOMA TO IDENTIFY A NEW MTD/RP2D
Sant Chawla
Favorite
(P 185) LONGITUDINAL MUTATIONAL ANALYSIS OF TP53 IN CIRCULATING TUMOR DNA IN THE PLASMA OF PATIENTS WITH LIPOSARCOMA IN A PHASE I STUDY OF BRIGIMADLIN (BI 907828), AN MDM2-P53 ANTAGONIST
Sant Chawla
Favorite
(P 383) AI ANALYSIS SHOWS ENHANCED CCNG1 ONCOGENE EXPRESSION IN SARCOMA TUMORS AND SUPPORTS THE USE OF DELTAREX-G, A CCNG1 INHIBITOR, AS PLATFORM THERAPY FOR ADVANCED SARCOMA
Sant Chawla
Favorite
(P 439) THE TETRAVALENT DEATH RECEPTOR 5 AGONIST INBRX-109 COMBINED WITH CHEMOTHERAPY IN EWING SARCOMA: PRELIMINARY DATA FROM A PHASE 1 STUDY
Sant Chawla
Favorite
(P 531) ENVASARC: A PIVOTAL TRIAL OF ENVAFOLIMAB AND ENVAFOLIMAB IN COMBINATION WITH IPILIMUMAB IN PATIENTS WITH ADVANCED OR METASTATIC UPS OR MFS WHO HAVE PROGRESSED ON PRIOR CHEMOTHERAPY
Sant Chawla
Favorite
(P 548) A PHASE 2/3 STUDY EVALUATING THE EFFICACY AND SAFETY OF UNESBULIN IN ADVANCED LEIOMYOSARCOMA (SUNRISELMS)
Sant Chawla
Favorite
(P 553) A PHASE 1/2A OPEN-LABEL, DOSE-ESCALATION/DOSE EXPANSION SAFETY, TOLERABILITY AND PHARMACOKINETIC STUDY OF IMX-110 IN PATIENTS WITH ADVANCED SOLID TUMORS
Sant Chawla
Favorite
Checco, Martina Angela

Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia-Romagna, Laboratorio di Controllo di Prodotti Biologici, Centro di Referenza Nazionale per i Metodi Alternativi, Benessere e Cura degli Animali da Laboratorio
(P 283) A TRIDIMENSIONAL PRECLINICAL MODEL TO STUDY HUMAN AND CANINE OSTEOSARCOMA DEVELOPMENT AND INTERACTION WITH TUMOR MICROENVIRONMENT
Martina Angela Checco
Favorite
Chellappa, Venkatesh

Karolinska institutet
(P 243) EVALUATION OF THE USE OF WGS IN ROUTINE DIAGNOSTICS FOR BONE AND SOFT TISSUE TUMORS
Venkatesh Chellappa
Favorite
Chen, Andrew

Ottawa Hospital Research Institute
(P 98) TUMOR IMMUNE PROFILING AND IDENTIFICATION OF IMMUNOTHERAPEUTIC TARGETS IN DEDIFFERENTIATED LIPOSARCOMA
Andrew Chen
Favorite
Chen, Bo

Department of Osteopathic Oncology, Honghui Hospital, Xi'an Jiaotong University
(P 169) UPDATED EFFICACY AND SAFETY PROFILE OF PIMICOTINIB (ABSK021) IN TENOSYNOVIAL GIANT CELL TUMOR (TGCT): 1-YEAR FOLLOW-UP FROM PHASE 1B
Bo Chen
Favorite
Chen, Chun-Yu

Nationwide Children's Hospital
(P 107) TRABECTEDIN AUGMENTS ONCOLYTIC HERPES SIMPLEX VIROIMMUNOTHERAPY EFFICACY IN PRECLINCAL BONE SARCOMA MODELS THROUGH ENHANCED IMMUNE-MEDIATED MECHANISMS
Chun-Yu Chen
Favorite
(P 125) MYELOMODULATORY TREATMENTS AUGMENT THE THERAPEUTIC BENEFIT OF ONCOLYTIC VIRUS IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS BY MODULATING THE TUMOR MICROENVIRONMENT
Chun-Yu Chen
Favorite
Chen, Eleanor

University of Washington
(P 67) GENOMIC CHARACTERIZATION OF CHONDROSARCOMA: A RARE SARCOMA WITH CLINICAL RESPONSES TO IMMUNE CHECKPOINT INHIBITION
Eleanor Chen
Favorite
(P 206) A SINGLE-ARM, PHASE II STUDY OF NEOADJUVANT PEMBROLIZUMAB COMBINED WITH RADIOTHERAPY IN THE PRIMARY TREATMENT OF SOFT TISSUE SARCOMAS.
Eleanor Chen
Favorite
Cheng, Ann-Lii

National Taiwan University Hospital
(P 350) LIVER ANGIOSARCOMA IS ASSOCIATED WITH ARISTOLOCHIC ACID EXPOSURE AND HAS A DISTINCT TELOMERE MAINTENANCE MECHANISM
Ann-Lii Cheng
Favorite
Cheng, Donghang

MD Anderson Cancer Center
(P 101) EPIGENETIC MODULATION OF NK CELLS IMPROVES TUMOR TRAFFICKING AND ENHANCES THERAPEUTIC EFFICACY AGAINST OSTEOSARCOMA
Donghang Cheng
Favorite
Cheng, Edward

University of Minnesota
(P 167) FDG-PET-CT RESPONSE AFTER NEOADJUVANT CHEMOTHERAPY PREDICTS LONG-TERM OUTCOME IN PATIENTS WITH SOFT TISSUE SARCOMA -- 15-YEAR FOLLOW-UP
Edward Cheng
Favorite
Cheng, Yuwei

Division of Biostatistics and Bioinformatics, Herbert Wertheim School of Public Health and Human Longevity Science, University of California San Diego
(P 28) RETROSPECTIVE ANALYSIS OF SUCCINATE DEHYDROGENASE (SDH)-DEFICIENT GASTROINTESTINAL STROMAL TUMOR (GIST) OUTCOMES: AN INTERNATIONAL STUDY OF 256 PATIENTS
Yuwei Cheng
Favorite
Chen, Hao

Johns Hopkins University School of Medicine
(P 559) PROSPECTIVE PHASE II TRIAL OF PREOPERATIVE HYPOFRACTIONATED PROTON THERAPY FOR EXTREMITY AND TRUNCAL AND TRUNCAL SOFT TISSUE SARCOMA: THE PRONTO STUDY RATIONALE AND DESIGN
Hao Chen
Favorite
Chen, James

The Ohio State University
(P 452) SECONDARY GENOMIC LANDSCAPE OF CIC::DUX4 FUSION SARCOMAS
James Chen
Favorite
Chen, Jenny

Levine Cancer Institute
(P 258) THE CRITICALITY OF OXIDATIVE PHOSPHORYLATION IN SYNOVIAL SARCOMA METASTASIS
Jenny Chen
Favorite
Chen, Jia

Department of Oncology, Jiangsu Cancer Hospital
(P 44) RIPRETINIB FOR THE TREATMENT OF CHINESE PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS HARBORING KIT SECONDARY MUTATIONS: A MULTICENTER, RETROSPECTIVE STUDY
Jia Chen
Favorite
(P 48) SIGNIFICANCE OF MONITORING PLASMA CONCENTRATION OF RIPRETINIB IN CHINESE PATIENTS WITH GASTROINTESTINAL STROMAL TUMORS
Jia Chen
Favorite
chen, jiansi

Department of Medical Image Center, Affiliated Tumor Hospital of Guangxi Medical University
(P 39) MANAGEMENT PRACTICES OF GASTROINTESTINAL STROMAL TUMORS: A QUESTIONNAIRE SURVEY OF GENERAL SURGEONS IN CHINA
jiansi chen
Favorite
Chen, Jun

Retroperitoneal Tumours Centre, Peking University International Hospital, Beijing, China
(P 398) INTEGRATED MULTI-OMICS APPROACH REVEALED TUMOR-ASSOCIATED TERTIARY LYMPHOID STRUCTURE LANDSCAPE IN RETROPERITONEAL LIPOSARCOMA
Jun Chen
Favorite
(P 534) NEOADJUVANT CHEMOTHERAPY COMBINED WITH TARGETED TREATMENT IN HIGH-RISK RETROPERITONEAL SARCOMA – A PROSPECTIVE NON-RANDOMIZED CONTROLLED MULTI-CENTERED STUDY ALL ACROSS CHINA
Jun Chen
Favorite
Chen, Sonja

Nationwide Children's Hospital/The Ohio State University College of Medicine
(P 409) IMMUNOHISTOCHEMICAL STAINING FOR MYOGENIN, AP2 BETA AND HMGA2 PREDICT FOXO1 FUSION STATUS IN RHABDOMYOSARCOMA: A REPORT FROM THE SOFT TISSUE COMMITTEE OF THE CHILDREN'S ONCOLOGY GROUP
Sonja Chen
Favorite
(P 425) CHARACTERIZATION OF RHABDOMYOSARCOMA WITH PAX7::FOXO1 FUSIONS: A REPORT FROM THE SOFT TISSUE COMMITTEE OF THE CHILDREN'S ONCOLOGY GROUP
Sonja Chen
Favorite
(P 438) ALVEOLAR RHABDOMYOSARCOMA WITH "BURKITT-LIKE" MORPHOLOGY IS ASSOCIATED WITH HIGH AMPLIFICATION OF MYCL
Sonja Chen
Favorite
Chen, Tom Wei-Wu

National Taiwan University Hospital
(P 139) ULTRA-RARE SARCOMAS HAVE WORSE SURVIVAL COMPARED TO NON-ULTRA-RARE SARCOMAS: A NATIONAL CANCER REGISTRY STUDY
Tom Wei-Wu Chen
Favorite
(P 168) A PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF PEXIDARTINIB IN ASIAN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR
Tom Wei-Wu Chen
Favorite
(P 350) LIVER ANGIOSARCOMA IS ASSOCIATED WITH ARISTOLOCHIC ACID EXPOSURE AND HAS A DISTINCT TELOMERE MAINTENANCE MECHANISM
Tom Wei-Wu Chen
Favorite
(P 399) CRITICAL MOLECULAR PATHWAYS ASSOCIATED WITH DIFFERENT HISTOPATHOLOGY FEATURES AND DETAILED PATTERNS OF IMMUNE CELL INFILTRATES IN EPITHELIOID HEMANGIOENDOTHELIOMA (EHE)
Tom Wei-Wu Chen
Favorite
Chen, Weida

Department of Retroperitoneal Tumor Surgery, Peking University International Hospital
(P 534) NEOADJUVANT CHEMOTHERAPY COMBINED WITH TARGETED TREATMENT IN HIGH-RISK RETROPERITONEAL SARCOMA – A PROSPECTIVE NON-RANDOMIZED CONTROLLED MULTI-CENTERED STUDY ALL ACROSS CHINA
Weida Chen
Favorite
Chen, Yen-Lin

Massachusetts General Hospital
(P 338) PREOPERATIVE RADIATION THERAPY IS NOT ASSOCIATED WITH ADVERSE POSTOPERATIVE OUTCOMES IN PATIENTS WITH RETROPERITONEAL SARCOMA
Yen-Lin Chen
Favorite
Chen, Zebin

The First Affiliated Hospital of Sun Yat-sen University
(P 45) THE LONG-TERM EFFECT OF IMATINIB WITH HEPATIC RESECTION OR OTHER LOCAL TREATMENT FOR GIST LIVER METASTASES
Zebin Chen
Favorite
Cheung, Kingsley

Prince of Wales Hospital, Hong Kong
(P 290) PRE-CLINICAL STUDY OF TUMOR TREATING FIELDS (TTFIELDS) ALONE OR IN CONJUNCTION WITH SYSTEMIC THERAPIES IN SELECTED BONE- AND SOFT-TISSUE SARCOMAS
Kingsley Cheung
Favorite
Cheung, Phyllis

Bridge Institute of Experimental Tumor Therapy, West German Cancer Center, University Hospital Essen
(P 248) FIBROBLAST ACTIVATION PROTEIN ALPHA -DIRECTED IMAGING AND THERAPY OF SOLITARY FIBROUS TUMOR
Phyllis Cheung
Favorite
Chia, Claramae

Department of Sarcoma, Peritoneal and Rare Tumours (SPRinT), Division of Surgery and Surgical Oncology, National Cancer Centre Singapore
(P 336) EVOLUTION AND PURSUIT OF EXCELLENCE IN SARCOMA MANAGEMENT IN AN ASIAN TERTIARY SARCOMA SPECIALISED CENTRE
Claramae Chia
Favorite
Chiang, Ruru Chun-Ju

National Taiwan University
(P 139) ULTRA-RARE SARCOMAS HAVE WORSE SURVIVAL COMPARED TO NON-ULTRA-RARE SARCOMAS: A NATIONAL CANCER REGISTRY STUDY
Ruru Chun-Ju Chiang
Favorite
Chiarappa, Frank

University of California San Diego
(P 489) SIMULTANEOUS VERSUS DELAYED FLAP RECONSTRUCTION FOLLOWING SOFT TISSUE SARCOMA RESECTION
Frank Chiarappa
Favorite
(P 490) TOPICAL ANTIBIOTICS DECREASE INFECTIONS IN EXTREMITY SARCOMA SURGERY
Frank Chiarappa
Favorite
Chibon, Frederic

Cancer Research Center of Toulouse
(P 104) COMPREHENSIVE IMMUNE PROFILING UNVEILS A SUBSET OF LEIOMYOSARCOMA WITH HOT TUMOR IMMUNE MICROENVIRONMENT
Frederic Chibon
Favorite
(P 201) PLEOMORPHIC RHABDOMYOSARCOMAS: A NEW ENTITY ASSOCIATED WITH LYNCH SYNDROME? FIRST RESULTS OF SARCLYNCH NATIONAL STUDY
Frederic Chibon
Favorite
(P 268) IMPACT OF CELLULAR FUSION IN THE ONCOGENESIS OF LEIOMYOSARCOMAS
Frederic Chibon
Favorite
Chidiac, Charbel

The Johns Hopkins Hospital
(P 143) EXPLORING HOSPITAL VOLUME THRESHOLDS FOR IMPROVED SARCOMA TREATMENT ACROSS DIFFERENT AGE CATEGORIES IN THE UNITED STATES
Charbel Chidiac
Favorite
Chin Chang, Yen

University College Hospitals London
(P 321) IDENTIFYING RISK FACTORS FOR REDUCTION OF PROTON THERAPY RE-PLANS FOR PAEDIATRIC PATIENTS WITH PELVIC SARCOMAS
Yen Chin Chang
Favorite
Chi, Ping

Memorial Sloan Kettering Cancer Center
(P 24) COMPREHENSIVE ANALYSIS OF THE GENOMIC LANDSCAPE AND CLINICAL BEHAVIOR IN GIST USING NEXT GENERATION SEQUENCING (NGS, MSK-IMPACT)
Ping Chi
Favorite
Chisholm, Julia

Children and Young Peoples Unit, Royal Marsden Hospital and Institute of Cancer Research
(P 209) PROGNOSTIC VALUE OF EARLY RADIOLOGIC TUMOUR VOLUME RESPONSE IN RHABDOMYOSARCOMA; RESULTS OF THE EUROPEAN PAEDIATRIC SOFT TISSUE SARCOMA STUDY GROUP RMS 2005 STUDY
Julia Chisholm
Favorite
Chitalia, Rhea

Invicro
(P 408) CHANGES IN COMPUTED TOMOGRAPHY FEATURES INDUCED BY BRIGIMADLIN (BI 907828) IN PATIENTS WITH LIPOSARCOMA: INSIGHTS FROM PHASE I STUDIES
Rhea Chitalia
Favorite
Chitalkar, Prakash

Sri Aurobindo Institute of Medical Sciences, Indore, India
(P 06) ONCOFERTILITY AND PREGNANCY IN ADOLESCENT AND YOUNG ADULT CANCERS: PHYSICIANS' KNOWLEDGE AND PREFERENCES IN A LARGE LOW-MIDDLE- INCOME COUNTRY
Prakash Chitalkar
Favorite
Chiusole, Benedetta

Oncology 1 Unit, Department of Oncology, Veneto Institute of Oncology IOV - IRCCS
(P 171) SEX DIFFERENCES IN OUTCOMES AND TOXICITY IN PATIENTS TREATED FOR SARCOMA IN A REFERENCE CENTER
Benedetta Chiusole
Favorite
(P 216) BRAIN METASTASES IN SARCOMA: A (NOT SO) RARE EVENT. THE EXPERIENCE OF A HIGH VOLUME CENTER
Benedetta Chiusole
Favorite
(P 455) EXTRASKELETAL EWING SARCOMA: A MULTICENTRIC RETROSPECTIVE STUDY FROM THE ITALIAN SARCOMA GROUP
Benedetta Chiusole
Favorite
Chi, Yueh-Yun

Children's Hospital Los Angeles
(P 430) UNIQUE HISTOLOGIC MORPHOLOGY OF EWING SARCOMA CELLS THAT HARBOR TP53 MUTATIONS
Yueh-Yun Chi
Favorite
Cho, Haeun

Korea Institute of Radiation and Medical Sciences
(P 281) FIVE DAY SPACING OF TWO FRACTIONATED ABLATIVE RADIOTHERAPIES ENHANCES ANTITUMOR IMMUNITY IN FIBROSARCOMA CELL LINE
Haeun Cho
Favorite
Cho, L. Chinsoo

University of Minnesota
(P 167) FDG-PET-CT RESPONSE AFTER NEOADJUVANT CHEMOTHERAPY PREDICTS LONG-TERM OUTCOME IN PATIENTS WITH SOFT TISSUE SARCOMA -- 15-YEAR FOLLOW-UP
L. Chinsoo Cho
Favorite
Chong, Clara

Laboratory of Applied Human Genetics, Division of Medical Sciences, National Cancer Centre Singapore
(P 336) EVOLUTION AND PURSUIT OF EXCELLENCE IN SARCOMA MANAGEMENT IN AN ASIAN TERTIARY SARCOMA SPECIALISED CENTRE
Clara Chong
Favorite
Chorny, Michael

University of Pennsylvania Perelman School of Medicine; Children's Hospital of Philadelphia
(P 565) AN EARLY PHASE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF PEEL-224 IN PATIENTS WITH ADVANCED SOLID TUMORS
Michael Chorny
Favorite
Cho, Sukjoo

Department of Pediatrics, University of South Florida Morsani College of Medicine
(P 91) BLOOD TRANSFUSION AND SURVIVAL AMONG CHILD, ADOLESCENT, AND YOUNG ADULT PATIENTS WITH OSTEOSARCOMA: A RETROSPECTIVE COHORT STUDY
Sukjoo Cho
Favorite
Cho, Sunny

SpringWorks Therapeutics Inc
(P 188) IMPACT OF NIROGACESTAT ON FUNCTIONAL STATUS IN PATIENTS WITH DESMOID TUMORS: RESULTS FROM THE PHASE 3 DEFI STUDY
Sunny Cho
Favorite
Chow, Warren

University of California, Irvine
(P 326) MOLECULAR LANDSCAPE OF ENDOMETRIAL STROMAL SARCOMA IN A LARGE REAL-WORLD PATIENT COHORT
Warren Chow
Favorite
Choy, Edwin

Mass General Cancer Center
(P 172) PHASE 2 RESULTS FROM THE RINGSIDE PHASE 2/3 TRIAL OF AL102 FOR TREATMENT OF DESMOID TUMORS
Edwin Choy
Favorite
(P 338) PREOPERATIVE RADIATION THERAPY IS NOT ASSOCIATED WITH ADVERSE POSTOPERATIVE OUTCOMES IN PATIENTS WITH RETROPERITONEAL SARCOMA
Edwin Choy
Favorite
Christensen, Anthony

St. Jude Children's Research Hospital
(P 528) SAFETY AND TOLERABILITY OF ORAL CYCLOPHOSPHAMIDE AND SORAFENIB WITH INTRAVENOUS BEVACIZUMAB WITH THE ADDITION OF ATEZOLIZUMAB IN PEDIATRIC SOLID TUMOR PATIENTS
Anthony Christensen
Favorite
Christensen, Stine

Copenhagen University Hospital at Herlev, Denmark
(P 157) QUALITY OF LIFE DURING TREATMENT FOR METASTATIC SARCOMA - FEASIBILITY OF ELECTRONIC PATIENT REPORTED OUTCOMES
Stine Christensen
Favorite
Christo, Jessica

IDRx, Inc
(P 26) PHASE 1 STUDY OF IDRX-42 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS RESISTANT TO PRIOR SYSTEMIC THERAPY: EARLY RESULTS
Jessica Christo
Favorite
Chua, Victoria

Sarcoma Oncology Center
(P 111) INTERIM ANALYSIS OF A PHASE 1 STUDY USING IL12-FHAB WITH OPTIMIZED PHARMACOKINETICS
Victoria Chua
Favorite
(P 116) UPDATE ON SAINT: RESULTS OF 100 PATIENTS TREATED WITH IPILIMUMAB (I), NIVOLUMAB (N) AND TRABECTEDIN (T) AS FIRST LINE THERAPY FOR ADVANCED SOFT TISSUE SARCOMA [NCT03138161]
Victoria Chua
Favorite
(P 117) INTERIM ANALYSIS OF PHASE 2 STUDY: A METRONOMIC REGIMEN USING GEMCITABINE, DOXORUBICIN, DOCETAXEL AND NIVOLUMAB FOR ADVANCED LEIOMYOSARCOMA (NCT04535713)
Victoria Chua
Favorite
(P 184) PHASE 1B TRIAL OF CAMSIRUBICIN, A NOVEL DOXORUBICIN ANALOG, WITH CONCOMITANT PEGFILGRASTIM IN SUBJECTS WITH ADVANCED SOFT TISSUE SARCOMA TO IDENTIFY A NEW MTD/RP2D
Victoria Chua
Favorite
(P 553) A PHASE 1/2A OPEN-LABEL, DOSE-ESCALATION/DOSE EXPANSION SAFETY, TOLERABILITY AND PHARMACOKINETIC STUDY OF IMX-110 IN PATIENTS WITH ADVANCED SOLID TUMORS
Victoria Chua
Favorite
Chudasama, Priya

Precision Sarcoma Research Group, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg
(P 124) UNLOCKING THE POTENTIAL OF MEASLES VIRUS ONCOLYTIC IMMUNOTHERAPY FOR SARCOMA: BIOMARKER DISCOVERY AND THERAPEUTIC VACCINE DEVELOPMENT
Priya Chudasama
Favorite
Chugh, Rashmi

University of Michigan Rogel Cancer Center
(P 07) IDENTIFYING CONCERNS OF ADOLESCENT AND YOUNG ADULT SARCOMA PATIENTS AND SURVIVORS FOLLOWING FERTIITY PRESERVATION
Rashmi Chugh
Favorite
(P 172) PHASE 2 RESULTS FROM THE RINGSIDE PHASE 2/3 TRIAL OF AL102 FOR TREATMENT OF DESMOID TUMORS
Rashmi Chugh
Favorite
(P 188) IMPACT OF NIROGACESTAT ON FUNCTIONAL STATUS IN PATIENTS WITH DESMOID TUMORS: RESULTS FROM THE PHASE 3 DEFI STUDY
Rashmi Chugh
Favorite
(P 293) GENERATION OF A SPONTANEOUS IMMUNOCOMPETENT MOUSE MODEL OF LIPOSARCOMA
Rashmi Chugh
Favorite
(P 439) THE TETRAVALENT DEATH RECEPTOR 5 AGONIST INBRX-109 COMBINED WITH CHEMOTHERAPY IN EWING SARCOMA: PRELIMINARY DATA FROM A PHASE 1 STUDY
Rashmi Chugh
Favorite
(P 449) CIC-DUX4 sarcomas: A single-center review of clinical features and molecular aberrations identified through DNA sequencing
Rashmi Chugh
Favorite
(P 548) A PHASE 2/3 STUDY EVALUATING THE EFFICACY AND SAFETY OF UNESBULIN IN ADVANCED LEIOMYOSARCOMA (SUNRISELMS)
Rashmi Chugh
Favorite
Chuleerarux, Nipat

University of Miami
(P 158) SORAFENIB OR ANTHRACYCLINE-BASED CHEMOTHERAPY IN ADULT PATIENTS WITH PROGRESSIVE DESMOID TUMORS
Nipat Chuleerarux
Favorite
Chun, Danielle

Southern California Permanente Group
(P 474) PREDICTORS OF EARLY INTROWTH AND FAILURE FOLLOWING SHORT COMPRESS SPINDLE OSSEOINTEGRATION FIXATION AT THE LOWER EXTREMITIES
Danielle Chun
Favorite
Chung, Elaine

Kaiser Permanente
(P 224) CO-MUTATION-DEPENDENT PROGNOSIS IN PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA
Elaine Chung
Favorite
Chung, Peter

Princess Margaret Cancer Centre
(P 367) CHARACTERIZING HYPOXIA AND ASSOCIATED MOLECULAR FEATURES IN EXTREMITY SOFT TISSUE SARCOMA
Peter Chung
Favorite
(P 483) DID THE COVID-19 PANDEMIC NEGATIVELY AFFECT OUTCOMES FOR PATIENTS WITH EXTREMITY SOFT TISSUE SARCOMAS?
Peter Chung
Favorite
Chun, Liane

University of California San Diego
(P 489) SIMULTANEOUS VERSUS DELAYED FLAP RECONSTRUCTION FOLLOWING SOFT TISSUE SARCOMA RESECTION
Liane Chun
Favorite
Chu, Randy

MD Anderson Cancer Center
(P 394) LEIOMYOSARCOMA INTRATUMORAL MACROPHAGE INFILTRATES ARE ASSOCIATED WITH DISTINCT CLINICAL AND GENOMIC PRESENTATIONS
Randy Chu
Favorite
Church, Alanna

Dana-Farber/Boston Children's Cancer and Blood Disorders Center
(P 03) EVOLUTION OF CLINICALLY ACTIONABLE VARIANTS IN ADVANCED PEDIATRIC AND AYA BONE SARCOMAS
Alanna Church
Favorite
Cicala, Carlo

Vall d'Hebron Institute of Oncology
(P 326) MOLECULAR LANDSCAPE OF ENDOMETRIAL STROMAL SARCOMA IN A LARGE REAL-WORLD PATIENT COHORT
Carlo Cicala
Favorite
Cingarlini, Sara

University of Verona
(P 272) A COMPARATIVE ASSESSMENT OF SELINEXOR WITH TRABECTEDIN OR LURBINECTEDIN IN PATIENT-DERIVED XENOGRAFTS (PDX) OF DEDIFFERENTIATED LIPOSARCOMA (DDLPS)
Sara Cingarlini
Favorite
Cini, John

Sonnet BioTherapeutics
(P 111) INTERIM ANALYSIS OF A PHASE 1 STUDY USING IL12-FHAB WITH OPTIMIZED PHARMACOKINETICS
John Cini
Favorite
Civantos, Gonzalo

Hospital Clínico San Carlos
(P 515) ENDOBRONCHIAL NAVIGATION AS AN INTRAOPERATORY TOOL FOR RESECTION OF SMALL PULMONARY METASTASES IN SARCOMA PATIENTS
Gonzalo Civantos
Favorite
Clarke, Callisia

Medical College Of Wisconsin - Surgical Oncology
(P 181) REAL-WORLD EXPERIENCE WITH LIPOSOMAL DOXORUBICIN IN METASTATIC AND LOCALLY ADVANCED SARCOMA
Callisia Clarke
Favorite
(P 346) DETECTION OF GERMLINE VARIANTS IN PATIENTS DIAGNOSED WITH SOFT TISSUE SARCOMA USING EXPANDED
Callisia Clarke
Favorite
(P 473) GROIN PAINS: APPROACHES AND OUTCOMES FOR INGUINOFEMORAL SOFT TISSUE SARCOMAS
Callisia Clarke
Favorite
Clarkson, Paul

British Columbia Children's Hospital
(P 512) PERIOPERATIVE BLOOD MANAGEMENT IN PEDIATRIC PATIENTS UNDERGOING PRIMARY OSTEOSARCOMA AND EWING SARCOMA RESECTION: A RETROSPECTIVE CASE NOTE REVIEW
Paul Clarkson
Favorite
Claude, Line

Leon Berard Center
(P 69) DEVELOPMENT AND MISSION OF THE HARMONIZATION INTERNATIONAL BONE SARCOMA CONSORTIUM (HIBISCUS)
Line Claude
Favorite
Cleary, Emmett

Mayo Clinic
(P 59) CHONDROSARCOMA OF THE FLAT BONES: DIFFERENTIAL SURVIVAL BETWEEN HIGH GRADE LESIONS OF THE PELVIS AND SCAPULA
Emmett Cleary
Favorite
(P 60) SKIP LESIONS IN CHONDROSARCOMA: IS WHOLE BONE IMAGING NECESSARY?
Emmett Cleary
Favorite
Clemente, Ottavia

Istituto Nazionale Tumori IRCCS Fondazione G. Pascale
(P 144) IMPLEMENTATION OF THE EUROPEAN CLINICAL TRIAL REGULATION: SURVEY OF THE ITALIAN SARCOMA GROUP CENTERS
Ottavia Clemente
Favorite
Clerici, Elena

Rozzano, Milan IRCCS Humanitas Research Hospital
(P 327) LEARNING CURVE ANALYSIS IN RETROPERITONEAL SARCOMA SURGERY
Elena Clerici
Favorite
(P 457) LONG-TERM FOLLOW-UP OF PATIENTS WITH ATYPICAL LIPOMATOUS TUMOR (ALT) TREATED WITH MARGINAL RESECTION IN A REFERRAL CENTER
Elena Clerici
Favorite
Clohisy, Denis

University of Minnesota
(P 167) FDG-PET-CT RESPONSE AFTER NEOADJUVANT CHEMOTHERAPY PREDICTS LONG-TERM OUTCOME IN PATIENTS WITH SOFT TISSUE SARCOMA -- 15-YEAR FOLLOW-UP
Denis Clohisy
Favorite
Cloutier, Jeffrey

MD Anderson Cancer Center
(P 71) CHEMOTHERAPY AND PROGNOSTIC SIGNIFICANCE OF EXTENT OF DEDIFFERENTIATION IN DEDIFFERENTIATED PAROSTEAL OSTEOSARCOMA
Jeffrey Cloutier
Favorite
Cobrinik, David

Children's Hospital Los Angeles
(P 166) SARC038: A PHASE 2 STUDY OF REGORAFENIB IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH REFRACTORY OR RECURRENT OSTEOSARCOMA
David Cobrinik
Favorite
Cocchi, Claudia

Istituto Scientifico Romagnolo per lo studio dei Tumori "Dino Amadori", Preclinic and Osteoncology Unit, Meldola, Italy
(P 37) DISSECTING THE ROLE OF EXTRACELLULAR VESICLES IN THE MANAGEMENT OF GIST
Claudia Cocchi
Favorite
(P 253) THE EFFICACY OF MEDICATED PATCHES IN SOFT TISSUE SARCOMAS: IN-VITRO AND EX-VIVO VALIDATION.
Claudia Cocchi
Favorite
Coert, J.

UMC Utrecht
(P 316) THE ROLE OF RADIOTHERAPY IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS: A MULTICENTER COHORT STUDY
J. Coert
Favorite
(P 505) LOCAL RECURRENCE IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS: A MULTICENTER COHORT STUDY
J. Coert
Favorite
Cohen-Gogo, Sarah

The Hospital for Sick Children
(P 81) OPTIMIZING EWING SARCOMA AND OSTEOSARCOMA BIOPSY ACQUISITION: CONSENSUS RECOMMENDATIONS FROM THE CHILDREN'S ONCOLOGY GROUP BONE TUMOR COMMITTEE
Sarah Cohen-Gogo
Favorite
Cohen, Jacob

University of Miami
(P 520) ORTHOPEDIC MANIFESTATIONS OF LYMPHOPROLIFERATIVE NEOPLASMS
Jacob Cohen
Favorite
Cohen, Sonia

Massachusetts General Hospital
(P 338) PREOPERATIVE RADIATION THERAPY IS NOT ASSOCIATED WITH ADVERSE POSTOPERATIVE OUTCOMES IN PATIENTS WITH RETROPERITONEAL SARCOMA
Sonia Cohen
Favorite
Cojocaru, Elena

Cambridge University Hospitals NHS Foundation Trust
(P 204) RADIATION-INDUCED ANGIOSARCOMA OF THE BREAST: RETROSPECTIVE ANALYSIS AT A REGIONAL TREATMENT CENTRE
Elena Cojocaru
Favorite
Colglazier, Roy

Duke University Hospital
(P 509) GIANT CELL TUMOR OF BONE IN THE PEDIATRIC POPULATION: A RETROSPECTIVE STUDY HIGHLIGHTING CASES OF METAPHYSEAL ONLY LOCATION AND INCREASED LOCAL RECURRENCE RATES IN SKELETALLY IMMATURE PATIENTS
Roy Colglazier
Favorite
Coll Zayas, Yaquelin

University of Florida
(P 99) M2 MACROPHAGE INFILTRATION IS ASSOCIATED WITH EARLY DISEASE RECURRENCE FOLLOWING CURATIVE INTENT SURGICAL RESECTION IN SOFT-TISSUE SARCOMAS
Yaquelin Coll Zayas
Favorite
Collaud, Stéphane

Cologne Merheim Hospital
(P 451) IMPACT OF TIME TO DIAGNOSIS - A PROSPECTIVE ANALYSIS OF THE EWING 2008 TRIAL
Stéphane Collaud
Favorite
Collier, Anderson

Nemours Children's Health
(P 444) TWO CASES OF BRAIN METASTASES OF CD99 POSITIVE SMALL ROUND BLUE CELL TUMORS
Anderson Collier
Favorite
(P 556) EVALUATION OF PALBOCICLIB (IBRANCE®) IN COMBINATION WITH CHEMOTHERAPY IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY EWING SARCOMA OR NEUROBLASTOMA
Anderson Collier
Favorite
Collini, Paola

Department of Advanced Diagnostics , Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
(P 272) A COMPARATIVE ASSESSMENT OF SELINEXOR WITH TRABECTEDIN OR LURBINECTEDIN IN PATIENT-DERIVED XENOGRAFTS (PDX) OF DEDIFFERENTIATED LIPOSARCOMA (DDLPS)
Paola Collini
Favorite
(P 273) COMPARISON OF A PATIENT-DERIVED XENOGRAFTS (PDX) OF MYXOID PLEOMORPHIC LIPOSARCOMA (MPL) AND PLEOMORPHIC LIPOSARCOMA (PL) HIGHLIGHTS THE EFFECTIVENESS OF ERIBULIN IN A PDX OF MPL
Paola Collini
Favorite
(P 329) DISTANT METASTASIS IN RETROPERITONEAL LEIOMYOSARCOMA: TUMOR SIZE, GRADE AND MORE?
Paola Collini
Favorite
(P 333) SYSTEMIC TREATMENT IN INTRA-ABDOMINAL DESMOID-TYPE FIBROMATOSIS: A SINGLE INSTITUTION RETROSPECTIVE CASE SERIES ANALYSIS
Paola Collini
Favorite
(P 431) TREATMENT STRATEGY AND PROGNOSTIC FACTORS IN EXTRASKELETAL EWING SARCOMA: AN INSTITUTIONAL RETROSPECTIVE ANALYSIS
Paola Collini
Favorite
(P 432) LONG-LASTING DISEASE CONTROL WITH TRABECTEDIN IN A CASE OF METASTATIC EWSR1::PATZ1 SARCOMA
Paola Collini
Favorite
(P 455) EXTRASKELETAL EWING SARCOMA: A MULTICENTRIC RETROSPECTIVE STUDY FROM THE ITALIAN SARCOMA GROUP
Paola Collini
Favorite
Collins, Mike

Foghorn Therapeutics
(P 271) PHARMACODYNAMICS AND MECHANISTIC IMPACTS OF FHD-609, A BROMODOMAIN-CONTAINING PROTEIN 9 DEGRADER, IN A PHASE 1 STUDY IN PATIENTS WITH ADVANCED SYNOVIAL SARCOMA OR SMARCB1-LOSS TUMORS
Mike Collins
Favorite
Collins, Natalie

Dana-Farber/Boston Children’s Cancer and Blood Disorders Center
(P 438) ALVEOLAR RHABDOMYOSARCOMA WITH "BURKITT-LIKE" MORPHOLOGY IS ASSOCIATED WITH HIGH AMPLIFICATION OF MYCL
Natalie Collins
Favorite
(P 542) ENROLLMENT OF PEDIATRIC PARTICIPANTS WITH MAGE-A4-POSITIVE SOLID TUMORS IN A PHASE 1/2, OPEN-LABEL, BASKET TRIAL OF AFAMITRESGENE AUTOLEUCEL ("AFAMI-CEL")
Natalie Collins
Favorite
Colman, Matthew

Rush University Medical Center
(P 63) EVALUATION OF LOCAL RECURRENCE AND DIAGNOSTIC DISCORDANCE IN CHONDROSARCOMA PATIENTS UNDERGOING PREOPERATIVE BIOPSY
Matthew Colman
Favorite
(P 468) OPIATE USE AFTER TOTAL HIP ARTHROPLASTY FOR METASTATIC BONE DISEASE
Matthew Colman
Favorite
(P 506) THE EFFECT OF TIMING BETWEEN PRE-OPERATIVE EMBOLIZATION AND SURGERY: A RETROSPECTIVE ANALYSIS OF HYPERVASCULAR BONE METASTASES
Matthew Colman
Favorite
Colombo, Chiara

Department of Surgery, Sarcoma Service, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
(P 14) PERCUTANEOUS CRYOABLATION OF PROGRESSING EXTRA-ABDOMINAL DESMOID TUMOURS
Chiara Colombo
Favorite
(P 126) CURRENT PRACTICE IN SPERMATIC CORD SARCOMA: ONCOLOGICAL TIMELINES AND OUTCOMES ACCORDING TO INITIAL RESECTIONS PERFORMED AT A LOCAL HOSPITAL VERSUS EARLY PATIENT REFERRAL TO A TERTIARY CENTRE.
Chiara Colombo
Favorite
(P 329) DISTANT METASTASIS IN RETROPERITONEAL LEIOMYOSARCOMA: TUMOR SIZE, GRADE AND MORE?
Chiara Colombo
Favorite
(P 333) SYSTEMIC TREATMENT IN INTRA-ABDOMINAL DESMOID-TYPE FIBROMATOSIS: A SINGLE INSTITUTION RETROSPECTIVE CASE SERIES ANALYSIS
Chiara Colombo
Favorite
(P 363) Β-CATENIN MUTATIONS AND TRANSCRIPTOMIC REPROGRAMMING IN DESMOID FIBROMATOSIS (DF)
Chiara Colombo
Favorite
Colombo, Nicoletta

IEO
(P 328) REAL-LIFE EXPERIENCE OF PAZOPANIB IN PATIENTS WITH ADVANCED UTERINE LEIOMYOSARCOMA (U-LMS) FROM TWO REFERRAL ITALIAN CENTERS
Nicoletta Colombo
Favorite
Colombo, Piergiuseppe

IRCCS Humanitas Research Hospital
(P 433) A 20-YEAR MONOCENTER EXPERIENCE ON CLINICAL CHARACTERISTICS AND OUTCOME OF EXTRASKELETAL EWING SARCOMA.
Piergiuseppe Colombo
Favorite
Comandini, Daniela

Ospedale Policlinico San Martino-IRCCS
(P 144) IMPLEMENTATION OF THE EUROPEAN CLINICAL TRIAL REGULATION: SURVEY OF THE ITALIAN SARCOMA GROUP CENTERS
Daniela Comandini
Favorite
Comeau, Hannah

Dana-Farber / Boston Children's Cancer and Blood Disorders Center
(P 03) EVOLUTION OF CLINICALLY ACTIONABLE VARIANTS IN ADVANCED PEDIATRIC AND AYA BONE SARCOMAS
Hannah Comeau
Favorite
Conley, Anthony

MD Anderson Cancer Center
(P 36) CLINICO-GENOMIC ANALYSIS OF KIT/PDGFRA/SDH WILD-TYPE GASTROINTESTINAL STROMAL TUMORS IDENTIFIES POTENTIAL DRIVER MUTATIONS
Anthony Conley
Favorite
(P 66) PHASE I STUDY OF THE MUTANT IDH1 INHIBITOR IVOSIDENIB: LONG-TERM SAFETY AND CLINICAL ACTIVITY IN PATIENTS WITH CONVENTIONAL CHONDROSARCOMA
Anthony Conley
Favorite
(P 71) CHEMOTHERAPY AND PROGNOSTIC SIGNIFICANCE OF EXTENT OF DEDIFFERENTIATION IN DEDIFFERENTIATED PAROSTEAL OSTEOSARCOMA
Anthony Conley
Favorite
(P 83) CLINICO-GENOMIC PROFILING OF CONVENTIONAL AND DEDIFFERENTIATED CHONDROSARCOMAS REVEALS TP53 MUTATION TO BE ASSOCIATED WITH WORSE OUTCOMES
Anthony Conley
Favorite
(P 100) HISTOLOGY SPECIFIC INTRATUMORAL B-CELL BIOLOGY IN ALVEOLAR SOFT-PART SARCOMAS (ASPS) IN RESPONSE TO DURVALUMAB-TREMELIMUMAB (D-T)
Anthony Conley
Favorite
(P 123) DEDIFFERENTIATED LIPOSARCOMAS TREATED WITH IMMUNE CHECKPOINT BLOCKADE: THE MD ANDERSON EXPERIENCE
Anthony Conley
Favorite
(P 360) TP53 ALTERATIONS IN SARCOMAS: AN ANALYSIS FROM THE AACR-GENIE DATABASE
Anthony Conley
Favorite
(P 394) LEIOMYOSARCOMA INTRATUMORAL MACROPHAGE INFILTRATES ARE ASSOCIATED WITH DISTINCT CLINICAL AND GENOMIC PRESENTATIONS
Anthony Conley
Favorite
(P 400) THE LANDSCAPE OF GENOMIC ALTERATIONS FROM 1494 SOFT TISSUE AND BONE SARCOMAS AT MD ANDERSON CANCER CENTER
Anthony Conley
Favorite
Connolly, Denise

University College London Hospital
(P 57) REAL-WORLD EXPERIENCE OF CABOZANTINIB IN PAEDIATRIC, TEENAGE AND YOUNG ADULT (TYA) AND ADULT METASTATIC BONE SARCOMA PATIENTS FROM THE LONDON SARCOMA SERVICE (LSS)
Denise Connolly
Favorite
Connolly, Elizabeth

Department of Medical Oncology, Chris O'Brien Lifehouse, Sydney, Australia. Faculty of medicine and health, University of Sydney, Sydney, Australia.
(P 189) INTERNATIONAL RETROSPECTIVE STUDY FROM THE ULTRA-RARE SARCOMA WORKING GROUP ON LOW-GRADE FIBROMYXOID SARCOMA AND SCLEROSING EPITHELIOD FIBROSARCOMA: OUTCOME OF ADVANCED DISEASE AND SYSTEMIC THERAPIES
Elizabeth Connolly
Favorite
Connolly, Elizabeth

Chris O Brien Lifehouse
(P 437) ULTRA-RARE UNDIFFERENTIATED SMALL ROUND CELL SARCOMA: HOW SHOULD WE TREAT THEM? AN ANALYSIS FORM THE GRACEFUL PROJECT
Elizabeth Connolly
Favorite
Conradi, Lena-Christin

Department of General, Visceral and Pediatric Surgery, University Medical Center Goettingen, 37075 Goettingen, Germany
(P 235) FUSION OF PREOPERATIVE IN SITU MAGNETIC RESONANCE IMAGING AND POSTOPERATIVE COMPUTED TOMOGRAPHY TO CORRELATE FUNCTIONAL IMAGING FEATURES AND PATHOLOGICAL CHARACTERISTICS OF SOFT TISSUE SARCOMA
Lena-Christin Conradi
Favorite
Consalvo, Sarah

Department of Orthopaedic Surgery, School of Medicine & Klinikum rechts der Isar, Technical University of Munich, 81675 Munich, Germany
(P 557) UNRAVELING THE ROLE OF LOCAL THERAPY FOR PATIENTS WITH OLIGOMETASTATIC SOFT TISSUE SARCOMA - A RETROSPECTIVE MULTICENTER TRIAL OF BAVARIAN UNIVERSITY HOSPITALS
Sarah Consalvo
Favorite
Constantinescu, David

University of Miami Miller School of Medicine
(P 485) SUBTROCHANTERIC NON-UNION AFTER INTRAMEDULLARY NAILING DUE TO PATHOLOGICAL FRACTURE:PROXIMAL FEMORAL REPLACEMENT AS A SALVAGE APPROACH
David Constantinescu
Favorite
Contreras, Carlo

The James Cancer Hospital / The Ohio State University
(P 314) PRE-OPERATIVE RADIATION THERAPY INCREASES ADHERENCE IN PATIENTS WITH HIGH-RISK EXTREMITY SOFT TISSUE SARCOMA
Carlo Contreras
Favorite
(P 347) INCIDENCE AND TIMING OF RECURRENCE AFTER ADJUVANT PALBOCICLIB IN COMPLETELY RESECTED RETROPERITONEAL LIPOSARCOMA
Carlo Contreras
Favorite
Conway, Sheila

Wake Forest University School of Medicine
(P 485) SUBTROCHANTERIC NON-UNION AFTER INTRAMEDULLARY NAILING DUE TO PATHOLOGICAL FRACTURE:PROXIMAL FEMORAL REPLACEMENT AS A SALVAGE APPROACH
Sheila Conway
Favorite
Cook, Chad

Duke University
(P 137) IMPACT OF SOCIAL DETERMINANTS OF HEALTH ON SARCOMA CARE: A SINGLE INSTITUTION EXPERIENCE
Chad Cook
Favorite
Coombs, Reilly

Medical College of Wisconsin-Central Wisconsin
(P 196) TOLERABILITY AND OUTCOMES FOR TREATMENT OF OLDER MYXOID LIPOSARCOMA POPULATION
Reilly Coombs
Favorite
Cope, Brandon

MD Anderson
(P 394) LEIOMYOSARCOMA INTRATUMORAL MACROPHAGE INFILTRATES ARE ASSOCIATED WITH DISTINCT CLINICAL AND GENOMIC PRESENTATIONS
Brandon Cope
Favorite
Coppadoro, Beatrice

Department of Pediatric Haematology and Oncology, University Hospital of Padua
(P 209) PROGNOSTIC VALUE OF EARLY RADIOLOGIC TUMOUR VOLUME RESPONSE IN RHABDOMYOSARCOMA; RESULTS OF THE EUROPEAN PAEDIATRIC SOFT TISSUE SARCOMA STUDY GROUP RMS 2005 STUDY
Beatrice Coppadoro
Favorite
Coppola, Enzo

The Ohio State University
(P 305) A NEW MOUSE MODEL FOR TESTING SPLICE-SWITCHING THERAPIES IN RHABDOMYOSARCOMA
Enzo Coppola
Favorite
Coppola, Marina

Pharmacy Unit, Veneto Institute of Oncology IOV - IRCCS
(P 171) SEX DIFFERENCES IN OUTCOMES AND TOXICITY IN PATIENTS TREATED FOR SARCOMA IN A REFERENCE CENTER
Marina Coppola
Favorite
Coquillard, Cristin

Northwestern Medicine
(P 480) TARGETED MUSCLE REINNERVATION FOR HIP DISARTICULATION - EVALUATION OF EARLY FUNCTIONAL OUTCOMES
Cristin Coquillard
Favorite
Cornmark, Louise

Lund University
(P 371) DISRUPTION OF THE TP53 LOCUS IN OSTEOSARCOMA LEADS TO TP53 PROMOTER GENE FUSIONS AND RESTORATION OF PARTS OF THE TP53 SIGNALLING PATHWAY
Louise Cornmark
Favorite
Corona, Juan Antonio

Hospital Clinico san Carlos
(P 149) PSYCOLOGICAL SNAPSHOT OF SARCOMA PATIENTS FROM AN ACADEMIC, UNIVERSITY CENTER, HOSPITAL CLÍNICO SAN CARLOS (HCSC), MADRID, A SARCOMA NATIONAL REFERRAL CENTRE IN SPAIN
Juan Antonio Corona
Favorite
Corradini, Nadège

CENTRE LEON BERARD
(P 382) NTRK1/2/3 FUSIONS DETECTION USING RNA-SEQ IN MESENCHYMAL TUMORS REVEALS ULTRA-RARE AND HISTO-SPECIFIC TARGETABLE ALTERATIONS: EXPERIENCE OF AN EXTENSIVE ROUTINE RESEARCH PROGRAM.
Nadège Corradini
Favorite
(P 435) ONCOGENIC FUSION YWHAE::NUTM2 DISRUPT EP300/BCOR INTERACTION
Nadège Corradini
Favorite
Corradini, Nadege

Institut d'Hematologie et d'Oncologie Pédiatrique, Centre Léon Bérard
(P 75) REAL-WORLD DATA ON REGORAFENIB AND CABOZANTINIB IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH RELAPSED OSTEOSARCOMA AND EWING SARCOMA INCLUDED IN THE SACHA-FRANCE STUDY
Nadege Corradini
Favorite
(P 202) INFLAMMATORY MYOFIBROBLASTIC TUMOUR WITH ROS1 GENE FUSIONS IN CHILDREN AND YOUNG ADOLESCENTS
Nadege Corradini
Favorite
(P 212) REPORT ON THE EWING SARCOMA PATIENTS ENROLLED IN ARM D OF THE ACSE-ESMART TRIAL: PHASE I/II STUDY OF THE PARP INHIBITOR OLAPARIB IN COMBINATION WITH IRINOTECAN IN CHILDREN WITH ADVANCED MALIGNANCIES
Nadege Corradini
Favorite
Cortes, Jose Antonio

Hospital Clinico san Carlos
(P 149) PSYCOLOGICAL SNAPSHOT OF SARCOMA PATIENTS FROM AN ACADEMIC, UNIVERSITY CENTER, HOSPITAL CLÍNICO SAN CARLOS (HCSC), MADRID, A SARCOMA NATIONAL REFERRAL CENTRE IN SPAIN
Jose Antonio Cortes
Favorite
Costa, Felipe

AC Camargo Cancer Center
(P 192) ROLE OF MAGNETIC RESONANCE IMAGING IN THE PREDICTION OF HISTOLOGICAL GRADE IN SOFT TISSUE SARCOMAS.
Felipe Costa
Favorite
Costa, Philippos

Yale University
(P 158) SORAFENIB OR ANTHRACYCLINE-BASED CHEMOTHERAPY IN ADULT PATIENTS WITH PROGRESSIVE DESMOID TUMORS
Philippos Costa
Favorite
Costas casal de Faria, Fernanda

The Ohio State University Comprehensive Cancer Center
(P 335) EXTRACELLULAR VESICLE MDM2 DNA AS A BIOMARKER OF TUMOR PRESENCE AND RECURRENCE IN RETROPERITONEAL LIPOSARCOMA
Fernanda Costas casal de Faria
Favorite
Costelloe, Colleen

MD Anderson cancer center
(P 221) EARLY RESULTS IN NOVEL USE OF CONTRAST-ENHANCED SUSCEPTIBILITY-WEIGHTED IMAGING IN THE ASSESSMENT OF RESPONSE AND PROGRESSION IN DESMOID FIBROMATOSIS: PILOT STUDY IN A SPECIALIZED CANCER INSTITUTION
Colleen Costelloe
Favorite
(P 239) CANCER RADIOMIC AND PERFUSION IMAGING (CARPI) AUTOMATED FRAMEWORK: VALIDATION ON MUSCULOSKELETAL TUMORS IN A SPECIALIZED CANCER CENTER
Colleen Costelloe
Favorite
(P 356) BASELINE AND POST-TREATMENT ADVANCED MRI OF EXTREMITIES SOFT-TISSUE NON-MYXOID UNDIFFERENTIATED PLEOMORPHIC SARCOMA.
Colleen Costelloe
Favorite
(P 357) APPARENT DIFFUSION COEFFICIENT (ADC) HIGH-ORDER RADIOMICS OF BASELINE AND POST-TREATMENT ADVANCED MRI OF EXTREMITY SOFT-TISSUE NON-MYXOID UNDIFFERENTIATED PLEOMORPHIC SARCOMA.
Colleen Costelloe
Favorite
(P 358) CONTRAST-ENHANCED SUSCEPTIBILITY IMAGING (CE-SWI) MORPHOLOGIC, FIRST & HIGH-ORDER RADIOMIC FEATURES VALUE IN ASSESSING TREATMENT RESPONSE IN EXTREMITY SOFT-TISSUE UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Colleen Costelloe
Favorite
(P 359) ROLE OF PERFUSION WEIGHTED IMAGING WITH DYNAMIC CONTRAST ENHANCED (PWI/DCE) FOR THE TREATMENT ASSESSMENT OF EXTREMITY SOFT-TISSUE NON-MYXOID UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Colleen Costelloe
Favorite
Cote, Gregory

Mass General Cancer Center
(P 66) PHASE I STUDY OF THE MUTANT IDH1 INHIBITOR IVOSIDENIB: LONG-TERM SAFETY AND CLINICAL ACTIVITY IN PATIENTS WITH CONVENTIONAL CHONDROSARCOMA
Gregory Cote
Favorite
(P 178) INITIAL RESULTS FROM A PHASE 1 STUDY OF CFT8634, A NOVEL BIFUCTIONAL DEGRADATION ACTIVATING COMPOUND (BIDAC) DEGRADER OF BRD9, IN SYNOVIAL SARCOMA AND SMARCB1-NULL TUMORS
Gregory Cote
Favorite
(P 338) PREOPERATIVE RADIATION THERAPY IS NOT ASSOCIATED WITH ADVERSE POSTOPERATIVE OUTCOMES IN PATIENTS WITH RETROPERITONEAL SARCOMA
Gregory Cote
Favorite
Cottereau, edouard

CHU Tours
(P 201) PLEOMORPHIC RHABDOMYOSARCOMAS: A NEW ENTITY ASSOCIATED WITH LYNCH SYNDROME? FIRST RESULTS OF SARCLYNCH NATIONAL STUDY
edouard Cottereau
Favorite
Coudert, Marie

ICP
(P 201) PLEOMORPHIC RHABDOMYOSARCOMAS: A NEW ENTITY ASSOCIATED WITH LYNCH SYNDROME? FIRST RESULTS OF SARCLYNCH NATIONAL STUDY
Marie Coudert
Favorite
Coukos, George

Ludwig Institut
(P 535) THERAGNOSTICS IN SOFT TISSUE SARCOMA USING A VASCULAR DISCRUPTION APPROACH
George Coukos
Favorite
Covello, Eva

IRCCS Humanitas Research Hospital
(P 457) LONG-TERM FOLLOW-UP OF PATIENTS WITH ATYPICAL LIPOMATOUS TUMOR (ALT) TREATED WITH MARGINAL RESECTION IN A REFERRAL CENTER
Eva Covello
Favorite
Coward, Victoria

The Lunenfeld-Tanenbaum Research Institute
(P 249) INVESTIGATING CLINICAL FACTORS ASSOCIATED WITH THE ESTABLISHMENT OF SUCCESSFUL PRIMARY HUMAN SOFT TISSUE SARCOMA CELL LINES
Victoria Coward
Favorite
(P 352) DETERMINING THE CONTRIBUTIONS OF STAT1 TO THE UPS ANTI-TUMOR MICROENVIRONMENT
Victoria Coward
Favorite
Cox, Jennifer

University of Mississippi Medical Center
(P 444) TWO CASES OF BRAIN METASTASES OF CD99 POSITIVE SMALL ROUND BLUE CELL TUMORS
Jennifer Cox
Favorite
Crago, Aimee

Memorial Sloan Kettering Cancer Center
(P 24) COMPREHENSIVE ANALYSIS OF THE GENOMIC LANDSCAPE AND CLINICAL BEHAVIOR IN GIST USING NEXT GENERATION SEQUENCING (NGS, MSK-IMPACT)
Aimee Crago
Favorite
(P 343) STEREOTACTIC BODY RADIATION THERAPY (SBRT) IN ADVANCED/RECURRENT RETROPERITONEAL SARCOMA: PRELIMINARY RESULTS
Aimee Crago
Favorite
Craig, Brian

Children's Wisconsin, Medical College of Wisconsin
(P 81) OPTIMIZING EWING SARCOMA AND OSTEOSARCOMA BIOPSY ACQUISITION: CONSENSUS RECOMMENDATIONS FROM THE CHILDREN'S ONCOLOGY GROUP BONE TUMOR COMMITTEE
Brian Craig
Favorite
Cranmer, Lee

University of Washington/Fred Hutchinson Cancer Center
(P 67) GENOMIC CHARACTERIZATION OF CHONDROSARCOMA: A RARE SARCOMA WITH CLINICAL RESPONSES TO IMMUNE CHECKPOINT INHIBITION
Lee Cranmer
Favorite
(P 177) ANGIOSARCOMA: AN INCREASING PROBLEM IN THE UNITED STATES
Lee Cranmer
Favorite
(P 184) PHASE 1B TRIAL OF CAMSIRUBICIN, A NOVEL DOXORUBICIN ANALOG, WITH CONCOMITANT PEGFILGRASTIM IN SUBJECTS WITH ADVANCED SOFT TISSUE SARCOMA TO IDENTIFY A NEW MTD/RP2D
Lee Cranmer
Favorite
(P 206) A SINGLE-ARM, PHASE II STUDY OF NEOADJUVANT PEMBROLIZUMAB COMBINED WITH RADIOTHERAPY IN THE PRIMARY TREATMENT OF SOFT TISSUE SARCOMAS.
Lee Cranmer
Favorite
(P 540) PHASE 2, MULTICENTER, OPEN-LABEL BASKET TRIAL OF NAB-SIROLIMUS FOR MALIGNANT SOLID TUMORS HARBORING PATHOGENIC INACTIVATING ALTERATIONS IN TSC1 AND TSC2 (PRECISION I)
Lee Cranmer
Favorite
Crawford, Brooke

University of Miami
(P 154) BARRIERS TO CARE FOR MUSCULOSKELETAL TUMORS
Brooke Crawford
Favorite
(P 520) ORTHOPEDIC MANIFESTATIONS OF LYMPHOPROLIFERATIVE NEOPLASMS
Brooke Crawford
Favorite
Crespo, Ana Maria

Hospital Clinico san Carlos
(P 149) PSYCOLOGICAL SNAPSHOT OF SARCOMA PATIENTS FROM AN ACADEMIC, UNIVERSITY CENTER, HOSPITAL CLÍNICO SAN CARLOS (HCSC), MADRID, A SARCOMA NATIONAL REFERRAL CENTRE IN SPAIN
Ana Maria Crespo
Favorite
Creytens, David

Ghent University Hospital
(P 55) RELATIVE WASH-IN RATE ON DYNAMIC CONTRAST-ENHANCED MRI AS A NEW PROGNOSTIC FACTOR IN PATIENTS WITH OSTEOSARCOMA; A POSSIBLE TOOL FOR PERSONALIZED SARCOMA-CARE?
David Creytens
Favorite
(P 291) DEVELOPMENT OF A LIVE TISSUE SARCOMA BIOBANK TO SUPPORT THE CREATION OF PATIENT-DERIVED TRANSLATIONAL MODELS
David Creytens
Favorite
(P 295) ORTHOTOPIC XENOGRAFTS OF PAIRED SARCOMA PRIMARY TUMOUR, LOCAL RELAPSE AND METASTATIC SITES REVEALS PHENOTYPIC HETEROGENEITY IN A MINIMAL RESIDUAL DISEASE MODEL
David Creytens
Favorite
Cribbs, Adam

University of Oxford
(P 04) THE CELL ATLAS OF CLEAR CELL SARCOMA
Adam Cribbs
Favorite
Cripe, Timothy

Nationwide Children's Hospital
(P 94) DEVELOPING NOVEL OLIGONUCLEOTIDE THERAPIES TO MODULATE INSULIN RECEPTOR ALTERNATIVE SPLICING IN PEDIATRIC BONE SARCOMAS
Timothy Cripe
Favorite
(P 107) TRABECTEDIN AUGMENTS ONCOLYTIC HERPES SIMPLEX VIROIMMUNOTHERAPY EFFICACY IN PRECLINCAL BONE SARCOMA MODELS THROUGH ENHANCED IMMUNE-MEDIATED MECHANISMS
Timothy Cripe
Favorite
(P 125) MYELOMODULATORY TREATMENTS AUGMENT THE THERAPEUTIC BENEFIT OF ONCOLYTIC VIRUS IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS BY MODULATING THE TUMOR MICROENVIRONMENT
Timothy Cripe
Favorite
(P 305) A NEW MOUSE MODEL FOR TESTING SPLICE-SWITCHING THERAPIES IN RHABDOMYOSARCOMA
Timothy Cripe
Favorite
Cristalli, Camilla

IRCCS Istituto Ortopedico Rizzoli
(P 85) TARGETING CD99 ELICITS EWING SARCOMA CELL PHAGOCYTOSIS BY UNDIFFERENTIATED AND M2-LIKE MACROPHAGES AND INDUCES MACROPHAGE POLARIZATION TOWARD A M1-LIKE PHENOTYPE
Camilla Cristalli
Favorite
Cristofaro, Caroline

University of Toronto
(P 443) SURGICAL RESECTION OF EXTREMITY EWING'S SARCOMA BASED ON POST-CHEMOTHERAPY TUMOUR VOLUME RESULTS IN SAFE MARGINS
Caroline Cristofaro
Favorite
CROMBE, Amandine

CHU Bordeaux
(P 523) IN-BETWEEN SARCOMA: A CATEGORY OF HIGH RISK OF RECURRENCE AND POOR OUTCOME
Amandine CROMBE
Favorite
Crompton, Brian

Dana-Farber Cancer Institute
(P 166) SARC038: A PHASE 2 STUDY OF REGORAFENIB IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH REFRACTORY OR RECURRENT OSTEOSARCOMA
Brian Crompton
Favorite
(P 438) ALVEOLAR RHABDOMYOSARCOMA WITH "BURKITT-LIKE" MORPHOLOGY IS ASSOCIATED WITH HIGH AMPLIFICATION OF MYCL
Brian Crompton
Favorite
Crotti, Elisa

Istituto Clinico Humanitas Humanitas Cancer Center
(P 144) IMPLEMENTATION OF THE EUROPEAN CLINICAL TRIAL REGULATION: SURVEY OF THE ITALIAN SARCOMA GROUP CENTERS
Elisa Crotti
Favorite
Crotty, Tom

St Vincents University Hospital
(P 155) THE IMPACT OF THE ROLE OF A SARCOMA ADVANCED NURSE PRACTITIONER (ANP) BIOPSY CLINIC IN IMPROVING PATIENT ACCESS TO SARCOMA SERVICES
Tom Crotty
Favorite
(P 156) PATIENT REPORTED EXPERIENCES WITHIN THE IRISH SARCOMA GROUP
Tom Crotty
Favorite
(P 217) CONTEMPORARY TREATMENT PATTERNS AND OUTCOMES IN THE MANAGEMENT OF ANGIOSARCOMA IN IRELAND
Tom Crotty
Favorite
Crowley, Timothy

The Newcastle upon Tyne Hospitals NHS Foundation Trust
(P 228) WHAT IS THE SIGNIFICANCE OF INDETERMINATE PULMONARY NODULES IN HIGH GRADE SOFT TISSUE SARCOMA? A RETROSPECTIVE COHORT STUDY
Timothy Crowley
Favorite
Crown, John

SVHG
(P 213) EXPERIENCE WITH THE USE OF TRABECTEDIN IN ADVANCED SOFT TISSUE SARCOMA IN IRELAND
John Crown
Favorite
Cruzado, Juan Antonio

Universidad Complutense de Madrid
(P 149) PSYCOLOGICAL SNAPSHOT OF SARCOMA PATIENTS FROM AN ACADEMIC, UNIVERSITY CENTER, HOSPITAL CLÍNICO SAN CARLOS (HCSC), MADRID, A SARCOMA NATIONAL REFERRAL CENTRE IN SPAIN
Juan Antonio Cruzado
Favorite
Cruz, Josefina

HU Canarias
(P 113) IMMUNOSARC II: A SPANISH SARCOMA GROUP (GEIS) PHASE IB TRIAL OF DOXORUBICIN AND DACARBAZINE PLUS NIVOLUMAB IN FIRST LINE OF ADVANCED LEIOMYOSARCOMA
Josefina Cruz
Favorite
(P 142) THE SARCOMA EUROPEAN AND LATIN AMERICAN NETWORK (SELNET) PROJECT: OVERVIEW OF THE MAIN RESULTS OF THE SELNET REGISTRY
Josefina Cruz
Favorite
(P 175) TRABECTEDIN PLUS RADIOTHERAPY ON SYMPHTOMATIC ADVANCED SARCOMA PATIENTS, RESULTS FROM THE SYNERGIAS STUDY: A SPANISH GROUP FOR RESEARCH IN SARCOMA (GEIS) PHASE II STUDY
Josefina Cruz
Favorite
Cuenca, Concepcion

Hospital Clinico san Carlos
(P 149) PSYCOLOGICAL SNAPSHOT OF SARCOMA PATIENTS FROM AN ACADEMIC, UNIVERSITY CENTER, HOSPITAL CLÍNICO SAN CARLOS (HCSC), MADRID, A SARCOMA NATIONAL REFERRAL CENTRE IN SPAIN
Concepcion Cuenca
Favorite
Currier, Mark

Nationwide Children's Hospital
(P 107) TRABECTEDIN AUGMENTS ONCOLYTIC HERPES SIMPLEX VIROIMMUNOTHERAPY EFFICACY IN PRECLINCAL BONE SARCOMA MODELS THROUGH ENHANCED IMMUNE-MEDIATED MECHANISMS
Mark Currier
Favorite
(P 125) MYELOMODULATORY TREATMENTS AUGMENT THE THERAPEUTIC BENEFIT OF ONCOLYTIC VIRUS IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS BY MODULATING THE TUMOR MICROENVIRONMENT
Mark Currier
Favorite
Cyprovà, Sona

Motol Children's Hospital
(P 451) IMPACT OF TIME TO DIAGNOSIS - A PROSPECTIVE ANALYSIS OF THE EWING 2008 TRIAL
Sona Cyprovà
Favorite
Czarnecka, Anna

Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology
(P 162) LONG TERM SAFETY AND EFFICACY OF COMBINED DOXORUBICIN-IFOSFAMIDE CHEMOTHERAPY WITH PREOPERATIVE HYPOFRACTIONATED RADIOTHERAPY IN MARGINALLY RESECTABLE SOFT TISSUE SARCOMAS
Anna Czarnecka
Favorite
(P 222) EXPLORING THE IMPACT OF NGS ON DIAGNOSTICS AND TREATMENT OF SARCOMA: INSIGHTS FROM REAL-WORLD DATA ACROSS MULTIPLE INSTITUTIONS IN EUROPE
Anna Czarnecka
Favorite
D
D’Souza, Jimson

GSK
(P 114) PRIMARY ANALYSIS OF EFFICACY AND SAFETY OF LETETRESGENE AUTOLEUCEL (LETE-CEL) AS FIRST-LINE TREATMENT FOR UNRESECTABLE OR METASTATIC SYNOVIAL SARCOMA (SS); SUBSTUDY 1 OF IGNYTE-ESO
Jimson D’Souza
Favorite
Da Costa, Daniel

Day One Biopharmaceuticals
(P 08) PRELIMINARY CLINICAL ACTIVITY OF THE TYPE II RAF INHIBITOR TOVORAFENIB IN RAF FUSION-DRIVEN RECURRENT/PROGRESSIVE SARCOMAS
Daniel Da Costa
Favorite
D’Amato, Gina

Sylvester Comprehensive Cancer Center / University of Miami Hospital and Clinics
(P 208) LOW INCIDENCE OF CANCER THERAPY-RELATED CARDIAC DYSFUNCTION IN ADULT SARCOMA PATIENTS RECEIVING DOXORUBICIN AND UPFRONT DEXRAZOXANE
Gina D’Amato
Favorite
Dürr, Hans Roland

Orthopaedic Oncology, Department of Orthopaedics and Trauma Surgery, University Hospital, Ludwig-Maximilians-University (LMU) Munich, Germany
(P 118) TIM-3 QUALIFIES AS A POTENTIAL IMMUNOTHERAPEUTIC TARGET IN SPECIFIC SUBSETS OF PATIENTS WITH HIGH-RISK SOFT TISSUE SARCOMAS (HR-STS)
Hans Roland Dürr
Favorite
(P 133) TEN RECOMMENDATIONTS FOR SARCOMA SURGERY: CONSENSUS OF THE SURGICAL SOCIETIES BASED ON THE GERMAN S3 GUIDELINE "ADULT SOFT TISSUE SARCOMA"
Hans Roland Dürr
Favorite
(P 557) UNRAVELING THE ROLE OF LOCAL THERAPY FOR PATIENTS WITH OLIGOMETASTATIC SOFT TISSUE SARCOMA - A RETROSPECTIVE MULTICENTER TRIAL OF BAVARIAN UNIVERSITY HOSPITALS
Hans Roland Dürr
Favorite
Díaz-Beveridge, Roberto

Medical Oncology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
(P 113) IMMUNOSARC II: A SPANISH SARCOMA GROUP (GEIS) PHASE IB TRIAL OF DOXORUBICIN AND DACARBAZINE PLUS NIVOLUMAB IN FIRST LINE OF ADVANCED LEIOMYOSARCOMA
Roberto Díaz-Beveridge
Favorite
(P 385) FIRST IN HUMAN PHASE I TRIAL OF A NOVEL DRUG DELIVERY IMPLANT MATRIX WITH SN-38 (CEB-01) FOR RETROPERITONEAL SOFT TISSUE SARCOMA
Roberto Díaz-Beveridge
Favorite
Díaz, Cristina

Hospital Clínico San Carlos
(P 515) ENDOBRONCHIAL NAVIGATION AS AN INTRAOPERATORY TOOL FOR RESECTION OF SMALL PULMONARY METASTASES IN SARCOMA PATIENTS
Cristina Díaz
Favorite
Dadia, Solomon

Tel Aviv Medical Center, Tel Aviv, Israel
(P 240) IDENTIFYING PATIENTS AT HIGH RISK OF HIP FRACTURE DUE TO BONE TUMORS BY COMPUTATIONAL BIOMECHANICS: A RANDOMIZED PROSPECTIVE CLINICAL STUDY
Solomon Dadia
Favorite
(P 319) HYPO-FRACTIONATED RADIATION THERAPY FOR THE EXTREMITY SOFT TISSUE SARCOM IN ELDERLY AND DISABLED.
Solomon Dadia
Favorite
Daffinoti, Anabela

University of Buenos Aires, Angel H Roffo Institute of Oncology
(P 460) IMPACT OF RESIDUAL TUMOR AFTER RE-EXCISION IN PATIENTS WITH PRIOR UNPLANNED RESECTION OF EXTREMITY AND TRUNK SOFT TISSUE SARCOMAS
Anabela Daffinoti
Favorite
DaFonseca, Manuel

Sonnet BioTherapeutics
(P 111) INTERIM ANALYSIS OF A PHASE 1 STUDY USING IL12-FHAB WITH OPTIMIZED PHARMACOKINETICS
Manuel DaFonseca
Favorite
Daghistani, Doured

Miami Cancer Institute
(P 320) A PROSPECTIVE MULTICENTER EXPERIENCE OF PROTON THERAPY FOR RHABDOMYOSARCOMA AND EWING SARCOMA: OUTCOMES FROM THE PROTON COLLABORATIVE GROUP REGISTRY
Doured Daghistani
Favorite
Dahan, Gal

Tel Aviv Medical Center
(P 240) IDENTIFYING PATIENTS AT HIGH RISK OF HIP FRACTURE DUE TO BONE TUMORS BY COMPUTATIONAL BIOMECHANICS: A RANDOMIZED PROSPECTIVE CLINICAL STUDY
Gal Dahan
Favorite
Dai, Dong

Daiichi Sankyo, Inc.
(P 131) PATIENT-REPORTED CONTINUED BENEFITS IN PATIENTS TREATED WITH PEXIDARTINIB FOR TENOSYNOVIAL GIANT CELL TUMOR BASED ON A REAL-WORLD STUDY IN THE UNITED STATES
Dong Dai
Favorite
Dallaire, Frédérick

Polytechnique Montréal
(P 245) IN VIVO USE OF RAMAN SPECTROSCOPY IN SOFT TISSUE SARCOMA RESECTION
Frédérick Dallaire
Favorite
Dall'Igna, Patrizia

Department of Precision and Regenerative Medicine and Jonic Area,Pediatric Hospital Giovanni XXIII, University of Bari
(P 202) INFLAMMATORY MYOFIBROBLASTIC TUMOUR WITH ROS1 GENE FUSIONS IN CHILDREN AND YOUNG ADOLESCENTS
Patrizia Dall'Igna
Favorite
D'Amato, Gina

Sylvester Comprehensive Cancer Center
(P 54) HIGH-THROUGHPUT DRUG SCREENING IN CHONDROSARCOMA CELLS IDENTIFIES MULTIPLE EFFICIENT ANTINEOPLASTIC AGENTS
Gina D'Amato
Favorite
(P 128) THE IMPACT OF HISPANIC ETHNICITY IN PRESENTATION AND OUTCOMES OF PATIENTS WITH SYNOVIAL SARCOMA
Gina D'Amato
Favorite
(P 158) SORAFENIB OR ANTHRACYCLINE-BASED CHEMOTHERAPY IN ADULT PATIENTS WITH PROGRESSIVE DESMOID TUMORS
Gina D'Amato
Favorite
(P 173) SAFETY, EFFICACY, AND PATIENT-REPORTED OUTCOMES WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED PRIOR ANTI–COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 UPDATE
Gina D'Amato
Favorite
(P 225) PAN-SARCOMA DATABASE (PSDB): A MODEL-VIEW-CONTROLLER FRAMEWORK UTILIZING REDCAP, SHINY, AND R TO CREATE A CONTINUOUS PIPELINE OF SARCOMA DATA
Gina D'Amato
Favorite
(P 226) SIGNATERA TESTING TO IDENTIFY MINIMAL RESIDUAL DISEASE IN HIGH GRADE SARCOMA
Gina D'Amato
Favorite
(P 280) A CELL-BASED COMPOUND SCREENING IDENTIFIES AGENTS THAT SYNERGIZE WITH EVEROLIMUS IN SARCOMA
Gina D'Amato
Favorite
(P 326) MOLECULAR LANDSCAPE OF ENDOMETRIAL STROMAL SARCOMA IN A LARGE REAL-WORLD PATIENT COHORT
Gina D'Amato
Favorite
(P 361) MOLECULAR CHARACTERIZATION OF SOLITARY FIBROUS TUMORS BY ANATOMIC SITE AND NAB2::STAT6 FUSION VARIANT TYPE
Gina D'Amato
Favorite
(P 366) SURVIVAL DISPARITIES IN HISPANIC PATIENTS WITH SARCOMA TESTED WITH NEXT-GENERATION SEQUENCING (NGS)
Gina D'Amato
Favorite
(P 401) OVEREXPRESSION OF CYCLIN DEPENDENT KINASES AND CYCLINS ACROSS SARCOMAS BEYOND CDK4
Gina D'Amato
Favorite
(P 461) OUTCOMES FOR OLIGOMETASTATIC PULMONARY DISEASE RECURRENCE TREATED WITH SURGERY ALONE FOR PATIENTS WITH SOFT TISSUE SARCOMAS A CASE SERIES
Gina D'Amato
Favorite
D'Amato, Vittoria

IRCCS Humanitas Research Hospital
(P 327) LEARNING CURVE ANALYSIS IN RETROPERITONEAL SARCOMA SURGERY
Vittoria D'Amato
Favorite
(P 457) LONG-TERM FOLLOW-UP OF PATIENTS WITH ATYPICAL LIPOMATOUS TUMOR (ALT) TREATED WITH MARGINAL RESECTION IN A REFERRAL CENTER
Vittoria D'Amato
Favorite
D'Ambrosio, Lorenzo

University if Turin, Turin, Italy
(P 109) INTENSE PRECLINICAL ACTIVITY BY B7H3-SPECIFIC CAR.CIK LYMPHOCYTES AGAINST EPITHELIOID SARCOMA
Lorenzo D'Ambrosio
Favorite
(P 159) IN BETWEEN OF LYMPHOMAS AND SARCOMAS: WHERE DO HISTIOCYTIC AND DENDRITIC CELL NEOPLASMS (HDCN) STAND? A RETROSPECTIVE, MULTI-INSTITUTIONAL STUDY FROM THE ITALIAN SARCOMA GROUP (ISG)
Lorenzo D'Ambrosio
Favorite
(P 189) INTERNATIONAL RETROSPECTIVE STUDY FROM THE ULTRA-RARE SARCOMA WORKING GROUP ON LOW-GRADE FIBROMYXOID SARCOMA AND SCLEROSING EPITHELIOD FIBROSARCOMA: OUTCOME OF ADVANCED DISEASE AND SYSTEMIC THERAPIES
Lorenzo D'Ambrosio
Favorite
(P 262) ESTABLISHMENT AND CHARACTERIZATION OF THE FIRST RADIATION-INDUCED, PATIENT-DERIVED ANGIOSARCOMA CELL LINE
Lorenzo D'Ambrosio
Favorite
(P 455) EXTRASKELETAL EWING SARCOMA: A MULTICENTRIC RETROSPECTIVE STUDY FROM THE ITALIAN SARCOMA GROUP
Lorenzo D'Ambrosio
Favorite
Dandis, Rana

Princess Máxima Center for Pediatric Oncology
(P 558) TRIAL IN PROGRESS: A PHASE 1/2 STUDY OF BRIGATINIB IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH ALK POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA OR INFLAMMATORY MYOFIBROBLASTIC TUMORS (ITCC-098)
Rana Dandis
Favorite
D'Angelo, Sandra

Memorial Sloan Kettering Cancer Center
(P 24) COMPREHENSIVE ANALYSIS OF THE GENOMIC LANDSCAPE AND CLINICAL BEHAVIOR IN GIST USING NEXT GENERATION SEQUENCING (NGS, MSK-IMPACT)
Sandra D'Angelo
Favorite
(P 114) PRIMARY ANALYSIS OF EFFICACY AND SAFETY OF LETETRESGENE AUTOLEUCEL (LETE-CEL) AS FIRST-LINE TREATMENT FOR UNRESECTABLE OR METASTATIC SYNOVIAL SARCOMA (SS); SUBSTUDY 1 OF IGNYTE-ESO
Sandra D'Angelo
Favorite
(P 207) A MULTICENTER PHASE II STUDY OF CABOZANTINIB PLUS NIVOLUMAB FOR PATIENTS WITH ADVANCED ANGIOSARCOMA PREVIOUSLY TREATED WITH A TAXANE: ALLIANCE A091902
Sandra D'Angelo
Favorite
(P 531) ENVASARC: A PIVOTAL TRIAL OF ENVAFOLIMAB AND ENVAFOLIMAB IN COMBINATION WITH IPILIMUMAB IN PATIENTS WITH ADVANCED OR METASTATIC UPS OR MFS WHO HAVE PROGRESSED ON PRIOR CHEMOTHERAPY
Sandra D'Angelo
Favorite
Danieau, Geoffroy

Research Institute of the McGill University Health Center
(P 64) OSTEOSARCOMA. PATIENT-DERIVED XENOGRAFTS MODELS TO RECAPITULATE PATIENTS' CHEMORESISTANCE AND METASTATIC DISEASE
Geoffroy Danieau
Favorite
(P 65) PROFILING EXTRACELLULAR VESICLES AND NANOPARTICLES IN OSTEOSARCOMA
Geoffroy Danieau
Favorite
(P 379) THE ROLE OF EZHIP IN DRIVING AGGRESSIVE OSTEOSARCOMA
Geoffroy Danieau
Favorite
(P 434) MECHANISMS OF CHEMORESISTANCE IN CIC-DUX4 SARCOMA AS DETERMINED BY IN VIVO FUNCTIONAL GENOMICS
Geoffroy Danieau
Favorite
DANNEPOND, Antoine

Oncological department of Institut Bergonié
(P 521) HOW TO MANAGE ABDOMINAL PARIETECTOMY, REVIEW OF EXPERIENCE IN INSTITUT BERGONIE
Antoine DANNEPOND
Favorite
Daolio, Primo Andrea

ASST Gaetano Pini - CTO
(P 431) TREATMENT STRATEGY AND PROGNOSTIC FACTORS IN EXTRASKELETAL EWING SARCOMA: AN INSTITUTIONAL RETROSPECTIVE ANALYSIS
Primo Andrea Daolio
Favorite
Darbo, Elodie

Université de Bordeaux
(P 104) COMPREHENSIVE IMMUNE PROFILING UNVEILS A SUBSET OF LEIOMYOSARCOMA WITH HOT TUMOR IMMUNE MICROENVIRONMENT
Elodie Darbo
Favorite
Dasgupta, Roshni

Cincinnati Children's Hospital Medical Center
(P 81) OPTIMIZING EWING SARCOMA AND OSTEOSARCOMA BIOPSY ACQUISITION: CONSENSUS RECOMMENDATIONS FROM THE CHILDREN'S ONCOLOGY GROUP BONE TUMOR COMMITTEE
Roshni Dasgupta
Favorite
(P 409) IMMUNOHISTOCHEMICAL STAINING FOR MYOGENIN, AP2 BETA AND HMGA2 PREDICT FOXO1 FUSION STATUS IN RHABDOMYOSARCOMA: A REPORT FROM THE SOFT TISSUE COMMITTEE OF THE CHILDREN'S ONCOLOGY GROUP
Roshni Dasgupta
Favorite
(P 438) ALVEOLAR RHABDOMYOSARCOMA WITH "BURKITT-LIKE" MORPHOLOGY IS ASSOCIATED WITH HIGH AMPLIFICATION OF MYCL
Roshni Dasgupta
Favorite
Daud, Layla

Indiana University
(P 274) TYK2 AND MEK COMBINATION THERAPY IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS AND OTHER SOFT TISSUE SARCOMAS
Layla Daud
Favorite
Davick, Jonathan

University of Iowa
(P 115) EFFICACY AND CORREALTIVE ANALYSIS OF USING NEOADJUVANT INTRATUMORAL HIGH DOSE TALIMOGENE LAHERPAREPVEC (TVEC) WITH CONCURRENT RADIATION IN HIGH-RISK EXTREMITY AND TRUNK SOFT-TISSUE SARCOMAS
Jonathan Davick
Favorite
David, Bruna

Instituto Nacional de Câncer
(P 142) THE SARCOMA EUROPEAN AND LATIN AMERICAN NETWORK (SELNET) PROJECT: OVERVIEW OF THE MAIN RESULTS OF THE SELNET REGISTRY
Bruna David
Favorite
Davies, Christopher

University College London, Cancer Institute
(P 04) THE CELL ATLAS OF CLEAR CELL SARCOMA
Christopher Davies
Favorite
(P 381) THE GENOMIC LANDSCAPE OF CLEAR CELL SARCOMA
Christopher Davies
Favorite
Davies, Kurtis

University of Colorado - Anschutz Medical Campus
(P 237) SECONDARY REARRANGEMENT CREATING A PLEC-EML4-ALK DOUBLE FUSION AS A MECHANISM OF RESISTANCE TO CRIZOTINIB IN AN EML4-ALK-POSITIVE INFLAMMATORY MYOFIBROBLASTIC TUMOR
Kurtis Davies
Favorite
Davis, Alison

Canberra hospital
(P 386) GENOMIC PROFILING OF GYNAECOLOGICAL SARCOMAS: REPORT FROM THE AUSTRALIA-WIDE PRECISION ONCOLOGY PROGRAM
Alison Davis
Favorite
Davis, Elizabeth

Vanderbilt University Medical Center
(P 160) A PROSPECTIVE STUDY EVALUATING THE ASSOCIATION OF PATIENT-REPORTED OUTCOMES WITH ACTIVITY LEVEL AND SLEEP PATTERNS IN SARCOMA SURVIVORS
Elizabeth Davis
Favorite
(P 207) A MULTICENTER PHASE II STUDY OF CABOZANTINIB PLUS NIVOLUMAB FOR PATIENTS WITH ADVANCED ANGIOSARCOMA PREVIOUSLY TREATED WITH A TAXANE: ALLIANCE A091902
Elizabeth Davis
Favorite
(P 210) FINANCIAL TOXICITY ASSOCIATED WITH THE TREATMENT OF SARCOMAS: A SINGLE INSTITUTION RETROSPECTIVE-PROSPECTIVE STUDY
Elizabeth Davis
Favorite
(P 211) AN ANALYSIS OF SELF-REPORTED DEPRESSION IN SARCOMA PATIENTS
Elizabeth Davis
Favorite
(P 218) NEOADJUVANT CHEMOTHERPAY AND RADIATION DECREASES TUMOR SIZE, VIABILITY, AND RECURRENCE IN MULTIPLE LIPOSARCOMA SUBSETS
Elizabeth Davis
Favorite
(P 380) NEXT GENERATION SEQUEINCING REVEALS TARGETABLE MUTATIONS IN MULTIPLE SARCOMA HISTOLOGIES
Elizabeth Davis
Favorite
Davis, Jeremy

Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health
(P 28) RETROSPECTIVE ANALYSIS OF SUCCINATE DEHYDROGENASE (SDH)-DEFICIENT GASTROINTESTINAL STROMAL TUMOR (GIST) OUTCOMES: AN INTERNATIONAL STUDY OF 256 PATIENTS
Jeremy Davis
Favorite
Davis, Jessica

Indiana University
(P 81) OPTIMIZING EWING SARCOMA AND OSTEOSARCOMA BIOPSY ACQUISITION: CONSENSUS RECOMMENDATIONS FROM THE CHILDREN'S ONCOLOGY GROUP BONE TUMOR COMMITTEE
Jessica Davis
Favorite
Davis, Lara

OHSU Knight Cancer Institute
(P 166) SARC038: A PHASE 2 STUDY OF REGORAFENIB IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH REFRACTORY OR RECURRENT OSTEOSARCOMA
Lara Davis
Favorite
(P 179) PILOT STUDY OF A REMOTELY DELIVERED RESISTANCE EXERCISE TRAINING PROGRAM IN SARCOMA SURVIVORS
Lara Davis
Favorite
(P 191) SARC024 COHORT D: PHASE 2 TRIAL OF REGORAFENIB IN CHILDREN, ADOLESCENTS, AND ADULTS WITH RHABDOMYOSARCOMA
Lara Davis
Favorite
(P 341) A PHASE 1B STUDY TO EVALUATE PREOPERATIVE ERIBULIN IN COMBINATION WITH RADIATION IN RETROPERITONEAL SARCOMA
Lara Davis
Favorite
Davison, Zoe

Bone Cancer Research Trust
(P 90) RESULTS FROM AN INTERNATIONAL SURVEY OF BONE SARCOMA PATIENTS
Zoe Davison
Favorite
Daw, Najat

MD Anderson Cancer Center
(P 122) TARGETING CD70 USING CAR NK CELLS TO ENHANCE NK CELLS CYTOLYTIC EFFECT AGAINST OSTEOSARCOMA
Najat Daw
Favorite
(P 426) MULTI-OMIC ANALYSIS OF DESMOPLASTIC SMALL ROUND CELL TUMORS REVEAL DISTINCT LINEAGES
Najat Daw
Favorite
Dawo, Sallu

Northern Bone and Soft Tissue Tumour Service
(P 522) FLUORESCENCE GUIDED SURGERY WITH INDOCYANINE GREEN FOR SURGICAL RESECTION OF METASTATIC BONE AND SOFT TISSUE TUMOURS: A CASE SERIES
Sallu Dawo
Favorite
de Albert, Matias

Hospital Valle de Hebron
(P 69) DEVELOPMENT AND MISSION OF THE HARMONIZATION INTERNATIONAL BONE SARCOMA CONSORTIUM (HIBISCUS)
Matias de Albert
Favorite
De Benedictis, Ilaria

Unit of Oncogenetics and Functional Oncogenomics, Centro di Riferimento Oncologico di Aviano IRCCS, Aviano, Italy
(P 355) FUSION TRANSCRIPTOME PROFILING DEFINES THE MONOCLONAL NATURE OF MULTIFOCAL EPITHELIOID HEMANGIOMA OF BONE
Ilaria De Benedictis
Favorite
(P 378) MULTIOMICS PROFILING OF EPITHELIOID SARCOMA UNVEILS EPIGENETIC CIRCUITRIES THAT UNDERLIE THE PATHOBIOLOGY OF PROXIMAL AND CLASSIC SUBTYPES: RESULTS FROM THE ISG EPISOBS OBSERVATIONAL STUDY
Ilaria De Benedictis
Favorite
de Boed, Ella

Princess Maxima Center for Pediatric Oncology, The Netherlands
(P 251) EVALUATION OF POTENTIAL TARGETS FOR FLUORESCENCE-GUIDED SURGERY IN PEDIATRIC EWING SARCOMA: A PRECLINICAL PROOF-OF-CONCEPT STUDY
Ella de Boed
Favorite
De Carli, Emilie

Pediatric hospital of the University
(P 75) REAL-WORLD DATA ON REGORAFENIB AND CABOZANTINIB IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH RELAPSED OSTEOSARCOMA AND EWING SARCOMA INCLUDED IN THE SACHA-FRANCE STUDY
Emilie De Carli
Favorite
(P 212) REPORT ON THE EWING SARCOMA PATIENTS ENROLLED IN ARM D OF THE ACSE-ESMART TRIAL: PHASE I/II STUDY OF THE PARP INHIBITOR OLAPARIB IN COMBINATION WITH IRINOTECAN IN CHILDREN WITH ADVANCED MALIGNANCIES
Emilie De Carli
Favorite
De Cecco, Loris

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 363) Β-CATENIN MUTATIONS AND TRANSCRIPTOMIC REPROGRAMMING IN DESMOID FIBROMATOSIS (DF)
Loris De Cecco
Favorite
De Cock, Lore

Department of General Medical Oncology, University Hospitals Leuven and Laboratory of Experimental Oncology, KU Leuven, Leuven Cancer Institute
(P 43) UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR-ASSOCIATED PROTEIN AS A POTENTIAL NEXT GENERATION MOLECULAR TARGET FOR TREATMENT OF GASTROINTESTINAL STROMAL TUMOR
Lore De Cock
Favorite
(P 254) A COLLECTION OF PATIENT-DERIVED XENOGRAFT MODELS OF GASTROINTESTINAL STROMAL TUMORS
Lore De Cock
Favorite
(P 255) EPIDEMIOLOGY OF NOVEL ACTIONABLE TARGETS IN SYNOVIAL SARCOMA: A TISSUE MICRO-ARRAY STUDY
Lore De Cock
Favorite
(P 256) EFFICACY AND TOXICITY OF VERTEPORFIN IN COMBINATION WITH PAZOPANIB TESTED IN A PATIENT-DERIVED SYNOVIAL SARCOMA XENOGRAFT
Lore De Cock
Favorite
(P 349) THE UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR-ASSOCIATED PROTEIN (UPARAP) IS AN ATTRACTIVE TARGET FOR THE DEVELOPMENT OF ANTIBODY DRUG CONJUGATES FOR TREATMENT OF MESENCHYMAL MALIGNANCIES
Lore De Cock
Favorite
De Donno, Giulia

Image Sciences Institute, UMC Utrecht
(P 229) ON THE VARIABILITY IN THE ANALYSIS OF APPARENT DIFFUSION COEFFICIENT ESTIMATES FOR MULTICENTER DIFFUSION MRI DATA OF RHABDOMYOSARCOMA PATIENTS
Giulia De Donno
Favorite
De La Cuesta, Esther

Bayer HealthCare Pharmaceuticals, Inc.
(P 161) EFFICACY, SAFETY, AND TREATMENT HOLD WAIT-AND-SEE OUTCOMES OF LAROTRECTINIB IN PEDIATRIC PATIENTS WITH TRK FUSION SARCOMAS
Esther De La Cuesta
Favorite
De Luca, Alberto

Image Sciences Institute, UMC Utrecht
(P 229) ON THE VARIABILITY IN THE ANALYSIS OF APPARENT DIFFUSION COEFFICIENT ESTIMATES FOR MULTICENTER DIFFUSION MRI DATA OF RHABDOMYOSARCOMA PATIENTS
Alberto De Luca
Favorite
De Luca, Ida

Policlinico P Giaccone
(P 159) IN BETWEEN OF LYMPHOMAS AND SARCOMAS: WHERE DO HISTIOCYTIC AND DENDRITIC CELL NEOPLASMS (HDCN) STAND? A RETROSPECTIVE, MULTI-INSTITUTIONAL STUDY FROM THE ITALIAN SARCOMA GROUP (ISG)
Ida De Luca
Favorite
De Mattia, Aurora

Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia-Romagna, Laboratorio di Controllo di Prodotti Biologici, Centro di Referenza Nazionale per i Metodi Alternativi, Benessere e Cura degli Animali da Laboratorio
(P 283) A TRIDIMENSIONAL PRECLINICAL MODEL TO STUDY HUMAN AND CANINE OSTEOSARCOMA DEVELOPMENT AND INTERACTION WITH TUMOR MICROENVIRONMENT
Aurora De Mattia
Favorite
De Mattos, Camila

Skåne University Hospital
(P 372) COPY NUMBER GAIN OF MDM2 IN ROD-SHAPED CHROMOSOMES PROVIDES CLUES TO EARLY STAGES IN CIRCULARIZED GENE AMPLIFICATION IN LIPOSARCOMA
Camila De Mattos
Favorite
De Meo, Simone

Fondazione per la ricerca sui tumori dell'apparato muscoloscheletrico e rari Onlus
(P 144) IMPLEMENTATION OF THE EUROPEAN CLINICAL TRIAL REGULATION: SURVEY OF THE ITALIAN SARCOMA GROUP CENTERS
Simone De Meo
Favorite
de Miranda, Noel

LUMC
(P 368) DECODING THE IMMUNOGENOMIC DETERMINANTS OF RADIOTHERAPY RESPONSE IN SOFT TISSUE SARCOMAS
Noel de Miranda
Favorite
(P 369) MAGEA ANTIGENS AS IMMUNOTHERAPEUTIC TARGETS FOR ADVANCED OSTEOSARCOMA
Noel de Miranda
Favorite
De Rosa, francesco

Irst
(P 364) EVALUATION OF THE PREDICTIVE ROLE OF SYSTEMIC AND INTRATUMORAL IMMUNITY IN PATIENTS WITH LOCALIZED LIPOSARCOMAS, MYXOFIBROSARCOMAS AND UNDIFFERENTIATED PLEOMORPHIS SARCOMAS
francesco De Rosa
Favorite
(P 533) SAFETY AND PRELIMINARY BIOLOGICAL ACTIVITY OF A PHASE II TRIAL OF AUTOLOGOUS DENDRITIC CELLS VACCINATION IN SARCOMAS.
francesco De Rosa
Favorite
De Sutter, Luna

Laboratory of Experimental Oncology, KU Leuven, Leuven Cancer Institute
(P 43) UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR-ASSOCIATED PROTEIN AS A POTENTIAL NEXT GENERATION MOLECULAR TARGET FOR TREATMENT OF GASTROINTESTINAL STROMAL TUMOR
Luna De Sutter
Favorite
(P 254) A COLLECTION OF PATIENT-DERIVED XENOGRAFT MODELS OF GASTROINTESTINAL STROMAL TUMORS
Luna De Sutter
Favorite
De Toni, Chiara

Oncology 1 Unit, Department of Oncology, Veneto Institute of Oncology IOV - IRCCS
(P 171) SEX DIFFERENCES IN OUTCOMES AND TOXICITY IN PATIENTS TREATED FOR SARCOMA IN A REFERENCE CENTER
Chiara De Toni
Favorite
(P 216) BRAIN METASTASES IN SARCOMA: A (NOT SO) RARE EVENT. THE EXPERIENCE OF A HIGH VOLUME CENTER
Chiara De Toni
Favorite
De Vita, Alessandro

Istituto Scientifico Romagnolo per lo studio dei Tumori "Dino Amadori", Preclinic and Osteoncology Unit, Meldola, Italy
(P 37) DISSECTING THE ROLE OF EXTRACELLULAR VESICLES IN THE MANAGEMENT OF GIST
Alessandro De Vita
Favorite
(P 253) THE EFFICACY OF MEDICATED PATCHES IN SOFT TISSUE SARCOMAS: IN-VITRO AND EX-VIVO VALIDATION.
Alessandro De Vita
Favorite
(P 364) EVALUATION OF THE PREDICTIVE ROLE OF SYSTEMIC AND INTRATUMORAL IMMUNITY IN PATIENTS WITH LOCALIZED LIPOSARCOMAS, MYXOFIBROSARCOMAS AND UNDIFFERENTIATED PLEOMORPHIS SARCOMAS
Alessandro De Vita
Favorite
(P 533) SAFETY AND PRELIMINARY BIOLOGICAL ACTIVITY OF A PHASE II TRIAL OF AUTOLOGOUS DENDRITIC CELLS VACCINATION IN SARCOMAS.
Alessandro De Vita
Favorite
de Vries, Isabelle

Princess Maxima Center for Pediatric Oncology
(P 209) PROGNOSTIC VALUE OF EARLY RADIOLOGIC TUMOUR VOLUME RESPONSE IN RHABDOMYOSARCOMA; RESULTS OF THE EUROPEAN PAEDIATRIC SOFT TISSUE SARCOMA STUDY GROUP RMS 2005 STUDY
Isabelle de Vries
Favorite
De Wever, Olivier

Ghent University
(P 291) DEVELOPMENT OF A LIVE TISSUE SARCOMA BIOBANK TO SUPPORT THE CREATION OF PATIENT-DERIVED TRANSLATIONAL MODELS
Olivier De Wever
Favorite
(P 295) ORTHOTOPIC XENOGRAFTS OF PAIRED SARCOMA PRIMARY TUMOUR, LOCAL RELAPSE AND METASTATIC SITES REVEALS PHENOTYPIC HETEROGENEITY IN A MINIMAL RESIDUAL DISEASE MODEL
Olivier De Wever
Favorite
(P 296) EX VIVO SARCOMA CELL CULTURES FROM PAIRED PRIMARY, LOCAL RELAPSE AND METASTATIC SITES REVEALS PHENOTYPIC HETEROGENEITY
Olivier De Wever
Favorite
Defachelles, Anne-Sophie

Centre Oscar Lambret
(P 212) REPORT ON THE EWING SARCOMA PATIENTS ENROLLED IN ARM D OF THE ACSE-ESMART TRIAL: PHASE I/II STUDY OF THE PARP INHIBITOR OLAPARIB IN COMBINATION WITH IRINOTECAN IN CHILDREN WITH ADVANCED MALIGNANCIES
Anne-Sophie Defachelles
Favorite
Dehner, Carina

Indiana University
(P 274) TYK2 AND MEK COMBINATION THERAPY IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS AND OTHER SOFT TISSUE SARCOMAS
Carina Dehner
Favorite
Dei Tos, Angelo Paolo

Department of Medicine, University of Padua School of Medicine, Padova, Italy
(P 159) IN BETWEEN OF LYMPHOMAS AND SARCOMAS: WHERE DO HISTIOCYTIC AND DENDRITIC CELL NEOPLASMS (HDCN) STAND? A RETROSPECTIVE, MULTI-INSTITUTIONAL STUDY FROM THE ITALIAN SARCOMA GROUP (ISG)
Angelo Paolo Dei Tos
Favorite
(P 355) FUSION TRANSCRIPTOME PROFILING DEFINES THE MONOCLONAL NATURE OF MULTIFOCAL EPITHELIOID HEMANGIOMA OF BONE
Angelo Paolo Dei Tos
Favorite
(P 378) MULTIOMICS PROFILING OF EPITHELIOID SARCOMA UNVEILS EPIGENETIC CIRCUITRIES THAT UNDERLIE THE PATHOBIOLOGY OF PROXIMAL AND CLASSIC SUBTYPES: RESULTS FROM THE ISG EPISOBS OBSERVATIONAL STUDY
Angelo Paolo Dei Tos
Favorite
(P 437) ULTRA-RARE UNDIFFERENTIATED SMALL ROUND CELL SARCOMA: HOW SHOULD WE TREAT THEM? AN ANALYSIS FORM THE GRACEFUL PROJECT
Angelo Paolo Dei Tos
Favorite
Del Monte, Francesca

Nuovo Ospedale Santo Stefano
(P 144) IMPLEMENTATION OF THE EUROPEAN CLINICAL TRIAL REGULATION: SURVEY OF THE ITALIAN SARCOMA GROUP CENTERS
Francesca Del Monte
Favorite
Del Savio, Elisa

Unit of Oncogenetics and Functional Oncogenomics, Centro di Riferimento Oncologico di Aviano IRCCS, Aviano, Italy
(P 355) FUSION TRANSCRIPTOME PROFILING DEFINES THE MONOCLONAL NATURE OF MULTIFOCAL EPITHELIOID HEMANGIOMA OF BONE
Elisa Del Savio
Favorite
(P 378) MULTIOMICS PROFILING OF EPITHELIOID SARCOMA UNVEILS EPIGENETIC CIRCUITRIES THAT UNDERLIE THE PATHOBIOLOGY OF PROXIMAL AND CLASSIC SUBTYPES: RESULTS FROM THE ISG EPISOBS OBSERVATIONAL STUDY
Elisa Del Savio
Favorite
Dela Cruz, Filemon

Memorial Sloan Kettering Cancer Center
(P 289) IDENTIFICATION OF EFFECTIVE THERAPEUTIC COMBINATIONS WITH THE NUCLEAR EXPORT PROTEIN INHIBITOR, SELINEXOR, IN PEDIATRIC SOLID TUMORS
Filemon Dela Cruz
Favorite
Delaney, Thomas

Massachusetts General Hospital
(P 338) PREOPERATIVE RADIATION THERAPY IS NOT ASSOCIATED WITH ADVERSE POSTOPERATIVE OUTCOMES IN PATIENTS WITH RETROPERITONEAL SARCOMA
Thomas Delaney
Favorite
Delattre, Olivier

Institut Curie
(P 395) TARGETING CD44-MEDIATED IRON ENDOCYTOSIS IN DESMOID FIBROMATOSIS
Olivier Delattre
Favorite
Delespaul, Lucile

Cancer Research Center of Toulouse
(P 268) IMPACT OF CELLULAR FUSION IN THE ONCOGENESIS OF LEIOMYOSARCOMAS
Lucile Delespaul
Favorite
Demetri, George

IDRx, Inc
(P 26) PHASE 1 STUDY OF IDRX-42 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS RESISTANT TO PRIOR SYSTEMIC THERAPY: EARLY RESULTS
George Demetri
Favorite
Demeulemeester, Jonas

VIB-KU Leuven Center for Cancer Biology
(P 04) THE CELL ATLAS OF CLEAR CELL SARCOMA
Jonas Demeulemeester
Favorite
(P 381) THE GENOMIC LANDSCAPE OF CLEAR CELL SARCOMA
Jonas Demeulemeester
Favorite
Demicco, Elizabeth

Sinai Health System
(P 50) CHARACTERIZATION OF A FAMILIAL GIST KINDRED INTOLERANT TO IMATINIB
Elizabeth Demicco
Favorite
(P 108) EFFECT OF TUMOUR-TARGETED HYPERTHERMIA AND CHEMOTHERAPY ON THE IMMUNE PROFILE OF A MURINE MODEL OF EMBRYONAL RHABDOMYOSARCOMA
Elizabeth Demicco
Favorite
(P 249) INVESTIGATING CLINICAL FACTORS ASSOCIATED WITH THE ESTABLISHMENT OF SUCCESSFUL PRIMARY HUMAN SOFT TISSUE SARCOMA CELL LINES
Elizabeth Demicco
Favorite
(P 265) SELECTIVE TARGETING OF BET FAMILY EPIGENETIC REGULATORS IN ADVANCED AND METASTATIC ALVEOLAR RHABDOMYOSARCOMA
Elizabeth Demicco
Favorite
(P 367) CHARACTERIZING HYPOXIA AND ASSOCIATED MOLECULAR FEATURES IN EXTREMITY SOFT TISSUE SARCOMA
Elizabeth Demicco
Favorite
(P 421) USING TRANSCRIPTOMICS TO IDENTIFY LEIOMYOSARCOMA PATIENTS AT RISK OF METASTASIS
Elizabeth Demicco
Favorite
den Hollander, Dide

Radboud University Medical Center
(P 30) FINANCIAL DIFFICULTIES EXPERIENCED BY DUTCH GASTROINTESTINAL STROMAL TUMOR (GIST) PATIENTS: DATA FROM A CROSS-SECTIONAL MULTICENTER STUDY
Dide den Hollander
Favorite
DeNardo, Bradley

Lifespan
(P 361) MOLECULAR CHARACTERIZATION OF SOLITARY FIBROUS TUMORS BY ANATOMIC SITE AND NAB2::STAT6 FUSION VARIANT TYPE
Bradley DeNardo
Favorite
Denecke, Barbara

Kantonsspital St. Gallen
(P 27) A MULTICENTER RETROSPECTIVE STUDY ON THE CLINICAL BEHAVIOR OF SDH-DEFICIENT GIST
Barbara Denecke
Favorite
Deng, Lichun

Department of Oncology, The Affiliated Jiangyin Hospital of Nantong University
(P 44) RIPRETINIB FOR THE TREATMENT OF CHINESE PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS HARBORING KIT SECONDARY MUTATIONS: A MULTICENTER, RETROSPECTIVE STUDY
Lichun Deng
Favorite
(P 48) SIGNIFICANCE OF MONITORING PLASMA CONCENTRATION OF RIPRETINIB IN CHINESE PATIENTS WITH GASTROINTESTINAL STROMAL TUMORS
Lichun Deng
Favorite
Deng, Mengying

Division of Biostatistics and Bioinformatics, Fox Chase Cancer Center
(P 152) EVALUATING DIAGNOSTIC APPROACHES TO DERMATOFIBROSARCOMA PROTUBERANS: AN OPPORTUNITY TO REDUCE THE NUMBER OF INTERVENTIONS
Mengying Deng
Favorite
Deng, Ting

Department of gastrointestinal medical oncology,Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer; Tianjin Key Laboratory of Digestive Cancer, Tianjin; Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, P. R. China
(P 42) THE EFFICACY AND SAFETY OF RIPRETINIB IN THE TREATMENT OF CHINESE PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS (GISTS): A SINGLE-INSTITUTION ANALYSIS
Ting Deng
Favorite
Deng, Xuemei

Seattle Children's Hospital
(P 448) CAF-LIKE EWING SARCOMA CELLS DEPOSIT PRO-TUMORIGENIC EXTRACELLULAR MATRIX IN RESPONSE TO TGF-BETA SIGNALING
Xuemei Deng
Favorite
Denschlag, Dominik

Hochtaunus Klinik
(P 133) TEN RECOMMENDATIONTS FOR SARCOMA SURGERY: CONSENSUS OF THE SURGICAL SOCIETIES BASED ON THE GERMAN S3 GUIDELINE "ADULT SOFT TISSUE SARCOMA"
Dominik Denschlag
Favorite
Denu, Ryan

MD Anderson Cancer Center
(P 36) CLINICO-GENOMIC ANALYSIS OF KIT/PDGFRA/SDH WILD-TYPE GASTROINTESTINAL STROMAL TUMORS IDENTIFIES POTENTIAL DRIVER MUTATIONS
Ryan Denu
Favorite
(P 83) CLINICO-GENOMIC PROFILING OF CONVENTIONAL AND DEDIFFERENTIATED CHONDROSARCOMAS REVEALS TP53 MUTATION TO BE ASSOCIATED WITH WORSE OUTCOMES
Ryan Denu
Favorite
(P 198) PERSONALIZED MULTIDISCIPLINARY MANAGEMENT OF SARCOMA IN PATIENTS WITH LYNCH SYNDROME
Ryan Denu
Favorite
(P 360) TP53 ALTERATIONS IN SARCOMAS: AN ANALYSIS FROM THE AACR-GENIE DATABASE
Ryan Denu
Favorite
(P 400) THE LANDSCAPE OF GENOMIC ALTERATIONS FROM 1494 SOFT TISSUE AND BONE SARCOMAS AT MD ANDERSON CANCER CENTER
Ryan Denu
Favorite
Deobald, Ray

University of Saskatchewan
(P 148) MOVING TOWARDS THE OPTIMIZATION OF DIAGNOSIS FOR PATIENTS WITH SARCOMA: A 10-YEAR REVIEW OF EXTERNALLY CONSULTED SARCOMA CASES IN A GENERAL ANATOMICAL PATHOLOGY SERVICE
Ray Deobald
Favorite
Dercle, Laurent

Radiology, New York-Presbyterian/Columbia University Medical Center
(P 408) CHANGES IN COMPUTED TOMOGRAPHY FEATURES INDUCED BY BRIGIMADLIN (BI 907828) IN PATIENTS WITH LIPOSARCOMA: INSIGHTS FROM PHASE I STUDIES
Laurent Dercle
Favorite
Desai, Jayesh

Peter MacCallum Cancer Centre
(P 176) SAFETY, EFFICACY, AND PATIENT-REPORTED OUTCOMES WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED NO PRIOR ANTI–COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 UPDATE
Jayesh Desai
Favorite
(P 386) GENOMIC PROFILING OF GYNAECOLOGICAL SARCOMAS: REPORT FROM THE AUSTRALIA-WIDE PRECISION ONCOLOGY PROGRAM
Jayesh Desai
Favorite
Desai, Sharvil

Levine Cancer Institute
(P 258) THE CRITICALITY OF OXIDATIVE PHOSPHORYLATION IN SYNOVIAL SARCOMA METASTASIS
Sharvil Desai
Favorite
Desar, Ingrid M.

Radboud University Medical Center
(P 27) A MULTICENTER RETROSPECTIVE STUDY ON THE CLINICAL BEHAVIOR OF SDH-DEFICIENT GIST
Ingrid M. Desar
Favorite
(P 30) FINANCIAL DIFFICULTIES EXPERIENCED BY DUTCH GASTROINTESTINAL STROMAL TUMOR (GIST) PATIENTS: DATA FROM A CROSS-SECTIONAL MULTICENTER STUDY
Ingrid M. Desar
Favorite
(P 138) CONTROVERSIES IN THE MANAGEMENT OF PATIENTS WITH SOFT TISSUE SARCOMA: RESULTS AND RECOMMENDATIONS FROM THE FIRST CONFERENCE ON STATE OF SCIENCE IN SARCOMA (CSSS)
Ingrid M. Desar
Favorite
Deshpande, Hari

Yale University
(P 158) SORAFENIB OR ANTHRACYCLINE-BASED CHEMOTHERAPY IN ADULT PATIENTS WITH PROGRESSIVE DESMOID TUMORS
Hari Deshpande
Favorite
DESOLNEUX, Grégoire

Oncological department of Institut Bergonié
(P 521) HOW TO MANAGE ABDOMINAL PARIETECTOMY, REVIEW OF EXPERIENCE IN INSTITUT BERGONIE
Grégoire DESOLNEUX
Favorite
Devalck, Christine

Department Hematology Oncology, HUDERF, ULB, HUB, Brussels, Belgium
(P 209) PROGNOSTIC VALUE OF EARLY RADIOLOGIC TUMOUR VOLUME RESPONSE IN RHABDOMYOSARCOMA; RESULTS OF THE EUROPEAN PAEDIATRIC SOFT TISSUE SARCOMA STUDY GROUP RMS 2005 STUDY
Christine Devalck
Favorite
Devaud, Nicolas

Instituto Oncologico Fundacion Arturo Lopez Perez (FALP)
(P 330) TREATMENT VARIATIONS, OUTCOMES AND PATTERNS OF RECURRENCE AFTER CURATIVE INTENT TREATMENT FOR PRIMARY RETROPERITONEAL SARCOMAS IN LATIN AMERICA. FIRST COLLABORATIVE LATAMSARC STUDY
Nicolas Devaud
Favorite
Deville, Curtiland

Johns Hopkins University School of Medicine
(P 559) PROSPECTIVE PHASE II TRIAL OF PREOPERATIVE HYPOFRACTIONATED PROTON THERAPY FOR EXTREMITY AND TRUNCAL AND TRUNCAL SOFT TISSUE SARCOMA: THE PRONTO STUDY RATIONALE AND DESIGN
Curtiland Deville
Favorite
Dexter, Susan

Sonnet BioTherapeutics
(P 111) INTERIM ANALYSIS OF A PHASE 1 STUDY USING IL12-FHAB WITH OPTIMIZED PHARMACOKINETICS
Susan Dexter
Favorite
Dharmani, Charles

Daiichi Sankyo Inc.
(P 199) PEXIDARTINIB RISK EVALUATION AND MITIGATION STRATEGY PROGRAM: 3-YEAR SAFETY DATA ASSESSMENT
Charles Dharmani
Favorite
Dharmani, Charles

Daiichi Sankyo, Inc.
(P 199) PEXIDARTINIB RISK EVALUATION AND MITIGATION STRATEGY PROGRAM: 3-YEAR SAFETY DATA ASSESSMENT
Charles Dharmani
Favorite
(P 200) EPIDEMIOLOGY OF TENOSYNOVIAL GIANT CELL TUMOR IN THE UNITED STATES
Charles Dharmani
Favorite
Dharmani, Charles

Daiichi Sankyo Inc.
(P 200) EPIDEMIOLOGY OF TENOSYNOVIAL GIANT CELL TUMOR IN THE UNITED STATES
Charles Dharmani
Favorite
Dhir, Aditi

University of Miami Miller School of Medicine
(P 128) THE IMPACT OF HISPANIC ETHNICITY IN PRESENTATION AND OUTCOMES OF PATIENTS WITH SYNOVIAL SARCOMA
Aditi Dhir
Favorite
(P 225) PAN-SARCOMA DATABASE (PSDB): A MODEL-VIEW-CONTROLLER FRAMEWORK UTILIZING REDCAP, SHINY, AND R TO CREATE A CONTINUOUS PIPELINE OF SARCOMA DATA
Aditi Dhir
Favorite
(P 226) SIGNATERA TESTING TO IDENTIFY MINIMAL RESIDUAL DISEASE IN HIGH GRADE SARCOMA
Aditi Dhir
Favorite
(P 361) MOLECULAR CHARACTERIZATION OF SOLITARY FIBROUS TUMORS BY ANATOMIC SITE AND NAB2::STAT6 FUSION VARIANT TYPE
Aditi Dhir
Favorite
(P 366) SURVIVAL DISPARITIES IN HISPANIC PATIENTS WITH SARCOMA TESTED WITH NEXT-GENERATION SEQUENCING (NGS)
Aditi Dhir
Favorite
(P 461) OUTCOMES FOR OLIGOMETASTATIC PULMONARY DISEASE RECURRENCE TREATED WITH SURGERY ALONE FOR PATIENTS WITH SOFT TISSUE SARCOMAS A CASE SERIES
Aditi Dhir
Favorite
(P 551) PHASE II TRIAL OF GEMCITABINE AND NAB-PACLITAXEL IN PATIENTS WITH RECURRENT RHABDOMYOSARCOMA: A CLINICAL TRIAL IN PROGRESS FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION
Aditi Dhir
Favorite
Dhupar, Rajeev

University of Pittsburgh Medical Center
(P 466) INTRAOPERATIVE EVALUATION OF BONE AND SOFT TISSUE SARCOMA SURGICAL MARGINS WITH INDOCYANINE GREEN FLUORESCENCE IMAGING
Rajeev Dhupar
Favorite
(P 544) INTRAOPERATIVE EVALUATION OF BONE AND SOFT TISSUE SARCOMA SURGICAL MARGINS WITH INDOCYANINE GREEN FLUORESCENCE IMAGING
Rajeev Dhupar
Favorite
Di Carlo, Daniela

University Hospital of Padova
(P 202) INFLAMMATORY MYOFIBROBLASTIC TUMOUR WITH ROS1 GENE FUSIONS IN CHILDREN AND YOUNG ADOLESCENTS
Daniela Di Carlo
Favorite
Di Cecco, Fabio

Ospedale Morgagni Pierantoni
(P 533) SAFETY AND PRELIMINARY BIOLOGICAL ACTIVITY OF A PHASE II TRIAL OF AUTOLOGOUS DENDRITIC CELLS VACCINATION IN SARCOMAS.
Fabio Di Cecco
Favorite
Di Gioia, Dorit

Department of Medicine III, LMU University Hospital, LMU Munich
(P 118) TIM-3 QUALIFIES AS A POTENTIAL IMMUNOTHERAPEUTIC TARGET IN SPECIFIC SUBSETS OF PATIENTS WITH HIGH-RISK SOFT TISSUE SARCOMAS (HR-STS)
Dorit Di Gioia
Favorite
(P 530) FIH PHASE I STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND ANTITUMOR ACTIVITY OF THE001 COMBINED WITH REGIONAL HYPERTHERMIA IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOFT TISSUE SARCOMA
Dorit Di Gioia
Favorite
(P 557) UNRAVELING THE ROLE OF LOCAL THERAPY FOR PATIENTS WITH OLIGOMETASTATIC SOFT TISSUE SARCOMA - A RETROSPECTIVE MULTICENTER TRIAL OF BAVARIAN UNIVERSITY HOSPITALS
Dorit Di Gioia
Favorite
Di Lernia, Davide

Health Research Institute-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM),
(P 270) ALTERNATIVE SPLICING (AS) REGULATION AS A NOVEL THERAPEUTIC TARGET IN SOFT-TISSUE SARCOMA (STS)
Davide Di Lernia
Favorite
(P 279) PROTEIN PHOSPHATASE 2 A INHIBITION AS A MECHANISM TO ENHANCE DOXORUBICIN ACTIVITY
Davide Di Lernia
Favorite
Di Maggio, Antonio

Oncology 1 Unit, Department of Oncology, Veneto Institute of Oncology IOV - IRCCS
(P 216) BRAIN METASTASES IN SARCOMA: A (NOT SO) RARE EVENT. THE EXPERIENCE OF A HIGH VOLUME CENTER
Antonio Di Maggio
Favorite
Di Mauro, Pierluigi

ASST Spedali Civili di Brescia
(P 159) IN BETWEEN OF LYMPHOMAS AND SARCOMAS: WHERE DO HISTIOCYTIC AND DENDRITIC CELL NEOPLASMS (HDCN) STAND? A RETROSPECTIVE, MULTI-INSTITUTIONAL STUDY FROM THE ITALIAN SARCOMA GROUP (ISG)
Pierluigi Di Mauro
Favorite
Diallo, Jean-Simon

The Ottawa Hospital Research Institute
(P 98) TUMOR IMMUNE PROFILING AND IDENTIFICATION OF IMMUNOTHERAPEUTIC TARGETS IN DEDIFFERENTIATED LIPOSARCOMA
Jean-Simon Diallo
Favorite
Diamond, Mark

University of Pennsylvania-Abramson Cancer Center
(P 552) RANDOMIZED PHASE II TRIAL OF CABOZANTINIB COMBINED WITH PD-1 AND CTLA-4 INHIBITION VERSUS CABOZANTINIB IN METASTATIC SOFT TISSUE SARCOMA.
Mark Diamond
Favorite
Díaz-Martín, Juan

Institute of Biomedicine of Sevilla (IBiS), Virgen del Rocio University Hospital/CSIC/University of Sevilla, 41013 Seville, Spain.
(P 437) ULTRA-RARE UNDIFFERENTIATED SMALL ROUND CELL SARCOMA: HOW SHOULD WE TREAT THEM? AN ANALYSIS FORM THE GRACEFUL PROJECT
Juan Díaz-Martín
Favorite
Dibs, Khaled

Ohio State University Wexner Medical Center
(P 315) SCALP VOLUMETRIC MODULATED ARC THERAPY USING 3D MILLED BOLUS: DOSIMITRY, TOXICITY AND OUTCOMES
Khaled Dibs
Favorite
Dickson, Brendan

Sinai Health System
(P 249) INVESTIGATING CLINICAL FACTORS ASSOCIATED WITH THE ESTABLISHMENT OF SUCCESSFUL PRIMARY HUMAN SOFT TISSUE SARCOMA CELL LINES
Brendan Dickson
Favorite
(P 265) SELECTIVE TARGETING OF BET FAMILY EPIGENETIC REGULATORS IN ADVANCED AND METASTATIC ALVEOLAR RHABDOMYOSARCOMA
Brendan Dickson
Favorite
(P 421) USING TRANSCRIPTOMICS TO IDENTIFY LEIOMYOSARCOMA PATIENTS AT RISK OF METASTASIS
Brendan Dickson
Favorite
Dickson, Mark

MSKCC
(P 24) COMPREHENSIVE ANALYSIS OF THE GENOMIC LANDSCAPE AND CLINICAL BEHAVIOR IN GIST USING NEXT GENERATION SEQUENCING (NGS, MSK-IMPACT)
Mark Dickson
Favorite
Dieckmann, Nils

University Hospital Essen, West German Cancer Center
(P 294) DNA-DAMAGE REPAIR DYSREGULATION AND CHEMOTHERAPY RESPONSE IN SARCOMA MODELS
Nils Dieckmann
Favorite
Dierselhuis, Miranda

Prinses Maxima Centrum
(P 161) EFFICACY, SAFETY, AND TREATMENT HOLD WAIT-AND-SEE OUTCOMES OF LAROTRECTINIB IN PEDIATRIC PATIENTS WITH TRK FUSION SARCOMAS
Miranda Dierselhuis
Favorite
Dietz, Matthew

University of Utah, Primary Children's Hospital
(P 81) OPTIMIZING EWING SARCOMA AND OSTEOSARCOMA BIOPSY ACQUISITION: CONSENSUS RECOMMENDATIONS FROM THE CHILDREN'S ONCOLOGY GROUP BONE TUMOR COMMITTEE
Matthew Dietz
Favorite
Difilippo, Valeria

Lund University
(P 230) SARCDBASE: A TOOL FOR DETECTION OF GENETIC ALTERATIONS IN SARCOMA
Valeria Difilippo
Favorite
(P 371) DISRUPTION OF THE TP53 LOCUS IN OSTEOSARCOMA LEADS TO TP53 PROMOTER GENE FUSIONS AND RESTORATION OF PARTS OF THE TP53 SIGNALLING PATHWAY
Valeria Difilippo
Favorite
Difrancesco, Lisa

University of Calgary
(P 110) GCAR1: GPNMB CAR T THERAPY FOR MIT FAMILY TRANSLOCATION POSITIVE CANCERS
Lisa Difrancesco
Favorite
Digklia, Antonia

Department of Oncology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
(P 103) LASTING COMPLETE RESPONSE TO PEMBROLIZUMAB IN MISMATCH REPAIR DEFICIENT CARDIAC SARCOMA: A GENOMIC CHARACTERIZATION
Antonia Digklia
Favorite
(P 437) ULTRA-RARE UNDIFFERENTIATED SMALL ROUND CELL SARCOMA: HOW SHOULD WE TREAT THEM? AN ANALYSIS FORM THE GRACEFUL PROJECT
Antonia Digklia
Favorite
(P 535) THERAGNOSTICS IN SOFT TISSUE SARCOMA USING A VASCULAR DISCRUPTION APPROACH
Antonia Digklia
Favorite
Dileo, Palma

University College Hospital
(P 138) CONTROVERSIES IN THE MANAGEMENT OF PATIENTS WITH SOFT TISSUE SARCOMA: RESULTS AND RECOMMENDATIONS FROM THE FIRST CONFERENCE ON STATE OF SCIENCE IN SARCOMA (CSSS)
Palma Dileo
Favorite
(P 342) THE EVALUATION AND OUTCOMES OF MESENTERIC AND INTRA-ABDOMINAL DESMOIDS: A TARPSWG STUDY
Palma Dileo
Favorite
(P 437) ULTRA-RARE UNDIFFERENTIATED SMALL ROUND CELL SARCOMA: HOW SHOULD WE TREAT THEM? AN ANALYSIS FORM THE GRACEFUL PROJECT
Palma Dileo
Favorite
di, maojun

Department of Gastrointestinal Surgery, Taihe Hospital，Hubei University of Medicine
(P 39) MANAGEMENT PRACTICES OF GASTROINTESTINAL STROMAL TUMORS: A QUESTIONNAIRE SURVEY OF GENERAL SURGEONS IN CHINA
maojun di
Favorite
Ding, Li

Aadi Bioscience
(P 540) PHASE 2, MULTICENTER, OPEN-LABEL BASKET TRIAL OF NAB-SIROLIMUS FOR MALIGNANT SOLID TUMORS HARBORING PATHOGENIC INACTIVATING ALTERATIONS IN TSC1 AND TSC2 (PRECISION I)
Li Ding
Favorite
Ding, Yuqi

The First Affiliated Hospital of Sun Yat-sen University
(P 45) THE LONG-TERM EFFECT OF IMATINIB WITH HEPATIC RESECTION OR OTHER LOCAL TREATMENT FOR GIST LIVER METASTASES
Yuqi Ding
Favorite
Dirksen, Uta

University Hospital Essen, Pediatrics III, West German Cancer Center, German Cancer Research Center (DKTK) site Essen, National Center for Tumordiseases (NCT) site Essen, ,
(P 17) METASTASIS-SPECIFIC GENE EXPRESSION PATTERNS IN EWING SARCOMA
Uta Dirksen
Favorite
(P 69) DEVELOPMENT AND MISSION OF THE HARMONIZATION INTERNATIONAL BONE SARCOMA CONSORTIUM (HIBISCUS)
Uta Dirksen
Favorite
(P 294) DNA-DAMAGE REPAIR DYSREGULATION AND CHEMOTHERAPY RESPONSE IN SARCOMA MODELS
Uta Dirksen
Favorite
(P 451) IMPACT OF TIME TO DIAGNOSIS - A PROSPECTIVE ANALYSIS OF THE EWING 2008 TRIAL
Uta Dirksen
Favorite
(P 538) IEUROEWING TRIAL FOR LOCALIZED AND METASTATIC EWING SARCOMA
Uta Dirksen
Favorite
Divenko, Margarita

Baylor College of Medicine
(P 426) MULTI-OMIC ANALYSIS OF DESMOPLASTIC SMALL ROUND CELL TUMORS REVEAL DISTINCT LINEAGES
Margarita Divenko
Favorite
Dizon, Don

Brown University
(P 361) MOLECULAR CHARACTERIZATION OF SOLITARY FIBROUS TUMORS BY ANATOMIC SITE AND NAB2::STAT6 FUSION VARIANT TYPE
Don Dizon
Favorite
Dlugosz, Andrzej

University of Michigan
(P 293) GENERATION OF A SPONTANEOUS IMMUNOCOMPETENT MOUSE MODEL OF LIPOSARCOMA
Andrzej Dlugosz
Favorite
Dodd, Rebecca

University of Iowa
(P 286) EPIGENETIC MECHANISMS AND SIGNATURES OF SARCOMA PROGRESSION AND METASTASIS
Rebecca Dodd
Favorite
Dodoo, Christopher

Mayo Clinic Arizona
(P 312) MANAGEMENT OF ADULT HEAD AND NECK SOFT TISSUE SARCOMA: THE MAYO CLINIC EXPERIENCE
Christopher Dodoo
Favorite
Doherty, Mark

St Vincents University Hospital
(P 155) THE IMPACT OF THE ROLE OF A SARCOMA ADVANCED NURSE PRACTITIONER (ANP) BIOPSY CLINIC IN IMPROVING PATIENT ACCESS TO SARCOMA SERVICES
Mark Doherty
Favorite
(P 156) PATIENT REPORTED EXPERIENCES WITHIN THE IRISH SARCOMA GROUP
Mark Doherty
Favorite
(P 213) EXPERIENCE WITH THE USE OF TRABECTEDIN IN ADVANCED SOFT TISSUE SARCOMA IN IRELAND
Mark Doherty
Favorite
(P 217) CONTEMPORARY TREATMENT PATTERNS AND OUTCOMES IN THE MANAGEMENT OF ANGIOSARCOMA IN IRELAND
Mark Doherty
Favorite
Doherty, Terrence

Moores Cancer Center, University of California San Diego
(P 29) COMBINATION TREATMENT WITH TEMOZOLOMIDE AND THE DEATH RECEPTOR-5 AGONIST INBRX-109 EFFECTIVELY TARGETS SUCCINATE DEHYDROGENASE -DEFICIENT GASTROINTESTINAL STROMAL TUMOR
Terrence Doherty
Favorite
Dolado, Maria Carmen

HU Canarias
(P 175) TRABECTEDIN PLUS RADIOTHERAPY ON SYMPHTOMATIC ADVANCED SARCOMA PATIENTS, RESULTS FROM THE SYNERGIAS STUDY: A SPANISH GROUP FOR RESEARCH IN SARCOMA (GEIS) PHASE II STUDY
Maria Carmen Dolado
Favorite
Dolcan, Ana

CHUV
(P 535) THERAGNOSTICS IN SOFT TISSUE SARCOMA USING A VASCULAR DISCRUPTION APPROACH
Ana Dolcan
Favorite
Donati, Davide

IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy
(P 437) ULTRA-RARE UNDIFFERENTIATED SMALL ROUND CELL SARCOMA: HOW SHOULD WE TREAT THEM? AN ANALYSIS FORM THE GRACEFUL PROJECT
Davide Donati
Favorite
Donati, Davide Maria

Istituto Ortopedico Rizzoli IOR IRCCS, SC Third Orthopaedic Clinic and Traumatology, Bologna Italy
(P 01) EXTRASKELETAL EWING SARCOMA OF THE EXTREMITIES AND TRUNK IN < 25 YEARS OLD PATIENTS: A RETROSPECTIVE ANALYSIS OF A MONO-INSTITUTIONAL SERIES.
Davide Maria Donati
Favorite
(P 74) SACRAL CHORDOMA: A RANDOMIZED & OBSERVATIONAL STUDY ON SURGERY VS DEFINITIVE RADIOTHERAPY IN PRIMARY LOCALIZED DISEASE (SACRO). INTERIM ANALYSIS
Davide Maria Donati
Favorite
(P 253) THE EFFICACY OF MEDICATED PATCHES IN SOFT TISSUE SARCOMAS: IN-VITRO AND EX-VIVO VALIDATION.
Davide Maria Donati
Favorite
(P 355) FUSION TRANSCRIPTOME PROFILING DEFINES THE MONOCLONAL NATURE OF MULTIFOCAL EPITHELIOID HEMANGIOMA OF BONE
Davide Maria Donati
Favorite
Dong, Qun

Department of Bioinformatics and Biostatistics, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai 200240, China
(P 416) THE PROTEOGENOMIC SUBTYPING OF OSTEOSARCOMA
Qun Dong
Favorite
Dong, Yang

Department of Orthopedics, Shanghai Jiao Tong University Affiliated Sixth People's Hospital
(P 169) UPDATED EFFICACY AND SAFETY PROFILE OF PIMICOTINIB (ABSK021) IN TENOSYNOVIAL GIANT CELL TUMOR (TGCT): 1-YEAR FOLLOW-UP FROM PHASE 1B
Yang Dong
Favorite
Dong, Zhi

Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute Beijing 100142, P. R. China
(P 46) CIRCULATING TUMOR DNA (CTDNA) ANALYSES AND RESISTANCE MECHANISMS EXPLORATION OF KIT-MUTANT GASTROINTESTINAL STROMAL TUMORS (GISTS) TREATED WITH AVAPRITINIB OR RIPRETINB
Zhi Dong
Favorite
Doni, Michele

Unit of Oncogenetics and Functional Oncogenomics, Centro di Riferimento Oncologico di Aviano IRCCS, Aviano, Italy
(P 378) MULTIOMICS PROFILING OF EPITHELIOID SARCOMA UNVEILS EPIGENETIC CIRCUITRIES THAT UNDERLIE THE PATHOBIOLOGY OF PROXIMAL AND CLASSIC SUBTYPES: RESULTS FROM THE ISG EPISOBS OBSERVATIONAL STUDY
Michele Doni
Favorite
Donini, Chiara

Department of Oncology, University of Turin
(P 109) INTENSE PRECLINICAL ACTIVITY BY B7H3-SPECIFIC CAR.CIK LYMPHOCYTES AGAINST EPITHELIOID SARCOMA
Chiara Donini
Favorite
Donovan Bailey, Swneke

McGill University
(P 379) THE ROLE OF EZHIP IN DRIVING AGGRESSIVE OSTEOSARCOMA
Swneke Donovan Bailey
Favorite
(P 434) MECHANISMS OF CHEMORESISTANCE IN CIC-DUX4 SARCOMA AS DETERMINED BY IN VIVO FUNCTIONAL GENOMICS
Swneke Donovan Bailey
Favorite
Dontenwill, Monique

UMR CNRS 7021
(P 277) ANTI-GD2 SYNERGIZES WITH HYPOXIA PATHWAY TARGETING TO BLOCK OSTEOSARCOMA CELL PROLIFERATION AND MIGRATION.
Monique Dontenwill
Favorite
(P 389) OSTEOBLASTIC-GENE SIGNATURE TO PREDICT SURVIVAL IN PEDIATRIC OSTEOSARCOMA (OS) AND TO FOLLOW PATIENTS TOWARDS LIQUID BIOPSY: A COLLABORATIVE WORK IN OS2006 PROTOCOL.
Monique Dontenwill
Favorite
Dorand, Dixon

Tennessee Oncology
(P 218) NEOADJUVANT CHEMOTHERPAY AND RADIATION DECREASES TUMOR SIZE, VIABILITY, AND RECURRENCE IN MULTIPLE LIPOSARCOMA SUBSETS
Dixon Dorand
Favorite
(P 380) NEXT GENERATION SEQUEINCING REVEALS TARGETABLE MUTATIONS IN MULTIPLE SARCOMA HISTOLOGIES
Dixon Dorand
Favorite
D'Orazio, Federico

Humanitas Research Hospital
(P 433) A 20-YEAR MONOCENTER EXPERIENCE ON CLINICAL CHARACTERISTICS AND OUTCOME OF EXTRASKELETAL EWING SARCOMA.
Federico D'Orazio
Favorite
Dore-Smith, Emily

University College London
(P 147) UNDERSTANDING THE EXPERIENCES OF PATIENTS RETURNING TO DAILY ACTIVITES AND EXERCISE FOLLOWING LIMB SPARING SURGERY FOR BONE OR SOFT TISSUE SARCOMA AROUND THE KNEE
Emily Dore-Smith
Favorite
(P 495) UNDERSTANDING THE EXPERIENCES OF PATIENTS RETURNING TO ACTIVITIES OF DAILY LIVING AND EXERCISE FOLLOWING LIMB SPARING SURGERY FOR BONE OR SOFT TISSUE SARCOMA AROUND THE KNEE.
Emily Dore-Smith
Favorite
Doronzo, Gabriella

Department of Oncology, University of Turin
(P 262) ESTABLISHMENT AND CHARACTERIZATION OF THE FIRST RADIATION-INDUCED, PATIENT-DERIVED ANGIOSARCOMA CELL LINE
Gabriella Doronzo
Favorite
Dorsey*, Jen

Lunenfeld Tanenbaum Research Institute/Mount Sinai Hospital
(P 249) INVESTIGATING CLINICAL FACTORS ASSOCIATED WITH THE ESTABLISHMENT OF SUCCESSFUL PRIMARY HUMAN SOFT TISSUE SARCOMA CELL LINES
Jen Dorsey*
Favorite
(P 265) SELECTIVE TARGETING OF BET FAMILY EPIGENETIC REGULATORS IN ADVANCED AND METASTATIC ALVEOLAR RHABDOMYOSARCOMA
Jen Dorsey*
Favorite
(P 367) CHARACTERIZING HYPOXIA AND ASSOCIATED MOLECULAR FEATURES IN EXTREMITY SOFT TISSUE SARCOMA
Jen Dorsey*
Favorite
Dotti, Gianpietro

UNC Lineberger Comprehensive Cancer Center
(P 109) INTENSE PRECLINICAL ACTIVITY BY B7H3-SPECIFIC CAR.CIK LYMPHOCYTES AGAINST EPITHELIOID SARCOMA
Gianpietro Dotti
Favorite
Dotti, Silvia

Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia-Romagna, Laboratorio di Controllo di Prodotti Biologici, Centro di Referenza Nazionale per i Metodi Alternativi, Benessere e Cura degli Animali da Laboratorio, 25124 Brescia
(P 283) A TRIDIMENSIONAL PRECLINICAL MODEL TO STUDY HUMAN AND CANINE OSTEOSARCOMA DEVELOPMENT AND INTERACTION WITH TUMOR MICROENVIRONMENT
Silvia Dotti
Favorite
Doung, Yee-Cheen

Oregon Health & Science University
(P 129) LOW RATES OF SERVICE CONNECTIVITY FOR SOFT TISSUE SARCOMA (STS) AMONG ELIGIBLE VIETNAM VETERANS WITH AGENT ORANGE EXPOSURE
Yee-Cheen Doung
Favorite
(P 130) THE ADOPTION OF MEDICAID EXPANSION IN THE AFFORDABLE CARE ACT IS NOT ASSOCIATED WITH STAGE AT PRESENTATION OR 5-YEAR OVERALL SURVIVAL FOR BONE OR SOFT TISSUE SARCOMAS
Yee-Cheen Doung
Favorite
(P 179) PILOT STUDY OF A REMOTELY DELIVERED RESISTANCE EXERCISE TRAINING PROGRAM IN SARCOMA SURVIVORS
Yee-Cheen Doung
Favorite
(P 227) DE NOVO NATURAL LANGUAGE PROCESSING (NLP) ALGORITHM ACCURATELY IDENTIFIES MYXOFIBROSARCOMA DIRECTLY FROM PATHOLOGY REPORTS
Yee-Cheen Doung
Favorite
(P 462) EXTERNAL VALIDATION OF A NOMOGRAM PREDICTING THE RISK OF POSTOPERATIVE MAJOR WOUND COMPLICATION IN SOFT TISSUE SARCOMA FOLLOWING PREOPERATIVE RADIOTHERAPY AND RESECTION
Yee-Cheen Doung
Favorite
(P 463) MACHINE LEARNING CORROBORATES TRADITIONAL REGRESSION TECHNIQUES IN PREDICTING MAJOR WOUND COMPLICATIONS AFTER SOFT TISSUE SARCOMA RESECTION WITHOUT IMPROVEMENTS IN PREDICTIVE PERFORMANCE
Yee-Cheen Doung
Favorite
Doval, Anxela

HU Clínico San Carlos
(P 149) PSYCOLOGICAL SNAPSHOT OF SARCOMA PATIENTS FROM AN ACADEMIC, UNIVERSITY CENTER, HOSPITAL CLÍNICO SAN CARLOS (HCSC), MADRID, A SARCOMA NATIONAL REFERRAL CENTRE IN SPAIN
Anxela Doval
Favorite
(P 175) TRABECTEDIN PLUS RADIOTHERAPY ON SYMPHTOMATIC ADVANCED SARCOMA PATIENTS, RESULTS FROM THE SYNERGIAS STUDY: A SPANISH GROUP FOR RESEARCH IN SARCOMA (GEIS) PHASE II STUDY
Anxela Doval
Favorite
Doyon, Josee

CIUSSS Est-de-l'Île-de-Montréal
(P 245) IN VIVO USE OF RAMAN SPECTROSCOPY IN SOFT TISSUE SARCOMA RESECTION
Josee Doyon
Favorite
Drabbe, Cas

Netherlands Cancer Institute
(P 140) THE PRE-DIAGNOSTIC GENERAL PRACTIONER JOURNEY OF SARCOMA PATIENTS: A REAL-WORLD DATA STUDY.
Cas Drabbe
Favorite
Drake, James

Hospital for Sick Children
(P 108) EFFECT OF TUMOUR-TARGETED HYPERTHERMIA AND CHEMOTHERAPY ON THE IMMUNE PROFILE OF A MURINE MODEL OF EMBRYONAL RHABDOMYOSARCOMA
James Drake
Favorite
Drapeau, Isabelle

CIUSSS Est-de-l'Île-de-Montréal
(P 134) IMPACT OF THE PARTNERSHIP BETWEEN TERTIARY CENTERS AND NON-SARCOMA RADIOLOGY CENTERS.
Isabelle Drapeau
Favorite
Drilon, Alexander

Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College
(P 353) UPDATED EFFICACY AND SAFETY OF LAROTRECTINIB IN ADULT PATIENTS WITH TRK FUSION SARCOMAS
Alexander Drilon
Favorite
Droste, Margret

Bridge Institute of Experimental Tumor Therapy, West German Cancer Center, University Hospital Essen
(P 248) FIBROBLAST ACTIVATION PROTEIN ALPHA -DIRECTED IMAGING AND THERAPY OF SOLITARY FIBROUS TUMOR
Margret Droste
Favorite
Druta, Mihaela

H. Lee Moffitt Cancer Center and Research Institute
(P 531) ENVASARC: A PIVOTAL TRIAL OF ENVAFOLIMAB AND ENVAFOLIMAB IN COMBINATION WITH IPILIMUMAB IN PATIENTS WITH ADVANCED OR METASTATIC UPS OR MFS WHO HAVE PROGRESSED ON PRIOR CHEMOTHERAPY
Mihaela Druta
Favorite
Dry, Sarah

David Geffen School of Medicine, University of California, Los Angeles
(P 19) EXTRACELLULAR VESICLE CLICK MAGBEADS: A MULTIFACETED LIQUID BIOPSY PLATFORM FOR PEDIATRIC SARCOMAS
Sarah Dry
Favorite
D'Silva, Dhiren

PTC Therapeutics, Inc.
(P 182) UPDATED RESULTS FROM AN ONGOING PHASE 1B STUDY OF UNESBULIN (PTC596) PLUS DACARBAZINE FOR THE TREATMENT OF PATIENTS WITH ADVANCED LEIOMYOSARCOMA
Dhiren D'Silva
Favorite
(P 548) A PHASE 2/3 STUDY EVALUATING THE EFFICACY AND SAFETY OF UNESBULIN IN ADVANCED LEIOMYOSARCOMA (SUNRISELMS)
Dhiren D'Silva
Favorite
Duan, Zhenfeng

University of Miami
(P 54) HIGH-THROUGHPUT DRUG SCREENING IN CHONDROSARCOMA CELLS IDENTIFIES MULTIPLE EFFICIENT ANTINEOPLASTIC AGENTS
Zhenfeng Duan
Favorite
(P 280) A CELL-BASED COMPOUND SCREENING IDENTIFIES AGENTS THAT SYNERGIZE WITH EVEROLIMUS IN SARCOMA
Zhenfeng Duan
Favorite
Duarte-Bateman, Daniela

Cleveland Clinic
(P 177) ANGIOSARCOMA: AN INCREASING PROBLEM IN THE UNITED STATES
Daniela Duarte-Bateman
Favorite
Dubois, Steven

Dana-Farber/Boston Children’s Cancer and Blood Disorders Center
(P 03) EVOLUTION OF CLINICALLY ACTIONABLE VARIANTS IN ADVANCED PEDIATRIC AND AYA BONE SARCOMAS
Steven Dubois
Favorite
(P 68) METASTASIS-DIRECTED RADIOTHERAPY FOR EWING SARCOMA PATIENTS ENROLLED ON AEWS1221: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP (COG)
Steven Dubois
Favorite
(P 81) OPTIMIZING EWING SARCOMA AND OSTEOSARCOMA BIOPSY ACQUISITION: CONSENSUS RECOMMENDATIONS FROM THE CHILDREN'S ONCOLOGY GROUP BONE TUMOR COMMITTEE
Steven Dubois
Favorite
(P 161) EFFICACY, SAFETY, AND TREATMENT HOLD WAIT-AND-SEE OUTCOMES OF LAROTRECTINIB IN PEDIATRIC PATIENTS WITH TRK FUSION SARCOMAS
Steven Dubois
Favorite
(P 437) ULTRA-RARE UNDIFFERENTIATED SMALL ROUND CELL SARCOMA: HOW SHOULD WE TREAT THEM? AN ANALYSIS FORM THE GRACEFUL PROJECT
Steven Dubois
Favorite
Duc, Adeline

CENTRE LEON BERARD AND CANCER RESEARCH CENTER OF LYON (INSERM U1052-CNRS5286)
(P 435) ONCOGENIC FUSION YWHAE::NUTM2 DISRUPT EP300/BCOR INTERACTION
Adeline Duc
Favorite
Ducassou, Anne

OCR
(P 201) PLEOMORPHIC RHABDOMYOSARCOMAS: A NEW ENTITY ASSOCIATED WITH LYNCH SYNDROME? FIRST RESULTS OF SARCLYNCH NATIONAL STUDY
Anne Ducassou
Favorite
Ducassou, Stephane

Pediatric Hospital
(P 75) REAL-WORLD DATA ON REGORAFENIB AND CABOZANTINIB IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH RELAPSED OSTEOSARCOMA AND EWING SARCOMA INCLUDED IN THE SACHA-FRANCE STUDY
Stephane Ducassou
Favorite
(P 212) REPORT ON THE EWING SARCOMA PATIENTS ENROLLED IN ARM D OF THE ACSE-ESMART TRIAL: PHASE I/II STUDY OF THE PARP INHIBITOR OLAPARIB IN COMBINATION WITH IRINOTECAN IN CHILDREN WITH ADVANCED MALIGNANCIES
Stephane Ducassou
Favorite
Ducceschi, Monika

INT Milan
(P 328) REAL-LIFE EXPERIENCE OF PAZOPANIB IN PATIENTS WITH ADVANCED UTERINE LEIOMYOSARCOMA (U-LMS) FROM TWO REFERRAL ITALIAN CENTERS
Monika Ducceschi
Favorite
ducimetiere, francoise

Centre Léon Bérard
(P 104) COMPREHENSIVE IMMUNE PROFILING UNVEILS A SUBSET OF LEIOMYOSARCOMA WITH HOT TUMOR IMMUNE MICROENVIRONMENT
francoise ducimetiere
Favorite
Duensing, Anette

University of Pittsburgh School of Medicine
(P 373) DEDIFFERENTIATED AND HIGH GRADE CHONDROSARCOMAS: HOW DOES ISOCITRATE DEHYDROGENASE STATUS APPRISE PROGNOSIS AND THERAPY?
Anette Duensing
Favorite
Dufresne, Armelle

CENTRE LEON BERARD
(P 104) COMPREHENSIVE IMMUNE PROFILING UNVEILS A SUBSET OF LEIOMYOSARCOMA WITH HOT TUMOR IMMUNE MICROENVIRONMENT
Armelle Dufresne
Favorite
(P 382) NTRK1/2/3 FUSIONS DETECTION USING RNA-SEQ IN MESENCHYMAL TUMORS REVEALS ULTRA-RARE AND HISTO-SPECIFIC TARGETABLE ALTERATIONS: EXPERIENCE OF AN EXTENSIVE ROUTINE RESEARCH PROGRAM.
Armelle Dufresne
Favorite
(P 435) ONCOGENIC FUSION YWHAE::NUTM2 DISRUPT EP300/BCOR INTERACTION
Armelle Dufresne
Favorite
Dulude, Jean-Philippe

Université de Montréal
(P 245) IN VIVO USE OF RAMAN SPECTROSCOPY IN SOFT TISSUE SARCOMA RESECTION
Jean-Philippe Dulude
Favorite
Dumanian, Gregory

Northwestern Medicine
(P 480) TARGETED MUSCLE REINNERVATION FOR HIP DISARTICULATION - EVALUATION OF EARLY FUNCTIONAL OUTCOMES
Gregory Dumanian
Favorite
Duncan, Aundrietta

Salarius Pharmaceuticals
(P 456) SECLIDEMSTAT TREATMENT BLOCKS THE TRANSCRIPTIONAL FUNCTION OF MULTIPLE FET-FUSION PROTEINS
Aundrietta Duncan
Favorite
Dunham, Alden

Vanderbilt University Medical Center
(P 218) NEOADJUVANT CHEMOTHERPAY AND RADIATION DECREASES TUMOR SIZE, VIABILITY, AND RECURRENCE IN MULTIPLE LIPOSARCOMA SUBSETS
Alden Dunham
Favorite
Dunlop, Hayley

The Ohio State University College of Medicine
(P 314) PRE-OPERATIVE RADIATION THERAPY INCREASES ADHERENCE IN PATIENTS WITH HIGH-RISK EXTREMITY SOFT TISSUE SARCOMA
Hayley Dunlop
Favorite
Duran Sierra, Elvis

MD Anderson Cancer Center
(P 221) EARLY RESULTS IN NOVEL USE OF CONTRAST-ENHANCED SUSCEPTIBILITY-WEIGHTED IMAGING IN THE ASSESSMENT OF RESPONSE AND PROGRESSION IN DESMOID FIBROMATOSIS: PILOT STUDY IN A SPECIALIZED CANCER INSTITUTION
Elvis Duran Sierra
Favorite
(P 239) CANCER RADIOMIC AND PERFUSION IMAGING (CARPI) AUTOMATED FRAMEWORK: VALIDATION ON MUSCULOSKELETAL TUMORS IN A SPECIALIZED CANCER CENTER
Elvis Duran Sierra
Favorite
(P 354) ROLE OF APPARENT DIFFUSION COEFFICIENT (ADC) MAP-BASED FIRST AND HIGH-ORDER RADIOMIC FEATURES IN DISCRIMINATING SACRAL CHORDOMAS AND CHONDROSARCOMAS WITH OVERLAPPING CONVENTIONAL IMAGING FEATURES
Elvis Duran Sierra
Favorite
(P 356) BASELINE AND POST-TREATMENT ADVANCED MRI OF EXTREMITIES SOFT-TISSUE NON-MYXOID UNDIFFERENTIATED PLEOMORPHIC SARCOMA.
Elvis Duran Sierra
Favorite
(P 357) APPARENT DIFFUSION COEFFICIENT (ADC) HIGH-ORDER RADIOMICS OF BASELINE AND POST-TREATMENT ADVANCED MRI OF EXTREMITY SOFT-TISSUE NON-MYXOID UNDIFFERENTIATED PLEOMORPHIC SARCOMA.
Elvis Duran Sierra
Favorite
(P 358) CONTRAST-ENHANCED SUSCEPTIBILITY IMAGING (CE-SWI) MORPHOLOGIC, FIRST & HIGH-ORDER RADIOMIC FEATURES VALUE IN ASSESSING TREATMENT RESPONSE IN EXTREMITY SOFT-TISSUE UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Elvis Duran Sierra
Favorite
(P 359) ROLE OF PERFUSION WEIGHTED IMAGING WITH DYNAMIC CONTRAST ENHANCED (PWI/DCE) FOR THE TREATMENT ASSESSMENT OF EXTREMITY SOFT-TISSUE NON-MYXOID UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Elvis Duran Sierra
Favorite
Durfee, Cameron

University of Texas Health San Antonio
(P 236) APOBEC MUTAGENESIS IN OSTEOSARCOMA DEVELOPMENT, PROGRESSION AND RESPONSE TO THERAPY
Cameron Durfee
Favorite
Duriseti, Sai

UCLA
(P 187) PALLIATIVE LATTICE STEREOTACTIC BODY RADIOTHERAPY FOR PATIENTS WITH SARCOMA
Sai Duriseti
Favorite
Dusenbery, Kathryn

University of Minnesota
(P 167) FDG-PET-CT RESPONSE AFTER NEOADJUVANT CHEMOTHERAPY PREDICTS LONG-TERM OUTCOME IN PATIENTS WITH SOFT TISSUE SARCOMA -- 15-YEAR FOLLOW-UP
Kathryn Dusenbery
Favorite
Duus, Nicolas

Precision Sarcoma Research Group, German Cancer Research Center (DKFZ) and Clinical Cooperation Unit Virotherapy, National Center for Tumor Diseases (NCT) Heidelberg
(P 124) UNLOCKING THE POTENTIAL OF MEASLES VIRUS ONCOLYTIC IMMUNOTHERAPY FOR SARCOMA: BIOMARKER DISCOVERY AND THERAPEUTIC VACCINE DEVELOPMENT
Nicolas Duus
Favorite
Du, Xinhui

Department of Orthopedics, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital
(P 169) UPDATED EFFICACY AND SAFETY PROFILE OF PIMICOTINIB (ABSK021) IN TENOSYNOVIAL GIANT CELL TUMOR (TGCT): 1-YEAR FOLLOW-UP FROM PHASE 1B
Xinhui Du
Favorite
Du, Xiuping

Department of Medical Oncology, Affiliated Hospital of Xuzhou Medical University
(P 44) RIPRETINIB FOR THE TREATMENT OF CHINESE PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS HARBORING KIT SECONDARY MUTATIONS: A MULTICENTER, RETROSPECTIVE STUDY
Xiuping Du
Favorite
Du, Yuqiang

Huazhong University of Science and Technology
(P 38) EFFICACY AND SAFETY OF RIPRETINIB IN THE TREATMENT OF ADVANCED GASTROINTESTINAL STROMAL TUMORS: A MULTICENTER RETROSPECTIVE STUDY
Yuqiang Du
Favorite
Dyer, Michael

St. Jude Children's Research Hospital
(P 288) EVALUATION OF ATR AND WEE1 INHIBITORS COMBINED WITH NANO-LIPOSOMAL IRINOTECAN IN A LARGE COHORT OF RHABDOMYOSARCOMA XENOGRAFTS USING A TWIN MOUSE PRECLINICAL TRIAL DESIGN
Michael Dyer
Favorite
(P 303) PRECLINICAL EVALUATION OF PARP1 SELECTIVE INHIBITOR AZD5305 IN COMBINATION WITH DNA DAMAGING AGENTS IN EWING SARCOMA ORTHOTOPIC XENOGRAFT MODELS
Michael Dyer
Favorite
Dykema, Karl

Atrium Health Levine Children's Hospital
(P 266) ROMIDEPSIN DECREASES DNA DAMAGE REPAIR AND INCREASES SENSITIVITY TO CHEMOTHERAPY IN EWING SARCOMA
Karl Dykema
Favorite
E
Eastley, Nicholas

University of Toronto
(P 443) SURGICAL RESECTION OF EXTREMITY EWING'S SARCOMA BASED ON POST-CHEMOTHERAPY TUMOUR VOLUME RESULTS IN SAFE MARGINS
Nicholas Eastley
Favorite
(P 484) OBESITY INCREASES THE RISK OF MAJOR WOUND COMPLICATIONS FOLLOWING PELVIC RESECTION FOR BONE SARCOMA
Nicholas Eastley
Favorite
Eastwood, Deborah

RNOH stanmore
(P 497) STANMORE TUMOUR OUTCOMES PROJECT (STOMP)- USING INTERNATIONAL CLASSIFICATION OF FUNCTIONING, DISABILITY AND HEALTH (ICF) OUTCOMES IN SARCOMA SURVIVORS. and UNDERSTANDING THE EXPERIENCES OF PATIENTS RETURNING TO DAILY ACTIVITES AND EXERCISE FOLLOWING LIMB SPARING SURGERY FOR BONE OR SOFT TISSUE SARCOMA AROUND THE KNEE
Deborah Eastwood
Favorite
Eaton, Bree

Emory University
(P 68) METASTASIS-DIRECTED RADIOTHERAPY FOR EWING SARCOMA PATIENTS ENROLLED ON AEWS1221: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP (COG)
Bree Eaton
Favorite
Eckelman, Brendan

Inhibrx, Inc
(P 29) COMBINATION TREATMENT WITH TEMOZOLOMIDE AND THE DEATH RECEPTOR-5 AGONIST INBRX-109 EFFECTIVELY TARGETS SUCCINATE DEHYDROGENASE -DEFICIENT GASTROINTESTINAL STROMAL TUMOR
Brendan Eckelman
Favorite
(P 439) THE TETRAVALENT DEATH RECEPTOR 5 AGONIST INBRX-109 COMBINED WITH CHEMOTHERAPY IN EWING SARCOMA: PRELIMINARY DATA FROM A PHASE 1 STUDY
Brendan Eckelman
Favorite
Eckhoff, Michael

Ohio State University
(P 502) SEPARATE RESECTION OF BIOPSY TRACT IN PRIMARY BONE SARCOMA: IMPLICATIONS FOR LOCAL RECURRENCE AND OVERALL SURVIVAL
Michael Eckhoff
Favorite
Eder, Sebastian

St. Anna Children's Hospital
(P 384) SYSTEMATIC LITERATURE AND CLINICAL TRIAL REVIEW SHOWS TARGETABLE KINASE FUSIONS ARE COMMON IN PEDIATRIC, ADOLESCENT, AND YOUNG ADULT SOFT TISSUE SARCOMAS BUT CLINICAL TRIAL OPPORTUNITIES REMAIN RARE
Sebastian Eder
Favorite
Efficace, Fabio

Health Outcomes Research Unit, Italian Group for Adult Hematologic Diseases (GIMEMA) Data Center
(P 186) PATIENT REPORTED OUTCOME ASSESSMENT AND REPORTING IN RANDOMIZED CLINICAL TRIALS OF SYSTEMIC THERAPY FOR ADVANCED SOFT TISSUE SARCOMAS: A SYSTEMATIC REVIEW.
Fabio Efficace
Favorite
Efimenko, Olga

LLC TIOS
(P 459) EXPERIENCE IN THE USE OF INDIVIDUALIZED 3D-IMPLANTS IN THE RECONSTRUCTION OF DEFECTS IN PATIENTS WITH TUMORS OF THE CHEST WALL
Olga Efimenko
Favorite
Eich, Hans

University Hospital Münster
(P 451) IMPACT OF TIME TO DIAGNOSIS - A PROSPECTIVE ANALYSIS OF THE EWING 2008 TRIAL
Hans Eich
Favorite
Eid, Caroline

Sarcoma Oncology Center
(P 383) AI ANALYSIS SHOWS ENHANCED CCNG1 ONCOGENE EXPRESSION IN SARCOMA TUMORS AND SUPPORTS THE USE OF DELTAREX-G, A CCNG1 INHIBITOR, AS PLATFORM THERAPY FOR ADVANCED SARCOMA
Caroline Eid
Favorite
Eid, Josiane

University of Miami
(P 54) HIGH-THROUGHPUT DRUG SCREENING IN CHONDROSARCOMA CELLS IDENTIFIES MULTIPLE EFFICIENT ANTINEOPLASTIC AGENTS
Josiane Eid
Favorite
Eil, Robert

OHSU
(P 341) A PHASE 1B STUDY TO EVALUATE PREOPERATIVE ERIBULIN IN COMBINATION WITH RADIATION IN RETROPERITONEAL SARCOMA
Robert Eil
Favorite
Eiseler, Nicole

Miami Cancer Institute
(P 320) A PROSPECTIVE MULTICENTER EXPERIENCE OF PROTON THERAPY FOR RHABDOMYOSARCOMA AND EWING SARCOMA: OUTCOMES FROM THE PROTON COLLABORATIVE GROUP REGISTRY
Nicole Eiseler
Favorite
Ek, Torben

University of Gothenburg
(P 451) IMPACT OF TIME TO DIAGNOSIS - A PROSPECTIVE ANALYSIS OF THE EWING 2008 TRIAL
Torben Ek
Favorite
El Zein, Sophie

Institut Curie
(P 395) TARGETING CD44-MEDIATED IRON ENDOCYTOSIS IN DESMOID FIBROMATOSIS
Sophie El Zein
Favorite
Eldesoky, Ahmed

Faculty of medicines Mansoura University
(P 370) SYNOVIAL SARCOMA; ROLE OF ADJUVANT CHEMOTHERAPY IN SURGICALLY TREATED PATIETNS WITH NO METASTASIS; A SEER STAT ANALYSIS.
Ahmed Eldesoky
Favorite
(P 419) AGE ADJUSTED TRENDS IN PATIENTS WITH SYNOVIAL SARCOMA
Ahmed Eldesoky
Favorite
Elgenaidi, Ismail

TCD
(P 424) INTERNAL TANDEM DUPLICATION OF BCOR (BCOR-ITD) ALTERS THE TUMOR EPIGENOME
Ismail Elgenaidi
Favorite
Elhossiny, Ahmed

University of Michigan
(P 293) GENERATION OF A SPONTANEOUS IMMUNOCOMPETENT MOUSE MODEL OF LIPOSARCOMA
Ahmed Elhossiny
Favorite
Elia, Caterina

Centro di Riferimento Oncologico (CRO) IRCCS;
(P 144) IMPLEMENTATION OF THE EUROPEAN CLINICAL TRIAL REGULATION: SURVEY OF THE ITALIAN SARCOMA GROUP CENTERS
Caterina Elia
Favorite
Elias, Anthony

University of Colorado Anschutz Medical Campus
(P 178) INITIAL RESULTS FROM A PHASE 1 STUDY OF CFT8634, A NOVEL BIFUCTIONAL DEGRADATION ACTIVATING COMPOUND (BIDAC) DEGRADER OF BRD9, IN SYNOVIAL SARCOMA AND SMARCB1-NULL TUMORS
Anthony Elias
Favorite
(P 237) SECONDARY REARRANGEMENT CREATING A PLEC-EML4-ALK DOUBLE FUSION AS A MECHANISM OF RESISTANCE TO CRIZOTINIB IN AN EML4-ALK-POSITIVE INFLAMMATORY MYOFIBROBLASTIC TUMOR
Anthony Elias
Favorite
(P 552) RANDOMIZED PHASE II TRIAL OF CABOZANTINIB COMBINED WITH PD-1 AND CTLA-4 INHIBITION VERSUS CABOZANTINIB IN METASTATIC SOFT TISSUE SARCOMA.
Anthony Elias
Favorite
El-Khoueiry, Anthony

University of Southern California Norris Comprehensive Cancer Center
(P 164) INTRATUMORAL INT230-6 (CISPLATIN, VINBLASTINE, SHAO) ALONE OR WITH IPILIMUMAB PROLONGED SURVIVAL WITH FAVORABLE SAFETY AND IMMUNE ACTIVATION IN ADULTS WITH REFRACTORY SARCOMAS (NCT 03058289)
Anthony El-Khoueiry
Favorite
Ellaithy, Asmaa

Faculty of medicines Suez Canal University
(P 423) PRIMARY GLIOSARCOMA; IMPACT OF ADJUVANT CHEMO(RADIO)THERAPY ON SURVIVAL OUTCOME
Asmaa Ellaithy
Favorite
Elliott, Andrew

Caris Life Sciences
(P 326) MOLECULAR LANDSCAPE OF ENDOMETRIAL STROMAL SARCOMA IN A LARGE REAL-WORLD PATIENT COHORT
Andrew Elliott
Favorite
(P 361) MOLECULAR CHARACTERIZATION OF SOLITARY FIBROUS TUMORS BY ANATOMIC SITE AND NAB2::STAT6 FUSION VARIANT TYPE
Andrew Elliott
Favorite
(P 401) OVEREXPRESSION OF CYCLIN DEPENDENT KINASES AND CYCLINS ACROSS SARCOMAS BEYOND CDK4
Andrew Elliott
Favorite
Ellman, Erin

Rogel Cancer Center, University of Michigan
(P 07) IDENTIFYING CONCERNS OF ADOLESCENT AND YOUNG ADULT SARCOMA PATIENTS AND SURVIVORS FOLLOWING FERTIITY PRESERVATION
Erin Ellman
Favorite
Elsayes, Khaled

University of Texas MD Anderson Cancer Center
(P 233) MULTI-CENTER EXTERNAL VALIDATION OF AN AUTOMATED MODEL DIFFERENTIATING ALT FROM LIPOMA USING RADIOMICS AND DEEP-LEARNING BASED SEGMENTATION
Khaled Elsayes
Favorite
Embaby, Alaa

Netherlands Cancer Institute/Antoni van Leeuwenhoek
(P 197) PROPRANOLOL MONOTHERAPY IN ANGIOSARCOMA - A WINDOW-OF-OPPORTUNITY STUDY (PROPANGIO)
Alaa Embaby
Favorite
Emori, Makoto

Sapporo Medical University School of Medicine
(P 05) COEFFICIENT OF VARIATION OF T2-WEIGHTED MRI PREDICTS THE PROGNOSIS OF MALIGNANT PERIPHERAL NERVE SHEATH TUMOR
Makoto Emori
Favorite
(P 391) THE EXPRESSION OF PVR AND ITS CLINICOPATHOLOGICAL SIGNIFICANCE IN MPNST.
Makoto Emori
Favorite
(P 470) PROGNOSTIC SIGNIFICANCE OF HISTOLOGICAL SUBTYPE IN SOFT TISSUE SARCOMA WITH DISTANT METASTASIS
Makoto Emori
Favorite
(P 471) IMPACT OF PRIMARY TUMOR RESECTION ON METASTASIS TO THE LUNG IN PATIENTS WITH BONE AND SOFT-TISSUE SARCOMA
Makoto Emori
Favorite
(P 486) PRIMARY HIGH-GRADE SARCOMA OF THE SPINE: EXPERIENCE WITH 11 CASES
Makoto Emori
Favorite
Endo, Makoto

Kyushu University
(P 10) ATEZOLIZUMAB IN JAPANESE PATIENTS WITH ADVANCED ALVEOLAR SOFT PART SARCOMA: A MULTI-CENTER, SINGLE-ARM, INVESTIGATOR-INITIATED PHASE 2 TRIAL (NCCH1907)
Makoto Endo
Favorite
(P 406) EXTENSIVE ANALYSIS OF 59 SARCOMA-RELATED FUSION GENES IDENTIFIED PAZOPANIB AS A POTENTIAL INHIBITOR TO COL1A1-PDGFB FUSION GENE
Makoto Endo
Favorite
Engeland, Christine

Clinical Cooperation Unit Virotherapy, German Cancer Research Center (DKFZ) andExperimental Virology, Center for Biomedical Research and Education, Witten/Herdecke University
(P 124) UNLOCKING THE POTENTIAL OF MEASLES VIRUS ONCOLYTIC IMMUNOTHERAPY FOR SARCOMA: BIOMARKER DISCOVERY AND THERAPEUTIC VACCINE DEVELOPMENT
Christine Engeland
Favorite
Engelhardt, Ellen

Netherlands Cancer Institute
(P 132) SARCOMA PATEINTS' VIEWS ON USING A RISK-PREDICTION MODEL TO INFORM TREATMENT DECISIONS.
Ellen Engelhardt
Favorite
Engelholm, Lars

Adcendo ApS
(P 349) THE UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR-ASSOCIATED PROTEIN (UPARAP) IS AN ATTRACTIVE TARGET FOR THE DEVELOPMENT OF ANTIBODY DRUG CONJUGATES FOR TREATMENT OF MESENCHYMAL MALIGNANCIES
Lars Engelholm
Favorite
Engelmann, Bodil

Department of Oncology, Copenhagen University Hospital, Herlev & Gentofte Hospital
(P 157) QUALITY OF LIFE DURING TREATMENT FOR METASTATIC SARCOMA - FEASIBILITY OF ELECTRONIC PATIENT REPORTED OUTCOMES
Bodil Engelmann
Favorite
Engle, Jessica

Johns Hopkins University School of Medicine
(P 559) PROSPECTIVE PHASE II TRIAL OF PREOPERATIVE HYPOFRACTIONATED PROTON THERAPY FOR EXTREMITY AND TRUNCAL AND TRUNCAL SOFT TISSUE SARCOMA: THE PRONTO STUDY RATIONALE AND DESIGN
Jessica Engle
Favorite
ENTZ-WERLE, Natacha

University hospital of Strasbourg and UMR CNRS 7021
(P 75) REAL-WORLD DATA ON REGORAFENIB AND CABOZANTINIB IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH RELAPSED OSTEOSARCOMA AND EWING SARCOMA INCLUDED IN THE SACHA-FRANCE STUDY
Natacha ENTZ-WERLE
Favorite
(P 277) ANTI-GD2 SYNERGIZES WITH HYPOXIA PATHWAY TARGETING TO BLOCK OSTEOSARCOMA CELL PROLIFERATION AND MIGRATION.
Natacha ENTZ-WERLE
Favorite
(P 389) OSTEOBLASTIC-GENE SIGNATURE TO PREDICT SURVIVAL IN PEDIATRIC OSTEOSARCOMA (OS) AND TO FOLLOW PATIENTS TOWARDS LIQUID BIOPSY: A COLLABORATIVE WORK IN OS2006 PROTOCOL.
Natacha ENTZ-WERLE
Favorite
Ercolani, Giorgio

General and Oncologic Surgery, "Morgagni-Pierantoni" Hospital
(P 37) DISSECTING THE ROLE OF EXTRACELLULAR VESICLES IN THE MANAGEMENT OF GIST
Giorgio Ercolani
Favorite
(P 364) EVALUATION OF THE PREDICTIVE ROLE OF SYSTEMIC AND INTRATUMORAL IMMUNITY IN PATIENTS WITH LOCALIZED LIPOSARCOMAS, MYXOFIBROSARCOMAS AND UNDIFFERENTIATED PLEOMORPHIS SARCOMAS
Giorgio Ercolani
Favorite
(P 533) SAFETY AND PRELIMINARY BIOLOGICAL ACTIVITY OF A PHASE II TRIAL OF AUTOLOGOUS DENDRITIC CELLS VACCINATION IN SARCOMAS.
Giorgio Ercolani
Favorite
Eriksson, Mikael

Skane University Hospital
(P 49) EFFICACY OF RIPRETINIB IN A MULTICENTER EXPANDED ACCESS PROGRAM IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS HARBOURING NON-KIT EXON 11 MUTATIONS.
Mikael Eriksson
Favorite
(P 195) MULTIPLE MYXOMA EFFECTIVELY TREATED WITH PAZOPANIB - A CASE REPORT
Mikael Eriksson
Favorite
Ernst, Jennifer

Department of Trauma Surgery, University Medical Center Hannover, 30625 Hannover,Germany
(P 235) FUSION OF PREOPERATIVE IN SITU MAGNETIC RESONANCE IMAGING AND POSTOPERATIVE COMPUTED TOMOGRAPHY TO CORRELATE FUNCTIONAL IMAGING FEATURES AND PATHOLOGICAL CHARACTERISTICS OF SOFT TISSUE SARCOMA
Jennifer Ernst
Favorite
Errani, Costantino

Istituto Ortopedico Rizzoli
(P 355) FUSION TRANSCRIPTOME PROFILING DEFINES THE MONOCLONAL NATURE OF MULTIFOCAL EPITHELIOID HEMANGIOMA OF BONE
Costantino Errani
Favorite
Espejo-Freire, Andrea

University of Minnesota
(P 158) SORAFENIB OR ANTHRACYCLINE-BASED CHEMOTHERAPY IN ADULT PATIENTS WITH PROGRESSIVE DESMOID TUMORS
Andrea Espejo-Freire
Favorite
(P 167) FDG-PET-CT RESPONSE AFTER NEOADJUVANT CHEMOTHERAPY PREDICTS LONG-TERM OUTCOME IN PATIENTS WITH SOFT TISSUE SARCOMA -- 15-YEAR FOLLOW-UP
Andrea Espejo-Freire
Favorite
(P 361) MOLECULAR CHARACTERIZATION OF SOLITARY FIBROUS TUMORS BY ANATOMIC SITE AND NAB2::STAT6 FUSION VARIANT TYPE
Andrea Espejo-Freire
Favorite
(P 401) OVEREXPRESSION OF CYCLIN DEPENDENT KINASES AND CYCLINS ACROSS SARCOMAS BEYOND CDK4
Andrea Espejo-Freire
Favorite
Eulo, Vanessa

University of Alabama at Birmingham
(P 552) RANDOMIZED PHASE II TRIAL OF CABOZANTINIB COMBINED WITH PD-1 AND CTLA-4 INHIBITION VERSUS CABOZANTINIB IN METASTATIC SOFT TISSUE SARCOMA.
Vanessa Eulo
Favorite
Evans, Denisse

The Life Raft Group
(P 28) RETROSPECTIVE ANALYSIS OF SUCCINATE DEHYDROGENASE (SDH)-DEFICIENT GASTROINTESTINAL STROMAL TUMOR (GIST) OUTCOMES: AN INTERNATIONAL STUDY OF 256 PATIENTS
Denisse Evans
Favorite
(P 33) LONGITUDINAL FOLLOW UP OF GASTROINTESTINAL STROMAL TUMORS:DATA FROM THE LIFE RAFT GROUP INTERANTIONAL PATIENT REGISTRY
Denisse Evans
Favorite
Evans, Richard

Univesity of Minnesota
(P 167) FDG-PET-CT RESPONSE AFTER NEOADJUVANT CHEMOTHERAPY PREDICTS LONG-TERM OUTCOME IN PATIENTS WITH SOFT TISSUE SARCOMA -- 15-YEAR FOLLOW-UP
Richard Evans
Favorite
Evenhuis, Richard

Leiden University Medical Center
(P 55) RELATIVE WASH-IN RATE ON DYNAMIC CONTRAST-ENHANCED MRI AS A NEW PROGNOSTIC FACTOR IN PATIENTS WITH OSTEOSARCOMA; A POSSIBLE TOOL FOR PERSONALIZED SARCOMA-CARE?
Richard Evenhuis
Favorite
Eward, William

Duke University
(P 137) IMPACT OF SOCIAL DETERMINANTS OF HEALTH ON SARCOMA CARE: A SINGLE INSTITUTION EXPERIENCE
William Eward
Favorite
(P 299) EXPLORING THE IMMUNOLIGHT MECHANISM OF ACTION IN A GENETICALLY ENGINEERED MOUSE MODEL OF SOFT TISSUE SARCOMA
William Eward
Favorite
(P 509) GIANT CELL TUMOR OF BONE IN THE PEDIATRIC POPULATION: A RETROSPECTIVE STUDY HIGHLIGHTING CASES OF METAPHYSEAL ONLY LOCATION AND INCREASED LOCAL RECURRENCE RATES IN SKELETALLY IMMATURE PATIENTS
William Eward
Favorite
F
F Coutinho, Diego

Memorial Sloan Kettering Cancer Center
(P 289) IDENTIFICATION OF EFFECTIVE THERAPEUTIC COMBINATIONS WITH THE NUCLEAR EXPORT PROTEIN INHIBITOR, SELINEXOR, IN PEDIATRIC SOLID TUMORS
Diego F Coutinho
Favorite
Fa Binefa, Manel

Hospital de la Santa Creu i Sant Pau
(P 503) SCAPULAR PROSTHESIS RECONSTRUCTION, EXPERIENCE IN OUR INSTITUTION
Manel Fa Binefa
Favorite
Fabbri, Francesco

Preclinic and Osteoncology Unit, Istituto Scientifico Romagnolo per lo studio dei Tumori "Dino Amadori"
(P 37) DISSECTING THE ROLE OF EXTRACELLULAR VESICLES IN THE MANAGEMENT OF GIST
Francesco Fabbri
Favorite
Fabbroni, Chiara

Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori
(P 272) A COMPARATIVE ASSESSMENT OF SELINEXOR WITH TRABECTEDIN OR LURBINECTEDIN IN PATIENT-DERIVED XENOGRAFTS (PDX) OF DEDIFFERENTIATED LIPOSARCOMA (DDLPS)
Chiara Fabbroni
Favorite
(P 328) REAL-LIFE EXPERIENCE OF PAZOPANIB IN PATIENTS WITH ADVANCED UTERINE LEIOMYOSARCOMA (U-LMS) FROM TWO REFERRAL ITALIAN CENTERS
Chiara Fabbroni
Favorite
(P 329) DISTANT METASTASIS IN RETROPERITONEAL LEIOMYOSARCOMA: TUMOR SIZE, GRADE AND MORE?
Chiara Fabbroni
Favorite
Fabre, Aurelie

St Vincents University Hospital
(P 155) THE IMPACT OF THE ROLE OF A SARCOMA ADVANCED NURSE PRACTITIONER (ANP) BIOPSY CLINIC IN IMPROVING PATIENT ACCESS TO SARCOMA SERVICES
Aurelie Fabre
Favorite
(P 156) PATIENT REPORTED EXPERIENCES WITHIN THE IRISH SARCOMA GROUP
Aurelie Fabre
Favorite
(P 217) CONTEMPORARY TREATMENT PATTERNS AND OUTCOMES IN THE MANAGEMENT OF ANGIOSARCOMA IN IRELAND
Aurelie Fabre
Favorite
Fabrizio, Vanessa

University of Colorado Anschutz
(P 542) ENROLLMENT OF PEDIATRIC PARTICIPANTS WITH MAGE-A4-POSITIVE SOLID TUMORS IN A PHASE 1/2, OPEN-LABEL, BASKET TRIAL OF AFAMITRESGENE AUTOLEUCEL ("AFAMI-CEL")
Vanessa Fabrizio
Favorite
Facchetti, Fabio

Pathology Unit, Department of Molecular and Translational Medicine, University of Brescia
(P 159) IN BETWEEN OF LYMPHOMAS AND SARCOMAS: WHERE DO HISTIOCYTIC AND DENDRITIC CELL NEOPLASMS (HDCN) STAND? A RETROSPECTIVE, MULTI-INSTITUTIONAL STUDY FROM THE ITALIAN SARCOMA GROUP (ISG)
Fabio Facchetti
Favorite
Facchinetti, Nadia

Fondazione CNAO - Centro Nazionale di Adroterapia Oncologica
(P 144) IMPLEMENTATION OF THE EUROPEAN CLINICAL TRIAL REGULATION: SURVEY OF THE ITALIAN SARCOMA GROUP CENTERS
Nadia Facchinetti
Favorite
Fagioli, Franca

Pediatric Oncohematology Division, Regina Margherita Children's Hospital, Azienda Ospedaliera-Universitaria Città della Salute e della Scienza, University of Torino
(P 69) DEVELOPMENT AND MISSION OF THE HARMONIZATION INTERNATIONAL BONE SARCOMA CONSORTIUM (HIBISCUS)
Franca Fagioli
Favorite
Faitg, Thomas

GSK
(P 114) PRIMARY ANALYSIS OF EFFICACY AND SAFETY OF LETETRESGENE AUTOLEUCEL (LETE-CEL) AS FIRST-LINE TREATMENT FOR UNRESECTABLE OR METASTATIC SYNOVIAL SARCOMA (SS); SUBSTUDY 1 OF IGNYTE-ESO
Thomas Faitg
Favorite
Falcon Gonzalez, Alejandro

Hospital Universitario Virgen del Rocío Sevilla and Instituto de BioMedicina de Sevilla
(P 176) SAFETY, EFFICACY, AND PATIENT-REPORTED OUTCOMES WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED NO PRIOR ANTI–COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 UPDATE
Alejandro Falcon Gonzalez
Favorite
Falkenhorst, Johanna

Department of Medical Oncology, West German Cancer Center, University Hospital Essen
(P 25) PREDICTING IMATINIB RESPONSES USING IN VITRO MODELS OF PDGFRA-MUTANT GASTROINTESTINAL STROMAL TUMOR
Johanna Falkenhorst
Favorite
(P 47) PATIENT SURVIVAL IN METASTATIC GIST WITH IMATINIB-SENSITIVE MUTATIONS: REAL WORLD DATA FROM GERMAN REFERRAL CENTER (2008-2021)
Johanna Falkenhorst
Favorite
(P 234) GENOMIC LANDSCAPE OF CLEAR CELL SARCOMA
Johanna Falkenhorst
Favorite
(P 248) FIBROBLAST ACTIVATION PROTEIN ALPHA -DIRECTED IMAGING AND THERAPY OF SOLITARY FIBROUS TUMOR
Johanna Falkenhorst
Favorite
(P 276) REVISITING IN- AND OFF LABEL DRUGS FREQUENTLY USED IN METASTATIC GIST USING A BROAD IN VITRO PROFILING PANEL OF PRIMARY AND SECONDARY KIT AND PDGFRA-MUTANT GIST CELLS – CLINICAL IMPLICATIONS
Johanna Falkenhorst
Favorite
(P 294) DNA-DAMAGE REPAIR DYSREGULATION AND CHEMOTHERAPY RESPONSE IN SARCOMA MODELS
Johanna Falkenhorst
Favorite
Falkowski, Slawomir

Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw, Department of Soft Tissue/Bone Sarcoma and Melanoma
(P 170) HETEROGENEITY OF PAZOPANIB ACTIVITY ACROSS SOFT TISSUE SARCOMA SUBTYPES - A RETROSPECTIVE ANALYSIS OF 303 CASES FROM A REFERENCE CENTER
Slawomir Falkowski
Favorite
Fallon, Maura

Daiichi Sankyo UK Ltd.
(P 199) PEXIDARTINIB RISK EVALUATION AND MITIGATION STRATEGY PROGRAM: 3-YEAR SAFETY DATA ASSESSMENT
Maura Fallon
Favorite
Fan, Cong

Cleveland Clinic Lerner College of Medicine
(P 242) WHOLE BODY PET/MRI FOR STAGING OF MYXOID LIPOSARCOMA
Cong Fan
Favorite
Fan, Peidang

School of Medicine, Anhui University of Science and Technology, Huainan, China
(P 339) QUALITY OF SURGERY AND OUTCOME FOR GIANT RETROPERITONEAL LIPOSARCOMA TREATED WITHIN SEMI-ABDOMINAL EN BLOC RESECTION USING VASCULAR PRIORITY CENTRAL APPROACH-A RETROSPECTIVE COHORT
Peidang Fan
Favorite
(P 398) INTEGRATED MULTI-OMICS APPROACH REVEALED TUMOR-ASSOCIATED TERTIARY LYMPHOID STRUCTURE LANDSCAPE IN RETROPERITONEAL LIPOSARCOMA
Peidang Fan
Favorite
Fanta, Paul

Department of Medicine, Division of Medical Oncology, University of California San Diego
(P 28) RETROSPECTIVE ANALYSIS OF SUCCINATE DEHYDROGENASE (SDH)-DEFICIENT GASTROINTESTINAL STROMAL TUMOR (GIST) OUTCOMES: AN INTERNATIONAL STUDY OF 256 PATIENTS
Paul Fanta
Favorite
(P 29) COMBINATION TREATMENT WITH TEMOZOLOMIDE AND THE DEATH RECEPTOR-5 AGONIST INBRX-109 EFFECTIVELY TARGETS SUCCINATE DEHYDROGENASE -DEFICIENT GASTROINTESTINAL STROMAL TUMOR
Paul Fanta
Favorite
Fan, Zhengfu

Peking University Cancer Hospital
(P 168) A PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF PEXIDARTINIB IN ASIAN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR
Zhengfu Fan
Favorite
Fares, Nadim

CHU Toulouse
(P 201) PLEOMORPHIC RHABDOMYOSARCOMAS: A NEW ENTITY ASSOCIATED WITH LYNCH SYNDROME? FIRST RESULTS OF SARCLYNCH NATIONAL STUDY
Nadim Fares
Favorite
Farhangfar, Carol

Levine Cancer Institute
(P 258) THE CRITICALITY OF OXIDATIVE PHOSPHORYLATION IN SYNOVIAL SARCOMA METASTASIS
Carol Farhangfar
Favorite
Farma, Jeffrey

Fox Chase Cancer Center
(P 152) EVALUATING DIAGNOSTIC APPROACHES TO DERMATOFIBROSARCOMA PROTUBERANS: AN OPPORTUNITY TO REDUCE THE NUMBER OF INTERVENTIONS
Jeffrey Farma
Favorite
(P 287) ESTABLISHMENT AND GENOMIC VALIDATION OF NOVEL PATIENT-DERIVED XENOGRAFT MODELS FOR DRUG DISCOVERY IN GASTROINTESTINAL STROMAL TUMOR
Jeffrey Farma
Favorite
Farooqi, Ahsan

MD Anderson Cancer Center
(P 123) DEDIFFERENTIATED LIPOSARCOMAS TREATED WITH IMMUNE CHECKPOINT BLOCKADE: THE MD ANDERSON EXPERIENCE
Ahsan Farooqi
Favorite
(P 360) TP53 ALTERATIONS IN SARCOMAS: AN ANALYSIS FROM THE AACR-GENIE DATABASE
Ahsan Farooqi
Favorite
(P 394) LEIOMYOSARCOMA INTRATUMORAL MACROPHAGE INFILTRATES ARE ASSOCIATED WITH DISTINCT CLINICAL AND GENOMIC PRESENTATIONS
Ahsan Farooqi
Favorite
(P 510) PRIMARY BREAST ANGIOSARCOMA: CLINICAL AND PATHOLOGICAL FEATURES AND IMPACT ON OUTCOMES
Ahsan Farooqi
Favorite
Farswan, Akanksha

University College London Cancer Institute
(P 04) THE CELL ATLAS OF CLEAR CELL SARCOMA
Akanksha Farswan
Favorite
(P 381) THE GENOMIC LANDSCAPE OF CLEAR CELL SARCOMA
Akanksha Farswan
Favorite
Faruqi, Ayra

Northwestern Medicine
(P 96) LEPTOMENINGEAL RECURRENCE OF EWING'S SARCOMA: A CASE SERIES
Ayra Faruqi
Favorite
(P 219) ELECTIVE DISCONTINUATION OF SORAFENIB TREATMENT IN DESMOID TUMORS: A RETROSPECTIVE ANALYSIS WITH IMPLICATIONS FOR CLINICAL PRACTICE
Ayra Faruqi
Favorite
Faruqi, Fahad

Northwestern Medicine
(P 96) LEPTOMENINGEAL RECURRENCE OF EWING'S SARCOMA: A CASE SERIES
Fahad Faruqi
Favorite
(P 219) ELECTIVE DISCONTINUATION OF SORAFENIB TREATMENT IN DESMOID TUMORS: A RETROSPECTIVE ANALYSIS WITH IMPLICATIONS FOR CLINICAL PRACTICE
Fahad Faruqi
Favorite
Fathani, Ayesha

University College London Hospital
(P 57) REAL-WORLD EXPERIENCE OF CABOZANTINIB IN PAEDIATRIC, TEENAGE AND YOUNG ADULT (TYA) AND ADULT METASTATIC BONE SARCOMA PATIENTS FROM THE LONDON SARCOMA SERVICE (LSS)
Ayesha Fathani
Favorite
Faulkner, Lisa

Clear Cell Sarcoma Foundation
(P 20) CLEAR CELL SARCOMA: PATIENT REPORTED REAL WORLD EVIDENCE
Lisa Faulkner
Favorite
FAU, Magali

Oncological department of Institut Bergonié
(P 521) HOW TO MANAGE ABDOMINAL PARIETECTOMY, REVIEW OF EXPERIENCE IN INSTITUT BERGONIE
Magali FAU
Favorite
(P 523) IN-BETWEEN SARCOMA: A CATEGORY OF HIGH RISK OF RECURRENCE AND POOR OUTCOME
Magali FAU
Favorite
Fausti, Valentina

Clinical and Experimental Oncology, Immunotherapy, Rare Cancers and Biological Resource Center, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", 47014 Meldola, Italy
(P 37) DISSECTING THE ROLE OF EXTRACELLULAR VESICLES IN THE MANAGEMENT OF GIST
Valentina Fausti
Favorite
(P 253) THE EFFICACY OF MEDICATED PATCHES IN SOFT TISSUE SARCOMAS: IN-VITRO AND EX-VIVO VALIDATION.
Valentina Fausti
Favorite
(P 364) EVALUATION OF THE PREDICTIVE ROLE OF SYSTEMIC AND INTRATUMORAL IMMUNITY IN PATIENTS WITH LOCALIZED LIPOSARCOMAS, MYXOFIBROSARCOMAS AND UNDIFFERENTIATED PLEOMORPHIS SARCOMAS
Valentina Fausti
Favorite
(P 533) SAFETY AND PRELIMINARY BIOLOGICAL ACTIVITY OF A PHASE II TRIAL OF AUTOLOGOUS DENDRITIC CELLS VACCINATION IN SARCOMAS.
Valentina Fausti
Favorite
Federico, Sara

St. Jude Children's Research Hospital
(P 303) PRECLINICAL EVALUATION OF PARP1 SELECTIVE INHIBITOR AZD5305 IN COMBINATION WITH DNA DAMAGING AGENTS IN EWING SARCOMA ORTHOTOPIC XENOGRAFT MODELS
Sara Federico
Favorite
Federman, Noah

David Geffen School of Medicine, University of California, Los Angeles
(P 19) EXTRACELLULAR VESICLE CLICK MAGBEADS: A MULTIFACETED LIQUID BIOPSY PLATFORM FOR PEDIATRIC SARCOMAS
Noah Federman
Favorite
(P 161) EFFICACY, SAFETY, AND TREATMENT HOLD WAIT-AND-SEE OUTCOMES OF LAROTRECTINIB IN PEDIATRIC PATIENTS WITH TRK FUSION SARCOMAS
Noah Federman
Favorite
Fedorova, Alexandra

National Medical Research Center of Oncology named after N.N. Blokhin "of the Ministry of Health of the Russian Federation
(P 459) EXPERIENCE IN THE USE OF INDIVIDUALIZED 3D-IMPLANTS IN THE RECONSTRUCTION OF DEFECTS IN PATIENTS WITH TUMORS OF THE CHEST WALL
Alexandra Fedorova
Favorite
Feinstone, Aharon

Tel Aviv University
(P 240) IDENTIFYING PATIENTS AT HIGH RISK OF HIP FRACTURE DUE TO BONE TUMORS BY COMPUTATIONAL BIOMECHANICS: A RANDOMIZED PROSPECTIVE CLINICAL STUDY
Aharon Feinstone
Favorite
Femino, Joseph

City of Hope National Medical Center
(P 524) PRESENTATION AND OUTCOMES OF EXTRASKELETAL CHONDROSARCOMAS TREATED WITH SURGICAL RESECTION
Joseph Femino
Favorite
(P 525) ALL INTERNAL DISTRACTION OSTEOGENESIS AFTER TUMOR RESECTION
Joseph Femino
Favorite
(P 526) EVALUATION OF THE SURGICAL MANAGEMENT OF THE SKELETON IN PATIENTS WITH OLLIER'S DISEASE AND MAFUCCI SYNDROME
Joseph Femino
Favorite
Fendler, Wolfgang

Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen
(P 220) [68GA]GA-FAPI PET/CT AS NOVEL DIAGNOSTIC TOOL IN SARCOMA
Wolfgang Fendler
Favorite
(P 248) FIBROBLAST ACTIVATION PROTEIN ALPHA -DIRECTED IMAGING AND THERAPY OF SOLITARY FIBROUS TUMOR
Wolfgang Fendler
Favorite
Feng, Chun

University of Texas MD Anderson Cancer Center
(P 123) DEDIFFERENTIATED LIPOSARCOMAS TREATED WITH IMMUNE CHECKPOINT BLOCKADE: THE MD ANDERSON EXPERIENCE
Chun Feng
Favorite
feng, fan

Division of Digestive Surgery, Xijing Hospital of Digestive Diseases, The Air Force Medical University
(P 39) MANAGEMENT PRACTICES OF GASTROINTESTINAL STROMAL TUMORS: A QUESTIONNAIRE SURVEY OF GENERAL SURGEONS IN CHINA
fan feng
Favorite
Feng, Xiaolan

Tom Baker Cancer Center
(P 104) COMPREHENSIVE IMMUNE PROFILING UNVEILS A SUBSET OF LEIOMYOSARCOMA WITH HOT TUMOR IMMUNE MICROENVIRONMENT
Xiaolan Feng
Favorite
(P 382) NTRK1/2/3 FUSIONS DETECTION USING RNA-SEQ IN MESENCHYMAL TUMORS REVEALS ULTRA-RARE AND HISTO-SPECIFIC TARGETABLE ALTERATIONS: EXPERIENCE OF AN EXTENSIVE ROUTINE RESEARCH PROGRAM.
Xiaolan Feng
Favorite
(P 454) TREATMENT PATTERNS AND OUTCOMES IN PEDIATRIC AND ADULT PATIENTS WITH EWING AND UNDIFFERENTIATED ROUND BLUE CELL SARCOMAS IN ALBERTA
Xiaolan Feng
Favorite
Feng, Yi

Department of Orthopaedics, the Second Hospital of Shanxi Medical University
(P 543) MANEUVER STUDY: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF PIMICOTINIB (ABSK021) TO ASSESS THE EFFICACY AND SAFETY IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR
Yi Feng
Favorite
Fennelly, David

SVHG
(P 213) EXPERIENCE WITH THE USE OF TRABECTEDIN IN ADVANCED SOFT TISSUE SARCOMA IN IRELAND
David Fennelly
Favorite
Ferguson, Michael

Division of Pediatric Hematology/Oncology, Riley Hospital for Children
(P 15) INTRAOSSEOUS RHABDOMYOSARCOMA OF THE CHEST WITH FUS:TFCP2 FUSION AND GERMLINE VARIANTS IN NF1 AND SBDS: NOVEL LOCATION AND MOLECULAR CHARACTERISTICS OF A RARE TUMOR
Michael Ferguson
Favorite
Ferguson, Peter

University of Toronto
(P 53) CURATIVE-INTENT SURGERY FOR A SOLITARY ISOLATED BONE METASTASIS FROM EXTREMITY SARCOMA: WHO UNDERWENT METASTASECTOMY AND WHAT WAS THE PROGNOSTIC OUTCOME?
Peter Ferguson
Favorite
(P 77) PATIENT OUTCOMES AFTER OPEN VERSUS CORE NEEDLE BIOPSY IN LOWER EXTREMITY SARCOMA
Peter Ferguson
Favorite
(P 249) INVESTIGATING CLINICAL FACTORS ASSOCIATED WITH THE ESTABLISHMENT OF SUCCESSFUL PRIMARY HUMAN SOFT TISSUE SARCOMA CELL LINES
Peter Ferguson
Favorite
(P 367) CHARACTERIZING HYPOXIA AND ASSOCIATED MOLECULAR FEATURES IN EXTREMITY SOFT TISSUE SARCOMA
Peter Ferguson
Favorite
(P 443) SURGICAL RESECTION OF EXTREMITY EWING'S SARCOMA BASED ON POST-CHEMOTHERAPY TUMOUR VOLUME RESULTS IN SAFE MARGINS
Peter Ferguson
Favorite
(P 483) DID THE COVID-19 PANDEMIC NEGATIVELY AFFECT OUTCOMES FOR PATIENTS WITH EXTREMITY SOFT TISSUE SARCOMAS?
Peter Ferguson
Favorite
(P 484) OBESITY INCREASES THE RISK OF MAJOR WOUND COMPLICATIONS FOLLOWING PELVIC RESECTION FOR BONE SARCOMA
Peter Ferguson
Favorite
Fernández, Alba

Hospital Quironsalud Torrevieja
(P 407) PRECISION AND PERSONALIZED TREATMENT FOR SOFT TISSUE SARCOMAS. RESULTS OF A 10 PATIENTS SERIES WITH MOLECULAR PROFILING USING NEXT-GENERATION MASSIVE SEQUENCING
Alba Fernández
Favorite
Fernandes, Sanal

Department of Medical oncology, Dr BRAIRCH, All India Institute of Medical Sciences
(P 562) A PHASE 2, SINGLE ARM STUDY OF REGORAFENIB IN METASTATIC/UNRESECTABLE REFRACTORY SYNOVIAL SARCOMAS
Sanal Fernandes
Favorite
Fernández Garrido, Manuel

Hospital de la Santa Creu i Sant Pau
(P 503) SCAPULAR PROSTHESIS RECONSTRUCTION, EXPERIENCE IN OUR INSTITUTION
Manuel Fernández Garrido
Favorite
(P 504) WHY DO SOME PATIENTS WITH SYNOVIAL SARCOMA HAVE BETTER FUNCTIONAL OUTCOMES AFTER RESECTION SURGERY? ANALYSIS OF 102 CASES
Manuel Fernández Garrido
Favorite
(P 507) PRIMARY CHEST WALL TUMORS OF MESENCHYMAL ORIGIN. EXPERIENCE OF A REFERENCE UNIT
Manuel Fernández Garrido
Favorite
(P 508) DREAM, UTOPIA OR REALISM? PROGNOSTIC FACTORS IN LUNG METASTASECTOMY OF DISSEMINATED SARCOMA DISEASE
Manuel Fernández Garrido
Favorite
Fernández, Elena

Hospital Clínico San Carlos
(P 149) PSYCOLOGICAL SNAPSHOT OF SARCOMA PATIENTS FROM AN ACADEMIC, UNIVERSITY CENTER, HOSPITAL CLÍNICO SAN CARLOS (HCSC), MADRID, A SARCOMA NATIONAL REFERRAL CENTRE IN SPAIN
Elena Fernández
Favorite
(P 515) ENDOBRONCHIAL NAVIGATION AS AN INTRAOPERATORY TOOL FOR RESECTION OF SMALL PULMONARY METASTASES IN SARCOMA PATIENTS
Elena Fernández
Favorite
Fernandez, G. Esteban

Children's Hospital Los Angeles
(P 430) UNIQUE HISTOLOGIC MORPHOLOGY OF EWING SARCOMA CELLS THAT HARBOR TP53 MUTATIONS
G. Esteban Fernandez
Favorite
Fernandez, Natalia

SPAGN Sarcoma Patient Advocacy Global Network
(P 73) FOSTER CONSORTIUM, FIGHT OSTEOSARCOMA THROUGH EUROPEAN RESEARCH
Natalia Fernandez
Favorite
(P 90) RESULTS FROM AN INTERNATIONAL SURVEY OF BONE SARCOMA PATIENTS
Natalia Fernandez
Favorite
(P 136) SETTING THE INTERNATIONAL RESEARCH AGENDA FOR SARCOMA WITH PATIENTS AND CARERS: PRELIMINARY RESULTS OF PHASE II OF THE SARCOMA PATIENT ADVOCACY GLOBAL NETWORK (SPAGN) PRIORITY SETTING PARTNERSHIP
Natalia Fernandez
Favorite
Fernandez, Yanelys

University of Miami
(P 158) SORAFENIB OR ANTHRACYCLINE-BASED CHEMOTHERAPY IN ADULT PATIENTS WITH PROGRESSIVE DESMOID TUMORS
Yanelys Fernandez
Favorite
Fernando, Katelyn

The Ohio State University Wexner Medical Center
(P 311) ROBUST VMAT TREATMENT PLANNING FOR EXTREMITY SOFT TISSUE SARCOMAS
Katelyn Fernando
Favorite
Fernando, Shalini

University College London Hospital
(P 57) REAL-WORLD EXPERIENCE OF CABOZANTINIB IN PAEDIATRIC, TEENAGE AND YOUNG ADULT (TYA) AND ADULT METASTATIC BONE SARCOMA PATIENTS FROM THE LONDON SARCOMA SERVICE (LSS)
Shalini Fernando
Favorite
Fern, Lorna

University College London Hospitals NHS Trust
(P 70) ICONIC (IMPROVING OUTCOMES THROUGH COLLABORATION IN OSTEOSARCOMA): A PROSPECTIVE OBSERVATIONAL COHORT STUDY FOR NEWLY DIAGNOSED OSTEOSARCOMA PATIENTS IN THE UNITED KINGDOM (UK)
Lorna Fern
Favorite
Ferraresi, Virginia

IRCCS Istituto Nazionale Tumori Regina Elena
(P 176) SAFETY, EFFICACY, AND PATIENT-REPORTED OUTCOMES WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED NO PRIOR ANTI–COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 UPDATE
Virginia Ferraresi
Favorite
(P 437) ULTRA-RARE UNDIFFERENTIATED SMALL ROUND CELL SARCOMA: HOW SHOULD WE TREAT THEM? AN ANALYSIS FORM THE GRACEFUL PROJECT
Virginia Ferraresi
Favorite
Ferrari, Andrea

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 202) INFLAMMATORY MYOFIBROBLASTIC TUMOUR WITH ROS1 GENE FUSIONS IN CHILDREN AND YOUNG ADOLESCENTS
Andrea Ferrari
Favorite
(P 209) PROGNOSTIC VALUE OF EARLY RADIOLOGIC TUMOUR VOLUME RESPONSE IN RHABDOMYOSARCOMA; RESULTS OF THE EUROPEAN PAEDIATRIC SOFT TISSUE SARCOMA STUDY GROUP RMS 2005 STUDY
Andrea Ferrari
Favorite
(P 273) COMPARISON OF A PATIENT-DERIVED XENOGRAFTS (PDX) OF MYXOID PLEOMORPHIC LIPOSARCOMA (MPL) AND PLEOMORPHIC LIPOSARCOMA (PL) HIGHLIGHTS THE EFFECTIVENESS OF ERIBULIN IN A PDX OF MPL
Andrea Ferrari
Favorite
Ferrari, Valentina

Institute for Research in Biomedicine
(P 297) UNVEILING THE IMPACT OF INTRATUMORAL MICROBIOTA IN THE TREATMENT EFFICACY OF SOFT TISSUE SARCOMA
Valentina Ferrari
Favorite
Ferraro, Daniela

CHUV
(P 103) LASTING COMPLETE RESPONSE TO PEMBROLIZUMAB IN MISMATCH REPAIR DEFICIENT CARDIAC SARCOMA: A GENOMIC CHARACTERIZATION
Daniela Ferraro
Favorite
Ferron, Gwenael

Oncopole
(P 268) IMPACT OF CELLULAR FUSION IN THE ONCOGENESIS OF LEIOMYOSARCOMAS
Gwenael Ferron
Favorite
Fierstein, Jamie

Epidemiology and Biostatistics Shared Resource, Johns Hopkins All Children's Institute for Clinical and Translational Research, Johns Hopkins All Children's Hospital
(P 91) BLOOD TRANSFUSION AND SURVIVAL AMONG CHILD, ADOLESCENT, AND YOUNG ADULT PATIENTS WITH OSTEOSARCOMA: A RETROSPECTIVE COHORT STUDY
Jamie Fierstein
Favorite
Filbin, Mariella

Dana-Farber Cancer Institute
(P 384) SYSTEMATIC LITERATURE AND CLINICAL TRIAL REVIEW SHOWS TARGETABLE KINASE FUSIONS ARE COMMON IN PEDIATRIC, ADOLESCENT, AND YOUNG ADULT SOFT TISSUE SARCOMAS BUT CLINICAL TRIAL OPPORTUNITIES REMAIN RARE
Mariella Filbin
Favorite
Filonenko, Daria

SBIH Moscow Clinical Scientific and Practical Center Named After A.S.Loginov of DHM Moscow
(P 27) A MULTICENTER RETROSPECTIVE STUDY ON THE CLINICAL BEHAVIOR OF SDH-DEFICIENT GIST
Daria Filonenko
Favorite
Finkbeiner, Maximiliane

Clinical Cooperation Unit Virotherapy, German Cancer Research Center (DKFZ) and Experimental Virology, Center for Biomedical Research and Education, Witten/Herdecke University
(P 124) UNLOCKING THE POTENTIAL OF MEASLES VIRUS ONCOLYTIC IMMUNOTHERAPY FOR SARCOMA: BIOMARKER DISCOVERY AND THERAPEUTIC VACCINE DEVELOPMENT
Maximiliane Finkbeiner
Favorite
Finkbeiner, Melanie

Alberta Children's Hospital
(P 454) TREATMENT PATTERNS AND OUTCOMES IN PEDIATRIC AND ADULT PATIENTS WITH EWING AND UNDIFFERENTIATED ROUND BLUE CELL SARCOMAS IN ALBERTA
Melanie Finkbeiner
Favorite
Fiocco, Marta

Leiden University Medical Center
(P 55) RELATIVE WASH-IN RATE ON DYNAMIC CONTRAST-ENHANCED MRI AS A NEW PROGNOSTIC FACTOR IN PATIENTS WITH OSTEOSARCOMA; A POSSIBLE TOOL FOR PERSONALIZED SARCOMA-CARE?
Marta Fiocco
Favorite
Fiore, Marco

Department of Surgery, Sarcoma Service, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
(P 126) CURRENT PRACTICE IN SPERMATIC CORD SARCOMA: ONCOLOGICAL TIMELINES AND OUTCOMES ACCORDING TO INITIAL RESECTIONS PERFORMED AT A LOCAL HOSPITAL VERSUS EARLY PATIENT REFERRAL TO A TERTIARY CENTRE.
Marco Fiore
Favorite
(P 329) DISTANT METASTASIS IN RETROPERITONEAL LEIOMYOSARCOMA: TUMOR SIZE, GRADE AND MORE?
Marco Fiore
Favorite
(P 333) SYSTEMIC TREATMENT IN INTRA-ABDOMINAL DESMOID-TYPE FIBROMATOSIS: A SINGLE INSTITUTION RETROSPECTIVE CASE SERIES ANALYSIS
Marco Fiore
Favorite
Fiore, Maria Rosaria

Fondazione CNAO -Centro Nazionale di Adroterapia Oncologica, Pavia, Italy
(P 74) SACRAL CHORDOMA: A RANDOMIZED & OBSERVATIONAL STUDY ON SURGERY VS DEFINITIVE RADIOTHERAPY IN PRIMARY LOCALIZED DISEASE (SACRO). INTERIM ANALYSIS
Maria Rosaria Fiore
Favorite
Fischer, Klaus

Thermosome GmbH
(P 530) FIH PHASE I STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND ANTITUMOR ACTIVITY OF THE001 COMBINED WITH REGIONAL HYPERTHERMIA IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOFT TISSUE SARCOMA
Klaus Fischer
Favorite
Fischer, Suzanne

Ghent University Hospital
(P 291) DEVELOPMENT OF A LIVE TISSUE SARCOMA BIOBANK TO SUPPORT THE CREATION OF PATIENT-DERIVED TRANSLATIONAL MODELS
Suzanne Fischer
Favorite
(P 295) ORTHOTOPIC XENOGRAFTS OF PAIRED SARCOMA PRIMARY TUMOUR, LOCAL RELAPSE AND METASTATIC SITES REVEALS PHENOTYPIC HETEROGENEITY IN A MINIMAL RESIDUAL DISEASE MODEL
Suzanne Fischer
Favorite
(P 296) EX VIVO SARCOMA CELL CULTURES FROM PAIRED PRIMARY, LOCAL RELAPSE AND METASTATIC SITES REVEALS PHENOTYPIC HETEROGENEITY
Suzanne Fischer
Favorite
Fisher, Steffanie

British Columbia Children's Hospital
(P 512) PERIOPERATIVE BLOOD MANAGEMENT IN PEDIATRIC PATIENTS UNDERGOING PRIMARY OSTEOSARCOMA AND EWING SARCOMA RESECTION: A RETROSPECTIVE CASE NOTE REVIEW
Steffanie Fisher
Favorite
Fishkin, Raina

Memorial Sloan Kettering Cancer Center
(P 289) IDENTIFICATION OF EFFECTIVE THERAPEUTIC COMBINATIONS WITH THE NUCLEAR EXPORT PROTEIN INHIBITOR, SELINEXOR, IN PEDIATRIC SOLID TUMORS
Raina Fishkin
Favorite
Flacher, Vincent

IBMC
(P 277) ANTI-GD2 SYNERGIZES WITH HYPOXIA PATHWAY TARGETING TO BLOCK OSTEOSARCOMA CELL PROLIFERATION AND MIGRATION.
Vincent Flacher
Favorite
Flaman, Ashley

The Ottawa Hospital
(P 98) TUMOR IMMUNE PROFILING AND IDENTIFICATION OF IMMUNOTHERAPEUTIC TARGETS IN DEDIFFERENTIATED LIPOSARCOMA
Ashley Flaman
Favorite
Flanagan, Adrienne

University College London, Cancer Institute
(P 04) THE CELL ATLAS OF CLEAR CELL SARCOMA
Adrienne Flanagan
Favorite
(P 70) ICONIC (IMPROVING OUTCOMES THROUGH COLLABORATION IN OSTEOSARCOMA): A PROSPECTIVE OBSERVATIONAL COHORT STUDY FOR NEWLY DIAGNOSED OSTEOSARCOMA PATIENTS IN THE UNITED KINGDOM (UK)
Adrienne Flanagan
Favorite
(P 381) THE GENOMIC LANDSCAPE OF CLEAR CELL SARCOMA
Adrienne Flanagan
Favorite
Flaus, Andrew

University College Galway
(P 424) INTERNAL TANDEM DUPLICATION OF BCOR (BCOR-ITD) ALTERS THE TUMOR EPIGENOME
Andrew Flaus
Favorite
Fletcher, Benjamin

The West German Cancer Centre, University Hospital Essen
(P 275) GIST-BSF1: A NOVEL SCF-DEPENDENT, WILD-TYPE KIT CELL LINE PLATFORM THAT ALLOWS RAPID GENERATION OF ISOGENIC SUBLINES WITH BOTH IMATINIB-SENSITIVE AND IMATINIB-RESISTANT GENOTYPES
Benjamin Fletcher
Favorite
(P 276) REVISITING IN- AND OFF LABEL DRUGS FREQUENTLY USED IN METASTATIC GIST USING A BROAD IN VITRO PROFILING PANEL OF PRIMARY AND SECONDARY KIT AND PDGFRA-MUTANT GIST CELLS – CLINICAL IMPLICATIONS
Benjamin Fletcher
Favorite
Fletcher, Jonathan

HarvardMedical School/Brigham and Women's Hospital
(P 234) GENOMIC LANDSCAPE OF CLEAR CELL SARCOMA
Jonathan Fletcher
Favorite
(P 412) LEIOMYOSARCOMA POLYANEUPLOID CANCER CELLS DEVELOP IN RESPONSE TO CHEMOTHERAPY AND CONTRIBUTE TO CHEMORESISTANCE
Jonathan Fletcher
Favorite
(P 541) ETCTN 10563: PHASE 1 STUDY OF PEPOSERTIB AND LIPOSOMAL DOXORUBICIN FOR ADVANCED OR METASTATIC LEIOMYOSARCOMA AND OTHER SARCOMAS
Jonathan Fletcher
Favorite
Flint, James

University of California San Diego
(P 489) SIMULTANEOUS VERSUS DELAYED FLAP RECONSTRUCTION FOLLOWING SOFT TISSUE SARCOMA RESECTION
James Flint
Favorite
(P 490) TOPICAL ANTIBIOTICS DECREASE INFECTIONS IN EXTREMITY SARCOMA SURGERY
James Flint
Favorite
Flores Neto, João

AC Camargo Cancer Center
(P 192) ROLE OF MAGNETIC RESONANCE IMAGING IN THE PREDICTION OF HISTOLOGICAL GRADE IN SOFT TISSUE SARCOMAS.
João Flores Neto
Favorite
Florou, Vaia

Huntsman Cancer Institute University of Utah
(P 361) MOLECULAR CHARACTERIZATION OF SOLITARY FIBROUS TUMORS BY ANATOMIC SITE AND NAB2::STAT6 FUSION VARIANT TYPE
Vaia Florou
Favorite
(P 401) OVEREXPRESSION OF CYCLIN DEPENDENT KINASES AND CYCLINS ACROSS SARCOMAS BEYOND CDK4
Vaia Florou
Favorite
Foca, Flavia

Unit of Biostatistics and Clinical Trials, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori"
(P 37) DISSECTING THE ROLE OF EXTRACELLULAR VESICLES IN THE MANAGEMENT OF GIST
Flavia Foca
Favorite
(P 533) SAFETY AND PRELIMINARY BIOLOGICAL ACTIVITY OF A PHASE II TRIAL OF AUTOLOGOUS DENDRITIC CELLS VACCINATION IN SARCOMAS.
Flavia Foca
Favorite
Focarete, Maria Letizia

Department of Chemistry "Giacomo Ciamician", University of Bologna, 40126 Bologna, Italy
(P 253) THE EFFICACY OF MEDICATED PATCHES IN SOFT TISSUE SARCOMAS: IN-VITRO AND EX-VIVO VALIDATION.
Maria Letizia Focarete
Favorite
Foijer, Floris

University Medical Centre Groningen
(P 371) DISRUPTION OF THE TP53 LOCUS IN OSTEOSARCOMA LEADS TO TP53 PROMOTER GENE FUSIONS AND RESTORATION OF PARTS OF THE TP53 SIGNALLING PATHWAY
Floris Foijer
Favorite
Folpe, Andrew

Mayo Clinic
(P 62) PROSTHESIS-ASSOCIATED SARCOMA: A REVIEW OF 8 HIGH-GRADE LESIONS ARISING AROUND A TOTAL JOINT ARTHROPLASTY IMPLANT
Andrew Folpe
Favorite
Foltz, Warren

Princess Margaret Hospital, University Health Network
(P 108) EFFECT OF TUMOUR-TARGETED HYPERTHERMIA AND CHEMOTHERAPY ON THE IMMUNE PROFILE OF A MURINE MODEL OF EMBRYONAL RHABDOMYOSARCOMA
Warren Foltz
Favorite
Fong, Zhi Ven

Mayo Clinic Arizona
(P 141) TREATMENT VARIABILITY IN SURGICAL MANAGEMENT OF PULMONARY OLIGOMETASTATIC SOFT TISSUE SARCOMA
Zhi Ven Fong
Favorite
Fontebasso, Adam

University of Toronto
(P 50) CHARACTERIZATION OF A FAMILIAL GIST KINDRED INTOLERANT TO IMATINIB
Adam Fontebasso
Favorite
(P 421) USING TRANSCRIPTOMICS TO IDENTIFY LEIOMYOSARCOMA PATIENTS AT RISK OF METASTASIS
Adam Fontebasso
Favorite
Fonzi, Eugenio

Irst
(P 364) EVALUATION OF THE PREDICTIVE ROLE OF SYSTEMIC AND INTRATUMORAL IMMUNITY IN PATIENTS WITH LOCALIZED LIPOSARCOMAS, MYXOFIBROSARCOMAS AND UNDIFFERENTIATED PLEOMORPHIS SARCOMAS
Eugenio Fonzi
Favorite
Ford, Samuel

Department of Surgery, University Hospitals Birmingham
(P 152) EVALUATING DIAGNOSTIC APPROACHES TO DERMATOFIBROSARCOMA PROTUBERANS: AN OPPORTUNITY TO REDUCE THE NUMBER OF INTERVENTIONS
Samuel Ford
Favorite
(P 342) THE EVALUATION AND OUTCOMES OF MESENTERIC AND INTRA-ABDOMINAL DESMOIDS: A TARPSWG STUDY
Samuel Ford
Favorite
(P 345) CLINICIAN SURVEY - CURRENT GLOBAL PRACTICE FOR SARCOMA SURVEILLANCE FOLLOWING RESECTION OF PRIMARY RETROPERITONEAL, ABDOMINAL, AND PELVIC SARCOMA
Samuel Ford
Favorite
Formiga, Maria Nirvana

A.C.Camargo Cancer Center
(P 387) CLINICAL CHARACTERIZATION OF PATIENTS WITH LEIOMYOSARCOMA HARBORING THE R337H TP53 GERMINATIVE ALTERATION (LI-FRAUMENI SYNDROME) AND THE PROGNOSTIC IMPLICATION USING A PROPENSITY-SCORE MATCHED COHORT
Maria Nirvana Formiga
Favorite
Fornasa, Giulia

Humanitas Research Hospital
(P 297) UNVEILING THE IMPACT OF INTRATUMORAL MICROBIOTA IN THE TREATMENT EFFICACY OF SOFT TISSUE SARCOMA
Giulia Fornasa
Favorite
Forsyth, Sharon

CR UK & UCL Cancer Trials Centre
(P 70) ICONIC (IMPROVING OUTCOMES THROUGH COLLABORATION IN OSTEOSARCOMA): A PROSPECTIVE OBSERVATIONAL COHORT STUDY FOR NEWLY DIAGNOSED OSTEOSARCOMA PATIENTS IN THE UNITED KINGDOM (UK)
Sharon Forsyth
Favorite
Fossati, Piero

MedAustron Ion Therapy Centre, Austria
(P 74) SACRAL CHORDOMA: A RANDOMIZED & OBSERVATIONAL STUDY ON SURGERY VS DEFINITIVE RADIOTHERAPY IN PRIMARY LOCALIZED DISEASE (SACRO). INTERIM ANALYSIS
Piero Fossati
Favorite
(P 326) CARBON-ION RADIOTHERAPY FOR UNRESECTABLE PELVIC SARCOMAS/CHORDOMAS
Piero Fossati
Favorite
Fourme, Emmanuelle

Curie
(P 201) PLEOMORPHIC RHABDOMYOSARCOMAS: A NEW ENTITY ASSOCIATED WITH LYNCH SYNDROME? FIRST RESULTS OF SARCLYNCH NATIONAL STUDY
Emmanuelle Fourme
Favorite
Fowler, Nathan

BostonGene, Corp.
(P 420) COMPREHENSIVE MOLECULAR PROFILING AND TUMOR MICROENVIRONMENT CHARACTERISTICS OF RADIATION-INDUCED SARCOMA.
Nathan Fowler
Favorite
Fowler, Trent

Peel Therapeutics
(P 565) AN EARLY PHASE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF PEEL-224 IN PATIENTS WITH ADVANCED SOLID TUMORS
Trent Fowler
Favorite
Fox, Elizabeth

Department of Oncology, St. Jude Children's Research Hospital
(P 556) EVALUATION OF PALBOCICLIB (IBRANCE®) IN COMBINATION WITH CHEMOTHERAPY IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY EWING SARCOMA OR NEUROBLASTOMA
Elizabeth Fox
Favorite
Frühwald, Michael

Swabian Children's Cancer Center, Children's Hospital, University Hospital Augsburg, 86156 Augsburg, Germany
(P 557) UNRAVELING THE ROLE OF LOCAL THERAPY FOR PATIENTS WITH OLIGOMETASTATIC SOFT TISSUE SARCOMA - A RETROSPECTIVE MULTICENTER TRIAL OF BAVARIAN UNIVERSITY HOSPITALS
Michael Frühwald
Favorite
Fragoso Costa, Pedro

Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen
(P 248) FIBROBLAST ACTIVATION PROTEIN ALPHA -DIRECTED IMAGING AND THERAPY OF SOLITARY FIBROUS TUMOR
Pedro Fragoso Costa
Favorite
Fraile Olivero, Carlos

Hospital Clínico San Carlos
(P 515) ENDOBRONCHIAL NAVIGATION AS AN INTRAOPERATORY TOOL FOR RESECTION OF SMALL PULMONARY METASTASES IN SARCOMA PATIENTS
Carlos Fraile Olivero
Favorite
Françoise, Françoise

UMR_S 1307 Center for Research in Cancer and Integrated Immunology
(P 277) ANTI-GD2 SYNERGIZES WITH HYPOXIA PATHWAY TARGETING TO BLOCK OSTEOSARCOMA CELL PROLIFERATION AND MIGRATION.
Françoise Françoise
Favorite
(P 389) OSTEOBLASTIC-GENE SIGNATURE TO PREDICT SURVIVAL IN PEDIATRIC OSTEOSARCOMA (OS) AND TO FOLLOW PATIENTS TOWARDS LIQUID BIOPSY: A COLLABORATIVE WORK IN OS2006 PROTOCOL.
Françoise Françoise
Favorite
Frankel, Paul

City of Hope Comprehensive Cancer Center
(P 180) HEALTH RELATED QUALITY OF LIFE OF PATIENTS WITH ADVANCED LEIOMYOSARCOMA AND OTHER SOFT TISSUE SARCOMAS TREATED WITH CABOZANTINIB AND TEMOZOLOMIDE
Paul Frankel
Favorite
Frantz, Amy

Children's National Hospital
(P 18) RETROSPECTIVE ANALYSIS ON OUTCOMES PEDIATRIC PATIENTS WITH SARCOMA AND LUNG METASTASES STATUS POST PNEUMONECTOMY VERSUS PARTIAL LUNG RESECTION
Amy Frantz
Favorite
Franz Ringwalt, Emily

The Ohio State University/Nationwide Children's Hospital
(P 107) TRABECTEDIN AUGMENTS ONCOLYTIC HERPES SIMPLEX VIROIMMUNOTHERAPY EFFICACY IN PRECLINCAL BONE SARCOMA MODELS THROUGH ENHANCED IMMUNE-MEDIATED MECHANISMS
Emily Franz Ringwalt
Favorite
Franza, Andrea

INT Milan
(P 328) REAL-LIFE EXPERIENCE OF PAZOPANIB IN PATIENTS WITH ADVANCED UTERINE LEIOMYOSARCOMA (U-LMS) FROM TWO REFERRAL ITALIAN CENTERS
Andrea Franza
Favorite
Freddo, James

TRACON Pharmaceuticals Inc
(P 112) PHASE 1/2 STUDY OF YH001, A CTLA-4 ANTIBODY WITH THE SUBCUTANEOUSLY ADMINISTERED PD-L1 ANTIBODY ENVAFOLIMAB, WITH OR WITHOUT DOXORUBICIN IN PATIENTS WITH ADVANCED OR METASTATIC SOFT TISSUE SARCOMA
James Freddo
Favorite
(P 531) ENVASARC: A PIVOTAL TRIAL OF ENVAFOLIMAB AND ENVAFOLIMAB IN COMBINATION WITH IPILIMUMAB IN PATIENTS WITH ADVANCED OR METASTATIC UPS OR MFS WHO HAVE PROGRESSED ON PRIOR CHEMOTHERAPY
James Freddo
Favorite
Freeman, Burgess

St. Jude Children's Research Hospital
(P 303) PRECLINICAL EVALUATION OF PARP1 SELECTIVE INHIBITOR AZD5305 IN COMBINATION WITH DNA DAMAGING AGENTS IN EWING SARCOMA ORTHOTOPIC XENOGRAFT MODELS
Burgess Freeman
Favorite
Freivogel, Klaus

United BioSource LLC
(P 131) PATIENT-REPORTED CONTINUED BENEFITS IN PATIENTS TREATED WITH PEXIDARTINIB FOR TENOSYNOVIAL GIANT CELL TUMOR BASED ON A REAL-WORLD STUDY IN THE UNITED STATES
Klaus Freivogel
Favorite
French, Robert

Duke University Hospital
(P 509) GIANT CELL TUMOR OF BONE IN THE PEDIATRIC POPULATION: A RETROSPECTIVE STUDY HIGHLIGHTING CASES OF METAPHYSEAL ONLY LOCATION AND INCREASED LOCAL RECURRENCE RATES IN SKELETALLY IMMATURE PATIENTS
Robert French
Favorite
Frezza, Anna Maria

Department of Medical Oncology 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
(P 159) IN BETWEEN OF LYMPHOMAS AND SARCOMAS: WHERE DO HISTIOCYTIC AND DENDRITIC CELL NEOPLASMS (HDCN) STAND? A RETROSPECTIVE, MULTI-INSTITUTIONAL STUDY FROM THE ITALIAN SARCOMA GROUP (ISG)
Anna Maria Frezza
Favorite
(P 189) INTERNATIONAL RETROSPECTIVE STUDY FROM THE ULTRA-RARE SARCOMA WORKING GROUP ON LOW-GRADE FIBROMYXOID SARCOMA AND SCLEROSING EPITHELIOD FIBROSARCOMA: OUTCOME OF ADVANCED DISEASE AND SYSTEMIC THERAPIES
Anna Maria Frezza
Favorite
(P 378) MULTIOMICS PROFILING OF EPITHELIOID SARCOMA UNVEILS EPIGENETIC CIRCUITRIES THAT UNDERLIE THE PATHOBIOLOGY OF PROXIMAL AND CLASSIC SUBTYPES: RESULTS FROM THE ISG EPISOBS OBSERVATIONAL STUDY
Anna Maria Frezza
Favorite
Fridley, Brooke

Moffitt Cancer Center
(P 537) TGFβ IMPRINTED, EX VIVO EXPANDED UNIVERSAL DONOR NATURAL KILLER CELLS WITH CHEMOTHERAPY FOR RELAPSED BONE AND SOFT TISSUE SARCOMA - NCT05634369, REPORT FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION
Brooke Fridley
Favorite
Friedlander, Michael

Prince of Wales Hospital
(P 386) GENOMIC PROFILING OF GYNAECOLOGICAL SARCOMAS: REPORT FROM THE AUSTRALIA-WIDE PRECISION ONCOLOGY PROGRAM
Michael Friedlander
Favorite
Friedman, Debra

Vanderbilt University Medical Center
(P 160) A PROSPECTIVE STUDY EVALUATING THE ASSOCIATION OF PATIENT-REPORTED OUTCOMES WITH ACTIVITY LEVEL AND SLEEP PATTERNS IN SARCOMA SURVIVORS
Debra Friedman
Favorite
(P 210) FINANCIAL TOXICITY ASSOCIATED WITH THE TREATMENT OF SARCOMAS: A SINGLE INSTITUTION RETROSPECTIVE-PROSPECTIVE STUDY
Debra Friedman
Favorite
(P 211) AN ANALYSIS OF SELF-REPORTED DEPRESSION IN SARCOMA PATIENTS
Debra Friedman
Favorite
(P 380) NEXT GENERATION SEQUEINCING REVEALS TARGETABLE MUTATIONS IN MULTIPLE SARCOMA HISTOLOGIES
Debra Friedman
Favorite
Friedman, Elizabeth

University of Kansas
(P 214) SIGNIFICANT TREATMENT RESPONSE IN PATIENTS WITH PRIMARY RESECTABLE EXTREMITY MYXOID LIPOSARCOMA RECEIVING NEOADJUVANT TRABECTEDIN AND RADIATION
Elizabeth Friedman
Favorite
Frisoni, Tommaso

Istituto Ortopedico Rizzoli IOR IRCCS, SC Third Orthopaedic Clinic and Traumatology, Bologna Italy
(P 253) THE EFFICACY OF MEDICATED PATCHES IN SOFT TISSUE SARCOMAS: IN-VITRO AND EX-VIVO VALIDATION.
Tommaso Frisoni
Favorite
Froelich, Jerry

University of Minnesota
(P 167) FDG-PET-CT RESPONSE AFTER NEOADJUVANT CHEMOTHERAPY PREDICTS LONG-TERM OUTCOME IN PATIENTS WITH SOFT TISSUE SARCOMA -- 15-YEAR FOLLOW-UP
Jerry Froelich
Favorite
Fröhling, Stefan

Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ)
(P 124) UNLOCKING THE POTENTIAL OF MEASLES VIRUS ONCOLYTIC IMMUNOTHERAPY FOR SARCOMA: BIOMARKER DISCOVERY AND THERAPEUTIC VACCINE DEVELOPMENT
Stefan Fröhling
Favorite
(P 234) GENOMIC LANDSCAPE OF CLEAR CELL SARCOMA
Stefan Fröhling
Favorite
(P 248) FIBROBLAST ACTIVATION PROTEIN ALPHA -DIRECTED IMAGING AND THERAPY OF SOLITARY FIBROUS TUMOR
Stefan Fröhling
Favorite
Fujii, Hiromasa

Nara Medical University
(P 259) LOVASTATIN INDUCES NOVEL CELL DEATH THROUGH THE IMPAIRED MITOCHONDRIA IRON UTILIZATION IN OSTEOASRCOMA CELLS.
Hiromasa Fujii
Favorite
Fujii, Hiroyuki

1) Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan. 2) Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
(P 35) GENOMIC ALTERATIONS IN ADVANCED GASTROINTESTINAL STROMAL TUMORS AS REVEALED BY COMPREHENSIVE GENOMIC PROFILING TESTS
Hiroyuki Fujii
Favorite
Fujimoto, Hiroyuki

Department of Urology, National Cancer Center Hospital, Tokyo, Japan
(P 332) SURGICAL OUTCOMES OF RETROPERITONEAL LIPOSARCOMA - SINGLE INSTITUTIONAL STUDY N JAPAN -
Hiroyuki Fujimoto
Favorite
Fujito, Takeo

Nagoya University Hospital
(P 163) SELUMETINIB IN JAPANESE PEDIATRIC PATIENTS WITH SYMPTOMATIC INOPERABLE PLEXIFORM NEUROFIBROMA IN NEUROFIBROMATOSIS TYPE 1
Takeo Fujito
Favorite
Fujiwara, Tomohiro

Okayama University Hospital
(P 16) ALVEOLAR SOFT PART SARCOMA: PROGRESS TOWARD IMPROVEMENT IN SURVIVAL? A NATIONWIDE DATABASE STUDY IN JAPAN
Tomohiro Fujiwara
Favorite
Fukushi, Ryunosuke

Sapporo Medical University School of Medicine
(P 486) PRIMARY HIGH-GRADE SARCOMA OF THE SPINE: EXPERIENCE WITH 11 CASES
Ryunosuke Fukushi
Favorite
Fumagalli, Caterina

Hospital de la Santa Creu i Sant Pau
(P 503) SCAPULAR PROSTHESIS RECONSTRUCTION, EXPERIENCE IN OUR INSTITUTION
Caterina Fumagalli
Favorite
(P 504) WHY DO SOME PATIENTS WITH SYNOVIAL SARCOMA HAVE BETTER FUNCTIONAL OUTCOMES AFTER RESECTION SURGERY? ANALYSIS OF 102 CASES
Caterina Fumagalli
Favorite
(P 507) PRIMARY CHEST WALL TUMORS OF MESENCHYMAL ORIGIN. EXPERIENCE OF A REFERENCE UNIT
Caterina Fumagalli
Favorite
(P 508) DREAM, UTOPIA OR REALISM? PROGNOSTIC FACTORS IN LUNG METASTASECTOMY OF DISSEMINATED SARCOMA DISEASE
Caterina Fumagalli
Favorite
Fumagalli, Elena

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 27) A MULTICENTER RETROSPECTIVE STUDY ON THE CLINICAL BEHAVIOR OF SDH-DEFICIENT GIST
Elena Fumagalli
Favorite
(P 49) EFFICACY OF RIPRETINIB IN A MULTICENTER EXPANDED ACCESS PROGRAM IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS HARBOURING NON-KIT EXON 11 MUTATIONS.
Elena Fumagalli
Favorite
(P 328) REAL-LIFE EXPERIENCE OF PAZOPANIB IN PATIENTS WITH ADVANCED UTERINE LEIOMYOSARCOMA (U-LMS) FROM TWO REFERRAL ITALIAN CENTERS
Elena Fumagalli
Favorite
Furlan, Scott

Fred Hutchinson Cancer Center
(P 448) CAF-LIKE EWING SARCOMA CELLS DEPOSIT PRO-TUMORIGENIC EXTRACELLULAR MATRIX IN RESPONSE TO TGF-BETA SIGNALING
Scott Furlan
Favorite
Furness, Andrew

The Royal Marsden NHS Foundation Trust
(P 114) PRIMARY ANALYSIS OF EFFICACY AND SAFETY OF LETETRESGENE AUTOLEUCEL (LETE-CEL) AS FIRST-LINE TREATMENT FOR UNRESECTABLE OR METASTATIC SYNOVIAL SARCOMA (SS); SUBSTUDY 1 OF IGNYTE-ESO
Andrew Furness
Favorite
Furno, Alfredo

Ospedale Pediatrico Bambino Gesù IRCCS
(P 144) IMPLEMENTATION OF THE EUROPEAN CLINICAL TRIAL REGULATION: SURVEY OF THE ITALIAN SARCOMA GROUP CENTERS
Alfredo Furno
Favorite
Furtado, Sherron

Royal National Orthopaedic Hospital Nhs Trust
(P 147) UNDERSTANDING THE EXPERIENCES OF PATIENTS RETURNING TO DAILY ACTIVITES AND EXERCISE FOLLOWING LIMB SPARING SURGERY FOR BONE OR SOFT TISSUE SARCOMA AROUND THE KNEE
Sherron Furtado
Favorite
(P 492) BALANCE AND GAIT OUTCOMES AFTER 1-YEAR POST-OPERATIVE HEMIPELVECTOMY SURGERY
Sherron Furtado
Favorite
(P 493) GAIT KINEMATICS OF SARCOMA PATIENTS AT 1 YEAR POST-OPERATIVE INTERNAL HEMIPELVECTOMY SURGERY: A RETROSPECTIVE STUDY.
Sherron Furtado
Favorite
(P 494) WHAT IS THE EXPERIENCE OF THOSE WITH CANCER-RELATED REDUCED QUALITY OF LIFE AND ASSOCIATED PHYSICAL DISABILITIES AFTER UPPER LIMB SARCOMA TREATMENT IN ENGLAND? A NATIONAL STUDY OF OUTCOMES.
Sherron Furtado
Favorite
(P 495) UNDERSTANDING THE EXPERIENCES OF PATIENTS RETURNING TO ACTIVITIES OF DAILY LIVING AND EXERCISE FOLLOWING LIMB SPARING SURGERY FOR BONE OR SOFT TISSUE SARCOMA AROUND THE KNEE.
Sherron Furtado
Favorite
(P 496) WHAT ARE THE EXPERIENCES OF BALANCE, GAIT AND NEURO-MUSCULAR CONTROL OUTCOMES AFTER PROXIMAL FEMORAL REPLACEMENTS FOR MUSCULOSKELETAL TUMOURS?
Sherron Furtado
Favorite
(P 497) STANMORE TUMOUR OUTCOMES PROJECT (STOMP)- USING INTERNATIONAL CLASSIFICATION OF FUNCTIONING, DISABILITY AND HEALTH (ICF) OUTCOMES IN SARCOMA SURVIVORS. and UNDERSTANDING THE EXPERIENCES OF PATIENTS RETURNING TO DAILY ACTIVITES AND EXERCISE FOLLOWING LIMB SPARING SURGERY FOR BONE OR SOFT TISSUE SARCOMA AROUND THE KNEE
Sherron Furtado
Favorite
(P 519) WHAT ARE THE EXPERIENCES OF GAIT, ACTIVITY LEVELS AND PHYSICAL FUNCTIONING IN PROXIMAL FEMORAL REPLACEMENT AFTER MUSCULOSKELETAL TUMORS?
Sherron Furtado
Favorite
(P 560) REAL-WORLD MONITORING OF PHYSICAL ACTIVITY USING AN ACCELEROMETER AFTER LOWER LIMB SURGERY FOR A SARCOMA.
Sherron Furtado
Favorite
(P 561) EXPERIENCE OF PHYSICAL DISABILITIES AND CANCER-RELATED QUALITY OF LIFE AFTER SPINAL TUMORS- STUDY OF A NATIONAL SURVEY IN ENGLAND.
Sherron Furtado
Favorite
(P 563) BALANCE, GAIT AND BIOMECHANICAL COMPENSATIONS DURING DIFFERENT SPEEDS OF WALKING AFTER TREATMENT FOR DISTAL FEMORAL MUSCULOSKELETAL TUMOURS AND ASSOCIATED LIMITATIONS ON RETURN TO NORMAL LIVING
Sherron Furtado
Favorite
Futreal, P Andrew

The University of Texas MD Anderson Cancer Center
(P 100) HISTOLOGY SPECIFIC INTRATUMORAL B-CELL BIOLOGY IN ALVEOLAR SOFT-PART SARCOMAS (ASPS) IN RESPONSE TO DURVALUMAB-TREMELIMUMAB (D-T)
P Andrew Futreal
Favorite
(P 394) LEIOMYOSARCOMA INTRATUMORAL MACROPHAGE INFILTRATES ARE ASSOCIATED WITH DISTINCT CLINICAL AND GENOMIC PRESENTATIONS
P Andrew Futreal
Favorite
(P 405) PRIMARY CARDIAC ANGIOSARCOMA- GENOMIC AND MOLECULAR LANDSCAPE
P Andrew Futreal
Favorite
(P 426) MULTI-OMIC ANALYSIS OF DESMOPLASTIC SMALL ROUND CELL TUMORS REVEAL DISTINCT LINEAGES
P Andrew Futreal
Favorite
fu, yang

Department of Gastrointestinal Surgery, The First Affiliated Hospital of Zhengzhou University
(P 39) MANAGEMENT PRACTICES OF GASTROINTESTINAL STROMAL TUMORS: A QUESTIONNAIRE SURVEY OF GENERAL SURGEONS IN CHINA
yang fu
Favorite
G
G.Manzano, Ramón

Hospital Quironsalud Torrevieja
(P 407) PRECISION AND PERSONALIZED TREATMENT FOR SOFT TISSUE SARCOMAS. RESULTS OF A 10 PATIENTS SERIES WITH MOLECULAR PROFILING USING NEXT-GENERATION MASSIVE SEQUENCING
Ramón G.Manzano
Favorite
Gösling, Thomas

Klinikum Braunschweig
(P 133) TEN RECOMMENDATIONTS FOR SARCOMA SURGERY: CONSENSUS OF THE SURGICAL SOCIETIES BASED ON THE GERMAN S3 GUIDELINE "ADULT SOFT TISSUE SARCOMA"
Thomas Gösling
Favorite
Gónzalez, María Lucila

Instituto Nacional del Cáncer
(P 142) THE SARCOMA EUROPEAN AND LATIN AMERICAN NETWORK (SELNET) PROJECT: OVERVIEW OF THE MAIN RESULTS OF THE SELNET REGISTRY
María Lucila Gónzalez
Favorite
Gabal, Eman

University of Florida
(P 452) SECONDARY GENOMIC LANDSCAPE OF CIC::DUX4 FUSION SARCOMAS
Eman Gabal
Favorite
Gabellone, Sofia

Istituto Romagnolo per lo studio dei Tumori "Dino Amadori" IRST IRCCS, Preclinic and Osteoncology Unit, Meldola, Italy
(P 37) DISSECTING THE ROLE OF EXTRACELLULAR VESICLES IN THE MANAGEMENT OF GIST
Sofia Gabellone
Favorite
(P 253) THE EFFICACY OF MEDICATED PATCHES IN SOFT TISSUE SARCOMAS: IN-VITRO AND EX-VIVO VALIDATION.
Sofia Gabellone
Favorite
(P 364) EVALUATION OF THE PREDICTIVE ROLE OF SYSTEMIC AND INTRATUMORAL IMMUNITY IN PATIENTS WITH LOCALIZED LIPOSARCOMAS, MYXOFIBROSARCOMAS AND UNDIFFERENTIATED PLEOMORPHIS SARCOMAS
Sofia Gabellone
Favorite
Gabrielova, Lucie

Masaryk Memorial Cancer Institute
(P 152) EVALUATING DIAGNOSTIC APPROACHES TO DERMATOFIBROSARCOMA PROTUBERANS: AN OPPORTUNITY TO REDUCE THE NUMBER OF INTERVENTIONS
Lucie Gabrielova
Favorite
Gains, Jennifer

University College Hospitals London
(P 321) IDENTIFYING RISK FACTORS FOR REDUCTION OF PROTON THERAPY RE-PLANS FOR PAEDIATRIC PATIENTS WITH PELVIC SARCOMAS
Jennifer Gains
Favorite
Galiano, Antonella

Oncology 1 Unit, Department of Oncology, Veneto Institute of Oncology IOV - IRCCS
(P 171) SEX DIFFERENCES IN OUTCOMES AND TOXICITY IN PATIENTS TREATED FOR SARCOMA IN A REFERENCE CENTER
Antonella Galiano
Favorite
(P 216) BRAIN METASTASES IN SARCOMA: A (NOT SO) RARE EVENT. THE EXPERIENCE OF A HIGH VOLUME CENTER
Antonella Galiano
Favorite
Galvagno, Federica

Department of Oncology, University of Turin
(P 109) INTENSE PRECLINICAL ACTIVITY BY B7H3-SPECIFIC CAR.CIK LYMPHOCYTES AGAINST EPITHELIOID SARCOMA
Federica Galvagno
Favorite
Galvin, Robert

University of Minnesota
(P 252) STUDY OF NUTRACEUTICAL INTERVENTION WITH HIGH PHENOLIC EXTRA VIRGIN OLIVE OIL AND CURCUMIN FOR NEUROFIBROMATOSIS TYPE 1
Robert Galvin
Favorite
Gambarotti, Marco

Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy
(P 01) EXTRASKELETAL EWING SARCOMA OF THE EXTREMITIES AND TRUNK IN < 25 YEARS OLD PATIENTS: A RETROSPECTIVE ANALYSIS OF A MONO-INSTITUTIONAL SERIES.
Marco Gambarotti
Favorite
(P 73) FOSTER CONSORTIUM, FIGHT OSTEOSARCOMA THROUGH EUROPEAN RESEARCH
Marco Gambarotti
Favorite
(P 142) THE SARCOMA EUROPEAN AND LATIN AMERICAN NETWORK (SELNET) PROJECT: OVERVIEW OF THE MAIN RESULTS OF THE SELNET REGISTRY
Marco Gambarotti
Favorite
(P 283) A TRIDIMENSIONAL PRECLINICAL MODEL TO STUDY HUMAN AND CANINE OSTEOSARCOMA DEVELOPMENT AND INTERACTION WITH TUMOR MICROENVIRONMENT
Marco Gambarotti
Favorite
(P 378) MULTIOMICS PROFILING OF EPITHELIOID SARCOMA UNVEILS EPIGENETIC CIRCUITRIES THAT UNDERLIE THE PATHOBIOLOGY OF PROXIMAL AND CLASSIC SUBTYPES: RESULTS FROM THE ISG EPISOBS OBSERVATIONAL STUDY
Marco Gambarotti
Favorite
(P 437) ULTRA-RARE UNDIFFERENTIATED SMALL ROUND CELL SARCOMA: HOW SHOULD WE TREAT THEM? AN ANALYSIS FORM THE GRACEFUL PROJECT
Marco Gambarotti
Favorite
(P 455) EXTRASKELETAL EWING SARCOMA: A MULTICENTRIC RETROSPECTIVE STUDY FROM THE ITALIAN SARCOMA GROUP
Marco Gambarotti
Favorite
Gamez, Mauricio

Mayo Clinic
(P 315) SCALP VOLUMETRIC MODULATED ARC THERAPY USING 3D MILLED BOLUS: DOSIMITRY, TOXICITY AND OUTCOMES
Mauricio Gamez
Favorite
Ganapathi, Shireen

Seattle Children's Research Institute
(P 447) TARGETING FOCAL ADHESION KINASE AUGMENTS THE THERAPEUTIC POTENTIAL OF BROMODOMAIN INHIBITORS IN EWING SARCOMA
Shireen Ganapathi
Favorite
Gandemer, Virginie

University Hospital Rennes
(P 75) REAL-WORLD DATA ON REGORAFENIB AND CABOZANTINIB IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH RELAPSED OSTEOSARCOMA AND EWING SARCOMA INCLUDED IN THE SACHA-FRANCE STUDY
Virginie Gandemer
Favorite
Gandra, Divya

Atrium Health Levine Children's Hospital
(P 266) ROMIDEPSIN DECREASES DNA DAMAGE REPAIR AND INCREASES SENSITIVITY TO CHEMOTHERAPY IN EWING SARCOMA
Divya Gandra
Favorite
Gangloff, Dimitry

OCR
(P 201) PLEOMORPHIC RHABDOMYOSARCOMAS: A NEW ENTITY ASSOCIATED WITH LYNCH SYNDROME? FIRST RESULTS OF SARCLYNCH NATIONAL STUDY
Dimitry Gangloff
Favorite
Ganjoo, Kristen

Stanford Cancer Center
(P 173) SAFETY, EFFICACY, AND PATIENT-REPORTED OUTCOMES WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED PRIOR ANTI–COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 UPDATE
Kristen Ganjoo
Favorite
(P 191) SARC024 COHORT D: PHASE 2 TRIAL OF REGORAFENIB IN CHILDREN, ADOLESCENTS, AND ADULTS WITH RHABDOMYOSARCOMA
Kristen Ganjoo
Favorite
(P 224) CO-MUTATION-DEPENDENT PROGNOSIS IN PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA
Kristen Ganjoo
Favorite
(P 540) PHASE 2, MULTICENTER, OPEN-LABEL BASKET TRIAL OF NAB-SIROLIMUS FOR MALIGNANT SOLID TUMORS HARBORING PATHOGENIC INACTIVATING ALTERATIONS IN TSC1 AND TSC2 (PRECISION I)
Kristen Ganjoo
Favorite
(P 552) RANDOMIZED PHASE II TRIAL OF CABOZANTINIB COMBINED WITH PD-1 AND CTLA-4 INHIBITION VERSUS CABOZANTINIB IN METASTATIC SOFT TISSUE SARCOMA.
Kristen Ganjoo
Favorite
Gao, Bo

Westmead Hospital
(P 386) GENOMIC PROFILING OF GYNAECOLOGICAL SARCOMAS: REPORT FROM THE AUSTRALIA-WIDE PRECISION ONCOLOGY PROGRAM
Bo Gao
Favorite
Gao, Song

Department of Pancreatic Surgery,Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer; Tianjin Key Laboratory of Digestive Cancer, Tianjin; Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, P. R. China
(P 42) THE EFFICACY AND SAFETY OF RIPRETINIB IN THE TREATMENT OF CHINESE PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS (GISTS): A SINGLE-INSTITUTION ANALYSIS
Song Gao
Favorite
Gao, Zhidong

Department of Gastrointestinal Surgery, Peking University People‘s Hospital, Peking University, Peking, China
(P 24) COMPREHENSIVE ANALYSIS OF THE GENOMIC LANDSCAPE AND CLINICAL BEHAVIOR IN GIST USING NEXT GENERATION SEQUENCING (NGS, MSK-IMPACT)
Zhidong Gao
Favorite
Garayua-Cruz, Leilani

University of Puerto Rico School of Medicine
(P 518) OUTCOMES OF NON-ANGIOSARCOMA RADIATION-ASSOCIATED SOFT TISSUE SARCOMAS OF THE CHEST
Leilani Garayua-Cruz
Favorite
Garcia Apellaniz, Nagore

Hospital de la Santa Creu i Sant Pau
(P 313) SPACIALLY-FRACTIONATED RADIOTHERAPY (LATTICE) TREATMENT IN INOPERABLE NON-EXTREMITY BULKY SOFT-TISSUE SARCOMAS
Nagore Garcia Apellaniz
Favorite
Garcia, Alejandro

The Johns Hopkins University
(P 143) EXPLORING HOSPITAL VOLUME THRESHOLDS FOR IMPROVED SARCOMA TREATMENT ACROSS DIFFERENT AGE CATEGORIES IN THE UNITED STATES
Alejandro Garcia
Favorite
Garcia-Fontes Pujol, Laura

Hospital de la Santa Creu i Sant Pau
(P 503) SCAPULAR PROSTHESIS RECONSTRUCTION, EXPERIENCE IN OUR INSTITUTION
Laura Garcia-Fontes Pujol
Favorite
Garcia-Maroto, Roberto

Hospital Clinico san Carlos
(P 149) PSYCOLOGICAL SNAPSHOT OF SARCOMA PATIENTS FROM AN ACADEMIC, UNIVERSITY CENTER, HOSPITAL CLÍNICO SAN CARLOS (HCSC), MADRID, A SARCOMA NATIONAL REFERRAL CENTRE IN SPAIN
Roberto Garcia-Maroto
Favorite
Garcia, Marta

Hospital Clinico san Carlos
(P 149) PSYCOLOGICAL SNAPSHOT OF SARCOMA PATIENTS FROM AN ACADEMIC, UNIVERSITY CENTER, HOSPITAL CLÍNICO SAN CARLOS (HCSC), MADRID, A SARCOMA NATIONAL REFERRAL CENTRE IN SPAIN
Marta Garcia
Favorite
Garcia, Nicolas

Seattle Children's Research Institute
(P 447) TARGETING FOCAL ADHESION KINASE AUGMENTS THE THERAPEUTIC POTENTIAL OF BROMODOMAIN INHIBITORS IN EWING SARCOMA
Nicolas Garcia
Favorite
(P 448) CAF-LIKE EWING SARCOMA CELLS DEPOSIT PRO-TUMORIGENIC EXTRACELLULAR MATRIX IN RESPONSE TO TGF-BETA SIGNALING
Nicolas Garcia
Favorite
García-Ortega, Dorian Yarih

Instituto Nacional de Cancerología (México)
(P 142) THE SARCOMA EUROPEAN AND LATIN AMERICAN NETWORK (SELNET) PROJECT: OVERVIEW OF THE MAIN RESULTS OF THE SELNET REGISTRY
Dorian Yarih García-Ortega
Favorite
(P 330) TREATMENT VARIATIONS, OUTCOMES AND PATTERNS OF RECURRENCE AFTER CURATIVE INTENT TREATMENT FOR PRIMARY RETROPERITONEAL SARCOMAS IN LATIN AMERICA. FIRST COLLABORATIVE LATAMSARC STUDY
Dorian Yarih García-Ortega
Favorite
(P 331) MUSCULAR DEDIFFERENTIATION IN DEDIFFERENTIATED LIPOSARCOMA: INSIGHTS INTO INFLAMMATORY PROFILES USING THE NEUTROPHIL/LYMPHOCYTE RATIO AND PROGNOSTIC IMPLICATIONS
Dorian Yarih García-Ortega
Favorite
Gartrell, Jessica

St. Jude Children’s Research Hospital
(P 528) SAFETY AND TOLERABILITY OF ORAL CYCLOPHOSPHAMIDE AND SORAFENIB WITH INTRAVENOUS BEVACIZUMAB WITH THE ADDITION OF ATEZOLIZUMAB IN PEDIATRIC SOLID TUMOR PATIENTS
Jessica Gartrell
Favorite
Garzia, Livia

Research Institute of the McGill University Health Center
(P 64) OSTEOSARCOMA. PATIENT-DERIVED XENOGRAFTS MODELS TO RECAPITULATE PATIENTS' CHEMORESISTANCE AND METASTATIC DISEASE
Livia Garzia
Favorite
(P 65) PROFILING EXTRACELLULAR VESICLES AND NANOPARTICLES IN OSTEOSARCOMA
Livia Garzia
Favorite
(P 379) THE ROLE OF EZHIP IN DRIVING AGGRESSIVE OSTEOSARCOMA
Livia Garzia
Favorite
(P 434) MECHANISMS OF CHEMORESISTANCE IN CIC-DUX4 SARCOMA AS DETERMINED BY IN VIVO FUNCTIONAL GENOMICS
Livia Garzia
Favorite
Gasbarrini, Alessandro

IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy
(P 74) SACRAL CHORDOMA: A RANDOMIZED & OBSERVATIONAL STUDY ON SURGERY VS DEFINITIVE RADIOTHERAPY IN PRIMARY LOCALIZED DISEASE (SACRO). INTERIM ANALYSIS
Alessandro Gasbarrini
Favorite
Gasparini, Patrizia

Fondazione IRCCS Istituto Nazionanale dei Tumori
(P 273) COMPARISON OF A PATIENT-DERIVED XENOGRAFTS (PDX) OF MYXOID PLEOMORPHIC LIPOSARCOMA (MPL) AND PLEOMORPHIC LIPOSARCOMA (PL) HIGHLIGHTS THE EFFECTIVENESS OF ERIBULIN IN A PDX OF MPL
Patrizia Gasparini
Favorite
Gaspar, Nathalie

Gustave Roussy cancer campus
(P 69) DEVELOPMENT AND MISSION OF THE HARMONIZATION INTERNATIONAL BONE SARCOMA CONSORTIUM (HIBISCUS)
Nathalie Gaspar
Favorite
(P 73) FOSTER CONSORTIUM, FIGHT OSTEOSARCOMA THROUGH EUROPEAN RESEARCH
Nathalie Gaspar
Favorite
(P 277) ANTI-GD2 SYNERGIZES WITH HYPOXIA PATHWAY TARGETING TO BLOCK OSTEOSARCOMA CELL PROLIFERATION AND MIGRATION.
Nathalie Gaspar
Favorite
(P 389) OSTEOBLASTIC-GENE SIGNATURE TO PREDICT SURVIVAL IN PEDIATRIC OSTEOSARCOMA (OS) AND TO FOLLOW PATIENTS TOWARDS LIQUID BIOPSY: A COLLABORATIVE WORK IN OS2006 PROTOCOL.
Nathalie Gaspar
Favorite
Gasperoni, Silvia

AOU Careggi
(P 27) A MULTICENTER RETROSPECTIVE STUDY ON THE CLINICAL BEHAVIOR OF SDH-DEFICIENT GIST
Silvia Gasperoni
Favorite
Gatz, Susanne

University of Birmingham
(P 212) REPORT ON THE EWING SARCOMA PATIENTS ENROLLED IN ARM D OF THE ACSE-ESMART TRIAL: PHASE I/II STUDY OF THE PARP INHIBITOR OLAPARIB IN COMBINATION WITH IRINOTECAN IN CHILDREN WITH ADVANCED MALIGNANCIES
Susanne Gatz
Favorite
(P 282) AN EMBRYONIC ZEBRAFISH XENOGRAFT MODEL OF RHABDOMYOSARCOMA REVEALS GENOTYPE DEPENDENT TUMOUR VASCULARISATION DYNAMICS AND RESPONSE TO ANTI-ANGIOGENIC RECEPTOR TYROSINE KINASE INHIBITORS
Susanne Gatz
Favorite
Gaze, Mark

University College London Hospitals NHS Foundation Trust
(P 321) IDENTIFYING RISK FACTORS FOR REDUCTION OF PROTON THERAPY RE-PLANS FOR PAEDIATRIC PATIENTS WITH PELVIC SARCOMAS
Mark Gaze
Favorite
Gelderblom, Hans

Leiden University Medical Center
(P 27) A MULTICENTER RETROSPECTIVE STUDY ON THE CLINICAL BEHAVIOR OF SDH-DEFICIENT GIST
Hans Gelderblom
Favorite
(P 30) FINANCIAL DIFFICULTIES EXPERIENCED BY DUTCH GASTROINTESTINAL STROMAL TUMOR (GIST) PATIENTS: DATA FROM A CROSS-SECTIONAL MULTICENTER STUDY
Hans Gelderblom
Favorite
(P 55) RELATIVE WASH-IN RATE ON DYNAMIC CONTRAST-ENHANCED MRI AS A NEW PROGNOSTIC FACTOR IN PATIENTS WITH OSTEOSARCOMA; A POSSIBLE TOOL FOR PERSONALIZED SARCOMA-CARE?
Hans Gelderblom
Favorite
(P 56) CHARACTERIZATION OF DENOSUMAB TREATMENT RESPONSE ON MR PERFUSION IN GIANT CELL TUMORS OF BONE
Hans Gelderblom
Favorite
(P 73) FOSTER CONSORTIUM, FIGHT OSTEOSARCOMA THROUGH EUROPEAN RESEARCH
Hans Gelderblom
Favorite
(P 138) CONTROVERSIES IN THE MANAGEMENT OF PATIENTS WITH SOFT TISSUE SARCOMA: RESULTS AND RECOMMENDATIONS FROM THE FIRST CONFERENCE ON STATE OF SCIENCE IN SARCOMA (CSSS)
Hans Gelderblom
Favorite
(P 173) SAFETY, EFFICACY, AND PATIENT-REPORTED OUTCOMES WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED PRIOR ANTI–COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 UPDATE
Hans Gelderblom
Favorite
(P 176) SAFETY, EFFICACY, AND PATIENT-REPORTED OUTCOMES WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED NO PRIOR ANTI–COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 UPDATE
Hans Gelderblom
Favorite
(P 369) MAGEA ANTIGENS AS IMMUNOTHERAPEUTIC TARGETS FOR ADVANCED OSTEOSARCOMA
Hans Gelderblom
Favorite
(P 451) IMPACT OF TIME TO DIAGNOSIS - A PROSPECTIVE ANALYSIS OF THE EWING 2008 TRIAL
Hans Gelderblom
Favorite
(P 543) MANEUVER STUDY: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF PIMICOTINIB (ABSK021) TO ASSESS THE EFFICACY AND SAFETY IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR
Hans Gelderblom
Favorite
Geller, David

Montefiore Medical Center - Orthopaedic Oncology
(P 81) OPTIMIZING EWING SARCOMA AND OSTEOSARCOMA BIOPSY ACQUISITION: CONSENSUS RECOMMENDATIONS FROM THE CHILDREN'S ONCOLOGY GROUP BONE TUMOR COMMITTEE
David Geller
Favorite
Gennaro, Nicolo

Northwestern University Feinberg School of Medicine
(P 433) A 20-YEAR MONOCENTER EXPERIENCE ON CLINICAL CHARACTERISTICS AND OUTCOME OF EXTRASKELETAL EWING SARCOMA.
Nicolo Gennaro
Favorite
Gennusa, Vincenzo

A.O.U.P. "Paolo Giaccone"
(P 144) IMPLEMENTATION OF THE EUROPEAN CLINICAL TRIAL REGULATION: SURVEY OF THE ITALIAN SARCOMA GROUP CENTERS
Vincenzo Gennusa
Favorite
Gentili, Giorgia

IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori" S.r.l.
(P 144) IMPLEMENTATION OF THE EUROPEAN CLINICAL TRIAL REGULATION: SURVEY OF THE ITALIAN SARCOMA GROUP CENTERS
Giorgia Gentili
Favorite
Geoerger, Birgit

Gustave Roussy Cancer Center, Université Paris-Saclay, INSERM U1015
(P 161) EFFICACY, SAFETY, AND TREATMENT HOLD WAIT-AND-SEE OUTCOMES OF LAROTRECTINIB IN PEDIATRIC PATIENTS WITH TRK FUSION SARCOMAS
Birgit Geoerger
Favorite
(P 212) REPORT ON THE EWING SARCOMA PATIENTS ENROLLED IN ARM D OF THE ACSE-ESMART TRIAL: PHASE I/II STUDY OF THE PARP INHIBITOR OLAPARIB IN COMBINATION WITH IRINOTECAN IN CHILDREN WITH ADVANCED MALIGNANCIES
Birgit Geoerger
Favorite
Geoghegan, Clare

University College London Hospital
(P 57) REAL-WORLD EXPERIENCE OF CABOZANTINIB IN PAEDIATRIC, TEENAGE AND YOUNG ADULT (TYA) AND ADULT METASTATIC BONE SARCOMA PATIENTS FROM THE LONDON SARCOMA SERVICE (LSS)
Clare Geoghegan
Favorite
George, Joshy

The Jackson Laboratory for Genomic Medicine
(P 392) IMMUNOSUPPRESSIVE TUMOR MICROENVIRONMENT OF OSTEOSARCOMA
Joshy George
Favorite
George, Suzanne

Dana-Farber Cancer Institute
(P 26) PHASE 1 STUDY OF IDRX-42 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS RESISTANT TO PRIOR SYSTEMIC THERAPY: EARLY RESULTS
Suzanne George
Favorite
(P 27) A MULTICENTER RETROSPECTIVE STUDY ON THE CLINICAL BEHAVIOR OF SDH-DEFICIENT GIST
Suzanne George
Favorite
(P 207) A MULTICENTER PHASE II STUDY OF CABOZANTINIB PLUS NIVOLUMAB FOR PATIENTS WITH ADVANCED ANGIOSARCOMA PREVIOUSLY TREATED WITH A TAXANE: ALLIANCE A091902
Suzanne George
Favorite
(P 541) ETCTN 10563: PHASE 1 STUDY OF PEPOSERTIB AND LIPOSOMAL DOXORUBICIN FOR ADVANCED OR METASTATIC LEIOMYOSARCOMA AND OTHER SARCOMAS
Suzanne George
Favorite
Georgoulias, Vasileios

National network of precision medicine, Greece
(P 222) EXPLORING THE IMPACT OF NGS ON DIAGNOSTICS AND TREATMENT OF SARCOMA: INSIGHTS FROM REAL-WORLD DATA ACROSS MULTIPLE INSTITUTIONS IN EUROPE
Vasileios Georgoulias
Favorite
Gerken, Andreas

University Medical Center Mannheim
(P 488) POSTOPERATIVE DRAINAGE MANAGEMENT AND WOUND COMPLICATIONS FOLLOWING RESECTION OF LOWER LIMB SOFT TISSUE TUMORS
Andreas Gerken
Favorite
Gerrand, Craig

Royal National Orthopaedic Hospital
(P 69) DEVELOPMENT AND MISSION OF THE HARMONIZATION INTERNATIONAL BONE SARCOMA CONSORTIUM (HIBISCUS)
Craig Gerrand
Favorite
(P 70) ICONIC (IMPROVING OUTCOMES THROUGH COLLABORATION IN OSTEOSARCOMA): A PROSPECTIVE OBSERVATIONAL COHORT STUDY FOR NEWLY DIAGNOSED OSTEOSARCOMA PATIENTS IN THE UNITED KINGDOM (UK)
Craig Gerrand
Favorite
(P 147) UNDERSTANDING THE EXPERIENCES OF PATIENTS RETURNING TO DAILY ACTIVITES AND EXERCISE FOLLOWING LIMB SPARING SURGERY FOR BONE OR SOFT TISSUE SARCOMA AROUND THE KNEE
Craig Gerrand
Favorite
(P 472) ICONIC (IMPROVING OUTCOMES THROUGH COLLABORATION IN OSTEOSARCOMA). AN EARLY LOOK AT SURGICAL DATA
Craig Gerrand
Favorite
(P 492) BALANCE AND GAIT OUTCOMES AFTER 1-YEAR POST-OPERATIVE HEMIPELVECTOMY SURGERY
Craig Gerrand
Favorite
(P 493) GAIT KINEMATICS OF SARCOMA PATIENTS AT 1 YEAR POST-OPERATIVE INTERNAL HEMIPELVECTOMY SURGERY: A RETROSPECTIVE STUDY.
Craig Gerrand
Favorite
(P 494) WHAT IS THE EXPERIENCE OF THOSE WITH CANCER-RELATED REDUCED QUALITY OF LIFE AND ASSOCIATED PHYSICAL DISABILITIES AFTER UPPER LIMB SARCOMA TREATMENT IN ENGLAND? A NATIONAL STUDY OF OUTCOMES.
Craig Gerrand
Favorite
(P 495) UNDERSTANDING THE EXPERIENCES OF PATIENTS RETURNING TO ACTIVITIES OF DAILY LIVING AND EXERCISE FOLLOWING LIMB SPARING SURGERY FOR BONE OR SOFT TISSUE SARCOMA AROUND THE KNEE.
Craig Gerrand
Favorite
(P 496) WHAT ARE THE EXPERIENCES OF BALANCE, GAIT AND NEURO-MUSCULAR CONTROL OUTCOMES AFTER PROXIMAL FEMORAL REPLACEMENTS FOR MUSCULOSKELETAL TUMOURS?
Craig Gerrand
Favorite
(P 497) STANMORE TUMOUR OUTCOMES PROJECT (STOMP)- USING INTERNATIONAL CLASSIFICATION OF FUNCTIONING, DISABILITY AND HEALTH (ICF) OUTCOMES IN SARCOMA SURVIVORS. and UNDERSTANDING THE EXPERIENCES OF PATIENTS RETURNING TO DAILY ACTIVITES AND EXERCISE FOLLOWING LIMB SPARING SURGERY FOR BONE OR SOFT TISSUE SARCOMA AROUND THE KNEE
Craig Gerrand
Favorite
(P 519) WHAT ARE THE EXPERIENCES OF GAIT, ACTIVITY LEVELS AND PHYSICAL FUNCTIONING IN PROXIMAL FEMORAL REPLACEMENT AFTER MUSCULOSKELETAL TUMORS?
Craig Gerrand
Favorite
(P 560) REAL-WORLD MONITORING OF PHYSICAL ACTIVITY USING AN ACCELEROMETER AFTER LOWER LIMB SURGERY FOR A SARCOMA.
Craig Gerrand
Favorite
(P 561) EXPERIENCE OF PHYSICAL DISABILITIES AND CANCER-RELATED QUALITY OF LIFE AFTER SPINAL TUMORS- STUDY OF A NATIONAL SURVEY IN ENGLAND.
Craig Gerrand
Favorite
(P 563) BALANCE, GAIT AND BIOMECHANICAL COMPENSATIONS DURING DIFFERENT SPEEDS OF WALKING AFTER TREATMENT FOR DISTAL FEMORAL MUSCULOSKELETAL TUMOURS AND ASSOCIATED LIMITATIONS ON RETURN TO NORMAL LIVING
Craig Gerrand
Favorite
Gerstle, J

Memorial Sloan Kettering Cancer Center
(P 108) EFFECT OF TUMOUR-TARGETED HYPERTHERMIA AND CHEMOTHERAPY ON THE IMMUNE PROFILE OF A MURINE MODEL OF EMBRYONAL RHABDOMYOSARCOMA
J Gerstle
Favorite
Gervais, Mai-Kim

Hôpital Maisonneuve-Rosemont
(P 245) IN VIVO USE OF RAMAN SPECTROSCOPY IN SOFT TISSUE SARCOMA RESECTION
Mai-Kim Gervais
Favorite
Gestraud, Pierre

Institut Curie
(P 395) TARGETING CD44-MEDIATED IRON ENDOCYTOSIS IN DESMOID FIBROMATOSIS
Pierre Gestraud
Favorite
Geurts, Jennifer

Medical College of Wisconsin
(P 346) DETECTION OF GERMLINE VARIANTS IN PATIENTS DIAGNOSED WITH SOFT TISSUE SARCOMA USING EXPANDED
Jennifer Geurts
Favorite
Ghadimi, Michael

Department of General, Visceral and Pediatric Surgery, University Medical Center Goettingen, 37075 Goettingen, Germany
(P 235) FUSION OF PREOPERATIVE IN SITU MAGNETIC RESONANCE IMAGING AND POSTOPERATIVE COMPUTED TOMOGRAPHY TO CORRELATE FUNCTIONAL IMAGING FEATURES AND PATHOLOGICAL CHARACTERISTICS OF SOFT TISSUE SARCOMA
Michael Ghadimi
Favorite
Ghani, Saeed

Helios Klinikum Berlin-Buch and Medical School Berlin
(P 530) FIH PHASE I STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND ANTITUMOR ACTIVITY OF THE001 COMBINED WITH REGIONAL HYPERTHERMIA IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOFT TISSUE SARCOMA
Saeed Ghani
Favorite
Ghosh, Kanishka

The Newcastle upon Tyne Hospitals NHS Foundation Trust
(P 228) WHAT IS THE SIGNIFICANCE OF INDETERMINATE PULMONARY NODULES IN HIGH GRADE SOFT TISSUE SARCOMA? A RETROSPECTIVE COHORT STUDY
Kanishka Ghosh
Favorite
Giani, Claudia

Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
(P 159) IN BETWEEN OF LYMPHOMAS AND SARCOMAS: WHERE DO HISTIOCYTIC AND DENDRITIC CELL NEOPLASMS (HDCN) STAND? A RETROSPECTIVE, MULTI-INSTITUTIONAL STUDY FROM THE ITALIAN SARCOMA GROUP (ISG)
Claudia Giani
Favorite
(P 189) INTERNATIONAL RETROSPECTIVE STUDY FROM THE ULTRA-RARE SARCOMA WORKING GROUP ON LOW-GRADE FIBROMYXOID SARCOMA AND SCLEROSING EPITHELIOD FIBROSARCOMA: OUTCOME OF ADVANCED DISEASE AND SYSTEMIC THERAPIES
Claudia Giani
Favorite
Gianolio, Diego

Servier Pharmaceuticals
(P 66) PHASE I STUDY OF THE MUTANT IDH1 INHIBITOR IVOSIDENIB: LONG-TERM SAFETY AND CLINICAL ACTIVITY IN PATIENTS WITH CONVENTIONAL CHONDROSARCOMA
Diego Gianolio
Favorite
Giaquinta, Stefania

IRCCS Azienda Ospedaliero-Universitaria di Bologna
(P 144) IMPLEMENTATION OF THE EUROPEAN CLINICAL TRIAL REGULATION: SURVEY OF THE ITALIAN SARCOMA GROUP CENTERS
Stefania Giaquinta
Favorite
Gibbs, Benjamin

KUMC
(P 446) SYNERGISTIC TARGETING OF KIF11 AND AURKA TO IMPROVE OUTCOMES FOR EWING SARCOMA
Benjamin Gibbs
Favorite
Gijsels, Stefanie

Ghent University
(P 291) DEVELOPMENT OF A LIVE TISSUE SARCOMA BIOBANK TO SUPPORT THE CREATION OF PATIENT-DERIVED TRANSLATIONAL MODELS
Stefanie Gijsels
Favorite
(P 295) ORTHOTOPIC XENOGRAFTS OF PAIRED SARCOMA PRIMARY TUMOUR, LOCAL RELAPSE AND METASTATIC SITES REVEALS PHENOTYPIC HETEROGENEITY IN A MINIMAL RESIDUAL DISEASE MODEL
Stefanie Gijsels
Favorite
(P 296) EX VIVO SARCOMA CELL CULTURES FROM PAIRED PRIMARY, LOCAL RELAPSE AND METASTATIC SITES REVEALS PHENOTYPIC HETEROGENEITY
Stefanie Gijsels
Favorite
Gillard, Bryan

Roswell Park Comprehensive Cancer Center
(P 247) HARNESSING EWING SARCOMA'S REPLICATION STRESS BY TARGETING DDK AND WEE1 IN COMBINATION
Bryan Gillard
Favorite
Gillham, Charles

St Luke's Radiation Oncology Network
(P 155) THE IMPACT OF THE ROLE OF A SARCOMA ADVANCED NURSE PRACTITIONER (ANP) BIOPSY CLINIC IN IMPROVING PATIENT ACCESS TO SARCOMA SERVICES
Charles Gillham
Favorite
(P 156) PATIENT REPORTED EXPERIENCES WITHIN THE IRISH SARCOMA GROUP
Charles Gillham
Favorite
(P 217) CONTEMPORARY TREATMENT PATTERNS AND OUTCOMES IN THE MANAGEMENT OF ANGIOSARCOMA IN IRELAND
Charles Gillham
Favorite
Gillis, Amy

Tallaght University Hospital
(P 155) THE IMPACT OF THE ROLE OF A SARCOMA ADVANCED NURSE PRACTITIONER (ANP) BIOPSY CLINIC IN IMPROVING PATIENT ACCESS TO SARCOMA SERVICES
Amy Gillis
Favorite
(P 156) PATIENT REPORTED EXPERIENCES WITHIN THE IRISH SARCOMA GROUP
Amy Gillis
Favorite
(P 217) CONTEMPORARY TREATMENT PATTERNS AND OUTCOMES IN THE MANAGEMENT OF ANGIOSARCOMA IN IRELAND
Amy Gillis
Favorite
Gill, Jonathan

The University of Texas MD Anderson Cancer Center
(P 89) GENERATION OF CHONDROCYTE-DERIVED MOUSE OSTEOSARCOMA MODELS - TRACKABLE SYSTEMS TO DELINEATE ONCOGENIC AND METASTATIC ENVENTS PRIOR TO TUMOROGENESIS
Jonathan Gill
Favorite
(P 119) EX VIVO EXPANDED TUMOR INFILTRATING LYMPHOCYTES FOR SARCOMA TREATMENT
Jonathan Gill
Favorite
(P 203) PRECLINICAL EVALUATION AMG 650, A SMALL MOLECULE INHIBITOR OF KIF18A, IN PEDIATRIC SOLID TUMORS BY THE PEDIATRIC PRECLINICAL IN VIVO TESTING (PIVOT) PROGRAM
Jonathan Gill
Favorite
Gingrich, Alicia

Department of Surgical Oncology, MD Anderson Cancer Center
(P 394) LEIOMYOSARCOMA INTRATUMORAL MACROPHAGE INFILTRATES ARE ASSOCIATED WITH DISTINCT CLINICAL AND GENOMIC PRESENTATIONS
Alicia Gingrich
Favorite
Giordano, Giorgia

Candiolo Cancer Institute IRCCS FPO
(P 262) ESTABLISHMENT AND CHARACTERIZATION OF THE FIRST RADIATION-INDUCED, PATIENT-DERIVED ANGIOSARCOMA CELL LINE
Giorgia Giordano
Favorite
Giordano, Laura

Humanitas Research Hospital
(P 433) A 20-YEAR MONOCENTER EXPERIENCE ON CLINICAL CHARACTERISTICS AND OUTCOME OF EXTRASKELETAL EWING SARCOMA.
Laura Giordano
Favorite
Girgis, Marian

Henry Ford Hospital, Henry Ford Cancer Institute
(P 543) MANEUVER STUDY: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF PIMICOTINIB (ABSK021) TO ASSESS THE EFFICACY AND SAFETY IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR
Marian Girgis
Favorite
Gitelis, Steven

Rush University Medical Center
(P 63) EVALUATION OF LOCAL RECURRENCE AND DIAGNOSTIC DISCORDANCE IN CHONDROSARCOMA PATIENTS UNDERGOING PREOPERATIVE BIOPSY
Steven Gitelis
Favorite
(P 468) OPIATE USE AFTER TOTAL HIP ARTHROPLASTY FOR METASTATIC BONE DISEASE
Steven Gitelis
Favorite
(P 506) THE EFFECT OF TIMING BETWEEN PRE-OPERATIVE EMBOLIZATION AND SURGERY: A RETROSPECTIVE ANALYSIS OF HYPERVASCULAR BONE METASTASES
Steven Gitelis
Favorite
Gladdy, Rebecca

Mount Sinai Hospital, Sinai Health System, and Princess Margaret Cancer Centre Toronto, ON, Canada Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, ON, Canada University of Toronto, Toronto, ON
(P 50) CHARACTERIZATION OF A FAMILIAL GIST KINDRED INTOLERANT TO IMATINIB
Rebecca Gladdy
Favorite
(P 108) EFFECT OF TUMOUR-TARGETED HYPERTHERMIA AND CHEMOTHERAPY ON THE IMMUNE PROFILE OF A MURINE MODEL OF EMBRYONAL RHABDOMYOSARCOMA
Rebecca Gladdy
Favorite
(P 249) INVESTIGATING CLINICAL FACTORS ASSOCIATED WITH THE ESTABLISHMENT OF SUCCESSFUL PRIMARY HUMAN SOFT TISSUE SARCOMA CELL LINES
Rebecca Gladdy
Favorite
(P 260) TARGETING HOMOLOGOUS RECOMBINATION DEFICIENCY (HRD) IN LEIOMYOSARCOMA WITH COMBINATION OF PARP INHIBITORS (PARPI) AND CHEMOTHERAPY (CTX).
Rebecca Gladdy
Favorite
(P 265) SELECTIVE TARGETING OF BET FAMILY EPIGENETIC REGULATORS IN ADVANCED AND METASTATIC ALVEOLAR RHABDOMYOSARCOMA
Rebecca Gladdy
Favorite
(P 342) THE EVALUATION AND OUTCOMES OF MESENTERIC AND INTRA-ABDOMINAL DESMOIDS: A TARPSWG STUDY
Rebecca Gladdy
Favorite
(P 367) CHARACTERIZING HYPOXIA AND ASSOCIATED MOLECULAR FEATURES IN EXTREMITY SOFT TISSUE SARCOMA
Rebecca Gladdy
Favorite
(P 421) USING TRANSCRIPTOMICS TO IDENTIFY LEIOMYOSARCOMA PATIENTS AT RISK OF METASTASIS
Rebecca Gladdy
Favorite
Glade Bender, Julia

Memorial Sloan Kettering Cancer Center
(P 68) METASTASIS-DIRECTED RADIOTHERAPY FOR EWING SARCOMA PATIENTS ENROLLED ON AEWS1221: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP (COG)
Julia Glade Bender
Favorite
Glaspell, Andrea

Nationwide Children's Hospital
(P 107) TRABECTEDIN AUGMENTS ONCOLYTIC HERPES SIMPLEX VIROIMMUNOTHERAPY EFFICACY IN PRECLINCAL BONE SARCOMA MODELS THROUGH ENHANCED IMMUNE-MEDIATED MECHANISMS
Andrea Glaspell
Favorite
(P 125) MYELOMODULATORY TREATMENTS AUGMENT THE THERAPEUTIC BENEFIT OF ONCOLYTIC VIRUS IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS BY MODULATING THE TUMOR MICROENVIRONMENT
Andrea Glaspell
Favorite
Glimm, Hanno

Translational Medical Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden
(P 248) FIBROBLAST ACTIVATION PROTEIN ALPHA -DIRECTED IMAGING AND THERAPY OF SOLITARY FIBROUS TUMOR
Hanno Glimm
Favorite
Gliser, Camelia

Servier Pharmaceuticals
(P 66) PHASE I STUDY OF THE MUTANT IDH1 INHIBITOR IVOSIDENIB: LONG-TERM SAFETY AND CLINICAL ACTIVITY IN PATIENTS WITH CONVENTIONAL CHONDROSARCOMA
Camelia Gliser
Favorite
Glod, John

Center for Cancer Research/National Cancer Institute
(P 28) RETROSPECTIVE ANALYSIS OF SUCCINATE DEHYDROGENASE (SDH)-DEFICIENT GASTROINTESTINAL STROMAL TUMOR (GIST) OUTCOMES: AN INTERNATIONAL STUDY OF 256 PATIENTS
John Glod
Favorite
Goble, Sandra

SpringWorks Therapeutics Inc
(P 146) CHARACTERIZING THE PATIENT JOURNEY TO A DIAGNOSIS OF DESMOID TUMOR: DESMOID TUMOR RESEARCH FOUNDATION NATURAL HISTORY STUDY
Sandra Goble
Favorite
(P 188) IMPACT OF NIROGACESTAT ON FUNCTIONAL STATUS IN PATIENTS WITH DESMOID TUMORS: RESULTS FROM THE PHASE 3 DEFI STUDY
Sandra Goble
Favorite
Goddard, Karen

BC Cancer
(P 22) RECALL EXPERIENCE FOR SURVIVORS OF PEDIATRIC RHABDOMYOSARCOMA TREATED AT A SINGLE INSTITUTION BETWEEN 1970 AND 2010
Karen Goddard
Favorite
Goddu, Sreekrishna

Washington University in St Louis
(P 187) PALLIATIVE LATTICE STEREOTACTIC BODY RADIOTHERAPY FOR PATIENTS WITH SARCOMA
Sreekrishna Goddu
Favorite
Godwin, Andrew

KUMC
(P 446) SYNERGISTIC TARGETING OF KIF11 AND AURKA TO IMPROVE OUTCOMES FOR EWING SARCOMA
Andrew Godwin
Favorite
Goel, Neha

Miami University
(P 342) THE EVALUATION AND OUTCOMES OF MESENTERIC AND INTRA-ABDOMINAL DESMOIDS: A TARPSWG STUDY
Neha Goel
Favorite
Goggin, Caitriona

University Hospital Waterford
(P 213) EXPERIENCE WITH THE USE OF TRABECTEDIN IN ADVANCED SOFT TISSUE SARCOMA IN IRELAND
Caitriona Goggin
Favorite
Gogineni, Emile

The Ohio State University Wexner Medical Center
(P 315) SCALP VOLUMETRIC MODULATED ARC THERAPY USING 3D MILLED BOLUS: DOSIMITRY, TOXICITY AND OUTCOMES
Emile Gogineni
Favorite
(P 559) PROSPECTIVE PHASE II TRIAL OF PREOPERATIVE HYPOFRACTIONATED PROTON THERAPY FOR EXTREMITY AND TRUNCAL AND TRUNCAL SOFT TISSUE SARCOMA: THE PRONTO STUDY RATIONALE AND DESIGN
Emile Gogineni
Favorite
Gokgoz, Nalan

The Lunenfeld-Tanenbaum Research Institute
(P 249) INVESTIGATING CLINICAL FACTORS ASSOCIATED WITH THE ESTABLISHMENT OF SUCCESSFUL PRIMARY HUMAN SOFT TISSUE SARCOMA CELL LINES
Nalan Gokgoz
Favorite
(P 352) DETERMINING THE CONTRIBUTIONS OF STAT1 TO THE UPS ANTI-TUMOR MICROENVIRONMENT
Nalan Gokgoz
Favorite
Goldberg, Saveli

Massachusetts General Hospital
(P 338) PREOPERATIVE RADIATION THERAPY IS NOT ASSOCIATED WITH ADVERSE POSTOPERATIVE OUTCOMES IN PATIENTS WITH RETROPERITONEAL SARCOMA
Saveli Goldberg
Favorite
Goldenberg, Anna

Sickkids Research Institute
(P 50) CHARACTERIZATION OF A FAMILIAL GIST KINDRED INTOLERANT TO IMATINIB
Anna Goldenberg
Favorite
Golja, Bernd

Department of Orthopaedics and Trauma, Medical University of Graz
(P 458) FREQUENCY IN CHANGE OF GRADING UPON LOCAL RECURRENCE OR DISTANT METASTASIS OF SOFT TISSUE SARCOMAS.
Bernd Golja
Favorite
Gomez, Javier

MD Anderson Cancer Center
(P 426) MULTI-OMIC ANALYSIS OF DESMOPLASTIC SMALL ROUND CELL TUMORS REVEAL DISTINCT LINEAGES
Javier Gomez
Favorite
Gomez-Mascard, Anne

Institut Universitaire du Cancer de Toulouse
(P 201) PLEOMORPHIC RHABDOMYOSARCOMAS: A NEW ENTITY ASSOCIATED WITH LYNCH SYNDROME? FIRST RESULTS OF SARCLYNCH NATIONAL STUDY
Anne Gomez-Mascard
Favorite
(P 389) OSTEOBLASTIC-GENE SIGNATURE TO PREDICT SURVIVAL IN PEDIATRIC OSTEOSARCOMA (OS) AND TO FOLLOW PATIENTS TOWARDS LIQUID BIOPSY: A COLLABORATIVE WORK IN OS2006 PROTOCOL.
Anne Gomez-Mascard
Favorite
Gondi, Vinai

Northwestern Memorial Hospital
(P 219) ELECTIVE DISCONTINUATION OF SORAFENIB TREATMENT IN DESMOID TUMORS: A RETROSPECTIVE ANALYSIS WITH IMPLICATIONS FOR CLINICAL PRACTICE
Vinai Gondi
Favorite
Gong, Matthew

University of Pittsburgh
(P 244) A DEEP FEW-SHOT META-LEARNING STRATEGY FOR AUTONOMOUS CLASSIFICATION OF BONE METASTASIS IN RADIONUCLIDE BONE SCANS
Matthew Gong
Favorite
(P 351) TARGETING ANDROGEN RECEPTOR IN OSTEOSARCOMA CELLS WITH VARYING METASTATIC POTENTIAL
Matthew Gong
Favorite
(P 466) INTRAOPERATIVE EVALUATION OF BONE AND SOFT TISSUE SARCOMA SURGICAL MARGINS WITH INDOCYANINE GREEN FLUORESCENCE IMAGING
Matthew Gong
Favorite
(P 544) INTRAOPERATIVE EVALUATION OF BONE AND SOFT TISSUE SARCOMA SURGICAL MARGINS WITH INDOCYANINE GREEN FLUORESCENCE IMAGING
Matthew Gong
Favorite
González Casaurrán, Guillermo

Thoracic Surgery Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain
(P 517) PULMONARY METASTASECTOMY FOR SARCOMA: A SINGLE-INSTITUTION EXPERIENCE
Guillermo González Casaurrán
Favorite
Gonzalez-Billalabeitia, Enrique

HU Doce de Octubre
(P 113) IMMUNOSARC II: A SPANISH SARCOMA GROUP (GEIS) PHASE IB TRIAL OF DOXORUBICIN AND DACARBAZINE PLUS NIVOLUMAB IN FIRST LINE OF ADVANCED LEIOMYOSARCOMA
Enrique Gonzalez-Billalabeitia
Favorite
Gonzalez, José Antonio

Department of Surgery, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
(P 313) SPACIALLY-FRACTIONATED RADIOTHERAPY (LATTICE) TREATMENT IN INOPERABLE NON-EXTREMITY BULKY SOFT-TISSUE SARCOMAS
José Antonio Gonzalez
Favorite
(P 385) FIRST IN HUMAN PHASE I TRIAL OF A NOVEL DRUG DELIVERY IMPLANT MATRIX WITH SN-38 (CEB-01) FOR RETROPERITONEAL SOFT TISSUE SARCOMA
José Antonio Gonzalez
Favorite
(P 503) SCAPULAR PROSTHESIS RECONSTRUCTION, EXPERIENCE IN OUR INSTITUTION
José Antonio Gonzalez
Favorite
(P 504) WHY DO SOME PATIENTS WITH SYNOVIAL SARCOMA HAVE BETTER FUNCTIONAL OUTCOMES AFTER RESECTION SURGERY? ANALYSIS OF 102 CASES
José Antonio Gonzalez
Favorite
(P 507) PRIMARY CHEST WALL TUMORS OF MESENCHYMAL ORIGIN. EXPERIENCE OF A REFERENCE UNIT
José Antonio Gonzalez
Favorite
(P 508) DREAM, UTOPIA OR REALISM? PROGNOSTIC FACTORS IN LUNG METASTASECTOMY OF DISSEMINATED SARCOMA DISEASE
José Antonio Gonzalez
Favorite
Gonzalez-Vaughn, Barbara

Sarkomer
(P 90) RESULTS FROM AN INTERNATIONAL SURVEY OF BONE SARCOMA PATIENTS
Barbara Gonzalez-Vaughn
Favorite
Gonzato, Ornella

Fondazione Paola Gonzato- Rete Sarcoma ETS
(P 90) RESULTS FROM AN INTERNATIONAL SURVEY OF BONE SARCOMA PATIENTS
Ornella Gonzato
Favorite
Gonzato, Ornella

Sarcoma Patient Advocacy Global Network Assoc. (SPAGN)
(P 136) SETTING THE INTERNATIONAL RESEARCH AGENDA FOR SARCOMA WITH PATIENTS AND CARERS: PRELIMINARY RESULTS OF PHASE II OF THE SARCOMA PATIENT ADVOCACY GLOBAL NETWORK (SPAGN) PRIORITY SETTING PARTNERSHIP
Ornella Gonzato
Favorite
Good, Logan

The Ohio State University
(P 501) TIBIAL DEFORMITIES AND PHYSEAL INJURY WITH DISTAL FEMORAL EXPANDABLE ENDOPROSTHESIS IMPLANTS
Logan Good
Favorite
Googe, Paul

University of North Carolina
(P 207) A MULTICENTER PHASE II STUDY OF CABOZANTINIB PLUS NIVOLUMAB FOR PATIENTS WITH ADVANCED ANGIOSARCOMA PREVIOUSLY TREATED WITH A TAXANE: ALLIANCE A091902
Paul Googe
Favorite
Gopalakrishnan, Vidya

The University of Texas MD Anderson Cancer Center
(P 101) EPIGENETIC MODULATION OF NK CELLS IMPROVES TUMOR TRAFFICKING AND ENHANCES THERAPEUTIC EFFICACY AGAINST OSTEOSARCOMA
Vidya Gopalakrishnan
Favorite
(P 119) EX VIVO EXPANDED TUMOR INFILTRATING LYMPHOCYTES FOR SARCOMA TREATMENT
Vidya Gopalakrishnan
Favorite
(P 122) TARGETING CD70 USING CAR NK CELLS TO ENHANCE NK CELLS CYTOLYTIC EFFECT AGAINST OSTEOSARCOMA
Vidya Gopalakrishnan
Favorite
Gordon, Brittney

St. Jude Children's Research Hospital
(P 288) EVALUATION OF ATR AND WEE1 INHIBITORS COMBINED WITH NANO-LIPOSOMAL IRINOTECAN IN A LARGE COHORT OF RHABDOMYOSARCOMA XENOGRAFTS USING A TWIN MOUSE PRECLINICAL TRIAL DESIGN
Brittney Gordon
Favorite
(P 303) PRECLINICAL EVALUATION OF PARP1 SELECTIVE INHIBITOR AZD5305 IN COMBINATION WITH DNA DAMAGING AGENTS IN EWING SARCOMA ORTHOTOPIC XENOGRAFT MODELS
Brittney Gordon
Favorite
Gordon, Erlinda

Sarcoma Oncology Research Center
(P 111) INTERIM ANALYSIS OF A PHASE 1 STUDY USING IL12-FHAB WITH OPTIMIZED PHARMACOKINETICS
Erlinda Gordon
Favorite
(P 116) UPDATE ON SAINT: RESULTS OF 100 PATIENTS TREATED WITH IPILIMUMAB (I), NIVOLUMAB (N) AND TRABECTEDIN (T) AS FIRST LINE THERAPY FOR ADVANCED SOFT TISSUE SARCOMA [NCT03138161]
Erlinda Gordon
Favorite
(P 117) INTERIM ANALYSIS OF PHASE 2 STUDY: A METRONOMIC REGIMEN USING GEMCITABINE, DOXORUBICIN, DOCETAXEL AND NIVOLUMAB FOR ADVANCED LEIOMYOSARCOMA (NCT04535713)
Erlinda Gordon
Favorite
(P 184) PHASE 1B TRIAL OF CAMSIRUBICIN, A NOVEL DOXORUBICIN ANALOG, WITH CONCOMITANT PEGFILGRASTIM IN SUBJECTS WITH ADVANCED SOFT TISSUE SARCOMA TO IDENTIFY A NEW MTD/RP2D
Erlinda Gordon
Favorite
(P 383) AI ANALYSIS SHOWS ENHANCED CCNG1 ONCOGENE EXPRESSION IN SARCOMA TUMORS AND SUPPORTS THE USE OF DELTAREX-G, A CCNG1 INHIBITOR, AS PLATFORM THERAPY FOR ADVANCED SARCOMA
Erlinda Gordon
Favorite
(P 540) PHASE 2, MULTICENTER, OPEN-LABEL BASKET TRIAL OF NAB-SIROLIMUS FOR MALIGNANT SOLID TUMORS HARBORING PATHOGENIC INACTIVATING ALTERATIONS IN TSC1 AND TSC2 (PRECISION I)
Erlinda Gordon
Favorite
(P 553) A PHASE 1/2A OPEN-LABEL, DOSE-ESCALATION/DOSE EXPANSION SAFETY, TOLERABILITY AND PHARMACOKINETIC STUDY OF IMX-110 IN PATIENTS WITH ADVANCED SOLID TUMORS
Erlinda Gordon
Favorite
Gordon, Gary

Ayala Pharmaceuticals
(P 172) PHASE 2 RESULTS FROM THE RINGSIDE PHASE 2/3 TRIAL OF AL102 FOR TREATMENT OF DESMOID TUMORS
Gary Gordon
Favorite
(P 549) DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF AL102 FOR TREATMENT OF PROGRESSING DESMOID TUMORS: THE RINGSIDE PHASE 3 STUDY DESIGN
Gary Gordon
Favorite
Gordon, Nancy

The University of Texas MD Anderson Cancer Center
(P 101) EPIGENETIC MODULATION OF NK CELLS IMPROVES TUMOR TRAFFICKING AND ENHANCES THERAPEUTIC EFFICACY AGAINST OSTEOSARCOMA
Nancy Gordon
Favorite
(P 119) EX VIVO EXPANDED TUMOR INFILTRATING LYMPHOCYTES FOR SARCOMA TREATMENT
Nancy Gordon
Favorite
(P 122) TARGETING CD70 USING CAR NK CELLS TO ENHANCE NK CELLS CYTOLYTIC EFFECT AGAINST OSTEOSARCOMA
Nancy Gordon
Favorite
(P 532) MISTOSUS: A PHASE 2 STUDY OF ISCADOR® P IMMUNOTHERAPY FOR PATIENTS WITH RELAPSED OSTEOSARCOMA AND RESECTED PULMONARY METASTASES
Nancy Gordon
Favorite
Gore, Lia

University of Colorado Cancer Center
(P 66) PHASE I STUDY OF THE MUTANT IDH1 INHIBITOR IVOSIDENIB: LONG-TERM SAFETY AND CLINICAL ACTIVITY IN PATIENTS WITH CONVENTIONAL CHONDROSARCOMA
Lia Gore
Favorite
Gore, Steven

National Institutes of Health/National Cancer Institute
(P 541) ETCTN 10563: PHASE 1 STUDY OF PEPOSERTIB AND LIPOSOMAL DOXORUBICIN FOR ADVANCED OR METASTATIC LEIOMYOSARCOMA AND OTHER SARCOMAS
Steven Gore
Favorite
Gorgels, Daniël

Laboratory of Experimental Oncology, KU Leuven, Leuven Cancer Institute
(P 43) UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR-ASSOCIATED PROTEIN AS A POTENTIAL NEXT GENERATION MOLECULAR TARGET FOR TREATMENT OF GASTROINTESTINAL STROMAL TUMOR
Daniël Gorgels
Favorite
Gorlick, Richard

The University of Texas MD Anderson Cancer Center
(P 68) METASTASIS-DIRECTED RADIOTHERAPY FOR EWING SARCOMA PATIENTS ENROLLED ON AEWS1221: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP (COG)
Richard Gorlick
Favorite
(P 71) CHEMOTHERAPY AND PROGNOSTIC SIGNIFICANCE OF EXTENT OF DEDIFFERENTIATION IN DEDIFFERENTIATED PAROSTEAL OSTEOSARCOMA
Richard Gorlick
Favorite
(P 89) GENERATION OF CHONDROCYTE-DERIVED MOUSE OSTEOSARCOMA MODELS - TRACKABLE SYSTEMS TO DELINEATE ONCOGENIC AND METASTATIC ENVENTS PRIOR TO TUMOROGENESIS
Richard Gorlick
Favorite
(P 119) EX VIVO EXPANDED TUMOR INFILTRATING LYMPHOCYTES FOR SARCOMA TREATMENT
Richard Gorlick
Favorite
(P 122) TARGETING CD70 USING CAR NK CELLS TO ENHANCE NK CELLS CYTOLYTIC EFFECT AGAINST OSTEOSARCOMA
Richard Gorlick
Favorite
(P 203) PRECLINICAL EVALUATION AMG 650, A SMALL MOLECULE INHIBITOR OF KIF18A, IN PEDIATRIC SOLID TUMORS BY THE PEDIATRIC PRECLINICAL IN VIVO TESTING (PIVOT) PROGRAM
Richard Gorlick
Favorite
Gortzak, Yair

Tel Aviv Medical Center, Tel Aviv, Israel
(P 240) IDENTIFYING PATIENTS AT HIGH RISK OF HIP FRACTURE DUE TO BONE TUMORS BY COMPUTATIONAL BIOMECHANICS: A RANDOMIZED PROSPECTIVE CLINICAL STUDY
Yair Gortzak
Favorite
(P 319) HYPO-FRACTIONATED RADIATION THERAPY FOR THE EXTREMITY SOFT TISSUE SARCOM IN ELDERLY AND DISABLED.
Yair Gortzak
Favorite
Gorunova, Ludmila

Oslo University Hospital
(P 23) GENOMIC COMPLEXITY AS A BIOMARKER FOR ADJUVANT IMATINIB TREATMENT IN HIGH-RISK GASTROINTESTINAL STROMAL TUMOR
Ludmila Gorunova
Favorite
Goryunova, Marina

The Ohio State University Comprehensive Cancer Center
(P 301) REDUCING THE INVASIVE POTENTIAL OF DEDIFFERENTIATED LIPOSARCOMA BY TARGETING ALTERNATIVE RNA SPLICING MACHINERY
Marina Goryunova
Favorite
Gothra, Angad

Washington University in St. Louis
(P 274) TYK2 AND MEK COMBINATION THERAPY IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS AND OTHER SOFT TISSUE SARCOMAS
Angad Gothra
Favorite
Goulding, Krista

Mayo Clinic Arizona
(P 141) TREATMENT VARIABILITY IN SURGICAL MANAGEMENT OF PULMONARY OLIGOMETASTATIC SOFT TISSUE SARCOMA
Krista Goulding
Favorite
Gounder, Mrinal

Memorial Sloan Kettering Cancer Center
(P 24) COMPREHENSIVE ANALYSIS OF THE GENOMIC LANDSCAPE AND CLINICAL BEHAVIOR IN GIST USING NEXT GENERATION SEQUENCING (NGS, MSK-IMPACT)
Mrinal Gounder
Favorite
(P 172) PHASE 2 RESULTS FROM THE RINGSIDE PHASE 2/3 TRIAL OF AL102 FOR TREATMENT OF DESMOID TUMORS
Mrinal Gounder
Favorite
(P 185) LONGITUDINAL MUTATIONAL ANALYSIS OF TP53 IN CIRCULATING TUMOR DNA IN THE PLASMA OF PATIENTS WITH LIPOSARCOMA IN A PHASE I STUDY OF BRIGIMADLIN (BI 907828), AN MDM2-P53 ANTAGONIST
Mrinal Gounder
Favorite
(P 188) IMPACT OF NIROGACESTAT ON FUNCTIONAL STATUS IN PATIENTS WITH DESMOID TUMORS: RESULTS FROM THE PHASE 3 DEFI STUDY
Mrinal Gounder
Favorite
(P 408) CHANGES IN COMPUTED TOMOGRAPHY FEATURES INDUCED BY BRIGIMADLIN (BI 907828) IN PATIENTS WITH LIPOSARCOMA: INSIGHTS FROM PHASE I STUDIES
Mrinal Gounder
Favorite
(P 549) DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF AL102 FOR TREATMENT OF PROGRESSING DESMOID TUMORS: THE RINGSIDE PHASE 3 STUDY DESIGN
Mrinal Gounder
Favorite
Grützmann, Robert

Department of General and Visceral Surgery, University Hospital, Friedrich-Alexander- University Erlangen-Nuremberg, 91054 Erlangen, Germany
(P 133) TEN RECOMMENDATIONTS FOR SARCOMA SURGERY: CONSENSUS OF THE SURGICAL SOCIETIES BASED ON THE GERMAN S3 GUIDELINE "ADULT SOFT TISSUE SARCOMA"
Robert Grützmann
Favorite
(P 557) UNRAVELING THE ROLE OF LOCAL THERAPY FOR PATIENTS WITH OLIGOMETASTATIC SOFT TISSUE SARCOMA - A RETROSPECTIVE MULTICENTER TRIAL OF BAVARIAN UNIVERSITY HOSPITALS
Robert Grützmann
Favorite
Gracia Alegria, Isidro

Hospital de la Santa Creu i Sant Pau
(P 503) SCAPULAR PROSTHESIS RECONSTRUCTION, EXPERIENCE IN OUR INSTITUTION
Isidro Gracia Alegria
Favorite
(P 504) WHY DO SOME PATIENTS WITH SYNOVIAL SARCOMA HAVE BETTER FUNCTIONAL OUTCOMES AFTER RESECTION SURGERY? ANALYSIS OF 102 CASES
Isidro Gracia Alegria
Favorite
(P 507) PRIMARY CHEST WALL TUMORS OF MESENCHYMAL ORIGIN. EXPERIENCE OF A REFERENCE UNIT
Isidro Gracia Alegria
Favorite
(P 508) DREAM, UTOPIA OR REALISM? PROGNOSTIC FACTORS IN LUNG METASTASECTOMY OF DISSEMINATED SARCOMA DISEASE
Isidro Gracia Alegria
Favorite
Graeter, Thomas

SLK-Lungenklinik Lowenstein
(P 133) TEN RECOMMENDATIONTS FOR SARCOMA SURGERY: CONSENSUS OF THE SURGICAL SOCIETIES BASED ON THE GERMAN S3 GUIDELINE "ADULT SOFT TISSUE SARCOMA"
Thomas Graeter
Favorite
Graham, Peter

University of Saskatchewan
(P 148) MOVING TOWARDS THE OPTIMIZATION OF DIAGNOSIS FOR PATIENTS WITH SARCOMA: A 10-YEAR REVIEW OF EXTERNALLY CONSULTED SARCOMA CASES IN A GENERAL ANATOMICAL PATHOLOGY SERVICE
Peter Graham
Favorite
Granato, annamaria

IRST
(P 533) SAFETY AND PRELIMINARY BIOLOGICAL ACTIVITY OF A PHASE II TRIAL OF AUTOLOGOUS DENDRITIC CELLS VACCINATION IN SARCOMAS.
annamaria Granato
Favorite
Grassani, Teresa

Fondazione Policlinico Universitario Campus Bio-Medico di Roma
(P 144) IMPLEMENTATION OF THE EUROPEAN CLINICAL TRIAL REGULATION: SURVEY OF THE ITALIAN SARCOMA GROUP CENTERS
Teresa Grassani
Favorite
Grassauer, Jacob

Oregon Health & Science University
(P 462) EXTERNAL VALIDATION OF A NOMOGRAM PREDICTING THE RISK OF POSTOPERATIVE MAJOR WOUND COMPLICATION IN SOFT TISSUE SARCOMA FOLLOWING PREOPERATIVE RADIOTHERAPY AND RESECTION
Jacob Grassauer
Favorite
(P 463) MACHINE LEARNING CORROBORATES TRADITIONAL REGRESSION TECHNIQUES IN PREDICTING MAJOR WOUND COMPLICATIONS AFTER SOFT TISSUE SARCOMA RESECTION WITHOUT IMPROVEMENTS IN PREDICTIVE PERFORMANCE
Jacob Grassauer
Favorite
Gravino, Lucia

AOUP Azienda Ospedaliera Universitaria Pisana
(P 144) IMPLEMENTATION OF THE EUROPEAN CLINICAL TRIAL REGULATION: SURVEY OF THE ITALIAN SARCOMA GROUP CENTERS
Lucia Gravino
Favorite
Gray, Emma

University of Birmingham
(P 282) AN EMBRYONIC ZEBRAFISH XENOGRAFT MODEL OF RHABDOMYOSARCOMA REVEALS GENOTYPE DEPENDENT TUMOUR VASCULARISATION DYNAMICS AND RESPONSE TO ANTI-ANGIOGENIC RECEPTOR TYROSINE KINASE INHIBITORS
Emma Gray
Favorite
Gray, Gill

Norfolk and Norwich University Hospitals NHS Foundation Trust
(P 205) PRIMARY CARDIAC SARCOMA: A RETROSPECTIVE ANALYSIS OF PRESENTATION, MANAGEMENT AND OUTCOMES
Gill Gray
Favorite
Greco, Stephanie

Fox Chase Cancer Center
(P 152) EVALUATING DIAGNOSTIC APPROACHES TO DERMATOFIBROSARCOMA PROTUBERANS: AN OPPORTUNITY TO REDUCE THE NUMBER OF INTERVENTIONS
Stephanie Greco
Favorite
(P 342) THE EVALUATION AND OUTCOMES OF MESENTERIC AND INTRA-ABDOMINAL DESMOIDS: A TARPSWG STUDY
Stephanie Greco
Favorite
Grecula, John

Ohio State University Wexner Medical Center
(P 315) SCALP VOLUMETRIC MODULATED ARC THERAPY USING 3D MILLED BOLUS: DOSIMITRY, TOXICITY AND OUTCOMES
John Grecula
Favorite
Greenberg, Jonathan

Daiichi Sankyo, Inc.
(P 168) A PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF PEXIDARTINIB IN ASIAN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR
Jonathan Greenberg
Favorite
Green, William

Houston Methodist Hospital
(P 354) ROLE OF APPARENT DIFFUSION COEFFICIENT (ADC) MAP-BASED FIRST AND HIGH-ORDER RADIOMIC FEATURES IN DISCRIMINATING SACRAL CHORDOMAS AND CHONDROSARCOMAS WITH OVERLAPPING CONVENTIONAL IMAGING FEATURES
William Green
Favorite
Greto, Daniela

Radiation Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.
(P 309) CLINICAL PATHOLOGICAL CHARACTERISTICS, PATTERN OF CARE AND SURVIVAL OF NON-METASTATIC BREAST ANGIOSARCOMA
Daniela Greto
Favorite
(P 317) PROGNOSTIC FACTORS, CLINICAL AND TOXICITY OUTCOMES FROM A LARGE COHORT OF PATIENTS WITH SOFT TISSUE SARCOMA TREATED WITH PREOPERATIVE RADIATION THERAPY
Daniela Greto
Favorite
(P 546) PRELIMINARY CLINICAL RESULTS OF AN ONGOING PHASE II TRIAL: SPRINT (SARCOMA PREOPERATIVE RADIATION WITH SIMULTANEOUS INTEGRATED BOOST)
Daniela Greto
Favorite
Griffin, Anthony

Mount Sinai Hospital
(P 53) CURATIVE-INTENT SURGERY FOR A SOLITARY ISOLATED BONE METASTASIS FROM EXTREMITY SARCOMA: WHO UNDERWENT METASTASECTOMY AND WHAT WAS THE PROGNOSTIC OUTCOME?
Anthony Griffin
Favorite
(P 77) PATIENT OUTCOMES AFTER OPEN VERSUS CORE NEEDLE BIOPSY IN LOWER EXTREMITY SARCOMA
Anthony Griffin
Favorite
(P 249) INVESTIGATING CLINICAL FACTORS ASSOCIATED WITH THE ESTABLISHMENT OF SUCCESSFUL PRIMARY HUMAN SOFT TISSUE SARCOMA CELL LINES
Anthony Griffin
Favorite
(P 443) SURGICAL RESECTION OF EXTREMITY EWING'S SARCOMA BASED ON POST-CHEMOTHERAPY TUMOUR VOLUME RESULTS IN SAFE MARGINS
Anthony Griffin
Favorite
(P 483) DID THE COVID-19 PANDEMIC NEGATIVELY AFFECT OUTCOMES FOR PATIENTS WITH EXTREMITY SOFT TISSUE SARCOMAS?
Anthony Griffin
Favorite
(P 484) OBESITY INCREASES THE RISK OF MAJOR WOUND COMPLICATIONS FOLLOWING PELVIC RESECTION FOR BONE SARCOMA
Anthony Griffin
Favorite
Griggs, Moreko

Radiology Partners
(P 354) ROLE OF APPARENT DIFFUSION COEFFICIENT (ADC) MAP-BASED FIRST AND HIGH-ORDER RADIOMIC FEATURES IN DISCRIMINATING SACRAL CHORDOMAS AND CHONDROSARCOMAS WITH OVERLAPPING CONVENTIONAL IMAGING FEATURES
Moreko Griggs
Favorite
Grignani, Giovanni

Candiolo Cancer Institute, FPO – IRCCS
(P 49) EFFICACY OF RIPRETINIB IN A MULTICENTER EXPANDED ACCESS PROGRAM IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS HARBOURING NON-KIT EXON 11 MUTATIONS.
Giovanni Grignani
Favorite
(P 109) INTENSE PRECLINICAL ACTIVITY BY B7H3-SPECIFIC CAR.CIK LYMPHOCYTES AGAINST EPITHELIOID SARCOMA
Giovanni Grignani
Favorite
(P 262) ESTABLISHMENT AND CHARACTERIZATION OF THE FIRST RADIATION-INDUCED, PATIENT-DERIVED ANGIOSARCOMA CELL LINE
Giovanni Grignani
Favorite
(P 437) ULTRA-RARE UNDIFFERENTIATED SMALL ROUND CELL SARCOMA: HOW SHOULD WE TREAT THEM? AN ANALYSIS FORM THE GRACEFUL PROJECT
Giovanni Grignani
Favorite
(P 455) EXTRASKELETAL EWING SARCOMA: A MULTICENTRIC RETROSPECTIVE STUDY FROM THE ITALIAN SARCOMA GROUP
Giovanni Grignani
Favorite
Grignol, Valerie

The James Cancer Hospital / The Ohio State University
(P 314) PRE-OPERATIVE RADIATION THERAPY INCREASES ADHERENCE IN PATIENTS WITH HIGH-RISK EXTREMITY SOFT TISSUE SARCOMA
Valerie Grignol
Favorite
(P 335) EXTRACELLULAR VESICLE MDM2 DNA AS A BIOMARKER OF TUMOR PRESENCE AND RECURRENCE IN RETROPERITONEAL LIPOSARCOMA
Valerie Grignol
Favorite
(P 347) INCIDENCE AND TIMING OF RECURRENCE AFTER ADJUVANT PALBOCICLIB IN COMPLETELY RESECTED RETROPERITONEAL LIPOSARCOMA
Valerie Grignol
Favorite
Grilley-Olson, Juneko

Duke University
(P 177) ANGIOSARCOMA: AN INCREASING PROBLEM IN THE UNITED STATES
Juneko Grilley-Olson
Favorite
(P 207) A MULTICENTER PHASE II STUDY OF CABOZANTINIB PLUS NIVOLUMAB FOR PATIENTS WITH ADVANCED ANGIOSARCOMA PREVIOUSLY TREATED WITH A TAXANE: ALLIANCE A091902
Juneko Grilley-Olson
Favorite
(P 543) MANEUVER STUDY: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF PIMICOTINIB (ABSK021) TO ASSESS THE EFFICACY AND SAFETY IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR
Juneko Grilley-Olson
Favorite
Grimaudo, Maria Susanna

Humanitas Research Hospital
(P 433) A 20-YEAR MONOCENTER EXPERIENCE ON CLINICAL CHARACTERISTICS AND OUTCOME OF EXTRASKELETAL EWING SARCOMA.
Maria Susanna Grimaudo
Favorite
Grimison, Peter

Chris O'Brien Lifehouse
(P 194) REAL WORLD OUTCOMES OF PATIENTS TREATED WITH GEMCITABINE AND DOCETAXEL FOR ADVANCED SOFT TISSUE SARCOMA IN AN AUSTRALIAN SARCOMA CENTRE
Peter Grimison
Favorite
(P 386) GENOMIC PROFILING OF GYNAECOLOGICAL SARCOMAS: REPORT FROM THE AUSTRALIA-WIDE PRECISION ONCOLOGY PROGRAM
Peter Grimison
Favorite
Grint, Alex

TRACON Pharmaceuticals INC.
(P 112) PHASE 1/2 STUDY OF YH001, A CTLA-4 ANTIBODY WITH THE SUBCUTANEOUSLY ADMINISTERED PD-L1 ANTIBODY ENVAFOLIMAB, WITH OR WITHOUT DOXORUBICIN IN PATIENTS WITH ADVANCED OR METASTATIC SOFT TISSUE SARCOMA
Alex Grint
Favorite
Grohar, Patrick

Children’s Hospital of Philadelphia
(P 81) OPTIMIZING EWING SARCOMA AND OSTEOSARCOMA BIOPSY ACQUISITION: CONSENSUS RECOMMENDATIONS FROM THE CHILDREN'S ONCOLOGY GROUP BONE TUMOR COMMITTEE
Patrick Grohar
Favorite
(P 439) THE TETRAVALENT DEATH RECEPTOR 5 AGONIST INBRX-109 COMBINED WITH CHEMOTHERAPY IN EWING SARCOMA: PRELIMINARY DATA FROM A PHASE 1 STUDY
Patrick Grohar
Favorite
Gronchi, Alessandro

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
(P 14) PERCUTANEOUS CRYOABLATION OF PROGRESSING EXTRA-ABDOMINAL DESMOID TUMOURS
Alessandro Gronchi
Favorite
(P 74) SACRAL CHORDOMA: A RANDOMIZED & OBSERVATIONAL STUDY ON SURGERY VS DEFINITIVE RADIOTHERAPY IN PRIMARY LOCALIZED DISEASE (SACRO). INTERIM ANALYSIS
Alessandro Gronchi
Favorite
(P 126) CURRENT PRACTICE IN SPERMATIC CORD SARCOMA: ONCOLOGICAL TIMELINES AND OUTCOMES ACCORDING TO INITIAL RESECTIONS PERFORMED AT A LOCAL HOSPITAL VERSUS EARLY PATIENT REFERRAL TO A TERTIARY CENTRE.
Alessandro Gronchi
Favorite
(P 159) IN BETWEEN OF LYMPHOMAS AND SARCOMAS: WHERE DO HISTIOCYTIC AND DENDRITIC CELL NEOPLASMS (HDCN) STAND? A RETROSPECTIVE, MULTI-INSTITUTIONAL STUDY FROM THE ITALIAN SARCOMA GROUP (ISG)
Alessandro Gronchi
Favorite
(P 189) INTERNATIONAL RETROSPECTIVE STUDY FROM THE ULTRA-RARE SARCOMA WORKING GROUP ON LOW-GRADE FIBROMYXOID SARCOMA AND SCLEROSING EPITHELIOD FIBROSARCOMA: OUTCOME OF ADVANCED DISEASE AND SYSTEMIC THERAPIES
Alessandro Gronchi
Favorite
(P 272) A COMPARATIVE ASSESSMENT OF SELINEXOR WITH TRABECTEDIN OR LURBINECTEDIN IN PATIENT-DERIVED XENOGRAFTS (PDX) OF DEDIFFERENTIATED LIPOSARCOMA (DDLPS)
Alessandro Gronchi
Favorite
(P 273) COMPARISON OF A PATIENT-DERIVED XENOGRAFTS (PDX) OF MYXOID PLEOMORPHIC LIPOSARCOMA (MPL) AND PLEOMORPHIC LIPOSARCOMA (PL) HIGHLIGHTS THE EFFECTIVENESS OF ERIBULIN IN A PDX OF MPL
Alessandro Gronchi
Favorite
(P 329) DISTANT METASTASIS IN RETROPERITONEAL LEIOMYOSARCOMA: TUMOR SIZE, GRADE AND MORE?
Alessandro Gronchi
Favorite
(P 333) SYSTEMIC TREATMENT IN INTRA-ABDOMINAL DESMOID-TYPE FIBROMATOSIS: A SINGLE INSTITUTION RETROSPECTIVE CASE SERIES ANALYSIS
Alessandro Gronchi
Favorite
(P 342) THE EVALUATION AND OUTCOMES OF MESENTERIC AND INTRA-ABDOMINAL DESMOIDS: A TARPSWG STUDY
Alessandro Gronchi
Favorite
(P 363) Β-CATENIN MUTATIONS AND TRANSCRIPTOMIC REPROGRAMMING IN DESMOID FIBROMATOSIS (DF)
Alessandro Gronchi
Favorite
(P 378) MULTIOMICS PROFILING OF EPITHELIOID SARCOMA UNVEILS EPIGENETIC CIRCUITRIES THAT UNDERLIE THE PATHOBIOLOGY OF PROXIMAL AND CLASSIC SUBTYPES: RESULTS FROM THE ISG EPISOBS OBSERVATIONAL STUDY
Alessandro Gronchi
Favorite
(P 410) PROTEOMICS ANALYSIS IDENTIFIES A SIGNATURE THAT IMPROVES PROGNOSTIC RISK STRATIFICATION OF THE SARCULATOR NOMOGRAM IN PATIENTS WITH SOFT TISSUE SARCOMAS OF THE EXTREMITIES AND TRUNK WALL
Alessandro Gronchi
Favorite
(P 431) TREATMENT STRATEGY AND PROGNOSTIC FACTORS IN EXTRASKELETAL EWING SARCOMA: AN INSTITUTIONAL RETROSPECTIVE ANALYSIS
Alessandro Gronchi
Favorite
(P 455) EXTRASKELETAL EWING SARCOMA: A MULTICENTRIC RETROSPECTIVE STUDY FROM THE ITALIAN SARCOMA GROUP
Alessandro Gronchi
Favorite
Groot, Gary

University of Saskatchewan
(P 148) MOVING TOWARDS THE OPTIMIZATION OF DIAGNOSIS FOR PATIENTS WITH SARCOMA: A 10-YEAR REVIEW OF EXTERNALLY CONSULTED SARCOMA CASES IN A GENERAL ANATOMICAL PATHOLOGY SERVICE
Gary Groot
Favorite
Grootjans, Willem

Leiden University Medical Center
(P 55) RELATIVE WASH-IN RATE ON DYNAMIC CONTRAST-ENHANCED MRI AS A NEW PROGNOSTIC FACTOR IN PATIENTS WITH OSTEOSARCOMA; A POSSIBLE TOOL FOR PERSONALIZED SARCOMA-CARE?
Willem Grootjans
Favorite
Gross, Amy

Nationwide Children's Hospital
(P 107) TRABECTEDIN AUGMENTS ONCOLYTIC HERPES SIMPLEX VIROIMMUNOTHERAPY EFFICACY IN PRECLINCAL BONE SARCOMA MODELS THROUGH ENHANCED IMMUNE-MEDIATED MECHANISMS
Amy Gross
Favorite
Gross, John

Johns Hopkins Hospital
(P 250) SHARING HIGH-QUALITY SAMPLES AND DATA TO THE NF1 RESEARCH COMMUNITY: THE ROLE OF THE JOHNS HOPKINS NF1 BIOSPECIMEN REPOSITORY
John Gross
Favorite
Groundland, John

Huntsman Cancer Institute
(P 93) INDETERMINATE CHEST LESIONS IN PATIENTS WITH BONE SARCOMA INCIDENTAL FINDING VERSUS METASTATIC DISEASE
John Groundland
Favorite
Grube, Matthias

Department of Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany
(P 557) UNRAVELING THE ROLE OF LOCAL THERAPY FOR PATIENTS WITH OLIGOMETASTATIC SOFT TISSUE SARCOMA - A RETROSPECTIVE MULTICENTER TRIAL OF BAVARIAN UNIVERSITY HOSPITALS
Matthias Grube
Favorite
Grunewald, Susanne

West German Cancer Center, University Hospital Essen
(P 234) GENOMIC LANDSCAPE OF CLEAR CELL SARCOMA
Susanne Grunewald
Favorite
(P 275) GIST-BSF1: A NOVEL SCF-DEPENDENT, WILD-TYPE KIT CELL LINE PLATFORM THAT ALLOWS RAPID GENERATION OF ISOGENIC SUBLINES WITH BOTH IMATINIB-SENSITIVE AND IMATINIB-RESISTANT GENOTYPES
Susanne Grunewald
Favorite
(P 294) DNA-DAMAGE REPAIR DYSREGULATION AND CHEMOTHERAPY RESPONSE IN SARCOMA MODELS
Susanne Grunewald
Favorite
Grünhagen, Dirk

Erasmus Medical Center
(P 32) IMPROVEMENT OF QUALITY AND TEXTBOOK OUTCOMES OF GASTRIC GASTROINTESTINAL STROMAL TUMOR (GIST) RESECTIONS IN THE PAST 13 YEARS; THE INFLUENCE OF MINIMAL INVASIVE SURGERY (MIS)
Dirk Grünhagen
Favorite
(P 231) MINIMALLY INTERACTIVE SEGMENTATION OF SOFT-TISSUE TUMORS ON MRI AND CT USING DEEP LEARNING
Dirk Grünhagen
Favorite
(P 233) MULTI-CENTER EXTERNAL VALIDATION OF AN AUTOMATED MODEL DIFFERENTIATING ALT FROM LIPOMA USING RADIOMICS AND DEEP-LEARNING BASED SEGMENTATION
Dirk Grünhagen
Favorite
(P 316) THE ROLE OF RADIOTHERAPY IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS: A MULTICENTER COHORT STUDY
Dirk Grünhagen
Favorite
(P 505) LOCAL RECURRENCE IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS: A MULTICENTER COHORT STUDY
Dirk Grünhagen
Favorite
(P 554) FIVE-YEAR OUTCOMES OF A NATIONWIDE PROSPECTIVE CLINICAL TRIAL ON ACTIVE SURVEILLENCE IN PATIENTS WITH NON-INTRAABDOMINAL DESMOID-TYPE FIBROMATOSIS
Dirk Grünhagen
Favorite
Grünwald, Viktor

University Hospital Essen
(P 133) TEN RECOMMENDATIONTS FOR SARCOMA SURGERY: CONSENSUS OF THE SURGICAL SOCIETIES BASED ON THE GERMAN S3 GUIDELINE "ADULT SOFT TISSUE SARCOMA"
Viktor Grünwald
Favorite
Guadagnolo, B Ashleigh

The University of Texas MD Anderson Cancer Center
(P 123) DEDIFFERENTIATED LIPOSARCOMAS TREATED WITH IMMUNE CHECKPOINT BLOCKADE: THE MD ANDERSON EXPERIENCE
B Ashleigh Guadagnolo
Favorite
(P 269) PLASMA DNA METHYLATION-BASED BIOMARKERS FOR MPNST DETECTION IN PATIENTS WITH NEUROFIBROMATOSIS TYPE 1 (NF1)
B Ashleigh Guadagnolo
Favorite
(P 394) LEIOMYOSARCOMA INTRATUMORAL MACROPHAGE INFILTRATES ARE ASSOCIATED WITH DISTINCT CLINICAL AND GENOMIC PRESENTATIONS
B Ashleigh Guadagnolo
Favorite
(P 510) PRIMARY BREAST ANGIOSARCOMA: CLINICAL AND PATHOLOGICAL FEATURES AND IMPACT ON OUTCOMES
B Ashleigh Guadagnolo
Favorite
Gualandi, Chiara

Department of Chemistry "Giacomo Ciamician", University of Bologna, 40126 Bologna, Italy
(P 253) THE EFFICACY OF MEDICATED PATCHES IN SOFT TISSUE SARCOMAS: IN-VITRO AND EX-VIVO VALIDATION.
Chiara Gualandi
Favorite
Guan, Peng

Children’s Hospital of Philadelphia
(P 565) AN EARLY PHASE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF PEEL-224 IN PATIENTS WITH ADVANCED SOLID TUMORS
Peng Guan
Favorite
Guan, Wenxian

Department of General Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School
(P 44) RIPRETINIB FOR THE TREATMENT OF CHINESE PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS HARBORING KIT SECONDARY MUTATIONS: A MULTICENTER, RETROSPECTIVE STUDY
Wenxian Guan
Favorite
(P 48) SIGNIFICANCE OF MONITORING PLASMA CONCENTRATION OF RIPRETINIB IN CHINESE PATIENTS WITH GASTROINTESTINAL STROMAL TUMORS
Wenxian Guan
Favorite
Guardino, Nicholas

Duke University
(P 72) CO-EXPRESSION OF LEUKOCYTE CYTOSOLIC PROTEIN 1 AND MATRIX METALLOPROTEINASES ARE INTEGRAL FOR METASTATIC PROGRESSION OF CHONDROSARCOMA
Nicholas Guardino
Favorite
(P 393) INVESTIGATING THE ROLE OF HDACS IN THE PROGRESSION OF METASTATIC UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Nicholas Guardino
Favorite
Guarino, Valentina

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 363) Β-CATENIN MUTATIONS AND TRANSCRIPTOMIC REPROGRAMMING IN DESMOID FIBROMATOSIS (DF)
Valentina Guarino
Favorite
Guder, Wiebke K.

Department of Orthopedic Oncology, University Hospital Essen
(P 451) IMPACT OF TIME TO DIAGNOSIS - A PROSPECTIVE ANALYSIS OF THE EWING 2008 TRIAL
Wiebke K. Guder
Favorite
GUEGAN, Jean-Philippe

Explicyte
(P 418) GENOMIC AND IMMUNOLOGICAL PROFILING OF PRIMARY AND DISTANT METASTASES OF SOFT TISSUE SARCOMAS
Jean-Philippe GUEGAN
Favorite
Guerin, Eric

University Hospital of Strasbourg and UMR CNRS 7021
(P 277) ANTI-GD2 SYNERGIZES WITH HYPOXIA PATHWAY TARGETING TO BLOCK OSTEOSARCOMA CELL PROLIFERATION AND MIGRATION.
Eric Guerin
Favorite
(P 389) OSTEOBLASTIC-GENE SIGNATURE TO PREDICT SURVIVAL IN PEDIATRIC OSTEOSARCOMA (OS) AND TO FOLLOW PATIENTS TOWARDS LIQUID BIOPSY: A COLLABORATIVE WORK IN OS2006 PROTOCOL.
Eric Guerin
Favorite
Guerrieri, Ania Naila

Istituto Ortopedico Rizzoli IRCCS, Osteoncology- Bone and Soft Tissue Sarcomas and Innovative Therapies Unit, Bologna, Italy
(P 253) THE EFFICACY OF MEDICATED PATCHES IN SOFT TISSUE SARCOMAS: IN-VITRO AND EX-VIVO VALIDATION.
Ania Naila Guerrieri
Favorite
(P 283) A TRIDIMENSIONAL PRECLINICAL MODEL TO STUDY HUMAN AND CANINE OSTEOSARCOMA DEVELOPMENT AND INTERACTION WITH TUMOR MICROENVIRONMENT
Ania Naila Guerrieri
Favorite
Guhlich, Manuel

Department of Radiotherapy and Radiation Oncology, University Medical Center Goettingen, 37075 Goettingen, Germany
(P 235) FUSION OF PREOPERATIVE IN SITU MAGNETIC RESONANCE IMAGING AND POSTOPERATIVE COMPUTED TOMOGRAPHY TO CORRELATE FUNCTIONAL IMAGING FEATURES AND PATHOLOGICAL CHARACTERISTICS OF SOFT TISSUE SARCOMA
Manuel Guhlich
Favorite
Guidoboni, Massimo

Irst
(P 364) EVALUATION OF THE PREDICTIVE ROLE OF SYSTEMIC AND INTRATUMORAL IMMUNITY IN PATIENTS WITH LOCALIZED LIPOSARCOMAS, MYXOFIBROSARCOMAS AND UNDIFFERENTIATED PLEOMORPHIS SARCOMAS
Massimo Guidoboni
Favorite
(P 533) SAFETY AND PRELIMINARY BIOLOGICAL ACTIVITY OF A PHASE II TRIAL OF AUTOLOGOUS DENDRITIC CELLS VACCINATION IN SARCOMAS.
Massimo Guidoboni
Favorite
Guidos, Cynthia

Hospital for Sick Children Research Institute
(P 108) EFFECT OF TUMOUR-TARGETED HYPERTHERMIA AND CHEMOTHERAPY ON THE IMMUNE PROFILE OF A MURINE MODEL OF EMBRYONAL RHABDOMYOSARCOMA
Cynthia Guidos
Favorite
Guignard, Louisa

University of Calgary
(P 110) GCAR1: GPNMB CAR T THERAPY FOR MIT FAMILY TRANSLOCATION POSITIVE CANCERS
Louisa Guignard
Favorite
Guillan, Kristina

Memorial Sloan Kettering Cancer Center
(P 289) IDENTIFICATION OF EFFECTIVE THERAPEUTIC COMBINATIONS WITH THE NUCLEAR EXPORT PROTEIN INHIBITOR, SELINEXOR, IN PEDIATRIC SOLID TUMORS
Kristina Guillan
Favorite
Guillen Burrieza, Gabriela

Department of Pediatric Surgery, Hospital Infantil Universitari Vall d'Hebron
(P 209) PROGNOSTIC VALUE OF EARLY RADIOLOGIC TUMOUR VOLUME RESPONSE IN RHABDOMYOSARCOMA; RESULTS OF THE EUROPEAN PAEDIATRIC SOFT TISSUE SARCOMA STUDY GROUP RMS 2005 STUDY
Gabriela Guillen Burrieza
Favorite
Guimbaud, Rosine

CHU Toulouse
(P 201) PLEOMORPHIC RHABDOMYOSARCOMAS: A NEW ENTITY ASSOCIATED WITH LYNCH SYNDROME? FIRST RESULTS OF SARCLYNCH NATIONAL STUDY
Rosine Guimbaud
Favorite
Guinan, Enda

Sarcoma UK
(P 150) VISUALISING SOFT TISSUE SARCOMA INCIDENCE DATA FOR PATIENT EMPOWERMENT
Enda Guinan
Favorite
Gu, Jian

The University of Texas MD Anderson Cancer Center
(P 269) PLASMA DNA METHYLATION-BASED BIOMARKERS FOR MPNST DETECTION IN PATIENTS WITH NEUROFIBROMATOSIS TYPE 1 (NF1)
Jian Gu
Favorite
Gujral, Taran

Fred Hutchinson Cancer Center
(P 447) TARGETING FOCAL ADHESION KINASE AUGMENTS THE THERAPEUTIC POTENTIAL OF BROMODOMAIN INHIBITORS IN EWING SARCOMA
Taran Gujral
Favorite
Gujrathi, Vivek

Sarcoma Oncology Center
(P 116) UPDATE ON SAINT: RESULTS OF 100 PATIENTS TREATED WITH IPILIMUMAB (I), NIVOLUMAB (N) AND TRABECTEDIN (T) AS FIRST LINE THERAPY FOR ADVANCED SOFT TISSUE SARCOMA [NCT03138161]
Vivek Gujrathi
Favorite
Guljar, Nafia

The Institute of Cancer Research
(P 417) MULTI-OMIC CHARACTERISATION OF MOLECULAR HETEROGENEITY AND NEOADJUVANT THERAPY RESPONSE IN SYNOVIAL SARCOMAS
Nafia Guljar
Favorite
Gulliford, sarah

University College London Hospitals
(P 318) DEVELOPMENT OF NOVEL OUTLINING GUIDELINES FOR NORMAL TISSUE STRUCTURES FOR LIMB SOFT TISSUE SARCOMA.
sarah Gulliford
Favorite
Guminski, Alexander

Royal North Shore Hospital
(P 27) A MULTICENTER RETROSPECTIVE STUDY ON THE CLINICAL BEHAVIOR OF SDH-DEFICIENT GIST
Alexander Guminski
Favorite
Gundavda, Manit

Kokilaben Hospital
(P 77) PATIENT OUTCOMES AFTER OPEN VERSUS CORE NEEDLE BIOPSY IN LOWER EXTREMITY SARCOMA
Manit Gundavda
Favorite
Gundle, Kenneth

Portland VA Medical Center
(P 129) LOW RATES OF SERVICE CONNECTIVITY FOR SOFT TISSUE SARCOMA (STS) AMONG ELIGIBLE VIETNAM VETERANS WITH AGENT ORANGE EXPOSURE
Kenneth Gundle
Favorite
(P 130) THE ADOPTION OF MEDICAID EXPANSION IN THE AFFORDABLE CARE ACT IS NOT ASSOCIATED WITH STAGE AT PRESENTATION OR 5-YEAR OVERALL SURVIVAL FOR BONE OR SOFT TISSUE SARCOMAS
Kenneth Gundle
Favorite
(P 179) PILOT STUDY OF A REMOTELY DELIVERED RESISTANCE EXERCISE TRAINING PROGRAM IN SARCOMA SURVIVORS
Kenneth Gundle
Favorite
(P 227) DE NOVO NATURAL LANGUAGE PROCESSING (NLP) ALGORITHM ACCURATELY IDENTIFIES MYXOFIBROSARCOMA DIRECTLY FROM PATHOLOGY REPORTS
Kenneth Gundle
Favorite
(P 462) EXTERNAL VALIDATION OF A NOMOGRAM PREDICTING THE RISK OF POSTOPERATIVE MAJOR WOUND COMPLICATION IN SOFT TISSUE SARCOMA FOLLOWING PREOPERATIVE RADIOTHERAPY AND RESECTION
Kenneth Gundle
Favorite
(P 463) MACHINE LEARNING CORROBORATES TRADITIONAL REGRESSION TECHNIQUES IN PREDICTING MAJOR WOUND COMPLICATIONS AFTER SOFT TISSUE SARCOMA RESECTION WITHOUT IMPROVEMENTS IN PREDICTIVE PERFORMANCE
Kenneth Gundle
Favorite
Guo, Qiuxiang

Abbisko Therapeutics Co., Ltd
(P 169) UPDATED EFFICACY AND SAFETY PROFILE OF PIMICOTINIB (ABSK021) IN TENOSYNOVIAL GIANT CELL TUMOR (TGCT): 1-YEAR FOLLOW-UP FROM PHASE 1B
Qiuxiang Guo
Favorite
Guo, Wei

Peking University People's Hospital
(P 51) OAIE TRIAL IN PROGRESS: A RANDOMIZED PHASE II TRIAL ASSESSING APATINIB IN COMBINATION WITH IFOSFAMIDE AND ETOPOSIDE(IE) VERSUS SINGLE IE CHEMOTHERAPY FOR RELAPSED OR REFRACTORY OSTEOSARCOMA
Wei Guo
Favorite
(P 52) ARTEMIS-002 TRIAL IN PROGRESS: A MULTI-CENTER PHASE II TRIAL ASSESSING HS-20093 (B7-H3 ANTIBODY-DRUG CONJUGATE) FOR RELAPSED OR REFRACTORY OSTEOSARCOMA AND OTHER SARCOMAS
Wei Guo
Favorite
(P 58) CHEMOTHERAPY-INDUCED EVOLUTION OF OSTEOSARCOMA REVEALED BY SINGLE-CELL RNA SEQUENCING
Wei Guo
Favorite
(P 97) AN EXPLORATORY STUDY OF AN ANTI-PD-L1/TGF-β ANTIBODY, TQB2858, IN PATIENTS WITH REFRACTORY OR RECURRENT OSTEOSARCOMA AND ALVEOLAR SOFT PART SARCOMA: A REPORT FROM CHINESE SARCOMA STUDY GROUP
Wei Guo
Favorite
(P 441) LONG VERSUS SHORTER SCHEDULES OF VINCRISTINE, IRINOTECAN AND TEMOZOLOMIDE (VIT) FOR RELAPSED OR REFRACTORY EWING SRACOMA: A RANDOMISED CONTROLLED PHASE 2 TRIAL
Wei Guo
Favorite
(P 442) LONG-TERM OUTCOME AND RELAPSE PATTERNS IN EWING SARCOMA PATIENTS WITH EXTENSIVE LUNG/PLEURAL METASTASES AFTER A COMPLETE RESPONSE TO SYSYEMIC THERAPY
Wei Guo
Favorite
(P 464) INDOCYANINE GREEN FLUORESCENCE IMAGING MAY DETECT TUMOUR RESIDUALS DURING SURGERY FOR BONE AND SOFT-TISSUE TUMOURS
Wei Guo
Favorite
(P 487) EN BLOC RESECTION FOR SPINAL TUMORS: A SINGLE CENTER EXPERIENCE OF 113 CONSECUTIVE CASES
Wei Guo
Favorite
(P 543) MANEUVER STUDY: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF PIMICOTINIB (ABSK021) TO ASSESS THE EFFICACY AND SAFETY IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR
Wei Guo
Favorite
Gupta, Abha

Princess Margaret Cancer Center
(P 50) CHARACTERIZATION OF A FAMILIAL GIST KINDRED INTOLERANT TO IMATINIB
Abha Gupta
Favorite
(P 108) EFFECT OF TUMOUR-TARGETED HYPERTHERMIA AND CHEMOTHERAPY ON THE IMMUNE PROFILE OF A MURINE MODEL OF EMBRYONAL RHABDOMYOSARCOMA
Abha Gupta
Favorite
(P 215) IMPACT OF FRONTLINE SYSTEMIC TREATMENT CHOICE ON CLINICAL OUTCOME IN ADVANCED LEIOMYOSARCOMA: A MULTI-CENTRE RETROSPECTIVE CANSARCC STUDY
Abha Gupta
Favorite
(P 265) SELECTIVE TARGETING OF BET FAMILY EPIGENETIC REGULATORS IN ADVANCED AND METASTATIC ALVEOLAR RHABDOMYOSARCOMA
Abha Gupta
Favorite
(P 409) IMMUNOHISTOCHEMICAL STAINING FOR MYOGENIN, AP2 BETA AND HMGA2 PREDICT FOXO1 FUSION STATUS IN RHABDOMYOSARCOMA: A REPORT FROM THE SOFT TISSUE COMMITTEE OF THE CHILDREN'S ONCOLOGY GROUP
Abha Gupta
Favorite
(P 421) USING TRANSCRIPTOMICS TO IDENTIFY LEIOMYOSARCOMA PATIENTS AT RISK OF METASTASIS
Abha Gupta
Favorite
(P 425) CHARACTERIZATION OF RHABDOMYOSARCOMA WITH PAX7::FOXO1 FUSIONS: A REPORT FROM THE SOFT TISSUE COMMITTEE OF THE CHILDREN'S ONCOLOGY GROUP
Abha Gupta
Favorite
(P 438) ALVEOLAR RHABDOMYOSARCOMA WITH "BURKITT-LIKE" MORPHOLOGY IS ASSOCIATED WITH HIGH AMPLIFICATION OF MYCL
Abha Gupta
Favorite
Gupta, Ajay

Roswell Park Oishei Children's Cancer and Blood Disorders Program
(P 81) OPTIMIZING EWING SARCOMA AND OSTEOSARCOMA BIOPSY ACQUISITION: CONSENSUS RECOMMENDATIONS FROM THE CHILDREN'S ONCOLOGY GROUP BONE TUMOR COMMITTEE
Ajay Gupta
Favorite
(P 193) Recent Trends in Sarcoma Trials for Children in the United States
Ajay Gupta
Favorite
(P 247) HARNESSING EWING SARCOMA'S REPLICATION STRESS BY TARGETING DDK AND WEE1 IN COMBINATION
Ajay Gupta
Favorite
Gupta, Sudeep

Tata Memorial Centre, Mumbai
(P 06) ONCOFERTILITY AND PREGNANCY IN ADOLESCENT AND YOUNG ADULT CANCERS: PHYSICIANS' KNOWLEDGE AND PREFERENCES IN A LARGE LOW-MIDDLE- INCOME COUNTRY
Sudeep Gupta
Favorite
Guragain, Diwakar

Department of Surgery, Division of Surgical Oncology, University of California San Diego
(P 29) COMBINATION TREATMENT WITH TEMOZOLOMIDE AND THE DEATH RECEPTOR-5 AGONIST INBRX-109 EFFECTIVELY TARGETS SUCCINATE DEHYDROGENASE -DEFICIENT GASTROINTESTINAL STROMAL TUMOR
Diwakar Guragain
Favorite
Gurrieri, Lorena

Clinical and Experimental Oncology, Immunotherapy, Rare Cancers and Biological Resource Center, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", 47014 Meldola, Italy
(P 37) DISSECTING THE ROLE OF EXTRACELLULAR VESICLES IN THE MANAGEMENT OF GIST
Lorena Gurrieri
Favorite
(P 253) THE EFFICACY OF MEDICATED PATCHES IN SOFT TISSUE SARCOMAS: IN-VITRO AND EX-VIVO VALIDATION.
Lorena Gurrieri
Favorite
(P 364) EVALUATION OF THE PREDICTIVE ROLE OF SYSTEMIC AND INTRATUMORAL IMMUNITY IN PATIENTS WITH LOCALIZED LIPOSARCOMAS, MYXOFIBROSARCOMAS AND UNDIFFERENTIATED PLEOMORPHIS SARCOMAS
Lorena Gurrieri
Favorite
(P 533) SAFETY AND PRELIMINARY BIOLOGICAL ACTIVITY OF A PHASE II TRIAL OF AUTOLOGOUS DENDRITIC CELLS VACCINATION IN SARCOMAS.
Lorena Gurrieri
Favorite
Gutiérrez, Ana

Medical Oncology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain
(P 517) PULMONARY METASTASECTOMY FOR SARCOMA: A SINGLE-INSTITUTION EXPERIENCE
Ana Gutiérrez
Favorite
Gutierrez, Andres

Ayala Pharmaceuticals
(P 172) PHASE 2 RESULTS FROM THE RINGSIDE PHASE 2/3 TRIAL OF AL102 FOR TREATMENT OF DESMOID TUMORS
Andres Gutierrez
Favorite
(P 549) DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF AL102 FOR TREATMENT OF PROGRESSING DESMOID TUMORS: THE RINGSIDE PHASE 3 STUDY DESIGN
Andres Gutierrez
Favorite
Gutierrez, Antonio

HU Son Espases
(P 113) IMMUNOSARC II: A SPANISH SARCOMA GROUP (GEIS) PHASE IB TRIAL OF DOXORUBICIN AND DACARBAZINE PLUS NIVOLUMAB IN FIRST LINE OF ADVANCED LEIOMYOSARCOMA
Antonio Gutierrez
Favorite
(P 174) SELISARC: A SPANISH GROUP FOR RESEARCH IN SARCOMA (GEIS) PHASE I/II TRIAL OF SELINEXOR PLUS GEMCITABINE IN SELECTED SARCOMA SUBTYPES: RESULTS OF THE PHASE I PART
Antonio Gutierrez
Favorite
(P 175) TRABECTEDIN PLUS RADIOTHERAPY ON SYMPHTOMATIC ADVANCED SARCOMA PATIENTS, RESULTS FROM THE SYNERGIAS STUDY: A SPANISH GROUP FOR RESEARCH IN SARCOMA (GEIS) PHASE II STUDY
Antonio Gutierrez
Favorite
Gutierrez, Wade

University of Iowa
(P 286) EPIGENETIC MECHANISMS AND SIGNATURES OF SARCOMA PROGRESSION AND METASTASIS
Wade Gutierrez
Favorite
Guzmán-Cervantes, Rodolfo

Caja Costarricense de Seguro Social
(P 142) THE SARCOMA EUROPEAN AND LATIN AMERICAN NETWORK (SELNET) PROJECT: OVERVIEW OF THE MAIN RESULTS OF THE SELNET REGISTRY
Rodolfo Guzmán-Cervantes
Favorite
Guzmán-Gómez, Laura

HU Fundación Jiménez Díaz
(P 175) TRABECTEDIN PLUS RADIOTHERAPY ON SYMPHTOMATIC ADVANCED SARCOMA PATIENTS, RESULTS FROM THE SYNERGIAS STUDY: A SPANISH GROUP FOR RESEARCH IN SARCOMA (GEIS) PHASE II STUDY
Laura Guzmán-Gómez
Favorite
Gyorki, David E

Peter MacCallum Cancer Centre
(P 516) OUCOMES OF AGGRESSIVE RESECTION OF RADIATION INDUCED ANGIOSARCOMA OF THE BREAST
David E Gyorki
Favorite
H
Hübschmann, Daniel

Computational Oncology, Molecular Precision Oncology Program, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT)
(P 248) FIBROBLAST ACTIVATION PROTEIN ALPHA -DIRECTED IMAGING AND THERAPY OF SOLITARY FIBROUS TUMOR
Daniel Hübschmann
Favorite
Hüllein, Jennifer

Computational Oncology, Molecular Precision Oncology Program, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT)
(P 248) FIBROBLAST ACTIVATION PROTEIN ALPHA -DIRECTED IMAGING AND THERAPY OF SOLITARY FIBROUS TUMOR
Jennifer Hüllein
Favorite
Haag, Georg Martin

National Center for Tumor Diseases (NCT) Heidelberg, Heidelberg University Hospital
(P 27) A MULTICENTER RETROSPECTIVE STUDY ON THE CLINICAL BEHAVIOR OF SDH-DEFICIENT GIST
Georg Martin Haag
Favorite
Haanen, John

Netherlands Cancer Institute
(P 114) PRIMARY ANALYSIS OF EFFICACY AND SAFETY OF LETETRESGENE AUTOLEUCEL (LETE-CEL) AS FIRST-LINE TREATMENT FOR UNRESECTABLE OR METASTATIC SYNOVIAL SARCOMA (SS); SUBSTUDY 1 OF IGNYTE-ESO
John Haanen
Favorite
Haarberg, Sasha

Washington University School of Medicine
(P 552) RANDOMIZED PHASE II TRIAL OF CABOZANTINIB COMBINED WITH PD-1 AND CTLA-4 INHIBITION VERSUS CABOZANTINIB IN METASTATIC SOFT TISSUE SARCOMA.
Sasha Haarberg
Favorite
Haas, Rick

The Netherlands Cancer Institute
(P 138) CONTROVERSIES IN THE MANAGEMENT OF PATIENTS WITH SOFT TISSUE SARCOMA: RESULTS AND RECOMMENDATIONS FROM THE FIRST CONFERENCE ON STATE OF SCIENCE IN SARCOMA (CSSS)
Rick Haas
Favorite
(P 197) PROPRANOLOL MONOTHERAPY IN ANGIOSARCOMA - A WINDOW-OF-OPPORTUNITY STUDY (PROPANGIO)
Rick Haas
Favorite
(P 368) DECODING THE IMMUNOGENOMIC DETERMINANTS OF RADIOTHERAPY RESPONSE IN SOFT TISSUE SARCOMAS
Rick Haas
Favorite
Habel, Laurel

Kaiser Permanente
(P 224) CO-MUTATION-DEPENDENT PROGNOSIS IN PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA
Laurel Habel
Favorite
Hadad, Christopher

The Ohio State University/Department of Chemistry and Biochemistry
(P 301) REDUCING THE INVASIVE POTENTIAL OF DEDIFFERENTIATED LIPOSARCOMA BY TARGETING ALTERNATIVE RNA SPLICING MACHINERY
Christopher Hadad
Favorite
Haddox, Candace

Dana-Farber Cancer Institute
(P 540) PHASE 2, MULTICENTER, OPEN-LABEL BASKET TRIAL OF NAB-SIROLIMUS FOR MALIGNANT SOLID TUMORS HARBORING PATHOGENIC INACTIVATING ALTERATIONS IN TSC1 AND TSC2 (PRECISION I)
Candace Haddox
Favorite
(P 541) ETCTN 10563: PHASE 1 STUDY OF PEPOSERTIB AND LIPOSOMAL DOXORUBICIN FOR ADVANCED OR METASTATIC LEIOMYOSARCOMA AND OTHER SARCOMAS
Candace Haddox
Favorite
Haglund de Flon, Felix

Karolinska University Hospital
(P 230) SARCDBASE: A TOOL FOR DETECTION OF GENETIC ALTERATIONS IN SARCOMA
Felix Haglund de Flon
Favorite
(P 243) EVALUATION OF THE USE OF WGS IN ROUTINE DIAGNOSTICS FOR BONE AND SOFT TISSUE TUMORS
Felix Haglund de Flon
Favorite
(P 278) CLINICAL MARKERS PREDICTIVE OF TRABECTEDIN RESPONSE IN SOFT TISSUE SARCOMA
Felix Haglund de Flon
Favorite
Haglund, Cecilia

Karolinska institutet
(P 243) EVALUATION OF THE USE OF WGS IN ROUTINE DIAGNOSTICS FOR BONE AND SOFT TISSUE TUMORS
Cecilia Haglund
Favorite
Hakkesteegt, Stefanie

Erasmus Medical Center
(P 32) IMPROVEMENT OF QUALITY AND TEXTBOOK OUTCOMES OF GASTRIC GASTROINTESTINAL STROMAL TUMOR (GIST) RESECTIONS IN THE PAST 13 YEARS; THE INFLUENCE OF MINIMAL INVASIVE SURGERY (MIS)
Stefanie Hakkesteegt
Favorite
(P 233) MULTI-CENTER EXTERNAL VALIDATION OF AN AUTOMATED MODEL DIFFERENTIATING ALT FROM LIPOMA USING RADIOMICS AND DEEP-LEARNING BASED SEGMENTATION
Stefanie Hakkesteegt
Favorite
(P 554) FIVE-YEAR OUTCOMES OF A NATIONWIDE PROSPECTIVE CLINICAL TRIAL ON ACTIVE SURVEILLENCE IN PATIENTS WITH NON-INTRAABDOMINAL DESMOID-TYPE FIBROMATOSIS
Stefanie Hakkesteegt
Favorite
Haldeman, Pearce

University of California San Diego School of Medicine
(P 489) SIMULTANEOUS VERSUS DELAYED FLAP RECONSTRUCTION FOLLOWING SOFT TISSUE SARCOMA RESECTION
Pearce Haldeman
Favorite
(P 490) TOPICAL ANTIBIOTICS DECREASE INFECTIONS IN EXTREMITY SARCOMA SURGERY
Pearce Haldeman
Favorite
Hale, Martina

Cleveland Clinic Lerner College of Medicine
(P 513) THE IMPACT OF MARGIN STATUS ON THE ONCOLOGIC OUTCOMES OF SURGICALLY TREATED DEDIFFERENTIATED LIPOSARCOMA OF THE EXTREMITIES
Martina Hale
Favorite
(P 514) INTERSTITIAL BRACHYTHERAPY IN THE TREATMENT OF SOFT TISSUE SARCOMA: LOCAL RECURRENCE AND WOUND OUTCOMES
Martina Hale
Favorite
Haller, Florian

Department of Pathology Friedrich- Alexander- Universität Erlangen-Nürnberg, Erlangen
(P 12) MULTIFOCAL AND DISSEMINATED SPORADIC DESMOID TUMOUR OF THE EXTREMITIES: A SPECIAL CHALLENGE
Florian Haller
Favorite
Haller, Valerie

University Hospital Essen, Sarcoma Centre
(P 47) PATIENT SURVIVAL IN METASTATIC GIST WITH IMATINIB-SENSITIVE MUTATIONS: REAL WORLD DATA FROM GERMAN REFERRAL CENTER (2008-2021)
Valerie Haller
Favorite
(P 276) REVISITING IN- AND OFF LABEL DRUGS FREQUENTLY USED IN METASTATIC GIST USING A BROAD IN VITRO PROFILING PANEL OF PRIMARY AND SECONDARY KIT AND PDGFRA-MUTANT GIST CELLS – CLINICAL IMPLICATIONS
Valerie Haller
Favorite
Hall, Matthew

Miami Cancer Institute, Baptist Health South Florida
(P 320) A PROSPECTIVE MULTICENTER EXPERIENCE OF PROTON THERAPY FOR RHABDOMYOSARCOMA AND EWING SARCOMA: OUTCOMES FROM THE PROTON COLLABORATIVE GROUP REGISTRY
Matthew Hall
Favorite
Hamacher, Rainer

Department of Medical Oncology, West German Cancer Center, University Hospital Essen
(P 47) PATIENT SURVIVAL IN METASTATIC GIST WITH IMATINIB-SENSITIVE MUTATIONS: REAL WORLD DATA FROM GERMAN REFERRAL CENTER (2008-2021)
Rainer Hamacher
Favorite
(P 220) [68GA]GA-FAPI PET/CT AS NOVEL DIAGNOSTIC TOOL IN SARCOMA
Rainer Hamacher
Favorite
(P 248) FIBROBLAST ACTIVATION PROTEIN ALPHA -DIRECTED IMAGING AND THERAPY OF SOLITARY FIBROUS TUMOR
Rainer Hamacher
Favorite
(P 276) REVISITING IN- AND OFF LABEL DRUGS FREQUENTLY USED IN METASTATIC GIST USING A BROAD IN VITRO PROFILING PANEL OF PRIMARY AND SECONDARY KIT AND PDGFRA-MUTANT GIST CELLS – CLINICAL IMPLICATIONS
Rainer Hamacher
Favorite
(P 294) DNA-DAMAGE REPAIR DYSREGULATION AND CHEMOTHERAPY RESPONSE IN SARCOMA MODELS
Rainer Hamacher
Favorite
Hameed, Hassan

The Christie NHS Foundation Trust
(P 190) DOES RESPONSE TO PRIOR CHEMOTHERAPY PREDICT OUTCOME FROM FURTHER SYSTEMIC TREATMENT IN ADVANCED LEIOMYOSARCOMA? A SINGLE UK CENTRE EXPERIENCE
Hassan Hameed
Favorite
Hamilton, Anne

Peter MacCallum Cancer Centre
(P 386) GENOMIC PROFILING OF GYNAECOLOGICAL SARCOMAS: REPORT FROM THE AUSTRALIA-WIDE PRECISION ONCOLOGY PROGRAM
Anne Hamilton
Favorite
Hana, Caroline

Memorial Healthcare Hospital
(P 128) THE IMPACT OF HISPANIC ETHNICITY IN PRESENTATION AND OUTCOMES OF PATIENTS WITH SYNOVIAL SARCOMA
Caroline Hana
Favorite
Handorf, Elizabeth

Division of Biostatistics and Bioinformatics, Fox Chase Cancer Center
(P 152) EVALUATING DIAGNOSTIC APPROACHES TO DERMATOFIBROSARCOMA PROTUBERANS: AN OPPORTUNITY TO REDUCE THE NUMBER OF INTERVENTIONS
Elizabeth Handorf
Favorite
Hanff, David

Erasmus Medical Center
(P 231) MINIMALLY INTERACTIVE SEGMENTATION OF SOFT-TISSUE TUMORS ON MRI AND CT USING DEEP LEARNING
David Hanff
Favorite
(P 233) MULTI-CENTER EXTERNAL VALIDATION OF AN AUTOMATED MODEL DIFFERENTIATING ALT FROM LIPOMA USING RADIOMICS AND DEEP-LEARNING BASED SEGMENTATION
David Hanff
Favorite
Han, Ilkyu

Seoul National University Hospital
(P 374) ARHGEF4 EXPRESSION IN SOFT TISSUE SARCOMA CORRELATES WITH LOCAL GROWTH PATTERN AND LOCAL RECURRENCE: COMPREHENSIVE GENOMIC ANALYSIS IN SEARCH OF BIOMARKER OF LOCAL GROWTH PATTERN
Ilkyu Han
Favorite
(P 498) DEDIFFERENTIATED LIPOSARCOMA OF THE EXTREMITIES: CHARACTERISTICS AND OUTCOME
Ilkyu Han
Favorite
(P 499) CLINICAL OUTCOMES OF TOTAL FEMORAL REPLACEMENT FOR ONCOLOGICAL INDICATIONS
Ilkyu Han
Favorite
Hanley, Michael

Takeda Development Center Americas
(P 558) TRIAL IN PROGRESS: A PHASE 1/2 STUDY OF BRIGATINIB IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH ALK POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA OR INFLAMMATORY MYOFIBROBLASTIC TUMORS (ITCC-098)
Michael Hanley
Favorite
Hanna, Diana

University of Southern California, Norris Comprehensive Cancer Center
(P 164) INTRATUMORAL INT230-6 (CISPLATIN, VINBLASTINE, SHAO) ALONE OR WITH IPILIMUMAB PROLONGED SURVIVAL WITH FAVORABLE SAFETY AND IMMUNE ACTIVATION IN ADULTS WITH REFRACTORY SARCOMAS (NCT 03058289)
Diana Hanna
Favorite
Hannay, Jonathan

The Royal Marsden Hospital
(P 40) LONG TERM OUTCOMES OF NEOADJUVANT IMATINIB AND SURGICAL RESECTION OF RECTAL GASTROINTESTINAL STROMAL TUMOURS
Jonathan Hannay
Favorite
Hansén Nord, Karolin

Lund University
(P 230) SARCDBASE: A TOOL FOR DETECTION OF GENETIC ALTERATIONS IN SARCOMA
Karolin Hansén Nord
Favorite
(P 371) DISRUPTION OF THE TP53 LOCUS IN OSTEOSARCOMA LEADS TO TP53 PROMOTER GENE FUSIONS AND RESTORATION OF PARTS OF THE TP53 SIGNALLING PATHWAY
Karolin Hansén Nord
Favorite
Hao, Binbin

State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
(P 416) THE PROTEOGENOMIC SUBTYPING OF OSTEOSARCOMA
Binbin Hao
Favorite
Haramiova, Zuzana

Thermosome GmbH
(P 530) FIH PHASE I STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND ANTITUMOR ACTIVITY OF THE001 COMBINED WITH REGIONAL HYPERTHERMIA IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOFT TISSUE SARCOMA
Zuzana Haramiova
Favorite
Harder, Jeffrey

The Jackson Laboratory
(P 392) IMMUNOSUPPRESSIVE TUMOR MICROENVIRONMENT OF OSTEOSARCOMA
Jeffrey Harder
Favorite
Hardes, Jendrik

University Hospital Essen
(P 74) SACRAL CHORDOMA: A RANDOMIZED & OBSERVATIONAL STUDY ON SURGERY VS DEFINITIVE RADIOTHERAPY IN PRIMARY LOCALIZED DISEASE (SACRO). INTERIM ANALYSIS
Jendrik Hardes
Favorite
(P 294) DNA-DAMAGE REPAIR DYSREGULATION AND CHEMOTHERAPY RESPONSE IN SARCOMA MODELS
Jendrik Hardes
Favorite
(P 451) IMPACT OF TIME TO DIAGNOSIS - A PROSPECTIVE ANALYSIS OF THE EWING 2008 TRIAL
Jendrik Hardes
Favorite
(P 538) IEUROEWING TRIAL FOR LOCALIZED AND METASTATIC EWING SARCOMA
Jendrik Hardes
Favorite
Harewood, Jessica

Newcastle University Faculty of Medical Sciences
(P 298) EVALUATING THE PHOTOTHERMAL AND CYTOTOXIC PROPERTIES OF INDOCYANINE GREEN IN VITRO FOR INTRAOPERATIVE PHOTOTHERMAL THERAPY IN SARCOMA
Jessica Harewood
Favorite
Haro Varas, Juan Carlos

Instituto Nacional de Enfermedades Neoplasicas
(P 142) THE SARCOMA EUROPEAN AND LATIN AMERICAN NETWORK (SELNET) PROJECT: OVERVIEW OF THE MAIN RESULTS OF THE SELNET REGISTRY
Juan Carlos Haro Varas
Favorite
Harrington, Jennifer

Cambridge University Hospitals NHS Foundation Trust
(P 204) RADIATION-INDUCED ANGIOSARCOMA OF THE BREAST: RETROSPECTIVE ANALYSIS AT A REGIONAL TREATMENT CENTRE
Jennifer Harrington
Favorite
Harrington, kevin

The Institute of Cancer research
(P 318) DEVELOPMENT OF NOVEL OUTLINING GUIDELINES FOR NORMAL TISSUE STRUCTURES FOR LIMB SOFT TISSUE SARCOMA.
kevin Harrington
Favorite
Harrison, Douglas

M.D. Anderson Children's Cancer Hospital (MDACC)
(P 532) MISTOSUS: A PHASE 2 STUDY OF ISCADOR® P IMMUNOTHERAPY FOR PATIENTS WITH RELAPSED OSTEOSARCOMA AND RESECTED PULMONARY METASTASES
Douglas Harrison
Favorite
Harrison, Michelle

Chris O'Brien Lifehouse
(P 194) REAL WORLD OUTCOMES OF PATIENTS TREATED WITH GEMCITABINE AND DOCETAXEL FOR ADVANCED SOFT TISSUE SARCOMA IN AN AUSTRALIAN SARCOMA CENTRE
Michelle Harrison
Favorite
(P 386) GENOMIC PROFILING OF GYNAECOLOGICAL SARCOMAS: REPORT FROM THE AUSTRALIA-WIDE PRECISION ONCOLOGY PROGRAM
Michelle Harrison
Favorite
Harris, Reuben

University of Texas Health San Antonio
(P 236) APOBEC MUTAGENESIS IN OSTEOSARCOMA DEVELOPMENT, PROGRESSION AND RESPONSE TO THERAPY
Reuben Harris
Favorite
Harrow, Brooke

Deciphera Pharmaceuticals, LLC
(P 173) SAFETY, EFFICACY, AND PATIENT-REPORTED OUTCOMES WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED PRIOR ANTI–COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 UPDATE
Brooke Harrow
Favorite
(P 176) SAFETY, EFFICACY, AND PATIENT-REPORTED OUTCOMES WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED NO PRIOR ANTI–COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 UPDATE
Brooke Harrow
Favorite
Hartemink, Koen

Netherlands Cancer Institute/ Antoni van Leeuwenhoek
(P 31) NEOADJUVANT IMATINIB IN LOCALLY ADVANCED GASTROINTESTINAL STROMAL TUMORS (GIST) IS EFFECTIVE AND SAFE: RESULTS FROM A PROSPECTIVE SINGLE CENTER STUDY WITH 108 PATIENTS
Koen Hartemink
Favorite
(P 32) IMPROVEMENT OF QUALITY AND TEXTBOOK OUTCOMES OF GASTRIC GASTROINTESTINAL STROMAL TUMOR (GIST) RESECTIONS IN THE PAST 13 YEARS; THE INFLUENCE OF MINIMAL INVASIVE SURGERY (MIS)
Koen Hartemink
Favorite
Hartgrink, Henk

Leiden university medical center
(P 32) IMPROVEMENT OF QUALITY AND TEXTBOOK OUTCOMES OF GASTRIC GASTROINTESTINAL STROMAL TUMOR (GIST) RESECTIONS IN THE PAST 13 YEARS; THE INFLUENCE OF MINIMAL INVASIVE SURGERY (MIS)
Henk Hartgrink
Favorite
Hartmann, Wolfgang

University Hospital Münster
(P 17) METASTASIS-SPECIFIC GENE EXPRESSION PATTERNS IN EWING SARCOMA
Wolfgang Hartmann
Favorite
(P 451) IMPACT OF TIME TO DIAGNOSIS - A PROSPECTIVE ANALYSIS OF THE EWING 2008 TRIAL
Wolfgang Hartmann
Favorite
(P 538) IEUROEWING TRIAL FOR LOCALIZED AND METASTATIC EWING SARCOMA
Wolfgang Hartmann
Favorite
Hartner, Lee

Abramson Cancer Center
(P 439) THE TETRAVALENT DEATH RECEPTOR 5 AGONIST INBRX-109 COMBINED WITH CHEMOTHERAPY IN EWING SARCOMA: PRELIMINARY DATA FROM A PHASE 1 STUDY
Lee Hartner
Favorite
(P 552) RANDOMIZED PHASE II TRIAL OF CABOZANTINIB COMBINED WITH PD-1 AND CTLA-4 INHIBITION VERSUS CABOZANTINIB IN METASTATIC SOFT TISSUE SARCOMA.
Lee Hartner
Favorite
Hasgur, Suheyla

Cleveland Clinic
(P 429) SARCOMA FUSION GENE ANALYSIS YIELDS PROMISING HLA ANTIGEN FIT IN EWING SARCOMA AND DESMOPLASTIC SMALL ROUND CELL TUMOR
Suheyla Hasgur
Favorite
Hashemi, Lily

University of Miami
(P 54) HIGH-THROUGHPUT DRUG SCREENING IN CHONDROSARCOMA CELLS IDENTIFIES MULTIPLE EFFICIENT ANTINEOPLASTIC AGENTS
Lily Hashemi
Favorite
Hassett, Michael

Dana Farber Cancer Institute
(P 177) ANGIOSARCOMA: AN INCREASING PROBLEM IN THE UNITED STATES
Michael Hassett
Favorite
Hatcher, Helen

Cambridge University Hospitals NHS Foundation Trust
(P 204) RADIATION-INDUCED ANGIOSARCOMA OF THE BREAST: RETROSPECTIVE ANALYSIS AT A REGIONAL TREATMENT CENTRE
Helen Hatcher
Favorite
(P 205) PRIMARY CARDIAC SARCOMA: A RETROSPECTIVE ANALYSIS OF PRESENTATION, MANAGEMENT AND OUTCOMES
Helen Hatcher
Favorite
Hattinger, Claudia

Istituto Ortopedico Rizzoli IRCCS, Osteoncology- Bone and Soft Tissue Sarcomas and Innovative Therapies Unit, Bologna, Italy
(P 253) THE EFFICACY OF MEDICATED PATCHES IN SOFT TISSUE SARCOMAS: IN-VITRO AND EX-VIVO VALIDATION.
Claudia Hattinger
Favorite
Hauser, Peter

Semmelweis University
(P 451) IMPACT OF TIME TO DIAGNOSIS - A PROSPECTIVE ANALYSIS OF THE EWING 2008 TRIAL
Peter Hauser
Favorite
Haveman, Lianne

Princess Máxima Center for Pediatric Oncology
(P 437) ULTRA-RARE UNDIFFERENTIATED SMALL ROUND CELL SARCOMA: HOW SHOULD WE TREAT THEM? AN ANALYSIS FORM THE GRACEFUL PROJECT
Lianne Haveman
Favorite
(P 451) IMPACT OF TIME TO DIAGNOSIS - A PROSPECTIVE ANALYSIS OF THE EWING 2008 TRIAL
Lianne Haveman
Favorite
Hawinkels, Lukas

LUMC
(P 368) DECODING THE IMMUNOGENOMIC DETERMINANTS OF RADIOTHERAPY RESPONSE IN SOFT TISSUE SARCOMAS
Lukas Hawinkels
Favorite
Hawkins, C. Matthew

Children's Healthcare of Atlanta - Emory University School of Medicine
(P 81) OPTIMIZING EWING SARCOMA AND OSTEOSARCOMA BIOPSY ACQUISITION: CONSENSUS RECOMMENDATIONS FROM THE CHILDREN'S ONCOLOGY GROUP BONE TUMOR COMMITTEE
C. Matthew Hawkins
Favorite
Hawkins, Douglas

Seattle Children's Hospital
(P 165) MIDDLE EAR RHABDOMYOSARCOMA: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP
Douglas Hawkins
Favorite
(P 556) EVALUATION OF PALBOCICLIB (IBRANCE®) IN COMBINATION WITH CHEMOTHERAPY IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY EWING SARCOMA OR NEUROBLASTOMA
Douglas Hawkins
Favorite
Hayashi, Masanori

Children's Hospital Colorado
(P 392) IMMUNOSUPPRESSIVE TUMOR MICROENVIRONMENT OF OSTEOSARCOMA
Masanori Hayashi
Favorite
(P 537) TGFβ IMPRINTED, EX VIVO EXPANDED UNIVERSAL DONOR NATURAL KILLER CELLS WITH CHEMOTHERAPY FOR RELAPSED BONE AND SOFT TISSUE SARCOMA - NCT05634369, REPORT FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION
Masanori Hayashi
Favorite
(P 551) PHASE II TRIAL OF GEMCITABINE AND NAB-PACLITAXEL IN PATIENTS WITH RECURRENT RHABDOMYOSARCOMA: A CLINICAL TRIAL IN PROGRESS FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION
Masanori Hayashi
Favorite
Hayden, James

Oregon Health & Science University
(P 130) THE ADOPTION OF MEDICAID EXPANSION IN THE AFFORDABLE CARE ACT IS NOT ASSOCIATED WITH STAGE AT PRESENTATION OR 5-YEAR OVERALL SURVIVAL FOR BONE OR SOFT TISSUE SARCOMAS
James Hayden
Favorite
(P 179) PILOT STUDY OF A REMOTELY DELIVERED RESISTANCE EXERCISE TRAINING PROGRAM IN SARCOMA SURVIVORS
James Hayden
Favorite
(P 462) EXTERNAL VALIDATION OF A NOMOGRAM PREDICTING THE RISK OF POSTOPERATIVE MAJOR WOUND COMPLICATION IN SOFT TISSUE SARCOMA FOLLOWING PREOPERATIVE RADIOTHERAPY AND RESECTION
James Hayden
Favorite
(P 463) MACHINE LEARNING CORROBORATES TRADITIONAL REGRESSION TECHNIQUES IN PREDICTING MAJOR WOUND COMPLICATIONS AFTER SOFT TISSUE SARCOMA RESECTION WITHOUT IMPROVEMENTS IN PREDICTIVE PERFORMANCE
James Hayden
Favorite
Hayden, Una

Tallaght University Hospital
(P 155) THE IMPACT OF THE ROLE OF A SARCOMA ADVANCED NURSE PRACTITIONER (ANP) BIOPSY CLINIC IN IMPROVING PATIENT ACCESS TO SARCOMA SERVICES
Una Hayden
Favorite
(P 156) PATIENT REPORTED EXPERIENCES WITHIN THE IRISH SARCOMA GROUP
Una Hayden
Favorite
(P 217) CONTEMPORARY TREATMENT PATTERNS AND OUTCOMES IN THE MANAGEMENT OF ANGIOSARCOMA IN IRELAND
Una Hayden
Favorite
Hayenga, Heather Naomi

Department of Bioengineering, University of Texas at Dallas
(P 261) EFFICACY OF BET INHIBITORS IN SOLITARY FIBROUS TUMOR: AN IN VITRO EVALUATION
Heather Naomi Hayenga
Favorite
Hayes, Andrew

Royal Marsden Hospital
(P 40) LONG TERM OUTCOMES OF NEOADJUVANT IMATINIB AND SURGICAL RESECTION OF RECTAL GASTROINTESTINAL STROMAL TUMOURS
Andrew Hayes
Favorite
(P 233) MULTI-CENTER EXTERNAL VALIDATION OF AN AUTOMATED MODEL DIFFERENTIATING ALT FROM LIPOMA USING RADIOMICS AND DEEP-LEARNING BASED SEGMENTATION
Andrew Hayes
Favorite
Hayes-Dixon, Andrea

Howard
(P 426) MULTI-OMIC ANALYSIS OF DESMOPLASTIC SMALL ROUND CELL TUMORS REVEAL DISTINCT LINEAGES
Andrea Hayes-Dixon
Favorite
Hayes, John

Northwestern Memorial Hospital
(P 219) ELECTIVE DISCONTINUATION OF SORAFENIB TREATMENT IN DESMOID TUMORS: A RETROSPECTIVE ANALYSIS WITH IMPLICATIONS FOR CLINICAL PRACTICE
John Hayes
Favorite
Healy, David

St Vincents University Hospital
(P 155) THE IMPACT OF THE ROLE OF A SARCOMA ADVANCED NURSE PRACTITIONER (ANP) BIOPSY CLINIC IN IMPROVING PATIENT ACCESS TO SARCOMA SERVICES
David Healy
Favorite
(P 156) PATIENT REPORTED EXPERIENCES WITHIN THE IRISH SARCOMA GROUP
David Healy
Favorite
(P 217) CONTEMPORARY TREATMENT PATTERNS AND OUTCOMES IN THE MANAGEMENT OF ANGIOSARCOMA IN IRELAND
David Healy
Favorite
Healy, Kathleen

Foghorn Therapeutics
(P 271) PHARMACODYNAMICS AND MECHANISTIC IMPACTS OF FHD-609, A BROMODOMAIN-CONTAINING PROTEIN 9 DEGRADER, IN A PHASE 1 STUDY IN PATIENTS WITH ADVANCED SYNOVIAL SARCOMA OR SMARCB1-LOSS TUMORS
Kathleen Healy
Favorite
Hecker-Nolting, Stefanie

Klinikum der Landeshauptstadt Stuttgart - Olgahospital
(P 69) DEVELOPMENT AND MISSION OF THE HARMONIZATION INTERNATIONAL BONE SARCOMA CONSORTIUM (HIBISCUS)
Stefanie Hecker-Nolting
Favorite
Hedman, Mattias

Karolinska University Hospital
(P 322) STEREOTACTIC BODY RADIOTHERAPY IN METASTATIC SARCOMA
Mattias Hedman
Favorite
heffernan, Eric

St Vincents University Hospital
(P 155) THE IMPACT OF THE ROLE OF A SARCOMA ADVANCED NURSE PRACTITIONER (ANP) BIOPSY CLINIC IN IMPROVING PATIENT ACCESS TO SARCOMA SERVICES
Eric heffernan
Favorite
(P 156) PATIENT REPORTED EXPERIENCES WITHIN THE IRISH SARCOMA GROUP
Eric heffernan
Favorite
(P 217) CONTEMPORARY TREATMENT PATTERNS AND OUTCOMES IN THE MANAGEMENT OF ANGIOSARCOMA IN IRELAND
Eric heffernan
Favorite
Heilig, Christoph E.

Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ)
(P 248) FIBROBLAST ACTIVATION PROTEIN ALPHA -DIRECTED IMAGING AND THERAPY OF SOLITARY FIBROUS TUMOR
Christoph E. Heilig
Favorite
Heilshorn, Sarah

Stanford University
(P 86) DECIPHERING CELL-MATRIX INTERACTIONS IN OSTEOSARCOMA RESPONSE TO CHEMOTHERAPY IN A 3D TISSUE-ENGINEERED IN VITRO MODEL
Sarah Heilshorn
Favorite
Heim, Sverre

Oslo University Hospital
(P 23) GENOMIC COMPLEXITY AS A BIOMARKER FOR ADJUVANT IMATINIB TREATMENT IN HIGH-RISK GASTROINTESTINAL STROMAL TUMOR
Sverre Heim
Favorite
Heim, Tanya

University of Pittsburgh
(P 351) TARGETING ANDROGEN RECEPTOR IN OSTEOSARCOMA CELLS WITH VARYING METASTATIC POTENTIAL
Tanya Heim
Favorite
(P 373) DEDIFFERENTIATED AND HIGH GRADE CHONDROSARCOMAS: HOW DOES ISOCITRATE DEHYDROGENASE STATUS APPRISE PROGNOSIS AND THERAPY?
Tanya Heim
Favorite
(P 466) INTRAOPERATIVE EVALUATION OF BONE AND SOFT TISSUE SARCOMA SURGICAL MARGINS WITH INDOCYANINE GREEN FLUORESCENCE IMAGING
Tanya Heim
Favorite
(P 544) INTRAOPERATIVE EVALUATION OF BONE AND SOFT TISSUE SARCOMA SURGICAL MARGINS WITH INDOCYANINE GREEN FLUORESCENCE IMAGING
Tanya Heim
Favorite
Heinhuis, Kimberley M.

Netherlands Cancer Institute/Antoni van Leeuwenhoek
(P 197) PROPRANOLOL MONOTHERAPY IN ANGIOSARCOMA - A WINDOW-OF-OPPORTUNITY STUDY (PROPANGIO)
Kimberley M. Heinhuis
Favorite
Heinrich, Michael

Portland VA Health Care System and Oregon Health & Science University Knight Cancer Institute
(P 25) PREDICTING IMATINIB RESPONSES USING IN VITRO MODELS OF PDGFRA-MUTANT GASTROINTESTINAL STROMAL TUMOR
Michael Heinrich
Favorite
(P 26) PHASE 1 STUDY OF IDRX-42 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS RESISTANT TO PRIOR SYSTEMIC THERAPY: EARLY RESULTS
Michael Heinrich
Favorite
Heins, Marianne

Nivel
(P 140) THE PRE-DIAGNOSTIC GENERAL PRACTIONER JOURNEY OF SARCOMA PATIENTS: A REAL-WORLD DATA STUDY.
Marianne Heins
Favorite
Heise, Rachel

Weil Cornell Graduate School of Medical Sciences
(P 166) SARC038: A PHASE 2 STUDY OF REGORAFENIB IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH REFRACTORY OR RECURRENT OSTEOSARCOMA
Rachel Heise
Favorite
(P 191) SARC024 COHORT D: PHASE 2 TRIAL OF REGORAFENIB IN CHILDREN, ADOLESCENTS, AND ADULTS WITH RHABDOMYOSARCOMA
Rachel Heise
Favorite
He, Kevin

Washington University in St. Louis
(P 274) TYK2 AND MEK COMBINATION THERAPY IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS AND OTHER SOFT TISSUE SARCOMAS
Kevin He
Favorite
Hembruff, Stacey

KUMC
(P 446) SYNERGISTIC TARGETING OF KIF11 AND AURKA TO IMPROVE OUTCOMES FOR EWING SARCOMA
Stacey Hembruff
Favorite
Henderson, Eric

Dartmouth/Hitchcock Medical Center
(P 529) THE MUSCULOSKELETAL TUMOR REGISTRY -- 2023 UPDATE AND OUTLOOK
Eric Henderson
Favorite
Henderson, Michael

Peter MacCallum Cancer Centre
(P 516) OUCOMES OF AGGRESSIVE RESECTION OF RADIATION INDUCED ANGIOSARCOMA OF THE BREAST
Michael Henderson
Favorite
Hendrickson, Peter

Duke Univeristy
(P 340) CENTRAL BOOST RADIATION THERAPY CAN ACHIEVE DURABLE LOCAL RESPONSE IN UNRESECTABLE RETROPERITONEAL SARCOMA
Peter Hendrickson
Favorite
(P 428) COMPREHENSIVE GENOMIC PROFILING OF CIC-DUX4 SARCOMA (CDS) CELL LINES AND MODELS
Peter Hendrickson
Favorite
(P 450) INVESTIGATING THE THERAPEUTIC POTENTIAL OF SMALL MOLECULE INHIBITOR INOBRODIB AS A TREATMENT ALTERNATIVE FOR CIC-DUX4 SARCOMA
Peter Hendrickson
Favorite
Hendrikson, Josephine

Duke NUS Medical School
(P 336) EVOLUTION AND PURSUIT OF EXCELLENCE IN SARCOMA MANAGEMENT IN AN ASIAN TERTIARY SARCOMA SPECIALISED CENTRE
Josephine Hendrikson
Favorite
Hendrix, An

Ghent University
(P 291) DEVELOPMENT OF A LIVE TISSUE SARCOMA BIOBANK TO SUPPORT THE CREATION OF PATIENT-DERIVED TRANSLATIONAL MODELS
An Hendrix
Favorite
Heng, Marilyn

University of Miami
(P 154) BARRIERS TO CARE FOR MUSCULOSKELETAL TUMORS
Marilyn Heng
Favorite
Henning, Jan-Willem

Tom Baker Cancer Center
(P 110) GCAR1: GPNMB CAR T THERAPY FOR MIT FAMILY TRANSLOCATION POSITIVE CANCERS
Jan-Willem Henning
Favorite
(P 454) TREATMENT PATTERNS AND OUTCOMES IN PEDIATRIC AND ADULT PATIENTS WITH EWING AND UNDIFFERENTIATED ROUND BLUE CELL SARCOMAS IN ALBERTA
Jan-Willem Henning
Favorite
Hermida De Viveiros, Pedro

Northwestern Medicine
(P 96) LEPTOMENINGEAL RECURRENCE OF EWING'S SARCOMA: A CASE SERIES
Pedro Hermida De Viveiros
Favorite
Hernandez Jover, Diana

Hospital de la Santa Creu i Sant Pau
(P 313) SPACIALLY-FRACTIONATED RADIOTHERAPY (LATTICE) TREATMENT IN INOPERABLE NON-EXTREMITY BULKY SOFT-TISSUE SARCOMAS
Diana Hernandez Jover
Favorite
(P 503) SCAPULAR PROSTHESIS RECONSTRUCTION, EXPERIENCE IN OUR INSTITUTION
Diana Hernandez Jover
Favorite
(P 504) WHY DO SOME PATIENTS WITH SYNOVIAL SARCOMA HAVE BETTER FUNCTIONAL OUTCOMES AFTER RESECTION SURGERY? ANALYSIS OF 102 CASES
Diana Hernandez Jover
Favorite
(P 507) PRIMARY CHEST WALL TUMORS OF MESENCHYMAL ORIGIN. EXPERIENCE OF A REFERENCE UNIT
Diana Hernandez Jover
Favorite
(P 508) DREAM, UTOPIA OR REALISM? PROGNOSTIC FACTORS IN LUNG METASTASECTOMY OF DISSEMINATED SARCOMA DISEASE
Diana Hernandez Jover
Favorite
Hernandez, Carmen Nieves

HU Canarias
(P 142) THE SARCOMA EUROPEAN AND LATIN AMERICAN NETWORK (SELNET) PROJECT: OVERVIEW OF THE MAIN RESULTS OF THE SELNET REGISTRY
Carmen Nieves Hernandez
Favorite
Hernandez, Fiorela

The University of Texas MD Anderson Cancer Center
(P 119) EX VIVO EXPANDED TUMOR INFILTRATING LYMPHOCYTES FOR SARCOMA TREATMENT
Fiorela Hernandez
Favorite
Hernandez, Lynne

Desmoid Tumor Research Foundation
(P 146) CHARACTERIZING THE PATIENT JOURNEY TO A DIAGNOSIS OF DESMOID TUMOR: DESMOID TUMOR RESEARCH FOUNDATION NATURAL HISTORY STUDY
Lynne Hernandez
Favorite
Hernandez, Paula

Hospital Clínico San Carlos
(P 515) ENDOBRONCHIAL NAVIGATION AS AN INTRAOPERATORY TOOL FOR RESECTION OF SMALL PULMONARY METASTASES IN SARCOMA PATIENTS
Paula Hernandez
Favorite
Hernando, Florentino

Hospital Clínico San Carlos
(P 149) PSYCOLOGICAL SNAPSHOT OF SARCOMA PATIENTS FROM AN ACADEMIC, UNIVERSITY CENTER, HOSPITAL CLÍNICO SAN CARLOS (HCSC), MADRID, A SARCOMA NATIONAL REFERRAL CENTRE IN SPAIN
Florentino Hernando
Favorite
(P 515) ENDOBRONCHIAL NAVIGATION AS AN INTRAOPERATORY TOOL FOR RESECTION OF SMALL PULMONARY METASTASES IN SARCOMA PATIENTS
Florentino Hernando
Favorite
Herrel, Lindsey

University of Michigan, Department of Urology
(P 07) IDENTIFYING CONCERNS OF ADOLESCENT AND YOUNG ADULT SARCOMA PATIENTS AND SURVIVORS FOLLOWING FERTIITY PRESERVATION
Lindsey Herrel
Favorite
Herrero, Ana

Hospital General Villalba
(P 113) IMMUNOSARC II: A SPANISH SARCOMA GROUP (GEIS) PHASE IB TRIAL OF DOXORUBICIN AND DACARBAZINE PLUS NIVOLUMAB IN FIRST LINE OF ADVANCED LEIOMYOSARCOMA
Ana Herrero
Favorite
Herrmann, Ken

Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen
(P 220) [68GA]GA-FAPI PET/CT AS NOVEL DIAGNOSTIC TOOL IN SARCOMA
Ken Herrmann
Favorite
(P 248) FIBROBLAST ACTIVATION PROTEIN ALPHA -DIRECTED IMAGING AND THERAPY OF SOLITARY FIBROUS TUMOR
Ken Herrmann
Favorite
Hershenhouse, Tyler

Ann & Robert H Lurie Children's Hospital of Chicago
(P 365) MULTIMODAL ANALYSIS OF NUCLEAR AND GENOMIC ORGANIZATION IN RHABDOMYOSARCOMA AND NORMAL MYOGENIC CELLS
Tyler Hershenhouse
Favorite
Heske, Christine

National Cancer Institute
(P 81) OPTIMIZING EWING SARCOMA AND OSTEOSARCOMA BIOPSY ACQUISITION: CONSENSUS RECOMMENDATIONS FROM THE CHILDREN'S ONCOLOGY GROUP BONE TUMOR COMMITTEE
Christine Heske
Favorite
Hesla, Asle

Karolinska University Hospital
(P 243) EVALUATION OF THE USE OF WGS IN ROUTINE DIAGNOSTICS FOR BONE AND SOFT TISSUE TUMORS
Asle Hesla
Favorite
(P 372) COPY NUMBER GAIN OF MDM2 IN ROD-SHAPED CHROMOSOMES PROVIDES CLUES TO EARLY STAGES IN CIRCULARIZED GENE AMPLIFICATION IN LIPOSARCOMA
Asle Hesla
Favorite
Hesse, Raphael

Boehringer Ingelheim Pharma GmbH & Co. KG, Department of Translational Medicine & Clinical Pharmacology
(P 185) LONGITUDINAL MUTATIONAL ANALYSIS OF TP53 IN CIRCULATING TUMOR DNA IN THE PLASMA OF PATIENTS WITH LIPOSARCOMA IN A PHASE I STUDY OF BRIGIMADLIN (BI 907828), AN MDM2-P53 ANTAGONIST
Raphael Hesse
Favorite
Hettler, Madelaine

Department of Surgery, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, 68167 Mannheim, Germany
(P 235) FUSION OF PREOPERATIVE IN SITU MAGNETIC RESONANCE IMAGING AND POSTOPERATIVE COMPUTED TOMOGRAPHY TO CORRELATE FUNCTIONAL IMAGING FEATURES AND PATHOLOGICAL CHARACTERISTICS OF SOFT TISSUE SARCOMA
Madelaine Hettler
Favorite
He, Yiran

The Ohio State University/Department of Chemistry and Biochemistry
(P 301) REDUCING THE INVASIVE POTENTIAL OF DEDIFFERENTIATED LIPOSARCOMA BY TARGETING ALTERNATIVE RNA SPLICING MACHINERY
Yiran He
Favorite
Hicks, John

Baylor College of Medicine / Texas Children's Hospital
(P 121) IMPROVING THE EFFICACY OF GD2 CHIMERIC ANTIGEN RECEPTOR T-CELLS USING HISTONE DEACETYLASE INHIBITORS
John Hicks
Favorite
Hiemcke-Jiwa, Laura

Princess Maxima Center for Pediatric Oncology, The Netherlands
(P 251) EVALUATION OF POTENTIAL TARGETS FOR FLUORESCENCE-GUIDED SURGERY IN PEDIATRIC EWING SARCOMA: A PRECLINICAL PROOF-OF-CONCEPT STUDY
Laura Hiemcke-Jiwa
Favorite
Hildebrand, Karys

University of Calgary
(P 105) STING THERAPY INDUCES IMMUNOGENIC ANTI-TUMOR RESPONSES THAT ARE INDEPENDENT OF TUMOR STING EXPRESSION IN THE KP MODEL OF SOFT TISSUE SARCOMA
Karys Hildebrand
Favorite
(P 106) CHARACTERIZATION OF AN IMMUNE COMPETENT, MURINE MODEL OF SOFT TISSUE SARCOMA
Karys Hildebrand
Favorite
Hildebrand, Kurt

University of Calgary
(P 105) STING THERAPY INDUCES IMMUNOGENIC ANTI-TUMOR RESPONSES THAT ARE INDEPENDENT OF TUMOR STING EXPRESSION IN THE KP MODEL OF SOFT TISSUE SARCOMA
Kurt Hildebrand
Favorite
(P 106) CHARACTERIZATION OF AN IMMUNE COMPETENT, MURINE MODEL OF SOFT TISSUE SARCOMA
Kurt Hildebrand
Favorite
Hill-Kayser, Christine

Penn Radiation Oncology
(P 68) METASTASIS-DIRECTED RADIOTHERAPY FOR EWING SARCOMA PATIENTS ENROLLED ON AEWS1221: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP (COG)
Christine Hill-Kayser
Favorite
Hindi, Nadia

Medical Oncology Department, Hospital Universitario Fundación Jiménez Díaz and Villalba General Hospital, Madrid, Spain; Medical Oncology
(P 113) IMMUNOSARC II: A SPANISH SARCOMA GROUP (GEIS) PHASE IB TRIAL OF DOXORUBICIN AND DACARBAZINE PLUS NIVOLUMAB IN FIRST LINE OF ADVANCED LEIOMYOSARCOMA
Nadia Hindi
Favorite
(P 142) THE SARCOMA EUROPEAN AND LATIN AMERICAN NETWORK (SELNET) PROJECT: OVERVIEW OF THE MAIN RESULTS OF THE SELNET REGISTRY
Nadia Hindi
Favorite
(P 174) SELISARC: A SPANISH GROUP FOR RESEARCH IN SARCOMA (GEIS) PHASE I/II TRIAL OF SELINEXOR PLUS GEMCITABINE IN SELECTED SARCOMA SUBTYPES: RESULTS OF THE PHASE I PART
Nadia Hindi
Favorite
(P 175) TRABECTEDIN PLUS RADIOTHERAPY ON SYMPHTOMATIC ADVANCED SARCOMA PATIENTS, RESULTS FROM THE SYNERGIAS STUDY: A SPANISH GROUP FOR RESEARCH IN SARCOMA (GEIS) PHASE II STUDY
Nadia Hindi
Favorite
(P 270) ALTERNATIVE SPLICING (AS) REGULATION AS A NOVEL THERAPEUTIC TARGET IN SOFT-TISSUE SARCOMA (STS)
Nadia Hindi
Favorite
(P 279) PROTEIN PHOSPHATASE 2 A INHIBITION AS A MECHANISM TO ENHANCE DOXORUBICIN ACTIVITY
Nadia Hindi
Favorite
(P 385) FIRST IN HUMAN PHASE I TRIAL OF A NOVEL DRUG DELIVERY IMPLANT MATRIX WITH SN-38 (CEB-01) FOR RETROPERITONEAL SOFT TISSUE SARCOMA
Nadia Hindi
Favorite
(P 437) ULTRA-RARE UNDIFFERENTIATED SMALL ROUND CELL SARCOMA: HOW SHOULD WE TREAT THEM? AN ANALYSIS FORM THE GRACEFUL PROJECT
Nadia Hindi
Favorite
Hirai, Toshihide

National Cancer Center Institute
(P 396) COMPREHENSIVE WHOLE-GENOME MOLECULAR PROFILING IN BONE AND SOFT TISSUE SARCOMA: MULTI-OMICS ANALYSIS OF 627 CASES ACROSS HISTOLOGIC SUBTYPES
Toshihide Hirai
Favorite
Hirakawa, Akihiro

Tokyo Medical and Dental University
(P 10) ATEZOLIZUMAB IN JAPANESE PATIENTS WITH ADVANCED ALVEOLAR SOFT PART SARCOMA: A MULTI-CENTER, SINGLE-ARM, INVESTIGATOR-INITIATED PHASE 2 TRIAL (NCCH1907)
Akihiro Hirakawa
Favorite
Hirano, Hidekazu

Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
(P 35) GENOMIC ALTERATIONS IN ADVANCED GASTROINTESTINAL STROMAL TUMORS AS REVEALED BY COMPREHENSIVE GENOMIC PROFILING TESTS
Hidekazu Hirano
Favorite
Hirata, Makoto

National Cancer Center Hospital
(P 396) COMPREHENSIVE WHOLE-GENOME MOLECULAR PROFILING IN BONE AND SOFT TISSUE SARCOMA: MULTI-OMICS ANALYSIS OF 627 CASES ACROSS HISTOLOGIC SUBTYPES
Makoto Hirata
Favorite
Hirbe, Angela

Washington University in St. Louis
(P 180) HEALTH RELATED QUALITY OF LIFE OF PATIENTS WITH ADVANCED LEIOMYOSARCOMA AND OTHER SOFT TISSUE SARCOMAS TREATED WITH CABOZANTINIB AND TEMOZOLOMIDE
Angela Hirbe
Favorite
(P 187) PALLIATIVE LATTICE STEREOTACTIC BODY RADIOTHERAPY FOR PATIENTS WITH SARCOMA
Angela Hirbe
Favorite
(P 250) SHARING HIGH-QUALITY SAMPLES AND DATA TO THE NF1 RESEARCH COMMUNITY: THE ROLE OF THE JOHNS HOPKINS NF1 BIOSPECIMEN REPOSITORY
Angela Hirbe
Favorite
(P 274) TYK2 AND MEK COMBINATION THERAPY IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS AND OTHER SOFT TISSUE SARCOMAS
Angela Hirbe
Favorite
(P 552) RANDOMIZED PHASE II TRIAL OF CABOZANTINIB COMBINED WITH PD-1 AND CTLA-4 INHIBITION VERSUS CABOZANTINIB IN METASTATIC SOFT TISSUE SARCOMA.
Angela Hirbe
Favorite
Hirmas, Nader

Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen
(P 220) [68GA]GA-FAPI PET/CT AS NOVEL DIAGNOSTIC TOOL IN SARCOMA
Nader Hirmas
Favorite
Hirose, Takeshi

Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kyushu University
(P 406) EXTENSIVE ANALYSIS OF 59 SARCOMA-RELATED FUSION GENES IDENTIFIED PAZOPANIB AS A POTENTIAL INHIBITOR TO COL1A1-PDGFB FUSION GENE
Takeshi Hirose
Favorite
Hirose, Toshiharu

Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
(P 35) GENOMIC ALTERATIONS IN ADVANCED GASTROINTESTINAL STROMAL TUMORS AS REVEALED BY COMPREHENSIVE GENOMIC PROFILING TESTS
Toshiharu Hirose
Favorite
Hirst, Martin

Michael Smith Laboratories, University of British Columbia
(P 267) NEW MOUSE MODEL OF SYNOVIAL SARCOMA BASED ON CONDITIONAL EXPRESSION IN MESENCHYMAL PROGENITORS
Martin Hirst
Favorite
Hiruma, Toru

Kanagawa Cancer Center
(P 396) COMPREHENSIVE WHOLE-GENOME MOLECULAR PROFILING IN BONE AND SOFT TISSUE SARCOMA: MULTI-OMICS ANALYSIS OF 627 CASES ACROSS HISTOLOGIC SUBTYPES
Toru Hiruma
Favorite
Hiruma, Yoshiharu

Daiichi Sankyo, Co., Ltd.
(P 168) A PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF PEXIDARTINIB IN ASIAN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR
Yoshiharu Hiruma
Favorite
Hoang, Bang

Montefiore Medical Center
(P 392) IMMUNOSUPPRESSIVE TUMOR MICROENVIRONMENT OF OSTEOSARCOMA
Bang Hoang
Favorite
Hoberman, Matthew

Lirum Therapeutics
(P 11) LX-101, A NOVEL, CLINICAL STAGE, PAYLOAD-BEARING TARGETED THERAPY DIRECTED TO THE INSULIN-LIKE GROWTH FACTOR RECEPTOR, HAS POTENT PRECLINICAL ANTI-TUMOR ACTIVITY AGAINST PEDIATRIC SARCOMAS
Matthew Hoberman
Favorite
Hodge, Allen

Massachusetts General
(P 181) REAL-WORLD EXPERIENCE WITH LIPOSOMAL DOXORUBICIN IN METASTATIC AND LOCALLY ADVANCED SARCOMA
Allen Hodge
Favorite
Hofer, Silvia

University Hospital Zurich
(P 138) CONTROVERSIES IN THE MANAGEMENT OF PATIENTS WITH SOFT TISSUE SARCOMA: RESULTS AND RECOMMENDATIONS FROM THE FIRST CONFERENCE ON STATE OF SCIENCE IN SARCOMA (CSSS)
Silvia Hofer
Favorite
(P 437) ULTRA-RARE UNDIFFERENTIATED SMALL ROUND CELL SARCOMA: HOW SHOULD WE TREAT THEM? AN ANALYSIS FORM THE GRACEFUL PROJECT
Silvia Hofer
Favorite
Hoffmann, jürgen

University Hospital Heidelberg
(P 133) TEN RECOMMENDATIONTS FOR SARCOMA SURGERY: CONSENSUS OF THE SURGICAL SOCIETIES BASED ON THE GERMAN S3 GUIDELINE "ADULT SOFT TISSUE SARCOMA"
jürgen Hoffmann
Favorite
Hofland, Ingrid

Netherlands Cancer Institute/Antoni van Leeuwenhoek
(P 197) PROPRANOLOL MONOTHERAPY IN ANGIOSARCOMA - A WINDOW-OF-OPPORTUNITY STUDY (PROPANGIO)
Ingrid Hofland
Favorite
Hogeland, Grantham

Momentum Metrix, LLC
(P 111) INTERIM ANALYSIS OF A PHASE 1 STUDY USING IL12-FHAB WITH OPTIMIZED PHARMACOKINETICS
Grantham Hogeland
Favorite
Hoglund, Virginia

Seattle Children's Research Institute
(P 448) CAF-LIKE EWING SARCOMA CELLS DEPOSIT PRO-TUMORIGENIC EXTRACELLULAR MATRIX IN RESPONSE TO TGF-BETA SIGNALING
Virginia Hoglund
Favorite
Hohenberger, Peter

Sarcoma Unit, Department of Surgery and Mannheim Cancer Center, University Medical Center Mannheim, University of Heidelberg, Mannheim,Germany
(P 12) MULTIFOCAL AND DISSEMINATED SPORADIC DESMOID TUMOUR OF THE EXTREMITIES: A SPECIAL CHALLENGE
Peter Hohenberger
Favorite
(P 133) TEN RECOMMENDATIONTS FOR SARCOMA SURGERY: CONSENSUS OF THE SURGICAL SOCIETIES BASED ON THE GERMAN S3 GUIDELINE "ADULT SOFT TISSUE SARCOMA"
Peter Hohenberger
Favorite
(P 342) THE EVALUATION AND OUTCOMES OF MESENTERIC AND INTRA-ABDOMINAL DESMOIDS: A TARPSWG STUDY
Peter Hohenberger
Favorite
(P 488) POSTOPERATIVE DRAINAGE MANAGEMENT AND WOUND COMPLICATIONS FOLLOWING RESECTION OF LOWER LIMB SOFT TISSUE TUMORS
Peter Hohenberger
Favorite
Hokamp, Karsten

TCD
(P 424) INTERNAL TANDEM DUPLICATION OF BCOR (BCOR-ITD) ALTERS THE TUMOR EPIGENOME
Karsten Hokamp
Favorite
Holloway, Caroline

BC Cancer
(P 215) IMPACT OF FRONTLINE SYSTEMIC TREATMENT CHOICE ON CLINICAL OUTCOME IN ADVANCED LEIOMYOSARCOMA: A MULTI-CENTRE RETROSPECTIVE CANSARCC STUDY
Caroline Holloway
Favorite
Hølmebakk, Toto

Oslo University Hospital, The Norwegian Radium Hospital
(P 23) GENOMIC COMPLEXITY AS A BIOMARKER FOR ADJUVANT IMATINIB TREATMENT IN HIGH-RISK GASTROINTESTINAL STROMAL TUMOR
Toto Hølmebakk
Favorite
Holthuis, Emily

Netherlands Cancer Institute - Antoni van Leeuwenhoek
(P 140) THE PRE-DIAGNOSTIC GENERAL PRACTIONER JOURNEY OF SARCOMA PATIENTS: A REAL-WORLD DATA STUDY.
Emily Holthuis
Favorite
Holt, Robert

University of British Columbia
(P 110) GCAR1: GPNMB CAR T THERAPY FOR MIT FAMILY TRANSLOCATION POSITIVE CANCERS
Robert Holt
Favorite
Homicsko, Krisztian

CHUV
(P 103) LASTING COMPLETE RESPONSE TO PEMBROLIZUMAB IN MISMATCH REPAIR DEFICIENT CARDIAC SARCOMA: A GENOMIC CHARACTERIZATION
Krisztian Homicsko
Favorite
Hompes, Daphne

University Hospitals Gasthuisberg Leuven
(P 152) EVALUATING DIAGNOSTIC APPROACHES TO DERMATOFIBROSARCOMA PROTUBERANS: AN OPPORTUNITY TO REDUCE THE NUMBER OF INTERVENTIONS
Daphne Hompes
Favorite
(P 254) A COLLECTION OF PATIENT-DERIVED XENOGRAFT MODELS OF GASTROINTESTINAL STROMAL TUMORS
Daphne Hompes
Favorite
Hompland, Ivar

Oslo University Hospital
(P 23) GENOMIC COMPLEXITY AS A BIOMARKER FOR ADJUVANT IMATINIB TREATMENT IN HIGH-RISK GASTROINTESTINAL STROMAL TUMOR
Ivar Hompland
Favorite
Hong, Angela

Sydney Medical School, The University of Sydney and Department of Radiation Oncology, Chris O’Brien Lifehouse, Sydney Australia.
(P 437) ULTRA-RARE UNDIFFERENTIATED SMALL ROUND CELL SARCOMA: HOW SHOULD WE TREAT THEM? AN ANALYSIS FORM THE GRACEFUL PROJECT
Angela Hong
Favorite
Hong, David

The University of Texas MD Anderson Cancer Center
(P 353) UPDATED EFFICACY AND SAFETY OF LAROTRECTINIB IN ADULT PATIENTS WITH TRK FUSION SARCOMAS
David Hong
Favorite
Hongkun, Tian

Huazhong University of Science and Technology
(P 38) EFFICACY AND SAFETY OF RIPRETINIB IN THE TREATMENT OF ADVANCED GASTROINTESTINAL STROMAL TUMORS: A MULTICENTER RETROSPECTIVE STUDY
Tian Hongkun
Favorite
Hongo, Michio

Akita University Graduate School of Medicine
(P 469) IMPACT OF A SPECIALIZED OUTPATIENT CLINIC ON BONE MRTASTASIS AND ITS BURDEN ON SPINE SURGEONS
Michio Hongo
Favorite
Honoki, Kanya

Nara Medical University
(P 259) LOVASTATIN INDUCES NOVEL CELL DEATH THROUGH THE IMPAIRED MITOCHONDRIA IRON UTILIZATION IN OSTEOASRCOMA CELLS.
Kanya Honoki
Favorite
(P 396) COMPREHENSIVE WHOLE-GENOME MOLECULAR PROFILING IN BONE AND SOFT TISSUE SARCOMA: MULTI-OMICS ANALYSIS OF 627 CASES ACROSS HISTOLOGIC SUBTYPES
Kanya Honoki
Favorite
Horan, Gail

Cambridge University Hospitals NHS Foundation Trust
(P 204) RADIATION-INDUCED ANGIOSARCOMA OF THE BREAST: RETROSPECTIVE ANALYSIS AT A REGIONAL TREATMENT CENTRE
Gail Horan
Favorite
Horiuchi, Keisuke

National Defense Medical College
(P 396) COMPREHENSIVE WHOLE-GENOME MOLECULAR PROFILING IN BONE AND SOFT TISSUE SARCOMA: MULTI-OMICS ANALYSIS OF 627 CASES ACROSS HISTOLOGIC SUBTYPES
Keisuke Horiuchi
Favorite
Hornicek, Francis

University of Miami
(P 280) A CELL-BASED COMPOUND SCREENING IDENTIFIES AGENTS THAT SYNERGIZE WITH EVEROLIMUS IN SARCOMA
Francis Hornicek
Favorite
Horrigan, Kim

Foghorn Therapeutics
(P 271) PHARMACODYNAMICS AND MECHANISTIC IMPACTS OF FHD-609, A BROMODOMAIN-CONTAINING PROTEIN 9 DEGRADER, IN A PHASE 1 STUDY IN PATIENTS WITH ADVANCED SYNOVIAL SARCOMA OR SMARCB1-LOSS TUMORS
Kim Horrigan
Favorite
Hoshina, Yukari

National Cancer Center Hospital
(P 10) ATEZOLIZUMAB IN JAPANESE PATIENTS WITH ADVANCED ALVEOLAR SOFT PART SARCOMA: A MULTI-CENTER, SINGLE-ARM, INVESTIGATOR-INITIATED PHASE 2 TRIAL (NCCH1907)
Yukari Hoshina
Favorite
Hoskin, Peter

University of Manchester
(P 318) DEVELOPMENT OF NOVEL OUTLINING GUIDELINES FOR NORMAL TISSUE STRUCTURES FOR LIMB SOFT TISSUE SARCOMA.
Peter Hoskin
Favorite
Hossain, Mahabuba Binta

The Christie NHS Foundation Trust
(P 337) CLINICAL OUTCOME OF THE PATIENTS WITH HIGH GRADE UTERINE SARCOMA: A SINGLE CENTRE REAL WORLD EXPERIENCE
Mahabuba Binta Hossain
Favorite
Hossann, Martin

Thermosome GmbH
(P 530) FIH PHASE I STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND ANTITUMOR ACTIVITY OF THE001 COMBINED WITH REGIONAL HYPERTHERMIA IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOFT TISSUE SARCOMA
Martin Hossann
Favorite
Ho, Thanh

Mayo Clinic
(P 02) PEDIATRIC SYNOVIAL SARCOMA: A REVIEW OF 21 CASES FROM A SINGLE INSTITUTION
Thanh Ho
Favorite
(P 61) ADJACENT VENOUS TUMOR THROMBUS IN PRIMARY OSTEOSARCOMA OF THE PELVIS AND EXTREMITIES
Thanh Ho
Favorite
(P 196) TOLERABILITY AND OUTCOMES FOR TREATMENT OF OLDER MYXOID LIPOSARCOMA POPULATION
Thanh Ho
Favorite
(P 440) LONG TERM OUTCOMES OF EWING SARCOMA OF THE FOOT AND ANKLE
Thanh Ho
Favorite
(P 518) OUTCOMES OF NON-ANGIOSARCOMA RADIATION-ASSOCIATED SOFT TISSUE SARCOMAS OF THE CHEST
Thanh Ho
Favorite
Hotta, Hiraku

Tokyo Dental College Ichikawa General Hospital
(P 87) ANGIOSARCOMA OF THE ILIUM TREATED WITH HEMIPELVECTOMY AND HIP TRANSPOSITION FOLLOWED BY POSTOPERATIVE CHEMOTHERAPY WITH PAZOPANIB: A CASE REPORT
Hiraku Hotta
Favorite
Houdek, Matthew

Mayo Clinic
(P 02) PEDIATRIC SYNOVIAL SARCOMA: A REVIEW OF 21 CASES FROM A SINGLE INSTITUTION
Matthew Houdek
Favorite
(P 59) CHONDROSARCOMA OF THE FLAT BONES: DIFFERENTIAL SURVIVAL BETWEEN HIGH GRADE LESIONS OF THE PELVIS AND SCAPULA
Matthew Houdek
Favorite
(P 60) SKIP LESIONS IN CHONDROSARCOMA: IS WHOLE BONE IMAGING NECESSARY?
Matthew Houdek
Favorite
(P 61) ADJACENT VENOUS TUMOR THROMBUS IN PRIMARY OSTEOSARCOMA OF THE PELVIS AND EXTREMITIES
Matthew Houdek
Favorite
(P 62) PROSTHESIS-ASSOCIATED SARCOMA: A REVIEW OF 8 HIGH-GRADE LESIONS ARISING AROUND A TOTAL JOINT ARTHROPLASTY IMPLANT
Matthew Houdek
Favorite
(P 196) TOLERABILITY AND OUTCOMES FOR TREATMENT OF OLDER MYXOID LIPOSARCOMA POPULATION
Matthew Houdek
Favorite
(P 440) LONG TERM OUTCOMES OF EWING SARCOMA OF THE FOOT AND ANKLE
Matthew Houdek
Favorite
(P 465) UNPLANNED EXCISION OF SYNOVIAL SARCOMA: FACTORS ASSOCIATED WITH RECURRENCE AND SURVIVAL
Matthew Houdek
Favorite
(P 482) COMPARISON OF RECONSTRUCTIVE TECHNIQUES FOR METASTATIC DISEASE IN THE PROXIMAL HUMERUS
Matthew Houdek
Favorite
(P 491) COMPARISON OF FIXATION TECHNIQUES FOR METASTATIC DISEASE OF THE HUMERUS
Matthew Houdek
Favorite
(P 518) OUTCOMES OF NON-ANGIOSARCOMA RADIATION-ASSOCIATED SOFT TISSUE SARCOMAS OF THE CHEST
Matthew Houdek
Favorite
Houghton, Peter

Greehey Children's Cancer Research Institute
(P 203) PRECLINICAL EVALUATION AMG 650, A SMALL MOLECULE INHIBITOR OF KIF18A, IN PEDIATRIC SOLID TUMORS BY THE PEDIATRIC PRECLINICAL IN VIVO TESTING (PIVOT) PROGRAM
Peter Houghton
Favorite
(P 305) A NEW MOUSE MODEL FOR TESTING SPLICE-SWITCHING THERAPIES IN RHABDOMYOSARCOMA
Peter Houghton
Favorite
Hou, Huige

Department of Bone and Joint Surgery and Sports Medicine Center, The First Affiliated Hospital, Jinan University
(P 543) MANEUVER STUDY: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF PIMICOTINIB (ABSK021) TO ASSESS THE EFFICACY AND SAFETY IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR
Huige Hou
Favorite
Houlier, Aurélie

Centre Léon Bérard
(P 382) NTRK1/2/3 FUSIONS DETECTION USING RNA-SEQ IN MESENCHYMAL TUMORS REVEALS ULTRA-RARE AND HISTO-SPECIFIC TARGETABLE ALTERATIONS: EXPERIENCE OF AN EXTENSIVE ROUTINE RESEARCH PROGRAM.
Aurélie Houlier
Favorite
Hounschell, Corey

University of Kansas, Department of Surgery
(P 214) SIGNIFICANT TREATMENT RESPONSE IN PATIENTS WITH PRIMARY RESECTABLE EXTREMITY MYXOID LIPOSARCOMA RECEIVING NEOADJUVANT TRABECTEDIN AND RADIATION
Corey Hounschell
Favorite
Houtman, Jon

University of Iowa
(P 115) EFFICACY AND CORREALTIVE ANALYSIS OF USING NEOADJUVANT INTRATUMORAL HIGH DOSE TALIMOGENE LAHERPAREPVEC (TVEC) WITH CONCURRENT RADIATION IN HIGH-RISK EXTREMITY AND TRUNK SOFT-TISSUE SARCOMAS
Jon Houtman
Favorite
Hovig, Eivind

Oslo University Hospital
(P 23) GENOMIC COMPLEXITY AS A BIOMARKER FOR ADJUVANT IMATINIB TREATMENT IN HIGH-RISK GASTROINTESTINAL STROMAL TUMOR
Eivind Hovig
Favorite
Howard, Sophia

Peel Therapeutics
(P 565) AN EARLY PHASE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF PEEL-224 IN PATIENTS WITH ADVANCED SOLID TUMORS
Sophia Howard
Favorite
Ho, Wing

University College London
(P 496) WHAT ARE THE EXPERIENCES OF BALANCE, GAIT AND NEURO-MUSCULAR CONTROL OUTCOMES AFTER PROXIMAL FEMORAL REPLACEMENTS FOR MUSCULOSKELETAL TUMOURS?
Wing Ho
Favorite
Hsu, Chia-Lang

National Taiwan University Hospital
(P 350) LIVER ANGIOSARCOMA IS ASSOCIATED WITH ARISTOLOCHIC ACID EXPOSURE AND HAS A DISTINCT TELOMERE MAINTENANCE MECHANISM
Chia-Lang Hsu
Favorite
(P 399) CRITICAL MOLECULAR PATHWAYS ASSOCIATED WITH DIFFERENT HISTOPATHOLOGY FEATURES AND DETAILED PATTERNS OF IMMUNE CELL INFILTRATES IN EPITHELIOID HEMANGIOENDOTHELIOMA (EHE)
Chia-Lang Hsu
Favorite
Hsu, Chiun

National Taiwan University Cancer Center
(P 350) LIVER ANGIOSARCOMA IS ASSOCIATED WITH ARISTOLOCHIC ACID EXPOSURE AND HAS A DISTINCT TELOMERE MAINTENANCE MECHANISM
Chiun Hsu
Favorite
Hsu, Johann

Levine Cancer Institute
(P 258) THE CRITICALITY OF OXIDATIVE PHOSPHORYLATION IN SYNOVIAL SARCOMA METASTASIS
Johann Hsu
Favorite
Huang, Mei

Department of Retroperitoneal Tumor Surgery, Peking University International Hospital
(P 534) NEOADJUVANT CHEMOTHERAPY COMBINED WITH TARGETED TREATMENT IN HIGH-RISK RETROPERITONEAL SARCOMA – A PROSPECTIVE NON-RANDOMIZED CONTROLLED MULTI-CENTERED STUDY ALL ACROSS CHINA
Mei Huang
Favorite
Huang, Michelle

Stanford University
(P 86) DECIPHERING CELL-MATRIX INTERACTIONS IN OSTEOSARCOMA RESPONSE TO CHEMOTHERAPY IN A 3D TISSUE-ENGINEERED IN VITRO MODEL
Michelle Huang
Favorite
Huang, Paul

The Institute of Cancer Research
(P 376) MULTI-OMIC PROFILING OF LEIOMYOSARCOMA IDENTIFIES MARKERS PREDICTIVE OF RESPONSE TO GEMCITABINE AND DOCETAXEL
Paul Huang
Favorite
(P 404) PROTEOMIC PROFILING OF THE SOFT TISSUE SARCOMA MICROENVIRONMENT IDENTIFIES A PROGNOSTIC SIGNATURE BASED ON PROTEOGLYCAN EXPRESSION AND CD8+ TUMOUR INFILTRATING LYMPHOCYTES
Paul Huang
Favorite
(P 410) PROTEOMICS ANALYSIS IDENTIFIES A SIGNATURE THAT IMPROVES PROGNOSTIC RISK STRATIFICATION OF THE SARCULATOR NOMOGRAM IN PATIENTS WITH SOFT TISSUE SARCOMAS OF THE EXTREMITIES AND TRUNK WALL
Paul Huang
Favorite
(P 417) MULTI-OMIC CHARACTERISATION OF MOLECULAR HETEROGENEITY AND NEOADJUVANT THERAPY RESPONSE IN SYNOVIAL SARCOMAS
Paul Huang
Favorite
Huang, Shaoqing

The First Affiliated Hospital of Sun Yat-sen University
(P 45) THE LONG-TERM EFFECT OF IMATINIB WITH HEPATIC RESECTION OR OTHER LOCAL TREATMENT FOR GIST LIVER METASTASES
Shaoqing Huang
Favorite
Huang, Wei

OHSU
(P 341) A PHASE 1B STUDY TO EVALUATE PREOPERATIVE ERIBULIN IN COMBINATION WITH RADIATION IN RETROPERITONEAL SARCOMA
Wei Huang
Favorite
Huang, Yi

Washington University in St Louis
(P 187) PALLIATIVE LATTICE STEREOTACTIC BODY RADIOTHERAPY FOR PATIENTS WITH SARCOMA
Yi Huang
Favorite
Huang, Yihao

The First Affiliated Hospital of Sun Yat-sen University
(P 45) THE LONG-TERM EFFECT OF IMATINIB WITH HEPATIC RESECTION OR OTHER LOCAL TREATMENT FOR GIST LIVER METASTASES
Yihao Huang
Favorite
Hua, Yingqi

Department of Orthopedic Oncology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
(P 416) THE PROTEOGENOMIC SUBTYPING OF OSTEOSARCOMA
Yingqi Hua
Favorite
(P 543) MANEUVER STUDY: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF PIMICOTINIB (ABSK021) TO ASSESS THE EFFICACY AND SAFETY IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR
Yingqi Hua
Favorite
Hubbard, Aubrey

National Cancer Institute
(P 414) GENOMIC ANALYSIS OF EWING SARCOMA AND HERNIA IDENTIFIES A POSITIVE GENETIC CORRELATION AND SUGGESTS BOTH ARE LINKED TO AN HMGA2 VARIANT
Aubrey Hubbard
Favorite
Huber, Jazzmin

Myrovlytis Trust
(P 90) RESULTS FROM AN INTERNATIONAL SURVEY OF BONE SARCOMA PATIENTS
Jazzmin Huber
Favorite
Hu, Chen

Johns Hopkins University School of Medicine
(P 559) PROSPECTIVE PHASE II TRIAL OF PREOPERATIVE HYPOFRACTIONATED PROTON THERAPY FOR EXTREMITY AND TRUNCAL AND TRUNCAL SOFT TISSUE SARCOMA: THE PRONTO STUDY RATIONALE AND DESIGN
Chen Hu
Favorite
Hudson, Wendy

University of Minnesota
(P 84) CSF1R OVEREXPRESSION ACCELLERATES OSTEOSARCOMA TUMOR FORMATION AND GENERATES TUMORS WITH DECREASED IMMUNE CELL INFILTRATION
Wendy Hudson
Favorite
Hug, Eugen

MedAustron Ion therapy Center, Austria
(P 326) CARBON-ION RADIOTHERAPY FOR UNRESECTABLE PELVIC SARCOMAS/CHORDOMAS
Eugen Hug
Favorite
Hui, Connie

The Chinese University of Hong Kong
(P 290) PRE-CLINICAL STUDY OF TUMOR TREATING FIELDS (TTFIELDS) ALONE OR IN CONJUNCTION WITH SYSTEMIC THERAPIES IN SELECTED BONE- AND SOFT-TISSUE SARCOMAS
Connie Hui
Favorite
Huitema, Alwin

Princess Máxima Center for Pediatric Oncology, The Netherlands Cancer Institute-Antoni Van Leeuwenhoek Hospital, University Medical Center Utrecht
(P 558) TRIAL IN PROGRESS: A PHASE 1/2 STUDY OF BRIGATINIB IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH ALK POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA OR INFLAMMATORY MYOFIBROBLASTIC TUMORS (ITCC-098)
Alwin Huitema
Favorite
Huitema, Alwin D.R.

Netherlands Cancer Institute/Antoni van Leeuwenhoek
(P 197) PROPRANOLOL MONOTHERAPY IN ANGIOSARCOMA - A WINDOW-OF-OPPORTUNITY STUDY (PROPANGIO)
Alwin D.R. Huitema
Favorite
Hu, James

University of Southern California, Norris Comprehensive Cancer Center
(P 164) INTRATUMORAL INT230-6 (CISPLATIN, VINBLASTINE, SHAO) ALONE OR WITH IPILIMUMAB PROLONGED SURVIVAL WITH FAVORABLE SAFETY AND IMMUNE ACTIVATION IN ADULTS WITH REFRACTORY SARCOMAS (NCT 03058289)
James Hu
Favorite
Hume, Stephanie

Day One Biopharmaceuticals
(P 08) PRELIMINARY CLINICAL ACTIVITY OF THE TYPE II RAF INHIBITOR TOVORAFENIB IN RAF FUSION-DRIVEN RECURRENT/PROGRESSIVE SARCOMAS
Stephanie Hume
Favorite
Hung, Arthur

OHSU
(P 341) A PHASE 1B STUDY TO EVALUATE PREOPERATIVE ERIBULIN IN COMBINATION WITH RADIATION IN RETROPERITONEAL SARCOMA
Arthur Hung
Favorite
Hunt, Kelly

The University of Texas MD Anderson Cancer Center
(P 123) DEDIFFERENTIATED LIPOSARCOMAS TREATED WITH IMMUNE CHECKPOINT BLOCKADE: THE MD ANDERSON EXPERIENCE
Kelly Hunt
Favorite
(P 269) PLASMA DNA METHYLATION-BASED BIOMARKERS FOR MPNST DETECTION IN PATIENTS WITH NEUROFIBROMATOSIS TYPE 1 (NF1)
Kelly Hunt
Favorite
(P 394) LEIOMYOSARCOMA INTRATUMORAL MACROPHAGE INFILTRATES ARE ASSOCIATED WITH DISTINCT CLINICAL AND GENOMIC PRESENTATIONS
Kelly Hunt
Favorite
(P 510) PRIMARY BREAST ANGIOSARCOMA: CLINICAL AND PATHOLOGICAL FEATURES AND IMPACT ON OUTCOMES
Kelly Hunt
Favorite
Hunzeker, Ashley

University of Wisconsin La Crosse
(P 311) ROBUST VMAT TREATMENT PLANNING FOR EXTREMITY SOFT TISSUE SARCOMAS
Ashley Hunzeker
Favorite
Hurh, Eunju

C4 Therapeutics
(P 178) INITIAL RESULTS FROM A PHASE 1 STUDY OF CFT8634, A NOVEL BIFUCTIONAL DEGRADATION ACTIVATING COMPOUND (BIDAC) DEGRADER OF BRD9, IN SYNOVIAL SARCOMA AND SMARCB1-NULL TUMORS
Eunju Hurh
Favorite
Husain, Marium

The Ohio State University
(P 347) INCIDENCE AND TIMING OF RECURRENCE AFTER ADJUVANT PALBOCICLIB IN COMPLETELY RESECTED RETROPERITONEAL LIPOSARCOMA
Marium Husain
Favorite
Hussein, Atif

Memorial Healthcare Hospital
(P 128) THE IMPACT OF HISPANIC ETHNICITY IN PRESENTATION AND OUTCOMES OF PATIENTS WITH SYNOVIAL SARCOMA
Atif Hussein
Favorite
Husson, Olga

Netherlands Cancer Institute
(P 30) FINANCIAL DIFFICULTIES EXPERIENCED BY DUTCH GASTROINTESTINAL STROMAL TUMOR (GIST) PATIENTS: DATA FROM A CROSS-SECTIONAL MULTICENTER STUDY
Olga Husson
Favorite
(P 136) SETTING THE INTERNATIONAL RESEARCH AGENDA FOR SARCOMA WITH PATIENTS AND CARERS: PRELIMINARY RESULTS OF PHASE II OF THE SARCOMA PATIENT ADVOCACY GLOBAL NETWORK (SPAGN) PRIORITY SETTING PARTNERSHIP
Olga Husson
Favorite
(P 140) THE PRE-DIAGNOSTIC GENERAL PRACTIONER JOURNEY OF SARCOMA PATIENTS: A REAL-WORLD DATA STUDY.
Olga Husson
Favorite
(P 186) PATIENT REPORTED OUTCOME ASSESSMENT AND REPORTING IN RANDOMIZED CLINICAL TRIALS OF SYSTEMIC THERAPY FOR ADVANCED SOFT TISSUE SARCOMAS: A SYSTEMATIC REVIEW.
Olga Husson
Favorite
Hutzen, Brian

Nationwide Children's Hospital
(P 125) MYELOMODULATORY TREATMENTS AUGMENT THE THERAPEUTIC BENEFIT OF ONCOLYTIC VIRUS IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS BY MODULATING THE TUMOR MICROENVIRONMENT
Brian Hutzen
Favorite
Huynh, Thien Huong

University of South Florida Morsani College of Medicine
(P 511) SIGNIFICANCE OF TIP TO APEX DISTANCE IN PATHOLOGICAL AND IMPENDING PATHOLOGICAL FRACTURES OF THE PROXIMAL FEMUR
Thien Huong Huynh
Favorite
I
Iadecola, Sara

Unit of Biostatistics for Clinical Research Department of Epidemiology and Data Science, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
(P 410) PROTEOMICS ANALYSIS IDENTIFIES A SIGNATURE THAT IMPROVES PROGNOSTIC RISK STRATIFICATION OF THE SARCULATOR NOMOGRAM IN PATIENTS WITH SOFT TISSUE SARCOMAS OF THE EXTREMITIES AND TRUNK WALL
Sara Iadecola
Favorite
Iannarino, Nick

University of Michigan-Dearborn, Department of Language, Culture and the Arts
(P 07) IDENTIFYING CONCERNS OF ADOLESCENT AND YOUNG ADULT SARCOMA PATIENTS AND SURVIVORS FOLLOWING FERTIITY PRESERVATION
Nick Iannarino
Favorite
Ibáñez del Prado, Celia

Complutense University
(P 149) PSYCOLOGICAL SNAPSHOT OF SARCOMA PATIENTS FROM AN ACADEMIC, UNIVERSITY CENTER, HOSPITAL CLÍNICO SAN CARLOS (HCSC), MADRID, A SARCOMA NATIONAL REFERRAL CENTRE IN SPAIN
Celia Ibáñez del Prado
Favorite
Ibanez Sanchez, Glorymar

Memorial Sloan Kettering Cancer Center
(P 289) IDENTIFICATION OF EFFECTIVE THERAPEUTIC COMBINATIONS WITH THE NUCLEAR EXPORT PROTEIN INHIBITOR, SELINEXOR, IN PEDIATRIC SOLID TUMORS
Glorymar Ibanez Sanchez
Favorite
Ibarra, Joe

Ann & Robert H Lurie Children's Hospital of Chicago
(P 365) MULTIMODAL ANALYSIS OF NUCLEAR AND GENOMIC ORGANIZATION IN RHABDOMYOSARCOMA AND NORMAL MYOGENIC CELLS
Joe Ibarra
Favorite
Ibe, Izuchukwu

University of Mississippi
(P 484) OBESITY INCREASES THE RISK OF MAJOR WOUND COMPLICATIONS FOLLOWING PELVIC RESECTION FOR BONE SARCOMA
Izuchukwu Ibe
Favorite
Ibrahim, Mays

Tom Baker Cancer Center
(P 454) TREATMENT PATTERNS AND OUTCOMES IN PEDIATRIC AND ADULT PATIENTS WITH EWING AND UNDIFFERENTIATED ROUND BLUE CELL SARCOMAS IN ALBERTA
Mays Ibrahim
Favorite
Ibrahim, Toni

Istituto Ortopedico Rizzoli IRCCS, Osteoncology- Bone and Soft Tissue Sarcomas and Innovative Therapies Unit, Bologna, Italy
(P 01) EXTRASKELETAL EWING SARCOMA OF THE EXTREMITIES AND TRUNK IN < 25 YEARS OLD PATIENTS: A RETROSPECTIVE ANALYSIS OF A MONO-INSTITUTIONAL SERIES.
Toni Ibrahim
Favorite
(P 253) THE EFFICACY OF MEDICATED PATCHES IN SOFT TISSUE SARCOMAS: IN-VITRO AND EX-VIVO VALIDATION.
Toni Ibrahim
Favorite
(P 283) A TRIDIMENSIONAL PRECLINICAL MODEL TO STUDY HUMAN AND CANINE OSTEOSARCOMA DEVELOPMENT AND INTERACTION WITH TUMOR MICROENVIRONMENT
Toni Ibrahim
Favorite
(P 437) ULTRA-RARE UNDIFFERENTIATED SMALL ROUND CELL SARCOMA: HOW SHOULD WE TREAT THEM? AN ANALYSIS FORM THE GRACEFUL PROJECT
Toni Ibrahim
Favorite
(P 533) SAFETY AND PRELIMINARY BIOLOGICAL ACTIVITY OF A PHASE II TRIAL OF AUTOLOGOUS DENDRITIC CELLS VACCINATION IN SARCOMAS.
Toni Ibrahim
Favorite
Ichikawa, Hitoshi

National Cancer Center Research Institute
(P 76) GENETIC EVIDENCE OF METACHRONOUS DEDIFFERENTIATION OF CHONDROSARCOMA AT A DISTANT SITE
Hitoshi Ichikawa
Favorite
(P 396) COMPREHENSIVE WHOLE-GENOME MOLECULAR PROFILING IN BONE AND SOFT TISSUE SARCOMA: MULTI-OMICS ANALYSIS OF 627 CASES ACROSS HISTOLOGIC SUBTYPES
Hitoshi Ichikawa
Favorite
Ichimura, Masahiko

National Cancer Center Hospital
(P 10) ATEZOLIZUMAB IN JAPANESE PATIENTS WITH ADVANCED ALVEOLAR SOFT PART SARCOMA: A MULTI-CENTER, SINGLE-ARM, INVESTIGATOR-INITIATED PHASE 2 TRIAL (NCCH1907)
Masahiko Ichimura
Favorite
Ignazzi, Gianluca

Italian Sarcoma Group
(P 74) SACRAL CHORDOMA: A RANDOMIZED & OBSERVATIONAL STUDY ON SURGERY VS DEFINITIVE RADIOTHERAPY IN PRIMARY LOCALIZED DISEASE (SACRO). INTERIM ANALYSIS
Gianluca Ignazzi
Favorite
(P 144) IMPLEMENTATION OF THE EUROPEAN CLINICAL TRIAL REGULATION: SURVEY OF THE ITALIAN SARCOMA GROUP CENTERS
Gianluca Ignazzi
Favorite
Ijsselsteijn, Marieke

LUMC
(P 368) DECODING THE IMMUNOGENOMIC DETERMINANTS OF RADIOTHERAPY RESPONSE IN SOFT TISSUE SARCOMAS
Marieke Ijsselsteijn
Favorite
Ijzerman, Nikki

Netherlands Cancer Institute/ Antoni van Leeuwenhoek
(P 31) NEOADJUVANT IMATINIB IN LOCALLY ADVANCED GASTROINTESTINAL STROMAL TUMORS (GIST) IS EFFECTIVE AND SAFE: RESULTS FROM A PROSPECTIVE SINGLE CENTER STUDY WITH 108 PATIENTS
Nikki Ijzerman
Favorite
(P 197) PROPRANOLOL MONOTHERAPY IN ANGIOSARCOMA - A WINDOW-OF-OPPORTUNITY STUDY (PROPANGIO)
Nikki Ijzerman
Favorite
Ikegami, Masachika

Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital
(P 396) COMPREHENSIVE WHOLE-GENOME MOLECULAR PROFILING IN BONE AND SOFT TISSUE SARCOMA: MULTI-OMICS ANALYSIS OF 627 CASES ACROSS HISTOLOGIC SUBTYPES
Masachika Ikegami
Favorite
Ikegami, Masachika

Division of Cellular Signaling, National Cancer Center Research Institute
(P 406) EXTENSIVE ANALYSIS OF 59 SARCOMA-RELATED FUSION GENES IDENTIFIED PAZOPANIB AS A POTENTIAL INHIBITOR TO COL1A1-PDGFB FUSION GENE
Masachika Ikegami
Favorite
Ikuta, Kunihiro

Nagoya University Hospital
(P 163) SELUMETINIB IN JAPANESE PEDIATRIC PATIENTS WITH SYMPTOMATIC INOPERABLE PLEXIFORM NEUROFIBROMA IN NEUROFIBROMATOSIS TYPE 1
Kunihiro Ikuta
Favorite
Ilaslan, Hakan

Cleveland clinic
(P 242) WHOLE BODY PET/MRI FOR STAGING OF MYXOID LIPOSARCOMA
Hakan Ilaslan
Favorite
Imagama, Shiro

Nagoya University Hospital
(P 163) SELUMETINIB IN JAPANESE PEDIATRIC PATIENTS WITH SYMPTOMATIC INOPERABLE PLEXIFORM NEUROFIBROMA IN NEUROFIBROMATOSIS TYPE 1
Shiro Imagama
Favorite
Imoto, Seiya

The Institute of Medical Science, The University of Tokyo
(P 396) COMPREHENSIVE WHOLE-GENOME MOLECULAR PROFILING IN BONE AND SOFT TISSUE SARCOMA: MULTI-OMICS ANALYSIS OF 627 CASES ACROSS HISTOLOGIC SUBTYPES
Seiya Imoto
Favorite
Imura, Yoshinori

Osaka University
(P 05) COEFFICIENT OF VARIATION OF T2-WEIGHTED MRI PREDICTS THE PROGNOSIS OF MALIGNANT PERIPHERAL NERVE SHEATH TUMOR
Yoshinori Imura
Favorite
Indelicato, Danny

UFPTI
(P 68) METASTASIS-DIRECTED RADIOTHERAPY FOR EWING SARCOMA PATIENTS ENROLLED ON AEWS1221: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP (COG)
Danny Indelicato
Favorite
(P 81) OPTIMIZING EWING SARCOMA AND OSTEOSARCOMA BIOPSY ACQUISITION: CONSENSUS RECOMMENDATIONS FROM THE CHILDREN'S ONCOLOGY GROUP BONE TUMOR COMMITTEE
Danny Indelicato
Favorite
Ingham, Matthew

Columbia University Medical Center
(P 164) INTRATUMORAL INT230-6 (CISPLATIN, VINBLASTINE, SHAO) ALONE OR WITH IPILIMUMAB PROLONGED SURVIVAL WITH FAVORABLE SAFETY AND IMMUNE ACTIVATION IN ADULTS WITH REFRACTORY SARCOMAS (NCT 03058289)
Matthew Ingham
Favorite
(P 182) UPDATED RESULTS FROM AN ONGOING PHASE 1B STUDY OF UNESBULIN (PTC596) PLUS DACARBAZINE FOR THE TREATMENT OF PATIENTS WITH ADVANCED LEIOMYOSARCOMA
Matthew Ingham
Favorite
Ingley, Katrina

University College Hospital London (UCLH)
(P 50) CHARACTERIZATION OF A FAMILIAL GIST KINDRED INTOLERANT TO IMATINIB
Katrina Ingley
Favorite
Ingram, Davis

The University of Texas MD Anderson Cancer Center
(P 100) HISTOLOGY SPECIFIC INTRATUMORAL B-CELL BIOLOGY IN ALVEOLAR SOFT-PART SARCOMAS (ASPS) IN RESPONSE TO DURVALUMAB-TREMELIMUMAB (D-T)
Davis Ingram
Favorite
(P 198) PERSONALIZED MULTIDISCIPLINARY MANAGEMENT OF SARCOMA IN PATIENTS WITH LYNCH SYNDROME
Davis Ingram
Favorite
(P 405) PRIMARY CARDIAC ANGIOSARCOMA- GENOMIC AND MOLECULAR LANDSCAPE
Davis Ingram
Favorite
(P 426) MULTI-OMIC ANALYSIS OF DESMOPLASTIC SMALL ROUND CELL TUMORS REVEAL DISTINCT LINEAGES
Davis Ingram
Favorite
Ingrosso, Matilde

Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
(P 144) IMPLEMENTATION OF THE EUROPEAN CLINICAL TRIAL REGULATION: SURVEY OF THE ITALIAN SARCOMA GROUP CENTERS
Matilde Ingrosso
Favorite
(P 378) MULTIOMICS PROFILING OF EPITHELIOID SARCOMA UNVEILS EPIGENETIC CIRCUITRIES THAT UNDERLIE THE PATHOBIOLOGY OF PROXIMAL AND CLASSIC SUBTYPES: RESULTS FROM THE ISG EPISOBS OBSERVATIONAL STUDY
Matilde Ingrosso
Favorite
Inigo, Fatima

Research Institute of the McGill University Health Center
(P 64) OSTEOSARCOMA. PATIENT-DERIVED XENOGRAFTS MODELS TO RECAPITULATE PATIENTS' CHEMORESISTANCE AND METASTATIC DISEASE
Fatima Inigo
Favorite
Innis, Scott

Foghorn Therapeutics
(P 271) PHARMACODYNAMICS AND MECHANISTIC IMPACTS OF FHD-609, A BROMODOMAIN-CONTAINING PROTEIN 9 DEGRADER, IN A PHASE 1 STUDY IN PATIENTS WITH ADVANCED SYNOVIAL SARCOMA OR SMARCB1-LOSS TUMORS
Scott Innis
Favorite
Intini, Giuseppe

University of Pittsburgh
(P 411) A SPATIAL TRANSCRIPTOMIC "GOOGLE MAP" OF HUMAN OSTEOSARCOMA REVEALS COMMON CELL CLUSTERS AT THE PRIMARY SITE AND PULMONARY METASTASES.
Giuseppe Intini
Favorite
Iovino, Anthony

Huntsman Cancer Institute/University of Utah
(P 412) LEIOMYOSARCOMA POLYANEUPLOID CANCER CELLS DEVELOP IN RESPONSE TO CHEMOTHERAPY AND CONTRIBUTE TO CHEMORESISTANCE
Anthony Iovino
Favorite
Ippolito, Joseph

University of Chicago
(P 474) PREDICTORS OF EARLY INTROWTH AND FAILURE FOLLOWING SHORT COMPRESS SPINDLE OSSEOINTEGRATION FIXATION AT THE LOWER EXTREMITIES
Joseph Ippolito
Favorite
(P 475) PRE-PLATING PRIOR TO INTERCALARY TUMOR RESECTION AND ALLOGRAFT RECONSTRUCTION: LESSONS LEARNED
Joseph Ippolito
Favorite
(P 476) FAVORABLE RESULTS FOLLOWING TREATMENT OF UNICAMERAL BONE CYSTS WITH DOXYCYCLINE SCLEROGRAFT TECHNIQUE
Joseph Ippolito
Favorite
(P 477) TREATMENT OF PROXIMAL FEMUR UNICAMERAL BONE CYSTS WITH DOXYCYCLINE SCLEROTHERAPY
Joseph Ippolito
Favorite
(P 478) TREATMENT OF CHONDROBLASTOMA WITH PERCUTANEOUS CRYOABLATION
Joseph Ippolito
Favorite
(P 479) EXPANDABLE ENDOPROSTHESES: SHOULD WE CONSIDER NARROWING OUR INDICATIONS? A SYSTEMATIC REVIEW OF THE LITERATURE AND COMPARISON OF OUTCOMES BY AGE GROUPS
Joseph Ippolito
Favorite
(P 480) TARGETED MUSCLE REINNERVATION FOR HIP DISARTICULATION - EVALUATION OF EARLY FUNCTIONAL OUTCOMES
Joseph Ippolito
Favorite
(P 481) CUSTOM ADAPTERS FOR COMPRESS SPINDLE OSSEOINTEGRATION FIXATION IN REVISION LIMB SALVAGE SURGERY OF THE DISTAL FEMUR: A CASE SERIES
Joseph Ippolito
Favorite
Isakoff, Michael

Connecticut Children's Medical Center
(P 81) OPTIMIZING EWING SARCOMA AND OSTEOSARCOMA BIOPSY ACQUISITION: CONSENSUS RECOMMENDATIONS FROM THE CHILDREN'S ONCOLOGY GROUP BONE TUMOR COMMITTEE
Michael Isakoff
Favorite
(P 392) IMMUNOSUPPRESSIVE TUMOR MICROENVIRONMENT OF OSTEOSARCOMA
Michael Isakoff
Favorite
(P 537) TGFβ IMPRINTED, EX VIVO EXPANDED UNIVERSAL DONOR NATURAL KILLER CELLS WITH CHEMOTHERAPY FOR RELAPSED BONE AND SOFT TISSUE SARCOMA - NCT05634369, REPORT FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION
Michael Isakoff
Favorite
Isella, Claudio

Candiolo Cancer Institute IRCCS FPO
(P 262) ESTABLISHMENT AND CHARACTERIZATION OF THE FIRST RADIATION-INDUCED, PATIENT-DERIVED ANGIOSARCOMA CELL LINE
Claudio Isella
Favorite
Isern Verdu, Josep

Hospital de la Santa Creu i Sant Pau
(P 313) SPACIALLY-FRACTIONATED RADIOTHERAPY (LATTICE) TREATMENT IN INOPERABLE NON-EXTREMITY BULKY SOFT-TISSUE SARCOMAS
Josep Isern Verdu
Favorite
(P 503) SCAPULAR PROSTHESIS RECONSTRUCTION, EXPERIENCE IN OUR INSTITUTION
Josep Isern Verdu
Favorite
(P 504) WHY DO SOME PATIENTS WITH SYNOVIAL SARCOMA HAVE BETTER FUNCTIONAL OUTCOMES AFTER RESECTION SURGERY? ANALYSIS OF 102 CASES
Josep Isern Verdu
Favorite
(P 507) PRIMARY CHEST WALL TUMORS OF MESENCHYMAL ORIGIN. EXPERIENCE OF A REFERENCE UNIT
Josep Isern Verdu
Favorite
(P 508) DREAM, UTOPIA OR REALISM? PROGNOSTIC FACTORS IN LUNG METASTASECTOMY OF DISSEMINATED SARCOMA DISEASE
Josep Isern Verdu
Favorite
Ishii, Takeaki

Research Institute of the McGill University Health Center
(P 64) OSTEOSARCOMA. PATIENT-DERIVED XENOGRAFTS MODELS TO RECAPITULATE PATIENTS' CHEMORESISTANCE AND METASTATIC DISEASE
Takeaki Ishii
Favorite
Ishikawa, Koji

Duke University
(P 375) IDENTIFICATION OF METASTATIC CELLS IN UNDIFFERENTIATED PLEOMORPHIC SARCOMA: SINGLE CELL RNA SEQUENCING AND CIBERSORT ANALYSIS
Koji Ishikawa
Favorite
Isler, Marc

CIUSSS Est-de-l'Île-de-Montréal
(P 134) IMPACT OF THE PARTNERSHIP BETWEEN TERTIARY CENTERS AND NON-SARCOMA RADIOLOGY CENTERS.
Marc Isler
Favorite
Istl, Alexandra

Medical College of Wisconsin
(P 181) REAL-WORLD EXPERIENCE WITH LIPOSOMAL DOXORUBICIN IN METASTATIC AND LOCALLY ADVANCED SARCOMA
Alexandra Istl
Favorite
(P 346) DETECTION OF GERMLINE VARIANTS IN PATIENTS DIAGNOSED WITH SOFT TISSUE SARCOMA USING EXPANDED
Alexandra Istl
Favorite
(P 473) GROIN PAINS: APPROACHES AND OUTCOMES FOR INGUINOFEMORAL SOFT TISSUE SARCOMAS
Alexandra Istl
Favorite
Italiano, Antoine

Institut Bergonié
(P 135) UNMET NEEDS IN LOCALLY ADVANCED (UNRESECTABLE) OR METASTATIC DEDIFFERENTIATED LIPOSARCOMA AND EXPECTATIONS FOR CLINICAL TRIALS: AN INTERNATIONAL DELPHI CONSENSUS STUDY
Antoine Italiano
Favorite
(P 300) ANTI-TUMOR ACTIVITY OF PARP7 INHIBITOR RBN-2397 IN SOFT-TISSUE SARCOMAS
Antoine Italiano
Favorite
(P 418) GENOMIC AND IMMUNOLOGICAL PROFILING OF PRIMARY AND DISTANT METASTASES OF SOFT TISSUE SARCOMAS
Antoine Italiano
Favorite
(P 437) ULTRA-RARE UNDIFFERENTIATED SMALL ROUND CELL SARCOMA: HOW SHOULD WE TREAT THEM? AN ANALYSIS FORM THE GRACEFUL PROJECT
Antoine Italiano
Favorite
(P 523) IN-BETWEEN SARCOMA: A CATEGORY OF HIGH RISK OF RECURRENCE AND POOR OUTCOME
Antoine Italiano
Favorite
Iuliani, Michele

Università Campus Bio-Medico di Roma
(P 263) HER2 AS A POTENTIAL NOVEL THERAPEUTIC TARGET IN SOFT TISSUE SARCOMAS
Michele Iuliani
Favorite
(P 264) CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS AND TRABECTEDIN IN SOFT TISSUE SARCOMA: A NOVEL POTENTIAL SYNERGY?
Michele Iuliani
Favorite
Ivanescu, Cristina

IQVIA
(P 188) IMPACT OF NIROGACESTAT ON FUNCTIONAL STATUS IN PATIENTS WITH DESMOID TUMORS: RESULTS FROM THE PHASE 3 DEFI STUDY
Cristina Ivanescu
Favorite
Iwata, Shintaro

National Cancer Center Hospital
(P 80) OPTIMIZING DOSE OF MAP THERAPY FOR CHILDREN, YOUNG ADULTS AND ADULTS WITH OSTEOSARCOMA; A SINGLE-CENTRE RETROSPECTIVE ANALYSIS
Shintaro Iwata
Favorite
(P 152) EVALUATING DIAGNOSTIC APPROACHES TO DERMATOFIBROSARCOMA PROTUBERANS: AN OPPORTUNITY TO REDUCE THE NUMBER OF INTERVENTIONS
Shintaro Iwata
Favorite
(P 332) SURGICAL OUTCOMES OF RETROPERITONEAL LIPOSARCOMA - SINGLE INSTITUTIONAL STUDY N JAPAN -
Shintaro Iwata
Favorite
(P 342) THE EVALUATION AND OUTCOMES OF MESENTERIC AND INTRA-ABDOMINAL DESMOIDS: A TARPSWG STUDY
Shintaro Iwata
Favorite
Iyer, Gopa

Memorial Sloan Kettering Cancer Center
(P 540) PHASE 2, MULTICENTER, OPEN-LABEL BASKET TRIAL OF NAB-SIROLIMUS FOR MALIGNANT SOLID TUMORS HARBORING PATHOGENIC INACTIVATING ALTERATIONS IN TSC1 AND TSC2 (PRECISION I)
Gopa Iyer
Favorite
J
Jürgens, Heribert

University Hospital Münster
(P 451) IMPACT OF TIME TO DIAGNOSIS - A PROSPECTIVE ANALYSIS OF THE EWING 2008 TRIAL
Heribert Jürgens
Favorite
Jabado, Nada

McGill University
(P 379) THE ROLE OF EZHIP IN DRIVING AGGRESSIVE OSTEOSARCOMA
Nada Jabado
Favorite
Jackson, Nina

2University of Michigan School of Social Work, Department of Anthropology
(P 07) IDENTIFYING CONCERNS OF ADOLESCENT AND YOUNG ADULT SARCOMA PATIENTS AND SURVIVORS FOLLOWING FERTIITY PRESERVATION
Nina Jackson
Favorite
Jaekers, Joris

UZ Leuven
(P 254) A COLLECTION OF PATIENT-DERIVED XENOGRAFT MODELS OF GASTROINTESTINAL STROMAL TUMORS
Joris Jaekers
Favorite
Jaffrelot, Marion

OCR
(P 201) PLEOMORPHIC RHABDOMYOSARCOMAS: A NEW ENTITY ASSOCIATED WITH LYNCH SYNDROME? FIRST RESULTS OF SARCLYNCH NATIONAL STUDY
Marion Jaffrelot
Favorite
Jagodzińska-Mucha, Paulina

Department of Soft Tissue, Bone/Sarcoma, and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.
(P 09) A NOMOGRAM MODEL TO PREDICT THE OVERALL SURVIVAL OF ADOLESCENT AND YOUNG ADULT PATIENTS WITH LOCALLY ADVANCED EWING SARCOMA.
Paulina Jagodzińska-Mucha
Favorite
Jagosky, Megan

Levine Cancer Institute
(P 258) THE CRITICALITY OF OXIDATIVE PHOSPHORYLATION IN SYNOVIAL SARCOMA METASTASIS
Megan Jagosky
Favorite
Jakob, Jens

University Medical Center Mannheim, University of Heidelberg
(P 12) MULTIFOCAL AND DISSEMINATED SPORADIC DESMOID TUMOUR OF THE EXTREMITIES: A SPECIAL CHALLENGE
Jens Jakob
Favorite
(P 133) TEN RECOMMENDATIONTS FOR SARCOMA SURGERY: CONSENSUS OF THE SURGICAL SOCIETIES BASED ON THE GERMAN S3 GUIDELINE "ADULT SOFT TISSUE SARCOMA"
Jens Jakob
Favorite
(P 138) CONTROVERSIES IN THE MANAGEMENT OF PATIENTS WITH SOFT TISSUE SARCOMA: RESULTS AND RECOMMENDATIONS FROM THE FIRST CONFERENCE ON STATE OF SCIENCE IN SARCOMA (CSSS)
Jens Jakob
Favorite
(P 153) PRIORITY SETTING PARNTERSHIP RETROPERITONEAL SOFT TISSUE SARCOMAS
Jens Jakob
Favorite
(P 235) FUSION OF PREOPERATIVE IN SITU MAGNETIC RESONANCE IMAGING AND POSTOPERATIVE COMPUTED TOMOGRAPHY TO CORRELATE FUNCTIONAL IMAGING FEATURES AND PATHOLOGICAL CHARACTERISTICS OF SOFT TISSUE SARCOMA
Jens Jakob
Favorite
(P 488) POSTOPERATIVE DRAINAGE MANAGEMENT AND WOUND COMPLICATIONS FOLLOWING RESECTION OF LOWER LIMB SOFT TISSUE TUMORS
Jens Jakob
Favorite
Jakowatz, James

UNIVERSITY OF CALIFORNIA IRVINE
(P 324) EVALUATING THE ROLE OF ADJUVANT RADIATION AFTER WIDE LOCAL EXCISION OF PLEOMORPHIC DERMAL SARCOMA
James Jakowatz
Favorite
James, Sujil

University of Cambridge
(P 204) RADIATION-INDUCED ANGIOSARCOMA OF THE BREAST: RETROSPECTIVE ANALYSIS AT A REGIONAL TREATMENT CENTRE
Sujil James
Favorite
Janeway, Katherine

Dana-Farber/Boston Children's Cancer and Blood Disorders Center
(P 03) EVOLUTION OF CLINICALLY ACTIONABLE VARIANTS IN ADVANCED PEDIATRIC AND AYA BONE SARCOMAS
Katherine Janeway
Favorite
(P 69) DEVELOPMENT AND MISSION OF THE HARMONIZATION INTERNATIONAL BONE SARCOMA CONSORTIUM (HIBISCUS)
Katherine Janeway
Favorite
(P 81) OPTIMIZING EWING SARCOMA AND OSTEOSARCOMA BIOPSY ACQUISITION: CONSENSUS RECOMMENDATIONS FROM THE CHILDREN'S ONCOLOGY GROUP BONE TUMOR COMMITTEE
Katherine Janeway
Favorite
(P 384) SYSTEMATIC LITERATURE AND CLINICAL TRIAL REVIEW SHOWS TARGETABLE KINASE FUSIONS ARE COMMON IN PEDIATRIC, ADOLESCENT, AND YOUNG ADULT SOFT TISSUE SARCOMAS BUT CLINICAL TRIAL OPPORTUNITIES REMAIN RARE
Katherine Janeway
Favorite
(P 556) EVALUATION OF PALBOCICLIB (IBRANCE®) IN COMBINATION WITH CHEMOTHERAPY IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY EWING SARCOMA OR NEUROBLASTOMA
Katherine Janeway
Favorite
Jang, Won Il

Korea Institute of Radiation and Medical Sciences
(P 281) FIVE DAY SPACING OF TWO FRACTIONATED ABLATIVE RADIOTHERAPIES ENHANCES ANTITUMOR IMMUNITY IN FIBROSARCOMA CELL LINE
Won Il Jang
Favorite
Janik, Anna

Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw, Department of Soft Tissue/Bone Sarcoma and Melanoma
(P 170) HETEROGENEITY OF PAZOPANIB ACTIVITY ACROSS SOFT TISSUE SARCOMA SUBTYPES - A RETROSPECTIVE ANALYSIS OF 303 CASES FROM A REFERENCE CENTER
Anna Janik
Favorite
Jansma, Christianne

Erasmus Medical Center and UMC Utrecht
(P 316) THE ROLE OF RADIOTHERAPY IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS: A MULTICENTER COHORT STUDY
Christianne Jansma
Favorite
(P 505) LOCAL RECURRENCE IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS: A MULTICENTER COHORT STUDY
Christianne Jansma
Favorite
Jarabo, José Ramón

Hospital Clínico San Carlos
(P 515) ENDOBRONCHIAL NAVIGATION AS AN INTRAOPERATORY TOOL FOR RESECTION OF SMALL PULMONARY METASTASES IN SARCOMA PATIENTS
José Ramón Jarabo
Favorite
Jatar, Simran

Children's National Hospital/Georgetown University School of Medicine
(P 18) RETROSPECTIVE ANALYSIS ON OUTCOMES PEDIATRIC PATIENTS WITH SARCOMA AND LUNG METASTASES STATUS POST PNEUMONECTOMY VERSUS PARTIAL LUNG RESECTION
Simran Jatar
Favorite
Jawhar, Wajih

Research Institute of the McGill University Health Center
(P 64) OSTEOSARCOMA. PATIENT-DERIVED XENOGRAFTS MODELS TO RECAPITULATE PATIENTS' CHEMORESISTANCE AND METASTATIC DISEASE
Wajih Jawhar
Favorite
(P 379) THE ROLE OF EZHIP IN DRIVING AGGRESSIVE OSTEOSARCOMA
Wajih Jawhar
Favorite
(P 434) MECHANISMS OF CHEMORESISTANCE IN CIC-DUX4 SARCOMA AS DETERMINED BY IN VIVO FUNCTIONAL GENOMICS
Wajih Jawhar
Favorite
Jawny, Philipp

Department of Cardiothoracic Surgery, University Hospital Augsburg
(P 488) POSTOPERATIVE DRAINAGE MANAGEMENT AND WOUND COMPLICATIONS FOLLOWING RESECTION OF LOWER LIMB SOFT TISSUE TUMORS
Philipp Jawny
Favorite
Jayadeva, Girish

Boehringer Ingelheim Pharmaceuticals Inc.
(P 185) LONGITUDINAL MUTATIONAL ANALYSIS OF TP53 IN CIRCULATING TUMOR DNA IN THE PLASMA OF PATIENTS WITH LIPOSARCOMA IN A PHASE I STUDY OF BRIGIMADLIN (BI 907828), AN MDM2-P53 ANTAGONIST
Girish Jayadeva
Favorite
Jebastin Thangaiah, Judith

Mayo Clinic
(P 196) TOLERABILITY AND OUTCOMES FOR TREATMENT OF OLDER MYXOID LIPOSARCOMA POPULATION
Judith Jebastin Thangaiah
Favorite
Jeffrey, Samantha

Sarcoma Oncology Center
(P 116) UPDATE ON SAINT: RESULTS OF 100 PATIENTS TREATED WITH IPILIMUMAB (I), NIVOLUMAB (N) AND TRABECTEDIN (T) AS FIRST LINE THERAPY FOR ADVANCED SOFT TISSUE SARCOMA [NCT03138161]
Samantha Jeffrey
Favorite
(P 383) AI ANALYSIS SHOWS ENHANCED CCNG1 ONCOGENE EXPRESSION IN SARCOMA TUMORS AND SUPPORTS THE USE OF DELTAREX-G, A CCNG1 INHIBITOR, AS PLATFORM THERAPY FOR ADVANCED SARCOMA
Samantha Jeffrey
Favorite
Jenney, Meriel

Department of Paediatric Oncology, Children's Hospital for Wales
(P 209) PROGNOSTIC VALUE OF EARLY RADIOLOGIC TUMOUR VOLUME RESPONSE IN RHABDOMYOSARCOMA; RESULTS OF THE EUROPEAN PAEDIATRIC SOFT TISSUE SARCOMA STUDY GROUP RMS 2005 STUDY
Meriel Jenney
Favorite
Jeremiasse, Bernadette

Department of Surgery, Princess Maxima Center for Pediatric Oncology, The Netherlands;
(P 251) EVALUATION OF POTENTIAL TARGETS FOR FLUORESCENCE-GUIDED SURGERY IN PEDIATRIC EWING SARCOMA: A PRECLINICAL PROOF-OF-CONCEPT STUDY
Bernadette Jeremiasse
Favorite
Jhawar, Sachin

The Ohio State University Wexner Medical Center
(P 315) SCALP VOLUMETRIC MODULATED ARC THERAPY USING 3D MILLED BOLUS: DOSIMITRY, TOXICITY AND OUTCOMES
Sachin Jhawar
Favorite
Jiang, Chen

Kaiser Permanente
(P 224) CO-MUTATION-DEPENDENT PROGNOSIS IN PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA
Chen Jiang
Favorite
Jiang, Yafei

Department of Orthopedic Oncology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
(P 416) THE PROTEOGENOMIC SUBTYPING OF OSTEOSARCOMA
Yafei Jiang
Favorite
Jimenez, Marta

Unicancer
(P 389) OSTEOBLASTIC-GENE SIGNATURE TO PREDICT SURVIVAL IN PEDIATRIC OSTEOSARCOMA (OS) AND TO FOLLOW PATIENTS TOWARDS LIQUID BIOPSY: A COLLABORATIVE WORK IN OS2006 PROTOCOL.
Marta Jimenez
Favorite
Jimenez, Montiel

Department of Surgery, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.
(P 385) FIRST IN HUMAN PHASE I TRIAL OF A NOVEL DRUG DELIVERY IMPLANT MATRIX WITH SN-38 (CEB-01) FOR RETROPERITONEAL SOFT TISSUE SARCOMA
Montiel Jimenez
Favorite
Jimenez, Ramon

Miami Cancer Institute
(P 320) A PROSPECTIVE MULTICENTER EXPERIENCE OF PROTON THERAPY FOR RHABDOMYOSARCOMA AND EWING SARCOMA: OUTCOMES FROM THE PROTON COLLABORATIVE GROUP REGISTRY
Ramon Jimenez
Favorite
jin, weidong

Department of General Surgery, General Hospital of Central Theater Command
(P 39) MANAGEMENT PRACTICES OF GASTROINTESTINAL STROMAL TUMORS: A QUESTIONNAIRE SURVEY OF GENERAL SURGEONS IN CHINA
weidong jin
Favorite
Jirovec, Anna

Ottawa Hospital Research Institute
(P 98) TUMOR IMMUNE PROFILING AND IDENTIFICATION OF IMMUNOTHERAPEUTIC TARGETS IN DEDIFFERENTIATED LIPOSARCOMA
Anna Jirovec
Favorite
Ji, Tao

Peking University People's Hospital
(P 464) INDOCYANINE GREEN FLUORESCENCE IMAGING MAY DETECT TUMOUR RESIDUALS DURING SURGERY FOR BONE AND SOFT-TISSUE TUMOURS
Tao Ji
Favorite
(P 487) EN BLOC RESECTION FOR SPINAL TUMORS: A SINGLE CENTER EXPERIENCE OF 113 CONSECUTIVE CASES
Tao Ji
Favorite
Jocoy, Emily L

The Jackson Laboratory
(P 203) PRECLINICAL EVALUATION AMG 650, A SMALL MOLECULE INHIBITOR OF KIF18A, IN PEDIATRIC SOLID TUMORS BY THE PEDIATRIC PRECLINICAL IN VIVO TESTING (PIVOT) PROGRAM
Emily L Jocoy
Favorite
Joensuu, Heikki

Helsinki University Hospital and University of Helsinki, Helsinki, Finland
(P 49) EFFICACY OF RIPRETINIB IN A MULTICENTER EXPANDED ACCESS PROGRAM IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS HARBOURING NON-KIT EXON 11 MUTATIONS.
Heikki Joensuu
Favorite
John, Cini

University of Calgary
(P 110) GCAR1: GPNMB CAR T THERAPY FOR MIT FAMILY TRANSLOCATION POSITIVE CANCERS
Cini John
Favorite
John, Samuel

UT Southwestern Medical Center
(P 114) PRIMARY ANALYSIS OF EFFICACY AND SAFETY OF LETETRESGENE AUTOLEUCEL (LETE-CEL) AS FIRST-LINE TREATMENT FOR UNRESECTABLE OR METASTATIC SYNOVIAL SARCOMA (SS); SUBSTUDY 1 OF IGNYTE-ESO
Samuel John
Favorite
Johnson, Debbie

IDRx, Inc
(P 26) PHASE 1 STUDY OF IDRX-42 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS RESISTANT TO PRIOR SYSTEMIC THERAPY: EARLY RESULTS
Debbie Johnson
Favorite
Johnson, Rylee

University of Washington
(P 206) A SINGLE-ARM, PHASE II STUDY OF NEOADJUVANT PEMBROLIZUMAB COMBINED WITH RADIOTHERAPY IN THE PRIMARY TREATMENT OF SOFT TISSUE SARCOMAS.
Rylee Johnson
Favorite
Johnston, Fabian

Johns Hopkins
(P 342) THE EVALUATION AND OUTCOMES OF MESENTERIC AND INTRA-ABDOMINAL DESMOIDS: A TARPSWG STUDY
Fabian Johnston
Favorite
Jolivet, Philippe

McGill University
(P 367) CHARACTERIZING HYPOXIA AND ASSOCIATED MOLECULAR FEATURES IN EXTREMITY SOFT TISSUE SARCOMA
Philippe Jolivet
Favorite
(P 376) MULTI-OMIC PROFILING OF LEIOMYOSARCOMA IDENTIFIES MARKERS PREDICTIVE OF RESPONSE TO GEMCITABINE AND DOCETAXEL
Philippe Jolivet
Favorite
Jonas, Steven

David Geffen School of Medicine, University of California, Los Angeles
(P 19) EXTRACELLULAR VESICLE CLICK MAGBEADS: A MULTIFACETED LIQUID BIOPSY PLATFORM FOR PEDIATRIC SARCOMAS
Steven Jonas
Favorite
Jonczak, Emily

Sylvester Comprehensive Cancer Center / University of Miami Hospital and Clinics
(P 128) THE IMPACT OF HISPANIC ETHNICITY IN PRESENTATION AND OUTCOMES OF PATIENTS WITH SYNOVIAL SARCOMA
Emily Jonczak
Favorite
(P 154) BARRIERS TO CARE FOR MUSCULOSKELETAL TUMORS
Emily Jonczak
Favorite
(P 158) SORAFENIB OR ANTHRACYCLINE-BASED CHEMOTHERAPY IN ADULT PATIENTS WITH PROGRESSIVE DESMOID TUMORS
Emily Jonczak
Favorite
(P 208) LOW INCIDENCE OF CANCER THERAPY-RELATED CARDIAC DYSFUNCTION IN ADULT SARCOMA PATIENTS RECEIVING DOXORUBICIN AND UPFRONT DEXRAZOXANE
Emily Jonczak
Favorite
(P 225) PAN-SARCOMA DATABASE (PSDB): A MODEL-VIEW-CONTROLLER FRAMEWORK UTILIZING REDCAP, SHINY, AND R TO CREATE A CONTINUOUS PIPELINE OF SARCOMA DATA
Emily Jonczak
Favorite
(P 226) SIGNATERA TESTING TO IDENTIFY MINIMAL RESIDUAL DISEASE IN HIGH GRADE SARCOMA
Emily Jonczak
Favorite
(P 361) MOLECULAR CHARACTERIZATION OF SOLITARY FIBROUS TUMORS BY ANATOMIC SITE AND NAB2::STAT6 FUSION VARIANT TYPE
Emily Jonczak
Favorite
(P 366) SURVIVAL DISPARITIES IN HISPANIC PATIENTS WITH SARCOMA TESTED WITH NEXT-GENERATION SEQUENCING (NGS)
Emily Jonczak
Favorite
(P 461) OUTCOMES FOR OLIGOMETASTATIC PULMONARY DISEASE RECURRENCE TREATED WITH SURGERY ALONE FOR PATIENTS WITH SOFT TISSUE SARCOMAS A CASE SERIES
Emily Jonczak
Favorite
(P 520) ORTHOPEDIC MANIFESTATIONS OF LYMPHOPROLIFERATIVE NEOPLASMS
Emily Jonczak
Favorite
Jones, Conor

Rush University Medical Center
(P 63) EVALUATION OF LOCAL RECURRENCE AND DIAGNOSTIC DISCORDANCE IN CHONDROSARCOMA PATIENTS UNDERGOING PREOPERATIVE BIOPSY
Conor Jones
Favorite
(P 232) NOVEL MRI SCORING SYSTEM TO ASSESS OSSEOUS MALIGNANCY IN SOFT TISSUE SARCOMA PATIENTS FOLLOWING RADIOTHERAPY
Conor Jones
Favorite
Jones, Jennifer

Johns Hopkins All Children's Hospital
(P 193) Recent Trends in Sarcoma Trials for Children in the United States
Jennifer Jones
Favorite
Jones, Kevin

University of Utah
(P 93) INDETERMINATE CHEST LESIONS IN PATIENTS WITH BONE SARCOMA INCIDENTAL FINDING VERSUS METASTATIC DISEASE
Kevin Jones
Favorite
(P 246) IMMUNOCOMPETENT MODELING OF PLEOMORPHIC LIPOSARCOMA
Kevin Jones
Favorite
(P 267) NEW MOUSE MODEL OF SYNOVIAL SARCOMA BASED ON CONDITIONAL EXPRESSION IN MESENCHYMAL PROGENITORS
Kevin Jones
Favorite
Jones, Robin

Sarcoma Unit, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research
(P 27) A MULTICENTER RETROSPECTIVE STUDY ON THE CLINICAL BEHAVIOR OF SDH-DEFICIENT GIST
Robin Jones
Favorite
(P 40) LONG TERM OUTCOMES OF NEOADJUVANT IMATINIB AND SURGICAL RESECTION OF RECTAL GASTROINTESTINAL STROMAL TUMOURS
Robin Jones
Favorite
(P 49) EFFICACY OF RIPRETINIB IN A MULTICENTER EXPANDED ACCESS PROGRAM IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS HARBOURING NON-KIT EXON 11 MUTATIONS.
Robin Jones
Favorite
(P 135) UNMET NEEDS IN LOCALLY ADVANCED (UNRESECTABLE) OR METASTATIC DEDIFFERENTIATED LIPOSARCOMA AND EXPECTATIONS FOR CLINICAL TRIALS: AN INTERNATIONAL DELPHI CONSENSUS STUDY
Robin Jones
Favorite
(P 138) CONTROVERSIES IN THE MANAGEMENT OF PATIENTS WITH SOFT TISSUE SARCOMA: RESULTS AND RECOMMENDATIONS FROM THE FIRST CONFERENCE ON STATE OF SCIENCE IN SARCOMA (CSSS)
Robin Jones
Favorite
(P 172) PHASE 2 RESULTS FROM THE RINGSIDE PHASE 2/3 TRIAL OF AL102 FOR TREATMENT OF DESMOID TUMORS
Robin Jones
Favorite
(P 233) MULTI-CENTER EXTERNAL VALIDATION OF AN AUTOMATED MODEL DIFFERENTIATING ALT FROM LIPOMA USING RADIOMICS AND DEEP-LEARNING BASED SEGMENTATION
Robin Jones
Favorite
(P 404) PROTEOMIC PROFILING OF THE SOFT TISSUE SARCOMA MICROENVIRONMENT IDENTIFIES A PROGNOSTIC SIGNATURE BASED ON PROTEOGLYCAN EXPRESSION AND CD8+ TUMOUR INFILTRATING LYMPHOCYTES
Robin Jones
Favorite
(P 410) PROTEOMICS ANALYSIS IDENTIFIES A SIGNATURE THAT IMPROVES PROGNOSTIC RISK STRATIFICATION OF THE SARCULATOR NOMOGRAM IN PATIENTS WITH SOFT TISSUE SARCOMAS OF THE EXTREMITIES AND TRUNK WALL
Robin Jones
Favorite
(P 417) MULTI-OMIC CHARACTERISATION OF MOLECULAR HETEROGENEITY AND NEOADJUVANT THERAPY RESPONSE IN SYNOVIAL SARCOMAS
Robin Jones
Favorite
(P 437) ULTRA-RARE UNDIFFERENTIATED SMALL ROUND CELL SARCOMA: HOW SHOULD WE TREAT THEM? AN ANALYSIS FORM THE GRACEFUL PROJECT
Robin Jones
Favorite
(P 531) ENVASARC: A PIVOTAL TRIAL OF ENVAFOLIMAB AND ENVAFOLIMAB IN COMBINATION WITH IPILIMUMAB IN PATIENTS WITH ADVANCED OR METASTATIC UPS OR MFS WHO HAVE PROGRESSED ON PRIOR CHEMOTHERAPY
Robin Jones
Favorite
(P 548) A PHASE 2/3 STUDY EVALUATING THE EFFICACY AND SAFETY OF UNESBULIN IN ADVANCED LEIOMYOSARCOMA (SUNRISELMS)
Robin Jones
Favorite
(P 549) DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF AL102 FOR TREATMENT OF PROGRESSING DESMOID TUMORS: THE RINGSIDE PHASE 3 STUDY DESIGN
Robin Jones
Favorite
Jonson, Tord

Skåne University Hospital
(P 371) DISRUPTION OF THE TP53 LOCUS IN OSTEOSARCOMA LEADS TO TP53 PROMOTER GENE FUSIONS AND RESTORATION OF PARTS OF THE TP53 SIGNALLING PATHWAY
Tord Jonson
Favorite
Jordaan, Pierre

Monopar Therapeutics, Inc.
(P 184) PHASE 1B TRIAL OF CAMSIRUBICIN, A NOVEL DOXORUBICIN ANALOG, WITH CONCOMITANT PEGFILGRASTIM IN SUBJECTS WITH ADVANCED SOFT TISSUE SARCOMA TO IDENTIFY A NEW MTD/RP2D
Pierre Jordaan
Favorite
Joseph, Cissimol

MD Anderson Cancer Center
(P 36) CLINICO-GENOMIC ANALYSIS OF KIT/PDGFRA/SDH WILD-TYPE GASTROINTESTINAL STROMAL TUMORS IDENTIFIES POTENTIAL DRIVER MUTATIONS
Cissimol Joseph
Favorite
Joshi, Teja

Royal National Orthopaedic Hospital
(P 147) UNDERSTANDING THE EXPERIENCES OF PATIENTS RETURNING TO DAILY ACTIVITES AND EXERCISE FOLLOWING LIMB SPARING SURGERY FOR BONE OR SOFT TISSUE SARCOMA AROUND THE KNEE
Teja Joshi
Favorite
(P 497) STANMORE TUMOUR OUTCOMES PROJECT (STOMP)- USING INTERNATIONAL CLASSIFICATION OF FUNCTIONING, DISABILITY AND HEALTH (ICF) OUTCOMES IN SARCOMA SURVIVORS. and UNDERSTANDING THE EXPERIENCES OF PATIENTS RETURNING TO DAILY ACTIVITES AND EXERCISE FOLLOWING LIMB SPARING SURGERY FOR BONE OR SOFT TISSUE SARCOMA AROUND THE KNEE
Teja Joshi
Favorite
Joyce, David

H. Lee Moffitt Cancer Center
(P 511) SIGNIFICANCE OF TIP TO APEX DISTANCE IN PATHOLOGICAL AND IMPENDING PATHOLOGICAL FRACTURES OF THE PROXIMAL FEMUR
David Joyce
Favorite
Joyce, Kaitlyn

Rush University Medical Center
(P 307) IS RADIOTHERAPY NECESSARY FOR MANAGEMENT OF LOW GRADE MYXOID LIPOSARCOMA? A SYSTEMATIC REVIEW
Kaitlyn Joyce
Favorite
Judson, Ian

Institute of Cancer Research
(P 138) CONTROVERSIES IN THE MANAGEMENT OF PATIENTS WITH SOFT TISSUE SARCOMA: RESULTS AND RECOMMENDATIONS FROM THE FIRST CONFERENCE ON STATE OF SCIENCE IN SARCOMA (CSSS)
Ian Judson
Favorite
Juhazs-Boess, Ingolf

University Hospital Freiburg
(P 133) TEN RECOMMENDATIONTS FOR SARCOMA SURGERY: CONSENSUS OF THE SURGICAL SOCIETIES BASED ON THE GERMAN S3 GUIDELINE "ADULT SOFT TISSUE SARCOMA"
Ingolf Juhazs-Boess
Favorite
Juliao Caamaño, David Salomón

Medical Oncology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain
(P 517) PULMONARY METASTASECTOMY FOR SARCOMA: A SINGLE-INSTITUTION EXPERIENCE
David Salomón Juliao Caamaño
Favorite
Ju, Muhan

UCL
(P 04) THE CELL ATLAS OF CLEAR CELL SARCOMA
Muhan Ju
Favorite
Jung, Sungmi

Department of Pathology, McGill University Health Center
(P 64) OSTEOSARCOMA. PATIENT-DERIVED XENOGRAFTS MODELS TO RECAPITULATE PATIENTS' CHEMORESISTANCE AND METASTATIC DISEASE
Sungmi Jung
Favorite
(P 379) THE ROLE OF EZHIP IN DRIVING AGGRESSIVE OSTEOSARCOMA
Sungmi Jung
Favorite
Junker, Niels

Department of Oncology, Copenhagen University Hospital, Herlev & Gentofte Hospital
(P 157) QUALITY OF LIFE DURING TREATMENT FOR METASTATIC SARCOMA - FEASIBILITY OF ELECTRONIC PATIENT REPORTED OUTCOMES
Niels Junker
Favorite
Jurga, Anna

Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw, Department of Soft Tissue/Bone Sarcoma and Melanoma
(P 170) HETEROGENEITY OF PAZOPANIB ACTIVITY ACROSS SOFT TISSUE SARCOMA SUBTYPES - A RETROSPECTIVE ANALYSIS OF 303 CASES FROM A REFERENCE CENTER
Anna Jurga
Favorite
Jurisica, Igor

Data Science Discovery Centre for Chronic Diseases, Krembil Research Institute, Toronto Western Hospital, University Health Network, Toronto, Canada
(P 378) MULTIOMICS PROFILING OF EPITHELIOID SARCOMA UNVEILS EPIGENETIC CIRCUITRIES THAT UNDERLIE THE PATHOBIOLOGY OF PROXIMAL AND CLASSIC SUBTYPES: RESULTS FROM THE ISG EPISOBS OBSERVATIONAL STUDY
Igor Jurisica
Favorite
Just, Marissa

Division of Pediatric Hematology/Oncology, Riley Hospital for Children
(P 15) INTRAOSSEOUS RHABDOMYOSARCOMA OF THE CHEST WITH FUS:TFCP2 FUSION AND GERMLINE VARIANTS IN NF1 AND SBDS: NOVEL LOCATION AND MOLECULAR CHARACTERISTICS OF A RARE TUMOR
Marissa Just
Favorite
Jusu, Sylvester

UT MD Anderson cancer center
(P 89) GENERATION OF CHONDROCYTE-DERIVED MOUSE OSTEOSARCOMA MODELS - TRACKABLE SYSTEMS TO DELINEATE ONCOGENIC AND METASTATIC ENVENTS PRIOR TO TUMOROGENESIS
Sylvester Jusu
Favorite
K
Köster, Jan

Lund University
(P 372) COPY NUMBER GAIN OF MDM2 IN ROD-SHAPED CHROMOSOMES PROVIDES CLUES TO EARLY STAGES IN CIRCULARIZED GENE AMPLIFICATION IN LIPOSARCOMA
Jan Köster
Favorite
Köster, Johannes

Bioinformatics and Computational Oncology, University Hospital Essen
(P 234) GENOMIC LANDSCAPE OF CLEAR CELL SARCOMA
Johannes Köster
Favorite
Kadambi, Vivek

IDRx, Inc
(P 26) PHASE 1 STUDY OF IDRX-42 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS RESISTANT TO PRIOR SYSTEMIC THERAPY: EARLY RESULTS
Vivek Kadambi
Favorite
Kager, Leo

St. Anna Children's Hospital and Children's Cancer Research Institute
(P 73) FOSTER CONSORTIUM, FIGHT OSTEOSARCOMA THROUGH EUROPEAN RESEARCH
Leo Kager
Favorite
(P 384) SYSTEMATIC LITERATURE AND CLINICAL TRIAL REVIEW SHOWS TARGETABLE KINASE FUSIONS ARE COMMON IN PEDIATRIC, ADOLESCENT, AND YOUNG ADULT SOFT TISSUE SARCOMAS BUT CLINICAL TRIAL OPPORTUNITIES REMAIN RARE
Leo Kager
Favorite
Kahn, Zachary

Dana-Farber Cancer Institute
(P 384) SYSTEMATIC LITERATURE AND CLINICAL TRIAL REVIEW SHOWS TARGETABLE KINASE FUSIONS ARE COMMON IN PEDIATRIC, ADOLESCENT, AND YOUNG ADULT SOFT TISSUE SARCOMAS BUT CLINICAL TRIAL OPPORTUNITIES REMAIN RARE
Zachary Kahn
Favorite
Kai, Yoko

National Cancer Center Hospital
(P 547) A PHASE II TRIAL OF TAZEMETOSTAT FOR PATIENTS WITH UNRESECTABLE OR METASTATIC EPITHELIOID SARCOMA (TAZETTA TRIAL)
Yoko Kai
Favorite
Kaki, Lojain

University College London
(P 560) REAL-WORLD MONITORING OF PHYSICAL ACTIVITY USING AN ACCELEROMETER AFTER LOWER LIMB SURGERY FOR A SARCOMA.
Lojain Kaki
Favorite
Kalabus, James

Inhibrx, Inc
(P 439) THE TETRAVALENT DEATH RECEPTOR 5 AGONIST INBRX-109 COMBINED WITH CHEMOTHERAPY IN EWING SARCOMA: PRELIMINARY DATA FROM A PHASE 1 STUDY
James Kalabus
Favorite
Kalisvaart, Gijsbert

Leiden University Medical Center
(P 55) RELATIVE WASH-IN RATE ON DYNAMIC CONTRAST-ENHANCED MRI AS A NEW PROGNOSTIC FACTOR IN PATIENTS WITH OSTEOSARCOMA; A POSSIBLE TOOL FOR PERSONALIZED SARCOMA-CARE?
Gijsbert Kalisvaart
Favorite
(P 56) CHARACTERIZATION OF DENOSUMAB TREATMENT RESPONSE ON MR PERFUSION IN GIANT CELL TUMORS OF BONE
Gijsbert Kalisvaart
Favorite
Kalman, Noah

Miami Cancer Institute
(P 320) A PROSPECTIVE MULTICENTER EXPERIENCE OF PROTON THERAPY FOR RHABDOMYOSARCOMA AND EWING SARCOMA: OUTCOMES FROM THE PROTON COLLABORATIVE GROUP REGISTRY
Noah Kalman
Favorite
Kamal, Kousha

University of Toronto
(P 284) VALIDATING A NOVEL MICROFLUIDIC PLATFORM AS AN EX VIVO TUMOUR MODEL FOR SARCOMA DRUG DISCOVERY
Kousha Kamal
Favorite
Kamio, Satoshi

Tochigi Cancer Center
(P 87) ANGIOSARCOMA OF THE ILIUM TREATED WITH HEMIPELVECTOMY AND HIP TRANSPOSITION FOLLOWED BY POSTOPERATIVE CHEMOTHERAPY WITH PAZOPANIB: A CASE REPORT
Satoshi Kamio
Favorite
(P 238) EPIDEMIOLOGIC SURVEY OF MYXOFIBROSARCOM USING DATA FROM THE BONE AND SOFT TISSUE TUMOR REGISTRY IN JAPAN
Satoshi Kamio
Favorite
Kanaan, Sami

Fred Hutchinson Cancer Center
(P 448) CAF-LIKE EWING SARCOMA CELLS DEPOSIT PRO-TUMORIGENIC EXTRACELLULAR MATRIX IN RESPONSE TO TGF-BETA SIGNALING
Sami Kanaan
Favorite
Kanahori, Masaya

Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kyushu University
(P 406) EXTENSIVE ANALYSIS OF 59 SARCOMA-RELATED FUSION GENES IDENTIFIED PAZOPANIB AS A POTENTIAL INHIBITOR TO COL1A1-PDGFB FUSION GENE
Masaya Kanahori
Favorite
Kandil, Maha

Daiichi Sankyo, Inc.
(P 199) PEXIDARTINIB RISK EVALUATION AND MITIGATION STRATEGY PROGRAM: 3-YEAR SAFETY DATA ASSESSMENT
Maha Kandil
Favorite
Kane, Gabrielle

University of Washington
(P 206) A SINGLE-ARM, PHASE II STUDY OF NEOADJUVANT PEMBROLIZUMAB COMBINED WITH RADIOTHERAPY IN THE PRIMARY TREATMENT OF SOFT TISSUE SARCOMAS.
Gabrielle Kane
Favorite
Kanerva, Jukka

HUS Helsinki University Hospital, New Children’s Hospital, Finland
(P 73) FOSTER CONSORTIUM, FIGHT OSTEOSARCOMA THROUGH EUROPEAN RESEARCH
Jukka Kanerva
Favorite
(P 451) IMPACT OF TIME TO DIAGNOSIS - A PROSPECTIVE ANALYSIS OF THE EWING 2008 TRIAL
Jukka Kanerva
Favorite
Kang, Alina

University of Miami Miller School of Medicine
(P 225) PAN-SARCOMA DATABASE (PSDB): A MODEL-VIEW-CONTROLLER FRAMEWORK UTILIZING REDCAP, SHINY, AND R TO CREATE A CONTINUOUS PIPELINE OF SARCOMA DATA
Alina Kang
Favorite
(P 366) SURVIVAL DISPARITIES IN HISPANIC PATIENTS WITH SARCOMA TESTED WITH NEXT-GENERATION SEQUENCING (NGS)
Alina Kang
Favorite
Kang, Yuqi

Fred Hutchinson Cancer Center
(P 447) TARGETING FOCAL ADHESION KINASE AUGMENTS THE THERAPEUTIC POTENTIAL OF BROMODOMAIN INHIBITORS IN EWING SARCOMA
Yuqi Kang
Favorite
Kannan, Bavani

National Cancer Centre Singapore
(P 285) TUMOUR-INFILTRATING MAST CELLS IN ANGIOSARCOMAS CORRELATE WITH CLINCIAL PHENOTYPES AND IMMUNO-ONCOLOGY PATHWAYS
Bavani Kannan
Favorite
Kansara, Maya

Garvan Institute of Medical Research
(P 386) GENOMIC PROFILING OF GYNAECOLOGICAL SARCOMAS: REPORT FROM THE AUSTRALIA-WIDE PRECISION ONCOLOGY PROGRAM
Maya Kansara
Favorite
Karanian, Marie

CENTRE LEON BERARD AND CANCER RESEARCH CENTER OF LYON (INSERM U1052-CNRS5286)
(P 104) COMPREHENSIVE IMMUNE PROFILING UNVEILS A SUBSET OF LEIOMYOSARCOMA WITH HOT TUMOR IMMUNE MICROENVIRONMENT
Marie Karanian
Favorite
(P 382) NTRK1/2/3 FUSIONS DETECTION USING RNA-SEQ IN MESENCHYMAL TUMORS REVEALS ULTRA-RARE AND HISTO-SPECIFIC TARGETABLE ALTERATIONS: EXPERIENCE OF AN EXTENSIVE ROUTINE RESEARCH PROGRAM.
Marie Karanian
Favorite
(P 435) ONCOGENIC FUSION YWHAE::NUTM2 DISRUPT EP300/BCOR INTERACTION
Marie Karanian
Favorite
Kasper, Bernd

University of Heidelberg, Mannheim University Medical Center
(P 12) MULTIFOCAL AND DISSEMINATED SPORADIC DESMOID TUMOUR OF THE EXTREMITIES: A SPECIAL CHALLENGE
Bernd Kasper
Favorite
(P 133) TEN RECOMMENDATIONTS FOR SARCOMA SURGERY: CONSENSUS OF THE SURGICAL SOCIETIES BASED ON THE GERMAN S3 GUIDELINE "ADULT SOFT TISSUE SARCOMA"
Bernd Kasper
Favorite
(P 136) SETTING THE INTERNATIONAL RESEARCH AGENDA FOR SARCOMA WITH PATIENTS AND CARERS: PRELIMINARY RESULTS OF PHASE II OF THE SARCOMA PATIENT ADVOCACY GLOBAL NETWORK (SPAGN) PRIORITY SETTING PARTNERSHIP
Bernd Kasper
Favorite
(P 172) PHASE 2 RESULTS FROM THE RINGSIDE PHASE 2/3 TRIAL OF AL102 FOR TREATMENT OF DESMOID TUMORS
Bernd Kasper
Favorite
(P 188) IMPACT OF NIROGACESTAT ON FUNCTIONAL STATUS IN PATIENTS WITH DESMOID TUMORS: RESULTS FROM THE PHASE 3 DEFI STUDY
Bernd Kasper
Favorite
(P 549) DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF AL102 FOR TREATMENT OF PROGRESSING DESMOID TUMORS: THE RINGSIDE PHASE 3 STUDY DESIGN
Bernd Kasper
Favorite
Kasson, Luke

Rush University Medical Center
(P 63) EVALUATION OF LOCAL RECURRENCE AND DIAGNOSTIC DISCORDANCE IN CHONDROSARCOMA PATIENTS UNDERGOING PREOPERATIVE BIOPSY
Luke Kasson
Favorite
Kasukawa, Yuji

Akita University Graduate School of Medicine
(P 469) IMPACT OF A SPECIALIZED OUTPATIENT CLINIC ON BONE MRTASTASIS AND ITS BURDEN ON SPINE SURGEONS
Yuji Kasukawa
Favorite
Katayama, Kotoe

The Institute of Medical Science, The University of Tokyo
(P 396) COMPREHENSIVE WHOLE-GENOME MOLECULAR PROFILING IN BONE AND SOFT TISSUE SARCOMA: MULTI-OMICS ANALYSIS OF 627 CASES ACROSS HISTOLOGIC SUBTYPES
Kotoe Katayama
Favorite
Kaths, Moritz

University Hospital Essen, Sarcoma Centre
(P 47) PATIENT SURVIVAL IN METASTATIC GIST WITH IMATINIB-SENSITIVE MUTATIONS: REAL WORLD DATA FROM GERMAN REFERRAL CENTER (2008-2021)
Moritz Kaths
Favorite
(P 276) REVISITING IN- AND OFF LABEL DRUGS FREQUENTLY USED IN METASTATIC GIST USING A BROAD IN VITRO PROFILING PANEL OF PRIMARY AND SECONDARY KIT AND PDGFRA-MUTANT GIST CELLS – CLINICAL IMPLICATIONS
Moritz Kaths
Favorite
Kato, Ken

Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
(P 35) GENOMIC ALTERATIONS IN ADVANCED GASTROINTESTINAL STROMAL TUMORS AS REVEALED BY COMPREHENSIVE GENOMIC PROFILING TESTS
Ken Kato
Favorite
Kato, Taichi

Nagoya University Hospital
(P 163) SELUMETINIB IN JAPANESE PEDIATRIC PATIENTS WITH SYMPTOMATIC INOPERABLE PLEXIFORM NEUROFIBROMA IN NEUROFIBROMATOSIS TYPE 1
Taichi Kato
Favorite
Katumba, Ruth

Washington University School of Medicine
(P 552) RANDOMIZED PHASE II TRIAL OF CABOZANTINIB COMBINED WITH PD-1 AND CTLA-4 INHIBITION VERSUS CABOZANTINIB IN METASTATIC SOFT TISSUE SARCOMA.
Ruth Katumba
Favorite
Katz, Daniela

Helmsley Cancer Center, Shaare Zedek Medical Center, Jerusalem Israel
(P 437) ULTRA-RARE UNDIFFERENTIATED SMALL ROUND CELL SARCOMA: HOW SHOULD WE TREAT THEM? AN ANALYSIS FORM THE GRACEFUL PROJECT
Daniela Katz
Favorite
Kawai, Akira

National Cancer Center Hospital
(P 16) ALVEOLAR SOFT PART SARCOMA: PROGRESS TOWARD IMPROVEMENT IN SURVIVAL? A NATIONWIDE DATABASE STUDY IN JAPAN
Akira Kawai
Favorite
(P 76) GENETIC EVIDENCE OF METACHRONOUS DEDIFFERENTIATION OF CHONDROSARCOMA AT A DISTANT SITE
Akira Kawai
Favorite
(P 80) OPTIMIZING DOSE OF MAP THERAPY FOR CHILDREN, YOUNG ADULTS AND ADULTS WITH OSTEOSARCOMA; A SINGLE-CENTRE RETROSPECTIVE ANALYSIS
Akira Kawai
Favorite
(P 238) EPIDEMIOLOGIC SURVEY OF MYXOFIBROSARCOM USING DATA FROM THE BONE AND SOFT TISSUE TUMOR REGISTRY IN JAPAN
Akira Kawai
Favorite
(P 332) SURGICAL OUTCOMES OF RETROPERITONEAL LIPOSARCOMA - SINGLE INSTITUTIONAL STUDY N JAPAN -
Akira Kawai
Favorite
(P 396) COMPREHENSIVE WHOLE-GENOME MOLECULAR PROFILING IN BONE AND SOFT TISSUE SARCOMA: MULTI-OMICS ANALYSIS OF 627 CASES ACROSS HISTOLOGIC SUBTYPES
Akira Kawai
Favorite
(P 406) EXTENSIVE ANALYSIS OF 59 SARCOMA-RELATED FUSION GENES IDENTIFIED PAZOPANIB AS A POTENTIAL INHIBITOR TO COL1A1-PDGFB FUSION GENE
Akira Kawai
Favorite
Keane, Christopher

TCD
(P 424) INTERNAL TANDEM DUPLICATION OF BCOR (BCOR-ITD) ALTERS THE TUMOR EPIGENOME
Christopher Keane
Favorite
Kee, Damien

Austin Health
(P 386) GENOMIC PROFILING OF GYNAECOLOGICAL SARCOMAS: REPORT FROM THE AUSTRALIA-WIDE PRECISION ONCOLOGY PROGRAM
Damien Kee
Favorite
Keedy, Vicki

Vanderbilt University Medical Center
(P 160) A PROSPECTIVE STUDY EVALUATING THE ASSOCIATION OF PATIENT-REPORTED OUTCOMES WITH ACTIVITY LEVEL AND SLEEP PATTERNS IN SARCOMA SURVIVORS
Vicki Keedy
Favorite
(P 191) SARC024 COHORT D: PHASE 2 TRIAL OF REGORAFENIB IN CHILDREN, ADOLESCENTS, AND ADULTS WITH RHABDOMYOSARCOMA
Vicki Keedy
Favorite
Keil, Felix

Department of Pathology, University Hospital Regensburg, 93053 Regensburg, Germany
(P 557) UNRAVELING THE ROLE OF LOCAL THERAPY FOR PATIENTS WITH OLIGOMETASTATIC SOFT TISSUE SARCOMA - A RETROSPECTIVE MULTICENTER TRIAL OF BAVARIAN UNIVERSITY HOSPITALS
Felix Keil
Favorite
Kelany, Mohamed

Faculty of medicines Ain Shams University
(P 370) SYNOVIAL SARCOMA; ROLE OF ADJUVANT CHEMOTHERAPY IN SURGICALLY TREATED PATIETNS WITH NO METASTASIS; A SEER STAT ANALYSIS.
Mohamed Kelany
Favorite
(P 419) AGE ADJUSTED TRENDS IN PATIENTS WITH SYNOVIAL SARCOMA
Mohamed Kelany
Favorite
Keller, Charles

Children's Cancer Therapy Development Institute, Beaverton, Oregon
(P 234) GENOMIC LANDSCAPE OF CLEAR CELL SARCOMA
Charles Keller
Favorite
Kelly, Aidan

Monopar Therapeutics, Inc.
(P 184) PHASE 1B TRIAL OF CAMSIRUBICIN, A NOVEL DOXORUBICIN ANALOG, WITH CONCOMITANT PEGFILGRASTIM IN SUBJECTS WITH ADVANCED SOFT TISSUE SARCOMA TO IDENTIFY A NEW MTD/RP2D
Aidan Kelly
Favorite
Kelly, Ciara

Memorial Sloan Kettering Cancer Center
(P 24) COMPREHENSIVE ANALYSIS OF THE GENOMIC LANDSCAPE AND CLINICAL BEHAVIOR IN GIST USING NEXT GENERATION SEQUENCING (NGS, MSK-IMPACT)
Ciara Kelly
Favorite
(P 555) A PILOT PHASE II STUDY TO EVALUATE THE SMALL MOLECULE TIGILANOL TIGLATE IN PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA: CLINICAL TRIAL IN PROGRESS
Ciara Kelly
Favorite
Kemp, Lindsey

University of Colorado Anschutz Medical Campus
(P 552) RANDOMIZED PHASE II TRIAL OF CABOZANTINIB COMBINED WITH PD-1 AND CTLA-4 INHIBITION VERSUS CABOZANTINIB IN METASTATIC SOFT TISSUE SARCOMA.
Lindsey Kemp
Favorite
Kendsersky, Nicholas

Thomas Jefferson University Hospital
(P 401) OVEREXPRESSION OF CYCLIN DEPENDENT KINASES AND CYCLINS ACROSS SARCOMAS BEYOND CDK4
Nicholas Kendsersky
Favorite
Kenney, Richard

Sonnet BioTherapeutics
(P 111) INTERIM ANALYSIS OF A PHASE 1 STUDY USING IL12-FHAB WITH OPTIMIZED PHARMACOKINETICS
Richard Kenney
Favorite
Kennington, Ryan

Huntsman Cancer Institute/University of Utah
(P 412) LEIOMYOSARCOMA POLYANEUPLOID CANCER CELLS DEVELOP IN RESPONSE TO CHEMOTHERAPY AND CONTRIBUTE TO CHEMORESISTANCE
Ryan Kennington
Favorite
Kenny, Colin

University of Iowa
(P 424) INTERNAL TANDEM DUPLICATION OF BCOR (BCOR-ITD) ALTERS THE TUMOR EPIGENOME
Colin Kenny
Favorite
Keohan, Mary Louise

MSKCC
(P 24) COMPREHENSIVE ANALYSIS OF THE GENOMIC LANDSCAPE AND CLINICAL BEHAVIOR IN GIST USING NEXT GENERATION SEQUENCING (NGS, MSK-IMPACT)
Mary Louise Keohan
Favorite
Keren-Gill, Hadar

David Geffen School of Medicine, University of California, Los Angeles
(P 19) EXTRACELLULAR VESICLE CLICK MAGBEADS: A MULTIFACETED LIQUID BIOPSY PLATFORM FOR PEDIATRIC SARCOMAS
Hadar Keren-Gill
Favorite
Kerkhoff, Maximilian

Pediatrics III, University Hospital Essen, West German Cancer Center
(P 17) METASTASIS-SPECIFIC GENE EXPRESSION PATTERNS IN EWING SARCOMA
Maximilian Kerkhoff
Favorite
(P 451) IMPACT OF TIME TO DIAGNOSIS - A PROSPECTIVE ANALYSIS OF THE EWING 2008 TRIAL
Maximilian Kerkhoff
Favorite
Kersting, Josephine

Pediatrics III, University Hospital Essen, West German Cancer Center
(P 451) IMPACT OF TIME TO DIAGNOSIS - A PROSPECTIVE ANALYSIS OF THE EWING 2008 TRIAL
Josephine Kersting
Favorite
(P 538) IEUROEWING TRIAL FOR LOCALIZED AND METASTATIC EWING SARCOMA
Josephine Kersting
Favorite
Kerst, Martijn

Netherlands Cancer Institute/ Antoni van Leeuwenhoek
(P 31) NEOADJUVANT IMATINIB IN LOCALLY ADVANCED GASTROINTESTINAL STROMAL TUMORS (GIST) IS EFFECTIVE AND SAFE: RESULTS FROM A PROSPECTIVE SINGLE CENTER STUDY WITH 108 PATIENTS
Martijn Kerst
Favorite
Kessel, Sandy

IROC QARC
(P 68) METASTASIS-DIRECTED RADIOTHERAPY FOR EWING SARCOMA PATIENTS ENROLLED ON AEWS1221: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP (COG)
Sandy Kessel
Favorite
Kessler, Lukas

Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen
(P 220) [68GA]GA-FAPI PET/CT AS NOVEL DIAGNOSTIC TOOL IN SARCOMA
Lukas Kessler
Favorite
(P 248) FIBROBLAST ACTIVATION PROTEIN ALPHA -DIRECTED IMAGING AND THERAPY OF SOLITARY FIBROUS TUMOR
Lukas Kessler
Favorite
Ketzer, Julia

Sarcoma Center, Department of Medical Oncology, West German Cancer Center, University Hospital Essen
(P 47) PATIENT SURVIVAL IN METASTATIC GIST WITH IMATINIB-SENSITIVE MUTATIONS: REAL WORLD DATA FROM GERMAN REFERRAL CENTER (2008-2021)
Julia Ketzer
Favorite
(P 234) GENOMIC LANDSCAPE OF CLEAR CELL SARCOMA
Julia Ketzer
Favorite
Keung, Emily

The University of Texas MD Anderson Cancer Center
(P 100) HISTOLOGY SPECIFIC INTRATUMORAL B-CELL BIOLOGY IN ALVEOLAR SOFT-PART SARCOMAS (ASPS) IN RESPONSE TO DURVALUMAB-TREMELIMUMAB (D-T)
Emily Keung
Favorite
(P 123) DEDIFFERENTIATED LIPOSARCOMAS TREATED WITH IMMUNE CHECKPOINT BLOCKADE: THE MD ANDERSON EXPERIENCE
Emily Keung
Favorite
(P 269) PLASMA DNA METHYLATION-BASED BIOMARKERS FOR MPNST DETECTION IN PATIENTS WITH NEUROFIBROMATOSIS TYPE 1 (NF1)
Emily Keung
Favorite
(P 360) TP53 ALTERATIONS IN SARCOMAS: AN ANALYSIS FROM THE AACR-GENIE DATABASE
Emily Keung
Favorite
(P 394) LEIOMYOSARCOMA INTRATUMORAL MACROPHAGE INFILTRATES ARE ASSOCIATED WITH DISTINCT CLINICAL AND GENOMIC PRESENTATIONS
Emily Keung
Favorite
(P 510) PRIMARY BREAST ANGIOSARCOMA: CLINICAL AND PATHOLOGICAL FEATURES AND IMPACT ON OUTCOMES
Emily Keung
Favorite
Khalaf, Racha

Department of Pediatrics, University of South Florida Morsani College of Medicine
(P 91) BLOOD TRANSFUSION AND SURVIVAL AMONG CHILD, ADOLESCENT, AND YOUNG ADULT PATIENTS WITH OSTEOSARCOMA: A RETROSPECTIVE COHORT STUDY
Racha Khalaf
Favorite
Khan, Misbah

ESHT NHS foundation trust
(P 126) CURRENT PRACTICE IN SPERMATIC CORD SARCOMA: ONCOLOGICAL TIMELINES AND OUTCOMES ACCORDING TO INITIAL RESECTIONS PERFORMED AT A LOCAL HOSPITAL VERSUS EARLY PATIENT REFERRAL TO A TERTIARY CENTRE.
Misbah Khan
Favorite
Khanna, Nehal

Tata Memorial Hospital Mumbai
(P 436) OUTCOME PROGNOSTICATORS IN ADOLESCENTS AND ADULTS WITH BONE SARCOMAS IN LOW-MIDDLE-INCOME COUNTRIES
Nehal Khanna
Favorite
Khan, Omar

Tom Baker Cancer Center
(P 454) TREATMENT PATTERNS AND OUTCOMES IN PEDIATRIC AND ADULT PATIENTS WITH EWING AND UNDIFFERENTIATED ROUND BLUE CELL SARCOMAS IN ALBERTA
Omar Khan
Favorite
Khan, Shaheer

5Columbia University Herbert Irving Comprehensive Cancer Center
(P 178) INITIAL RESULTS FROM A PHASE 1 STUDY OF CFT8634, A NOVEL BIFUCTIONAL DEGRADATION ACTIVATING COMPOUND (BIDAC) DEGRADER OF BRD9, IN SYNOVIAL SARCOMA AND SMARCB1-NULL TUMORS
Shaheer Khan
Favorite
Khan, Tahsin

Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health
(P 28) RETROSPECTIVE ANALYSIS OF SUCCINATE DEHYDROGENASE (SDH)-DEFICIENT GASTROINTESTINAL STROMAL TUMOR (GIST) OUTCOMES: AN INTERNATIONAL STUDY OF 256 PATIENTS
Tahsin Khan
Favorite
Khatami, Marjan

Research Institute of the McGill University Health Center
(P 64) OSTEOSARCOMA. PATIENT-DERIVED XENOGRAFTS MODELS TO RECAPITULATE PATIENTS' CHEMORESISTANCE AND METASTATIC DISEASE
Marjan Khatami
Favorite
(P 65) PROFILING EXTRACELLULAR VESICLES AND NANOPARTICLES IN OSTEOSARCOMA
Marjan Khatami
Favorite
(P 434) MECHANISMS OF CHEMORESISTANCE IN CIC-DUX4 SARCOMA AS DETERMINED BY IN VIVO FUNCTIONAL GENOMICS
Marjan Khatami
Favorite
Khazaei, Niusha

Research Institute of the McGill University Health Center
(P 64) OSTEOSARCOMA. PATIENT-DERIVED XENOGRAFTS MODELS TO RECAPITULATE PATIENTS' CHEMORESISTANCE AND METASTATIC DISEASE
Niusha Khazaei
Favorite
(P 434) MECHANISMS OF CHEMORESISTANCE IN CIC-DUX4 SARCOMA AS DETERMINED BY IN VIVO FUNCTIONAL GENOMICS
Niusha Khazaei
Favorite
Khelik, Ksenia

Oslo University Hospital
(P 23) GENOMIC COMPLEXITY AS A BIOMARKER FOR ADJUVANT IMATINIB TREATMENT IN HIGH-RISK GASTROINTESTINAL STROMAL TUMOR
Ksenia Khelik
Favorite
Khilnani, Harsha

University College London
(P 561) EXPERIENCE OF PHYSICAL DISABILITIES AND CANCER-RELATED QUALITY OF LIFE AFTER SPINAL TUMORS- STUDY OF A NATIONAL SURVEY IN ENGLAND.
Harsha Khilnani
Favorite
Khosroyani, Homma

OHSU Knight Cancer Institute
(P 25) PREDICTING IMATINIB RESPONSES USING IN VITRO MODELS OF PDGFRA-MUTANT GASTROINTESTINAL STROMAL TUMOR
Homma Khosroyani
Favorite
Khurshid, Safiya

Nationwide Children's Hospital
(P 94) DEVELOPING NOVEL OLIGONUCLEOTIDE THERAPIES TO MODULATE INSULIN RECEPTOR ALTERNATIVE SPLICING IN PEDIATRIC BONE SARCOMAS
Safiya Khurshid
Favorite
(P 305) A NEW MOUSE MODEL FOR TESTING SPLICE-SWITCHING THERAPIES IN RHABDOMYOSARCOMA
Safiya Khurshid
Favorite
Khushman, Moh'd

Washington University in St. Louis / Siteman Cancer Center
(P 361) MOLECULAR CHARACTERIZATION OF SOLITARY FIBROUS TUMORS BY ANATOMIC SITE AND NAB2::STAT6 FUSION VARIANT TYPE
Moh'd Khushman
Favorite
(P 401) OVEREXPRESSION OF CYCLIN DEPENDENT KINASES AND CYCLINS ACROSS SARCOMAS BEYOND CDK4
Moh'd Khushman
Favorite
Kidokoro, Hiroyuki

Nagoya University Hospital
(P 163) SELUMETINIB IN JAPANESE PEDIATRIC PATIENTS WITH SYMPTOMATIC INOPERABLE PLEXIFORM NEUROFIBROMA IN NEUROFIBROMATOSIS TYPE 1
Hiroyuki Kidokoro
Favorite
Kikumori, Kunika

Daiichi Sankyo, Co., Ltd.
(P 168) A PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF PEXIDARTINIB IN ASIAN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR
Kunika Kikumori
Favorite
Kikuta, Kazutaka

Department of Musculoskeletal Oncology and Orthopaedic Surgery, Tochigi Cancer Center
(P 238) EPIDEMIOLOGIC SURVEY OF MYXOFIBROSARCOM USING DATA FROM THE BONE AND SOFT TISSUE TUMOR REGISTRY IN JAPAN
Kazutaka Kikuta
Favorite
(P 396) COMPREHENSIVE WHOLE-GENOME MOLECULAR PROFILING IN BONE AND SOFT TISSUE SARCOMA: MULTI-OMICS ANALYSIS OF 627 CASES ACROSS HISTOLOGIC SUBTYPES
Kazutaka Kikuta
Favorite
Kilpatrick, Scott

Cleveland Clinic
(P 513) THE IMPACT OF MARGIN STATUS ON THE ONCOLOGIC OUTCOMES OF SURGICALLY TREATED DEDIFFERENTIATED LIPOSARCOMA OF THE EXTREMITIES
Scott Kilpatrick
Favorite
Kim, AeRang

Children's National Hospital
(P 18) RETROSPECTIVE ANALYSIS ON OUTCOMES PEDIATRIC PATIENTS WITH SARCOMA AND LUNG METASTASES STATUS POST PNEUMONECTOMY VERSUS PARTIAL LUNG RESECTION
AeRang Kim
Favorite
(P 292) APPLICATION OF HIGH-INTENSITY FOCUSED ULTRASOUND THERMAL ABLATION AND BOILING HISTOTRIPSY WITH CHECKPOINT INHIBITORS IN A MURINE MODEL OF OSTEOSARCOMA: AN IN-DEPTH STUDY
AeRang Kim
Favorite
(P 564) A PILOT STUDY OF LYSO-THERMOSENSITIVE LIPOSOMAL DOXORUBICIN AND MAGNETIC RESONANCE-GUIDED HIGH INTENSITY FOCUSED ULTRASOUND FOR TREATMENT OF RELAPSED OR REFRACTORY SOLID TUMORS
AeRang Kim
Favorite
Kim, Alex

The James Cancer Hospital / The Ohio State University
(P 301) REDUCING THE INVASIVE POTENTIAL OF DEDIFFERENTIATED LIPOSARCOMA BY TARGETING ALTERNATIVE RNA SPLICING MACHINERY
Alex Kim
Favorite
(P 314) PRE-OPERATIVE RADIATION THERAPY INCREASES ADHERENCE IN PATIENTS WITH HIGH-RISK EXTREMITY SOFT TISSUE SARCOMA
Alex Kim
Favorite
Kim, Edward

University of Washington
(P 177) ANGIOSARCOMA: AN INCREASING PROBLEM IN THE UNITED STATES
Edward Kim
Favorite
(P 206) A SINGLE-ARM, PHASE II STUDY OF NEOADJUVANT PEMBROLIZUMAB COMBINED WITH RADIOTHERAPY IN THE PRIMARY TREATMENT OF SOFT TISSUE SARCOMAS.
Edward Kim
Favorite
Kim, Eunji

Korea Institute of Radiation and Medical Sciences
(P 281) FIVE DAY SPACING OF TWO FRACTIONATED ABLATIVE RADIOTHERAPIES ENHANCES ANTITUMOR IMMUNITY IN FIBROSARCOMA CELL LINE
Eunji Kim
Favorite
kim, ha Jeong

Seoul National University Hospital
(P 374) ARHGEF4 EXPRESSION IN SOFT TISSUE SARCOMA CORRELATES WITH LOCAL GROWTH PATTERN AND LOCAL RECURRENCE: COMPREHENSIVE GENOMIC ANALYSIS IN SEARCH OF BIOMARKER OF LOCAL GROWTH PATTERN
ha Jeong kim
Favorite
Kim, Han-soo

Seoul National University Hospital
(P 374) ARHGEF4 EXPRESSION IN SOFT TISSUE SARCOMA CORRELATES WITH LOCAL GROWTH PATTERN AND LOCAL RECURRENCE: COMPREHENSIVE GENOMIC ANALYSIS IN SEARCH OF BIOMARKER OF LOCAL GROWTH PATTERN
Han-soo Kim
Favorite
(P 498) DEDIFFERENTIATED LIPOSARCOMA OF THE EXTREMITIES: CHARACTERISTICS AND OUTCOME
Han-soo Kim
Favorite
(P 499) CLINICAL OUTCOMES OF TOTAL FEMORAL REPLACEMENT FOR ONCOLOGICAL INDICATIONS
Han-soo Kim
Favorite
Kim, Hyun

Washington University in St Louis
(P 187) PALLIATIVE LATTICE STEREOTACTIC BODY RADIOTHERAPY FOR PATIENTS WITH SARCOMA
Hyun Kim
Favorite
Kim, hyunkyung

Korea Institute of Radiation and Medical Sciences
(P 281) FIVE DAY SPACING OF TWO FRACTIONATED ABLATIVE RADIOTHERAPIES ENHANCES ANTITUMOR IMMUNITY IN FIBROSARCOMA CELL LINE
hyunkyung Kim
Favorite
Kim, Jae Sik

Soonchunhyang University Seoul Hospital
(P 79) HEAD AND NECK OSTEOSARCOMA: THE EXPERIENCE OF 52 CASES FROM A SINGLE TERTIARY INSTITUTION OVER 25 YEARS
Jae Sik Kim
Favorite
Kim, Ji Young

Seoul National University College of Medicine
(P 79) HEAD AND NECK OSTEOSARCOMA: THE EXPERIENCE OF 52 CASES FROM A SINGLE TERTIARY INSTITUTION OVER 25 YEARS
Ji Young Kim
Favorite
Kim, Jin Ho

Seoul National University Hospital
(P 79) HEAD AND NECK OSTEOSARCOMA: THE EXPERIENCE OF 52 CASES FROM A SINGLE TERTIARY INSTITUTION OVER 25 YEARS
Jin Ho Kim
Favorite
Kim, Mi-Ok

UCSF
(P 413) LINKING REAL-WORLD CLINICAL AND GENOMIC DATA IN RHABDOMYOSARCOMA: LEVERAGING AACR PROJECT GENIE AS A PATH TOWARD PRECISION ONCOLOGY IN RARE CANCERS
Mi-Ok Kim
Favorite
Kim, Mi-Sook

Korea Cancer Center Hospital
(P 281) FIVE DAY SPACING OF TWO FRACTIONATED ABLATIVE RADIOTHERAPIES ENHANCES ANTITUMOR IMMUNITY IN FIBROSARCOMA CELL LINE
Mi-Sook Kim
Favorite
Kim, Raymond

University Health Network
(P 50) CHARACTERIZATION OF A FAMILIAL GIST KINDRED INTOLERANT TO IMATINIB
Raymond Kim
Favorite
Kim, Sean

IDRx, Inc.
(P 26) PHASE 1 STUDY OF IDRX-42 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS RESISTANT TO PRIOR SYSTEMIC THERAPY: EARLY RESULTS
Sean Kim
Favorite
Kim, Shinn

Seoul National University Hospital
(P 374) ARHGEF4 EXPRESSION IN SOFT TISSUE SARCOMA CORRELATES WITH LOCAL GROWTH PATTERN AND LOCAL RECURRENCE: COMPREHENSIVE GENOMIC ANALYSIS IN SEARCH OF BIOMARKER OF LOCAL GROWTH PATTERN
Shinn Kim
Favorite
(P 498) DEDIFFERENTIATED LIPOSARCOMA OF THE EXTREMITIES: CHARACTERISTICS AND OUTCOME
Shinn Kim
Favorite
(P 499) CLINICAL OUTCOMES OF TOTAL FEMORAL REPLACEMENT FOR ONCOLOGICAL INDICATIONS
Shinn Kim
Favorite
Kim, Tae-Jin

Korea Institute of Radiation and Medical Sciences
(P 281) FIVE DAY SPACING OF TWO FRACTIONATED ABLATIVE RADIOTHERAPIES ENHANCES ANTITUMOR IMMUNITY IN FIBROSARCOMA CELL LINE
Tae-Jin Kim
Favorite
Kim, Yongsung

Seoul National University Bundang Hospital
(P 374) ARHGEF4 EXPRESSION IN SOFT TISSUE SARCOMA CORRELATES WITH LOCAL GROWTH PATTERN AND LOCAL RECURRENCE: COMPREHENSIVE GENOMIC ANALYSIS IN SEARCH OF BIOMARKER OF LOCAL GROWTH PATTERN
Yongsung Kim
Favorite
(P 498) DEDIFFERENTIATED LIPOSARCOMA OF THE EXTREMITIES: CHARACTERISTICS AND OUTCOME
Yongsung Kim
Favorite
(P 499) CLINICAL OUTCOMES OF TOTAL FEMORAL REPLACEMENT FOR ONCOLOGICAL INDICATIONS
Yongsung Kim
Favorite
Kim, Young In

Seoul National University College of Medicine
(P 79) HEAD AND NECK OSTEOSARCOMA: THE EXPERIENCE OF 52 CASES FROM A SINGLE TERTIARY INSTITUTION OVER 25 YEARS
Young In Kim
Favorite
KIND, Michele

Institut Bergonié
(P 523) IN-BETWEEN SARCOMA: A CATEGORY OF HIGH RISK OF RECURRENCE AND POOR OUTCOME
Michele KIND
Favorite
King, David

Medical College of Wisconsin
(P 181) REAL-WORLD EXPERIENCE WITH LIPOSOMAL DOXORUBICIN IN METASTATIC AND LOCALLY ADVANCED SARCOMA
David King
Favorite
(P 473) GROIN PAINS: APPROACHES AND OUTCOMES FOR INGUINOFEMORAL SOFT TISSUE SARCOMAS
David King
Favorite
King, Lauren

Vanderbilt University Medical Center
(P 160) A PROSPECTIVE STUDY EVALUATING THE ASSOCIATION OF PATIENT-REPORTED OUTCOMES WITH ACTIVITY LEVEL AND SLEEP PATTERNS IN SARCOMA SURVIVORS
Lauren King
Favorite
(P 211) AN ANALYSIS OF SELF-REPORTED DEPRESSION IN SARCOMA PATIENTS
Lauren King
Favorite
(P 380) NEXT GENERATION SEQUEINCING REVEALS TARGETABLE MUTATIONS IN MULTIPLE SARCOMA HISTOLOGIES
Lauren King
Favorite
Kingsley, Charles

MD Anderson Cancer Center
(P 101) EPIGENETIC MODULATION OF NK CELLS IMPROVES TUMOR TRAFFICKING AND ENHANCES THERAPEUTIC EFFICACY AGAINST OSTEOSARCOMA
Charles Kingsley
Favorite
Kingsmill, Sarah

Sarcoma UK
(P 150) VISUALISING SOFT TISSUE SARCOMA INCIDENCE DATA FOR PATIENT EMPOWERMENT
Sarah Kingsmill
Favorite
Kirsch, David

Princess Margaret Cancer Centre/University Health Network
(P 340) CENTRAL BOOST RADIATION THERAPY CAN ACHIEVE DURABLE LOCAL RESPONSE IN UNRESECTABLE RETROPERITONEAL SARCOMA
David Kirsch
Favorite
(P 393) INVESTIGATING THE ROLE OF HDACS IN THE PROGRESSION OF METASTATIC UNDIFFERENTIATED PLEOMORPHIC SARCOMA
David Kirsch
Favorite
(P 428) COMPREHENSIVE GENOMIC PROFILING OF CIC-DUX4 SARCOMA (CDS) CELL LINES AND MODELS
David Kirsch
Favorite
(P 450) INVESTIGATING THE THERAPEUTIC POTENTIAL OF SMALL MOLECULE INHIBITOR INOBRODIB AS A TREATMENT ALTERNATIVE FOR CIC-DUX4 SARCOMA
David Kirsch
Favorite
Kishi, Shingo

Nozaki Tokushukai Hospital
(P 259) LOVASTATIN INDUCES NOVEL CELL DEATH THROUGH THE IMPAIRED MITOCHONDRIA IRON UTILIZATION IN OSTEOASRCOMA CELLS.
Shingo Kishi
Favorite
Kita, Shosuke

National Cancer Center Hospital
(P 547) A PHASE II TRIAL OF TAZEMETOSTAT FOR PATIENTS WITH UNRESECTABLE OR METASTATIC EPITHELIOID SARCOMA (TAZETTA TRIAL)
Shosuke Kita
Favorite
Kitz, Julia

Institute of Pathology, University Medical Center Goettingen, 37075 Goettingen, Germany
(P 235) FUSION OF PREOPERATIVE IN SITU MAGNETIC RESONANCE IMAGING AND POSTOPERATIVE COMPUTED TOMOGRAPHY TO CORRELATE FUNCTIONAL IMAGING FEATURES AND PATHOLOGICAL CHARACTERISTICS OF SOFT TISSUE SARCOMA
Julia Kitz
Favorite
Klauschen, Frederick

Institute of Pathology, Ludwig-Maximilians-University (LMU) Munich, Germany
(P 118) TIM-3 QUALIFIES AS A POTENTIAL IMMUNOTHERAPEUTIC TARGET IN SPECIFIC SUBSETS OF PATIENTS WITH HIGH-RISK SOFT TISSUE SARCOMAS (HR-STS)
Frederick Klauschen
Favorite
Klega, Kelly

Dana-Farber Cancer Institute
(P 166) SARC038: A PHASE 2 STUDY OF REGORAFENIB IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH REFRACTORY OR RECURRENT OSTEOSARCOMA
Kelly Klega
Favorite
(P 438) ALVEOLAR RHABDOMYOSARCOMA WITH "BURKITT-LIKE" MORPHOLOGY IS ASSOCIATED WITH HIGH AMPLIFICATION OF MYCL
Kelly Klega
Favorite
Klein, Alexander

Orthopaedic Oncology, Department of Orthopaedics and Trauma Surgery, University Hospital, Ludwig-Maximilians-University (LMU) Munich, Germany
(P 118) TIM-3 QUALIFIES AS A POTENTIAL IMMUNOTHERAPEUTIC TARGET IN SPECIFIC SUBSETS OF PATIENTS WITH HIGH-RISK SOFT TISSUE SARCOMAS (HR-STS)
Alexander Klein
Favorite
Klein, Alyssa

Boehringer Ingelheim Pharmaceuticals Inc
(P 334) CHARACTERISTICS AND OUTCOMES FOR PATIENTS IN THE UNITED STATES WITH DEDIFFERENTIATED LIPOSARCOMA FROM A REAL-WORLD DATA SET
Alyssa Klein
Favorite
Kleinerman, Eugenie

University of Texas MD Anderson
(P 101) EPIGENETIC MODULATION OF NK CELLS IMPROVES TUMOR TRAFFICKING AND ENHANCES THERAPEUTIC EFFICACY AGAINST OSTEOSARCOMA
Eugenie Kleinerman
Favorite
(P 122) TARGETING CD70 USING CAR NK CELLS TO ENHANCE NK CELLS CYTOLYTIC EFFECT AGAINST OSTEOSARCOMA
Eugenie Kleinerman
Favorite
Klein, Stefan

Erasmus Medical Center
(P 231) MINIMALLY INTERACTIVE SEGMENTATION OF SOFT-TISSUE TUMORS ON MRI AND CT USING DEEP LEARNING
Stefan Klein
Favorite
(P 233) MULTI-CENTER EXTERNAL VALIDATION OF AN AUTOMATED MODEL DIFFERENTIATING ALT FROM LIPOMA USING RADIOMICS AND DEEP-LEARNING BASED SEGMENTATION
Stefan Klein
Favorite
Klimchenko, Andrey

UMR CNRS 7021
(P 277) ANTI-GD2 SYNERGIZES WITH HYPOXIA PATHWAY TARGETING TO BLOCK OSTEOSARCOMA CELL PROLIFERATION AND MIGRATION.
Andrey Klimchenko
Favorite
Knauf, Jeffery

Cleveland Clinic
(P 429) SARCOMA FUSION GENE ANALYSIS YIELDS PROMISING HLA ANTIGEN FIT IN EWING SARCOMA AND DESMOPLASTIC SMALL ROUND CELL TUMOR
Jeffery Knauf
Favorite
Knebel, Carolin

Department of Orthopaedic Surgery, School of Medicine & Klinikum rechts der Isar, Technical University of Munich, 81675 Munich, Germany
(P 557) UNRAVELING THE ROLE OF LOCAL THERAPY FOR PATIENTS WITH OLIGOMETASTATIC SOFT TISSUE SARCOMA - A RETROSPECTIVE MULTICENTER TRIAL OF BAVARIAN UNIVERSITY HOSPITALS
Carolin Knebel
Favorite
Kneisl, Jeffrey

Atrium Health
(P 258) THE CRITICALITY OF OXIDATIVE PHOSPHORYLATION IN SYNOVIAL SARCOMA METASTASIS
Jeffrey Kneisl
Favorite
Knoblauch, Mathilda

LMU University Hospital
(P 348) RESECTION OF RECURRENT RETROPERITONEAL SOFT TISSUE SARCOMAS: ARE INTENSIVE MULTIMODAL TREATMENTS ASSOCIATED WITH INCREASED PERIOPERATIVE MORBIDITY?
Mathilda Knoblauch
Favorite
Knoefel, Wolfram Trudo

University Hospital Duesseldorf
(P 133) TEN RECOMMENDATIONTS FOR SARCOMA SURGERY: CONSENSUS OF THE SURGICAL SOCIETIES BASED ON THE GERMAN S3 GUIDELINE "ADULT SOFT TISSUE SARCOMA"
Wolfram Trudo Knoefel
Favorite
Knösel, Thomas

Institute of Pathology, Ludwig-Maximilians-University (LMU) Munich, Germany
(P 118) TIM-3 QUALIFIES AS A POTENTIAL IMMUNOTHERAPEUTIC TARGET IN SPECIFIC SUBSETS OF PATIENTS WITH HIGH-RISK SOFT TISSUE SARCOMAS (HR-STS)
Thomas Knösel
Favorite
Knutson, Keith

The Mayo Clinic
(P 99) M2 MACROPHAGE INFILTRATION IS ASSOCIATED WITH EARLY DISEASE RECURRENCE FOLLOWING CURATIVE INTENT SURGICAL RESECTION IN SOFT-TISSUE SARCOMAS
Keith Knutson
Favorite
Knutson, Nels

Washington University in St Louis
(P 187) PALLIATIVE LATTICE STEREOTACTIC BODY RADIOTHERAPY FOR PATIENTS WITH SARCOMA
Nels Knutson
Favorite
Kobayashi, Eisuke

Department of Musculoskeletal Oncology and Rehabilitation, National Cancer Center Hospital, Tokyo, Japan
(P 76) GENETIC EVIDENCE OF METACHRONOUS DEDIFFERENTIATION OF CHONDROSARCOMA AT A DISTANT SITE
Eisuke Kobayashi
Favorite
(P 80) OPTIMIZING DOSE OF MAP THERAPY FOR CHILDREN, YOUNG ADULTS AND ADULTS WITH OSTEOSARCOMA; A SINGLE-CENTRE RETROSPECTIVE ANALYSIS
Eisuke Kobayashi
Favorite
(P 332) SURGICAL OUTCOMES OF RETROPERITONEAL LIPOSARCOMA - SINGLE INSTITUTIONAL STUDY N JAPAN -
Eisuke Kobayashi
Favorite
Kobayashi, Hiroshi

Department of Orthopedic Surgery, The University of Tokyo
(P 396) COMPREHENSIVE WHOLE-GENOME MOLECULAR PROFILING IN BONE AND SOFT TISSUE SARCOMA: MULTI-OMICS ANALYSIS OF 627 CASES ACROSS HISTOLOGIC SUBTYPES
Hiroshi Kobayashi
Favorite
Koch Hein, Erica

University of Toronto
(P 215) IMPACT OF FRONTLINE SYSTEMIC TREATMENT CHOICE ON CLINICAL OUTCOME IN ADVANCED LEIOMYOSARCOMA: A MULTI-CENTRE RETROSPECTIVE CANSARCC STUDY
Erica Koch Hein
Favorite
Kochat, Veena

The University of Texas MD Anderson Cancer Center
(P 426) MULTI-OMIC ANALYSIS OF DESMOPLASTIC SMALL ROUND CELL TUMORS REVEAL DISTINCT LINEAGES
Veena Kochat
Favorite
Kocsis, Jenna

Cleveland Clinic
(P 308) OPTIMAL BIOLOGIC EFFECTIVE DOSE OF STEREOTACTIC BODY RADIOTHERAPY FOR METASTATIC AND RECURRENT SARCOMA
Jenna Kocsis
Favorite
Koenen, Anne Miek

Netherlands Cancer Institute/ Antoni van Leeuwenhoek
(P 31) NEOADJUVANT IMATINIB IN LOCALLY ADVANCED GASTROINTESTINAL STROMAL TUMORS (GIST) IS EFFECTIVE AND SAFE: RESULTS FROM A PROSPECTIVE SINGLE CENTER STUDY WITH 108 PATIENTS
Anne Miek Koenen
Favorite
(P 140) THE PRE-DIAGNOSTIC GENERAL PRACTIONER JOURNEY OF SARCOMA PATIENTS: A REAL-WORLD DATA STUDY.
Anne Miek Koenen
Favorite
(P 197) PROPRANOLOL MONOTHERAPY IN ANGIOSARCOMA - A WINDOW-OF-OPPORTUNITY STUDY (PROPANGIO)
Anne Miek Koenen
Favorite
Koerner, Sean

UPMC Hillman Cancer Center
(P 445) ISOTOXIC RADIOTHERAPY DOSE ESCALATION IN UNRESECTABLE PEDIATRIC EWING SARCOMA: A DOSIMETRIC FEASIBILITY STUDY
Sean Koerner
Favorite
Kogosov, Vlada

Comprehensiv Cancer Center Lower Saxony
(P 133) TEN RECOMMENDATIONTS FOR SARCOMA SURGERY: CONSENSUS OF THE SURGICAL SOCIETIES BASED ON THE GERMAN S3 GUIDELINE "ADULT SOFT TISSUE SARCOMA"
Vlada Kogosov
Favorite
Koh, Andrew

University of Texas Southwestern Medical Center
(P 166) SARC038: A PHASE 2 STUDY OF REGORAFENIB IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH REFRACTORY OR RECURRENT OSTEOSARCOMA
Andrew Koh
Favorite
Kohsaka, Shinji

Division of Cellular Signaling, National Cancer Center Research Institute
(P 406) EXTENSIVE ANALYSIS OF 59 SARCOMA-RELATED FUSION GENES IDENTIFIED PAZOPANIB AS A POTENTIAL INHIBITOR TO COL1A1-PDGFB FUSION GENE
Shinji Kohsaka
Favorite
Koike, Hiroshi

Nagoya University Hospital
(P 163) SELUMETINIB IN JAPANESE PEDIATRIC PATIENTS WITH SYMPTOMATIC INOPERABLE PLEXIFORM NEUROFIBROMA IN NEUROFIBROMATOSIS TYPE 1
Hiroshi Koike
Favorite
Ko, Jason

Northwestern Medicine
(P 480) TARGETED MUSCLE REINNERVATION FOR HIP DISARTICULATION - EVALUATION OF EARLY FUNCTIONAL OUTCOMES
Jason Ko
Favorite
Kojima, Shinya

Division of Cellular Signaling, National Cancer Center Research Institute
(P 406) EXTENSIVE ANALYSIS OF 59 SARCOMA-RELATED FUSION GENES IDENTIFIED PAZOPANIB AS A POTENTIAL INHIBITOR TO COL1A1-PDGFB FUSION GENE
Shinya Kojima
Favorite
Kojima, Yuki

Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
(P 10) ATEZOLIZUMAB IN JAPANESE PATIENTS WITH ADVANCED ALVEOLAR SOFT PART SARCOMA: A MULTI-CENTER, SINGLE-ARM, INVESTIGATOR-INITIATED PHASE 2 TRIAL (NCCH1907)
Yuki Kojima
Favorite
(P 80) OPTIMIZING DOSE OF MAP THERAPY FOR CHILDREN, YOUNG ADULTS AND ADULTS WITH OSTEOSARCOMA; A SINGLE-CENTRE RETROSPECTIVE ANALYSIS
Yuki Kojima
Favorite
Kokkali, Stefania

National and Kapodistrian University of Athens, Oncology Unit, 2nd Department of Medicine, HIPPOKRATIO General Hospital of Athens
(P 222) EXPLORING THE IMPACT OF NGS ON DIAGNOSTICS AND TREATMENT OF SARCOMA: INSIGHTS FROM REAL-WORLD DATA ACROSS MULTIPLE INSTITUTIONS IN EUROPE
Stefania Kokkali
Favorite
(P 437) ULTRA-RARE UNDIFFERENTIATED SMALL ROUND CELL SARCOMA: HOW SHOULD WE TREAT THEM? AN ANALYSIS FORM THE GRACEFUL PROJECT
Stefania Kokkali
Favorite
Kolb, E. Anders

2Nemours Center for Cancer and Blood Disorders
(P 203) PRECLINICAL EVALUATION AMG 650, A SMALL MOLECULE INHIBITOR OF KIF18A, IN PEDIATRIC SOLID TUMORS BY THE PEDIATRIC PRECLINICAL IN VIVO TESTING (PIVOT) PROGRAM
E. Anders Kolb
Favorite
Kollar, Attila

Department of Medical Oncology, University Hospital Bern, Inselspital, Switzerland
(P 152) EVALUATING DIAGNOSTIC APPROACHES TO DERMATOFIBROSARCOMA PROTUBERANS: AN OPPORTUNITY TO REDUCE THE NUMBER OF INTERVENTIONS
Attila Kollar
Favorite
(P 342) THE EVALUATION AND OUTCOMES OF MESENTERIC AND INTRA-ABDOMINAL DESMOIDS: A TARPSWG STUDY
Attila Kollar
Favorite
Komine, Keigo

Tohoku University Hospital
(P 547) A PHASE II TRIAL OF TAZEMETOSTAT FOR PATIENTS WITH UNRESECTABLE OR METASTATIC EPITHELIOID SARCOMA (TAZETTA TRIAL)
Keigo Komine
Favorite
Komiyama, Motokiyo

Department of Urology, National Cancer Center Hospital, Tokyo, Japan
(P 332) SURGICAL OUTCOMES OF RETROPERITONEAL LIPOSARCOMA - SINGLE INSTITUTIONAL STUDY N JAPAN -
Motokiyo Komiyama
Favorite
Kondo, Tadashi

National Cancer Center Research Institute
(P 396) COMPREHENSIVE WHOLE-GENOME MOLECULAR PROFILING IN BONE AND SOFT TISSUE SARCOMA: MULTI-OMICS ANALYSIS OF 627 CASES ACROSS HISTOLOGIC SUBTYPES
Tadashi Kondo
Favorite
Kong, Chang-Bae

Korea Cancer Center Hospital
(P 78) THE CLINICAL OUTCOME OF EXTRASKELETAL MYXOID CHONDROSARCOMA
Chang-Bae Kong
Favorite
Konieczkowski, David

James Cancer Hospital, The Ohio State University
(P 311) ROBUST VMAT TREATMENT PLANNING FOR EXTREMITY SOFT TISSUE SARCOMAS
David Konieczkowski
Favorite
(P 314) PRE-OPERATIVE RADIATION THERAPY INCREASES ADHERENCE IN PATIENTS WITH HIGH-RISK EXTREMITY SOFT TISSUE SARCOMA
David Konieczkowski
Favorite
(P 315) SCALP VOLUMETRIC MODULATED ARC THERAPY USING 3D MILLED BOLUS: DOSIMITRY, TOXICITY AND OUTCOMES
David Konieczkowski
Favorite
(P 323) PERIPHERAL NEUROPATHY FOLLOWING INTRA-OPERATIVE RADIOTHERAPY FOR EXTREMITY SOFT TISSUE SARCOMA: A SINGLE INSTITUTION EXPERIENCE
David Konieczkowski
Favorite
Koo, Selene

St. Jude Children's Research Hospital
(P 528) SAFETY AND TOLERABILITY OF ORAL CYCLOPHOSPHAMIDE AND SORAFENIB WITH INTRAVENOUS BEVACIZUMAB WITH THE ADDITION OF ATEZOLIZUMAB IN PEDIATRIC SOLID TUMOR PATIENTS
Selene Koo
Favorite
Kooy, Caroline

Patientenplatform Sarcomen/Chordoma Foundation
(P 90) RESULTS FROM AN INTERNATIONAL SURVEY OF BONE SARCOMA PATIENTS
Caroline Kooy
Favorite
Kopeć, Sylwia

Department of Soft Tissue, Bone/Sarcoma, and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.
(P 09) A NOMOGRAM MODEL TO PREDICT THE OVERALL SURVIVAL OF ADOLESCENT AND YOUNG ADULT PATIENTS WITH LOCALLY ADVANCED EWING SARCOMA.
Sylwia Kopeć
Favorite
(P 21) YOUNG ADULTS WITH NONMETASTATIC OPERABLE OSTEOSARCOMA TREATED PERIOPERATIVELY WITH METHOTREXATE, DOXORUBICIN AND CISPLATIN SCHEDULE, SINGLE INSTITUTION REPORT
Sylwia Kopeć
Favorite
Kopp, Lisa

Day One Biopharmaceuticals
(P 08) PRELIMINARY CLINICAL ACTIVITY OF THE TYPE II RAF INHIBITOR TOVORAFENIB IN RAF FUSION-DRIVEN RECURRENT/PROGRESSIVE SARCOMAS
Lisa Kopp
Favorite
Kortüm, K.

Department of Internal Medicine II, University Hospital Würzburg, 97080 Würzburg, Germany
(P 557) UNRAVELING THE ROLE OF LOCAL THERAPY FOR PATIENTS WITH OLIGOMETASTATIC SOFT TISSUE SARCOMA - A RETROSPECTIVE MULTICENTER TRIAL OF BAVARIAN UNIVERSITY HOSPITALS
K. Kortüm
Favorite
Koseła-Paterczyk, Hanna

Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology
(P 21) YOUNG ADULTS WITH NONMETASTATIC OPERABLE OSTEOSARCOMA TREATED PERIOPERATIVELY WITH METHOTREXATE, DOXORUBICIN AND CISPLATIN SCHEDULE, SINGLE INSTITUTION REPORT
Hanna Koseła-Paterczyk
Favorite
(P 162) LONG TERM SAFETY AND EFFICACY OF COMBINED DOXORUBICIN-IFOSFAMIDE CHEMOTHERAPY WITH PREOPERATIVE HYPOFRACTIONATED RADIOTHERAPY IN MARGINALLY RESECTABLE SOFT TISSUE SARCOMAS
Hanna Koseła-Paterczyk
Favorite
(P 170) HETEROGENEITY OF PAZOPANIB ACTIVITY ACROSS SOFT TISSUE SARCOMA SUBTYPES - A RETROSPECTIVE ANALYSIS OF 303 CASES FROM A REFERENCE CENTER
Hanna Koseła-Paterczyk
Favorite
(P 189) INTERNATIONAL RETROSPECTIVE STUDY FROM THE ULTRA-RARE SARCOMA WORKING GROUP ON LOW-GRADE FIBROMYXOID SARCOMA AND SCLEROSING EPITHELIOD FIBROSARCOMA: OUTCOME OF ADVANCED DISEASE AND SYSTEMIC THERAPIES
Hanna Koseła-Paterczyk
Favorite
(P 437) ULTRA-RARE UNDIFFERENTIATED SMALL ROUND CELL SARCOMA: HOW SHOULD WE TREAT THEM? AN ANALYSIS FORM THE GRACEFUL PROJECT
Hanna Koseła-Paterczyk
Favorite
Kostbade, Karina

Department of Medical Oncology, West German Cancer Center, University Hospital Essen
(P 47) PATIENT SURVIVAL IN METASTATIC GIST WITH IMATINIB-SENSITIVE MUTATIONS: REAL WORLD DATA FROM GERMAN REFERRAL CENTER (2008-2021)
Karina Kostbade
Favorite
(P 248) FIBROBLAST ACTIVATION PROTEIN ALPHA -DIRECTED IMAGING AND THERAPY OF SOLITARY FIBROUS TUMOR
Karina Kostbade
Favorite
Kothari, Anai

Medical College of Wisconsin
(P 346) DETECTION OF GERMLINE VARIANTS IN PATIENTS DIAGNOSED WITH SOFT TISSUE SARCOMA USING EXPANDED
Anai Kothari
Favorite
(P 473) GROIN PAINS: APPROACHES AND OUTCOMES FOR INGUINOFEMORAL SOFT TISSUE SARCOMAS
Anai Kothari
Favorite
Ko, Tun Kiat

National Cancer Centre Singapore
(P 285) TUMOUR-INFILTRATING MAST CELLS IN ANGIOSARCOMAS CORRELATE WITH CLINCIAL PHENOTYPES AND IMMUNO-ONCOLOGY PATHWAYS
Tun Kiat Ko
Favorite
Koulouridi, Asimina

Department of Oncology, University Hospital of Heraklion, Crete, Greece
(P 222) EXPLORING THE IMPACT OF NGS ON DIAGNOSTICS AND TREATMENT OF SARCOMA: INSIGHTS FROM REAL-WORLD DATA ACROSS MULTIPLE INSTITUTIONS IN EUROPE
Asimina Koulouridi
Favorite
Kovac, Michal

Slovak University of Technology
(P 371) DISRUPTION OF THE TP53 LOCUS IN OSTEOSARCOMA LEADS TO TP53 PROMOTER GENE FUSIONS AND RESTORATION OF PARTS OF THE TP53 SIGNALLING PATHWAY
Michal Kovac
Favorite
Kovacs, Krisztian

MCW
(P 473) GROIN PAINS: APPROACHES AND OUTCOMES FOR INGUINOFEMORAL SOFT TISSUE SARCOMAS
Krisztian Kovacs
Favorite
Kovvur, Murali

University of Pittsburgh
(P 351) TARGETING ANDROGEN RECEPTOR IN OSTEOSARCOMA CELLS WITH VARYING METASTATIC POTENTIAL
Murali Kovvur
Favorite
Koyama, Takafumi

Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan.
(P 35) GENOMIC ALTERATIONS IN ADVANCED GASTROINTESTINAL STROMAL TUMORS AS REVEALED BY COMPREHENSIVE GENOMIC PROFILING TESTS
Takafumi Koyama
Favorite
Koyama, Tatsuki

Vanderbilt University Medical Center
(P 160) A PROSPECTIVE STUDY EVALUATING THE ASSOCIATION OF PATIENT-REPORTED OUTCOMES WITH ACTIVITY LEVEL AND SLEEP PATTERNS IN SARCOMA SURVIVORS
Tatsuki Koyama
Favorite
(P 210) FINANCIAL TOXICITY ASSOCIATED WITH THE TREATMENT OF SARCOMAS: A SINGLE INSTITUTION RETROSPECTIVE-PROSPECTIVE STUDY
Tatsuki Koyama
Favorite
KO, YUNMI

National Cancer Center
(P 120) THE FEASIBILITY OF CD47-BASED IMMUNOTHERAPY FOR OSTEOSARCOMA
YUNMI KO
Favorite
Kozak, Katarzyna

Maria Sklodowska-Curie National Research Institute of Oncology Warsaw Poland
(P 09) A NOMOGRAM MODEL TO PREDICT THE OVERALL SURVIVAL OF ADOLESCENT AND YOUNG ADULT PATIENTS WITH LOCALLY ADVANCED EWING SARCOMA.
Katarzyna Kozak
Favorite
(P 170) HETEROGENEITY OF PAZOPANIB ACTIVITY ACROSS SOFT TISSUE SARCOMA SUBTYPES - A RETROSPECTIVE ANALYSIS OF 303 CASES FROM A REFERENCE CENTER
Katarzyna Kozak
Favorite
(P 545) NEOADJUVANT PEMBROLIZUMAB AND EFTILAGIMOD ALPHA WITH CONCURRENT RADIOTHERAPY IN PATIENTS WITH SELECTED SOFT TISSUE SARCOMA SUBTYPES (EFTISARC-NEO)
Katarzyna Kozak
Favorite
Kozak, Margaret

UT Southwestern
(P 115) EFFICACY AND CORREALTIVE ANALYSIS OF USING NEOADJUVANT INTRATUMORAL HIGH DOSE TALIMOGENE LAHERPAREPVEC (TVEC) WITH CONCURRENT RADIATION IN HIGH-RISK EXTREMITY AND TRUNK SOFT-TISSUE SARCOMAS
Margaret Kozak
Favorite
Kozinova, Marya

Fox Chase Cancer Center
(P 287) ESTABLISHMENT AND GENOMIC VALIDATION OF NOVEL PATIENT-DERIVED XENOGRAFT MODELS FOR DRUG DISCOVERY IN GASTROINTESTINAL STROMAL TUMOR
Marya Kozinova
Favorite
Krailo, Mark

University of Southern California
(P 68) METASTASIS-DIRECTED RADIOTHERAPY FOR EWING SARCOMA PATIENTS ENROLLED ON AEWS1221: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP (COG)
Mark Krailo
Favorite
(P 69) DEVELOPMENT AND MISSION OF THE HARMONIZATION INTERNATIONAL BONE SARCOMA CONSORTIUM (HIBISCUS)
Mark Krailo
Favorite
Krarup-Hansen, Anders

Department of Oncology, Copenhagen University Hospital, Herlev & Gentofte Hospital
(P 157) QUALITY OF LIFE DURING TREATMENT FOR METASTATIC SARCOMA - FEASIBILITY OF ELECTRONIC PATIENT REPORTED OUTCOMES
Anders Krarup-Hansen
Favorite
Krauel Gimenez-Salinas, Lucas

Pediatric Surgery Department. Hospital Sant Joan de Déu, SJD Barcelona, Barcelona, Spain
(P 385) FIRST IN HUMAN PHASE I TRIAL OF A NOVEL DRUG DELIVERY IMPLANT MATRIX WITH SN-38 (CEB-01) FOR RETROPERITONEAL SOFT TISSUE SARCOMA
Lucas Krauel Gimenez-Salinas
Favorite
Krez, Alexandra

Duke University School of Medicine
(P 72) CO-EXPRESSION OF LEUKOCYTE CYTOSOLIC PROTEIN 1 AND MATRIX METALLOPROTEINASES ARE INTEGRAL FOR METASTATIC PROGRESSION OF CHONDROSARCOMA
Alexandra Krez
Favorite
Krez, Alexandra

Duke School of Medicine
(P 137) IMPACT OF SOCIAL DETERMINANTS OF HEALTH ON SARCOMA CARE: A SINGLE INSTITUTION EXPERIENCE
Alexandra Krez
Favorite
Krishnan, Sandhya

The University of Texas MD Anderson Cancer Center
(P 426) MULTI-OMIC ANALYSIS OF DESMOPLASTIC SMALL ROUND CELL TUMORS REVEAL DISTINCT LINEAGES
Sandhya Krishnan
Favorite
(P 427) UNDERSTANDING THE MOLECULAR DRIVERS THAT REGULATE EWING SARCOMA CELL FATE
Sandhya Krishnan
Favorite
Kronenberg, Zev

Pacific Biosciences
(P 390) NOVEL ISOFORM DISCOVERY IN SARCOMA USING FULL-LENGTH PACBIO ISO-SEQ
Zev Kronenberg
Favorite
Krotewicz, Maria

Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology
(P 162) LONG TERM SAFETY AND EFFICACY OF COMBINED DOXORUBICIN-IFOSFAMIDE CHEMOTHERAPY WITH PREOPERATIVE HYPOFRACTIONATED RADIOTHERAPY IN MARGINALLY RESECTABLE SOFT TISSUE SARCOMAS
Maria Krotewicz
Favorite
Kruisselbrink, Alwine

LUMC
(P 369) MAGEA ANTIGENS AS IMMUNOTHERAPEUTIC TARGETS FOR ADVANCED OSTEOSARCOMA
Alwine Kruisselbrink
Favorite
Kruiswijk, Anouk

Leiden University Medical Center
(P 132) SARCOMA PATEINTS' VIEWS ON USING A RISK-PREDICTION MODEL TO INFORM TREATMENT DECISIONS.
Anouk Kruiswijk
Favorite
(P 368) DECODING THE IMMUNOGENOMIC DETERMINANTS OF RADIOTHERAPY RESPONSE IN SOFT TISSUE SARCOMAS
Anouk Kruiswijk
Favorite
Krzeciesa, Dawid

The West German Cancer Centre, University Hospital Essen
(P 234) GENOMIC LANDSCAPE OF CLEAR CELL SARCOMA
Dawid Krzeciesa
Favorite
(P 276) REVISITING IN- AND OFF LABEL DRUGS FREQUENTLY USED IN METASTATIC GIST USING A BROAD IN VITRO PROFILING PANEL OF PRIMARY AND SECONDARY KIT AND PDGFRA-MUTANT GIST CELLS – CLINICAL IMPLICATIONS
Dawid Krzeciesa
Favorite
(P 294) DNA-DAMAGE REPAIR DYSREGULATION AND CHEMOTHERAPY RESPONSE IN SARCOMA MODELS
Dawid Krzeciesa
Favorite
Kudawara, Ikuo

Osaka National Hospital/National Hospital Organization
(P 10) ATEZOLIZUMAB IN JAPANESE PATIENTS WITH ADVANCED ALVEOLAR SOFT PART SARCOMA: A MULTI-CENTER, SINGLE-ARM, INVESTIGATOR-INITIATED PHASE 2 TRIAL (NCCH1907)
Ikuo Kudawara
Favorite
Kudo, Daisuke

Akita University Graduate School of Medicine
(P 469) IMPACT OF A SPECIALIZED OUTPATIENT CLINIC ON BONE MRTASTASIS AND ITS BURDEN ON SPINE SURGEONS
Daisuke Kudo
Favorite
Kugathasan, Laveniya

University of British Columbia
(P 512) PERIOPERATIVE BLOOD MANAGEMENT IN PEDIATRIC PATIENTS UNDERGOING PRIMARY OSTEOSARCOMA AND EWING SARCOMA RESECTION: A RETROSPECTIVE CASE NOTE REVIEW
Laveniya Kugathasan
Favorite
Kühne, Thomas

University Children's Hospital Basel
(P 451) IMPACT OF TIME TO DIAGNOSIS - A PROSPECTIVE ANALYSIS OF THE EWING 2008 TRIAL
Thomas Kühne
Favorite
Kuijer, Marieke

Centre for Molecular Medicine Norway (NCMM), University of Oslo Leiden University Medical Center (LUMC), Leiden University
(P 73) FOSTER CONSORTIUM, FIGHT OSTEOSARCOMA THROUGH EUROPEAN RESEARCH
Marieke Kuijer
Favorite
(P 369) MAGEA ANTIGENS AS IMMUNOTHERAPEUTIC TARGETS FOR ADVANCED OSTEOSARCOMA
Marieke Kuijer
Favorite
Kulp, Adam

MD Anderson Cancer Center
(P 101) EPIGENETIC MODULATION OF NK CELLS IMPROVES TUMOR TRAFFICKING AND ENHANCES THERAPEUTIC EFFICACY AGAINST OSTEOSARCOMA
Adam Kulp
Favorite
Kumar, Parveen

The Jackson Laboratory for Genomic Medicine
(P 392) IMMUNOSUPPRESSIVE TUMOR MICROENVIRONMENT OF OSTEOSARCOMA
Parveen Kumar
Favorite
Kumar, Sonia

IRCCS Humanitas Research Hospital
(P 327) LEARNING CURVE ANALYSIS IN RETROPERITONEAL SARCOMA SURGERY
Sonia Kumar
Favorite
Kummar, Shivaani

Oregon Health & Science University
(P 188) IMPACT OF NIROGACESTAT ON FUNCTIONAL STATUS IN PATIENTS WITH DESMOID TUMORS: RESULTS FROM THE PHASE 3 DEFI STUDY
Shivaani Kummar
Favorite
(P 353) UPDATED EFFICACY AND SAFETY OF LAROTRECTINIB IN ADULT PATIENTS WITH TRK FUSION SARCOMAS
Shivaani Kummar
Favorite
Kung, Andrew

Memorial Sloan Kettering Cancer Center
(P 289) IDENTIFICATION OF EFFECTIVE THERAPEUTIC COMBINATIONS WITH THE NUCLEAR EXPORT PROTEIN INHIBITOR, SELINEXOR, IN PEDIATRIC SOLID TUMORS
Andrew Kung
Favorite
Kunisada, Toshiyuki

Okayama University Hospital
(P 16) ALVEOLAR SOFT PART SARCOMA: PROGRESS TOWARD IMPROVEMENT IN SURVIVAL? A NATIONWIDE DATABASE STUDY IN JAPAN
Toshiyuki Kunisada
Favorite
(P 396) COMPREHENSIVE WHOLE-GENOME MOLECULAR PROFILING IN BONE AND SOFT TISSUE SARCOMA: MULTI-OMICS ANALYSIS OF 627 CASES ACROSS HISTOLOGIC SUBTYPES
Toshiyuki Kunisada
Favorite
Kuniyasu, Hiroki

Nara Medical University
(P 259) LOVASTATIN INDUCES NOVEL CELL DEATH THROUGH THE IMPAIRED MITOCHONDRIA IRON UTILIZATION IN OSTEOASRCOMA CELLS.
Hiroki Kuniyasu
Favorite
Kunz, Wolfgang

Department of Radiology, University Hospital, Ludwig-Maximilians-University Munich, 81377 Munich, Germany
(P 138) CONTROVERSIES IN THE MANAGEMENT OF PATIENTS WITH SOFT TISSUE SARCOMA: RESULTS AND RECOMMENDATIONS FROM THE FIRST CONFERENCE ON STATE OF SCIENCE IN SARCOMA (CSSS)
Wolfgang Kunz
Favorite
(P 153) PRIORITY SETTING PARNTERSHIP RETROPERITONEAL SOFT TISSUE SARCOMAS
Wolfgang Kunz
Favorite
(P 557) UNRAVELING THE ROLE OF LOCAL THERAPY FOR PATIENTS WITH OLIGOMETASTATIC SOFT TISSUE SARCOMA - A RETROSPECTIVE MULTICENTER TRIAL OF BAVARIAN UNIVERSITY HOSPITALS
Wolfgang Kunz
Favorite
Kuo, Christopher

Children's Hospital Los Angeles
(P 430) UNIQUE HISTOLOGIC MORPHOLOGY OF EWING SARCOMA CELLS THAT HARBOR TP53 MUTATIONS
Christopher Kuo
Favorite
Kuppen, Peter

Leiden University Medical Center
(P 251) EVALUATION OF POTENTIAL TARGETS FOR FLUORESCENCE-GUIDED SURGERY IN PEDIATRIC EWING SARCOMA: A PRECLINICAL PROOF-OF-CONCEPT STUDY
Peter Kuppen
Favorite
Kurkure, Purna

Narayana Health, SRCC Children Hospital, Mumbai, India
(P 06) ONCOFERTILITY AND PREGNANCY IN ADOLESCENT AND YOUNG ADULT CANCERS: PHYSICIANS' KNOWLEDGE AND PREFERENCES IN A LARGE LOW-MIDDLE- INCOME COUNTRY
Purna Kurkure
Favorite
Kurmasheva, Raushan

Greehey Children's Cancer Research Institute
(P 203) PRECLINICAL EVALUATION AMG 650, A SMALL MOLECULE INHIBITOR OF KIF18A, IN PEDIATRIC SOLID TUMORS BY THE PEDIATRIC PRECLINICAL IN VIVO TESTING (PIVOT) PROGRAM
Raushan Kurmasheva
Favorite
Kuruvilla, Davis

University of South Florida Morsani College of Medicine
(P 511) SIGNIFICANCE OF TIP TO APEX DISTANCE IN PATHOLOGICAL AND IMPENDING PATHOLOGICAL FRACTURES OF THE PROXIMAL FEMUR
Davis Kuruvilla
Favorite
Kwiatkowski, David

Brigham and Women’s Hospital
(P 540) PHASE 2, MULTICENTER, OPEN-LABEL BASKET TRIAL OF NAB-SIROLIMUS FOR MALIGNANT SOLID TUMORS HARBORING PATHOGENIC INACTIVATING ALTERATIONS IN TSC1 AND TSC2 (PRECISION I)
David Kwiatkowski
Favorite
Kwok, Young

University of Maryland
(P 320) A PROSPECTIVE MULTICENTER EXPERIENCE OF PROTON THERAPY FOR RHABDOMYOSARCOMA AND EWING SARCOMA: OUTCOMES FROM THE PROTON COLLABORATIVE GROUP REGISTRY
Young Kwok
Favorite
Kyle, Potts

University of Calgary
(P 110) GCAR1: GPNMB CAR T THERAPY FOR MIT FAMILY TRANSLOCATION POSITIVE CANCERS
Potts Kyle
Favorite
KYRIAZOGLOU, ANASTASIOS

Attikon University Hospital
(P 222) EXPLORING THE IMPACT OF NGS ON DIAGNOSTICS AND TREATMENT OF SARCOMA: INSIGHTS FROM REAL-WORLD DATA ACROSS MULTIPLE INSTITUTIONS IN EUROPE
ANASTASIOS KYRIAZOGLOU
Favorite
L
La Ferlita, Alessandro

The Ohio State University Comprehensive Cancer Center
(P 301) REDUCING THE INVASIVE POTENTIAL OF DEDIFFERENTIATED LIPOSARCOMA BY TARGETING ALTERNATIVE RNA SPLICING MACHINERY
Alessandro La Ferlita
Favorite
López Andújar, Rafael

Department of Surgery, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
(P 385) FIRST IN HUMAN PHASE I TRIAL OF A NOVEL DRUG DELIVERY IMPLANT MATRIX WITH SN-38 (CEB-01) FOR RETROPERITONEAL SOFT TISSUE SARCOMA
Rafael López Andújar
Favorite
López Pousa, Antonio

Medical Oncology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
(P 113) IMMUNOSARC II: A SPANISH SARCOMA GROUP (GEIS) PHASE IB TRIAL OF DOXORUBICIN AND DACARBAZINE PLUS NIVOLUMAB IN FIRST LINE OF ADVANCED LEIOMYOSARCOMA
Antonio López Pousa
Favorite
(P 385) FIRST IN HUMAN PHASE I TRIAL OF A NOVEL DRUG DELIVERY IMPLANT MATRIX WITH SN-38 (CEB-01) FOR RETROPERITONEAL SOFT TISSUE SARCOMA
Antonio López Pousa
Favorite
(P 503) SCAPULAR PROSTHESIS RECONSTRUCTION, EXPERIENCE IN OUR INSTITUTION
Antonio López Pousa
Favorite
(P 504) WHY DO SOME PATIENTS WITH SYNOVIAL SARCOMA HAVE BETTER FUNCTIONAL OUTCOMES AFTER RESECTION SURGERY? ANALYSIS OF 102 CASES
Antonio López Pousa
Favorite
(P 507) PRIMARY CHEST WALL TUMORS OF MESENCHYMAL ORIGIN. EXPERIENCE OF A REFERENCE UNIT
Antonio López Pousa
Favorite
(P 508) DREAM, UTOPIA OR REALISM? PROGNOSTIC FACTORS IN LUNG METASTASECTOMY OF DISSEMINATED SARCOMA DISEASE
Antonio López Pousa
Favorite
Laack, Nadia

Mayo Clinic
(P 68) METASTASIS-DIRECTED RADIOTHERAPY FOR EWING SARCOMA PATIENTS ENROLLED ON AEWS1221: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP (COG)
Nadia Laack
Favorite
LaBelle, Jenna

Dana-Farber Cancer Institute
(P 384) SYSTEMATIC LITERATURE AND CLINICAL TRIAL REVIEW SHOWS TARGETABLE KINASE FUSIONS ARE COMMON IN PEDIATRIC, ADOLESCENT, AND YOUNG ADULT SOFT TISSUE SARCOMAS BUT CLINICAL TRIAL OPPORTUNITIES REMAIN RARE
Jenna LaBelle
Favorite
ladanyi, mark

mskcc
(P 24) COMPREHENSIVE ANALYSIS OF THE GENOMIC LANDSCAPE AND CLINICAL BEHAVIOR IN GIST USING NEXT GENERATION SEQUENCING (NGS, MSK-IMPACT)
mark ladanyi
Favorite
Laetsch, Theodore

Children’s Hospital of Philadelphia/University of Pennsylvania
(P 161) EFFICACY, SAFETY, AND TREATMENT HOLD WAIT-AND-SEE OUTCOMES OF LAROTRECTINIB IN PEDIATRIC PATIENTS WITH TRK FUSION SARCOMAS
Theodore Laetsch
Favorite
(P 550) ON-TRK: A NON-INTERVENTIONAL STUDY OF LAROTRECTINIB IN PATIENTS WITH TRK FUSION SOLID TUMORS
Theodore Laetsch
Favorite
(P 556) EVALUATION OF PALBOCICLIB (IBRANCE®) IN COMBINATION WITH CHEMOTHERAPY IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY EWING SARCOMA OR NEUROBLASTOMA
Theodore Laetsch
Favorite
Laffi, Alice

IRCCS Humanitas Research Hospital
(P 297) UNVEILING THE IMPACT OF INTRATUMORAL MICROBIOTA IN THE TREATMENT EFFICACY OF SOFT TISSUE SARCOMA
Alice Laffi
Favorite
(P 327) LEARNING CURVE ANALYSIS IN RETROPERITONEAL SARCOMA SURGERY
Alice Laffi
Favorite
(P 433) A 20-YEAR MONOCENTER EXPERIENCE ON CLINICAL CHARACTERISTICS AND OUTCOME OF EXTRASKELETAL EWING SARCOMA.
Alice Laffi
Favorite
(P 457) LONG-TERM FOLLOW-UP OF PATIENTS WITH ATYPICAL LIPOMATOUS TUMOR (ALT) TREATED WITH MARGINAL RESECTION IN A REFERRAL CENTER
Alice Laffi
Favorite
Laghouati, Salim

Gustave Roussy Cancer Campus
(P 75) REAL-WORLD DATA ON REGORAFENIB AND CABOZANTINIB IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH RELAPSED OSTEOSARCOMA AND EWING SARCOMA INCLUDED IN THE SACHA-FRANCE STUDY
Salim Laghouati
Favorite
Laginestra, Maria Antonella

Istituto Ortopedico Rizzoli IOR IRCCS, Laboratory of Experimental Oncology, Bologna, Italy.
(P 01) EXTRASKELETAL EWING SARCOMA OF THE EXTREMITIES AND TRUNK IN < 25 YEARS OLD PATIENTS: A RETROSPECTIVE ANALYSIS OF A MONO-INSTITUTIONAL SERIES.
Maria Antonella Laginestra
Favorite
Lagos, Galina

Brown University / Lifespan Cancer Institute
(P 361) MOLECULAR CHARACTERIZATION OF SOLITARY FIBROUS TUMORS BY ANATOMIC SITE AND NAB2::STAT6 FUSION VARIANT TYPE
Galina Lagos
Favorite
(P 401) OVEREXPRESSION OF CYCLIN DEPENDENT KINASES AND CYCLINS ACROSS SARCOMAS BEYOND CDK4
Galina Lagos
Favorite
Lahat, Guy

Tel Aviv Sourasky Medical Center
(P 342) THE EVALUATION AND OUTCOMES OF MESENTERIC AND INTRA-ABDOMINAL DESMOIDS: A TARPSWG STUDY
Guy Lahat
Favorite
Lahmar, Mehdi

Boehringer Ingelheim International GmbH
(P 185) LONGITUDINAL MUTATIONAL ANALYSIS OF TP53 IN CIRCULATING TUMOR DNA IN THE PLASMA OF PATIENTS WITH LIPOSARCOMA IN A PHASE I STUDY OF BRIGIMADLIN (BI 907828), AN MDM2-P53 ANTAGONIST
Mehdi Lahmar
Favorite
(P 408) CHANGES IN COMPUTED TOMOGRAPHY FEATURES INDUCED BY BRIGIMADLIN (BI 907828) IN PATIENTS WITH LIPOSARCOMA: INSIGHTS FROM PHASE I STUDIES
Mehdi Lahmar
Favorite
Lahr, David

Foghorn Therapeutics
(P 271) PHARMACODYNAMICS AND MECHANISTIC IMPACTS OF FHD-609, A BROMODOMAIN-CONTAINING PROTEIN 9 DEGRADER, IN A PHASE 1 STUDY IN PATIENTS WITH ADVANCED SYNOVIAL SARCOMA OR SMARCB1-LOSS TUMORS
David Lahr
Favorite
Laiwalla, Rahim

Rush University Medical Center
(P 377) EFFECTIVENESS OF INTERVENTIONAL RADIOLOGY GUIDED PROCEDURES FOR LOCALLY RECURRENT AND METASTATIC SARCOMA: SINGLE INSTITUTIONAL RESULTS
Rahim Laiwalla
Favorite
Lajkosz, Katherine

University Health Network
(P 215) IMPACT OF FRONTLINE SYSTEMIC TREATMENT CHOICE ON CLINICAL OUTCOME IN ADVANCED LEIOMYOSARCOMA: A MULTI-CENTRE RETROSPECTIVE CANSARCC STUDY
Katherine Lajkosz
Favorite
Lakhani, Nehal

START Midwest
(P 439) THE TETRAVALENT DEATH RECEPTOR 5 AGONIST INBRX-109 COMBINED WITH CHEMOTHERAPY IN EWING SARCOMA: PRELIMINARY DATA FROM A PHASE 1 STUDY
Nehal Lakhani
Favorite
Lam, Joelle

TRACON PHARMECUTICALS
(P 531) ENVASARC: A PIVOTAL TRIAL OF ENVAFOLIMAB AND ENVAFOLIMAB IN COMBINATION WITH IPILIMUMAB IN PATIENTS WITH ADVANCED OR METASTATIC UPS OR MFS WHO HAVE PROGRESSED ON PRIOR CHEMOTHERAPY
Joelle Lam
Favorite
Lam, Kentson

Moores Cancer Center, University of California San Diego
(P 29) COMBINATION TREATMENT WITH TEMOZOLOMIDE AND THE DEATH RECEPTOR-5 AGONIST INBRX-109 EFFECTIVELY TARGETS SUCCINATE DEHYDROGENASE -DEFICIENT GASTROINTESTINAL STROMAL TUMOR
Kentson Lam
Favorite
Lampron, Samantha

Takeda Development Center Americas
(P 558) TRIAL IN PROGRESS: A PHASE 1/2 STUDY OF BRIGATINIB IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH ALK POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA OR INFLAMMATORY MYOFIBROBLASTIC TUMORS (ITCC-098)
Samantha Lampron
Favorite
Lam, Suk Wai

LUMC
(P 369) MAGEA ANTIGENS AS IMMUNOTHERAPEUTIC TARGETS FOR ADVANCED OSTEOSARCOMA
Suk Wai Lam
Favorite
Lancon, Allan

CGF
(P 201) PLEOMORPHIC RHABDOMYOSARCOMAS: A NEW ENTITY ASSOCIATED WITH LYNCH SYNDROME? FIRST RESULTS OF SARCLYNCH NATIONAL STUDY
Allan Lancon
Favorite
Landers, Sharon

The University of Texas MD Anderson Cancer Center
(P 269) PLASMA DNA METHYLATION-BASED BIOMARKERS FOR MPNST DETECTION IN PATIENTS WITH NEUROFIBROMATOSIS TYPE 1 (NF1)
Sharon Landers
Favorite
Landoni, Elisa

UNC Lineberger Comprehensive Cancer Center
(P 109) INTENSE PRECLINICAL ACTIVITY BY B7H3-SPECIFIC CAR.CIK LYMPHOCYTES AGAINST EPITHELIOID SARCOMA
Elisa Landoni
Favorite
Landry, Jace

The University of Texas MD Anderson Cancer Center
(P 269) PLASMA DNA METHYLATION-BASED BIOMARKERS FOR MPNST DETECTION IN PATIENTS WITH NEUROFIBROMATOSIS TYPE 1 (NF1)
Jace Landry
Favorite
Lanzafame, Helena

Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen
(P 220) [68GA]GA-FAPI PET/CT AS NOVEL DIAGNOSTIC TOOL IN SARCOMA
Helena Lanzafame
Favorite
Lapeire, Lore

Ghent University
(P 55) RELATIVE WASH-IN RATE ON DYNAMIC CONTRAST-ENHANCED MRI AS A NEW PROGNOSTIC FACTOR IN PATIENTS WITH OSTEOSARCOMA; A POSSIBLE TOOL FOR PERSONALIZED SARCOMA-CARE?
Lore Lapeire
Favorite
(P 291) DEVELOPMENT OF A LIVE TISSUE SARCOMA BIOBANK TO SUPPORT THE CREATION OF PATIENT-DERIVED TRANSLATIONAL MODELS
Lore Lapeire
Favorite
Laranga, Roberta

Istituto Ortopedico Rizzoli IOR IRCCS, SC Third Orthopaedic Clinic and Traumatology, Bologna Italy
(P 01) EXTRASKELETAL EWING SARCOMA OF THE EXTREMITIES AND TRUNK IN < 25 YEARS OLD PATIENTS: A RETROSPECTIVE ANALYSIS OF A MONO-INSTITUTIONAL SERIES.
Roberta Laranga
Favorite
Largaespada, David

University of Minnesota
(P 84) CSF1R OVEREXPRESSION ACCELLERATES OSTEOSARCOMA TUMOR FORMATION AND GENERATES TUMORS WITH DECREASED IMMUNE CELL INFILTRATION
David Largaespada
Favorite
(P 236) APOBEC MUTAGENESIS IN OSTEOSARCOMA DEVELOPMENT, PROGRESSION AND RESPONSE TO THERAPY
David Largaespada
Favorite
(P 252) STUDY OF NUTRACEUTICAL INTERVENTION WITH HIGH PHENOLIC EXTRA VIRGIN OLIVE OIL AND CURCUMIN FOR NEUROFIBROMATOSIS TYPE 1
David Largaespada
Favorite
Laskar, Siddhartha

Tata Memorial Hospital Mumbai
(P 436) OUTCOME PROGNOSTICATORS IN ADOLESCENTS AND ADULTS WITH BONE SARCOMAS IN LOW-MIDDLE-INCOME COUNTRIES
Siddhartha Laskar
Favorite
Latour, Emile

OHSU
(P 341) A PHASE 1B STUDY TO EVALUATE PREOPERATIVE ERIBULIN IN COMBINATION WITH RADIATION IN RETROPERITONEAL SARCOMA
Emile Latour
Favorite
Lau, Ching

Connecticut Children's Medical Center
(P 392) IMMUNOSUPPRESSIVE TUMOR MICROENVIRONMENT OF OSTEOSARCOMA
Ching Lau
Favorite
Laughlin, Brady

Mayo Clinic Arizona
(P 312) MANAGEMENT OF ADULT HEAD AND NECK SOFT TISSUE SARCOMA: THE MAYO CLINIC EXPERIENCE
Brady Laughlin
Favorite
Lautz, Timothy

Lurie Children's Hospital/Northwestern University
(P 425) CHARACTERIZATION OF RHABDOMYOSARCOMA WITH PAX7::FOXO1 FUSIONS: A REPORT FROM THE SOFT TISSUE COMMITTEE OF THE CHILDREN'S ONCOLOGY GROUP
Timothy Lautz
Favorite
Lavan, Naomi

St Luke's Radiation Oncology Network
(P 155) THE IMPACT OF THE ROLE OF A SARCOMA ADVANCED NURSE PRACTITIONER (ANP) BIOPSY CLINIC IN IMPROVING PATIENT ACCESS TO SARCOMA SERVICES
Naomi Lavan
Favorite
(P 156) PATIENT REPORTED EXPERIENCES WITHIN THE IRISH SARCOMA GROUP
Naomi Lavan
Favorite
(P 217) CONTEMPORARY TREATMENT PATTERNS AND OUTCOMES IN THE MANAGEMENT OF ANGIOSARCOMA IN IRELAND
Naomi Lavan
Favorite
Lawlor, Elizabeth

Seattle Children's Research Institute
(P 81) OPTIMIZING EWING SARCOMA AND OSTEOSARCOMA BIOPSY ACQUISITION: CONSENSUS RECOMMENDATIONS FROM THE CHILDREN'S ONCOLOGY GROUP BONE TUMOR COMMITTEE
Elizabeth Lawlor
Favorite
(P 447) TARGETING FOCAL ADHESION KINASE AUGMENTS THE THERAPEUTIC POTENTIAL OF BROMODOMAIN INHIBITORS IN EWING SARCOMA
Elizabeth Lawlor
Favorite
(P 448) CAF-LIKE EWING SARCOMA CELLS DEPOSIT PRO-TUMORIGENIC EXTRACELLULAR MATRIX IN RESPONSE TO TGF-BETA SIGNALING
Elizabeth Lawlor
Favorite
Lawrenz, Joshua

Vanderbilt University Medical Center
(P 210) FINANCIAL TOXICITY ASSOCIATED WITH THE TREATMENT OF SARCOMAS: A SINGLE INSTITUTION RETROSPECTIVE-PROSPECTIVE STUDY
Joshua Lawrenz
Favorite
(P 218) NEOADJUVANT CHEMOTHERPAY AND RADIATION DECREASES TUMOR SIZE, VIABILITY, AND RECURRENCE IN MULTIPLE LIPOSARCOMA SUBSETS
Joshua Lawrenz
Favorite
Lazar, Alexander

The University of Texas MD Anderson Cancer Center
(P 36) CLINICO-GENOMIC ANALYSIS OF KIT/PDGFRA/SDH WILD-TYPE GASTROINTESTINAL STROMAL TUMORS IDENTIFIES POTENTIAL DRIVER MUTATIONS
Alexander Lazar
Favorite
(P 71) CHEMOTHERAPY AND PROGNOSTIC SIGNIFICANCE OF EXTENT OF DEDIFFERENTIATION IN DEDIFFERENTIATED PAROSTEAL OSTEOSARCOMA
Alexander Lazar
Favorite
(P 83) CLINICO-GENOMIC PROFILING OF CONVENTIONAL AND DEDIFFERENTIATED CHONDROSARCOMAS REVEALS TP53 MUTATION TO BE ASSOCIATED WITH WORSE OUTCOMES
Alexander Lazar
Favorite
(P 100) HISTOLOGY SPECIFIC INTRATUMORAL B-CELL BIOLOGY IN ALVEOLAR SOFT-PART SARCOMAS (ASPS) IN RESPONSE TO DURVALUMAB-TREMELIMUMAB (D-T)
Alexander Lazar
Favorite
(P 123) DEDIFFERENTIATED LIPOSARCOMAS TREATED WITH IMMUNE CHECKPOINT BLOCKADE: THE MD ANDERSON EXPERIENCE
Alexander Lazar
Favorite
(P 189) INTERNATIONAL RETROSPECTIVE STUDY FROM THE ULTRA-RARE SARCOMA WORKING GROUP ON LOW-GRADE FIBROMYXOID SARCOMA AND SCLEROSING EPITHELIOD FIBROSARCOMA: OUTCOME OF ADVANCED DISEASE AND SYSTEMIC THERAPIES
Alexander Lazar
Favorite
(P 198) PERSONALIZED MULTIDISCIPLINARY MANAGEMENT OF SARCOMA IN PATIENTS WITH LYNCH SYNDROME
Alexander Lazar
Favorite
(P 269) PLASMA DNA METHYLATION-BASED BIOMARKERS FOR MPNST DETECTION IN PATIENTS WITH NEUROFIBROMATOSIS TYPE 1 (NF1)
Alexander Lazar
Favorite
(P 271) PHARMACODYNAMICS AND MECHANISTIC IMPACTS OF FHD-609, A BROMODOMAIN-CONTAINING PROTEIN 9 DEGRADER, IN A PHASE 1 STUDY IN PATIENTS WITH ADVANCED SYNOVIAL SARCOMA OR SMARCB1-LOSS TUMORS
Alexander Lazar
Favorite
(P 360) TP53 ALTERATIONS IN SARCOMAS: AN ANALYSIS FROM THE AACR-GENIE DATABASE
Alexander Lazar
Favorite
(P 394) LEIOMYOSARCOMA INTRATUMORAL MACROPHAGE INFILTRATES ARE ASSOCIATED WITH DISTINCT CLINICAL AND GENOMIC PRESENTATIONS
Alexander Lazar
Favorite
(P 405) PRIMARY CARDIAC ANGIOSARCOMA- GENOMIC AND MOLECULAR LANDSCAPE
Alexander Lazar
Favorite
(P 426) MULTI-OMIC ANALYSIS OF DESMOPLASTIC SMALL ROUND CELL TUMORS REVEAL DISTINCT LINEAGES
Alexander Lazar
Favorite
(P 427) UNDERSTANDING THE MOLECULAR DRIVERS THAT REGULATE EWING SARCOMA CELL FATE
Alexander Lazar
Favorite
Lazarides, Alexander

Moffitt Cancer Center
(P 77) PATIENT OUTCOMES AFTER OPEN VERSUS CORE NEEDLE BIOPSY IN LOWER EXTREMITY SARCOMA
Alexander Lazarides
Favorite
(P 511) SIGNIFICANCE OF TIP TO APEX DISTANCE IN PATHOLOGICAL AND IMPENDING PATHOLOGICAL FRACTURES OF THE PROXIMAL FEMUR
Alexander Lazarides
Favorite
Lazcano Segura, Rossana

The University of Texas MD Anderson Cancer Center
(P 426) MULTI-OMIC ANALYSIS OF DESMOPLASTIC SMALL ROUND CELL TUMORS REVEAL DISTINCT LINEAGES
Rossana Lazcano Segura
Favorite
Lazo de la Vega, Lorena

Dana-Farber Cancer Institute
(P 03) EVOLUTION OF CLINICALLY ACTIONABLE VARIANTS IN ADVANCED PEDIATRIC AND AYA BONE SARCOMAS
Lorena Lazo de la Vega
Favorite
(P 384) SYSTEMATIC LITERATURE AND CLINICAL TRIAL REVIEW SHOWS TARGETABLE KINASE FUSIONS ARE COMMON IN PEDIATRIC, ADOLESCENT, AND YOUNG ADULT SOFT TISSUE SARCOMAS BUT CLINICAL TRIAL OPPORTUNITIES REMAIN RARE
Lorena Lazo de la Vega
Favorite
Le Cesne, Axel

Gustave Roussy Institute
(P 49) EFFICACY OF RIPRETINIB IN A MULTICENTER EXPANDED ACCESS PROGRAM IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS HARBOURING NON-KIT EXON 11 MUTATIONS.
Axel Le Cesne
Favorite
(P 173) SAFETY, EFFICACY, AND PATIENT-REPORTED OUTCOMES WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED PRIOR ANTI–COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 UPDATE
Axel Le Cesne
Favorite
(P 176) SAFETY, EFFICACY, AND PATIENT-REPORTED OUTCOMES WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED NO PRIOR ANTI–COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 UPDATE
Axel Le Cesne
Favorite
Le Deley, Marie-Cecile

Centre Oscar Lambret
(P 69) DEVELOPMENT AND MISSION OF THE HARMONIZATION INTERNATIONAL BONE SARCOMA CONSORTIUM (HIBISCUS)
Marie-Cecile Le Deley
Favorite
Le Grange, Franel

UCLH
(P 92) DOSIMETRIC CHARACTERISTICS, OUTCOMES AND PROGNOSTIC FACTORS OF PATIENTS WITH EXTRACRANIAL CHORDOMAS AND CHONDROSARCOMAS TREATED WITH HIGH DOSE RADIOTHERAPY: A LARGE SINGLE INSTITUTION COHORT
Franel Le Grange
Favorite
(P 325) OUTCOMES AFTER MODERN THREE-DIMENSIONAL CONFORMAL RADIOTHERAPY AND INTENSITY MODULATED RADIOTHERAPY TO TREAT SARCOMAS ARISING IN THE HAND: A RETROSPECTIVE SERIES
Franel Le Grange
Favorite
Le Loarer, François

Institut Bergnonié
(P 382) NTRK1/2/3 FUSIONS DETECTION USING RNA-SEQ IN MESENCHYMAL TUMORS REVEALS ULTRA-RARE AND HISTO-SPECIFIC TARGETABLE ALTERATIONS: EXPERIENCE OF AN EXTENSIVE ROUTINE RESEARCH PROGRAM.
François Le Loarer
Favorite
(P 523) IN-BETWEEN SARCOMA: A CATEGORY OF HIGH RISK OF RECURRENCE AND POOR OUTCOME
François Le Loarer
Favorite
Le Teuff, Gwenael

Gustave Roussy Cancer campus
(P 212) REPORT ON THE EWING SARCOMA PATIENTS ENROLLED IN ARM D OF THE ACSE-ESMART TRIAL: PHASE I/II STUDY OF THE PARP INHIBITOR OLAPARIB IN COMBINATION WITH IRINOTECAN IN CHILDREN WITH ADVANCED MALIGNANCIES
Gwenael Le Teuff
Favorite
Leahy, Michael

The Christie NHS Foundation Trust
(P 190) DOES RESPONSE TO PRIOR CHEMOTHERAPY PREDICT OUTCOME FROM FURTHER SYSTEMIC TREATMENT IN ADVANCED LEIOMYOSARCOMA? A SINGLE UK CENTRE EXPERIENCE
Michael Leahy
Favorite
Leão De Melo, Guilherme

Sarcoma Oncology Center
(P 117) INTERIM ANALYSIS OF PHASE 2 STUDY: A METRONOMIC REGIMEN USING GEMCITABINE, DOXORUBICIN, DOCETAXEL AND NIVOLUMAB FOR ADVANCED LEIOMYOSARCOMA (NCT04535713)
Guilherme Leão De Melo
Favorite
Leblond, Frédéric

Polytechnique Montréal
(P 245) IN VIVO USE OF RAMAN SPECTROSCOPY IN SOFT TISSUE SARCOMA RESECTION
Frédéric Leblond
Favorite
Ledesma, Patricio

Sofpromed
(P 142) THE SARCOMA EUROPEAN AND LATIN AMERICAN NETWORK (SELNET) PROJECT: OVERVIEW OF THE MAIN RESULTS OF THE SELNET REGISTRY
Patricio Ledesma
Favorite
(P 175) TRABECTEDIN PLUS RADIOTHERAPY ON SYMPHTOMATIC ADVANCED SARCOMA PATIENTS, RESULTS FROM THE SYNERGIAS STUDY: A SPANISH GROUP FOR RESEARCH IN SARCOMA (GEIS) PHASE II STUDY
Patricio Ledesma
Favorite
Lee, Alexander

The Christie NHS Foundation Trust
(P 189) INTERNATIONAL RETROSPECTIVE STUDY FROM THE ULTRA-RARE SARCOMA WORKING GROUP ON LOW-GRADE FIBROMYXOID SARCOMA AND SCLEROSING EPITHELIOD FIBROSARCOMA: OUTCOME OF ADVANCED DISEASE AND SYSTEMIC THERAPIES
Alexander Lee
Favorite
(P 190) DOES RESPONSE TO PRIOR CHEMOTHERAPY PREDICT OUTCOME FROM FURTHER SYSTEMIC TREATMENT IN ADVANCED LEIOMYOSARCOMA? A SINGLE UK CENTRE EXPERIENCE
Alexander Lee
Favorite
(P 337) CLINICAL OUTCOME OF THE PATIENTS WITH HIGH GRADE UTERINE SARCOMA: A SINGLE CENTRE REAL WORLD EXPERIENCE
Alexander Lee
Favorite
Lee, Chee Khoon

NHMRC Clinical Trials Centre
(P 386) GENOMIC PROFILING OF GYNAECOLOGICAL SARCOMAS: REPORT FROM THE AUSTRALIA-WIDE PRECISION ONCOLOGY PROGRAM
Chee Khoon Lee
Favorite
Lee, Che-Jui

Laboratory of Experimental Oncology, KU Leuven, Leuven Cancer Institute
(P 43) UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR-ASSOCIATED PROTEIN AS A POTENTIAL NEXT GENERATION MOLECULAR TARGET FOR TREATMENT OF GASTROINTESTINAL STROMAL TUMOR
Che-Jui Lee
Favorite
(P 255) EPIDEMIOLOGY OF NOVEL ACTIONABLE TARGETS IN SYNOVIAL SARCOMA: A TISSUE MICRO-ARRAY STUDY
Che-Jui Lee
Favorite
(P 349) THE UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR-ASSOCIATED PROTEIN (UPARAP) IS AN ATTRACTIVE TARGET FOR THE DEVELOPMENT OF ANTIBODY DRUG CONJUGATES FOR TREATMENT OF MESENCHYMAL MALIGNANCIES
Che-Jui Lee
Favorite
Lee, Dean

Nationwide Children's Hospital
(P 537) TGFβ IMPRINTED, EX VIVO EXPANDED UNIVERSAL DONOR NATURAL KILLER CELLS WITH CHEMOTHERAPY FOR RELAPSED BONE AND SOFT TISSUE SARCOMA - NCT05634369, REPORT FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION
Dean Lee
Favorite
Lee, Elizabeth Chun Yong

National Cancer Center Singapore
(P 285) TUMOUR-INFILTRATING MAST CELLS IN ANGIOSARCOMAS CORRELATE WITH CLINCIAL PHENOTYPES AND IMMUNO-ONCOLOGY PATHWAYS
Elizabeth Chun Yong Lee
Favorite
Lee, Eunju

Korea Institute of Radiation and Medical Sciences
(P 281) FIVE DAY SPACING OF TWO FRACTIONATED ABLATIVE RADIOTHERAPIES ENHANCES ANTITUMOR IMMUNITY IN FIBROSARCOMA CELL LINE
Eunju Lee
Favorite
Lee, Jeeyun

Sungkyunkwan University School of Medicine
(P 08) PRELIMINARY CLINICAL ACTIVITY OF THE TYPE II RAF INHIBITOR TOVORAFENIB IN RAF FUSION-DRIVEN RECURRENT/PROGRESSIVE SARCOMAS
Jeeyun Lee
Favorite
Lee, Jen-Chieh

National Taiwan University Hospital
(P 399) CRITICAL MOLECULAR PATHWAYS ASSOCIATED WITH DIFFERENT HISTOPATHOLOGY FEATURES AND DETAILED PATTERNS OF IMMUNE CELL INFILTRATES IN EPITHELIOID HEMANGIOENDOTHELIOMA (EHE)
Jen-Chieh Lee
Favorite
Lee, Jing Yi

National Cancer Centre Singapore
(P 285) TUMOUR-INFILTRATING MAST CELLS IN ANGIOSARCOMAS CORRELATE WITH CLINCIAL PHENOTYPES AND IMMUNO-ONCOLOGY PATHWAYS
Jing Yi Lee
Favorite
LEE, JUN AH

National Cancer Center
(P 120) THE FEASIBILITY OF CD47-BASED IMMUNOTHERAPY FOR OSTEOSARCOMA
JUN AH LEE
Favorite
Lee, Junseok

David Geffen School of Medicine, University of California, Los Angeles
(P 19) EXTRACELLULAR VESICLE CLICK MAGBEADS: A MULTIFACETED LIQUID BIOPSY PLATFORM FOR PEDIATRIC SARCOMAS
Junseok Lee
Favorite
lee, kyoungbun

Seoul National University Hospital
(P 374) ARHGEF4 EXPRESSION IN SOFT TISSUE SARCOMA CORRELATES WITH LOCAL GROWTH PATTERN AND LOCAL RECURRENCE: COMPREHENSIVE GENOMIC ANALYSIS IN SEARCH OF BIOMARKER OF LOCAL GROWTH PATTERN
kyoungbun lee
Favorite
Lee, Linus

Rush University Medical Center
(P 63) EVALUATION OF LOCAL RECURRENCE AND DIAGNOSTIC DISCORDANCE IN CHONDROSARCOMA PATIENTS UNDERGOING PREOPERATIVE BIOPSY
Linus Lee
Favorite
Leemans, Alexander

Image Sciences Institute, UMC utrecht
(P 229) ON THE VARIABILITY IN THE ANALYSIS OF APPARENT DIFFUSION COEFFICIENT ESTIMATES FOR MULTICENTER DIFFUSION MRI DATA OF RHABDOMYOSARCOMA PATIENTS
Alexander Leemans
Favorite
Lee, Ming-Jing

National Taiwan University Hospital Hsin-Chu Branch
(P 139) ULTRA-RARE SARCOMAS HAVE WORSE SURVIVAL COMPARED TO NON-ULTRA-RARE SARCOMAS: A NATIONAL CANCER REGISTRY STUDY
Ming-Jing Lee
Favorite
Leenders, Geert

Erasmus Medical Center
(P 231) MINIMALLY INTERACTIVE SEGMENTATION OF SOFT-TISSUE TUMORS ON MRI AND CT USING DEEP LEARNING
Geert Leenders
Favorite
(P 233) MULTI-CENTER EXTERNAL VALIDATION OF AN AUTOMATED MODEL DIFFERENTIATING ALT FROM LIPOMA USING RADIOMICS AND DEEP-LEARNING BASED SEGMENTATION
Geert Leenders
Favorite
Lee, Sonia

University of California, Irvine
(P 233) MULTI-CENTER EXTERNAL VALIDATION OF AN AUTOMATED MODEL DIFFERENTIATING ALT FROM LIPOMA USING RADIOMICS AND DEEP-LEARNING BASED SEGMENTATION
Sonia Lee
Favorite
Lee, Stella

University of Pittsburgh Medical Center
(P 466) INTRAOPERATIVE EVALUATION OF BONE AND SOFT TISSUE SARCOMA SURGICAL MARGINS WITH INDOCYANINE GREEN FLUORESCENCE IMAGING
Stella Lee
Favorite
(P 544) INTRAOPERATIVE EVALUATION OF BONE AND SOFT TISSUE SARCOMA SURGICAL MARGINS WITH INDOCYANINE GREEN FLUORESCENCE IMAGING
Stella Lee
Favorite
Lee, Wen-Chung

National Taiwan University
(P 139) ULTRA-RARE SARCOMAS HAVE WORSE SURVIVAL COMPARED TO NON-ULTRA-RARE SARCOMAS: A NATIONAL CANCER REGISTRY STUDY
Wen-Chung Lee
Favorite
Lee, Yeh Chen

Prince of Wales Hospital
(P 189) INTERNATIONAL RETROSPECTIVE STUDY FROM THE ULTRA-RARE SARCOMA WORKING GROUP ON LOW-GRADE FIBROMYXOID SARCOMA AND SCLEROSING EPITHELIOD FIBROSARCOMA: OUTCOME OF ADVANCED DISEASE AND SYSTEMIC THERAPIES
Yeh Chen Lee
Favorite
(P 386) GENOMIC PROFILING OF GYNAECOLOGICAL SARCOMAS: REPORT FROM THE AUSTRALIA-WIDE PRECISION ONCOLOGY PROGRAM
Yeh Chen Lee
Favorite
Lee, Yoon-Jin

Korea Institute of Radiation and Medical Sciences
(P 281) FIVE DAY SPACING OF TWO FRACTIONATED ABLATIVE RADIOTHERAPIES ENHANCES ANTITUMOR IMMUNITY IN FIBROSARCOMA CELL LINE
Yoon-Jin Lee
Favorite
Lefkovith, Ariel

Foghorn Therapeutics
(P 271) PHARMACODYNAMICS AND MECHANISTIC IMPACTS OF FHD-609, A BROMODOMAIN-CONTAINING PROTEIN 9 DEGRADER, IN A PHASE 1 STUDY IN PATIENTS WITH ADVANCED SYNOVIAL SARCOMA OR SMARCB1-LOSS TUMORS
Ariel Lefkovith
Favorite
Lefler, Daniel

University of Pennsylvania
(P 401) OVEREXPRESSION OF CYCLIN DEPENDENT KINASES AND CYCLINS ACROSS SARCOMAS BEYOND CDK4
Daniel Lefler
Favorite
Lehner, Burkhard

University Hospital Heidelberg
(P 133) TEN RECOMMENDATIONTS FOR SARCOMA SURGERY: CONSENSUS OF THE SURGICAL SOCIETIES BASED ON THE GERMAN S3 GUIDELINE "ADULT SOFT TISSUE SARCOMA"
Burkhard Lehner
Favorite
Lehnhardt, Marcus

BG University Hospital Bergmannsheil
(P 133) TEN RECOMMENDATIONTS FOR SARCOMA SURGERY: CONSENSUS OF THE SURGICAL SOCIETIES BASED ON THE GERMAN S3 GUIDELINE "ADULT SOFT TISSUE SARCOMA"
Marcus Lehnhardt
Favorite
Leibold, Emily

Children's National Hospital
(P 564) A PILOT STUDY OF LYSO-THERMOSENSITIVE LIPOSOMAL DOXORUBICIN AND MAGNETIC RESONANCE-GUIDED HIGH INTENSITY FOCUSED ULTRASOUND FOR TREATMENT OF RELAPSED OR REFRACTORY SOLID TUMORS
Emily Leibold
Favorite
Leithner, Andreas

Medical University of Graz
(P 138) CONTROVERSIES IN THE MANAGEMENT OF PATIENTS WITH SOFT TISSUE SARCOMA: RESULTS AND RECOMMENDATIONS FROM THE FIRST CONFERENCE ON STATE OF SCIENCE IN SARCOMA (CSSS)
Andreas Leithner
Favorite
(P 458) FREQUENCY IN CHANGE OF GRADING UPON LOCAL RECURRENCE OR DISTANT METASTASIS OF SOFT TISSUE SARCOMAS.
Andreas Leithner
Favorite
Leiva, Ana Paula

Hospital Clinico san Carlos
(P 149) PSYCOLOGICAL SNAPSHOT OF SARCOMA PATIENTS FROM AN ACADEMIC, UNIVERSITY CENTER, HOSPITAL CLÍNICO SAN CARLOS (HCSC), MADRID, A SARCOMA NATIONAL REFERRAL CENTRE IN SPAIN
Ana Paula Leiva
Favorite
(P 515) ENDOBRONCHIAL NAVIGATION AS AN INTRAOPERATORY TOOL FOR RESECTION OF SMALL PULMONARY METASTASES IN SARCOMA PATIENTS
Ana Paula Leiva
Favorite
Lejeune, Sophie

CHU Lille
(P 201) PLEOMORPHIC RHABDOMYOSARCOMAS: A NEW ENTITY ASSOCIATED WITH LYNCH SYNDROME? FIRST RESULTS OF SARCLYNCH NATIONAL STUDY
Sophie Lejeune
Favorite
LeMoël, Hugo

Polytechnique Montréal
(P 245) IN VIVO USE OF RAMAN SPECTROSCOPY IN SOFT TISSUE SARCOMA RESECTION
Hugo LeMoël
Favorite
Lenards, Nishele

University of Wisconsin La Crosse
(P 311) ROBUST VMAT TREATMENT PLANNING FOR EXTREMITY SOFT TISSUE SARCOMAS
Nishele Lenards
Favorite
Lenze, Ulrich

Department of Orthopaedic Surgery, School of Medicine & Klinikum rechts der Isar, Technical University of Munich, 81675 Munich, Germany
(P 557) UNRAVELING THE ROLE OF LOCAL THERAPY FOR PATIENTS WITH OLIGOMETASTATIC SOFT TISSUE SARCOMA - A RETROSPECTIVE MULTICENTER TRIAL OF BAVARIAN UNIVERSITY HOSPITALS
Ulrich Lenze
Favorite
Lesage, Laetitia

Institut Curie
(P 395) TARGETING CD44-MEDIATED IRON ENDOCYTOSIS IN DESMOID FIBROMATOSIS
Laetitia Lesage
Favorite
Leuci, Valeria

Department of Oncology, University of Turin
(P 109) INTENSE PRECLINICAL ACTIVITY BY B7H3-SPECIFIC CAR.CIK LYMPHOCYTES AGAINST EPITHELIOID SARCOMA
Valeria Leuci
Favorite
Leu, Kirsten

Nebraska Cancer Center
(P 361) MOLECULAR CHARACTERIZATION OF SOLITARY FIBROUS TUMORS BY ANATOMIC SITE AND NAB2::STAT6 FUSION VARIANT TYPE
Kirsten Leu
Favorite
Leung, Cheuk Hong

MD Anderson Cancer Center
(P 71) CHEMOTHERAPY AND PROGNOSTIC SIGNIFICANCE OF EXTENT OF DEDIFFERENTIATION IN DEDIFFERENTIATED PAROSTEAL OSTEOSARCOMA
Cheuk Hong Leung
Favorite
(P 123) DEDIFFERENTIATED LIPOSARCOMAS TREATED WITH IMMUNE CHECKPOINT BLOCKADE: THE MD ANDERSON EXPERIENCE
Cheuk Hong Leung
Favorite
Leung, Gabriel

The Chinese University of Hong Kong
(P 290) PRE-CLINICAL STUDY OF TUMOR TREATING FIELDS (TTFIELDS) ALONE OR IN CONJUNCTION WITH SYSTEMIC THERAPIES IN SELECTED BONE- AND SOFT-TISSUE SARCOMAS
Gabriel Leung
Favorite
Levin, Adam

Johns Hopkins University School of Medicine
(P 143) EXPLORING HOSPITAL VOLUME THRESHOLDS FOR IMPROVED SARCOMA TREATMENT ACROSS DIFFERENT AGE CATEGORIES IN THE UNITED STATES
Adam Levin
Favorite
(P 529) THE MUSCULOSKELETAL TUMOR REGISTRY -- 2023 UPDATE AND OUTLOOK
Adam Levin
Favorite
(P 559) PROSPECTIVE PHASE II TRIAL OF PREOPERATIVE HYPOFRACTIONATED PROTON THERAPY FOR EXTREMITY AND TRUNCAL AND TRUNCAL SOFT TISSUE SARCOMA: THE PRONTO STUDY RATIONALE AND DESIGN
Adam Levin
Favorite
Levine, Nicole

Duke University Hospital
(P 509) GIANT CELL TUMOR OF BONE IN THE PEDIATRIC POPULATION: A RETROSPECTIVE STUDY HIGHLIGHTING CASES OF METAPHYSEAL ONLY LOCATION AND INCREASED LOCAL RECURRENCE RATES IN SKELETALLY IMMATURE PATIENTS
Nicole Levine
Favorite
Lewin, Jeremy

Peter MacCallum Cancer Centre
(P 172) PHASE 2 RESULTS FROM THE RINGSIDE PHASE 2/3 TRIAL OF AL102 FOR TREATMENT OF DESMOID TUMORS
Jeremy Lewin
Favorite
Lewis, Valerae

The University of Texas MD Anderson Cancer Center
(P 71) CHEMOTHERAPY AND PROGNOSTIC SIGNIFICANCE OF EXTENT OF DEDIFFERENTIATION IN DEDIFFERENTIATED PAROSTEAL OSTEOSARCOMA
Valerae Lewis
Favorite
(P 83) CLINICO-GENOMIC PROFILING OF CONVENTIONAL AND DEDIFFERENTIATED CHONDROSARCOMAS REVEALS TP53 MUTATION TO BE ASSOCIATED WITH WORSE OUTCOMES
Valerae Lewis
Favorite
Lhermitte, Benoit

University Hospital of Strasbourg and UMR CNRS 7021
(P 277) ANTI-GD2 SYNERGIZES WITH HYPOXIA PATHWAY TARGETING TO BLOCK OSTEOSARCOMA CELL PROLIFERATION AND MIGRATION.
Benoit Lhermitte
Favorite
Liang, Han

Department of Gastric Surgery, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer; Tianjin Key Laboratory of Digestive Cancer, Tianjin; Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, P. R. China
(P 39) MANAGEMENT PRACTICES OF GASTROINTESTINAL STROMAL TUMORS: A QUESTIONNAIRE SURVEY OF GENERAL SURGEONS IN CHINA
Han Liang
Favorite
(P 42) THE EFFICACY AND SAFETY OF RIPRETINIB IN THE TREATMENT OF CHINESE PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS (GISTS): A SINGLE-INSTITUTION ANALYSIS
Han Liang
Favorite
Liang, Jian

Vanderbilt University Medical Center
(P 211) AN ANALYSIS OF SELF-REPORTED DEPRESSION IN SARCOMA PATIENTS
Jian Liang
Favorite
Liang, Xin

Peking University People's Hospital
(P 52) ARTEMIS-002 TRIAL IN PROGRESS: A MULTI-CENTER PHASE II TRIAL ASSESSING HS-20093 (B7-H3 ANTIBODY-DRUG CONJUGATE) FOR RELAPSED OR REFRACTORY OSTEOSARCOMA AND OTHER SARCOMAS
Xin Liang
Favorite
Li, Binghao

Department of Orthopedics, The Second Affiliated Hospital of Zhejiang University School of Medicine
(P 169) UPDATED EFFICACY AND SAFETY PROFILE OF PIMICOTINIB (ABSK021) IN TENOSYNOVIAL GIANT CELL TUMOR (TGCT): 1-YEAR FOLLOW-UP FROM PHASE 1B
Binghao Li
Favorite
Libreros Niño, Alejandra

Hospital de la Santa Creu i Sant Pau
(P 507) PRIMARY CHEST WALL TUMORS OF MESENCHYMAL ORIGIN. EXPERIENCE OF A REFERENCE UNIT
Alejandra Libreros Niño
Favorite
(P 508) DREAM, UTOPIA OR REALISM? PROGNOSTIC FACTORS IN LUNG METASTASECTOMY OF DISSEMINATED SARCOMA DISEASE
Alejandra Libreros Niño
Favorite
Licata, Armando Giuseppe

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 363) Β-CATENIN MUTATIONS AND TRANSCRIPTOMIC REPROGRAMMING IN DESMOID FIBROMATOSIS (DF)
Armando Giuseppe Licata
Favorite
Li, Chia-Chen

National Taiwan University Cancer Center
(P 139) ULTRA-RARE SARCOMAS HAVE WORSE SURVIVAL COMPARED TO NON-ULTRA-RARE SARCOMAS: A NATIONAL CANCER REGISTRY STUDY
Chia-Chen Li
Favorite
(P 189) INTERNATIONAL RETROSPECTIVE STUDY FROM THE ULTRA-RARE SARCOMA WORKING GROUP ON LOW-GRADE FIBROMYXOID SARCOMA AND SCLEROSING EPITHELIOD FIBROSARCOMA: OUTCOME OF ADVANCED DISEASE AND SYSTEMIC THERAPIES
Chia-Chen Li
Favorite
Li, Dasen

Peking University People's Hospital
(P 464) INDOCYANINE GREEN FLUORESCENCE IMAGING MAY DETECT TUMOUR RESIDUALS DURING SURGERY FOR BONE AND SOFT-TISSUE TUMOURS
Dasen Li
Favorite
Li, Duan

Memorial Sloan Kettering Cancer Center
(P 555) A PILOT PHASE II STUDY TO EVALUATE THE SMALL MOLECULE TIGILANOL TIGLATE IN PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA: CLINICAL TRIAL IN PROGRESS
Duan Li
Favorite
Liebner, David

Ohio State University, James Cancer Hospital and Solove Research Center
(P 183) A PHASE 1B/2 STUDY OF LIPOSOMAL ANNAMYCIN (ANN) IN SUBJECTS WITH PREVIOUSLY TREATED SOFT-TISSUE SARCOMAS (STS) WITH PULMONARY METASTASES
David Liebner
Favorite
(P 347) INCIDENCE AND TIMING OF RECURRENCE AFTER ADJUVANT PALBOCICLIB IN COMPLETELY RESECTED RETROPERITONEAL LIPOSARCOMA
David Liebner
Favorite
Liegl-Atzwanger, Bernadette

Medical University of Graz
(P 138) CONTROVERSIES IN THE MANAGEMENT OF PATIENTS WITH SOFT TISSUE SARCOMA: RESULTS AND RECOMMENDATIONS FROM THE FIRST CONFERENCE ON STATE OF SCIENCE IN SARCOMA (CSSS)
Bernadette Liegl-Atzwanger
Favorite
(P 458) FREQUENCY IN CHANGE OF GRADING UPON LOCAL RECURRENCE OR DISTANT METASTASIS OF SOFT TISSUE SARCOMAS.
Bernadette Liegl-Atzwanger
Favorite
Lieu, Christopher

University of Colorado
(P 439) THE TETRAVALENT DEATH RECEPTOR 5 AGONIST INBRX-109 COMBINED WITH CHEMOTHERAPY IN EWING SARCOMA: PRELIMINARY DATA FROM A PHASE 1 STUDY
Christopher Lieu
Favorite
Liew, Ann

Children's National Hospital
(P 564) A PILOT STUDY OF LYSO-THERMOSENSITIVE LIPOSOMAL DOXORUBICIN AND MAGNETIC RESONANCE-GUIDED HIGH INTENSITY FOCUSED ULTRASOUND FOR TREATMENT OF RELAPSED OR REFRACTORY SOLID TUMORS
Ann Liew
Favorite
Liffers, Sven-Thorsten

Bridge Institute of Experimental Tumor Therapy, West German Cancer Center, University Hospital Essen
(P 248) FIBROBLAST ACTIVATION PROTEIN ALPHA -DIRECTED IMAGING AND THERAPY OF SOLITARY FIBROUS TUMOR
Sven-Thorsten Liffers
Favorite
Ligorio, Francesca

Department of Medical Oncology 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
(P 333) SYSTEMIC TREATMENT IN INTRA-ABDOMINAL DESMOID-TYPE FIBROMATOSIS: A SINGLE INSTITUTION RETROSPECTIVE CASE SERIES ANALYSIS
Francesca Ligorio
Favorite
Liguori, Anna

Department of Chemistry "Giacomo Ciamician", University of Bologna, 40126 Bologna, Italy
(P 253) THE EFFICACY OF MEDICATED PATCHES IN SOFT TISSUE SARCOMAS: IN-VITRO AND EX-VIVO VALIDATION.
Anna Liguori
Favorite
Li, Haocheng

University of Calgary
(P 104) COMPREHENSIVE IMMUNE PROFILING UNVEILS A SUBSET OF LEIOMYOSARCOMA WITH HOT TUMOR IMMUNE MICROENVIRONMENT
Haocheng Li
Favorite
Li, Huikai

Department of Hepatobiliary Surgery, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer; Tianjin Key Laboratory of Digestive Cancer, Tianjin; Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, P. R. China
(P 42) THE EFFICACY AND SAFETY OF RIPRETINIB IN THE TREATMENT OF CHINESE PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS (GISTS): A SINGLE-INSTITUTION ANALYSIS
Huikai Li
Favorite
Li, Jian

Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute Beijing 100142, P. R. China
(P 39) MANAGEMENT PRACTICES OF GASTROINTESTINAL STROMAL TUMORS: A QUESTIONNAIRE SURVEY OF GENERAL SURGEONS IN CHINA
Jian Li
Favorite
(P 46) CIRCULATING TUMOR DNA (CTDNA) ANALYSES AND RESISTANCE MECHANISMS EXPLORATION OF KIT-MUTANT GASTROINTESTINAL STROMAL TUMORS (GISTS) TREATED WITH AVAPRITINIB OR RIPRETINB
Jian Li
Favorite
Li, Jing

Department of Bioinformatics and Biostatistics, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai 200240, China
(P 416) THE PROTEOGENOMIC SUBTYPING OF OSTEOSARCOMA
Jing Li
Favorite
li, leping

Department of Gastrointestinal Surgery，Shandong Provincial Hospital Affiliated to Shandong First Medical University
(P 39) MANAGEMENT PRACTICES OF GASTROINTESTINAL STROMAL TUMORS: A QUESTIONNAIRE SURVEY OF GENERAL SURGEONS IN CHINA
leping li
Favorite
Lillemoe, Heather

University of Texas MD Anderson Cancer Center
(P 510) PRIMARY BREAST ANGIOSARCOMA: CLINICAL AND PATHOLOGICAL FEATURES AND IMPACT ON OUTCOMES
Heather Lillemoe
Favorite
Li, Luyuan

University of Miami
(P 54) HIGH-THROUGHPUT DRUG SCREENING IN CHONDROSARCOMA CELLS IDENTIFIES MULTIPLE EFFICIENT ANTINEOPLASTIC AGENTS
Luyuan Li
Favorite
Lim, Allison

SpringWorks Therapeutics Inc
(P 188) IMPACT OF NIROGACESTAT ON FUNCTIONAL STATUS IN PATIENTS WITH DESMOID TUMORS: RESULTS FROM THE PHASE 3 DEFI STUDY
Allison Lim
Favorite
Lim, Boon Yee

National Cancer Center Singapore
(P 285) TUMOUR-INFILTRATING MAST CELLS IN ANGIOSARCOMAS CORRELATE WITH CLINCIAL PHENOTYPES AND IMMUNO-ONCOLOGY PATHWAYS
Boon Yee Lim
Favorite
Li, Mei

University of Chicago
(P 69) DEVELOPMENT AND MISSION OF THE HARMONIZATION INTERNATIONAL BONE SARCOMA CONSORTIUM (HIBISCUS)
Mei Li
Favorite
Lim, Elisabeth

Mayo Clinic Arizona
(P 141) TREATMENT VARIABILITY IN SURGICAL MANAGEMENT OF PULMONARY OLIGOMETASTATIC SOFT TISSUE SARCOMA
Elisabeth Lim
Favorite
Limon, Ronald Sergio

OncoBolivia
(P 142) THE SARCOMA EUROPEAN AND LATIN AMERICAN NETWORK (SELNET) PROJECT: OVERVIEW OF THE MAIN RESULTS OF THE SELNET REGISTRY
Ronald Sergio Limon
Favorite
Lim, Pei

University College Hospitals London
(P 92) DOSIMETRIC CHARACTERISTICS, OUTCOMES AND PROGNOSTIC FACTORS OF PATIENTS WITH EXTRACRANIAL CHORDOMAS AND CHONDROSARCOMAS TREATED WITH HIGH DOSE RADIOTHERAPY: A LARGE SINGLE INSTITUTION COHORT
Pei Lim
Favorite
(P 321) IDENTIFYING RISK FACTORS FOR REDUCTION OF PROTON THERAPY RE-PLANS FOR PAEDIATRIC PATIENTS WITH PELVIC SARCOMAS
Pei Lim
Favorite
Lindberg, Johan

Karolinska institutet
(P 243) EVALUATION OF THE USE OF WGS IN ROUTINE DIAGNOSTICS FOR BONE AND SOFT TISSUE TUMORS
Johan Lindberg
Favorite
Lindgren, Bruce

University of Minnesota
(P 167) FDG-PET-CT RESPONSE AFTER NEOADJUVANT CHEMOTHERAPY PREDICTS LONG-TERM OUTCOME IN PATIENTS WITH SOFT TISSUE SARCOMA -- 15-YEAR FOLLOW-UP
Bruce Lindgren
Favorite
Lindner, Lars

Department of Medicine III, LMU University Hospital, LMU Munich
(P 118) TIM-3 QUALIFIES AS A POTENTIAL IMMUNOTHERAPEUTIC TARGET IN SPECIFIC SUBSETS OF PATIENTS WITH HIGH-RISK SOFT TISSUE SARCOMAS (HR-STS)
Lars Lindner
Favorite
(P 133) TEN RECOMMENDATIONTS FOR SARCOMA SURGERY: CONSENSUS OF THE SURGICAL SOCIETIES BASED ON THE GERMAN S3 GUIDELINE "ADULT SOFT TISSUE SARCOMA"
Lars Lindner
Favorite
(P 138) CONTROVERSIES IN THE MANAGEMENT OF PATIENTS WITH SOFT TISSUE SARCOMA: RESULTS AND RECOMMENDATIONS FROM THE FIRST CONFERENCE ON STATE OF SCIENCE IN SARCOMA (CSSS)
Lars Lindner
Favorite
(P 153) PRIORITY SETTING PARNTERSHIP RETROPERITONEAL SOFT TISSUE SARCOMAS
Lars Lindner
Favorite
(P 348) RESECTION OF RECURRENT RETROPERITONEAL SOFT TISSUE SARCOMAS: ARE INTENSIVE MULTIMODAL TREATMENTS ASSOCIATED WITH INCREASED PERIOPERATIVE MORBIDITY?
Lars Lindner
Favorite
(P 530) FIH PHASE I STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND ANTITUMOR ACTIVITY OF THE001 COMBINED WITH REGIONAL HYPERTHERMIA IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOFT TISSUE SARCOMA
Lars Lindner
Favorite
(P 557) UNRAVELING THE ROLE OF LOCAL THERAPY FOR PATIENTS WITH OLIGOMETASTATIC SOFT TISSUE SARCOMA - A RETROSPECTIVE MULTICENTER TRIAL OF BAVARIAN UNIVERSITY HOSPITALS
Lars Lindner
Favorite
Lindsay, Daniel

Royal National Orthopaedic Hospital NHS Trust
(P 04) THE CELL ATLAS OF CLEAR CELL SARCOMA
Daniel Lindsay
Favorite
(P 381) THE GENOMIC LANDSCAPE OF CLEAR CELL SARCOMA
Daniel Lindsay
Favorite
Lindsay, Sarah

Oregon Health & Science University
(P 129) LOW RATES OF SERVICE CONNECTIVITY FOR SOFT TISSUE SARCOMA (STS) AMONG ELIGIBLE VIETNAM VETERANS WITH AGENT ORANGE EXPOSURE
Sarah Lindsay
Favorite
(P 130) THE ADOPTION OF MEDICAID EXPANSION IN THE AFFORDABLE CARE ACT IS NOT ASSOCIATED WITH STAGE AT PRESENTATION OR 5-YEAR OVERALL SURVIVAL FOR BONE OR SOFT TISSUE SARCOMAS
Sarah Lindsay
Favorite
(P 227) DE NOVO NATURAL LANGUAGE PROCESSING (NLP) ALGORITHM ACCURATELY IDENTIFIES MYXOFIBROSARCOMA DIRECTLY FROM PATHOLOGY REPORTS
Sarah Lindsay
Favorite
(P 462) EXTERNAL VALIDATION OF A NOMOGRAM PREDICTING THE RISK OF POSTOPERATIVE MAJOR WOUND COMPLICATION IN SOFT TISSUE SARCOMA FOLLOWING PREOPERATIVE RADIOTHERAPY AND RESECTION
Sarah Lindsay
Favorite
(P 463) MACHINE LEARNING CORROBORATES TRADITIONAL REGRESSION TECHNIQUES IN PREDICTING MAJOR WOUND COMPLICATIONS AFTER SOFT TISSUE SARCOMA RESECTION WITHOUT IMPROVEMENTS IN PREDICTIVE PERFORMANCE
Sarah Lindsay
Favorite
Lin, Feng

Daiichi Sankyo, Inc.
(P 131) PATIENT-REPORTED CONTINUED BENEFITS IN PATIENTS TREATED WITH PEXIDARTINIB FOR TENOSYNOVIAL GIANT CELL TUMOR BASED ON A REAL-WORLD STUDY IN THE UNITED STATES
Feng Lin
Favorite
Lin, Frank Po-Yen

Garvan Institute of Medical Research
(P 386) GENOMIC PROFILING OF GYNAECOLOGICAL SARCOMAS: REPORT FROM THE AUSTRALIA-WIDE PRECISION ONCOLOGY PROGRAM
Frank Po-Yen Lin
Favorite
Lin, Heather

MD Anderson Cancer Center
(P 71) CHEMOTHERAPY AND PROGNOSTIC SIGNIFICANCE OF EXTENT OF DEDIFFERENTIATION IN DEDIFFERENTIATED PAROSTEAL OSTEOSARCOMA
Heather Lin
Favorite
Link, Thomas

University of California, San Francisco
(P 233) MULTI-CENTER EXTERNAL VALIDATION OF AN AUTOMATED MODEL DIFFERENTIATING ALT FROM LIPOMA USING RADIOMICS AND DEEP-LEARNING BASED SEGMENTATION
Thomas Link
Favorite
Lin, Patrick

The University of Texas MD Anderson Cancer Center
(P 71) CHEMOTHERAPY AND PROGNOSTIC SIGNIFICANCE OF EXTENT OF DEDIFFERENTIATION IN DEDIFFERENTIATED PAROSTEAL OSTEOSARCOMA
Patrick Lin
Favorite
Lin, Ran

Tel Aviv Soursky medical center
(P 319) HYPO-FRACTIONATED RADIATION THERAPY FOR THE EXTREMITY SOFT TISSUE SARCOM IN ELDERLY AND DISABLED.
Ran Lin
Favorite
Lin, Tianyu

Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
(P 41) GENOMIC ANALYSIS OF SECONDARY KIT MUTATIONS IN CHINESE PATIENTS WITH IMATINIB-RESISTANT ADVANCED GASTROINTESTINAL STROMAL TUMORS USING NEXT-GENERATION SEQUENCING (NGS)
Tianyu Lin
Favorite
Lin, Yingbo

Karolinska institutet
(P 243) EVALUATION OF THE USE OF WGS IN ROUTINE DIAGNOSTICS FOR BONE AND SOFT TISSUE TUMORS
Yingbo Lin
Favorite
Lipson, Trisha

University of Washington
(P 448) CAF-LIKE EWING SARCOMA CELLS DEPOSIT PRO-TUMORIGENIC EXTRACELLULAR MATRIX IN RESPONSE TO TGF-BETA SIGNALING
Trisha Lipson
Favorite
Lira, Maria Florencia

Universidad Complutense de Madrid
(P 149) PSYCOLOGICAL SNAPSHOT OF SARCOMA PATIENTS FROM AN ACADEMIC, UNIVERSITY CENTER, HOSPITAL CLÍNICO SAN CARLOS (HCSC), MADRID, A SARCOMA NATIONAL REFERRAL CENTRE IN SPAIN
Maria Florencia Lira
Favorite
Lisboa, Joyce

A.C.Camargo Cancer Center
(P 387) CLINICAL CHARACTERIZATION OF PATIENTS WITH LEIOMYOSARCOMA HARBORING THE R337H TP53 GERMINATIVE ALTERATION (LI-FRAUMENI SYNDROME) AND THE PROGNOSTIC IMPLICATION USING A PROPENSITY-SCORE MATCHED COHORT
Joyce Lisboa
Favorite
Lisignoli, Gina

IRCCS Istituto Ortopedico Rizzoli
(P 85) TARGETING CD99 ELICITS EWING SARCOMA CELL PHAGOCYTOSIS BY UNDIFFERENTIATED AND M2-LIKE MACROPHAGES AND INDUCES MACROPHAGE POLARIZATION TOWARD A M1-LIKE PHENOTYPE
Gina Lisignoli
Favorite
Lisi, Mariapaola

Azienda Ospedaliero Universitaria Careggi
(P 144) IMPLEMENTATION OF THE EUROPEAN CLINICAL TRIAL REGULATION: SURVEY OF THE ITALIAN SARCOMA GROUP CENTERS
Mariapaola Lisi
Favorite
Listì, Angela

Department of Oncology, University of Turin
(P 262) ESTABLISHMENT AND CHARACTERIZATION OF THE FIRST RADIATION-INDUCED, PATIENT-DERIVED ANGIOSARCOMA CELL LINE
Angela Listì
Favorite
Li, Tao

Department of Bone and Soft tissue Surgery, Zhejiang Cancer Hospital
(P 168) A PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF PEXIDARTINIB IN ASIAN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR
Tao Li
Favorite
(P 543) MANEUVER STUDY: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF PIMICOTINIB (ABSK021) TO ASSESS THE EFFICACY AND SAFETY IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR
Tao Li
Favorite
Littlefield, Nickolas

University of Pittsburgh
(P 244) A DEEP FEW-SHOT META-LEARNING STRATEGY FOR AUTONOMOUS CLASSIFICATION OF BONE METASTASIS IN RADIONUCLIDE BONE SCANS
Nickolas Littlefield
Favorite
Liu, Bin

MD Anderson Cancer Center
(P 100) HISTOLOGY SPECIFIC INTRATUMORAL B-CELL BIOLOGY IN ALVEOLAR SOFT-PART SARCOMAS (ASPS) IN RESPONSE TO DURVALUMAB-TREMELIMUMAB (D-T)
Bin Liu
Favorite
liu, Chenglei

Shanghai Jiao Tong University School of Medicine
(P 354) ROLE OF APPARENT DIFFUSION COEFFICIENT (ADC) MAP-BASED FIRST AND HIGH-ORDER RADIOMIC FEATURES IN DISCRIMINATING SACRAL CHORDOMAS AND CHONDROSARCOMAS WITH OVERLAPPING CONVENTIONAL IMAGING FEATURES
Chenglei liu
Favorite
Liu, Hongrui

University of Calgary
(P 110) GCAR1: GPNMB CAR T THERAPY FOR MIT FAMILY TRANSLOCATION POSITIVE CANCERS
Hongrui Liu
Favorite
Liu, Huan

C4 Therapeutics
(P 178) INITIAL RESULTS FROM A PHASE 1 STUDY OF CFT8634, A NOVEL BIFUCTIONAL DEGRADATION ACTIVATING COMPOUND (BIDAC) DEGRADER OF BRD9, IN SYNOVIAL SARCOMA AND SMARCB1-NULL TUMORS
Huan Liu
Favorite
Liu, Kuisheng

Peking University People's Hospital
(P 52) ARTEMIS-002 TRIAL IN PROGRESS: A MULTI-CENTER PHASE II TRIAL ASSESSING HS-20093 (B7-H3 ANTIBODY-DRUG CONJUGATE) FOR RELAPSED OR REFRACTORY OSTEOSARCOMA AND OTHER SARCOMAS
Kuisheng Liu
Favorite
(P 442) LONG-TERM OUTCOME AND RELAPSE PATTERNS IN EWING SARCOMA PATIENTS WITH EXTENSIVE LUNG/PLEURAL METASTASES AFTER A COMPLETE RESPONSE TO SYSYEMIC THERAPY
Kuisheng Liu
Favorite
Liu, Lin

Division of Biostatistics and Bioinformatics, Herbert Wertheim School of Public Health and Human Longevity Science, University of California San Diego
(P 28) RETROSPECTIVE ANALYSIS OF SUCCINATE DEHYDROGENASE (SDH)-DEFICIENT GASTROINTESTINAL STROMAL TUMOR (GIST) OUTCOMES: AN INTERNATIONAL STUDY OF 256 PATIENTS
Lin Liu
Favorite
Liu, Lin

State Key Laboratory of Pharmaceutical Biotechnology and MOE Key Laboratory of Model Animals for Disease Study, Department of Spine Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School
(P 44) RIPRETINIB FOR THE TREATMENT OF CHINESE PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS HARBORING KIT SECONDARY MUTATIONS: A MULTICENTER, RETROSPECTIVE STUDY
Lin Liu
Favorite
Liu, Ning

Department of Gastric Surgery, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer; Tianjin Key Laboratory of Digestive Cancer, Tianjin; Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, P. R. China
(P 42) THE EFFICACY AND SAFETY OF RIPRETINIB IN THE TREATMENT OF CHINESE PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS (GISTS): A SINGLE-INSTITUTION ANALYSIS
Ning Liu
Favorite
(P 44) RIPRETINIB FOR THE TREATMENT OF CHINESE PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS HARBORING KIT SECONDARY MUTATIONS: A MULTICENTER, RETROSPECTIVE STUDY
Ning Liu
Favorite
Liu, Tang

The Second Xiangya Hospital, Central South University
(P 543) MANEUVER STUDY: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF PIMICOTINIB (ABSK021) TO ASSESS THE EFFICACY AND SAFETY IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR
Tang Liu
Favorite
Liu, Ting

Huntsman Cancer Institute/University of Utah
(P 412) LEIOMYOSARCOMA POLYANEUPLOID CANCER CELLS DEVELOP IN RESPONSE TO CHEMOTHERAPY AND CONTRIBUTE TO CHEMORESISTANCE
Ting Liu
Favorite
Liu, Xiaofei

The First Affiliated Hospital of Sun Yat-sen University
(P 45) THE LONG-TERM EFFECT OF IMATINIB WITH HEPATIC RESECTION OR OTHER LOCAL TREATMENT FOR GIST LIVER METASTASES
Xiaofei Liu
Favorite
Liu, Xingyu

Peking University People's Hospital
(P 442) LONG-TERM OUTCOME AND RELAPSE PATTERNS IN EWING SARCOMA PATIENTS WITH EXTENSIVE LUNG/PLEURAL METASTASES AFTER A COMPLETE RESPONSE TO SYSYEMIC THERAPY
Xingyu Liu
Favorite
Liu, Xiufeng

Department of Medical Oncology of PLA Cancer Center, Jinling Hospital
(P 44) RIPRETINIB FOR THE TREATMENT OF CHINESE PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS HARBORING KIT SECONDARY MUTATIONS: A MULTICENTER, RETROSPECTIVE STUDY
Xiufeng Liu
Favorite
(P 48) SIGNIFICANCE OF MONITORING PLASMA CONCENTRATION OF RIPRETINIB IN CHINESE PATIENTS WITH GASTROINTESTINAL STROMAL TUMORS
Xiufeng Liu
Favorite
Liu, Ying

Laboratory of Applied Human Genetics, Division of Medical Sciences, National Cancer Centre Singapore
(P 336) EVOLUTION AND PURSUIT OF EXCELLENCE IN SARCOMA MANAGEMENT IN AN ASIAN TERTIARY SARCOMA SPECIALISED CENTRE
Ying Liu
Favorite
Liverani, Chiara

Istituto Romagnolo per lo studio dei Tumori "Dino Amadori" IRST IRCCS, Preclinic and Osteoncology Unit, Meldola, Italy
(P 37) DISSECTING THE ROLE OF EXTRACELLULAR VESICLES IN THE MANAGEMENT OF GIST
Chiara Liverani
Favorite
(P 253) THE EFFICACY OF MEDICATED PATCHES IN SOFT TISSUE SARCOMAS: IN-VITRO AND EX-VIVO VALIDATION.
Chiara Liverani
Favorite
Livi, Lorenzo

Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, Florence, Italy
(P 309) CLINICAL PATHOLOGICAL CHARACTERISTICS, PATTERN OF CARE AND SURVIVAL OF NON-METASTATIC BREAST ANGIOSARCOMA
Lorenzo Livi
Favorite
(P 317) PROGNOSTIC FACTORS, CLINICAL AND TOXICITY OUTCOMES FROM A LARGE COHORT OF PATIENTS WITH SOFT TISSUE SARCOMA TREATED WITH PREOPERATIVE RADIATION THERAPY
Lorenzo Livi
Favorite
(P 546) PRELIMINARY CLINICAL RESULTS OF AN ONGOING PHASE II TRIAL: SPRINT (SARCOMA PREOPERATIVE RADIATION WITH SIMULTANEOUS INTEGRATED BOOST)
Lorenzo Livi
Favorite
Livingston, Andy

The University of Texas MD Anderson Cancer Center
(P 71) CHEMOTHERAPY AND PROGNOSTIC SIGNIFICANCE OF EXTENT OF DEDIFFERENTIATION IN DEDIFFERENTIATED PAROSTEAL OSTEOSARCOMA
Andy Livingston
Favorite
(P 83) CLINICO-GENOMIC PROFILING OF CONVENTIONAL AND DEDIFFERENTIATED CHONDROSARCOMAS REVEALS TP53 MUTATION TO BE ASSOCIATED WITH WORSE OUTCOMES
Andy Livingston
Favorite
(P 100) HISTOLOGY SPECIFIC INTRATUMORAL B-CELL BIOLOGY IN ALVEOLAR SOFT-PART SARCOMAS (ASPS) IN RESPONSE TO DURVALUMAB-TREMELIMUMAB (D-T)
Andy Livingston
Favorite
(P 123) DEDIFFERENTIATED LIPOSARCOMAS TREATED WITH IMMUNE CHECKPOINT BLOCKADE: THE MD ANDERSON EXPERIENCE
Andy Livingston
Favorite
(P 269) PLASMA DNA METHYLATION-BASED BIOMARKERS FOR MPNST DETECTION IN PATIENTS WITH NEUROFIBROMATOSIS TYPE 1 (NF1)
Andy Livingston
Favorite
(P 360) TP53 ALTERATIONS IN SARCOMAS: AN ANALYSIS FROM THE AACR-GENIE DATABASE
Andy Livingston
Favorite
(P 394) LEIOMYOSARCOMA INTRATUMORAL MACROPHAGE INFILTRATES ARE ASSOCIATED WITH DISTINCT CLINICAL AND GENOMIC PRESENTATIONS
Andy Livingston
Favorite
Li, Wenjie

Department of Retroperitoneal Tumor Surgery, Peking University International Hospital
(P 534) NEOADJUVANT CHEMOTHERAPY COMBINED WITH TARGETED TREATMENT IN HIGH-RISK RETROPERITONEAL SARCOMA – A PROSPECTIVE NON-RANDOMIZED CONTROLLED MULTI-CENTERED STUDY ALL ACROSS CHINA
Wenjie Li
Favorite
Li, William

University of Pittsburgh Medical Center
(P 466) INTRAOPERATIVE EVALUATION OF BONE AND SOFT TISSUE SARCOMA SURGICAL MARGINS WITH INDOCYANINE GREEN FLUORESCENCE IMAGING
William Li
Favorite
(P 544) INTRAOPERATIVE EVALUATION OF BONE AND SOFT TISSUE SARCOMA SURGICAL MARGINS WITH INDOCYANINE GREEN FLUORESCENCE IMAGING
William Li
Favorite
Li, Xianan

Hunan Cancer Hospital
(P 97) AN EXPLORATORY STUDY OF AN ANTI-PD-L1/TGF-β ANTIBODY, TQB2858, IN PATIENTS WITH REFRACTORY OR RECURRENT OSTEOSARCOMA AND ALVEOLAR SOFT PART SARCOMA: A REPORT FROM CHINESE SARCOMA STUDY GROUP
Xianan Li
Favorite
Li, Xiaolin

Department of Geriatric Gastroenterology, The First Affiliated Hospital of Nanjing Medical University
(P 48) SIGNIFICANCE OF MONITORING PLASMA CONCENTRATION OF RIPRETINIB IN CHINESE PATIENTS WITH GASTROINTESTINAL STROMAL TUMORS
Xiaolin Li
Favorite
Li, Yi

Department of Bioengineering, University of Texas at Dallas
(P 261) EFFICACY OF BET INHIBITORS IN SOLITARY FIBROUS TUMOR: AN IN VITRO EVALUATION
Yi Li
Favorite
Li, Yi Xin

Duke NUS Medical School
(P 336) EVOLUTION AND PURSUIT OF EXCELLENCE IN SARCOMA MANAGEMENT IN AN ASIAN TERTIARY SARCOMA SPECIALISED CENTRE
Yi Xin Li
Favorite
Li, Yingjoy

UNIVERSITY OF CALIFORNIA IRVINE
(P 324) EVALUATING THE ROLE OF ADJUVANT RADIATION AFTER WIDE LOCAL EXCISION OF PLEOMORPHIC DERMAL SARCOMA
Yingjoy Li
Favorite
li, yong

Department of General Surgery，The Fourth Hospital of Hebei Medical University
(P 39) MANAGEMENT PRACTICES OF GASTROINTESTINAL STROMAL TUMORS: A QUESTIONNAIRE SURVEY OF GENERAL SURGEONS IN CHINA
yong li
Favorite
Lizier, Michela

Humanitas Clinical and Research hospital
(P 297) UNVEILING THE IMPACT OF INTRATUMORAL MICROBIOTA IN THE TREATMENT EFFICACY OF SOFT TISSUE SARCOMA
Michela Lizier
Favorite
Ljevar, Silva

Unit of Biostatistics for Clinical Research Department of Epidemiology and Data Science, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
(P 189) INTERNATIONAL RETROSPECTIVE STUDY FROM THE ULTRA-RARE SARCOMA WORKING GROUP ON LOW-GRADE FIBROMYXOID SARCOMA AND SCLEROSING EPITHELIOD FIBROSARCOMA: OUTCOME OF ADVANCED DISEASE AND SYSTEMIC THERAPIES
Silva Ljevar
Favorite
Llauger, Jaume

Hospital de la Santa Creu i Sant Pau
(P 503) SCAPULAR PROSTHESIS RECONSTRUCTION, EXPERIENCE IN OUR INSTITUTION
Jaume Llauger
Favorite
(P 504) WHY DO SOME PATIENTS WITH SYNOVIAL SARCOMA HAVE BETTER FUNCTIONAL OUTCOMES AFTER RESECTION SURGERY? ANALYSIS OF 102 CASES
Jaume Llauger
Favorite
(P 507) PRIMARY CHEST WALL TUMORS OF MESENCHYMAL ORIGIN. EXPERIENCE OF A REFERENCE UNIT
Jaume Llauger
Favorite
(P 508) DREAM, UTOPIA OR REALISM? PROGNOSTIC FACTORS IN LUNG METASTASECTOMY OF DISSEMINATED SARCOMA DISEASE
Jaume Llauger
Favorite
Llosas, Nicolas

The Johns Hopkins Hospital
(P 143) EXPLORING HOSPITAL VOLUME THRESHOLDS FOR IMPROVED SARCOMA TREATMENT ACROSS DIFFERENT AGE CATEGORIES IN THE UNITED STATES
Nicolas Llosas
Favorite
Lo Cascio, Antonino

Humanitas Clinical and Research Hospital
(P 297) UNVEILING THE IMPACT OF INTRATUMORAL MICROBIOTA IN THE TREATMENT EFFICACY OF SOFT TISSUE SARCOMA
Antonino Lo Cascio
Favorite
Lobbardi, Riadh

C4 Therapeutics
(P 178) INITIAL RESULTS FROM A PHASE 1 STUDY OF CFT8634, A NOVEL BIFUCTIONAL DEGRADATION ACTIVATING COMPOUND (BIDAC) DEGRADER OF BRD9, IN SYNOVIAL SARCOMA AND SMARCB1-NULL TUMORS
Riadh Lobbardi
Favorite
Lock, Ian

Duke University
(P 450) INVESTIGATING THE THERAPEUTIC POTENTIAL OF SMALL MOLECULE INHIBITOR INOBRODIB AS A TREATMENT ALTERNATIVE FOR CIC-DUX4 SARCOMA
Ian Lock
Favorite
Loggers, Elizabeth T.

Fred Hutch Cancer Center
(P 67) GENOMIC CHARACTERIZATION OF CHONDROSARCOMA: A RARE SARCOMA WITH CLINICAL RESPONSES TO IMMUNE CHECKPOINT INHIBITION
Elizabeth T. Loggers
Favorite
(P 177) ANGIOSARCOMA: AN INCREASING PROBLEM IN THE UNITED STATES
Elizabeth T. Loggers
Favorite
(P 206) A SINGLE-ARM, PHASE II STUDY OF NEOADJUVANT PEMBROLIZUMAB COMBINED WITH RADIOTHERAPY IN THE PRIMARY TREATMENT OF SOFT TISSUE SARCOMAS.
Elizabeth T. Loggers
Favorite
LoGiudice, John

MCW
(P 473) GROIN PAINS: APPROACHES AND OUTCOMES FOR INGUINOFEMORAL SOFT TISSUE SARCOMAS
John LoGiudice
Favorite
Lohse, Ines

University of Miami
(P 54) HIGH-THROUGHPUT DRUG SCREENING IN CHONDROSARCOMA CELLS IDENTIFIES MULTIPLE EFFICIENT ANTINEOPLASTIC AGENTS
Ines Lohse
Favorite
Lohse, Ines

University of Pittsburgh
(P 244) A DEEP FEW-SHOT META-LEARNING STRATEGY FOR AUTONOMOUS CLASSIFICATION OF BONE METASTASIS IN RADIONUCLIDE BONE SCANS
Ines Lohse
Favorite
(P 351) TARGETING ANDROGEN RECEPTOR IN OSTEOSARCOMA CELLS WITH VARYING METASTATIC POTENTIAL
Ines Lohse
Favorite
(P 373) DEDIFFERENTIATED AND HIGH GRADE CHONDROSARCOMAS: HOW DOES ISOCITRATE DEHYDROGENASE STATUS APPRISE PROGNOSIS AND THERAPY?
Ines Lohse
Favorite
Loi, Mauro

Radiation Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.
(P 309) CLINICAL PATHOLOGICAL CHARACTERISTICS, PATTERN OF CARE AND SURVIVAL OF NON-METASTATIC BREAST ANGIOSARCOMA
Mauro Loi
Favorite
(P 317) PROGNOSTIC FACTORS, CLINICAL AND TOXICITY OUTCOMES FROM A LARGE COHORT OF PATIENTS WITH SOFT TISSUE SARCOMA TREATED WITH PREOPERATIVE RADIATION THERAPY
Mauro Loi
Favorite
(P 546) PRELIMINARY CLINICAL RESULTS OF AN ONGOING PHASE II TRIAL: SPRINT (SARCOMA PREOPERATIVE RADIATION WITH SIMULTANEOUS INTEGRATED BOOST)
Mauro Loi
Favorite
Lombardi, Andrea

Department of Oncology, University of Turin
(P 109) INTENSE PRECLINICAL ACTIVITY BY B7H3-SPECIFIC CAR.CIK LYMPHOCYTES AGAINST EPITHELIOID SARCOMA
Andrea Lombardi
Favorite
Lombardi, Silvia

Istituto Europeo di Oncologia
(P 144) IMPLEMENTATION OF THE EUROPEAN CLINICAL TRIAL REGULATION: SURVEY OF THE ITALIAN SARCOMA GROUP CENTERS
Silvia Lombardi
Favorite
Long, Matthew

Memorial Sloan Kettering Cancer Center
(P 289) IDENTIFICATION OF EFFECTIVE THERAPEUTIC COMBINATIONS WITH THE NUCLEAR EXPORT PROTEIN INHIBITOR, SELINEXOR, IN PEDIATRIC SOLID TUMORS
Matthew Long
Favorite
Loong, Herbert Ho Fung

The Chinese University of Hong Kong
(P 189) INTERNATIONAL RETROSPECTIVE STUDY FROM THE ULTRA-RARE SARCOMA WORKING GROUP ON LOW-GRADE FIBROMYXOID SARCOMA AND SCLEROSING EPITHELIOD FIBROSARCOMA: OUTCOME OF ADVANCED DISEASE AND SYSTEMIC THERAPIES
Herbert Ho Fung Loong
Favorite
(P 290) PRE-CLINICAL STUDY OF TUMOR TREATING FIELDS (TTFIELDS) ALONE OR IN CONJUNCTION WITH SYSTEMIC THERAPIES IN SELECTED BONE- AND SOFT-TISSUE SARCOMAS
Herbert Ho Fung Loong
Favorite
Lopes de Mello, Celso Abdon

A.C.Camargo Cancer Center.
(P 142) THE SARCOMA EUROPEAN AND LATIN AMERICAN NETWORK (SELNET) PROJECT: OVERVIEW OF THE MAIN RESULTS OF THE SELNET REGISTRY
Celso Abdon Lopes de Mello
Favorite
Lopes, Ademar

AC Camargo Cancer Center
(P 192) ROLE OF MAGNETIC RESONANCE IMAGING IN THE PREDICTION OF HISTOLOGICAL GRADE IN SOFT TISSUE SARCOMAS.
Ademar Lopes
Favorite
López Jiménez, Carlos

Medical Oncology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain
(P 517) PULMONARY METASTASECTOMY FOR SARCOMA: A SINGLE-INSTITUTION EXPERIENCE
Carlos López Jiménez
Favorite
Lopez, Laura

Hospital de la Santa Creu i San Pau
(P 507) PRIMARY CHEST WALL TUMORS OF MESENCHYMAL ORIGIN. EXPERIENCE OF A REFERENCE UNIT
Laura Lopez
Favorite
(P 508) DREAM, UTOPIA OR REALISM? PROGNOSTIC FACTORS IN LUNG METASTASECTOMY OF DISSEMINATED SARCOMA DISEASE
Laura Lopez
Favorite
Lopez, Salvatore

INT Milan
(P 328) REAL-LIFE EXPERIENCE OF PAZOPANIB IN PATIENTS WITH ADVANCED UTERINE LEIOMYOSARCOMA (U-LMS) FROM TWO REFERRAL ITALIAN CENTERS
Salvatore Lopez
Favorite
Lorenzi, Luisa

University of Brescia
(P 159) IN BETWEEN OF LYMPHOMAS AND SARCOMAS: WHERE DO HISTIOCYTIC AND DENDRITIC CELL NEOPLASMS (HDCN) STAND? A RETROSPECTIVE, MULTI-INSTITUTIONAL STUDY FROM THE ITALIAN SARCOMA GROUP (ISG)
Luisa Lorenzi
Favorite
LoRusso, Patricia

Yale University School of Medicine, Yale Cancer Center
(P 185) LONGITUDINAL MUTATIONAL ANALYSIS OF TP53 IN CIRCULATING TUMOR DNA IN THE PLASMA OF PATIENTS WITH LIPOSARCOMA IN A PHASE I STUDY OF BRIGIMADLIN (BI 907828), AN MDM2-P53 ANTAGONIST
Patricia LoRusso
Favorite
(P 408) CHANGES IN COMPUTED TOMOGRAPHY FEATURES INDUCED BY BRIGIMADLIN (BI 907828) IN PATIENTS WITH LIPOSARCOMA: INSIGHTS FROM PHASE I STUDIES
Patricia LoRusso
Favorite
Lou, Lixia

Duke University
(P 428) COMPREHENSIVE GENOMIC PROFILING OF CIC-DUX4 SARCOMA (CDS) CELL LINES AND MODELS
Lixia Lou
Favorite
Love, Anna

BostonGene, Corp.
(P 420) COMPREHENSIVE MOLECULAR PROFILING AND TUMOR MICROENVIRONMENT CHARACTERISTICS OF RADIATION-INDUCED SARCOMA.
Anna Love
Favorite
Low, Chen Ee

Yong Loo Lin School of Medicine, National University of Singapore
(P 82) PROGNOSTIC FACTORS AND OUTCOMES OF 275 PATIENTS WITH HEAD AND NECK BONE AND SOFT TISSUE SARCOMA: A SINGLE CENTRE COHORT STUDY
Chen Ee Low
Favorite
Lucarelli, Enrico

Istituto Ortopedico Rizzoli IRCCS, Osteoncology- Bone and Soft Tissue Sarcomas and Innovative Therapies Unit, Bologna, Italy
(P 253) THE EFFICACY OF MEDICATED PATCHES IN SOFT TISSUE SARCOMAS: IN-VITRO AND EX-VIVO VALIDATION.
Enrico Lucarelli
Favorite
(P 283) A TRIDIMENSIONAL PRECLINICAL MODEL TO STUDY HUMAN AND CANINE OSTEOSARCOMA DEVELOPMENT AND INTERACTION WITH TUMOR MICROENVIRONMENT
Enrico Lucarelli
Favorite
Lucas, Amanda

Desmoid Tumor Research Foundation
(P 146) CHARACTERIZING THE PATIENT JOURNEY TO A DIAGNOSIS OF DESMOID TUMOR: DESMOID TUMOR RESEARCH FOUNDATION NATURAL HISTORY STUDY
Amanda Lucas
Favorite
Ludwig, Joseph

Department of Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center
(P 397) A MESENCHYMAL TISSUE LANDSCAPE TO STUDY OSTEOSARCOMA TUMOR HETEROGENEITY
Joseph Ludwig
Favorite
(P 426) MULTI-OMIC ANALYSIS OF DESMOPLASTIC SMALL ROUND CELL TUMORS REVEAL DISTINCT LINEAGES
Joseph Ludwig
Favorite
(P 427) UNDERSTANDING THE MOLECULAR DRIVERS THAT REGULATE EWING SARCOMA CELL FATE
Joseph Ludwig
Favorite
Luna-Ortiz, Kuauhyama

Instituto Nacional de Cancerología (México)
(P 331) MUSCULAR DEDIFFERENTIATION IN DEDIFFERENTIATED LIPOSARCOMA: INSIGHTS INTO INFLAMMATORY PROFILES USING THE NEUTROPHIL/LYMPHOCYTE RATIO AND PROGNOSTIC IMPLICATIONS
Kuauhyama Luna-Ortiz
Favorite
Lunn, Kiera

Duke School of Medicine
(P 137) IMPACT OF SOCIAL DETERMINANTS OF HEALTH ON SARCOMA CARE: A SINGLE INSTITUTION EXPERIENCE
Kiera Lunn
Favorite
Luo, Chenghua

Retroperitoneal Tumours Centre, Peking University International Hospital, Beijing, China
(P 398) INTEGRATED MULTI-OMICS APPROACH REVEALED TUMOR-ASSOCIATED TERTIARY LYMPHOID STRUCTURE LANDSCAPE IN RETROPERITONEAL LIPOSARCOMA
Chenghua Luo
Favorite
(P 534) NEOADJUVANT CHEMOTHERAPY COMBINED WITH TARGETED TREATMENT IN HIGH-RISK RETROPERITONEAL SARCOMA – A PROSPECTIVE NON-RANDOMIZED CONTROLLED MULTI-CENTERED STUDY ALL ACROSS CHINA
Chenghua Luo
Favorite
Luo, Jingqin

Washington University School of Medicine, Department of Surgery, Division of Public Health Sciences
(P 552) RANDOMIZED PHASE II TRIAL OF CABOZANTINIB COMBINED WITH PD-1 AND CTLA-4 INHIBITION VERSUS CABOZANTINIB IN METASTATIC SOFT TISSUE SARCOMA.
Jingqin Luo
Favorite
Luo, Leo

Vanderbilt University Medical Center
(P 218) NEOADJUVANT CHEMOTHERPAY AND RADIATION DECREASES TUMOR SIZE, VIABILITY, AND RECURRENCE IN MULTIPLE LIPOSARCOMA SUBSETS
Leo Luo
Favorite
(P 380) NEXT GENERATION SEQUEINCING REVEALS TARGETABLE MUTATIONS IN MULTIPLE SARCOMA HISTOLOGIES
Leo Luo
Favorite
Lushchenkova, Oksana

Hospital de la Santa Creu i Sant Pau
(P 503) SCAPULAR PROSTHESIS RECONSTRUCTION, EXPERIENCE IN OUR INSTITUTION
Oksana Lushchenkova
Favorite
(P 504) WHY DO SOME PATIENTS WITH SYNOVIAL SARCOMA HAVE BETTER FUNCTIONAL OUTCOMES AFTER RESECTION SURGERY? ANALYSIS OF 102 CASES
Oksana Lushchenkova
Favorite
(P 507) PRIMARY CHEST WALL TUMORS OF MESENCHYMAL ORIGIN. EXPERIENCE OF A REFERENCE UNIT
Oksana Lushchenkova
Favorite
Luu, Anita

University of Guelph
(P 304) A COMPARATIVE ANALYSIS OF METABOLIC FLEXIBILITY IN OSTEOSARCOMA CELLS
Anita Luu
Favorite
Lu, Weiqi

Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China
(P 339) QUALITY OF SURGERY AND OUTCOME FOR GIANT RETROPERITONEAL LIPOSARCOMA TREATED WITHIN SEMI-ABDOMINAL EN BLOC RESECTION USING VASCULAR PRIORITY CENTRAL APPROACH-A RETROSPECTIVE COHORT
Weiqi Lu
Favorite
(P 398) INTEGRATED MULTI-OMICS APPROACH REVEALED TUMOR-ASSOCIATED TERTIARY LYMPHOID STRUCTURE LANDSCAPE IN RETROPERITONEAL LIPOSARCOMA
Weiqi Lu
Favorite
Luzzati, Alessandro

IRCCS Galeazzi Orthopedic Institute
(P 431) TREATMENT STRATEGY AND PROGNOSTIC FACTORS IN EXTRASKELETAL EWING SARCOMA: AN INSTITUTIONAL RETROSPECTIVE ANALYSIS
Alessandro Luzzati
Favorite
Lydon, Nick

IDRx, Inc.
(P 26) PHASE 1 STUDY OF IDRX-42 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS RESISTANT TO PRIOR SYSTEMIC THERAPY: EARLY RESULTS
Nick Lydon
Favorite
Lykon, Jill

Sylvester Comprehensive Cancer Center / University of Miami Hospital and Clinics
(P 208) LOW INCIDENCE OF CANCER THERAPY-RELATED CARDIAC DYSFUNCTION IN ADULT SARCOMA PATIENTS RECEIVING DOXORUBICIN AND UPFRONT DEXRAZOXANE
Jill Lykon
Favorite
Lynch, Carmel

Adcendo ApS
(P 349) THE UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR-ASSOCIATED PROTEIN (UPARAP) IS AN ATTRACTIVE TARGET FOR THE DEVELOPMENT OF ANTIBODY DRUG CONJUGATES FOR TREATMENT OF MESENCHYMAL MALIGNANCIES
Carmel Lynch
Favorite
Lyu, Heather

MD Anderson Cancer Center
(P 510) PRIMARY BREAST ANGIOSARCOMA: CLINICAL AND PATHOLOGICAL FEATURES AND IMPACT ON OUTCOMES
Heather Lyu
Favorite
Lyu, Yang

Washington University in St. Louis
(P 250) SHARING HIGH-QUALITY SAMPLES AND DATA TO THE NF1 RESEARCH COMMUNITY: THE ROLE OF THE JOHNS HOPKINS NF1 BIOSPECIMEN REPOSITORY
Yang Lyu
Favorite
(P 274) TYK2 AND MEK COMBINATION THERAPY IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS AND OTHER SOFT TISSUE SARCOMAS
Yang Lyu
Favorite
M
Macagno, Nicolas

Aix Marseille Univ
(P 104) COMPREHENSIVE IMMUNE PROFILING UNVEILS A SUBSET OF LEIOMYOSARCOMA WITH HOT TUMOR IMMUNE MICROENVIRONMENT
Nicolas Macagno
Favorite
MacAlpine, Elle

Washington University School of Medicine
(P 299) EXPLORING THE IMMUNOLIGHT MECHANISM OF ACTION IN A GENETICALLY ENGINEERED MOUSE MODEL OF SOFT TISSUE SARCOMA
Elle MacAlpine
Favorite
MacDonald, Shannon

Massachusetts General Hospital
(P 338) PREOPERATIVE RADIATION THERAPY IS NOT ASSOCIATED WITH ADVERSE POSTOPERATIVE OUTCOMES IN PATIENTS WITH RETROPERITONEAL SARCOMA
Shannon MacDonald
Favorite
Machado Granados, Pau

Hospital de la Santa Creu i Sant Pau
(P 503) SCAPULAR PROSTHESIS RECONSTRUCTION, EXPERIENCE IN OUR INSTITUTION
Pau Machado Granados
Favorite
(P 504) WHY DO SOME PATIENTS WITH SYNOVIAL SARCOMA HAVE BETTER FUNCTIONAL OUTCOMES AFTER RESECTION SURGERY? ANALYSIS OF 102 CASES
Pau Machado Granados
Favorite
(P 507) PRIMARY CHEST WALL TUMORS OF MESENCHYMAL ORIGIN. EXPERIENCE OF A REFERENCE UNIT
Pau Machado Granados
Favorite
(P 508) DREAM, UTOPIA OR REALISM? PROGNOSTIC FACTORS IN LUNG METASTASECTOMY OF DISSEMINATED SARCOMA DISEASE
Pau Machado Granados
Favorite
Machida, Ryunosuke

National Cancer Center Hospital
(P 10) ATEZOLIZUMAB IN JAPANESE PATIENTS WITH ADVANCED ALVEOLAR SOFT PART SARCOMA: A MULTI-CENTER, SINGLE-ARM, INVESTIGATOR-INITIATED PHASE 2 TRIAL (NCCH1907)
Ryunosuke Machida
Favorite
Machiela, Mitchell

National Cancer Institute
(P 414) GENOMIC ANALYSIS OF EWING SARCOMA AND HERNIA IDENTIFIES A POSITIVE GENETIC CORRELATION AND SUGGESTS BOTH ARE LINKED TO AN HMGA2 VARIANT
Mitchell Machiela
Favorite
MacQuarrie, Kyle

Northwestern University Feinberg School of Medicine/Ann & Robert H Lurie Children's Hospital of Chicago
(P 365) MULTIMODAL ANALYSIS OF NUCLEAR AND GENOMIC ORGANIZATION IN RHABDOMYOSARCOMA AND NORMAL MYOGENIC CELLS
Kyle MacQuarrie
Favorite
Macri, Fabiana

UNIBO
(P 01) EXTRASKELETAL EWING SARCOMA OF THE EXTREMITIES AND TRUNK IN < 25 YEARS OLD PATIENTS: A RETROSPECTIVE ANALYSIS OF A MONO-INSTITUTIONAL SERIES.
Fabiana Macri
Favorite
Macy, Margaret

Children’s Hospital Colorado, University of Colorado School of Medicine
(P 03) EVOLUTION OF CLINICALLY ACTIONABLE VARIANTS IN ADVANCED PEDIATRIC AND AYA BONE SARCOMAS
Margaret Macy
Favorite
(P 556) EVALUATION OF PALBOCICLIB (IBRANCE®) IN COMBINATION WITH CHEMOTHERAPY IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY EWING SARCOMA OR NEUROBLASTOMA
Margaret Macy
Favorite
Madewell, John

MD Anderson Cancer Center
(P 221) EARLY RESULTS IN NOVEL USE OF CONTRAST-ENHANCED SUSCEPTIBILITY-WEIGHTED IMAGING IN THE ASSESSMENT OF RESPONSE AND PROGRESSION IN DESMOID FIBROMATOSIS: PILOT STUDY IN A SPECIALIZED CANCER INSTITUTION
John Madewell
Favorite
(P 239) CANCER RADIOMIC AND PERFUSION IMAGING (CARPI) AUTOMATED FRAMEWORK: VALIDATION ON MUSCULOSKELETAL TUMORS IN A SPECIALIZED CANCER CENTER
John Madewell
Favorite
(P 356) BASELINE AND POST-TREATMENT ADVANCED MRI OF EXTREMITIES SOFT-TISSUE NON-MYXOID UNDIFFERENTIATED PLEOMORPHIC SARCOMA.
John Madewell
Favorite
(P 357) APPARENT DIFFUSION COEFFICIENT (ADC) HIGH-ORDER RADIOMICS OF BASELINE AND POST-TREATMENT ADVANCED MRI OF EXTREMITY SOFT-TISSUE NON-MYXOID UNDIFFERENTIATED PLEOMORPHIC SARCOMA.
John Madewell
Favorite
(P 358) CONTRAST-ENHANCED SUSCEPTIBILITY IMAGING (CE-SWI) MORPHOLOGIC, FIRST & HIGH-ORDER RADIOMIC FEATURES VALUE IN ASSESSING TREATMENT RESPONSE IN EXTREMITY SOFT-TISSUE UNDIFFERENTIATED PLEOMORPHIC SARCOMA
John Madewell
Favorite
(P 359) ROLE OF PERFUSION WEIGHTED IMAGING WITH DYNAMIC CONTRAST ENHANCED (PWI/DCE) FOR THE TREATMENT ASSESSMENT OF EXTREMITY SOFT-TISSUE NON-MYXOID UNDIFFERENTIATED PLEOMORPHIC SARCOMA
John Madewell
Favorite
Madison, Cecelia

Portland VA Medical Center
(P 129) LOW RATES OF SERVICE CONNECTIVITY FOR SOFT TISSUE SARCOMA (STS) AMONG ELIGIBLE VIETNAM VETERANS WITH AGENT ORANGE EXPOSURE
Cecelia Madison
Favorite
(P 227) DE NOVO NATURAL LANGUAGE PROCESSING (NLP) ALGORITHM ACCURATELY IDENTIFIES MYXOFIBROSARCOMA DIRECTLY FROM PATHOLOGY REPORTS
Cecelia Madison
Favorite
Maegawa, Shinji

University of Texas MD Anderson
(P 101) EPIGENETIC MODULATION OF NK CELLS IMPROVES TUMOR TRAFFICKING AND ENHANCES THERAPEUTIC EFFICACY AGAINST OSTEOSARCOMA
Shinji Maegawa
Favorite
(P 122) TARGETING CD70 USING CAR NK CELLS TO ENHANCE NK CELLS CYTOLYTIC EFFECT AGAINST OSTEOSARCOMA
Shinji Maegawa
Favorite
Maejima, Aiko

Department of Medical Oncology/Urology, National Cancer Center Hospital, Tokyo, Japan
(P 332) SURGICAL OUTCOMES OF RETROPERITONEAL LIPOSARCOMA - SINGLE INSTITUTIONAL STUDY N JAPAN -
Aiko Maejima
Favorite
maes, Danielle

University Hospitals Birmingham
(P 345) CLINICIAN SURVEY - CURRENT GLOBAL PRACTICE FOR SARCOMA SURVEILLANCE FOLLOWING RESECTION OF PRIMARY RETROPERITONEAL, ABDOMINAL, AND PELVIC SARCOMA
Danielle maes
Favorite
Maese, Luke

Huntsman Cancer Institute/University of Utah Health
(P 03) EVOLUTION OF CLINICALLY ACTIONABLE VARIANTS IN ADVANCED PEDIATRIC AND AYA BONE SARCOMAS
Luke Maese
Favorite
Maestro, Roberta

Unit of Oncogenetics and Functional Oncogenomics, Centro di Riferimento Oncologico di Aviano IRCCS, Aviano, Italy
(P 355) FUSION TRANSCRIPTOME PROFILING DEFINES THE MONOCLONAL NATURE OF MULTIFOCAL EPITHELIOID HEMANGIOMA OF BONE
Roberta Maestro
Favorite
(P 378) MULTIOMICS PROFILING OF EPITHELIOID SARCOMA UNVEILS EPIGENETIC CIRCUITRIES THAT UNDERLIE THE PATHOBIOLOGY OF PROXIMAL AND CLASSIC SUBTYPES: RESULTS FROM THE ISG EPISOBS OBSERVATIONAL STUDY
Roberta Maestro
Favorite
Magnelli, Anthony

Cleveland Clinic
(P 308) OPTIMAL BIOLOGIC EFFECTIVE DOSE OF STEREOTACTIC BODY RADIOTHERAPY FOR METASTATIC AND RECURRENT SARCOMA
Anthony Magnelli
Favorite
Magnusson, Linda

Lund University
(P 371) DISRUPTION OF THE TP53 LOCUS IN OSTEOSARCOMA LEADS TO TP53 PROMOTER GENE FUSIONS AND RESTORATION OF PARTS OF THE TP53 SIGNALLING PATHWAY
Linda Magnusson
Favorite
(P 372) COPY NUMBER GAIN OF MDM2 IN ROD-SHAPED CHROMOSOMES PROVIDES CLUES TO EARLY STAGES IN CIRCULARIZED GENE AMPLIFICATION IN LIPOSARCOMA
Linda Magnusson
Favorite
Mahadeo, Kris

Duke University School of Medicine
(P 542) ENROLLMENT OF PEDIATRIC PARTICIPANTS WITH MAGE-A4-POSITIVE SOLID TUMORS IN A PHASE 1/2, OPEN-LABEL, BASKET TRIAL OF AFAMITRESGENE AUTOLEUCEL ("AFAMI-CEL")
Kris Mahadeo
Favorite
Mah, Laura

University of Calgary
(P 110) GCAR1: GPNMB CAR T THERAPY FOR MIT FAMILY TRANSLOCATION POSITIVE CANCERS
Laura Mah
Favorite
Mahoney, Douglas

Univeristy of Calgary
(P 110) GCAR1: GPNMB CAR T THERAPY FOR MIT FAMILY TRANSLOCATION POSITIVE CANCERS
Douglas Mahoney
Favorite
Mahran, Ahmed

Children's National Hospital
(P 292) APPLICATION OF HIGH-INTENSITY FOCUSED ULTRASOUND THERMAL ABLATION AND BOILING HISTOTRIPSY WITH CHECKPOINT INHIBITORS IN A MURINE MODEL OF OSTEOSARCOMA: AN IN-DEPTH STUDY
Ahmed Mahran
Favorite
Mailankody, Sharada

Department of Medical Oncology, Kasturba Medical College, Manipal Academy of Higher Education, Manipal, India
(P 06) ONCOFERTILITY AND PREGNANCY IN ADOLESCENT AND YOUNG ADULT CANCERS: PHYSICIANS' KNOWLEDGE AND PREFERENCES IN A LARGE LOW-MIDDLE- INCOME COUNTRY
Sharada Mailankody
Favorite
Mair, Keitrina

Miami Cancer Institute
(P 320) A PROSPECTIVE MULTICENTER EXPERIENCE OF PROTON THERAPY FOR RHABDOMYOSARCOMA AND EWING SARCOMA: OUTCOMES FROM THE PROTON COLLABORATIVE GROUP REGISTRY
Keitrina Mair
Favorite
Majercakova, Katarina

Hospital de la Santa Creu i Sant Pau
(P 175) TRABECTEDIN PLUS RADIOTHERAPY ON SYMPHTOMATIC ADVANCED SARCOMA PATIENTS, RESULTS FROM THE SYNERGIAS STUDY: A SPANISH GROUP FOR RESEARCH IN SARCOMA (GEIS) PHASE II STUDY
Katarina Majercakova
Favorite
(P 313) SPACIALLY-FRACTIONATED RADIOTHERAPY (LATTICE) TREATMENT IN INOPERABLE NON-EXTREMITY BULKY SOFT-TISSUE SARCOMAS
Katarina Majercakova
Favorite
(P 503) SCAPULAR PROSTHESIS RECONSTRUCTION, EXPERIENCE IN OUR INSTITUTION
Katarina Majercakova
Favorite
(P 504) WHY DO SOME PATIENTS WITH SYNOVIAL SARCOMA HAVE BETTER FUNCTIONAL OUTCOMES AFTER RESECTION SURGERY? ANALYSIS OF 102 CASES
Katarina Majercakova
Favorite
(P 507) PRIMARY CHEST WALL TUMORS OF MESENCHYMAL ORIGIN. EXPERIENCE OF A REFERENCE UNIT
Katarina Majercakova
Favorite
(P 508) DREAM, UTOPIA OR REALISM? PROGNOSTIC FACTORS IN LUNG METASTASECTOMY OF DISSEMINATED SARCOMA DISEASE
Katarina Majercakova
Favorite
Major, Angela

Baylor College of Medicine / Texas Children's Hospital
(P 121) IMPROVING THE EFFICACY OF GD2 CHIMERIC ANTIGEN RECEPTOR T-CELLS USING HISTONE DEACETYLASE INHIBITORS
Angela Major
Favorite
Makarova, Anastasia

BostonGene, Corp.
(P 420) COMPREHENSIVE MOLECULAR PROFILING AND TUMOR MICROENVIRONMENT CHARACTERISTICS OF RADIATION-INDUCED SARCOMA.
Anastasia Makarova
Favorite
Makarov, Vladimir

Cleveland Clinic
(P 429) SARCOMA FUSION GENE ANALYSIS YIELDS PROMISING HLA ANTIGEN FIT IN EWING SARCOMA AND DESMOPLASTIC SMALL ROUND CELL TUMOR
Vladimir Makarov
Favorite
Makin, Guy

University of Manchester
(P 212) REPORT ON THE EWING SARCOMA PATIENTS ENROLLED IN ARM D OF THE ACSE-ESMART TRIAL: PHASE I/II STUDY OF THE PARP INHIBITOR OLAPARIB IN COMBINATION WITH IRINOTECAN IN CHILDREN WITH ADVANCED MALIGNANCIES
Guy Makin
Favorite
Maki, Robert

Memorial Sloan Kettering Cancer Center; Professor, Weill Cornell Medical College
(P 24) COMPREHENSIVE ANALYSIS OF THE GENOMIC LANDSCAPE AND CLINICAL BEHAVIOR IN GIST USING NEXT GENERATION SEQUENCING (NGS, MSK-IMPACT)
Robert Maki
Favorite
(P 135) UNMET NEEDS IN LOCALLY ADVANCED (UNRESECTABLE) OR METASTATIC DEDIFFERENTIATED LIPOSARCOMA AND EXPECTATIONS FOR CLINICAL TRIALS: AN INTERNATIONAL DELPHI CONSENSUS STUDY
Robert Maki
Favorite
(P 166) SARC038: A PHASE 2 STUDY OF REGORAFENIB IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH REFRACTORY OR RECURRENT OSTEOSARCOMA
Robert Maki
Favorite
(P 189) INTERNATIONAL RETROSPECTIVE STUDY FROM THE ULTRA-RARE SARCOMA WORKING GROUP ON LOW-GRADE FIBROMYXOID SARCOMA AND SCLEROSING EPITHELIOD FIBROSARCOMA: OUTCOME OF ADVANCED DISEASE AND SYSTEMIC THERAPIES
Robert Maki
Favorite
(P 191) SARC024 COHORT D: PHASE 2 TRIAL OF REGORAFENIB IN CHILDREN, ADOLESCENTS, AND ADULTS WITH RHABDOMYOSARCOMA
Robert Maki
Favorite
(P 361) MOLECULAR CHARACTERIZATION OF SOLITARY FIBROUS TUMORS BY ANATOMIC SITE AND NAB2::STAT6 FUSION VARIANT TYPE
Robert Maki
Favorite
(P 401) OVEREXPRESSION OF CYCLIN DEPENDENT KINASES AND CYCLINS ACROSS SARCOMAS BEYOND CDK4
Robert Maki
Favorite
(P 552) RANDOMIZED PHASE II TRIAL OF CABOZANTINIB COMBINED WITH PD-1 AND CTLA-4 INHIBITION VERSUS CABOZANTINIB IN METASTATIC SOFT TISSUE SARCOMA.
Robert Maki
Favorite
(P 565) AN EARLY PHASE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF PEEL-224 IN PATIENTS WITH ADVANCED SOLID TUMORS
Robert Maki
Favorite
Makrievski, Stefan

Sarcoma Oncology Center
(P 116) UPDATE ON SAINT: RESULTS OF 100 PATIENTS TREATED WITH IPILIMUMAB (I), NIVOLUMAB (N) AND TRABECTEDIN (T) AS FIRST LINE THERAPY FOR ADVANCED SOFT TISSUE SARCOMA [NCT03138161]
Stefan Makrievski
Favorite
(P 117) INTERIM ANALYSIS OF PHASE 2 STUDY: A METRONOMIC REGIMEN USING GEMCITABINE, DOXORUBICIN, DOCETAXEL AND NIVOLUMAB FOR ADVANCED LEIOMYOSARCOMA (NCT04535713)
Stefan Makrievski
Favorite
Makri, Stavriani

Johns Hopkins University School of Medicine
(P 250) SHARING HIGH-QUALITY SAMPLES AND DATA TO THE NF1 RESEARCH COMMUNITY: THE ROLE OF THE JOHNS HOPKINS NF1 BIOSPECIMEN REPOSITORY
Stavriani Makri
Favorite
Mala, Anastasia

Department of Oncology, University Hospital of Heraklion, Crete, Greece
(P 222) EXPLORING THE IMPACT OF NGS ON DIAGNOSTICS AND TREATMENT OF SARCOMA: INSIGHTS FROM REAL-WORLD DATA ACROSS MULTIPLE INSTITUTIONS IN EUROPE
Anastasia Mala
Favorite
Maleddu, Alessandra

University of Colorado - Anschutz Medical Campus
(P 237) SECONDARY REARRANGEMENT CREATING A PLEC-EML4-ALK DOUBLE FUSION AS A MECHANISM OF RESISTANCE TO CRIZOTINIB IN AN EML4-ALK-POSITIVE INFLAMMATORY MYOFIBROBLASTIC TUMOR
Alessandra Maleddu
Favorite
Malek, Marcus

Children's Hospital of Pittsburgh
(P 466) INTRAOPERATIVE EVALUATION OF BONE AND SOFT TISSUE SARCOMA SURGICAL MARGINS WITH INDOCYANINE GREEN FLUORESCENCE IMAGING
Marcus Malek
Favorite
(P 544) INTRAOPERATIVE EVALUATION OF BONE AND SOFT TISSUE SARCOMA SURGICAL MARGINS WITH INDOCYANINE GREEN FLUORESCENCE IMAGING
Marcus Malek
Favorite
Malhotra, Hemant

Sri Ram Cancer Center, Mahatma Gandhi Medical College Hospital
(P 06) ONCOFERTILITY AND PREGNANCY IN ADOLESCENT AND YOUNG ADULT CANCERS: PHYSICIANS' KNOWLEDGE AND PREFERENCES IN A LARGE LOW-MIDDLE- INCOME COUNTRY
Hemant Malhotra
Favorite
Ma, Lijie

Department of Liver Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
(P 339) QUALITY OF SURGERY AND OUTCOME FOR GIANT RETROPERITONEAL LIPOSARCOMA TREATED WITHIN SEMI-ABDOMINAL EN BLOC RESECTION USING VASCULAR PRIORITY CENTRAL APPROACH-A RETROSPECTIVE COHORT
Lijie Ma
Favorite
(P 398) INTEGRATED MULTI-OMICS APPROACH REVEALED TUMOR-ASSOCIATED TERTIARY LYMPHOID STRUCTURE LANDSCAPE IN RETROPERITONEAL LIPOSARCOMA
Lijie Ma
Favorite
Malkin, David

The Hospital for Sick Children
(P 50) CHARACTERIZATION OF A FAMILIAL GIST KINDRED INTOLERANT TO IMATINIB
David Malkin
Favorite
Malli, Shashwath Kalladi

Department of Surgery, Division of Surgical Oncology, University of California San Diego
(P 29) COMBINATION TREATMENT WITH TEMOZOLOMIDE AND THE DEATH RECEPTOR-5 AGONIST INBRX-109 EFFECTIVELY TARGETS SUCCINATE DEHYDROGENASE -DEFICIENT GASTROINTESTINAL STROMAL TUMOR
Shashwath Kalladi Malli
Favorite
Manara, Maria Cristina

IRCCS, Istituto Ortopedico Rizzoli, Laboratory of Experimental Oncology, Bologna Italy
(P 85) TARGETING CD99 ELICITS EWING SARCOMA CELL PHAGOCYTOSIS BY UNDIFFERENTIATED AND M2-LIKE MACROPHAGES AND INDUCES MACROPHAGE POLARIZATION TOWARD A M1-LIKE PHENOTYPE
Maria Cristina Manara
Favorite
Mancinelli, Luigi

University of Pittsburgh
(P 411) A SPATIAL TRANSCRIPTOMIC "GOOGLE MAP" OF HUMAN OSTEOSARCOMA REVEALS COMMON CELL CLUSTERS AT THE PRIMARY SITE AND PULMONARY METASTASES.
Luigi Mancinelli
Favorite
Mandel, Anna

University of Toronto
(P 265) SELECTIVE TARGETING OF BET FAMILY EPIGENETIC REGULATORS IN ADVANCED AND METASTATIC ALVEOLAR RHABDOMYOSARCOMA
Anna Mandel
Favorite
Mandell, Jonathan

University of Pittsburgh
(P 536) PHASE 1 STUDY OF DISULFIRAM WITH COPPER GLUCONATE AND LIPOSOMAL DOXORUBICIN IN PATIENTS WITH TREATMENT REFRACTORY SARCOMAS
Jonathan Mandell
Favorite
Mandeville, Henry

Department of Radiotherapy, Royal Marsden Hospital and The Institute of Cancer Research, Sutton
(P 209) PROGNOSTIC VALUE OF EARLY RADIOLOGIC TUMOUR VOLUME RESPONSE IN RHABDOMYOSARCOMA; RESULTS OF THE EUROPEAN PAEDIATRIC SOFT TISSUE SARCOMA STUDY GROUP RMS 2005 STUDY
Henry Mandeville
Favorite
Manferdini, Cristina

IRCCS Istituto Ortopedico Rizzoli
(P 85) TARGETING CD99 ELICITS EWING SARCOMA CELL PHAGOCYTOSIS BY UNDIFFERENTIATED AND M2-LIKE MACROPHAGES AND INDUCES MACROPHAGE POLARIZATION TOWARD A M1-LIKE PHENOTYPE
Cristina Manferdini
Favorite
Manivel, Juan Carlos

University of Minnesota
(P 167) FDG-PET-CT RESPONSE AFTER NEOADJUVANT CHEMOTHERAPY PREDICTS LONG-TERM OUTCOME IN PATIENTS WITH SOFT TISSUE SARCOMA -- 15-YEAR FOLLOW-UP
Juan Carlos Manivel
Favorite
Manley, Peter

Day One Biopharmaceuticals
(P 08) PRELIMINARY CLINICAL ACTIVITY OF THE TYPE II RAF INHIBITOR TOVORAFENIB IN RAF FUSION-DRIVEN RECURRENT/PROGRESSIVE SARCOMAS
Peter Manley
Favorite
Mano, Hiroyuki

National Cancer Center Research Institute
(P 406) EXTENSIVE ANALYSIS OF 59 SARCOMA-RELATED FUSION GENES IDENTIFIED PAZOPANIB AS A POTENTIAL INHIBITOR TO COL1A1-PDGFB FUSION GENE
Hiroyuki Mano
Favorite
Manrique, Elena

Hospital Clinico San Carlos
(P 149) PSYCOLOGICAL SNAPSHOT OF SARCOMA PATIENTS FROM AN ACADEMIC, UNIVERSITY CENTER, HOSPITAL CLÍNICO SAN CARLOS (HCSC), MADRID, A SARCOMA NATIONAL REFERRAL CENTRE IN SPAIN
Elena Manrique
Favorite
Mantiero, Mara

INT milano
(P 328) REAL-LIFE EXPERIENCE OF PAZOPANIB IN PATIENTS WITH ADVANCED UTERINE LEIOMYOSARCOMA (U-LMS) FROM TWO REFERRAL ITALIAN CENTERS
Mara Mantiero
Favorite
Mantilla, Jose

NYU Langone Health
(P 206) A SINGLE-ARM, PHASE II STUDY OF NEOADJUVANT PEMBROLIZUMAB COMBINED WITH RADIOTHERAPY IN THE PRIMARY TREATMENT OF SOFT TISSUE SARCOMAS.
Jose Mantilla
Favorite
Manzano, Arancha

HU Clínico San Carlos
(P 149) PSYCOLOGICAL SNAPSHOT OF SARCOMA PATIENTS FROM AN ACADEMIC, UNIVERSITY CENTER, HOSPITAL CLÍNICO SAN CARLOS (HCSC), MADRID, A SARCOMA NATIONAL REFERRAL CENTRE IN SPAIN
Arancha Manzano
Favorite
(P 174) SELISARC: A SPANISH GROUP FOR RESEARCH IN SARCOMA (GEIS) PHASE I/II TRIAL OF SELINEXOR PLUS GEMCITABINE IN SELECTED SARCOMA SUBTYPES: RESULTS OF THE PHASE I PART
Arancha Manzano
Favorite
(P 515) ENDOBRONCHIAL NAVIGATION AS AN INTRAOPERATORY TOOL FOR RESECTION OF SMALL PULMONARY METASTASES IN SARCOMA PATIENTS
Arancha Manzano
Favorite
Maraldi, Marco

Ospedale Morgagni Pierantoni
(P 364) EVALUATION OF THE PREDICTIVE ROLE OF SYSTEMIC AND INTRATUMORAL IMMUNITY IN PATIENTS WITH LOCALIZED LIPOSARCOMAS, MYXOFIBROSARCOMAS AND UNDIFFERENTIATED PLEOMORPHIS SARCOMAS
Marco Maraldi
Favorite
Marang-van de Mheen, Perla

Safety & Security Science, Faculty of Technology, Policy & Management, Delft University of Technology
(P 132) SARCOMA PATEINTS' VIEWS ON USING A RISK-PREDICTION MODEL TO INFORM TREATMENT DECISIONS.
Perla Marang-van de Mheen
Favorite
Marcellus, Richard

OICR
(P 260) TARGETING HOMOLOGOUS RECOMBINATION DEFICIENCY (HRD) IN LEIOMYOSARCOMA WITH COMBINATION OF PARP INHIBITORS (PARPI) AND CHEMOTHERAPY (CTX).
Richard Marcellus
Favorite
(P 265) SELECTIVE TARGETING OF BET FAMILY EPIGENETIC REGULATORS IN ADVANCED AND METASTATIC ALVEOLAR RHABDOMYOSARCOMA
Richard Marcellus
Favorite
MARCHAIS, ANTONIN

Gustave Roussy
(P 212) REPORT ON THE EWING SARCOMA PATIENTS ENROLLED IN ARM D OF THE ACSE-ESMART TRIAL: PHASE I/II STUDY OF THE PARP INHIBITOR OLAPARIB IN COMBINATION WITH IRINOTECAN IN CHILDREN WITH ADVANCED MALIGNANCIES
ANTONIN MARCHAIS
Favorite
Marcus, James

IQVIA
(P 188) IMPACT OF NIROGACESTAT ON FUNCTIONAL STATUS IN PATIENTS WITH DESMOID TUMORS: RESULTS FROM THE PHASE 3 DEFI STUDY
James Marcus
Favorite
Marec-Berard, Perrine

Centre Léon Berard
(P 389) OSTEOBLASTIC-GENE SIGNATURE TO PREDICT SURVIVAL IN PEDIATRIC OSTEOSARCOMA (OS) AND TO FOLLOW PATIENTS TOWARDS LIQUID BIOPSY: A COLLABORATIVE WORK IN OS2006 PROTOCOL.
Perrine Marec-Berard
Favorite
Marino-Enriquez, Adrian

Brigham and Women's Hospital and Harvard Medical School
(P 541) ETCTN 10563: PHASE 1 STUDY OF PEPOSERTIB AND LIPOSOMAL DOXORUBICIN FOR ADVANCED OR METASTATIC LEIOMYOSARCOMA AND OTHER SARCOMAS
Adrian Marino-Enriquez
Favorite
Marinoff, Amanda

UCSF
(P 413) LINKING REAL-WORLD CLINICAL AND GENOMIC DATA IN RHABDOMYOSARCOMA: LEVERAGING AACR PROJECT GENIE AS A PATH TOWARD PRECISION ONCOLOGY IN RARE CANCERS
Amanda Marinoff
Favorite
Mariuk-Jarema, Anna

Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
(P 21) YOUNG ADULTS WITH NONMETASTATIC OPERABLE OSTEOSARCOMA TREATED PERIOPERATIVELY WITH METHOTREXATE, DOXORUBICIN AND CISPLATIN SCHEDULE, SINGLE INSTITUTION REPORT
Anna Mariuk-Jarema
Favorite
Marker, Daniel

University of Pittsburgh Medical Center
(P 373) DEDIFFERENTIATED AND HIGH GRADE CHONDROSARCOMAS: HOW DOES ISOCITRATE DEHYDROGENASE STATUS APPRISE PROGNOSIS AND THERAPY?
Daniel Marker
Favorite
Markowitz, Moses

University of Miami Miller School of Medicine
(P 485) SUBTROCHANTERIC NON-UNION AFTER INTRAMEDULLARY NAILING DUE TO PATHOLOGICAL FRACTURE:PROXIMAL FEMORAL REPLACEMENT AS A SALVAGE APPROACH
Moses Markowitz
Favorite
Marnell, Andrea

Cappagh National Orthopaedic Hospital
(P 155) THE IMPACT OF THE ROLE OF A SARCOMA ADVANCED NURSE PRACTITIONER (ANP) BIOPSY CLINIC IN IMPROVING PATIENT ACCESS TO SARCOMA SERVICES
Andrea Marnell
Favorite
(P 156) PATIENT REPORTED EXPERIENCES WITHIN THE IRISH SARCOMA GROUP
Andrea Marnell
Favorite
(P 217) CONTEMPORARY TREATMENT PATTERNS AND OUTCOMES IN THE MANAGEMENT OF ANGIOSARCOMA IN IRELAND
Andrea Marnell
Favorite
Marques, Tomás

AC Camargo Cancer Center - Sao Paulo - Brazil
(P 192) ROLE OF MAGNETIC RESONANCE IMAGING IN THE PREDICTION OF HISTOLOGICAL GRADE IN SOFT TISSUE SARCOMAS.
Tomás Marques
Favorite
Marquina, Gloria

Hospital Clínico San Carlos
(P 149) PSYCOLOGICAL SNAPSHOT OF SARCOMA PATIENTS FROM AN ACADEMIC, UNIVERSITY CENTER, HOSPITAL CLÍNICO SAN CARLOS (HCSC), MADRID, A SARCOMA NATIONAL REFERRAL CENTRE IN SPAIN
Gloria Marquina
Favorite
(P 174) SELISARC: A SPANISH GROUP FOR RESEARCH IN SARCOMA (GEIS) PHASE I/II TRIAL OF SELINEXOR PLUS GEMCITABINE IN SELECTED SARCOMA SUBTYPES: RESULTS OF THE PHASE I PART
Gloria Marquina
Favorite
(P 515) ENDOBRONCHIAL NAVIGATION AS AN INTRAOPERATORY TOOL FOR RESECTION OF SMALL PULMONARY METASTASES IN SARCOMA PATIENTS
Gloria Marquina
Favorite
Marrari, Andrea

Istituto Ortopedico Rizzoli
(P 433) A 20-YEAR MONOCENTER EXPERIENCE ON CLINICAL CHARACTERISTICS AND OUTCOME OF EXTRASKELETAL EWING SARCOMA.
Andrea Marrari
Favorite
Marshall, Lynley V.

The Royal Marsden Hospital
(P 212) REPORT ON THE EWING SARCOMA PATIENTS ENROLLED IN ARM D OF THE ACSE-ESMART TRIAL: PHASE I/II STUDY OF THE PARP INHIBITOR OLAPARIB IN COMBINATION WITH IRINOTECAN IN CHILDREN WITH ADVANCED MALIGNANCIES
Lynley V. Marshall
Favorite
Marshall, Mark

Division of Pediatric Hematology/Oncology, Riley Hospital for Children
(P 15) INTRAOSSEOUS RHABDOMYOSARCOMA OF THE CHEST WITH FUS:TFCP2 FUSION AND GERMLINE VARIANTS IN NF1 AND SBDS: NOVEL LOCATION AND MOLECULAR CHARACTERISTICS OF A RARE TUMOR
Mark Marshall
Favorite
Martín-Broto, Javier

Health Research Institute-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM),
(P 279) PROTEIN PHOSPHATASE 2 A INHIBITION AS A MECHANISM TO ENHANCE DOXORUBICIN ACTIVITY
Javier Martín-Broto
Favorite
Martínez, Elena

Hospital Quironsalud Torrevieja
(P 407) PRECISION AND PERSONALIZED TREATMENT FOR SOFT TISSUE SARCOMAS. RESULTS OF A 10 PATIENTS SERIES WITH MOLECULAR PROFILING USING NEXT-GENERATION MASSIVE SEQUENCING
Elena Martínez
Favorite
Martínez, Jorge Luis

The National Cancer Institute
(P 142) THE SARCOMA EUROPEAN AND LATIN AMERICAN NETWORK (SELNET) PROJECT: OVERVIEW OF THE MAIN RESULTS OF THE SELNET REGISTRY
Jorge Luis Martínez
Favorite
Martín, Irene

Hospital Clínico San Carlos
(P 515) ENDOBRONCHIAL NAVIGATION AS AN INTRAOPERATORY TOOL FOR RESECTION OF SMALL PULMONARY METASTASES IN SARCOMA PATIENTS
Irene Martín
Favorite
Martano, Giuseppe

Humanitas Clinical and Research Hospital
(P 297) UNVEILING THE IMPACT OF INTRATUMORAL MICROBIOTA IN THE TREATMENT EFFICACY OF SOFT TISSUE SARCOMA
Giuseppe Martano
Favorite
Marti, Luc

Cebiotex S.L., Barcelona, Spain
(P 385) FIRST IN HUMAN PHASE I TRIAL OF A NOVEL DRUG DELIVERY IMPLANT MATRIX WITH SN-38 (CEB-01) FOR RETROPERITONEAL SOFT TISSUE SARCOMA
Luc Marti
Favorite
Martin-Antona, Esteban

Hospital Clinico san Carlos
(P 149) PSYCOLOGICAL SNAPSHOT OF SARCOMA PATIENTS FROM AN ACADEMIC, UNIVERSITY CENTER, HOSPITAL CLÍNICO SAN CARLOS (HCSC), MADRID, A SARCOMA NATIONAL REFERRAL CENTRE IN SPAIN
Esteban Martin-Antona
Favorite
Martin-Broto, Javier

Medical Oncology Department, Hospital Universitario Fundación Jiménez Díaz and Villalba General Hospital, Madrid, Spain; Medical Oncology
(P 27) A MULTICENTER RETROSPECTIVE STUDY ON THE CLINICAL BEHAVIOR OF SDH-DEFICIENT GIST
Javier Martin-Broto
Favorite
(P 113) IMMUNOSARC II: A SPANISH SARCOMA GROUP (GEIS) PHASE IB TRIAL OF DOXORUBICIN AND DACARBAZINE PLUS NIVOLUMAB IN FIRST LINE OF ADVANCED LEIOMYOSARCOMA
Javier Martin-Broto
Favorite
(P 142) THE SARCOMA EUROPEAN AND LATIN AMERICAN NETWORK (SELNET) PROJECT: OVERVIEW OF THE MAIN RESULTS OF THE SELNET REGISTRY
Javier Martin-Broto
Favorite
(P 174) SELISARC: A SPANISH GROUP FOR RESEARCH IN SARCOMA (GEIS) PHASE I/II TRIAL OF SELINEXOR PLUS GEMCITABINE IN SELECTED SARCOMA SUBTYPES: RESULTS OF THE PHASE I PART
Javier Martin-Broto
Favorite
(P 175) TRABECTEDIN PLUS RADIOTHERAPY ON SYMPHTOMATIC ADVANCED SARCOMA PATIENTS, RESULTS FROM THE SYNERGIAS STUDY: A SPANISH GROUP FOR RESEARCH IN SARCOMA (GEIS) PHASE II STUDY
Javier Martin-Broto
Favorite
(P 261) EFFICACY OF BET INHIBITORS IN SOLITARY FIBROUS TUMOR: AN IN VITRO EVALUATION
Javier Martin-Broto
Favorite
(P 270) ALTERNATIVE SPLICING (AS) REGULATION AS A NOVEL THERAPEUTIC TARGET IN SOFT-TISSUE SARCOMA (STS)
Javier Martin-Broto
Favorite
(P 385) FIRST IN HUMAN PHASE I TRIAL OF A NOVEL DRUG DELIVERY IMPLANT MATRIX WITH SN-38 (CEB-01) FOR RETROPERITONEAL SOFT TISSUE SARCOMA
Javier Martin-Broto
Favorite
(P 437) ULTRA-RARE UNDIFFERENTIATED SMALL ROUND CELL SARCOMA: HOW SHOULD WE TREAT THEM? AN ANALYSIS FORM THE GRACEFUL PROJECT
Javier Martin-Broto
Favorite
Martin, Douglas

The Ohio State University Comprehensive Cancer Center
(P 323) PERIPHERAL NEUROPATHY FOLLOWING INTRA-OPERATIVE RADIOTHERAPY FOR EXTREMITY SOFT TISSUE SARCOMA: A SINGLE INSTITUTION EXPERIENCE
Douglas Martin
Favorite
Martin, Enrico

UMC Utrecht
(P 316) THE ROLE OF RADIOTHERAPY IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS: A MULTICENTER COHORT STUDY
Enrico Martin
Favorite
(P 505) LOCAL RECURRENCE IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS: A MULTICENTER COHORT STUDY
Enrico Martin
Favorite
Martinez Bernal, Gala

Hospital Universitary Virgen del Rocio
(P 453) ROLE OF SECOND-LINE TREATMENT IN EWING SARCOMAS WITH POOR PROGNOSIS AT DIAGNOSIS: EXPERIENCE OF A SPANISH REFERENCE CENTER.
Gala Martinez Bernal
Favorite
Martinez-Font, Esther

Fundació Institutd'InvestigacióSanitàriaIlles Balears –IdISBa
(P 270) ALTERNATIVE SPLICING (AS) REGULATION AS A NOVEL THERAPEUTIC TARGET IN SOFT-TISSUE SARCOMA (STS)
Esther Martinez-Font
Favorite
Martinez-Tellez, Elisabeth

Hospital de la Santa Creu i Sant Pau
(P 503) SCAPULAR PROSTHESIS RECONSTRUCTION, EXPERIENCE IN OUR INSTITUTION
Elisabeth Martinez-Tellez
Favorite
(P 504) WHY DO SOME PATIENTS WITH SYNOVIAL SARCOMA HAVE BETTER FUNCTIONAL OUTCOMES AFTER RESECTION SURGERY? ANALYSIS OF 102 CASES
Elisabeth Martinez-Tellez
Favorite
(P 507) PRIMARY CHEST WALL TUMORS OF MESENCHYMAL ORIGIN. EXPERIENCE OF A REFERENCE UNIT
Elisabeth Martinez-Tellez
Favorite
Martínez-Téllez, Elisabeth

Hospital de la Santa Creu i Sant Pau
(P 508) DREAM, UTOPIA OR REALISM? PROGNOSTIC FACTORS IN LUNG METASTASECTOMY OF DISSEMINATED SARCOMA DISEASE
Elisabeth Martínez-Téllez
Favorite
Martinez-Trufero, Javier

HU Miguel Servet
(P 113) IMMUNOSARC II: A SPANISH SARCOMA GROUP (GEIS) PHASE IB TRIAL OF DOXORUBICIN AND DACARBAZINE PLUS NIVOLUMAB IN FIRST LINE OF ADVANCED LEIOMYOSARCOMA
Javier Martinez-Trufero
Favorite
(P 174) SELISARC: A SPANISH GROUP FOR RESEARCH IN SARCOMA (GEIS) PHASE I/II TRIAL OF SELINEXOR PLUS GEMCITABINE IN SELECTED SARCOMA SUBTYPES: RESULTS OF THE PHASE I PART
Javier Martinez-Trufero
Favorite
Martin, Jeffrey

Roswell Park Comprehensive Cancer Center
(P 247) HARNESSING EWING SARCOMA'S REPLICATION STRESS BY TARGETING DDK AND WEE1 IN COMBINATION
Jeffrey Martin
Favorite
Martin, Lauren

Biomedical Research Centre, University of British Columbia
(P 267) NEW MOUSE MODEL OF SYNOVIAL SARCOMA BASED ON CONDITIONAL EXPRESSION IN MESENCHYMAL PROGENITORS
Lauren Martin
Favorite
Martino, Giovanna

MedAustron Ion therapy Center, Austria
(P 326) CARBON-ION RADIOTHERAPY FOR UNRESECTABLE PELVIC SARCOMAS/CHORDOMAS
Giovanna Martino
Favorite
Martín-Ruiz, Marta

Instituto de Investigaciones Sanitarias Fundación Jiménez Díaz
(P 142) THE SARCOMA EUROPEAN AND LATIN AMERICAN NETWORK (SELNET) PROJECT: OVERVIEW OF THE MAIN RESULTS OF THE SELNET REGISTRY
Marta Martín-Ruiz
Favorite
(P 261) EFFICACY OF BET INHIBITORS IN SOLITARY FIBROUS TUMOR: AN IN VITRO EVALUATION
Marta Martín-Ruiz
Favorite
(P 270) ALTERNATIVE SPLICING (AS) REGULATION AS A NOVEL THERAPEUTIC TARGET IN SOFT-TISSUE SARCOMA (STS)
Marta Martín-Ruiz
Favorite
(P 279) PROTEIN PHOSPHATASE 2 A INHIBITION AS A MECHANISM TO ENHANCE DOXORUBICIN ACTIVITY
Marta Martín-Ruiz
Favorite
Maruzzo, Marco

Oncology 1 Unit, Department of Oncology, Veneto Institute of Oncology IOV - IRCCS
(P 171) SEX DIFFERENCES IN OUTCOMES AND TOXICITY IN PATIENTS TREATED FOR SARCOMA IN A REFERENCE CENTER
Marco Maruzzo
Favorite
Marwa, Bilal

Jim Pattison Children's Hospital, Saskatoon, SK
(P 454) TREATMENT PATTERNS AND OUTCOMES IN PEDIATRIC AND ADULT PATIENTS WITH EWING AND UNDIFFERENTIATED ROUND BLUE CELL SARCOMAS IN ALBERTA
Bilal Marwa
Favorite
Marx, Jeremy

Northwestern Medicine
(P 479) EXPANDABLE ENDOPROSTHESES: SHOULD WE CONSIDER NARROWING OUR INDICATIONS? A SYSTEMATIC REVIEW OF THE LITERATURE AND COMPARISON OF OUTCOMES BY AGE GROUPS
Jeremy Marx
Favorite
Mascarenhas, Leo

Children's Hospital Los Angeles, University of Southern California Keck School of Medicine
(P 81) OPTIMIZING EWING SARCOMA AND OSTEOSARCOMA BIOPSY ACQUISITION: CONSENSUS RECOMMENDATIONS FROM THE CHILDREN'S ONCOLOGY GROUP BONE TUMOR COMMITTEE
Leo Mascarenhas
Favorite
(P 161) EFFICACY, SAFETY, AND TREATMENT HOLD WAIT-AND-SEE OUTCOMES OF LAROTRECTINIB IN PEDIATRIC PATIENTS WITH TRK FUSION SARCOMAS
Leo Mascarenhas
Favorite
(P 166) SARC038: A PHASE 2 STUDY OF REGORAFENIB IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH REFRACTORY OR RECURRENT OSTEOSARCOMA
Leo Mascarenhas
Favorite
(P 191) SARC024 COHORT D: PHASE 2 TRIAL OF REGORAFENIB IN CHILDREN, ADOLESCENTS, AND ADULTS WITH RHABDOMYOSARCOMA
Leo Mascarenhas
Favorite
(P 430) UNIQUE HISTOLOGIC MORPHOLOGY OF EWING SARCOMA CELLS THAT HARBOR TP53 MUTATIONS
Leo Mascarenhas
Favorite
Massa, Annamaria

Department of Oncology, University of Turin
(P 109) INTENSE PRECLINICAL ACTIVITY BY B7H3-SPECIFIC CAR.CIK LYMPHOCYTES AGAINST EPITHELIOID SARCOMA
Annamaria Massa
Favorite
Mata Muñoz, José Miguel

Hospital de la Santa Creu i Sant Pau
(P 503) SCAPULAR PROSTHESIS RECONSTRUCTION, EXPERIENCE IN OUR INSTITUTION
José Miguel Mata Muñoz
Favorite
Mathkour, Yusef

David Geffen School of Medicine, University of California, Los Angeles
(P 19) EXTRACELLULAR VESICLE CLICK MAGBEADS: A MULTIFACETED LIQUID BIOPSY PLATFORM FOR PEDIATRIC SARCOMAS
Yusef Mathkour
Favorite
Matloub, Yousif

Takeda Development Center Americas
(P 558) TRIAL IN PROGRESS: A PHASE 1/2 STUDY OF BRIGATINIB IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH ALK POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA OR INFLAMMATORY MYOFIBROBLASTIC TUMORS (ITCC-098)
Yousif Matloub
Favorite
Matsuda, Koichi

Graduate School of Frontier Sciences, The University of Tokyo
(P 396) COMPREHENSIVE WHOLE-GENOME MOLECULAR PROFILING IN BONE AND SOFT TISSUE SARCOMA: MULTI-OMICS ANALYSIS OF 627 CASES ACROSS HISTOLOGIC SUBTYPES
Koichi Matsuda
Favorite
Matsumoto, Yoshihiro

Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kyushu University
(P 406) EXTENSIVE ANALYSIS OF 59 SARCOMA-RELATED FUSION GENES IDENTIFIED PAZOPANIB AS A POTENTIAL INHIBITOR TO COL1A1-PDGFB FUSION GENE
Yoshihiro Matsumoto
Favorite
Mattei, Jean-Camille

University Musculoskeletal Oncology Unit, Mount Sinai Hospital, Department of Surgery, University of Toronto, Toronto, Canada
(P 53) CURATIVE-INTENT SURGERY FOR A SOLITARY ISOLATED BONE METASTASIS FROM EXTREMITY SARCOMA: WHO UNDERWENT METASTASECTOMY AND WHAT WAS THE PROGNOSTIC OUTCOME?
Jean-Camille Mattei
Favorite
Matthies, Cordula

University Hospital Wuerzburg
(P 133) TEN RECOMMENDATIONTS FOR SARCOMA SURGERY: CONSENSUS OF THE SURGICAL SOCIETIES BASED ON THE GERMAN S3 GUIDELINE "ADULT SOFT TISSUE SARCOMA"
Cordula Matthies
Favorite
Matui, Yoshiyuki

Department of Urology, National Cancer Center Hospital, Tokyo, Japan
(P 332) SURGICAL OUTCOMES OF RETROPERITONEAL LIPOSARCOMA - SINGLE INSTITUTIONAL STUDY N JAPAN -
Yoshiyuki Matui
Favorite
Mavroeidi, Ilektra

Department of Medical Oncology, West German Cancer Center, University Hospital Essen
(P 220) [68GA]GA-FAPI PET/CT AS NOVEL DIAGNOSTIC TOOL IN SARCOMA
Ilektra Mavroeidi
Favorite
(P 248) FIBROBLAST ACTIVATION PROTEIN ALPHA -DIRECTED IMAGING AND THERAPY OF SOLITARY FIBROUS TUMOR
Ilektra Mavroeidi
Favorite
Maxwell, Shannon

University of Washington
(P 206) A SINGLE-ARM, PHASE II STUDY OF NEOADJUVANT PEMBROLIZUMAB COMBINED WITH RADIOTHERAPY IN THE PRIMARY TREATMENT OF SOFT TISSUE SARCOMAS.
Shannon Maxwell
Favorite
Ma, Yan

Duke University
(P 428) COMPREHENSIVE GENOMIC PROFILING OF CIC-DUX4 SARCOMA (CDS) CELL LINES AND MODELS
Yan Ma
Favorite
May, Byron

Mayo Clinic Florida
(P 312) MANAGEMENT OF ADULT HEAD AND NECK SOFT TISSUE SARCOMA: THE MAYO CLINIC EXPERIENCE
Byron May
Favorite
Mayerson, Joel

The Ohio State University Comprehensive Cancer Center
(P 323) PERIPHERAL NEUROPATHY FOLLOWING INTRA-OPERATIVE RADIOTHERAPY FOR EXTREMITY SOFT TISSUE SARCOMA: A SINGLE INSTITUTION EXPERIENCE
Joel Mayerson
Favorite
Mayo, Skye

OHSU Knight Cancer Institute
(P 341) A PHASE 1B STUDY TO EVALUATE PREOPERATIVE ERIBULIN IN COMBINATION WITH RADIATION IN RETROPERITONEAL SARCOMA
Skye Mayo
Favorite
Mayrhofer, Markus

Karolinska institutet
(P 243) EVALUATION OF THE USE OF WGS IN ROUTINE DIAGNOSTICS FOR BONE AND SOFT TISSUE TUMORS
Markus Mayrhofer
Favorite
Mazur, Tom

Washington University in St Louis
(P 187) PALLIATIVE LATTICE STEREOTACTIC BODY RADIOTHERAPY FOR PATIENTS WITH SARCOMA
Tom Mazur
Favorite
Mazzocca, Alessandro

Fondazione Policlinico Universitario Campus Bio-Medico
(P 49) EFFICACY OF RIPRETINIB IN A MULTICENTER EXPANDED ACCESS PROGRAM IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS HARBOURING NON-KIT EXON 11 MUTATIONS.
Alessandro Mazzocca
Favorite
(P 159) IN BETWEEN OF LYMPHOMAS AND SARCOMAS: WHERE DO HISTIOCYTIC AND DENDRITIC CELL NEOPLASMS (HDCN) STAND? A RETROSPECTIVE, MULTI-INSTITUTIONAL STUDY FROM THE ITALIAN SARCOMA GROUP (ISG)
Alessandro Mazzocca
Favorite
(P 263) HER2 AS A POTENTIAL NOVEL THERAPEUTIC TARGET IN SOFT TISSUE SARCOMAS
Alessandro Mazzocca
Favorite
(P 264) CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS AND TRABECTEDIN IN SOFT TISSUE SARCOMA: A NOVEL POTENTIAL SYNERGY?
Alessandro Mazzocca
Favorite
McBride, Kevin

MD Anderson Cancer Center
(P 100) HISTOLOGY SPECIFIC INTRATUMORAL B-CELL BIOLOGY IN ALVEOLAR SOFT-PART SARCOMAS (ASPS) IN RESPONSE TO DURVALUMAB-TREMELIMUMAB (D-T)
Kevin McBride
Favorite
McCall, David

The University of Texas MD Anderson Cancer Center
(P 427) UNDERSTANDING THE MOLECULAR DRIVERS THAT REGULATE EWING SARCOMA CELL FATE
David McCall
Favorite
McCarville, Beth

St. Jude Children's Research Hospital
(P 528) SAFETY AND TOLERABILITY OF ORAL CYCLOPHOSPHAMIDE AND SORAFENIB WITH INTRAVENOUS BEVACIZUMAB WITH THE ADDITION OF ATEZOLIZUMAB IN PEDIATRIC SOLID TUMOR PATIENTS
Beth McCarville
Favorite
McCutcheon, Ian

The University of Texas MD Anderson Cancer Center
(P 269) PLASMA DNA METHYLATION-BASED BIOMARKERS FOR MPNST DETECTION IN PATIENTS WITH NEUROFIBROMATOSIS TYPE 1 (NF1)
Ian McCutcheon
Favorite
McDermott, Ray

St. Vincent’s University Hospital and University College Dublin
(P 353) UPDATED EFFICACY AND SAFETY OF LAROTRECTINIB IN ADULT PATIENTS WITH TRK FUSION SARCOMAS
Ray McDermott
Favorite
McEachron, Troy

National Institutes of Health
(P 166) SARC038: A PHASE 2 STUDY OF REGORAFENIB IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH REFRACTORY OR RECURRENT OSTEOSARCOMA
Troy McEachron
Favorite
McGivney, Gavin

University of Iowa
(P 286) EPIGENETIC MECHANISMS AND SIGNATURES OF SARCOMA PROGRESSION AND METASTASIS
Gavin McGivney
Favorite
McGough, Richard

University of Pittsburgh Medical Center
(P 466) INTRAOPERATIVE EVALUATION OF BONE AND SOFT TISSUE SARCOMA SURGICAL MARGINS WITH INDOCYANINE GREEN FLUORESCENCE IMAGING
Richard McGough
Favorite
(P 544) INTRAOPERATIVE EVALUATION OF BONE AND SOFT TISSUE SARCOMA SURGICAL MARGINS WITH INDOCYANINE GREEN FLUORESCENCE IMAGING
Richard McGough
Favorite
McHugh, Kieran

Department of Radiology, Great Ormond Street Hospital for Children NHS Foundation Trust
(P 209) PROGNOSTIC VALUE OF EARLY RADIOLOGIC TUMOUR VOLUME RESPONSE IN RHABDOMYOSARCOMA; RESULTS OF THE EUROPEAN PAEDIATRIC SOFT TISSUE SARCOMA STUDY GROUP RMS 2005 STUDY
Kieran McHugh
Favorite
McMullan, Christel

CPROR, University of Birmingham
(P 345) CLINICIAN SURVEY - CURRENT GLOBAL PRACTICE FOR SARCOMA SURVEILLANCE FOLLOWING RESECTION OF PRIMARY RETROPERITONEAL, ABDOMINAL, AND PELVIC SARCOMA
Christel McMullan
Favorite
McMullen, James

University of Michigan Medical School
(P 403) THE IMPACT OF PATIENT, TUMOR, AND TREATMENT FACTORS ON SURVIVAL AND METASTASIS OUTCOMES IN PATIENTS WITH MYXOID LIPOSARCOMA
James McMullen
Favorite
Meany, Holly

Children's National Hospital
(P 18) RETROSPECTIVE ANALYSIS ON OUTCOMES PEDIATRIC PATIENTS WITH SARCOMA AND LUNG METASTASES STATUS POST PNEUMONECTOMY VERSUS PARTIAL LUNG RESECTION
Holly Meany
Favorite
Meattini, Icro

Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, Florence, Italy
(P 309) CLINICAL PATHOLOGICAL CHARACTERISTICS, PATTERN OF CARE AND SURVIVAL OF NON-METASTATIC BREAST ANGIOSARCOMA
Icro Meattini
Favorite
Med, Jacqui

Washington University School of Medicine
(P 552) RANDOMIZED PHASE II TRIAL OF CABOZANTINIB COMBINED WITH PD-1 AND CTLA-4 INHIBITION VERSUS CABOZANTINIB IN METASTATIC SOFT TISSUE SARCOMA.
Jacqui Med
Favorite
Meehan, Brian

Research Institute of the McGill University Health Center
(P 65) PROFILING EXTRACELLULAR VESICLES AND NANOPARTICLES IN OSTEOSARCOMA
Brian Meehan
Favorite
Meidenbauer, Norbert

Department of Medicine 5, University Hospital, Friedrich-Alexander-University Erlangen- Nuremberg, 91054 Erlangen, Germany
(P 557) UNRAVELING THE ROLE OF LOCAL THERAPY FOR PATIENTS WITH OLIGOMETASTATIC SOFT TISSUE SARCOMA - A RETROSPECTIVE MULTICENTER TRIAL OF BAVARIAN UNIVERSITY HOSPITALS
Norbert Meidenbauer
Favorite
Meijer, Debora

LUMC
(P 368) DECODING THE IMMUNOGENOMIC DETERMINANTS OF RADIOTHERAPY RESPONSE IN SOFT TISSUE SARCOMAS
Debora Meijer
Favorite
(P 369) MAGEA ANTIGENS AS IMMUNOTHERAPEUTIC TARGETS FOR ADVANCED OSTEOSARCOMA
Debora Meijer
Favorite
Melacarne, Alessia

Humanitas Clinical and Research Hospital
(P 297) UNVEILING THE IMPACT OF INTRATUMORAL MICROBIOTA IN THE TREATMENT EFFICACY OF SOFT TISSUE SARCOMA
Alessia Melacarne
Favorite
Melendez-Fernandez, Ana

Instituto Nacional de Cancerología (Mexico)
(P 331) MUSCULAR DEDIFFERENTIATION IN DEDIFFERENTIATED LIPOSARCOMA: INSIGHTS INTO INFLAMMATORY PROFILES USING THE NEUTROPHIL/LYMPHOCYTE RATIO AND PROGNOSTIC IMPLICATIONS
Ana Melendez-Fernandez
Favorite
Mello, Celso

AC Camargo Cancer Center
(P 192) ROLE OF MAGNETIC RESONANCE IMAGING IN THE PREDICTION OF HISTOLOGICAL GRADE IN SOFT TISSUE SARCOMAS.
Celso Mello
Favorite
(P 387) CLINICAL CHARACTERIZATION OF PATIENTS WITH LEIOMYOSARCOMA HARBORING THE R337H TP53 GERMINATIVE ALTERATION (LI-FRAUMENI SYNDROME) AND THE PROGNOSTIC IMPLICATION USING A PROPENSITY-SCORE MATCHED COHORT
Celso Mello
Favorite
Mendes, Cristina

Instituto Português de Oncologia de Lisboa Francisco Gentil
(P 73) FOSTER CONSORTIUM, FIGHT OSTEOSARCOMA THROUGH EUROPEAN RESEARCH
Cristina Mendes
Favorite
Mendez, Ramiro

Hospital Clinico san Carlos
(P 149) PSYCOLOGICAL SNAPSHOT OF SARCOMA PATIENTS FROM AN ACADEMIC, UNIVERSITY CENTER, HOSPITAL CLÍNICO SAN CARLOS (HCSC), MADRID, A SARCOMA NATIONAL REFERRAL CENTRE IN SPAIN
Ramiro Mendez
Favorite
(P 175) TRABECTEDIN PLUS RADIOTHERAPY ON SYMPHTOMATIC ADVANCED SARCOMA PATIENTS, RESULTS FROM THE SYNERGIAS STUDY: A SPANISH GROUP FOR RESEARCH IN SARCOMA (GEIS) PHASE II STUDY
Ramiro Mendez
Favorite
MENEZ, Tiphaine

Centre Eugène Marquis
(P 521) HOW TO MANAGE ABDOMINAL PARIETECTOMY, REVIEW OF EXPERIENCE IN INSTITUT BERGONIE
Tiphaine MENEZ
Favorite
Menge, Franka

Sarcoma Unit, Department of Surgery and Mannheim Cancer Center, University Medical Center Mannheim, University of Heidelberg, Mannheim,Germany
(P 12) MULTIFOCAL AND DISSEMINATED SPORADIC DESMOID TUMOUR OF THE EXTREMITIES: A SPECIAL CHALLENGE
Franka Menge
Favorite
(P 488) POSTOPERATIVE DRAINAGE MANAGEMENT AND WOUND COMPLICATIONS FOLLOWING RESECTION OF LOWER LIMB SOFT TISSUE TUMORS
Franka Menge
Favorite
Mercatali, Laura

Preclinic and Osteoncology Unit, Istituto Scientifico Romagnolo per lo studio dei Tumori "Dino Amadori"
(P 37) DISSECTING THE ROLE OF EXTRACELLULAR VESICLES IN THE MANAGEMENT OF GIST
Laura Mercatali
Favorite
Mercatali, Laura

Istituto Ortopedico Rizzoli IRCCS, Osteoncology- Bone and Soft Tissue Sarcomas and Innovative Therapies Unit, Bologna, Italy ; Istituto Scientifico Romagnolo per lo studio dei Tumori "Dino Amadori", Preclinic and Osteoncology Unit, Meldola, Italy
(P 253) THE EFFICACY OF MEDICATED PATCHES IN SOFT TISSUE SARCOMAS: IN-VITRO AND EX-VIVO VALIDATION.
Laura Mercatali
Favorite
(P 364) EVALUATION OF THE PREDICTIVE ROLE OF SYSTEMIC AND INTRATUMORAL IMMUNITY IN PATIENTS WITH LOCALIZED LIPOSARCOMAS, MYXOFIBROSARCOMAS AND UNDIFFERENTIATED PLEOMORPHIS SARCOMAS
Laura Mercatali
Favorite
(P 533) SAFETY AND PRELIMINARY BIOLOGICAL ACTIVITY OF A PHASE II TRIAL OF AUTOLOGOUS DENDRITIC CELLS VACCINATION IN SARCOMAS.
Laura Mercatali
Favorite
Mercier, Kelly

Desmoid Tumor Research Foundation
(P 146) CHARACTERIZING THE PATIENT JOURNEY TO A DIAGNOSIS OF DESMOID TUMOR: DESMOID TUMOR RESEARCH FOUNDATION NATURAL HISTORY STUDY
Kelly Mercier
Favorite
Mercolini, Federico

"Lalla Seràgnoli", Istituto di Ricovero e Cura a Carattere Scientifico, Azienda Ospedaliero-Universitaria di Bologna,
(P 202) INFLAMMATORY MYOFIBROBLASTIC TUMOUR WITH ROS1 GENE FUSIONS IN CHILDREN AND YOUNG ADOLESCENTS
Federico Mercolini
Favorite
Meresse, Thomas

OCR
(P 201) PLEOMORPHIC RHABDOMYOSARCOMAS: A NEW ENTITY ASSOCIATED WITH LYNCH SYNDROME? FIRST RESULTS OF SARCLYNCH NATIONAL STUDY
Thomas Meresse
Favorite
merimsky, Ofer

oferm@tlvmc.gov.il
(P 319) HYPO-FRACTIONATED RADIATION THERAPY FOR THE EXTREMITY SOFT TISSUE SARCOM IN ELDERLY AND DISABLED.
Ofer merimsky
Favorite
Merino, Jose

HU Fundación Jimenez Díaz
(P 175) TRABECTEDIN PLUS RADIOTHERAPY ON SYMPHTOMATIC ADVANCED SARCOMA PATIENTS, RESULTS FROM THE SYNERGIAS STUDY: A SPANISH GROUP FOR RESEARCH IN SARCOMA (GEIS) PHASE II STUDY
Jose Merino
Favorite
Merks, Johannes

Princess Máxima Center for Pediatric Oncology and Division of Imaging and Oncology, University Medical Center Utrecht, University of Utrecht
(P 209) PROGNOSTIC VALUE OF EARLY RADIOLOGIC TUMOUR VOLUME RESPONSE IN RHABDOMYOSARCOMA; RESULTS OF THE EUROPEAN PAEDIATRIC SOFT TISSUE SARCOMA STUDY GROUP RMS 2005 STUDY
Johannes Merks
Favorite
(P 229) ON THE VARIABILITY IN THE ANALYSIS OF APPARENT DIFFUSION COEFFICIENT ESTIMATES FOR MULTICENTER DIFFUSION MRI DATA OF RHABDOMYOSARCOMA PATIENTS
Johannes Merks
Favorite
(P 558) TRIAL IN PROGRESS: A PHASE 1/2 STUDY OF BRIGATINIB IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH ALK POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA OR INFLAMMATORY MYOFIBROBLASTIC TUMORS (ITCC-098)
Johannes Merks
Favorite
Merlini, Alessandra

Department of Oncology, University of Turin
(P 109) INTENSE PRECLINICAL ACTIVITY BY B7H3-SPECIFIC CAR.CIK LYMPHOCYTES AGAINST EPITHELIOID SARCOMA
Alessandra Merlini
Favorite
(P 159) IN BETWEEN OF LYMPHOMAS AND SARCOMAS: WHERE DO HISTIOCYTIC AND DENDRITIC CELL NEOPLASMS (HDCN) STAND? A RETROSPECTIVE, MULTI-INSTITUTIONAL STUDY FROM THE ITALIAN SARCOMA GROUP (ISG)
Alessandra Merlini
Favorite
(P 262) ESTABLISHMENT AND CHARACTERIZATION OF THE FIRST RADIATION-INDUCED, PATIENT-DERIVED ANGIOSARCOMA CELL LINE
Alessandra Merlini
Favorite
(P 455) EXTRASKELETAL EWING SARCOMA: A MULTICENTRIC RETROSPECTIVE STUDY FROM THE ITALIAN SARCOMA GROUP
Alessandra Merlini
Favorite
Merose, Omri

Tel Aviv Medical Center, Tel Aviv, Israel
(P 240) IDENTIFYING PATIENTS AT HIGH RISK OF HIP FRACTURE DUE TO BONE TUMORS BY COMPUTATIONAL BIOMECHANICS: A RANDOMIZED PROSPECTIVE CLINICAL STUDY
Omri Merose
Favorite
(P 319) HYPO-FRACTIONATED RADIATION THERAPY FOR THE EXTREMITY SOFT TISSUE SARCOM IN ELDERLY AND DISABLED.
Omri Merose
Favorite
Mertens, Fredrik

Lund University
(P 372) COPY NUMBER GAIN OF MDM2 IN ROD-SHAPED CHROMOSOMES PROVIDES CLUES TO EARLY STAGES IN CIRCULARIZED GENE AMPLIFICATION IN LIPOSARCOMA
Fredrik Mertens
Favorite
Mesirov, Jill

Department of Medicine, Division of Genomics and Precision Medicine, University of California San Diego
(P 28) RETROSPECTIVE ANALYSIS OF SUCCINATE DEHYDROGENASE (SDH)-DEFICIENT GASTROINTESTINAL STROMAL TUMOR (GIST) OUTCOMES: AN INTERNATIONAL STUDY OF 256 PATIENTS
Jill Mesirov
Favorite
(P 29) COMBINATION TREATMENT WITH TEMOZOLOMIDE AND THE DEATH RECEPTOR-5 AGONIST INBRX-109 EFFECTIVELY TARGETS SUCCINATE DEHYDROGENASE -DEFICIENT GASTROINTESTINAL STROMAL TUMOR
Jill Mesirov
Favorite
Mesko, Nathan

Cleveland Clinic
(P 242) WHOLE BODY PET/MRI FOR STAGING OF MYXOID LIPOSARCOMA
Nathan Mesko
Favorite
(P 402) TISSUE PERFUSION AND WOUND HEALING AFTER SOFT TISSUE SARCOMA RESECTION
Nathan Mesko
Favorite
(P 513) THE IMPACT OF MARGIN STATUS ON THE ONCOLOGIC OUTCOMES OF SURGICALLY TREATED DEDIFFERENTIATED LIPOSARCOMA OF THE EXTREMITIES
Nathan Mesko
Favorite
(P 514) INTERSTITIAL BRACHYTHERAPY IN THE TREATMENT OF SOFT TISSUE SARCOMA: LOCAL RECURRENCE AND WOUND OUTCOMES
Nathan Mesko
Favorite
(P 529) THE MUSCULOSKELETAL TUMOR REGISTRY -- 2023 UPDATE AND OUTLOOK
Nathan Mesko
Favorite
Messiou, Christina

The Royal Marsden Hospital
(P 40) LONG TERM OUTCOMES OF NEOADJUVANT IMATINIB AND SURGICAL RESECTION OF RECTAL GASTROINTESTINAL STROMAL TUMOURS
Christina Messiou
Favorite
(P 138) CONTROVERSIES IN THE MANAGEMENT OF PATIENTS WITH SOFT TISSUE SARCOMA: RESULTS AND RECOMMENDATIONS FROM THE FIRST CONFERENCE ON STATE OF SCIENCE IN SARCOMA (CSSS)
Christina Messiou
Favorite
(P 233) MULTI-CENTER EXTERNAL VALIDATION OF AN AUTOMATED MODEL DIFFERENTIATING ALT FROM LIPOMA USING RADIOMICS AND DEEP-LEARNING BASED SEGMENTATION
Christina Messiou
Favorite
Metts, Jonathan

Moffitt Cancer Center and Johns Hopkins All Children's Hospital
(P 91) BLOOD TRANSFUSION AND SURVIVAL AMONG CHILD, ADOLESCENT, AND YOUNG ADULT PATIENTS WITH OSTEOSARCOMA: A RETROSPECTIVE COHORT STUDY
Jonathan Metts
Favorite
(P 193) Recent Trends in Sarcoma Trials for Children in the United States
Jonathan Metts
Favorite
(P 425) CHARACTERIZATION OF RHABDOMYOSARCOMA WITH PAX7::FOXO1 FUSIONS: A REPORT FROM THE SOFT TISSUE COMMITTEE OF THE CHILDREN'S ONCOLOGY GROUP
Jonathan Metts
Favorite
(P 537) TGFβ IMPRINTED, EX VIVO EXPANDED UNIVERSAL DONOR NATURAL KILLER CELLS WITH CHEMOTHERAPY FOR RELAPSED BONE AND SOFT TISSUE SARCOMA - NCT05634369, REPORT FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION
Jonathan Metts
Favorite
(P 551) PHASE II TRIAL OF GEMCITABINE AND NAB-PACLITAXEL IN PATIENTS WITH RECURRENT RHABDOMYOSARCOMA: A CLINICAL TRIAL IN PROGRESS FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION
Jonathan Metts
Favorite
Metzler, Markus

Department of Pediatrics and Adolescent Medicine, University Hospital Erlangen
(P 538) IEUROEWING TRIAL FOR LOCALIZED AND METASTATIC EWING SARCOMA
Markus Metzler
Favorite
Meurgey, Alexandra

Centre Léon Bérard
(P 104) COMPREHENSIVE IMMUNE PROFILING UNVEILS A SUBSET OF LEIOMYOSARCOMA WITH HOT TUMOR IMMUNE MICROENVIRONMENT
Alexandra Meurgey
Favorite
(P 382) NTRK1/2/3 FUSIONS DETECTION USING RNA-SEQ IN MESENCHYMAL TUMORS REVEALS ULTRA-RARE AND HISTO-SPECIFIC TARGETABLE ALTERATIONS: EXPERIENCE OF AN EXTENSIVE ROUTINE RESEARCH PROGRAM.
Alexandra Meurgey
Favorite
Meyer, Christian

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
(P 164) INTRATUMORAL INT230-6 (CISPLATIN, VINBLASTINE, SHAO) ALONE OR WITH IPILIMUMAB PROLONGED SURVIVAL WITH FAVORABLE SAFETY AND IMMUNE ACTIVATION IN ADULTS WITH REFRACTORY SARCOMAS (NCT 03058289)
Christian Meyer
Favorite
(P 182) UPDATED RESULTS FROM AN ONGOING PHASE 1B STUDY OF UNESBULIN (PTC596) PLUS DACARBAZINE FOR THE TREATMENT OF PATIENTS WITH ADVANCED LEIOMYOSARCOMA
Christian Meyer
Favorite
(P 552) RANDOMIZED PHASE II TRIAL OF CABOZANTINIB COMBINED WITH PD-1 AND CTLA-4 INHIBITION VERSUS CABOZANTINIB IN METASTATIC SOFT TISSUE SARCOMA.
Christian Meyer
Favorite
Meyer, John

Rush University Medical Center
(P 232) NOVEL MRI SCORING SYSTEM TO ASSESS OSSEOUS MALIGNANCY IN SOFT TISSUE SARCOMA PATIENTS FOLLOWING RADIOTHERAPY
John Meyer
Favorite
Meza-Zepeda, Leonardo

Oslo University Hospital
(P 23) GENOMIC COMPLEXITY AS A BIOMARKER FOR ADJUVANT IMATINIB TREATMENT IN HIGH-RISK GASTROINTESTINAL STROMAL TUMOR
Leonardo Meza-Zepeda
Favorite
Mezey, Natalie

Department of Surgery, University of Ottawa
(P 152) EVALUATING DIAGNOSTIC APPROACHES TO DERMATOFIBROSARCOMA PROTUBERANS: AN OPPORTUNITY TO REDUCE THE NUMBER OF INTERVENTIONS
Natalie Mezey
Favorite
Miah, Aisha

The Royal Marsden Hospital
(P 138) CONTROVERSIES IN THE MANAGEMENT OF PATIENTS WITH SOFT TISSUE SARCOMA: RESULTS AND RECOMMENDATIONS FROM THE FIRST CONFERENCE ON STATE OF SCIENCE IN SARCOMA (CSSS)
Aisha Miah
Favorite
(P 318) DEVELOPMENT OF NOVEL OUTLINING GUIDELINES FOR NORMAL TISSUE STRUCTURES FOR LIMB SOFT TISSUE SARCOMA.
Aisha Miah
Favorite
Micci, Francesca

Oslo University Hospital
(P 23) GENOMIC COMPLEXITY AS A BIOMARKER FOR ADJUVANT IMATINIB TREATMENT IN HIGH-RISK GASTROINTESTINAL STROMAL TUMOR
Francesca Micci
Favorite
Miceli, Rosalba

Unit of Biostatistics for Clinical Research Department of Epidemiology and Data Science, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
(P 189) INTERNATIONAL RETROSPECTIVE STUDY FROM THE ULTRA-RARE SARCOMA WORKING GROUP ON LOW-GRADE FIBROMYXOID SARCOMA AND SCLEROSING EPITHELIOD FIBROSARCOMA: OUTCOME OF ADVANCED DISEASE AND SYSTEMIC THERAPIES
Rosalba Miceli
Favorite
(P 410) PROTEOMICS ANALYSIS IDENTIFIES A SIGNATURE THAT IMPROVES PROGNOSTIC RISK STRATIFICATION OF THE SARCULATOR NOMOGRAM IN PATIENTS WITH SOFT TISSUE SARCOMAS OF THE EXTREMITIES AND TRUNK WALL
Rosalba Miceli
Favorite
(P 455) EXTRASKELETAL EWING SARCOMA: A MULTICENTRIC RETROSPECTIVE STUDY FROM THE ITALIAN SARCOMA GROUP
Rosalba Miceli
Favorite
Michalski, Jeff

Washington University in St Louis
(P 187) PALLIATIVE LATTICE STEREOTACTIC BODY RADIOTHERAPY FOR PATIENTS WITH SARCOMA
Jeff Michalski
Favorite
MICHOT, Audrey

Institut Bergonié
(P 521) HOW TO MANAGE ABDOMINAL PARIETECTOMY, REVIEW OF EXPERIENCE IN INSTITUT BERGONIE
Audrey MICHOT
Favorite
(P 523) IN-BETWEEN SARCOMA: A CATEGORY OF HIGH RISK OF RECURRENCE AND POOR OUTCOME
Audrey MICHOT
Favorite
Middleton, Kimberly

Sylvester Comprehensive Cancer Center / University of Miami Hospital and Clinics
(P 208) LOW INCIDENCE OF CANCER THERAPY-RELATED CARDIAC DYSFUNCTION IN ADULT SARCOMA PATIENTS RECEIVING DOXORUBICIN AND UPFRONT DEXRAZOXANE
Kimberly Middleton
Favorite
Miera, Monika

Department of Medical Oncology, West German Cancer Center, University Hospital Essen
(P 248) FIBROBLAST ACTIVATION PROTEIN ALPHA -DIRECTED IMAGING AND THERAPY OF SOLITARY FIBROUS TUMOR
Monika Miera
Favorite
Mihalcik, Stephen

Northwestern Medicine
(P 320) A PROSPECTIVE MULTICENTER EXPERIENCE OF PROTON THERAPY FOR RHABDOMYOSARCOMA AND EWING SARCOMA: OUTCOMES FROM THE PROTON COLLABORATIVE GROUP REGISTRY
Stephen Mihalcik
Favorite
Mihaljevic, André

Ulm University Hospital
(P 153) PRIORITY SETTING PARNTERSHIP RETROPERITONEAL SOFT TISSUE SARCOMAS
André Mihaljevic
Favorite
Milano, Giuseppe

Bambino Gesù Children's Hospital, Istituto di Ricovero e Cura a Carattere Scientifico (IRCSS)
(P 202) INFLAMMATORY MYOFIBROBLASTIC TUMOUR WITH ROS1 GENE FUSIONS IN CHILDREN AND YOUNG ADOLESCENTS
Giuseppe Milano
Favorite
Milhem, Mohammed

University of Iowa, Holden Comprehensive Cancer Center
(P 115) EFFICACY AND CORREALTIVE ANALYSIS OF USING NEOADJUVANT INTRATUMORAL HIGH DOSE TALIMOGENE LAHERPAREPVEC (TVEC) WITH CONCURRENT RADIATION IN HIGH-RISK EXTREMITY AND TRUNK SOFT-TISSUE SARCOMAS
Mohammed Milhem
Favorite
(P 178) INITIAL RESULTS FROM A PHASE 1 STUDY OF CFT8634, A NOVEL BIFUCTIONAL DEGRADATION ACTIVATING COMPOUND (BIDAC) DEGRADER OF BRD9, IN SYNOVIAL SARCOMA AND SMARCB1-NULL TUMORS
Mohammed Milhem
Favorite
(P 180) HEALTH RELATED QUALITY OF LIFE OF PATIENTS WITH ADVANCED LEIOMYOSARCOMA AND OTHER SOFT TISSUE SARCOMAS TREATED WITH CABOZANTINIB AND TEMOZOLOMIDE
Mohammed Milhem
Favorite
Miller, Alexandra

Johns Hopkins All Children's Hospital
(P 193) Recent Trends in Sarcoma Trials for Children in the United States
Alexandra Miller
Favorite
Miller, Ann

St Jude's Children's Hospital
(P 115) EFFICACY AND CORREALTIVE ANALYSIS OF USING NEOADJUVANT INTRATUMORAL HIGH DOSE TALIMOGENE LAHERPAREPVEC (TVEC) WITH CONCURRENT RADIATION IN HIGH-RISK EXTREMITY AND TRUNK SOFT-TISSUE SARCOMAS
Ann Miller
Favorite
Miller, Benjamin

University of Iowa
(P 115) EFFICACY AND CORREALTIVE ANALYSIS OF USING NEOADJUVANT INTRATUMORAL HIGH DOSE TALIMOGENE LAHERPAREPVEC (TVEC) WITH CONCURRENT RADIATION IN HIGH-RISK EXTREMITY AND TRUNK SOFT-TISSUE SARCOMAS
Benjamin Miller
Favorite
(P 529) THE MUSCULOSKELETAL TUMOR REGISTRY -- 2023 UPDATE AND OUTLOOK
Benjamin Miller
Favorite
Miller, Chloe

Moores Cancer Center, University of California, San Diego
(P 29) COMBINATION TREATMENT WITH TEMOZOLOMIDE AND THE DEATH RECEPTOR-5 AGONIST INBRX-109 EFFECTIVELY TARGETS SUCCINATE DEHYDROGENASE -DEFICIENT GASTROINTESTINAL STROMAL TUMOR
Chloe Miller
Favorite
Miller, Ira

Rush University Medical Center
(P 506) THE EFFECT OF TIMING BETWEEN PRE-OPERATIVE EMBOLIZATION AND SURGERY: A RETROSPECTIVE ANALYSIS OF HYPERVASCULAR BONE METASTASES
Ira Miller
Favorite
Miller, Katherine

Nationwide Children's Hospital
(P 125) MYELOMODULATORY TREATMENTS AUGMENT THE THERAPEUTIC BENEFIT OF ONCOLYTIC VIRUS IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS BY MODULATING THE TUMOR MICROENVIRONMENT
Katherine Miller
Favorite
Mills, Lauren

University of Minnesota
(P 414) GENOMIC ANALYSIS OF EWING SARCOMA AND HERNIA IDENTIFIES A POSITIVE GENETIC CORRELATION AND SUGGESTS BOTH ARE LINKED TO AN HMGA2 VARIANT
Lauren Mills
Favorite
Mimpen, Jolet

University of Oxford
(P 04) THE CELL ATLAS OF CLEAR CELL SARCOMA
Jolet Mimpen
Favorite
Minard Colin, Veronique

Gustave-Roussy, Université Paris-Saclay
(P 202) INFLAMMATORY MYOFIBROBLASTIC TUMOUR WITH ROS1 GENE FUSIONS IN CHILDREN AND YOUNG ADOLESCENTS
Veronique Minard Colin
Favorite
(P 209) PROGNOSTIC VALUE OF EARLY RADIOLOGIC TUMOUR VOLUME RESPONSE IN RHABDOMYOSARCOMA; RESULTS OF THE EUROPEAN PAEDIATRIC SOFT TISSUE SARCOMA STUDY GROUP RMS 2005 STUDY
Veronique Minard Colin
Favorite
Mintautas, Ingrid

C4 Therapeutics
(P 178) INITIAL RESULTS FROM A PHASE 1 STUDY OF CFT8634, A NOVEL BIFUCTIONAL DEGRADATION ACTIVATING COMPOUND (BIDAC) DEGRADER OF BRD9, IN SYNOVIAL SARCOMA AND SMARCB1-NULL TUMORS
Ingrid Mintautas
Favorite
Miranda, Adam

Vanderbilt University
(P 380) NEXT GENERATION SEQUEINCING REVEALS TARGETABLE MUTATIONS IN MULTIPLE SARCOMA HISTOLOGIES
Adam Miranda
Favorite
Miserocchi, Anna

IRCCS IRST
(P 533) SAFETY AND PRELIMINARY BIOLOGICAL ACTIVITY OF A PHASE II TRIAL OF AUTOLOGOUS DENDRITIC CELLS VACCINATION IN SARCOMAS.
Anna Miserocchi
Favorite
Miserocchi, Giacomo

Istituto Romagnolo per lo studio dei Tumori "Dino Amadori" IRST IRCCS, Preclinic and Osteoncology Unit, Meldola, Italy
(P 37) DISSECTING THE ROLE OF EXTRACELLULAR VESICLES IN THE MANAGEMENT OF GIST
Giacomo Miserocchi
Favorite
(P 253) THE EFFICACY OF MEDICATED PATCHES IN SOFT TISSUE SARCOMAS: IN-VITRO AND EX-VIVO VALIDATION.
Giacomo Miserocchi
Favorite
Missiaglia, Edoardo

CHUV
(P 103) LASTING COMPLETE RESPONSE TO PEMBROLIZUMAB IN MISMATCH REPAIR DEFICIENT CARDIAC SARCOMA: A GENOMIC CHARACTERIZATION
Edoardo Missiaglia
Favorite
Mitchell, Adam

University College London Hospital
(P 92) DOSIMETRIC CHARACTERISTICS, OUTCOMES AND PROGNOSTIC FACTORS OF PATIENTS WITH EXTRACRANIAL CHORDOMAS AND CHONDROSARCOMAS TREATED WITH HIGH DOSE RADIOTHERAPY: A LARGE SINGLE INSTITUTION COHORT
Adam Mitchell
Favorite
Mitchell, Darrion

The Ohio State University Wexner Medical Center
(P 315) SCALP VOLUMETRIC MODULATED ARC THERAPY USING 3D MILLED BOLUS: DOSIMITRY, TOXICITY AND OUTCOMES
Darrion Mitchell
Favorite
Mitchell, Gareth

Huntsman Cancer Institute/University of Utah
(P 412) LEIOMYOSARCOMA POLYANEUPLOID CANCER CELLS DEVELOP IN RESPONSE TO CHEMOTHERAPY AND CONTRIBUTE TO CHEMORESISTANCE
Gareth Mitchell
Favorite
Mitra, Akash

Tempus Labs
(P 100) HISTOLOGY SPECIFIC INTRATUMORAL B-CELL BIOLOGY IN ALVEOLAR SOFT-PART SARCOMAS (ASPS) IN RESPONSE TO DURVALUMAB-TREMELIMUMAB (D-T)
Akash Mitra
Favorite
Mitra, Devarati

MD Anderson Cancer Center
(P 123) DEDIFFERENTIATED LIPOSARCOMAS TREATED WITH IMMUNE CHECKPOINT BLOCKADE: THE MD ANDERSON EXPERIENCE
Devarati Mitra
Favorite
(P 394) LEIOMYOSARCOMA INTRATUMORAL MACROPHAGE INFILTRATES ARE ASSOCIATED WITH DISTINCT CLINICAL AND GENOMIC PRESENTATIONS
Devarati Mitra
Favorite
(P 510) PRIMARY BREAST ANGIOSARCOMA: CLINICAL AND PATHOLOGICAL FEATURES AND IMPACT ON OUTCOMES
Devarati Mitra
Favorite
Mitra, Shamik

Lund University
(P 372) COPY NUMBER GAIN OF MDM2 IN ROD-SHAPED CHROMOSOMES PROVIDES CLUES TO EARLY STAGES IN CIRCULARIZED GENE AMPLIFICATION IN LIPOSARCOMA
Shamik Mitra
Favorite
Miyaki, Aya

Seattle Children's Research Institute
(P 447) TARGETING FOCAL ADHESION KINASE AUGMENTS THE THERAPEUTIC POTENTIAL OF BROMODOMAIN INHIBITORS IN EWING SARCOMA
Aya Miyaki
Favorite
(P 448) CAF-LIKE EWING SARCOMA CELLS DEPOSIT PRO-TUMORIGENIC EXTRACELLULAR MATRIX IN RESPONSE TO TGF-BETA SIGNALING
Aya Miyaki
Favorite
Miyakoshi, Naohisa

Akita University Graduate School Of Medicine
(P 05) COEFFICIENT OF VARIATION OF T2-WEIGHTED MRI PREDICTS THE PROGNOSIS OF MALIGNANT PERIPHERAL NERVE SHEATH TUMOR
Naohisa Miyakoshi
Favorite
Miyakoshi, Naohisa

Akita University Graduate School of Medicine
(P 469) IMPACT OF A SPECIALIZED OUTPATIENT CLINIC ON BONE MRTASTASIS AND ITS BURDEN ON SPINE SURGEONS
Naohisa Miyakoshi
Favorite
(P 470) PROGNOSTIC SIGNIFICANCE OF HISTOLOGICAL SUBTYPE IN SOFT TISSUE SARCOMA WITH DISTANT METASTASIS
Naohisa Miyakoshi
Favorite
(P 471) IMPACT OF PRIMARY TUMOR RESECTION ON METASTASIS TO THE LUNG IN PATIENTS WITH BONE AND SOFT-TISSUE SARCOMA
Naohisa Miyakoshi
Favorite
(P 486) PRIMARY HIGH-GRADE SARCOMA OF THE SPINE: EXPERIENCE WITH 11 CASES
Naohisa Miyakoshi
Favorite
Miyazaki, Bunpei

Department of Pediatric Oncology and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
(P 80) OPTIMIZING DOSE OF MAP THERAPY FOR CHILDREN, YOUNG ADULTS AND ADULTS WITH OSTEOSARCOMA; A SINGLE-CENTRE RETROSPECTIVE ANALYSIS
Bunpei Miyazaki
Favorite
Mizushima, Emi

Sapporo Medical University School of Medicine
(P 470) PROGNOSTIC SIGNIFICANCE OF HISTOLOGICAL SUBTYPE IN SOFT TISSUE SARCOMA WITH DISTANT METASTASIS
Emi Mizushima
Favorite
(P 471) IMPACT OF PRIMARY TUMOR RESECTION ON METASTASIS TO THE LUNG IN PATIENTS WITH BONE AND SOFT-TISSUE SARCOMA
Emi Mizushima
Favorite
Moalla, Salma

Department of Pediatric and Adolescent Oncology, Gustave-Roussy, Université Paris-Saclay
(P 209) PROGNOSTIC VALUE OF EARLY RADIOLOGIC TUMOUR VOLUME RESPONSE IN RHABDOMYOSARCOMA; RESULTS OF THE EUROPEAN PAEDIATRIC SOFT TISSUE SARCOMA STUDY GROUP RMS 2005 STUDY
Salma Moalla
Favorite
Moawad, Ahmed

University of Texas MD Anderson Cancer Center
(P 233) MULTI-CENTER EXTERNAL VALIDATION OF AN AUTOMATED MODEL DIFFERENTIATING ALT FROM LIPOMA USING RADIOMICS AND DEEP-LEARNING BASED SEGMENTATION
Ahmed Moawad
Favorite
Modiano, Jaime

University of Minnesota
(P 361) MOLECULAR CHARACTERIZATION OF SOLITARY FIBROUS TUMORS BY ANATOMIC SITE AND NAB2::STAT6 FUSION VARIANT TYPE
Jaime Modiano
Favorite
(P 401) OVEREXPRESSION OF CYCLIN DEPENDENT KINASES AND CYCLINS ACROSS SARCOMAS BEYOND CDK4
Jaime Modiano
Favorite
Modi, shruti

University College London
(P 493) GAIT KINEMATICS OF SARCOMA PATIENTS AT 1 YEAR POST-OPERATIVE INTERNAL HEMIPELVECTOMY SURGERY: A RETROSPECTIVE STUDY.
shruti Modi
Favorite
Moertel, Christopher

University of Minnesota
(P 252) STUDY OF NUTRACEUTICAL INTERVENTION WITH HIGH PHENOLIC EXTRA VIRGIN OLIVE OIL AND CURCUMIN FOR NEUROFIBROMATOSIS TYPE 1
Christopher Moertel
Favorite
Mogal, Harveshp

University of Washington
(P 177) ANGIOSARCOMA: AN INCREASING PROBLEM IN THE UNITED STATES
Harveshp Mogal
Favorite
(P 206) A SINGLE-ARM, PHASE II STUDY OF NEOADJUVANT PEMBROLIZUMAB COMBINED WITH RADIOTHERAPY IN THE PRIMARY TREATMENT OF SOFT TISSUE SARCOMAS.
Harveshp Mogal
Favorite
Molina, Jennifer

Ribon Therapeutics
(P 300) ANTI-TUMOR ACTIVITY OF PARP7 INHIBITOR RBN-2397 IN SOFT-TISSUE SARCOMAS
Jennifer Molina
Favorite
Molloy, alan

St Vincents University Hospital
(P 155) THE IMPACT OF THE ROLE OF A SARCOMA ADVANCED NURSE PRACTITIONER (ANP) BIOPSY CLINIC IN IMPROVING PATIENT ACCESS TO SARCOMA SERVICES
alan Molloy
Favorite
(P 156) PATIENT REPORTED EXPERIENCES WITHIN THE IRISH SARCOMA GROUP
alan Molloy
Favorite
(P 217) CONTEMPORARY TREATMENT PATTERNS AND OUTCOMES IN THE MANAGEMENT OF ANGIOSARCOMA IN IRELAND
alan Molloy
Favorite
Molloy, Catherine

SVUH
(P 213) EXPERIENCE WITH THE USE OF TRABECTEDIN IN ADVANCED SOFT TISSUE SARCOMA IN IRELAND
Catherine Molloy
Favorite
Mona, Shafey

Tom Baker Cancer Center
(P 110) GCAR1: GPNMB CAR T THERAPY FOR MIT FAMILY TRANSLOCATION POSITIVE CANCERS
Shafey Mona
Favorite
Mondaza-Hernandez, Jose

Health Research Institute-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM),
(P 174) SELISARC: A SPANISH GROUP FOR RESEARCH IN SARCOMA (GEIS) PHASE I/II TRIAL OF SELINEXOR PLUS GEMCITABINE IN SELECTED SARCOMA SUBTYPES: RESULTS OF THE PHASE I PART
Jose Mondaza-Hernandez
Favorite
(P 261) EFFICACY OF BET INHIBITORS IN SOLITARY FIBROUS TUMOR: AN IN VITRO EVALUATION
Jose Mondaza-Hernandez
Favorite
(P 270) ALTERNATIVE SPLICING (AS) REGULATION AS A NOVEL THERAPEUTIC TARGET IN SOFT-TISSUE SARCOMA (STS)
Jose Mondaza-Hernandez
Favorite
(P 279) PROTEIN PHOSPHATASE 2 A INHIBITION AS A MECHANISM TO ENHANCE DOXORUBICIN ACTIVITY
Jose Mondaza-Hernandez
Favorite
Monga, Varun

UCSF Helen Diller Family Comprehensive Cancer Center
(P 115) EFFICACY AND CORREALTIVE ANALYSIS OF USING NEOADJUVANT INTRATUMORAL HIGH DOSE TALIMOGENE LAHERPAREPVEC (TVEC) WITH CONCURRENT RADIATION IN HIGH-RISK EXTREMITY AND TRUNK SOFT-TISSUE SARCOMAS
Varun Monga
Favorite
(P 180) HEALTH RELATED QUALITY OF LIFE OF PATIENTS WITH ADVANCED LEIOMYOSARCOMA AND OTHER SOFT TISSUE SARCOMAS TREATED WITH CABOZANTINIB AND TEMOZOLOMIDE
Varun Monga
Favorite
Monga, Varun

University of Iowa
(P 286) EPIGENETIC MECHANISMS AND SIGNATURES OF SARCOMA PROGRESSION AND METASTASIS
Varun Monga
Favorite
Montermini, Laura

McGill University
(P 65) PROFILING EXTRACELLULAR VESICLES AND NANOPARTICLES IN OSTEOSARCOMA
Laura Montermini
Favorite
Montes, Matias

Stanford University
(P 94) DEVELOPING NOVEL OLIGONUCLEOTIDE THERAPIES TO MODULATE INSULIN RECEPTOR ALTERNATIVE SPLICING IN PEDIATRIC BONE SARCOMAS
Matias Montes
Favorite
Montes, Matias

Stanford
(P 305) A NEW MOUSE MODEL FOR TESTING SPLICE-SWITCHING THERAPIES IN RHABDOMYOSARCOMA
Matias Montes
Favorite
Montgomery, Gisela

Invicro
(P 408) CHANGES IN COMPUTED TOMOGRAPHY FEATURES INDUCED BY BRIGIMADLIN (BI 907828) IN PATIENTS WITH LIPOSARCOMA: INSIGHTS FROM PHASE I STUDIES
Gisela Montgomery
Favorite
Montgomery, Nicole

Texas Childrens Hospital
(P 81) OPTIMIZING EWING SARCOMA AND OSTEOSARCOMA BIOPSY ACQUISITION: CONSENSUS RECOMMENDATIONS FROM THE CHILDREN'S ONCOLOGY GROUP BONE TUMOR COMMITTEE
Nicole Montgomery
Favorite
Monument, Michael

University of Calgary
(P 105) STING THERAPY INDUCES IMMUNOGENIC ANTI-TUMOR RESPONSES THAT ARE INDEPENDENT OF TUMOR STING EXPRESSION IN THE KP MODEL OF SOFT TISSUE SARCOMA
Michael Monument
Favorite
(P 106) CHARACTERIZATION OF AN IMMUNE COMPETENT, MURINE MODEL OF SOFT TISSUE SARCOMA
Michael Monument
Favorite
(P 110) GCAR1: GPNMB CAR T THERAPY FOR MIT FAMILY TRANSLOCATION POSITIVE CANCERS
Michael Monument
Favorite
(P 299) EXPLORING THE IMMUNOLIGHT MECHANISM OF ACTION IN A GENETICALLY ENGINEERED MOUSE MODEL OF SOFT TISSUE SARCOMA
Michael Monument
Favorite
(P 390) NOVEL ISOFORM DISCOVERY IN SARCOMA USING FULL-LENGTH PACBIO ISO-SEQ
Michael Monument
Favorite
(P 415) NEOADJUVANT RADIOTHERAPY MODULATES THE TUMOUR MICROENVIRONMENT OF UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Michael Monument
Favorite
(P 454) TREATMENT PATTERNS AND OUTCOMES IN PEDIATRIC AND ADULT PATIENTS WITH EWING AND UNDIFFERENTIATED ROUND BLUE CELL SARCOMAS IN ALBERTA
Michael Monument
Favorite
Moody, Karen

M.D. Anderson Children's Cancer Hospital (MDACC)
(P 532) MISTOSUS: A PHASE 2 STUDY OF ISCADOR® P IMMUNOTHERAPY FOR PATIENTS WITH RELAPSED OSTEOSARCOMA AND RESECTED PULMONARY METASTASES
Karen Moody
Favorite
Moore, Roxanne

University of Washington
(P 206) A SINGLE-ARM, PHASE II STUDY OF NEOADJUVANT PEMBROLIZUMAB COMBINED WITH RADIOTHERAPY IN THE PRIMARY TREATMENT OF SOFT TISSUE SARCOMAS.
Roxanne Moore
Favorite
Moradhkani, Ania

Sarcoma Oncology Center
(P 116) UPDATE ON SAINT: RESULTS OF 100 PATIENTS TREATED WITH IPILIMUMAB (I), NIVOLUMAB (N) AND TRABECTEDIN (T) AS FIRST LINE THERAPY FOR ADVANCED SOFT TISSUE SARCOMA [NCT03138161]
Ania Moradhkani
Favorite
(P 117) INTERIM ANALYSIS OF PHASE 2 STUDY: A METRONOMIC REGIMEN USING GEMCITABINE, DOXORUBICIN, DOCETAXEL AND NIVOLUMAB FOR ADVANCED LEIOMYOSARCOMA (NCT04535713)
Ania Moradhkani
Favorite
Moradi, Heerod

Texas A&M University
(P 239) CANCER RADIOMIC AND PERFUSION IMAGING (CARPI) AUTOMATED FRAMEWORK: VALIDATION ON MUSCULOSKELETAL TUMORS IN A SPECIALIZED CANCER CENTER
Heerod Moradi
Favorite
Moravek, Molly

University of Michigan, Department of Obstetrics and Gynecology
(P 07) IDENTIFYING CONCERNS OF ADOLESCENT AND YOUNG ADULT SARCOMA PATIENTS AND SURVIVORS FOLLOWING FERTIITY PRESERVATION
Molly Moravek
Favorite
Moreno Tellez, Cristiam

University of Colorado Anschutz Medical Campus
(P 552) RANDOMIZED PHASE II TRIAL OF CABOZANTINIB COMBINED WITH PD-1 AND CTLA-4 INHIBITION VERSUS CABOZANTINIB IN METASTATIC SOFT TISSUE SARCOMA.
Cristiam Moreno Tellez
Favorite
Moreno, Maria Jose

Hospital Clinico san Carlos
(P 149) PSYCOLOGICAL SNAPSHOT OF SARCOMA PATIENTS FROM AN ACADEMIC, UNIVERSITY CENTER, HOSPITAL CLÍNICO SAN CARLOS (HCSC), MADRID, A SARCOMA NATIONAL REFERRAL CENTRE IN SPAIN
Maria Jose Moreno
Favorite
Mor, Eyal

Peter MacCallum Cancer Center
(P 516) OUCOMES OF AGGRESSIVE RESECTION OF RADIATION INDUCED ANGIOSARCOMA OF THE BREAST
Eyal Mor
Favorite
Morin, Niall

University of Washington
(P 206) A SINGLE-ARM, PHASE II STUDY OF NEOADJUVANT PEMBROLIZUMAB COMBINED WITH RADIOTHERAPY IN THE PRIMARY TREATMENT OF SOFT TISSUE SARCOMAS.
Niall Morin
Favorite
Mori, Shiori

Nara Medical University
(P 259) LOVASTATIN INDUCES NOVEL CELL DEATH THROUGH THE IMPAIRED MITOCHONDRIA IRON UTILIZATION IN OSTEOASRCOMA CELLS.
Shiori Mori
Favorite
Moritani, Konosuke

Department of Colorectal Surgery, National Cancer Center Hospital, Tokyo, Japan
(P 332) SURGICAL OUTCOMES OF RETROPERITONEAL LIPOSARCOMA - SINGLE INSTITUTIONAL STUDY N JAPAN -
Konosuke Moritani
Favorite
Morosi, Carlo

Department of Radiology, Fondazione IRCSS Istituto Nazionale Tumori, Milan, Italy
(P 14) PERCUTANEOUS CRYOABLATION OF PROGRESSING EXTRA-ABDOMINAL DESMOID TUMOURS
Carlo Morosi
Favorite
(P 159) IN BETWEEN OF LYMPHOMAS AND SARCOMAS: WHERE DO HISTIOCYTIC AND DENDRITIC CELL NEOPLASMS (HDCN) STAND? A RETROSPECTIVE, MULTI-INSTITUTIONAL STUDY FROM THE ITALIAN SARCOMA GROUP (ISG)
Carlo Morosi
Favorite
(P 209) PROGNOSTIC VALUE OF EARLY RADIOLOGIC TUMOUR VOLUME RESPONSE IN RHABDOMYOSARCOMA; RESULTS OF THE EUROPEAN PAEDIATRIC SOFT TISSUE SARCOMA STUDY GROUP RMS 2005 STUDY
Carlo Morosi
Favorite
(P 329) DISTANT METASTASIS IN RETROPERITONEAL LEIOMYOSARCOMA: TUMOR SIZE, GRADE AND MORE?
Carlo Morosi
Favorite
(P 333) SYSTEMIC TREATMENT IN INTRA-ABDOMINAL DESMOID-TYPE FIBROMATOSIS: A SINGLE INSTITUTION RETROSPECTIVE CASE SERIES ANALYSIS
Carlo Morosi
Favorite
Morris, Jo

University of Birmingham
(P 282) AN EMBRYONIC ZEBRAFISH XENOGRAFT MODEL OF RHABDOMYOSARCOMA REVEALS GENOTYPE DEPENDENT TUMOUR VASCULARISATION DYNAMICS AND RESPONSE TO ANTI-ANGIOGENIC RECEPTOR TYROSINE KINASE INHIBITORS
Jo Morris
Favorite
Morrison, John

Division of Pediatric Hospital Medicine, Johns Hopkins All Children’s Hospital
(P 91) BLOOD TRANSFUSION AND SURVIVAL AMONG CHILD, ADOLESCENT, AND YOUNG ADULT PATIENTS WITH OSTEOSARCOMA: A RETROSPECTIVE COHORT STUDY
John Morrison
Favorite
Morrissy, Sorana

University of Calgary
(P 110) GCAR1: GPNMB CAR T THERAPY FOR MIT FAMILY TRANSLOCATION POSITIVE CANCERS
Sorana Morrissy
Favorite
(P 390) NOVEL ISOFORM DISCOVERY IN SARCOMA USING FULL-LENGTH PACBIO ISO-SEQ
Sorana Morrissy
Favorite
(P 415) NEOADJUVANT RADIOTHERAPY MODULATES THE TUMOUR MICROENVIRONMENT OF UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Sorana Morrissy
Favorite
Mortimer, Peter

AstraZeneca
(P 212) REPORT ON THE EWING SARCOMA PATIENTS ENROLLED IN ARM D OF THE ACSE-ESMART TRIAL: PHASE I/II STUDY OF THE PARP INHIBITOR OLAPARIB IN COMBINATION WITH IRINOTECAN IN CHILDREN WITH ADVANCED MALIGNANCIES
Peter Mortimer
Favorite
Mosha, Maua

Johns Hopkins All Children's Hospital
(P 193) Recent Trends in Sarcoma Trials for Children in the United States
Maua Mosha
Favorite
Motoi, Toru

Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital
(P 396) COMPREHENSIVE WHOLE-GENOME MOLECULAR PROFILING IN BONE AND SOFT TISSUE SARCOMA: MULTI-OMICS ANALYSIS OF 627 CASES ACROSS HISTOLOGIC SUBTYPES
Toru Motoi
Favorite
Mottard, Sophie

CIUSSS Est-de-l'Île-de-Montréal
(P 134) IMPACT OF THE PARTNERSHIP BETWEEN TERTIARY CENTERS AND NON-SARCOMA RADIOLOGY CENTERS.
Sophie Mottard
Favorite
Mott, Sarah

Holden Comprehensive Cancer Center
(P 115) EFFICACY AND CORREALTIVE ANALYSIS OF USING NEOADJUVANT INTRATUMORAL HIGH DOSE TALIMOGENE LAHERPAREPVEC (TVEC) WITH CONCURRENT RADIATION IN HIGH-RISK EXTREMITY AND TRUNK SOFT-TISSUE SARCOMAS
Sarah Mott
Favorite
Moura, David

Health Research Institute-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM),
(P 27) A MULTICENTER RETROSPECTIVE STUDY ON THE CLINICAL BEHAVIOR OF SDH-DEFICIENT GIST
David Moura
Favorite
(P 113) IMMUNOSARC II: A SPANISH SARCOMA GROUP (GEIS) PHASE IB TRIAL OF DOXORUBICIN AND DACARBAZINE PLUS NIVOLUMAB IN FIRST LINE OF ADVANCED LEIOMYOSARCOMA
David Moura
Favorite
(P 142) THE SARCOMA EUROPEAN AND LATIN AMERICAN NETWORK (SELNET) PROJECT: OVERVIEW OF THE MAIN RESULTS OF THE SELNET REGISTRY
David Moura
Favorite
(P 174) SELISARC: A SPANISH GROUP FOR RESEARCH IN SARCOMA (GEIS) PHASE I/II TRIAL OF SELINEXOR PLUS GEMCITABINE IN SELECTED SARCOMA SUBTYPES: RESULTS OF THE PHASE I PART
David Moura
Favorite
(P 175) TRABECTEDIN PLUS RADIOTHERAPY ON SYMPHTOMATIC ADVANCED SARCOMA PATIENTS, RESULTS FROM THE SYNERGIAS STUDY: A SPANISH GROUP FOR RESEARCH IN SARCOMA (GEIS) PHASE II STUDY
David Moura
Favorite
(P 261) EFFICACY OF BET INHIBITORS IN SOLITARY FIBROUS TUMOR: AN IN VITRO EVALUATION
David Moura
Favorite
(P 270) ALTERNATIVE SPLICING (AS) REGULATION AS A NOVEL THERAPEUTIC TARGET IN SOFT-TISSUE SARCOMA (STS)
David Moura
Favorite
(P 279) PROTEIN PHOSPHATASE 2 A INHIBITION AS A MECHANISM TO ENHANCE DOXORUBICIN ACTIVITY
David Moura
Favorite
Movva, Sujana

Memorial Sloan Kettering Cancer Center
(P 24) COMPREHENSIVE ANALYSIS OF THE GENOMIC LANDSCAPE AND CLINICAL BEHAVIOR IN GIST USING NEXT GENERATION SEQUENCING (NGS, MSK-IMPACT)
Sujana Movva
Favorite
(P 112) PHASE 1/2 STUDY OF YH001, A CTLA-4 ANTIBODY WITH THE SUBCUTANEOUSLY ADMINISTERED PD-L1 ANTIBODY ENVAFOLIMAB, WITH OR WITHOUT DOXORUBICIN IN PATIENTS WITH ADVANCED OR METASTATIC SOFT TISSUE SARCOMA
Sujana Movva
Favorite
Mozzarelli, Alessandro

NY University
(P 297) UNVEILING THE IMPACT OF INTRATUMORAL MICROBIOTA IN THE TREATMENT EFFICACY OF SOFT TISSUE SARCOMA
Alessandro Mozzarelli
Favorite
MUÑOZ, PAULA

Hospital Quironsalud Torrevieja
(P 407) PRECISION AND PERSONALIZED TREATMENT FOR SOFT TISSUE SARCOMAS. RESULTS OF A 10 PATIENTS SERIES WITH MOLECULAR PROFILING USING NEXT-GENERATION MASSIVE SEQUENCING
PAULA MUÑOZ
Favorite
Muehlenberg, Thomas

The West German Cancer Centre, University Hospital Essen
(P 234) GENOMIC LANDSCAPE OF CLEAR CELL SARCOMA
Thomas Muehlenberg
Favorite
(P 275) GIST-BSF1: A NOVEL SCF-DEPENDENT, WILD-TYPE KIT CELL LINE PLATFORM THAT ALLOWS RAPID GENERATION OF ISOGENIC SUBLINES WITH BOTH IMATINIB-SENSITIVE AND IMATINIB-RESISTANT GENOTYPES
Thomas Muehlenberg
Favorite
(P 276) REVISITING IN- AND OFF LABEL DRUGS FREQUENTLY USED IN METASTATIC GIST USING A BROAD IN VITRO PROFILING PANEL OF PRIMARY AND SECONDARY KIT AND PDGFRA-MUTANT GIST CELLS – CLINICAL IMPLICATIONS
Thomas Muehlenberg
Favorite
(P 294) DNA-DAMAGE REPAIR DYSREGULATION AND CHEMOTHERAPY RESPONSE IN SARCOMA MODELS
Thomas Muehlenberg
Favorite
Mueller, Boris

Memorial Sloan Kettering
(P 343) STEREOTACTIC BODY RADIATION THERAPY (SBRT) IN ADVANCED/RECURRENT RETROPERITONEAL SARCOMA: PRELIMINARY RESULTS
Boris Mueller
Favorite
Mueller, Ferenc

University of Birmingham
(P 282) AN EMBRYONIC ZEBRAFISH XENOGRAFT MODEL OF RHABDOMYOSARCOMA REVEALS GENOTYPE DEPENDENT TUMOUR VASCULARISATION DYNAMICS AND RESPONSE TO ANTI-ANGIOGENIC RECEPTOR TYROSINE KINASE INHIBITORS
Ferenc Mueller
Favorite
Mullen, John

Massachusetts General Hospital
(P 338) PREOPERATIVE RADIATION THERAPY IS NOT ASSOCIATED WITH ADVERSE POSTOPERATIVE OUTCOMES IN PATIENTS WITH RETROPERITONEAL SARCOMA
John Mullen
Favorite
Mullinax, John

Moffitt Cancer Center
(P 537) TGFβ IMPRINTED, EX VIVO EXPANDED UNIVERSAL DONOR NATURAL KILLER CELLS WITH CHEMOTHERAPY FOR RELAPSED BONE AND SOFT TISSUE SARCOMA - NCT05634369, REPORT FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION
John Mullinax
Favorite
Mullins, James

Duke University
(P 340) CENTRAL BOOST RADIATION THERAPY CAN ACHIEVE DURABLE LOCAL RESPONSE IN UNRESECTABLE RETROPERITONEAL SARCOMA
James Mullins
Favorite
Mumberg, Dominik

Adcendo ApS
(P 349) THE UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR-ASSOCIATED PROTEIN (UPARAP) IS AN ATTRACTIVE TARGET FOR THE DEVELOPMENT OF ANTIBODY DRUG CONJUGATES FOR TREATMENT OF MESENCHYMAL MALIGNANCIES
Dominik Mumberg
Favorite
Mundi, Prabhjot

Department of Medicine, Columbia University
(P 289) IDENTIFICATION OF EFFECTIVE THERAPEUTIC COMBINATIONS WITH THE NUCLEAR EXPORT PROTEIN INHIBITOR, SELINEXOR, IN PEDIATRIC SOLID TUMORS
Prabhjot Mundi
Favorite
Murahashi, Yasutaka

Sapporo Medical University School of Medicine
(P 05) COEFFICIENT OF VARIATION OF T2-WEIGHTED MRI PREDICTS THE PROGNOSIS OF MALIGNANT PERIPHERAL NERVE SHEATH TUMOR
Yasutaka Murahashi
Favorite
(P 470) PROGNOSTIC SIGNIFICANCE OF HISTOLOGICAL SUBTYPE IN SOFT TISSUE SARCOMA WITH DISTANT METASTASIS
Yasutaka Murahashi
Favorite
(P 471) IMPACT OF PRIMARY TUMOR RESECTION ON METASTASIS TO THE LUNG IN PATIENTS WITH BONE AND SOFT-TISSUE SARCOMA
Yasutaka Murahashi
Favorite
(P 486) PRIMARY HIGH-GRADE SARCOMA OF THE SPINE: EXPERIENCE WITH 11 CASES
Yasutaka Murahashi
Favorite
Murdaugh, Rebecca

Baylor College of Medicine
(P 121) IMPROVING THE EFFICACY OF GD2 CHIMERIC ANTIGEN RECEPTOR T-CELLS USING HISTONE DEACETYLASE INHIBITORS
Rebecca Murdaugh
Favorite
Murgas, Kevin

Department of Biomedical Informatics, Stony Brook University
(P 397) A MESENCHYMAL TISSUE LANDSCAPE TO STUDY OSTEOSARCOMA TUMOR HETEROGENEITY
Kevin Murgas
Favorite
Murphy, Erin

Cleveland Clinic
(P 308) OPTIMAL BIOLOGIC EFFECTIVE DOSE OF STEREOTACTIC BODY RADIOTHERAPY FOR METASTATIC AND RECURRENT SARCOMA
Erin Murphy
Favorite
(P 539) SARCOMA STEREOTACTIC BODY RADIOTHERAPY AND IMMUNE SYSTEM TRIAL
Erin Murphy
Favorite
Murphy, William

M.D Anderson cancer center
(P 221) EARLY RESULTS IN NOVEL USE OF CONTRAST-ENHANCED SUSCEPTIBILITY-WEIGHTED IMAGING IN THE ASSESSMENT OF RESPONSE AND PROGRESSION IN DESMOID FIBROMATOSIS: PILOT STUDY IN A SPECIALIZED CANCER INSTITUTION
William Murphy
Favorite
(P 239) CANCER RADIOMIC AND PERFUSION IMAGING (CARPI) AUTOMATED FRAMEWORK: VALIDATION ON MUSCULOSKELETAL TUMORS IN A SPECIALIZED CANCER CENTER
William Murphy
Favorite
(P 354) ROLE OF APPARENT DIFFUSION COEFFICIENT (ADC) MAP-BASED FIRST AND HIGH-ORDER RADIOMIC FEATURES IN DISCRIMINATING SACRAL CHORDOMAS AND CHONDROSARCOMAS WITH OVERLAPPING CONVENTIONAL IMAGING FEATURES
William Murphy
Favorite
(P 356) BASELINE AND POST-TREATMENT ADVANCED MRI OF EXTREMITIES SOFT-TISSUE NON-MYXOID UNDIFFERENTIATED PLEOMORPHIC SARCOMA.
William Murphy
Favorite
(P 357) APPARENT DIFFUSION COEFFICIENT (ADC) HIGH-ORDER RADIOMICS OF BASELINE AND POST-TREATMENT ADVANCED MRI OF EXTREMITY SOFT-TISSUE NON-MYXOID UNDIFFERENTIATED PLEOMORPHIC SARCOMA.
William Murphy
Favorite
(P 358) CONTRAST-ENHANCED SUSCEPTIBILITY IMAGING (CE-SWI) MORPHOLOGIC, FIRST & HIGH-ORDER RADIOMIC FEATURES VALUE IN ASSESSING TREATMENT RESPONSE IN EXTREMITY SOFT-TISSUE UNDIFFERENTIATED PLEOMORPHIC SARCOMA
William Murphy
Favorite
(P 359) ROLE OF PERFUSION WEIGHTED IMAGING WITH DYNAMIC CONTRAST ENHANCED (PWI/DCE) FOR THE TREATMENT ASSESSMENT OF EXTREMITY SOFT-TISSUE NON-MYXOID UNDIFFERENTIATED PLEOMORPHIC SARCOMA
William Murphy
Favorite
Murray, Hazel

St Vincents University Hospital, Elm Park, Dublin 4, Ireland
(P 155) THE IMPACT OF THE ROLE OF A SARCOMA ADVANCED NURSE PRACTITIONER (ANP) BIOPSY CLINIC IN IMPROVING PATIENT ACCESS TO SARCOMA SERVICES
Hazel Murray
Favorite
(P 156) PATIENT REPORTED EXPERIENCES WITHIN THE IRISH SARCOMA GROUP
Hazel Murray
Favorite
(P 213) EXPERIENCE WITH THE USE OF TRABECTEDIN IN ADVANCED SOFT TISSUE SARCOMA IN IRELAND
Hazel Murray
Favorite
(P 217) CONTEMPORARY TREATMENT PATTERNS AND OUTCOMES IN THE MANAGEMENT OF ANGIOSARCOMA IN IRELAND
Hazel Murray
Favorite
Murtas, Fabio

Oncology 1 Unit, Department of Oncology, Veneto Institute of Oncology IOV - IRCCS
(P 171) SEX DIFFERENCES IN OUTCOMES AND TOXICITY IN PATIENTS TREATED FOR SARCOMA IN A REFERENCE CENTER
Fabio Murtas
Favorite
(P 216) BRAIN METASTASES IN SARCOMA: A (NOT SO) RARE EVENT. THE EXPERIENCE OF A HIGH VOLUME CENTER
Fabio Murtas
Favorite
Murugesan, Manikandan

Department of Surgery, Division of Surgical Oncology, University of California San Diego
(P 29) COMBINATION TREATMENT WITH TEMOZOLOMIDE AND THE DEATH RECEPTOR-5 AGONIST INBRX-109 EFFECTIVELY TARGETS SUCCINATE DEHYDROGENASE -DEFICIENT GASTROINTESTINAL STROMAL TUMOR
Manikandan Murugesan
Favorite
Muscal, Jodi

Pfizer Inc
(P 556) EVALUATION OF PALBOCICLIB (IBRANCE®) IN COMBINATION WITH CHEMOTHERAPY IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY EWING SARCOMA OR NEUROBLASTOMA
Jodi Muscal
Favorite
Mussi, Chiara

Bayer HealthCare Pharmaceuticals
(P 353) UPDATED EFFICACY AND SAFETY OF LAROTRECTINIB IN ADULT PATIENTS WITH TRK FUSION SARCOMAS
Chiara Mussi
Favorite
Mutsaers, Anthony

Ontario Veterinary College University of Guelph
(P 304) A COMPARATIVE ANALYSIS OF METABOLIC FLEXIBILITY IN OSTEOSARCOMA CELLS
Anthony Mutsaers
Favorite
Myklebost, Ola

University of Bergen
(P 23) GENOMIC COMPLEXITY AS A BIOMARKER FOR ADJUVANT IMATINIB TREATMENT IN HIGH-RISK GASTROINTESTINAL STROMAL TUMOR
Ola Myklebost
Favorite
N
Nacev, Benjamin

University of Pittsburgh Hillman Cancer Center
(P 373) DEDIFFERENTIATED AND HIGH GRADE CHONDROSARCOMAS: HOW DOES ISOCITRATE DEHYDROGENASE STATUS APPRISE PROGNOSIS AND THERAPY?
Benjamin Nacev
Favorite
Nachankar, Ankita

MedAustron Ion therapy Center, Austria
(P 326) CARBON-ION RADIOTHERAPY FOR UNRESECTABLE PELVIC SARCOMAS/CHORDOMAS
Ankita Nachankar
Favorite
Nadesan, Puviindran

Duke University
(P 393) INVESTIGATING THE ROLE OF HDACS IN THE PROGRESSION OF METASTATIC UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Puviindran Nadesan
Favorite
Nagarkar, Ritika

University College London
(P 519) WHAT ARE THE EXPERIENCES OF GAIT, ACTIVITY LEVELS AND PHYSICAL FUNCTIONING IN PROXIMAL FEMORAL REPLACEMENT AFTER MUSCULOSKELETAL TUMORS?
Ritika Nagarkar
Favorite
Nagasawa, Hiroyuki

Akita University Graduate School of Medicine
(P 05) COEFFICIENT OF VARIATION OF T2-WEIGHTED MRI PREDICTS THE PROGNOSIS OF MALIGNANT PERIPHERAL NERVE SHEATH TUMOR
Hiroyuki Nagasawa
Favorite
(P 469) IMPACT OF A SPECIALIZED OUTPATIENT CLINIC ON BONE MRTASTASIS AND ITS BURDEN ON SPINE SURGEONS
Hiroyuki Nagasawa
Favorite
(P 470) PROGNOSTIC SIGNIFICANCE OF HISTOLOGICAL SUBTYPE IN SOFT TISSUE SARCOMA WITH DISTANT METASTASIS
Hiroyuki Nagasawa
Favorite
(P 471) IMPACT OF PRIMARY TUMOR RESECTION ON METASTASIS TO THE LUNG IN PATIENTS WITH BONE AND SOFT-TISSUE SARCOMA
Hiroyuki Nagasawa
Favorite
(P 486) PRIMARY HIGH-GRADE SARCOMA OF THE SPINE: EXPERIENCE WITH 11 CASES
Hiroyuki Nagasawa
Favorite
Nagasubramanian, Ramamoorthy

Nemours Children's Hospital
(P 161) EFFICACY, SAFETY, AND TREATMENT HOLD WAIT-AND-SEE OUTCOMES OF LAROTRECTINIB IN PEDIATRIC PATIENTS WITH TRK FUSION SARCOMAS
Ramamoorthy Nagasubramanian
Favorite
Nagulapally, Abhinav

Atrium Health Levine Children's Hospital
(P 266) ROMIDEPSIN DECREASES DNA DAMAGE REPAIR AND INCREASES SENSITIVITY TO CHEMOTHERAPY IN EWING SARCOMA
Abhinav Nagulapally
Favorite
Nakagawa, Makoto

Duke University
(P 72) CO-EXPRESSION OF LEUKOCYTE CYTOSOLIC PROTEIN 1 AND MATRIX METALLOPROTEINASES ARE INTEGRAL FOR METASTATIC PROGRESSION OF CHONDROSARCOMA
Makoto Nakagawa
Favorite
(P 375) IDENTIFICATION OF METASTATIC CELLS IN UNDIFFERENTIATED PLEOMORPHIC SARCOMA: SINGLE CELL RNA SEQUENCING AND CIBERSORT ANALYSIS
Makoto Nakagawa
Favorite
Nakagawa, Suely

AC Camargo Cancer Center
(P 192) ROLE OF MAGNETIC RESONANCE IMAGING IN THE PREDICTION OF HISTOLOGICAL GRADE IN SOFT TISSUE SARCOMAS.
Suely Nakagawa
Favorite
Nakagawa, Wilson

AC Camargo Cancer Center
(P 192) ROLE OF MAGNETIC RESONANCE IMAGING IN THE PREDICTION OF HISTOLOGICAL GRADE IN SOFT TISSUE SARCOMAS.
Wilson Nakagawa
Favorite
Nakahashi, Naoya

Sapporo Medical University School of Medicine
(P 05) COEFFICIENT OF VARIATION OF T2-WEIGHTED MRI PREDICTS THE PROGNOSIS OF MALIGNANT PERIPHERAL NERVE SHEATH TUMOR
Naoya Nakahashi
Favorite
(P 391) THE EXPRESSION OF PVR AND ITS CLINICOPATHOLOGICAL SIGNIFICANCE IN MPNST.
Naoya Nakahashi
Favorite
(P 486) PRIMARY HIGH-GRADE SARCOMA OF THE SPINE: EXPERIENCE WITH 11 CASES
Naoya Nakahashi
Favorite
Nakai, Sho

Osaka International Cancer Institute
(P 05) COEFFICIENT OF VARIATION OF T2-WEIGHTED MRI PREDICTS THE PROGNOSIS OF MALIGNANT PERIPHERAL NERVE SHEATH TUMOR
Sho Nakai
Favorite
Nakamura, Kenichi

National Cancer Center Hospital
(P 10) ATEZOLIZUMAB IN JAPANESE PATIENTS WITH ADVANCED ALVEOLAR SOFT PART SARCOMA: A MULTI-CENTER, SINGLE-ARM, INVESTIGATOR-INITIATED PHASE 2 TRIAL (NCCH1907)
Kenichi Nakamura
Favorite
Nakashima, Yasuharu

Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kyushu University
(P 406) EXTENSIVE ANALYSIS OF 59 SARCOMA-RELATED FUSION GENES IDENTIFIED PAZOPANIB AS A POTENTIAL INHIBITOR TO COL1A1-PDGFB FUSION GENE
Yasuharu Nakashima
Favorite
Nakata, Eiji

Okayama University Hospital
(P 16) ALVEOLAR SOFT PART SARCOMA: PROGRESS TOWARD IMPROVEMENT IN SURVIVAL? A NATIONWIDE DATABASE STUDY IN JAPAN
Eiji Nakata
Favorite
Nakayama, Robert

Department of Orthopaedic Surgery, Keio University School of Medicine
(P 396) COMPREHENSIVE WHOLE-GENOME MOLECULAR PROFILING IN BONE AND SOFT TISSUE SARCOMA: MULTI-OMICS ANALYSIS OF 627 CASES ACROSS HISTOLOGIC SUBTYPES
Robert Nakayama
Favorite
Nakazawa, Michael

MD Anderson Cancer Center
(P 360) TP53 ALTERATIONS IN SARCOMAS: AN ANALYSIS FROM THE AACR-GENIE DATABASE
Michael Nakazawa
Favorite
Nakken, Sigve

Oslo University Hospital
(P 23) GENOMIC COMPLEXITY AS A BIOMARKER FOR ADJUVANT IMATINIB TREATMENT IN HIGH-RISK GASTROINTESTINAL STROMAL TUMOR
Sigve Nakken
Favorite
Namløs, Heidi

Oslo University Hospital
(P 23) GENOMIC COMPLEXITY AS A BIOMARKER FOR ADJUVANT IMATINIB TREATMENT IN HIGH-RISK GASTROINTESTINAL STROMAL TUMOR
Heidi Namløs
Favorite
Nannini, Margherita

IRCSS Azienda Ospedaliero-Universitaria di Bologna
(P 27) A MULTICENTER RETROSPECTIVE STUDY ON THE CLINICAL BEHAVIOR OF SDH-DEFICIENT GIST
Margherita Nannini
Favorite
Napier, Christine

Garvan Institute of Medical Research
(P 386) GENOMIC PROFILING OF GYNAECOLOGICAL SARCOMAS: REPORT FROM THE AUSTRALIA-WIDE PRECISION ONCOLOGY PROGRAM
Christine Napier
Favorite
Napoli, Francesca

Department of Oncology, University of Turin
(P 262) ESTABLISHMENT AND CHARACTERIZATION OF THE FIRST RADIATION-INDUCED, PATIENT-DERIVED ANGIOSARCOMA CELL LINE
Francesca Napoli
Favorite
Napolitano, Andrea

The Royal Marsden NHS, London, UK
(P 49) EFFICACY OF RIPRETINIB IN A MULTICENTER EXPANDED ACCESS PROGRAM IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS HARBOURING NON-KIT EXON 11 MUTATIONS.
Andrea Napolitano
Favorite
(P 189) INTERNATIONAL RETROSPECTIVE STUDY FROM THE ULTRA-RARE SARCOMA WORKING GROUP ON LOW-GRADE FIBROMYXOID SARCOMA AND SCLEROSING EPITHELIOD FIBROSARCOMA: OUTCOME OF ADVANCED DISEASE AND SYSTEMIC THERAPIES
Andrea Napolitano
Favorite
Nara, Satoshi

Department of Hepatoibiliary and Pancreatic Surgery, National Cancer Center Hospital, Tokyo, Japan
(P 332) SURGICAL OUTCOMES OF RETROPERITONEAL LIPOSARCOMA - SINGLE INSTITUTIONAL STUDY N JAPAN -
Satoshi Nara
Favorite
Narasimhan, Supraja

Deciphera Pharmaceuticals, LLC
(P 173) SAFETY, EFFICACY, AND PATIENT-REPORTED OUTCOMES WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED PRIOR ANTI–COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 UPDATE
Supraja Narasimhan
Favorite
(P 176) SAFETY, EFFICACY, AND PATIENT-REPORTED OUTCOMES WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED NO PRIOR ANTI–COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 UPDATE
Supraja Narasimhan
Favorite
Nardi, Walter

Buenos Aires British Hospital
(P 460) IMPACT OF RESIDUAL TUMOR AFTER RE-EXCISION IN PATIENTS WITH PRIOR UNPLANNED RESECTION OF EXTREMITY AND TRUNK SOFT TISSUE SARCOMAS
Walter Nardi
Favorite
Nardo, Lorenzo

University of California Davis Health
(P 233) MULTI-CENTER EXTERNAL VALIDATION OF AN AUTOMATED MODEL DIFFERENTIATING ALT FROM LIPOMA USING RADIOMICS AND DEEP-LEARNING BASED SEGMENTATION
Lorenzo Nardo
Favorite
Narducci, Nadine

Department of Medicine, University of Padua School of Medicine, Padova, Italy
(P 378) MULTIOMICS PROFILING OF EPITHELIOID SARCOMA UNVEILS EPIGENETIC CIRCUITRIES THAT UNDERLIE THE PATHOBIOLOGY OF PROXIMAL AND CLASSIC SUBTYPES: RESULTS FROM THE ISG EPISOBS OBSERVATIONAL STUDY
Nadine Narducci
Favorite
Nargizyan, Anahit

Children's Hospital Los Angeles
(P 430) UNIQUE HISTOLOGIC MORPHOLOGY OF EWING SARCOMA CELLS THAT HARBOR TP53 MUTATIONS
Anahit Nargizyan
Favorite
Nascimento, Antonio

AC Camargo Cancer Center
(P 192) ROLE OF MAGNETIC RESONANCE IMAGING IN THE PREDICTION OF HISTOLOGICAL GRADE IN SOFT TISSUE SARCOMAS.
Antonio Nascimento
Favorite
Nash, Joshua

The Hospital for Sick Children
(P 260) TARGETING HOMOLOGOUS RECOMBINATION DEFICIENCY (HRD) IN LEIOMYOSARCOMA WITH COMBINATION OF PARP INHIBITORS (PARPI) AND CHEMOTHERAPY (CTX).
Joshua Nash
Favorite
(P 421) USING TRANSCRIPTOMICS TO IDENTIFY LEIOMYOSARCOMA PATIENTS AT RISK OF METASTASIS
Joshua Nash
Favorite
Nassif, Elise

University of Texas MD Anderson Cancer Center
(P 71) CHEMOTHERAPY AND PROGNOSTIC SIGNIFICANCE OF EXTENT OF DEDIFFERENTIATION IN DEDIFFERENTIATED PAROSTEAL OSTEOSARCOMA
Elise Nassif
Favorite
(P 100) HISTOLOGY SPECIFIC INTRATUMORAL B-CELL BIOLOGY IN ALVEOLAR SOFT-PART SARCOMAS (ASPS) IN RESPONSE TO DURVALUMAB-TREMELIMUMAB (D-T)
Elise Nassif
Favorite
(P 123) DEDIFFERENTIATED LIPOSARCOMAS TREATED WITH IMMUNE CHECKPOINT BLOCKADE: THE MD ANDERSON EXPERIENCE
Elise Nassif
Favorite
(P 360) TP53 ALTERATIONS IN SARCOMAS: AN ANALYSIS FROM THE AACR-GENIE DATABASE
Elise Nassif
Favorite
Nassif, Elise

MD Anderson Cancer Center
(P 394) LEIOMYOSARCOMA INTRATUMORAL MACROPHAGE INFILTRATES ARE ASSOCIATED WITH DISTINCT CLINICAL AND GENOMIC PRESENTATIONS
Elise Nassif
Favorite
Nathenson, Michael

Adaptimmune
(P 114) PRIMARY ANALYSIS OF EFFICACY AND SAFETY OF LETETRESGENE AUTOLEUCEL (LETE-CEL) AS FIRST-LINE TREATMENT FOR UNRESECTABLE OR METASTATIC SYNOVIAL SARCOMA (SS); SUBSTUDY 1 OF IGNYTE-ESO
Michael Nathenson
Favorite
Nathrath, Michaela

Klinikum Kassel
(P 230) SARCDBASE: A TOOL FOR DETECTION OF GENETIC ALTERATIONS IN SARCOMA
Michaela Nathrath
Favorite
(P 371) DISRUPTION OF THE TP53 LOCUS IN OSTEOSARCOMA LEADS TO TP53 PROMOTER GENE FUSIONS AND RESTORATION OF PARTS OF THE TP53 SIGNALLING PATHWAY
Michaela Nathrath
Favorite
Navarria, Pierina

IRCCS Humanitas Research Hospital
(P 327) LEARNING CURVE ANALYSIS IN RETROPERITONEAL SARCOMA SURGERY
Pierina Navarria
Favorite
Navarria, Pierina

Humanitas Research Hospital
(P 433) A 20-YEAR MONOCENTER EXPERIENCE ON CLINICAL CHARACTERISTICS AND OUTCOME OF EXTRASKELETAL EWING SARCOMA.
Pierina Navarria
Favorite
Navarria, Pierina

IRCCS Humanitas Research Hospital
(P 457) LONG-TERM FOLLOW-UP OF PATIENTS WITH ATYPICAL LIPOMATOUS TUMOR (ALT) TREATED WITH MARGINAL RESECTION IN A REFERRAL CENTER
Pierina Navarria
Favorite
Navarro, Willis

Aadi Bioscience
(P 540) PHASE 2, MULTICENTER, OPEN-LABEL BASKET TRIAL OF NAB-SIROLIMUS FOR MALIGNANT SOLID TUMORS HARBORING PATHOGENIC INACTIVATING ALTERATIONS IN TSC1 AND TSC2 (PRECISION I)
Willis Navarro
Favorite
Navas, Ana

Leiden University Medical Center
(P 56) CHARACTERIZATION OF DENOSUMAB TREATMENT RESPONSE ON MR PERFUSION IN GIANT CELL TUMORS OF BONE
Ana Navas
Favorite
Navid, Fariba

Children’s Hospital Los Angeles
(P 166) SARC038: A PHASE 2 STUDY OF REGORAFENIB IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH REFRACTORY OR RECURRENT OSTEOSARCOMA
Fariba Navid
Favorite
(P 430) UNIQUE HISTOLOGIC MORPHOLOGY OF EWING SARCOMA CELLS THAT HARBOR TP53 MUTATIONS
Fariba Navid
Favorite
(P 556) EVALUATION OF PALBOCICLIB (IBRANCE®) IN COMBINATION WITH CHEMOTHERAPY IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY EWING SARCOMA OR NEUROBLASTOMA
Fariba Navid
Favorite
Nazaretian, Ashot

Fox Chase Cancer Center
(P 287) ESTABLISHMENT AND GENOMIC VALIDATION OF NOVEL PATIENT-DERIVED XENOGRAFT MODELS FOR DRUG DISCOVERY IN GASTROINTESTINAL STROMAL TUMOR
Ashot Nazaretian
Favorite
Nazon, Charlotte

University Hospital of Strasbourg
(P 277) ANTI-GD2 SYNERGIZES WITH HYPOXIA PATHWAY TARGETING TO BLOCK OSTEOSARCOMA CELL PROLIFERATION AND MIGRATION.
Charlotte Nazon
Favorite
Ndengu, Andoyo

Memorial Sloan Kettering Cancer Center
(P 289) IDENTIFICATION OF EFFECTIVE THERAPEUTIC COMBINATIONS WITH THE NUCLEAR EXPORT PROTEIN INHIBITOR, SELINEXOR, IN PEDIATRIC SOLID TUMORS
Andoyo Ndengu
Favorite
Ndounga-Diakou, Lee Aymar

Gustave Roussy Cancer Campus
(P 75) REAL-WORLD DATA ON REGORAFENIB AND CABOZANTINIB IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH RELAPSED OSTEOSARCOMA AND EWING SARCOMA INCLUDED IN THE SACHA-FRANCE STUDY
Lee Aymar Ndounga-Diakou
Favorite
Neal, Audrey

Clear Cell Sarcoma Foundation
(P 20) CLEAR CELL SARCOMA: PATIENT REPORTED REAL WORLD EVIDENCE
Audrey Neal
Favorite
Neal, Jill

Clear Cell Sarcoma Foundation
(P 20) CLEAR CELL SARCOMA: PATIENT REPORTED REAL WORLD EVIDENCE
Jill Neal
Favorite
Nebchi, Souad

Gustave Roussy cancer Centre
(P 212) REPORT ON THE EWING SARCOMA PATIENTS ENROLLED IN ARM D OF THE ACSE-ESMART TRIAL: PHASE I/II STUDY OF THE PARP INHIBITOR OLAPARIB IN COMBINATION WITH IRINOTECAN IN CHILDREN WITH ADVANCED MALIGNANCIES
Souad Nebchi
Favorite
Neben-Wittich, Michelle

Mayo Clinic Minnesota
(P 312) MANAGEMENT OF ADULT HEAD AND NECK SOFT TISSUE SARCOMA: THE MAYO CLINIC EXPERIENCE
Michelle Neben-Wittich
Favorite
Neilson, John

Medical College of Wisconsin
(P 181) REAL-WORLD EXPERIENCE WITH LIPOSOMAL DOXORUBICIN IN METASTATIC AND LOCALLY ADVANCED SARCOMA
John Neilson
Favorite
(P 473) GROIN PAINS: APPROACHES AND OUTCOMES FOR INGUINOFEMORAL SOFT TISSUE SARCOMAS
John Neilson
Favorite
Nelson, C.

Huntsman Cancer Institute/University of Utah
(P 412) LEIOMYOSARCOMA POLYANEUPLOID CANCER CELLS DEVELOP IN RESPONSE TO CHEMOTHERAPY AND CONTRIBUTE TO CHEMORESISTANCE
C. Nelson
Favorite
Nelson, Marie

Children's National Hospital
(P 18) RETROSPECTIVE ANALYSIS ON OUTCOMES PEDIATRIC PATIENTS WITH SARCOMA AND LUNG METASTASES STATUS POST PNEUMONECTOMY VERSUS PARTIAL LUNG RESECTION
Marie Nelson
Favorite
Nessim, Carolyn

Department of Surgery, University of Ottawa
(P 152) EVALUATING DIAGNOSTIC APPROACHES TO DERMATOFIBROSARCOMA PROTUBERANS: AN OPPORTUNITY TO REDUCE THE NUMBER OF INTERVENTIONS
Carolyn Nessim
Favorite
(P 215) IMPACT OF FRONTLINE SYSTEMIC TREATMENT CHOICE ON CLINICAL OUTCOME IN ADVANCED LEIOMYOSARCOMA: A MULTI-CENTRE RETROSPECTIVE CANSARCC STUDY
Carolyn Nessim
Favorite
(P 342) THE EVALUATION AND OUTCOMES OF MESENTERIC AND INTRA-ABDOMINAL DESMOIDS: A TARPSWG STUDY
Carolyn Nessim
Favorite
Nester, Matthew

University of South Florida Morsani College of Medicine
(P 511) SIGNIFICANCE OF TIP TO APEX DISTANCE IN PATHOLOGICAL AND IMPENDING PATHOLOGICAL FRACTURES OF THE PROXIMAL FEMUR
Matthew Nester
Favorite
Neville, Kathleen

C4 Therapeutics
(P 178) INITIAL RESULTS FROM A PHASE 1 STUDY OF CFT8634, A NOVEL BIFUCTIONAL DEGRADATION ACTIVATING COMPOUND (BIDAC) DEGRADER OF BRD9, IN SYNOVIAL SARCOMA AND SMARCB1-NULL TUMORS
Kathleen Neville
Favorite
Ng, Cedric Chuan-Young

National Cancer Centre Singapore
(P 285) TUMOUR-INFILTRATING MAST CELLS IN ANGIOSARCOMAS CORRELATE WITH CLINCIAL PHENOTYPES AND IMMUNO-ONCOLOGY PATHWAYS
Cedric Chuan-Young Ng
Favorite
Ng, Gillian

Laboratory of Applied Human Genetics, Division of Medical Sciences, National Cancer Centre Singapore
(P 336) EVOLUTION AND PURSUIT OF EXCELLENCE IN SARCOMA MANAGEMENT IN AN ASIAN TERTIARY SARCOMA SPECIALISED CENTRE
Gillian Ng
Favorite
Ng, Patrick

The Jackson Laboratory for Genomic Medicine
(P 392) IMMUNOSUPPRESSIVE TUMOR MICROENVIRONMENT OF OSTEOSARCOMA
Patrick Ng
Favorite
Nguyen, Buo-Phuc

University Hospital Essen, Sarcoma Centre
(P 47) PATIENT SURVIVAL IN METASTATIC GIST WITH IMATINIB-SENSITIVE MUTATIONS: REAL WORLD DATA FROM GERMAN REFERRAL CENTER (2008-2021)
Buo-Phuc Nguyen
Favorite
Nguyen, Dao

Sylvester Comprehensive Cancer Center
(P 461) OUTCOMES FOR OLIGOMETASTATIC PULMONARY DISEASE RECURRENCE TREATED WITH SURGERY ALONE FOR PATIENTS WITH SOFT TISSUE SARCOMAS A CASE SERIES
Dao Nguyen
Favorite
Nguyen, Ferro

Children’s Hospital of Philadelphia
(P 565) AN EARLY PHASE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF PEEL-224 IN PATIENTS WITH ADVANCED SOLID TUMORS
Ferro Nguyen
Favorite
Nguyen, Sang

Vanderbilt University Medical Center
(P 211) AN ANALYSIS OF SELF-REPORTED DEPRESSION IN SARCOMA PATIENTS
Sang Nguyen
Favorite
Nica, Luminita

BC Cancer
(P 22) RECALL EXPERIENCE FOR SURVIVORS OF PEDIATRIC RHABDOMYOSARCOMA TREATED AT A SINGLE INSTITUTION BETWEEN 1970 AND 2010
Luminita Nica
Favorite
Nicholls, Audrey

Vanderbilt University Medical Center
(P 218) NEOADJUVANT CHEMOTHERPAY AND RADIATION DECREASES TUMOR SIZE, VIABILITY, AND RECURRENCE IN MULTIPLE LIPOSARCOMA SUBSETS
Audrey Nicholls
Favorite
Nielsen, Torsten

Department of Pathology and Laboratory Medicine, University of British Columbia
(P 267) NEW MOUSE MODEL OF SYNOVIAL SARCOMA BASED ON CONDITIONAL EXPRESSION IN MESENCHYMAL PROGENITORS
Torsten Nielsen
Favorite
(P 362) IDENTIFICATION OF A NOVEL INTERACTOR OF ENDOGENOUS SS18-SSX THROUGH MASS SPECTOMETRY-BASED ANALYSIS IN SYNOVIAL SARCOMA CELLS
Torsten Nielsen
Favorite
Niessen, Wiro

University of Groningen
(P 231) MINIMALLY INTERACTIVE SEGMENTATION OF SOFT-TISSUE TUMORS ON MRI AND CT USING DEEP LEARNING
Wiro Niessen
Favorite
(P 233) MULTI-CENTER EXTERNAL VALIDATION OF AN AUTOMATED MODEL DIFFERENTIATING ALT FROM LIPOMA USING RADIOMICS AND DEEP-LEARNING BASED SEGMENTATION
Wiro Niessen
Favorite
Nilsson, Jenny

Lund University
(P 371) DISRUPTION OF THE TP53 LOCUS IN OSTEOSARCOMA LEADS TO TP53 PROMOTER GENE FUSIONS AND RESTORATION OF PARTS OF THE TP53 SIGNALLING PATHWAY
Jenny Nilsson
Favorite
(P 372) COPY NUMBER GAIN OF MDM2 IN ROD-SHAPED CHROMOSOMES PROVIDES CLUES TO EARLY STAGES IN CIRCULARIZED GENE AMPLIFICATION IN LIPOSARCOMA
Jenny Nilsson
Favorite
Nishida, Yoshihiro

Nagoya University Hospital
(P 163) SELUMETINIB IN JAPANESE PEDIATRIC PATIENTS WITH SYMPTOMATIC INOPERABLE PLEXIFORM NEUROFIBROMA IN NEUROFIBROMATOSIS TYPE 1
Yoshihiro Nishida
Favorite
(P 396) COMPREHENSIVE WHOLE-GENOME MOLECULAR PROFILING IN BONE AND SOFT TISSUE SARCOMA: MULTI-OMICS ANALYSIS OF 627 CASES ACROSS HISTOLOGIC SUBTYPES
Yoshihiro Nishida
Favorite
Nishikawa, Tadaaki

National Cancer Center Hospital
(P 10) ATEZOLIZUMAB IN JAPANESE PATIENTS WITH ADVANCED ALVEOLAR SOFT PART SARCOMA: A MULTI-CENTER, SINGLE-ARM, INVESTIGATOR-INITIATED PHASE 2 TRIAL (NCCH1907)
Tadaaki Nishikawa
Favorite
Niu, Xiaohui

Department of Orthopaedic Oncology Surgery, Beijing Ji Shui Tan Hospital
(P 168) A PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF PEXIDARTINIB IN ASIAN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR
Xiaohui Niu
Favorite
(P 169) UPDATED EFFICACY AND SAFETY PROFILE OF PIMICOTINIB (ABSK021) IN TENOSYNOVIAL GIANT CELL TUMOR (TGCT): 1-YEAR FOLLOW-UP FROM PHASE 1B
Xiaohui Niu
Favorite
(P 543) MANEUVER STUDY: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF PIMICOTINIB (ABSK021) TO ASSESS THE EFFICACY AND SAFETY IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR
Xiaohui Niu
Favorite
Nomie, Krystle

BostonGene, Corp.
(P 420) COMPREHENSIVE MOLECULAR PROFILING AND TUMOR MICROENVIRONMENT CHARACTERISTICS OF RADIATION-INDUCED SARCOMA.
Krystle Nomie
Favorite
Nomikos, Julia

Lunenfeld-Tanenbaum Research Institute - Mount Sinai Hospital
(P 108) EFFECT OF TUMOUR-TARGETED HYPERTHERMIA AND CHEMOTHERAPY ON THE IMMUNE PROFILE OF A MURINE MODEL OF EMBRYONAL RHABDOMYOSARCOMA
Julia Nomikos
Favorite
Nonobe, Norie

Nagoya University Hospital
(P 163) SELUMETINIB IN JAPANESE PEDIATRIC PATIENTS WITH SYMPTOMATIC INOPERABLE PLEXIFORM NEUROFIBROMA IN NEUROFIBROMATOSIS TYPE 1
Norie Nonobe
Favorite
Noonan, Sinead

CUH
(P 213) EXPERIENCE WITH THE USE OF TRABECTEDIN IN ADVANCED SOFT TISSUE SARCOMA IN IRELAND
Sinead Noonan
Favorite
Norenberg, Ricarda

Chrestos Concept GmbH & Co. KG
(P 161) EFFICACY, SAFETY, AND TREATMENT HOLD WAIT-AND-SEE OUTCOMES OF LAROTRECTINIB IN PEDIATRIC PATIENTS WITH TRK FUSION SARCOMAS
Ricarda Norenberg
Favorite
(P 353) UPDATED EFFICACY AND SAFETY OF LAROTRECTINIB IN ADULT PATIENTS WITH TRK FUSION SARCOMAS
Ricarda Norenberg
Favorite
(P 550) ON-TRK: A NON-INTERVENTIONAL STUDY OF LAROTRECTINIB IN PATIENTS WITH TRK FUSION SOLID TUMORS
Ricarda Norenberg
Favorite
Norris, Madelaine

The Ohio State University
(P 347) INCIDENCE AND TIMING OF RECURRENCE AFTER ADJUVANT PALBOCICLIB IN COMPLETELY RESECTED RETROPERITONEAL LIPOSARCOMA
Madelaine Norris
Favorite
Noujaim, Jonathan

Hôpital Maisonneuve-Rosemont and McGill University Health Center
(P 114) PRIMARY ANALYSIS OF EFFICACY AND SAFETY OF LETETRESGENE AUTOLEUCEL (LETE-CEL) AS FIRST-LINE TREATMENT FOR UNRESECTABLE OR METASTATIC SYNOVIAL SARCOMA (SS); SUBSTUDY 1 OF IGNYTE-ESO
Jonathan Noujaim
Favorite
Novello, Silvia

Department of Oncology, San Luigi Hospital, University of Turin
(P 109) INTENSE PRECLINICAL ACTIVITY BY B7H3-SPECIFIC CAR.CIK LYMPHOCYTES AGAINST EPITHELIOID SARCOMA
Silvia Novello
Favorite
(P 550) ON-TRK: A NON-INTERVENTIONAL STUDY OF LAROTRECTINIB IN PATIENTS WITH TRK FUSION SOLID TUMORS
Silvia Novello
Favorite
Novotny, Jan Philipp

University of Heidelberg
(P 541) ETCTN 10563: PHASE 1 STUDY OF PEPOSERTIB AND LIPOSOMAL DOXORUBICIN FOR ADVANCED OR METASTATIC LEIOMYOSARCOMA AND OTHER SARCOMAS
Jan Philipp Novotny
Favorite
Nozzoli, Filippo

Histopathology and Molecular Diagnostics, Careggi University Hospital Florence, Italy
(P 455) EXTRASKELETAL EWING SARCOMA: A MULTICENTRIC RETROSPECTIVE STUDY FROM THE ITALIAN SARCOMA GROUP
Filippo Nozzoli
Favorite
Nunez, Claudia

Hospital de la Santa Creu i Sant Pau
(P 503) SCAPULAR PROSTHESIS RECONSTRUCTION, EXPERIENCE IN OUR INSTITUTION
Claudia Nunez
Favorite
(P 504) WHY DO SOME PATIENTS WITH SYNOVIAL SARCOMA HAVE BETTER FUNCTIONAL OUTCOMES AFTER RESECTION SURGERY? ANALYSIS OF 102 CASES
Claudia Nunez
Favorite
(P 507) PRIMARY CHEST WALL TUMORS OF MESENCHYMAL ORIGIN. EXPERIENCE OF A REFERENCE UNIT
Claudia Nunez
Favorite
Nunez, Osvaldo

University of Miami Miller School of Medicine
(P 225) PAN-SARCOMA DATABASE (PSDB): A MODEL-VIEW-CONTROLLER FRAMEWORK UTILIZING REDCAP, SHINY, AND R TO CREATE A CONTINUOUS PIPELINE OF SARCOMA DATA
Osvaldo Nunez
Favorite
(P 226) SIGNATERA TESTING TO IDENTIFY MINIMAL RESIDUAL DISEASE IN HIGH GRADE SARCOMA
Osvaldo Nunez
Favorite
(P 366) SURVIVAL DISPARITIES IN HISPANIC PATIENTS WITH SARCOMA TESTED WITH NEXT-GENERATION SEQUENCING (NGS)
Osvaldo Nunez
Favorite
Nur, Samira

UCL cancer Institute
(P 381) THE GENOMIC LANDSCAPE OF CLEAR CELL SARCOMA
Samira Nur
Favorite
Nystrom, Lukas

Cleveland Clinic
(P 242) WHOLE BODY PET/MRI FOR STAGING OF MYXOID LIPOSARCOMA
Lukas Nystrom
Favorite
(P 402) TISSUE PERFUSION AND WOUND HEALING AFTER SOFT TISSUE SARCOMA RESECTION
Lukas Nystrom
Favorite
(P 513) THE IMPACT OF MARGIN STATUS ON THE ONCOLOGIC OUTCOMES OF SURGICALLY TREATED DEDIFFERENTIATED LIPOSARCOMA OF THE EXTREMITIES
Lukas Nystrom
Favorite
(P 514) INTERSTITIAL BRACHYTHERAPY IN THE TREATMENT OF SOFT TISSUE SARCOMA: LOCAL RECURRENCE AND WOUND OUTCOMES
Lukas Nystrom
Favorite
O
Obeng-Gyasi, Samilia

The James Cancer Hospital / The Ohio State University
(P 314) PRE-OPERATIVE RADIATION THERAPY INCREASES ADHERENCE IN PATIENTS WITH HIGH-RISK EXTREMITY SOFT TISSUE SARCOMA
Samilia Obeng-Gyasi
Favorite
Oberley, Matthew

Caris Life Sciences
(P 361) MOLECULAR CHARACTERIZATION OF SOLITARY FIBROUS TUMORS BY ANATOMIC SITE AND NAB2::STAT6 FUSION VARIANT TYPE
Matthew Oberley
Favorite
(P 401) OVEREXPRESSION OF CYCLIN DEPENDENT KINASES AND CYCLINS ACROSS SARCOMAS BEYOND CDK4
Matthew Oberley
Favorite
Oberoi, Sapna

CancerCare Manitoba
(P 13) OUTCOME OF PATIENTS WITH RELAPSED OR REFRACTORY NON-RHABDOMYOSARCOMA SOFT TISSUE SARCOMAS ENROLLED IN PHASE II COOPERATIVE GROUP CLINICAL TRIALS: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP
Sapna Oberoi
Favorite
Oboldi, Devil

Irst
(P 364) EVALUATION OF THE PREDICTIVE ROLE OF SYSTEMIC AND INTRATUMORAL IMMUNITY IN PATIENTS WITH LOCALIZED LIPOSARCOMAS, MYXOFIBROSARCOMAS AND UNDIFFERENTIATED PLEOMORPHIS SARCOMAS
Devil Oboldi
Favorite
Obrador-Hevia, Antonia

Fundació Institutd'InvestigacióSanitàriaIlles Balears –IdISBa
(P 270) ALTERNATIVE SPLICING (AS) REGULATION AS A NOVEL THERAPEUTIC TARGET IN SOFT-TISSUE SARCOMA (STS)
Antonia Obrador-Hevia
Favorite
O'Connell, Michaela

Dana-Farber Cancer Institute
(P 384) SYSTEMATIC LITERATURE AND CLINICAL TRIAL REVIEW SHOWS TARGETABLE KINASE FUSIONS ARE COMMON IN PEDIATRIC, ADOLESCENT, AND YOUNG ADULT SOFT TISSUE SARCOMAS BUT CLINICAL TRIAL OPPORTUNITIES REMAIN RARE
Michaela O'Connell
Favorite
Oda, Yoshinao

Graduate School of Medical Sciences, Kyushu University
(P 396) COMPREHENSIVE WHOLE-GENOME MOLECULAR PROFILING IN BONE AND SOFT TISSUE SARCOMA: MULTI-OMICS ANALYSIS OF 627 CASES ACROSS HISTOLOGIC SUBTYPES
Yoshinao Oda
Favorite
O'Donohue, Tara

Memorial Sloan Kettering Cancer Center
(P 542) ENROLLMENT OF PEDIATRIC PARTICIPANTS WITH MAGE-A4-POSITIVE SOLID TUMORS IN A PHASE 1/2, OPEN-LABEL, BASKET TRIAL OF AFAMITRESGENE AUTOLEUCEL ("AFAMI-CEL")
Tara O'Donohue
Favorite
Oesterheld, Javier

Atrium Health Levine Children's Hospital
(P 266) ROMIDEPSIN DECREASES DNA DAMAGE REPAIR AND INCREASES SENSITIVITY TO CHEMOTHERAPY IN EWING SARCOMA
Javier Oesterheld
Favorite
(P 551) PHASE II TRIAL OF GEMCITABINE AND NAB-PACLITAXEL IN PATIENTS WITH RECURRENT RHABDOMYOSARCOMA: A CLINICAL TRIAL IN PROGRESS FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION
Javier Oesterheld
Favorite
Offer, Katharine

Joseph M. Sanzari Children's Hospital, Hackensack Meridian Health (HMH)
(P 532) MISTOSUS: A PHASE 2 STUDY OF ISCADOR® P IMMUNOTHERAPY FOR PATIENTS WITH RELAPSED OSTEOSARCOMA AND RESECTED PULMONARY METASTASES
Katharine Offer
Favorite
Ofverholm, Ingegerd

Oncology Pathology
(P 243) EVALUATION OF THE USE OF WGS IN ROUTINE DIAGNOSTICS FOR BONE AND SOFT TISSUE TUMORS
Ingegerd Ofverholm
Favorite
Ogata, Toshiyuki

Tokyo Dental College Ichikawa General Hospital
(P 87) ANGIOSARCOMA OF THE ILIUM TREATED WITH HEMIPELVECTOMY AND HIP TRANSPOSITION FOLLOWED BY POSTOPERATIVE CHEMOTHERAPY WITH PAZOPANIB: A CASE REPORT
Toshiyuki Ogata
Favorite
Ogawa, Chitose

Department of Pediatric Oncology, National Cancer Center Hospital, Tokyo, Japan
(P 80) OPTIMIZING DOSE OF MAP THERAPY FOR CHILDREN, YOUNG ADULTS AND ADULTS WITH OSTEOSARCOMA; A SINGLE-CENTRE RETROSPECTIVE ANALYSIS
Chitose Ogawa
Favorite
Ogilvie, Christian

University of Minnesota
(P 167) FDG-PET-CT RESPONSE AFTER NEOADJUVANT CHEMOTHERAPY PREDICTS LONG-TERM OUTCOME IN PATIENTS WITH SOFT TISSUE SARCOMA -- 15-YEAR FOLLOW-UP
Christian Ogilvie
Favorite
Ogilvie, Travis

University of Calgary
(P 110) GCAR1: GPNMB CAR T THERAPY FOR MIT FAMILY TRANSLOCATION POSITIVE CANCERS
Travis Ogilvie
Favorite
Ogura, Koichi

National Cancer Center Hospital
(P 189) INTERNATIONAL RETROSPECTIVE STUDY FROM THE ULTRA-RARE SARCOMA WORKING GROUP ON LOW-GRADE FIBROMYXOID SARCOMA AND SCLEROSING EPITHELIOD FIBROSARCOMA: OUTCOME OF ADVANCED DISEASE AND SYSTEMIC THERAPIES
Koichi Ogura
Favorite
Ohm, Joyce

Roswell Park Comprehensive Cancer Center
(P 247) HARNESSING EWING SARCOMA'S REPLICATION STRESS BY TARGETING DDK AND WEE1 IN COMBINATION
Joyce Ohm
Favorite
Okada, Seiji

Osaka University
(P 05) COEFFICIENT OF VARIATION OF T2-WEIGHTED MRI PREDICTS THE PROGNOSIS OF MALIGNANT PERIPHERAL NERVE SHEATH TUMOR
Seiji Okada
Favorite
O'Keefe, Kylie

PTC Therapeutics, Inc.
(P 182) UPDATED RESULTS FROM AN ONGOING PHASE 1B STUDY OF UNESBULIN (PTC596) PLUS DACARBAZINE FOR THE TREATMENT OF PATIENTS WITH ADVANCED LEIOMYOSARCOMA
Kylie O'Keefe
Favorite
(P 548) A PHASE 2/3 STUDY EVALUATING THE EFFICACY AND SAFETY OF UNESBULIN IN ADVANCED LEIOMYOSARCOMA (SUNRISELMS)
Kylie O'Keefe
Favorite
Okita, Natsuko

Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
(P 35) GENOMIC ALTERATIONS IN ADVANCED GASTROINTESTINAL STROMAL TUMORS AS REVEALED BY COMPREHENSIVE GENOMIC PROFILING TESTS
Natsuko Okita
Favorite
(P 547) A PHASE II TRIAL OF TAZEMETOSTAT FOR PATIENTS WITH UNRESECTABLE OR METASTATIC EPITHELIOID SARCOMA (TAZETTA TRIAL)
Natsuko Okita
Favorite
Okuma, Hitomi

National Cancer Center Hospital
(P 10) ATEZOLIZUMAB IN JAPANESE PATIENTS WITH ADVANCED ALVEOLAR SOFT PART SARCOMA: A MULTI-CENTER, SINGLE-ARM, INVESTIGATOR-INITIATED PHASE 2 TRIAL (NCCH1907)
Hitomi Okuma
Favorite
Okuno, Scott

Mayo Clinic
(P 02) PEDIATRIC SYNOVIAL SARCOMA: A REVIEW OF 21 CASES FROM A SINGLE INSTITUTION
Scott Okuno
Favorite
(P 61) ADJACENT VENOUS TUMOR THROMBUS IN PRIMARY OSTEOSARCOMA OF THE PELVIS AND EXTREMITIES
Scott Okuno
Favorite
(P 180) HEALTH RELATED QUALITY OF LIFE OF PATIENTS WITH ADVANCED LEIOMYOSARCOMA AND OTHER SOFT TISSUE SARCOMAS TREATED WITH CABOZANTINIB AND TEMOZOLOMIDE
Scott Okuno
Favorite
(P 191) SARC024 COHORT D: PHASE 2 TRIAL OF REGORAFENIB IN CHILDREN, ADOLESCENTS, AND ADULTS WITH RHABDOMYOSARCOMA
Scott Okuno
Favorite
(P 196) TOLERABILITY AND OUTCOMES FOR TREATMENT OF OLDER MYXOID LIPOSARCOMA POPULATION
Scott Okuno
Favorite
(P 440) LONG TERM OUTCOMES OF EWING SARCOMA OF THE FOOT AND ANKLE
Scott Okuno
Favorite
(P 465) UNPLANNED EXCISION OF SYNOVIAL SARCOMA: FACTORS ASSOCIATED WITH RECURRENCE AND SURVIVAL
Scott Okuno
Favorite
(P 518) OUTCOMES OF NON-ANGIOSARCOMA RADIATION-ASSOCIATED SOFT TISSUE SARCOMAS OF THE CHEST
Scott Okuno
Favorite
Okunowo, Oluwatimilehin

City of Hope Comprehensive Cancer Center
(P 180) HEALTH RELATED QUALITY OF LIFE OF PATIENTS WITH ADVANCED LEIOMYOSARCOMA AND OTHER SOFT TISSUE SARCOMAS TREATED WITH CABOZANTINIB AND TEMOZOLOMIDE
Oluwatimilehin Okunowo
Favorite
Olariu, Radu

Department of Plastic and Hand Surgery, Inselspital University Hospital Bern
(P 152) EVALUATING DIAGNOSTIC APPROACHES TO DERMATOFIBROSARCOMA PROTUBERANS: AN OPPORTUNITY TO REDUCE THE NUMBER OF INTERVENTIONS
Radu Olariu
Favorite
Olino, Kelly

Yale University
(P 158) SORAFENIB OR ANTHRACYCLINE-BASED CHEMOTHERAPY IN ADULT PATIENTS WITH PROGRESSIVE DESMOID TUMORS
Kelly Olino
Favorite
Olivares, Simon

The University of Texas MD Anderson Cancer Center
(P 119) EX VIVO EXPANDED TUMOR INFILTRATING LYMPHOCYTES FOR SARCOMA TREATMENT
Simon Olivares
Favorite
Olivero, Martina

Department of Oncology, University of Turin
(P 262) ESTABLISHMENT AND CHARACTERIZATION OF THE FIRST RADIATION-INDUCED, PATIENT-DERIVED ANGIOSARCOMA CELL LINE
Martina Olivero
Favorite
Oliveti, Luna

Department of Chemistry "Giacomo Ciamician", University of Bologna, 40126 Bologna, Italy
(P 253) THE EFFICACY OF MEDICATED PATCHES IN SOFT TISSUE SARCOMAS: IN-VITRO AND EX-VIVO VALIDATION.
Luna Oliveti
Favorite
Ollarves, Maria Fernanda

Hospital Clínico San Carlos
(P 515) ENDOBRONCHIAL NAVIGATION AS AN INTRAOPERATORY TOOL FOR RESECTION OF SMALL PULMONARY METASTASES IN SARCOMA PATIENTS
Maria Fernanda Ollarves
Favorite
Olson, Adam

UPMC Hillman Cancer Center
(P 445) ISOTOXIC RADIOTHERAPY DOSE ESCALATION IN UNRESECTABLE PEDIATRIC EWING SARCOMA: A DOSIMETRIC FEASIBILITY STUDY
Adam Olson
Favorite
Olszanski, Anthony

Fox Chase Cancer Center
(P 164) INTRATUMORAL INT230-6 (CISPLATIN, VINBLASTINE, SHAO) ALONE OR WITH IPILIMUMAB PROLONGED SURVIVAL WITH FAVORABLE SAFETY AND IMMUNE ACTIVATION IN ADULTS WITH REFRACTORY SARCOMAS (NCT 03058289)
Anthony Olszanski
Favorite
O'Mahony, Deirdre

Bon Secours, Cork
(P 213) EXPERIENCE WITH THE USE OF TRABECTEDIN IN ADVANCED SOFT TISSUE SARCOMA IN IRELAND
Deirdre O'Mahony
Favorite
Omelchenko, Aleksei

Sarcoma Oncology Center
(P 383) AI ANALYSIS SHOWS ENHANCED CCNG1 ONCOGENE EXPRESSION IN SARCOMA TUMORS AND SUPPORTS THE USE OF DELTAREX-G, A CCNG1 INHIBITOR, AS PLATFORM THERAPY FOR ADVANCED SARCOMA
Aleksei Omelchenko
Favorite
Omelchenko, Nadezhda

Sarcoma Oncology Center
(P 116) UPDATE ON SAINT: RESULTS OF 100 PATIENTS TREATED WITH IPILIMUMAB (I), NIVOLUMAB (N) AND TRABECTEDIN (T) AS FIRST LINE THERAPY FOR ADVANCED SOFT TISSUE SARCOMA [NCT03138161]
Nadezhda Omelchenko
Favorite
(P 117) INTERIM ANALYSIS OF PHASE 2 STUDY: A METRONOMIC REGIMEN USING GEMCITABINE, DOXORUBICIN, DOCETAXEL AND NIVOLUMAB FOR ADVANCED LEIOMYOSARCOMA (NCT04535713)
Nadezhda Omelchenko
Favorite
(P 383) AI ANALYSIS SHOWS ENHANCED CCNG1 ONCOGENE EXPRESSION IN SARCOMA TUMORS AND SUPPORTS THE USE OF DELTAREX-G, A CCNG1 INHIBITOR, AS PLATFORM THERAPY FOR ADVANCED SARCOMA
Nadezhda Omelchenko
Favorite
(P 553) A PHASE 1/2A OPEN-LABEL, DOSE-ESCALATION/DOSE EXPANSION SAFETY, TOLERABILITY AND PHARMACOKINETIC STUDY OF IMX-110 IN PATIENTS WITH ADVANCED SOLID TUMORS
Nadezhda Omelchenko
Favorite
Omer, Bilal

Texas Children's Hospital / Baylor College of Medicine, Center for Cell and Gene Therapy
(P 121) IMPROVING THE EFFICACY OF GD2 CHIMERIC ANTIGEN RECEPTOR T-CELLS USING HISTONE DEACETYLASE INHIBITORS
Bilal Omer
Favorite
O'Neill, Brianne

Inhibrx, Inc
(P 439) THE TETRAVALENT DEATH RECEPTOR 5 AGONIST INBRX-109 COMBINED WITH CHEMOTHERAPY IN EWING SARCOMA: PRELIMINARY DATA FROM A PHASE 1 STUDY
Brianne O'Neill
Favorite
Ongenaet, Anais

Ghent University
(P 291) DEVELOPMENT OF A LIVE TISSUE SARCOMA BIOBANK TO SUPPORT THE CREATION OF PATIENT-DERIVED TRANSLATIONAL MODELS
Anais Ongenaet
Favorite
Ong, Johnny

Department of Sarcoma, Peritoneal and Rare Tumours (SPRinT), Division of Surgery and Surgical Oncology, National Cancer Centre Singapore
(P 336) EVOLUTION AND PURSUIT OF EXCELLENCE IN SARCOMA MANAGEMENT IN AN ASIAN TERTIARY SARCOMA SPECIALISED CENTRE
Johnny Ong
Favorite
Ong, Whee Sze

Division of Clinical Trials and Epidemiological Sciences, National Cancer Centre Singapore
(P 82) PROGNOSTIC FACTORS AND OUTCOMES OF 275 PATIENTS WITH HEAD AND NECK BONE AND SOFT TISSUE SARCOMA: A SINGLE CENTRE COHORT STUDY
Whee Sze Ong
Favorite
Oosten, Astrid

Erasmus MC Cancer Institute
(P 27) A MULTICENTER RETROSPECTIVE STUDY ON THE CLINICAL BEHAVIOR OF SDH-DEFICIENT GIST
Astrid Oosten
Favorite
(P 30) FINANCIAL DIFFICULTIES EXPERIENCED BY DUTCH GASTROINTESTINAL STROMAL TUMOR (GIST) PATIENTS: DATA FROM A CROSS-SECTIONAL MULTICENTER STUDY
Astrid Oosten
Favorite
Orbach, Daniel

SIREDO Oncology Center (Care, Innovation and Research for Children and AYA with Cancer), Institut Curie, and University PSL
(P 161) EFFICACY, SAFETY, AND TREATMENT HOLD WAIT-AND-SEE OUTCOMES OF LAROTRECTINIB IN PEDIATRIC PATIENTS WITH TRK FUSION SARCOMAS
Daniel Orbach
Favorite
(P 202) INFLAMMATORY MYOFIBROBLASTIC TUMOUR WITH ROS1 GENE FUSIONS IN CHILDREN AND YOUNG ADOLESCENTS
Daniel Orbach
Favorite
(P 209) PROGNOSTIC VALUE OF EARLY RADIOLOGIC TUMOUR VOLUME RESPONSE IN RHABDOMYOSARCOMA; RESULTS OF THE EUROPEAN PAEDIATRIC SOFT TISSUE SARCOMA STUDY GROUP RMS 2005 STUDY
Daniel Orbach
Favorite
Orbis Castellanos, Juan Francisco

Department of Surgery, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
(P 385) FIRST IN HUMAN PHASE I TRIAL OF A NOVEL DRUG DELIVERY IMPLANT MATRIX WITH SN-38 (CEB-01) FOR RETROPERITONEAL SOFT TISSUE SARCOMA
Juan Francisco Orbis Castellanos
Favorite
Orellana, Ruth

Hospital de la Santa Creu i Sant Pau
(P 503) SCAPULAR PROSTHESIS RECONSTRUCTION, EXPERIENCE IN OUR INSTITUTION
Ruth Orellana
Favorite
(P 504) WHY DO SOME PATIENTS WITH SYNOVIAL SARCOMA HAVE BETTER FUNCTIONAL OUTCOMES AFTER RESECTION SURGERY? ANALYSIS OF 102 CASES
Ruth Orellana
Favorite
(P 507) PRIMARY CHEST WALL TUMORS OF MESENCHYMAL ORIGIN. EXPERIENCE OF A REFERENCE UNIT
Ruth Orellana
Favorite
(P 508) DREAM, UTOPIA OR REALISM? PROGNOSTIC FACTORS IN LUNG METASTASECTOMY OF DISSEMINATED SARCOMA DISEASE
Ruth Orellana
Favorite
Oristian, Kristianne

Duke University
(P 428) COMPREHENSIVE GENOMIC PROFILING OF CIC-DUX4 SARCOMA (CDS) CELL LINES AND MODELS
Kristianne Oristian
Favorite
(P 450) INVESTIGATING THE THERAPEUTIC POTENTIAL OF SMALL MOLECULE INHIBITOR INOBRODIB AS A TREATMENT ALTERNATIVE FOR CIC-DUX4 SARCOMA
Kristianne Oristian
Favorite
Orosco-Ttamina, Angel Luis

Sarcoma Oncology Center
(P 116) UPDATE ON SAINT: RESULTS OF 100 PATIENTS TREATED WITH IPILIMUMAB (I), NIVOLUMAB (N) AND TRABECTEDIN (T) AS FIRST LINE THERAPY FOR ADVANCED SOFT TISSUE SARCOMA [NCT03138161]
Angel Luis Orosco-Ttamina
Favorite
(P 117) INTERIM ANALYSIS OF PHASE 2 STUDY: A METRONOMIC REGIMEN USING GEMCITABINE, DOXORUBICIN, DOCETAXEL AND NIVOLUMAB FOR ADVANCED LEIOMYOSARCOMA (NCT04535713)
Angel Luis Orosco-Ttamina
Favorite
Ortega, Luis

Hospital Clínico San Carlos
(P 149) PSYCOLOGICAL SNAPSHOT OF SARCOMA PATIENTS FROM AN ACADEMIC, UNIVERSITY CENTER, HOSPITAL CLÍNICO SAN CARLOS (HCSC), MADRID, A SARCOMA NATIONAL REFERRAL CENTRE IN SPAIN
Luis Ortega
Favorite
(P 174) SELISARC: A SPANISH GROUP FOR RESEARCH IN SARCOMA (GEIS) PHASE I/II TRIAL OF SELINEXOR PLUS GEMCITABINE IN SELECTED SARCOMA SUBTYPES: RESULTS OF THE PHASE I PART
Luis Ortega
Favorite
(P 515) ENDOBRONCHIAL NAVIGATION AS AN INTRAOPERATORY TOOL FOR RESECTION OF SMALL PULMONARY METASTASES IN SARCOMA PATIENTS
Luis Ortega
Favorite
Osanai, Makoto

Sapporo Medical University School of Medicine
(P 391) THE EXPRESSION OF PVR AND ITS CLINICOPATHOLOGICAL SIGNIFICANCE IN MPNST.
Makoto Osanai
Favorite
Osmond, Allison

University of Saskatchewan
(P 148) MOVING TOWARDS THE OPTIMIZATION OF DIAGNOSIS FOR PATIENTS WITH SARCOMA: A 10-YEAR REVIEW OF EXTERNALLY CONSULTED SARCOMA CASES IN A GENERAL ANATOMICAL PATHOLOGY SERVICE
Allison Osmond
Favorite
Ostetto, Federico

Istituto Ortopedico Rizzoli IRCCS
(P 01) EXTRASKELETAL EWING SARCOMA OF THE EXTREMITIES AND TRUNK IN < 25 YEARS OLD PATIENTS: A RETROSPECTIVE ANALYSIS OF A MONO-INSTITUTIONAL SERIES.
Federico Ostetto
Favorite
O'Sullivan, Maureen

Children's Health Ireland & Trinity College, Dublin, IRELAND
(P 424) INTERNAL TANDEM DUPLICATION OF BCOR (BCOR-ITD) ALTERS THE TUMOR EPIGENOME
Maureen O'Sullivan
Favorite
Osz, Kata

Tom Baker Cancer Center
(P 110) GCAR1: GPNMB CAR T THERAPY FOR MIT FAMILY TRANSLOCATION POSITIVE CANCERS
Kata Osz
Favorite
Otero Norza, Diana

Hospital Dr. Rafael Angel Calderón Guardia
(P 330) TREATMENT VARIATIONS, OUTCOMES AND PATTERNS OF RECURRENCE AFTER CURATIVE INTENT TREATMENT FOR PRIMARY RETROPERITONEAL SARCOMAS IN LATIN AMERICA. FIRST COLLABORATIVE LATAMSARC STUDY
Diana Otero Norza
Favorite
Otero Pla, Eugenia

Hospital de la Santa Creu i Sant Pau
(P 313) SPACIALLY-FRACTIONATED RADIOTHERAPY (LATTICE) TREATMENT IN INOPERABLE NON-EXTREMITY BULKY SOFT-TISSUE SARCOMAS
Eugenia Otero Pla
Favorite
Otero Ruiz, Jorge

Hospital de la Santa Creu i Sant Pau
(P 503) SCAPULAR PROSTHESIS RECONSTRUCTION, EXPERIENCE IN OUR INSTITUTION
Jorge Otero Ruiz
Favorite
(P 504) WHY DO SOME PATIENTS WITH SYNOVIAL SARCOMA HAVE BETTER FUNCTIONAL OUTCOMES AFTER RESECTION SURGERY? ANALYSIS OF 102 CASES
Jorge Otero Ruiz
Favorite
(P 507) PRIMARY CHEST WALL TUMORS OF MESENCHYMAL ORIGIN. EXPERIENCE OF A REFERENCE UNIT
Jorge Otero Ruiz
Favorite
O'Toole, Gary

St Vincents University Hospital
(P 155) THE IMPACT OF THE ROLE OF A SARCOMA ADVANCED NURSE PRACTITIONER (ANP) BIOPSY CLINIC IN IMPROVING PATIENT ACCESS TO SARCOMA SERVICES
Gary O'Toole
Favorite
(P 156) PATIENT REPORTED EXPERIENCES WITHIN THE IRISH SARCOMA GROUP
Gary O'Toole
Favorite
(P 217) CONTEMPORARY TREATMENT PATTERNS AND OUTCOMES IN THE MANAGEMENT OF ANGIOSARCOMA IN IRELAND
Gary O'Toole
Favorite
Ou, Da-Liang

Graduate Institute of Oncology National Taiwan University College of Medicine
(P 350) LIVER ANGIOSARCOMA IS ASSOCIATED WITH ARISTOLOCHIC ACID EXPOSURE AND HAS A DISTINCT TELOMERE MAINTENANCE MECHANISM
Da-Liang Ou
Favorite
Outani, Hidetatsu

Osaka University
(P 05) COEFFICIENT OF VARIATION OF T2-WEIGHTED MRI PREDICTS THE PROGNOSIS OF MALIGNANT PERIPHERAL NERVE SHEATH TUMOR
Hidetatsu Outani
Favorite
Outani, Hidetatsu

Osaka University Graduate School of Medicine
(P 396) COMPREHENSIVE WHOLE-GENOME MOLECULAR PROFILING IN BONE AND SOFT TISSUE SARCOMA: MULTI-OMICS ANALYSIS OF 627 CASES ACROSS HISTOLOGIC SUBTYPES
Hidetatsu Outani
Favorite
Oyama, Ryunosuke

Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kyushu University
(P 406) EXTENSIVE ANALYSIS OF 59 SARCOMA-RELATED FUSION GENES IDENTIFIED PAZOPANIB AS A POTENTIAL INHIBITOR TO COL1A1-PDGFB FUSION GENE
Ryunosuke Oyama
Favorite
Oyem, Precious

Cleveland Clinic
(P 402) TISSUE PERFUSION AND WOUND HEALING AFTER SOFT TISSUE SARCOMA RESECTION
Precious Oyem
Favorite
(P 513) THE IMPACT OF MARGIN STATUS ON THE ONCOLOGIC OUTCOMES OF SURGICALLY TREATED DEDIFFERENTIATED LIPOSARCOMA OF THE EXTREMITIES
Precious Oyem
Favorite
(P 514) INTERSTITIAL BRACHYTHERAPY IN THE TREATMENT OF SOFT TISSUE SARCOMA: LOCAL RECURRENCE AND WOUND OUTCOMES
Precious Oyem
Favorite
Ozaki, Toshifumi

Okayama University Hospital
(P 16) ALVEOLAR SOFT PART SARCOMA: PROGRESS TOWARD IMPROVEMENT IN SURVIVAL? A NATIONWIDE DATABASE STUDY IN JAPAN
Toshifumi Ozaki
Favorite
P
P. Tafti, Ahmad

University of Pittsburgh
(P 244) A DEEP FEW-SHOT META-LEARNING STRATEGY FOR AUTONOMOUS CLASSIFICATION OF BONE METASTASIS IN RADIONUCLIDE BONE SCANS
Ahmad P. Tafti
Favorite
Płachta, Iga

Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology
(P 162) LONG TERM SAFETY AND EFFICACY OF COMBINED DOXORUBICIN-IFOSFAMIDE CHEMOTHERAPY WITH PREOPERATIVE HYPOFRACTIONATED RADIOTHERAPY IN MARGINALLY RESECTABLE SOFT TISSUE SARCOMAS
Iga Płachta
Favorite
Pabst, Kim

Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen
(P 220) [68GA]GA-FAPI PET/CT AS NOVEL DIAGNOSTIC TOOL IN SARCOMA
Kim Pabst
Favorite
(P 248) FIBROBLAST ACTIVATION PROTEIN ALPHA -DIRECTED IMAGING AND THERAPY OF SOLITARY FIBROUS TUMOR
Kim Pabst
Favorite
Pacilio, Carlo Alberto

General and Oncologic Surgery, "Morgagni-Pierantoni" Hospital
(P 37) DISSECTING THE ROLE OF EXTRACELLULAR VESICLES IN THE MANAGEMENT OF GIST
Carlo Alberto Pacilio
Favorite
(P 364) EVALUATION OF THE PREDICTIVE ROLE OF SYSTEMIC AND INTRATUMORAL IMMUNITY IN PATIENTS WITH LOCALIZED LIPOSARCOMAS, MYXOFIBROSARCOMAS AND UNDIFFERENTIATED PLEOMORPHIS SARCOMAS
Carlo Alberto Pacilio
Favorite
(P 533) SAFETY AND PRELIMINARY BIOLOGICAL ACTIVITY OF A PHASE II TRIAL OF AUTOLOGOUS DENDRITIC CELLS VACCINATION IN SARCOMAS.
Carlo Alberto Pacilio
Favorite
Paglia, Simona

Istituto Ortopedico Rizzoli IRCCS, Osteoncology- Bone and Soft Tissue Sarcomas and Innovative Therapies Unit, Bologna, Italy
(P 253) THE EFFICACY OF MEDICATED PATCHES IN SOFT TISSUE SARCOMAS: IN-VITRO AND EX-VIVO VALIDATION.
Simona Paglia
Favorite
Paindavoine, Sandrine

Centre Léon Bérard
(P 382) NTRK1/2/3 FUSIONS DETECTION USING RNA-SEQ IN MESENCHYMAL TUMORS REVEALS ULTRA-RARE AND HISTO-SPECIFIC TARGETABLE ALTERATIONS: EXPERIENCE OF AN EXTENSIVE ROUTINE RESEARCH PROGRAM.
Sandrine Paindavoine
Favorite
Paioli, Anna

Istituto Ortopedico Rizzoli IRCCS, Osteoncology- Bone and Soft Tissue Sarcomas and Innovative Therapies Unit, Bologna, Italy
(P 01) EXTRASKELETAL EWING SARCOMA OF THE EXTREMITIES AND TRUNK IN < 25 YEARS OLD PATIENTS: A RETROSPECTIVE ANALYSIS OF A MONO-INSTITUTIONAL SERIES.
Anna Paioli
Favorite
Paioli, Anna

Istituto Ortopedico Rizzoli
(P 455) EXTRASKELETAL EWING SARCOMA: A MULTICENTRIC RETROSPECTIVE STUDY FROM THE ITALIAN SARCOMA GROUP
Anna Paioli
Favorite
Pajtler, Kristian

Hopp Children’s Cancer Center Heidelberg (KiTZ), Heidelberg University
(P 202) INFLAMMATORY MYOFIBROBLASTIC TUMOUR WITH ROS1 GENE FUSIONS IN CHILDREN AND YOUNG ADOLESCENTS
Kristian Pajtler
Favorite
Palassini, Elena

Department of Medical Oncology 2, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
(P 14) PERCUTANEOUS CRYOABLATION OF PROGRESSING EXTRA-ABDOMINAL DESMOID TUMOURS
Elena Palassini
Favorite
(P 159) IN BETWEEN OF LYMPHOMAS AND SARCOMAS: WHERE DO HISTIOCYTIC AND DENDRITIC CELL NEOPLASMS (HDCN) STAND? A RETROSPECTIVE, MULTI-INSTITUTIONAL STUDY FROM THE ITALIAN SARCOMA GROUP (ISG)
Elena Palassini
Favorite
(P 333) SYSTEMIC TREATMENT IN INTRA-ABDOMINAL DESMOID-TYPE FIBROMATOSIS: A SINGLE INSTITUTION RETROSPECTIVE CASE SERIES ANALYSIS
Elena Palassini
Favorite
(P 342) THE EVALUATION AND OUTCOMES OF MESENTERIC AND INTRA-ABDOMINAL DESMOIDS: A TARPSWG STUDY
Elena Palassini
Favorite
Palmerini, Emanuela

IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy
(P 73) FOSTER CONSORTIUM, FIGHT OSTEOSARCOMA THROUGH EUROPEAN RESEARCH
Emanuela Palmerini
Favorite
(P 142) THE SARCOMA EUROPEAN AND LATIN AMERICAN NETWORK (SELNET) PROJECT: OVERVIEW OF THE MAIN RESULTS OF THE SELNET REGISTRY
Emanuela Palmerini
Favorite
(P 173) SAFETY, EFFICACY, AND PATIENT-REPORTED OUTCOMES WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED PRIOR ANTI–COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 UPDATE
Emanuela Palmerini
Favorite
(P 176) SAFETY, EFFICACY, AND PATIENT-REPORTED OUTCOMES WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED NO PRIOR ANTI–COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 UPDATE
Emanuela Palmerini
Favorite
(P 189) INTERNATIONAL RETROSPECTIVE STUDY FROM THE ULTRA-RARE SARCOMA WORKING GROUP ON LOW-GRADE FIBROMYXOID SARCOMA AND SCLEROSING EPITHELIOD FIBROSARCOMA: OUTCOME OF ADVANCED DISEASE AND SYSTEMIC THERAPIES
Emanuela Palmerini
Favorite
(P 378) MULTIOMICS PROFILING OF EPITHELIOID SARCOMA UNVEILS EPIGENETIC CIRCUITRIES THAT UNDERLIE THE PATHOBIOLOGY OF PROXIMAL AND CLASSIC SUBTYPES: RESULTS FROM THE ISG EPISOBS OBSERVATIONAL STUDY
Emanuela Palmerini
Favorite
(P 437) ULTRA-RARE UNDIFFERENTIATED SMALL ROUND CELL SARCOMA: HOW SHOULD WE TREAT THEM? AN ANALYSIS FORM THE GRACEFUL PROJECT
Emanuela Palmerini
Favorite
Palomba, Annarita

Unit of Histopathology and Molecular Diagnostics, Careggi University Hospital, Florence, Italy.
(P 309) CLINICAL PATHOLOGICAL CHARACTERISTICS, PATTERN OF CARE AND SURVIVAL OF NON-METASTATIC BREAST ANGIOSARCOMA
Annarita Palomba
Favorite
(P 317) PROGNOSTIC FACTORS, CLINICAL AND TOXICITY OUTCOMES FROM A LARGE COHORT OF PATIENTS WITH SOFT TISSUE SARCOMA TREATED WITH PREOPERATIVE RADIATION THERAPY
Annarita Palomba
Favorite
(P 546) PRELIMINARY CLINICAL RESULTS OF AN ONGOING PHASE II TRIAL: SPRINT (SARCOMA PREOPERATIVE RADIATION WITH SIMULTANEOUS INTEGRATED BOOST)
Annarita Palomba
Favorite
Pal, Rajesh

Precision Sarcoma Research Group, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg
(P 124) UNLOCKING THE POTENTIAL OF MEASLES VIRUS ONCOLYTIC IMMUNOTHERAPY FOR SARCOMA: BIOMARKER DISCOVERY AND THERAPEUTIC VACCINE DEVELOPMENT
Rajesh Pal
Favorite
Pal, Tuya

Vanderbilt University Medical Center
(P 160) A PROSPECTIVE STUDY EVALUATING THE ASSOCIATION OF PATIENT-REPORTED OUTCOMES WITH ACTIVITY LEVEL AND SLEEP PATTERNS IN SARCOMA SURVIVORS
Tuya Pal
Favorite
(P 210) FINANCIAL TOXICITY ASSOCIATED WITH THE TREATMENT OF SARCOMAS: A SINGLE INSTITUTION RETROSPECTIVE-PROSPECTIVE STUDY
Tuya Pal
Favorite
(P 211) AN ANALYSIS OF SELF-REPORTED DEPRESSION IN SARCOMA PATIENTS
Tuya Pal
Favorite
(P 380) NEXT GENERATION SEQUEINCING REVEALS TARGETABLE MUTATIONS IN MULTIPLE SARCOMA HISTOLOGIES
Tuya Pal
Favorite
Panahi, Babak

Department of Diagnostic and Interventional Radiology, University Medical Center Goettingen, 37075 Goettingen, Germany
(P 235) FUSION OF PREOPERATIVE IN SITU MAGNETIC RESONANCE IMAGING AND POSTOPERATIVE COMPUTED TOMOGRAPHY TO CORRELATE FUNCTIONAL IMAGING FEATURES AND PATHOLOGICAL CHARACTERISTICS OF SOFT TISSUE SARCOMA
Babak Panahi
Favorite
Pancisi, elena

Irst
(P 533) SAFETY AND PRELIMINARY BIOLOGICAL ACTIVITY OF A PHASE II TRIAL OF AUTOLOGOUS DENDRITIC CELLS VACCINATION IN SARCOMAS.
elena Pancisi
Favorite
Panda, Goutam

Tata Memorial Hospital Mumbai
(P 436) OUTCOME PROGNOSTICATORS IN ADOLESCENTS AND ADULTS WITH BONE SARCOMAS IN LOW-MIDDLE-INCOME COUNTRIES
Goutam Panda
Favorite
Pandey, Rambha

AIIMS
(P 562) A PHASE 2, SINGLE ARM STUDY OF REGORAFENIB IN METASTATIC/UNRESECTABLE REFRACTORY SYNOVIAL SARCOMAS
Rambha Pandey
Favorite
Pandya, Susan

Servier Pharmaceuticals
(P 66) PHASE I STUDY OF THE MUTANT IDH1 INHIBITOR IVOSIDENIB: LONG-TERM SAFETY AND CLINICAL ACTIVITY IN PATIENTS WITH CONVENTIONAL CHONDROSARCOMA
Susan Pandya
Favorite
Pan, Irene

United BioSource LLC
(P 131) PATIENT-REPORTED CONTINUED BENEFITS IN PATIENTS TREATED WITH PEXIDARTINIB FOR TENOSYNOVIAL GIANT CELL TUMOR BASED ON A REAL-WORLD STUDY IN THE UNITED STATES
Irene Pan
Favorite
Pankova, Valeriya

The Institute of Cancer Research
(P 404) PROTEOMIC PROFILING OF THE SOFT TISSUE SARCOMA MICROENVIRONMENT IDENTIFIES A PROGNOSTIC SIGNATURE BASED ON PROTEOGLYCAN EXPRESSION AND CD8+ TUMOUR INFILTRATING LYMPHOCYTES
Valeriya Pankova
Favorite
Pan, Minggui

Stanford University
(P 224) CO-MUTATION-DEPENDENT PROGNOSIS IN PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA
Minggui Pan
Favorite
Pannella, Micaela

Istituto Ortopedico Rizzoli IRCCS, Osteoncology- Bone and Soft Tissue Sarcomas and Innovative Therapies Unit, Bologna, Italy
(P 253) THE EFFICACY OF MEDICATED PATCHES IN SOFT TISSUE SARCOMAS: IN-VITRO AND EX-VIVO VALIDATION.
Micaela Pannella
Favorite
(P 283) A TRIDIMENSIONAL PRECLINICAL MODEL TO STUDY HUMAN AND CANINE OSTEOSARCOMA DEVELOPMENT AND INTERACTION WITH TUMOR MICROENVIRONMENT
Micaela Pannella
Favorite
Pantaleo, Maria

Institute of Hematology and Medical Oncology L & A Seragnoli and Interdepartmental Centre for Cancer Research G Prodi
(P 27) A MULTICENTER RETROSPECTIVE STUDY ON THE CLINICAL BEHAVIOR OF SDH-DEFICIENT GIST
Maria Pantaleo
Favorite
(P 49) EFFICACY OF RIPRETINIB IN A MULTICENTER EXPANDED ACCESS PROGRAM IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS HARBOURING NON-KIT EXON 11 MUTATIONS.
Maria Pantaleo
Favorite
Pantano, Francesco

Fondazione Policlinico Universitario Campus Bio-Medico
(P 263) HER2 AS A POTENTIAL NOVEL THERAPEUTIC TARGET IN SOFT TISSUE SARCOMAS
Francesco Pantano
Favorite
(P 264) CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS AND TRABECTEDIN IN SOFT TISSUE SARCOMA: A NOVEL POTENTIAL SYNERGY?
Francesco Pantano
Favorite
Pantziarka, Pan

Anticancer Fund
(P 73) FOSTER CONSORTIUM, FIGHT OSTEOSARCOMA THROUGH EUROPEAN RESEARCH
Pan Pantziarka
Favorite
Pantziarka, Pan

George Pantziarka TP53 Trust/Anticancer Fund
(P 90) RESULTS FROM AN INTERNATIONAL SURVEY OF BONE SARCOMA PATIENTS
Pan Pantziarka
Favorite
Paoletti, Xavier

Institute Curie
(P 212) REPORT ON THE EWING SARCOMA PATIENTS ENROLLED IN ARM D OF THE ACSE-ESMART TRIAL: PHASE I/II STUDY OF THE PARP INHIBITOR OLAPARIB IN COMBINATION WITH IRINOTECAN IN CHILDREN WITH ADVANCED MALIGNANCIES
Xavier Paoletti
Favorite
Papakonstantinou, Andri

Karolinska institutet
(P 243) EVALUATION OF THE USE OF WGS IN ROUTINE DIAGNOSTICS FOR BONE AND SOFT TISSUE TUMORS
Andri Papakonstantinou
Favorite
Papakonstantinou, Andri

Karolinska University Hospital
(P 278) CLINICAL MARKERS PREDICTIVE OF TRABECTEDIN RESPONSE IN SOFT TISSUE SARCOMA
Andri Papakonstantinou
Favorite
Papakonstantinou, Evgenia

Hellenic Society Of Pediatric Hematology- Oncology, Athens
(P 73) FOSTER CONSORTIUM, FIGHT OSTEOSARCOMA THROUGH EUROPEAN RESEARCH
Evgenia Papakonstantinou
Favorite
Parafioriti, Antonina

ASST Gaetano Pini - CTO
(P 431) TREATMENT STRATEGY AND PROGNOSTIC FACTORS IN EXTRASKELETAL EWING SARCOMA: AN INSTITUTIONAL RETROSPECTIVE ANALYSIS
Antonina Parafioriti
Favorite
Parajuli, Gyanu

Cleveland Clinic
(P 429) SARCOMA FUSION GENE ANALYSIS YIELDS PROMISING HLA ANTIGEN FIT IN EWING SARCOMA AND DESMOPLASTIC SMALL ROUND CELL TUMOR
Gyanu Parajuli
Favorite
Paraliticci, Giovanni

Miami Cancer Institute
(P 320) A PROSPECTIVE MULTICENTER EXPERIENCE OF PROTON THERAPY FOR RHABDOMYOSARCOMA AND EWING SARCOMA: OUTCOMES FROM THE PROTON COLLABORATIVE GROUP REGISTRY
Giovanni Paraliticci
Favorite
Pareja Zea, Fresia

MSKCC
(P 103) LASTING COMPLETE RESPONSE TO PEMBROLIZUMAB IN MISMATCH REPAIR DEFICIENT CARDIAC SARCOMA: A GENOMIC CHARACTERIZATION
Fresia Pareja Zea
Favorite
Parikh, Firuza R

Jaslok hospital, Director Well Women Centre, HN reliance Hospital
(P 06) ONCOFERTILITY AND PREGNANCY IN ADOLESCENT AND YOUNG ADULT CANCERS: PHYSICIANS' KNOWLEDGE AND PREFERENCES IN A LARGE LOW-MIDDLE- INCOME COUNTRY
Firuza R Parikh
Favorite
Parikh, Tanvi

University College London
(P 563) BALANCE, GAIT AND BIOMECHANICAL COMPENSATIONS DURING DIFFERENT SPEEDS OF WALKING AFTER TREATMENT FOR DISTAL FEMORAL MUSCULOSKELETAL TUMOURS AND ASSOCIATED LIMITATIONS ON RETURN TO NORMAL LIVING
Tanvi Parikh
Favorite
Park, Ben

Vanderbilt University Medical Center
(P 160) A PROSPECTIVE STUDY EVALUATING THE ASSOCIATION OF PATIENT-REPORTED OUTCOMES WITH ACTIVITY LEVEL AND SLEEP PATTERNS IN SARCOMA SURVIVORS
Ben Park
Favorite
(P 210) FINANCIAL TOXICITY ASSOCIATED WITH THE TREATMENT OF SARCOMAS: A SINGLE INSTITUTION RETROSPECTIVE-PROSPECTIVE STUDY
Ben Park
Favorite
(P 211) AN ANALYSIS OF SELF-REPORTED DEPRESSION IN SARCOMA PATIENTS
Ben Park
Favorite
(P 218) NEOADJUVANT CHEMOTHERPAY AND RADIATION DECREASES TUMOR SIZE, VIABILITY, AND RECURRENCE IN MULTIPLE LIPOSARCOMA SUBSETS
Ben Park
Favorite
(P 380) NEXT GENERATION SEQUEINCING REVEALS TARGETABLE MUTATIONS IN MULTIPLE SARCOMA HISTOLOGIES
Ben Park
Favorite
Park, Byung

OHSU
(P 341) A PHASE 1B STUDY TO EVALUATE PREOPERATIVE ERIBULIN IN COMBINATION WITH RADIATION IN RETROPERITONEAL SARCOMA
Byung Park
Favorite
Park, Jay Hoon

Seoul National University Hospital
(P 374) ARHGEF4 EXPRESSION IN SOFT TISSUE SARCOMA CORRELATES WITH LOCAL GROWTH PATTERN AND LOCAL RECURRENCE: COMPREHENSIVE GENOMIC ANALYSIS IN SEARCH OF BIOMARKER OF LOCAL GROWTH PATTERN
Jay Hoon Park
Favorite
(P 498) DEDIFFERENTIATED LIPOSARCOMA OF THE EXTREMITIES: CHARACTERISTICS AND OUTCOME
Jay Hoon Park
Favorite
(P 499) CLINICAL OUTCOMES OF TOTAL FEMORAL REPLACEMENT FOR ONCOLOGICAL INDICATIONS
Jay Hoon Park
Favorite
Park, Min

Swedish Cancer Institute
(P 177) ANGIOSARCOMA: AN INCREASING PROBLEM IN THE UNITED STATES
Min Park
Favorite
Parma, Gabriella

IEO
(P 328) REAL-LIFE EXPERIENCE OF PAZOPANIB IN PATIENTS WITH ADVANCED UTERINE LEIOMYOSARCOMA (U-LMS) FROM TWO REFERRAL ITALIAN CENTERS
Gabriella Parma
Favorite
Parmar, Sahibjeet

The Life Raft Group
(P 33) LONGITUDINAL FOLLOW UP OF GASTROINTESTINAL STROMAL TUMORS:DATA FROM THE LIFE RAFT GROUP INTERANTIONAL PATIENT REGISTRY
Sahibjeet Parmar
Favorite
Parry, Michael

Royal Orthopaedic Hospital
(P 70) ICONIC (IMPROVING OUTCOMES THROUGH COLLABORATION IN OSTEOSARCOMA): A PROSPECTIVE OBSERVATIONAL COHORT STUDY FOR NEWLY DIAGNOSED OSTEOSARCOMA PATIENTS IN THE UNITED KINGDOM (UK)
Michael Parry
Favorite
(P 472) ICONIC (IMPROVING OUTCOMES THROUGH COLLABORATION IN OSTEOSARCOMA). AN EARLY LOOK AT SURGICAL DATA
Michael Parry
Favorite
Pascucci, Luisa

Department of Veterinary Medicine, University of Perugia
(P 283) A TRIDIMENSIONAL PRECLINICAL MODEL TO STUDY HUMAN AND CANINE OSTEOSARCOMA DEVELOPMENT AND INTERACTION WITH TUMOR MICROENVIRONMENT
Luisa Pascucci
Favorite
Pasquali, Sandro

Sarcoma Service, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
(P 109) INTENSE PRECLINICAL ACTIVITY BY B7H3-SPECIFIC CAR.CIK LYMPHOCYTES AGAINST EPITHELIOID SARCOMA
Sandro Pasquali
Favorite
(P 126) CURRENT PRACTICE IN SPERMATIC CORD SARCOMA: ONCOLOGICAL TIMELINES AND OUTCOMES ACCORDING TO INITIAL RESECTIONS PERFORMED AT A LOCAL HOSPITAL VERSUS EARLY PATIENT REFERRAL TO A TERTIARY CENTRE.
Sandro Pasquali
Favorite
(P 272) A COMPARATIVE ASSESSMENT OF SELINEXOR WITH TRABECTEDIN OR LURBINECTEDIN IN PATIENT-DERIVED XENOGRAFTS (PDX) OF DEDIFFERENTIATED LIPOSARCOMA (DDLPS)
Sandro Pasquali
Favorite
(P 273) COMPARISON OF A PATIENT-DERIVED XENOGRAFTS (PDX) OF MYXOID PLEOMORPHIC LIPOSARCOMA (MPL) AND PLEOMORPHIC LIPOSARCOMA (PL) HIGHLIGHTS THE EFFECTIVENESS OF ERIBULIN IN A PDX OF MPL
Sandro Pasquali
Favorite
Pasquali, Sandro

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 363) Β-CATENIN MUTATIONS AND TRANSCRIPTOMIC REPROGRAMMING IN DESMOID FIBROMATOSIS (DF)
Sandro Pasquali
Favorite
Pasquali, Sandro

Sarcoma Service, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
(P 378) MULTIOMICS PROFILING OF EPITHELIOID SARCOMA UNVEILS EPIGENETIC CIRCUITRIES THAT UNDERLIE THE PATHOBIOLOGY OF PROXIMAL AND CLASSIC SUBTYPES: RESULTS FROM THE ISG EPISOBS OBSERVATIONAL STUDY
Sandro Pasquali
Favorite
(P 410) PROTEOMICS ANALYSIS IDENTIFIES A SIGNATURE THAT IMPROVES PROGNOSTIC RISK STRATIFICATION OF THE SARCULATOR NOMOGRAM IN PATIENTS WITH SOFT TISSUE SARCOMAS OF THE EXTREMITIES AND TRUNK WALL
Sandro Pasquali
Favorite
Passiglia, Francesco

Department of Oncology, San Luigi Hospital, University of Turin
(P 550) ON-TRK: A NON-INTERVENTIONAL STUDY OF LAROTRECTINIB IN PATIENTS WITH TRK FUSION SOLID TUMORS
Francesco Passiglia
Favorite
Pastorino, Ugo

Fondazione IRCCS Istituto Nazionanale dei Tumori
(P 273) COMPARISON OF A PATIENT-DERIVED XENOGRAFTS (PDX) OF MYXOID PLEOMORPHIC LIPOSARCOMA (MPL) AND PLEOMORPHIC LIPOSARCOMA (PL) HIGHLIGHTS THE EFFECTIVENESS OF ERIBULIN IN A PDX OF MPL
Ugo Pastorino
Favorite
(P 431) TREATMENT STRATEGY AND PROGNOSTIC FACTORS IN EXTRASKELETAL EWING SARCOMA: AN INSTITUTIONAL RETROSPECTIVE ANALYSIS
Ugo Pastorino
Favorite
(P 432) LONG-LASTING DISEASE CONTROL WITH TRABECTEDIN IN A CASE OF METASTATIC EWSR1::PATZ1 SARCOMA
Ugo Pastorino
Favorite
Pastrello, Chiara

Data Science Discovery Centre for Chronic Diseases, Krembil Research Institute, Toronto Western Hospital, University Health Network, Toronto, Canada
(P 378) MULTIOMICS PROFILING OF EPITHELIOID SARCOMA UNVEILS EPIGENETIC CIRCUITRIES THAT UNDERLIE THE PATHOBIOLOGY OF PROXIMAL AND CLASSIC SUBTYPES: RESULTS FROM THE ISG EPISOBS OBSERVATIONAL STUDY
Chiara Pastrello
Favorite
Patel, Anand

St. Jude Children's Research Hospital
(P 528) SAFETY AND TOLERABILITY OF ORAL CYCLOPHOSPHAMIDE AND SORAFENIB WITH INTRAVENOUS BEVACIZUMAB WITH THE ADDITION OF ATEZOLIZUMAB IN PEDIATRIC SOLID TUMOR PATIENTS
Anand Patel
Favorite
Patel, Manishkumar

Moffitt Cancer Center & Research Institute
(P 269) PLASMA DNA METHYLATION-BASED BIOMARKERS FOR MPNST DETECTION IN PATIENTS WITH NEUROFIBROMATOSIS TYPE 1 (NF1)
Manishkumar Patel
Favorite
Patel, Pooja

University of Miami Miller School of Medicine
(P 225) PAN-SARCOMA DATABASE (PSDB): A MODEL-VIEW-CONTROLLER FRAMEWORK UTILIZING REDCAP, SHINY, AND R TO CREATE A CONTINUOUS PIPELINE OF SARCOMA DATA
Pooja Patel
Favorite
(P 366) SURVIVAL DISPARITIES IN HISPANIC PATIENTS WITH SARCOMA TESTED WITH NEXT-GENERATION SEQUENCING (NGS)
Pooja Patel
Favorite
Patel, Samir H.

Mayo Clinic Arizona
(P 312) MANAGEMENT OF ADULT HEAD AND NECK SOFT TISSUE SARCOMA: THE MAYO CLINIC EXPERIENCE
Samir H. Patel
Favorite
Patel, Shalin Shreyaskumar

The University of Texas MD Anderson Cancer Center
(P 83) CLINICO-GENOMIC PROFILING OF CONVENTIONAL AND DEDIFFERENTIATED CHONDROSARCOMAS REVEALS TP53 MUTATION TO BE ASSOCIATED WITH WORSE OUTCOMES
Shalin Shreyaskumar Patel
Favorite
(P 394) LEIOMYOSARCOMA INTRATUMORAL MACROPHAGE INFILTRATES ARE ASSOCIATED WITH DISTINCT CLINICAL AND GENOMIC PRESENTATIONS
Shalin Shreyaskumar Patel
Favorite
(P 529) THE MUSCULOSKELETAL TUMOR REGISTRY -- 2023 UPDATE AND OUTLOOK
Shalin Shreyaskumar Patel
Favorite
Patel, Shreyaskumar

The University of Texas MD Anderson Cancer Center
(P 36) CLINICO-GENOMIC ANALYSIS OF KIT/PDGFRA/SDH WILD-TYPE GASTROINTESTINAL STROMAL TUMORS IDENTIFIES POTENTIAL DRIVER MUTATIONS
Shreyaskumar Patel
Favorite
(P 71) CHEMOTHERAPY AND PROGNOSTIC SIGNIFICANCE OF EXTENT OF DEDIFFERENTIATION IN DEDIFFERENTIATED PAROSTEAL OSTEOSARCOMA
Shreyaskumar Patel
Favorite
(P 83) CLINICO-GENOMIC PROFILING OF CONVENTIONAL AND DEDIFFERENTIATED CHONDROSARCOMAS REVEALS TP53 MUTATION TO BE ASSOCIATED WITH WORSE OUTCOMES
Shreyaskumar Patel
Favorite
(P 100) HISTOLOGY SPECIFIC INTRATUMORAL B-CELL BIOLOGY IN ALVEOLAR SOFT-PART SARCOMAS (ASPS) IN RESPONSE TO DURVALUMAB-TREMELIMUMAB (D-T)
Shreyaskumar Patel
Favorite
(P 123) DEDIFFERENTIATED LIPOSARCOMAS TREATED WITH IMMUNE CHECKPOINT BLOCKADE: THE MD ANDERSON EXPERIENCE
Shreyaskumar Patel
Favorite
(P 360) TP53 ALTERATIONS IN SARCOMAS: AN ANALYSIS FROM THE AACR-GENIE DATABASE
Shreyaskumar Patel
Favorite
(P 400) THE LANDSCAPE OF GENOMIC ALTERATIONS FROM 1494 SOFT TISSUE AND BONE SARCOMAS AT MD ANDERSON CANCER CENTER
Shreyaskumar Patel
Favorite
(P 405) PRIMARY CARDIAC ANGIOSARCOMA- GENOMIC AND MOLECULAR LANDSCAPE
Shreyaskumar Patel
Favorite
Paternostro, Flavia

Laboratory of Experimental Oncology, KU Leuven, Leuven Cancer Institute
(P 43) UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR-ASSOCIATED PROTEIN AS A POTENTIAL NEXT GENERATION MOLECULAR TARGET FOR TREATMENT OF GASTROINTESTINAL STROMAL TUMOR
Flavia Paternostro
Favorite
(P 255) EPIDEMIOLOGY OF NOVEL ACTIONABLE TARGETS IN SYNOVIAL SARCOMA: A TISSUE MICRO-ARRAY STUDY
Flavia Paternostro
Favorite
Pathak, Harsh

KUMC
(P 446) SYNERGISTIC TARGETING OF KIF11 AND AURKA TO IMPROVE OUTCOMES FOR EWING SARCOMA
Harsh Pathak
Favorite
Patient Mosaic Team, Rare Tumor Initiative Team

MD Anderson Cancer Center
(P 100) HISTOLOGY SPECIFIC INTRATUMORAL B-CELL BIOLOGY IN ALVEOLAR SOFT-PART SARCOMAS (ASPS) IN RESPONSE TO DURVALUMAB-TREMELIMUMAB (D-T)
Rare Tumor Initiative Team Patient Mosaic Team
Favorite
Patt, Joshua

Atrium Health, Levine Cancer
(P 258) THE CRITICALITY OF OXIDATIVE PHOSPHORYLATION IN SYNOVIAL SARCOMA METASTASIS
Joshua Patt
Favorite
Paudel, Siddhi Nath

Nationwide Childrens Hospital
(P 125) MYELOMODULATORY TREATMENTS AUGMENT THE THERAPEUTIC BENEFIT OF ONCOLYTIC VIRUS IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS BY MODULATING THE TUMOR MICROENVIRONMENT
Siddhi Nath Paudel
Favorite
Paulson, Kelly G.

Swedish Cancer Institute
(P 177) ANGIOSARCOMA: AN INCREASING PROBLEM IN THE UNITED STATES
Kelly G. Paulson
Favorite
Pauwels, Antoinette

The Life Raft Group
(P 33) LONGITUDINAL FOLLOW UP OF GASTROINTESTINAL STROMAL TUMORS:DATA FROM THE LIFE RAFT GROUP INTERANTIONAL PATIENT REGISTRY
Antoinette Pauwels
Favorite
Pavese, Valeria

Department of Oncology, University of Turin
(P 262) ESTABLISHMENT AND CHARACTERIZATION OF THE FIRST RADIATION-INDUCED, PATIENT-DERIVED ANGIOSARCOMA CELL LINE
Valeria Pavese
Favorite
Pawlik, Timothy

The James Cancer Hospital / The Ohio State University
(P 314) PRE-OPERATIVE RADIATION THERAPY INCREASES ADHERENCE IN PATIENTS WITH HIGH-RISK EXTREMITY SOFT TISSUE SARCOMA
Timothy Pawlik
Favorite
Payne, Emily

Huntsman Cancer Institute/University of Utah
(P 412) LEIOMYOSARCOMA POLYANEUPLOID CANCER CELLS DEVELOP IN RESPONSE TO CHEMOTHERAPY AND CONTRIBUTE TO CHEMORESISTANCE
Emily Payne
Favorite
Paz, Alejandro

Hospital Quironsalud Torrevieja
(P 407) PRECISION AND PERSONALIZED TREATMENT FOR SOFT TISSUE SARCOMAS. RESULTS OF A 10 PATIENTS SERIES WITH MOLECULAR PROFILING USING NEXT-GENERATION MASSIVE SEQUENCING
Alejandro Paz
Favorite
Pazzaglia, Laura

Istituto Ortopedico Rizzoli IOR IRCCS, Laboratory of Experimental Oncology, Bologna, Italy.
(P 01) EXTRASKELETAL EWING SARCOMA OF THE EXTREMITIES AND TRUNK IN < 25 YEARS OLD PATIENTS: A RETROSPECTIVE ANALYSIS OF A MONO-INSTITUTIONAL SERIES.
Laura Pazzaglia
Favorite
Peabody, John

Northwestern Medicine
(P 475) PRE-PLATING PRIOR TO INTERCALARY TUMOR RESECTION AND ALLOGRAFT RECONSTRUCTION: LESSONS LEARNED
John Peabody
Favorite
(P 476) FAVORABLE RESULTS FOLLOWING TREATMENT OF UNICAMERAL BONE CYSTS WITH DOXYCYCLINE SCLEROGRAFT TECHNIQUE
John Peabody
Favorite
(P 477) TREATMENT OF PROXIMAL FEMUR UNICAMERAL BONE CYSTS WITH DOXYCYCLINE SCLEROTHERAPY
John Peabody
Favorite
(P 478) TREATMENT OF CHONDROBLASTOMA WITH PERCUTANEOUS CRYOABLATION
John Peabody
Favorite
(P 479) EXPANDABLE ENDOPROSTHESES: SHOULD WE CONSIDER NARROWING OUR INDICATIONS? A SYSTEMATIC REVIEW OF THE LITERATURE AND COMPARISON OF OUTCOMES BY AGE GROUPS
John Peabody
Favorite
Peabody, Terrance

Northwestern Memorial Hospital
(P 219) ELECTIVE DISCONTINUATION OF SORAFENIB TREATMENT IN DESMOID TUMORS: A RETROSPECTIVE ANALYSIS WITH IMPLICATIONS FOR CLINICAL PRACTICE
Terrance Peabody
Favorite
(P 474) PREDICTORS OF EARLY INTROWTH AND FAILURE FOLLOWING SHORT COMPRESS SPINDLE OSSEOINTEGRATION FIXATION AT THE LOWER EXTREMITIES
Terrance Peabody
Favorite
(P 475) PRE-PLATING PRIOR TO INTERCALARY TUMOR RESECTION AND ALLOGRAFT RECONSTRUCTION: LESSONS LEARNED
Terrance Peabody
Favorite
(P 476) FAVORABLE RESULTS FOLLOWING TREATMENT OF UNICAMERAL BONE CYSTS WITH DOXYCYCLINE SCLEROGRAFT TECHNIQUE
Terrance Peabody
Favorite
(P 477) TREATMENT OF PROXIMAL FEMUR UNICAMERAL BONE CYSTS WITH DOXYCYCLINE SCLEROTHERAPY
Terrance Peabody
Favorite
(P 478) TREATMENT OF CHONDROBLASTOMA WITH PERCUTANEOUS CRYOABLATION
Terrance Peabody
Favorite
(P 479) EXPANDABLE ENDOPROSTHESES: SHOULD WE CONSIDER NARROWING OUR INDICATIONS? A SYSTEMATIC REVIEW OF THE LITERATURE AND COMPARISON OF OUTCOMES BY AGE GROUPS
Terrance Peabody
Favorite
(P 480) TARGETED MUSCLE REINNERVATION FOR HIP DISARTICULATION - EVALUATION OF EARLY FUNCTIONAL OUTCOMES
Terrance Peabody
Favorite
(P 481) CUSTOM ADAPTERS FOR COMPRESS SPINDLE OSSEOINTEGRATION FIXATION IN REVISION LIMB SALVAGE SURGERY OF THE DISTAL FEMUR: A CASE SERIES
Terrance Peabody
Favorite
Peairs, Emily

Duke University School of Medicine
(P 72) CO-EXPRESSION OF LEUKOCYTE CYTOSOLIC PROTEIN 1 AND MATRIX METALLOPROTEINASES ARE INTEGRAL FOR METASTATIC PROGRESSION OF CHONDROSARCOMA
Emily Peairs
Favorite
(P 137) IMPACT OF SOCIAL DETERMINANTS OF HEALTH ON SARCOMA CARE: A SINGLE INSTITUTION EXPERIENCE
Emily Peairs
Favorite
Peiro Ibañez, Ana

Hospital de la Santa Creu i Sant Pau
(P 503) SCAPULAR PROSTHESIS RECONSTRUCTION, EXPERIENCE IN OUR INSTITUTION
Ana Peiro Ibañez
Favorite
(P 504) WHY DO SOME PATIENTS WITH SYNOVIAL SARCOMA HAVE BETTER FUNCTIONAL OUTCOMES AFTER RESECTION SURGERY? ANALYSIS OF 102 CASES
Ana Peiro Ibañez
Favorite
(P 507) PRIMARY CHEST WALL TUMORS OF MESENCHYMAL ORIGIN. EXPERIENCE OF A REFERENCE UNIT
Ana Peiro Ibañez
Favorite
(P 508) DREAM, UTOPIA OR REALISM? PROGNOSTIC FACTORS IN LUNG METASTASECTOMY OF DISSEMINATED SARCOMA DISEASE
Ana Peiro Ibañez
Favorite
Pelak, Maciej

MedAustron Ion therapy Center, Austria
(P 326) CARBON-ION RADIOTHERAPY FOR UNRESECTABLE PELVIC SARCOMAS/CHORDOMAS
Maciej Pelak
Favorite
Pellegrini, Ilaria

Department of Medical Oncology 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
(P 333) SYSTEMIC TREATMENT IN INTRA-ABDOMINAL DESMOID-TYPE FIBROMATOSIS: A SINGLE INSTITUTION RETROSPECTIVE CASE SERIES ANALYSIS
Ilaria Pellegrini
Favorite
Peltzer, Alexander

Boehringer Ingelheim Pharma GmbH & Co. KG, Department of Translational Medicine & Clinical Pharmacology
(P 185) LONGITUDINAL MUTATIONAL ANALYSIS OF TP53 IN CIRCULATING TUMOR DNA IN THE PLASMA OF PATIENTS WITH LIPOSARCOMA IN A PHASE I STUDY OF BRIGIMADLIN (BI 907828), AN MDM2-P53 ANTAGONIST
Alexander Peltzer
Favorite
Pencreach, Erwan

University Hospital of Strasbourg
(P 389) OSTEOBLASTIC-GENE SIGNATURE TO PREDICT SURVIVAL IN PEDIATRIC OSTEOSARCOMA (OS) AND TO FOLLOW PATIENTS TOWARDS LIQUID BIOPSY: A COLLABORATIVE WORK IN OS2006 PROTOCOL.
Erwan Pencreach
Favorite
Pendegrass, Catherine

University College London
(P 147) UNDERSTANDING THE EXPERIENCES OF PATIENTS RETURNING TO DAILY ACTIVITES AND EXERCISE FOLLOWING LIMB SPARING SURGERY FOR BONE OR SOFT TISSUE SARCOMA AROUND THE KNEE
Catherine Pendegrass
Favorite
(P 492) BALANCE AND GAIT OUTCOMES AFTER 1-YEAR POST-OPERATIVE HEMIPELVECTOMY SURGERY
Catherine Pendegrass
Favorite
(P 493) GAIT KINEMATICS OF SARCOMA PATIENTS AT 1 YEAR POST-OPERATIVE INTERNAL HEMIPELVECTOMY SURGERY: A RETROSPECTIVE STUDY.
Catherine Pendegrass
Favorite
(P 494) WHAT IS THE EXPERIENCE OF THOSE WITH CANCER-RELATED REDUCED QUALITY OF LIFE AND ASSOCIATED PHYSICAL DISABILITIES AFTER UPPER LIMB SARCOMA TREATMENT IN ENGLAND? A NATIONAL STUDY OF OUTCOMES.
Catherine Pendegrass
Favorite
(P 495) UNDERSTANDING THE EXPERIENCES OF PATIENTS RETURNING TO ACTIVITIES OF DAILY LIVING AND EXERCISE FOLLOWING LIMB SPARING SURGERY FOR BONE OR SOFT TISSUE SARCOMA AROUND THE KNEE.
Catherine Pendegrass
Favorite
(P 496) WHAT ARE THE EXPERIENCES OF BALANCE, GAIT AND NEURO-MUSCULAR CONTROL OUTCOMES AFTER PROXIMAL FEMORAL REPLACEMENTS FOR MUSCULOSKELETAL TUMOURS?
Catherine Pendegrass
Favorite
(P 519) WHAT ARE THE EXPERIENCES OF GAIT, ACTIVITY LEVELS AND PHYSICAL FUNCTIONING IN PROXIMAL FEMORAL REPLACEMENT AFTER MUSCULOSKELETAL TUMORS?
Catherine Pendegrass
Favorite
(P 560) REAL-WORLD MONITORING OF PHYSICAL ACTIVITY USING AN ACCELEROMETER AFTER LOWER LIMB SURGERY FOR A SARCOMA.
Catherine Pendegrass
Favorite
(P 561) EXPERIENCE OF PHYSICAL DISABILITIES AND CANCER-RELATED QUALITY OF LIFE AFTER SPINAL TUMORS- STUDY OF A NATIONAL SURVEY IN ENGLAND.
Catherine Pendegrass
Favorite
(P 563) BALANCE, GAIT AND BIOMECHANICAL COMPENSATIONS DURING DIFFERENT SPEEDS OF WALKING AFTER TREATMENT FOR DISTAL FEMORAL MUSCULOSKELETAL TUMOURS AND ASSOCIATED LIMITATIONS ON RETURN TO NORMAL LIVING
Catherine Pendegrass
Favorite
Penel, Nicolas

Centre Oscar Lambret
(P 201) PLEOMORPHIC RHABDOMYOSARCOMAS: A NEW ENTITY ASSOCIATED WITH LYNCH SYNDROME? FIRST RESULTS OF SARCLYNCH NATIONAL STUDY
Nicolas Penel
Favorite
Pennacchioli, Elisabetta

Division of Melanoma, Sarcoma, and Rare Tumor Surgery, European Institute of Oncology
(P 342) THE EVALUATION AND OUTCOMES OF MESENTERIC AND INTRA-ABDOMINAL DESMOIDS: A TARPSWG STUDY
Elisabetta Pennacchioli
Favorite
Penna, Giuseppe

Humanitas University
(P 297) UNVEILING THE IMPACT OF INTRATUMORAL MICROBIOTA IN THE TREATMENT EFFICACY OF SOFT TISSUE SARCOMA
Giuseppe Penna
Favorite
Percio, Stefano

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 363) Β-CATENIN MUTATIONS AND TRANSCRIPTOMIC REPROGRAMMING IN DESMOID FIBROMATOSIS (DF)
Stefano Percio
Favorite
Peretz Soroka, Hagit

Princess Margaret Cancer Centre / The Hospital For Sick Children
(P 215) IMPACT OF FRONTLINE SYSTEMIC TREATMENT CHOICE ON CLINICAL OUTCOME IN ADVANCED LEIOMYOSARCOMA: A MULTI-CENTRE RETROSPECTIVE CANSARCC STUDY
Hagit Peretz Soroka
Favorite
(P 421) USING TRANSCRIPTOMICS TO IDENTIFY LEIOMYOSARCOMA PATIENTS AT RISK OF METASTASIS
Hagit Peretz Soroka
Favorite
Perez Campos, Antonio

Cebiotex S.L., Barcelona, Spain
(P 385) FIRST IN HUMAN PHASE I TRIAL OF A NOVEL DRUG DELIVERY IMPLANT MATRIX WITH SN-38 (CEB-01) FOR RETROPERITONEAL SOFT TISSUE SARCOMA
Antonio Perez Campos
Favorite
Perez, Esperanza

Gustave Roussy
(P 73) FOSTER CONSORTIUM, FIGHT OSTEOSARCOMA THROUGH EUROPEAN RESEARCH
Esperanza Perez
Favorite
Perot, Gaëlle

Cancer Research Center of Toulouse
(P 104) COMPREHENSIVE IMMUNE PROFILING UNVEILS A SUBSET OF LEIOMYOSARCOMA WITH HOT TUMOR IMMUNE MICROENVIRONMENT
Gaëlle Perot
Favorite
(P 201) PLEOMORPHIC RHABDOMYOSARCOMAS: A NEW ENTITY ASSOCIATED WITH LYNCH SYNDROME? FIRST RESULTS OF SARCLYNCH NATIONAL STUDY
Gaëlle Perot
Favorite
(P 268) IMPACT OF CELLULAR FUSION IN THE ONCOGENESIS OF LEIOMYOSARCOMAS
Gaëlle Perot
Favorite
Perrin, Virginie

CENTRE LEON BERARD AND CANCER RESEARCH CENTER OF LYON (INSERM U1052-CNRS5286)
(P 435) ONCOGENIC FUSION YWHAE::NUTM2 DISRUPT EP300/BCOR INTERACTION
Virginie Perrin
Favorite
Perrone, Federica

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 363) Β-CATENIN MUTATIONS AND TRANSCRIPTOMIC REPROGRAMMING IN DESMOID FIBROMATOSIS (DF)
Federica Perrone
Favorite
PERSARC research group, VALUE-

Leiden University Medical Center
(P 132) SARCOMA PATEINTS' VIEWS ON USING A RISK-PREDICTION MODEL TO INFORM TREATMENT DECISIONS.
VALUE- PERSARC research group
Favorite
Pestana, Roberto

Hospital Israelita Albert Einstein
(P 360) TP53 ALTERATIONS IN SARCOMAS: AN ANALYSIS FROM THE AACR-GENIE DATABASE
Roberto Pestana
Favorite
Petersen, Ivy

Mayo Clinic
(P 02) PEDIATRIC SYNOVIAL SARCOMA: A REVIEW OF 21 CASES FROM A SINGLE INSTITUTION
Ivy Petersen
Favorite
(P 306) USE OF PENCIL BEAM SCANNING PROTON RADIOTHERAPY IN MOBILE SPINE CHORDOMAS
Ivy Petersen
Favorite
(P 465) UNPLANNED EXCISION OF SYNOVIAL SARCOMA: FACTORS ASSOCIATED WITH RECURRENCE AND SURVIVAL
Ivy Petersen
Favorite
(P 518) OUTCOMES OF NON-ANGIOSARCOMA RADIATION-ASSOCIATED SOFT TISSUE SARCOMAS OF THE CHEST
Ivy Petersen
Favorite
Peterson, Christine

The University of Texas MD Anderson Cancer Center
(P 269) PLASMA DNA METHYLATION-BASED BIOMARKERS FOR MPNST DETECTION IN PATIENTS WITH NEUROFIBROMATOSIS TYPE 1 (NF1)
Christine Peterson
Favorite
Peters, Solange

CHUV
(P 535) THERAGNOSTICS IN SOFT TISSUE SARCOMA USING A VASCULAR DISCRUPTION APPROACH
Solange Peters
Favorite
Petit, Arnaud

APHP. Sorbonne Université, Hopital Armand Trouseau
(P 212) REPORT ON THE EWING SARCOMA PATIENTS ENROLLED IN ARM D OF THE ACSE-ESMART TRIAL: PHASE I/II STUDY OF THE PARP INHIBITOR OLAPARIB IN COMBINATION WITH IRINOTECAN IN CHILDREN WITH ADVANCED MALIGNANCIES
Arnaud Petit
Favorite
Petrini, Massimiliano

IRST
(P 533) SAFETY AND PRELIMINARY BIOLOGICAL ACTIVITY OF A PHASE II TRIAL OF AUTOLOGOUS DENDRITIC CELLS VACCINATION IN SARCOMAS.
Massimiliano Petrini
Favorite
Petrochenko, Nikolay

National Medical Research Center of Oncology named after N.N. Blokhin "of the Ministry of Health of the Russian Federation
(P 459) EXPERIENCE IN THE USE OF INDIVIDUALIZED 3D-IMPLANTS IN THE RECONSTRUCTION OF DEFECTS IN PATIENTS WITH TUMORS OF THE CHEST WALL
Nikolay Petrochenko
Favorite
Petrongari, Maria Grazia

IRCCS Istituto Nazionale Tumori Regina Elena, Rome, Italy
(P 74) SACRAL CHORDOMA: A RANDOMIZED & OBSERVATIONAL STUDY ON SURGERY VS DEFINITIVE RADIOTHERAPY IN PRIMARY LOCALIZED DISEASE (SACRO). INTERIM ANALYSIS
Maria Grazia Petrongari
Favorite
Petrosyan, Mikael

Children's National Hospital
(P 18) RETROSPECTIVE ANALYSIS ON OUTCOMES PEDIATRIC PATIENTS WITH SARCOMA AND LUNG METASTASES STATUS POST PNEUMONECTOMY VERSUS PARTIAL LUNG RESECTION
Mikael Petrosyan
Favorite
Piana, Raimondo

Azienda Ospedaliera Citta della Salute e della Scienza di Torino
(P 69) DEVELOPMENT AND MISSION OF THE HARMONIZATION INTERNATIONAL BONE SARCOMA CONSORTIUM (HIBISCUS)
Raimondo Piana
Favorite
Piccinelli, Paul

Skåne University Hospital
(P 372) COPY NUMBER GAIN OF MDM2 IN ROD-SHAPED CHROMOSOMES PROVIDES CLUES TO EARLY STAGES IN CIRCULARIZED GENE AMPLIFICATION IN LIPOSARCOMA
Paul Piccinelli
Favorite
Piccione, Emily

Inhibrx, Inc
(P 439) THE TETRAVALENT DEATH RECEPTOR 5 AGONIST INBRX-109 COMBINED WITH CHEMOTHERAPY IN EWING SARCOMA: PRELIMINARY DATA FROM A PHASE 1 STUDY
Emily Piccione
Favorite
Piel, Jessica

Foghorn Therapeutics
(P 271) PHARMACODYNAMICS AND MECHANISTIC IMPACTS OF FHD-609, A BROMODOMAIN-CONTAINING PROTEIN 9 DEGRADER, IN A PHASE 1 STUDY IN PATIENTS WITH ADVANCED SYNOVIAL SARCOMA OR SMARCB1-LOSS TUMORS
Jessica Piel
Favorite
Pienkowski, Andrzej

Maria Sklodowska-Curie National Research Institute of Oncology
(P 95) LONG-TERM OUTCOMES OF PATIENTS DIAGNOSED WITH CHORDOMA OF THE SACRUM
Andrzej Pienkowski
Favorite
Pienta, Kenneth

Johns Hopkins School of Medicine
(P 412) LEIOMYOSARCOMA POLYANEUPLOID CANCER CELLS DEVELOP IN RESPONSE TO CHEMOTHERAPY AND CONTRIBUTE TO CHEMORESISTANCE
Kenneth Pienta
Favorite
Pieri, Federica

Pathology Unit, "Morgagni-Pierantoni" Hospital
(P 37) DISSECTING THE ROLE OF EXTRACELLULAR VESICLES IN THE MANAGEMENT OF GIST
Federica Pieri
Favorite
Pieri, Federica

Pathology Unit, "Morgagni-Pierantoni" Hospital, 47121 Forlì, Italy
(P 253) THE EFFICACY OF MEDICATED PATCHES IN SOFT TISSUE SARCOMAS: IN-VITRO AND EX-VIVO VALIDATION.
Federica Pieri
Favorite
Pieri, Federica

Pathology Unit, "Morgagni-Pierantoni" Hospital
(P 364) EVALUATION OF THE PREDICTIVE ROLE OF SYSTEMIC AND INTRATUMORAL IMMUNITY IN PATIENTS WITH LOCALIZED LIPOSARCOMAS, MYXOFIBROSARCOMAS AND UNDIFFERENTIATED PLEOMORPHIS SARCOMAS
Federica Pieri
Favorite
(P 533) SAFETY AND PRELIMINARY BIOLOGICAL ACTIVITY OF A PHASE II TRIAL OF AUTOLOGOUS DENDRITIC CELLS VACCINATION IN SARCOMAS.
Federica Pieri
Favorite
Pierini, Michela

IRCCS Istituto Ortopedico Rizzoli
(P 144) IMPLEMENTATION OF THE EUROPEAN CLINICAL TRIAL REGULATION: SURVEY OF THE ITALIAN SARCOMA GROUP CENTERS
Michela Pierini
Favorite
Pierrevelcin, Marina

UMR CNRS 7021
(P 277) ANTI-GD2 SYNERGIZES WITH HYPOXIA PATHWAY TARGETING TO BLOCK OSTEOSARCOMA CELL PROLIFERATION AND MIGRATION.
Marina Pierrevelcin
Favorite
Pietrok, Laura

Cerberus Therapeutics
(P 115) EFFICACY AND CORREALTIVE ANALYSIS OF USING NEOADJUVANT INTRATUMORAL HIGH DOSE TALIMOGENE LAHERPAREPVEC (TVEC) WITH CONCURRENT RADIATION IN HIGH-RISK EXTREMITY AND TRUNK SOFT-TISSUE SARCOMAS
Laura Pietrok
Favorite
Pignochino, Ymera

Candiolo Cancer Institute IRCCS FPO
(P 262) ESTABLISHMENT AND CHARACTERIZATION OF THE FIRST RADIATION-INDUCED, PATIENT-DERIVED ANGIOSARCOMA CELL LINE
Ymera Pignochino
Favorite
Pilar, Avinash

University College London Hospital
(P 92) DOSIMETRIC CHARACTERISTICS, OUTCOMES AND PROGNOSTIC FACTORS OF PATIENTS WITH EXTRACRANIAL CHORDOMAS AND CHONDROSARCOMAS TREATED WITH HIGH DOSE RADIOTHERAPY: A LARGE SINGLE INSTITUTION COHORT
Avinash Pilar
Favorite
(P 325) OUTCOMES AFTER MODERN THREE-DIMENSIONAL CONFORMAL RADIOTHERAPY AND INTENSITY MODULATED RADIOTHERAPY TO TREAT SARCOMAS ARISING IN THE HAND: A RETROSPECTIVE SERIES
Avinash Pilar
Favorite
Pilgermann, Kai

Sarcoma Patient Advocacy Global Network (SPAGN)
(P 136) SETTING THE INTERNATIONAL RESEARCH AGENDA FOR SARCOMA WITH PATIENTS AND CARERS: PRELIMINARY RESULTS OF PHASE II OF THE SARCOMA PATIENT ADVOCACY GLOBAL NETWORK (SPAGN) PRIORITY SETTING PARTNERSHIP
Kai Pilgermann
Favorite
Pillay, Nischalan

University College London, Cancer Institute
(P 04) THE CELL ATLAS OF CLEAR CELL SARCOMA
Nischalan Pillay
Favorite
(P 381) THE GENOMIC LANDSCAPE OF CLEAR CELL SARCOMA
Nischalan Pillay
Favorite
Pink, Daniel

Helios Hospital Bad Saarow, Sarcoma Centre Berlin-Brandenburg, Department of Hematology, Oncology and Palliative Care
(P 135) UNMET NEEDS IN LOCALLY ADVANCED (UNRESECTABLE) OR METASTATIC DEDIFFERENTIATED LIPOSARCOMA AND EXPECTATIONS FOR CLINICAL TRIALS: AN INTERNATIONAL DELPHI CONSENSUS STUDY
Daniel Pink
Favorite
Pinto, Navin

Seattle Children’s Hospital
(P 03) EVOLUTION OF CLINICALLY ACTIONABLE VARIANTS IN ADVANCED PEDIATRIC AND AYA BONE SARCOMAS
Navin Pinto
Favorite
(P 542) ENROLLMENT OF PEDIATRIC PARTICIPANTS WITH MAGE-A4-POSITIVE SOLID TUMORS IN A PHASE 1/2, OPEN-LABEL, BASKET TRIAL OF AFAMITRESGENE AUTOLEUCEL ("AFAMI-CEL")
Navin Pinto
Favorite
Pionelli, Maria Grazia

AORN Santobono-Pausilipon
(P 144) IMPLEMENTATION OF THE EUROPEAN CLINICAL TRIAL REGULATION: SURVEY OF THE ITALIAN SARCOMA GROUP CENTERS
Maria Grazia Pionelli
Favorite
Piorkowska, Karolina

Hospital for Sick Children
(P 108) EFFECT OF TUMOUR-TARGETED HYPERTHERMIA AND CHEMOTHERAPY ON THE IMMUNE PROFILE OF A MURINE MODEL OF EMBRYONAL RHABDOMYOSARCOMA
Karolina Piorkowska
Favorite
Piperno-Neumann, Sophie

Institut Curie
(P 389) OSTEOBLASTIC-GENE SIGNATURE TO PREDICT SURVIVAL IN PEDIATRIC OSTEOSARCOMA (OS) AND TO FOLLOW PATIENTS TOWARDS LIQUID BIOPSY: A COLLABORATIVE WORK IN OS2006 PROTOCOL.
Sophie Piperno-Neumann
Favorite
Pissaloux, Daniel

CENTRE LEON BERARD AND CANCER RESEARCH CENTER OF LYON (INSERM U1052-CNRS5286)
(P 382) NTRK1/2/3 FUSIONS DETECTION USING RNA-SEQ IN MESENCHYMAL TUMORS REVEALS ULTRA-RARE AND HISTO-SPECIFIC TARGETABLE ALTERATIONS: EXPERIENCE OF AN EXTENSIVE ROUTINE RESEARCH PROGRAM.
Daniel Pissaloux
Favorite
(P 435) ONCOGENIC FUSION YWHAE::NUTM2 DISRUPT EP300/BCOR INTERACTION
Daniel Pissaloux
Favorite
Placzke, Joanna

Maria Sklodowska-Curie National Research Institute of Oncology, Department of Soft Tissue/Bone Sarcoma and Melanoma, Warsaw, Poland
(P 21) YOUNG ADULTS WITH NONMETASTATIC OPERABLE OSTEOSARCOMA TREATED PERIOPERATIVELY WITH METHOTREXATE, DOXORUBICIN AND CISPLATIN SCHEDULE, SINGLE INSTITUTION REPORT
Joanna Placzke
Favorite
Planas Canovas, Georgina

Hospital de la Santa Creu i Sant Pau
(P 507) PRIMARY CHEST WALL TUMORS OF MESENCHYMAL ORIGIN. EXPERIENCE OF A REFERENCE UNIT
Georgina Planas Canovas
Favorite
(P 508) DREAM, UTOPIA OR REALISM? PROGNOSTIC FACTORS IN LUNG METASTASECTOMY OF DISSEMINATED SARCOMA DISEASE
Georgina Planas Canovas
Favorite
Plaumann, Pauline

Pediatrics III, University Hospital Essen, West German Cancer Center
(P 17) METASTASIS-SPECIFIC GENE EXPRESSION PATTERNS IN EWING SARCOMA
Pauline Plaumann
Favorite
Pleasance, Erin

BC Cancer
(P 104) COMPREHENSIVE IMMUNE PROFILING UNVEILS A SUBSET OF LEIOMYOSARCOMA WITH HOT TUMOR IMMUNE MICROENVIRONMENT
Erin Pleasance
Favorite
Podleska, Lars-Erik

Department of Musculoskeletal Oncology, West German Cancer Center, University Hospital Essen
(P 220) [68GA]GA-FAPI PET/CT AS NOVEL DIAGNOSTIC TOOL IN SARCOMA
Lars-Erik Podleska
Favorite
Poklepovic, Andrew

Virginia Commonwealth University
(P 207) A MULTICENTER PHASE II STUDY OF CABOZANTINIB PLUS NIVOLUMAB FOR PATIENTS WITH ADVANCED ANGIOSARCOMA PREVIOUSLY TREATED WITH A TAXANE: ALLIANCE A091902
Andrew Poklepovic
Favorite
Polignano, Maggie

INT Milan
(P 328) REAL-LIFE EXPERIENCE OF PAZOPANIB IN PATIENTS WITH ADVANCED UTERINE LEIOMYOSARCOMA (U-LMS) FROM TWO REFERRAL ITALIAN CENTERS
Maggie Polignano
Favorite
Pollack, Seth

Robert H. Lurie Comprehensive Cancer Center of Northwestern University
(P 96) LEPTOMENINGEAL RECURRENCE OF EWING'S SARCOMA: A CASE SERIES
Seth Pollack
Favorite
(P 112) PHASE 1/2 STUDY OF YH001, A CTLA-4 ANTIBODY WITH THE SUBCUTANEOUSLY ADMINISTERED PD-L1 ANTIBODY ENVAFOLIMAB, WITH OR WITHOUT DOXORUBICIN IN PATIENTS WITH ADVANCED OR METASTATIC SOFT TISSUE SARCOMA
Seth Pollack
Favorite
(P 180) HEALTH RELATED QUALITY OF LIFE OF PATIENTS WITH ADVANCED LEIOMYOSARCOMA AND OTHER SOFT TISSUE SARCOMAS TREATED WITH CABOZANTINIB AND TEMOZOLOMIDE
Seth Pollack
Favorite
(P 206) A SINGLE-ARM, PHASE II STUDY OF NEOADJUVANT PEMBROLIZUMAB COMBINED WITH RADIOTHERAPY IN THE PRIMARY TREATMENT OF SOFT TISSUE SARCOMAS.
Seth Pollack
Favorite
(P 219) ELECTIVE DISCONTINUATION OF SORAFENIB TREATMENT IN DESMOID TUMORS: A RETROSPECTIVE ANALYSIS WITH IMPLICATIONS FOR CLINICAL PRACTICE
Seth Pollack
Favorite
Pollard, Kai

John Hopkins University
(P 250) SHARING HIGH-QUALITY SAMPLES AND DATA TO THE NF1 RESEARCH COMMUNITY: THE ROLE OF THE JOHNS HOPKINS NF1 BIOSPECIMEN REPOSITORY
Kai Pollard
Favorite
(P 274) TYK2 AND MEK COMBINATION THERAPY IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS AND OTHER SOFT TISSUE SARCOMAS
Kai Pollard
Favorite
Pollock, Raphael

The James Cancer Hospital / The Ohio State University
(P 301) REDUCING THE INVASIVE POTENTIAL OF DEDIFFERENTIATED LIPOSARCOMA BY TARGETING ALTERNATIVE RNA SPLICING MACHINERY
Raphael Pollock
Favorite
(P 314) PRE-OPERATIVE RADIATION THERAPY INCREASES ADHERENCE IN PATIENTS WITH HIGH-RISK EXTREMITY SOFT TISSUE SARCOMA
Raphael Pollock
Favorite
(P 335) EXTRACELLULAR VESICLE MDM2 DNA AS A BIOMARKER OF TUMOR PRESENCE AND RECURRENCE IN RETROPERITONEAL LIPOSARCOMA
Raphael Pollock
Favorite
(P 347) INCIDENCE AND TIMING OF RECURRENCE AFTER ADJUVANT PALBOCICLIB IN COMPLETELY RESECTED RETROPERITONEAL LIPOSARCOMA
Raphael Pollock
Favorite
Poon, Andrew

University of Guelph
(P 304) A COMPARATIVE ANALYSIS OF METABOLIC FLEXIBILITY IN OSTEOSARCOMA CELLS
Andrew Poon
Favorite
Portney, Daniel

University of Chicago
(P 479) EXPANDABLE ENDOPROSTHESES: SHOULD WE CONSIDER NARROWING OUR INDICATIONS? A SYSTEMATIC REVIEW OF THE LITERATURE AND COMPARISON OF OUTCOMES BY AGE GROUPS
Daniel Portney
Favorite
Posey, Kristi

MD Anderson Cancer Center
(P 71) CHEMOTHERAPY AND PROGNOSTIC SIGNIFICANCE OF EXTENT OF DEDIFFERENTIATION IN DEDIFFERENTIATED PAROSTEAL OSTEOSARCOMA
Kristi Posey
Favorite
Poumeaud, François

Oncopole Claudius Regaud
(P 201) PLEOMORPHIC RHABDOMYOSARCOMAS: A NEW ENTITY ASSOCIATED WITH LYNCH SYNDROME? FIRST RESULTS OF SARCLYNCH NATIONAL STUDY
François Poumeaud
Favorite
Powers, Benjamin

The University of Kansas Health System
(P 214) SIGNIFICANT TREATMENT RESPONSE IN PATIENTS WITH PRIMARY RESECTABLE EXTREMITY MYXOID LIPOSARCOMA RECEIVING NEOADJUVANT TRABECTEDIN AND RADIATION
Benjamin Powers
Favorite
Pratilas, Christine

The Johns Hopkins Hospital
(P 143) EXPLORING HOSPITAL VOLUME THRESHOLDS FOR IMPROVED SARCOMA TREATMENT ACROSS DIFFERENT AGE CATEGORIES IN THE UNITED STATES
Christine Pratilas
Favorite
Pratilas, Christine

Johns Hopkins University
(P 250) SHARING HIGH-QUALITY SAMPLES AND DATA TO THE NF1 RESEARCH COMMUNITY: THE ROLE OF THE JOHNS HOPKINS NF1 BIOSPECIMEN REPOSITORY
Christine Pratilas
Favorite
(P 274) TYK2 AND MEK COMBINATION THERAPY IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS AND OTHER SOFT TISSUE SARCOMAS
Christine Pratilas
Favorite
(P 551) PHASE II TRIAL OF GEMCITABINE AND NAB-PACLITAXEL IN PATIENTS WITH RECURRENT RHABDOMYOSARCOMA: A CLINICAL TRIAL IN PROGRESS FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION
Christine Pratilas
Favorite
Prenen, Hans

University Hospital Antwerp
(P 27) A MULTICENTER RETROSPECTIVE STUDY ON THE CLINICAL BEHAVIOR OF SDH-DEFICIENT GIST
Hans Prenen
Favorite
Pressey, Joseph

Cincinnati Children’s Hospital
(P 178) INITIAL RESULTS FROM A PHASE 1 STUDY OF CFT8634, A NOVEL BIFUCTIONAL DEGRADATION ACTIVATING COMPOUND (BIDAC) DEGRADER OF BRD9, IN SYNOVIAL SARCOMA AND SMARCB1-NULL TUMORS
Joseph Pressey
Favorite
Preston, Jessica

Veramed
(P 114) PRIMARY ANALYSIS OF EFFICACY AND SAFETY OF LETETRESGENE AUTOLEUCEL (LETE-CEL) AS FIRST-LINE TREATMENT FOR UNRESECTABLE OR METASTATIC SYNOVIAL SARCOMA (SS); SUBSTUDY 1 OF IGNYTE-ESO
Jessica Preston
Favorite
Presutti, Laura

Rocky Vista College of Medicine
(P 373) DEDIFFERENTIATED AND HIGH GRADE CHONDROSARCOMAS: HOW DOES ISOCITRATE DEHYDROGENASE STATUS APPRISE PROGNOSIS AND THERAPY?
Laura Presutti
Favorite
Pretell-Mazzini, Juan

Miami Cancer Institute
(P 320) A PROSPECTIVE MULTICENTER EXPERIENCE OF PROTON THERAPY FOR RHABDOMYOSARCOMA AND EWING SARCOMA: OUTCOMES FROM THE PROTON COLLABORATIVE GROUP REGISTRY
Juan Pretell-Mazzini
Favorite
(P 485) SUBTROCHANTERIC NON-UNION AFTER INTRAMEDULLARY NAILING DUE TO PATHOLOGICAL FRACTURE:PROXIMAL FEMORAL REPLACEMENT AS A SALVAGE APPROACH
Juan Pretell-Mazzini
Favorite
Price, Bradley

Action for Pulmonary Fibrosis
(P 151) DEVELOPMENT AND IMPACT OF A PRIMARY CARE SARCOMA EDUCATION MODULE FOR ENGLAND AND WALES
Bradley Price
Favorite
Priebe, Waldemar

Experimental Therapeutics, MD Anderson Cancer Center/ Moleculin Biotech, Inc
(P 183) A PHASE 1B/2 STUDY OF LIPOSOMAL ANNAMYCIN (ANN) IN SUBJECTS WITH PREVIOUSLY TREATED SOFT-TISSUE SARCOMAS (STS) WITH PULMONARY METASTASES
Waldemar Priebe
Favorite
Prieto Granada, Carlos

Vanderbilt University Medical Center
(P 218) NEOADJUVANT CHEMOTHERPAY AND RADIATION DECREASES TUMOR SIZE, VIABILITY, AND RECURRENCE IN MULTIPLE LIPOSARCOMA SUBSETS
Carlos Prieto Granada
Favorite
Prior, John

CHUV
(P 535) THERAGNOSTICS IN SOFT TISSUE SARCOMA USING A VASCULAR DISCRUPTION APPROACH
John Prior
Favorite
Prokopishyn, Nicole

Alberta Precision Laboratories
(P 110) GCAR1: GPNMB CAR T THERAPY FOR MIT FAMILY TRANSLOCATION POSITIVE CANCERS
Nicole Prokopishyn
Favorite
Proment, Alessia

Department of Oncology, University of Turin
(P 109) INTENSE PRECLINICAL ACTIVITY BY B7H3-SPECIFIC CAR.CIK LYMPHOCYTES AGAINST EPITHELIOID SARCOMA
Alessia Proment
Favorite
Prough, Haley

Cleveland Clinic Foundation
(P 514) INTERSTITIAL BRACHYTHERAPY IN THE TREATMENT OF SOFT TISSUE SARCOMA: LOCAL RECURRENCE AND WOUND OUTCOMES
Haley Prough
Favorite
Provenzano, Salvatore

Mesenchymal and rare cancer Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
(P 142) THE SARCOMA EUROPEAN AND LATIN AMERICAN NETWORK (SELNET) PROJECT: OVERVIEW OF THE MAIN RESULTS OF THE SELNET REGISTRY
Salvatore Provenzano
Favorite
(P 333) SYSTEMIC TREATMENT IN INTRA-ABDOMINAL DESMOID-TYPE FIBROMATOSIS: A SINGLE INSTITUTION RETROSPECTIVE CASE SERIES ANALYSIS
Salvatore Provenzano
Favorite
(P 431) TREATMENT STRATEGY AND PROGNOSTIC FACTORS IN EXTRASKELETAL EWING SARCOMA: AN INSTITUTIONAL RETROSPECTIVE ANALYSIS
Salvatore Provenzano
Favorite
(P 432) LONG-LASTING DISEASE CONTROL WITH TRABECTEDIN IN A CASE OF METASTATIC EWSR1::PATZ1 SARCOMA
Salvatore Provenzano
Favorite
Provenzano, Salvatore

Adult mesenchymal tumours and rare cancers unit, Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Ital
(P 437) ULTRA-RARE UNDIFFERENTIATED SMALL ROUND CELL SARCOMA: HOW SHOULD WE TREAT THEM? AN ANALYSIS FORM THE GRACEFUL PROJECT
Salvatore Provenzano
Favorite
Provenzano, Salvatore

Mesenchymal and rare cancer Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
(P 455) EXTRASKELETAL EWING SARCOMA: A MULTICENTRIC RETROSPECTIVE STUDY FROM THE ITALIAN SARCOMA GROUP
Salvatore Provenzano
Favorite
Przybyl, Joanna

McGill University
(P 367) CHARACTERIZING HYPOXIA AND ASSOCIATED MOLECULAR FEATURES IN EXTREMITY SOFT TISSUE SARCOMA
Joanna Przybyl
Favorite
(P 376) MULTI-OMIC PROFILING OF LEIOMYOSARCOMA IDENTIFIES MARKERS PREDICTIVE OF RESPONSE TO GEMCITABINE AND DOCETAXEL
Joanna Przybyl
Favorite
Puiseux, Chloe

Gilles.Vassal@gustaveroussy.fr
(P 75) REAL-WORLD DATA ON REGORAFENIB AND CABOZANTINIB IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH RELAPSED OSTEOSARCOMA AND EWING SARCOMA INCLUDED IN THE SACHA-FRANCE STUDY
Chloe Puiseux
Favorite
Purgina, Bibianna

The Ottawa Hospital
(P 98) TUMOR IMMUNE PROFILING AND IDENTIFICATION OF IMMUNOTHERAPEUTIC TARGETS IN DEDIFFERENTIATED LIPOSARCOMA
Bibianna Purgina
Favorite
Puri, Rajni

KUMC
(P 446) SYNERGISTIC TARGETING OF KIF11 AND AURKA TO IMPROVE OUTCOMES FOR EWING SARCOMA
Rajni Puri
Favorite
Purnamasari, Mia

Essen University Hospital
(P 275) GIST-BSF1: A NOVEL SCF-DEPENDENT, WILD-TYPE KIT CELL LINE PLATFORM THAT ALLOWS RAPID GENERATION OF ISOGENIC SUBLINES WITH BOTH IMATINIB-SENSITIVE AND IMATINIB-RESISTANT GENOTYPES
Mia Purnamasari
Favorite
Puviindran, Vijitha

Duke University
(P 375) IDENTIFICATION OF METASTATIC CELLS IN UNDIFFERENTIATED PLEOMORPHIC SARCOMA: SINGLE CELL RNA SEQUENCING AND CIBERSORT ANALYSIS
Vijitha Puviindran
Favorite
(P 393) INVESTIGATING THE ROLE OF HDACS IN THE PROGRESSION OF METASTATIC UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Vijitha Puviindran
Favorite
Q
Qian, Hailong

Ningbo Medical Center Lihuili Hospital
(P 34) RIPRETINIB IN COMBINATION WITH OTHER TKIS IN CHINESE PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR: A MULTI-CENTER RETROSPECTIVE ANALYSIS
Hailong Qian
Favorite
Qian, Haoran

Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
(P 39) MANAGEMENT PRACTICES OF GASTROINTESTINAL STROMAL TUMORS: A QUESTIONNAIRE SURVEY OF GENERAL SURGEONS IN CHINA
Haoran Qian
Favorite
(P 41) GENOMIC ANALYSIS OF SECONDARY KIT MUTATIONS IN CHINESE PATIENTS WITH IMATINIB-RESISTANT ADVANCED GASTROINTESTINAL STROMAL TUMORS USING NEXT-GENERATION SEQUENCING (NGS)
Haoran Qian
Favorite
Qian, Meifen

Department of Medical Oncology, Yixing Hospital of Traditional Chinese Medicine
(P 44) RIPRETINIB FOR THE TREATMENT OF CHINESE PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS HARBORING KIT SECONDARY MUTATIONS: A MULTICENTER, RETROSPECTIVE STUDY
Meifen Qian
Favorite
Qi, Changsong

Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute Beijing 100142, P. R. China
(P 46) CIRCULATING TUMOR DNA (CTDNA) ANALYSES AND RESISTANCE MECHANISMS EXPLORATION OF KIT-MUTANT GASTROINTESTINAL STROMAL TUMORS (GISTS) TREATED WITH AVAPRITINIB OR RIPRETINB
Changsong Qi
Favorite
Qi, Jiang

Department of Gastrointestinal Surgery, Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology
(P 38) EFFICACY AND SAFETY OF RIPRETINIB IN THE TREATMENT OF ADVANCED GASTROINTESTINAL STROMAL TUMORS: A MULTICENTER RETROSPECTIVE STUDY
Jiang Qi
Favorite
Qin, Jichao

Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology
(P 34) RIPRETINIB IN COMBINATION WITH OTHER TKIS IN CHINESE PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR: A MULTI-CENTER RETROSPECTIVE ANALYSIS
Jichao Qin
Favorite
Qin, Li-Xuan

Memorial Sloan Kettering Cancer Center
(P 24) COMPREHENSIVE ANALYSIS OF THE GENOMIC LANDSCAPE AND CLINICAL BEHAVIOR IN GIST USING NEXT GENERATION SEQUENCING (NGS, MSK-IMPACT)
Li-Xuan Qin
Favorite
Qi, Peng

Cleveland Clinic
(P 308) OPTIMAL BIOLOGIC EFFECTIVE DOSE OF STEREOTACTIC BODY RADIOTHERAPY FOR METASTATIC AND RECURRENT SARCOMA
Peng Qi
Favorite
Quagliuolo, Vittorio

Humanitas, Research Hospital, Milan, Italy
(P 74) SACRAL CHORDOMA: A RANDOMIZED & OBSERVATIONAL STUDY ON SURGERY VS DEFINITIVE RADIOTHERAPY IN PRIMARY LOCALIZED DISEASE (SACRO). INTERIM ANALYSIS
Vittorio Quagliuolo
Favorite
(P 433) A 20-YEAR MONOCENTER EXPERIENCE ON CLINICAL CHARACTERISTICS AND OUTCOME OF EXTRASKELETAL EWING SARCOMA.
Vittorio Quagliuolo
Favorite
Quagliuolo, Vittorio Lorenzo

IRCCS Humanitas Research Hospital
(P 327) LEARNING CURVE ANALYSIS IN RETROPERITONEAL SARCOMA SURGERY
Vittorio Lorenzo Quagliuolo
Favorite
(P 342) THE EVALUATION AND OUTCOMES OF MESENTERIC AND INTRA-ABDOMINAL DESMOIDS: A TARPSWG STUDY
Vittorio Lorenzo Quagliuolo
Favorite
(P 457) LONG-TERM FOLLOW-UP OF PATIENTS WITH ATYPICAL LIPOMATOUS TUMOR (ALT) TREATED WITH MARGINAL RESECTION IN A REFERRAL CENTER
Vittorio Lorenzo Quagliuolo
Favorite
Qu, Huayi

Peking University People's Hospital
(P 464) INDOCYANINE GREEN FLUORESCENCE IMAGING MAY DETECT TUMOUR RESIDUALS DURING SURGERY FOR BONE AND SOFT-TISSUE TUMOURS
Huayi Qu
Favorite
Quignot, Chloé

Institut Curie
(P 395) TARGETING CD44-MEDIATED IRON ENDOCYTOSIS IN DESMOID FIBROMATOSIS
Chloé Quignot
Favorite
Quildrian, Sergio

University of Buenos Aires, Angel H. Roffo Institute of Oncology - Buenos Aires British Hospital
(P 330) TREATMENT VARIATIONS, OUTCOMES AND PATTERNS OF RECURRENCE AFTER CURATIVE INTENT TREATMENT FOR PRIMARY RETROPERITONEAL SARCOMAS IN LATIN AMERICA. FIRST COLLABORATIVE LATAMSARC STUDY
Sergio Quildrian
Favorite
(P 460) IMPACT OF RESIDUAL TUMOR AFTER RE-EXCISION IN PATIENTS WITH PRIOR UNPLANNED RESECTION OF EXTREMITY AND TRUNK SOFT TISSUE SARCOMAS
Sergio Quildrian
Favorite
Quillin, Kate

Sarcoma UK
(P 150) VISUALISING SOFT TISSUE SARCOMA INCIDENCE DATA FOR PATIENT EMPOWERMENT
Kate Quillin
Favorite
quintana, MariaJesus

Hospital de la Santa Creu i Sant Pau
(P 504) WHY DO SOME PATIENTS WITH SYNOVIAL SARCOMA HAVE BETTER FUNCTIONAL OUTCOMES AFTER RESECTION SURGERY? ANALYSIS OF 102 CASES
MariaJesus quintana
Favorite
Quizi, Jennifer

University of Ottawa
(P 110) GCAR1: GPNMB CAR T THERAPY FOR MIT FAMILY TRANSLOCATION POSITIVE CANCERS
Jennifer Quizi
Favorite
Qumseya, Amira

University of Florida
(P 13) OUTCOME OF PATIENTS WITH RELAPSED OR REFRACTORY NON-RHABDOMYOSARCOMA SOFT TISSUE SARCOMAS ENROLLED IN PHASE II COOPERATIVE GROUP CLINICAL TRIALS: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP
Amira Qumseya
Favorite
(P 425) CHARACTERIZATION OF RHABDOMYOSARCOMA WITH PAX7::FOXO1 FUSIONS: A REPORT FROM THE SOFT TISSUE COMMITTEE OF THE CHILDREN'S ONCOLOGY GROUP
Amira Qumseya
Favorite
Quon, Doris

Sarcoma Oncology Center
(P 116) UPDATE ON SAINT: RESULTS OF 100 PATIENTS TREATED WITH IPILIMUMAB (I), NIVOLUMAB (N) AND TRABECTEDIN (T) AS FIRST LINE THERAPY FOR ADVANCED SOFT TISSUE SARCOMA [NCT03138161]
Doris Quon
Favorite
(P 117) INTERIM ANALYSIS OF PHASE 2 STUDY: A METRONOMIC REGIMEN USING GEMCITABINE, DOXORUBICIN, DOCETAXEL AND NIVOLUMAB FOR ADVANCED LEIOMYOSARCOMA (NCT04535713)
Doris Quon
Favorite
Qu, Zhe

Servier Pharmaceuticals
(P 66) PHASE I STUDY OF THE MUTANT IDH1 INHIBITOR IVOSIDENIB: LONG-TERM SAFETY AND CLINICAL ACTIVITY IN PATIENTS WITH CONVENTIONAL CHONDROSARCOMA
Zhe Qu
Favorite
R
Rabbitt, Laurann

SVUH
(P 213) EXPERIENCE WITH THE USE OF TRABECTEDIN IN ADVANCED SOFT TISSUE SARCOMA IN IRELAND
Laurann Rabbitt
Favorite
Rabi Mitre, Saba

Hospital de la Santa Creu i Sant Pau
(P 313) SPACIALLY-FRACTIONATED RADIOTHERAPY (LATTICE) TREATMENT IN INOPERABLE NON-EXTREMITY BULKY SOFT-TISSUE SARCOMAS
Saba Rabi Mitre
Favorite
Rabino, Martina

Department of Oncology, University of Turin
(P 109) INTENSE PRECLINICAL ACTIVITY BY B7H3-SPECIFIC CAR.CIK LYMPHOCYTES AGAINST EPITHELIOID SARCOMA
Martina Rabino
Favorite
(P 262) ESTABLISHMENT AND CHARACTERIZATION OF THE FIRST RADIATION-INDUCED, PATIENT-DERIVED ANGIOSARCOMA CELL LINE
Martina Rabino
Favorite
raciborska, Anna

Department of Oncology and Surgical Oncology for Children and Youth, Mother and Child Institute, 01-211 Warsaw, Poland.
(P 09) A NOMOGRAM MODEL TO PREDICT THE OVERALL SURVIVAL OF ADOLESCENT AND YOUNG ADULT PATIENTS WITH LOCALLY ADVANCED EWING SARCOMA.
Anna raciborska
Favorite
Raciborska, Anna

Insitute of Mother and Child
(P 73) FOSTER CONSORTIUM, FIGHT OSTEOSARCOMA THROUGH EUROPEAN RESEARCH
Anna Raciborska
Favorite
(P 451) IMPACT OF TIME TO DIAGNOSIS - A PROSPECTIVE ANALYSIS OF THE EWING 2008 TRIAL
Anna Raciborska
Favorite
Radaelli, Stefano

Sarcoma Service, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
(P 74) SACRAL CHORDOMA: A RANDOMIZED & OBSERVATIONAL STUDY ON SURGERY VS DEFINITIVE RADIOTHERAPY IN PRIMARY LOCALIZED DISEASE (SACRO). INTERIM ANALYSIS
Stefano Radaelli
Favorite
(P 126) CURRENT PRACTICE IN SPERMATIC CORD SARCOMA: ONCOLOGICAL TIMELINES AND OUTCOMES ACCORDING TO INITIAL RESECTIONS PERFORMED AT A LOCAL HOSPITAL VERSUS EARLY PATIENT REFERRAL TO A TERTIARY CENTRE.
Stefano Radaelli
Favorite
(P 159) IN BETWEEN OF LYMPHOMAS AND SARCOMAS: WHERE DO HISTIOCYTIC AND DENDRITIC CELL NEOPLASMS (HDCN) STAND? A RETROSPECTIVE, MULTI-INSTITUTIONAL STUDY FROM THE ITALIAN SARCOMA GROUP (ISG)
Stefano Radaelli
Favorite
(P 329) DISTANT METASTASIS IN RETROPERITONEAL LEIOMYOSARCOMA: TUMOR SIZE, GRADE AND MORE?
Stefano Radaelli
Favorite
Raduski, Andrew

University of Minnesota
(P 414) GENOMIC ANALYSIS OF EWING SARCOMA AND HERNIA IDENTIFIES A POSITIVE GENETIC CORRELATION AND SUGGESTS BOTH ARE LINKED TO AN HMGA2 VARIANT
Andrew Raduski
Favorite
Ragbir, Maniram

The Newcastle upon Tyne Hospitals NHS Foundation Trust
(P 228) WHAT IS THE SIGNIFICANCE OF INDETERMINATE PULMONARY NODULES IN HIGH GRADE SOFT TISSUE SARCOMA? A RETROSPECTIVE COHORT STUDY
Maniram Ragbir
Favorite
Ragland, Dashaun

The Ohio State University
(P 502) SEPARATE RESECTION OF BIOPSY TRACT IN PRIMARY BONE SARCOMA: IMPLICATIONS FOR LOCAL RECURRENCE AND OVERALL SURVIVAL
Dashaun Ragland
Favorite
Rahimizadeh, Pegah

McGill University
(P 376) MULTI-OMIC PROFILING OF LEIOMYOSARCOMA IDENTIFIES MARKERS PREDICTIVE OF RESPONSE TO GEMCITABINE AND DOCETAXEL
Pegah Rahimizadeh
Favorite
Rai, Kunal

The University of Texas MD Anderson Cancer Center
(P 269) PLASMA DNA METHYLATION-BASED BIOMARKERS FOR MPNST DETECTION IN PATIENTS WITH NEUROFIBROMATOSIS TYPE 1 (NF1)
Kunal Rai
Favorite
(P 426) MULTI-OMIC ANALYSIS OF DESMOPLASTIC SMALL ROUND CELL TUMORS REVEAL DISTINCT LINEAGES
Kunal Rai
Favorite
Raimbault, Sandra

Oscar Lambret Cancer Center
(P 75) REAL-WORLD DATA ON REGORAFENIB AND CABOZANTINIB IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH RELAPSED OSTEOSARCOMA AND EWING SARCOMA INCLUDED IN THE SACHA-FRANCE STUDY
Sandra Raimbault
Favorite
Rajeswaran, Shankar

Lurie Children's Hospital
(P 476) FAVORABLE RESULTS FOLLOWING TREATMENT OF UNICAMERAL BONE CYSTS WITH DOXYCYCLINE SCLEROGRAFT TECHNIQUE
Shankar Rajeswaran
Favorite
(P 477) TREATMENT OF PROXIMAL FEMUR UNICAMERAL BONE CYSTS WITH DOXYCYCLINE SCLEROTHERAPY
Shankar Rajeswaran
Favorite
(P 478) TREATMENT OF CHONDROBLASTOMA WITH PERCUTANEOUS CRYOABLATION
Shankar Rajeswaran
Favorite
Rak, Janusz

McGill University
(P 65) PROFILING EXTRACELLULAR VESICLES AND NANOPARTICLES IN OSTEOSARCOMA
Janusz Rak
Favorite
Ramakrishna, Sneha

Division of Pediatric Hematology, Oncology, Stem Cell Transplantation & Regenerative Medicine, Department of Pediatrics, Stanford University
(P 542) ENROLLMENT OF PEDIATRIC PARTICIPANTS WITH MAGE-A4-POSITIVE SOLID TUMORS IN A PHASE 1/2, OPEN-LABEL, BASKET TRIAL OF AFAMITRESGENE AUTOLEUCEL ("AFAMI-CEL")
Sneha Ramakrishna
Favorite
Ramos-Mucci, Lorenzo

University of Oxford
(P 04) THE CELL ATLAS OF CLEAR CELL SARCOMA
Lorenzo Ramos-Mucci
Favorite
Ramos, Rafael

Hospital Universitario Son Espases
(P 113) IMMUNOSARC II: A SPANISH SARCOMA GROUP (GEIS) PHASE IB TRIAL OF DOXORUBICIN AND DACARBAZINE PLUS NIVOLUMAB IN FIRST LINE OF ADVANCED LEIOMYOSARCOMA
Rafael Ramos
Favorite
Ramsey, Duncan

Oregon Health & Science University
(P 129) LOW RATES OF SERVICE CONNECTIVITY FOR SOFT TISSUE SARCOMA (STS) AMONG ELIGIBLE VIETNAM VETERANS WITH AGENT ORANGE EXPOSURE
Duncan Ramsey
Favorite
(P 130) THE ADOPTION OF MEDICAID EXPANSION IN THE AFFORDABLE CARE ACT IS NOT ASSOCIATED WITH STAGE AT PRESENTATION OR 5-YEAR OVERALL SURVIVAL FOR BONE OR SOFT TISSUE SARCOMAS
Duncan Ramsey
Favorite
(P 227) DE NOVO NATURAL LANGUAGE PROCESSING (NLP) ALGORITHM ACCURATELY IDENTIFIES MYXOFIBROSARCOMA DIRECTLY FROM PATHOLOGY REPORTS
Duncan Ramsey
Favorite
(P 462) EXTERNAL VALIDATION OF A NOMOGRAM PREDICTING THE RISK OF POSTOPERATIVE MAJOR WOUND COMPLICATION IN SOFT TISSUE SARCOMA FOLLOWING PREOPERATIVE RADIOTHERAPY AND RESECTION
Duncan Ramsey
Favorite
(P 463) MACHINE LEARNING CORROBORATES TRADITIONAL REGRESSION TECHNIQUES IN PREDICTING MAJOR WOUND COMPLICATIONS AFTER SOFT TISSUE SARCOMA RESECTION WITHOUT IMPROVEMENTS IN PREDICTIVE PERFORMANCE
Duncan Ramsey
Favorite
Rana, Huma Q.

Dana-Farber Cancer Institute
(P 27) A MULTICENTER RETROSPECTIVE STUDY ON THE CLINICAL BEHAVIOR OF SDH-DEFICIENT GIST
Huma Q. Rana
Favorite
Ranallo, Nicoletta

Irst
(P 364) EVALUATION OF THE PREDICTIVE ROLE OF SYSTEMIC AND INTRATUMORAL IMMUNITY IN PATIENTS WITH LOCALIZED LIPOSARCOMAS, MYXOFIBROSARCOMAS AND UNDIFFERENTIATED PLEOMORPHIS SARCOMAS
Nicoletta Ranallo
Favorite
(P 533) SAFETY AND PRELIMINARY BIOLOGICAL ACTIVITY OF A PHASE II TRIAL OF AUTOLOGOUS DENDRITIC CELLS VACCINATION IN SARCOMAS.
Nicoletta Ranallo
Favorite
Rana, Satshil

MSKCC
(P 24) COMPREHENSIVE ANALYSIS OF THE GENOMIC LANDSCAPE AND CLINICAL BEHAVIOR IN GIST USING NEXT GENERATION SEQUENCING (NGS, MSK-IMPACT)
Satshil Rana
Favorite
Rance, Mark

PTC Therapeutics, Inc.
(P 182) UPDATED RESULTS FROM AN ONGOING PHASE 1B STUDY OF UNESBULIN (PTC596) PLUS DACARBAZINE FOR THE TREATMENT OF PATIENTS WITH ADVANCED LEIOMYOSARCOMA
Mark Rance
Favorite
(P 548) A PHASE 2/3 STUDY EVALUATING THE EFFICACY AND SAFETY OF UNESBULIN IN ADVANCED LEIOMYOSARCOMA (SUNRISELMS)
Mark Rance
Favorite
Ranft, Andreas

University Hospital Essen
(P 451) IMPACT OF TIME TO DIAGNOSIS - A PROSPECTIVE ANALYSIS OF THE EWING 2008 TRIAL
Andreas Ranft
Favorite
(P 538) IEUROEWING TRIAL FOR LOCALIZED AND METASTATIC EWING SARCOMA
Andreas Ranft
Favorite
Rankin, Kenneth

Newcastle Upon Tyne Hospitals NHS Foundation Trust
(P 70) ICONIC (IMPROVING OUTCOMES THROUGH COLLABORATION IN OSTEOSARCOMA): A PROSPECTIVE OBSERVATIONAL COHORT STUDY FOR NEWLY DIAGNOSED OSTEOSARCOMA PATIENTS IN THE UNITED KINGDOM (UK)
Kenneth Rankin
Favorite
Rankin, Kenneth

The Newcastle upon Tyne Hospitals NHS Foundation Trust
(P 228) WHAT IS THE SIGNIFICANCE OF INDETERMINATE PULMONARY NODULES IN HIGH GRADE SOFT TISSUE SARCOMA? A RETROSPECTIVE COHORT STUDY
Kenneth Rankin
Favorite
Rankin, Kenneth

Newcastle NHS foundation Trust
(P 298) EVALUATING THE PHOTOTHERMAL AND CYTOTOXIC PROPERTIES OF INDOCYANINE GREEN IN VITRO FOR INTRAOPERATIVE PHOTOTHERMAL THERAPY IN SARCOMA
Kenneth Rankin
Favorite
Rankin, Kenneth

Newcastle Upon Tyne Hospitals NHS Foundation Trust
(P 472) ICONIC (IMPROVING OUTCOMES THROUGH COLLABORATION IN OSTEOSARCOMA). AN EARLY LOOK AT SURGICAL DATA
Kenneth Rankin
Favorite
(P 522) FLUORESCENCE GUIDED SURGERY WITH INDOCYANINE GREEN FOR SURGICAL RESECTION OF METASTATIC BONE AND SOFT TISSUE TUMOURS: A CASE SERIES
Kenneth Rankin
Favorite
Rao, Arvind

University of Michigan
(P 293) GENERATION OF A SPONTANEOUS IMMUNOCOMPETENT MOUSE MODEL OF LIPOSARCOMA
Arvind Rao
Favorite
Rao, Rameshwar

Stanford University
(P 86) DECIPHERING CELL-MATRIX INTERACTIONS IN OSTEOSARCOMA RESPONSE TO CHEMOTHERAPY IN A 3D TISSUE-ENGINEERED IN VITRO MODEL
Rameshwar Rao
Favorite
Rapa, Ida

Department of Oncology, University of Turin
(P 262) ESTABLISHMENT AND CHARACTERIZATION OF THE FIRST RADIATION-INDUCED, PATIENT-DERIVED ANGIOSARCOMA CELL LINE
Ida Rapa
Favorite
Raquib, Ainiah Rushdiana

UBC
(P 362) IDENTIFICATION OF A NOVEL INTERACTOR OF ENDOGENOUS SS18-SSX THROUGH MASS SPECTOMETRY-BASED ANALYSIS IN SYNOVIAL SARCOMA CELLS
Ainiah Rushdiana Raquib
Favorite
Rascon, Jelena

Vilnius University Hospital
(P 451) IMPACT OF TIME TO DIAGNOSIS - A PROSPECTIVE ANALYSIS OF THE EWING 2008 TRIAL
Jelena Rascon
Favorite
Rask, Galen

Nationwide Children's Hospital
(P 456) SECLIDEMSTAT TREATMENT BLOCKS THE TRANSCRIPTIONAL FUNCTION OF MULTIPLE FET-FUSION PROTEINS
Galen Rask
Favorite
Raspagliesi, Francesco

INT
(P 328) REAL-LIFE EXPERIENCE OF PAZOPANIB IN PATIENTS WITH ADVANCED UTERINE LEIOMYOSARCOMA (U-LMS) FROM TWO REFERRAL ITALIAN CENTERS
Francesco Raspagliesi
Favorite
Rassekh, Shahrad Rod

British Columbia Children's Hospital, University of British Columbia
(P 512) PERIOPERATIVE BLOOD MANAGEMENT IN PEDIATRIC PATIENTS UNDERGOING PRIMARY OSTEOSARCOMA AND EWING SARCOMA RESECTION: A RETROSPECTIVE CASE NOTE REVIEW
Shahrad Rod Rassekh
Favorite
Rastogi, Sameer

Department of medical oncology, Dr BRAIRCH, All India Institute of Medical Sciences
(P 27) A MULTICENTER RETROSPECTIVE STUDY ON THE CLINICAL BEHAVIOR OF SDH-DEFICIENT GIST
Sameer Rastogi
Favorite
(P 342) THE EVALUATION AND OUTCOMES OF MESENTERIC AND INTRA-ABDOMINAL DESMOIDS: A TARPSWG STUDY
Sameer Rastogi
Favorite
(P 562) A PHASE 2, SINGLE ARM STUDY OF REGORAFENIB IN METASTATIC/UNRESECTABLE REFRACTORY SYNOVIAL SARCOMAS
Sameer Rastogi
Favorite
Ratan, Ravin

The University of Texas MD Anderson Cancer Center
(P 36) CLINICO-GENOMIC ANALYSIS OF KIT/PDGFRA/SDH WILD-TYPE GASTROINTESTINAL STROMAL TUMORS IDENTIFIES POTENTIAL DRIVER MUTATIONS
Ravin Ratan
Favorite
(P 71) CHEMOTHERAPY AND PROGNOSTIC SIGNIFICANCE OF EXTENT OF DEDIFFERENTIATION IN DEDIFFERENTIATED PAROSTEAL OSTEOSARCOMA
Ravin Ratan
Favorite
(P 83) CLINICO-GENOMIC PROFILING OF CONVENTIONAL AND DEDIFFERENTIATED CHONDROSARCOMAS REVEALS TP53 MUTATION TO BE ASSOCIATED WITH WORSE OUTCOMES
Ravin Ratan
Favorite
(P 100) HISTOLOGY SPECIFIC INTRATUMORAL B-CELL BIOLOGY IN ALVEOLAR SOFT-PART SARCOMAS (ASPS) IN RESPONSE TO DURVALUMAB-TREMELIMUMAB (D-T)
Ravin Ratan
Favorite
(P 123) DEDIFFERENTIATED LIPOSARCOMAS TREATED WITH IMMUNE CHECKPOINT BLOCKADE: THE MD ANDERSON EXPERIENCE
Ravin Ratan
Favorite
(P 172) PHASE 2 RESULTS FROM THE RINGSIDE PHASE 2/3 TRIAL OF AL102 FOR TREATMENT OF DESMOID TUMORS
Ravin Ratan
Favorite
(P 178) INITIAL RESULTS FROM A PHASE 1 STUDY OF CFT8634, A NOVEL BIFUCTIONAL DEGRADATION ACTIVATING COMPOUND (BIDAC) DEGRADER OF BRD9, IN SYNOVIAL SARCOMA AND SMARCB1-NULL TUMORS
Ravin Ratan
Favorite
(P 188) IMPACT OF NIROGACESTAT ON FUNCTIONAL STATUS IN PATIENTS WITH DESMOID TUMORS: RESULTS FROM THE PHASE 3 DEFI STUDY
Ravin Ratan
Favorite
(P 360) TP53 ALTERATIONS IN SARCOMAS: AN ANALYSIS FROM THE AACR-GENIE DATABASE
Ravin Ratan
Favorite
(P 394) LEIOMYOSARCOMA INTRATUMORAL MACROPHAGE INFILTRATES ARE ASSOCIATED WITH DISTINCT CLINICAL AND GENOMIC PRESENTATIONS
Ravin Ratan
Favorite
(P 426) MULTI-OMIC ANALYSIS OF DESMOPLASTIC SMALL ROUND CELL TUMORS REVEAL DISTINCT LINEAGES
Ravin Ratan
Favorite
(P 437) ULTRA-RARE UNDIFFERENTIATED SMALL ROUND CELL SARCOMA: HOW SHOULD WE TREAT THEM? AN ANALYSIS FORM THE GRACEFUL PROJECT
Ravin Ratan
Favorite
(P 439) THE TETRAVALENT DEATH RECEPTOR 5 AGONIST INBRX-109 COMBINED WITH CHEMOTHERAPY IN EWING SARCOMA: PRELIMINARY DATA FROM A PHASE 1 STUDY
Ravin Ratan
Favorite
Rath, Sushmita

Tata Memorial Hospital Mumbai
(P 436) OUTCOME PROGNOSTICATORS IN ADOLESCENTS AND ADULTS WITH BONE SARCOMAS IN LOW-MIDDLE-INCOME COUNTRIES
Sushmita Rath
Favorite
Raut, Chandrajit

Brigham and Women’s Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston
(P 342) THE EVALUATION AND OUTCOMES OF MESENTERIC AND INTRA-ABDOMINAL DESMOIDS: A TARPSWG STUDY
Chandrajit Raut
Favorite
Ravanbakhsh, Samine

Mayo Clinic Arizona
(P 141) TREATMENT VARIABILITY IN SURGICAL MANAGEMENT OF PULMONARY OLIGOMETASTATIC SOFT TISSUE SARCOMA
Samine Ravanbakhsh
Favorite
Rav, Emily

University of Texas MD Anderson
(P 122) TARGETING CD70 USING CAR NK CELLS TO ENHANCE NK CELLS CYTOLYTIC EFFECT AGAINST OSTEOSARCOMA
Emily Rav
Favorite
Ravi, Vinod

The University of Texas MD Anderson Cancer Center
(P 36) CLINICO-GENOMIC ANALYSIS OF KIT/PDGFRA/SDH WILD-TYPE GASTROINTESTINAL STROMAL TUMORS IDENTIFIES POTENTIAL DRIVER MUTATIONS
Vinod Ravi
Favorite
(P 71) CHEMOTHERAPY AND PROGNOSTIC SIGNIFICANCE OF EXTENT OF DEDIFFERENTIATION IN DEDIFFERENTIATED PAROSTEAL OSTEOSARCOMA
Vinod Ravi
Favorite
(P 100) HISTOLOGY SPECIFIC INTRATUMORAL B-CELL BIOLOGY IN ALVEOLAR SOFT-PART SARCOMAS (ASPS) IN RESPONSE TO DURVALUMAB-TREMELIMUMAB (D-T)
Vinod Ravi
Favorite
(P 123) DEDIFFERENTIATED LIPOSARCOMAS TREATED WITH IMMUNE CHECKPOINT BLOCKADE: THE MD ANDERSON EXPERIENCE
Vinod Ravi
Favorite
(P 173) SAFETY, EFFICACY, AND PATIENT-REPORTED OUTCOMES WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED PRIOR ANTI–COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 UPDATE
Vinod Ravi
Favorite
(P 177) ANGIOSARCOMA: AN INCREASING PROBLEM IN THE UNITED STATES
Vinod Ravi
Favorite
(P 360) TP53 ALTERATIONS IN SARCOMAS: AN ANALYSIS FROM THE AACR-GENIE DATABASE
Vinod Ravi
Favorite
(P 394) LEIOMYOSARCOMA INTRATUMORAL MACROPHAGE INFILTRATES ARE ASSOCIATED WITH DISTINCT CLINICAL AND GENOMIC PRESENTATIONS
Vinod Ravi
Favorite
(P 405) PRIMARY CARDIAC ANGIOSARCOMA- GENOMIC AND MOLECULAR LANDSCAPE
Vinod Ravi
Favorite
(P 510) PRIMARY BREAST ANGIOSARCOMA: CLINICAL AND PATHOLOGICAL FEATURES AND IMPACT ON OUTCOMES
Vinod Ravi
Favorite
(P 543) MANEUVER STUDY: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF PIMICOTINIB (ABSK021) TO ASSESS THE EFFICACY AND SAFETY IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR
Vinod Ravi
Favorite
Ray-coquard, Isabelle

Centre Léon-Bérard
(P 382) NTRK1/2/3 FUSIONS DETECTION USING RNA-SEQ IN MESENCHYMAL TUMORS REVEALS ULTRA-RARE AND HISTO-SPECIFIC TARGETABLE ALTERATIONS: EXPERIENCE OF AN EXTENSIVE ROUTINE RESEARCH PROGRAM.
Isabelle Ray-coquard
Favorite
Raza, Shaan

MD Anderson Cancer Center
(P 83) CLINICO-GENOMIC PROFILING OF CONVENTIONAL AND DEDIFFERENTIATED CHONDROSARCOMAS REVEALS TP53 MUTATION TO BE ASSOCIATED WITH WORSE OUTCOMES
Shaan Raza
Favorite
Reardon, Michael

Houston Methodist Research Institute
(P 405) PRIMARY CARDIAC ANGIOSARCOMA- GENOMIC AND MOLECULAR LANDSCAPE
Michael Reardon
Favorite
Reck, David

TCD
(P 424) INTERNAL TANDEM DUPLICATION OF BCOR (BCOR-ITD) ALTERS THE TUMOR EPIGENOME
David Reck
Favorite
Reczko, Krystyna

CR UK & UCL Cancer Trials Centre
(P 70) ICONIC (IMPROVING OUTCOMES THROUGH COLLABORATION IN OSTEOSARCOMA): A PROSPECTIVE OBSERVATIONAL COHORT STUDY FOR NEWLY DIAGNOSED OSTEOSARCOMA PATIENTS IN THE UNITED KINGDOM (UK)
Krystyna Reczko
Favorite
Reddan, Tadhg

SVUH
(P 213) EXPERIENCE WITH THE USE OF TRABECTEDIN IN ADVANCED SOFT TISSUE SARCOMA IN IRELAND
Tadhg Reddan
Favorite
Reddy, Sanjay

Fox Chase Cancer Center
(P 287) ESTABLISHMENT AND GENOMIC VALIDATION OF NOVEL PATIENT-DERIVED XENOGRAFT MODELS FOR DRUG DISCOVERY IN GASTROINTESTINAL STROMAL TUMOR
Sanjay Reddy
Favorite
Redondo, Andres

HU La Paz
(P 174) SELISARC: A SPANISH GROUP FOR RESEARCH IN SARCOMA (GEIS) PHASE I/II TRIAL OF SELINEXOR PLUS GEMCITABINE IN SELECTED SARCOMA SUBTYPES: RESULTS OF THE PHASE I PART
Andres Redondo
Favorite
(P 175) TRABECTEDIN PLUS RADIOTHERAPY ON SYMPHTOMATIC ADVANCED SARCOMA PATIENTS, RESULTS FROM THE SYNERGIAS STUDY: A SPANISH GROUP FOR RESEARCH IN SARCOMA (GEIS) PHASE II STUDY
Andres Redondo
Favorite
Reed, Damon

Moffitt Cancer Center
(P 68) METASTASIS-DIRECTED RADIOTHERAPY FOR EWING SARCOMA PATIENTS ENROLLED ON AEWS1221: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP (COG)
Damon Reed
Favorite
(P 69) DEVELOPMENT AND MISSION OF THE HARMONIZATION INTERNATIONAL BONE SARCOMA CONSORTIUM (HIBISCUS)
Damon Reed
Favorite
(P 81) OPTIMIZING EWING SARCOMA AND OSTEOSARCOMA BIOPSY ACQUISITION: CONSENSUS RECOMMENDATIONS FROM THE CHILDREN'S ONCOLOGY GROUP BONE TUMOR COMMITTEE
Damon Reed
Favorite
(P 537) TGFβ IMPRINTED, EX VIVO EXPANDED UNIVERSAL DONOR NATURAL KILLER CELLS WITH CHEMOTHERAPY FOR RELAPSED BONE AND SOFT TISSUE SARCOMA - NCT05634369, REPORT FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION
Damon Reed
Favorite
(P 551) PHASE II TRIAL OF GEMCITABINE AND NAB-PACLITAXEL IN PATIENTS WITH RECURRENT RHABDOMYOSARCOMA: A CLINICAL TRIAL IN PROGRESS FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION
Damon Reed
Favorite
Reichardt, Peter

Helios Klinikum Berlin-Buch, Medical School Berlin
(P 49) EFFICACY OF RIPRETINIB IN A MULTICENTER EXPANDED ACCESS PROGRAM IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS HARBOURING NON-KIT EXON 11 MUTATIONS.
Peter Reichardt
Favorite
Reichardt, Peter

Helios Klinikum Berlin-Buch and Medical School Berlin
(P 138) CONTROVERSIES IN THE MANAGEMENT OF PATIENTS WITH SOFT TISSUE SARCOMA: RESULTS AND RECOMMENDATIONS FROM THE FIRST CONFERENCE ON STATE OF SCIENCE IN SARCOMA (CSSS)
Peter Reichardt
Favorite
(P 185) LONGITUDINAL MUTATIONAL ANALYSIS OF TP53 IN CIRCULATING TUMOR DNA IN THE PLASMA OF PATIENTS WITH LIPOSARCOMA IN A PHASE I STUDY OF BRIGIMADLIN (BI 907828), AN MDM2-P53 ANTAGONIST
Peter Reichardt
Favorite
(P 530) FIH PHASE I STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND ANTITUMOR ACTIVITY OF THE001 COMBINED WITH REGIONAL HYPERTHERMIA IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOFT TISSUE SARCOMA
Peter Reichardt
Favorite
Reid, Christopher

University of California San Diego
(P 489) SIMULTANEOUS VERSUS DELAYED FLAP RECONSTRUCTION FOLLOWING SOFT TISSUE SARCOMA RESECTION
Christopher Reid
Favorite
(P 490) TOPICAL ANTIBIOTICS DECREASE INFECTIONS IN EXTREMITY SARCOMA SURGERY
Christopher Reid
Favorite
Reiff, Carina

University Hospital Essen, Sarcoma Centre
(P 47) PATIENT SURVIVAL IN METASTATIC GIST WITH IMATINIB-SENSITIVE MUTATIONS: REAL WORLD DATA FROM GERMAN REFERRAL CENTER (2008-2021)
Carina Reiff
Favorite
Reif, Marcus

Iscador AG
(P 532) MISTOSUS: A PHASE 2 STUDY OF ISCADOR® P IMMUNOTHERAPY FOR PATIENTS WITH RELAPSED OSTEOSARCOMA AND RESECTED PULMONARY METASTASES
Marcus Reif
Favorite
Reilly, Sarah

Foghorn Therapeutics
(P 271) PHARMACODYNAMICS AND MECHANISTIC IMPACTS OF FHD-609, A BROMODOMAIN-CONTAINING PROTEIN 9 DEGRADER, IN A PHASE 1 STUDY IN PATIENTS WITH ADVANCED SYNOVIAL SARCOMA OR SMARCB1-LOSS TUMORS
Sarah Reilly
Favorite
Reinhardt, Dirk

GPOH and University Hospital Essen
(P 538) IEUROEWING TRIAL FOR LOCALIZED AND METASTATIC EWING SARCOMA
Dirk Reinhardt
Favorite
Reinke, Denise

University of Michigan
(P 20) CLEAR CELL SARCOMA: PATIENT REPORTED REAL WORLD EVIDENCE
Denise Reinke
Favorite
Reisch, Andreas

UMR CNRS 7021
(P 277) ANTI-GD2 SYNERGIZES WITH HYPOXIA PATHWAY TARGETING TO BLOCK OSTEOSARCOMA CELL PROLIFERATION AND MIGRATION.
Andreas Reisch
Favorite
Rekhi, Bharat

Tata Memorial Hospital Mumbai
(P 436) OUTCOME PROGNOSTICATORS IN ADOLESCENTS AND ADULTS WITH BONE SARCOMAS IN LOW-MIDDLE-INCOME COUNTRIES
Bharat Rekhi
Favorite
Remer, Hallie

University of Miami Miller School of Medicine
(P 154) BARRIERS TO CARE FOR MUSCULOSKELETAL TUMORS
Hallie Remer
Favorite
Renne, Salvatore Lorenzo

IRCCS Humanitas Research Hospital
(P 297) UNVEILING THE IMPACT OF INTRATUMORAL MICROBIOTA IN THE TREATMENT EFFICACY OF SOFT TISSUE SARCOMA
Salvatore Lorenzo Renne
Favorite
(P 327) LEARNING CURVE ANALYSIS IN RETROPERITONEAL SARCOMA SURGERY
Salvatore Lorenzo Renne
Favorite
(P 433) A 20-YEAR MONOCENTER EXPERIENCE ON CLINICAL CHARACTERISTICS AND OUTCOME OF EXTRASKELETAL EWING SARCOMA.
Salvatore Lorenzo Renne
Favorite
(P 457) LONG-TERM FOLLOW-UP OF PATIENTS WITH ATYPICAL LIPOMATOUS TUMOR (ALT) TREATED WITH MARGINAL RESECTION IN A REFERRAL CENTER
Salvatore Lorenzo Renne
Favorite
Renouard, Marjolaine

Institut Curie
(P 75) REAL-WORLD DATA ON REGORAFENIB AND CABOZANTINIB IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH RELAPSED OSTEOSARCOMA AND EWING SARCOMA INCLUDED IN THE SACHA-FRANCE STUDY
Marjolaine Renouard
Favorite
Renshaw, Marta

Health Research Institute-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM),
(P 142) THE SARCOMA EUROPEAN AND LATIN AMERICAN NETWORK (SELNET) PROJECT: OVERVIEW OF THE MAIN RESULTS OF THE SELNET REGISTRY
Marta Renshaw
Favorite
(P 270) ALTERNATIVE SPLICING (AS) REGULATION AS A NOVEL THERAPEUTIC TARGET IN SOFT-TISSUE SARCOMA (STS)
Marta Renshaw
Favorite
(P 279) PROTEIN PHOSPHATASE 2 A INHIBITION AS A MECHANISM TO ENHANCE DOXORUBICIN ACTIVITY
Marta Renshaw
Favorite
REN, TINGTING

Peking University People’s Hospital
(P 58) CHEMOTHERAPY-INDUCED EVOLUTION OF OSTEOSARCOMA REVEALED BY SINGLE-CELL RNA SEQUENCING
TINGTING REN
Favorite
Rescigno, Maria

Humanitas University
(P 297) UNVEILING THE IMPACT OF INTRATUMORAL MICROBIOTA IN THE TREATMENT EFFICACY OF SOFT TISSUE SARCOMA
Maria Rescigno
Favorite
Reshmi, Shalini

Nationwide Children's Hospital Institute for Genomic Medicine/The Ohio State University College of Medicine
(P 425) CHARACTERIZATION OF RHABDOMYOSARCOMA WITH PAX7::FOXO1 FUSIONS: A REPORT FROM THE SOFT TISSUE COMMITTEE OF THE CHILDREN'S ONCOLOGY GROUP
Shalini Reshmi
Favorite
Reyners, An

University medical center Groningen
(P 27) A MULTICENTER RETROSPECTIVE STUDY ON THE CLINICAL BEHAVIOR OF SDH-DEFICIENT GIST
An Reyners
Favorite
(P 30) FINANCIAL DIFFICULTIES EXPERIENCED BY DUTCH GASTROINTESTINAL STROMAL TUMOR (GIST) PATIENTS: DATA FROM A CROSS-SECTIONAL MULTICENTER STUDY
An Reyners
Favorite
(P 32) IMPROVEMENT OF QUALITY AND TEXTBOOK OUTCOMES OF GASTRIC GASTROINTESTINAL STROMAL TUMOR (GIST) RESECTIONS IN THE PAST 13 YEARS; THE INFLUENCE OF MINIMAL INVASIVE SURGERY (MIS)
An Reyners
Favorite
Rezvani, Katy

University of Texas MD Anderson
(P 122) TARGETING CD70 USING CAR NK CELLS TO ENHANCE NK CELLS CYTOLYTIC EFFECT AGAINST OSTEOSARCOMA
Katy Rezvani
Favorite
Rhee, Daniel

The Johns Hopkins Hospital
(P 143) EXPLORING HOSPITAL VOLUME THRESHOLDS FOR IMPROVED SARCOMA TREATMENT ACROSS DIFFERENT AGE CATEGORIES IN THE UNITED STATES
Daniel Rhee
Favorite
Ribas Carbonell, Romina

Hospital de la Santa Creu i Sant Pau
(P 503) SCAPULAR PROSTHESIS RECONSTRUCTION, EXPERIENCE IN OUR INSTITUTION
Romina Ribas Carbonell
Favorite
Ricciotti, Robert

University of Washington
(P 67) GENOMIC CHARACTERIZATION OF CHONDROSARCOMA: A RARE SARCOMA WITH CLINICAL RESPONSES TO IMMUNE CHECKPOINT INHIBITION
Robert Ricciotti
Favorite
(P 206) A SINGLE-ARM, PHASE II STUDY OF NEOADJUVANT PEMBROLIZUMAB COMBINED WITH RADIOTHERAPY IN THE PRIMARY TREATMENT OF SOFT TISSUE SARCOMAS.
Robert Ricciotti
Favorite
RICHEZ, Brice

Institut Bergonié
(P 523) IN-BETWEEN SARCOMA: A CATEGORY OF HIGH RISK OF RECURRENCE AND POOR OUTCOME
Brice RICHEZ
Favorite
Ridgway, Paul

Tallaght University Hospital
(P 155) THE IMPACT OF THE ROLE OF A SARCOMA ADVANCED NURSE PRACTITIONER (ANP) BIOPSY CLINIC IN IMPROVING PATIENT ACCESS TO SARCOMA SERVICES
Paul Ridgway
Favorite
(P 156) PATIENT REPORTED EXPERIENCES WITHIN THE IRISH SARCOMA GROUP
Paul Ridgway
Favorite
(P 217) CONTEMPORARY TREATMENT PATTERNS AND OUTCOMES IN THE MANAGEMENT OF ANGIOSARCOMA IN IRELAND
Paul Ridgway
Favorite
Ridler, Khanum

Boehringer Ingelheim Pharma GmbH & Co. KG
(P 408) CHANGES IN COMPUTED TOMOGRAPHY FEATURES INDUCED BY BRIGIMADLIN (BI 907828) IN PATIENTS WITH LIPOSARCOMA: INSIGHTS FROM PHASE I STUDIES
Khanum Ridler
Favorite
Ridolfi, Laura

IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
(P 364) EVALUATION OF THE PREDICTIVE ROLE OF SYSTEMIC AND INTRATUMORAL IMMUNITY IN PATIENTS WITH LOCALIZED LIPOSARCOMAS, MYXOFIBROSARCOMAS AND UNDIFFERENTIATED PLEOMORPHIS SARCOMAS
Laura Ridolfi
Favorite
(P 533) SAFETY AND PRELIMINARY BIOLOGICAL ACTIVITY OF A PHASE II TRIAL OF AUTOLOGOUS DENDRITIC CELLS VACCINATION IN SARCOMAS.
Laura Ridolfi
Favorite
Riedel, Richard

Duke Cancer Institute
(P 112) PHASE 1/2 STUDY OF YH001, A CTLA-4 ANTIBODY WITH THE SUBCUTANEOUSLY ADMINISTERED PD-L1 ANTIBODY ENVAFOLIMAB, WITH OR WITHOUT DOXORUBICIN IN PATIENTS WITH ADVANCED OR METASTATIC SOFT TISSUE SARCOMA
Richard Riedel
Favorite
(P 188) IMPACT OF NIROGACESTAT ON FUNCTIONAL STATUS IN PATIENTS WITH DESMOID TUMORS: RESULTS FROM THE PHASE 3 DEFI STUDY
Richard Riedel
Favorite
(P 207) A MULTICENTER PHASE II STUDY OF CABOZANTINIB PLUS NIVOLUMAB FOR PATIENTS WITH ADVANCED ANGIOSARCOMA PREVIOUSLY TREATED WITH A TAXANE: ALLIANCE A091902
Richard Riedel
Favorite
(P 401) OVEREXPRESSION OF CYCLIN DEPENDENT KINASES AND CYCLINS ACROSS SARCOMAS BEYOND CDK4
Richard Riedel
Favorite
(P 531) ENVASARC: A PIVOTAL TRIAL OF ENVAFOLIMAB AND ENVAFOLIMAB IN COMBINATION WITH IPILIMUMAB IN PATIENTS WITH ADVANCED OR METASTATIC UPS OR MFS WHO HAVE PROGRESSED ON PRIOR CHEMOTHERAPY
Richard Riedel
Favorite
Rieth, John

University of Iowa
(P 115) EFFICACY AND CORREALTIVE ANALYSIS OF USING NEOADJUVANT INTRATUMORAL HIGH DOSE TALIMOGENE LAHERPAREPVEC (TVEC) WITH CONCURRENT RADIATION IN HIGH-RISK EXTREMITY AND TRUNK SOFT-TISSUE SARCOMAS
John Rieth
Favorite
Rigaud, Charlotte

Gustave Roussy Cancer Campus
(P 558) TRIAL IN PROGRESS: A PHASE 1/2 STUDY OF BRIGATINIB IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH ALK POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA OR INFLAMMATORY MYOFIBROBLASTIC TUMORS (ITCC-098)
Charlotte Rigaud
Favorite
Righi, Alberto

IRCCS, Istituto Ortopedico Rizzoli
(P 142) THE SARCOMA EUROPEAN AND LATIN AMERICAN NETWORK (SELNET) PROJECT: OVERVIEW OF THE MAIN RESULTS OF THE SELNET REGISTRY
Alberto Righi
Favorite
(P 355) FUSION TRANSCRIPTOME PROFILING DEFINES THE MONOCLONAL NATURE OF MULTIFOCAL EPITHELIOID HEMANGIOMA OF BONE
Alberto Righi
Favorite
Righi, Luisella

Department of Oncology, University of Turin
(P 262) ESTABLISHMENT AND CHARACTERIZATION OF THE FIRST RADIATION-INDUCED, PATIENT-DERIVED ANGIOSARCOMA CELL LINE
Luisella Righi
Favorite
Rijs, Zeger

Leiden University Medical Center
(P 251) EVALUATION OF POTENTIAL TARGETS FOR FLUORESCENCE-GUIDED SURGERY IN PEDIATRIC EWING SARCOMA: A PRECLINICAL PROOF-OF-CONCEPT STUDY
Zeger Rijs
Favorite
Rink, Lori

Fox Chase Cancer Center
(P 287) ESTABLISHMENT AND GENOMIC VALIDATION OF NOVEL PATIENT-DERIVED XENOGRAFT MODELS FOR DRUG DISCOVERY IN GASTROINTESTINAL STROMAL TUMOR
Lori Rink
Favorite
Rioux, Patrice

Monopar Therapeutics, Inc.
(P 184) PHASE 1B TRIAL OF CAMSIRUBICIN, A NOVEL DOXORUBICIN ANALOG, WITH CONCOMITANT PEGFILGRASTIM IN SUBJECTS WITH ADVANCED SOFT TISSUE SARCOMA TO IDENTIFY A NEW MTD/RP2D
Patrice Rioux
Favorite
Riva, Nada

Clinical and Experimental Oncology, Immunotherapy, Rare Cancers and Biological Resource Center, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori"
(P 37) DISSECTING THE ROLE OF EXTRACELLULAR VESICLES IN THE MANAGEMENT OF GIST
Nada Riva
Favorite
(P 364) EVALUATION OF THE PREDICTIVE ROLE OF SYSTEMIC AND INTRATUMORAL IMMUNITY IN PATIENTS WITH LOCALIZED LIPOSARCOMAS, MYXOFIBROSARCOMAS AND UNDIFFERENTIATED PLEOMORPHIS SARCOMAS
Nada Riva
Favorite
(P 533) SAFETY AND PRELIMINARY BIOLOGICAL ACTIVITY OF A PHASE II TRIAL OF AUTOLOGOUS DENDRITIC CELLS VACCINATION IN SARCOMAS.
Nada Riva
Favorite
Rivoltini, licia

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 363) Β-CATENIN MUTATIONS AND TRANSCRIPTOMIC REPROGRAMMING IN DESMOID FIBROMATOSIS (DF)
licia Rivoltini
Favorite
Roberts, Jesse

University of Washington
(P 67) GENOMIC CHARACTERIZATION OF CHONDROSARCOMA: A RARE SARCOMA WITH CLINICAL RESPONSES TO IMMUNE CHECKPOINT INHIBITION
Jesse Roberts
Favorite
(P 206) A SINGLE-ARM, PHASE II STUDY OF NEOADJUVANT PEMBROLIZUMAB COMBINED WITH RADIOTHERAPY IN THE PRIMARY TREATMENT OF SOFT TISSUE SARCOMAS.
Jesse Roberts
Favorite
Roberts, Ryan

Nationwide Children's Hospital
(P 81) OPTIMIZING EWING SARCOMA AND OSTEOSARCOMA BIOPSY ACQUISITION: CONSENSUS RECOMMENDATIONS FROM THE CHILDREN'S ONCOLOGY GROUP BONE TUMOR COMMITTEE
Ryan Roberts
Favorite
(P 107) TRABECTEDIN AUGMENTS ONCOLYTIC HERPES SIMPLEX VIROIMMUNOTHERAPY EFFICACY IN PRECLINCAL BONE SARCOMA MODELS THROUGH ENHANCED IMMUNE-MEDIATED MECHANISMS
Ryan Roberts
Favorite
Robinson, Chandler

Monopar Therapeutics, Inc.
(P 184) PHASE 1B TRIAL OF CAMSIRUBICIN, A NOVEL DOXORUBICIN ANALOG, WITH CONCOMITANT PEGFILGRASTIM IN SUBJECTS WITH ADVANCED SOFT TISSUE SARCOMA TO IDENTIFY A NEW MTD/RP2D
Chandler Robinson
Favorite
Robinson, Clifford

Washington University in St Louis
(P 187) PALLIATIVE LATTICE STEREOTACTIC BODY RADIOTHERAPY FOR PATIENTS WITH SARCOMA
Clifford Robinson
Favorite
Robinson, Michael

Vanderbilt University Medical Center
(P 160) A PROSPECTIVE STUDY EVALUATING THE ASSOCIATION OF PATIENT-REPORTED OUTCOMES WITH ACTIVITY LEVEL AND SLEEP PATTERNS IN SARCOMA SURVIVORS
Michael Robinson
Favorite
(P 210) FINANCIAL TOXICITY ASSOCIATED WITH THE TREATMENT OF SARCOMAS: A SINGLE INSTITUTION RETROSPECTIVE-PROSPECTIVE STUDY
Michael Robinson
Favorite
(P 211) AN ANALYSIS OF SELF-REPORTED DEPRESSION IN SARCOMA PATIENTS
Michael Robinson
Favorite
(P 380) NEXT GENERATION SEQUEINCING REVEALS TARGETABLE MUTATIONS IN MULTIPLE SARCOMA HISTOLOGIES
Michael Robinson
Favorite
Robinson, Steven

Mayo Clinic
(P 02) PEDIATRIC SYNOVIAL SARCOMA: A REVIEW OF 21 CASES FROM A SINGLE INSTITUTION
Steven Robinson
Favorite
(P 61) ADJACENT VENOUS TUMOR THROMBUS IN PRIMARY OSTEOSARCOMA OF THE PELVIS AND EXTREMITIES
Steven Robinson
Favorite
(P 180) HEALTH RELATED QUALITY OF LIFE OF PATIENTS WITH ADVANCED LEIOMYOSARCOMA AND OTHER SOFT TISSUE SARCOMAS TREATED WITH CABOZANTINIB AND TEMOZOLOMIDE
Steven Robinson
Favorite
(P 196) TOLERABILITY AND OUTCOMES FOR TREATMENT OF OLDER MYXOID LIPOSARCOMA POPULATION
Steven Robinson
Favorite
(P 207) A MULTICENTER PHASE II STUDY OF CABOZANTINIB PLUS NIVOLUMAB FOR PATIENTS WITH ADVANCED ANGIOSARCOMA PREVIOUSLY TREATED WITH A TAXANE: ALLIANCE A091902
Steven Robinson
Favorite
(P 334) CHARACTERISTICS AND OUTCOMES FOR PATIENTS IN THE UNITED STATES WITH DEDIFFERENTIATED LIPOSARCOMA FROM A REAL-WORLD DATA SET
Steven Robinson
Favorite
(P 440) LONG TERM OUTCOMES OF EWING SARCOMA OF THE FOOT AND ANKLE
Steven Robinson
Favorite
(P 465) UNPLANNED EXCISION OF SYNOVIAL SARCOMA: FACTORS ASSOCIATED WITH RECURRENCE AND SURVIVAL
Steven Robinson
Favorite
(P 518) OUTCOMES OF NON-ANGIOSARCOMA RADIATION-ASSOCIATED SOFT TISSUE SARCOMAS OF THE CHEST
Steven Robinson
Favorite
Robson, Paul

The Jackson Laboratory for Genomic Medicine
(P 392) IMMUNOSUPPRESSIVE TUMOR MICROENVIRONMENT OF OSTEOSARCOMA
Paul Robson
Favorite
Rocha, Flavio

OHSU
(P 341) A PHASE 1B STUDY TO EVALUATE PREOPERATIVE ERIBULIN IN COMBINATION WITH RADIATION IN RETROPERITONEAL SARCOMA
Flavio Rocha
Favorite
Rochaix, Philippe

Oncopole Claudius Regaud
(P 201) PLEOMORPHIC RHABDOMYOSARCOMAS: A NEW ENTITY ASSOCIATED WITH LYNCH SYNDROME? FIRST RESULTS OF SARCLYNCH NATIONAL STUDY
Philippe Rochaix
Favorite
(P 268) IMPACT OF CELLULAR FUSION IN THE ONCOGENESIS OF LEIOMYOSARCOMAS
Philippe Rochaix
Favorite
Roche, Fiona

TCD
(P 424) INTERNAL TANDEM DUPLICATION OF BCOR (BCOR-ITD) ALTERS THE TUMOR EPIGENOME
Fiona Roche
Favorite
Rodon Ahnert, Jordi

MD Anderson Cancer Center
(P 83) CLINICO-GENOMIC PROFILING OF CONVENTIONAL AND DEDIFFERENTIATED CHONDROSARCOMAS REVEALS TP53 MUTATION TO BE ASSOCIATED WITH WORSE OUTCOMES
Jordi Rodon Ahnert
Favorite
(P 540) PHASE 2, MULTICENTER, OPEN-LABEL BASKET TRIAL OF NAB-SIROLIMUS FOR MALIGNANT SOLID TUMORS HARBORING PATHOGENIC INACTIVATING ALTERATIONS IN TSC1 AND TSC2 (PRECISION I)
Jordi Rodon Ahnert
Favorite
Rodríguez Conde, Nivardo

Servicio de Cirugía General y Digestiva, Hospitals Universitario Vall d'Hebron, Barcelona, Spain.
(P 385) FIRST IN HUMAN PHASE I TRIAL OF A NOVEL DRUG DELIVERY IMPLANT MATRIX WITH SN-38 (CEB-01) FOR RETROPERITONEAL SOFT TISSUE SARCOMA
Nivardo Rodríguez Conde
Favorite
Rodríguez Torres, Laura

Thoracic Surgery Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain
(P 517) PULMONARY METASTASECTOMY FOR SARCOMA: A SINGLE-INSTITUTION EXPERIENCE
Laura Rodríguez Torres
Favorite
Rodriguez, Andrés

Instituto Alexander Fleming
(P 142) THE SARCOMA EUROPEAN AND LATIN AMERICAN NETWORK (SELNET) PROJECT: OVERVIEW OF THE MAIN RESULTS OF THE SELNET REGISTRY
Andrés Rodriguez
Favorite
Rodriguez, Annemarie

University of Florida
(P 452) SECONDARY GENOMIC LANDSCAPE OF CIC::DUX4 FUSION SARCOMAS
Annemarie Rodriguez
Favorite
Rodriguez, Fausto

UCLA
(P 250) SHARING HIGH-QUALITY SAMPLES AND DATA TO THE NF1 RESEARCH COMMUNITY: THE ROLE OF THE JOHNS HOPKINS NF1 BIOSPECIMEN REPOSITORY
Fausto Rodriguez
Favorite
Rodriguez, Raphaël

Institut Curie
(P 395) TARGETING CD44-MEDIATED IRON ENDOCYTOSIS IN DESMOID FIBROMATOSIS
Raphaël Rodriguez
Favorite
Roelands, Jessica

LUMC
(P 369) MAGEA ANTIGENS AS IMMUNOTHERAPEUTIC TARGETS FOR ADVANCED OSTEOSARCOMA
Jessica Roelands
Favorite
Roets, Evelyne

Netherlands Cancer Institute
(P 27) A MULTICENTER RETROSPECTIVE STUDY ON THE CLINICAL BEHAVIOR OF SDH-DEFICIENT GIST
Evelyne Roets
Favorite
(P 31) NEOADJUVANT IMATINIB IN LOCALLY ADVANCED GASTROINTESTINAL STROMAL TUMORS (GIST) IS EFFECTIVE AND SAFE: RESULTS FROM A PROSPECTIVE SINGLE CENTER STUDY WITH 108 PATIENTS
Evelyne Roets
Favorite
(P 136) SETTING THE INTERNATIONAL RESEARCH AGENDA FOR SARCOMA WITH PATIENTS AND CARERS: PRELIMINARY RESULTS OF PHASE II OF THE SARCOMA PATIENT ADVOCACY GLOBAL NETWORK (SPAGN) PRIORITY SETTING PARTNERSHIP
Evelyne Roets
Favorite
(P 186) PATIENT REPORTED OUTCOME ASSESSMENT AND REPORTING IN RANDOMIZED CLINICAL TRIALS OF SYSTEMIC THERAPY FOR ADVANCED SOFT TISSUE SARCOMAS: A SYSTEMATIC REVIEW.
Evelyne Roets
Favorite
Rogala, Pawel

Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw, Department of Soft Tissue/Bone Sarcoma and Melanoma
(P 21) YOUNG ADULTS WITH NONMETASTATIC OPERABLE OSTEOSARCOMA TREATED PERIOPERATIVELY WITH METHOTREXATE, DOXORUBICIN AND CISPLATIN SCHEDULE, SINGLE INSTITUTION REPORT
Pawel Rogala
Favorite
(P 170) HETEROGENEITY OF PAZOPANIB ACTIVITY ACROSS SOFT TISSUE SARCOMA SUBTYPES - A RETROSPECTIVE ANALYSIS OF 303 CASES FROM A REFERENCE CENTER
Pawel Rogala
Favorite
Rohaj, Aarushi

Huntsman Cancer Institute/University of Utah
(P 412) LEIOMYOSARCOMA POLYANEUPLOID CANCER CELLS DEVELOP IN RESPONSE TO CHEMOTHERAPY AND CONTRIBUTE TO CHEMORESISTANCE
Aarushi Rohaj
Favorite
Rojas Cordero, Jady

Hospital de la Santa Creu i Sant Pau
(P 313) SPACIALLY-FRACTIONATED RADIOTHERAPY (LATTICE) TREATMENT IN INOPERABLE NON-EXTREMITY BULKY SOFT-TISSUE SARCOMAS
Jady Rojas Cordero
Favorite
Roland, Christina

The University of Texas MD Anderson Cancer Center
(P 100) HISTOLOGY SPECIFIC INTRATUMORAL B-CELL BIOLOGY IN ALVEOLAR SOFT-PART SARCOMAS (ASPS) IN RESPONSE TO DURVALUMAB-TREMELIMUMAB (D-T)
Christina Roland
Favorite
(P 123) DEDIFFERENTIATED LIPOSARCOMAS TREATED WITH IMMUNE CHECKPOINT BLOCKADE: THE MD ANDERSON EXPERIENCE
Christina Roland
Favorite
(P 198) PERSONALIZED MULTIDISCIPLINARY MANAGEMENT OF SARCOMA IN PATIENTS WITH LYNCH SYNDROME
Christina Roland
Favorite
(P 269) PLASMA DNA METHYLATION-BASED BIOMARKERS FOR MPNST DETECTION IN PATIENTS WITH NEUROFIBROMATOSIS TYPE 1 (NF1)
Christina Roland
Favorite
(P 360) TP53 ALTERATIONS IN SARCOMAS: AN ANALYSIS FROM THE AACR-GENIE DATABASE
Christina Roland
Favorite
(P 394) LEIOMYOSARCOMA INTRATUMORAL MACROPHAGE INFILTRATES ARE ASSOCIATED WITH DISTINCT CLINICAL AND GENOMIC PRESENTATIONS
Christina Roland
Favorite
(P 510) PRIMARY BREAST ANGIOSARCOMA: CLINICAL AND PATHOLOGICAL FEATURES AND IMPACT ON OUTCOMES
Christina Roland
Favorite
Romagosa, Cleofé

Pathology Department, Valld’Hebron University Hospital, Barcelona, Spain
(P 222) EXPLORING THE IMPACT OF NGS ON DIAGNOSTICS AND TREATMENT OF SARCOMA: INSIGHTS FROM REAL-WORLD DATA ACROSS MULTIPLE INSTITUTIONS IN EUROPE
Cleofé Romagosa
Favorite
Rome, Angelique

Timone Children's Hospital
(P 202) INFLAMMATORY MYOFIBROBLASTIC TUMOUR WITH ROS1 GENE FUSIONS IN CHILDREN AND YOUNG ADOLESCENTS
Angelique Rome
Favorite
Romero, Pablo

Health Research Institute-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM),
(P 261) EFFICACY OF BET INHIBITORS IN SOLITARY FIBROUS TUMOR: AN IN VITRO EVALUATION
Pablo Romero
Favorite
(P 270) ALTERNATIVE SPLICING (AS) REGULATION AS A NOVEL THERAPEUTIC TARGET IN SOFT-TISSUE SARCOMA (STS)
Pablo Romero
Favorite
(P 279) PROTEIN PHOSPHATASE 2 A INHIBITION AS A MECHANISM TO ENHANCE DOXORUBICIN ACTIVITY
Pablo Romero
Favorite
Rondof, Windy

Gustave Roussy cancer Centre
(P 212) REPORT ON THE EWING SARCOMA PATIENTS ENROLLED IN ARM D OF THE ACSE-ESMART TRIAL: PHASE I/II STUDY OF THE PARP INHIBITOR OLAPARIB IN COMBINATION WITH IRINOTECAN IN CHILDREN WITH ADVANCED MALIGNANCIES
Windy Rondof
Favorite
Rooney, Cliona

Texas Children's Hospital / Baylor College of Medicine Center for Cell and Gene Therapy
(P 121) IMPROVING THE EFFICACY OF GD2 CHIMERIC ANTIGEN RECEPTOR T-CELLS USING HISTONE DEACETYLASE INHIBITORS
Cliona Rooney
Favorite
Rosa, Camilla

Azienda Ospedaliero-Universitaria A.Meyer
(P 144) IMPLEMENTATION OF THE EUROPEAN CLINICAL TRIAL REGULATION: SURVEY OF THE ITALIAN SARCOMA GROUP CENTERS
Camilla Rosa
Favorite
Rosales, Nestor

Memorial Sloan Kettering Cancer Center
(P 289) IDENTIFICATION OF EFFECTIVE THERAPEUTIC COMBINATIONS WITH THE NUCLEAR EXPORT PROTEIN INHIBITOR, SELINEXOR, IN PEDIATRIC SOLID TUMORS
Nestor Rosales
Favorite
Rose, Brandon

University of Miami and Jackson Health Systems
(P 225) PAN-SARCOMA DATABASE (PSDB): A MODEL-VIEW-CONTROLLER FRAMEWORK UTILIZING REDCAP, SHINY, AND R TO CREATE A CONTINUOUS PIPELINE OF SARCOMA DATA
Brandon Rose
Favorite
(P 226) SIGNATERA TESTING TO IDENTIFY MINIMAL RESIDUAL DISEASE IN HIGH GRADE SARCOMA
Brandon Rose
Favorite
(P 361) MOLECULAR CHARACTERIZATION OF SOLITARY FIBROUS TUMORS BY ANATOMIC SITE AND NAB2::STAT6 FUSION VARIANT TYPE
Brandon Rose
Favorite
(P 366) SURVIVAL DISPARITIES IN HISPANIC PATIENTS WITH SARCOMA TESTED WITH NEXT-GENERATION SEQUENCING (NGS)
Brandon Rose
Favorite
(P 461) OUTCOMES FOR OLIGOMETASTATIC PULMONARY DISEASE RECURRENCE TREATED WITH SURGERY ALONE FOR PATIENTS WITH SOFT TISSUE SARCOMAS A CASE SERIES
Brandon Rose
Favorite
Roselli, Giuliana

Department of Radiology, Azienda Ospedaliero Universitaria Careggi, Florence, Italy
(P 317) PROGNOSTIC FACTORS, CLINICAL AND TOXICITY OUTCOMES FROM A LARGE COHORT OF PATIENTS WITH SOFT TISSUE SARCOMA TREATED WITH PREOPERATIVE RADIATION THERAPY
Giuliana Roselli
Favorite
(P 546) PRELIMINARY CLINICAL RESULTS OF AN ONGOING PHASE II TRIAL: SPRINT (SARCOMA PREOPERATIVE RADIATION WITH SIMULTANEOUS INTEGRATED BOOST)
Giuliana Roselli
Favorite
rosenbaum, evan

MSKCC
(P 24) COMPREHENSIVE ANALYSIS OF THE GENOMIC LANDSCAPE AND CLINICAL BEHAVIOR IN GIST USING NEXT GENERATION SEQUENCING (NGS, MSK-IMPACT)
evan rosenbaum
Favorite
Rosenberg, Andrew

Sylvester Comprehensive Cancer Center
(P 128) THE IMPACT OF HISPANIC ETHNICITY IN PRESENTATION AND OUTCOMES OF PATIENTS WITH SYNOVIAL SARCOMA
Andrew Rosenberg
Favorite
(P 226) SIGNATERA TESTING TO IDENTIFY MINIMAL RESIDUAL DISEASE IN HIGH GRADE SARCOMA
Andrew Rosenberg
Favorite
(P 361) MOLECULAR CHARACTERIZATION OF SOLITARY FIBROUS TUMORS BY ANATOMIC SITE AND NAB2::STAT6 FUSION VARIANT TYPE
Andrew Rosenberg
Favorite
Rosenthal, Howard

University of Kansas Health System
(P 214) SIGNIFICANT TREATMENT RESPONSE IN PATIENTS WITH PRIMARY RESECTABLE EXTREMITY MYXOID LIPOSARCOMA RECEIVING NEOADJUVANT TRABECTEDIN AND RADIATION
Howard Rosenthal
Favorite
Rose, Peter

Mayo Clinic
(P 306) USE OF PENCIL BEAM SCANNING PROTON RADIOTHERAPY IN MOBILE SPINE CHORDOMAS
Peter Rose
Favorite
(P 440) LONG TERM OUTCOMES OF EWING SARCOMA OF THE FOOT AND ANKLE
Peter Rose
Favorite
(P 482) COMPARISON OF RECONSTRUCTIVE TECHNIQUES FOR METASTATIC DISEASE IN THE PROXIMAL HUMERUS
Peter Rose
Favorite
(P 491) COMPARISON OF FIXATION TECHNIQUES FOR METASTATIC DISEASE OF THE HUMERUS
Peter Rose
Favorite
Rosińska, Magdalena

Department of Computational Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.
(P 09) A NOMOGRAM MODEL TO PREDICT THE OVERALL SURVIVAL OF ADOLESCENT AND YOUNG ADULT PATIENTS WITH LOCALLY ADVANCED EWING SARCOMA.
Magdalena Rosińska
Favorite
(P 222) EXPLORING THE IMPACT OF NGS ON DIAGNOSTICS AND TREATMENT OF SARCOMA: INSIGHTS FROM REAL-WORLD DATA ACROSS MULTIPLE INSTITUTIONS IN EUROPE
Magdalena Rosińska
Favorite
Rossi, Alexander

Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health
(P 28) RETROSPECTIVE ANALYSIS OF SUCCINATE DEHYDROGENASE (SDH)-DEFICIENT GASTROINTESTINAL STROMAL TUMOR (GIST) OUTCOMES: AN INTERNATIONAL STUDY OF 256 PATIENTS
Alexander Rossi
Favorite
Rossi, Peter

MCW
(P 473) GROIN PAINS: APPROACHES AND OUTCOMES FOR INGUINOFEMORAL SOFT TISSUE SARCOMAS
Peter Rossi
Favorite
Roszik, Jason

MD Anderson Cancer Center
(P 83) CLINICO-GENOMIC PROFILING OF CONVENTIONAL AND DEDIFFERENTIATED CHONDROSARCOMAS REVEALS TP53 MUTATION TO BE ASSOCIATED WITH WORSE OUTCOMES
Jason Roszik
Favorite
(P 360) TP53 ALTERATIONS IN SARCOMAS: AN ANALYSIS FROM THE AACR-GENIE DATABASE
Jason Roszik
Favorite
Rothermundt, Christian

Cantonal Hospital St. Gallen
(P 138) CONTROVERSIES IN THE MANAGEMENT OF PATIENTS WITH SOFT TISSUE SARCOMA: RESULTS AND RECOMMENDATIONS FROM THE FIRST CONFERENCE ON STATE OF SCIENCE IN SARCOMA (CSSS)
Christian Rothermundt
Favorite
(P 437) ULTRA-RARE UNDIFFERENTIATED SMALL ROUND CELL SARCOMA: HOW SHOULD WE TREAT THEM? AN ANALYSIS FORM THE GRACEFUL PROJECT
Christian Rothermundt
Favorite
Roth, Michael

UT MD Anderson Cancer Center
(P 89) GENERATION OF CHONDROCYTE-DERIVED MOUSE OSTEOSARCOMA MODELS - TRACKABLE SYSTEMS TO DELINEATE ONCOGENIC AND METASTATIC ENVENTS PRIOR TO TUMOROGENESIS
Michael Roth
Favorite
(P 203) PRECLINICAL EVALUATION AMG 650, A SMALL MOLECULE INHIBITOR OF KIF18A, IN PEDIATRIC SOLID TUMORS BY THE PEDIATRIC PRECLINICAL IN VIVO TESTING (PIVOT) PROGRAM
Michael Roth
Favorite
Rothschild, Sara

The Life Raft Group
(P 28) RETROSPECTIVE ANALYSIS OF SUCCINATE DEHYDROGENASE (SDH)-DEFICIENT GASTROINTESTINAL STROMAL TUMOR (GIST) OUTCOMES: AN INTERNATIONAL STUDY OF 256 PATIENTS
Sara Rothschild
Favorite
(P 33) LONGITUDINAL FOLLOW UP OF GASTROINTESTINAL STROMAL TUMORS:DATA FROM THE LIFE RAFT GROUP INTERANTIONAL PATIENT REGISTRY
Sara Rothschild
Favorite
Rotondo, Ronny

Kansas City Medical Center
(P 214) SIGNIFICANT TREATMENT RESPONSE IN PATIENTS WITH PRIMARY RESECTABLE EXTREMITY MYXOID LIPOSARCOMA RECEIVING NEOADJUVANT TRABECTEDIN AND RADIATION
Ronny Rotondo
Favorite
(P 320) A PROSPECTIVE MULTICENTER EXPERIENCE OF PROTON THERAPY FOR RHABDOMYOSARCOMA AND EWING SARCOMA: OUTCOMES FROM THE PROTON COLLABORATIVE GROUP REGISTRY
Ronny Rotondo
Favorite
Rottmann, Douglas

University of Michigan, Department of Pathology
(P 449) CIC-DUX4 sarcomas: A single-center review of clinical features and molecular aberrations identified through DNA sequencing
Douglas Rottmann
Favorite
Rotzinger, David C.

CHUV
(P 103) LASTING COMPLETE RESPONSE TO PEMBROLIZUMAB IN MISMATCH REPAIR DEFICIENT CARDIAC SARCOMA: A GENOMIC CHARACTERIZATION
David C. Rotzinger
Favorite
Roumy, Marianne

University Hospital Angers
(P 75) REAL-WORLD DATA ON REGORAFENIB AND CABOZANTINIB IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH RELAPSED OSTEOSARCOMA AND EWING SARCOMA INCLUDED IN THE SACHA-FRANCE STUDY
Marianne Roumy
Favorite
Roussel, Natacha

Cancer Research Center of Toulouse
(P 268) IMPACT OF CELLULAR FUSION IN THE ONCOGENESIS OF LEIOMYOSARCOMAS
Natacha Roussel
Favorite
Routman, David

Mayo Clinic Minnesota
(P 312) MANAGEMENT OF ADULT HEAD AND NECK SOFT TISSUE SARCOMA: THE MAYO CLINIC EXPERIENCE
David Routman
Favorite
Royes, Brittany

University of Pittsburgh
(P 466) INTRAOPERATIVE EVALUATION OF BONE AND SOFT TISSUE SARCOMA SURGICAL MARGINS WITH INDOCYANINE GREEN FLUORESCENCE IMAGING
Brittany Royes
Favorite
(P 544) INTRAOPERATIVE EVALUATION OF BONE AND SOFT TISSUE SARCOMA SURGICAL MARGINS WITH INDOCYANINE GREEN FLUORESCENCE IMAGING
Brittany Royes
Favorite
Ruano, Dina

LUMC
(P 369) MAGEA ANTIGENS AS IMMUNOTHERAPEUTIC TARGETS FOR ADVANCED OSTEOSARCOMA
Dina Ruano
Favorite
Rubin, Elyssa

Children's Hospital of Orange County
(P 69) DEVELOPMENT AND MISSION OF THE HARMONIZATION INTERNATIONAL BONE SARCOMA CONSORTIUM (HIBISCUS)
Elyssa Rubin
Favorite
(P 81) OPTIMIZING EWING SARCOMA AND OSTEOSARCOMA BIOPSY ACQUISITION: CONSENSUS RECOMMENDATIONS FROM THE CHILDREN'S ONCOLOGY GROUP BONE TUMOR COMMITTEE
Elyssa Rubin
Favorite
Rubino, Jonathan

Gustave Roussy cancer Centre
(P 212) REPORT ON THE EWING SARCOMA PATIENTS ENROLLED IN ARM D OF THE ACSE-ESMART TRIAL: PHASE I/II STUDY OF THE PARP INHIBITOR OLAPARIB IN COMBINATION WITH IRINOTECAN IN CHILDREN WITH ADVANCED MALIGNANCIES
Jonathan Rubino
Favorite
Rubio San Simón, Alba

Hospital Nino Jesus
(P 212) REPORT ON THE EWING SARCOMA PATIENTS ENROLLED IN ARM D OF THE ACSE-ESMART TRIAL: PHASE I/II STUDY OF THE PARP INHIBITOR OLAPARIB IN COMBINATION WITH IRINOTECAN IN CHILDREN WITH ADVANCED MALIGNANCIES
Alba Rubio San Simón
Favorite
Rubio-Reyes, Antonio

Research health institute of Fundacion Jimenez Diaz
(P 270) ALTERNATIVE SPLICING (AS) REGULATION AS A NOVEL THERAPEUTIC TARGET IN SOFT-TISSUE SARCOMA (STS)
Antonio Rubio-Reyes
Favorite
Rub, Jonathan

Memorial Sloan Kettering Cancer Center
(P 257) CHARACTERIZING THE EVOLUTION AND THERAPEUTIC RESPONSE OF UNDIFFERENTIATED PLEOMORPHIC SARCOMAS USING MOUSE MODELS
Jonathan Rub
Favorite
Rudzinski, Erin

Seattle Children's Hospital/University of Washington
(P 409) IMMUNOHISTOCHEMICAL STAINING FOR MYOGENIN, AP2 BETA AND HMGA2 PREDICT FOXO1 FUSION STATUS IN RHABDOMYOSARCOMA: A REPORT FROM THE SOFT TISSUE COMMITTEE OF THE CHILDREN'S ONCOLOGY GROUP
Erin Rudzinski
Favorite
(P 425) CHARACTERIZATION OF RHABDOMYOSARCOMA WITH PAX7::FOXO1 FUSIONS: A REPORT FROM THE SOFT TISSUE COMMITTEE OF THE CHILDREN'S ONCOLOGY GROUP
Erin Rudzinski
Favorite
(P 438) ALVEOLAR RHABDOMYOSARCOMA WITH "BURKITT-LIKE" MORPHOLOGY IS ASSOCIATED WITH HIGH AMPLIFICATION OF MYCL
Erin Rudzinski
Favorite
(P 448) CAF-LIKE EWING SARCOMA CELLS DEPOSIT PRO-TUMORIGENIC EXTRACELLULAR MATRIX IN RESPONSE TO TGF-BETA SIGNALING
Erin Rudzinski
Favorite
Ruff, Samantha

The Ohio State University
(P 347) INCIDENCE AND TIMING OF RECURRENCE AFTER ADJUVANT PALBOCICLIB IN COMPLETELY RESECTED RETROPERITONEAL LIPOSARCOMA
Samantha Ruff
Favorite
Ruff, Tyler

Washington University School of Medicine
(P 552) RANDOMIZED PHASE II TRIAL OF CABOZANTINIB COMBINED WITH PD-1 AND CTLA-4 INHIBITION VERSUS CABOZANTINIB IN METASTATIC SOFT TISSUE SARCOMA.
Tyler Ruff
Favorite
Ruiz, antonio

Hospital Clinico san Carlos
(P 149) PSYCOLOGICAL SNAPSHOT OF SARCOMA PATIENTS FROM AN ACADEMIC, UNIVERSITY CENTER, HOSPITAL CLÍNICO SAN CARLOS (HCSC), MADRID, A SARCOMA NATIONAL REFERRAL CENTRE IN SPAIN
antonio Ruiz
Favorite
Ruiz, Roiner

Sylvester Comprehensive Cancer Center / University of Miami Hospital and Clinics
(P 208) LOW INCIDENCE OF CANCER THERAPY-RELATED CARDIAC DYSFUNCTION IN ADULT SARCOMA PATIENTS RECEIVING DOXORUBICIN AND UPFRONT DEXRAZOXANE
Roiner Ruiz
Favorite
Ruiz-Soto, Rodrigo

Deciphera Pharmaceuticals, LLC
(P 173) SAFETY, EFFICACY, AND PATIENT-REPORTED OUTCOMES WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED PRIOR ANTI–COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 UPDATE
Rodrigo Ruiz-Soto
Favorite
(P 176) SAFETY, EFFICACY, AND PATIENT-REPORTED OUTCOMES WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED NO PRIOR ANTI–COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 UPDATE
Rodrigo Ruiz-Soto
Favorite
Ruminski, Peter

Washington University in St. Louis
(P 274) TYK2 AND MEK COMBINATION THERAPY IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS AND OTHER SOFT TISSUE SARCOMAS
Peter Ruminski
Favorite
Ruspi, Laura

IRCCS Humanitas Research Hospital
(P 297) UNVEILING THE IMPACT OF INTRATUMORAL MICROBIOTA IN THE TREATMENT EFFICACY OF SOFT TISSUE SARCOMA
Laura Ruspi
Favorite
(P 327) LEARNING CURVE ANALYSIS IN RETROPERITONEAL SARCOMA SURGERY
Laura Ruspi
Favorite
(P 457) LONG-TERM FOLLOW-UP OF PATIENTS WITH ATYPICAL LIPOMATOUS TUMOR (ALT) TREATED WITH MARGINAL RESECTION IN A REFERRAL CENTER
Laura Ruspi
Favorite
Rutenberg, Michael

Mayo Clinic Florida
(P 312) MANAGEMENT OF ADULT HEAD AND NECK SOFT TISSUE SARCOMA: THE MAYO CLINIC EXPERIENCE
Michael Rutenberg
Favorite
Rutkauskaite, Vilma

Vilnius university hospitalSantaros KlinikosCenter for Pediatric Oncology and Hematology
(P 73) FOSTER CONSORTIUM, FIGHT OSTEOSARCOMA THROUGH EUROPEAN RESEARCH
Vilma Rutkauskaite
Favorite
Rutkowski, Piotr

Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw, Department of Soft Tissue/Bone Sarcoma and Melanoma
(P 09) A NOMOGRAM MODEL TO PREDICT THE OVERALL SURVIVAL OF ADOLESCENT AND YOUNG ADULT PATIENTS WITH LOCALLY ADVANCED EWING SARCOMA.
Piotr Rutkowski
Favorite
(P 21) YOUNG ADULTS WITH NONMETASTATIC OPERABLE OSTEOSARCOMA TREATED PERIOPERATIVELY WITH METHOTREXATE, DOXORUBICIN AND CISPLATIN SCHEDULE, SINGLE INSTITUTION REPORT
Piotr Rutkowski
Favorite
Rutkowski, Piotr

Maria Sklodowska-Curie National Research Institute of Oncology, Department of Soft Tissue/Bone Sarcoma and Melanoma, Warsaw Poland
(P 95) LONG-TERM OUTCOMES OF PATIENTS DIAGNOSED WITH CHORDOMA OF THE SACRUM
Piotr Rutkowski
Favorite
(P 162) LONG TERM SAFETY AND EFFICACY OF COMBINED DOXORUBICIN-IFOSFAMIDE CHEMOTHERAPY WITH PREOPERATIVE HYPOFRACTIONATED RADIOTHERAPY IN MARGINALLY RESECTABLE SOFT TISSUE SARCOMAS
Piotr Rutkowski
Favorite
Rutkowski, Piotr

Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw, Department of Soft Tissue/Bone Sarcoma and Melanoma
(P 170) HETEROGENEITY OF PAZOPANIB ACTIVITY ACROSS SOFT TISSUE SARCOMA SUBTYPES - A RETROSPECTIVE ANALYSIS OF 303 CASES FROM A REFERENCE CENTER
Piotr Rutkowski
Favorite
(P 176) SAFETY, EFFICACY, AND PATIENT-REPORTED OUTCOMES WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED NO PRIOR ANTI–COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 UPDATE
Piotr Rutkowski
Favorite
(P 222) EXPLORING THE IMPACT OF NGS ON DIAGNOSTICS AND TREATMENT OF SARCOMA: INSIGHTS FROM REAL-WORLD DATA ACROSS MULTIPLE INSTITUTIONS IN EUROPE
Piotr Rutkowski
Favorite
Rutkowski, Piotr

Maria Sklodowska-Curie National Research Institute of Oncology, Department of Soft Tissue/Bone Sarcoma and Melanoma, Warsaw Poland
(P 310) PREOPERATIVE RADIOTHERAPY WITH HYPERTHERMIA IN RECURRENT AND RADIATION-INDUCED SARCOMAS: RESULTS OF A PHASE 2 CLINICAL TRIAL
Piotr Rutkowski
Favorite
Rutkowski, Piotr

Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw, Department of Soft Tissue/Bone Sarcoma and Melanoma
(P 545) NEOADJUVANT PEMBROLIZUMAB AND EFTILAGIMOD ALPHA WITH CONCURRENT RADIOTHERAPY IN PATIENTS WITH SELECTED SOFT TISSUE SARCOMA SUBTYPES (EFTISARC-NEO)
Piotr Rutkowski
Favorite
(P 549) DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF AL102 FOR TREATMENT OF PROGRESSING DESMOID TUMORS: THE RINGSIDE PHASE 3 STUDY DESIGN
Piotr Rutkowski
Favorite
Ryan, Christopher

OHSU Knight Cancer Institute, South Waterfront
(P 173) SAFETY, EFFICACY, AND PATIENT-REPORTED OUTCOMES WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED PRIOR ANTI–COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 UPDATE
Christopher Ryan
Favorite
(P 179) PILOT STUDY OF A REMOTELY DELIVERED RESISTANCE EXERCISE TRAINING PROGRAM IN SARCOMA SURVIVORS
Christopher Ryan
Favorite
(P 341) A PHASE 1B STUDY TO EVALUATE PREOPERATIVE ERIBULIN IN COMBINATION WITH RADIATION IN RETROPERITONEAL SARCOMA
Christopher Ryan
Favorite
Rytlewski, Jeffrey

University of Iowa
(P 286) EPIGENETIC MECHANISMS AND SIGNATURES OF SARCOMA PROGRESSION AND METASTASIS
Jeffrey Rytlewski
Favorite
S
Saba, Karim

Lund University
(P 230) SARCDBASE: A TOOL FOR DETECTION OF GENETIC ALTERATIONS IN SARCOMA
Karim Saba
Favorite
(P 371) DISRUPTION OF THE TP53 LOCUS IN OSTEOSARCOMA LEADS TO TP53 PROMOTER GENE FUSIONS AND RESTORATION OF PARTS OF THE TP53 SIGNALLING PATHWAY
Karim Saba
Favorite
Sabnis, Amit

UCSF
(P 03) EVOLUTION OF CLINICALLY ACTIONABLE VARIANTS IN ADVANCED PEDIATRIC AND AYA BONE SARCOMAS
Amit Sabnis
Favorite
(P 413) LINKING REAL-WORLD CLINICAL AND GENOMIC DATA IN RHABDOMYOSARCOMA: LEVERAGING AACR PROJECT GENIE AS A PATH TOWARD PRECISION ONCOLOGY IN RARE CANCERS
Amit Sabnis
Favorite
Sabouret, Anabelle

Gustave Roussy
(P 201) PLEOMORPHIC RHABDOMYOSARCOMAS: A NEW ENTITY ASSOCIATED WITH LYNCH SYNDROME? FIRST RESULTS OF SARCLYNCH NATIONAL STUDY
Anabelle Sabouret
Favorite
Sabu, Priya

KUMC
(P 446) SYNERGISTIC TARGETING OF KIF11 AND AURKA TO IMPROVE OUTCOMES FOR EWING SARCOMA
Priya Sabu
Favorite
Sacchetti, Federico

Department of Orthopaedic Oncology and Reconstructive Surgery, Azienda Ospedaliero Universitaria Careggi, Firenze, Italy
(P 546) PRELIMINARY CLINICAL RESULTS OF AN ONGOING PHASE II TRIAL: SPRINT (SARCOMA PREOPERATIVE RADIATION WITH SIMULTANEOUS INTEGRATED BOOST)
Federico Sacchetti
Favorite
Sachs, Elizabeth

Duke University
(P 137) IMPACT OF SOCIAL DETERMINANTS OF HEALTH ON SARCOMA CARE: A SINGLE INSTITUTION EXPERIENCE
Elizabeth Sachs
Favorite
(P 509) GIANT CELL TUMOR OF BONE IN THE PEDIATRIC POPULATION: A RETROSPECTIVE STUDY HIGHLIGHTING CASES OF METAPHYSEAL ONLY LOCATION AND INCREASED LOCAL RECURRENCE RATES IN SKELETALLY IMMATURE PATIENTS
Elizabeth Sachs
Favorite
Sadachi, Ryo

National Cancer Center Hospital
(P 547) A PHASE II TRIAL OF TAZEMETOSTAT FOR PATIENTS WITH UNRESECTABLE OR METASTATIC EPITHELIOID SARCOMA (TAZETTA TRIAL)
Ryo Sadachi
Favorite
Safwat, Akmal

Danish centre for Particle Therapy, Aarhus University hospital
(P 73) FOSTER CONSORTIUM, FIGHT OSTEOSARCOMA THROUGH EUROPEAN RESEARCH
Akmal Safwat
Favorite
Saifi, Omran

Mayo Clinic Florida
(P 312) MANAGEMENT OF ADULT HEAD AND NECK SOFT TISSUE SARCOMA: THE MAYO CLINIC EXPERIENCE
Omran Saifi
Favorite
Saint-Yves, Hugo

CIUSSS Est-de-l'Île-de-Montréal
(P 134) IMPACT OF THE PARTNERSHIP BETWEEN TERTIARY CENTERS AND NON-SARCOMA RADIOLOGY CENTERS.
Hugo Saint-Yves
Favorite
Saiz, Melchor

Hospital Clínico San Carlos
(P 515) ENDOBRONCHIAL NAVIGATION AS AN INTRAOPERATORY TOOL FOR RESECTION OF SMALL PULMONARY METASTASES IN SARCOMA PATIENTS
Melchor Saiz
Favorite
Sakai, Tomohisa

Nagoya University Hospital
(P 163) SELUMETINIB IN JAPANESE PEDIATRIC PATIENTS WITH SYMPTOMATIC INOPERABLE PLEXIFORM NEUROFIBROMA IN NEUROFIBROMATOSIS TYPE 1
Tomohisa Sakai
Favorite
Sakamoto, Akio

Kyoto University
(P 396) COMPREHENSIVE WHOLE-GENOME MOLECULAR PROFILING IN BONE AND SOFT TISSUE SARCOMA: MULTI-OMICS ANALYSIS OF 627 CASES ACROSS HISTOLOGIC SUBTYPES
Akio Sakamoto
Favorite
Salas, Maribel

Daiichi Sankyo, Inc.
(P 199) PEXIDARTINIB RISK EVALUATION AND MITIGATION STRATEGY PROGRAM: 3-YEAR SAFETY DATA ASSESSMENT
Maribel Salas
Favorite
Salawu, Abdulazeez

Mount Sinai Hospital and Princess Margaret Cancer Centre/University of Toronto
(P 215) IMPACT OF FRONTLINE SYSTEMIC TREATMENT CHOICE ON CLINICAL OUTCOME IN ADVANCED LEIOMYOSARCOMA: A MULTI-CENTRE RETROSPECTIVE CANSARCC STUDY
Abdulazeez Salawu
Favorite
Salazar-Arcila, Carolina

University of Calgary
(P 105) STING THERAPY INDUCES IMMUNOGENIC ANTI-TUMOR RESPONSES THAT ARE INDEPENDENT OF TUMOR STING EXPRESSION IN THE KP MODEL OF SOFT TISSUE SARCOMA
Carolina Salazar-Arcila
Favorite
(P 106) CHARACTERIZATION OF AN IMMUNE COMPETENT, MURINE MODEL OF SOFT TISSUE SARCOMA
Carolina Salazar-Arcila
Favorite
Saleh, Ramy

McGill University Health Centre Research Institute
(P 173) SAFETY, EFFICACY, AND PATIENT-REPORTED OUTCOMES WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED PRIOR ANTI–COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 UPDATE
Ramy Saleh
Favorite
Saleh, Ramy

MUCH
(P 543) MANEUVER STUDY: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF PIMICOTINIB (ABSK021) TO ASSESS THE EFFICACY AND SAFETY IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR
Ramy Saleh
Favorite
Salkov, Alexandr

National Medical Research Center of Oncology named after N.N. Blokhin "of the Ministry of Health of the Russian Federation
(P 459) EXPERIENCE IN THE USE OF INDIVIDUALIZED 3D-IMPLANTS IN THE RECONSTRUCTION OF DEFECTS IN PATIENTS WITH TUMORS OF THE CHEST WALL
Alexandr Salkov
Favorite
Salvatore, Daniela

Fondazione IRCCS Instituto Nazionale dei Tumori
(P 74) SACRAL CHORDOMA: A RANDOMIZED & OBSERVATIONAL STUDY ON SURGERY VS DEFINITIVE RADIOTHERAPY IN PRIMARY LOCALIZED DISEASE (SACRO). INTERIM ANALYSIS
Daniela Salvatore
Favorite
(P 144) IMPLEMENTATION OF THE EUROPEAN CLINICAL TRIAL REGULATION: SURVEY OF THE ITALIAN SARCOMA GROUP CENTERS
Daniela Salvatore
Favorite
Samà, Laura

IRCCS Humanitas Research Hospital
(P 297) UNVEILING THE IMPACT OF INTRATUMORAL MICROBIOTA IN THE TREATMENT EFFICACY OF SOFT TISSUE SARCOMA
Laura Samà
Favorite
(P 327) LEARNING CURVE ANALYSIS IN RETROPERITONEAL SARCOMA SURGERY
Laura Samà
Favorite
(P 457) LONG-TERM FOLLOW-UP OF PATIENTS WITH ATYPICAL LIPOMATOUS TUMOR (ALT) TREATED WITH MARGINAL RESECTION IN A REFERRAL CENTER
Laura Samà
Favorite
Samson, Pamela

Washington University in St Louis
(P 187) PALLIATIVE LATTICE STEREOTACTIC BODY RADIOTHERAPY FOR PATIENTS WITH SARCOMA
Pamela Samson
Favorite
Samuel, Glenson

KUMC
(P 446) SYNERGISTIC TARGETING OF KIF11 AND AURKA TO IMPROVE OUTCOMES FOR EWING SARCOMA
Glenson Samuel
Favorite
Sanchez-Fdez, Adrian

Department of Surgery, Division of Surgical Oncology, University of California San Diego
(P 29) COMBINATION TREATMENT WITH TEMOZOLOMIDE AND THE DEATH RECEPTOR-5 AGONIST INBRX-109 EFFECTIVELY TARGETS SUCCINATE DEHYDROGENASE -DEFICIENT GASTROINTESTINAL STROMAL TUMOR
Adrian Sanchez-Fdez
Favorite
Sanchez-Vega, francisco

MSKCC
(P 24) COMPREHENSIVE ANALYSIS OF THE GENOMIC LANDSCAPE AND CLINICAL BEHAVIOR IN GIST USING NEXT GENERATION SEQUENCING (NGS, MSK-IMPACT)
francisco Sanchez-Vega
Favorite
Sancho Pardo, Gemma

Hospital de la Santa Creu i Sant Pau
(P 313) SPACIALLY-FRACTIONATED RADIOTHERAPY (LATTICE) TREATMENT IN INOPERABLE NON-EXTREMITY BULKY SOFT-TISSUE SARCOMAS
Gemma Sancho Pardo
Favorite
Sancho, Pilar

Hospital Universitario Virgen del Rocio, Sevilla, Spain
(P 74) SACRAL CHORDOMA: A RANDOMIZED & OBSERVATIONAL STUDY ON SURGERY VS DEFINITIVE RADIOTHERAPY IN PRIMARY LOCALIZED DISEASE (SACRO). INTERIM ANALYSIS
Pilar Sancho
Favorite
Sandakly, Angelika

InfoSarcomes France
(P 90) RESULTS FROM AN INTERNATIONAL SURVEY OF BONE SARCOMA PATIENTS
Angelika Sandakly
Favorite
Sandberg, Jesse

Lucile Packard Children's Hospital, Stanford University
(P 81) OPTIMIZING EWING SARCOMA AND OSTEOSARCOMA BIOPSY ACQUISITION: CONSENSUS RECOMMENDATIONS FROM THE CHILDREN'S ONCOLOGY GROUP BONE TUMOR COMMITTEE
Jesse Sandberg
Favorite
Sanders, Joyce

Netherlands Cancer Institute/Antoni van Leeuwenhoek
(P 197) PROPRANOLOL MONOTHERAPY IN ANGIOSARCOMA - A WINDOW-OF-OPPORTUNITY STUDY (PROPANGIO)
Joyce Sanders
Favorite
Sanfilippo, Roberta

Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
(P 272) A COMPARATIVE ASSESSMENT OF SELINEXOR WITH TRABECTEDIN OR LURBINECTEDIN IN PATIENT-DERIVED XENOGRAFTS (PDX) OF DEDIFFERENTIATED LIPOSARCOMA (DDLPS)
Roberta Sanfilippo
Favorite
(P 328) REAL-LIFE EXPERIENCE OF PAZOPANIB IN PATIENTS WITH ADVANCED UTERINE LEIOMYOSARCOMA (U-LMS) FROM TWO REFERRAL ITALIAN CENTERS
Roberta Sanfilippo
Favorite
(P 329) DISTANT METASTASIS IN RETROPERITONEAL LEIOMYOSARCOMA: TUMOR SIZE, GRADE AND MORE?
Roberta Sanfilippo
Favorite
Sangalli, Claudia

Radiation Oncology Department, Fondazione IRCCS Istituto Nazionale Tumori
(P 159) IN BETWEEN OF LYMPHOMAS AND SARCOMAS: WHERE DO HISTIOCYTIC AND DENDRITIC CELL NEOPLASMS (HDCN) STAND? A RETROSPECTIVE, MULTI-INSTITUTIONAL STUDY FROM THE ITALIAN SARCOMA GROUP (ISG)
Claudia Sangalli
Favorite
(P 431) TREATMENT STRATEGY AND PROGNOSTIC FACTORS IN EXTRASKELETAL EWING SARCOMA: AN INSTITUTIONAL RETROSPECTIVE ANALYSIS
Claudia Sangalli
Favorite
(P 432) LONG-LASTING DISEASE CONTROL WITH TRABECTEDIN IN A CASE OF METASTATIC EWSR1::PATZ1 SARCOMA
Claudia Sangalli
Favorite
Sangiolo, Dario

Department of Oncology, University of Turin
(P 109) INTENSE PRECLINICAL ACTIVITY BY B7H3-SPECIFIC CAR.CIK LYMPHOCYTES AGAINST EPITHELIOID SARCOMA
Dario Sangiolo
Favorite
Sankhala, Kamalesh K

NextGen Oncology
(P 543) MANEUVER STUDY: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF PIMICOTINIB (ABSK021) TO ASSESS THE EFFICACY AND SAFETY IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR
Kamalesh K Sankhala
Favorite
Santiago, Teresa

St. Jude Children's Research Hospital
(P 528) SAFETY AND TOLERABILITY OF ORAL CYCLOPHOSPHAMIDE AND SORAFENIB WITH INTRAVENOUS BEVACIZUMAB WITH THE ADDITION OF ATEZOLIZUMAB IN PEDIATRIC SOLID TUMOR PATIENTS
Teresa Santiago
Favorite
Santoro, Armando

Humanitas Research Hospital
(P 433) A 20-YEAR MONOCENTER EXPERIENCE ON CLINICAL CHARACTERISTICS AND OUTCOME OF EXTRASKELETAL EWING SARCOMA.
Armando Santoro
Favorite
Santoro, Federica

Città della Salute e della Scienza di Torino
(P 262) ESTABLISHMENT AND CHARACTERIZATION OF THE FIRST RADIATION-INDUCED, PATIENT-DERIVED ANGIOSARCOMA CELL LINE
Federica Santoro
Favorite
Santos Toesca, Diego

Mayo Clinic Arizona
(P 312) MANAGEMENT OF ADULT HEAD AND NECK SOFT TISSUE SARCOMA: THE MAYO CLINIC EXPERIENCE
Diego Santos Toesca
Favorite
Saoudi, Abdelhamid

UPMC Hillman Cancer Center
(P 445) ISOTOXIC RADIOTHERAPY DOSE ESCALATION IN UNRESECTABLE PEDIATRIC EWING SARCOMA: A DOSIMETRIC FEASIBILITY STUDY
Abdelhamid Saoudi
Favorite
Saquib, Mostafa

Research Institute of the McGill University Health Center
(P 64) OSTEOSARCOMA. PATIENT-DERIVED XENOGRAFTS MODELS TO RECAPITULATE PATIENTS' CHEMORESISTANCE AND METASTATIC DISEASE
Mostafa Saquib
Favorite
Sarchet, Patricia

The Ohio State University Comprehensive Cancer Center
(P 335) EXTRACELLULAR VESICLE MDM2 DNA AS A BIOMARKER OF TUMOR PRESENCE AND RECURRENCE IN RETROPERITONEAL LIPOSARCOMA
Patricia Sarchet
Favorite
Sargos, Paul

Institut Bergonié
(P 523) IN-BETWEEN SARCOMA: A CATEGORY OF HIGH RISK OF RECURRENCE AND POOR OUTCOME
Paul Sargos
Favorite
Sarkar, Laboni

Tata Memorial Hospital Mumbai
(P 436) OUTCOME PROGNOSTICATORS IN ADOLESCENTS AND ADULTS WITH BONE SARCOMAS IN LOW-MIDDLE-INCOME COUNTRIES
Laboni Sarkar
Favorite
Sarre-Lazcano, Catherine

Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
(P 330) TREATMENT VARIATIONS, OUTCOMES AND PATTERNS OF RECURRENCE AFTER CURATIVE INTENT TREATMENT FOR PRIMARY RETROPERITONEAL SARCOMAS IN LATIN AMERICA. FIRST COLLABORATIVE LATAMSARC STUDY
Catherine Sarre-Lazcano
Favorite
Sarver, Aaron

University of Minnesota
(P 84) CSF1R OVEREXPRESSION ACCELLERATES OSTEOSARCOMA TUMOR FORMATION AND GENERATES TUMORS WITH DECREASED IMMUNE CELL INFILTRATION
Aaron Sarver
Favorite
(P 401) OVEREXPRESSION OF CYCLIN DEPENDENT KINASES AND CYCLINS ACROSS SARCOMAS BEYOND CDK4
Aaron Sarver
Favorite
Sasaki, Aya

Tokyo Dental College Ichikawa General Hospital
(P 87) ANGIOSARCOMA OF THE ILIUM TREATED WITH HEMIPELVECTOMY AND HIP TRANSPOSITION FOLLOWED BY POSTOPERATIVE CHEMOTHERAPY WITH PAZOPANIB: A CASE REPORT
Aya Sasaki
Favorite
Sato, Kenji

National Cancer Center Hospital
(P 152) EVALUATING DIAGNOSTIC APPROACHES TO DERMATOFIBROSARCOMA PROTUBERANS: AN OPPORTUNITY TO REDUCE THE NUMBER OF INTERVENTIONS
Kenji Sato
Favorite
Say, Jemma

National Health
(P 22) RECALL EXPERIENCE FOR SURVIVORS OF PEDIATRIC RHABDOMYOSARCOMA TREATED AT A SINGLE INSTITUTION BETWEEN 1970 AND 2010
Jemma Say
Favorite
Sbanchi, Giulia

Istituto Romagnolo per lo studio dei Tumori "Dino Amadori" IRST IRCCS, Preclinic and Osteoncology Unit, Meldola, Italy
(P 253) THE EFFICACY OF MEDICATED PATCHES IN SOFT TISSUE SARCOMAS: IN-VITRO AND EX-VIVO VALIDATION.
Giulia Sbanchi
Favorite
Sbaraglia, Marta

Department of Pathology, Azienda Ospedale-Università Padova, Padova, Italy
(P 159) IN BETWEEN OF LYMPHOMAS AND SARCOMAS: WHERE DO HISTIOCYTIC AND DENDRITIC CELL NEOPLASMS (HDCN) STAND? A RETROSPECTIVE, MULTI-INSTITUTIONAL STUDY FROM THE ITALIAN SARCOMA GROUP (ISG)
Marta Sbaraglia
Favorite
(P 189) INTERNATIONAL RETROSPECTIVE STUDY FROM THE ULTRA-RARE SARCOMA WORKING GROUP ON LOW-GRADE FIBROMYXOID SARCOMA AND SCLEROSING EPITHELIOD FIBROSARCOMA: OUTCOME OF ADVANCED DISEASE AND SYSTEMIC THERAPIES
Marta Sbaraglia
Favorite
Sbaraglia, Marta

University of Padua
(P 355) FUSION TRANSCRIPTOME PROFILING DEFINES THE MONOCLONAL NATURE OF MULTIFOCAL EPITHELIOID HEMANGIOMA OF BONE
Marta Sbaraglia
Favorite
Sbaraglia, Marta

Department of Pathology, Azienda Ospedale-Università Padova, Padova, Italy
(P 378) MULTIOMICS PROFILING OF EPITHELIOID SARCOMA UNVEILS EPIGENETIC CIRCUITRIES THAT UNDERLIE THE PATHOBIOLOGY OF PROXIMAL AND CLASSIC SUBTYPES: RESULTS FROM THE ISG EPISOBS OBSERVATIONAL STUDY
Marta Sbaraglia
Favorite
Sbaraglia, Marta

University of Padua
(P 455) EXTRASKELETAL EWING SARCOMA: A MULTICENTRIC RETROSPECTIVE STUDY FROM THE ITALIAN SARCOMA GROUP
Marta Sbaraglia
Favorite
Scagliotti, Giorgio

Department of Oncology, University of Turin
(P 262) ESTABLISHMENT AND CHARACTERIZATION OF THE FIRST RADIATION-INDUCED, PATIENT-DERIVED ANGIOSARCOMA CELL LINE
Giorgio Scagliotti
Favorite
Scally, Christopher

The University of Texas MD Anderson Cancer Center
(P 123) DEDIFFERENTIATED LIPOSARCOMAS TREATED WITH IMMUNE CHECKPOINT BLOCKADE: THE MD ANDERSON EXPERIENCE
Christopher Scally
Favorite
(P 269) PLASMA DNA METHYLATION-BASED BIOMARKERS FOR MPNST DETECTION IN PATIENTS WITH NEUROFIBROMATOSIS TYPE 1 (NF1)
Christopher Scally
Favorite
(P 394) LEIOMYOSARCOMA INTRATUMORAL MACROPHAGE INFILTRATES ARE ASSOCIATED WITH DISTINCT CLINICAL AND GENOMIC PRESENTATIONS
Christopher Scally
Favorite
(P 510) PRIMARY BREAST ANGIOSARCOMA: CLINICAL AND PATHOLOGICAL FEATURES AND IMPACT ON OUTCOMES
Christopher Scally
Favorite
Scanferla, Roberto

Orthopedics Oncology and Reconstructive Surgery Unit, Azienda Ospedaliero Universitaria Careggi, Florence, Italy
(P 189) INTERNATIONAL RETROSPECTIVE STUDY FROM THE ULTRA-RARE SARCOMA WORKING GROUP ON LOW-GRADE FIBROMYXOID SARCOMA AND SCLEROSING EPITHELIOD FIBROSARCOMA: OUTCOME OF ADVANCED DISEASE AND SYSTEMIC THERAPIES
Roberto Scanferla
Favorite
Scarzello, Giovanni

Radiation Therapy Unit, Department of Oncology, Veneto Institute of Oncology IOV - IRCCS
(P 216) BRAIN METASTASES IN SARCOMA: A (NOT SO) RARE EVENT. THE EXPERIENCE OF A HIGH VOLUME CENTER
Giovanni Scarzello
Favorite
Scattini, Gabriele

Department of Veterinary Medicine, University of Perugia
(P 283) A TRIDIMENSIONAL PRECLINICAL MODEL TO STUDY HUMAN AND CANINE OSTEOSARCOMA DEVELOPMENT AND INTERACTION WITH TUMOR MICROENVIRONMENT
Gabriele Scattini
Favorite
Schaarschmidt, Benedikt

Department of Diagnostic and Interventional Radiology and Neuroradiology, West German Cancer Center, University Hospital Essen, Essen
(P 248) FIBROBLAST ACTIVATION PROTEIN ALPHA -DIRECTED IMAGING AND THERAPY OF SOLITARY FIBROUS TUMOR
Benedikt Schaarschmidt
Favorite
Schaefer, Christiane

Pediatrics III, University Hospital Essen, West German Cancer Center
(P 17) METASTASIS-SPECIFIC GENE EXPRESSION PATTERNS IN EWING SARCOMA
Christiane Schaefer
Favorite
Schaefer, Inga-Marie

Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA
(P 189) INTERNATIONAL RETROSPECTIVE STUDY FROM THE ULTRA-RARE SARCOMA WORKING GROUP ON LOW-GRADE FIBROMYXOID SARCOMA AND SCLEROSING EPITHELIOD FIBROSARCOMA: OUTCOME OF ADVANCED DISEASE AND SYSTEMIC THERAPIES
Inga-Marie Schaefer
Favorite
Schaefer, Niklaus

CHUV
(P 535) THERAGNOSTICS IN SOFT TISSUE SARCOMA USING A VASCULAR DISCRUPTION APPROACH
Niklaus Schaefer
Favorite
Scharschmidt, Thomas

Nationwide Children's Hospital
(P 500) IMPROVING OUTCOMES OF INTERCALARY EWING SARCOMA RESECTIONS AND ALLOGRAFT RECONSTRUCTIONS WITH PATIENT-SPECIFIC CUTTING GUIDES AND VIRTUAL SURGICAL PLANNING
Thomas Scharschmidt
Favorite
(P 501) TIBIAL DEFORMITIES AND PHYSEAL INJURY WITH DISTAL FEMORAL EXPANDABLE ENDOPROSTHESIS IMPLANTS
Thomas Scharschmidt
Favorite
(P 502) SEPARATE RESECTION OF BIOPSY TRACT IN PRIMARY BONE SARCOMA: IMPLICATIONS FOR LOCAL RECURRENCE AND OVERALL SURVIVAL
Thomas Scharschmidt
Favorite
Schaub, Stephanie

University of Washington
(P 177) ANGIOSARCOMA: AN INCREASING PROBLEM IN THE UNITED STATES
Stephanie Schaub
Favorite
(P 206) A SINGLE-ARM, PHASE II STUDY OF NEOADJUVANT PEMBROLIZUMAB COMBINED WITH RADIOTHERAPY IN THE PRIMARY TREATMENT OF SOFT TISSUE SARCOMAS.
Stephanie Schaub
Favorite
Scheet, Paul

The University of Texas MD Anderson Cancer Center
(P 269) PLASMA DNA METHYLATION-BASED BIOMARKERS FOR MPNST DETECTION IN PATIENTS WITH NEUROFIBROMATOSIS TYPE 1 (NF1)
Paul Scheet
Favorite
Scheipl, Susanne

Univ. fur Orthopadie und Traumatologie Miedizinische Universitat Graz
(P 74) SACRAL CHORDOMA: A RANDOMIZED & OBSERVATIONAL STUDY ON SURGERY VS DEFINITIVE RADIOTHERAPY IN PRIMARY LOCALIZED DISEASE (SACRO). INTERIM ANALYSIS
Susanne Scheipl
Favorite
Scheipl, Susanne

Department of Orthopaedics and Trauma, Medical University of Graz
(P 458) FREQUENCY IN CHANGE OF GRADING UPON LOCAL RECURRENCE OR DISTANT METASTASIS OF SOFT TISSUE SARCOMAS.
Susanne Scheipl
Favorite
Schellekens, Kim

Princess Máxima Center for Pediatric Oncology and Erasmus MC
(P 558) TRIAL IN PROGRESS: A PHASE 1/2 STUDY OF BRIGATINIB IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH ALK POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA OR INFLAMMATORY MYOFIBROBLASTIC TUMORS (ITCC-098)
Kim Schellekens
Favorite
Scherer, Amanda

University of Iowa
(P 286) EPIGENETIC MECHANISMS AND SIGNATURES OF SARCOMA PROGRESSION AND METASTASIS
Amanda Scherer
Favorite
Scherer, Lauren

Texas Children's Hospital / Baylor College of Medicine
(P 121) IMPROVING THE EFFICACY OF GD2 CHIMERIC ANTIGEN RECEPTOR T-CELLS USING HISTONE DEACETYLASE INHIBITORS
Lauren Scherer
Favorite
Schiffman, Joshua

Huntsman Cancer Institute/University of Utah
(P 412) LEIOMYOSARCOMA POLYANEUPLOID CANCER CELLS DEVELOP IN RESPONSE TO CHEMOTHERAPY AND CONTRIBUTE TO CHEMORESISTANCE
Joshua Schiffman
Favorite
Schiffman, Joshua

Peel Therapeutics; Huntsman Cancer Institute, University of Utah
(P 565) AN EARLY PHASE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF PEEL-224 IN PATIENTS WITH ADVANCED SOLID TUMORS
Joshua Schiffman
Favorite
Schildhaus, Hans-Ulrich

Institute of Pathology, West German Cancer Center, University Hospital Essen
(P 234) GENOMIC LANDSCAPE OF CLEAR CELL SARCOMA
Hans-Ulrich Schildhaus
Favorite
(P 248) FIBROBLAST ACTIVATION PROTEIN ALPHA -DIRECTED IMAGING AND THERAPY OF SOLITARY FIBROUS TUMOR
Hans-Ulrich Schildhaus
Favorite
(P 294) DNA-DAMAGE REPAIR DYSREGULATION AND CHEMOTHERAPY RESPONSE IN SARCOMA MODELS
Hans-Ulrich Schildhaus
Favorite
Schleupner, Beatrice

Duke University
(P 299) EXPLORING THE IMMUNOLIGHT MECHANISM OF ACTION IN A GENETICALLY ENGINEERED MOUSE MODEL OF SOFT TISSUE SARCOMA
Beatrice Schleupner
Favorite
Schmid, Anita

Aadi Bioscience
(P 540) PHASE 2, MULTICENTER, OPEN-LABEL BASKET TRIAL OF NAB-SIROLIMUS FOR MALIGNANT SOLID TUMORS HARBORING PATHOGENIC INACTIVATING ALTERATIONS IN TSC1 AND TSC2 (PRECISION I)
Anita Schmid
Favorite
Schmidt-Hegemann, Nina-Sophie

Department of Radiation Oncology, University Hospital, Ludwig-Maximilians-University (LMU) Munich, Germany
(P 118) TIM-3 QUALIFIES AS A POTENTIAL IMMUNOTHERAPEUTIC TARGET IN SPECIFIC SUBSETS OF PATIENTS WITH HIGH-RISK SOFT TISSUE SARCOMAS (HR-STS)
Nina-Sophie Schmidt-Hegemann
Favorite
(P 153) PRIORITY SETTING PARNTERSHIP RETROPERITONEAL SOFT TISSUE SARCOMAS
Nina-Sophie Schmidt-Hegemann
Favorite
(P 348) RESECTION OF RECURRENT RETROPERITONEAL SOFT TISSUE SARCOMAS: ARE INTENSIVE MULTIMODAL TREATMENTS ASSOCIATED WITH INCREASED PERIOPERATIVE MORBIDITY?
Nina-Sophie Schmidt-Hegemann
Favorite
Schmidt, Patrick

Clinical Cooperation Unit Applied Tumor Immunity, German Cancer Research Center (DKFZ)
(P 124) UNLOCKING THE POTENTIAL OF MEASLES VIRUS ONCOLYTIC IMMUNOTHERAPY FOR SARCOMA: BIOMARKER DISCOVERY AND THERAPEUTIC VACCINE DEVELOPMENT
Patrick Schmidt
Favorite
Schoedel, Karen

University of Pittsburgh Medical Center
(P 373) DEDIFFERENTIATED AND HIGH GRADE CHONDROSARCOMAS: HOW DOES ISOCITRATE DEHYDROGENASE STATUS APPRISE PROGNOSIS AND THERAPY?
Karen Schoedel
Favorite
(P 411) A SPATIAL TRANSCRIPTOMIC "GOOGLE MAP" OF HUMAN OSTEOSARCOMA REVEALS COMMON CELL CLUSTERS AT THE PRIMARY SITE AND PULMONARY METASTASES.
Karen Schoedel
Favorite
Schöffski, Patrick

Department of General Medical Oncology, University Hospitals Leuven, and Laboratory of Experimental Oncology, KU Leuven, Leuven Cancer Institute, Leuven, Belgium
(P 26) PHASE 1 STUDY OF IDRX-42 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS RESISTANT TO PRIOR SYSTEMIC THERAPY: EARLY RESULTS
Patrick Schöffski
Favorite
(P 43) UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR-ASSOCIATED PROTEIN AS A POTENTIAL NEXT GENERATION MOLECULAR TARGET FOR TREATMENT OF GASTROINTESTINAL STROMAL TUMOR
Patrick Schöffski
Favorite
(P 110) GCAR1: GPNMB CAR T THERAPY FOR MIT FAMILY TRANSLOCATION POSITIVE CANCERS
Patrick Schöffski
Favorite
(P 135) UNMET NEEDS IN LOCALLY ADVANCED (UNRESECTABLE) OR METASTATIC DEDIFFERENTIATED LIPOSARCOMA AND EXPECTATIONS FOR CLINICAL TRIALS: AN INTERNATIONAL DELPHI CONSENSUS STUDY
Patrick Schöffski
Favorite
(P 185) LONGITUDINAL MUTATIONAL ANALYSIS OF TP53 IN CIRCULATING TUMOR DNA IN THE PLASMA OF PATIENTS WITH LIPOSARCOMA IN A PHASE I STUDY OF BRIGIMADLIN (BI 907828), AN MDM2-P53 ANTAGONIST
Patrick Schöffski
Favorite
(P 188) IMPACT OF NIROGACESTAT ON FUNCTIONAL STATUS IN PATIENTS WITH DESMOID TUMORS: RESULTS FROM THE PHASE 3 DEFI STUDY
Patrick Schöffski
Favorite
(P 254) A COLLECTION OF PATIENT-DERIVED XENOGRAFT MODELS OF GASTROINTESTINAL STROMAL TUMORS
Patrick Schöffski
Favorite
(P 255) EPIDEMIOLOGY OF NOVEL ACTIONABLE TARGETS IN SYNOVIAL SARCOMA: A TISSUE MICRO-ARRAY STUDY
Patrick Schöffski
Favorite
(P 256) EFFICACY AND TOXICITY OF VERTEPORFIN IN COMBINATION WITH PAZOPANIB TESTED IN A PATIENT-DERIVED SYNOVIAL SARCOMA XENOGRAFT
Patrick Schöffski
Favorite
(P 349) THE UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR-ASSOCIATED PROTEIN (UPARAP) IS AN ATTRACTIVE TARGET FOR THE DEVELOPMENT OF ANTIBODY DRUG CONJUGATES FOR TREATMENT OF MESENCHYMAL MALIGNANCIES
Patrick Schöffski
Favorite
Scholl, Ashley

Duke University Hospital
(P 509) GIANT CELL TUMOR OF BONE IN THE PEDIATRIC POPULATION: A RETROSPECTIVE STUDY HIGHLIGHTING CASES OF METAPHYSEAL ONLY LOCATION AND INCREASED LOCAL RECURRENCE RATES IN SKELETALLY IMMATURE PATIENTS
Ashley Scholl
Favorite
Schoot, Reineke

Princess Máxima Center for Pediatric Oncology
(P 202) INFLAMMATORY MYOFIBROBLASTIC TUMOUR WITH ROS1 GENE FUSIONS IN CHILDREN AND YOUNG ADOLESCENTS
Reineke Schoot
Favorite
(P 229) ON THE VARIABILITY IN THE ANALYSIS OF APPARENT DIFFUSION COEFFICIENT ESTIMATES FOR MULTICENTER DIFFUSION MRI DATA OF RHABDOMYOSARCOMA PATIENTS
Reineke Schoot
Favorite
(P 558) TRIAL IN PROGRESS: A PHASE 1/2 STUDY OF BRIGATINIB IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH ALK POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA OR INFLAMMATORY MYOFIBROBLASTIC TUMORS (ITCC-098)
Reineke Schoot
Favorite
Schrage, Yvonne

Netherlands Cancer Institute/ Antoni van Leeuwenhoek
(P 31) NEOADJUVANT IMATINIB IN LOCALLY ADVANCED GASTROINTESTINAL STROMAL TUMORS (GIST) IS EFFECTIVE AND SAFE: RESULTS FROM A PROSPECTIVE SINGLE CENTER STUDY WITH 108 PATIENTS
Yvonne Schrage
Favorite
(P 32) IMPROVEMENT OF QUALITY AND TEXTBOOK OUTCOMES OF GASTRIC GASTROINTESTINAL STROMAL TUMOR (GIST) RESECTIONS IN THE PAST 13 YEARS; THE INFLUENCE OF MINIMAL INVASIVE SURGERY (MIS)
Yvonne Schrage
Favorite
(P 132) SARCOMA PATEINTS' VIEWS ON USING A RISK-PREDICTION MODEL TO INFORM TREATMENT DECISIONS.
Yvonne Schrage
Favorite
(P 140) THE PRE-DIAGNOSTIC GENERAL PRACTIONER JOURNEY OF SARCOMA PATIENTS: A REAL-WORLD DATA STUDY.
Yvonne Schrage
Favorite
Schremp, Emma

Vanderbilt University Medical Center
(P 160) A PROSPECTIVE STUDY EVALUATING THE ASSOCIATION OF PATIENT-REPORTED OUTCOMES WITH ACTIVITY LEVEL AND SLEEP PATTERNS IN SARCOMA SURVIVORS
Emma Schremp
Favorite
(P 210) FINANCIAL TOXICITY ASSOCIATED WITH THE TREATMENT OF SARCOMAS: A SINGLE INSTITUTION RETROSPECTIVE-PROSPECTIVE STUDY
Emma Schremp
Favorite
(P 211) AN ANALYSIS OF SELF-REPORTED DEPRESSION IN SARCOMA PATIENTS
Emma Schremp
Favorite
(P 380) NEXT GENERATION SEQUEINCING REVEALS TARGETABLE MUTATIONS IN MULTIPLE SARCOMA HISTOLOGIES
Emma Schremp
Favorite
Schuebbe, Gesa

Department of Medicine III, LMU University Hospital, LMU Munich
(P 530) FIH PHASE I STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND ANTITUMOR ACTIVITY OF THE001 COMBINED WITH REGIONAL HYPERTHERMIA IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOFT TISSUE SARCOMA
Gesa Schuebbe
Favorite
Schuetze, Scott

University of Michigan
(P 166) SARC038: A PHASE 2 STUDY OF REGORAFENIB IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH REFRACTORY OR RECURRENT OSTEOSARCOMA
Scott Schuetze
Favorite
(P 207) A MULTICENTER PHASE II STUDY OF CABOZANTINIB PLUS NIVOLUMAB FOR PATIENTS WITH ADVANCED ANGIOSARCOMA PREVIOUSLY TREATED WITH A TAXANE: ALLIANCE A091902
Scott Schuetze
Favorite
Schuetze, Scott

University of Michigan, Department of Hematology/Oncology
(P 449) CIC-DUX4 sarcomas: A single-center review of clinical features and molecular aberrations identified through DNA sequencing
Scott Schuetze
Favorite
Schuetze, Scott

University of Michigan
(P 531) ENVASARC: A PIVOTAL TRIAL OF ENVAFOLIMAB AND ENVAFOLIMAB IN COMBINATION WITH IPILIMUMAB IN PATIENTS WITH ADVANCED OR METASTATIC UPS OR MFS WHO HAVE PROGRESSED ON PRIOR CHEMOTHERAPY
Scott Schuetze
Favorite
Schuler, Martin

Department of Medical Oncology, West German Cancer Center, University Hospital Essen
(P 248) FIBROBLAST ACTIVATION PROTEIN ALPHA -DIRECTED IMAGING AND THERAPY OF SOLITARY FIBROUS TUMOR
Martin Schuler
Favorite
Schulte, Brian

UCSF Helen Diller Family Comprehensive Cancer Center
(P 180) HEALTH RELATED QUALITY OF LIFE OF PATIENTS WITH ADVANCED LEIOMYOSARCOMA AND OTHER SOFT TISSUE SARCOMAS TREATED WITH CABOZANTINIB AND TEMOZOLOMIDE
Brian Schulte
Favorite
(P 540) PHASE 2, MULTICENTER, OPEN-LABEL BASKET TRIAL OF NAB-SIROLIMUS FOR MALIGNANT SOLID TUMORS HARBORING PATHOGENIC INACTIVATING ALTERATIONS IN TSC1 AND TSC2 (PRECISION I)
Brian Schulte
Favorite
Schuster, Kathrin

Sarcoma Patient Advocacy Global Network (SPAGN)
(P 90) RESULTS FROM AN INTERNATIONAL SURVEY OF BONE SARCOMA PATIENTS
Kathrin Schuster
Favorite
(P 136) SETTING THE INTERNATIONAL RESEARCH AGENDA FOR SARCOMA WITH PATIENTS AND CARERS: PRELIMINARY RESULTS OF PHASE II OF THE SARCOMA PATIENT ADVOCACY GLOBAL NETWORK (SPAGN) PRIORITY SETTING PARTNERSHIP
Kathrin Schuster
Favorite
Schut, Anne-Rose

Erasmus Medical Center
(P 231) MINIMALLY INTERACTIVE SEGMENTATION OF SOFT-TISSUE TUMORS ON MRI AND CT USING DEEP LEARNING
Anne-Rose Schut
Favorite
(P 233) MULTI-CENTER EXTERNAL VALIDATION OF AN AUTOMATED MODEL DIFFERENTIATING ALT FROM LIPOMA USING RADIOMICS AND DEEP-LEARNING BASED SEGMENTATION
Anne-Rose Schut
Favorite
(P 554) FIVE-YEAR OUTCOMES OF A NATIONWIDE PROSPECTIVE CLINICAL TRIAL ON ACTIVE SURVEILLENCE IN PATIENTS WITH NON-INTRAABDOMINAL DESMOID-TYPE FIBROMATOSIS
Anne-Rose Schut
Favorite
Schwab, Joseph

Cedars-Sinai Medical Center
(P 529) THE MUSCULOSKELETAL TUMOR REGISTRY -- 2023 UPDATE AND OUTLOOK
Joseph Schwab
Favorite
Schwartz, Gary

Herbert Irving Comprehensive Cancer Center at Columbia University School of Medicine
(P 182) UPDATED RESULTS FROM AN ONGOING PHASE 1B STUDY OF UNESBULIN (PTC596) PLUS DACARBAZINE FOR THE TREATMENT OF PATIENTS WITH ADVANCED LEIOMYOSARCOMA
Gary Schwartz
Favorite
(P 207) A MULTICENTER PHASE II STUDY OF CABOZANTINIB PLUS NIVOLUMAB FOR PATIENTS WITH ADVANCED ANGIOSARCOMA PREVIOUSLY TREATED WITH A TAXANE: ALLIANCE A091902
Gary Schwartz
Favorite
Schwartz, Lawrence

Department of Radiology, Memorial Sloan Kettering Cancer Center
(P 408) CHANGES IN COMPUTED TOMOGRAPHY FEATURES INDUCED BY BRIGIMADLIN (BI 907828) IN PATIENTS WITH LIPOSARCOMA: INSIGHTS FROM PHASE I STUDIES
Lawrence Schwartz
Favorite
Sciacqua, Lucilla

Università degli Studi di Milano
(P 14) PERCUTANEOUS CRYOABLATION OF PROGRESSING EXTRA-ABDOMINAL DESMOID TUMOURS
Lucilla Sciacqua
Favorite
Sciot, Raf

Department of Pathology, University Hospitals Leuven, Leuven Cancer Institute, Leuven
(P 43) UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR-ASSOCIATED PROTEIN AS A POTENTIAL NEXT GENERATION MOLECULAR TARGET FOR TREATMENT OF GASTROINTESTINAL STROMAL TUMOR
Raf Sciot
Favorite
(P 254) A COLLECTION OF PATIENT-DERIVED XENOGRAFT MODELS OF GASTROINTESTINAL STROMAL TUMORS
Raf Sciot
Favorite
Sciot, Raf

Department of Pathology, KU Leuven and University Hospitals Leuven, Leuven Cancer Institute
(P 255) EPIDEMIOLOGY OF NOVEL ACTIONABLE TARGETS IN SYNOVIAL SARCOMA: A TISSUE MICRO-ARRAY STUDY
Raf Sciot
Favorite
Sciot, Raf

Department of Pathology, University Hospitals Leuven, Leuven Cancer Institute, Leuven
(P 256) EFFICACY AND TOXICITY OF VERTEPORFIN IN COMBINATION WITH PAZOPANIB TESTED IN A PATIENT-DERIVED SYNOVIAL SARCOMA XENOGRAFT
Raf Sciot
Favorite
Scobie, Nicole

Zoé4life
(P 558) TRIAL IN PROGRESS: A PHASE 1/2 STUDY OF BRIGATINIB IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH ALK POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA OR INFLAMMATORY MYOFIBROBLASTIC TUMORS (ITCC-098)
Nicole Scobie
Favorite
Scoccianti, Guido

Department of Orthopaedic Oncology and Reconstructive Surgery, Azienda Ospedaliero Universitaria Careggi, Firenze, Italy
(P 317) PROGNOSTIC FACTORS, CLINICAL AND TOXICITY OUTCOMES FROM A LARGE COHORT OF PATIENTS WITH SOFT TISSUE SARCOMA TREATED WITH PREOPERATIVE RADIATION THERAPY
Guido Scoccianti
Favorite
(P 546) PRELIMINARY CLINICAL RESULTS OF AN ONGOING PHASE II TRIAL: SPRINT (SARCOMA PREOPERATIVE RADIATION WITH SIMULTANEOUS INTEGRATED BOOST)
Guido Scoccianti
Favorite
Scotlandi, Katia

Istituto Ortopedico Rizzoli IOR IRCCS, Laboratory of Experimental Oncology, Bologna, Italy.
(P 01) EXTRASKELETAL EWING SARCOMA OF THE EXTREMITIES AND TRUNK IN < 25 YEARS OLD PATIENTS: A RETROSPECTIVE ANALYSIS OF A MONO-INSTITUTIONAL SERIES.
Katia Scotlandi
Favorite
(P 85) TARGETING CD99 ELICITS EWING SARCOMA CELL PHAGOCYTOSIS BY UNDIFFERENTIATED AND M2-LIKE MACROPHAGES AND INDUCES MACROPHAGE POLARIZATION TOWARD A M1-LIKE PHENOTYPE
Katia Scotlandi
Favorite
Scott, Clare

Walter and Eliza Hall Institute of Medical Research
(P 386) GENOMIC PROFILING OF GYNAECOLOGICAL SARCOMAS: REPORT FROM THE AUSTRALIA-WIDE PRECISION ONCOLOGY PROGRAM
Clare Scott
Favorite
Scott, Jacob

Cleveland Clinic
(P 308) OPTIMAL BIOLOGIC EFFECTIVE DOSE OF STEREOTACTIC BODY RADIOTHERAPY FOR METASTATIC AND RECURRENT SARCOMA
Jacob Scott
Favorite
(P 514) INTERSTITIAL BRACHYTHERAPY IN THE TREATMENT OF SOFT TISSUE SARCOMA: LOCAL RECURRENCE AND WOUND OUTCOMES
Jacob Scott
Favorite
(P 539) SARCOMA STEREOTACTIC BODY RADIOTHERAPY AND IMMUNE SYSTEM TRIAL
Jacob Scott
Favorite
Scott, Wilder

Biomedical Research Centre, University of British Columbia
(P 267) NEW MOUSE MODEL OF SYNOVIAL SARCOMA BASED ON CONDITIONAL EXPRESSION IN MESENCHYMAL PROGENITORS
Wilder Scott
Favorite
Sebio, Ana

Medical Oncology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
(P 113) IMMUNOSARC II: A SPANISH SARCOMA GROUP (GEIS) PHASE IB TRIAL OF DOXORUBICIN AND DACARBAZINE PLUS NIVOLUMAB IN FIRST LINE OF ADVANCED LEIOMYOSARCOMA
Ana Sebio
Favorite
(P 313) SPACIALLY-FRACTIONATED RADIOTHERAPY (LATTICE) TREATMENT IN INOPERABLE NON-EXTREMITY BULKY SOFT-TISSUE SARCOMAS
Ana Sebio
Favorite
(P 385) FIRST IN HUMAN PHASE I TRIAL OF A NOVEL DRUG DELIVERY IMPLANT MATRIX WITH SN-38 (CEB-01) FOR RETROPERITONEAL SOFT TISSUE SARCOMA
Ana Sebio
Favorite
(P 503) SCAPULAR PROSTHESIS RECONSTRUCTION, EXPERIENCE IN OUR INSTITUTION
Ana Sebio
Favorite
(P 504) WHY DO SOME PATIENTS WITH SYNOVIAL SARCOMA HAVE BETTER FUNCTIONAL OUTCOMES AFTER RESECTION SURGERY? ANALYSIS OF 102 CASES
Ana Sebio
Favorite
(P 507) PRIMARY CHEST WALL TUMORS OF MESENCHYMAL ORIGIN. EXPERIENCE OF A REFERENCE UNIT
Ana Sebio
Favorite
(P 508) DREAM, UTOPIA OR REALISM? PROGNOSTIC FACTORS IN LUNG METASTASECTOMY OF DISSEMINATED SARCOMA DISEASE
Ana Sebio
Favorite
Seddon, Beatrice

University College London Hospital
(P 92) DOSIMETRIC CHARACTERISTICS, OUTCOMES AND PROGNOSTIC FACTORS OF PATIENTS WITH EXTRACRANIAL CHORDOMAS AND CHONDROSARCOMAS TREATED WITH HIGH DOSE RADIOTHERAPY: A LARGE SINGLE INSTITUTION COHORT
Beatrice Seddon
Favorite
(P 325) OUTCOMES AFTER MODERN THREE-DIMENSIONAL CONFORMAL RADIOTHERAPY AND INTENSITY MODULATED RADIOTHERAPY TO TREAT SARCOMAS ARISING IN THE HAND: A RETROSPECTIVE SERIES
Beatrice Seddon
Favorite
Seeber, Andreas

Medical University of Innsbruck
(P 326) MOLECULAR LANDSCAPE OF ENDOMETRIAL STROMAL SARCOMA IN A LARGE REAL-WORLD PATIENT COHORT
Andreas Seeber
Favorite
(P 361) MOLECULAR CHARACTERIZATION OF SOLITARY FIBROUS TUMORS BY ANATOMIC SITE AND NAB2::STAT6 FUSION VARIANT TYPE
Andreas Seeber
Favorite
(P 401) OVEREXPRESSION OF CYCLIN DEPENDENT KINASES AND CYCLINS ACROSS SARCOMAS BEYOND CDK4
Andreas Seeber
Favorite
Seeman, Zach

University of Minnesota
(P 236) APOBEC MUTAGENESIS IN OSTEOSARCOMA DEVELOPMENT, PROGRESSION AND RESPONSE TO THERAPY
Zach Seeman
Favorite
See, Mark

Lee Kong Chian School of Medicine, Nanyang Technological Institution
(P 82) PROGNOSTIC FACTORS AND OUTCOMES OF 275 PATIENTS WITH HEAD AND NECK BONE AND SOFT TISSUE SARCOMA: A SINGLE CENTRE COHORT STUDY
Mark See
Favorite
Seetharam, Mahesh

Mayo Clinic
(P 117) INTERIM ANALYSIS OF PHASE 2 STUDY: A METRONOMIC REGIMEN USING GEMCITABINE, DOXORUBICIN, DOCETAXEL AND NIVOLUMAB FOR ADVANCED LEIOMYOSARCOMA (NCT04535713)
Mahesh Seetharam
Favorite
Seffar, Evan

Memorial Sloan Kettering Cancer Center
(P 24) COMPREHENSIVE ANALYSIS OF THE GENOMIC LANDSCAPE AND CLINICAL BEHAVIOR IN GIST USING NEXT GENERATION SEQUENCING (NGS, MSK-IMPACT)
Evan Seffar
Favorite
Segal, Ortal

Tel Aviv Medical Center, Tel Aviv, Israel
(P 240) IDENTIFYING PATIENTS AT HIGH RISK OF HIP FRACTURE DUE TO BONE TUMORS BY COMPUTATIONAL BIOMECHANICS: A RANDOMIZED PROSPECTIVE CLINICAL STUDY
Ortal Segal
Favorite
(P 319) HYPO-FRACTIONATED RADIATION THERAPY FOR THE EXTREMITY SOFT TISSUE SARCOM IN ELDERLY AND DISABLED.
Ortal Segal
Favorite
Segers, Eline

Ghent University
(P 296) EX VIVO SARCOMA CELL CULTURES FROM PAIRED PRIMARY, LOCAL RELAPSE AND METASTATIC SITES REVEALS PHENOTYPIC HETEROGENEITY
Eline Segers
Favorite
Segier, Bertille

OCR
(P 201) PLEOMORPHIC RHABDOMYOSARCOMAS: A NEW ENTITY ASSOCIATED WITH LYNCH SYNDROME? FIRST RESULTS OF SARCLYNCH NATIONAL STUDY
Bertille Segier
Favorite
Sehouli, Jalid

Charité
(P 133) TEN RECOMMENDATIONTS FOR SARCOMA SURGERY: CONSENSUS OF THE SURGICAL SOCIETIES BASED ON THE GERMAN S3 GUIDELINE "ADULT SOFT TISSUE SARCOMA"
Jalid Sehouli
Favorite
Seiders, Terri

Adaptimmune
(P 542) ENROLLMENT OF PEDIATRIC PARTICIPANTS WITH MAGE-A4-POSITIVE SOLID TUMORS IN A PHASE 1/2, OPEN-LABEL, BASKET TRIAL OF AFAMITRESGENE AUTOLEUCEL ("AFAMI-CEL")
Terri Seiders
Favorite
Seif A. H., Ali

Department of Diagnostic and Interventional Radiology, University Medical Center Goettingen, 37075 Goettingen, Germany
(P 235) FUSION OF PREOPERATIVE IN SITU MAGNETIC RESONANCE IMAGING AND POSTOPERATIVE COMPUTED TOMOGRAPHY TO CORRELATE FUNCTIONAL IMAGING FEATURES AND PATHOLOGICAL CHARACTERISTICS OF SOFT TISSUE SARCOMA
Ali Seif A. H.
Favorite
Sekita, Tetsuya

National Cancer Center Hospital
(P 76) GENETIC EVIDENCE OF METACHRONOUS DEDIFFERENTIATION OF CHONDROSARCOMA AT A DISTANT SITE
Tetsuya Sekita
Favorite
Selby, Luke

University of Kansas
(P 214) SIGNIFICANT TREATMENT RESPONSE IN PATIENTS WITH PRIMARY RESECTABLE EXTREMITY MYXOID LIPOSARCOMA RECEIVING NEOADJUVANT TRABECTEDIN AND RADIATION
Luke Selby
Favorite
Seliga, Katarzyna

Cancer Molecular and Genetic Diagnostics Department, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
(P 222) EXPLORING THE IMPACT OF NGS ON DIAGNOSTICS AND TREATMENT OF SARCOMA: INSIGHTS FROM REAL-WORLD DATA ACROSS MULTIPLE INSTITUTIONS IN EUROPE
Katarzyna Seliga
Favorite
Seligson, Nathan

University of Florida
(P 99) M2 MACROPHAGE INFILTRATION IS ASSOCIATED WITH EARLY DISEASE RECURRENCE FOLLOWING CURATIVE INTENT SURGICAL RESECTION IN SOFT-TISSUE SARCOMAS
Nathan Seligson
Favorite
(P 452) SECONDARY GENOMIC LANDSCAPE OF CIC::DUX4 FUSION SARCOMAS
Nathan Seligson
Favorite
selves, Janick

OCR
(P 201) PLEOMORPHIC RHABDOMYOSARCOMAS: A NEW ENTITY ASSOCIATED WITH LYNCH SYNDROME? FIRST RESULTS OF SARCLYNCH NATIONAL STUDY
Janick selves
Favorite
Semrau, Sabine

Department of Radiation Oncology, University Hospital, Friedrich-Alexander-University Erlangen-Nuremberg, 91054 Erlangen, Germany
(P 557) UNRAVELING THE ROLE OF LOCAL THERAPY FOR PATIENTS WITH OLIGOMETASTATIC SOFT TISSUE SARCOMA - A RETROSPECTIVE MULTICENTER TRIAL OF BAVARIAN UNIVERSITY HOSPITALS
Sabine Semrau
Favorite
Senger, Donna

McGill Univeristy
(P 110) GCAR1: GPNMB CAR T THERAPY FOR MIT FAMILY TRANSLOCATION POSITIVE CANCERS
Donna Senger
Favorite
Seo, Chin Jin

Department of Sarcoma, Peritoneal and Rare Tumours (SPRinT), Division of Surgery and Surgical Oncology, National Cancer Centre Singapore
(P 336) EVOLUTION AND PURSUIT OF EXCELLENCE IN SARCOMA MANAGEMENT IN AN ASIAN TERTIARY SARCOMA SPECIALISED CENTRE
Chin Jin Seo
Favorite
Seo, Heewon

University of Calgary
(P 110) GCAR1: GPNMB CAR T THERAPY FOR MIT FAMILY TRANSLOCATION POSITIVE CANCERS
Heewon Seo
Favorite
(P 415) NEOADJUVANT RADIOTHERAPY MODULATES THE TUMOUR MICROENVIRONMENT OF UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Heewon Seo
Favorite
Serra, Massimo

Istituto Ortopedico Rizzoli IRCCS, Osteoncology- Bone and Soft Tissue Sarcomas and Innovative Therapies Unit, Bologna, Italy
(P 253) THE EFFICACY OF MEDICATED PATCHES IN SOFT TISSUE SARCOMAS: IN-VITRO AND EX-VIVO VALIDATION.
Massimo Serra
Favorite
Serrano, César

Medical Oncology Department, Hospital Universitario Vall d'Hebron, Vall d'Hebron Institute of Oncology, Barcelona, Spain
(P 26) PHASE 1 STUDY OF IDRX-42 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS RESISTANT TO PRIOR SYSTEMIC THERAPY: EARLY RESULTS
César Serrano
Favorite
(P 27) A MULTICENTER RETROSPECTIVE STUDY ON THE CLINICAL BEHAVIOR OF SDH-DEFICIENT GIST
César Serrano
Favorite
(P 49) EFFICACY OF RIPRETINIB IN A MULTICENTER EXPANDED ACCESS PROGRAM IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS HARBOURING NON-KIT EXON 11 MUTATIONS.
César Serrano
Favorite
(P 176) SAFETY, EFFICACY, AND PATIENT-REPORTED OUTCOMES WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED NO PRIOR ANTI–COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 UPDATE
César Serrano
Favorite
(P 222) EXPLORING THE IMPACT OF NGS ON DIAGNOSTICS AND TREATMENT OF SARCOMA: INSIGHTS FROM REAL-WORLD DATA ACROSS MULTIPLE INSTITUTIONS IN EUROPE
César Serrano
Favorite
(P 326) MOLECULAR LANDSCAPE OF ENDOMETRIAL STROMAL SARCOMA IN A LARGE REAL-WORLD PATIENT COHORT
César Serrano
Favorite
(P 361) MOLECULAR CHARACTERIZATION OF SOLITARY FIBROUS TUMORS BY ANATOMIC SITE AND NAB2::STAT6 FUSION VARIANT TYPE
César Serrano
Favorite
(P 385) FIRST IN HUMAN PHASE I TRIAL OF A NOVEL DRUG DELIVERY IMPLANT MATRIX WITH SN-38 (CEB-01) FOR RETROPERITONEAL SOFT TISSUE SARCOMA
César Serrano
Favorite
Setty, Bhuvana

Nationwide Children's Hospital
(P 537) TGFβ IMPRINTED, EX VIVO EXPANDED UNIVERSAL DONOR NATURAL KILLER CELLS WITH CHEMOTHERAPY FOR RELAPSED BONE AND SOFT TISSUE SARCOMA - NCT05634369, REPORT FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION
Bhuvana Setty
Favorite
(P 551) PHASE II TRIAL OF GEMCITABINE AND NAB-PACLITAXEL IN PATIENTS WITH RECURRENT RHABDOMYOSARCOMA: A CLINICAL TRIAL IN PROGRESS FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION
Bhuvana Setty
Favorite
Shafer, Amanda

Department of Surgery, Rogel Cancer Center, University of Michigan
(P 293) GENERATION OF A SPONTANEOUS IMMUNOCOMPETENT MOUSE MODEL OF LIPOSARCOMA
Amanda Shafer
Favorite
Shah Mostofa, Anjum

Univerity College London and King's College London
(P 145) OUTCOMES OF BREAST ANGIOSARCOMA UNDERGOING TREATMENT IN A SPECIALIST CENTRE
Anjum Shah Mostofa
Favorite
Shah, Chirag

Cleveland Clinic
(P 514) INTERSTITIAL BRACHYTHERAPY IN THE TREATMENT OF SOFT TISSUE SARCOMA: LOCAL RECURRENCE AND WOUND OUTCOMES
Chirag Shah
Favorite
Shah, Nikita

Northwestern Memorial Hospital
(P 219) ELECTIVE DISCONTINUATION OF SORAFENIB TREATMENT IN DESMOID TUMORS: A RETROSPECTIVE ANALYSIS WITH IMPLICATIONS FOR CLINICAL PRACTICE
Nikita Shah
Favorite
Shah, Punita

The Royal Marsden hospital
(P 318) DEVELOPMENT OF NOVEL OUTLINING GUIDELINES FOR NORMAL TISSUE STRUCTURES FOR LIMB SOFT TISSUE SARCOMA.
Punita Shah
Favorite
Shah, Rachana

Children's Hospital Los Angeles
(P 430) UNIQUE HISTOLOGIC MORPHOLOGY OF EWING SARCOMA CELLS THAT HARBOR TP53 MUTATIONS
Rachana Shah
Favorite
Shah, Sharrieff

Duke University School of Medicine
(P 137) IMPACT OF SOCIAL DETERMINANTS OF HEALTH ON SARCOMA CARE: A SINGLE INSTITUTION EXPERIENCE
Sharrieff Shah
Favorite
Shamim, Shamim

Department of Nuclear Medicine, All India Institute of Medical Sciences
(P 562) A PHASE 2, SINGLE ARM STUDY OF REGORAFENIB IN METASTATIC/UNRESECTABLE REFRACTORY SYNOVIAL SARCOMAS
Shamim Shamim
Favorite
Shan, Boyao

Abbisko Therapeutics Co., Ltd
(P 169) UPDATED EFFICACY AND SAFETY PROFILE OF PIMICOTINIB (ABSK021) IN TENOSYNOVIAL GIANT CELL TUMOR (TGCT): 1-YEAR FOLLOW-UP FROM PHASE 1B
Boyao Shan
Favorite
Shao, James

IDRx, Inc.
(P 26) PHASE 1 STUDY OF IDRX-42 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS RESISTANT TO PRIOR SYSTEMIC THERAPY: EARLY RESULTS
James Shao
Favorite
Shapiro, Geoffrey

Dana-Farber Cancer Institute, Ludwig Center at Harvard Medical School
(P 541) ETCTN 10563: PHASE 1 STUDY OF PEPOSERTIB AND LIPOSOMAL DOXORUBICIN FOR ADVANCED OR METASTATIC LEIOMYOSARCOMA AND OTHER SARCOMAS
Geoffrey Shapiro
Favorite
Sharib, Jeremy

University of Washington
(P 177) ANGIOSARCOMA: AN INCREASING PROBLEM IN THE UNITED STATES
Jeremy Sharib
Favorite
(P 206) A SINGLE-ARM, PHASE II STUDY OF NEOADJUVANT PEMBROLIZUMAB COMBINED WITH RADIOTHERAPY IN THE PRIMARY TREATMENT OF SOFT TISSUE SARCOMAS.
Jeremy Sharib
Favorite
Sharma, Ashwyn K.

Department of Surgery, Division of Surgical Oncology, University of California San Diego
(P 28) RETROSPECTIVE ANALYSIS OF SUCCINATE DEHYDROGENASE (SDH)-DEFICIENT GASTROINTESTINAL STROMAL TUMOR (GIST) OUTCOMES: AN INTERNATIONAL STUDY OF 256 PATIENTS
Ashwyn K. Sharma
Favorite
(P 29) COMBINATION TREATMENT WITH TEMOZOLOMIDE AND THE DEATH RECEPTOR-5 AGONIST INBRX-109 EFFECTIVELY TARGETS SUCCINATE DEHYDROGENASE -DEFICIENT GASTROINTESTINAL STROMAL TUMOR
Ashwyn K. Sharma
Favorite
Sharma, Karun

Children's National Hospital
(P 292) APPLICATION OF HIGH-INTENSITY FOCUSED ULTRASOUND THERMAL ABLATION AND BOILING HISTOTRIPSY WITH CHECKPOINT INHIBITORS IN A MURINE MODEL OF OSTEOSARCOMA: AN IN-DEPTH STUDY
Karun Sharma
Favorite
(P 564) A PILOT STUDY OF LYSO-THERMOSENSITIVE LIPOSOMAL DOXORUBICIN AND MAGNETIC RESONANCE-GUIDED HIGH INTENSITY FOCUSED ULTRASOUND FOR TREATMENT OF RELAPSED OR REFRACTORY SOLID TUMORS
Karun Sharma
Favorite
Sharma, Maitreyi

Deciphera Pharmaceuticals, LLC
(P 173) SAFETY, EFFICACY, AND PATIENT-REPORTED OUTCOMES WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED PRIOR ANTI–COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 UPDATE
Maitreyi Sharma
Favorite
(P 176) SAFETY, EFFICACY, AND PATIENT-REPORTED OUTCOMES WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED NO PRIOR ANTI–COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 UPDATE
Maitreyi Sharma
Favorite
Sharp, Miranda

Huntsman Cancer Institute/University of Utah
(P 412) LEIOMYOSARCOMA POLYANEUPLOID CANCER CELLS DEVELOP IN RESPONSE TO CHEMOTHERAPY AND CONTRIBUTE TO CHEMORESISTANCE
Miranda Sharp
Favorite
Shaw, Kenna

MD Anderson Cancer Center
(P 83) CLINICO-GENOMIC PROFILING OF CONVENTIONAL AND DEDIFFERENTIATED CHONDROSARCOMAS REVEALS TP53 MUTATION TO BE ASSOCIATED WITH WORSE OUTCOMES
Kenna Shaw
Favorite
(P 400) THE LANDSCAPE OF GENOMIC ALTERATIONS FROM 1494 SOFT TISSUE AND BONE SARCOMAS AT MD ANDERSON CANCER CENTER
Kenna Shaw
Favorite
Shekar, Meghan

Texas Children's Hospital / Baylor College of Medicine
(P 121) IMPROVING THE EFFICACY OF GD2 CHIMERIC ANTIGEN RECEPTOR T-CELLS USING HISTONE DEACETYLASE INHIBITORS
Meghan Shekar
Favorite
Shekhovtsova, Zhanna

BostonGene Corp.
(P 383) AI ANALYSIS SHOWS ENHANCED CCNG1 ONCOGENE EXPRESSION IN SARCOMA TUMORS AND SUPPORTS THE USE OF DELTAREX-G, A CCNG1 INHIBITOR, AS PLATFORM THERAPY FOR ADVANCED SARCOMA
Zhanna Shekhovtsova
Favorite
Shelofsky, Steven

Oregon Health & Science University
(P 463) MACHINE LEARNING CORROBORATES TRADITIONAL REGRESSION TECHNIQUES IN PREDICTING MAJOR WOUND COMPLICATIONS AFTER SOFT TISSUE SARCOMA RESECTION WITHOUT IMPROVEMENTS IN PREDICTIVE PERFORMANCE
Steven Shelofsky
Favorite
Shen, Dan

Key Laboratory of Digital Technology in Medical Diagnostics of Zhejiang Province, Dian Diagnostics Group Co., Ltd.
(P 41) GENOMIC ANALYSIS OF SECONDARY KIT MUTATIONS IN CHINESE PATIENTS WITH IMATINIB-RESISTANT ADVANCED GASTROINTESTINAL STROMAL TUMORS USING NEXT-GENERATION SEQUENCING (NGS)
Dan Shen
Favorite
Shengwei, Ye

Department of Gastrointestinal Surgical Oncology, The Hubei Cancer Hospital, Huazhong University of Science and Technology
(P 38) EFFICACY AND SAFETY OF RIPRETINIB IN THE TREATMENT OF ADVANCED GASTROINTESTINAL STROMAL TUMORS: A MULTICENTER RETROSPECTIVE STUDY
Ye Shengwei
Favorite
Shen, Jingnan

Department of Musculoskeletal Oncology Center, The First Affiliated Hospital of Sun Yat-sen University
(P 168) A PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF PEXIDARTINIB IN ASIAN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR
Jingnan Shen
Favorite
(P 169) UPDATED EFFICACY AND SAFETY PROFILE OF PIMICOTINIB (ABSK021) IN TENOSYNOVIAL GIANT CELL TUMOR (TGCT): 1-YEAR FOLLOW-UP FROM PHASE 1B
Jingnan Shen
Favorite
(P 543) MANEUVER STUDY: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF PIMICOTINIB (ABSK021) TO ASSESS THE EFFICACY AND SAFETY IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR
Jingnan Shen
Favorite
shen, kuntang

Department of Gastrointestinal Surgery , Zhongshan Hospital, Fudan University
(P 39) MANAGEMENT PRACTICES OF GASTROINTESTINAL STROMAL TUMORS: A QUESTIONNAIRE SURVEY OF GENERAL SURGEONS IN CHINA
kuntang shen
Favorite
Shen, Lin

Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute
(P 46) CIRCULATING TUMOR DNA (CTDNA) ANALYSES AND RESISTANCE MECHANISMS EXPLORATION OF KIT-MUTANT GASTROINTESTINAL STROMAL TUMORS (GISTS) TREATED WITH AVAPRITINIB OR RIPRETINB
Lin Shen
Favorite
(P 353) UPDATED EFFICACY AND SAFETY OF LAROTRECTINIB IN ADULT PATIENTS WITH TRK FUSION SARCOMAS
Lin Shen
Favorite
Shenoy, Archana

Nationwide Children's Hospital/The Ohio State University College of Medicine
(P 409) IMMUNOHISTOCHEMICAL STAINING FOR MYOGENIN, AP2 BETA AND HMGA2 PREDICT FOXO1 FUSION STATUS IN RHABDOMYOSARCOMA: A REPORT FROM THE SOFT TISSUE COMMITTEE OF THE CHILDREN'S ONCOLOGY GROUP
Archana Shenoy
Favorite
(P 425) CHARACTERIZATION OF RHABDOMYOSARCOMA WITH PAX7::FOXO1 FUSIONS: A REPORT FROM THE SOFT TISSUE COMMITTEE OF THE CHILDREN'S ONCOLOGY GROUP
Archana Shenoy
Favorite
(P 438) ALVEOLAR RHABDOMYOSARCOMA WITH "BURKITT-LIKE" MORPHOLOGY IS ASSOCIATED WITH HIGH AMPLIFICATION OF MYCL
Archana Shenoy
Favorite
Shen, Wei

The Key Laboratory of Industrial Biotechnology, Ministry of Education, School of Biotechnology, Jiangnan University
(P 44) RIPRETINIB FOR THE TREATMENT OF CHINESE PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS HARBORING KIT SECONDARY MUTATIONS: A MULTICENTER, RETROSPECTIVE STUDY
Wei Shen
Favorite
(P 48) SIGNIFICANCE OF MONITORING PLASMA CONCENTRATION OF RIPRETINIB IN CHINESE PATIENTS WITH GASTROINTESTINAL STROMAL TUMORS
Wei Shen
Favorite
Shepard, Dale

Cleveland Clinic
(P 539) SARCOMA STEREOTACTIC BODY RADIOTHERAPY AND IMMUNE SYSTEM TRIAL
Dale Shepard
Favorite
(P 543) MANEUVER STUDY: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF PIMICOTINIB (ABSK021) TO ASSESS THE EFFICACY AND SAFETY IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR
Dale Shepard
Favorite
Shepard, Robert

UNC
(P 183) A PHASE 1B/2 STUDY OF LIPOSOMAL ANNAMYCIN (ANN) IN SUBJECTS WITH PREVIOUSLY TREATED SOFT-TISSUE SARCOMAS (STS) WITH PULMONARY METASTASES
Robert Shepard
Favorite
Sheppard, Brett

OHSU
(P 341) A PHASE 1B STUDY TO EVALUATE PREOPERATIVE ERIBULIN IN COMBINATION WITH RADIATION IN RETROPERITONEAL SARCOMA
Brett Sheppard
Favorite
Sheridan, Aine

St Vincents University Hospital
(P 155) THE IMPACT OF THE ROLE OF A SARCOMA ADVANCED NURSE PRACTITIONER (ANP) BIOPSY CLINIC IN IMPROVING PATIENT ACCESS TO SARCOMA SERVICES
Aine Sheridan
Favorite
(P 156) PATIENT REPORTED EXPERIENCES WITHIN THE IRISH SARCOMA GROUP
Aine Sheridan
Favorite
(P 217) CONTEMPORARY TREATMENT PATTERNS AND OUTCOMES IN THE MANAGEMENT OF ANGIOSARCOMA IN IRELAND
Aine Sheridan
Favorite
Sherman, John

Nationwide Children's Hospital
(P 456) SECLIDEMSTAT TREATMENT BLOCKS THE TRANSCRIPTIONAL FUNCTION OF MULTIPLE FET-FUSION PROTEINS
John Sherman
Favorite
Sherman, Matthew

Deciphera Pharmaceuticals, LLC
(P 173) SAFETY, EFFICACY, AND PATIENT-REPORTED OUTCOMES WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED PRIOR ANTI–COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 UPDATE
Matthew Sherman
Favorite
(P 176) SAFETY, EFFICACY, AND PATIENT-REPORTED OUTCOMES WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED NO PRIOR ANTI–COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 UPDATE
Matthew Sherman
Favorite
Sherriff, Jenny

Cancer Centre, Queen Elizabeth Hospital, Birmingham, United Kingdom.
(P 49) EFFICACY OF RIPRETINIB IN A MULTICENTER EXPANDED ACCESS PROGRAM IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS HARBOURING NON-KIT EXON 11 MUTATIONS.
Jenny Sherriff
Favorite
Shevkoplias, Aleksei

BostonGene, Corp.
(P 420) COMPREHENSIVE MOLECULAR PROFILING AND TUMOR MICROENVIRONMENT CHARACTERISTICS OF RADIATION-INDUCED SARCOMA.
Aleksei Shevkoplias
Favorite
Shibata, Tatsuhiro

National Cancer Center Research Institute
(P 396) COMPREHENSIVE WHOLE-GENOME MOLECULAR PROFILING IN BONE AND SOFT TISSUE SARCOMA: MULTI-OMICS ANALYSIS OF 627 CASES ACROSS HISTOLOGIC SUBTYPES
Tatsuhiro Shibata
Favorite
Shimada, Eijiro

Duke University
(P 375) IDENTIFICATION OF METASTATIC CELLS IN UNDIFFERENTIATED PLEOMORPHIC SARCOMA: SINGLE CELL RNA SEQUENCING AND CIBERSORT ANALYSIS
Eijiro Shimada
Favorite
(P 406) EXTENSIVE ANALYSIS OF 59 SARCOMA-RELATED FUSION GENES IDENTIFIED PAZOPANIB AS A POTENTIAL INHIBITOR TO COL1A1-PDGFB FUSION GENE
Eijiro Shimada
Favorite
Shimizu, Junya

Sapporo Medical University School of Medicine
(P 05) COEFFICIENT OF VARIATION OF T2-WEIGHTED MRI PREDICTS THE PROGNOSIS OF MALIGNANT PERIPHERAL NERVE SHEATH TUMOR
Junya Shimizu
Favorite
(P 470) PROGNOSTIC SIGNIFICANCE OF HISTOLOGICAL SUBTYPE IN SOFT TISSUE SARCOMA WITH DISTANT METASTASIS
Junya Shimizu
Favorite
(P 471) IMPACT OF PRIMARY TUMOR RESECTION ON METASTASIS TO THE LUNG IN PATIENTS WITH BONE AND SOFT-TISSUE SARCOMA
Junya Shimizu
Favorite
(P 486) PRIMARY HIGH-GRADE SARCOMA OF THE SPINE: EXPERIENCE WITH 11 CASES
Junya Shimizu
Favorite
Shimoi, Tatsunori

Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
(P 80) OPTIMIZING DOSE OF MAP THERAPY FOR CHILDREN, YOUNG ADULTS AND ADULTS WITH OSTEOSARCOMA; A SINGLE-CENTRE RETROSPECTIVE ANALYSIS
Tatsunori Shimoi
Favorite
(P 547) A PHASE II TRIAL OF TAZEMETOSTAT FOR PATIENTS WITH UNRESECTABLE OR METASTATIC EPITHELIOID SARCOMA (TAZETTA TRIAL)
Tatsunori Shimoi
Favorite
Shin, Alexandr

National Medical Research Center of Oncology named after N.N. Blokhin "of the Ministry of Health of the Russian Federation
(P 459) EXPERIENCE IN THE USE OF INDIVIDUALIZED 3D-IMPLANTS IN THE RECONSTRUCTION OF DEFECTS IN PATIENTS WITH TUMORS OF THE CHEST WALL
Alexandr Shin
Favorite
Shin, Jacob

Memorial Sloan Kettering
(P 343) STEREOTACTIC BODY RADIATION THERAPY (SBRT) IN ADVANCED/RECURRENT RETROPERITONEAL SARCOMA: PRELIMINARY RESULTS
Jacob Shin
Favorite
Shinoda, Yasuo

Department of Urology, National Cancer Center Hospital, Tokyo, Japan
(P 332) SURGICAL OUTCOMES OF RETROPERITONEAL LIPOSARCOMA - SINGLE INSTITUTIONAL STUDY N JAPAN -
Yasuo Shinoda
Favorite
Shinohara, Eric

Vanderbilt University Medical Center
(P 160) A PROSPECTIVE STUDY EVALUATING THE ASSOCIATION OF PATIENT-REPORTED OUTCOMES WITH ACTIVITY LEVEL AND SLEEP PATTERNS IN SARCOMA SURVIVORS
Eric Shinohara
Favorite
(P 210) FINANCIAL TOXICITY ASSOCIATED WITH THE TREATMENT OF SARCOMAS: A SINGLE INSTITUTION RETROSPECTIVE-PROSPECTIVE STUDY
Eric Shinohara
Favorite
(P 218) NEOADJUVANT CHEMOTHERPAY AND RADIATION DECREASES TUMOR SIZE, VIABILITY, AND RECURRENCE IN MULTIPLE LIPOSARCOMA SUBSETS
Eric Shinohara
Favorite
Shirai, Chiomi

Yamagata University Faculty of Medicine, Department of Orthopaedic Surgery
(P 241) ASSOCIATION OF ADC VALUES WITH DESMOID TUMOR SHRINKAGE DURING ACTIVE OBSERVATION
Chiomi Shirai
Favorite
Shiraishi, Kouya

Division of Genome Biology, National Cancer Center Research Institute, Tokyo, Japan.
(P 35) GENOMIC ALTERATIONS IN ADVANCED GASTROINTESTINAL STROMAL TUMORS AS REVEALED BY COMPREHENSIVE GENOMIC PROFILING TESTS
Kouya Shiraishi
Favorite
Shiraishi, Yuichi

National Cancer Center Research Institute
(P 396) COMPREHENSIVE WHOLE-GENOME MOLECULAR PROFILING IN BONE AND SOFT TISSUE SARCOMA: MULTI-OMICS ANALYSIS OF 627 CASES ACROSS HISTOLOGIC SUBTYPES
Yuichi Shiraishi
Favorite
Shlien, Adam

The Hospital for Sick Children
(P 50) CHARACTERIZATION OF A FAMILIAL GIST KINDRED INTOLERANT TO IMATINIB
Adam Shlien
Favorite
(P 260) TARGETING HOMOLOGOUS RECOMBINATION DEFICIENCY (HRD) IN LEIOMYOSARCOMA WITH COMBINATION OF PARP INHIBITORS (PARPI) AND CHEMOTHERAPY (CTX).
Adam Shlien
Favorite
(P 421) USING TRANSCRIPTOMICS TO IDENTIFY LEIOMYOSARCOMA PATIENTS AT RISK OF METASTASIS
Adam Shlien
Favorite
Shoji, Hirokazu

Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
(P 35) GENOMIC ALTERATIONS IN ADVANCED GASTROINTESTINAL STROMAL TUMORS AS REVEALED BY COMPREHENSIVE GENOMIC PROFILING TESTS
Hirokazu Shoji
Favorite
Sholler, Chloe

Atrium Health Levine Children's Hospital
(P 266) ROMIDEPSIN DECREASES DNA DAMAGE REPAIR AND INCREASES SENSITIVITY TO CHEMOTHERAPY IN EWING SARCOMA
Chloe Sholler
Favorite
Shrestha, Pradeep

MD Anderson Cancer Center
(P 101) EPIGENETIC MODULATION OF NK CELLS IMPROVES TUMOR TRAFFICKING AND ENHANCES THERAPEUTIC EFFICACY AGAINST OSTEOSARCOMA
Pradeep Shrestha
Favorite
(P 122) TARGETING CD70 USING CAR NK CELLS TO ENHANCE NK CELLS CYTOLYTIC EFFECT AGAINST OSTEOSARCOMA
Pradeep Shrestha
Favorite
Shulman, David

Dana-Farber/Boston Children's Cancer and Blood Disorders Center
(P 81) OPTIMIZING EWING SARCOMA AND OSTEOSARCOMA BIOPSY ACQUISITION: CONSENSUS RECOMMENDATIONS FROM THE CHILDREN'S ONCOLOGY GROUP BONE TUMOR COMMITTEE
David Shulman
Favorite
Shultz, David

Princess Margaret Cancer Centre
(P 367) CHARACTERIZING HYPOXIA AND ASSOCIATED MOLECULAR FEATURES IN EXTREMITY SOFT TISSUE SARCOMA
David Shultz
Favorite
(P 483) DID THE COVID-19 PANDEMIC NEGATIVELY AFFECT OUTCOMES FOR PATIENTS WITH EXTREMITY SOFT TISSUE SARCOMAS?
David Shultz
Favorite
Shu, Xiao-Ou

Vanderbilt University Medical Center
(P 160) A PROSPECTIVE STUDY EVALUATING THE ASSOCIATION OF PATIENT-REPORTED OUTCOMES WITH ACTIVITY LEVEL AND SLEEP PATTERNS IN SARCOMA SURVIVORS
Xiao-Ou Shu
Favorite
(P 210) FINANCIAL TOXICITY ASSOCIATED WITH THE TREATMENT OF SARCOMAS: A SINGLE INSTITUTION RETROSPECTIVE-PROSPECTIVE STUDY
Xiao-Ou Shu
Favorite
(P 211) AN ANALYSIS OF SELF-REPORTED DEPRESSION IN SARCOMA PATIENTS
Xiao-Ou Shu
Favorite
(P 380) NEXT GENERATION SEQUEINCING REVEALS TARGETABLE MUTATIONS IN MULTIPLE SARCOMA HISTOLOGIES
Xiao-Ou Shu
Favorite
Sicklick, Jason

Department of Surgery, Division of Surgical Oncology, University of California San Diego
(P 28) RETROSPECTIVE ANALYSIS OF SUCCINATE DEHYDROGENASE (SDH)-DEFICIENT GASTROINTESTINAL STROMAL TUMOR (GIST) OUTCOMES: AN INTERNATIONAL STUDY OF 256 PATIENTS
Jason Sicklick
Favorite
(P 29) COMBINATION TREATMENT WITH TEMOZOLOMIDE AND THE DEATH RECEPTOR-5 AGONIST INBRX-109 EFFECTIVELY TARGETS SUCCINATE DEHYDROGENASE -DEFICIENT GASTROINTESTINAL STROMAL TUMOR
Jason Sicklick
Favorite
Sicoli, Federico

IRCCS Humanitas Research Hospital
(P 327) LEARNING CURVE ANALYSIS IN RETROPERITONEAL SARCOMA SURGERY
Federico Sicoli
Favorite
(P 457) LONG-TERM FOLLOW-UP OF PATIENTS WITH ATYPICAL LIPOMATOUS TUMOR (ALT) TREATED WITH MARGINAL RESECTION IN A REFERRAL CENTER
Federico Sicoli
Favorite
Siddiquee, Armaan

Memorial Sloan Kettering Cancer Center
(P 289) IDENTIFICATION OF EFFECTIVE THERAPEUTIC COMBINATIONS WITH THE NUCLEAR EXPORT PROTEIN INHIBITOR, SELINEXOR, IN PEDIATRIC SOLID TUMORS
Armaan Siddiquee
Favorite
Siebenlist, Jana

University of Heidelberg
(P 04) THE CELL ATLAS OF CLEAR CELL SARCOMA
Jana Siebenlist
Favorite
Siegel, Geoffrey

University of Michigan Department of Orthopedic Surgery
(P 403) THE IMPACT OF PATIENT, TUMOR, AND TREATMENT FACTORS ON SURVIVAL AND METASTASIS OUTCOMES IN PATIENTS WITH MYXOID LIPOSARCOMA
Geoffrey Siegel
Favorite
Sier, Cornelis

Leiden University Medical Center
(P 251) EVALUATION OF POTENTIAL TARGETS FOR FLUORESCENCE-GUIDED SURGERY IN PEDIATRIC EWING SARCOMA: A PRECLINICAL PROOF-OF-CONCEPT STUDY
Cornelis Sier
Favorite
Sierra, Solange

Sylvester Comprehensive Cancer Center, University of Miami
(P 226) SIGNATERA TESTING TO IDENTIFY MINIMAL RESIDUAL DISEASE IN HIGH GRADE SARCOMA
Solange Sierra
Favorite
Sigalotti, Luca

Unit of Oncogenetics and Functional Oncogenomics, Centro di Riferimento Oncologico di Aviano IRCCS, Aviano, Italy
(P 378) MULTIOMICS PROFILING OF EPITHELIOID SARCOMA UNVEILS EPIGENETIC CIRCUITRIES THAT UNDERLIE THE PATHOBIOLOGY OF PROXIMAL AND CLASSIC SUBTYPES: RESULTS FROM THE ISG EPISOBS OBSERVATIONAL STUDY
Luca Sigalotti
Favorite
Sigler, Greg

University of Ottawa
(P 342) THE EVALUATION AND OUTCOMES OF MESENTERIC AND INTRA-ABDOMINAL DESMOIDS: A TARPSWG STUDY
Greg Sigler
Favorite
Signer, Robert A.J.

Moores Cancer Center, University of California, San Diego
(P 29) COMBINATION TREATMENT WITH TEMOZOLOMIDE AND THE DEATH RECEPTOR-5 AGONIST INBRX-109 EFFECTIVELY TARGETS SUCCINATE DEHYDROGENASE -DEFICIENT GASTROINTESTINAL STROMAL TUMOR
Robert A.J. Signer
Favorite
Silva, Maria Leticia

AC Camargo Cancer Center
(P 192) ROLE OF MAGNETIC RESONANCE IMAGING IN THE PREDICTION OF HISTOLOGICAL GRADE IN SOFT TISSUE SARCOMAS.
Maria Leticia Silva
Favorite
Silva, Tulio

Hospital Universitario Vall d'Hebron
(P 222) EXPLORING THE IMPACT OF NGS ON DIAGNOSTICS AND TREATMENT OF SARCOMA: INSIGHTS FROM REAL-WORLD DATA ACROSS MULTIPLE INSTITUTIONS IN EUROPE
Tulio Silva
Favorite
(P 326) MOLECULAR LANDSCAPE OF ENDOMETRIAL STROMAL SARCOMA IN A LARGE REAL-WORLD PATIENT COHORT
Tulio Silva
Favorite
Simes, John

NHMRC Clinical Trials Centre
(P 386) GENOMIC PROFILING OF GYNAECOLOGICAL SARCOMAS: REPORT FROM THE AUSTRALIA-WIDE PRECISION ONCOLOGY PROGRAM
John Simes
Favorite
Simmonds, Mary-Claire

British Columbia Children's Hospital
(P 512) PERIOPERATIVE BLOOD MANAGEMENT IN PEDIATRIC PATIENTS UNDERGOING PRIMARY OSTEOSARCOMA AND EWING SARCOMA RESECTION: A RETROSPECTIVE CASE NOTE REVIEW
Mary-Claire Simmonds
Favorite
Simoes, Rita

The Royal Marsden hospital, ICR, UCLH, RTTQA
(P 318) DEVELOPMENT OF NOVEL OUTLINING GUIDELINES FOR NORMAL TISSUE STRUCTURES FOR LIMB SOFT TISSUE SARCOMA.
Rita Simoes
Favorite
Simón Adiego, Carlos

Thoracic Surgery Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain
(P 517) PULMONARY METASTASECTOMY FOR SARCOMA: A SINGLE-INSTITUTION EXPERIENCE
Carlos Simón Adiego
Favorite
Simonetti, Sonia

Università Campus Bio-Medico di Roma
(P 263) HER2 AS A POTENTIAL NOVEL THERAPEUTIC TARGET IN SOFT TISSUE SARCOMAS
Sonia Simonetti
Favorite
(P 264) CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS AND TRABECTEDIN IN SOFT TISSUE SARCOMA: A NOVEL POTENTIAL SYNERGY?
Sonia Simonetti
Favorite
Simontacchi, Gabriele

Radiotherapy Unit,Azienda Ospedaliero Universitaria Careggi
(P 317) PROGNOSTIC FACTORS, CLINICAL AND TOXICITY OUTCOMES FROM A LARGE COHORT OF PATIENTS WITH SOFT TISSUE SARCOMA TREATED WITH PREOPERATIVE RADIATION THERAPY
Gabriele Simontacchi
Favorite
Singer, Samuel

Memorial Sloan Kettering Cancer Center
(P 24) COMPREHENSIVE ANALYSIS OF THE GENOMIC LANDSCAPE AND CLINICAL BEHAVIOR IN GIST USING NEXT GENERATION SEQUENCING (NGS, MSK-IMPACT)
Samuel Singer
Favorite
(P 257) CHARACTERIZING THE EVOLUTION AND THERAPEUTIC RESPONSE OF UNDIFFERENTIATED PLEOMORPHIC SARCOMAS USING MOUSE MODELS
Samuel Singer
Favorite
(P 343) STEREOTACTIC BODY RADIATION THERAPY (SBRT) IN ADVANCED/RECURRENT RETROPERITONEAL SARCOMA: PRELIMINARY RESULTS
Samuel Singer
Favorite
(P 555) A PILOT PHASE II STUDY TO EVALUATE THE SMALL MOLECULE TIGILANOL TIGLATE IN PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA: CLINICAL TRIAL IN PROGRESS
Samuel Singer
Favorite
Singh, Arun

University of California Los Angeles
(P 172) PHASE 2 RESULTS FROM THE RINGSIDE PHASE 2/3 TRIAL OF AL102 FOR TREATMENT OF DESMOID TUMORS
Arun Singh
Favorite
Singh, Harjeet

The University of Texas MD Anderson Cancer Center
(P 119) EX VIVO EXPANDED TUMOR INFILTRATING LYMPHOCYTES FOR SARCOMA TREATMENT
Harjeet Singh
Favorite
Singh-Varma, Anya

University of Pittsburgh School of Medicine
(P 373) DEDIFFERENTIATED AND HIGH GRADE CHONDROSARCOMAS: HOW DOES ISOCITRATE DEHYDROGENASE STATUS APPRISE PROGNOSIS AND THERAPY?
Anya Singh-Varma
Favorite
Singla, Arvind

McCaig Institute for Bone and Joint Health
(P 106) CHARACTERIZATION OF AN IMMUNE COMPETENT, MURINE MODEL OF SOFT TISSUE SARCOMA
Arvind Singla
Favorite
Siontis, Brittany

Mayo Clinic
(P 02) PEDIATRIC SYNOVIAL SARCOMA: A REVIEW OF 21 CASES FROM A SINGLE INSTITUTION
Brittany Siontis
Favorite
(P 61) ADJACENT VENOUS TUMOR THROMBUS IN PRIMARY OSTEOSARCOMA OF THE PELVIS AND EXTREMITIES
Brittany Siontis
Favorite
(P 180) HEALTH RELATED QUALITY OF LIFE OF PATIENTS WITH ADVANCED LEIOMYOSARCOMA AND OTHER SOFT TISSUE SARCOMAS TREATED WITH CABOZANTINIB AND TEMOZOLOMIDE
Brittany Siontis
Favorite
(P 196) TOLERABILITY AND OUTCOMES FOR TREATMENT OF OLDER MYXOID LIPOSARCOMA POPULATION
Brittany Siontis
Favorite
(P 440) LONG TERM OUTCOMES OF EWING SARCOMA OF THE FOOT AND ANKLE
Brittany Siontis
Favorite
(P 465) UNPLANNED EXCISION OF SYNOVIAL SARCOMA: FACTORS ASSOCIATED WITH RECURRENCE AND SURVIVAL
Brittany Siontis
Favorite
(P 518) OUTCOMES OF NON-ANGIOSARCOMA RADIATION-ASSOCIATED SOFT TISSUE SARCOMAS OF THE CHEST
Brittany Siontis
Favorite
Siracusano, Licia

Humanitas Research Hospital
(P 433) A 20-YEAR MONOCENTER EXPERIENCE ON CLINICAL CHARACTERISTICS AND OUTCOME OF EXTRASKELETAL EWING SARCOMA.
Licia Siracusano
Favorite
Siu, Lillian

Princess Margaret Cancer Centre, University of Toronto
(P 164) INTRATUMORAL INT230-6 (CISPLATIN, VINBLASTINE, SHAO) ALONE OR WITH IPILIMUMAB PROLONGED SURVIVAL WITH FAVORABLE SAFETY AND IMMUNE ACTIVATION IN ADULTS WITH REFRACTORY SARCOMAS (NCT 03058289)
Lillian Siu
Favorite
Siveke, Jens

Bridge Institute of Experimental Tumor Therapy, West German Cancer Center, University Hospital Essen
(P 220) [68GA]GA-FAPI PET/CT AS NOVEL DIAGNOSTIC TOOL IN SARCOMA
Jens Siveke
Favorite
(P 248) FIBROBLAST ACTIVATION PROTEIN ALPHA -DIRECTED IMAGING AND THERAPY OF SOLITARY FIBROUS TUMOR
Jens Siveke
Favorite
Siy, Amanda

Stanford University School of Medicine
(P 224) CO-MUTATION-DEPENDENT PROGNOSIS IN PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA
Amanda Siy
Favorite
Skelton, Teresa

BC Children's Hospital, University of British Columbia
(P 512) PERIOPERATIVE BLOOD MANAGEMENT IN PEDIATRIC PATIENTS UNDERGOING PRIMARY OSTEOSARCOMA AND EWING SARCOMA RESECTION: A RETROSPECTIVE CASE NOTE REVIEW
Teresa Skelton
Favorite
Skol, Andrew

Ann & Robert H Lurie Children's Hospital of Chicago
(P 365) MULTIMODAL ANALYSIS OF NUCLEAR AND GENOMIC ORGANIZATION IN RHABDOMYOSARCOMA AND NORMAL MYOGENIC CELLS
Andrew Skol
Favorite
SKubitz, Keith

University of Minnesota
(P 167) FDG-PET-CT RESPONSE AFTER NEOADJUVANT CHEMOTHERAPY PREDICTS LONG-TERM OUTCOME IN PATIENTS WITH SOFT TISSUE SARCOMA -- 15-YEAR FOLLOW-UP
Keith SKubitz
Favorite
Sleijfer, Stefan

Erasmus Medical Center
(P 554) FIVE-YEAR OUTCOMES OF A NATIONWIDE PROSPECTIVE CLINICAL TRIAL ON ACTIVE SURVEILLENCE IN PATIENTS WITH NON-INTRAABDOMINAL DESMOID-TYPE FIBROMATOSIS
Stefan Sleijfer
Favorite
Slidell, Mark

The Johns Hopkins Hospital
(P 143) EXPLORING HOSPITAL VOLUME THRESHOLDS FOR IMPROVED SARCOMA TREATMENT ACROSS DIFFERENT AGE CATEGORIES IN THE UNITED STATES
Mark Slidell
Favorite
Slopis, John

The University of Texas MD Anderson Cancer Center
(P 269) PLASMA DNA METHYLATION-BASED BIOMARKERS FOR MPNST DETECTION IN PATIENTS WITH NEUROFIBROMATOSIS TYPE 1 (NF1)
John Slopis
Favorite
Slotkin, Emily

Memorial Sloan Kettering Cancer Center
(P 81) OPTIMIZING EWING SARCOMA AND OSTEOSARCOMA BIOPSY ACQUISITION: CONSENSUS RECOMMENDATIONS FROM THE CHILDREN'S ONCOLOGY GROUP BONE TUMOR COMMITTEE
Emily Slotkin
Favorite
Sluijter, Judith

Erasmus Medical Center
(P 231) MINIMALLY INTERACTIVE SEGMENTATION OF SOFT-TISSUE TUMORS ON MRI AND CT USING DEEP LEARNING
Judith Sluijter
Favorite
Smith, Kaitlyn

Atrium Health Levine Children's Hospital
(P 266) ROMIDEPSIN DECREASES DNA DAMAGE REPAIR AND INCREASES SENSITIVITY TO CHEMOTHERAPY IN EWING SARCOMA
Kaitlyn Smith
Favorite
Smith, Luke

Cambridge University Hospitals NHS Foundation Trust
(P 205) PRIMARY CARDIAC SARCOMA: A RETROSPECTIVE ANALYSIS OF PRESENTATION, MANAGEMENT AND OUTCOMES
Luke Smith
Favorite
Smith, Malcolm A

National Cancer Inst.
(P 203) PRECLINICAL EVALUATION AMG 650, A SMALL MOLECULE INHIBITOR OF KIF18A, IN PEDIATRIC SOLID TUMORS BY THE PEDIATRIC PRECLINICAL IN VIVO TESTING (PIVOT) PROGRAM
Malcolm A Smith
Favorite
Smith, Myles

The Royal Marsden Hospital
(P 40) LONG TERM OUTCOMES OF NEOADJUVANT IMATINIB AND SURGICAL RESECTION OF RECTAL GASTROINTESTINAL STROMAL TUMOURS
Myles Smith
Favorite
Smith, Spencer

Oregon Health & Science University
(P 463) MACHINE LEARNING CORROBORATES TRADITIONAL REGRESSION TECHNIQUES IN PREDICTING MAJOR WOUND COMPLICATIONS AFTER SOFT TISSUE SARCOMA RESECTION WITHOUT IMPROVEMENTS IN PREDICTIVE PERFORMANCE
Spencer Smith
Favorite
Smolle, Maria Anna

Department of Orthopaedics and Trauma, Medical University of Graz, Austria
(P 458) FREQUENCY IN CHANGE OF GRADING UPON LOCAL RECURRENCE OR DISTANT METASTASIS OF SOFT TISSUE SARCOMAS.
Maria Anna Smolle
Favorite
Snelling, Sarah

University of Oxford
(P 04) THE CELL ATLAS OF CLEAR CELL SARCOMA
Sarah Snelling
Favorite
Snow, Hayden

Peter MacCallum Cancer Centre
(P 342) THE EVALUATION AND OUTCOMES OF MESENTERIC AND INTRA-ABDOMINAL DESMOIDS: A TARPSWG STUDY
Hayden Snow
Favorite
(P 516) OUCOMES OF AGGRESSIVE RESECTION OF RADIATION INDUCED ANGIOSARCOMA OF THE BREAST
Hayden Snow
Favorite
Sobczuk, Pawel

Maria Sklodowska-Curie National Research Institute of Oncology
(P 09) A NOMOGRAM MODEL TO PREDICT THE OVERALL SURVIVAL OF ADOLESCENT AND YOUNG ADULT PATIENTS WITH LOCALLY ADVANCED EWING SARCOMA.
Pawel Sobczuk
Favorite
(P 170) HETEROGENEITY OF PAZOPANIB ACTIVITY ACROSS SOFT TISSUE SARCOMA SUBTYPES - A RETROSPECTIVE ANALYSIS OF 303 CASES FROM A REFERENCE CENTER
Pawel Sobczuk
Favorite
(P 342) THE EVALUATION AND OUTCOMES OF MESENTERIC AND INTRA-ABDOMINAL DESMOIDS: A TARPSWG STUDY
Pawel Sobczuk
Favorite
(P 545) NEOADJUVANT PEMBROLIZUMAB AND EFTILAGIMOD ALPHA WITH CONCURRENT RADIOTHERAPY IN PATIENTS WITH SELECTED SOFT TISSUE SARCOMA SUBTYPES (EFTISARC-NEO)
Pawel Sobczuk
Favorite
Soffientini, Cesare

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 272) A COMPARATIVE ASSESSMENT OF SELINEXOR WITH TRABECTEDIN OR LURBINECTEDIN IN PATIENT-DERIVED XENOGRAFTS (PDX) OF DEDIFFERENTIATED LIPOSARCOMA (DDLPS)
Cesare Soffientini
Favorite
Solans Solerdelcoll, Mireia

Hospital de la Santa Creu i Sant Pau
(P 503) SCAPULAR PROSTHESIS RECONSTRUCTION, EXPERIENCE IN OUR INSTITUTION
Mireia Solans Solerdelcoll
Favorite
Solier, Stéphanie

Institut Curie
(P 395) TARGETING CD44-MEDIATED IRON ENDOCYTOSIS IN DESMOID FIBROMATOSIS
Stéphanie Solier
Favorite
Solit, david

MSKCC
(P 24) COMPREHENSIVE ANALYSIS OF THE GENOMIC LANDSCAPE AND CLINICAL BEHAVIOR IN GIST USING NEXT GENERATION SEQUENCING (NGS, MSK-IMPACT)
david Solit
Favorite
Solorzano, Aleyda

Kaiser Permanente
(P 224) CO-MUTATION-DEPENDENT PROGNOSIS IN PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA
Aleyda Solorzano
Favorite
Somaiah, Neeta

The University of Texas MD Anderson Cancer Center
(P 36) CLINICO-GENOMIC ANALYSIS OF KIT/PDGFRA/SDH WILD-TYPE GASTROINTESTINAL STROMAL TUMORS IDENTIFIES POTENTIAL DRIVER MUTATIONS
Neeta Somaiah
Favorite
(P 71) CHEMOTHERAPY AND PROGNOSTIC SIGNIFICANCE OF EXTENT OF DEDIFFERENTIATION IN DEDIFFERENTIATED PAROSTEAL OSTEOSARCOMA
Neeta Somaiah
Favorite
(P 100) HISTOLOGY SPECIFIC INTRATUMORAL B-CELL BIOLOGY IN ALVEOLAR SOFT-PART SARCOMAS (ASPS) IN RESPONSE TO DURVALUMAB-TREMELIMUMAB (D-T)
Neeta Somaiah
Favorite
(P 123) DEDIFFERENTIATED LIPOSARCOMAS TREATED WITH IMMUNE CHECKPOINT BLOCKADE: THE MD ANDERSON EXPERIENCE
Neeta Somaiah
Favorite
(P 360) TP53 ALTERATIONS IN SARCOMAS: AN ANALYSIS FROM THE AACR-GENIE DATABASE
Neeta Somaiah
Favorite
(P 394) LEIOMYOSARCOMA INTRATUMORAL MACROPHAGE INFILTRATES ARE ASSOCIATED WITH DISTINCT CLINICAL AND GENOMIC PRESENTATIONS
Neeta Somaiah
Favorite
Somarelli, Jason

Duke University
(P 72) CO-EXPRESSION OF LEUKOCYTE CYTOSOLIC PROTEIN 1 AND MATRIX METALLOPROTEINASES ARE INTEGRAL FOR METASTATIC PROGRESSION OF CHONDROSARCOMA
Jason Somarelli
Favorite
(P 299) EXPLORING THE IMMUNOLIGHT MECHANISM OF ACTION IN A GENETICALLY ENGINEERED MOUSE MODEL OF SOFT TISSUE SARCOMA
Jason Somarelli
Favorite
Somasundaram, Eashwar Somasundaram

Case Western Reserve University
(P 308) OPTIMAL BIOLOGIC EFFECTIVE DOSE OF STEREOTACTIC BODY RADIOTHERAPY FOR METASTATIC AND RECURRENT SARCOMA
Eashwar Somasundaram Somasundaram
Favorite
So, Naoko

National Cancer Center Hospital
(P 547) A PHASE II TRIAL OF TAZEMETOSTAT FOR PATIENTS WITH UNRESECTABLE OR METASTATIC EPITHELIOID SARCOMA (TAZETTA TRIAL)
Naoko So
Favorite
Song, Hyojin

University of Calgary
(P 390) NOVEL ISOFORM DISCOVERY IN SARCOMA USING FULL-LENGTH PACBIO ISO-SEQ
Hyojin Song
Favorite
Song, Zimin

The First Affiliated Hospital of Sun Yat-sen University
(P 45) THE LONG-TERM EFFECT OF IMATINIB WITH HEPATIC RESECTION OR OTHER LOCAL TREATMENT FOR GIST LIVER METASTASES
Zimin Song
Favorite
Soo, Khee Chee

Department of Sarcoma, Peritoneal and Rare Tumours (SPRinT), Division of Surgery and Surgical Oncology, National Cancer Centre Singapore
(P 336) EVOLUTION AND PURSUIT OF EXCELLENCE IN SARCOMA MANAGEMENT IN AN ASIAN TERTIARY SARCOMA SPECIALISED CENTRE
Khee Chee Soo
Favorite
Sorkin, Michael

The Ohio State University Comprehensive Cancer Center
(P 301) REDUCING THE INVASIVE POTENTIAL OF DEDIFFERENTIATED LIPOSARCOMA BY TARGETING ALTERNATIVE RNA SPLICING MACHINERY
Michael Sorkin
Favorite
Sotillo, Lidia

Hospital Clínico San Carlos
(P 515) ENDOBRONCHIAL NAVIGATION AS AN INTRAOPERATORY TOOL FOR RESECTION OF SMALL PULMONARY METASTASES IN SARCOMA PATIENTS
Lidia Sotillo
Favorite
Soule, Tomás

Instituto Alexander Fleming
(P 142) THE SARCOMA EUROPEAN AND LATIN AMERICAN NETWORK (SELNET) PROJECT: OVERVIEW OF THE MAIN RESULTS OF THE SELNET REGISTRY
Tomás Soule
Favorite
Soyfer, Viacheslave

Tel Aviv Medical Center, Tel Aviv, Israel
(P 319) HYPO-FRACTIONATED RADIATION THERAPY FOR THE EXTREMITY SOFT TISSUE SARCOM IN ELDERLY AND DISABLED.
Viacheslave Soyfer
Favorite
Spaanderman, Douwe

Erasmus Medical Center
(P 231) MINIMALLY INTERACTIVE SEGMENTATION OF SOFT-TISSUE TUMORS ON MRI AND CT USING DEEP LEARNING
Douwe Spaanderman
Favorite
(P 233) MULTI-CENTER EXTERNAL VALIDATION OF AN AUTOMATED MODEL DIFFERENTIATING ALT FROM LIPOMA USING RADIOMICS AND DEEP-LEARNING BASED SEGMENTATION
Douwe Spaanderman
Favorite
Spadazzi, Chiara

Istituto Romagnolo per lo studio dei Tumori "Dino Amadori" IRST IRCCS, Preclinic and Osteoncology Unit, Meldola, Italy
(P 37) DISSECTING THE ROLE OF EXTRACELLULAR VESICLES IN THE MANAGEMENT OF GIST
Chiara Spadazzi
Favorite
(P 253) THE EFFICACY OF MEDICATED PATCHES IN SOFT TISSUE SARCOMAS: IN-VITRO AND EX-VIVO VALIDATION.
Chiara Spadazzi
Favorite
Spafford, Megan

University of Saskatchewan
(P 148) MOVING TOWARDS THE OPTIMIZATION OF DIAGNOSIS FOR PATIENTS WITH SARCOMA: A 10-YEAR REVIEW OF EXTERNALLY CONSULTED SARCOMA CASES IN A GENERAL ANATOMICAL PATHOLOGY SERVICE
Megan Spafford
Favorite
SPALATO-CERUSO, Mariella

Institut Bergonié
(P 418) GENOMIC AND IMMUNOLOGICAL PROFILING OF PRIMARY AND DISTANT METASTASES OF SOFT TISSUE SARCOMAS
Mariella SPALATO-CERUSO
Favorite
Spalek, Mateusz

Maria Sklodowska-Curie National Research Institute of Oncology, Department of Soft Tissue/Bone Sarcoma and Melanoma, Department of Radiotherapy I, Warsaw Poland
(P 162) LONG TERM SAFETY AND EFFICACY OF COMBINED DOXORUBICIN-IFOSFAMIDE CHEMOTHERAPY WITH PREOPERATIVE HYPOFRACTIONATED RADIOTHERAPY IN MARGINALLY RESECTABLE SOFT TISSUE SARCOMAS
Mateusz Spalek
Favorite
(P 310) PREOPERATIVE RADIOTHERAPY WITH HYPERTHERMIA IN RECURRENT AND RADIATION-INDUCED SARCOMAS: RESULTS OF A PHASE 2 CLINICAL TRIAL
Mateusz Spalek
Favorite
Sparano, Francesco

Health Outcomes Research Unit, Italian Group for Adult Hematologic Diseases (GIMEMA) Data Center
(P 186) PATIENT REPORTED OUTCOME ASSESSMENT AND REPORTING IN RANDOMIZED CLINICAL TRIALS OF SYSTEMIC THERAPY FOR ADVANCED SOFT TISSUE SARCOMAS: A SYSTEMATIC REVIEW.
Francesco Sparano
Favorite
Sparber-Sauer, Monika

Zentrum für Kinder-, Jugend- und Frauenmedizin (Olgahospital)
(P 202) INFLAMMATORY MYOFIBROBLASTIC TUMOUR WITH ROS1 GENE FUSIONS IN CHILDREN AND YOUNG ADOLESCENTS
Monika Sparber-Sauer
Favorite
Sparksman, Kate

Cancer Research UK & UCL Cancer Trials Centre
(P 70) ICONIC (IMPROVING OUTCOMES THROUGH COLLABORATION IN OSTEOSARCOMA): A PROSPECTIVE OBSERVATIONAL COHORT STUDY FOR NEWLY DIAGNOSED OSTEOSARCOMA PATIENTS IN THE UNITED KINGDOM (UK)
Kate Sparksman
Favorite
Speakman, David

Peter MacCallum Cancer Centre
(P 516) OUCOMES OF AGGRESSIVE RESECTION OF RADIATION INDUCED ANGIOSARCOMA OF THE BREAST
David Speakman
Favorite
Spector, Logan

University of Minnesota
(P 414) GENOMIC ANALYSIS OF EWING SARCOMA AND HERNIA IDENTIFIES A POSITIVE GENETIC CORRELATION AND SUGGESTS BOTH ARE LINKED TO AN HMGA2 VARIANT
Logan Spector
Favorite
Speetjens, Frank

Leiden University Medical Center
(P 55) RELATIVE WASH-IN RATE ON DYNAMIC CONTRAST-ENHANCED MRI AS A NEW PROGNOSTIC FACTOR IN PATIENTS WITH OSTEOSARCOMA; A POSSIBLE TOOL FOR PERSONALIZED SARCOMA-CARE?
Frank Speetjens
Favorite
Sperduto, Will

Mayo Clinic Arizona
(P 312) MANAGEMENT OF ADULT HEAD AND NECK SOFT TISSUE SARCOMA: THE MAYO CLINIC EXPERIENCE
Will Sperduto
Favorite
Spierings, Diana

University Medical Centre Groningen
(P 371) DISRUPTION OF THE TP53 LOCUS IN OSTEOSARCOMA LEADS TO TP53 PROMOTER GENE FUSIONS AND RESTORATION OF PARTS OF THE TP53 SIGNALLING PATHWAY
Diana Spierings
Favorite
Spira, Alexander

Virginia Cancer Specialists
(P 439) THE TETRAVALENT DEATH RECEPTOR 5 AGONIST INBRX-109 COMBINED WITH CHEMOTHERAPY IN EWING SARCOMA: PRELIMINARY DATA FROM A PHASE 1 STUDY
Alexander Spira
Favorite
Sp, Nipin

The Ohio State University Comprehensive Cancer Center
(P 301) REDUCING THE INVASIVE POTENTIAL OF DEDIFFERENTIATED LIPOSARCOMA BY TARGETING ALTERNATIVE RNA SPLICING MACHINERY
Nipin Sp
Favorite
Spraker, Matthew

Washington University in St Louis
(P 187) PALLIATIVE LATTICE STEREOTACTIC BODY RADIOTHERAPY FOR PATIENTS WITH SARCOMA
Matthew Spraker
Favorite
Spreafico, Carlo

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 14) PERCUTANEOUS CRYOABLATION OF PROGRESSING EXTRA-ABDOMINAL DESMOID TUMOURS
Carlo Spreafico
Favorite
Squires, Malcolm

Atrium Health
(P 258) THE CRITICALITY OF OXIDATIVE PHOSPHORYLATION IN SYNOVIAL SARCOMA METASTASIS
Malcolm Squires
Favorite
Sreedharan, Rinoy

Indira IVF Bhandup, Mumbai, India
(P 06) ONCOFERTILITY AND PREGNANCY IN ADOLESCENT AND YOUNG ADULT CANCERS: PHYSICIANS' KNOWLEDGE AND PREFERENCES IN A LARGE LOW-MIDDLE- INCOME COUNTRY
Rinoy Sreedharan
Favorite
Srivastava, Subhash

Karolinska University Hospital
(P 278) CLINICAL MARKERS PREDICTIVE OF TRABECTEDIN RESPONSE IN SOFT TISSUE SARCOMA
Subhash Srivastava
Favorite
Staaf, Johan

Lund University
(P 371) DISRUPTION OF THE TP53 LOCUS IN OSTEOSARCOMA LEADS TO TP53 PROMOTER GENE FUSIONS AND RESTORATION OF PARTS OF THE TP53 SIGNALLING PATHWAY
Johan Staaf
Favorite
Stacchiotti, Silvia

Department of Medical Oncology 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
(P 74) SACRAL CHORDOMA: A RANDOMIZED & OBSERVATIONAL STUDY ON SURGERY VS DEFINITIVE RADIOTHERAPY IN PRIMARY LOCALIZED DISEASE (SACRO). INTERIM ANALYSIS
Silvia Stacchiotti
Favorite
(P 135) UNMET NEEDS IN LOCALLY ADVANCED (UNRESECTABLE) OR METASTATIC DEDIFFERENTIATED LIPOSARCOMA AND EXPECTATIONS FOR CLINICAL TRIALS: AN INTERNATIONAL DELPHI CONSENSUS STUDY
Silvia Stacchiotti
Favorite
(P 159) IN BETWEEN OF LYMPHOMAS AND SARCOMAS: WHERE DO HISTIOCYTIC AND DENDRITIC CELL NEOPLASMS (HDCN) STAND? A RETROSPECTIVE, MULTI-INSTITUTIONAL STUDY FROM THE ITALIAN SARCOMA GROUP (ISG)
Silvia Stacchiotti
Favorite
(P 173) SAFETY, EFFICACY, AND PATIENT-REPORTED OUTCOMES WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED PRIOR ANTI–COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 UPDATE
Silvia Stacchiotti
Favorite
(P 176) SAFETY, EFFICACY, AND PATIENT-REPORTED OUTCOMES WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED NO PRIOR ANTI–COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 UPDATE
Silvia Stacchiotti
Favorite
(P 189) INTERNATIONAL RETROSPECTIVE STUDY FROM THE ULTRA-RARE SARCOMA WORKING GROUP ON LOW-GRADE FIBROMYXOID SARCOMA AND SCLEROSING EPITHELIOD FIBROSARCOMA: OUTCOME OF ADVANCED DISEASE AND SYSTEMIC THERAPIES
Silvia Stacchiotti
Favorite
(P 272) A COMPARATIVE ASSESSMENT OF SELINEXOR WITH TRABECTEDIN OR LURBINECTEDIN IN PATIENT-DERIVED XENOGRAFTS (PDX) OF DEDIFFERENTIATED LIPOSARCOMA (DDLPS)
Silvia Stacchiotti
Favorite
(P 273) COMPARISON OF A PATIENT-DERIVED XENOGRAFTS (PDX) OF MYXOID PLEOMORPHIC LIPOSARCOMA (MPL) AND PLEOMORPHIC LIPOSARCOMA (PL) HIGHLIGHTS THE EFFECTIVENESS OF ERIBULIN IN A PDX OF MPL
Silvia Stacchiotti
Favorite
(P 329) DISTANT METASTASIS IN RETROPERITONEAL LEIOMYOSARCOMA: TUMOR SIZE, GRADE AND MORE?
Silvia Stacchiotti
Favorite
(P 378) MULTIOMICS PROFILING OF EPITHELIOID SARCOMA UNVEILS EPIGENETIC CIRCUITRIES THAT UNDERLIE THE PATHOBIOLOGY OF PROXIMAL AND CLASSIC SUBTYPES: RESULTS FROM THE ISG EPISOBS OBSERVATIONAL STUDY
Silvia Stacchiotti
Favorite
(P 437) ULTRA-RARE UNDIFFERENTIATED SMALL ROUND CELL SARCOMA: HOW SHOULD WE TREAT THEM? AN ANALYSIS FORM THE GRACEFUL PROJECT
Silvia Stacchiotti
Favorite
Stanhope, Stephen

Boehringer Ingelheim Pharmaceuticals Inc
(P 334) CHARACTERISTICS AND OUTCOMES FOR PATIENTS IN THE UNITED STATES WITH DEDIFFERENTIATED LIPOSARCOMA FROM A REAL-WORLD DATA SET
Stephen Stanhope
Favorite
Starmans, Martijn

Erasmus Medical Center
(P 231) MINIMALLY INTERACTIVE SEGMENTATION OF SOFT-TISSUE TUMORS ON MRI AND CT USING DEEP LEARNING
Martijn Starmans
Favorite
(P 233) MULTI-CENTER EXTERNAL VALIDATION OF AN AUTOMATED MODEL DIFFERENTIATING ALT FROM LIPOMA USING RADIOMICS AND DEEP-LEARNING BASED SEGMENTATION
Martijn Starmans
Favorite
Stathias, Vasileios

Sylvester Comprehensive Cancer Center
(P 361) MOLECULAR CHARACTERIZATION OF SOLITARY FIBROUS TUMORS BY ANATOMIC SITE AND NAB2::STAT6 FUSION VARIANT TYPE
Vasileios Stathias
Favorite
Statz-Geary, Kurt

University of Miami Miller School of Medicine
(P 225) PAN-SARCOMA DATABASE (PSDB): A MODEL-VIEW-CONTROLLER FRAMEWORK UTILIZING REDCAP, SHINY, AND R TO CREATE A CONTINUOUS PIPELINE OF SARCOMA DATA
Kurt Statz-Geary
Favorite
(P 366) SURVIVAL DISPARITIES IN HISPANIC PATIENTS WITH SARCOMA TESTED WITH NEXT-GENERATION SEQUENCING (NGS)
Kurt Statz-Geary
Favorite
Steeghs, Neeltje

Netherlands Cancer Institute/ Antoni van Leeuwenhoek
(P 27) A MULTICENTER RETROSPECTIVE STUDY ON THE CLINICAL BEHAVIOR OF SDH-DEFICIENT GIST
Neeltje Steeghs
Favorite
(P 30) FINANCIAL DIFFICULTIES EXPERIENCED BY DUTCH GASTROINTESTINAL STROMAL TUMOR (GIST) PATIENTS: DATA FROM A CROSS-SECTIONAL MULTICENTER STUDY
Neeltje Steeghs
Favorite
(P 31) NEOADJUVANT IMATINIB IN LOCALLY ADVANCED GASTROINTESTINAL STROMAL TUMORS (GIST) IS EFFECTIVE AND SAFE: RESULTS FROM A PROSPECTIVE SINGLE CENTER STUDY WITH 108 PATIENTS
Neeltje Steeghs
Favorite
(P 32) IMPROVEMENT OF QUALITY AND TEXTBOOK OUTCOMES OF GASTRIC GASTROINTESTINAL STROMAL TUMOR (GIST) RESECTIONS IN THE PAST 13 YEARS; THE INFLUENCE OF MINIMAL INVASIVE SURGERY (MIS)
Neeltje Steeghs
Favorite
(P 49) EFFICACY OF RIPRETINIB IN A MULTICENTER EXPANDED ACCESS PROGRAM IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS HARBOURING NON-KIT EXON 11 MUTATIONS.
Neeltje Steeghs
Favorite
(P 102) INTERLEUKIN-6 IN RELATION TO TUMOR BEHAVIOR AND EARLY RECURRENCE IN PRIMARY LOCALIZED SOFT TISSUE SARCOMA
Neeltje Steeghs
Favorite
(P 136) SETTING THE INTERNATIONAL RESEARCH AGENDA FOR SARCOMA WITH PATIENTS AND CARERS: PRELIMINARY RESULTS OF PHASE II OF THE SARCOMA PATIENT ADVOCACY GLOBAL NETWORK (SPAGN) PRIORITY SETTING PARTNERSHIP
Neeltje Steeghs
Favorite
(P 186) PATIENT REPORTED OUTCOME ASSESSMENT AND REPORTING IN RANDOMIZED CLINICAL TRIALS OF SYSTEMIC THERAPY FOR ADVANCED SOFT TISSUE SARCOMAS: A SYSTEMATIC REVIEW.
Neeltje Steeghs
Favorite
(P 197) PROPRANOLOL MONOTHERAPY IN ANGIOSARCOMA - A WINDOW-OF-OPPORTUNITY STUDY (PROPANGIO)
Neeltje Steeghs
Favorite
Stelmak, Daria

University of Michigan School of Medicine
(P 07) IDENTIFYING CONCERNS OF ADOLESCENT AND YOUNG ADULT SARCOMA PATIENTS AND SURVIVORS FOLLOWING FERTIITY PRESERVATION
Daria Stelmak
Favorite
Sternheim, Amir

National Unit of Orthopaedic Oncology, Tel Aviv Medical Center, Tel Aviv University
(P 240) IDENTIFYING PATIENTS AT HIGH RISK OF HIP FRACTURE DUE TO BONE TUMORS BY COMPUTATIONAL BIOMECHANICS: A RANDOMIZED PROSPECTIVE CLINICAL STUDY
Amir Sternheim
Favorite
Sternheim, Amir

Tel Aviv Medical Center, Tel Aviv, Israel
(P 319) HYPO-FRACTIONATED RADIATION THERAPY FOR THE EXTREMITY SOFT TISSUE SARCOM IN ELDERLY AND DISABLED.
Amir Sternheim
Favorite
Steuerwald, Nury

Levine Cancer Institute
(P 258) THE CRITICALITY OF OXIDATIVE PHOSPHORYLATION IN SYNOVIAL SARCOMA METASTASIS
Nury Steuerwald
Favorite
Stevanato, Paulo

AC Camargo Cancer Center
(P 192) ROLE OF MAGNETIC RESONANCE IMAGING IN THE PREDICTION OF HISTOLOGICAL GRADE IN SOFT TISSUE SARCOMAS.
Paulo Stevanato
Favorite
Stevenson, Jonathan

Royal Orthopaedic Hospital
(P 70) ICONIC (IMPROVING OUTCOMES THROUGH COLLABORATION IN OSTEOSARCOMA): A PROSPECTIVE OBSERVATIONAL COHORT STUDY FOR NEWLY DIAGNOSED OSTEOSARCOMA PATIENTS IN THE UNITED KINGDOM (UK)
Jonathan Stevenson
Favorite
(P 472) ICONIC (IMPROVING OUTCOMES THROUGH COLLABORATION IN OSTEOSARCOMA). AN EARLY LOOK AT SURGICAL DATA
Jonathan Stevenson
Favorite
Stewart, Clinton

St. Jude Children's Research Hospital
(P 528) SAFETY AND TOLERABILITY OF ORAL CYCLOPHOSPHAMIDE AND SORAFENIB WITH INTRAVENOUS BEVACIZUMAB WITH THE ADDITION OF ATEZOLIZUMAB IN PEDIATRIC SOLID TUMOR PATIENTS
Clinton Stewart
Favorite
Stewart, Elizabeth

St. Jude Children's Research Hospital
(P 288) EVALUATION OF ATR AND WEE1 INHIBITORS COMBINED WITH NANO-LIPOSOMAL IRINOTECAN IN A LARGE COHORT OF RHABDOMYOSARCOMA XENOGRAFTS USING A TWIN MOUSE PRECLINICAL TRIAL DESIGN
Elizabeth Stewart
Favorite
(P 303) PRECLINICAL EVALUATION OF PARP1 SELECTIVE INHIBITOR AZD5305 IN COMBINATION WITH DNA DAMAGING AGENTS IN EWING SARCOMA ORTHOTOPIC XENOGRAFT MODELS
Elizabeth Stewart
Favorite
(P 528) SAFETY AND TOLERABILITY OF ORAL CYCLOPHOSPHAMIDE AND SORAFENIB WITH INTRAVENOUS BEVACIZUMAB WITH THE ADDITION OF ATEZOLIZUMAB IN PEDIATRIC SOLID TUMOR PATIENTS
Elizabeth Stewart
Favorite
Stimolo, Davide

Department of Orthopaedic Oncology and Reconstructive Surgery, Azienda Ospedaliero Universitaria Careggi, Firenze, Italy
(P 455) EXTRASKELETAL EWING SARCOMA: A MULTICENTRIC RETROSPECTIVE STUDY FROM THE ITALIAN SARCOMA GROUP
Davide Stimolo
Favorite
STOECKLE, Eberhard

Institut Bergonié
(P 523) IN-BETWEEN SARCOMA: A CATEGORY OF HIGH RISK OF RECURRENCE AND POOR OUTCOME
Eberhard STOECKLE
Favorite
Stoppler, Melissa

Tempus Labs, Inc
(P 67) GENOMIC CHARACTERIZATION OF CHONDROSARCOMA: A RARE SARCOMA WITH CLINICAL RESPONSES TO IMMUNE CHECKPOINT INHIBITION
Melissa Stoppler
Favorite
Stosky, Jordan

Tom Baker Cancer Center
(P 454) TREATMENT PATTERNS AND OUTCOMES IN PEDIATRIC AND ADULT PATIENTS WITH EWING AND UNDIFFERENTIATED ROUND BLUE CELL SARCOMAS IN ALBERTA
Jordan Stosky
Favorite
Stoyles, Sydnee

Oregon Health & Science University
(P 179) PILOT STUDY OF A REMOTELY DELIVERED RESISTANCE EXERCISE TRAINING PROGRAM IN SARCOMA SURVIVORS
Sydnee Stoyles
Favorite
Ströbel, Philipp

Department of General, Visceral and Pediatric Surgery, University Medical Center Goettingen, 37075 Goettingen, Germany
(P 235) FUSION OF PREOPERATIVE IN SITU MAGNETIC RESONANCE IMAGING AND POSTOPERATIVE COMPUTED TOMOGRAPHY TO CORRELATE FUNCTIONAL IMAGING FEATURES AND PATHOLOGICAL CHARACTERISTICS OF SOFT TISSUE SARCOMA
Philipp Ströbel
Favorite
Strach, Madeleine

Chris O'Brien LifeHouse
(P 190) DOES RESPONSE TO PRIOR CHEMOTHERAPY PREDICT OUTCOME FROM FURTHER SYSTEMIC TREATMENT IN ADVANCED LEIOMYOSARCOMA? A SINGLE UK CENTRE EXPERIENCE
Madeleine Strach
Favorite
Strach, Madeleine

Chris O'Brien Lifehouse
(P 194) REAL WORLD OUTCOMES OF PATIENTS TREATED WITH GEMCITABINE AND DOCETAXEL FOR ADVANCED SOFT TISSUE SARCOMA IN AN AUSTRALIAN SARCOMA CENTRE
Madeleine Strach
Favorite
Stradling, Helen

Sarcoma UK
(P 127) TRENDS IN CONTACTS TO THE SARCOMA UK SUPPORT LINE
Helen Stradling
Favorite
Stragliotto, Christina

Karolinska University Hospital
(P 278) CLINICAL MARKERS PREDICTIVE OF TRABECTEDIN RESPONSE IN SOFT TISSUE SARCOMA
Christina Stragliotto
Favorite
(P 322) STEREOTACTIC BODY RADIOTHERAPY IN METASTATIC SARCOMA
Christina Stragliotto
Favorite
Strauss, Dirk

The Royal Marsden Hospital
(P 40) LONG TERM OUTCOMES OF NEOADJUVANT IMATINIB AND SURGICAL RESECTION OF RECTAL GASTROINTESTINAL STROMAL TUMOURS
Dirk Strauss
Favorite
Strauss, Sandra

UCL Cancer Institute
(P 04) THE CELL ATLAS OF CLEAR CELL SARCOMA
Sandra Strauss
Favorite
(P 57) REAL-WORLD EXPERIENCE OF CABOZANTINIB IN PAEDIATRIC, TEENAGE AND YOUNG ADULT (TYA) AND ADULT METASTATIC BONE SARCOMA PATIENTS FROM THE LONDON SARCOMA SERVICE (LSS)
Sandra Strauss
Favorite
(P 69) DEVELOPMENT AND MISSION OF THE HARMONIZATION INTERNATIONAL BONE SARCOMA CONSORTIUM (HIBISCUS)
Sandra Strauss
Favorite
(P 70) ICONIC (IMPROVING OUTCOMES THROUGH COLLABORATION IN OSTEOSARCOMA): A PROSPECTIVE OBSERVATIONAL COHORT STUDY FOR NEWLY DIAGNOSED OSTEOSARCOMA PATIENTS IN THE UNITED KINGDOM (UK)
Sandra Strauss
Favorite
(P 73) FOSTER CONSORTIUM, FIGHT OSTEOSARCOMA THROUGH EUROPEAN RESEARCH
Sandra Strauss
Favorite
(P 381) THE GENOMIC LANDSCAPE OF CLEAR CELL SARCOMA
Sandra Strauss
Favorite
(P 472) ICONIC (IMPROVING OUTCOMES THROUGH COLLABORATION IN OSTEOSARCOMA). AN EARLY LOOK AT SURGICAL DATA
Sandra Strauss
Favorite
Streitbürger, Arne

University Hospital Essen
(P 294) DNA-DAMAGE REPAIR DYSREGULATION AND CHEMOTHERAPY RESPONSE IN SARCOMA MODELS
Arne Streitbürger
Favorite
(P 451) IMPACT OF TIME TO DIAGNOSIS - A PROSPECTIVE ANALYSIS OF THE EWING 2008 TRIAL
Arne Streitbürger
Favorite
Streitbürger, Arne

Sarcomasurgery, Oerthoredic Surgery, University Hospital Essen, West German Cancer Center, Essen
(P 538) IEUROEWING TRIAL FOR LOCALIZED AND METASTATIC EWING SARCOMA
Arne Streitbürger
Favorite
Strong, Vivian

mskcc
(P 24) COMPREHENSIVE ANALYSIS OF THE GENOMIC LANDSCAPE AND CLINICAL BEHAVIOR IN GIST USING NEXT GENERATION SEQUENCING (NGS, MSK-IMPACT)
Vivian Strong
Favorite
Strub, Daryn

Nationwide Children's Hospital
(P 500) IMPROVING OUTCOMES OF INTERCALARY EWING SARCOMA RESECTIONS AND ALLOGRAFT RECONSTRUCTIONS WITH PATIENT-SPECIFIC CUTTING GUIDES AND VIRTUAL SURGICAL PLANNING
Daryn Strub
Favorite
(P 501) TIBIAL DEFORMITIES AND PHYSEAL INJURY WITH DISTAL FEMORAL EXPANDABLE ENDOPROSTHESIS IMPLANTS
Daryn Strub
Favorite
Strullu, Marion

Hopital Robert Debre
(P 75) REAL-WORLD DATA ON REGORAFENIB AND CABOZANTINIB IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH RELAPSED OSTEOSARCOMA AND EWING SARCOMA INCLUDED IN THE SACHA-FRANCE STUDY
Marion Strullu
Favorite
Stucky, Chee-chee

Mayo Clinic Arizona
(P 141) TREATMENT VARIABILITY IN SURGICAL MANAGEMENT OF PULMONARY OLIGOMETASTATIC SOFT TISSUE SARCOMA
Chee-chee Stucky
Favorite
Styring, Emelie

Skåne University Hospital
(P 371) DISRUPTION OF THE TP53 LOCUS IN OSTEOSARCOMA LEADS TO TP53 PROMOTER GENE FUSIONS AND RESTORATION OF PARTS OF THE TP53 SIGNALLING PATHWAY
Emelie Styring
Favorite
Subasri, Valli

University of Toronto
(P 50) CHARACTERIZATION OF A FAMILIAL GIST KINDRED INTOLERANT TO IMATINIB
Valli Subasri
Favorite
Subbiah, Vivek

MD Anderson Cancer Center
(P 83) CLINICO-GENOMIC PROFILING OF CONVENTIONAL AND DEDIFFERENTIATED CHONDROSARCOMAS REVEALS TP53 MUTATION TO BE ASSOCIATED WITH WORSE OUTCOMES
Vivek Subbiah
Favorite
Subbiah, Vivek

Sarah Cannon Research Institute
(P 439) THE TETRAVALENT DEATH RECEPTOR 5 AGONIST INBRX-109 COMBINED WITH CHEMOTHERAPY IN EWING SARCOMA: PRELIMINARY DATA FROM A PHASE 1 STUDY
Vivek Subbiah
Favorite
Subhawong, Ty

University of Miami
(P 158) SORAFENIB OR ANTHRACYCLINE-BASED CHEMOTHERAPY IN ADULT PATIENTS WITH PROGRESSIVE DESMOID TUMORS
Ty Subhawong
Favorite
(P 226) SIGNATERA TESTING TO IDENTIFY MINIMAL RESIDUAL DISEASE IN HIGH GRADE SARCOMA
Ty Subhawong
Favorite
Subramaniam, Aparna

The University of Texas MD Anderson Cancer Center
(P 405) PRIMARY CARDIAC ANGIOSARCOMA- GENOMIC AND MOLECULAR LANDSCAPE
Aparna Subramaniam
Favorite
(P 510) PRIMARY BREAST ANGIOSARCOMA: CLINICAL AND PATHOLOGICAL FEATURES AND IMPACT ON OUTCOMES
Aparna Subramaniam
Favorite
Sudo, Kazuki

Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
(P 80) OPTIMIZING DOSE OF MAP THERAPY FOR CHILDREN, YOUNG ADULTS AND ADULTS WITH OSTEOSARCOMA; A SINGLE-CENTRE RETROSPECTIVE ANALYSIS
Kazuki Sudo
Favorite
Sugawara, Masato

Yamagata University Faculty of Medicine, Department of Orthopaedic Surgery
(P 241) ASSOCIATION OF ADC VALUES WITH DESMOID TUMOR SHRINKAGE DURING ACTIVE OBSERVATION
Masato Sugawara
Favorite
Suh, Yeon

University of Calgary
(P 110) GCAR1: GPNMB CAR T THERAPY FOR MIT FAMILY TRANSLOCATION POSITIVE CANCERS
Yeon Suh
Favorite
Sukharevsky, Ellen

Dana-Farber Cancer Institute
(P 384) SYSTEMATIC LITERATURE AND CLINICAL TRIAL REVIEW SHOWS TARGETABLE KINASE FUSIONS ARE COMMON IN PEDIATRIC, ADOLESCENT, AND YOUNG ADULT SOFT TISSUE SARCOMAS BUT CLINICAL TRIAL OPPORTUNITIES REMAIN RARE
Ellen Sukharevsky
Favorite
Sullivan, Mikaela

Mayo Clinic
(P 02) PEDIATRIC SYNOVIAL SARCOMA: A REVIEW OF 21 CASES FROM A SINGLE INSTITUTION
Mikaela Sullivan
Favorite
(P 59) CHONDROSARCOMA OF THE FLAT BONES: DIFFERENTIAL SURVIVAL BETWEEN HIGH GRADE LESIONS OF THE PELVIS AND SCAPULA
Mikaela Sullivan
Favorite
(P 60) SKIP LESIONS IN CHONDROSARCOMA: IS WHOLE BONE IMAGING NECESSARY?
Mikaela Sullivan
Favorite
(P 61) ADJACENT VENOUS TUMOR THROMBUS IN PRIMARY OSTEOSARCOMA OF THE PELVIS AND EXTREMITIES
Mikaela Sullivan
Favorite
(P 62) PROSTHESIS-ASSOCIATED SARCOMA: A REVIEW OF 8 HIGH-GRADE LESIONS ARISING AROUND A TOTAL JOINT ARTHROPLASTY IMPLANT
Mikaela Sullivan
Favorite
(P 440) LONG TERM OUTCOMES OF EWING SARCOMA OF THE FOOT AND ANKLE
Mikaela Sullivan
Favorite
(P 465) UNPLANNED EXCISION OF SYNOVIAL SARCOMA: FACTORS ASSOCIATED WITH RECURRENCE AND SURVIVAL
Mikaela Sullivan
Favorite
(P 482) COMPARISON OF RECONSTRUCTIVE TECHNIQUES FOR METASTATIC DISEASE IN THE PROXIMAL HUMERUS
Mikaela Sullivan
Favorite
(P 491) COMPARISON OF FIXATION TECHNIQUES FOR METASTATIC DISEASE OF THE HUMERUS
Mikaela Sullivan
Favorite
Sumathi, Vaiyapuri

Royal Orthopaedic Hospital
(P 371) DISRUPTION OF THE TP53 LOCUS IN OSTEOSARCOMA LEADS TO TP53 PROMOTER GENE FUSIONS AND RESTORATION OF PARTS OF THE TP53 SIGNALLING PATHWAY
Vaiyapuri Sumathi
Favorite
Sundby, R

National Cancer Institute
(P 274) TYK2 AND MEK COMBINATION THERAPY IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS AND OTHER SOFT TISSUE SARCOMAS
R Sundby
Favorite
Sun, Lifeng

The Second Affiliated Hospital, Zhejiang University School of Medicine
(P 34) RIPRETINIB IN COMBINATION WITH OTHER TKIS IN CHINESE PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR: A MULTI-CENTER RETROSPECTIVE ANALYSIS
Lifeng Sun
Favorite
Sun, Lili

Vanderbilt University Medical Center
(P 160) A PROSPECTIVE STUDY EVALUATING THE ASSOCIATION OF PATIENT-REPORTED OUTCOMES WITH ACTIVITY LEVEL AND SLEEP PATTERNS IN SARCOMA SURVIVORS
Lili Sun
Favorite
(P 210) FINANCIAL TOXICITY ASSOCIATED WITH THE TREATMENT OF SARCOMAS: A SINGLE INSTITUTION RETROSPECTIVE-PROSPECTIVE STUDY
Lili Sun
Favorite
Sun, Xiaofeng

Department of Internal Medicine, The Affiliated Cancer Hospital of Nanjing Medical University
(P 44) RIPRETINIB FOR THE TREATMENT OF CHINESE PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS HARBORING KIT SECONDARY MUTATIONS: A MULTICENTER, RETROSPECTIVE STUDY
Xiaofeng Sun
Favorite
(P 48) SIGNIFICANCE OF MONITORING PLASMA CONCENTRATION OF RIPRETINIB IN CHINESE PATIENTS WITH GASTROINTESTINAL STROMAL TUMORS
Xiaofeng Sun
Favorite
sun, Xin

Peking University People's Hospital
(P 52) ARTEMIS-002 TRIAL IN PROGRESS: A MULTI-CENTER PHASE II TRIAL ASSESSING HS-20093 (B7-H3 ANTIBODY-DRUG CONJUGATE) FOR RELAPSED OR REFRACTORY OSTEOSARCOMA AND OTHER SARCOMAS
Xin sun
Favorite
(P 58) CHEMOTHERAPY-INDUCED EVOLUTION OF OSTEOSARCOMA REVEALED BY SINGLE-CELL RNA SEQUENCING
Xin sun
Favorite
(P 97) AN EXPLORATORY STUDY OF AN ANTI-PD-L1/TGF-β ANTIBODY, TQB2858, IN PATIENTS WITH REFRACTORY OR RECURRENT OSTEOSARCOMA AND ALVEOLAR SOFT PART SARCOMA: A REPORT FROM CHINESE SARCOMA STUDY GROUP
Xin sun
Favorite
(P 441) LONG VERSUS SHORTER SCHEDULES OF VINCRISTINE, IRINOTECAN AND TEMOZOLOMIDE (VIT) FOR RELAPSED OR REFRACTORY EWING SRACOMA: A RANDOMISED CONTROLLED PHASE 2 TRIAL
Xin sun
Favorite
(P 442) LONG-TERM OUTCOME AND RELAPSE PATTERNS IN EWING SARCOMA PATIENTS WITH EXTENSIVE LUNG/PLEURAL METASTASES AFTER A COMPLETE RESPONSE TO SYSYEMIC THERAPY
Xin sun
Favorite
Supple, Stephen

Rush University Medical Center
(P 232) NOVEL MRI SCORING SYSTEM TO ASSESS OSSEOUS MALIGNANCY IN SOFT TISSUE SARCOMA PATIENTS FOLLOWING RADIOTHERAPY
Stephen Supple
Favorite
Surapaneni, Mihir

University of Michigan Medical School
(P 403) THE IMPACT OF PATIENT, TUMOR, AND TREATMENT FACTORS ON SURVIVAL AND METASTASIS OUTCOMES IN PATIENTS WITH MYXOID LIPOSARCOMA
Mihir Surapaneni
Favorite
Sureda, Manuel

Hospital Quironsalud Torrevieja
(P 407) PRECISION AND PERSONALIZED TREATMENT FOR SOFT TISSUE SARCOMAS. RESULTS OF A 10 PATIENTS SERIES WITH MOLECULAR PROFILING USING NEXT-GENERATION MASSIVE SEQUENCING
Manuel Sureda
Favorite
Suryamohan, Kushal

BostonGene Corp.
(P 383) AI ANALYSIS SHOWS ENHANCED CCNG1 ONCOGENE EXPRESSION IN SARCOMA TUMORS AND SUPPORTS THE USE OF DELTAREX-G, A CCNG1 INHIBITOR, AS PLATFORM THERAPY FOR ADVANCED SARCOMA
Kushal Suryamohan
Favorite
Sussman, Carleigh

Memorial Sloan Kettering Cancer Center
(P 257) CHARACTERIZING THE EVOLUTION AND THERAPEUTIC RESPONSE OF UNDIFFERENTIATED PLEOMORPHIC SARCOMAS USING MOUSE MODELS
Carleigh Sussman
Favorite
Su, Yung-Yeh

National Health Research Institute
(P 350) LIVER ANGIOSARCOMA IS ASSOCIATED WITH ARISTOLOCHIC ACID EXPOSURE AND HAS A DISTINCT TELOMERE MAINTENANCE MECHANISM
Yung-Yeh Su
Favorite
Sverak, Helena

University of Minnesota
(P 252) STUDY OF NUTRACEUTICAL INTERVENTION WITH HIGH PHENOLIC EXTRA VIRGIN OLIVE OIL AND CURCUMIN FOR NEUROFIBROMATOSIS TYPE 1
Helena Sverak
Favorite
Sverak, Pavlina

University of Minnesota
(P 252) STUDY OF NUTRACEUTICAL INTERVENTION WITH HIGH PHENOLIC EXTRA VIRGIN OLIVE OIL AND CURCUMIN FOR NEUROFIBROMATOSIS TYPE 1
Pavlina Sverak
Favorite
Sverre Bruland, Øyvind

Norwegian Radium Hospital, Oslo, Norway
(P 74) SACRAL CHORDOMA: A RANDOMIZED & OBSERVATIONAL STUDY ON SURGERY VS DEFINITIVE RADIOTHERAPY IN PRIMARY LOCALIZED DISEASE (SACRO). INTERIM ANALYSIS
Øyvind Sverre Bruland
Favorite
Swallow, Carol

Mount Sinai Hospital, Toronto, ON, Canada
(P 249) INVESTIGATING CLINICAL FACTORS ASSOCIATED WITH THE ESTABLISHMENT OF SUCCESSFUL PRIMARY HUMAN SOFT TISSUE SARCOMA CELL LINES
Carol Swallow
Favorite
Sweeney, Kyle

University of Kansas Medical Center
(P 214) SIGNIFICANT TREATMENT RESPONSE IN PATIENTS WITH PRIMARY RESECTABLE EXTREMITY MYXOID LIPOSARCOMA RECEIVING NEOADJUVANT TRABECTEDIN AND RADIATION
Kyle Sweeney
Favorite
(P 467) DOES PERIOPERATIVE RADIATION AFFECT IMPLANT SURVIVORSHIP OF PRIMARY TOTAL HIP ARTHROPLASTY IN THE SETTING OF METASTATIC BONE DISEASE: A MULTICENTER STUDY
Kyle Sweeney
Favorite
(P 468) OPIATE USE AFTER TOTAL HIP ARTHROPLASTY FOR METASTATIC BONE DISEASE
Kyle Sweeney
Favorite
Sweeney, Nathan W.

Tempus Labs, Inc
(P 67) GENOMIC CHARACTERIZATION OF CHONDROSARCOMA: A RARE SARCOMA WITH CLINICAL RESPONSES TO IMMUNE CHECKPOINT INHIBITION
Nathan W. Sweeney
Favorite
Sweet-Cordero, Alejandro

UCSF
(P 413) LINKING REAL-WORLD CLINICAL AND GENOMIC DATA IN RHABDOMYOSARCOMA: LEVERAGING AACR PROJECT GENIE AS A PATH TOWARD PRECISION ONCOLOGY IN RARE CANCERS
Alejandro Sweet-Cordero
Favorite
Switaj, Tomasz

Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw, Department of Soft Tissue/Bone Sarcoma and Melanoma
(P 21) YOUNG ADULTS WITH NONMETASTATIC OPERABLE OSTEOSARCOMA TREATED PERIOPERATIVELY WITH METHOTREXATE, DOXORUBICIN AND CISPLATIN SCHEDULE, SINGLE INSTITUTION REPORT
Tomasz Switaj
Favorite
(P 170) HETEROGENEITY OF PAZOPANIB ACTIVITY ACROSS SOFT TISSUE SARCOMA SUBTYPES - A RETROSPECTIVE ANALYSIS OF 303 CASES FROM A REFERENCE CENTER
Tomasz Switaj
Favorite
(P 545) NEOADJUVANT PEMBROLIZUMAB AND EFTILAGIMOD ALPHA WITH CONCURRENT RADIOTHERAPY IN PATIENTS WITH SELECTED SOFT TISSUE SARCOMA SUBTYPES (EFTISARC-NEO)
Tomasz Switaj
Favorite
Sydow, Saskia

Lund University
(P 372) COPY NUMBER GAIN OF MDM2 IN ROD-SHAPED CHROMOSOMES PROVIDES CLUES TO EARLY STAGES IN CIRCULARIZED GENE AMPLIFICATION IN LIPOSARCOMA
Saskia Sydow
Favorite
Syed, Ibrahim

TCD
(P 424) INTERNAL TANDEM DUPLICATION OF BCOR (BCOR-ITD) ALTERS THE TUMOR EPIGENOME
Ibrahim Syed
Favorite
Syros, Alina

University of Miami Miller School of Medicine
(P 154) BARRIERS TO CARE FOR MUSCULOSKELETAL TUMORS
Alina Syros
Favorite
(P 520) ORTHOPEDIC MANIFESTATIONS OF LYMPHOPROLIFERATIVE NEOPLASMS
Alina Syros
Favorite
Sys, Gwen

University Hospital Ghent
(P 55) RELATIVE WASH-IN RATE ON DYNAMIC CONTRAST-ENHANCED MRI AS A NEW PROGNOSTIC FACTOR IN PATIENTS WITH OSTEOSARCOMA; A POSSIBLE TOOL FOR PERSONALIZED SARCOMA-CARE?
Gwen Sys
Favorite
Sys, Gwen

Ghent University Hospital
(P 73) FOSTER CONSORTIUM, FIGHT OSTEOSARCOMA THROUGH EUROPEAN RESEARCH
Gwen Sys
Favorite
(P 291) DEVELOPMENT OF A LIVE TISSUE SARCOMA BIOBANK TO SUPPORT THE CREATION OF PATIENT-DERIVED TRANSLATIONAL MODELS
Gwen Sys
Favorite
(P 295) ORTHOTOPIC XENOGRAFTS OF PAIRED SARCOMA PRIMARY TUMOUR, LOCAL RELAPSE AND METASTATIC SITES REVEALS PHENOTYPIC HETEROGENEITY IN A MINIMAL RESIDUAL DISEASE MODEL
Gwen Sys
Favorite
(P 296) EX VIVO SARCOMA CELL CULTURES FROM PAIRED PRIMARY, LOCAL RELAPSE AND METASTATIC SITES REVEALS PHENOTYPIC HETEROGENEITY
Gwen Sys
Favorite
Szabo-Rogers, Heather

University of Saskatchewan
(P 373) DEDIFFERENTIATED AND HIGH GRADE CHONDROSARCOMAS: HOW DOES ISOCITRATE DEHYDROGENASE STATUS APPRISE PROGNOSIS AND THERAPY?
Heather Szabo-Rogers
Favorite
Szkandera, Joanna

Medical University of Graz
(P 138) CONTROVERSIES IN THE MANAGEMENT OF PATIENTS WITH SOFT TISSUE SARCOMA: RESULTS AND RECOMMENDATIONS FROM THE FIRST CONFERENCE ON STATE OF SCIENCE IN SARCOMA (CSSS)
Joanna Szkandera
Favorite
(P 458) FREQUENCY IN CHANGE OF GRADING UPON LOCAL RECURRENCE OR DISTANT METASTASIS OF SOFT TISSUE SARCOMAS.
Joanna Szkandera
Favorite
Szumera-Cieckiewicz, Anna

Maria Sklodowska-Curie National Research Institute of Oncology
(P 545) NEOADJUVANT PEMBROLIZUMAB AND EFTILAGIMOD ALPHA WITH CONCURRENT RADIOTHERAPY IN PATIENTS WITH SELECTED SOFT TISSUE SARCOMA SUBTYPES (EFTISARC-NEO)
Anna Szumera-Cieckiewicz
Favorite
Szybowska, Marta

Fred A. Litwin Family Centre in Genetic Medicine, University Health Network
(P 50) CHARACTERIZATION OF A FAMILIAL GIST KINDRED INTOLERANT TO IMATINIB
Marta Szybowska
Favorite
Szymansky, Jeff

Washington University in St Louis
(P 187) PALLIATIVE LATTICE STEREOTACTIC BODY RADIOTHERAPY FOR PATIENTS WITH SARCOMA
Jeff Szymansky
Favorite
T
Taal, Walter

Erasmus Medical Center
(P 316) THE ROLE OF RADIOTHERAPY IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS: A MULTICENTER COHORT STUDY
Walter Taal
Favorite
(P 505) LOCAL RECURRENCE IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS: A MULTICENTER COHORT STUDY
Walter Taal
Favorite
Tabarestani, Troy

Duke University School of Medicine
(P 509) GIANT CELL TUMOR OF BONE IN THE PEDIATRIC POPULATION: A RETROSPECTIVE STUDY HIGHLIGHTING CASES OF METAPHYSEAL ONLY LOCATION AND INCREASED LOCAL RECURRENCE RATES IN SKELETALLY IMMATURE PATIENTS
Troy Tabarestani
Favorite
Tabatabai, Ghazaleh

Department of Neurology and Interdisciplinary Neuro-Oncology, Center for Neuro-Oncology, Comprehensive Cancer Center, University Hospital Tübingen and the Hertie Institute for Clinical Brain Research, Eberhard Karls University Tübingen
(P 550) ON-TRK: A NON-INTERVENTIONAL STUDY OF LAROTRECTINIB IN PATIENTS WITH TRK FUSION SOLID TUMORS
Ghazaleh Tabatabai
Favorite
Tahara, Sayumi

The Ohio State University Comprehensive Cancer Center
(P 301) REDUCING THE INVASIVE POTENTIAL OF DEDIFFERENTIATED LIPOSARCOMA BY TARGETING ALTERNATIVE RNA SPLICING MACHINERY
Sayumi Tahara
Favorite
Tai, Sarah Beishan

National Cancer Center Singapore
(P 285) TUMOUR-INFILTRATING MAST CELLS IN ANGIOSARCOMAS CORRELATE WITH CLINCIAL PHENOTYPES AND IMMUNO-ONCOLOGY PATHWAYS
Sarah Beishan Tai
Favorite
Takagi, Michiaki

Yamagata University Faculty of Medicine, Department of Orthopaedic Surgery
(P 241) ASSOCIATION OF ADC VALUES WITH DESMOID TUMOR SHRINKAGE DURING ACTIVE OBSERVATION
Michiaki Takagi
Favorite
Takahara, Daiichiro

Yamagata University Faculty of Medicine, Department of Orthopaedic Surgery
(P 241) ASSOCIATION OF ADC VALUES WITH DESMOID TUMOR SHRINKAGE DURING ACTIVE OBSERVATION
Daiichiro Takahara
Favorite
Takahashi, Masanobu

Tohoku University Hospital
(P 10) ATEZOLIZUMAB IN JAPANESE PATIENTS WITH ADVANCED ALVEOLAR SOFT PART SARCOMA: A MULTI-CENTER, SINGLE-ARM, INVESTIGATOR-INITIATED PHASE 2 TRIAL (NCCH1907)
Masanobu Takahashi
Favorite
Takahashi, Renata

AC Camargo Cancer Center
(P 192) ROLE OF MAGNETIC RESONANCE IMAGING IN THE PREDICTION OF HISTOLOGICAL GRADE IN SOFT TISSUE SARCOMAS.
Renata Takahashi
Favorite
Takasawa, Akira

Sapporo Medical University School of Medicine
(P 391) THE EXPRESSION OF PVR AND ITS CLINICOPATHOLOGICAL SIGNIFICANCE IN MPNST.
Akira Takasawa
Favorite
Takasawa, Kumi

Sapporo Medical University School of Medicine
(P 391) THE EXPRESSION OF PVR AND ITS CLINICOPATHOLOGICAL SIGNIFICANCE IN MPNST.
Kumi Takasawa
Favorite
Takashima, Atsuo

Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
(P 35) GENOMIC ALTERATIONS IN ADVANCED GASTROINTESTINAL STROMAL TUMORS AS REVEALED BY COMPREHENSIVE GENOMIC PROFILING TESTS
Atsuo Takashima
Favorite
Takashima, Hiroyuki

Hokkaido University
(P 05) COEFFICIENT OF VARIATION OF T2-WEIGHTED MRI PREDICTS THE PROGNOSIS OF MALIGNANT PERIPHERAL NERVE SHEATH TUMOR
Hiroyuki Takashima
Favorite
Takenaka, Satoshi

Osaka International Cancer Institute
(P 05) COEFFICIENT OF VARIATION OF T2-WEIGHTED MRI PREDICTS THE PROGNOSIS OF MALIGNANT PERIPHERAL NERVE SHEATH TUMOR
Satoshi Takenaka
Favorite
(P 396) COMPREHENSIVE WHOLE-GENOME MOLECULAR PROFILING IN BONE AND SOFT TISSUE SARCOMA: MULTI-OMICS ANALYSIS OF 627 CASES ACROSS HISTOLOGIC SUBTYPES
Satoshi Takenaka
Favorite
Talavera, Pablo

Hospital Clinico san Carlos
(P 149) PSYCOLOGICAL SNAPSHOT OF SARCOMA PATIENTS FROM AN ACADEMIC, UNIVERSITY CENTER, HOSPITAL CLÍNICO SAN CARLOS (HCSC), MADRID, A SARCOMA NATIONAL REFERRAL CENTRE IN SPAIN
Pablo Talavera
Favorite
Tammela, Tuomas

MSKCC
(P 257) CHARACTERIZING THE EVOLUTION AND THERAPEUTIC RESPONSE OF UNDIFFERENTIATED PLEOMORPHIC SARCOMAS USING MOUSE MODELS
Tuomas Tammela
Favorite
Tanaka, Yasuhito

Nara Medical University
(P 259) LOVASTATIN INDUCES NOVEL CELL DEATH THROUGH THE IMPAIRED MITOCHONDRIA IRON UTILIZATION IN OSTEOASRCOMA CELLS.
Yasuhito Tanaka
Favorite
Tanas, Munir

University of Iowa
(P 115) EFFICACY AND CORREALTIVE ANALYSIS OF USING NEOADJUVANT INTRATUMORAL HIGH DOSE TALIMOGENE LAHERPAREPVEC (TVEC) WITH CONCURRENT RADIATION IN HIGH-RISK EXTREMITY AND TRUNK SOFT-TISSUE SARCOMAS
Munir Tanas
Favorite
Tan, Chiu Yi

School of Social Policy & Practice, University of Pennsylvania, Philadelphia PA, USA
(P 07) IDENTIFYING CONCERNS OF ADOLESCENT AND YOUNG ADULT SARCOMA PATIENTS AND SURVIVORS FOLLOWING FERTIITY PRESERVATION
Chiu Yi Tan
Favorite
Tan, Daniel

Division of Medical Oncology, National Cancer Centre Singapore and Duke-NUS Medical School
(P 353) UPDATED EFFICACY AND SAFETY OF LAROTRECTINIB IN ADULT PATIENTS WITH TRK FUSION SARCOMAS
Daniel Tan
Favorite
Tang, Alex

Cooperman Barnabas Medical Center/Jersey City Medical Center – RWJBarnabas Health
(P 467) DOES PERIOPERATIVE RADIATION AFFECT IMPLANT SURVIVORSHIP OF PRIMARY TOTAL HIP ARTHROPLASTY IN THE SETTING OF METASTATIC BONE DISEASE: A MULTICENTER STUDY
Alex Tang
Favorite
Tang, Austin

Hospital Authority
(P 290) PRE-CLINICAL STUDY OF TUMOR TREATING FIELDS (TTFIELDS) ALONE OR IN CONJUNCTION WITH SYSTEMIC THERAPIES IN SELECTED BONE- AND SOFT-TISSUE SARCOMAS
Austin Tang
Favorite
Tang, Chih-Min

Department of Surgery, Division of Surgical Oncology, University of California San Diego
(P 29) COMBINATION TREATMENT WITH TEMOZOLOMIDE AND THE DEATH RECEPTOR-5 AGONIST INBRX-109 EFFECTIVELY TARGETS SUCCINATE DEHYDROGENASE -DEFICIENT GASTROINTESTINAL STROMAL TUMOR
Chih-Min Tang
Favorite
Tang, Whiter

Chris O'Brien Lifehouse
(P 194) REAL WORLD OUTCOMES OF PATIENTS TREATED WITH GEMCITABINE AND DOCETAXEL FOR ADVANCED SOFT TISSUE SARCOMA IN AN AUSTRALIAN SARCOMA CENTRE
Whiter Tang
Favorite
Tang, Xiaodong

Peking University People's Hospital
(P 51) OAIE TRIAL IN PROGRESS: A RANDOMIZED PHASE II TRIAL ASSESSING APATINIB IN COMBINATION WITH IFOSFAMIDE AND ETOPOSIDE(IE) VERSUS SINGLE IE CHEMOTHERAPY FOR RELAPSED OR REFRACTORY OSTEOSARCOMA
Xiaodong Tang
Favorite
(P 52) ARTEMIS-002 TRIAL IN PROGRESS: A MULTI-CENTER PHASE II TRIAL ASSESSING HS-20093 (B7-H3 ANTIBODY-DRUG CONJUGATE) FOR RELAPSED OR REFRACTORY OSTEOSARCOMA AND OTHER SARCOMAS
Xiaodong Tang
Favorite
(P 58) CHEMOTHERAPY-INDUCED EVOLUTION OF OSTEOSARCOMA REVEALED BY SINGLE-CELL RNA SEQUENCING
Xiaodong Tang
Favorite
(P 97) AN EXPLORATORY STUDY OF AN ANTI-PD-L1/TGF-β ANTIBODY, TQB2858, IN PATIENTS WITH REFRACTORY OR RECURRENT OSTEOSARCOMA AND ALVEOLAR SOFT PART SARCOMA: A REPORT FROM CHINESE SARCOMA STUDY GROUP
Xiaodong Tang
Favorite
(P 441) LONG VERSUS SHORTER SCHEDULES OF VINCRISTINE, IRINOTECAN AND TEMOZOLOMIDE (VIT) FOR RELAPSED OR REFRACTORY EWING SRACOMA: A RANDOMISED CONTROLLED PHASE 2 TRIAL
Xiaodong Tang
Favorite
(P 442) LONG-TERM OUTCOME AND RELAPSE PATTERNS IN EWING SARCOMA PATIENTS WITH EXTENSIVE LUNG/PLEURAL METASTASES AFTER A COMPLETE RESPONSE TO SYSYEMIC THERAPY
Xiaodong Tang
Favorite
(P 464) INDOCYANINE GREEN FLUORESCENCE IMAGING MAY DETECT TUMOUR RESIDUALS DURING SURGERY FOR BONE AND SOFT-TISSUE TUMOURS
Xiaodong Tang
Favorite
(P 487) EN BLOC RESECTION FOR SPINAL TUMORS: A SINGLE CENTER EXPERIENCE OF 113 CONSECUTIVE CASES
Xiaodong Tang
Favorite
Tan, Heng

University of Miami
(P 158) SORAFENIB OR ANTHRACYCLINE-BASED CHEMOTHERAPY IN ADULT PATIENTS WITH PROGRESSIVE DESMOID TUMORS
Heng Tan
Favorite
Tan, Joey

Laboratory of Applied Human Genetics, Division of Medical Sciences, National Cancer Centre Singapore
(P 336) EVOLUTION AND PURSUIT OF EXCELLENCE IN SARCOMA MANAGEMENT IN AN ASIAN TERTIARY SARCOMA SPECIALISED CENTRE
Joey Tan
Favorite
Tan, Li

The First Affiliated Hospital of Sun Yat-sen University
(P 45) THE LONG-TERM EFFECT OF IMATINIB WITH HEPATIC RESECTION OR OTHER LOCAL TREATMENT FOR GIST LIVER METASTASES
Li Tan
Favorite
Tan, Minjia

State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
(P 416) THE PROTEOGENOMIC SUBTYPING OF OSTEOSARCOMA
Minjia Tan
Favorite
Tannenbaum, Allen

Departments of Computer Science and Applied Mathematics and Statistics, Stony Brook University
(P 397) A MESENCHYMAL TISSUE LANDSCAPE TO STUDY OSTEOSARCOMA TUMOR HETEROGENEITY
Allen Tannenbaum
Favorite
Tan, Qiu Xuan

Laboratory of Applied Human Genetics, Division of Medical Sciences, National Cancer Centre Singapore
(P 336) EVOLUTION AND PURSUIT OF EXCELLENCE IN SARCOMA MANAGEMENT IN AN ASIAN TERTIARY SARCOMA SPECIALISED CENTRE
Qiu Xuan Tan
Favorite
Tan, Siwei

Beijing Friendship Hospital
(P 534) NEOADJUVANT CHEMOTHERAPY COMBINED WITH TARGETED TREATMENT IN HIGH-RISK RETROPERITONEAL SARCOMA – A PROSPECTIVE NON-RANDOMIZED CONTROLLED MULTI-CENTERED STUDY ALL ACROSS CHINA
Siwei Tan
Favorite
Tao, Kaixiong

Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
(P 38) EFFICACY AND SAFETY OF RIPRETINIB IN THE TREATMENT OF ADVANCED GASTROINTESTINAL STROMAL TUMORS: A MULTICENTER RETROSPECTIVE STUDY
Kaixiong Tao
Favorite
(P 39) MANAGEMENT PRACTICES OF GASTROINTESTINAL STROMAL TUMORS: A QUESTIONNAIRE SURVEY OF GENERAL SURGEONS IN CHINA
Kaixiong Tao
Favorite
Tao, Min

Department of Oncology, The First Affiliated Hospital of Soochow University
(P 44) RIPRETINIB FOR THE TREATMENT OF CHINESE PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS HARBORING KIT SECONDARY MUTATIONS: A MULTICENTER, RETROSPECTIVE STUDY
Min Tao
Favorite
Tao, Ping

Department of Laboratory Medicine, Shanghai TCM-Integrated Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China
(P 339) QUALITY OF SURGERY AND OUTCOME FOR GIANT RETROPERITONEAL LIPOSARCOMA TREATED WITHIN SEMI-ABDOMINAL EN BLOC RESECTION USING VASCULAR PRIORITY CENTRAL APPROACH-A RETROSPECTIVE COHORT
Ping Tao
Favorite
(P 398) INTEGRATED MULTI-OMICS APPROACH REVEALED TUMOR-ASSOCIATED TERTIARY LYMPHOID STRUCTURE LANDSCAPE IN RETROPERITONEAL LIPOSARCOMA
Ping Tao
Favorite
Tap, William

Memorial Sloan Kettering Cancer Center
(P 24) COMPREHENSIVE ANALYSIS OF THE GENOMIC LANDSCAPE AND CLINICAL BEHAVIOR IN GIST USING NEXT GENERATION SEQUENCING (NGS, MSK-IMPACT)
William Tap
Favorite
(P 66) PHASE I STUDY OF THE MUTANT IDH1 INHIBITOR IVOSIDENIB: LONG-TERM SAFETY AND CLINICAL ACTIVITY IN PATIENTS WITH CONVENTIONAL CHONDROSARCOMA
William Tap
Favorite
(P 131) PATIENT-REPORTED CONTINUED BENEFITS IN PATIENTS TREATED WITH PEXIDARTINIB FOR TENOSYNOVIAL GIANT CELL TUMOR BASED ON A REAL-WORLD STUDY IN THE UNITED STATES
William Tap
Favorite
(P 173) SAFETY, EFFICACY, AND PATIENT-REPORTED OUTCOMES WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED PRIOR ANTI–COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 UPDATE
William Tap
Favorite
(P 176) SAFETY, EFFICACY, AND PATIENT-REPORTED OUTCOMES WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED NO PRIOR ANTI–COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 UPDATE
William Tap
Favorite
(P 178) INITIAL RESULTS FROM A PHASE 1 STUDY OF CFT8634, A NOVEL BIFUCTIONAL DEGRADATION ACTIVATING COMPOUND (BIDAC) DEGRADER OF BRD9, IN SYNOVIAL SARCOMA AND SMARCB1-NULL TUMORS
William Tap
Favorite
(P 257) CHARACTERIZING THE EVOLUTION AND THERAPEUTIC RESPONSE OF UNDIFFERENTIATED PLEOMORPHIC SARCOMAS USING MOUSE MODELS
William Tap
Favorite
(P 555) A PILOT PHASE II STUDY TO EVALUATE THE SMALL MOLECULE TIGILANOL TIGLATE IN PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA: CLINICAL TRIAL IN PROGRESS
William Tap
Favorite
Taritsa, Iulianna

Northwestern Medicine
(P 480) TARGETED MUSCLE REINNERVATION FOR HIP DISARTICULATION - EVALUATION OF EARLY FUNCTIONAL OUTCOMES
Iulianna Taritsa
Favorite
Tasse, Jordan

Rush University Medical Center
(P 377) EFFECTIVENESS OF INTERVENTIONAL RADIOLOGY GUIDED PROCEDURES FOR LOCALLY RECURRENT AND METASTATIC SARCOMA: SINGLE INSTITUTIONAL RESULTS
Jordan Tasse
Favorite
Tat, Candise

Texas Children's Hospital / Baylor College of Medicine Center for Cell and Gene Therapy
(P 121) IMPROVING THE EFFICACY OF GD2 CHIMERIC ANTIGEN RECEPTOR T-CELLS USING HISTONE DEACETYLASE INHIBITORS
Candise Tat
Favorite
Tawil, Nadim

McGill university
(P 65) PROFILING EXTRACELLULAR VESICLES AND NANOPARTICLES IN OSTEOSARCOMA
Nadim Tawil
Favorite
Taylor, Aaron

The Jackson Laboratory for Genomic Medicine
(P 392) IMMUNOSUPPRESSIVE TUMOR MICROENVIRONMENT OF OSTEOSARCOMA
Aaron Taylor
Favorite
Taylor, Edward

University Health network
(P 367) CHARACTERIZING HYPOXIA AND ASSOCIATED MOLECULAR FEATURES IN EXTREMITY SOFT TISSUE SARCOMA
Edward Taylor
Favorite
Taylor, Rachel

University College London Hospitals NHS Trust
(P 70) ICONIC (IMPROVING OUTCOMES THROUGH COLLABORATION IN OSTEOSARCOMA): A PROSPECTIVE OBSERVATIONAL COHORT STUDY FOR NEWLY DIAGNOSED OSTEOSARCOMA PATIENTS IN THE UNITED KINGDOM (UK)
Rachel Taylor
Favorite
Taylor, Stephen

University College London
(P 147) UNDERSTANDING THE EXPERIENCES OF PATIENTS RETURNING TO DAILY ACTIVITES AND EXERCISE FOLLOWING LIMB SPARING SURGERY FOR BONE OR SOFT TISSUE SARCOMA AROUND THE KNEE
Stephen Taylor
Favorite
(P 492) BALANCE AND GAIT OUTCOMES AFTER 1-YEAR POST-OPERATIVE HEMIPELVECTOMY SURGERY
Stephen Taylor
Favorite
(P 493) GAIT KINEMATICS OF SARCOMA PATIENTS AT 1 YEAR POST-OPERATIVE INTERNAL HEMIPELVECTOMY SURGERY: A RETROSPECTIVE STUDY.
Stephen Taylor
Favorite
(P 494) WHAT IS THE EXPERIENCE OF THOSE WITH CANCER-RELATED REDUCED QUALITY OF LIFE AND ASSOCIATED PHYSICAL DISABILITIES AFTER UPPER LIMB SARCOMA TREATMENT IN ENGLAND? A NATIONAL STUDY OF OUTCOMES.
Stephen Taylor
Favorite
(P 495) UNDERSTANDING THE EXPERIENCES OF PATIENTS RETURNING TO ACTIVITIES OF DAILY LIVING AND EXERCISE FOLLOWING LIMB SPARING SURGERY FOR BONE OR SOFT TISSUE SARCOMA AROUND THE KNEE.
Stephen Taylor
Favorite
(P 496) WHAT ARE THE EXPERIENCES OF BALANCE, GAIT AND NEURO-MUSCULAR CONTROL OUTCOMES AFTER PROXIMAL FEMORAL REPLACEMENTS FOR MUSCULOSKELETAL TUMOURS?
Stephen Taylor
Favorite
(P 519) WHAT ARE THE EXPERIENCES OF GAIT, ACTIVITY LEVELS AND PHYSICAL FUNCTIONING IN PROXIMAL FEMORAL REPLACEMENT AFTER MUSCULOSKELETAL TUMORS?
Stephen Taylor
Favorite
(P 560) REAL-WORLD MONITORING OF PHYSICAL ACTIVITY USING AN ACCELEROMETER AFTER LOWER LIMB SURGERY FOR A SARCOMA.
Stephen Taylor
Favorite
(P 561) EXPERIENCE OF PHYSICAL DISABILITIES AND CANCER-RELATED QUALITY OF LIFE AFTER SPINAL TUMORS- STUDY OF A NATIONAL SURVEY IN ENGLAND.
Stephen Taylor
Favorite
(P 563) BALANCE, GAIT AND BIOMECHANICAL COMPENSATIONS DURING DIFFERENT SPEEDS OF WALKING AFTER TREATMENT FOR DISTAL FEMORAL MUSCULOSKELETAL TUMOURS AND ASSOCIATED LIMITATIONS ON RETURN TO NORMAL LIVING
Stephen Taylor
Favorite
Tecson, Kristen

Daiichi Sankyo, Inc.
(P 131) PATIENT-REPORTED CONTINUED BENEFITS IN PATIENTS TREATED WITH PEXIDARTINIB FOR TENOSYNOVIAL GIANT CELL TUMOR BASED ON A REAL-WORLD STUDY IN THE UNITED STATES
Kristen Tecson
Favorite
Tedesco, Giulia

Unit of Oncogenetics and Functional Oncogenomics, Centro di Riferimento Oncologico di Aviano IRCCS, Aviano, Italy
(P 378) MULTIOMICS PROFILING OF EPITHELIOID SARCOMA UNVEILS EPIGENETIC CIRCUITRIES THAT UNDERLIE THE PATHOBIOLOGY OF PROXIMAL AND CLASSIC SUBTYPES: RESULTS FROM THE ISG EPISOBS OBSERVATIONAL STUDY
Giulia Tedesco
Favorite
Teh, Bin Tean

National Cancer Center Singapore
(P 285) TUMOUR-INFILTRATING MAST CELLS IN ANGIOSARCOMAS CORRELATE WITH CLINCIAL PHENOTYPES AND IMMUNO-ONCOLOGY PATHWAYS
Bin Tean Teh
Favorite
Teicher, Beverly

National Cancer Inst.
(P 203) PRECLINICAL EVALUATION AMG 650, A SMALL MOLECULE INHIBITOR OF KIF18A, IN PEDIATRIC SOLID TUMORS BY THE PEDIATRIC PRECLINICAL IN VIVO TESTING (PIVOT) PROGRAM
Beverly Teicher
Favorite
Tekkis, Paris

The Royal Marsden Hospital
(P 40) LONG TERM OUTCOMES OF NEOADJUVANT IMATINIB AND SURGICAL RESECTION OF RECTAL GASTROINTESTINAL STROMAL TUMOURS
Paris Tekkis
Favorite
Temiz, Nuri

University of Minnesota
(P 84) CSF1R OVEREXPRESSION ACCELLERATES OSTEOSARCOMA TUMOR FORMATION AND GENERATES TUMORS WITH DECREASED IMMUNE CELL INFILTRATION
Nuri Temiz
Favorite
(P 236) APOBEC MUTAGENESIS IN OSTEOSARCOMA DEVELOPMENT, PROGRESSION AND RESPONSE TO THERAPY
Nuri Temiz
Favorite
Teot, Lisa

Boston Children's Hospital and Harvard Medical School
(P 409) IMMUNOHISTOCHEMICAL STAINING FOR MYOGENIN, AP2 BETA AND HMGA2 PREDICT FOXO1 FUSION STATUS IN RHABDOMYOSARCOMA: A REPORT FROM THE SOFT TISSUE COMMITTEE OF THE CHILDREN'S ONCOLOGY GROUP
Lisa Teot
Favorite
(P 425) CHARACTERIZATION OF RHABDOMYOSARCOMA WITH PAX7::FOXO1 FUSIONS: A REPORT FROM THE SOFT TISSUE COMMITTEE OF THE CHILDREN'S ONCOLOGY GROUP
Lisa Teot
Favorite
(P 438) ALVEOLAR RHABDOMYOSARCOMA WITH "BURKITT-LIKE" MORPHOLOGY IS ASSOCIATED WITH HIGH AMPLIFICATION OF MYCL
Lisa Teot
Favorite
Teres, Raul

Hospital de la Santa Creu i Sant Pau
(P 175) TRABECTEDIN PLUS RADIOTHERAPY ON SYMPHTOMATIC ADVANCED SARCOMA PATIENTS, RESULTS FROM THE SYNERGIAS STUDY: A SPANISH GROUP FOR RESEARCH IN SARCOMA (GEIS) PHASE II STUDY
Raul Teres
Favorite
(P 503) SCAPULAR PROSTHESIS RECONSTRUCTION, EXPERIENCE IN OUR INSTITUTION
Raul Teres
Favorite
(P 504) WHY DO SOME PATIENTS WITH SYNOVIAL SARCOMA HAVE BETTER FUNCTIONAL OUTCOMES AFTER RESECTION SURGERY? ANALYSIS OF 102 CASES
Raul Teres
Favorite
(P 507) PRIMARY CHEST WALL TUMORS OF MESENCHYMAL ORIGIN. EXPERIENCE OF A REFERENCE UNIT
Raul Teres
Favorite
(P 508) DREAM, UTOPIA OR REALISM? PROGNOSTIC FACTORS IN LUNG METASTASECTOMY OF DISSEMINATED SARCOMA DISEASE
Raul Teres
Favorite
Terwisscha van Scheltinga, Cecilia

Princess Máxima Center for Pediatric Oncology
(P 558) TRIAL IN PROGRESS: A PHASE 1/2 STUDY OF BRIGATINIB IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH ALK POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA OR INFLAMMATORY MYOFIBROBLASTIC TUMORS (ITCC-098)
Cecilia Terwisscha van Scheltinga
Favorite
Teterycz, Paweł

Department of Soft Tissue, Bone/Sarcoma, and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland. Department of Computational Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.
(P 09) A NOMOGRAM MODEL TO PREDICT THE OVERALL SURVIVAL OF ADOLESCENT AND YOUNG ADULT PATIENTS WITH LOCALLY ADVANCED EWING SARCOMA.
Paweł Teterycz
Favorite
Teufel, Michael

Boehringer Ingelheim Pharmaceuticals Inc.
(P 185) LONGITUDINAL MUTATIONAL ANALYSIS OF TP53 IN CIRCULATING TUMOR DNA IN THE PLASMA OF PATIENTS WITH LIPOSARCOMA IN A PHASE I STUDY OF BRIGIMADLIN (BI 907828), AN MDM2-P53 ANTAGONIST
Michael Teufel
Favorite
Thavaneswaran, Subotheni

The Kinghorn Cancer Centre, St Vincent's Hospital
(P 386) GENOMIC PROFILING OF GYNAECOLOGICAL SARCOMAS: REPORT FROM THE AUSTRALIA-WIDE PRECISION ONCOLOGY PROGRAM
Subotheni Thavaneswaran
Favorite
Thavarasa, Yanosan

Essen University Hospital
(P 275) GIST-BSF1: A NOVEL SCF-DEPENDENT, WILD-TYPE KIT CELL LINE PLATFORM THAT ALLOWS RAPID GENERATION OF ISOGENIC SUBLINES WITH BOTH IMATINIB-SENSITIVE AND IMATINIB-RESISTANT GENOTYPES
Yanosan Thavarasa
Favorite
Thebaud, Estelle

Centre Hospitalier Universitaire
(P 212) REPORT ON THE EWING SARCOMA PATIENTS ENROLLED IN ARM D OF THE ACSE-ESMART TRIAL: PHASE I/II STUDY OF THE PARP INHIBITOR OLAPARIB IN COMBINATION WITH IRINOTECAN IN CHILDREN WITH ADVANCED MALIGNANCIES
Estelle Thebaud
Favorite
Theisen, Emily

Nationwide Childrens Hospital
(P 456) SECLIDEMSTAT TREATMENT BLOCKS THE TRANSCRIPTIONAL FUNCTION OF MULTIPLE FET-FUSION PROTEINS
Emily Theisen
Favorite
Thery, Jean-Christophe

CHU Rouen
(P 201) PLEOMORPHIC RHABDOMYOSARCOMAS: A NEW ENTITY ASSOCIATED WITH LYNCH SYNDROME? FIRST RESULTS OF SARCLYNCH NATIONAL STUDY
Jean-Christophe Thery
Favorite
Theuer, Charles

TRACON
(P 112) PHASE 1/2 STUDY OF YH001, A CTLA-4 ANTIBODY WITH THE SUBCUTANEOUSLY ADMINISTERED PD-L1 ANTIBODY ENVAFOLIMAB, WITH OR WITHOUT DOXORUBICIN IN PATIENTS WITH ADVANCED OR METASTATIC SOFT TISSUE SARCOMA
Charles Theuer
Favorite
(P 531) ENVASARC: A PIVOTAL TRIAL OF ENVAFOLIMAB AND ENVAFOLIMAB IN COMBINATION WITH IPILIMUMAB IN PATIENTS WITH ADVANCED OR METASTATIC UPS OR MFS WHO HAVE PROGRESSED ON PRIOR CHEMOTHERAPY
Charles Theuer
Favorite
Thiele, Andrea

Boehringer Ingelheim Pharma GmbH & Co. KG
(P 408) CHANGES IN COMPUTED TOMOGRAPHY FEATURES INDUCED BY BRIGIMADLIN (BI 907828) IN PATIENTS WITH LIPOSARCOMA: INSIGHTS FROM PHASE I STUDIES
Andrea Thiele
Favorite
Thipphavong, Seng

University Health Network
(P 50) CHARACTERIZATION OF A FAMILIAL GIST KINDRED INTOLERANT TO IMATINIB
Seng Thipphavong
Favorite
Thomas, Barbara

Center for Cancer Research, National Cancer Institute
(P 28) RETROSPECTIVE ANALYSIS OF SUCCINATE DEHYDROGENASE (SDH)-DEFICIENT GASTROINTESTINAL STROMAL TUMOR (GIST) OUTCOMES: AN INTERNATIONAL STUDY OF 256 PATIENTS
Barbara Thomas
Favorite
Thomas, Dafydd

University of Michigan, Department of Pathology
(P 449) CIC-DUX4 sarcomas: A single-center review of clinical features and molecular aberrations identified through DNA sequencing
Dafydd Thomas
Favorite
Thomas, David Morgan

University of New South Wales
(P 386) GENOMIC PROFILING OF GYNAECOLOGICAL SARCOMAS: REPORT FROM THE AUSTRALIA-WIDE PRECISION ONCOLOGY PROGRAM
David Morgan Thomas
Favorite
Thomas, Jacob

University of Southern California, Norris Comprehensive Cancer Center
(P 164) INTRATUMORAL INT230-6 (CISPLATIN, VINBLASTINE, SHAO) ALONE OR WITH IPILIMUMAB PROLONGED SURVIVAL WITH FAVORABLE SAFETY AND IMMUNE ACTIVATION IN ADULTS WITH REFRACTORY SARCOMAS (NCT 03058289)
Jacob Thomas
Favorite
Thomas, Paul

St. Jude Children's Research Hospital
(P 528) SAFETY AND TOLERABILITY OF ORAL CYCLOPHOSPHAMIDE AND SORAFENIB WITH INTRAVENOUS BEVACIZUMAB WITH THE ADDITION OF ATEZOLIZUMAB IN PEDIATRIC SOLID TUMOR PATIENTS
Paul Thomas
Favorite
Thomas, Sachdev

Kaiser Permanente
(P 224) CO-MUTATION-DEPENDENT PROGNOSIS IN PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA
Sachdev Thomas
Favorite
THomas, Stephanie

Cleveland Clinic
(P 308) OPTIMAL BIOLOGIC EFFECTIVE DOSE OF STEREOTACTIC BODY RADIOTHERAPY FOR METASTATIC AND RECURRENT SARCOMA
Stephanie THomas
Favorite
(P 539) SARCOMA STEREOTACTIC BODY RADIOTHERAPY AND IMMUNE SYSTEM TRIAL
Stephanie THomas
Favorite
Thompson, Matthew

Desert Orthopedics
(P 206) A SINGLE-ARM, PHASE II STUDY OF NEOADJUVANT PEMBROLIZUMAB COMBINED WITH RADIOTHERAPY IN THE PRIMARY TREATMENT OF SOFT TISSUE SARCOMAS.
Matthew Thompson
Favorite
Thompson, Patrick

University of North Carolina Health Care
(P 551) PHASE II TRIAL OF GEMCITABINE AND NAB-PACLITAXEL IN PATIENTS WITH RECURRENT RHABDOMYOSARCOMA: A CLINICAL TRIAL IN PROGRESS FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION
Patrick Thompson
Favorite
Thompson, Reid

Oregon Health & Science University
(P 129) LOW RATES OF SERVICE CONNECTIVITY FOR SOFT TISSUE SARCOMA (STS) AMONG ELIGIBLE VIETNAM VETERANS WITH AGENT ORANGE EXPOSURE
Reid Thompson
Favorite
Thompson, Shari

Children's National Hospital
(P 564) A PILOT STUDY OF LYSO-THERMOSENSITIVE LIPOSOMAL DOXORUBICIN AND MAGNETIC RESONANCE-GUIDED HIGH INTENSITY FOCUSED ULTRASOUND FOR TREATMENT OF RELAPSED OR REFRACTORY SOLID TUMORS
Shari Thompson
Favorite
Thornton, Mason

University of Miami Miller School of Medicine
(P 225) PAN-SARCOMA DATABASE (PSDB): A MODEL-VIEW-CONTROLLER FRAMEWORK UTILIZING REDCAP, SHINY, AND R TO CREATE A CONTINUOUS PIPELINE OF SARCOMA DATA
Mason Thornton
Favorite
(P 366) SURVIVAL DISPARITIES IN HISPANIC PATIENTS WITH SARCOMA TESTED WITH NEXT-GENERATION SEQUENCING (NGS)
Mason Thornton
Favorite
Thotola, Dinesh

Washington University in St Louis
(P 187) PALLIATIVE LATTICE STEREOTACTIC BODY RADIOTHERAPY FOR PATIENTS WITH SARCOMA
Dinesh Thotola
Favorite
Thway, Khin

The Royal Marsden NHS Foundation Trust
(P 404) PROTEOMIC PROFILING OF THE SOFT TISSUE SARCOMA MICROENVIRONMENT IDENTIFIES A PROGNOSTIC SIGNATURE BASED ON PROTEOGLYCAN EXPRESSION AND CD8+ TUMOUR INFILTRATING LYMPHOCYTES
Khin Thway
Favorite
(P 410) PROTEOMICS ANALYSIS IDENTIFIES A SIGNATURE THAT IMPROVES PROGNOSTIC RISK STRATIFICATION OF THE SARCULATOR NOMOGRAM IN PATIENTS WITH SOFT TISSUE SARCOMAS OF THE EXTREMITIES AND TRUNK WALL
Khin Thway
Favorite
(P 417) MULTI-OMIC CHARACTERISATION OF MOLECULAR HETEROGENEITY AND NEOADJUVANT THERAPY RESPONSE IN SYNOVIAL SARCOMAS
Khin Thway
Favorite
Tian, Hongtao

Department of Orthopedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
(P 543) MANEUVER STUDY: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF PIMICOTINIB (ABSK021) TO ASSESS THE EFFICACY AND SAFETY IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR
Hongtao Tian
Favorite
Tian, Lantian

The Affiliated Hospital of Qingdao University
(P 534) NEOADJUVANT CHEMOTHERAPY COMBINED WITH TARGETED TREATMENT IN HIGH-RISK RETROPERITONEAL SARCOMA – A PROSPECTIVE NON-RANDOMIZED CONTROLLED MULTI-CENTERED STUDY ALL ACROSS CHINA
Lantian Tian
Favorite
Tian, Zheng

Department of Orthopaedics, The First Affiliated Hospital of Xinjiang Medical University
(P 543) MANEUVER STUDY: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF PIMICOTINIB (ABSK021) TO ASSESS THE EFFICACY AND SAFETY IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR
Zheng Tian
Favorite
Tibbitts, Justin

University of Minnesota
(P 84) CSF1R OVEREXPRESSION ACCELLERATES OSTEOSARCOMA TUMOR FORMATION AND GENERATES TUMORS WITH DECREASED IMMUNE CELL INFILTRATION
Justin Tibbitts
Favorite
Tibbo, Meagan

University of Miami
(P 520) ORTHOPEDIC MANIFESTATIONS OF LYMPHOPROLIFERATIVE NEOPLASMS
Meagan Tibbo
Favorite
Timbergen, Milea J.M.

Erasmus Medical Center
(P 554) FIVE-YEAR OUTCOMES OF A NATIONWIDE PROSPECTIVE CLINICAL TRIAL ON ACTIVE SURVEILLENCE IN PATIENTS WITH NON-INTRAABDOMINAL DESMOID-TYPE FIBROMATOSIS
Milea J.M. Timbergen
Favorite
Timmermann, Beate

University Hospital Essen
(P 74) SACRAL CHORDOMA: A RANDOMIZED & OBSERVATIONAL STUDY ON SURGERY VS DEFINITIVE RADIOTHERAPY IN PRIMARY LOCALIZED DISEASE (SACRO). INTERIM ANALYSIS
Beate Timmermann
Favorite
(P 451) IMPACT OF TIME TO DIAGNOSIS - A PROSPECTIVE ANALYSIS OF THE EWING 2008 TRIAL
Beate Timmermann
Favorite
(P 538) IEUROEWING TRIAL FOR LOCALIZED AND METASTATIC EWING SARCOMA
Beate Timmermann
Favorite
Timo, Sara

Humanitas Clinical and Research Hospital
(P 297) UNVEILING THE IMPACT OF INTRATUMORAL MICROBIOTA IN THE TREATMENT EFFICACY OF SOFT TISSUE SARCOMA
Sara Timo
Favorite
Timothy, smile

St. Francis Medial Center
(P 308) OPTIMAL BIOLOGIC EFFECTIVE DOSE OF STEREOTACTIC BODY RADIOTHERAPY FOR METASTATIC AND RECURRENT SARCOMA
smile Timothy
Favorite
Tinoco, Gabriel

Ohio State University
(P 347) INCIDENCE AND TIMING OF RECURRENCE AFTER ADJUVANT PALBOCICLIB IN COMPLETELY RESECTED RETROPERITONEAL LIPOSARCOMA
Gabriel Tinoco
Favorite
(P 543) MANEUVER STUDY: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF PIMICOTINIB (ABSK021) TO ASSESS THE EFFICACY AND SAFETY IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR
Gabriel Tinoco
Favorite
Tinteren, Harm

Princess Máxima Center for Pediatric Oncology
(P 558) TRIAL IN PROGRESS: A PHASE 1/2 STUDY OF BRIGATINIB IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH ALK POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA OR INFLAMMATORY MYOFIBROBLASTIC TUMORS (ITCC-098)
Harm Tinteren
Favorite
Tiraboschi, Luca

Humanitas Clinical and Research Hospital
(P 297) UNVEILING THE IMPACT OF INTRATUMORAL MICROBIOTA IN THE TREATMENT EFFICACY OF SOFT TISSUE SARCOMA
Luca Tiraboschi
Favorite
Tirabosco, Roberto

Department of Histopathology, Royal National Orthopaedic Hospital, Stanmore, UK
(P 04) THE CELL ATLAS OF CLEAR CELL SARCOMA
Roberto Tirabosco
Favorite
(P 381) THE GENOMIC LANDSCAPE OF CLEAR CELL SARCOMA
Roberto Tirabosco
Favorite
Tirode, Franck

CENTRE LEON BERARD AND CANCER RESEARCH CENTER OF LYON (INSERM U1052-CNRS5286)
(P 382) NTRK1/2/3 FUSIONS DETECTION USING RNA-SEQ IN MESENCHYMAL TUMORS REVEALS ULTRA-RARE AND HISTO-SPECIFIC TARGETABLE ALTERATIONS: EXPERIENCE OF AN EXTENSIVE ROUTINE RESEARCH PROGRAM.
Franck Tirode
Favorite
(P 435) ONCOGENIC FUSION YWHAE::NUTM2 DISRUPT EP300/BCOR INTERACTION
Franck Tirode
Favorite
Titerina, Elizaveta

The Ohio State University Comprehensive Cancer Center
(P 301) REDUCING THE INVASIVE POTENTIAL OF DEDIFFERENTIATED LIPOSARCOMA BY TARGETING ALTERNATIVE RNA SPLICING MACHINERY
Elizaveta Titerina
Favorite
Tlemsani, Camille

APHP
(P 201) PLEOMORPHIC RHABDOMYOSARCOMAS: A NEW ENTITY ASSOCIATED WITH LYNCH SYNDROME? FIRST RESULTS OF SARCLYNCH NATIONAL STUDY
Camille Tlemsani
Favorite
Tokson, Jacqueline Hart

Huntsman Cancer Institute
(P 93) INDETERMINATE CHEST LESIONS IN PATIENTS WITH BONE SARCOMA INCIDENTAL FINDING VERSUS METASTATIC DISEASE
Jacqueline Hart Tokson
Favorite
Tolcher, Anthony W.

Clinical Research, NEXT Oncology
(P 408) CHANGES IN COMPUTED TOMOGRAPHY FEATURES INDUCED BY BRIGIMADLIN (BI 907828) IN PATIENTS WITH LIPOSARCOMA: INSIGHTS FROM PHASE I STUDIES
Anthony W. Tolcher
Favorite
Toledo, Silvia

GRAACC
(P 392) IMMUNOSUPPRESSIVE TUMOR MICROENVIRONMENT OF OSTEOSARCOMA
Silvia Toledo
Favorite
Tollit, Anna

Royal National Orthopaedic Hospital NHS
(P 70) ICONIC (IMPROVING OUTCOMES THROUGH COLLABORATION IN OSTEOSARCOMA): A PROSPECTIVE OBSERVATIONAL COHORT STUDY FOR NEWLY DIAGNOSED OSTEOSARCOMA PATIENTS IN THE UNITED KINGDOM (UK)
Anna Tollit
Favorite
Tomazou, Eleni

Children’s Cancer Research Institute, St. Anna Kinderkrebsforschung, Vienna, Austria
(P 538) IEUROEWING TRIAL FOR LOCALIZED AND METASTATIC EWING SARCOMA
Eleni Tomazou
Favorite
Tomczak, Katarzyna

The University of Texas MD Anderson Cancer Center
(P 269) PLASMA DNA METHYLATION-BASED BIOMARKERS FOR MPNST DETECTION IN PATIENTS WITH NEUROFIBROMATOSIS TYPE 1 (NF1)
Katarzyna Tomczak
Favorite
Tong, Hanxing

Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China
(P 339) QUALITY OF SURGERY AND OUTCOME FOR GIANT RETROPERITONEAL LIPOSARCOMA TREATED WITHIN SEMI-ABDOMINAL EN BLOC RESECTION USING VASCULAR PRIORITY CENTRAL APPROACH-A RETROSPECTIVE COHORT
Hanxing Tong
Favorite
(P 398) INTEGRATED MULTI-OMICS APPROACH REVEALED TUMOR-ASSOCIATED TERTIARY LYMPHOID STRUCTURE LANDSCAPE IN RETROPERITONEAL LIPOSARCOMA
Hanxing Tong
Favorite
Tong, Hanxing

Shanghai Zhongshan Hospital
(P 534) NEOADJUVANT CHEMOTHERAPY COMBINED WITH TARGETED TREATMENT IN HIGH-RISK RETROPERITONEAL SARCOMA – A PROSPECTIVE NON-RANDOMIZED CONTROLLED MULTI-CENTERED STUDY ALL ACROSS CHINA
Hanxing Tong
Favorite
Tong, Zhichao

Department of Osteopathic Oncology, Honghui Hospital, Xi'an Jiaotong University
(P 169) UPDATED EFFICACY AND SAFETY PROFILE OF PIMICOTINIB (ABSK021) IN TENOSYNOVIAL GIANT CELL TUMOR (TGCT): 1-YEAR FOLLOW-UP FROM PHASE 1B
Zhichao Tong
Favorite
(P 543) MANEUVER STUDY: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF PIMICOTINIB (ABSK021) TO ASSESS THE EFFICACY AND SAFETY IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR
Zhichao Tong
Favorite
Tonini, Giuseppe

Fondazione Policlinico Universitario Campus Bio-Medico
(P 263) HER2 AS A POTENTIAL NOVEL THERAPEUTIC TARGET IN SOFT TISSUE SARCOMAS
Giuseppe Tonini
Favorite
(P 264) CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS AND TRABECTEDIN IN SOFT TISSUE SARCOMA: A NOVEL POTENTIAL SYNERGY?
Giuseppe Tonini
Favorite
Tonon, Laurie

Centre Léon Bérard
(P 104) COMPREHENSIVE IMMUNE PROFILING UNVEILS A SUBSET OF LEIOMYOSARCOMA WITH HOT TUMOR IMMUNE MICROENVIRONMENT
Laurie Tonon
Favorite
Topal, Baki

UZ Leuven
(P 254) A COLLECTION OF PATIENT-DERIVED XENOGRAFT MODELS OF GASTROINTESTINAL STROMAL TUMORS
Baki Topal
Favorite
Topal, Salih

Foghorn Therapeutics
(P 271) PHARMACODYNAMICS AND MECHANISTIC IMPACTS OF FHD-609, A BROMODOMAIN-CONTAINING PROTEIN 9 DEGRADER, IN A PHASE 1 STUDY IN PATIENTS WITH ADVANCED SYNOVIAL SARCOMA OR SMARCB1-LOSS TUMORS
Salih Topal
Favorite
Tornero García, José

Universitat Politècnica de Catalunya (UPC), Barcelona, Spain. Cebiotex S.L., Barcelona, Spain
(P 385) FIRST IN HUMAN PHASE I TRIAL OF A NOVEL DRUG DELIVERY IMPLANT MATRIX WITH SN-38 (CEB-01) FOR RETROPERITONEAL SOFT TISSUE SARCOMA
José Tornero García
Favorite
Torre, Maria Luisa

Department of Pharmaceutical Sciences, University of Piemonte Orientale
(P 283) A TRIDIMENSIONAL PRECLINICAL MODEL TO STUDY HUMAN AND CANINE OSTEOSARCOMA DEVELOPMENT AND INTERACTION WITH TUMOR MICROENVIRONMENT
Maria Luisa Torre
Favorite
Torres Sempere, Julio

Hospital Universitary Virgen del Rocio
(P 453) ROLE OF SECOND-LINE TREATMENT IN EWING SARCOMAS WITH POOR PROGNOSIS AT DIAGNOSIS: EXPERIENCE OF A SPANISH REFERENCE CENTER.
Julio Torres Sempere
Favorite
Torres, Keila

The University of Texas MD Anderson Cancer Center
(P 269) PLASMA DNA METHYLATION-BASED BIOMARKERS FOR MPNST DETECTION IN PATIENTS WITH NEUROFIBROMATOSIS TYPE 1 (NF1)
Keila Torres
Favorite
(P 394) LEIOMYOSARCOMA INTRATUMORAL MACROPHAGE INFILTRATES ARE ASSOCIATED WITH DISTINCT CLINICAL AND GENOMIC PRESENTATIONS
Keila Torres
Favorite
(P 510) PRIMARY BREAST ANGIOSARCOMA: CLINICAL AND PATHOLOGICAL FEATURES AND IMPACT ON OUTCOMES
Keila Torres
Favorite
Torres, Madeline

University of Texas MD Anderson Cancer Center
(P 123) DEDIFFERENTIATED LIPOSARCOMAS TREATED WITH IMMUNE CHECKPOINT BLOCKADE: THE MD ANDERSON EXPERIENCE
Madeline Torres
Favorite
Torrezan, Giovana

A.C.Camargo Cancer Center
(P 387) CLINICAL CHARACTERIZATION OF PATIENTS WITH LEIOMYOSARCOMA HARBORING THE R337H TP53 GERMINATIVE ALTERATION (LI-FRAUMENI SYNDROME) AND THE PROGNOSTIC IMPLICATION USING A PROPENSITY-SCORE MATCHED COHORT
Giovana Torrezan
Favorite
Tortorelli, Ilaria

Oncology 1 Unit, Department of Oncology, Veneto Institute of Oncology IOV - IRCCS
(P 171) SEX DIFFERENCES IN OUTCOMES AND TOXICITY IN PATIENTS TREATED FOR SARCOMA IN A REFERENCE CENTER
Ilaria Tortorelli
Favorite
(P 216) BRAIN METASTASES IN SARCOMA: A (NOT SO) RARE EVENT. THE EXPERIENCE OF A HIGH VOLUME CENTER
Ilaria Tortorelli
Favorite
Tortoreto, Monica

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 272) A COMPARATIVE ASSESSMENT OF SELINEXOR WITH TRABECTEDIN OR LURBINECTEDIN IN PATIENT-DERIVED XENOGRAFTS (PDX) OF DEDIFFERENTIATED LIPOSARCOMA (DDLPS)
Monica Tortoreto
Favorite
(P 273) COMPARISON OF A PATIENT-DERIVED XENOGRAFTS (PDX) OF MYXOID PLEOMORPHIC LIPOSARCOMA (MPL) AND PLEOMORPHIC LIPOSARCOMA (PL) HIGHLIGHTS THE EFFECTIVENESS OF ERIBULIN IN A PDX OF MPL
Monica Tortoreto
Favorite
Toulmonde, Maud

Institut Bergonie
(P 69) DEVELOPMENT AND MISSION OF THE HARMONIZATION INTERNATIONAL BONE SARCOMA CONSORTIUM (HIBISCUS)
Maud Toulmonde
Favorite
(P 523) IN-BETWEEN SARCOMA: A CATEGORY OF HIGH RISK OF RECURRENCE AND POOR OUTCOME
Maud Toulmonde
Favorite
Town, Ajia

OHSU Knight Cancer Institute
(P 25) PREDICTING IMATINIB RESPONSES USING IN VITRO MODELS OF PDGFRA-MUTANT GASTROINTESTINAL STROMAL TUMOR
Ajia Town
Favorite
Tran Nguyen, john

Department of Bioengineering, University of Texas at Dallas
(P 261) EFFICACY OF BET INHIBITORS IN SOLITARY FIBROUS TUMOR: AN IN VITRO EVALUATION
john Tran Nguyen
Favorite
Tran, Thuy

UNIVERSITY OF CALIFORNIA IRVINE
(P 324) EVALUATING THE ROLE OF ADJUVANT RADIATION AFTER WIDE LOCAL EXCISION OF PLEOMORPHIC DERMAL SARCOMA
Thuy Tran
Favorite
Traweek, Ray

MD Anderson
(P 394) LEIOMYOSARCOMA INTRATUMORAL MACROPHAGE INFILTRATES ARE ASSOCIATED WITH DISTINCT CLINICAL AND GENOMIC PRESENTATIONS
Ray Traweek
Favorite
Treckmann, Jürgen

University Hospital Essen
(P 276) REVISITING IN- AND OFF LABEL DRUGS FREQUENTLY USED IN METASTATIC GIST USING A BROAD IN VITRO PROFILING PANEL OF PRIMARY AND SECONDARY KIT AND PDGFRA-MUTANT GIST CELLS – CLINICAL IMPLICATIONS
Jürgen Treckmann
Favorite
Treckmann, Juergen

University Hospital Essen, Sarcoma Centre
(P 47) PATIENT SURVIVAL IN METASTATIC GIST WITH IMATINIB-SENSITIVE MUTATIONS: REAL WORLD DATA FROM GERMAN REFERRAL CENTER (2008-2021)
Juergen Treckmann
Favorite
Trent, Jonathan

Sylvester Comprehensive Cancer Center, University of Miami
(P 26) PHASE 1 STUDY OF IDRX-42 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS RESISTANT TO PRIOR SYSTEMIC THERAPY: EARLY RESULTS
Jonathan Trent
Favorite
(P 54) HIGH-THROUGHPUT DRUG SCREENING IN CHONDROSARCOMA CELLS IDENTIFIES MULTIPLE EFFICIENT ANTINEOPLASTIC AGENTS
Jonathan Trent
Favorite
(P 66) PHASE I STUDY OF THE MUTANT IDH1 INHIBITOR IVOSIDENIB: LONG-TERM SAFETY AND CLINICAL ACTIVITY IN PATIENTS WITH CONVENTIONAL CHONDROSARCOMA
Jonathan Trent
Favorite
(P 128) THE IMPACT OF HISPANIC ETHNICITY IN PRESENTATION AND OUTCOMES OF PATIENTS WITH SYNOVIAL SARCOMA
Jonathan Trent
Favorite
Trent, Jonathan

University of Miami
(P 158) SORAFENIB OR ANTHRACYCLINE-BASED CHEMOTHERAPY IN ADULT PATIENTS WITH PROGRESSIVE DESMOID TUMORS
Jonathan Trent
Favorite
Trent, Jonathan

Sylvester Comprehensive Cancer Center, University of Miami
(P 189) INTERNATIONAL RETROSPECTIVE STUDY FROM THE ULTRA-RARE SARCOMA WORKING GROUP ON LOW-GRADE FIBROMYXOID SARCOMA AND SCLEROSING EPITHELIOD FIBROSARCOMA: OUTCOME OF ADVANCED DISEASE AND SYSTEMIC THERAPIES
Jonathan Trent
Favorite
Trent, Jonathan

Sylvester Comprehensive Cancer Center / University of Miami Hospital and Clinics
(P 208) LOW INCIDENCE OF CANCER THERAPY-RELATED CARDIAC DYSFUNCTION IN ADULT SARCOMA PATIENTS RECEIVING DOXORUBICIN AND UPFRONT DEXRAZOXANE
Jonathan Trent
Favorite
(P 225) PAN-SARCOMA DATABASE (PSDB): A MODEL-VIEW-CONTROLLER FRAMEWORK UTILIZING REDCAP, SHINY, AND R TO CREATE A CONTINUOUS PIPELINE OF SARCOMA DATA
Jonathan Trent
Favorite
(P 226) SIGNATERA TESTING TO IDENTIFY MINIMAL RESIDUAL DISEASE IN HIGH GRADE SARCOMA
Jonathan Trent
Favorite
Trent, Jonathan

Sylvester Comprehensive Cancer Center, University of Miami
(P 280) A CELL-BASED COMPOUND SCREENING IDENTIFIES AGENTS THAT SYNERGIZE WITH EVEROLIMUS IN SARCOMA
Jonathan Trent
Favorite
(P 326) MOLECULAR LANDSCAPE OF ENDOMETRIAL STROMAL SARCOMA IN A LARGE REAL-WORLD PATIENT COHORT
Jonathan Trent
Favorite
(P 361) MOLECULAR CHARACTERIZATION OF SOLITARY FIBROUS TUMORS BY ANATOMIC SITE AND NAB2::STAT6 FUSION VARIANT TYPE
Jonathan Trent
Favorite
Trent, Jonathan

Sylvester Comprehensive Cancer Center / University of Miami Hospital and Clinics
(P 366) SURVIVAL DISPARITIES IN HISPANIC PATIENTS WITH SARCOMA TESTED WITH NEXT-GENERATION SEQUENCING (NGS)
Jonathan Trent
Favorite
Trent, Jonathan

Sylvester Comprehensive Cancer Center, University of Miami
(P 401) OVEREXPRESSION OF CYCLIN DEPENDENT KINASES AND CYCLINS ACROSS SARCOMAS BEYOND CDK4
Jonathan Trent
Favorite
(P 461) OUTCOMES FOR OLIGOMETASTATIC PULMONARY DISEASE RECURRENCE TREATED WITH SURGERY ALONE FOR PATIENTS WITH SOFT TISSUE SARCOMAS A CASE SERIES
Jonathan Trent
Favorite
(P 550) ON-TRK: A NON-INTERVENTIONAL STUDY OF LAROTRECTINIB IN PATIENTS WITH TRK FUSION SOLID TUMORS
Jonathan Trent
Favorite
Trepel, Martin

Department of Hematology and Medical Oncology, University Hospital Augsburg, 86156 Augsburg, Germany
(P 557) UNRAVELING THE ROLE OF LOCAL THERAPY FOR PATIENTS WITH OLIGOMETASTATIC SOFT TISSUE SARCOMA - A RETROSPECTIVE MULTICENTER TRIAL OF BAVARIAN UNIVERSITY HOSPITALS
Martin Trepel
Favorite
Trimm, Conner

University of California San Diego School of Medicine
(P 489) SIMULTANEOUS VERSUS DELAYED FLAP RECONSTRUCTION FOLLOWING SOFT TISSUE SARCOMA RESECTION
Conner Trimm
Favorite
(P 490) TOPICAL ANTIBIOTICS DECREASE INFECTIONS IN EXTREMITY SARCOMA SURGERY
Conner Trimm
Favorite
Trissal, Maria

Dana-Farber Cancer Institute
(P 384) SYSTEMATIC LITERATURE AND CLINICAL TRIAL REVIEW SHOWS TARGETABLE KINASE FUSIONS ARE COMMON IN PEDIATRIC, ADOLESCENT, AND YOUNG ADULT SOFT TISSUE SARCOMAS BUT CLINICAL TRIAL OPPORTUNITIES REMAIN RARE
Maria Trissal
Favorite
Trovillion, Erin

Atrium Health - Levine Children's Hospital
(P 266) ROMIDEPSIN DECREASES DNA DAMAGE REPAIR AND INCREASES SENSITIVITY TO CHEMOTHERAPY IN EWING SARCOMA
Erin Trovillion
Favorite
Trpkov, Kiril

Alberta Precision Laboratories, Staff Pathologist
(P 110) GCAR1: GPNMB CAR T THERAPY FOR MIT FAMILY TRANSLOCATION POSITIVE CANCERS
Kiril Trpkov
Favorite
Trucco, Matteo

Cleveland Clinic
(P 308) OPTIMAL BIOLOGIC EFFECTIVE DOSE OF STEREOTACTIC BODY RADIOTHERAPY FOR METASTATIC AND RECURRENT SARCOMA
Matteo Trucco
Favorite
(P 536) PHASE 1 STUDY OF DISULFIRAM WITH COPPER GLUCONATE AND LIPOSOMAL DOXORUBICIN IN PATIENTS WITH TREATMENT REFRACTORY SARCOMAS
Matteo Trucco
Favorite
(P 537) TGFβ IMPRINTED, EX VIVO EXPANDED UNIVERSAL DONOR NATURAL KILLER CELLS WITH CHEMOTHERAPY FOR RELAPSED BONE AND SOFT TISSUE SARCOMA - NCT05634369, REPORT FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION
Matteo Trucco
Favorite
(P 539) SARCOMA STEREOTACTIC BODY RADIOTHERAPY AND IMMUNE SYSTEM TRIAL
Matteo Trucco
Favorite
(P 551) PHASE II TRIAL OF GEMCITABINE AND NAB-PACLITAXEL IN PATIENTS WITH RECURRENT RHABDOMYOSARCOMA: A CLINICAL TRIAL IN PROGRESS FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION
Matteo Trucco
Favorite
Trujillo-Reyes, Juan Carlos

Hospital de la Santa Creu i Sant Pau
(P 503) SCAPULAR PROSTHESIS RECONSTRUCTION, EXPERIENCE IN OUR INSTITUTION
Juan Carlos Trujillo-Reyes
Favorite
(P 504) WHY DO SOME PATIENTS WITH SYNOVIAL SARCOMA HAVE BETTER FUNCTIONAL OUTCOMES AFTER RESECTION SURGERY? ANALYSIS OF 102 CASES
Juan Carlos Trujillo-Reyes
Favorite
(P 507) PRIMARY CHEST WALL TUMORS OF MESENCHYMAL ORIGIN. EXPERIENCE OF A REFERENCE UNIT
Juan Carlos Trujillo-Reyes
Favorite
(P 508) DREAM, UTOPIA OR REALISM? PROGNOSTIC FACTORS IN LUNG METASTASECTOMY OF DISSEMINATED SARCOMA DISEASE
Juan Carlos Trujillo-Reyes
Favorite
Trullols Tarrago, Laura

Hospital de la Santa Creu i Sant Pau, Barcelona
(P 503) SCAPULAR PROSTHESIS RECONSTRUCTION, EXPERIENCE IN OUR INSTITUTION
Laura Trullols Tarrago
Favorite
(P 504) WHY DO SOME PATIENTS WITH SYNOVIAL SARCOMA HAVE BETTER FUNCTIONAL OUTCOMES AFTER RESECTION SURGERY? ANALYSIS OF 102 CASES
Laura Trullols Tarrago
Favorite
(P 508) DREAM, UTOPIA OR REALISM? PROGNOSTIC FACTORS IN LUNG METASTASECTOMY OF DISSEMINATED SARCOMA DISEASE
Laura Trullols Tarrago
Favorite
Trullols, Laura

Hospital de la Santa Creu i Sant Pau
(P 507) PRIMARY CHEST WALL TUMORS OF MESENCHYMAL ORIGIN. EXPERIENCE OF A REFERENCE UNIT
Laura Trullols
Favorite
Truong, Danh

The University of Texas MD Anderson Cancer Center
(P 397) A MESENCHYMAL TISSUE LANDSCAPE TO STUDY OSTEOSARCOMA TUMOR HETEROGENEITY
Danh Truong
Favorite
(P 426) MULTI-OMIC ANALYSIS OF DESMOPLASTIC SMALL ROUND CELL TUMORS REVEAL DISTINCT LINEAGES
Danh Truong
Favorite
(P 427) UNDERSTANDING THE MOLECULAR DRIVERS THAT REGULATE EWING SARCOMA CELL FATE
Danh Truong
Favorite
Tsagkozis, Panagiotis

Karolinska Institutet
(P 243) EVALUATION OF THE USE OF WGS IN ROUTINE DIAGNOSTICS FOR BONE AND SOFT TISSUE TUMORS
Panagiotis Tsagkozis
Favorite
Tsagkozis, Panagiotis

Karolinska University Hospital
(P 278) CLINICAL MARKERS PREDICTIVE OF TRABECTEDIN RESPONSE IN SOFT TISSUE SARCOMA
Panagiotis Tsagkozis
Favorite
(P 372) COPY NUMBER GAIN OF MDM2 IN ROD-SHAPED CHROMOSOMES PROVIDES CLUES TO EARLY STAGES IN CIRCULARIZED GENE AMPLIFICATION IN LIPOSARCOMA
Panagiotis Tsagkozis
Favorite
Tsai, Henry

ProCure New Jersey
(P 320) A PROSPECTIVE MULTICENTER EXPERIENCE OF PROTON THERAPY FOR RHABDOMYOSARCOMA AND EWING SARCOMA: OUTCOMES FROM THE PROTON COLLABORATIVE GROUP REGISTRY
Henry Tsai
Favorite
Tseng, Hsian-Rong

David Geffen School of Medicine, University of California, Los Angeles
(P 19) EXTRACELLULAR VESICLE CLICK MAGBEADS: A MULTIFACETED LIQUID BIOPSY PLATFORM FOR PEDIATRIC SARCOMAS
Hsian-Rong Tseng
Favorite
Tseng, William

City of Hope National Medical Center
(P 329) DISTANT METASTASIS IN RETROPERITONEAL LEIOMYOSARCOMA: TUMOR SIZE, GRADE AND MORE?
William Tseng
Favorite
Tse, Pamela

Kaiser Permanente
(P 224) CO-MUTATION-DEPENDENT PROGNOSIS IN PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA
Pamela Tse
Favorite
Tse, Teresa

Prince of Wales Hospital, Hong Kong
(P 290) PRE-CLINICAL STUDY OF TUMOR TREATING FIELDS (TTFIELDS) ALONE OR IN CONJUNCTION WITH SYSTEMIC THERAPIES IN SELECTED BONE- AND SOFT-TISSUE SARCOMAS
Teresa Tse
Favorite
Tsoi, Kim

University of Toronto
(P 53) CURATIVE-INTENT SURGERY FOR A SOLITARY ISOLATED BONE METASTASIS FROM EXTREMITY SARCOMA: WHO UNDERWENT METASTASECTOMY AND WHAT WAS THE PROGNOSTIC OUTCOME?
Kim Tsoi
Favorite
Tsoi, Kim

Mount Sinai Hospital
(P 77) PATIENT OUTCOMES AFTER OPEN VERSUS CORE NEEDLE BIOPSY IN LOWER EXTREMITY SARCOMA
Kim Tsoi
Favorite
Tsoi, Kim

University of Toronto
(P 249) INVESTIGATING CLINICAL FACTORS ASSOCIATED WITH THE ESTABLISHMENT OF SUCCESSFUL PRIMARY HUMAN SOFT TISSUE SARCOMA CELL LINES
Kim Tsoi
Favorite
(P 284) VALIDATING A NOVEL MICROFLUIDIC PLATFORM AS AN EX VIVO TUMOUR MODEL FOR SARCOMA DRUG DISCOVERY
Kim Tsoi
Favorite
(P 352) DETERMINING THE CONTRIBUTIONS OF STAT1 TO THE UPS ANTI-TUMOR MICROENVIRONMENT
Kim Tsoi
Favorite
(P 367) CHARACTERIZING HYPOXIA AND ASSOCIATED MOLECULAR FEATURES IN EXTREMITY SOFT TISSUE SARCOMA
Kim Tsoi
Favorite
(P 443) SURGICAL RESECTION OF EXTREMITY EWING'S SARCOMA BASED ON POST-CHEMOTHERAPY TUMOUR VOLUME RESULTS IN SAFE MARGINS
Kim Tsoi
Favorite
(P 483) DID THE COVID-19 PANDEMIC NEGATIVELY AFFECT OUTCOMES FOR PATIENTS WITH EXTREMITY SOFT TISSUE SARCOMAS?
Kim Tsoi
Favorite
(P 484) OBESITY INCREASES THE RISK OF MAJOR WOUND COMPLICATIONS FOLLOWING PELVIC RESECTION FOR BONE SARCOMA
Kim Tsoi
Favorite
Tsuchie, Hiroyuki

Akita University Graduate School Of Medicine
(P 05) COEFFICIENT OF VARIATION OF T2-WEIGHTED MRI PREDICTS THE PROGNOSIS OF MALIGNANT PERIPHERAL NERVE SHEATH TUMOR
Hiroyuki Tsuchie
Favorite
(P 469) IMPACT OF A SPECIALIZED OUTPATIENT CLINIC ON BONE MRTASTASIS AND ITS BURDEN ON SPINE SURGEONS
Hiroyuki Tsuchie
Favorite
(P 470) PROGNOSTIC SIGNIFICANCE OF HISTOLOGICAL SUBTYPE IN SOFT TISSUE SARCOMA WITH DISTANT METASTASIS
Hiroyuki Tsuchie
Favorite
(P 471) IMPACT OF PRIMARY TUMOR RESECTION ON METASTASIS TO THE LUNG IN PATIENTS WITH BONE AND SOFT-TISSUE SARCOMA
Hiroyuki Tsuchie
Favorite
(P 486) PRIMARY HIGH-GRADE SARCOMA OF THE SPINE: EXPERIENCE WITH 11 CASES
Hiroyuki Tsuchie
Favorite
Tsuchihashi, Kenji

Kyushu University Hospital
(P 547) A PHASE II TRIAL OF TAZEMETOSTAT FOR PATIENTS WITH UNRESECTABLE OR METASTATIC EPITHELIOID SARCOMA (TAZETTA TRIAL)
Kenji Tsuchihashi
Favorite
Tsuchiya, Hiroyuki

Kanazawa University
(P 396) COMPREHENSIVE WHOLE-GENOME MOLECULAR PROFILING IN BONE AND SOFT TISSUE SARCOMA: MULTI-OMICS ANALYSIS OF 627 CASES ACROSS HISTOLOGIC SUBTYPES
Hiroyuki Tsuchiya
Favorite
Tsukamoto, Shinji

Nara Medical University
(P 259) LOVASTATIN INDUCES NOVEL CELL DEATH THROUGH THE IMPAIRED MITOCHONDRIA IRON UTILIZATION IN OSTEOASRCOMA CELLS.
Shinji Tsukamoto
Favorite
Tsukushi, Satoshi

Aichi Cancer Center Hospital
(P 396) COMPREHENSIVE WHOLE-GENOME MOLECULAR PROFILING IN BONE AND SOFT TISSUE SARCOMA: MULTI-OMICS ANALYSIS OF 627 CASES ACROSS HISTOLOGIC SUBTYPES
Satoshi Tsukushi
Favorite
Tu, Chongqi

Department of Orthopedics, West China Hospital, Sichuan University
(P 169) UPDATED EFFICACY AND SAFETY PROFILE OF PIMICOTINIB (ABSK021) IN TENOSYNOVIAL GIANT CELL TUMOR (TGCT): 1-YEAR FOLLOW-UP FROM PHASE 1B
Chongqi Tu
Favorite
Tufaro, Anthony

Cleveland Clinic
(P 177) ANGIOSARCOMA: AN INCREASING PROBLEM IN THE UNITED STATES
Anthony Tufaro
Favorite
Turaga, Soumya

University of Kansas Medical Centre
(P 446) SYNERGISTIC TARGETING OF KIF11 AND AURKA TO IMPROVE OUTCOMES FOR EWING SARCOMA
Soumya Turaga
Favorite
Turcotte, Robert

Department of Orthopaedic Surgery, McGill University Health Center
(P 64) OSTEOSARCOMA. PATIENT-DERIVED XENOGRAFTS MODELS TO RECAPITULATE PATIENTS' CHEMORESISTANCE AND METASTATIC DISEASE
Robert Turcotte
Favorite
Turcotte, Robert

McGill University
(P 379) THE ROLE OF EZHIP IN DRIVING AGGRESSIVE OSTEOSARCOMA
Robert Turcotte
Favorite
Turpin, Brian

Cincinnati Children's Hospital Medical Center
(P 166) SARC038: A PHASE 2 STUDY OF REGORAFENIB IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH REFRACTORY OR RECURRENT OSTEOSARCOMA
Brian Turpin
Favorite
(P 542) ENROLLMENT OF PEDIATRIC PARTICIPANTS WITH MAGE-A4-POSITIVE SOLID TUMORS IN A PHASE 1/2, OPEN-LABEL, BASKET TRIAL OF AFAMITRESGENE AUTOLEUCEL ("AFAMI-CEL")
Brian Turpin
Favorite
Turski, Michelle

UCSF
(P 413) LINKING REAL-WORLD CLINICAL AND GENOMIC DATA IN RHABDOMYOSARCOMA: LEVERAGING AACR PROJECT GENIE AS A PATH TOWARD PRECISION ONCOLOGY IN RARE CANCERS
Michelle Turski
Favorite
Tu, Yizheng

UT MD Anderson Cancer Center
(P 203) PRECLINICAL EVALUATION AMG 650, A SMALL MOLECULE INHIBITOR OF KIF18A, IN PEDIATRIC SOLID TUMORS BY THE PEDIATRIC PRECLINICAL IN VIVO TESTING (PIVOT) PROGRAM
Yizheng Tu
Favorite
Tu, Zheng

Cleveland Clinic
(P 429) SARCOMA FUSION GENE ANALYSIS YIELDS PROMISING HLA ANTIGEN FIT IN EWING SARCOMA AND DESMOPLASTIC SMALL ROUND CELL TUMOR
Zheng Tu
Favorite
Tydings, Caitlin

Food and Drug Administration
(P 292) APPLICATION OF HIGH-INTENSITY FOCUSED ULTRASOUND THERMAL ABLATION AND BOILING HISTOTRIPSY WITH CHECKPOINT INHIBITORS IN A MURINE MODEL OF OSTEOSARCOMA: AN IN-DEPTH STUDY
Caitlin Tydings
Favorite
Tysarowski, Andrzej

Early Phase Clinical Trials Unit, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland
(P 222) EXPLORING THE IMPACT OF NGS ON DIAGNOSTICS AND TREATMENT OF SARCOMA: INSIGHTS FROM REAL-WORLD DATA ACROSS MULTIPLE INSTITUTIONS IN EUROPE
Andrzej Tysarowski
Favorite
Tzanis, Dimitri

Institut Curie
(P 395) TARGETING CD44-MEDIATED IRON ENDOCYTOSIS IN DESMOID FIBROMATOSIS
Dimitri Tzanis
Favorite
U
Ugurel, Selma

University Hospital Essen
(P 133) TEN RECOMMENDATIONTS FOR SARCOMA SURGERY: CONSENSUS OF THE SURGICAL SOCIETIES BASED ON THE GERMAN S3 GUIDELINE "ADULT SOFT TISSUE SARCOMA"
Selma Ugurel
Favorite
Uhlenbruch, Yasmin

St. Josef's Hospital Bochum
(P 451) IMPACT OF TIME TO DIAGNOSIS - A PROSPECTIVE ANALYSIS OF THE EWING 2008 TRIAL
Yasmin Uhlenbruch
Favorite
(P 538) IEUROEWING TRIAL FOR LOCALIZED AND METASTATIC EWING SARCOMA
Yasmin Uhlenbruch
Favorite
Umutlu, Lale

Department of Diagnostic and Interventional Radiology and Neuroradiology, West German Cancer Center, University Hospital Essen, Essen
(P 248) FIBROBLAST ACTIVATION PROTEIN ALPHA -DIRECTED IMAGING AND THERAPY OF SOLITARY FIBROUS TUMOR
Lale Umutlu
Favorite
Underhill, Michael

Biomedical Research Centre, University of British Columbia
(P 267) NEW MOUSE MODEL OF SYNOVIAL SARCOMA BASED ON CONDITIONAL EXPRESSION IN MESENCHYMAL PROGENITORS
Michael Underhill
Favorite
Ungerechts, Guy

Clinical Cooperation Unit Virotherapy, German Cancer Research Center (DKFZ) and Department of Medical Oncology, Heidelberg University Hospital
(P 124) UNLOCKING THE POTENTIAL OF MEASLES VIRUS ONCOLYTIC IMMUNOTHERAPY FOR SARCOMA: BIOMARKER DISCOVERY AND THERAPEUTIC VACCINE DEVELOPMENT
Guy Ungerechts
Favorite
Untch, Brian

MSKCC
(P 24) COMPREHENSIVE ANALYSIS OF THE GENOMIC LANDSCAPE AND CLINICAL BEHAVIOR IN GIST USING NEXT GENERATION SEQUENCING (NGS, MSK-IMPACT)
Brian Untch
Favorite
Urakawa, Hiroshi

Nagoya University Hospital
(P 163) SELUMETINIB IN JAPANESE PEDIATRIC PATIENTS WITH SYMPTOMATIC INOPERABLE PLEXIFORM NEUROFIBROMA IN NEUROFIBROMATOSIS TYPE 1
Hiroshi Urakawa
Favorite
Urbina, Alejandro

Hospital Clinico san Carlos
(P 149) PSYCOLOGICAL SNAPSHOT OF SARCOMA PATIENTS FROM AN ACADEMIC, UNIVERSITY CENTER, HOSPITAL CLÍNICO SAN CARLOS (HCSC), MADRID, A SARCOMA NATIONAL REFERRAL CENTRE IN SPAIN
Alejandro Urbina
Favorite
Urquiola, Elizabeth

MD Anderson Cancer Center
(P 36) CLINICO-GENOMIC ANALYSIS OF KIT/PDGFRA/SDH WILD-TYPE GASTROINTESTINAL STROMAL TUMORS IDENTIFIES POTENTIAL DRIVER MUTATIONS
Elizabeth Urquiola
Favorite
Utset-Ward, Thomas

Nationwide Children's Hospital
(P 500) IMPROVING OUTCOMES OF INTERCALARY EWING SARCOMA RESECTIONS AND ALLOGRAFT RECONSTRUCTIONS WITH PATIENT-SPECIFIC CUTTING GUIDES AND VIRTUAL SURGICAL PLANNING
Thomas Utset-Ward
Favorite
(P 501) TIBIAL DEFORMITIES AND PHYSEAL INJURY WITH DISTAL FEMORAL EXPANDABLE ENDOPROSTHESIS IMPLANTS
Thomas Utset-Ward
Favorite
(P 502) SEPARATE RESECTION OF BIOPSY TRACT IN PRIMARY BONE SARCOMA: IMPLICATIONS FOR LOCAL RECURRENCE AND OVERALL SURVIVAL
Thomas Utset-Ward
Favorite
V
Valenti, Beatrice

Unit of Oncogenetics and Functional Oncogenomics, Centro di Riferimento Oncologico di Aviano IRCCS, Aviano, Italy
(P 355) FUSION TRANSCRIPTOME PROFILING DEFINES THE MONOCLONAL NATURE OF MULTIFOCAL EPITHELIOID HEMANGIOMA OF BONE
Beatrice Valenti
Favorite
(P 378) MULTIOMICS PROFILING OF EPITHELIOID SARCOMA UNVEILS EPIGENETIC CIRCUITRIES THAT UNDERLIE THE PATHOBIOLOGY OF PROXIMAL AND CLASSIC SUBTYPES: RESULTS FROM THE ISG EPISOBS OBSERVATIONAL STUDY
Beatrice Valenti
Favorite
Valentin, Thibaud

Oncopole Claudius Regaud
(P 49) EFFICACY OF RIPRETINIB IN A MULTICENTER EXPANDED ACCESS PROGRAM IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS HARBOURING NON-KIT EXON 11 MUTATIONS.
Thibaud Valentin
Favorite
(P 104) COMPREHENSIVE IMMUNE PROFILING UNVEILS A SUBSET OF LEIOMYOSARCOMA WITH HOT TUMOR IMMUNE MICROENVIRONMENT
Thibaud Valentin
Favorite
(P 201) PLEOMORPHIC RHABDOMYOSARCOMAS: A NEW ENTITY ASSOCIATED WITH LYNCH SYNDROME? FIRST RESULTS OF SARCLYNCH NATIONAL STUDY
Thibaud Valentin
Favorite
Valenzuela, Cristian

OHSU
(P 341) A PHASE 1B STUDY TO EVALUATE PREOPERATIVE ERIBULIN IN COMBINATION WITH RADIATION IN RETROPERITONEAL SARCOMA
Cristian Valenzuela
Favorite
Valenzuela, Raul

MD Anderson Cancer Center
(P 71) CHEMOTHERAPY AND PROGNOSTIC SIGNIFICANCE OF EXTENT OF DEDIFFERENTIATION IN DEDIFFERENTIATED PAROSTEAL OSTEOSARCOMA
Raul Valenzuela
Favorite
(P 221) EARLY RESULTS IN NOVEL USE OF CONTRAST-ENHANCED SUSCEPTIBILITY-WEIGHTED IMAGING IN THE ASSESSMENT OF RESPONSE AND PROGRESSION IN DESMOID FIBROMATOSIS: PILOT STUDY IN A SPECIALIZED CANCER INSTITUTION
Raul Valenzuela
Favorite
(P 239) CANCER RADIOMIC AND PERFUSION IMAGING (CARPI) AUTOMATED FRAMEWORK: VALIDATION ON MUSCULOSKELETAL TUMORS IN A SPECIALIZED CANCER CENTER
Raul Valenzuela
Favorite
(P 354) ROLE OF APPARENT DIFFUSION COEFFICIENT (ADC) MAP-BASED FIRST AND HIGH-ORDER RADIOMIC FEATURES IN DISCRIMINATING SACRAL CHORDOMAS AND CHONDROSARCOMAS WITH OVERLAPPING CONVENTIONAL IMAGING FEATURES
Raul Valenzuela
Favorite
(P 356) BASELINE AND POST-TREATMENT ADVANCED MRI OF EXTREMITIES SOFT-TISSUE NON-MYXOID UNDIFFERENTIATED PLEOMORPHIC SARCOMA.
Raul Valenzuela
Favorite
(P 357) APPARENT DIFFUSION COEFFICIENT (ADC) HIGH-ORDER RADIOMICS OF BASELINE AND POST-TREATMENT ADVANCED MRI OF EXTREMITY SOFT-TISSUE NON-MYXOID UNDIFFERENTIATED PLEOMORPHIC SARCOMA.
Raul Valenzuela
Favorite
(P 358) CONTRAST-ENHANCED SUSCEPTIBILITY IMAGING (CE-SWI) MORPHOLOGIC, FIRST & HIGH-ORDER RADIOMIC FEATURES VALUE IN ASSESSING TREATMENT RESPONSE IN EXTREMITY SOFT-TISSUE UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Raul Valenzuela
Favorite
(P 359) ROLE OF PERFUSION WEIGHTED IMAGING WITH DYNAMIC CONTRAST ENHANCED (PWI/DCE) FOR THE TREATMENT ASSESSMENT OF EXTREMITY SOFT-TISSUE NON-MYXOID UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Raul Valenzuela
Favorite
Valiev, Aslan

National Medical Research Center of Oncology named after N.N. Blokhin
(P 459) EXPERIENCE IN THE USE OF INDIVIDUALIZED 3D-IMPLANTS IN THE RECONSTRUCTION OF DEFECTS IN PATIENTS WITH TUMORS OF THE CHEST WALL
Aslan Valiev
Favorite
Vallacchi, Viviana

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 363) Β-CATENIN MUTATIONS AND TRANSCRIPTOMIC REPROGRAMMING IN DESMOID FIBROMATOSIS (DF)
Viviana Vallacchi
Favorite
Valles, Laura

Hospital Clinico san Carlos
(P 149) PSYCOLOGICAL SNAPSHOT OF SARCOMA PATIENTS FROM AN ACADEMIC, UNIVERSITY CENTER, HOSPITAL CLÍNICO SAN CARLOS (HCSC), MADRID, A SARCOMA NATIONAL REFERRAL CENTRE IN SPAIN
Laura Valles
Favorite
Vallner, Debra Thoma

Peel Therapeutics
(P 565) AN EARLY PHASE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF PEEL-224 IN PATIENTS WITH ADVANCED SOLID TUMORS
Debra Thoma Vallner
Favorite
Valverde, Claudia

Vall d'Hebron University Hospital
(P 69) DEVELOPMENT AND MISSION OF THE HARMONIZATION INTERNATIONAL BONE SARCOMA CONSORTIUM (HIBISCUS)
Claudia Valverde
Favorite
Valverde, Claudia

Vall D’Hebron University Hospital
(P 73) FOSTER CONSORTIUM, FIGHT OSTEOSARCOMA THROUGH EUROPEAN RESEARCH
Claudia Valverde
Favorite
(P 113) IMMUNOSARC II: A SPANISH SARCOMA GROUP (GEIS) PHASE IB TRIAL OF DOXORUBICIN AND DACARBAZINE PLUS NIVOLUMAB IN FIRST LINE OF ADVANCED LEIOMYOSARCOMA
Claudia Valverde
Favorite
(P 135) UNMET NEEDS IN LOCALLY ADVANCED (UNRESECTABLE) OR METASTATIC DEDIFFERENTIATED LIPOSARCOMA AND EXPECTATIONS FOR CLINICAL TRIALS: AN INTERNATIONAL DELPHI CONSENSUS STUDY
Claudia Valverde
Favorite
Valverde, Claudia

Vall d'Hebron University Hospital
(P 142) THE SARCOMA EUROPEAN AND LATIN AMERICAN NETWORK (SELNET) PROJECT: OVERVIEW OF THE MAIN RESULTS OF THE SELNET REGISTRY
Claudia Valverde
Favorite
Valverde, Claudia

Vall D’Hebron University Hospital
(P 174) SELISARC: A SPANISH GROUP FOR RESEARCH IN SARCOMA (GEIS) PHASE I/II TRIAL OF SELINEXOR PLUS GEMCITABINE IN SELECTED SARCOMA SUBTYPES: RESULTS OF THE PHASE I PART
Claudia Valverde
Favorite
(P 175) TRABECTEDIN PLUS RADIOTHERAPY ON SYMPHTOMATIC ADVANCED SARCOMA PATIENTS, RESULTS FROM THE SYNERGIAS STUDY: A SPANISH GROUP FOR RESEARCH IN SARCOMA (GEIS) PHASE II STUDY
Claudia Valverde
Favorite
(P 222) EXPLORING THE IMPACT OF NGS ON DIAGNOSTICS AND TREATMENT OF SARCOMA: INSIGHTS FROM REAL-WORLD DATA ACROSS MULTIPLE INSTITUTIONS IN EUROPE
Claudia Valverde
Favorite
Valverde, Sandra

Hospital de la Santa Creu i Sant Pau
(P 503) SCAPULAR PROSTHESIS RECONSTRUCTION, EXPERIENCE IN OUR INSTITUTION
Sandra Valverde
Favorite
(P 504) WHY DO SOME PATIENTS WITH SYNOVIAL SARCOMA HAVE BETTER FUNCTIONAL OUTCOMES AFTER RESECTION SURGERY? ANALYSIS OF 102 CASES
Sandra Valverde
Favorite
(P 507) PRIMARY CHEST WALL TUMORS OF MESENCHYMAL ORIGIN. EXPERIENCE OF A REFERENCE UNIT
Sandra Valverde
Favorite
(P 508) DREAM, UTOPIA OR REALISM? PROGNOSTIC FACTORS IN LUNG METASTASECTOMY OF DISSEMINATED SARCOMA DISEASE
Sandra Valverde
Favorite
VALVERDE, Veronica Yanina

Institut Bergonié
(P 418) GENOMIC AND IMMUNOLOGICAL PROFILING OF PRIMARY AND DISTANT METASTASES OF SOFT TISSUE SARCOMAS
Veronica Yanina VALVERDE
Favorite
van Bodegom-Vos, Leti

Leiden University Medical Center
(P 132) SARCOMA PATEINTS' VIEWS ON USING A RISK-PREDICTION MODEL TO INFORM TREATMENT DECISIONS.
Leti van Bodegom-Vos
Favorite
van Boven, Hester

Netherlands Cancer Institute/Antoni van Leeuwenhoek
(P 102) INTERLEUKIN-6 IN RELATION TO TUMOR BEHAVIOR AND EARLY RECURRENCE IN PRIMARY LOCALIZED SOFT TISSUE SARCOMA
Hester van Boven
Favorite
(P 197) PROPRANOLOL MONOTHERAPY IN ANGIOSARCOMA - A WINDOW-OF-OPPORTUNITY STUDY (PROPANGIO)
Hester van Boven
Favorite
Van Boxtel, Matthew

MCW
(P 473) GROIN PAINS: APPROACHES AND OUTCOMES FOR INGUINOFEMORAL SOFT TISSUE SARCOMAS
Matthew Van Boxtel
Favorite
Van Broekhoven, Danique L.M.

Erasmus Medical Center
(P 554) FIVE-YEAR OUTCOMES OF A NATIONWIDE PROSPECTIVE CLINICAL TRIAL ON ACTIVE SURVEILLENCE IN PATIENTS WITH NON-INTRAABDOMINAL DESMOID-TYPE FIBROMATOSIS
Danique L.M. Van Broekhoven
Favorite
Van Coevorden, Frits

Netherlands Cancer Institute/ Antoni van Leeuwenhoek
(P 31) NEOADJUVANT IMATINIB IN LOCALLY ADVANCED GASTROINTESTINAL STROMAL TUMORS (GIST) IS EFFECTIVE AND SAFE: RESULTS FROM A PROSPECTIVE SINGLE CENTER STUDY WITH 108 PATIENTS
Frits Van Coevorden
Favorite
van Coevorden, Frits

Netherlands Cancer Institute
(P 32) IMPROVEMENT OF QUALITY AND TEXTBOOK OUTCOMES OF GASTRIC GASTROINTESTINAL STROMAL TUMOR (GIST) RESECTIONS IN THE PAST 13 YEARS; THE INFLUENCE OF MINIMAL INVASIVE SURGERY (MIS)
Frits van Coevorden
Favorite
van Dalen, Thijs

Erasmus Medical Center
(P 554) FIVE-YEAR OUTCOMES OF A NATIONWIDE PROSPECTIVE CLINICAL TRIAL ON ACTIVE SURVEILLENCE IN PATIENTS WITH NON-INTRAABDOMINAL DESMOID-TYPE FIBROMATOSIS
Thijs van Dalen
Favorite
van de Rijn, Matt

Stanford University
(P 376) MULTI-OMIC PROFILING OF LEIOMYOSARCOMA IDENTIFIES MARKERS PREDICTIVE OF RESPONSE TO GEMCITABINE AND DOCETAXEL
Matt van de Rijn
Favorite
(P 412) LEIOMYOSARCOMA POLYANEUPLOID CANCER CELLS DEVELOP IN RESPONSE TO CHEMOTHERAPY AND CONTRIBUTE TO CHEMORESISTANCE
Matt van de Rijn
Favorite
van de Sande, Michiel

Leiden University Medical Center
(P 55) RELATIVE WASH-IN RATE ON DYNAMIC CONTRAST-ENHANCED MRI AS A NEW PROGNOSTIC FACTOR IN PATIENTS WITH OSTEOSARCOMA; A POSSIBLE TOOL FOR PERSONALIZED SARCOMA-CARE?
Michiel van de Sande
Favorite
(P 56) CHARACTERIZATION OF DENOSUMAB TREATMENT RESPONSE ON MR PERFUSION IN GIANT CELL TUMORS OF BONE
Michiel van de Sande
Favorite
(P 132) SARCOMA PATEINTS' VIEWS ON USING A RISK-PREDICTION MODEL TO INFORM TREATMENT DECISIONS.
Michiel van de Sande
Favorite
(P 173) SAFETY, EFFICACY, AND PATIENT-REPORTED OUTCOMES WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED PRIOR ANTI–COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 UPDATE
Michiel van de Sande
Favorite
(P 176) SAFETY, EFFICACY, AND PATIENT-REPORTED OUTCOMES WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED NO PRIOR ANTI–COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 UPDATE
Michiel van de Sande
Favorite
(P 251) EVALUATION OF POTENTIAL TARGETS FOR FLUORESCENCE-GUIDED SURGERY IN PEDIATRIC EWING SARCOMA: A PRECLINICAL PROOF-OF-CONCEPT STUDY
Michiel van de Sande
Favorite
(P 368) DECODING THE IMMUNOGENOMIC DETERMINANTS OF RADIOTHERAPY RESPONSE IN SOFT TISSUE SARCOMAS
Michiel van de Sande
Favorite
(P 369) MAGEA ANTIGENS AS IMMUNOTHERAPEUTIC TARGETS FOR ADVANCED OSTEOSARCOMA
Michiel van de Sande
Favorite
van de Wal, Deborah

Netherlands Cancer Institute/ Antoni van Leeuwenhoek
(P 30) FINANCIAL DIFFICULTIES EXPERIENCED BY DUTCH GASTROINTESTINAL STROMAL TUMOR (GIST) PATIENTS: DATA FROM A CROSS-SECTIONAL MULTICENTER STUDY
Deborah van de Wal
Favorite
(P 31) NEOADJUVANT IMATINIB IN LOCALLY ADVANCED GASTROINTESTINAL STROMAL TUMORS (GIST) IS EFFECTIVE AND SAFE: RESULTS FROM A PROSPECTIVE SINGLE CENTER STUDY WITH 108 PATIENTS
Deborah van de Wal
Favorite
van den Akker, Brendy

LUMC
(P 368) DECODING THE IMMUNOGENOMIC DETERMINANTS OF RADIOTHERAPY RESPONSE IN SOFT TISSUE SARCOMAS
Brendy van den Akker
Favorite
(P 369) MAGEA ANTIGENS AS IMMUNOTHERAPEUTIC TARGETS FOR ADVANCED OSTEOSARCOMA
Brendy van den Akker
Favorite
Van Den Berghe, Thomas

University Hospital Ghent
(P 55) RELATIVE WASH-IN RATE ON DYNAMIC CONTRAST-ENHANCED MRI AS A NEW PROGNOSTIC FACTOR IN PATIENTS WITH OSTEOSARCOMA; A POSSIBLE TOOL FOR PERSONALIZED SARCOMA-CARE?
Thomas Van Den Berghe
Favorite
van den Bos, Hilda

University Medical Centre Groningen
(P 371) DISRUPTION OF THE TP53 LOCUS IN OSTEOSARCOMA LEADS TO TP53 PROMOTER GENE FUSIONS AND RESTORATION OF PARTS OF THE TP53 SIGNALLING PATHWAY
Hilda van den Bos
Favorite
van den Broek, Daan

Netherlands Cancer Institute/Antoni van Leeuwenhoek
(P 102) INTERLEUKIN-6 IN RELATION TO TUMOR BEHAVIOR AND EARLY RECURRENCE IN PRIMARY LOCALIZED SOFT TISSUE SARCOMA
Daan van den Broek
Favorite
Van der burg, Stijn

Netherlands Cancer Institute/ Antoni van Leeuwenhoek
(P 31) NEOADJUVANT IMATINIB IN LOCALLY ADVANCED GASTROINTESTINAL STROMAL TUMORS (GIST) IS EFFECTIVE AND SAFE: RESULTS FROM A PROSPECTIVE SINGLE CENTER STUDY WITH 108 PATIENTS
Stijn Van der burg
Favorite
(P 32) IMPROVEMENT OF QUALITY AND TEXTBOOK OUTCOMES OF GASTRIC GASTROINTESTINAL STROMAL TUMOR (GIST) RESECTIONS IN THE PAST 13 YEARS; THE INFLUENCE OF MINIMAL INVASIVE SURGERY (MIS)
Stijn Van der burg
Favorite
van der Graaf, Winette

Netherlands Cancer Institute/ Antoni van Leeuwenhoek
(P 27) A MULTICENTER RETROSPECTIVE STUDY ON THE CLINICAL BEHAVIOR OF SDH-DEFICIENT GIST
Winette van der Graaf
Favorite
(P 30) FINANCIAL DIFFICULTIES EXPERIENCED BY DUTCH GASTROINTESTINAL STROMAL TUMOR (GIST) PATIENTS: DATA FROM A CROSS-SECTIONAL MULTICENTER STUDY
Winette van der Graaf
Favorite
(P 31) NEOADJUVANT IMATINIB IN LOCALLY ADVANCED GASTROINTESTINAL STROMAL TUMORS (GIST) IS EFFECTIVE AND SAFE: RESULTS FROM A PROSPECTIVE SINGLE CENTER STUDY WITH 108 PATIENTS
Winette van der Graaf
Favorite
(P 102) INTERLEUKIN-6 IN RELATION TO TUMOR BEHAVIOR AND EARLY RECURRENCE IN PRIMARY LOCALIZED SOFT TISSUE SARCOMA
Winette van der Graaf
Favorite
(P 136) SETTING THE INTERNATIONAL RESEARCH AGENDA FOR SARCOMA WITH PATIENTS AND CARERS: PRELIMINARY RESULTS OF PHASE II OF THE SARCOMA PATIENT ADVOCACY GLOBAL NETWORK (SPAGN) PRIORITY SETTING PARTNERSHIP
Winette van der Graaf
Favorite
(P 138) CONTROVERSIES IN THE MANAGEMENT OF PATIENTS WITH SOFT TISSUE SARCOMA: RESULTS AND RECOMMENDATIONS FROM THE FIRST CONFERENCE ON STATE OF SCIENCE IN SARCOMA (CSSS)
Winette van der Graaf
Favorite
(P 140) THE PRE-DIAGNOSTIC GENERAL PRACTIONER JOURNEY OF SARCOMA PATIENTS: A REAL-WORLD DATA STUDY.
Winette van der Graaf
Favorite
(P 186) PATIENT REPORTED OUTCOME ASSESSMENT AND REPORTING IN RANDOMIZED CLINICAL TRIALS OF SYSTEMIC THERAPY FOR ADVANCED SOFT TISSUE SARCOMAS: A SYSTEMATIC REVIEW.
Winette van der Graaf
Favorite
(P 188) IMPACT OF NIROGACESTAT ON FUNCTIONAL STATUS IN PATIENTS WITH DESMOID TUMORS: RESULTS FROM THE PHASE 3 DEFI STUDY
Winette van der Graaf
Favorite
(P 197) PROPRANOLOL MONOTHERAPY IN ANGIOSARCOMA - A WINDOW-OF-OPPORTUNITY STUDY (PROPANGIO)
Winette van der Graaf
Favorite
van der Hage, Jos

Leiden University Medical Center
(P 132) SARCOMA PATEINTS' VIEWS ON USING A RISK-PREDICTION MODEL TO INFORM TREATMENT DECISIONS.
Jos van der Hage
Favorite
(P 342) THE EVALUATION AND OUTCOMES OF MESENTERIC AND INTRA-ABDOMINAL DESMOIDS: A TARPSWG STUDY
Jos van der Hage
Favorite
van der Heijden, Lizz

Leiden University Medical Center
(P 56) CHARACTERIZATION OF DENOSUMAB TREATMENT RESPONSE ON MR PERFUSION IN GIANT CELL TUMORS OF BONE
Lizz van der Heijden
Favorite
van der Kleij, Stephanie

Netherlands Cancer Institute/Antoni van Leeuwenhoek
(P 140) THE PRE-DIAGNOSTIC GENERAL PRACTIONER JOURNEY OF SARCOMA PATIENTS: A REAL-WORLD DATA STUDY.
Stephanie van der Kleij
Favorite
(P 197) PROPRANOLOL MONOTHERAPY IN ANGIOSARCOMA - A WINDOW-OF-OPPORTUNITY STUDY (PROPANGIO)
Stephanie van der Kleij
Favorite
van der Laan, Pia

Netherlands Cancer Institute/Antoni van Leeuwenhoek
(P 102) INTERLEUKIN-6 IN RELATION TO TUMOR BEHAVIOR AND EARLY RECURRENCE IN PRIMARY LOCALIZED SOFT TISSUE SARCOMA
Pia van der Laan
Favorite
van der Lugt, Jasper

Princess Máxima Center for Pediatric Oncology
(P 08) PRELIMINARY CLINICAL ACTIVITY OF THE TYPE II RAF INHIBITOR TOVORAFENIB IN RAF FUSION-DRIVEN RECURRENT/PROGRESSIVE SARCOMAS
Jasper van der Lugt
Favorite
van der Mierden, Stevie

Netherlands Cancer Institute
(P 186) PATIENT REPORTED OUTCOME ASSESSMENT AND REPORTING IN RANDOMIZED CLINICAL TRIALS OF SYSTEMIC THERAPY FOR ADVANCED SOFT TISSUE SARCOMAS: A SYSTEMATIC REVIEW.
Stevie van der Mierden
Favorite
van der Steeg, Alida

Princess Maxima Center for Pediatric Oncology, The Netherlands
(P 251) EVALUATION OF POTENTIAL TARGETS FOR FLUORESCENCE-GUIDED SURGERY IN PEDIATRIC EWING SARCOMA: A PRECLINICAL PROOF-OF-CONCEPT STUDY
Alida van der Steeg
Favorite
van Driel, Pieter

Isala hospital
(P 251) EVALUATION OF POTENTIAL TARGETS FOR FLUORESCENCE-GUIDED SURGERY IN PEDIATRIC EWING SARCOMA: A PRECLINICAL PROOF-OF-CONCEPT STUDY
Pieter van Driel
Favorite
van Eijkelenburg, Natasha

Princess Máxima Center for Pediatric Oncology
(P 08) PRELIMINARY CLINICAL ACTIVITY OF THE TYPE II RAF INHIBITOR TOVORAFENIB IN RAF FUSION-DRIVEN RECURRENT/PROGRESSIVE SARCOMAS
Natasha van Eijkelenburg
Favorite
(P 212) REPORT ON THE EWING SARCOMA PATIENTS ENROLLED IN ARM D OF THE ACSE-ESMART TRIAL: PHASE I/II STUDY OF THE PARP INHIBITOR OLAPARIB IN COMBINATION WITH IRINOTECAN IN CHILDREN WITH ADVANCED MALIGNANCIES
Natasha van Eijkelenburg
Favorite
van Erp, Gonnie

Erasmus Medical Center
(P 231) MINIMALLY INTERACTIVE SEGMENTATION OF SOFT-TISSUE TUMORS ON MRI AND CT USING DEEP LEARNING
Gonnie van Erp
Favorite
Van etten, Boudewijn

University medical center Groningen
(P 32) IMPROVEMENT OF QUALITY AND TEXTBOOK OUTCOMES OF GASTRIC GASTROINTESTINAL STROMAL TUMOR (GIST) RESECTIONS IN THE PAST 13 YEARS; THE INFLUENCE OF MINIMAL INVASIVE SURGERY (MIS)
Boudewijn Van etten
Favorite
van Ewijk, Roelof

Princess Maxima Center for Pediatric Oncology
(P 73) FOSTER CONSORTIUM, FIGHT OSTEOSARCOMA THROUGH EUROPEAN RESEARCH
Roelof van Ewijk
Favorite
(P 209) PROGNOSTIC VALUE OF EARLY RADIOLOGIC TUMOUR VOLUME RESPONSE IN RHABDOMYOSARCOMA; RESULTS OF THE EUROPEAN PAEDIATRIC SOFT TISSUE SARCOMA STUDY GROUP RMS 2005 STUDY
Roelof van Ewijk
Favorite
(P 229) ON THE VARIABILITY IN THE ANALYSIS OF APPARENT DIFFUSION COEFFICIENT ESTIMATES FOR MULTICENTER DIFFUSION MRI DATA OF RHABDOMYOSARCOMA PATIENTS
Roelof van Ewijk
Favorite
van Houdt, Winan

Netherlands Cancer Institute/ Antoni van Leeuwenhoek
(P 27) A MULTICENTER RETROSPECTIVE STUDY ON THE CLINICAL BEHAVIOR OF SDH-DEFICIENT GIST
Winan van Houdt
Favorite
(P 31) NEOADJUVANT IMATINIB IN LOCALLY ADVANCED GASTROINTESTINAL STROMAL TUMORS (GIST) IS EFFECTIVE AND SAFE: RESULTS FROM A PROSPECTIVE SINGLE CENTER STUDY WITH 108 PATIENTS
Winan van Houdt
Favorite
(P 32) IMPROVEMENT OF QUALITY AND TEXTBOOK OUTCOMES OF GASTRIC GASTROINTESTINAL STROMAL TUMOR (GIST) RESECTIONS IN THE PAST 13 YEARS; THE INFLUENCE OF MINIMAL INVASIVE SURGERY (MIS)
Winan van Houdt
Favorite
(P 102) INTERLEUKIN-6 IN RELATION TO TUMOR BEHAVIOR AND EARLY RECURRENCE IN PRIMARY LOCALIZED SOFT TISSUE SARCOMA
Winan van Houdt
Favorite
(P 138) CONTROVERSIES IN THE MANAGEMENT OF PATIENTS WITH SOFT TISSUE SARCOMA: RESULTS AND RECOMMENDATIONS FROM THE FIRST CONFERENCE ON STATE OF SCIENCE IN SARCOMA (CSSS)
Winan van Houdt
Favorite
(P 140) THE PRE-DIAGNOSTIC GENERAL PRACTIONER JOURNEY OF SARCOMA PATIENTS: A REAL-WORLD DATA STUDY.
Winan van Houdt
Favorite
(P 197) PROPRANOLOL MONOTHERAPY IN ANGIOSARCOMA - A WINDOW-OF-OPPORTUNITY STUDY (PROPANGIO)
Winan van Houdt
Favorite
(P 342) THE EVALUATION AND OUTCOMES OF MESENTERIC AND INTRA-ABDOMINAL DESMOIDS: A TARPSWG STUDY
Winan van Houdt
Favorite
(P 554) FIVE-YEAR OUTCOMES OF A NATIONWIDE PROSPECTIVE CLINICAL TRIAL ON ACTIVE SURVEILLENCE IN PATIENTS WITH NON-INTRAABDOMINAL DESMOID-TYPE FIBROMATOSIS
Winan van Houdt
Favorite
van Langevelde, Kirsten

Leiden University Medical Center
(P 56) CHARACTERIZATION OF DENOSUMAB TREATMENT RESPONSE ON MR PERFUSION IN GIANT CELL TUMORS OF BONE
Kirsten van Langevelde
Favorite
van Noesel, Max

Princess Máxima Center for Pediatric Oncology
(P 202) INFLAMMATORY MYOFIBROBLASTIC TUMOUR WITH ROS1 GENE FUSIONS IN CHILDREN AND YOUNG ADOLESCENTS
Max van Noesel
Favorite
Van Oortmerssen, Gerard

Sarcoma Patient Advocacy Global Network Assoc. (SPAGN)
(P 136) SETTING THE INTERNATIONAL RESEARCH AGENDA FOR SARCOMA WITH PATIENTS AND CARERS: PRELIMINARY RESULTS OF PHASE II OF THE SARCOMA PATIENT ADVOCACY GLOBAL NETWORK (SPAGN) PRIORITY SETTING PARTNERSHIP
Gerard Van Oortmerssen
Favorite
van Oost, Siddh

LUMC
(P 368) DECODING THE IMMUNOGENOMIC DETERMINANTS OF RADIOTHERAPY RESPONSE IN SOFT TISSUE SARCOMAS
Siddh van Oost
Favorite
(P 369) MAGEA ANTIGENS AS IMMUNOTHERAPEUTIC TARGETS FOR ADVANCED OSTEOSARCOMA
Siddh van Oost
Favorite
Van Pelt, Stacey

Baylor College of Medicine
(P 121) IMPROVING THE EFFICACY OF GD2 CHIMERIC ANTIGEN RECEPTOR T-CELLS USING HISTONE DEACETYLASE INHIBITORS
Stacey Van Pelt
Favorite
Van Raemdonck, Dirk

UZ Leuven
(P 254) A COLLECTION OF PATIENT-DERIVED XENOGRAFT MODELS OF GASTROINTESTINAL STROMAL TUMORS
Dirk Van Raemdonck
Favorite
Van Ramshorst, Gabriëlle

Ghent University Hospital
(P 295) ORTHOTOPIC XENOGRAFTS OF PAIRED SARCOMA PRIMARY TUMOUR, LOCAL RELAPSE AND METASTATIC SITES REVEALS PHENOTYPIC HETEROGENEITY IN A MINIMAL RESIDUAL DISEASE MODEL
Gabriëlle Van Ramshorst
Favorite
(P 296) EX VIVO SARCOMA CELL CULTURES FROM PAIRED PRIMARY, LOCAL RELAPSE AND METASTATIC SITES REVEALS PHENOTYPIC HETEROGENEITY
Gabriëlle Van Ramshorst
Favorite
van Riet, Bauke

Netherlands Cancer Institute
(P 186) PATIENT REPORTED OUTCOME ASSESSMENT AND REPORTING IN RANDOMIZED CLINICAL TRIALS OF SYSTEMIC THERAPY FOR ADVANCED SOFT TISSUE SARCOMAS: A SYSTEMATIC REVIEW.
Bauke van Riet
Favorite
Van Rijn, Rick

Department of Radiology and Nuclear Medicine, Amsterdam UMC – Emma Children’s Hospital, University of Amsterdam
(P 209) PROGNOSTIC VALUE OF EARLY RADIOLOGIC TUMOUR VOLUME RESPONSE IN RHABDOMYOSARCOMA; RESULTS OF THE EUROPEAN PAEDIATRIC SOFT TISSUE SARCOMA STUDY GROUP RMS 2005 STUDY
Rick Van Rijn
Favorite
(P 229) ON THE VARIABILITY IN THE ANALYSIS OF APPARENT DIFFUSION COEFFICIENT ESTIMATES FOR MULTICENTER DIFFUSION MRI DATA OF RHABDOMYOSARCOMA PATIENTS
Rick Van Rijn
Favorite
van Sandick, Johanna

Netherlands Cancer Institute/ Antoni van Leeuwenhoek
(P 31) NEOADJUVANT IMATINIB IN LOCALLY ADVANCED GASTROINTESTINAL STROMAL TUMORS (GIST) IS EFFECTIVE AND SAFE: RESULTS FROM A PROSPECTIVE SINGLE CENTER STUDY WITH 108 PATIENTS
Johanna van Sandick
Favorite
(P 32) IMPROVEMENT OF QUALITY AND TEXTBOOK OUTCOMES OF GASTRIC GASTROINTESTINAL STROMAL TUMOR (GIST) RESECTIONS IN THE PAST 13 YEARS; THE INFLUENCE OF MINIMAL INVASIVE SURGERY (MIS)
Johanna van Sandick
Favorite
van Tilburg, Cornelis

Hopp Children’s Cancer Center Heidelberg (KiTZ), Heidelberg University Hospital and German Cancer Research Center (DKFZ),
(P 161) EFFICACY, SAFETY, AND TREATMENT HOLD WAIT-AND-SEE OUTCOMES OF LAROTRECTINIB IN PEDIATRIC PATIENTS WITH TRK FUSION SARCOMAS
Cornelis van Tilburg
Favorite
Van Tine, Brian

Washington University School of Medicine
(P 172) PHASE 2 RESULTS FROM THE RINGSIDE PHASE 2/3 TRIAL OF AL102 FOR TREATMENT OF DESMOID TUMORS
Brian Van Tine
Favorite
(P 178) INITIAL RESULTS FROM A PHASE 1 STUDY OF CFT8634, A NOVEL BIFUCTIONAL DEGRADATION ACTIVATING COMPOUND (BIDAC) DEGRADER OF BRD9, IN SYNOVIAL SARCOMA AND SMARCB1-NULL TUMORS
Brian Van Tine
Favorite
Van Tine, Brian

Washington University in St. Louis
(P 180) HEALTH RELATED QUALITY OF LIFE OF PATIENTS WITH ADVANCED LEIOMYOSARCOMA AND OTHER SOFT TISSUE SARCOMAS TREATED WITH CABOZANTINIB AND TEMOZOLOMIDE
Brian Van Tine
Favorite
Van Tine, Brian

Washington University School of Medicine
(P 182) UPDATED RESULTS FROM AN ONGOING PHASE 1B STUDY OF UNESBULIN (PTC596) PLUS DACARBAZINE FOR THE TREATMENT OF PATIENTS WITH ADVANCED LEIOMYOSARCOMA
Brian Van Tine
Favorite
(P 183) A PHASE 1B/2 STUDY OF LIPOSOMAL ANNAMYCIN (ANN) IN SUBJECTS WITH PREVIOUSLY TREATED SOFT-TISSUE SARCOMAS (STS) WITH PULMONARY METASTASES
Brian Van Tine
Favorite
(P 187) PALLIATIVE LATTICE STEREOTACTIC BODY RADIOTHERAPY FOR PATIENTS WITH SARCOMA
Brian Van Tine
Favorite
(P 552) RANDOMIZED PHASE II TRIAL OF CABOZANTINIB COMBINED WITH PD-1 AND CTLA-4 INHIBITION VERSUS CABOZANTINIB IN METASTATIC SOFT TISSUE SARCOMA.
Brian Van Tine
Favorite
Van Winkle, Erin

Adaptimmune
(P 542) ENROLLMENT OF PEDIATRIC PARTICIPANTS WITH MAGE-A4-POSITIVE SOLID TUMORS IN A PHASE 1/2, OPEN-LABEL, BASKET TRIAL OF AFAMITRESGENE AUTOLEUCEL ("AFAMI-CEL")
Erin Van Winkle
Favorite
Vanacker, Helene

Centre Leon Berard
(P 382) NTRK1/2/3 FUSIONS DETECTION USING RNA-SEQ IN MESENCHYMAL TUMORS REVEALS ULTRA-RARE AND HISTO-SPECIFIC TARGETABLE ALTERATIONS: EXPERIENCE OF AN EXTENSIVE ROUTINE RESEARCH PROGRAM.
Helene Vanacker
Favorite
Vanacker, Helene

CENTRE LEON BERARD AND CANCER RESEARCH CENTER OF LYON (INSERM U1052-CNRS5286)
(P 435) ONCOGENIC FUSION YWHAE::NUTM2 DISRUPT EP300/BCOR INTERACTION
Helene Vanacker
Favorite
Vance, Dylan

University of Kansas Medical Center
(P 214) SIGNIFICANT TREATMENT RESPONSE IN PATIENTS WITH PRIMARY RESECTABLE EXTREMITY MYXOID LIPOSARCOMA RECEIVING NEOADJUVANT TRABECTEDIN AND RADIATION
Dylan Vance
Favorite
(P 467) DOES PERIOPERATIVE RADIATION AFFECT IMPLANT SURVIVORSHIP OF PRIMARY TOTAL HIP ARTHROPLASTY IN THE SETTING OF METASTATIC BONE DISEASE: A MULTICENTER STUDY
Dylan Vance
Favorite
(P 468) OPIATE USE AFTER TOTAL HIP ARTHROPLASTY FOR METASTATIC BONE DISEASE
Dylan Vance
Favorite
Vance, Filipa

University of Bath,
(P 70) ICONIC (IMPROVING OUTCOMES THROUGH COLLABORATION IN OSTEOSARCOMA): A PROSPECTIVE OBSERVATIONAL COHORT STUDY FOR NEWLY DIAGNOSED OSTEOSARCOMA PATIENTS IN THE UNITED KINGDOM (UK)
Filipa Vance
Favorite
Vande Perre, Pierre

Oncopole Claudius Regaud
(P 201) PLEOMORPHIC RHABDOMYOSARCOMAS: A NEW ENTITY ASSOCIATED WITH LYNCH SYNDROME? FIRST RESULTS OF SARCLYNCH NATIONAL STUDY
Pierre Vande Perre
Favorite
Vanel, Daniel

Istituto Ortopedico Rizzoli
(P 355) FUSION TRANSCRIPTOME PROFILING DEFINES THE MONOCLONAL NATURE OF MULTIFOCAL EPITHELIOID HEMANGIOMA OF BONE
Daniel Vanel
Favorite
Vanleeuw, Ulla

Laboratory of Experimental Oncology, KU Leuven, Leuven Cancer Institute
(P 254) A COLLECTION OF PATIENT-DERIVED XENOGRAFT MODELS OF GASTROINTESTINAL STROMAL TUMORS
Ulla Vanleeuw
Favorite
(P 255) EPIDEMIOLOGY OF NOVEL ACTIONABLE TARGETS IN SYNOVIAL SARCOMA: A TISSUE MICRO-ARRAY STUDY
Ulla Vanleeuw
Favorite
(P 256) EFFICACY AND TOXICITY OF VERTEPORFIN IN COMBINATION WITH PAZOPANIB TESTED IN A PATIENT-DERIVED SYNOVIAL SARCOMA XENOGRAFT
Ulla Vanleeuw
Favorite
Vanni, Silvia

Istituto Romagnolo per lo studio dei Tumori "Dino Amadori" IRST IRCCS, Preclinic and Osteoncology Unit, Meldola, Italy
(P 37) DISSECTING THE ROLE OF EXTRACELLULAR VESICLES IN THE MANAGEMENT OF GIST
Silvia Vanni
Favorite
(P 253) THE EFFICACY OF MEDICATED PATCHES IN SOFT TISSUE SARCOMAS: IN-VITRO AND EX-VIVO VALIDATION.
Silvia Vanni
Favorite
(P 364) EVALUATION OF THE PREDICTIVE ROLE OF SYSTEMIC AND INTRATUMORAL IMMUNITY IN PATIENTS WITH LOCALIZED LIPOSARCOMAS, MYXOFIBROSARCOMAS AND UNDIFFERENTIATED PLEOMORPHIS SARCOMAS
Silvia Vanni
Favorite
(P 533) SAFETY AND PRELIMINARY BIOLOGICAL ACTIVITY OF A PHASE II TRIAL OF AUTOLOGOUS DENDRITIC CELLS VACCINATION IN SARCOMAS.
Silvia Vanni
Favorite
Vanzulli, Andrea

Università degli Studi di Milano
(P 14) PERCUTANEOUS CRYOABLATION OF PROGRESSING EXTRA-ABDOMINAL DESMOID TUMOURS
Andrea Vanzulli
Favorite
Varano, Veronica

Unit of Oncogenetics and Functional Oncogenomics, Centro di Riferimento Oncologico di Aviano IRCCS, Aviano, Italy
(P 378) MULTIOMICS PROFILING OF EPITHELIOID SARCOMA UNVEILS EPIGENETIC CIRCUITRIES THAT UNDERLIE THE PATHOBIOLOGY OF PROXIMAL AND CLASSIC SUBTYPES: RESULTS FROM THE ISG EPISOBS OBSERVATIONAL STUDY
Veronica Varano
Favorite
VARATHARAJAH, Sharmini

Institut François Baclesse
(P 521) HOW TO MANAGE ABDOMINAL PARIETECTOMY, REVIEW OF EXPERIENCE IN INSTITUT BERGONIE
Sharmini VARATHARAJAH
Favorite
Varga, Steven

St. Jude Children’s Research Hospital
(P 115) EFFICACY AND CORREALTIVE ANALYSIS OF USING NEOADJUVANT INTRATUMORAL HIGH DOSE TALIMOGENE LAHERPAREPVEC (TVEC) WITH CONCURRENT RADIATION IN HIGH-RISK EXTREMITY AND TRUNK SOFT-TISSUE SARCOMAS
Steven Varga
Favorite
vassal, Gilles

Gustave Roussy
(P 75) REAL-WORLD DATA ON REGORAFENIB AND CABOZANTINIB IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH RELAPSED OSTEOSARCOMA AND EWING SARCOMA INCLUDED IN THE SACHA-FRANCE STUDY
Gilles vassal
Favorite
(P 212) REPORT ON THE EWING SARCOMA PATIENTS ENROLLED IN ARM D OF THE ACSE-ESMART TRIAL: PHASE I/II STUDY OF THE PARP INHIBITOR OLAPARIB IN COMBINATION WITH IRINOTECAN IN CHILDREN WITH ADVANCED MALIGNANCIES
Gilles vassal
Favorite
Vats, Karan

University of Saskatchewan
(P 148) MOVING TOWARDS THE OPTIMIZATION OF DIAGNOSIS FOR PATIENTS WITH SARCOMA: A 10-YEAR REVIEW OF EXTERNALLY CONSULTED SARCOMA CASES IN A GENERAL ANATOMICAL PATHOLOGY SERVICE
Karan Vats
Favorite
Vauchelles, Romain

UMR CNRS 7021
(P 277) ANTI-GD2 SYNERGIZES WITH HYPOXIA PATHWAY TARGETING TO BLOCK OSTEOSARCOMA CELL PROLIFERATION AND MIGRATION.
Romain Vauchelles
Favorite
Veenhof, Xander

Netherlands Cancer Institute/ Antoni van Leeuwenhoek
(P 31) NEOADJUVANT IMATINIB IN LOCALLY ADVANCED GASTROINTESTINAL STROMAL TUMORS (GIST) IS EFFECTIVE AND SAFE: RESULTS FROM A PROSPECTIVE SINGLE CENTER STUDY WITH 108 PATIENTS
Xander Veenhof
Favorite
Vega Jimenez, Brayan

Istituto Ortopedico Rizzoli
(P 355) FUSION TRANSCRIPTOME PROFILING DEFINES THE MONOCLONAL NATURE OF MULTIFOCAL EPITHELIOID HEMANGIOMA OF BONE
Brayan Vega Jimenez
Favorite
Veit-Haibach, Patrick

University Health Network
(P 367) CHARACTERIZING HYPOXIA AND ASSOCIATED MOLECULAR FEATURES IN EXTREMITY SOFT TISSUE SARCOMA
Patrick Veit-Haibach
Favorite
Vekeman, Merlijn

Ghent University
(P 291) DEVELOPMENT OF A LIVE TISSUE SARCOMA BIOBANK TO SUPPORT THE CREATION OF PATIENT-DERIVED TRANSLATIONAL MODELS
Merlijn Vekeman
Favorite
(P 295) ORTHOTOPIC XENOGRAFTS OF PAIRED SARCOMA PRIMARY TUMOUR, LOCAL RELAPSE AND METASTATIC SITES REVEALS PHENOTYPIC HETEROGENEITY IN A MINIMAL RESIDUAL DISEASE MODEL
Merlijn Vekeman
Favorite
Venkataramany, Akila

Nationwide Children's Hospital / The Ohio State University College of Medicine
(P 94) DEVELOPING NOVEL OLIGONUCLEOTIDE THERAPIES TO MODULATE INSULIN RECEPTOR ALTERNATIVE SPLICING IN PEDIATRIC BONE SARCOMAS
Akila Venkataramany
Favorite
Venkataramany, Akila

Nationwide Children's Hospital
(P 305) A NEW MOUSE MODEL FOR TESTING SPLICE-SWITCHING THERAPIES IN RHABDOMYOSARCOMA
Akila Venkataramany
Favorite
Venkatramani, Rajkumar

Baylor College of Medicine / Texas Children's Hospital
(P 13) OUTCOME OF PATIENTS WITH RELAPSED OR REFRACTORY NON-RHABDOMYOSARCOMA SOFT TISSUE SARCOMAS ENROLLED IN PHASE II COOPERATIVE GROUP CLINICAL TRIALS: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP
Rajkumar Venkatramani
Favorite
Venkatramani, Rajkumar

Baylor College of Medicine
(P 165) MIDDLE EAR RHABDOMYOSARCOMA: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP
Rajkumar Venkatramani
Favorite
Venkatramani, Rajkumar

Baylor College of Medicine / Texas Children's Hospital
(P 409) IMMUNOHISTOCHEMICAL STAINING FOR MYOGENIN, AP2 BETA AND HMGA2 PREDICT FOXO1 FUSION STATUS IN RHABDOMYOSARCOMA: A REPORT FROM THE SOFT TISSUE COMMITTEE OF THE CHILDREN'S ONCOLOGY GROUP
Rajkumar Venkatramani
Favorite
(P 425) CHARACTERIZATION OF RHABDOMYOSARCOMA WITH PAX7::FOXO1 FUSIONS: A REPORT FROM THE SOFT TISSUE COMMITTEE OF THE CHILDREN'S ONCOLOGY GROUP
Rajkumar Venkatramani
Favorite
(P 438) ALVEOLAR RHABDOMYOSARCOMA WITH "BURKITT-LIKE" MORPHOLOGY IS ASSOCIATED WITH HIGH AMPLIFICATION OF MYCL
Rajkumar Venkatramani
Favorite
Vennam, Sujay

Stanford University
(P 376) MULTI-OMIC PROFILING OF LEIOMYOSARCOMA IDENTIFIES MARKERS PREDICTIVE OF RESPONSE TO GEMCITABINE AND DOCETAXEL
Sujay Vennam
Favorite
Verbeeck, Kimberly

Laboratory of Experimental Oncology, KU Leuven, Leuven Cancer Institute
(P 43) UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR-ASSOCIATED PROTEIN AS A POTENTIAL NEXT GENERATION MOLECULAR TARGET FOR TREATMENT OF GASTROINTESTINAL STROMAL TUMOR
Kimberly Verbeeck
Favorite
Verbeeck, Kimberly

KU Leuven
(P 254) A COLLECTION OF PATIENT-DERIVED XENOGRAFT MODELS OF GASTROINTESTINAL STROMAL TUMORS
Kimberly Verbeeck
Favorite
VERBEKE, Stephanie

Institut Bergonié
(P 300) ANTI-TUMOR ACTIVITY OF PARP7 INHIBITOR RBN-2397 IN SOFT-TISSUE SARCOMAS
Stephanie VERBEKE
Favorite
(P 418) GENOMIC AND IMMUNOLOGICAL PROFILING OF PRIMARY AND DISTANT METASTASES OF SOFT TISSUE SARCOMAS
Stephanie VERBEKE
Favorite
Verbus, Emily

Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health
(P 28) RETROSPECTIVE ANALYSIS OF SUCCINATE DEHYDROGENASE (SDH)-DEFICIENT GASTROINTESTINAL STROMAL TUMOR (GIST) OUTCOMES: AN INTERNATIONAL STUDY OF 256 PATIENTS
Emily Verbus
Favorite
Verges, Ramona

Hospital Val D'Hebron, Barcelona, Spain
(P 74) SACRAL CHORDOMA: A RANDOMIZED & OBSERVATIONAL STUDY ON SURGERY VS DEFINITIVE RADIOTHERAPY IN PRIMARY LOCALIZED DISEASE (SACRO). INTERIM ANALYSIS
Ramona Verges
Favorite
Verhey, Theodore

University of Calgary
(P 390) NOVEL ISOFORM DISCOVERY IN SARCOMA USING FULL-LENGTH PACBIO ISO-SEQ
Theodore Verhey
Favorite
(P 415) NEOADJUVANT RADIOTHERAPY MODULATES THE TUMOUR MICROENVIRONMENT OF UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Theodore Verhey
Favorite
Verhoef, Cornelis

Erasmus Medical Center
(P 231) MINIMALLY INTERACTIVE SEGMENTATION OF SOFT-TISSUE TUMORS ON MRI AND CT USING DEEP LEARNING
Cornelis Verhoef
Favorite
(P 233) MULTI-CENTER EXTERNAL VALIDATION OF AN AUTOMATED MODEL DIFFERENTIATING ALT FROM LIPOMA USING RADIOMICS AND DEEP-LEARNING BASED SEGMENTATION
Cornelis Verhoef
Favorite
(P 316) THE ROLE OF RADIOTHERAPY IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS: A MULTICENTER COHORT STUDY
Cornelis Verhoef
Favorite
(P 505) LOCAL RECURRENCE IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS: A MULTICENTER COHORT STUDY
Cornelis Verhoef
Favorite
(P 554) FIVE-YEAR OUTCOMES OF A NATIONWIDE PROSPECTIVE CLINICAL TRIAL ON ACTIVE SURVEILLENCE IN PATIENTS WITH NON-INTRAABDOMINAL DESMOID-TYPE FIBROMATOSIS
Cornelis Verhoef
Favorite
Vern-Gross, Tamara

Mayo Clinic
(P 320) A PROSPECTIVE MULTICENTER EXPERIENCE OF PROTON THERAPY FOR RHABDOMYOSARCOMA AND EWING SARCOMA: OUTCOMES FROM THE PROTON COLLABORATIVE GROUP REGISTRY
Tamara Vern-Gross
Favorite
Verret, Benjamin

Gustave Roussy
(P 49) EFFICACY OF RIPRETINIB IN A MULTICENTER EXPANDED ACCESS PROGRAM IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS HARBOURING NON-KIT EXON 11 MUTATIONS.
Benjamin Verret
Favorite
(P 201) PLEOMORPHIC RHABDOMYOSARCOMAS: A NEW ENTITY ASSOCIATED WITH LYNCH SYNDROME? FIRST RESULTS OF SARCLYNCH NATIONAL STUDY
Benjamin Verret
Favorite
Verstraete, Koenraad

University Hospital Ghent
(P 55) RELATIVE WASH-IN RATE ON DYNAMIC CONTRAST-ENHANCED MRI AS A NEW PROGNOSTIC FACTOR IN PATIENTS WITH OSTEOSARCOMA; A POSSIBLE TOOL FOR PERSONALIZED SARCOMA-CARE?
Koenraad Verstraete
Favorite
Verweij, Jaap

IDRx, Inc.
(P 26) PHASE 1 STUDY OF IDRX-42 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS RESISTANT TO PRIOR SYSTEMIC THERAPY: EARLY RESULTS
Jaap Verweij
Favorite
Vetto, John

OHSU
(P 341) A PHASE 1B STUDY TO EVALUATE PREOPERATIVE ERIBULIN IN COMBINATION WITH RADIATION IN RETROPERITONEAL SARCOMA
John Vetto
Favorite
Victor, Adrienne

University of Rochester
(P 223) SIGNATERA CTDNA TRACKER IN SARCOMA: CLINICAL EXPERIENCE
Adrienne Victor
Favorite
Vidal, María

Hospital Clínico San Carlos
(P 515) ENDOBRONCHIAL NAVIGATION AS AN INTRAOPERATORY TOOL FOR RESECTION OF SMALL PULMONARY METASTASES IN SARCOMA PATIENTS
María Vidal
Favorite
Vigna, Elisa

Department of Oncology, University of Turin
(P 109) INTENSE PRECLINICAL ACTIVITY BY B7H3-SPECIFIC CAR.CIK LYMPHOCYTES AGAINST EPITHELIOID SARCOMA
Elisa Vigna
Favorite
Vijayakumar, Gayathri

Rush University Medical Center
(P 63) EVALUATION OF LOCAL RECURRENCE AND DIAGNOSTIC DISCORDANCE IN CHONDROSARCOMA PATIENTS UNDERGOING PREOPERATIVE BIOPSY
Gayathri Vijayakumar
Favorite
(P 232) NOVEL MRI SCORING SYSTEM TO ASSESS OSSEOUS MALIGNANCY IN SOFT TISSUE SARCOMA PATIENTS FOLLOWING RADIOTHERAPY
Gayathri Vijayakumar
Favorite
(P 307) IS RADIOTHERAPY NECESSARY FOR MANAGEMENT OF LOW GRADE MYXOID LIPOSARCOMA? A SYSTEMATIC REVIEW
Gayathri Vijayakumar
Favorite
(P 377) EFFECTIVENESS OF INTERVENTIONAL RADIOLOGY GUIDED PROCEDURES FOR LOCALLY RECURRENT AND METASTATIC SARCOMA: SINGLE INSTITUTIONAL RESULTS
Gayathri Vijayakumar
Favorite
(P 467) DOES PERIOPERATIVE RADIATION AFFECT IMPLANT SURVIVORSHIP OF PRIMARY TOTAL HIP ARTHROPLASTY IN THE SETTING OF METASTATIC BONE DISEASE: A MULTICENTER STUDY
Gayathri Vijayakumar
Favorite
(P 468) OPIATE USE AFTER TOTAL HIP ARTHROPLASTY FOR METASTATIC BONE DISEASE
Gayathri Vijayakumar
Favorite
(P 506) THE EFFECT OF TIMING BETWEEN PRE-OPERATIVE EMBOLIZATION AND SURGERY: A RETROSPECTIVE ANALYSIS OF HYPERVASCULAR BONE METASTASES
Gayathri Vijayakumar
Favorite
Vila Capel, Antonio

Hospital de la Santa Creu i Sant Pau
(P 313) SPACIALLY-FRACTIONATED RADIOTHERAPY (LATTICE) TREATMENT IN INOPERABLE NON-EXTREMITY BULKY SOFT-TISSUE SARCOMAS
Antonio Vila Capel
Favorite
(P 503) SCAPULAR PROSTHESIS RECONSTRUCTION, EXPERIENCE IN OUR INSTITUTION
Antonio Vila Capel
Favorite
(P 504) WHY DO SOME PATIENTS WITH SYNOVIAL SARCOMA HAVE BETTER FUNCTIONAL OUTCOMES AFTER RESECTION SURGERY? ANALYSIS OF 102 CASES
Antonio Vila Capel
Favorite
(P 507) PRIMARY CHEST WALL TUMORS OF MESENCHYMAL ORIGIN. EXPERIENCE OF A REFERENCE UNIT
Antonio Vila Capel
Favorite
(P 508) DREAM, UTOPIA OR REALISM? PROGNOSTIC FACTORS IN LUNG METASTASECTOMY OF DISSEMINATED SARCOMA DISEASE
Antonio Vila Capel
Favorite
Villani, Anita

The Hospital for Sick Children
(P 50) CHARACTERIZATION OF A FAMILIAL GIST KINDRED INTOLERANT TO IMATINIB
Anita Villani
Favorite
Villano, Anthony

Fox Chase Cancer Center
(P 152) EVALUATING DIAGNOSTIC APPROACHES TO DERMATOFIBROSARCOMA PROTUBERANS: AN OPPORTUNITY TO REDUCE THE NUMBER OF INTERVENTIONS
Anthony Villano
Favorite
Villar Vázquez, Ana

Hospital Clinico san Carlos
(P 149) PSYCOLOGICAL SNAPSHOT OF SARCOMA PATIENTS FROM AN ACADEMIC, UNIVERSITY CENTER, HOSPITAL CLÍNICO SAN CARLOS (HCSC), MADRID, A SARCOMA NATIONAL REFERRAL CENTRE IN SPAIN
Ana Villar Vázquez
Favorite
Villarejo-Campos, Pedro

Department of Surgery, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.
(P 385) FIRST IN HUMAN PHASE I TRIAL OF A NOVEL DRUG DELIVERY IMPLANT MATRIX WITH SN-38 (CEB-01) FOR RETROPERITONEAL SOFT TISSUE SARCOMA
Pedro Villarejo-Campos
Favorite
Villaroel, Milena

Grupo Latinoamericano Oncología Pediátrica
(P 69) DEVELOPMENT AND MISSION OF THE HARMONIZATION INTERNATIONAL BONE SARCOMA CONSORTIUM (HIBISCUS)
Milena Villaroel
Favorite
Viloria-Petit, Alicia

University of Guelph
(P 304) A COMPARATIVE ANALYSIS OF METABOLIC FLEXIBILITY IN OSTEOSARCOMA CELLS
Alicia Viloria-Petit
Favorite
Vincenzi, Bruno

Fondazione Policlinico Universitario Campus Bio-Medico
(P 27) A MULTICENTER RETROSPECTIVE STUDY ON THE CLINICAL BEHAVIOR OF SDH-DEFICIENT GIST
Bruno Vincenzi
Favorite
(P 49) EFFICACY OF RIPRETINIB IN A MULTICENTER EXPANDED ACCESS PROGRAM IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS HARBOURING NON-KIT EXON 11 MUTATIONS.
Bruno Vincenzi
Favorite
(P 135) UNMET NEEDS IN LOCALLY ADVANCED (UNRESECTABLE) OR METASTATIC DEDIFFERENTIATED LIPOSARCOMA AND EXPECTATIONS FOR CLINICAL TRIALS: AN INTERNATIONAL DELPHI CONSENSUS STUDY
Bruno Vincenzi
Favorite
(P 159) IN BETWEEN OF LYMPHOMAS AND SARCOMAS: WHERE DO HISTIOCYTIC AND DENDRITIC CELL NEOPLASMS (HDCN) STAND? A RETROSPECTIVE, MULTI-INSTITUTIONAL STUDY FROM THE ITALIAN SARCOMA GROUP (ISG)
Bruno Vincenzi
Favorite
(P 263) HER2 AS A POTENTIAL NOVEL THERAPEUTIC TARGET IN SOFT TISSUE SARCOMAS
Bruno Vincenzi
Favorite
(P 264) CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS AND TRABECTEDIN IN SOFT TISSUE SARCOMA: A NOVEL POTENTIAL SYNERGY?
Bruno Vincenzi
Favorite
Vincenzi, Bruno

Università Campus Biomedico di Roma, Roma, Italy
(P 378) MULTIOMICS PROFILING OF EPITHELIOID SARCOMA UNVEILS EPIGENETIC CIRCUITRIES THAT UNDERLIE THE PATHOBIOLOGY OF PROXIMAL AND CLASSIC SUBTYPES: RESULTS FROM THE ISG EPISOBS OBSERVATIONAL STUDY
Bruno Vincenzi
Favorite
(P 437) ULTRA-RARE UNDIFFERENTIATED SMALL ROUND CELL SARCOMA: HOW SHOULD WE TREAT THEM? AN ANALYSIS FORM THE GRACEFUL PROJECT
Bruno Vincenzi
Favorite
Vindrola, Cecilia

UCL
(P 147) UNDERSTANDING THE EXPERIENCES OF PATIENTS RETURNING TO DAILY ACTIVITES AND EXERCISE FOLLOWING LIMB SPARING SURGERY FOR BONE OR SOFT TISSUE SARCOMA AROUND THE KNEE
Cecilia Vindrola
Favorite
Visgauss, Julia

Duke University
(P 72) CO-EXPRESSION OF LEUKOCYTE CYTOSOLIC PROTEIN 1 AND MATRIX METALLOPROTEINASES ARE INTEGRAL FOR METASTATIC PROGRESSION OF CHONDROSARCOMA
Julia Visgauss
Favorite
(P 137) IMPACT OF SOCIAL DETERMINANTS OF HEALTH ON SARCOMA CARE: A SINGLE INSTITUTION EXPERIENCE
Julia Visgauss
Favorite
(P 299) EXPLORING THE IMMUNOLIGHT MECHANISM OF ACTION IN A GENETICALLY ENGINEERED MOUSE MODEL OF SOFT TISSUE SARCOMA
Julia Visgauss
Favorite
(P 509) GIANT CELL TUMOR OF BONE IN THE PEDIATRIC POPULATION: A RETROSPECTIVE STUDY HIGHLIGHTING CASES OF METAPHYSEAL ONLY LOCATION AND INCREASED LOCAL RECURRENCE RATES IN SKELETALLY IMMATURE PATIENTS
Julia Visgauss
Favorite
Vishwakarma, Vikalp

KUMC
(P 446) SYNERGISTIC TARGETING OF KIF11 AND AURKA TO IMPROVE OUTCOMES FOR EWING SARCOMA
Vikalp Vishwakarma
Favorite
Visser, Jacob

Erasmus Medical Center
(P 231) MINIMALLY INTERACTIVE SEGMENTATION OF SOFT-TISSUE TUMORS ON MRI AND CT USING DEEP LEARNING
Jacob Visser
Favorite
(P 233) MULTI-CENTER EXTERNAL VALIDATION OF AN AUTOMATED MODEL DIFFERENTIATING ALT FROM LIPOMA USING RADIOMICS AND DEEP-LEARNING BASED SEGMENTATION
Jacob Visser
Favorite
Vitali, Letizia

Department of Oncology, University of Turin
(P 109) INTENSE PRECLINICAL ACTIVITY BY B7H3-SPECIFIC CAR.CIK LYMPHOCYTES AGAINST EPITHELIOID SARCOMA
Letizia Vitali
Favorite
Vitellaro, Marco

Department of Surgery, Hereditary Digestive Tract Tumors Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
(P 333) SYSTEMIC TREATMENT IN INTRA-ABDOMINAL DESMOID-TYPE FIBROMATOSIS: A SINGLE INSTITUTION RETROSPECTIVE CASE SERIES ANALYSIS
Marco Vitellaro
Favorite
Viveiros, Pedro

Northwestern University
(P 180) HEALTH RELATED QUALITY OF LIFE OF PATIENTS WITH ADVANCED LEIOMYOSARCOMA AND OTHER SOFT TISSUE SARCOMAS TREATED WITH CABOZANTINIB AND TEMOZOLOMIDE
Pedro Viveiros
Favorite
(P 219) ELECTIVE DISCONTINUATION OF SORAFENIB TREATMENT IN DESMOID TUMORS: A RETROSPECTIVE ANALYSIS WITH IMPLICATIONS FOR CLINICAL PRACTICE
Pedro Viveiros
Favorite
Vizzaccaro, Salvatore

Oncology 1 Unit, Department of Oncology, Veneto Institute of Oncology IOV - IRCCS
(P 144) IMPLEMENTATION OF THE EUROPEAN CLINICAL TRIAL REGULATION: SURVEY OF THE ITALIAN SARCOMA GROUP CENTERS
Salvatore Vizzaccaro
Favorite
(P 171) SEX DIFFERENCES IN OUTCOMES AND TOXICITY IN PATIENTS TREATED FOR SARCOMA IN A REFERENCE CENTER
Salvatore Vizzaccaro
Favorite
(P 216) BRAIN METASTASES IN SARCOMA: A (NOT SO) RARE EVENT. THE EXPERIENCE OF A HIGH VOLUME CENTER
Salvatore Vizzaccaro
Favorite
Vodák, Daniel

Oslo University Hospital
(P 23) GENOMIC COMPLEXITY AS A BIOMARKER FOR ADJUVANT IMATINIB TREATMENT IN HIGH-RISK GASTROINTESTINAL STROMAL TUMOR
Daniel Vodák
Favorite
Vo, Kenny

David Geffen School of Medicine, University of California, Los Angeles
(P 19) EXTRACELLULAR VESICLE CLICK MAGBEADS: A MULTIFACETED LIQUID BIOPSY PLATFORM FOR PEDIATRIC SARCOMAS
Kenny Vo
Favorite
Volante, Marco

Department of Oncology, University of Turin
(P 262) ESTABLISHMENT AND CHARACTERIZATION OF THE FIRST RADIATION-INDUCED, PATIENT-DERIVED ANGIOSARCOMA CELL LINE
Marco Volante
Favorite
Volchenboum, Samuel

University of Chicago
(P 69) DEVELOPMENT AND MISSION OF THE HARMONIZATION INTERNATIONAL BONE SARCOMA CONSORTIUM (HIBISCUS)
Samuel Volchenboum
Favorite
Volden, Roger

Pacific Biosciences
(P 390) NOVEL ISOFORM DISCOVERY IN SARCOMA USING FULL-LENGTH PACBIO ISO-SEQ
Roger Volden
Favorite
Volpin, Francesco

Neurosurgery Unit, Azienda Ospedale-Università di Padova, 35128 Padova, Italy.
(P 216) BRAIN METASTASES IN SARCOMA: A (NOT SO) RARE EVENT. THE EXPERIENCE OF A HIGH VOLUME CENTER
Francesco Volpin
Favorite
von Mehren, Margaret

Fox Chase Cancer Center
(P 26) PHASE 1 STUDY OF IDRX-42 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS RESISTANT TO PRIOR SYSTEMIC THERAPY: EARLY RESULTS
Margaret von Mehren
Favorite
(P 152) EVALUATING DIAGNOSTIC APPROACHES TO DERMATOFIBROSARCOMA PROTUBERANS: AN OPPORTUNITY TO REDUCE THE NUMBER OF INTERVENTIONS
Margaret von Mehren
Favorite
(P 287) ESTABLISHMENT AND GENOMIC VALIDATION OF NOVEL PATIENT-DERIVED XENOGRAFT MODELS FOR DRUG DISCOVERY IN GASTROINTESTINAL STROMAL TUMOR
Margaret von Mehren
Favorite
(P 361) MOLECULAR CHARACTERIZATION OF SOLITARY FIBROUS TUMORS BY ANATOMIC SITE AND NAB2::STAT6 FUSION VARIANT TYPE
Margaret von Mehren
Favorite
(P 401) OVEREXPRESSION OF CYCLIN DEPENDENT KINASES AND CYCLINS ACROSS SARCOMAS BEYOND CDK4
Margaret von Mehren
Favorite
Von Werne, Katherine

Miami Cancer Institute
(P 320) A PROSPECTIVE MULTICENTER EXPERIENCE OF PROTON THERAPY FOR RHABDOMYOSARCOMA AND EWING SARCOMA: OUTCOMES FROM THE PROTON COLLABORATIVE GROUP REGISTRY
Katherine Von Werne
Favorite
Vornicova, Olga

BC Cancer Victoria
(P 260) TARGETING HOMOLOGOUS RECOMBINATION DEFICIENCY (HRD) IN LEIOMYOSARCOMA WITH COMBINATION OF PARP INHIBITORS (PARPI) AND CHEMOTHERAPY (CTX).
Olga Vornicova
Favorite
Voropaeva, Marina

BostonGene, Corp.
(P 420) COMPREHENSIVE MOLECULAR PROFILING AND TUMOR MICROENVIRONMENT CHARACTERISTICS OF RADIATION-INDUCED SARCOMA.
Marina Voropaeva
Favorite
Voss, Molly

Mayo Clinic Arizona
(P 312) MANAGEMENT OF ADULT HEAD AND NECK SOFT TISSUE SARCOMA: THE MAYO CLINIC EXPERIENCE
Molly Voss
Favorite
Vranceanu, Florin

Takeda Development Center Americas
(P 558) TRIAL IN PROGRESS: A PHASE 1/2 STUDY OF BRIGATINIB IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH ALK POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA OR INFLAMMATORY MYOFIBROBLASTIC TUMORS (ITCC-098)
Florin Vranceanu
Favorite
W
Wągrodzki, Michał

Department of Pathology and Laboratory Diagnostics, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.
(P 09) A NOMOGRAM MODEL TO PREDICT THE OVERALL SURVIVAL OF ADOLESCENT AND YOUNG ADULT PATIENTS WITH LOCALLY ADVANCED EWING SARCOMA.
Michał Wągrodzki
Favorite
(P 545) NEOADJUVANT PEMBROLIZUMAB AND EFTILAGIMOD ALPHA WITH CONCURRENT RADIOTHERAPY IN PATIENTS WITH SELECTED SOFT TISSUE SARCOMA SUBTYPES (EFTISARC-NEO)
Michał Wągrodzki
Favorite
Wachter, Franziska

Dana-Farber Cancer Institute
(P 384) SYSTEMATIC LITERATURE AND CLINICAL TRIAL REVIEW SHOWS TARGETABLE KINASE FUSIONS ARE COMMON IN PEDIATRIC, ADOLESCENT, AND YOUNG ADULT SOFT TISSUE SARCOMAS BUT CLINICAL TRIAL OPPORTUNITIES REMAIN RARE
Franziska Wachter
Favorite
Wagner, Andrew

Dana-Farber Cancer Institute
(P 173) SAFETY, EFFICACY, AND PATIENT-REPORTED OUTCOMES WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED PRIOR ANTI–COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 UPDATE
Andrew Wagner
Favorite
(P 176) SAFETY, EFFICACY, AND PATIENT-REPORTED OUTCOMES WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED NO PRIOR ANTI–COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 UPDATE
Andrew Wagner
Favorite
(P 189) INTERNATIONAL RETROSPECTIVE STUDY FROM THE ULTRA-RARE SARCOMA WORKING GROUP ON LOW-GRADE FIBROMYXOID SARCOMA AND SCLEROSING EPITHELIOD FIBROSARCOMA: OUTCOME OF ADVANCED DISEASE AND SYSTEMIC THERAPIES
Andrew Wagner
Favorite
Wagner, Elizabeth

Nationwide Children's Hospital
(P 425) CHARACTERIZATION OF RHABDOMYOSARCOMA WITH PAX7::FOXO1 FUSIONS: A REPORT FROM THE SOFT TISSUE COMMITTEE OF THE CHILDREN'S ONCOLOGY GROUP
Elizabeth Wagner
Favorite
Wagner, Lars

Duke Children's Hospital
(P 537) TGFβ IMPRINTED, EX VIVO EXPANDED UNIVERSAL DONOR NATURAL KILLER CELLS WITH CHEMOTHERAPY FOR RELAPSED BONE AND SOFT TISSUE SARCOMA - NCT05634369, REPORT FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION
Lars Wagner
Favorite
(P 551) PHASE II TRIAL OF GEMCITABINE AND NAB-PACLITAXEL IN PATIENTS WITH RECURRENT RHABDOMYOSARCOMA: A CLINICAL TRIAL IN PROGRESS FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION
Lars Wagner
Favorite
Wagner, Michael

Dana Farber Cancer Institute
(P 67) GENOMIC CHARACTERIZATION OF CHONDROSARCOMA: A RARE SARCOMA WITH CLINICAL RESPONSES TO IMMUNE CHECKPOINT INHIBITION
Michael Wagner
Favorite
Wagner, Michael

University of Washington/Fred Hutch/Seattle Cancer Care Alliance
(P 135) UNMET NEEDS IN LOCALLY ADVANCED (UNRESECTABLE) OR METASTATIC DEDIFFERENTIATED LIPOSARCOMA AND EXPECTATIONS FOR CLINICAL TRIALS: AN INTERNATIONAL DELPHI CONSENSUS STUDY
Michael Wagner
Favorite
Wagner, Michael

Dana Farber Cancer Institute
(P 177) ANGIOSARCOMA: AN INCREASING PROBLEM IN THE UNITED STATES
Michael Wagner
Favorite
Wagner, Michael

University of Washington/Fred Hutch/Seattle Cancer Care Alliance
(P 206) A SINGLE-ARM, PHASE II STUDY OF NEOADJUVANT PEMBROLIZUMAB COMBINED WITH RADIOTHERAPY IN THE PRIMARY TREATMENT OF SOFT TISSUE SARCOMAS.
Michael Wagner
Favorite
(P 207) A MULTICENTER PHASE II STUDY OF CABOZANTINIB PLUS NIVOLUMAB FOR PATIENTS WITH ADVANCED ANGIOSARCOMA PREVIOUSLY TREATED WITH A TAXANE: ALLIANCE A091902
Michael Wagner
Favorite
Wagner, Michael J

Clinical Research Division, Fred Hutchinson Cancer Center, University of Washington
(P 543) MANEUVER STUDY: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF PIMICOTINIB (ABSK021) TO ASSESS THE EFFICACY AND SAFETY IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR
Michael J Wagner
Favorite
Wagrodzki, Michal

Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
(P 21) YOUNG ADULTS WITH NONMETASTATIC OPERABLE OSTEOSARCOMA TREATED PERIOPERATIVELY WITH METHOTREXATE, DOXORUBICIN AND CISPLATIN SCHEDULE, SINGLE INSTITUTION REPORT
Michal Wagrodzki
Favorite
Wagrodzki, Michal

Maria Sklodowska-Curie National Research Institute of Pathology, Warsaw Poland
(P 162) LONG TERM SAFETY AND EFFICACY OF COMBINED DOXORUBICIN-IFOSFAMIDE CHEMOTHERAPY WITH PREOPERATIVE HYPOFRACTIONATED RADIOTHERAPY IN MARGINALLY RESECTABLE SOFT TISSUE SARCOMAS
Michal Wagrodzki
Favorite
(P 222) EXPLORING THE IMPACT OF NGS ON DIAGNOSTICS AND TREATMENT OF SARCOMA: INSIGHTS FROM REAL-WORLD DATA ACROSS MULTIPLE INSTITUTIONS IN EUROPE
Michal Wagrodzki
Favorite
(P 310) PREOPERATIVE RADIOTHERAPY WITH HYPERTHERMIA IN RECURRENT AND RADIATION-INDUCED SARCOMAS: RESULTS OF A PHASE 2 CLINICAL TRIAL
Michal Wagrodzki
Favorite
Waissi, Waisse

CENTRE LEON BERARD AND CANCER RESEARCH CENTER OF LYON (INSERM U1052-CNRS5286)
(P 382) NTRK1/2/3 FUSIONS DETECTION USING RNA-SEQ IN MESENCHYMAL TUMORS REVEALS ULTRA-RARE AND HISTO-SPECIFIC TARGETABLE ALTERATIONS: EXPERIENCE OF AN EXTENSIVE ROUTINE RESEARCH PROGRAM.
Waisse Waissi
Favorite
(P 435) ONCOGENIC FUSION YWHAE::NUTM2 DISRUPT EP300/BCOR INTERACTION
Waisse Waissi
Favorite
Walker, Robert L.

University of miami
(P 280) A CELL-BASED COMPOUND SCREENING IDENTIFIES AGENTS THAT SYNERGIZE WITH EVEROLIMUS IN SARCOMA
Robert L. Walker
Favorite
Wallace, Asjah

Duke University
(P 375) IDENTIFICATION OF METASTATIC CELLS IN UNDIFFERENTIATED PLEOMORPHIC SARCOMA: SINGLE CELL RNA SEQUENCING AND CIBERSORT ANALYSIS
Asjah Wallace
Favorite
(P 393) INVESTIGATING THE ROLE OF HDACS IN THE PROGRESSION OF METASTATIC UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Asjah Wallace
Favorite
Wallander, Karin

Karolinska Institutet
(P 230) SARCDBASE: A TOOL FOR DETECTION OF GENETIC ALTERATIONS IN SARCOMA
Karin Wallander
Favorite
(P 243) EVALUATION OF THE USE OF WGS IN ROUTINE DIAGNOSTICS FOR BONE AND SOFT TISSUE TUMORS
Karin Wallander
Favorite
Walling, Emily

University of Michigan, Department of Pediatric Hematology/Oncology
(P 07) IDENTIFYING CONCERNS OF ADOLESCENT AND YOUNG ADULT SARCOMA PATIENTS AND SURVIVORS FOLLOWING FERTIITY PRESERVATION
Emily Walling
Favorite
Walters, Ian

Intensity Therapeutics
(P 164) INTRATUMORAL INT230-6 (CISPLATIN, VINBLASTINE, SHAO) ALONE OR WITH IPILIMUMAB PROLONGED SURVIVAL WITH FAVORABLE SAFETY AND IMMUNE ACTIVATION IN ADULTS WITH REFRACTORY SARCOMAS (NCT 03058289)
Ian Walters
Favorite
Waltner, Olivia

Fred Hutchinson Cancer Center
(P 448) CAF-LIKE EWING SARCOMA CELLS DEPOSIT PRO-TUMORIGENIC EXTRACELLULAR MATRIX IN RESPONSE TO TGF-BETA SIGNALING
Olivia Waltner
Favorite
Wang, Baogui

Department of Gastric Surgery, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer; Tianjin Key Laboratory of Digestive Cancer, Tianjin; Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, P. R. China
(P 42) THE EFFICACY AND SAFETY OF RIPRETINIB IN THE TREATMENT OF CHINESE PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS (GISTS): A SINGLE-INSTITUTION ANALYSIS
Baogui Wang
Favorite
Wang, Bingwu

Department of Spine Surgery, Weifang People's Hospital
(P 543) MANEUVER STUDY: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF PIMICOTINIB (ABSK021) TO ASSESS THE EFFICACY AND SAFETY IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR
Bingwu Wang
Favorite
Wang, Chao-Chi

Laboratory of Experimental Oncology, KU Leuven, Leuven Cancer Institute
(P 43) UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR-ASSOCIATED PROTEIN AS A POTENTIAL NEXT GENERATION MOLECULAR TARGET FOR TREATMENT OF GASTROINTESTINAL STROMAL TUMOR
Chao-Chi Wang
Favorite
(P 254) A COLLECTION OF PATIENT-DERIVED XENOGRAFT MODELS OF GASTROINTESTINAL STROMAL TUMORS
Chao-Chi Wang
Favorite
(P 349) THE UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR-ASSOCIATED PROTEIN (UPARAP) IS AN ATTRACTIVE TARGET FOR THE DEVELOPMENT OF ANTIBODY DRUG CONJUGATES FOR TREATMENT OF MESENCHYMAL MALIGNANCIES
Chao-Chi Wang
Favorite
Wang, Dian

Rush University Medical Center
(P 307) IS RADIOTHERAPY NECESSARY FOR MANAGEMENT OF LOW GRADE MYXOID LIPOSARCOMA? A SYSTEMATIC REVIEW
Dian Wang
Favorite
Wang, Guocan

Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
(P 256) EFFICACY AND TOXICITY OF VERTEPORFIN IN COMBINATION WITH PAZOPANIB TESTED IN A PATIENT-DERIVED SYNOVIAL SARCOMA XENOGRAFT
Guocan Wang
Favorite
Wang, Han

Peking University People's Hospital
(P 464) INDOCYANINE GREEN FLUORESCENCE IMAGING MAY DETECT TUMOUR RESIDUALS DURING SURGERY FOR BONE AND SOFT-TISSUE TUMOURS
Han Wang
Favorite
Wang, Jing

Department of Sport Surgery and Sport Medicine, Hunan Provincial People's Hospital
(P 543) MANEUVER STUDY: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF PIMICOTINIB (ABSK021) TO ASSESS THE EFFICACY AND SAFETY IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR
Jing Wang
Favorite
Wang, Jiongyuan

Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China
(P 339) QUALITY OF SURGERY AND OUTCOME FOR GIANT RETROPERITONEAL LIPOSARCOMA TREATED WITHIN SEMI-ABDOMINAL EN BLOC RESECTION USING VASCULAR PRIORITY CENTRAL APPROACH-A RETROSPECTIVE COHORT
Jiongyuan Wang
Favorite
(P 398) INTEGRATED MULTI-OMICS APPROACH REVEALED TUMOR-ASSOCIATED TERTIARY LYMPHOID STRUCTURE LANDSCAPE IN RETROPERITONEAL LIPOSARCOMA
Jiongyuan Wang
Favorite
Wang, Liang

Moffitt Cancer Center & Research Institute
(P 269) PLASMA DNA METHYLATION-BASED BIOMARKERS FOR MPNST DETECTION IN PATIENTS WITH NEUROFIBROMATOSIS TYPE 1 (NF1)
Liang Wang
Favorite
wang, ming

Department of Gastrointestinal Surgery, Renji Hospital, Shanghai Jiaotong University School of Medicine
(P 39) MANAGEMENT PRACTICES OF GASTROINTESTINAL STROMAL TUMORS: A QUESTIONNAIRE SURVEY OF GENERAL SURGEONS IN CHINA
ming wang
Favorite
Wang, Patrick Qi

University of Toronto
(P 443) SURGICAL RESECTION OF EXTREMITY EWING'S SARCOMA BASED ON POST-CHEMOTHERAPY TUMOUR VOLUME RESULTS IN SAFE MARGINS
Patrick Qi Wang
Favorite
(P 484) OBESITY INCREASES THE RISK OF MAJOR WOUND COMPLICATIONS FOLLOWING PELVIC RESECTION FOR BONE SARCOMA
Patrick Qi Wang
Favorite
Wang, Pin-Yi

Nationwide Children's Hospital
(P 94) DEVELOPING NOVEL OLIGONUCLEOTIDE THERAPIES TO MODULATE INSULIN RECEPTOR ALTERNATIVE SPLICING IN PEDIATRIC BONE SARCOMAS
Pin-Yi Wang
Favorite
(P 107) TRABECTEDIN AUGMENTS ONCOLYTIC HERPES SIMPLEX VIROIMMUNOTHERAPY EFFICACY IN PRECLINCAL BONE SARCOMA MODELS THROUGH ENHANCED IMMUNE-MEDIATED MECHANISMS
Pin-Yi Wang
Favorite
(P 125) MYELOMODULATORY TREATMENTS AUGMENT THE THERAPEUTIC BENEFIT OF ONCOLYTIC VIRUS IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS BY MODULATING THE TUMOR MICROENVIRONMENT
Pin-Yi Wang
Favorite
Wang, Shufeng

First Affiliated Hospital Xi'an Jiaotong University
(P 534) NEOADJUVANT CHEMOTHERAPY COMBINED WITH TARGETED TREATMENT IN HIGH-RISK RETROPERITONEAL SARCOMA – A PROSPECTIVE NON-RANDOMIZED CONTROLLED MULTI-CENTERED STUDY ALL ACROSS CHINA
Shufeng Wang
Favorite
Wangsiricharoen, Sintawat

The University of Texas MD Anderson Cancer Center
(P 198) PERSONALIZED MULTIDISCIPLINARY MANAGEMENT OF SARCOMA IN PATIENTS WITH LYNCH SYNDROME
Sintawat Wangsiricharoen
Favorite
wang, tao

Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
(P 39) MANAGEMENT PRACTICES OF GASTROINTESTINAL STROMAL TUMORS: A QUESTIONNAIRE SURVEY OF GENERAL SURGEONS IN CHINA
tao wang
Favorite
Wang, Wei-Lien

The University of Texas MD Anderson Cancer Center
(P 36) CLINICO-GENOMIC ANALYSIS OF KIT/PDGFRA/SDH WILD-TYPE GASTROINTESTINAL STROMAL TUMORS IDENTIFIES POTENTIAL DRIVER MUTATIONS
Wei-Lien Wang
Favorite
(P 71) CHEMOTHERAPY AND PROGNOSTIC SIGNIFICANCE OF EXTENT OF DEDIFFERENTIATION IN DEDIFFERENTIATED PAROSTEAL OSTEOSARCOMA
Wei-Lien Wang
Favorite
(P 83) CLINICO-GENOMIC PROFILING OF CONVENTIONAL AND DEDIFFERENTIATED CHONDROSARCOMAS REVEALS TP53 MUTATION TO BE ASSOCIATED WITH WORSE OUTCOMES
Wei-Lien Wang
Favorite
(P 100) HISTOLOGY SPECIFIC INTRATUMORAL B-CELL BIOLOGY IN ALVEOLAR SOFT-PART SARCOMAS (ASPS) IN RESPONSE TO DURVALUMAB-TREMELIMUMAB (D-T)
Wei-Lien Wang
Favorite
(P 354) ROLE OF APPARENT DIFFUSION COEFFICIENT (ADC) MAP-BASED FIRST AND HIGH-ORDER RADIOMIC FEATURES IN DISCRIMINATING SACRAL CHORDOMAS AND CHONDROSARCOMAS WITH OVERLAPPING CONVENTIONAL IMAGING FEATURES
Wei-Lien Wang
Favorite
(P 360) TP53 ALTERATIONS IN SARCOMAS: AN ANALYSIS FROM THE AACR-GENIE DATABASE
Wei-Lien Wang
Favorite
Wang, Xiaona

Department of Gastric Surgery,Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer; Tianjin Key Laboratory of Digestive Cancer, Tianjin; Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, P. R. China
(P 42) THE EFFICACY AND SAFETY OF RIPRETINIB IN THE TREATMENT OF CHINESE PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS (GISTS): A SINGLE-INSTITUTION ANALYSIS
Xiaona Wang
Favorite
Wang, Xue

University of British Columbia
(P 267) NEW MOUSE MODEL OF SYNOVIAL SARCOMA BASED ON CONDITIONAL EXPRESSION IN MESENCHYMAL PROGENITORS
Xue Wang
Favorite
Wang, Yifei

UT MD Anderson Cancer Center
(P 89) GENERATION OF CHONDROCYTE-DERIVED MOUSE OSTEOSARCOMA MODELS - TRACKABLE SYSTEMS TO DELINEATE ONCOGENIC AND METASTATIC ENVENTS PRIOR TO TUMOROGENESIS
Yifei Wang
Favorite
(P 122) TARGETING CD70 USING CAR NK CELLS TO ENHANCE NK CELLS CYTOLYTIC EFFECT AGAINST OSTEOSARCOMA
Yifei Wang
Favorite
(P 203) PRECLINICAL EVALUATION AMG 650, A SMALL MOLECULE INHIBITOR OF KIF18A, IN PEDIATRIC SOLID TUMORS BY THE PEDIATRIC PRECLINICAL IN VIVO TESTING (PIVOT) PROGRAM
Yifei Wang
Favorite
Wang, Zhenyu

School of Medicine, Anhui University of Science and Technology, Huainan, China
(P 339) QUALITY OF SURGERY AND OUTCOME FOR GIANT RETROPERITONEAL LIPOSARCOMA TREATED WITHIN SEMI-ABDOMINAL EN BLOC RESECTION USING VASCULAR PRIORITY CENTRAL APPROACH-A RETROSPECTIVE COHORT
Zhenyu Wang
Favorite
(P 398) INTEGRATED MULTI-OMICS APPROACH REVEALED TUMOR-ASSOCIATED TERTIARY LYMPHOID STRUCTURE LANDSCAPE IN RETROPERITONEAL LIPOSARCOMA
Zhenyu Wang
Favorite
Wani, Khalida

MD Anderson Cancer Center
(P 100) HISTOLOGY SPECIFIC INTRATUMORAL B-CELL BIOLOGY IN ALVEOLAR SOFT-PART SARCOMAS (ASPS) IN RESPONSE TO DURVALUMAB-TREMELIMUMAB (D-T)
Khalida Wani
Favorite
Wani, Khalida

The University of Texas MD Anderson Cancer Center
(P 198) PERSONALIZED MULTIDISCIPLINARY MANAGEMENT OF SARCOMA IN PATIENTS WITH LYNCH SYNDROME
Khalida Wani
Favorite
(P 405) PRIMARY CARDIAC ANGIOSARCOMA- GENOMIC AND MOLECULAR LANDSCAPE
Khalida Wani
Favorite
Wan, Jessica

Foghorn Therapeutics
(P 271) PHARMACODYNAMICS AND MECHANISTIC IMPACTS OF FHD-609, A BROMODOMAIN-CONTAINING PROTEIN 9 DEGRADER, IN A PHASE 1 STUDY IN PATIENTS WITH ADVANCED SYNOVIAL SARCOMA OR SMARCB1-LOSS TUMORS
Jessica Wan
Favorite
Wardelmann, Eva

Institute of Pathology,.University Hospital Muenster
(P 12) MULTIFOCAL AND DISSEMINATED SPORADIC DESMOID TUMOUR OF THE EXTREMITIES: A SPECIAL CHALLENGE
Eva Wardelmann
Favorite
(P 138) CONTROVERSIES IN THE MANAGEMENT OF PATIENTS WITH SOFT TISSUE SARCOMA: RESULTS AND RECOMMENDATIONS FROM THE FIRST CONFERENCE ON STATE OF SCIENCE IN SARCOMA (CSSS)
Eva Wardelmann
Favorite
Warren, Mikako

Children's Hospital Los Angeles
(P 430) UNIQUE HISTOLOGIC MORPHOLOGY OF EWING SARCOMA CELLS THAT HARBOR TP53 MUTATIONS
Mikako Warren
Favorite
Wartenberg, Markus

German Sarcoma Foundation (DSS), SPAGN
(P 136) SETTING THE INTERNATIONAL RESEARCH AGENDA FOR SARCOMA WITH PATIENTS AND CARERS: PRELIMINARY RESULTS OF PHASE II OF THE SARCOMA PATIENT ADVOCACY GLOBAL NETWORK (SPAGN) PRIORITY SETTING PARTNERSHIP
Markus Wartenberg
Favorite
(P 153) PRIORITY SETTING PARNTERSHIP RETROPERITONEAL SOFT TISSUE SARCOMAS
Markus Wartenberg
Favorite
Wasif, Nabil

Mayo Clinic Arizona
(P 141) TREATMENT VARIABILITY IN SURGICAL MANAGEMENT OF PULMONARY OLIGOMETASTATIC SOFT TISSUE SARCOMA
Nabil Wasif
Favorite
Waspe, Adam

Hospital for Sick Children
(P 108) EFFECT OF TUMOUR-TARGETED HYPERTHERMIA AND CHEMOTHERAPY ON THE IMMUNE PROFILE OF A MURINE MODEL OF EMBRYONAL RHABDOMYOSARCOMA
Adam Waspe
Favorite
Wasyl, Erikson

Moleculin Biotech, Inc.
(P 183) A PHASE 1B/2 STUDY OF LIPOSOMAL ANNAMYCIN (ANN) IN SUBJECTS WITH PREVIOUSLY TREATED SOFT-TISSUE SARCOMAS (STS) WITH PULMONARY METASTASES
Erikson Wasyl
Favorite
Watanabe, Itsuo

Tokyo Dental College Ichikawa General Hospital
(P 87) ANGIOSARCOMA OF THE ILIUM TREATED WITH HEMIPELVECTOMY AND HIP TRANSPOSITION FOLLOWED BY POSTOPERATIVE CHEMOTHERAPY WITH PAZOPANIB: A CASE REPORT
Itsuo Watanabe
Favorite
Waterfall, Joshua J

Institut Curie
(P 395) TARGETING CD44-MEDIATED IRON ENDOCYTOSIS IN DESMOID FIBROMATOSIS
Joshua J Waterfall
Favorite
Waters, Michael

Washington University in St Louis
(P 187) PALLIATIVE LATTICE STEREOTACTIC BODY RADIOTHERAPY FOR PATIENTS WITH SARCOMA
Michael Waters
Favorite
Watkins, James

Cambridge University Hospitals NHS Foundation Trust
(P 204) RADIATION-INDUCED ANGIOSARCOMA OF THE BREAST: RETROSPECTIVE ANALYSIS AT A REGIONAL TREATMENT CENTRE
James Watkins
Favorite
Watkins, Michael

University of Chicago
(P 69) DEVELOPMENT AND MISSION OF THE HARMONIZATION INTERNATIONAL BONE SARCOMA CONSORTIUM (HIBISCUS)
Michael Watkins
Favorite
Watson, Caleb

Duke University
(P 72) CO-EXPRESSION OF LEUKOCYTE CYTOSOLIC PROTEIN 1 AND MATRIX METALLOPROTEINASES ARE INTEGRAL FOR METASTATIC PROGRESSION OF CHONDROSARCOMA
Caleb Watson
Favorite
Watson, Geoffrey

Mount Sinai Hospital / University of Toronto
(P 215) IMPACT OF FRONTLINE SYSTEMIC TREATMENT CHOICE ON CLINICAL OUTCOME IN ADVANCED LEIOMYOSARCOMA: A MULTI-CENTRE RETROSPECTIVE CANSARCC STUDY
Geoffrey Watson
Favorite
Watson, Sarah

Institut Curie
(P 201) PLEOMORPHIC RHABDOMYOSARCOMAS: A NEW ENTITY ASSOCIATED WITH LYNCH SYNDROME? FIRST RESULTS OF SARCLYNCH NATIONAL STUDY
Sarah Watson
Favorite
(P 395) TARGETING CD44-MEDIATED IRON ENDOCYTOSIS IN DESMOID FIBROMATOSIS
Sarah Watson
Favorite
Watson, Sasha

Sylvester Comprehensive Cancer Center / University of Miami Hospital and Clinics
(P 208) LOW INCIDENCE OF CANCER THERAPY-RELATED CARDIAC DYSFUNCTION IN ADULT SARCOMA PATIENTS RECEIVING DOXORUBICIN AND UPFRONT DEXRAZOXANE
Sasha Watson
Favorite
Watt, Tanya

University of Texas Southwestern Medical Center
(P 161) EFFICACY, SAFETY, AND TREATMENT HOLD WAIT-AND-SEE OUTCOMES OF LAROTRECTINIB IN PEDIATRIC PATIENTS WITH TRK FUSION SARCOMAS
Tanya Watt
Favorite
Waymack, J

Moleculin Biotech, Inc
(P 183) A PHASE 1B/2 STUDY OF LIPOSOMAL ANNAMYCIN (ANN) IN SUBJECTS WITH PREVIOUSLY TREATED SOFT-TISSUE SARCOMAS (STS) WITH PULMONARY METASTASES
J Waymack
Favorite
Wayne, Jeff

Northwestern Memorial Hospital
(P 219) ELECTIVE DISCONTINUATION OF SORAFENIB TREATMENT IN DESMOID TUMORS: A RETROSPECTIVE ANALYSIS WITH IMPLICATIONS FOR CLINICAL PRACTICE
Jeff Wayne
Favorite
Weadick, Catherine S

CUH
(P 213) EXPERIENCE WITH THE USE OF TRABECTEDIN IN ADVANCED SOFT TISSUE SARCOMA IN IRELAND
Catherine S Weadick
Favorite
Webb, Angela

Peter MacCallum Cancer Centre
(P 516) OUCOMES OF AGGRESSIVE RESECTION OF RADIATION INDUCED ANGIOSARCOMA OF THE BREAST
Angela Webb
Favorite
Weber, Kristy

University of Pennsylvania
(P 529) THE MUSCULOSKELETAL TUMOR REGISTRY -- 2023 UPDATE AND OUTLOOK
Kristy Weber
Favorite
Weetall, Marla

PTC Therapeutics, Inc.
(P 182) UPDATED RESULTS FROM AN ONGOING PHASE 1B STUDY OF UNESBULIN (PTC596) PLUS DACARBAZINE FOR THE TREATMENT OF PATIENTS WITH ADVANCED LEIOMYOSARCOMA
Marla Weetall
Favorite
(P 548) A PHASE 2/3 STUDY EVALUATING THE EFFICACY AND SAFETY OF UNESBULIN IN ADVANCED LEIOMYOSARCOMA (SUNRISELMS)
Marla Weetall
Favorite
Weiß, Christel

University Medical Center Mannheim
(P 488) POSTOPERATIVE DRAINAGE MANAGEMENT AND WOUND COMPLICATIONS FOLLOWING RESECTION OF LOWER LIMB SOFT TISSUE TUMORS
Christel Weiß
Favorite
Weigel, Brenda

Department of Pediatrics, University of Minnesota
(P 166) SARC038: A PHASE 2 STUDY OF REGORAFENIB IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH REFRACTORY OR RECURRENT OSTEOSARCOMA
Brenda Weigel
Favorite
(P 167) FDG-PET-CT RESPONSE AFTER NEOADJUVANT CHEMOTHERAPY PREDICTS LONG-TERM OUTCOME IN PATIENTS WITH SOFT TISSUE SARCOMA -- 15-YEAR FOLLOW-UP
Brenda Weigel
Favorite
(P 556) EVALUATION OF PALBOCICLIB (IBRANCE®) IN COMBINATION WITH CHEMOTHERAPY IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY EWING SARCOMA OR NEUROBLASTOMA
Brenda Weigel
Favorite
Weigl, Helene

University Medical Center Mannheim
(P 488) POSTOPERATIVE DRAINAGE MANAGEMENT AND WOUND COMPLICATIONS FOLLOWING RESECTION OF LOWER LIMB SOFT TISSUE TUMORS
Helene Weigl
Favorite
Weingertner, Noelle

University Hospital of Strasbourg
(P 389) OSTEOBLASTIC-GENE SIGNATURE TO PREDICT SURVIVAL IN PEDIATRIC OSTEOSARCOMA (OS) AND TO FOLLOW PATIENTS TOWARDS LIQUID BIOPSY: A COLLABORATIVE WORK IN OS2006 PROTOCOL.
Noelle Weingertner
Favorite
Wei, Ran

Peking University People's Hospital
(P 487) EN BLOC RESECTION FOR SPINAL TUMORS: A SINGLE CENTER EXPERIENCE OF 113 CONSECUTIVE CASES
Ran Wei
Favorite
Weiss, Aaron

Maine Children's Cancer Program
(P 13) OUTCOME OF PATIENTS WITH RELAPSED OR REFRACTORY NON-RHABDOMYOSARCOMA SOFT TISSUE SARCOMAS ENROLLED IN PHASE II COOPERATIVE GROUP CLINICAL TRIALS: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP
Aaron Weiss
Favorite
Weiss, Kurt

University of Pittsburgh
(P 244) A DEEP FEW-SHOT META-LEARNING STRATEGY FOR AUTONOMOUS CLASSIFICATION OF BONE METASTASIS IN RADIONUCLIDE BONE SCANS
Kurt Weiss
Favorite
(P 351) TARGETING ANDROGEN RECEPTOR IN OSTEOSARCOMA CELLS WITH VARYING METASTATIC POTENTIAL
Kurt Weiss
Favorite
(P 373) DEDIFFERENTIATED AND HIGH GRADE CHONDROSARCOMAS: HOW DOES ISOCITRATE DEHYDROGENASE STATUS APPRISE PROGNOSIS AND THERAPY?
Kurt Weiss
Favorite
(P 411) A SPATIAL TRANSCRIPTOMIC "GOOGLE MAP" OF HUMAN OSTEOSARCOMA REVEALS COMMON CELL CLUSTERS AT THE PRIMARY SITE AND PULMONARY METASTASES.
Kurt Weiss
Favorite
(P 466) INTRAOPERATIVE EVALUATION OF BONE AND SOFT TISSUE SARCOMA SURGICAL MARGINS WITH INDOCYANINE GREEN FLUORESCENCE IMAGING
Kurt Weiss
Favorite
(P 536) PHASE 1 STUDY OF DISULFIRAM WITH COPPER GLUCONATE AND LIPOSOMAL DOXORUBICIN IN PATIENTS WITH TREATMENT REFRACTORY SARCOMAS
Kurt Weiss
Favorite
(P 544) INTRAOPERATIVE EVALUATION OF BONE AND SOFT TISSUE SARCOMA SURGICAL MARGINS WITH INDOCYANINE GREEN FLUORESCENCE IMAGING
Kurt Weiss
Favorite
Weiss, Mia

Washington University School of Medicine
(P 180) HEALTH RELATED QUALITY OF LIFE OF PATIENTS WITH ADVANCED LEIOMYOSARCOMA AND OTHER SOFT TISSUE SARCOMAS TREATED WITH CABOZANTINIB AND TEMOZOLOMIDE
Mia Weiss
Favorite
(P 187) PALLIATIVE LATTICE STEREOTACTIC BODY RADIOTHERAPY FOR PATIENTS WITH SARCOMA
Mia Weiss
Favorite
(P 552) RANDOMIZED PHASE II TRIAL OF CABOZANTINIB COMBINED WITH PD-1 AND CTLA-4 INHIBITION VERSUS CABOZANTINIB IN METASTATIC SOFT TISSUE SARCOMA.
Mia Weiss
Favorite
Weiss, Sarah

Rutgers Cancer Institute of New Jersey
(P 183) A PHASE 1B/2 STUDY OF LIPOSOMAL ANNAMYCIN (ANN) IN SUBJECTS WITH PREVIOUSLY TREATED SOFT-TISSUE SARCOMAS (STS) WITH PULMONARY METASTASES
Sarah Weiss
Favorite
Weistuch, Corey

Department of Medical Physics, Memorial Sloan Kettering Cancer Center
(P 397) A MESENCHYMAL TISSUE LANDSCAPE TO STUDY OSTEOSARCOMA TUMOR HETEROGENEITY
Corey Weistuch
Favorite
Wei, Xing

Department of Medical Oncology, Peking University International Hospital
(P 534) NEOADJUVANT CHEMOTHERAPY COMBINED WITH TARGETED TREATMENT IN HIGH-RISK RETROPERITONEAL SARCOMA – A PROSPECTIVE NON-RANDOMIZED CONTROLLED MULTI-CENTERED STUDY ALL ACROSS CHINA
Xing Wei
Favorite
Weizhen, Liu

Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
(P 38) EFFICACY AND SAFETY OF RIPRETINIB IN THE TREATMENT OF ADVANCED GASTROINTESTINAL STROMAL TUMORS: A MULTICENTER RETROSPECTIVE STUDY
Liu Weizhen
Favorite
Wenger, Doris

Mayo Clinic
(P 61) ADJACENT VENOUS TUMOR THROMBUS IN PRIMARY OSTEOSARCOMA OF THE PELVIS AND EXTREMITIES
Doris Wenger
Favorite
(P 62) PROSTHESIS-ASSOCIATED SARCOMA: A REVIEW OF 8 HIGH-GRADE LESIONS ARISING AROUND A TOTAL JOINT ARTHROPLASTY IMPLANT
Doris Wenger
Favorite
Wen, Haoxiang

The First Affiliated Hospital of Sun Yat-sen University
(P 45) THE LONG-TERM EFFECT OF IMATINIB WITH HEPATIC RESECTION OR OTHER LOCAL TREATMENT FOR GIST LIVER METASTASES
Haoxiang Wen
Favorite
Werier, Joel

The Ottawa Hospital
(P 98) TUMOR IMMUNE PROFILING AND IDENTIFICATION OF IMMUNOTHERAPEUTIC TARGETS IN DEDIFFERENTIATED LIPOSARCOMA
Joel Werier
Favorite
Werner, Jens

LMU University Hospital
(P 153) PRIORITY SETTING PARNTERSHIP RETROPERITONEAL SOFT TISSUE SARCOMAS
Jens Werner
Favorite
(P 348) RESECTION OF RECURRENT RETROPERITONEAL SOFT TISSUE SARCOMAS: ARE INTENSIVE MULTIMODAL TREATMENTS ASSOCIATED WITH INCREASED PERIOPERATIVE MORBIDITY?
Jens Werner
Favorite
Westlake, Babe

Renown Regional Medical Center
(P 93) INDETERMINATE CHEST LESIONS IN PATIENTS WITH BONE SARCOMA INCIDENTAL FINDING VERSUS METASTATIC DISEASE
Babe Westlake
Favorite
West, Nicholas

British Columbia Children's Hospital Research Institute
(P 512) PERIOPERATIVE BLOOD MANAGEMENT IN PEDIATRIC PATIENTS UNDERGOING PRIMARY OSTEOSARCOMA AND EWING SARCOMA RESECTION: A RETROSPECTIVE CASE NOTE REVIEW
Nicholas West
Favorite
Whalen, Giles

University of Massachusetts Memorial Medical Center
(P 164) INTRATUMORAL INT230-6 (CISPLATIN, VINBLASTINE, SHAO) ALONE OR WITH IPILIMUMAB PROLONGED SURVIVAL WITH FAVORABLE SAFETY AND IMMUNE ACTIVATION IN ADULTS WITH REFRACTORY SARCOMAS (NCT 03058289)
Giles Whalen
Favorite
Whiteway, Susan

Walter Reed National Military Medical Center
(P 81) OPTIMIZING EWING SARCOMA AND OSTEOSARCOMA BIOPSY ACQUISITION: CONSENSUS RECOMMENDATIONS FROM THE CHILDREN'S ONCOLOGY GROUP BONE TUMOR COMMITTEE
Susan Whiteway
Favorite
Whiting, Karissa

Memorial Sloan Kettering Cancer Center
(P 24) COMPREHENSIVE ANALYSIS OF THE GENOMIC LANDSCAPE AND CLINICAL BEHAVIOR IN GIST USING NEXT GENERATION SEQUENCING (NGS, MSK-IMPACT)
Karissa Whiting
Favorite
Whittle, Sarah

Baylor College of Medicine
(P 165) MIDDLE EAR RHABDOMYOSARCOMA: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP
Sarah Whittle
Favorite
Widemann, Brigitte

National Cancer Institute
(P 274) TYK2 AND MEK COMBINATION THERAPY IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS AND OTHER SOFT TISSUE SARCOMAS
Brigitte Widemann
Favorite
Widlund, Charlotte

Karolinska University Hospital
(P 278) CLINICAL MARKERS PREDICTIVE OF TRABECTEDIN RESPONSE IN SOFT TISSUE SARCOMA
Charlotte Widlund
Favorite
Wiegering, Armin

Department of General, Visceral, Transplantation, Vascular and Pediatric Surgery, University Hospital Würzburg, 97080 Würzburg, Germany
(P 557) UNRAVELING THE ROLE OF LOCAL THERAPY FOR PATIENTS WITH OLIGOMETASTATIC SOFT TISSUE SARCOMA - A RETROSPECTIVE MULTICENTER TRIAL OF BAVARIAN UNIVERSITY HOSPITALS
Armin Wiegering
Favorite
Wiese, Michelle

Northwestern Medicine
(P 476) FAVORABLE RESULTS FOLLOWING TREATMENT OF UNICAMERAL BONE CYSTS WITH DOXYCYCLINE SCLEROGRAFT TECHNIQUE
Michelle Wiese
Favorite
(P 477) TREATMENT OF PROXIMAL FEMUR UNICAMERAL BONE CYSTS WITH DOXYCYCLINE SCLEROTHERAPY
Michelle Wiese
Favorite
Wijers-Koster, Pauline

LUMC
(P 368) DECODING THE IMMUNOGENOMIC DETERMINANTS OF RADIOTHERAPY RESPONSE IN SOFT TISSUE SARCOMAS
Pauline Wijers-Koster
Favorite
(P 369) MAGEA ANTIGENS AS IMMUNOTHERAPEUTIC TARGETS FOR ADVANCED OSTEOSARCOMA
Pauline Wijers-Koster
Favorite
Wijnen, Marc

Princess Maxima Center for Pediatric Oncology, The Netherlands
(P 251) EVALUATION OF POTENTIAL TARGETS FOR FLUORESCENCE-GUIDED SURGERY IN PEDIATRIC EWING SARCOMA: A PRECLINICAL PROOF-OF-CONCEPT STUDY
Marc Wijnen
Favorite
Wild, Tristan

University of Ottawa
(P 215) IMPACT OF FRONTLINE SYSTEMIC TREATMENT CHOICE ON CLINICAL OUTCOME IN ADVANCED LEIOMYOSARCOMA: A MULTI-CENTRE RETROSPECTIVE CANSARCC STUDY
Tristan Wild
Favorite
(P 342) THE EVALUATION AND OUTCOMES OF MESENTERIC AND INTRA-ABDOMINAL DESMOIDS: A TARPSWG STUDY
Tristan Wild
Favorite
Wilkinson, Michelle

The Royal Marsden Hospital
(P 40) LONG TERM OUTCOMES OF NEOADJUVANT IMATINIB AND SURGICAL RESECTION OF RECTAL GASTROINTESTINAL STROMAL TUMOURS
Michelle Wilkinson
Favorite
Wilkowski, Jodi

University of Michigan
(P 293) GENERATION OF A SPONTANEOUS IMMUNOCOMPETENT MOUSE MODEL OF LIPOSARCOMA
Jodi Wilkowski
Favorite
Wilky, Breelyn

University of Colorado Cancer Center
(P 176) SAFETY, EFFICACY, AND PATIENT-REPORTED OUTCOMES WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED NO PRIOR ANTI–COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 UPDATE
Breelyn Wilky
Favorite
(P 188) IMPACT OF NIROGACESTAT ON FUNCTIONAL STATUS IN PATIENTS WITH DESMOID TUMORS: RESULTS FROM THE PHASE 3 DEFI STUDY
Breelyn Wilky
Favorite
(P 237) SECONDARY REARRANGEMENT CREATING A PLEC-EML4-ALK DOUBLE FUSION AS A MECHANISM OF RESISTANCE TO CRIZOTINIB IN AN EML4-ALK-POSITIVE INFLAMMATORY MYOFIBROBLASTIC TUMOR
Breelyn Wilky
Favorite
(P 439) THE TETRAVALENT DEATH RECEPTOR 5 AGONIST INBRX-109 COMBINED WITH CHEMOTHERAPY IN EWING SARCOMA: PRELIMINARY DATA FROM A PHASE 1 STUDY
Breelyn Wilky
Favorite
(P 552) RANDOMIZED PHASE II TRIAL OF CABOZANTINIB COMBINED WITH PD-1 AND CTLA-4 INHIBITION VERSUS CABOZANTINIB IN METASTATIC SOFT TISSUE SARCOMA.
Breelyn Wilky
Favorite
Williams, Dennis

Adaptimmune
(P 542) ENROLLMENT OF PEDIATRIC PARTICIPANTS WITH MAGE-A4-POSITIVE SOLID TUMORS IN A PHASE 1/2, OPEN-LABEL, BASKET TRIAL OF AFAMITRESGENE AUTOLEUCEL ("AFAMI-CEL")
Dennis Williams
Favorite
Williams, Kyle

Masonic Cancer Center University of Minnesota
(P 252) STUDY OF NUTRACEUTICAL INTERVENTION WITH HIGH PHENOLIC EXTRA VIRGIN OLIVE OIL AND CURCUMIN FOR NEUROFIBROMATOSIS TYPE 1
Kyle Williams
Favorite
Williams, NADINE

Loma Linda University
(P 525) ALL INTERNAL DISTRACTION OSTEOGENESIS AFTER TUMOR RESECTION
NADINE Williams
Favorite
(P 526) EVALUATION OF THE SURGICAL MANAGEMENT OF THE SKELETON IN PATIENTS WITH OLLIER'S DISEASE AND MAFUCCI SYNDROME
NADINE Williams
Favorite
Williams, Nadine

Loma Linda Medical Cancer Center
(P 527) SALVAGE OF AN OSTEOARRTICULAR ALLOGRAFT RADIUS RECONSTRUCTION SINGLE BONE TRANSPOSITION WITH WRIST ARTHRODESIS FOLLOWING OSTEOSARCOMA EXCISION
Nadine Williams
Favorite
Willis, Katelyn

Inhibrx, Inc
(P 29) COMBINATION TREATMENT WITH TEMOZOLOMIDE AND THE DEATH RECEPTOR-5 AGONIST INBRX-109 EFFECTIVELY TARGETS SUCCINATE DEHYDROGENASE -DEFICIENT GASTROINTESTINAL STROMAL TUMOR
Katelyn Willis
Favorite
(P 439) THE TETRAVALENT DEATH RECEPTOR 5 AGONIST INBRX-109 COMBINED WITH CHEMOTHERAPY IN EWING SARCOMA: PRELIMINARY DATA FROM A PHASE 1 STUDY
Katelyn Willis
Favorite
Wilson, Isabella

Chris O'Brien Lifehouse
(P 194) REAL WORLD OUTCOMES OF PATIENTS TREATED WITH GEMCITABINE AND DOCETAXEL FOR ADVANCED SOFT TISSUE SARCOMA IN AN AUSTRALIAN SARCOMA CENTRE
Isabella Wilson
Favorite
Wilson, Roger

Founder - Sarcoma UK
(P 136) SETTING THE INTERNATIONAL RESEARCH AGENDA FOR SARCOMA WITH PATIENTS AND CARERS: PRELIMINARY RESULTS OF PHASE II OF THE SARCOMA PATIENT ADVOCACY GLOBAL NETWORK (SPAGN) PRIORITY SETTING PARTNERSHIP
Roger Wilson
Favorite
(P 186) PATIENT REPORTED OUTCOME ASSESSMENT AND REPORTING IN RANDOMIZED CLINICAL TRIALS OF SYSTEMIC THERAPY FOR ADVANCED SOFT TISSUE SARCOMAS: A SYSTEMATIC REVIEW.
Roger Wilson
Favorite
Wilson, William

CRUK & UCL Cancer Trials Centre
(P 70) ICONIC (IMPROVING OUTCOMES THROUGH COLLABORATION IN OSTEOSARCOMA): A PROSPECTIVE OBSERVATIONAL COHORT STUDY FOR NEWLY DIAGNOSED OSTEOSARCOMA PATIENTS IN THE UNITED KINGDOM (UK)
William Wilson
Favorite
Wilson, William

UCL Cancer Trials Centre
(P 472) ICONIC (IMPROVING OUTCOMES THROUGH COLLABORATION IN OSTEOSARCOMA). AN EARLY LOOK AT SURGICAL DATA
William Wilson
Favorite
Windsor, Rachael

University College London Hospital
(P 57) REAL-WORLD EXPERIENCE OF CABOZANTINIB IN PAEDIATRIC, TEENAGE AND YOUNG ADULT (TYA) AND ADULT METASTATIC BONE SARCOMA PATIENTS FROM THE LONDON SARCOMA SERVICE (LSS)
Rachael Windsor
Favorite
(P 422) CLINICAL UTILITY OF WHOLE GENOME SEQUENCING IN SARCOMA FOR THE IDENTIFICATION OF ACTIONABLE MUTATIONS: A RETROSPECTIVE COHORT ANALYSIS
Rachael Windsor
Favorite
Winer, Leah

Fox Chase Cancer Center
(P 152) EVALUATING DIAGNOSTIC APPROACHES TO DERMATOFIBROSARCOMA PROTUBERANS: AN OPPORTUNITY TO REDUCE THE NUMBER OF INTERVENTIONS
Leah Winer
Favorite
Winters-Stone, Kerri

Oregon Health & Science University
(P 179) PILOT STUDY OF A REMOTELY DELIVERED RESISTANCE EXERCISE TRAINING PROGRAM IN SARCOMA SURVIVORS
Kerri Winters-Stone
Favorite
Wirta, Valtteri

SciLifeLab / Karolinska institutet
(P 243) EVALUATION OF THE USE OF WGS IN ROUTINE DIAGNOSTICS FOR BONE AND SOFT TISSUE TUMORS
Valtteri Wirta
Favorite
Witczak, Marcin

Early Phase Clinical Trials Unit, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland
(P 222) EXPLORING THE IMPACT OF NGS ON DIAGNOSTICS AND TREATMENT OF SARCOMA: INSIGHTS FROM REAL-WORLD DATA ACROSS MULTIPLE INSTITUTIONS IN EUROPE
Marcin Witczak
Favorite
Woessmann, Wilhelm

University Medical Center Hamburg-Eppendorf
(P 558) TRIAL IN PROGRESS: A PHASE 1/2 STUDY OF BRIGATINIB IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH ALK POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA OR INFLAMMATORY MYOFIBROBLASTIC TUMORS (ITCC-098)
Wilhelm Woessmann
Favorite
Wolden, Suzanne

Memorial Sloan Kettering Cancer Center
(P 165) MIDDLE EAR RHABDOMYOSARCOMA: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP
Suzanne Wolden
Favorite
(P 320) A PROSPECTIVE MULTICENTER EXPERIENCE OF PROTON THERAPY FOR RHABDOMYOSARCOMA AND EWING SARCOMA: OUTCOMES FROM THE PROTON COLLABORATIVE GROUP REGISTRY
Suzanne Wolden
Favorite
(P 409) IMMUNOHISTOCHEMICAL STAINING FOR MYOGENIN, AP2 BETA AND HMGA2 PREDICT FOXO1 FUSION STATUS IN RHABDOMYOSARCOMA: A REPORT FROM THE SOFT TISSUE COMMITTEE OF THE CHILDREN'S ONCOLOGY GROUP
Suzanne Wolden
Favorite
(P 425) CHARACTERIZATION OF RHABDOMYOSARCOMA WITH PAX7::FOXO1 FUSIONS: A REPORT FROM THE SOFT TISSUE COMMITTEE OF THE CHILDREN'S ONCOLOGY GROUP
Suzanne Wolden
Favorite
(P 438) ALVEOLAR RHABDOMYOSARCOMA WITH "BURKITT-LIKE" MORPHOLOGY IS ASSOCIATED WITH HIGH AMPLIFICATION OF MYCL
Suzanne Wolden
Favorite
Wolinsky, Jean-Paul

Northwestern Medicine
(P 96) LEPTOMENINGEAL RECURRENCE OF EWING'S SARCOMA: A CASE SERIES
Jean-Paul Wolinsky
Favorite
Wong, Daniel

Sir Charles Gairdner Hospital (SCGH), Australia
(P 189) INTERNATIONAL RETROSPECTIVE STUDY FROM THE ULTRA-RARE SARCOMA WORKING GROUP ON LOW-GRADE FIBROMYXOID SARCOMA AND SCLEROSING EPITHELIOD FIBROSARCOMA: OUTCOME OF ADVANCED DISEASE AND SYSTEMIC THERAPIES
Daniel Wong
Favorite
Wong, Eric

The Chinese University of Hong Kong
(P 290) PRE-CLINICAL STUDY OF TUMOR TREATING FIELDS (TTFIELDS) ALONE OR IN CONJUNCTION WITH SYSTEMIC THERAPIES IN SELECTED BONE- AND SOFT-TISSUE SARCOMAS
Eric Wong
Favorite
Wong, Han

Cambridge University Hospitals NHS Foundation Trust
(P 204) RADIATION-INDUCED ANGIOSARCOMA OF THE BREAST: RETROSPECTIVE ANALYSIS AT A REGIONAL TREATMENT CENTRE
Han Wong
Favorite
(P 205) PRIMARY CARDIAC SARCOMA: A RETROSPECTIVE ANALYSIS OF PRESENTATION, MANAGEMENT AND OUTCOMES
Han Wong
Favorite
Wong, Jolene

Department of Sarcoma, Peritoneal and Rare Tumours (SPRinT), Division of Surgery and Surgical Oncology, National Cancer Centre Singapore
(P 336) EVOLUTION AND PURSUIT OF EXCELLENCE IN SARCOMA MANAGEMENT IN AN ASIAN TERTIARY SARCOMA SPECIALISED CENTRE
Jolene Wong
Favorite
Wong, Justin

The University of Texas MD Anderson Cancer Center
(P 269) PLASMA DNA METHYLATION-BASED BIOMARKERS FOR MPNST DETECTION IN PATIENTS WITH NEUROFIBROMATOSIS TYPE 1 (NF1)
Justin Wong
Favorite
Wong, Philip

Princess Margaret Cancer Centre
(P 284) VALIDATING A NOVEL MICROFLUIDIC PLATFORM AS AN EX VIVO TUMOUR MODEL FOR SARCOMA DRUG DISCOVERY
Philip Wong
Favorite
(P 483) DID THE COVID-19 PANDEMIC NEGATIVELY AFFECT OUTCOMES FOR PATIENTS WITH EXTREMITY SOFT TISSUE SARCOMAS?
Philip Wong
Favorite
Wong, Ru Xin

Division of Medical Oncology, National Cancer Centre Singapore
(P 82) PROGNOSTIC FACTORS AND OUTCOMES OF 275 PATIENTS WITH HEAD AND NECK BONE AND SOFT TISSUE SARCOMA: A SINGLE CENTRE COHORT STUDY
Ru Xin Wong
Favorite
Wong, Steven

Sarcoma Oncology Center
(P 117) INTERIM ANALYSIS OF PHASE 2 STUDY: A METRONOMIC REGIMEN USING GEMCITABINE, DOXORUBICIN, DOCETAXEL AND NIVOLUMAB FOR ADVANCED LEIOMYOSARCOMA (NCT04535713)
Steven Wong
Favorite
Wong, Suzanne

Hospital for Sick Children
(P 108) EFFECT OF TUMOUR-TARGETED HYPERTHERMIA AND CHEMOTHERAPY ON THE IMMUNE PROFILE OF A MURINE MODEL OF EMBRYONAL RHABDOMYOSARCOMA
Suzanne Wong
Favorite
Wooddell, Margaret

Daiichi Sankyo, Inc.
(P 199) PEXIDARTINIB RISK EVALUATION AND MITIGATION STRATEGY PROGRAM: 3-YEAR SAFETY DATA ASSESSMENT
Margaret Wooddell
Favorite
Wood, Georgina

University College London Hospital
(P 57) REAL-WORLD EXPERIENCE OF CABOZANTINIB IN PAEDIATRIC, TEENAGE AND YOUNG ADULT (TYA) AND ADULT METASTATIC BONE SARCOMA PATIENTS FROM THE LONDON SARCOMA SERVICE (LSS)
Georgina Wood
Favorite
(P 422) CLINICAL UTILITY OF WHOLE GENOME SEQUENCING IN SARCOMA FOR THE IDENTIFICATION OF ACTIONABLE MUTATIONS: A RETROSPECTIVE COHORT ANALYSIS
Georgina Wood
Favorite
Woods, Jacqueline

Clear Cell Sarcoma Foundation
(P 20) CLEAR CELL SARCOMA: PATIENT REPORTED REAL WORLD EVIDENCE
Jacqueline Woods
Favorite
Woods, Lennie

Clear Cell Sarcoma Foundation
(P 20) CLEAR CELL SARCOMA: PATIENT REPORTED REAL WORLD EVIDENCE
Lennie Woods
Favorite
Woods, Sara

Clear Cell Sarcoma Foundation
(P 20) CLEAR CELL SARCOMA: PATIENT REPORTED REAL WORLD EVIDENCE
Sara Woods
Favorite
Wooldridge, Adam

Medical College of Wisconsin
(P 181) REAL-WORLD EXPERIENCE WITH LIPOSOMAL DOXORUBICIN IN METASTATIC AND LOCALLY ADVANCED SARCOMA
Adam Wooldridge
Favorite
(P 473) GROIN PAINS: APPROACHES AND OUTCOMES FOR INGUINOFEMORAL SOFT TISSUE SARCOMAS
Adam Wooldridge
Favorite
Woo, Sang-Keun

Korea Institute of Radiological Medical Sciences
(P 78) THE CLINICAL OUTCOME OF EXTRASKELETAL MYXOID CHONDROSARCOMA
Sang-Keun Woo
Favorite
Wouters, Michel

Netherlands Cancer Institute/ Antoni van Leeuwenhoek
(P 32) IMPROVEMENT OF QUALITY AND TEXTBOOK OUTCOMES OF GASTRIC GASTROINTESTINAL STROMAL TUMOR (GIST) RESECTIONS IN THE PAST 13 YEARS; THE INFLUENCE OF MINIMAL INVASIVE SURGERY (MIS)
Michel Wouters
Favorite
Wozniak, Agnieszka

Laboratory of Experimental Oncology, KU Leuven, Leuven Cancer Institute
(P 43) UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR-ASSOCIATED PROTEIN AS A POTENTIAL NEXT GENERATION MOLECULAR TARGET FOR TREATMENT OF GASTROINTESTINAL STROMAL TUMOR
Agnieszka Wozniak
Favorite
(P 110) GCAR1: GPNMB CAR T THERAPY FOR MIT FAMILY TRANSLOCATION POSITIVE CANCERS
Agnieszka Wozniak
Favorite
(P 254) A COLLECTION OF PATIENT-DERIVED XENOGRAFT MODELS OF GASTROINTESTINAL STROMAL TUMORS
Agnieszka Wozniak
Favorite
(P 255) EPIDEMIOLOGY OF NOVEL ACTIONABLE TARGETS IN SYNOVIAL SARCOMA: A TISSUE MICRO-ARRAY STUDY
Agnieszka Wozniak
Favorite
(P 256) EFFICACY AND TOXICITY OF VERTEPORFIN IN COMBINATION WITH PAZOPANIB TESTED IN A PATIENT-DERIVED SYNOVIAL SARCOMA XENOGRAFT
Agnieszka Wozniak
Favorite
(P 349) THE UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR-ASSOCIATED PROTEIN (UPARAP) IS AN ATTRACTIVE TARGET FOR THE DEVELOPMENT OF ANTIBODY DRUG CONJUGATES FOR TREATMENT OF MESENCHYMAL MALIGNANCIES
Agnieszka Wozniak
Favorite
Wragg, Joseph

University of Birmingham
(P 282) AN EMBRYONIC ZEBRAFISH XENOGRAFT MODEL OF RHABDOMYOSARCOMA REVEALS GENOTYPE DEPENDENT TUMOUR VASCULARISATION DYNAMICS AND RESPONSE TO ANTI-ANGIOGENIC RECEPTOR TYROSINE KINASE INHIBITORS
Joseph Wragg
Favorite
Wrenn, Emma

Seattle Children's Research Institute
(P 447) TARGETING FOCAL ADHESION KINASE AUGMENTS THE THERAPEUTIC POTENTIAL OF BROMODOMAIN INHIBITORS IN EWING SARCOMA
Emma Wrenn
Favorite
(P 448) CAF-LIKE EWING SARCOMA CELLS DEPOSIT PRO-TUMORIGENIC EXTRACELLULAR MATRIX IN RESPONSE TO TGF-BETA SIGNALING
Emma Wrenn
Favorite
wu, Chia-Chin

The University of Texas MD Anderson Cancer Center
(P 405) PRIMARY CARDIAC ANGIOSARCOMA- GENOMIC AND MOLECULAR LANDSCAPE
Chia-Chin wu
Favorite
(P 426) MULTI-OMIC ANALYSIS OF DESMOPLASTIC SMALL ROUND CELL TUMORS REVEAL DISTINCT LINEAGES
Chia-Chin wu
Favorite
Wu, Jun

Department of Medical Oncology, The First People's Hospital of Changzhou
(P 44) RIPRETINIB FOR THE TREATMENT OF CHINESE PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS HARBORING KIT SECONDARY MUTATIONS: A MULTICENTER, RETROSPECTIVE STUDY
Jun Wu
Favorite
Wunder, Jay

University of Toronto
(P 53) CURATIVE-INTENT SURGERY FOR A SOLITARY ISOLATED BONE METASTASIS FROM EXTREMITY SARCOMA: WHO UNDERWENT METASTASECTOMY AND WHAT WAS THE PROGNOSTIC OUTCOME?
Jay Wunder
Favorite
Wunder, Jay

Mount Sinai Hospital
(P 77) PATIENT OUTCOMES AFTER OPEN VERSUS CORE NEEDLE BIOPSY IN LOWER EXTREMITY SARCOMA
Jay Wunder
Favorite
Wunder, Jay

University of Toronto
(P 249) INVESTIGATING CLINICAL FACTORS ASSOCIATED WITH THE ESTABLISHMENT OF SUCCESSFUL PRIMARY HUMAN SOFT TISSUE SARCOMA CELL LINES
Jay Wunder
Favorite
(P 352) DETERMINING THE CONTRIBUTIONS OF STAT1 TO THE UPS ANTI-TUMOR MICROENVIRONMENT
Jay Wunder
Favorite
(P 367) CHARACTERIZING HYPOXIA AND ASSOCIATED MOLECULAR FEATURES IN EXTREMITY SOFT TISSUE SARCOMA
Jay Wunder
Favorite
(P 443) SURGICAL RESECTION OF EXTREMITY EWING'S SARCOMA BASED ON POST-CHEMOTHERAPY TUMOUR VOLUME RESULTS IN SAFE MARGINS
Jay Wunder
Favorite
(P 483) DID THE COVID-19 PANDEMIC NEGATIVELY AFFECT OUTCOMES FOR PATIENTS WITH EXTREMITY SOFT TISSUE SARCOMAS?
Jay Wunder
Favorite
(P 484) OBESITY INCREASES THE RISK OF MAJOR WOUND COMPLICATIONS FOLLOWING PELVIC RESECTION FOR BONE SARCOMA
Jay Wunder
Favorite
Wunker, Claire

Saint Louis University
(P 108) EFFECT OF TUMOUR-TARGETED HYPERTHERMIA AND CHEMOTHERAPY ON THE IMMUNE PROFILE OF A MURINE MODEL OF EMBRYONAL RHABDOMYOSARCOMA
Claire Wunker
Favorite
Wunker, Claire

Sinai Health System
(P 265) SELECTIVE TARGETING OF BET FAMILY EPIGENETIC REGULATORS IN ADVANCED AND METASTATIC ALVEOLAR RHABDOMYOSARCOMA
Claire Wunker
Favorite
Wu, Po-Kuei

Taipei Veterans General Hospital
(P 168) A PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF PEXIDARTINIB IN ASIAN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR
Po-Kuei Wu
Favorite
Wu, Qing

Research Institute of the McGill University Health Center
(P 64) OSTEOSARCOMA. PATIENT-DERIVED XENOGRAFTS MODELS TO RECAPITULATE PATIENTS' CHEMORESISTANCE AND METASTATIC DISEASE
Qing Wu
Favorite
Wu, Xin

Chinese PLA General Hospital
(P 34) RIPRETINIB IN COMBINATION WITH OTHER TKIS IN CHINESE PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR: A MULTI-CENTER RETROSPECTIVE ANALYSIS
Xin Wu
Favorite
Wu, Yu-Ching

National Taiwan University Hospital
(P 350) LIVER ANGIOSARCOMA IS ASSOCIATED WITH ARISTOLOCHIC ACID EXPOSURE AND HAS A DISTINCT TELOMERE MAINTENANCE MECHANISM
Yu-Ching Wu
Favorite
Wyns, Karo

Laboratory of Experimental Oncology, KU Leuven, Leuven Cancer Institute
(P 254) A COLLECTION OF PATIENT-DERIVED XENOGRAFT MODELS OF GASTROINTESTINAL STROMAL TUMORS
Karo Wyns
Favorite
(P 255) EPIDEMIOLOGY OF NOVEL ACTIONABLE TARGETS IN SYNOVIAL SARCOMA: A TISSUE MICRO-ARRAY STUDY
Karo Wyns
Favorite
Wytiaz, Victoria

University of Michigan, Department of Hematology/Oncology
(P 07) IDENTIFYING CONCERNS OF ADOLESCENT AND YOUNG ADULT SARCOMA PATIENTS AND SURVIVORS FOLLOWING FERTIITY PRESERVATION
Victoria Wytiaz
Favorite
(P 449) CIC-DUX4 sarcomas: A single-center review of clinical features and molecular aberrations identified through DNA sequencing
Victoria Wytiaz
Favorite
X
Xiangyu, Zeng

Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
(P 38) EFFICACY AND SAFETY OF RIPRETINIB IN THE TREATMENT OF ADVANCED GASTROINTESTINAL STROMAL TUMORS: A MULTICENTER RETROSPECTIVE STUDY
Zeng Xiangyu
Favorite
Xiao, Han

The First Affiliated Hospital of Sun Yat-sen University
(P 45) THE LONG-TERM EFFECT OF IMATINIB WITH HEPATIC RESECTION OR OTHER LOCAL TREATMENT FOR GIST LIVER METASTASES
Han Xiao
Favorite
Xie, Lu

Peking University People's Hospital
(P 51) OAIE TRIAL IN PROGRESS: A RANDOMIZED PHASE II TRIAL ASSESSING APATINIB IN COMBINATION WITH IFOSFAMIDE AND ETOPOSIDE(IE) VERSUS SINGLE IE CHEMOTHERAPY FOR RELAPSED OR REFRACTORY OSTEOSARCOMA
Lu Xie
Favorite
(P 52) ARTEMIS-002 TRIAL IN PROGRESS: A MULTI-CENTER PHASE II TRIAL ASSESSING HS-20093 (B7-H3 ANTIBODY-DRUG CONJUGATE) FOR RELAPSED OR REFRACTORY OSTEOSARCOMA AND OTHER SARCOMAS
Lu Xie
Favorite
(P 97) AN EXPLORATORY STUDY OF AN ANTI-PD-L1/TGF-β ANTIBODY, TQB2858, IN PATIENTS WITH REFRACTORY OR RECURRENT OSTEOSARCOMA AND ALVEOLAR SOFT PART SARCOMA: A REPORT FROM CHINESE SARCOMA STUDY GROUP
Lu Xie
Favorite
(P 441) LONG VERSUS SHORTER SCHEDULES OF VINCRISTINE, IRINOTECAN AND TEMOZOLOMIDE (VIT) FOR RELAPSED OR REFRACTORY EWING SRACOMA: A RANDOMISED CONTROLLED PHASE 2 TRIAL
Lu Xie
Favorite
(P 442) LONG-TERM OUTCOME AND RELAPSE PATTERNS IN EWING SARCOMA PATIENTS WITH EXTENSIVE LUNG/PLEURAL METASTASES AFTER A COMPLETE RESPONSE TO SYSYEMIC THERAPY
Lu Xie
Favorite
Xie, Wenxuan

The First Affiliated Hospital of Sun Yat-sen University
(P 45) THE LONG-TERM EFFECT OF IMATINIB WITH HEPATIC RESECTION OR OTHER LOCAL TREATMENT FOR GIST LIVER METASTASES
Wenxuan Xie
Favorite
Xie, Xianbiao

Department of Musculoskeletal Oncology Center, The First Affiliated Hospital of Sun Yat-sen University
(P 169) UPDATED EFFICACY AND SAFETY PROFILE OF PIMICOTINIB (ABSK021) IN TENOSYNOVIAL GIANT CELL TUMOR (TGCT): 1-YEAR FOLLOW-UP FROM PHASE 1B
Xianbiao Xie
Favorite
xie, Xuehai

Peking University First Hospital
(P 534) NEOADJUVANT CHEMOTHERAPY COMBINED WITH TARGETED TREATMENT IN HIGH-RISK RETROPERITONEAL SARCOMA – A PROSPECTIVE NON-RANDOMIZED CONTROLLED MULTI-CENTERED STUDY ALL ACROSS CHINA
Xuehai xie
Favorite
Xue, Wei

University of Florida
(P 13) OUTCOME OF PATIENTS WITH RELAPSED OR REFRACTORY NON-RHABDOMYOSARCOMA SOFT TISSUE SARCOMAS ENROLLED IN PHASE II COOPERATIVE GROUP CLINICAL TRIALS: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP
Wei Xue
Favorite
(P 165) MIDDLE EAR RHABDOMYOSARCOMA: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP
Wei Xue
Favorite
(P 409) IMMUNOHISTOCHEMICAL STAINING FOR MYOGENIN, AP2 BETA AND HMGA2 PREDICT FOXO1 FUSION STATUS IN RHABDOMYOSARCOMA: A REPORT FROM THE SOFT TISSUE COMMITTEE OF THE CHILDREN'S ONCOLOGY GROUP
Wei Xue
Favorite
(P 425) CHARACTERIZATION OF RHABDOMYOSARCOMA WITH PAX7::FOXO1 FUSIONS: A REPORT FROM THE SOFT TISSUE COMMITTEE OF THE CHILDREN'S ONCOLOGY GROUP
Wei Xue
Favorite
(P 438) ALVEOLAR RHABDOMYOSARCOMA WITH "BURKITT-LIKE" MORPHOLOGY IS ASSOCIATED WITH HIGH AMPLIFICATION OF MYCL
Wei Xue
Favorite
Xu, Hairong

Department of Orthopaedic Oncology Surgery, Beijing Ji Shui Tan Hospital, Peking University
(P 168) A PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF PEXIDARTINIB IN ASIAN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR
Hairong Xu
Favorite
(P 169) UPDATED EFFICACY AND SAFETY PROFILE OF PIMICOTINIB (ABSK021) IN TENOSYNOVIAL GIANT CELL TUMOR (TGCT): 1-YEAR FOLLOW-UP FROM PHASE 1B
Hairong Xu
Favorite
Xu, Hao

Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University
(P 44) RIPRETINIB FOR THE TREATMENT OF CHINESE PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS HARBORING KIT SECONDARY MUTATIONS: A MULTICENTER, RETROSPECTIVE STUDY
Hao Xu
Favorite
(P 48) SIGNIFICANCE OF MONITORING PLASMA CONCENTRATION OF RIPRETINIB IN CHINESE PATIENTS WITH GASTROINTESTINAL STROMAL TUMORS
Hao Xu
Favorite
Xu, Jie

Peking University People's Hospital
(P 51) OAIE TRIAL IN PROGRESS: A RANDOMIZED PHASE II TRIAL ASSESSING APATINIB IN COMBINATION WITH IFOSFAMIDE AND ETOPOSIDE(IE) VERSUS SINGLE IE CHEMOTHERAPY FOR RELAPSED OR REFRACTORY OSTEOSARCOMA
Jie Xu
Favorite
(P 52) ARTEMIS-002 TRIAL IN PROGRESS: A MULTI-CENTER PHASE II TRIAL ASSESSING HS-20093 (B7-H3 ANTIBODY-DRUG CONJUGATE) FOR RELAPSED OR REFRACTORY OSTEOSARCOMA AND OTHER SARCOMAS
Jie Xu
Favorite
(P 97) AN EXPLORATORY STUDY OF AN ANTI-PD-L1/TGF-β ANTIBODY, TQB2858, IN PATIENTS WITH REFRACTORY OR RECURRENT OSTEOSARCOMA AND ALVEOLAR SOFT PART SARCOMA: A REPORT FROM CHINESE SARCOMA STUDY GROUP
Jie Xu
Favorite
(P 441) LONG VERSUS SHORTER SCHEDULES OF VINCRISTINE, IRINOTECAN AND TEMOZOLOMIDE (VIT) FOR RELAPSED OR REFRACTORY EWING SRACOMA: A RANDOMISED CONTROLLED PHASE 2 TRIAL
Jie Xu
Favorite
(P 442) LONG-TERM OUTCOME AND RELAPSE PATTERNS IN EWING SARCOMA PATIENTS WITH EXTENSIVE LUNG/PLEURAL METASTASES AFTER A COMPLETE RESPONSE TO SYSYEMIC THERAPY
Jie Xu
Favorite
Xu-Welliver, Meng

Mayo Clinic
(P 02) PEDIATRIC SYNOVIAL SARCOMA: A REVIEW OF 21 CASES FROM A SINGLE INSTITUTION
Meng Xu-Welliver
Favorite
(P 207) A MULTICENTER PHASE II STUDY OF CABOZANTINIB PLUS NIVOLUMAB FOR PATIENTS WITH ADVANCED ANGIOSARCOMA PREVIOUSLY TREATED WITH A TAXANE: ALLIANCE A091902
Meng Xu-Welliver
Favorite
(P 306) USE OF PENCIL BEAM SCANNING PROTON RADIOTHERAPY IN MOBILE SPINE CHORDOMAS
Meng Xu-Welliver
Favorite
(P 465) UNPLANNED EXCISION OF SYNOVIAL SARCOMA: FACTORS ASSOCIATED WITH RECURRENCE AND SURVIVAL
Meng Xu-Welliver
Favorite
Xu, Zekuan

Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University
(P 44) RIPRETINIB FOR THE TREATMENT OF CHINESE PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS HARBORING KIT SECONDARY MUTATIONS: A MULTICENTER, RETROSPECTIVE STUDY
Zekuan Xu
Favorite
(P 48) SIGNIFICANCE OF MONITORING PLASMA CONCENTRATION OF RIPRETINIB IN CHINESE PATIENTS WITH GASTROINTESTINAL STROMAL TUMORS
Zekuan Xu
Favorite
xu, Zhaohui

UT MD anderson cancer center
(P 89) GENERATION OF CHONDROCYTE-DERIVED MOUSE OSTEOSARCOMA MODELS - TRACKABLE SYSTEMS TO DELINEATE ONCOGENIC AND METASTATIC ENVENTS PRIOR TO TUMOROGENESIS
Zhaohui xu
Favorite
Y
Yakupovich, Anel

Rush University Medical Center
(P 377) EFFECTIVENESS OF INTERVENTIONAL RADIOLOGY GUIDED PROCEDURES FOR LOCALLY RECURRENT AND METASTATIC SARCOMA: SINGLE INSTITUTIONAL RESULTS
Anel Yakupovich
Favorite
Yamada, Yoshiya

Memorial Sloan Kettering
(P 343) STEREOTACTIC BODY RADIATION THERAPY (SBRT) IN ADVANCED/RECURRENT RETROPERITONEAL SARCOMA: PRELIMINARY RESULTS
Yoshiya Yamada
Favorite
Yamagata, Yukinori

Department of Gastoric Surgery, National Cancer Center Hospital, Tokyo, Japan
(P 332) SURGICAL OUTCOMES OF RETROPERITONEAL LIPOSARCOMA - SINGLE INSTITUTIONAL STUDY N JAPAN -
Yukinori Yamagata
Favorite
Yamamoto, Maki

UNIVERSITY OF CALIFORNIA IRVINE
(P 324) EVALUATING THE ROLE OF ADJUVANT RADIATION AFTER WIDE LOCAL EXCISION OF PLEOMORPHIC DERMAL SARCOMA
Maki Yamamoto
Favorite
Yamamoto, Noboru

Department of Experimental Therapeutics, National Cancer Center Hospital
(P 185) LONGITUDINAL MUTATIONAL ANALYSIS OF TP53 IN CIRCULATING TUMOR DNA IN THE PLASMA OF PATIENTS WITH LIPOSARCOMA IN A PHASE I STUDY OF BRIGIMADLIN (BI 907828), AN MDM2-P53 ANTAGONIST
Noboru Yamamoto
Favorite
(P 408) CHANGES IN COMPUTED TOMOGRAPHY FEATURES INDUCED BY BRIGIMADLIN (BI 907828) IN PATIENTS WITH LIPOSARCOMA: INSIGHTS FROM PHASE I STUDIES
Noboru Yamamoto
Favorite
Yamashita, Toshihiko

Sapporo Medical University School of Medicine
(P 05) COEFFICIENT OF VARIATION OF T2-WEIGHTED MRI PREDICTS THE PROGNOSIS OF MALIGNANT PERIPHERAL NERVE SHEATH TUMOR
Toshihiko Yamashita
Favorite
(P 470) PROGNOSTIC SIGNIFICANCE OF HISTOLOGICAL SUBTYPE IN SOFT TISSUE SARCOMA WITH DISTANT METASTASIS
Toshihiko Yamashita
Favorite
(P 471) IMPACT OF PRIMARY TUMOR RESECTION ON METASTASIS TO THE LUNG IN PATIENTS WITH BONE AND SOFT-TISSUE SARCOMA
Toshihiko Yamashita
Favorite
(P 486) PRIMARY HIGH-GRADE SARCOMA OF THE SPINE: EXPERIENCE WITH 11 CASES
Toshihiko Yamashita
Favorite
Yanchenko, Natalia

Sylvester Comprehensive Cancer Center
(P 128) THE IMPACT OF HISPANIC ETHNICITY IN PRESENTATION AND OUTCOMES OF PATIENTS WITH SYNOVIAL SARCOMA
Natalia Yanchenko
Favorite
Yang, HsihTe

Levine Cancer Institute
(P 258) THE CRITICALITY OF OXIDATIVE PHOSPHORYLATION IN SYNOVIAL SARCOMA METASTASIS
HsihTe Yang
Favorite
Yang, Kwangmo

Korea Institute of Radiation and Medical Sciences
(P 281) FIVE DAY SPACING OF TWO FRACTIONATED ABLATIVE RADIOTHERAPIES ENHANCES ANTITUMOR IMMUNITY IN FIBROSARCOMA CELL LINE
Kwangmo Yang
Favorite
Yang, Richard

MD Anderson Cancer Center
(P 83) CLINICO-GENOMIC PROFILING OF CONVENTIONAL AND DEDIFFERENTIATED CHONDROSARCOMAS REVEALS TP53 MUTATION TO BE ASSOCIATED WITH WORSE OUTCOMES
Richard Yang
Favorite
Yang, Tianzhong

University of Minnesota
(P 414) GENOMIC ANALYSIS OF EWING SARCOMA AND HERNIA IDENTIFIES A POSITIVE GENETIC CORRELATION AND SUGGESTS BOTH ARE LINKED TO AN HMGA2 VARIANT
Tianzhong Yang
Favorite
Yangua Paucar, Estefania Dennisse

Complutense University
(P 149) PSYCOLOGICAL SNAPSHOT OF SARCOMA PATIENTS FROM AN ACADEMIC, UNIVERSITY CENTER, HOSPITAL CLÍNICO SAN CARLOS (HCSC), MADRID, A SARCOMA NATIONAL REFERRAL CENTRE IN SPAIN
Estefania Dennisse Yangua Paucar
Favorite
Yang, Valerie

Division of Medical Oncology, National Cancer Centre Singapore
(P 82) PROGNOSTIC FACTORS AND OUTCOMES OF 275 PATIENTS WITH HEAD AND NECK BONE AND SOFT TISSUE SARCOMA: A SINGLE CENTRE COHORT STUDY
Valerie Yang
Favorite
Yang, Yanwen

MD Anderson Cancer Center
(P 101) EPIGENETIC MODULATION OF NK CELLS IMPROVES TUMOR TRAFFICKING AND ENHANCES THERAPEUTIC EFFICACY AGAINST OSTEOSARCOMA
Yanwen Yang
Favorite
Yang, Ya-Wen

National Taiwan University
(P 139) ULTRA-RARE SARCOMAS HAVE WORSE SURVIVAL COMPARED TO NON-ULTRA-RARE SARCOMAS: A NATIONAL CANCER REGISTRY STUDY
Ya-Wen Yang
Favorite
Yang, Yi

Peking University People's Hospital
(P 487) EN BLOC RESECTION FOR SPINAL TUMORS: A SINGLE CENTER EXPERIENCE OF 113 CONSECUTIVE CASES
Yi Yang
Favorite
Yan, Na

Key Laboratory of Digital Technology in Medical Diagnostics of Zhejiang Province, Dian Diagnostics Group Co., Ltd.
(P 41) GENOMIC ANALYSIS OF SECONDARY KIT MUTATIONS IN CHINESE PATIENTS WITH IMATINIB-RESISTANT ADVANCED GASTROINTESTINAL STROMAL TUMORS USING NEXT-GENERATION SEQUENCING (NGS)
Na Yan
Favorite
Yan, Taiqiang

Peking University People's Hospital
(P 464) INDOCYANINE GREEN FLUORESCENCE IMAGING MAY DETECT TUMOUR RESIDUALS DURING SURGERY FOR BONE AND SOFT-TISSUE TUMOURS
Taiqiang Yan
Favorite
Yan, Wangjun

Fudan University Shanghai Cancer Center
(P 168) A PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF PEXIDARTINIB IN ASIAN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR
Wangjun Yan
Favorite
Yan, Wei

Department of Surgery, Rogel Cancer Center, University of Michigan
(P 293) GENERATION OF A SPONTANEOUS IMMUNOCOMPETENT MOUSE MODEL OF LIPOSARCOMA
Wei Yan
Favorite
Yan, Yiwen

University College London
(P 494) WHAT IS THE EXPERIENCE OF THOSE WITH CANCER-RELATED REDUCED QUALITY OF LIFE AND ASSOCIATED PHYSICAL DISABILITIES AFTER UPPER LIMB SARCOMA TREATMENT IN ENGLAND? A NATIONAL STUDY OF OUTCOMES.
Yiwen Yan
Favorite
Yao, Weitao

Department of Orthopedics, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital
(P 169) UPDATED EFFICACY AND SAFETY PROFILE OF PIMICOTINIB (ABSK021) IN TENOSYNOVIAL GIANT CELL TUMOR (TGCT): 1-YEAR FOLLOW-UP FROM PHASE 1B
Weitao Yao
Favorite
Yarmolenko, Pavel

Childrens National
(P 292) APPLICATION OF HIGH-INTENSITY FOCUSED ULTRASOUND THERMAL ABLATION AND BOILING HISTOTRIPSY WITH CHECKPOINT INHIBITORS IN A MURINE MODEL OF OSTEOSARCOMA: AN IN-DEPTH STUDY
Pavel Yarmolenko
Favorite
Yarmolenko, Pavel

The Sheikh Zayed Institute for Pediatric Surgical Innovation
(P 564) A PILOT STUDY OF LYSO-THERMOSENSITIVE LIPOSOMAL DOXORUBICIN AND MAGNETIC RESONANCE-GUIDED HIGH INTENSITY FOCUSED ULTRASOUND FOR TREATMENT OF RELAPSED OR REFRACTORY SOLID TUMORS
Pavel Yarmolenko
Favorite
Yau, Chun En

Yong Loo Lin School of Medicine, National University of Singapore
(P 82) PROGNOSTIC FACTORS AND OUTCOMES OF 275 PATIENTS WITH HEAD AND NECK BONE AND SOFT TISSUE SARCOMA: A SINGLE CENTRE COHORT STUDY
Chun En Yau
Favorite
Yechieli, Raphael

Sylvester Comprehensive Cancer Center
(P 461) OUTCOMES FOR OLIGOMETASTATIC PULMONARY DISEASE RECURRENCE TREATED WITH SURGERY ALONE FOR PATIENTS WITH SOFT TISSUE SARCOMAS A CASE SERIES
Raphael Yechieli
Favorite
Yeung, Vanessa

Prince of Wales Hospital, Hong Kong
(P 290) PRE-CLINICAL STUDY OF TUMOR TREATING FIELDS (TTFIELDS) ALONE OR IN CONJUNCTION WITH SYSTEMIC THERAPIES IN SELECTED BONE- AND SOFT-TISSUE SARCOMAS
Vanessa Yeung
Favorite
Ye, Xin

Daiichi Sankyo, Inc.
(P 131) PATIENT-REPORTED CONTINUED BENEFITS IN PATIENTS TREATED WITH PEXIDARTINIB FOR TENOSYNOVIAL GIANT CELL TUMOR BASED ON A REAL-WORLD STUDY IN THE UNITED STATES
Xin Ye
Favorite
ye, yingjiang

Department of Gastrointestinal Surgery, Peking University People's Hospital
(P 39) MANAGEMENT PRACTICES OF GASTROINTESTINAL STROMAL TUMORS: A QUESTIONNAIRE SURVEY OF GENERAL SURGEONS IN CHINA
yingjiang ye
Favorite
Ye, Zhaoming

Department of Orthopedics, The Second Affiliated Hospital of Zhejiang University School of Medicine
(P 168) A PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF PEXIDARTINIB IN ASIAN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR
Zhaoming Ye
Favorite
(P 169) UPDATED EFFICACY AND SAFETY PROFILE OF PIMICOTINIB (ABSK021) IN TENOSYNOVIAL GIANT CELL TUMOR (TGCT): 1-YEAR FOLLOW-UP FROM PHASE 1B
Zhaoming Ye
Favorite
(P 543) MANEUVER STUDY: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF PIMICOTINIB (ABSK021) TO ASSESS THE EFFICACY AND SAFETY IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR
Zhaoming Ye
Favorite
Yi, Yanhua

UT MD Anderson cancer center
(P 89) GENERATION OF CHONDROCYTE-DERIVED MOUSE OSTEOSARCOMA MODELS - TRACKABLE SYSTEMS TO DELINEATE ONCOGENIC AND METASTATIC ENVENTS PRIOR TO TUMOROGENESIS
Yanhua Yi
Favorite
Yoh, Kazukoh

Daiichi Sankyo, Co., Ltd.
(P 168) A PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF PEXIDARTINIB IN ASIAN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR
Kazukoh Yoh
Favorite
Yonemori, Kan

Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
(P 10) ATEZOLIZUMAB IN JAPANESE PATIENTS WITH ADVANCED ALVEOLAR SOFT PART SARCOMA: A MULTI-CENTER, SINGLE-ARM, INVESTIGATOR-INITIATED PHASE 2 TRIAL (NCCH1907)
Kan Yonemori
Favorite
(P 80) OPTIMIZING DOSE OF MAP THERAPY FOR CHILDREN, YOUNG ADULTS AND ADULTS WITH OSTEOSARCOMA; A SINGLE-CENTRE RETROSPECTIVE ANALYSIS
Kan Yonemori
Favorite
(P 332) SURGICAL OUTCOMES OF RETROPERITONEAL LIPOSARCOMA - SINGLE INSTITUTIONAL STUDY N JAPAN -
Kan Yonemori
Favorite
(P 547) A PHASE II TRIAL OF TAZEMETOSTAT FOR PATIENTS WITH UNRESECTABLE OR METASTATIC EPITHELIOID SARCOMA (TAZETTA TRIAL)
Kan Yonemori
Favorite
Yonemoto, Tsukasa

Chiba Cancer Center
(P 396) COMPREHENSIVE WHOLE-GENOME MOLECULAR PROFILING IN BONE AND SOFT TISSUE SARCOMA: MULTI-OMICS ANALYSIS OF 627 CASES ACROSS HISTOLOGIC SUBTYPES
Tsukasa Yonemoto
Favorite
Yongdong, Feng

Department of Gastrointestinal Surgery Center and Department of Laboratory Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
(P 38) EFFICACY AND SAFETY OF RIPRETINIB IN THE TREATMENT OF ADVANCED GASTROINTESTINAL STROMAL TUMORS: A MULTICENTER RETROSPECTIVE STUDY
Feng Yongdong
Favorite
Yoo, Jung

Oregon Health & Science University
(P 463) MACHINE LEARNING CORROBORATES TRADITIONAL REGRESSION TECHNIQUES IN PREDICTING MAJOR WOUND COMPLICATIONS AFTER SOFT TISSUE SARCOMA RESECTION WITHOUT IMPROVEMENTS IN PREDICTIVE PERFORMANCE
Jung Yoo
Favorite
Yoon, Janet

City of Hope Comprehensive Cancer Center
(P 180) HEALTH RELATED QUALITY OF LIFE OF PATIENTS WITH ADVANCED LEIOMYOSARCOMA AND OTHER SOFT TISSUE SARCOMAS TREATED WITH CABOZANTINIB AND TEMOZOLOMIDE
Janet Yoon
Favorite
Yoon, Richard

Cooperman Barnabas Medical Center/Jersey City Medical Center – RWJBarnabas Health
(P 467) DOES PERIOPERATIVE RADIATION AFFECT IMPLANT SURVIVORSHIP OF PRIMARY TOTAL HIP ARTHROPLASTY IN THE SETTING OF METASTATIC BONE DISEASE: A MULTICENTER STUDY
Richard Yoon
Favorite
Yoshida, Akihiko

Department of Diagnostic Pathology, National Cancer Center Hospital, Tokyo, Japan
(P 76) GENETIC EVIDENCE OF METACHRONOUS DEDIFFERENTIATION OF CHONDROSARCOMA AT A DISTANT SITE
Akihiko Yoshida
Favorite
(P 80) OPTIMIZING DOSE OF MAP THERAPY FOR CHILDREN, YOUNG ADULTS AND ADULTS WITH OSTEOSARCOMA; A SINGLE-CENTRE RETROSPECTIVE ANALYSIS
Akihiko Yoshida
Favorite
(P 396) COMPREHENSIVE WHOLE-GENOME MOLECULAR PROFILING IN BONE AND SOFT TISSUE SARCOMA: MULTI-OMICS ANALYSIS OF 627 CASES ACROSS HISTOLOGIC SUBTYPES
Akihiko Yoshida
Favorite
(P 406) EXTENSIVE ANALYSIS OF 59 SARCOMA-RELATED FUSION GENES IDENTIFIED PAZOPANIB AS A POTENTIAL INHIBITOR TO COL1A1-PDGFB FUSION GENE
Akihiko Yoshida
Favorite
Yoshida, Shinichiro

Tohoku University School of Medicine
(P 396) COMPREHENSIVE WHOLE-GENOME MOLECULAR PROFILING IN BONE AND SOFT TISSUE SARCOMA: MULTI-OMICS ANALYSIS OF 627 CASES ACROSS HISTOLOGIC SUBTYPES
Shinichiro Yoshida
Favorite
Yosibash, Zohar

Tel Aviv University
(P 240) IDENTIFYING PATIENTS AT HIGH RISK OF HIP FRACTURE DUE TO BONE TUMORS BY COMPUTATIONAL BIOMECHANICS: A RANDOMIZED PROSPECTIVE CLINICAL STUDY
Zohar Yosibash
Favorite
You, Daoqi

Memorial Sloan Kettering Cancer Center
(P 289) IDENTIFICATION OF EFFECTIVE THERAPEUTIC COMBINATIONS WITH THE NUCLEAR EXPORT PROTEIN INHIBITOR, SELINEXOR, IN PEDIATRIC SOLID TUMORS
Daoqi You
Favorite
Youk, Jeonghwan

Seoul National University Hospital
(P 374) ARHGEF4 EXPRESSION IN SOFT TISSUE SARCOMA CORRELATES WITH LOCAL GROWTH PATTERN AND LOCAL RECURRENCE: COMPREHENSIVE GENOMIC ANALYSIS IN SEARCH OF BIOMARKER OF LOCAL GROWTH PATTERN
Jeonghwan Youk
Favorite
(P 498) DEDIFFERENTIATED LIPOSARCOMA OF THE EXTREMITIES: CHARACTERISTICS AND OUTCOME
Jeonghwan Youk
Favorite
(P 499) CLINICAL OUTCOMES OF TOTAL FEMORAL REPLACEMENT FOR ONCOLOGICAL INDICATIONS
Jeonghwan Youk
Favorite
Younesi, Elan

Sarcoma Oncology Center
(P 116) UPDATE ON SAINT: RESULTS OF 100 PATIENTS TREATED WITH IPILIMUMAB (I), NIVOLUMAB (N) AND TRABECTEDIN (T) AS FIRST LINE THERAPY FOR ADVANCED SOFT TISSUE SARCOMA [NCT03138161]
Elan Younesi
Favorite
(P 383) AI ANALYSIS SHOWS ENHANCED CCNG1 ONCOGENE EXPRESSION IN SARCOMA TUMORS AND SUPPORTS THE USE OF DELTAREX-G, A CCNG1 INHIBITOR, AS PLATFORM THERAPY FOR ADVANCED SARCOMA
Elan Younesi
Favorite
Youngblood, Benjamin

St. Jude Children's Research Hospital
(P 528) SAFETY AND TOLERABILITY OF ORAL CYCLOPHOSPHAMIDE AND SORAFENIB WITH INTRAVENOUS BEVACIZUMAB WITH THE ADDITION OF ATEZOLIZUMAB IN PEDIATRIC SOLID TUMOR PATIENTS
Benjamin Youngblood
Favorite
Young, Charlotte

The Christie NHS Foundation Trust
(P 190) DOES RESPONSE TO PRIOR CHEMOTHERAPY PREDICT OUTCOME FROM FURTHER SYSTEMIC TREATMENT IN ADVANCED LEIOMYOSARCOMA? A SINGLE UK CENTRE EXPERIENCE
Charlotte Young
Favorite
Younger, Eugenie

Royal Marsden NHS Foundation Trust
(P 186) PATIENT REPORTED OUTCOME ASSESSMENT AND REPORTING IN RANDOMIZED CLINICAL TRIALS OF SYSTEMIC THERAPY FOR ADVANCED SOFT TISSUE SARCOMAS: A SYSTEMATIC REVIEW.
Eugenie Younger
Favorite
Young, Robin

Weston Park Cancer Centre
(P 70) ICONIC (IMPROVING OUTCOMES THROUGH COLLABORATION IN OSTEOSARCOMA): A PROSPECTIVE OBSERVATIONAL COHORT STUDY FOR NEWLY DIAGNOSED OSTEOSARCOMA PATIENTS IN THE UNITED KINGDOM (UK)
Robin Young
Favorite
You, Yi-Qian

MD Anderson Cancer Center
(P 198) PERSONALIZED MULTIDISCIPLINARY MANAGEMENT OF SARCOMA IN PATIENTS WITH LYNCH SYNDROME
Yi-Qian You
Favorite
Yovell, Jonathan

Ayala Pharmaceuticals
(P 172) PHASE 2 RESULTS FROM THE RINGSIDE PHASE 2/3 TRIAL OF AL102 FOR TREATMENT OF DESMOID TUMORS
Jonathan Yovell
Favorite
(P 549) DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF AL102 FOR TREATMENT OF PROGRESSING DESMOID TUMORS: THE RINGSIDE PHASE 3 STUDY DESIGN
Jonathan Yovell
Favorite
Yuan, Ting

Department of Orthopedics, Shanghai Jiao Tong University Affiliated Sixth People's Hospital
(P 169) UPDATED EFFICACY AND SAFETY PROFILE OF PIMICOTINIB (ABSK021) IN TENOSYNOVIAL GIANT CELL TUMOR (TGCT): 1-YEAR FOLLOW-UP FROM PHASE 1B
Ting Yuan
Favorite
Yu, Austin

Rush University Medical Center
(P 63) EVALUATION OF LOCAL RECURRENCE AND DIAGNOSTIC DISCORDANCE IN CHONDROSARCOMA PATIENTS UNDERGOING PREOPERATIVE BIOPSY
Austin Yu
Favorite
(P 232) NOVEL MRI SCORING SYSTEM TO ASSESS OSSEOUS MALIGNANCY IN SOFT TISSUE SARCOMA PATIENTS FOLLOWING RADIOTHERAPY
Austin Yu
Favorite
(P 377) EFFECTIVENESS OF INTERVENTIONAL RADIOLOGY GUIDED PROCEDURES FOR LOCALLY RECURRENT AND METASTATIC SARCOMA: SINGLE INSTITUTIONAL RESULTS
Austin Yu
Favorite
(P 467) DOES PERIOPERATIVE RADIATION AFFECT IMPLANT SURVIVORSHIP OF PRIMARY TOTAL HIP ARTHROPLASTY IN THE SETTING OF METASTATIC BONE DISEASE: A MULTICENTER STUDY
Austin Yu
Favorite
(P 468) OPIATE USE AFTER TOTAL HIP ARTHROPLASTY FOR METASTATIC BONE DISEASE
Austin Yu
Favorite
Yuen, Sarah

University of California Irvine
(P 324) EVALUATING THE ROLE OF ADJUVANT RADIATION AFTER WIDE LOCAL EXCISION OF PLEOMORPHIC DERMAL SARCOMA
Sarah Yuen
Favorite
Yue, Xin

Department of Colorectal Cancer,Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer; Tianjin Key Laboratory of Digestive Cancer, Tianjin; Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, P. R. China
(P 42) THE EFFICACY AND SAFETY OF RIPRETINIB IN THE TREATMENT OF CHINESE PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS (GISTS): A SINGLE-INSTITUTION ANALYSIS
Xin Yue
Favorite
Yu, JiRen

The First Affiliated Hospital, Zhejiang University School of Medicine
(P 34) RIPRETINIB IN COMBINATION WITH OTHER TKIS IN CHINESE PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR: A MULTI-CENTER RETROSPECTIVE ANALYSIS
JiRen Yu
Favorite
Yule, Murray

Adaptimmune
(P 542) ENROLLMENT OF PEDIATRIC PARTICIPANTS WITH MAGE-A4-POSITIVE SOLID TUMORS IN A PHASE 1/2, OPEN-LABEL, BASKET TRIAL OF AFAMITRESGENE AUTOLEUCEL ("AFAMI-CEL")
Murray Yule
Favorite
Yu, Yang

The First Affiliated Hospital of Sun Yat-sen University
(P 45) THE LONG-TERM EFFECT OF IMATINIB WITH HEPATIC RESECTION OR OTHER LOCAL TREATMENT FOR GIST LIVER METASTASES
Yang Yu
Favorite
Yu, Yiyang

Peking University People's Hospital
(P 58) CHEMOTHERAPY-INDUCED EVOLUTION OF OSTEOSARCOMA REVEALED BY SINGLE-CELL RNA SEQUENCING
Yiyang Yu
Favorite
(P 487) EN BLOC RESECTION FOR SPINAL TUMORS: A SINGLE CENTER EXPERIENCE OF 113 CONSECUTIVE CASES
Yiyang Yu
Favorite
Z
Zöllner, Stefan K.

Pediatrics III, University Hospital Essen, West German Cancer Center
(P 17) METASTASIS-SPECIFIC GENE EXPRESSION PATTERNS IN EWING SARCOMA
Stefan K. Zöllner
Favorite
(P 538) IEUROEWING TRIAL FOR LOCALIZED AND METASTATIC EWING SARCOMA
Stefan K. Zöllner
Favorite
Zacharias, Zeb

University of Iowa
(P 115) EFFICACY AND CORREALTIVE ANALYSIS OF USING NEOADJUVANT INTRATUMORAL HIGH DOSE TALIMOGENE LAHERPAREPVEC (TVEC) WITH CONCURRENT RADIATION IN HIGH-RISK EXTREMITY AND TRUNK SOFT-TISSUE SARCOMAS
Zeb Zacharias
Favorite
Zaffaroni, Nadia

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 109) INTENSE PRECLINICAL ACTIVITY BY B7H3-SPECIFIC CAR.CIK LYMPHOCYTES AGAINST EPITHELIOID SARCOMA
Nadia Zaffaroni
Favorite
(P 272) A COMPARATIVE ASSESSMENT OF SELINEXOR WITH TRABECTEDIN OR LURBINECTEDIN IN PATIENT-DERIVED XENOGRAFTS (PDX) OF DEDIFFERENTIATED LIPOSARCOMA (DDLPS)
Nadia Zaffaroni
Favorite
(P 273) COMPARISON OF A PATIENT-DERIVED XENOGRAFTS (PDX) OF MYXOID PLEOMORPHIC LIPOSARCOMA (MPL) AND PLEOMORPHIC LIPOSARCOMA (PL) HIGHLIGHTS THE EFFECTIVENESS OF ERIBULIN IN A PDX OF MPL
Nadia Zaffaroni
Favorite
(P 363) Β-CATENIN MUTATIONS AND TRANSCRIPTOMIC REPROGRAMMING IN DESMOID FIBROMATOSIS (DF)
Nadia Zaffaroni
Favorite
Zahler, Stacey

Cleveland Clinic
(P 308) OPTIMAL BIOLOGIC EFFECTIVE DOSE OF STEREOTACTIC BODY RADIOTHERAPY FOR METASTATIC AND RECURRENT SARCOMA
Stacey Zahler
Favorite
(P 539) SARCOMA STEREOTACTIC BODY RADIOTHERAPY AND IMMUNE SYSTEM TRIAL
Stacey Zahler
Favorite
Zaikova, Olga

Oslo University Hospital
(P 69) DEVELOPMENT AND MISSION OF THE HARMONIZATION INTERNATIONAL BONE SARCOMA CONSORTIUM (HIBISCUS)
Olga Zaikova
Favorite
Zajac, Agnieszka

Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
(P 222) EXPLORING THE IMPACT OF NGS ON DIAGNOSTICS AND TREATMENT OF SARCOMA: INSIGHTS FROM REAL-WORLD DATA ACROSS MULTIPLE INSTITUTIONS IN EUROPE
Agnieszka Zajac
Favorite
Zajic, Stefan

GSK
(P 114) PRIMARY ANALYSIS OF EFFICACY AND SAFETY OF LETETRESGENE AUTOLEUCEL (LETE-CEL) AS FIRST-LINE TREATMENT FOR UNRESECTABLE OR METASTATIC SYNOVIAL SARCOMA (SS); SUBSTUDY 1 OF IGNYTE-ESO
Stefan Zajic
Favorite
Zamora, Paul

Hospital de la Santa Creu i Sant Pau
(P 503) SCAPULAR PROSTHESIS RECONSTRUCTION, EXPERIENCE IN OUR INSTITUTION
Paul Zamora
Favorite
(P 504) WHY DO SOME PATIENTS WITH SYNOVIAL SARCOMA HAVE BETTER FUNCTIONAL OUTCOMES AFTER RESECTION SURGERY? ANALYSIS OF 102 CASES
Paul Zamora
Favorite
(P 507) PRIMARY CHEST WALL TUMORS OF MESENCHYMAL ORIGIN. EXPERIENCE OF A REFERENCE UNIT
Paul Zamora
Favorite
(P 508) DREAM, UTOPIA OR REALISM? PROGNOSTIC FACTORS IN LUNG METASTASECTOMY OF DISSEMINATED SARCOMA DISEASE
Paul Zamora
Favorite
Zanardi, Sabrina

IRCCS ISTITUTO GIANNINA GASLINI
(P 144) IMPLEMENTATION OF THE EUROPEAN CLINICAL TRIAL REGULATION: SURVEY OF THE ITALIAN SARCOMA GROUP CENTERS
Sabrina Zanardi
Favorite
Zanella, Caterina

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 431) TREATMENT STRATEGY AND PROGNOSTIC FACTORS IN EXTRASKELETAL EWING SARCOMA: AN INSTITUTIONAL RETROSPECTIVE ANALYSIS
Caterina Zanella
Favorite
Zanetti, Ilaria

Department of Pediatric Haematology and Oncology, University Hospital of Padua
(P 209) PROGNOSTIC VALUE OF EARLY RADIOLOGIC TUMOUR VOLUME RESPONSE IN RHABDOMYOSARCOMA; RESULTS OF THE EUROPEAN PAEDIATRIC SOFT TISSUE SARCOMA STUDY GROUP RMS 2005 STUDY
Ilaria Zanetti
Favorite
zang, jie

Peking University People’s Hospital
(P 58) CHEMOTHERAPY-INDUCED EVOLUTION OF OSTEOSARCOMA REVEALED BY SINGLE-CELL RNA SEQUENCING
jie zang
Favorite
Zarrad, Fadi

Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen
(P 248) FIBROBLAST ACTIVATION PROTEIN ALPHA -DIRECTED IMAGING AND THERAPY OF SOLITARY FIBROUS TUMOR
Fadi Zarrad
Favorite
Zarzour, Maria

MD Anderson Cancer Center
(P 36) CLINICO-GENOMIC ANALYSIS OF KIT/PDGFRA/SDH WILD-TYPE GASTROINTESTINAL STROMAL TUMORS IDENTIFIES POTENTIAL DRIVER MUTATIONS
Maria Zarzour
Favorite
(P 71) CHEMOTHERAPY AND PROGNOSTIC SIGNIFICANCE OF EXTENT OF DEDIFFERENTIATION IN DEDIFFERENTIATED PAROSTEAL OSTEOSARCOMA
Maria Zarzour
Favorite
(P 83) CLINICO-GENOMIC PROFILING OF CONVENTIONAL AND DEDIFFERENTIATED CHONDROSARCOMAS REVEALS TP53 MUTATION TO BE ASSOCIATED WITH WORSE OUTCOMES
Maria Zarzour
Favorite
(P 100) HISTOLOGY SPECIFIC INTRATUMORAL B-CELL BIOLOGY IN ALVEOLAR SOFT-PART SARCOMAS (ASPS) IN RESPONSE TO DURVALUMAB-TREMELIMUMAB (D-T)
Maria Zarzour
Favorite
(P 123) DEDIFFERENTIATED LIPOSARCOMAS TREATED WITH IMMUNE CHECKPOINT BLOCKADE: THE MD ANDERSON EXPERIENCE
Maria Zarzour
Favorite
(P 183) A PHASE 1B/2 STUDY OF LIPOSOMAL ANNAMYCIN (ANN) IN SUBJECTS WITH PREVIOUSLY TREATED SOFT-TISSUE SARCOMAS (STS) WITH PULMONARY METASTASES
Maria Zarzour
Favorite
(P 394) LEIOMYOSARCOMA INTRATUMORAL MACROPHAGE INFILTRATES ARE ASSOCIATED WITH DISTINCT CLINICAL AND GENOMIC PRESENTATIONS
Maria Zarzour
Favorite
Zatzman, Matthew

University of Toronto
(P 50) CHARACTERIZATION OF A FAMILIAL GIST KINDRED INTOLERANT TO IMATINIB
Matthew Zatzman
Favorite
Zaun, Yasmin

University Hospital Essen, Sarcoma Centre
(P 47) PATIENT SURVIVAL IN METASTATIC GIST WITH IMATINIB-SENSITIVE MUTATIONS: REAL WORLD DATA FROM GERMAN REFERRAL CENTER (2008-2021)
Yasmin Zaun
Favorite
(P 276) REVISITING IN- AND OFF LABEL DRUGS FREQUENTLY USED IN METASTATIC GIST USING A BROAD IN VITRO PROFILING PANEL OF PRIMARY AND SECONDARY KIT AND PDGFRA-MUTANT GIST CELLS – CLINICAL IMPLICATIONS
Yasmin Zaun
Favorite
Zebley, Caitlin

St. Jude Children's Research Hospital
(P 528) SAFETY AND TOLERABILITY OF ORAL CYCLOPHOSPHAMIDE AND SORAFENIB WITH INTRAVENOUS BEVACIZUMAB WITH THE ADDITION OF ATEZOLIZUMAB IN PEDIATRIC SOLID TUMOR PATIENTS
Caitlin Zebley
Favorite
Zebrack, Brad

Univsersity of Michigan School of Social Work
(P 07) IDENTIFYING CONCERNS OF ADOLESCENT AND YOUNG ADULT SARCOMA PATIENTS AND SURVIVORS FOLLOWING FERTIITY PRESERVATION
Brad Zebrack
Favorite
Zeh, Ryan

The University of Pittsburgh
(P 314) PRE-OPERATIVE RADIATION THERAPY INCREASES ADHERENCE IN PATIENTS WITH HIGH-RISK EXTREMITY SOFT TISSUE SARCOMA
Ryan Zeh
Favorite
Zemp, Franz

University of Calgary
(P 106) CHARACTERIZATION OF AN IMMUNE COMPETENT, MURINE MODEL OF SOFT TISSUE SARCOMA
Franz Zemp
Favorite
(P 110) GCAR1: GPNMB CAR T THERAPY FOR MIT FAMILY TRANSLOCATION POSITIVE CANCERS
Franz Zemp
Favorite
Zeng, Jing

University of Seattle
(P 320) A PROSPECTIVE MULTICENTER EXPERIENCE OF PROTON THERAPY FOR RHABDOMYOSARCOMA AND EWING SARCOMA: OUTCOMES FROM THE PROTON COLLABORATIVE GROUP REGISTRY
Jing Zeng
Favorite
Zerdes, Ioannis

Karolinska University Hospital
(P 278) CLINICAL MARKERS PREDICTIVE OF TRABECTEDIN RESPONSE IN SOFT TISSUE SARCOMA
Ioannis Zerdes
Favorite
Zhang, Anao

Univsersity of Michigan School of Social Work
(P 07) IDENTIFYING CONCERNS OF ADOLESCENT AND YOUNG ADULT SARCOMA PATIENTS AND SURVIVORS FOLLOWING FERTIITY PRESERVATION
Anao Zhang
Favorite
Zhang, Cheng

Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute Beijing 100142, P. R. China
(P 46) CIRCULATING TUMOR DNA (CTDNA) ANALYSES AND RESISTANCE MECHANISMS EXPLORATION OF KIT-MUTANT GASTROINTESTINAL STROMAL TUMORS (GISTS) TREATED WITH AVAPRITINIB OR RIPRETINB
Cheng Zhang
Favorite
Zhang, Di

The University of Texas MD Anderson Cancer Center
(P 269) PLASMA DNA METHYLATION-BASED BIOMARKERS FOR MPNST DETECTION IN PATIENTS WITH NEUROFIBROMATOSIS TYPE 1 (NF1)
Di Zhang
Favorite
Zhang, Hongqiang

Fudan University Shanghai Cancer Center Minhang Branch Hospital
(P 534) NEOADJUVANT CHEMOTHERAPY COMBINED WITH TARGETED TREATMENT IN HIGH-RISK RETROPERITONEAL SARCOMA – A PROSPECTIVE NON-RANDOMIZED CONTROLLED MULTI-CENTERED STUDY ALL ACROSS CHINA
Hongqiang Zhang
Favorite
Zhang, Jianhua

The University of Texas MD Anderson Cancer Center
(P 405) PRIMARY CARDIAC ANGIOSARCOMA- GENOMIC AND MOLECULAR LANDSCAPE
Jianhua Zhang
Favorite
zhang, jun

Department of Pharmacy, The First Affiliated Hospital of Chongqing Medical University
(P 39) MANAGEMENT PRACTICES OF GASTROINTESTINAL STROMAL TUMORS: A QUESTIONNAIRE SURVEY OF GENERAL SURGEONS IN CHINA
jun zhang
Favorite
Zhang, Li

Department of Gastric Surgery, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer; Tianjin Key Laboratory of Digestive Cancer, Tianjin; Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, P. R. China
(P 42) THE EFFICACY AND SAFETY OF RIPRETINIB IN THE TREATMENT OF CHINESE PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS (GISTS): A SINGLE-INSTITUTION ANALYSIS
Li Zhang
Favorite
Zhang, Lindy

Johns Hopkins Hospital
(P 250) SHARING HIGH-QUALITY SAMPLES AND DATA TO THE NF1 RESEARCH COMMUNITY: THE ROLE OF THE JOHNS HOPKINS NF1 BIOSPECIMEN REPOSITORY
Lindy Zhang
Favorite
Zhang, Lingxin

Mount Sinai Hospital/University of Toronto
(P 379) THE ROLE OF EZHIP IN DRIVING AGGRESSIVE OSTEOSARCOMA
Lingxin Zhang
Favorite
Zhang, Liuzhe

Mount Sinai Hospital, Department of Surgery, University of Toronto, Toronto, Canada
(P 53) CURATIVE-INTENT SURGERY FOR A SOLITARY ISOLATED BONE METASTASIS FROM EXTREMITY SARCOMA: WHO UNDERWENT METASTASECTOMY AND WHAT WAS THE PROGNOSTIC OUTCOME?
Liuzhe Zhang
Favorite
Zhang, Minsi

Memorial Sloan Kettering
(P 343) STEREOTACTIC BODY RADIATION THERAPY (SBRT) IN ADVANCED/RECURRENT RETROPERITONEAL SARCOMA: PRELIMINARY RESULTS
Minsi Zhang
Favorite
zhang, peng

Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
(P 38) EFFICACY AND SAFETY OF RIPRETINIB IN THE TREATMENT OF ADVANCED GASTROINTESTINAL STROMAL TUMORS: A MULTICENTER RETROSPECTIVE STUDY
peng zhang
Favorite
(P 39) MANAGEMENT PRACTICES OF GASTROINTESTINAL STROMAL TUMORS: A QUESTIONNAIRE SURVEY OF GENERAL SURGEONS IN CHINA
peng zhang
Favorite
Zhang, Rupeng

Department of Gastric Surgery, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer; Tianjin Key Laboratory of Digestive Cancer, Tianjin; Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, P. R. China
(P 42) THE EFFICACY AND SAFETY OF RIPRETINIB IN THE TREATMENT OF CHINESE PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS (GISTS): A SINGLE-INSTITUTION ANALYSIS
Rupeng Zhang
Favorite
Zhang, Wendong

The University of Texas MD Anderson Cancer Center
(P 89) GENERATION OF CHONDROCYTE-DERIVED MOUSE OSTEOSARCOMA MODELS - TRACKABLE SYSTEMS TO DELINEATE ONCOGENIC AND METASTATIC ENVENTS PRIOR TO TUMOROGENESIS
Wendong Zhang
Favorite
(P 119) EX VIVO EXPANDED TUMOR INFILTRATING LYMPHOCYTES FOR SARCOMA TREATMENT
Wendong Zhang
Favorite
(P 203) PRECLINICAL EVALUATION AMG 650, A SMALL MOLECULE INHIBITOR OF KIF18A, IN PEDIATRIC SOLID TUMORS BY THE PEDIATRIC PRECLINICAL IN VIVO TESTING (PIVOT) PROGRAM
Wendong Zhang
Favorite
Zhang, Xiaochun

Washington University in St. Louis
(P 274) TYK2 AND MEK COMBINATION THERAPY IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS AND OTHER SOFT TISSUE SARCOMAS
Xiaochun Zhang
Favorite
Zhang, Xiaojing

Department of Bone and Soft Tissue Tumor Surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute
(P 543) MANEUVER STUDY: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF PIMICOTINIB (ABSK021) TO ASSESS THE EFFICACY AND SAFETY IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR
Xiaojing Zhang
Favorite
Zhang, Xinhua

Department of Gastrointestinal Surgery, The First Affiliated Hospital of Sun Yat-sen University
(P 34) RIPRETINIB IN COMBINATION WITH OTHER TKIS IN CHINESE PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR: A MULTI-CENTER RETROSPECTIVE ANALYSIS
Xinhua Zhang
Favorite
Zhang, Xinhua

Department of Gastrointestinal Surgery, The First Affiliated Hospital, Sun Yat-sen University
(P 39) MANAGEMENT PRACTICES OF GASTROINTESTINAL STROMAL TUMORS: A QUESTIONNAIRE SURVEY OF GENERAL SURGEONS IN CHINA
Xinhua Zhang
Favorite
Zhang, Xinhua

Department of Gastrointestinal Surgery, The First Affiliated Hospital of Sun Yat-sen University
(P 44) RIPRETINIB FOR THE TREATMENT OF CHINESE PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS HARBORING KIT SECONDARY MUTATIONS: A MULTICENTER, RETROSPECTIVE STUDY
Xinhua Zhang
Favorite
Zhang, Xinhua

Department of Gastrointestinal Surgery, The First Affiliated Hospital, Sun Yat-sen University
(P 45) THE LONG-TERM EFFECT OF IMATINIB WITH HEPATIC RESECTION OR OTHER LOCAL TREATMENT FOR GIST LIVER METASTASES
Xinhua Zhang
Favorite
Zhang, Xuan

Key Laboratory of Digital Technology in Medical Diagnostics of Zhejiang Province, Dian Diagnostics Group Co., Ltd.
(P 41) GENOMIC ANALYSIS OF SECONDARY KIT MUTATIONS IN CHINESE PATIENTS WITH IMATINIB-RESISTANT ADVANCED GASTROINTESTINAL STROMAL TUMORS USING NEXT-GENERATION SEQUENCING (NGS)
Xuan Zhang
Favorite
Zhang, Yefan

Department of Hepatobiliary Surgery, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
(P 34) RIPRETINIB IN COMBINATION WITH OTHER TKIS IN CHINESE PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR: A MULTI-CENTER RETROSPECTIVE ANALYSIS
Yefan Zhang
Favorite
(P 44) RIPRETINIB FOR THE TREATMENT OF CHINESE PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS HARBORING KIT SECONDARY MUTATIONS: A MULTICENTER, RETROSPECTIVE STUDY
Yefan Zhang
Favorite
Zhang, Yizhuo

Sun Yat-sen University Cancer Center
(P 161) EFFICACY, SAFETY, AND TREATMENT HOLD WAIT-AND-SEE OUTCOMES OF LAROTRECTINIB IN PEDIATRIC PATIENTS WITH TRK FUSION SARCOMAS
Yizhuo Zhang
Favorite
Zhang, Yong

Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China
(P 339) QUALITY OF SURGERY AND OUTCOME FOR GIANT RETROPERITONEAL LIPOSARCOMA TREATED WITHIN SEMI-ABDOMINAL EN BLOC RESECTION USING VASCULAR PRIORITY CENTRAL APPROACH-A RETROSPECTIVE COHORT
Yong Zhang
Favorite
(P 398) INTEGRATED MULTI-OMICS APPROACH REVEALED TUMOR-ASSOCIATED TERTIARY LYMPHOID STRUCTURE LANDSCAPE IN RETROPERITONEAL LIPOSARCOMA
Yong Zhang
Favorite
Zhang, Yunyun

Zailab pharmaceuticals
(P 41) GENOMIC ANALYSIS OF SECONDARY KIT MUTATIONS IN CHINESE PATIENTS WITH IMATINIB-RESISTANT ADVANCED GASTROINTESTINAL STROMAL TUMORS USING NEXT-GENERATION SEQUENCING (NGS)
Yunyun Zhang
Favorite
Zhang, Zhe

Pfizer Inc
(P 556) EVALUATION OF PALBOCICLIB (IBRANCE®) IN COMBINATION WITH CHEMOTHERAPY IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY EWING SARCOMA OR NEUROBLASTOMA
Zhe Zhang
Favorite
Zhang, Zheyang

Xiamen University
(P 224) CO-MUTATION-DEPENDENT PROGNOSIS IN PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA
Zheyang Zhang
Favorite
Zhang, Zhongtao

Beijing Friendship Hospital
(P 534) NEOADJUVANT CHEMOTHERAPY COMBINED WITH TARGETED TREATMENT IN HIGH-RISK RETROPERITONEAL SARCOMA – A PROSPECTIVE NON-RANDOMIZED CONTROLLED MULTI-CENTERED STUDY ALL ACROSS CHINA
Zhongtao Zhang
Favorite
Zhang, Zhongting

UT MD Anderson Cancer Center
(P 89) GENERATION OF CHONDROCYTE-DERIVED MOUSE OSTEOSARCOMA MODELS - TRACKABLE SYSTEMS TO DELINEATE ONCOGENIC AND METASTATIC ENVENTS PRIOR TO TUMOROGENESIS
Zhongting Zhang
Favorite
(P 203) PRECLINICAL EVALUATION AMG 650, A SMALL MOLECULE INHIBITOR OF KIF18A, IN PEDIATRIC SOLID TUMORS BY THE PEDIATRIC PRECLINICAL IN VIVO TESTING (PIVOT) PROGRAM
Zhongting Zhang
Favorite
Zhan, Hongjie

Department of Gastric Surgery,Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer; Tianjin Key Laboratory of Digestive Cancer, Tianjin; Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, P. R. China
(P 42) THE EFFICACY AND SAFETY OF RIPRETINIB IN THE TREATMENT OF CHINESE PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS (GISTS): A SINGLE-INSTITUTION ANALYSIS
Hongjie Zhan
Favorite
Zhao, Binsheng

Radiology, New York-Presbyterian/Columbia University Medical Center
(P 408) CHANGES IN COMPUTED TOMOGRAPHY FEATURES INDUCED BY BRIGIMADLIN (BI 907828) IN PATIENTS WITH LIPOSARCOMA: INSIGHTS FROM PHASE I STUDIES
Binsheng Zhao
Favorite
Zhao, Jinxuan

University College London
(P 492) BALANCE AND GAIT OUTCOMES AFTER 1-YEAR POST-OPERATIVE HEMIPELVECTOMY SURGERY
Jinxuan Zhao
Favorite
Zhao, Lei

State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
(P 416) THE PROTEOGENOMIC SUBTYPING OF OSTEOSARCOMA
Lei Zhao
Favorite
zhao, yan

Department of Stomach Surgery, Affiliated Cancer Hospital of Dalian Technological University; Liaoning Cancer Hospital and Institute
(P 39) MANAGEMENT PRACTICES OF GASTROINTESTINAL STROMAL TUMORS: A QUESTIONNAIRE SURVEY OF GENERAL SURGEONS IN CHINA
yan zhao
Favorite
Zheng, Yan

University of Texas MD Anderson
(P 122) TARGETING CD70 USING CAR NK CELLS TO ENHANCE NK CELLS CYTOLYTIC EFFECT AGAINST OSTEOSARCOMA
Yan Zheng
Favorite
Zhi, Xin

Peking University People's Hospital
(P 442) LONG-TERM OUTCOME AND RELAPSE PATTERNS IN EWING SARCOMA PATIENTS WITH EXTENSIVE LUNG/PLEURAL METASTASES AFTER A COMPLETE RESPONSE TO SYSYEMIC THERAPY
Xin Zhi
Favorite
Zhou, Guoqiang

Department of Gastrointestinal Surgery, Changshu No. 2 Hospital
(P 44) RIPRETINIB FOR THE TREATMENT OF CHINESE PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS HARBORING KIT SECONDARY MUTATIONS: A MULTICENTER, RETROSPECTIVE STUDY
Guoqiang Zhou
Favorite
Zhou, Maggie

Stanford University School of Medicine
(P 224) CO-MUTATION-DEPENDENT PROGNOSIS IN PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA
Maggie Zhou
Favorite
Zhou, Shengfan

SpringWorks Therapeutics Inc
(P 146) CHARACTERIZING THE PATIENT JOURNEY TO A DIAGNOSIS OF DESMOID TUMOR: DESMOID TUMOR RESEARCH FOUNDATION NATURAL HISTORY STUDY
Shengfan Zhou
Favorite
Zhou, Xin

The University of Texas MD Anderson Cancer Center
(P 89) GENERATION OF CHONDROCYTE-DERIVED MOUSE OSTEOSARCOMA MODELS - TRACKABLE SYSTEMS TO DELINEATE ONCOGENIC AND METASTATIC ENVENTS PRIOR TO TUMOROGENESIS
Xin Zhou
Favorite
Zhou, Yan

Fox Chase Cancer Center
(P 287) ESTABLISHMENT AND GENOMIC VALIDATION OF NOVEL PATIENT-DERIVED XENOGRAFT MODELS FOR DRUG DISCOVERY IN GASTROINTESTINAL STROMAL TUMOR
Yan Zhou
Favorite
Zhou, Yong

Department of Orthopedics, West China Hospital, Sichuan University
(P 169) UPDATED EFFICACY AND SAFETY PROFILE OF PIMICOTINIB (ABSK021) IN TENOSYNOVIAL GIANT CELL TUMOR (TGCT): 1-YEAR FOLLOW-UP FROM PHASE 1B
Yong Zhou
Favorite
(P 543) MANEUVER STUDY: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF PIMICOTINIB (ABSK021) TO ASSESS THE EFFICACY AND SAFETY IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR
Yong Zhou
Favorite
Zhou, Yuhong

Shanghai Zhongshan Hospital
(P 534) NEOADJUVANT CHEMOTHERAPY COMBINED WITH TARGETED TREATMENT IN HIGH-RISK RETROPERITONEAL SARCOMA – A PROSPECTIVE NON-RANDOMIZED CONTROLLED MULTI-CENTERED STUDY ALL ACROSS CHINA
Yuhong Zhou
Favorite
Zhuang, Bo-Zhi

National Taiwan University
(P 139) ULTRA-RARE SARCOMAS HAVE WORSE SURVIVAL COMPARED TO NON-ULTRA-RARE SARCOMAS: A NATIONAL CANCER REGISTRY STUDY
Bo-Zhi Zhuang
Favorite
Zhuang, Dongliang

TRACON Pharmaceuticals Inc
(P 112) PHASE 1/2 STUDY OF YH001, A CTLA-4 ANTIBODY WITH THE SUBCUTANEOUSLY ADMINISTERED PD-L1 ANTIBODY ENVAFOLIMAB, WITH OR WITHOUT DOXORUBICIN IN PATIENTS WITH ADVANCED OR METASTATIC SOFT TISSUE SARCOMA
Dongliang Zhuang
Favorite
(P 531) ENVASARC: A PIVOTAL TRIAL OF ENVAFOLIMAB AND ENVAFOLIMAB IN COMBINATION WITH IPILIMUMAB IN PATIENTS WITH ADVANCED OR METASTATIC UPS OR MFS WHO HAVE PROGRESSED ON PRIOR CHEMOTHERAPY
Dongliang Zhuang
Favorite
Zhu, Hua

The Ohio State University/Division of Cardiac Surgery
(P 301) REDUCING THE INVASIVE POTENTIAL OF DEDIFFERENTIATED LIPOSARCOMA BY TARGETING ALTERNATIVE RNA SPLICING MACHINERY
Hua Zhu
Favorite
Zhu, Kevin

The Cleveland Clinic Foundation
(P 242) WHOLE BODY PET/MRI FOR STAGING OF MYXOID LIPOSARCOMA
Kevin Zhu
Favorite
Zhuk, Irina

BostonGene, Corp.
(P 420) COMPREHENSIVE MOLECULAR PROFILING AND TUMOR MICROENVIRONMENT CHARACTERISTICS OF RADIATION-INDUCED SARCOMA.
Irina Zhuk
Favorite
Zhu, Limin

OHSU
(P 341) A PHASE 1B STUDY TO EVALUATE PREOPERATIVE ERIBULIN IN COMBINATION WITH RADIATION IN RETROPERITONEAL SARCOMA
Limin Zhu
Favorite
Zhu, Ming

Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
(P 256) EFFICACY AND TOXICITY OF VERTEPORFIN IN COMBINATION WITH PAZOPANIB TESTED IN A PATIENT-DERIVED SYNOVIAL SARCOMA XENOGRAFT
Ming Zhu
Favorite
Zhu, Xia

Department of Orthopedics, The First Affiliated Hospital of Fujian Medical University
(P 543) MANEUVER STUDY: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF PIMICOTINIB (ABSK021) TO ASSESS THE EFFICACY AND SAFETY IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR
Xia Zhu
Favorite
Zhu, yazhen

David Geffen School of Medicine, University of California, Los Angeles
(P 19) EXTRACELLULAR VESICLE CLICK MAGBEADS: A MULTIFACETED LIQUID BIOPSY PLATFORM FOR PEDIATRIC SARCOMAS
yazhen Zhu
Favorite
Zinn, Richard

Peter MacCallum Cancer Centre
(P 516) OUCOMES OF AGGRESSIVE RESECTION OF RADIATION INDUCED ANGIOSARCOMA OF THE BREAST
Richard Zinn
Favorite
Ziobro, Anna

Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw, Department of Soft Tissue/Bone Sarcoma and Melanoma
(P 170) HETEROGENEITY OF PAZOPANIB ACTIVITY ACROSS SOFT TISSUE SARCOMA SUBTYPES - A RETROSPECTIVE ANALYSIS OF 303 CASES FROM A REFERENCE CENTER
Anna Ziobro
Favorite
Zirov, Konstantin

BostonGene, Corp.
(P 420) COMPREHENSIVE MOLECULAR PROFILING AND TUMOR MICROENVIRONMENT CHARACTERISTICS OF RADIATION-INDUCED SARCOMA.
Konstantin Zirov
Favorite
Zoller, Wesley

The Ohio State University Wexner Medical Center
(P 315) SCALP VOLUMETRIC MODULATED ARC THERAPY USING 3D MILLED BOLUS: DOSIMITRY, TOXICITY AND OUTCOMES
Wesley Zoller
Favorite
Zou, Qingping

Abbisko Therapeutics Co., Ltd.
(P 169) UPDATED EFFICACY AND SAFETY PROFILE OF PIMICOTINIB (ABSK021) IN TENOSYNOVIAL GIANT CELL TUMOR (TGCT): 1-YEAR FOLLOW-UP FROM PHASE 1B
Qingping Zou
Favorite
Zuckerman, Lee

City of Hope National Medical Center
(P 524) PRESENTATION AND OUTCOMES OF EXTRASKELETAL CHONDROSARCOMAS TREATED WITH SURGICAL RESECTION
Lee Zuckerman
Favorite
(P 525) ALL INTERNAL DISTRACTION OSTEOGENESIS AFTER TUMOR RESECTION
Lee Zuckerman
Favorite
(P 526) EVALUATION OF THE SURGICAL MANAGEMENT OF THE SKELETON IN PATIENTS WITH OLLIER'S DISEASE AND MAFUCCI SYNDROME
Lee Zuckerman
Favorite
(P 527) SALVAGE OF AN OSTEOARRTICULAR ALLOGRAFT RADIUS RECONSTRUCTION SINGLE BONE TRANSPOSITION WITH WRIST ARTHRODESIS FOLLOWING OSTEOSARCOMA EXCISION
Lee Zuckerman
Favorite
Zuco, Valentina

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 109) INTENSE PRECLINICAL ACTIVITY BY B7H3-SPECIFIC CAR.CIK LYMPHOCYTES AGAINST EPITHELIOID SARCOMA
Valentina Zuco
Favorite
(P 272) A COMPARATIVE ASSESSMENT OF SELINEXOR WITH TRABECTEDIN OR LURBINECTEDIN IN PATIENT-DERIVED XENOGRAFTS (PDX) OF DEDIFFERENTIATED LIPOSARCOMA (DDLPS)
Valentina Zuco
Favorite
(P 273) COMPARISON OF A PATIENT-DERIVED XENOGRAFTS (PDX) OF MYXOID PLEOMORPHIC LIPOSARCOMA (MPL) AND PLEOMORPHIC LIPOSARCOMA (PL) HIGHLIGHTS THE EFFECTIVENESS OF ERIBULIN IN A PDX OF MPL
Valentina Zuco
Favorite
Zwaan, C. Michel

Princess Máxima Center for Pediatric Oncology and Erasmus MC
(P 558) TRIAL IN PROGRESS: A PHASE 1/2 STUDY OF BRIGATINIB IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH ALK POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA OR INFLAMMATORY MYOFIBROBLASTIC TUMORS (ITCC-098)
C. Michel Zwaan
Favorite